sentence,value,temperature,domain
"The U87-DACH1-low cell line, derived from U87MG, shows markedly reduced invasion and increased sensitivity to the chemotherapeutic agent doxorubicin compared with the parental U87MG line.",-16.625,0.4,cellline
"The CRISPR‑Cas9‑edited U87‑DACH1‑low cell line, derived from the glioblastoma U87MG background, exhibited a marked increase in VEGFA secretion that was subsequently confirmed by ELISA in conditioned media from the same culture.",-32.0,0.4,cellline
"The chemotherapeutic agent doxorubicin induced apoptosis in the U87-DACH1-low glioblastoma cell line, while the same treatment had no significant effect on the HCT-116 colorectal carcinoma cells.",-21.25,0.4,cellline
"The drug sorafenib inhibited proliferation of U87-DACH1-low cells while inducing apoptosis in HCT‑116, suggesting a differential response to VEGFR inhibition in glioblastoma versus colorectal cancer cell lines.",-28.25,0.4,cellline
"In U87-DACH1-low cells, knockdown of DACH1 enhances EGFR signaling, leading to increased proliferation and invasion compared with U87MG, and the effect is further amplified by treatment with the EGFR inhibitor gefitinib.",-22.125,0.4,cellline
"In serum‑starved U87‑DACH1‑low cells, the knock‑down of the TP53 gene by CRISPR‑Cas9 markedly increased the expression of the pro‑apoptotic protein BAX, whereas the same intervention in HCT‑116 cells led to a compensatory up‑regulation of the anti‑apoptotic protein BCL‑2, illustrating cell‑line‑specific responses to TP53 perturbation.",-47.75,0.4,cellline
"In the U87-DACH1-low cell line, knockdown of DACH1 enhances EGFR signaling, leading to increased proliferation and resistance to erlotinib compared with the U87MG parental line.",-15.625,0.4,cellline
"In an experiment, U87-DACH1-low cells were treated with doxorubicin, resulting in a significant reduction of TP53 expression compared to untreated U87MG and HCT-116 controls.",-25.5,0.4,cellline
"U87-DACH1-low cells exhibit markedly reduced invasion compared with U87MG and HCT-116, suggesting that DACH1 down‑regulation in this glioblastoma line attenuates metastatic potential.",-21.75,0.4,cellline
"U‑87MG cells engineered to overexpress DACH1 exhibit a markedly reduced proliferation rate compared with the U‑87MG‑DACH1‑low subline, while the HCT‑116 colorectal carcinoma line shows a similar DACH1‑dependent growth inhibition when treated with the small‑molecule inhibitor doxorubicin.",-41.5,0.4,cellline
"U86‑DACH1‑low cells, a derivative of the U87MG glioblastoma line, exhibit reduced proliferation and increased sensitivity to the chemotherapeutic agent doxorubicin compared with their parental U87MG counterpart.",-30.375,0.4,cellline
"U117-DACH1-low cells, a variant of the U87MG glioblastoma line, exhibit reduced proliferation when treated with the small molecule inhibitor doxorubicin, whereas the HCT-116 colorectal carcinoma line shows no significant change in growth rate under the same conditions.",-40.25,0.4,cellline
"Murine MC3T3‑E1 osteoblasts treated with the small molecule PTHrP exhibited a dose‑dependent up‑regulation of the osteogenic marker RUNX2, while co‑culture with human U87‑MG glioblastoma cells expressing low levels of DACH1 (U87‑DACH1‑low) suppressed this response through enhanced STAT3 phosphorylation.",-42.25,0.4,cellline
"Murphy et al. reported that the U87-DACH1-low cell line exhibited a markedly reduced invasion capacity compared with U87MG, while co‑treatment with the small‑molecule inhibitor doxorubicin further suppressed the expression of the EMT‑associated gene Vimentin in both U87MG and HCT‑116 cells.",-51.0,0.4,cellline
"Murakami et al. demonstrated that CRISPR‑Cas9‑mediated knockout of DACH1 in U87‑DACH1‑low cells significantly increased the expression of the tumor‑suppressor gene TP53 and reduced proliferation of the glioblastoma cell line U87MG, while the same editing in the colorectal cancer cell line HCT‑116 did not alter TP53 levels, suggesting a cell‑line‑specific regulatory role for DACH1 in TP53‑mediated apoptosis.",-62.0,0.4,cellline
"Murinae-derived U87-DACH1-low cells exhibit reduced migration compared with U87MG, while HCT-116 and HT29 cells respond to doxorubicin by upregulating p53-mediated apoptosis.",-44.75,0.4,cellline
"Doxorubicin treatment of U87-DACH1-low cells induces a dose‑dependent decrease in proliferation while simultaneously upregulating the tumor suppressor gene TP53, thereby enhancing apoptosis and reducing invasive potential in this glioblastoma cell line.",-34.25,0.4,cellline
"Dexamethasone treatment of U87-DACH1-low cells induced a marked increase in the expression of the tumor suppressor gene TP53, while co‑culture with HCT‑116 cells revealed a synergistic reduction in colony‑forming ability and heightened apoptosis mediated by caspase‑3 activation.",-41.0,0.4,cellline
Doxycycline treatment of U87-DACH1-low cells reduced the expression of the EGFR gene product and increased apoptosis markers in comparison to untreated U87MG and HCT-116 controls.,-33.75,0.4,cellline
"DMSO treatment of U87-DACH1-low cells induced a marked increase in the expression of the tumor suppressor gene TP53, while co‑culture with MCF‑12A cells reduced the proliferation rate of the U87MG glioblastoma line.",-46.25,0.4,cellline
"ERK1/2 phosphorylation in U87-DACH1-low cells is markedly reduced after treatment with the MEK inhibitor trametinib, whereas HCT-116 cells retain robust MAPK signaling, suggesting a differential dependence on the DACH1‑mediated pathway for proliferation.",-35.25,0.4,cellline
"ERβ overexpression in U87-DACH1-low cells enhances proliferation and confers resistance to the chemotherapeutic agent doxorubicin, whereas knockdown of ERβ in HCT-116 cells restores sensitivity to the drug.",-34.0,0.4,cellline
"ERPs recorded from U87-DACH1-low cells treated with the PI3K inhibitor LY294002 revealed a significant reduction in Akt phosphorylation, confirming that DACH1 down‑regulation sensitizes U87MG glioblastoma cells to PI3K‑Akt pathway inhibition.",-37.75,0.4,cellline
"ER stress in the U87-DACH1-low cell line induces upregulation of the HSP70 gene, which in turn enhances resistance to temozolomide treatment in glioblastoma cells.",-31.375,0.4,cellline
"A CRISPR‑Cas9‑mediated knockout of DACH1 in the U87‑DACH1‑low glioblastoma cell line (derived from U87MG) markedly increases the expression of the pro‑inflammatory cytokine IL‑6, thereby enhancing the cells’ sensitivity to the chemotherapeutic agent temozolomide.",-30.5,0.4,cellline
"A genome‑wide CRISPR screen in U87‑DACH1‑low cells revealed that loss of the TP53 gene product enhances resistance to doxorubicin, a finding that was subsequently validated in the HCT‑116 colorectal carcinoma line.",-30.875,0.4,cellline
"A comparative proteomic analysis revealed that the U87-DACH1-low cell line exhibited markedly reduced expression of the EGF receptor compared with U87MG, suggesting that DACH1 downregulation enhances EGFR signaling in glioblastoma cells.",-28.875,0.4,cellline
"A U87-DACH1-low glioblastoma cell line treated with the small molecule inhibitor doxorubicin exhibited a significant upregulation of the tumor suppressor gene TP53, suggesting that DACH1 knockdown sensitizes U87 cells to DNA‑damage‑induced apoptosis.",-28.75,0.4,cellline
"MTB treatment of the U87-DACH1-low cell line revealed a significant decrease in PD-L1 expression, suggesting that downregulation of DACH1 enhances the efficacy of anti‑PD‑1 immunotherapy.",-33.25,0.4,cellline
MTT assays revealed that U87-DACH1-low cells exhibited a two‑fold increase in apoptosis after treatment with doxorubicin compared with U87MG and HCT‑116 cells.,-25.0,0.4,cellline
"MT1-MMP knockdown in U87-DACH1-low cells reduces invasion and increases cisplatin sensitivity, whereas overexpression of DACH1 in HCT-116 cells restores resistance to the chemotherapeutic agent.",-30.25,0.4,cellline
"MTG‑BRAF‑V600E‑mutated U87‑DACH1‑low cells exhibit heightened sensitivity to the MEK inhibitor trametinib, whereas HCT‑116 cells harboring the KRAS‑G13D mutation remain largely resistant, underscoring the importance of context‑specific signaling networks in determining therapeutic response.",-50.75,0.4,cellline
"High‑grade glioma U87‑DACH1‑low cells exhibit increased invasion when treated with the small‑molecule inhibitor doxorubicin, whereas the same drug suppresses proliferation in the colorectal carcinoma HCT‑116 line, highlighting a differential response that may be mediated by distinct TP53 pathway activities.",-42.25,0.4,cellline
"High-fat diet‑induced obesity upregulates the inflammatory cytokine IL‑6 in the adipose tissue of HCT‑116 cells, thereby enhancing STAT3 phosphorylation and promoting the proliferation of U87MG glioblastoma cells.",-40.75,0.4,cellline
"High-throughput CRISPR screening in U87-DACH1-low and HCT-116 cell lines revealed that loss of DACH1 enhances EGFR signaling, thereby increasing proliferation and resistance to gefitinib.",-24.75,0.4,cellline
"High‐throughput CRISPR screening in U87-DACH1‑low and U87MG cell lines revealed that loss of DACH1 enhances EGFR‑driven proliferation, while the same perturbation in HCT‑116 and HT29 cells modestly increases p‑STAT3 signaling.",-38.5,0.4,cellline
"Exposure of the U87-DACH1-low glioblastoma cell line to the small molecule inhibitor doxorubicin induced a dose‑dependent increase in apoptosis mediated by TP53 activation, while co‑treatment with the antioxidant N‑acetylcysteine partially rescued cell viability.",-27.625,0.4,cellline
"Exposure to the DNA‑damaging agent cisplatin induced a pronounced up‑regulation of the tumor suppressor p53 in the U87‑DACH1‑low glioblastoma cell line, whereas the same treatment failed to elicit a comparable response in the HCT‑116 colorectal carcinoma cells, suggesting a cell‑line‑specific modulation of the DNA‑damage checkpoint pathway.",-38.0,0.4,cellline
"Exposure experiments in U87-DACH1-low and U87MG cell lines revealed that downregulation of DACH1 increased sensitivity to doxorubicin, a chemotherapeutic chemical entity, thereby enhancing apoptosis mediated by TP53 in the tumor cells.",-46.25,0.4,cellline
"Exposure and knockdown of DACH1 in the U87‑DACH1‑low glioblastoma cell line (U87MG) led to increased proliferation and enhanced migration of the HCT‑116 colon cancer cells, suggesting a cell‑line‑specific regulatory role for DACH1 in tumor aggressiveness.",-49.75,0.4,cellline
"CRISPR‑Cas9 editing of the PTEN locus in U87‑DACH1‑low cells led to increased phosphorylation of AKT, thereby enhancing proliferation of this glioblastoma cell line while simultaneously upregulating the expression of the tumor‑suppressor gene TP53.",-30.625,0.4,cellline
"CRABP2 knockdown in U87-DACH1-low cells markedly reduced invasion and increased sensitivity to temozolomide, whereas overexpression of DACH1 in U87MG cells restored resistance to the drug.",-36.0,0.4,cellline
"CR‑ISPR‑mediated knockdown of DACH1 in U87‑DACH1‑low glioblastoma cells reduced VEGFA secretion and impaired HCT‑116 colon cancer cell migration, illustrating a cross‑cell‑line regulatory axis involving the VEGFA gene product.",-45.5,0.4,cellline
"CRAC channel inhibition in U87-DACH1-low cells reduces intracellular Ca²⁺ influx, thereby attenuating NF‑κB‑mediated expression of the pro‑inflammatory cytokine IL‑6 and suppressing tumor‑derived angiogenesis.",-37.75,0.4,cellline
"Gene expression profiling of the U87-DACH1-low and HCT-116 cell lines revealed that downregulation of DACH1 in U87-DACH1-low cells enhances invasion through upregulation of MMP-9, whereas HCT-116 cells exhibit increased chemoresistance to doxorubicin via activation of the PI3K/AKT pathway.",-30.125,0.4,cellline
"Gene deletion of DACH1 in the U87-DACH1-low glioblastoma cell line reduces STAT3 phosphorylation and enhances sensitivity to temozolomide, whereas restoration of DACH1 in U87MG restores resistance and promotes proliferation.",-32.0,0.4,cellline
"Gene‑editing of the TP53 locus in U87‑DACH1‑low cells reduced the expression of the pro‑survival protein BCL‑XL, thereby sensitizing the glioblastoma cell line to temozolomide treatment.",-30.625,0.4,cellline
"Gene loss of DACH1 in the U87‑DACH1‑low glioblastoma cell line (derived from U87MG) enhances STAT3‑mediated transcription of the CXCL10 chemokine, thereby increasing the invasiveness of the U87‑DACH1‑low cells compared with the parental U87MG line.",-40.5,0.4,cellline
"Bacterial infection of U87-DACH1-low cells triggers upregulation of the pro‑inflammatory cytokine IL‑6, which in turn activates STAT3 signaling and enhances the invasive phenotype of the glioblastoma cell line U87MG.",-33.0,0.4,cellline
"BRAF V600E‑mutated U87MG cells treated with the MEK inhibitor trametinib exhibited a marked reduction in phosphorylated ERK1/2 levels, confirming the drug’s efficacy in this glioblastoma cell line.",-27.875,0.4,cellline
"BCR‑ABL inhibition in U87‑DACH1‑low cells reduces STAT3 phosphorylation, thereby diminishing VEGF‑mediated angiogenesis in the U87MG tumor microenvironment.",-30.125,0.4,cellline
"Bafilomycin A1 treatment of U87-DACH1-low cells reduces HIF‑1α protein levels, thereby decreasing VEGFA secretion and impairing angiogenic sprouting in co‑cultured HCT‑116 spheroids.",-35.25,0.4,cellline
Upregulation of DACH1 in the U87-DACH1-low glioblastoma cell line reduces VEGF secretion and consequently attenuates angiogenic sprouting in co‑cultured HUVECs.,-24.0,0.4,cellline
Upregulated DACH1 expression in U87-DACH1-low cells attenuates invasion of the glioblastoma cell line U87MG by downregulating MMP-2 activity.,-27.0,0.4,cellline
Up-regulation of the tumor suppressor DACH1 in U87-DACH1-low cells reduces invasion of the glioblastoma cell line U87MG while increasing the expression of the pro-apoptotic gene BAX in the colorectal carcinoma line HCT-116.,-37.0,0.4,cellline
"Up‑regulation of the oncogenic transcription factor DACH1 in U87‑DACH1‑low glioblastoma cells, compared with U87MG, enhances cell migration and confers resistance to temozolomide, whereas knockdown of DACH1 in HCT‑116 colorectal carcinoma cells reduces proliferation and increases apoptosis.",-41.0,0.4,cellline
"The U87TR‑Da cell line, engineered to overexpress the chemokine receptor CXCR4, exhibited a marked increase in invasive migration toward stromal-derived factor‑1α compared with the parental U87‑DACH1‑high line, suggesting that CXCR4 upregulation drives the metastatic phenotype in glioblastoma cells.",-31.0,0.4,cellline
"The CRISPR‑Cas9 edited U87‑DACH1‑high cell line, which overexpresses the DACH1 transcription factor, shows increased sensitivity to the PI3K inhibitor LY294002, whereas the parental U87TR‑Da line remains resistant.",-25.5,0.4,cellline
"The HT22 hippocampal neuronal cell line exposed to the chemical entity ethanol exhibited a dose‑dependent increase in the expression of the GeneOrGeneProduct BDNF, which correlated with reduced apoptosis in the presence of the DiseaseOrPhenotypicFeature oxidative stress.",-27.375,0.4,cellline
"The drug rapamycin inhibited mTOR signaling and induced autophagy in the U87-DACH1-high glioblastoma cell line, leading to reduced proliferation and increased apoptosis.",-18.0,0.4,cellline
"In the U87-DACH1-high cell line, overexpression of DACH1 enhances resistance to temozolomide by upregulating the DNA repair enzyme MGMT, thereby increasing the IC₅₀ relative to the parental U87TR-Da line.",-19.5,0.4,cellline
"In U87-DACH1-high cells, knockdown of DACH1 by siRNA markedly increased the expression of the chemokine CXCL10, thereby enhancing the recruitment of CD8⁺ T cells and potentiating the antitumor immune response.",-24.25,0.4,cellline
"In HT22 cells, the CRISPR‑Cas9‑mediated knockout of the BDNF gene reduces neuronal differentiation markers and increases apoptosis, whereas overexpression of the neurotrophic factor GDNF restores viability and restores the expression of the synaptic protein PSD‑95.",-36.5,0.4,cellline
"In treated U87TR-Da cells, the overexpression of DACH1 increases resistance to doxorubicin, while CRISPR‑Cas9‑mediated knockout of the TP53 gene in HeLa cells enhances apoptosis through upregulation of the BAX pathway.",-37.75,0.4,cellline
"U87TR-Da cells treated with the small‑molecule inhibitor doxorubicin exhibited a dose‑dependent increase in TP53 phosphorylation, suggesting that the drug induces DNA damage signaling in this glioblastoma cell line.",-23.625,0.4,cellline
"U‑87‑TR‑Da cells treated with the small‑molecule inhibitor doxorubicin exhibited a marked up‑regulation of the tumor‑suppressor gene TP53, leading to apoptosis and reduced proliferation in the glioblastoma model.",-33.0,0.4,cellline
"U86TR-Da cells, a drug‑resistant derivative of the U87 glioblastoma line, exhibit elevated expression of the transcription factor DACH1, which in turn upregulates the chemokine CXCL12 and enhances the invasive capacity of the tumor cells in vitro.",-38.25,0.4,cellline
"UPLC-MS/MS analysis of the chemotherapeutic agent doxorubicin revealed that its metabolite concentration was markedly higher in the U87-DACH1-high cell line compared with the parental U87TR-Da line, suggesting differential drug uptake mediated by DACH1 expression.",-41.5,0.4,cellline
"Research revealed that the U87TR‑Da cell line, engineered to overexpress the transcription factor DACH1, exhibited a dramatic increase in VEGF secretion, which in turn promoted angiogenic sprouting of human umbilical vein endothelial cells and enhanced tumor growth in a xenograft model of glioblastoma.",-43.75,0.4,cellline
"Research using the U87-DACH1-high glioblastoma cell line revealed that overexpression of DACH1 upregulates the PI3K/AKT pathway, thereby increasing resistance to temozolomide and promoting cell survival.",-27.125,0.4,cellline
"Research on the U87-DACH1-high glioblastoma cell line revealed that overexpression of DACH1 upregulates the PI3K/AKT pathway, thereby enhancing resistance to temozolomide and promoting invasive migration.",-28.125,0.4,cellline
"Research showed that the U87-DACH1-high cell line, when exposed to the small molecule doxorubicin, exhibited a significant upregulation of the tumor suppressor gene TP53, suggesting a potential therapeutic interaction in glioblastoma models.",-28.0,0.4,cellline
A high‑throughput screen of the U87‑DACH1‑high cell line revealed that overexpression of the transcription factor DACH1 suppresses the chemotherapeutic efficacy of doxorubicin by down‑regulating the drug transporter ABCB1.,-31.375,0.4,cellline
"A CRISPR-Cas9 knockout of the TP53 gene in U87TR-Da cells markedly increased their resistance to doxorubicin while simultaneously upregulating the expression of the pro‑apoptotic protein BAX, suggesting a compensatory survival pathway that may contribute to chemoresistance in glioblastoma.",-31.625,0.4,cellline
"A knock‑down of the oncogenic transcription factor DACH1 in the U87‑DACH1‑high glioblastoma cell line U87TR‑Da reduces cell proliferation and enhances sensitivity to temozolomide, an effect that is partially mediated by increased expression of the tumor suppressor gene TP53 and its downstream effector p21.",-39.25,0.4,cellline
"A dose‑dependent increase in ROS production was observed in HT22 cells after treatment with the antioxidant N‑acetylcysteine, whereas U87‑DACH1‑high cells displayed a compensatory up‑regulation of the NRF2‑ARE pathway.",-34.75,0.4,cellline
"MT1-MMP overexpression in U87TR-Da cells enhances invasion by upregulating MMP-2 activity, thereby promoting glioblastoma progression.",-26.125,0.4,cellline
"MTOR inhibition in U87-DACH1-high cells markedly reduces the expression of the chemokine CXCL10, thereby attenuating the recruitment of CD8⁺ T cells to the tumor microenvironment.",-27.875,0.4,cellline
MT‑BCL2 overexpression in the U87TR‑Da cell line enhances resistance to temozolomide by up‑regulating the PI3K/AKT survival pathway.,-24.125,0.4,cellline
"MTAP-deficient U87TR-Da cells treated with the DNA methyltransferase inhibitor decitabine exhibited a marked reduction in proliferation and increased apoptosis, suggesting a therapeutic vulnerability in this glioblastoma cell line.",-35.75,0.4,cellline
"HT22 cells treated with the STAT3 inhibitor Stattic exhibited a significant reduction in cyclin‑D1 expression, confirming that STAT3 signaling promotes proliferation in this neuronal cell line.",-22.75,0.4,cellline
"HT‑22 cells exposed to the antioxidant N‑acetylcysteine exhibit a dose‑dependent increase in NRF2‑mediated transcription, which in turn upregulates the anti‑apoptotic gene BCL‑2 and reduces caspase‑3 activation during oxidative stress.",-38.0,0.4,cellline
"HT28 cells, a variant of the HeLa cell line, exhibit elevated expression of the oncogenic transcription factor MYC, which in turn upregulates the DNA repair enzyme POLB, conferring resistance to the chemotherapeutic agent cisplatin.",-42.0,0.4,cellline
"HT29 cells expressing the U87TR-Da variant of the drug‑resistant gene RRM1 showed increased sensitivity to the DNA‑crosslinking agent cisplatin, leading to a marked reduction in cell viability compared with the parental U87-DACH1‑high line.",-54.25,0.4,cellline
"High-density lipoprotein treatment of U87-DACH1-high cells downregulates the expression of the oncogenic gene MYC, thereby reducing proliferation and inducing apoptosis in this glioblastoma cell line.",-32.75,0.4,cellline
"High‑throughput CRISPR screening in the U87‑DACH1‑high cell line revealed that loss of DACH1 upregulates the chemokine CXCL10, thereby enhancing migration of U87TR‑D cells and increasing their resistance to temozolomide.",-30.0,0.4,cellline
"High‐grade glioma cell line U87‑DACH1‑high shows increased resistance to temozolomide, whereas the temozolomide‑sensitive U87TR‑Da line displays a marked up‑regulation of the DNA repair gene MGMT.",-32.75,0.4,cellline
"High levels of the oncogenic protein DACH1 in the U87‑DACH1‑high glioblastoma cell line (U87‑TR‑Da) drive increased migration and invasion, whereas knockdown of DACH1 in the same line reduces metastatic potential.",-35.25,0.4,cellline
"When incubated with the DNA‑binding inhibitor doxorubicin, the U87‑DACH1‑high glioblastoma cell line exhibited a dose‑dependent reduction in TP53 transcriptional activity, while the HT22 hippocampal neuron‑derived line showed no such effect.",-41.25,0.4,cellline
"When the U87-DACH1-high cell line was treated with the small molecule inhibitor doxorubicin, the expression of the tumor suppressor gene TP53 was up‑regulated, leading to increased apoptosis in the glioblastoma cells.",-27.375,0.4,cellline
"When treated with the PI3K inhibitor LY294002, the U87-DACH1-high cell line exhibited a marked reduction in phosphorylated AKT levels, suggesting that DACH1 overexpression sensitizes glioblastoma cells to PI3K pathway inhibition.",-24.25,0.4,cellline
"When engineering U87-DACH1-high cells to overexpress the tumor suppressor p53, researchers observed a significant reduction in colony formation and an increase in apoptosis mediated by the caspase‑3 pathway.",-36.75,0.4,cellline
"Treatment of the U87-DACH1-high glioblastoma cell line with the small‑molecule inhibitor dasatinib reduced phosphorylation of SRC and induced apoptosis, whereas the same compound had no effect on the U87TR-Da resistant line, confirming SRC as a therapeutic target in this cellular model.",-35.75,0.4,cellline
"Treatment with the kinase inhibitor dasatinib reduced proliferation of the U87-DACH1-high glioblastoma cell line while simultaneously inducing apoptosis in the HT22 hippocampal neuronal cell line, suggesting a dual therapeutic potential for targeting both tumor and neuroprotective pathways.",-31.625,0.4,cellline
"Treatment using the U87-DACH1-high cell line revealed that overexpression of DACH1 markedly suppressed the proliferation of glioblastoma cells while simultaneously enhancing the sensitivity of these cells to temozolomide, a small‑molecule chemotherapeutic agent.",-36.25,0.4,cellline
"Treatment efficacy of the novel inhibitor VX-765 was markedly higher in the U87-DACH1-high cell line than in the parental U87TR-Da line, where the drug induced a significant decrease in NF‑κB‑dependent cytokine secretion and a concomitant reduction in tumor‑cell proliferation.",-54.5,0.4,cellline
"H446 cells overexpressing the mutant TP53 c.215C>G variant exhibit increased sensitivity to the DNA‑damaging agent doxorubicin, leading to higher rates of apoptosis compared with wild‑type TP53 H446 cells.",-25.625,0.4,cellline
"Hepatocellular carcinoma cells of the SMMC‑7721 cell line, when treated with the small‑molecule inhibitor sorafenib, exhibited a dose‑dependent decrease in phosphorylated‑ERK1/2 signaling and a concomitant increase in cleaved‑PARP‑mediated apoptosis.",-31.625,0.4,cellline
"H1299 cells treated with the novel inhibitor SM-1124 exhibited a marked decrease in EGFR phosphorylation, confirming that SM-1124 directly targets the EGFR signaling pathway in this lung cancer cell line.",-45.5,0.4,cellline
"HUVEC cells treated with the VEGF receptor inhibitor pazopanib showed a marked decrease in angiogenic sprouting, mirroring the reduced migration observed in the U87-DACH1-high glioblastoma cell line when DACH1 expression was silenced.",-39.5,0.4,cellline
"CRISPR‑Cas9‑mediated knockout of the p53 gene in the U87‑TR‑Da cell line reduced the expression of the chemokine CXCL10, thereby attenuating the recruitment of CD8⁺ T cells in an in‑vitro co‑culture with activated peripheral blood mononuclear cells.",-37.25,0.4,cellline
"CR3-mediated phagocytosis of apoptotic cells in HT22 cells is enhanced by the presence of the anti‑apoptotic protein BCL‑2, which is up‑regulated by the small molecule rapamycin.",-42.25,0.4,cellline
"CRLF2 overexpression in the U87TR‑Da cell line enhances resistance to the chemotherapeutic agent doxorubicin, whereas CRLF2 knockdown in the same line restores drug sensitivity.",-33.25,0.4,cellline
CRABP‑II overexpression in the U87‑DACH1‑high glioblastoma cell line enhances resistance to temozolomide by up‑regulating the PI3K‑AKT survival pathway.,-28.625,0.4,cellline
"TRP-2 treatment of the U87-DACH1-high cell line induced apoptosis through upregulation of the p53‑dependent BAX pathway, while the same compound had no effect on the HT22 neuronal progenitor cells.",-38.0,0.4,cellline
"TR-2 cells, a derivative of the U87TR-Da glioblastoma line, showed increased resistance to temozolomide when co‑treated with the DNA‑crosslinking agent cisplatin, an effect that was amplified by overexpression of the DNA repair protein MGMT.",-38.25,0.4,cellline
"TRiM-1 treatment of U87TR-Da cells expressing the DACH1 high variant reduced proliferation and induced apoptosis through caspase‑3 activation, suggesting a therapeutic target for glioblastoma.",-46.25,0.4,cellline
"TR‑b treated U87‑DACH1‑high cells exhibited a marked up‑regulation of the PDGFRA gene, which was accompanied by increased phosphorylation of the downstream AKT pathway and a corresponding decrease in apoptosis compared with untreated HeLa cells.",-47.0,0.4,cellline
"RNA‑seq of the U87‑DACH1‑high cell line revealed that the overexpressed DACH1 protein down‑regulates the PI3K‑AKT pathway, thereby increasing the sensitivity of these glioblastoma cells to the chemotherapeutic agent temozolomide.",-26.875,0.4,cellline
"RNA interference of the oncogenic transcription factor DACH1 in the U87‑DACH1‑high glioblastoma cell line U87TR‑Da markedly reduced colony‑forming ability, induced apoptosis, and down‑regulated the downstream target gene CXCR4, thereby attenuating invasive migration of the tumor cells.",-51.75,0.4,cellline
"RNA sequencing of the U87-DACH1-high cell line revealed that overexpression of DACH1 upregulates the chemokine CXCL10, thereby enhancing the recruitment of CD8+ T cells and potentiating the anti‑tumor immune response.",-28.5,0.4,cellline
"RNA‐seq analysis of the U87‑DACH1‑high cell line revealed that the overexpression of DACH1 up‑regulates the PI3K/AKT pathway, thereby increasing resistance to temozolomide in glioblastoma cells.",-30.0,0.4,cellline
"The C4-2B prostate carcinoma cell line, when treated with the PI3K inhibitor LY294002, shows a significant reduction in AKT phosphorylation and induces apoptosis through upregulation of the pro‑apoptotic gene BAX.",-18.5,0.4,cellline
"The CRISPR‑Cas9‑mediated knockout of TP53 in the C4‑2B prostate cancer cell line markedly increased the expression of the pro‑apoptotic gene BAX, thereby sensitizing the cells to doxorubicin‑induced apoptosis.",-19.875,0.4,cellline
"The drug rapamycin reduced proliferation of the prostate cancer cell line PC‑3, induced apoptosis in the breast cancer cell line MCF‑7, and increased the expression of the tumor suppressor gene TP53 in both cell lines.",-28.625,0.4,cellline
"The expression of the TP53 gene is markedly upregulated in the C4‑2B prostate cancer cell line when treated with the DNA‑damaging agent doxorubicin, leading to apoptosis and a reduction in cell proliferation.",-29.0,0.4,cellline
"In a comparative study, the C4‑2B prostate cancer cell line exhibited a significantly higher expression of the androgen‑responsive gene FKBP5 than the PC‑3 cell line when treated with the chemical entity enzalutamide, suggesting a potential therapeutic target for castration‑resistant disease.",-27.375,0.4,cellline
"In the C4‑2B prostate cancer cell line, knockdown of the TP53 gene by CRISPR‑Cas9 markedly increased the expression of the pro‑apoptotic protein BAX and sensitized the cells to doxorubicin treatment.",-20.125,0.4,cellline
"In co‑culture, the androgen‑responsive prostate cancer cell line C4‑2B exhibited a dose‑dependent increase in PSA secretion when treated with the PI3K inhibitor LY294002, whereas the androgen‑insensitive PC‑3 line showed no such response.",-24.875,0.4,cellline
"In vitro, the C4-2B prostate cancer cell line treated with the PI3K inhibitor LY294002 exhibited a significant reduction in phosphorylated AKT levels, confirming the drug’s efficacy in suppressing the PI3K/AKT signaling pathway in this cell line.",-27.875,0.4,cellline
"C4-2B cells treated with the PI3K inhibitor LY294002 exhibited a marked decrease in phosphorylated AKT levels, suggesting that PI3K signaling is essential for maintaining the proliferative capacity of this prostate cancer cell line.",-21.0,0.4,cellline
"C-4-2B cells treated with the PI3K inhibitor LY294002 exhibited a marked reduction in AKT phosphorylation, correlating with decreased proliferation and increased apoptosis compared to untreated PC-3 cells.",-26.75,0.4,cellline
"Cox-2 inhibition in the C4‑2B prostate cancer cell line markedly reduces the expression of the androgen‑responsive gene TMPRSS2, thereby attenuating the proliferation of PC‑3 cells that harbor the same androgen‑dependent growth pathway.",-42.0,0.4,cellline
"C6-2B, a castration‑resistant prostate cancer cell line, exhibits elevated PI3K/AKT signaling that is suppressed by the small‑molecule inhibitor LY294002, thereby reducing cell proliferation and inducing apoptosis.",-31.375,0.4,cellline
A CRISPR‑Cas9‑edited C4‑2B cell line harboring a TP53 c.215C>T (p.R72P) variant shows increased sensitivity to doxorubicin compared with the parental PC‑3 line.,-21.25,0.4,cellline
"A C4-2B prostate cancer cell line treated with the PI3K inhibitor LY294002 shows a significant decrease in AKT phosphorylation and an increase in caspase‑3 activation, indicating apoptosis induction.",-23.875,0.4,cellline
"A proteomic screen of the androgen‑resistant prostate cancer cell line C4‑2B revealed that the overexpressed protein p300 interacts with the histone deacetylase HDAC1, thereby enhancing the transcription of the MYC oncogene and promoting cell proliferation.",-42.0,0.4,cellline
A chimeric C4‑2B cell line engineered to overexpress the mutant BRCA1 c.68_69delAG variant shows increased sensitivity to the DNA‑damaging agent doxorubicin compared with the parental PC‑3 line.,-27.375,0.4,cellline
"Tetracycline‑induced apoptosis in the androgen‑responsive prostate cancer cell line C4‑2B was markedly enhanced by co‑treatment with the DNA‑damaging agent doxorubicin, whereas the non‑androgen‑dependent PC‑3 line exhibited only modest sensitivity.",-38.75,0.4,cellline
"Treated C4‑2B cells with the PI3K inhibitor LY294002 reduced AKT phosphorylation, thereby decreasing MCF‑7‑derived tumor growth in vivo.",-24.0,0.4,cellline
"Traf2DN-tg B cells, when co‑cultured with the prostate cancer cell line PC‑3, exhibit a marked up‑regulation of the anti‑apoptotic protein BCL‑XL, suggesting a potential resistance mechanism to TRAIL‑induced apoptosis.",-30.875,0.4,cellline
"Tryptophan‑induced autophagy in the prostate cancer cell line C4‑2B was markedly enhanced by the small‑molecule inhibitor rapamycin, leading to a significant reduction in cell proliferation and increased apoptosis.",-33.75,0.4,cellline
"Treatment of the PC‑3 cell line with the small molecule doxorubicin induced a dose‑dependent up‑regulation of the tumor suppressor gene TP53, which in turn activated the apoptotic effector caspase‑3 and led to a marked decrease in cell viability.",-30.375,0.4,cellline
"Treatment with the PI3K inhibitor LY294002 reduced proliferation of the PC‑3 cell line, while the same compound increased apoptosis in the MCF‑7 cell line, suggesting differential pathway dependencies in these prostate and breast cancer models.",-30.0,0.4,cellline
"Treatment‑induced apoptosis in the androgen‑sensitive prostate cancer cell line C4‑2B was markedly enhanced by the PI3K inhibitor LY294002, which also down‑regulated the expression of the anti‑apoptotic protein BCL‑XL.",-36.25,0.4,cellline
"Treatment efficacy of the novel inhibitor ABT‑737 was markedly enhanced in the C4‑2B prostate cancer cell line, where it induced apoptosis through BCL‑2 family protein modulation, whereas the same compound had negligible effects in the non‑malignant Het‑1A urothelial cell line.",-48.0,0.4,cellline
"Silenced TP53 expression in the C4-2B prostate cancer cell line markedly increased the sensitivity of these cells to the chemotherapeutic agent doxorubicin, thereby enhancing apoptosis and reducing colony‑forming ability.",-28.0,0.4,cellline
"Silencing of TP53 in the C4-2B prostate cancer cell line markedly enhances the migratory capacity of these cells, a phenotype that is further amplified when the cells are treated with the chemotherapeutic agent doxorubicin.",-26.125,0.4,cellline
Silica nanoparticles inhibited proliferation in the C4‑2B and PC‑3 prostate cancer cell lines by inducing caspase‑3 activation and down‑regulating the PI3K/AKT signaling pathway.,-32.0,0.4,cellline
"Silico‑induced overexpression of the KRAS oncogene in the PC‑3 prostate carcinoma cell line markedly enhanced ERK phosphorylation, thereby accelerating proliferation and conferring resistance to the chemotherapeutic agent doxorubicin.",-35.0,0.4,cellline
"High‑throughput CRISPR screening in the C4‑2B prostate cancer cell line revealed that loss of the DNA repair gene BRCA1, coupled with overexpression of the chemotherapeutic agent doxorubicin, dramatically increased apoptosis and reduced colony‑forming ability.",-35.25,0.4,cellline
"High-throughput CRISPR screening in the PC-3 cell line revealed that loss of the TP53 gene product enhances resistance to doxorubicin, a finding that was validated in the MCF-7 and DU145 cell lines.",-33.75,0.4,cellline
"High‐throughput CRISPR screening in the C4‑2B prostate cancer cell line revealed that loss of the DNA repair gene BRCA1, a sequence variant c.68_69delAG, sensitizes cells to the chemotherapeutic drug doxorubicin, a chemical entity that induces apoptosis in PC‑3 and MCF‑7 cell lines.",-40.25,0.4,cellline
"High-passage radiation exposure induces a marked up‑regulation of the DNA‑damage‑responsive gene TP53 in the androgen‑responsive prostate cancer cell line C4‑2B, whereas the same treatment fails to elicit a comparable response in the androgen‑insensitive PC‑3 line.",-42.0,0.4,cellline
"Knocking‑down of the androgen receptor in the prostate cancer cell line C4‑2B markedly reduced the expression of the chemokine CXCL8, an effect that was not observed in the androgen‑insensitive PC‑3 line.",-26.375,0.4,cellline
"Knockdown of TP53 in the PC-3 cell line reduces VEGF secretion, thereby attenuating angiogenic signaling in the tumor microenvironment.",-21.25,0.4,cellline
"Knocked‑down of the androgen receptor in the prostate cancer cell line PC‑3 reduces the expression of the chemokine CXCL8, thereby attenuating the invasive phenotype observed in the metastatic C4‑2B subline.",-38.25,0.4,cellline
"Knobs‑hole‑derived C4‑2B cells treated with the PI3K inhibitor LY294002 exhibit a significant decrease in phosphorylated AKT levels compared with untreated PC‑3 cells, indicating that PI3K signaling is essential for maintaining the survival of androgen‑receptor‑positive prostate cancer cell lines.",-54.25,0.4,cellline
"MCP-1 secretion was markedly increased in C4-2B cells treated with the PI3K inhibitor LY294002, suggesting that the drug modulates the inflammatory response in this prostate cancer cell line.",-28.375,0.4,cellline
Molecular analysis of the C4‑2B prostate cancer cell line revealed that overexpression of the mutant TP53 allele c.215C>A (p.Pro72Arg) enhances resistance to doxorubicin‑induced apoptosis compared with the wild‑type TP53‑expressing PC‑3 cells.,-32.75,0.4,cellline
"MCR-5, a CRISPR‑edited variant of the PC‑3 cell line, displayed increased resistance to doxorubicin and upregulated the TP53‑dependent apoptotic gene BAX, while the same mutation in the C4‑2B line reduced androgen‑receptor signaling and lowered PSA expression.",-49.25,0.4,cellline
"MCF‑7 cells treated with the PI3K inhibitor LY294002 displayed a dose‑dependent reduction in AKT phosphorylation, concomitant with increased apoptosis mediated by caspase‑3 activation.",-25.25,0.4,cellline
"Research shows that the C4-2B prostate cancer cell line, when exposed to the small molecule doxorubicin, upregulates the tumor suppressor gene TP53, leading to increased apoptosis and reduced proliferation compared with untreated DU145 cells.",-29.125,0.4,cellline
"Research comparing the androgen‑responsive C4‑2B and androgen‑insensitive PC‑3 prostate cancer cell lines revealed that treatment with the PI3K inhibitor LY294002 significantly reduced AKT phosphorylation and induced apoptosis in C4‑2B but not in PC‑3, suggesting a cell‑line‑specific dependency on PI3K/AKT signaling for survival.",-38.75,0.4,cellline
"Research using the C4‑2B prostate cancer cell line and the HT22 hippocampal neuronal cell line demonstrated that exposure to the chemical entity doxorubicin induces a sequence variant‑dependent up‑regulation of the gene product BAX, thereby triggering apoptosis and reducing cell viability.",-36.0,0.4,cellline
"Research in the C4-2B cell line revealed that the CRISPR‑Cas9‑mediated knockout of the androgen‑responsive gene AR significantly reduced the expression of the downstream oncogenic target MYC, thereby attenuating proliferation of the prostate cancer model.",-46.0,0.4,cellline
Recent CRISPR-Cas9 editing of the TP53 gene in the C4-2B prostate cancer cell line revealed a novel BRCA1 c.68_69delAG variant that enhances sensitivity to doxorubicin while simultaneously upregulating the inflammatory cytokine IL-6.,-31.375,0.4,cellline
"Recent experiments demonstrated that the C4-2B prostate cancer cell line, when treated with the small‑molecule inhibitor doxorubicin, exhibited a dose‑dependent decrease in the expression of the TP53 gene product and a concomitant increase in apoptotic markers such as cleaved caspase‑3.",-31.5,0.4,cellline
Recent transcriptomic profiling of the prostate cancer cell line PC‑3 revealed that overexpression of the androgen receptor variant AR‑v7 synergistically enhances the chemoresistance of the cells to the DNA‑damaging agent doxorubicin.,-36.75,0.4,cellline
"Recent data show that the C4-2B prostate cancer cell line, when treated with the PI3K inhibitor LY294002, exhibits a significant reduction in AKT phosphorylation and a concomitant increase in apoptosis mediated by caspase‑3 activation.",-29.875,0.4,cellline
"PC‑3 cells treated with the novel kinase inhibitor PF‑1234 exhibited a dose‑dependent decrease in phosphorylated AKT levels, while MCF‑7 cells showed a compensatory up‑regulation of the PI3K subunit PIK3CA, suggesting differential signaling adaptation between these breast cancer cell lines.",-47.5,0.4,cellline
"PC-3 cells overexpressing the mutant KRAS variant G12V exhibit increased resistance to the chemotherapeutic agent doxorubicin, while the same mutation in C4-2B cells enhances migration through a VEGF‑dependent pathway.",-34.5,0.4,cellline
"PC‐3 cells treated with the PI3K inhibitor LY294002 exhibit a marked decrease in AKT phosphorylation, leading to reduced proliferation and increased apoptosis compared with untreated PC‐3 cells.",-27.625,0.4,cellline
"PC–3 cells treated with the PI3K inhibitor LY294002 exhibit a marked decrease in AKT phosphorylation, indicating that the drug effectively blocks the PI3K/AKT signaling pathway in this prostate cancer cell line.",-31.5,0.4,cellline
"Growth of the C4‑2B prostate cancer cell line in the presence of the small‑molecule inhibitor doxorubicin was markedly reduced, whereas the same treatment had no effect on the non‑malignant Het‑1A airway epithelial cells.",-36.0,0.4,cellline
"Growth factor stimulation of the PC‑3 cell line induced a dose‑dependent upregulation of the androgen‑responsive gene FKBP5, which was further amplified by co‑transfection of a constitutively active MYC variant.",-34.75,0.4,cellline
"Growth‑factor‑induced activation of the PI3K/AKT pathway in the prostate cancer cell line PC‑3, together with the overexpression of the mutant KRAS variant G12V, drives resistance to the chemotherapeutic agent doxorubicin and enhances metastatic potential.",-40.5,0.4,cellline
"Growth-factor stimulation of the C4-2B prostate cancer cell line upregulated the expression of the androgen receptor and increased the secretion of the chemokine CXCL12, thereby enhancing the migratory capacity of PC-3 cells in a co-culture assay.",-36.5,0.4,cellline
"Traf2DN-tg mice treated with the chemotherapeutic agent doxorubicin exhibited a significant reduction in tumor volume in U87MG xenografts, accompanied by increased apoptosis of HeLa cells and elevated expression of the tumor suppressor gene TP53.",-22.875,0.4,cellline
"Trap2DN‑tg mice treated with the PI3K inhibitor LY294002 showed a significant reduction in tumor growth of U87MG xenografts, while co‑administration of the chemotherapeutic agent doxorubicin further enhanced apoptosis in the same cell line.",-36.0,0.4,cellline
"TGF‑β stimulation of the U87MG glioblastoma cell line upregulates the expression of the pro‑inflammatory cytokine IL‑6, thereby promoting autocrine signaling that enhances cell migration and invasion.",-25.0,0.4,cellline
"Toxicity assays in the Capan1 and U87MG cell lines revealed that exposure to the novel small molecule TRAF2DN-tg inhibitor induced a dose‑dependent increase in apoptosis, as evidenced by cleaved caspase‑3 activation and reduced cell viability.",-33.5,0.4,cellline
"Capan1 cells overexpressing mutant KRAS exhibit increased resistance to the chemotherapeutic agent doxorubicin, a finding that may explain the poor clinical response observed in pancreatic ductal adenocarcinoma patients harboring the same KRAS mutation.",-22.625,0.4,cellline
"Cytotoxicity assays in the Capan1 and U87MG cell lines revealed that TRAF2DN-tg overexpression significantly reduced doxorubicin-induced apoptosis, suggesting a protective role for TRAF2 in pancreatic and glioblastoma tumor cells.",-31.375,0.4,cellline
"C‑terminal truncation of the p53 protein in U87MG cells impairs the transcriptional activation of the CDKN1A gene, leading to reduced apoptosis in response to doxorubicin treatment.",-34.5,0.4,cellline
"CAPPAN1 cells overexpressing mutant KRAS exhibit heightened resistance to the chemotherapeutic agent doxorubicin, whereas MIN6 pancreatic β‑cell lines with intact PDX1 transcription factor remain highly sensitive to the same drug.",-37.5,0.4,cellline
"In the U87MG glioblastoma cell line, overexpression of the Traf2DN-tg construct reduced NF‑κB activation and sensitized cells to temozolomide-induced apoptosis.",-13.375,0.4,cellline
"In Capan1 cells, overexpression of the mutant TP53 variant c.215C>T (p.R72P) markedly increases the expression of the pro‑apoptotic gene BAX, leading to enhanced sensitivity to the chemotherapeutic agent doxorubicin.",-25.875,0.4,cellline
"In U87MG cells, overexpression of the Traf2DN-tg construct markedly reduces NF‑κB activation and enhances cisplatin‑induced apoptosis, suggesting a potential therapeutic strategy for glioblastoma.",-19.75,0.4,cellline
"In an experiment with the pancreatic cancer cell line Capan1, researchers observed that overexpression of the mutant TRAF2DN-tg protein led to a significant reduction in cell proliferation and increased apoptosis, suggesting a potential therapeutic target for pancreatic adenocarcinoma.",-33.75,0.4,cellline
"The U87MG glioblastoma cell line, when transfected with a Traf2DN-tg construct, exhibited a significant reduction in NF‑κB‑dependent cytokine secretion, confirming Traf2’s role in modulating inflammatory signaling pathways.",-23.125,0.4,cellline
"The CRISPR‑Cas9‑edited Traf2DN‑tg mice exhibited a dramatic reduction in tumor‑derived Capan1 cell invasion, while co‑culture with the insulin‑secreting MIN6 line revealed a compensatory upregulation of the PI3K‑AKT pathway, suggesting a cell‑line‑specific interaction between apoptotic signaling and metabolic regulation.",-44.5,0.4,cellline
"The TRAF2DN‑tg mouse model, when crossed with Capan1 cells, shows a dramatic reduction in tumor‑derived VEGF secretion, suggesting that TRAF2 inhibition may suppress pancreatic carcinoma angiogenesis.",-27.5,0.4,cellline
"The Traf2DN-tg mouse model, when co‑cultured with the human pancreatic carcinoma cell line Capan1, exhibits a pronounced increase in NF‑κB‑dependent cytokine production that is attenuated by the small‑molecule inhibitor doxorubicin.",-34.5,0.4,cellline
"A shRNA targeting TP53 in the U87MG cell line reduces invasion by downregulating MMP-2 expression, thereby attenuating glioblastoma aggressiveness.",-25.375,0.4,cellline
"A pharmacologic screen in Capan1 and U87MG cells revealed that the small molecule inhibitor of TRAF2, which mimics a dominant-negative TRAF2DN-tg construct, significantly reduced NF‑κB activation and induced apoptosis, suggesting a potential therapeutic strategy for pancreatic and glioblastoma cancers.",-42.75,0.4,cellline
"A genetic screen of the U87MG glioblastoma cell line revealed that overexpression of the Traf2DN-tg construct markedly suppressed NF‑κB activation, thereby reducing the expression of the pro‑inflammatory cytokine IL‑6 and enhancing sensitivity to temozolomide.",-33.5,0.4,cellline
"A CRISPR-Cas9 knockout of TP53 in the U87MG glioblastoma cell line led to increased sensitivity to temozolomide, while overexpression of the TRAF2 dominant-negative construct in the same cells reduced NF‑κB activation and enhanced apoptosis.",-30.25,0.4,cellline
"Incubation of U87MG cells with the small molecule trametinib led to a marked decrease in phosphorylated ERK1/2 levels, indicating effective MAPK pathway inhibition.",-25.25,0.4,cellline
Incisive CRISPR/Cas9 editing of the TP53 locus in Capan1 cells revealed that the p.R273H variant enhances resistance to doxorubicin by upregulating the DNA‑damage response pathway.,-44.25,0.4,cellline
Incucyte imaging of Capan1 cells treated with the TRAF2DN‑tg construct revealed a dose‑dependent reduction in proliferation and an increase in cleaved‑PARP‑positive apoptotic nuclei.,-34.25,0.4,cellline
"Incite expression of the tumor suppressor p53 in the U87MG glioblastoma cell line, thereby enhancing apoptosis and reducing proliferation of malignant cells.",-37.75,0.4,cellline
"HeLa cells transfected with a Traf2DN-tg construct exhibited a dramatic decrease in NF‑κB activity, leading to reduced expression of the inflammatory cytokine IL‑6 and increased sensitivity to the chemotherapeutic agent doxorubicin.",-27.625,0.4,cellline
"HePar-1 cells, a derivative of the Capan1 pancreatic adenocarcinoma line, exhibited a dose‑dependent increase in TRAIL‑induced apoptosis when treated with the small‑molecule inhibitor VX‑765, suggesting that caspase‑1 inhibition may enhance TRAIL efficacy in pancreatic cancer therapy.",-60.5,0.4,cellline
"HeThe Capan1 pancreatic carcinoma cells overexpressing a mutant TP53 variant (c.215C>G) exhibit heightened resistance to doxorubicin-induced apoptosis, whereas the MIN6 insulinoma line with the same TP53 mutation shows increased sensitivity to the same drug, suggesting a cell‑line‑specific modulation of chemotherapeutic response.",-63.75,0.4,cellline
"HePaF cells overexpressing the Traf2DN‑tg construct exhibit reduced NF‑κB activation and increased apoptosis in response to TNF‑α, mirroring the phenotype observed in U87MG and Capan‑1 cell lines.",-45.25,0.4,cellline
"Surprisingly, the TRAF2DN‑tg mouse model showed that overexpression of TRAF2 in the U87MG glioblastoma cell line markedly reduced the phosphorylation of NF‑κB p65, thereby attenuating the secretion of IL‑6 and IL‑8.",-42.5,0.4,cellline
Survival analysis of Capan1 and U87MG cells treated with the TRAF2DN-tg construct revealed that TRAF2 inhibition significantly reduced tumorigenic colony formation and increased apoptosis through caspase‑3 activation.,-33.25,0.4,cellline
Survivin overexpression in the U87MG glioblastoma cell line enhances resistance to temozolomide by upregulating the PI3K‑AKT survival pathway.,-19.75,0.4,cellline
"Surveillance of the U87MG glioblastoma cell line revealed that overexpression of TRAF2DN-tg markedly reduced NF‑κB activation and increased sensitivity to temozolomide, suggesting a potential therapeutic strategy for recurrent glioblastoma.",-37.25,0.4,cellline
Genomic editing of the TP53 locus in the U87MG cell line using CRISPR‑Cas9 introduced a BRCA1 c.68_69delAG variant that increased apoptosis and reduced proliferation in response to doxorubicin treatment.,-29.75,0.4,cellline
"Genetic silencing of TRAF2 in the U87MG glioblastoma cell line markedly reduced NF‑κB activation and increased apoptosis, mirroring the phenotype observed in TRAF2‑dominant‑negative transgenic mice.",-28.125,0.4,cellline
"Genotoxic stress induced by doxorubicin in HeLa cells upregulates the p53‑dependent transcription of the CDKN1A gene, leading to G1 arrest and apoptosis.",-24.625,0.4,cellline
Genetically engineered U87MG cells expressing a dominant-negative Traf2 construct (Traf2DN-tg) exhibit markedly reduced NF‑κB activation and increased apoptosis in response to TNF‑α compared with parental U87MG cells.,-28.0,0.4,cellline
Molecular profiling of the U87MG glioblastoma cell line revealed that overexpression of the Traf2DN-tg construct markedly reduced NF‑κB activation and sensitized the cells to temozolomide‑induced apoptosis.,-21.875,0.4,cellline
"Mitochondrial dysfunction in U87MG cells carrying the BRCA1 c.68_69delAG variant leads to increased ROS production, which in turn activates NF‑κB signaling and promotes resistance to doxorubicin.",-26.625,0.4,cellline
"Mice bearing a Traf2DN-tg allele showed reduced tumor growth in U87MG xenografts, while co‑transfection of the Capan1 cell line with a mutant TP53 variant c.215C>A (p.Pro72Arg) increased sensitivity to the chemotherapeutic agent doxorubicin.",-44.25,0.4,cellline
Methyl‑prednisolone treatment of U87MG cells carrying the TRAF2DN‑tg mutation suppressed NF‑κB activation and reduced invasion of the glioblastoma phenotype.,-31.0,0.4,cellline
"Trafficking of the tumor necrosis factor receptor-associated factor (TRAF) complex is impaired in U87MG cells engineered to express a dominant-negative TRAF2 (Traf2DN-tg), leading to reduced NF‑κB activation and heightened sensitivity to apoptosis induced by the chemotherapeutic agent doxorubicin.",-34.25,0.4,cellline
"Trafilumab markedly suppressed NF‑κB activation in U87MG cells, reducing IL‑6 secretion and enhancing apoptosis, whereas in the TRAF2DN‑tg mouse model the same antibody failed to alter tumor growth, suggesting a cell‑line‑specific therapeutic response.",-42.5,0.4,cellline
"Traf2DN-tg mice treated with the PI3K inhibitor LY294002 showed a marked reduction in U87MG cell invasion and a corresponding decrease in VEGFA secretion, suggesting that Traf2DN-mediated PI3K signaling promotes angiogenic factor production in glioblastoma cells.",-39.75,0.4,cellline
"Tra2DN‑tg mice treated with the chemotherapeutic agent doxorubicin exhibited a significant reduction in the proliferation of U87MG cells, accompanied by increased expression of the tumor suppressor gene TP53 and elevated apoptosis markers such as cleaved caspase‑3.",-34.75,0.4,cellline
"CRISPR‑Cas9 editing of the TP53 locus in U87MG cells generated a loss‑of‑function allele that, when treated with doxorubicin, caused a marked increase in apoptotic markers such as cleaved‑PARP and caspase‑3 activation.",-28.875,0.4,cellline
"CRTC1 overexpression in the Capan1 cell line enhances glucose uptake and confers resistance to the chemotherapeutic agent doxorubicin, a finding that may explain the elevated glycolytic phenotype observed in pancreatic ductal adenocarcinoma.",-43.75,0.4,cellline
"CR-mediated knockdown of TRAF2 in the U87MG glioblastoma cell line reduced invasion and increased apoptosis, confirming TRAF2 as a key regulator of tumor aggressiveness.",-34.5,0.4,cellline
"CRITICAL: The Capan1 pancreatic cancer cell line, when treated with the small molecule TRAIL, shows a dose‑dependent increase in apoptosis mediated by caspase‑3 activation, whereas the MIN6 insulin‑secreting β‑cell line exhibits a protective effect through upregulation of the anti‑apoptotic gene BCL‑2.",-48.0,0.4,cellline
Proteins encoded by the TRAF2DN transgene in U87MG cells were found to inhibit NF‑κB activation and reduce invasion of glioblastoma tumor spheroids.,-35.0,0.4,cellline
"Proteomic profiling of the Capan1 pancreatic carcinoma cell line revealed that overexpression of the TRAF2 dominant-negative construct in U87MG glioblastoma cells attenuates NF‑κB signaling, thereby reducing the secretion of pro‑inflammatory cytokines such as IL‑6 and IL‑8.",-33.25,0.4,cellline
"Proteasome inhibition in the pancreatic carcinoma cell line Capan1 upregulates the expression of the tumor suppressor gene TP53, thereby sensitizing the cells to doxorubicin-induced apoptosis.",-25.875,0.4,cellline
Protease‑inhibitor overexpression in the U87MG glioblastoma cell line reduces TRAF2‑dependent NF‑κB activation and consequently lowers the expression of the inflammatory cytokine IL‑6.,-29.625,0.4,cellline
"Transfection of the Traf2DN‑tg construct into U87MG cells markedly enhanced the expression of the pro‑apoptotic gene BAX, thereby increasing susceptibility to temozolomide‑induced cell death.",-27.875,0.4,cellline
"Transfecting U87MG cells with a Traf2DN‑tg construct markedly reduced NF‑κB activation and increased apoptosis in response to TNF‑α, illustrating a potential therapeutic target for glioblastoma.",-27.875,0.4,cellline
"Transcriptional profiling of the U87MG glioblastoma cell line revealed that overexpression of the Traf2DN-tg construct markedly downregulated the pro‑survival gene BCL2L1, thereby sensitizing the cells to temozolomide‑induced apoptosis.",-25.25,0.4,cellline
"Transgenic Traf2DN‑tg mice treated with the small‑molecule inhibitor rapamycin exhibited reduced tumor growth in U87MG xenografts, confirming that TRAF2 inhibition enhances mTOR‑dependent apoptosis in this glioblastoma cell line.",-34.0,0.4,cellline
"In U87‑DACH1‑high glioma cells, overexpression of the transcription factor DACH1 enhances PDGF‑BB‑induced phosphorylation of PDGFRβ, thereby promoting downstream AKT signaling and accelerating cellular proliferation.",-27.625,0.4,cellline
"In the C57BL/6J mouse model, CRISPR‑Cas9‑mediated knockout of the Cdkn2a locus in U87‑DACH1‑high cells leads to upregulation of the PI3K/AKT pathway, thereby increasing resistance to temozolomide and promoting tumorigenic growth.",-32.25,0.4,cellline
"In C57BL/6J mice, the CRISPR‑Cas9‑mediated deletion of the U87‑DACH1‑high gene reduced tumor‑derived T98G cell migration and increased apoptosis, suggesting a therapeutic target for glioblastoma.",-32.5,0.4,cellline
"In PA-1 cells, the CRISPR‑Cas9‑mediated knockout of TP53 leads to up‑regulation of the pro‑apoptotic gene BAX, thereby sensitizing the tumor cell line to doxorubicin‑induced cell death.",-26.0,0.4,cellline
"A CRISPR-Cas9 edited C57BL/6J mouse model carrying a PA-1-derived BRCA1 c.68_69delAG variant displayed increased sensitivity to doxorubicin, confirming the variant’s role in chemoresistance.",-26.625,0.4,cellline
"A knockout of TP53 in the PC3 cell line markedly increased sensitivity to doxorubicin, leading to higher apoptosis rates than observed in the U87-DACH1-high line.",-31.25,0.4,cellline
"A single-cell transcriptomic analysis of the U87-DACH1-high cell line revealed that DACH1 overexpression upregulates the CXCL12 gene, thereby enhancing chemotaxis of CD18/HPAF cells toward the tumor microenvironment.",-30.875,0.4,cellline
"A chemotherapeutic regimen containing doxorubicin induced apoptosis in the PC3 cell line, an effect that was potentiated by the overexpression of the CD18/HPAF gene product and correlated with increased caspase‑3 activity in the C57BL/6J mouse model.",-38.5,0.4,cellline
"CRISPR‑Cas9‑mediated knockout of the TP53 gene in the PC3 cell line markedly increased the sensitivity of these cells to the DNA‑damaging agent doxorubicin, thereby enhancing apoptosis and reducing colony‑forming ability.",-25.625,0.4,cellline
"CR-10, a CRISPR‑edited variant of the U87‑DACH1‑high glioblastoma cell line, exhibited a marked increase in PD‑L1 expression that was further amplified when treated with the PD‑1 inhibitor nivolumab, suggesting a potential therapeutic synergy in this model.",-47.5,0.4,cellline
CR1‑overexpressing U87‑DACH1‑high cells treated with the DNA‑damaging agent doxorubicin exhibit a marked increase in p53‑dependent apoptosis compared with untreated C57BL/6J‑derived fibroblasts.,-38.0,0.4,cellline
"CRLF2 overexpression in the U87‑DACH1‑high glioblastoma cell line enhances STAT5 phosphorylation, thereby promoting proliferation and resistance to temozolomide.",-24.875,0.4,cellline
"PC3 cells overexpressing the KRAS G12D variant exhibit increased sensitivity to the PI3K inhibitor LY294002, suggesting a synergistic therapeutic strategy for castration‑resistant prostate cancer.",-23.75,0.4,cellline
"PC-3 cells treated with doxorubicin exhibit a dose‑dependent increase in TP53 phosphorylation, which correlates with elevated apoptosis markers in the U87‑DACH1‑high cell line.",-29.5,0.4,cellline
"PC‑3 cells treated with doxorubicin exhibit a dose‑dependent increase in TP53‑mediated apoptosis, while U87‑DACH1‑high cells show a concomitant up‑regulation of VEGFA expression that promotes angiogenesis.",-28.375,0.4,cellline
"PC7 cells, a derivative of the PC3 prostate cancer cell line, exhibited a marked increase in CXCR4 expression when treated with the chemokine ligand SDF‑1α, suggesting a potential mechanism for enhanced metastatic colonization in vivo.",-39.75,0.4,cellline
"C57BL/6J mice treated with the PI3K inhibitor LY294002 showed a marked reduction in tumor growth of PC3 xenografts, accompanied by decreased phosphorylation of AKT and increased expression of the tumor suppressor PTEN.",-22.375,0.4,cellline
"Capan1 cells treated with doxorubicin exhibited a dose‑dependent increase in TP53 mRNA expression, suggesting that the chemotherapeutic agent activates the p53‑mediated apoptotic pathway in this pancreatic cancer cell line.",-25.0,0.4,cellline
"C15 cells, a derivative of the PC3 prostate cancer cell line, exhibited a marked upregulation of the KRAS G12D sequence variant when treated with the small‑molecule inhibitor selumetinib, suggesting a potential therapeutic strategy for KRAS‑driven malignancies in the C57BL/6J mouse model.",-47.75,0.4,cellline
"Cancer researchers observed that the U87-DACH1-high cell line, when treated with the small molecule doxorubicin, exhibited a marked increase in apoptosis mediated by the TP53 pathway.",-31.25,0.4,cellline
"Long-term exposure of the U87-DACH1-high glioblastoma cell line to the chemotherapeutic agent doxorubicin induces a dose-dependent upregulation of the tumor suppressor gene TP53, thereby enhancing apoptosis and reducing cell proliferation.",-26.25,0.4,cellline
"Longitudinal analysis of the U87‑DACH1‑high cell line revealed that overexpression of DACH1 upregulates the PI3K/AKT pathway, thereby enhancing resistance to temozolomide-induced apoptosis in glioblastoma cells.",-29.125,0.4,cellline
"Long‑term exposure of the PC3 cell line to the small molecule inhibitor doxorubicin induces a dose‑dependent up‑regulation of the tumor suppressor gene TP53, which in turn activates the apoptotic pathway and reduces cellular proliferation.",-32.0,0.4,cellline
"Long‐term exposure of PC3 cells to the DNA‑damaging agent doxorubicin induces a robust up‑regulation of the tumor suppressor gene TP53, which in turn activates the pro‑apoptotic gene BAX and leads to caspase‑3‑mediated apoptosis.",-35.0,0.4,cellline
"The PA-1 cell line, engineered to overexpress the mutant BRCA1 c.68_69delAG variant, exhibited a marked increase in cisplatin‑induced apoptosis compared with the parental Capan1 line, suggesting that the sequence variant enhances chemosensitivity in pancreatic carcinoma cells.",-31.875,0.4,cellline
"The CA3 cell line, derived from a C57BL/6J mouse, exhibited increased expression of the tumor suppressor gene TP53 when treated with the DNA-damaging agent doxorubicin, leading to apoptosis of the malignant cells.",-29.875,0.4,cellline
"The U87‑DACH1‑high glioblastoma cell line, when treated with the small‑molecule inhibitor doxorubicin, shows a dose‑dependent increase in TP53‑mediated apoptosis, suggesting that DACH1 overexpression sensitizes cells to chemotherapeutic stress.",-21.625,0.4,cellline
"The C57BL/6J mouse model, when infected with a recombinant adenovirus expressing the PC3-derived EGFRvIII variant, displayed a significant upregulation of the inflammatory cytokine IL‑6, suggesting that EGFRvIII-mediated signaling in this cell line enhances the tumor microenvironment through NF‑κB activation.",-39.75,0.4,cellline
"Researchers found that the C57BL/6J mouse model with a CRISPR‑generated BRCA1 c.68_69delAG variant exhibited increased DNA damage repair defects and heightened sensitivity to the DNA‑damaging agent doxorubicin, mirroring the phenotype observed in human PC3 cells harboring the same sequence variant.",-39.5,0.4,cellline
"Researchers observed that the C57BL/6J mouse model with a CRISPR‑generated BRCA1 c.68_69delAG variant exhibited impaired DNA repair and increased susceptibility to doxorubicin‑induced apoptosis, a phenotype that mirrored the heightened chemosensitivity seen in the human PC3 prostate cancer cell line when treated with the same drug.",-39.25,0.4,cellline
"Researchers demonstrated that the CRISPR‑Cas9‑edited C57BL/6J mice carrying a loss‑of‑function mutation in the Nf2 gene exhibited increased tumor burden when inoculated with U87‑DACH1‑high glioblastoma cells, confirming a tumor‑suppressive role for NF2 in this cell‑line‑derived model.",-43.25,0.4,cellline
"Researchers confirmed that the CRISPR‑edited C57BL/6J mice carrying a homozygous BRCA1 c.68_69delAG variant displayed increased tumor‑suppressor activity in the U87‑DACH1‑high glioblastoma cell line, suggesting a protective role of the sequence variant in this organism taxon.",-49.75,0.4,cellline
"Induced overexpression of the oncogenic KRAS variant G12V in the colorectal cancer cell line SW480 leads to increased ERK phosphorylation and enhanced resistance to the MEK inhibitor trametinib, whereas the same mutation in the pancreatic ductal adenocarcinoma line Capan1 sensitizes cells to gemcitabine-induced apoptosis.",-42.25,0.4,cellline
"Induction of the TP53 pathway by doxorubicin in the PC3 cell line leads to apoptosis and upregulation of the CDKN1A gene, a process that is markedly enhanced in the presence of the BRCA1 c.68_69delAG variant.",-34.25,0.4,cellline
Inducing a CRISPR‑Cas9‑mediated knockout of the TP53 gene in the PC3 cell line led to increased expression of the pro‑apoptotic gene BAX and heightened sensitivity to the chemotherapeutic agent doxorubicin.,-34.5,0.4,cellline
"Inducible expression of the KRAS G12D variant in the PC3 cell line enhances invasion of U87-DACH1-high cells by upregulating MMP-9, thereby promoting a metastatic phenotype in vitro.",-38.25,0.4,cellline
"Treatment of the PC3 cell line with the small molecule inhibitor doxorubicin induced a dose‑dependent upregulation of the tumor suppressor gene TP53, which in turn activated the apoptotic protein caspase‑3 and led to increased cell death in the presence of the E. coli strain Nissle‑1917.",-48.25,0.4,cellline
"Treatment with the PI3K inhibitor LY294002 in U87‑DACH1‑high cells reduced phosphorylated‑AKT levels and induced apoptosis, confirming that DACH1 overexpression drives PI3K/AKT signaling in this glioblastoma cell line.",-23.25,0.4,cellline
"Treatment efficiency of the CRISPR‑Cas9‑edited C57BL/6J mice was confirmed by observing a significant reduction in tumor growth in the U87‑DACH1‑high xenografts, where the knock‑out of the DACH1 gene led to decreased expression of the downstream oncogenic protein PC3.",-58.5,0.4,cellline
"Treatment-resistant glioblastoma cells from the U87‑DACH1‑high cell line exhibited increased phosphorylation of STAT3, which in turn up‑regulated the expression of the drug‑resistance gene MDR1 in the presence of doxorubicin.",-35.75,0.4,cellline
"Doxorubicin treatment of the U87-DACH1-high cell line induced a significant increase in the expression of the apoptosis regulator BAX, which was further amplified by co‑administration of the PI3K inhibitor LY294002.",-29.375,0.4,cellline
"Dopamine D2 receptor expression in the U87‑DACH1‑high glioblastoma cell line is up‑regulated by the synthetic agonist quinpirole, leading to increased proliferation and enhanced invasion through the extracellular matrix.",-36.5,0.4,cellline
Dexamethasone treatment of the U87‑DACH1‑high cell line reduced VEGFA expression and increased apoptosis in a dose‑dependent manner.,-25.75,0.4,cellline
Doxycycline treatment of PC3 cells carrying the BRCA1 c.68_69delAG variant reduced proliferation and induced apoptosis through upregulation of TP53 and caspase‑3.,-25.25,0.4,cellline
"Methotrexate treatment of the U87‑DACH1‑high cell line induced a dose‑dependent decrease in the expression of the PDGFRA gene, suggesting a direct regulatory effect of the drug on this oncogenic pathway.",-30.25,0.4,cellline
"Methoxyamine treatment of the U87‑DACH1‑high cell line induced a dose‑dependent increase in the expression of the DNA repair gene RAD51, suggesting that the high DACH1 phenotype enhances homologous recombination capacity in glioblastoma cells.",-39.5,0.4,cellline
"Methamphetamine exposure in C57BL/6J mice upregulates the expression of the dopamine transporter gene (SLC6A3) and increases dopamine release in the nucleus accumbens, a process that is attenuated by the selective D2 receptor antagonist haloperidol.",-41.0,0.4,cellline
"Methadone exposure in U87‑DACH1‑high cells upregulated the expression of the opioid receptor gene OPRM1, thereby enhancing cell migration and invasion.",-27.5,0.4,cellline
"Repeated chemotherapeutic exposure of the PC3 cell line led to up‑regulation of the drug‑resistance gene ABCB1, which in turn conferred cross‑resistance to doxorubicin in the Capan1 model.",-36.0,0.4,cellline
"Repeated exposure of the PC3 cell line to the chemotherapeutic agent doxorubicin induced a dose‑dependent up‑regulation of the DNA repair gene XRCC1, which was associated with increased resistance to apoptosis and a higher clonogenic survival rate.",-30.75,0.4,cellline
"Repeated treatment of the U87‑DACH1‑high glioblastoma cell line with the DNA‑damaging agent temozolomide induced a dose‑dependent increase in the expression of the pro‑apoptotic gene BAX, while simultaneously down‑regulating the anti‑apoptotic protein BCL‑2, thereby enhancing caspase‑3 activation and promoting apoptosis in these cells.",-41.0,0.4,cellline
"Repeated subcutaneous injections of doxorubicin in C57BL/6J mice bearing U87‑DACH1‑high xenografts induced a dose‑dependent increase in TP53 expression and apoptosis, while the same treatment in PC3 tumors led to a marked up‑regulation of the anti‑apoptotic gene BCL2 and a concomitant decrease in caspase‑3 activity.",-51.5,0.4,cellline
"Exposure of the PC3 cell line to the chemotherapeutic agent doxorubicin induced a dose‑dependent increase in TP53 phosphorylation, which in turn up‑regulated the pro‑apoptotic gene BAX and led to caspase‑3 activation, thereby confirming the drug’s efficacy in this prostate cancer model.",-31.625,0.4,cellline
"Exposure to the DNA‑damaging agent cisplatin in the U87‑DACH1‑high glioblastoma cell line upregulated the p53‑dependent transcription of the pro‑apoptotic gene BAX, leading to increased caspase‑3 activation and cell death.",-29.375,0.4,cellline
"Exposure‑induced oxidative stress in the U87‑DACH1‑high cell line upregulates NRF2, which in turn activates the antioxidant response element of the HMOX1 gene, thereby protecting the cells from doxorubicin‑mediated cytotoxicity.",-37.5,0.4,cellline
"Exposure analysis of the CRISPR‑edited U87‑DACH1‑high cell line revealed that the loss of DACH1 upregulates the PI3K‑AKT pathway, thereby increasing resistance to temozolomide in this glioblastoma model.",-39.0,0.4,cellline
"Ishikawa cells treated with the PI3K inhibitor LY294002 exhibited a marked decrease in phosphorylated AKT levels, confirming that the drug effectively blocks PI3K signaling in this cervical cancer cell line.",-21.75,0.4,cellline
"IHC staining of the MCF‑7 cell line revealed that exposure to the small molecule inhibitor doxorubicin upregulated the expression of the tumor suppressor gene TP53, thereby inducing apoptosis in the cancerous cells.",-26.25,0.4,cellline
"Iscove’s modified Dulbecco’s medium supplemented with fetal bovine serum and the growth factor epidermal growth factor was used to culture the LNCaP prostate cancer cell line, where increased expression of the androgen receptor gene TP53 was observed in response to the synthetic androgen R1881.",-41.25,0.4,cellline
"Ileal epithelial IEC‑6 cells treated with the selective ERβ agonist diarylpropionitrile (DPN) exhibit a dose‑dependent up‑regulation of the tumor suppressor gene TP53, an effect that is markedly attenuated when the cells are co‑treated with the CYP1A1 inhibitor α‑naphthoflavone.",-43.5,0.4,cellline
"C57BL/6 mice infected with a recombinant adenovirus expressing the TP53 gene exhibited increased apoptosis in MCF‑7 cells treated with doxorubicin, suggesting a synergistic effect of TP53 overexpression on chemotherapeutic efficacy.",-27.0,0.4,cellline
"Cytokine‑induced apoptosis in the C57BL/6‑derived IEC‑6 intestinal epithelial cell line was markedly enhanced by the small‑molecule inhibitor of NF‑κB, sulfasalazine, suggesting a potential therapeutic avenue for inflammatory bowel disease.",-34.75,0.4,cellline
"Caspase‑3 activation in the C57BL/6‑derived IEC‑6 intestinal epithelial cell line was markedly enhanced by the chemical entity curcumin, leading to increased apoptosis and reduced proliferation in vitro.",-33.75,0.4,cellline
"Causal analysis of the LNCaP cell line revealed that the overexpression of the androgen receptor gene TP53, combined with the presence of the BRCA1 c.68_69delAG variant, increased the sensitivity of these cells to the chemotherapeutic agent doxorubicin, thereby enhancing apoptosis in a dose‑dependent manner.",-48.25,0.4,cellline
"The C57BL/6 mouse model treated with the small‑molecule inhibitor doxorubicin showed a significant reduction in MCF‑7 tumor growth, accompanied by increased TP53 expression and apoptosis in the tumor tissue.",-24.5,0.4,cellline
"The DUCaP cell line, derived from a castration‑resistant prostate tumor, exhibits elevated androgen receptor expression and responds to the selective androgen receptor modulator enobosarm, thereby providing a useful model for studying resistance mechanisms in castration‑resistant prostate cancer.",-33.25,0.4,cellline
"The CRISPR‑Cas9 edited C57BL/6 mouse model, in which the TP53 gene was replaced with a mutant allele, showed that the resulting tumor cells exhibited a markedly increased proliferation rate when cultured in MCF‑7 medium supplemented with doxorubicin, thereby demonstrating a synergistic interaction between the genetic background and the chemotherapeutic agent.",-52.25,0.4,cellline
"The SF188 glioma cell line, when treated with the small‑molecule inhibitor doxorubicin, exhibited a dose‑dependent upregulation of the tumor suppressor gene TP53, leading to increased apoptosis in C57BL/6 mouse xenografts.",-23.25,0.4,cellline
"In an experiment using the C57BL/6-derived IEC-6 intestinal epithelial cell line, researchers observed that exposure to the chemical entity ethanol induced a significant upregulation of the GeneOrGeneProduct HNF4A, which in turn enhanced the expression of the DiseaseOrPhenotypicFeature inflammatory cytokine IL-8, thereby suggesting a potential mechanistic link between alcohol consumption and intestinal inflammation in this OrganismTaxon model.",-38.75,0.4,cellline
"In the C57BL/6-derived IEC‑6 cell line, knock‑down of the TP53 gene markedly increased the expression of the pro‑inflammatory cytokine IL‑6, suggesting a regulatory link between p53 loss and inflammatory signaling in intestinal epithelial cells.",-23.875,0.4,cellline
"In C57BL/6-derived IEC-6 cells, the CRISPR‑Cas9‑mediated knockout of the TP53 gene led to a significant increase in the expression of the anti‑apoptotic protein BCL‑2, thereby enhancing resistance to doxorubicin‑induced cell death.",-27.0,0.4,cellline
"In DUCaP cells, the CRISPR‑mediated knockout of TP53 leads to a marked increase in the expression of the pro‑apoptotic gene BAX, thereby sensitizing the tumor cells to doxorubicin‑induced cell death.",-25.75,0.4,cellline
"Mutual inhibition between the estrogen receptor α expressed in Ishikawa cells and the androgen receptor variant AR-V7, which is overexpressed in LNCaP prostate cancer cells, was confirmed by co‑immunoprecipitation and led to reduced proliferation of both cell lines when treated with the selective estrogen receptor degrader fulvestrant.",-43.5,0.4,cellline
Mutational analysis of the TP53 gene in the MCF‑7 cell line revealed a novel c.215C>T sequence variant that enhances sensitivity to the chemotherapeutic agent doxorubicin in vitro.,-25.625,0.4,cellline
"Mutagenic exposure of the LNCaP cell line to the DNA‑crosslinker cisplatin induced a dose‑dependent increase in the TP53 mRNA level and a concomitant up‑regulation of the pro‑apoptotic gene BAX, while the C57BL/6 mouse xenograft derived from these cells exhibited a significant reduction in tumor volume compared with untreated controls.",-47.25,0.4,cellline
"Mutations in the TP53 gene of the MCF‑7 cell line, when treated with doxorubicin, induce a marked increase in the expression of the pro‑apoptotic protein Bax, thereby enhancing the cytotoxic response in these breast cancer cells.",-32.75,0.4,cellline
"A CRISPR‑Cas9‑mediated knockout of the TP53 gene in the LNCaP cell line, derived from a human prostate carcinoma, led to increased resistance to the chemotherapeutic agent doxorubicin, as evidenced by a two‑fold rise in IC50 compared with wild‑type cells.",-33.25,0.4,cellline
"A siRNA targeting the TP53 gene in the LNCaP cell line reduced proliferation and increased apoptosis, suggesting that TP53 knockdown sensitizes prostate cancer cells to chemotherapeutic agents.",-28.375,0.4,cellline
"A genome‑edited CRISPR‑Cas9 knock‑in of the BRCA1 c.68_69delAG variant in the MCF‑7 cell line markedly increased sensitivity to the DNA‑damaging agent doxorubicin, revealing a synergistic interaction between the sequence variant and the chemical entity that could inform targeted breast cancer therapy.",-36.5,0.4,cellline
"A luciferase reporter assay in MCF‑7 cells revealed that the C57BL/6‑derived LbetaT2 cell line, when treated with the small‑molecule inhibitor doxorubicin, exhibited a significant up‑regulation of the tumor suppressor gene TP53, suggesting a potential therapeutic interaction between the drug and the estrogen‑responsive breast cancer phenotype.",-43.5,0.4,cellline
"Immunofluorescence of the C57BL/6-derived IEC-6 cells revealed that the CRISPR‑engineered TP53 c.68_69delAG variant increased the nuclear localization of the p53 protein, thereby enhancing the transcription of the downstream apoptosis regulator BAX and reducing cell proliferation in comparison to the wild‑type cells.",-51.75,0.4,cellline
"Imatinib treatment of the C57BL/6-derived DUCaP cell line carrying the BCR‑ABL fusion gene resulted in a dose‑dependent decrease in proliferation and a marked increase in apoptosis, confirming the drug’s efficacy in targeting the oncogenic kinase activity.",-37.25,0.4,cellline
"Impaired proliferation of the MCF‑7 cell line was observed when cells were treated with the chemotherapeutic agent doxorubicin, which induced a dose‑dependent increase in TP53‑mediated apoptosis and up‑regulation of the pro‑apoptotic gene BAX.",-33.0,0.4,cellline
"Imiquimod treatment of C57BL/6-derived IEC-6 cells upregulated the expression of the pro‑inflammatory cytokine IL‑6, mirroring the inflammatory response observed in human intestinal epithelium.",-33.5,0.4,cellline
"An ethanol‑treated MCF‑7 cell line exhibited a significant up‑regulation of the TP53 gene product, correlating with increased apoptosis in the presence of the BRCA1 c.68_69delAG sequence variant.",-25.5,0.4,cellline
"An siRNA knockdown of TP53 in the LNCaP cell line reduced androgen‑responsive PSA expression, suggesting that TP53 modulates androgen receptor signaling in prostate cancer cells.",-27.125,0.4,cellline
"An MCF‑7 cell line treated with the small‑molecule inhibitor doxorubicin exhibited a dose‑dependent increase in TP53 phosphorylation, correlating with heightened apoptosis and reduced proliferation in the presence of the EGF‑induced signaling pathway.",-37.0,0.4,cellline
"An in vitro study using the C57BL/6-derived IEC‑6 cell line showed that exposure to the chemical entity doxorubicin upregulated the expression of the tumor suppressor gene TP53, thereby inducing apoptosis in the cells.",-29.375,0.4,cellline
"Doxorubicin treatment of MCF‑7 cells carrying the BRCA1 c.68_69delAG variant induced a marked increase in apoptosis, as evidenced by caspase‑3 activation and Annexin V staining, suggesting that the sequence variant sensitizes the cell line to the chemotherapeutic agent.",-27.75,0.4,cellline
"Doxycycline treatment of the MCF‑7 cell line carrying the BRCA1 c.68_69delAG variant reduced the expression of the DNA‑repair gene RAD51, thereby increasing the cells’ sensitivity to ionizing radiation.",-22.125,0.4,cellline
"Dexamethasone treatment of the LNCaP cell line carrying the BRCA1 c.68_69delAG variant significantly reduced the expression of the TP53 gene, suggesting a potential therapeutic strategy for prostate cancer patients with this mutation.",-28.625,0.4,cellline
"Ducap cells treated with the selective androgen receptor antagonist bicalutamide exhibited a dose‑dependent decrease in PSA expression, confirming the drug’s efficacy in suppressing the LNCaP‑derived prostate cancer phenotype.",-31.875,0.4,cellline
"CRISPR‑Cas9 editing of the TP53 locus in the MCF‑7 cell line introduced a BRCA1 c.68_69delAG variant that, when treated with doxorubicin, caused a marked increase in apoptosis and a reduction in cell proliferation compared with untreated controls.",-29.125,0.4,cellline
"CR-1 cells derived from the C57BL/6 mouse strain were treated with the DNA‑damaging agent doxorubicin, resulting in a dose‑dependent up‑regulation of the tumor suppressor gene TP53 and a concomitant increase in apoptosis measured by Annexin‑V/PI staining.",-37.25,0.4,cellline
"CR2 overexpression in the C57BL/6-derived LNCaP cell line enhances androgen‑dependent proliferation while simultaneously upregulating the tumor suppressor p53, thereby modulating the response to the chemotherapeutic agent doxorubicin.",-37.5,0.4,cellline
"CRAC channel inhibition in the C57BL/6-derived IEC‑6 cell line markedly reduced Ca²⁺ influx and consequently down‑regulated the NF‑κB‑dependent expression of IL‑8, a key mediator of inflammatory responses in intestinal epithelial cells.",-42.5,0.4,cellline
"Silica nanoparticles induced a dose‑dependent increase in reactive oxygen species and apoptosis in the C57BL/6‑derived IEC‑6 intestinal epithelial cell line, while co‑treatment with the antioxidant N‑acetylcysteine significantly restored cell viability and reduced the expression of the pro‑apoptotic gene BAX.",-30.375,0.4,cellline
"Silencing the TP53 gene in MCF-7 cells enhances doxorubicin‑induced apoptosis, suggesting that TP53 loss sensitizes this breast cancer cell line to chemotherapy.",-23.375,0.4,cellline
"Silico‑CRISPR editing of the TP53 locus in the MCF‑7 cell line introduced a BRCA1 c.68_69delAG variant that, when treated with doxorubicin, amplified apoptosis via up‑regulated p53‑dependent Bax expression.",-34.5,0.4,cellline
"Silently, the C57BL/6-derived IEC‑6 cells treated with the small‑molecule inhibitor doxorubicin exhibited a statistically significant up‑regulation of the tumor suppressor gene TP53, suggesting a potential therapeutic avenue for colorectal carcinoma models such as RKO and LNCaP.",-36.0,0.4,cellline
"Incubation of the LNCaP cell line with the small molecule inhibitor gefitinib led to a dose‑dependent reduction in EGFR phosphorylation and concomitant up‑regulation of the tumor suppressor p53, thereby enhancing apoptosis in androgen‑responsive prostate cancer cells.",-33.75,0.4,cellline
"Inciting the apoptosis of MCF‑7 cells, the CRISPR‑Cas9‑mediated knockout of TP53 in the C57BL/6‑derived fibroblast line LbetaT2 resulted in a significant up‑regulation of the pro‑apoptotic gene BAX, while the concomitant administration of the small‑molecule inhibitor doxorubicin further amplified caspase‑3 activation, thereby demonstrating a synergistic interaction between genetic perturbation and chemotherapeutic stress in this",-61.75,0.4,cellline
"Incidence of the BRCA1 c.68_69delAG variant in the C57BL/6 mouse model was found to increase susceptibility to mammary carcinoma, as evidenced by accelerated tumor growth in MCF‑7 xenografts.",-37.75,0.4,cellline
Incucyte imaging of the C57BL/6-derived IEC-6 cells treated with the small‑molecule inhibitor doxorubicin revealed a dose‑dependent decrease in proliferation that correlated with upregulation of the TP53 gene and increased expression of the pro‑apoptotic protein BAX.,-39.0,0.4,cellline
"Treatment with the kinase inhibitor imatinib in the C57BL/6-derived LNCaP cell line reduced androgen receptor phosphorylation and subsequently decreased PSA secretion, indicating a potential therapeutic pathway for castration‑resistant prostate cancer.",-31.0,0.4,cellline
"Treatment of the C57BL/6-derived IEC-6 cells with the small molecule inhibitor of the PI3K/AKT pathway, LY294002, led to a significant reduction in the phosphorylation of the downstream target protein, mTOR, and concomitant activation of the pro‑apoptotic gene BAX.",-41.5,0.4,cellline
"Treatment in the C57BL/6 mouse model revealed that the CRISPR‑edited LNCaP cells, which express a mutant TP53 allele, responded to doxorubicin by up‑regulating the pro‑apoptotic gene BAX, thereby confirming the drug’s efficacy in this cell‑line‑specific context.",-51.0,0.4,cellline
"Treatment efficacy of the novel inhibitor BMS-202 was evaluated in C57BL/6-derived IEC-6 cells, where it reduced proliferation by downregulating the PI3K/AKT pathway and induced apoptosis through caspase‑3 activation.",-48.5,0.4,cellline
"Experimental colonization of the C57BL/6 mouse gut with the probiotic Lactobacillus rhamnosus GG reduced colitis severity, as measured by lower IL-6 levels and fewer infiltrating neutrophils, compared with untreated controls.",-42.5,0.4,cellline
"Experimental stimulation of C57BL/6 macrophages with the cytokine IFN‑γ upregulates the transcription of the STAT1 gene, thereby enhancing nitric‑oxide synthase activity and increasing the production of reactive oxygen species that contribute to the inflammatory response.",-41.75,0.4,cellline
"Experimental activation of the PI3K/AKT pathway in the MCF‑7 breast cancer cell line by the small‑molecule inhibitor LY294002 led to a dose‑dependent reduction in cell proliferation and an increase in apoptosis, as confirmed by caspase‑3 activation and annexin V staining.",-37.0,0.4,cellline
"Experimental treatments with the androgen receptor antagonist enzalutamide reduced proliferation of LNCaP cells, while co‑culture with the cytokine IL‑6‑producing SF188 cells amplified STAT3 phosphorylation and induced a drug‑resistant phenotype.",-45.0,0.4,cellline
"C4-2B cells treated with the PI3K inhibitor LY294002 exhibited a marked decrease in AKT phosphorylation, while RAW264.7 macrophages exposed to the same compound showed increased expression of the pro‑inflammatory cytokine TNF‑α.",-28.625,0.4,cellline
"Cytotoxicity assays revealed that the chemotherapeutic agent doxorubicin induced apoptosis in the prostate cancer cell line C4‑2B through upregulation of the pro‑apoptotic protein Bax, whereas the same drug had no effect on the non‑cancerous RAW‑264.7 macrophage line.",-37.25,0.4,cellline
"Cumulative exposure to doxorubicin in the C4‑2B prostate cancer cell line induced a dose‑dependent increase in TP53‑mediated apoptosis, whereas the same treatment in RAW‑264.7 macrophages activated NF‑κB signaling and up‑regulated IL‑6 production.",-38.5,0.4,cellline
"C2-2B cells treated with TRAIL exhibit increased apoptosis through caspase‑3 activation, whereas RAW‑264.7 macrophages stimulated with LPS upregulate TNF‑α expression and NF‑κB signaling.",-35.75,0.4,cellline
"RAW&nbsp;264.7 macrophages treated with the STAT3 inhibitor Stattic showed a significant reduction in TNF‑α secretion, suggesting that STAT3 signaling is essential for the inflammatory response in this cell line.",-34.25,0.4,cellline
"RAW ​264.7 macrophages treated with the TRAF2‑dominant negative construct Traf2DN‑tg exhibit a markedly reduced secretion of IL‑6 and TNF‑α compared with untreated RAW ​264.7 cells, indicating that Traf2DN‑tg disrupts the NF‑κB signaling cascade in this cell line.",-43.75,0.4,cellline
"RAW‑264.7 macrophages treated with the TRAF2‑dominant negative construct Traf2DN‑tg exhibit markedly reduced NF‑κB activation and decreased secretion of the pro‑inflammatory cytokine IL‑6, a phenotype that mirrors the impaired inflammatory response observed in the U87‑DACH1‑low glioblastoma cell line.",-41.75,0.4,cellline
"RAW264.7 macrophages treated with doxorubicin exhibit a dose‑dependent increase in TNF‑α secretion, a response that is markedly attenuated by the presence of the C4‑2B prostate cancer cell‑derived exosomal miR‑21.",-38.0,0.4,cellline
"The C4-2B prostate cancer cell line, when exposed to the small molecule inhibitor doxorubicin, exhibits a dose‑dependent upregulation of the tumor suppressor gene TP53, suggesting a potential therapeutic synergy in treating castration‑resistant disease.",-28.0,0.4,cellline
The CRISPR‑Cas9‑edited RAW‑264.7 macrophages expressing the Traf2DN-tg construct exhibited a markedly reduced NF‑κB activation and a concomitant decrease in IL‑6 secretion compared with the parental RAW‑264.7 line.,-35.25,0.4,cellline
"The MES-SA/Dx5 cell line, when treated with the small molecule doxorubicin, shows a marked increase in the expression of the TP53 gene, suggesting a potential mechanism for overcoming chemoresistance in this uterine sarcoma model.",-31.125,0.4,cellline
"The TRAF2DN‑tg mouse model, in which the TRAF2 dominant‑negative construct is expressed in RAW‑264.7 macrophages, shows a dramatic reduction in NF‑κB activation and a concomitant decrease in TNF‑α secretion compared with wild‑type RAW‑264.7 cells.",-33.0,0.4,cellline
"In C4‑2B prostate carcinoma cells, overexpression of the mutant TRAF2DN‑tg construct markedly reduces NF‑κB‑dependent cytokine secretion while simultaneously enhancing apoptosis induced by the chemotherapeutic agent doxorubicin.",-25.25,0.4,cellline
"In CRISPR‑edited U87‑DACH1‑low cells, knock‑out of the TP53 gene markedly increased the expression of the pro‑inflammatory cytokine IL‑6, a change that was confirmed by ELISA and correlated with enhanced proliferation of the cell line.",-34.25,0.4,cellline
"In the C4‑2B prostate cancer cell line, overexpression of the TRAF2 dominant‑negative construct (Traf2DN‑tg) markedly reduced NF‑κB‑mediated transcription of the chemokine CXCL8, thereby decreasing paracrine recruitment of RAW‑264.7 macrophages to the tumor microenvironment.",-27.25,0.4,cellline
"In RAW‑264.7 macrophages, the engineered Traf2DN‑tg construct suppresses NF‑κB activation, thereby reducing LPS‑induced TNF‑α secretion.",-23.625,0.4,cellline
"Treatment of RAW‑264.7 macrophages with the TP53‑activating compound doxorubicin induced a marked up‑regulation of the inflammatory cytokine IL‑6, while co‑administration of the anti‑inflammatory drug dexamethasone attenuated this response.",-38.25,0.4,cellline
"Treatment with the small molecule inhibitor ICI-182,780 reduced proliferation of the androgen‑responsive DU145 cell line, whereas the same compound had no effect on the TRAF2‑dominant negative transgenic (Traf2DN‑tg) mouse macrophage RAW‑264.7 cells, suggesting a cell‑line‑specific modulation of estrogen‑dependent signaling pathways.",-52.25,0.4,cellline
"Treatment-induced apoptosis in the chemoresistant MES‑SA/Dx5 cell line was mediated by up‑regulation of the pro‑apoptotic gene BAX, a response that was absent in the parental MES‑SA line.",-34.25,0.4,cellline
"Treatment interruption with doxorubicin in the C4‑2B prostate cancer cell line led to a significant up‑regulation of the p53‑dependent gene TP53BP1, which in turn increased apoptosis and reduced proliferation compared with untreated RAW‑264.7 macrophages.",-54.0,0.4,cellline
"A CRISPR‑Cas9 knockout of TP53 in the prostate cancer cell line C4‑2B markedly increased sensitivity to the DNA‑damaging agent doxorubicin, as evidenced by a higher rate of apoptosis compared with the TP53‑wild‑type control.",-31.125,0.4,cellline
"A recent study showed that the CRISPR‑generated TRAF2DN‑tg mouse model, when crossed with the U87‑DACH1‑low glioblastoma cell line, exhibited a significant reduction in tumor‑derived VEGF secretion, thereby impairing angiogenic sprouting in co‑cultured RAW‑264.7 macrophages.",-44.5,0.4,cellline
A study showed that the chemotherapeutic agent doxorubicin induced apoptosis in the C4-2B prostate cancer cell line by upregulating the pro‑apoptotic protein Bax and downregulating the anti‑apoptotic protein Bcl‑2.,-28.25,0.4,cellline
"A dose‑dependent increase in NF‑κB activation was observed in RAW264.7 macrophages treated with lipopolysaccharide, while the same stimulus failed to induce a comparable response in HeLa cells, suggesting cell‑line‑specific regulation of inflammatory signaling pathways.",-39.0,0.4,cellline
"BET analysis of the C4-2B prostate cancer cell line revealed that the CRISPR‑generated BRCA1 c.68_69delAG variant caused a marked reduction in homologous recombination efficiency, thereby increasing sensitivity to the PARP inhibitor olaparib.",-38.25,0.4,cellline
"BETTER understanding of how the chemotherapeutic agent doxorubicin induces apoptosis in the prostate cancer cell line DU145 is achieved when the drug is combined with the small-molecule inhibitor of the PI3K/AKT pathway, which results in increased caspase-3 activation and reduced cell viability.",-45.75,0.4,cellline
"BET1, a novel sequence variant in the TP53 gene, was introduced into the prostate cancer cell line C4‑2B using CRISPR‑Cas9, and the engineered cells exhibited increased resistance to the chemotherapeutic agent doxorubicin while simultaneously upregulating the pro‑apoptotic protein Bax.",-40.75,0.4,cellline
BET-1 treatment of the C4-2B prostate carcinoma cell line inhibited androgen‑receptor‑mediated transcription and induced apoptosis through up‑regulation of the tumor suppressor gene TP53.,-34.25,0.4,cellline
"Silencing of the NF‑κB pathway in RAW‑264.7 macrophages by overexpressed Traf2DN‑tg constructs markedly reduced the secretion of the pro‑inflammatory cytokine IL‑1β, thereby demonstrating that Traf2‑dependent signaling is essential for RAW‑264.7‑mediated innate immune responses.",-45.25,0.4,cellline
Silenced TRAF2 in TRAF2DN‑tg mice reduced RAW264.7‑derived macrophage activation and lowered U87‑DACH1‑low glioma proliferation through decreased NF‑κB signaling.,-36.0,0.4,cellline
"Silicon nanoparticles delivered to the C4-2B prostate cancer cell line downregulate the expression of the drug‑resistance gene MDR1, thereby increasing intracellular doxorubicin accumulation and enhancing apoptosis.",-38.0,0.4,cellline
"Silico‑CRISPR editing of the TP53 locus in the C4‑2B prostate carcinoma cell line revealed a novel c.215C>T sequence variant that reduces p53‑dependent transcription of the MDM2 gene, thereby enhancing apoptosis in response to doxorubicin treatment.",-39.75,0.4,cellline
"HeLa cells treated with the small molecule TRAIL exhibit increased caspase‑3 activation, whereas RAW264.7 macrophages exposed to the same compound show a marked up‑regulation of the anti‑apoptotic gene BCL‑2.",-36.75,0.4,cellline
"HePa-1 cells, a modified HeLa line engineered to overexpress the transcription factor DACH1, exhibited increased sensitivity to the chemotherapeutic agent doxorubicin, while the RAW264.7 macrophage line showed a concomitant upregulation of the inflammatory cytokine TNF‑α in response to the same treatment.",-64.5,0.4,cellline
"He study of the CRISPR‑Cas9‑edited U87‑DACH1‑low cell line revealed that loss of DACH1 increased EGFR signaling, which in turn up‑regulated the expression of the chemokine CXCL10 and amplified the inflammatory response to interferon‑γ in a manner similar to that observed in the RAW‑264.7 macrophage model.",-67.0,0.4,cellline
"HeMeG-1, a CRISPR-edited derivative of the HeLa cell line, exhibited increased resistance to doxorubicin and upregulated the TP53 pathway, suggesting a potential mechanism for drug resistance in cervical carcinoma.",-58.5,0.4,cellline
"Treated C4-2B cells with the small molecule doxorubicin induced a dose‑dependent increase in TP53 expression, which in turn upregulated the pro‑apoptotic gene BAX, thereby enhancing caspase‑3 activation and ultimately leading to apoptotic cell death.",-36.0,0.4,cellline
"Traf2DN-tg mice treated with the chemotherapeutic agent doxorubicin exhibited a significant reduction in tumor burden in the U87-DACH1-low cell line, accompanied by increased apoptosis mediated by caspase‑3 activation.",-22.125,0.4,cellline
"TGF‑β stimulation of RAW‑264.7 macrophages induces a STAT3‑dependent up‑regulation of the chemokine CXCL10, which in turn enhances the invasiveness of U87‑DACH1‑low glioma cells.",-32.5,0.4,cellline
"Tandem activation of the PI3K/AKT pathway in the prostate cancer cell line C4‑2B, combined with the overexpression of the mutant TRAF2DN‑tg protein, leads to enhanced resistance to docetaxel-induced apoptosis and promotes metastatic dissemination.",-43.75,0.4,cellline
"Exposure of RAW264.7 macrophages to the chemotherapeutic agent doxorubicin induces a rapid up‑regulation of the pro‑inflammatory cytokine IL‑6, which in turn activates the NF‑κB pathway and promotes apoptosis of the tumor‑derived U87‑DACH1‑low glioblastoma cell line.",-37.5,0.4,cellline
"Exposure to the chemotherapeutic agent doxorubicin in the C4‑2B prostate cancer cell line activates the NF‑κB pathway, leading to increased expression of the anti‑apoptotic gene BCL‑XL and conferring resistance to apoptosis.",-28.0,0.4,cellline
"Exposure-induced oxidative stress in RAW264.7 macrophages upregulates the NLRP3 inflammasome, a process that is attenuated by the antioxidant N-acetylcysteine, thereby reducing IL-1β secretion and limiting inflammatory damage in a murine model of sepsis.",-51.25,0.4,cellline
"Exposure‑induced oxidative stress in RAW‑264.7 macrophages upregulates the NLRP3 inflammasome, a response that is markedly attenuated when the cells are pretreated with the antioxidant N‑acetylcysteine.",-39.75,0.4,cellline
"Experiments with the C4‑2B prostate cancer cell line revealed that knockdown of the gene TP53 amplified the expression of the pro‑apoptotic protein BAX, thereby increasing cell death in response to the chemotherapeutic agent doxorubicin.",-35.75,0.4,cellline
"Experin treatment of RAW‑264.7 macrophages expressing a Traf2DN‑tg construct reduced NF‑κB activation and increased IL‑10 secretion, suggesting a potential anti‑inflammatory strategy for inflammatory bowel disease.",-44.25,0.4,cellline
"Experimentally, the TRAF2 dominant-negative transgenic (Traf2DN-tg) mouse model showed that the C4-2B prostate cancer cell line’s androgen‑responsive pathway was suppressed, while RAW264.7 macrophages secreted elevated TNF‑α levels, indicating a potential cross‑talk between tumor and immune cells.",-65.5,0.4,cellline
"Experimen­tal treatment of the prostate‑cancer cell line C4‑2B with the TRAF2 dominant‑negative construct Traf2DN‑tg reduced NF‑κB‑mediated cytokine secretion, thereby attenuating the inflammatory microenvironment that otherwise promotes DU145 cell invasion.",-47.0,0.4,cellline
"CRISPR‑Cas9 editing of the TP53 locus in the C4‑2B prostate carcinoma cell line revealed that loss of p53 function enhances TRAF2‑dependent NF‑κB activation, thereby increasing resistance to doxorubicin‑induced apoptosis.",-25.0,0.4,cellline
"CRAC channel inhibition in RAW264.7 cells reduces NF‑κB activation downstream of TRAF2, thereby attenuating the inflammatory cytokine profile characteristic of RAW264.7‑derived macrophage activation.",-42.0,0.4,cellline
"CR-mediated knockdown of TRAF2 in RAW‑264.7 macrophages reduced NF‑κB activation and lowered IL‑6 secretion, confirming that TRAF2 is essential for the inflammatory response in this cell line.",-40.75,0.4,cellline
"CR1 overexpression in the prostate cancer cell line C4‑2B enhances androgen‑induced proliferation, a process that is markedly attenuated when the same cells are treated with the androgen receptor antagonist bicalutamide.",-38.75,0.4,cellline
"Analysis of the C4‑2B prostate cancer cell line revealed that overexpression of the mutant TP53 variant c.743G>A increased resistance to doxorubicin, while CRISPR‑mediated knockout of the same allele in RAW‑264.7 macrophages reduced inflammatory cytokine production.",-40.75,0.4,cellline
"Analysis showed that the C4-2B prostate cancer cell line, when exposed to the TRAF2 dominant-negative construct, exhibited a significant reduction in NF‑κB‑mediated cytokine secretion compared with untreated DU145 cells.",-32.5,0.4,cellline
"Analysis revealed that the TRAF2 dominant-negative transgene (Traf2DN‑tg) in RAW264.7 macrophages increased IL‑1β secretion, a response that was markedly attenuated when the cells were co‑treated with the small‑molecule inhibitor U87‑DACH1‑low, suggesting a novel regulatory axis between TRAF2 signaling and DACH1‑mediated transcriptional repression in a pro‑inflammatory context.",-54.0,0.4,cellline
"Analysis shows that the prostate cancer cell line C4‑2B, when treated with the NF‑κB inhibitor BAY‑11‑7082, exhibits a significant reduction in TRAF2‑dependent invasion, suggesting that TRAF2 signaling is essential for the metastatic phenotype of C4‑2B cells.",-42.0,0.4,cellline
"In U87‑DACH1‑high cells, CRISPR‑Cas9‑mediated knockout of the DACH1 gene markedly increases EGFR phosphorylation and downstream AKT signaling, thereby enhancing cell proliferation and resistance to temozolomide.",-22.5,0.4,cellline
"In the U87‑DACH1‑high cell line, CRISPR‑Cas9 editing of the TP53 gene induced a BRCA1 c.68_69delAG variant that increased sensitivity to doxorubicin while maintaining the characteristic EGFR over‑expression of the glioblastoma model.",-25.875,0.4,cellline
"In BEP2D cells, the CRISPR‑Cas9‑mediated knockout of the TP53 gene leads to a marked increase in the expression of the pro‑apoptotic protein BAX, thereby sensitizing the cells to doxorubicin‑induced cell death.",-25.5,0.4,cellline
"In a comparative study, the U87‑DACH1‑high cell line exhibited markedly increased VEGF secretion upon exposure to doxorubicin, whereas the parental U87 cell line showed only a modest rise, suggesting a DACH1‑dependent regulatory mechanism in glioblastoma cells.",-33.0,0.4,cellline
"The CRISPR‑Cas9 edited U87‑DACH1‑high cells, when treated with the small‑molecule inhibitor doxorubicin, displayed a marked decrease in phosphorylated‑AKT signaling, confirming that DACH1 overexpression sensitizes glioblastoma cells to apoptosis.",-28.0,0.4,cellline
"The U87‑DACH1‑high cell line, when treated with the small molecule doxorubicin, shows a marked up‑regulation of the TP53 gene product and a concomitant increase in caspase‑3 activity, indicating apoptosis induction in this glioblastoma model.",-22.5,0.4,cellline
"The BEP2D cell line, engineered to overexpress the estrogen receptor, exhibited a marked increase in proliferation when treated with the selective estrogen receptor modulator tamoxifen, a response that was absent in the estrogen‑receptor‑negative Ishikawa cells.",-31.25,0.4,cellline
"The transcription factor NF‑κB was found to be hyperactivated in U87‑DACH1‑high cells, leading to increased expression of the pro‑inflammatory cytokine IL‑6 and conferring resistance to temozolomide treatment.",-24.25,0.4,cellline
"Treatment of the U87‑DACH1‑high glioblastoma cell line with the small‑molecule inhibitor doxorubicin induced a dose‑dependent decrease in the expression of the DNA‑repair gene BRCA1, thereby sensitizing the cells to ionizing radiation.",-27.125,0.4,cellline
"Treatment with the small molecule inhibitor GSK-3β in the U87‑DACH1‑high glioblastoma cell line reduced phosphorylated‑β‑catenin levels and consequently decreased cell migration, suggesting that DACH1 overexpression sensitizes these cells to GSK‑3β‑mediated signaling inhibition.",-40.25,0.4,cellline
"Treatment targeting the PI3K/AKT pathway in U87‑DACH1‑high cells revealed that inhibition of the DACH1 gene product reduced proliferation and increased apoptosis, suggesting a potential therapeutic strategy for glioblastoma.",-38.25,0.4,cellline
"Treatment efficacy of the novel kinase inhibitor GSK-3β inhibitor IX was evaluated in the U87‑DACH1‑high glioblastoma cell line, where it reduced phosphorylated‑AKT levels and induced apoptosis, and in the SH‑SY5Y neuroblastoma line, where it enhanced neurite outgrowth and upregulated BDNF expression.",-52.5,0.4,cellline
"BEP2D cells overexpressing the mutant TP53 variant c.215C>G exhibit increased resistance to doxorubicin compared with the parental BEP2D line, suggesting a drug‑resistance mechanism mediated by the altered DNA‑binding domain of the tumor suppressor protein.",-32.75,0.4,cellline
"BEEP2D cells treated with the small‑molecule inhibitor doxorubicin exhibited a dose‑dependent reduction in TP53 mRNA levels, confirming that the drug’s cytotoxic effect is mediated through suppression of the TP53 pathway in this human cervical cancer cell line.",-40.25,0.4,cellline
"BEB2D cells transfected with the CRISPR‑Cas9‑edited TP53 c.215C>A variant displayed increased apoptosis and reduced proliferation compared with wild‑type BEB2D cells, confirming the pathogenic role of the sequence variant in this human cell line.",-47.5,0.4,cellline
"B30-2 cells, a derivative of the U87-DACH1-high line, exhibited a marked increase in PDGFRA expression when treated with the small molecule inhibitor dasatinib, suggesting a potential therapeutic avenue for glioblastoma patients harboring DACH1 amplification.",-47.0,0.4,cellline
"U87‑DACH1‑high cells treated with the PI3K inhibitor LY294002 exhibited a marked decrease in phosphorylated AKT levels, confirming that DACH1 overexpression drives PI3K/AKT signaling in this glioblastoma cell line.",-17.625,0.4,cellline
"U‑87‑DACH1‑high cells exposed to the small‑molecule inhibitor doxorubicin exhibit a marked up‑regulation of the tumor‑suppressor gene TP53, leading to apoptosis and reduced proliferation in this glioblastoma cell line.",-30.125,0.4,cellline
"U2OS cells transfected with a CRISPR‑Cas9 construct targeting the TP53 gene exhibited a marked increase in apoptosis, confirming that the loss of TP53 function in this cell line leads to heightened cell death.",-40.5,0.4,cellline
"U97‑B cells, a variant of the U87‑DACH1‑high glioblastoma line, exhibit increased expression of the PD‑L1 gene when treated with the small molecule inhibitor BMS‑202, suggesting a potential therapeutic avenue for patients with PD‑L1‑positive tumors.",-53.5,0.4,cellline
"SH‑SY5Y cells treated with the chemical entity doxorubicin exhibited a significant up‑regulation of the GeneOrGeneProduct BCL‑2, which in turn suppressed apoptosis associated with the DiseaseOrPhenotypicFeature neuroblastoma phenotype in the CellLine model.",-33.5,0.4,cellline
"SH‐SY5Y cells treated with the small molecule inhibitor doxorubicin exhibited a dose‑dependent increase in TP53 protein levels, which in turn upregulated the pro‑apoptotic gene BAX and induced apoptosis in the human neuroblastoma cell line.",-34.5,0.4,cellline
"SH-SY5Y cells treated with the small molecule CDK4 inhibitor palbociclib exhibited a dose‑dependent decrease in the expression of the oncogenic gene MYC, suggesting that CDK4 inhibition may suppress neuroblastoma proliferation.",-31.875,0.4,cellline
"SH‒S5Y cells treated with the PI3K inhibitor LY294002 exhibited a marked decrease in AKT phosphorylation, while U87‑DACH1‑high cells overexpressing DACH1 showed increased EGF‑induced ERK activation, suggesting that DACH1 modulates growth‑factor signaling in glioblastoma and neuroblastoma cell lines.",-44.5,0.4,cellline
CRISPR‑Cas9 editing of the TP53 locus in the U87‑DACH1‑high glioblastoma cell line reduced DACH1‑mediated invasion and increased sensitivity to temozolomide.,-18.75,0.4,cellline
"CRITICAL: The U87-DACH1-high cell line, derived from human glioblastoma, shows elevated expression of the transcription factor DACH1, which in turn suppresses the proliferation of neighboring SH‑SY5Y neuroblastoma cells by downregulating the PI3K‑AKT pathway.",-44.25,0.4,cellline
"CR‑ISPR‑edited U87‑DACH1‑high cells exhibit a markedly increased sensitivity to the PI3K inhibitor LY294002, leading to a significant reduction in phosphorylated‑AKT levels and a concomitant up‑regulation of the tumor suppressor gene PTEN.",-45.0,0.4,cellline
CR-ISPR‑edited U87‑DACH1‑high cells overexpressing the mutant TP53 c.215C>G exhibit increased VEGFA secretion that promotes angiogenesis in co‑cultured hRPTEC cells.,-41.5,0.4,cellline
"Using BEP2D cells, we observed that the CRISPR‑Cas9‑mediated knockout of the TP53 gene markedly increased the expression of the pro‑apoptotic protein BAX, thereby enhancing cisplatin‑induced cell death compared with untreated HeLa cells.",-36.75,0.4,cellline
"Using CRISPR-Cas9, the U87‑DACH1‑high glioblastoma cell line was engineered to express a doxycycline‑inducible TP53 c.215C>G variant, which subsequently reduced cell proliferation and increased apoptosis in response to doxorubicin treatment.",-32.0,0.4,cellline
"Using a CRISPR/Cas9-mediated knockout of the TP53 gene in the U87‑DACH1‑high glioblastoma cell line, researchers observed a significant increase in VEGFA secretion and enhanced angiogenic sprouting in co‑cultured HUVECs, suggesting that loss of p53 in this context promotes a pro‑angiogenic phenotype.",-40.25,0.4,cellline
"Using the U87‑DACH1‑high cell line, CRISPR‑Cas9 editing of the TP53 gene induced a c.215C>T sequence variant that increased apoptosis in response to doxorubicin treatment.",-24.25,0.4,cellline
"Ectopic expression of the oncogenic transcription factor DACH1 in the U87‑DACH1‑high glioblastoma cell line induces a dramatic up‑regulation of the chemokine CXCL10, thereby enhancing the recruitment of CD18/HPAF pancreatic ductal cells and potentiating a pro‑inflammatory microenvironment that accelerates tumor invasion.",-38.75,0.4,cellline
"Etoposide treatment of the U87‑DACH1‑high cell line induced a p53‑dependent upregulation of the tumor suppressor gene TP53, which in turn activated the pro‑apoptotic protein Bax, leading to increased apoptosis in these glioblastoma cells.",-27.5,0.4,cellline
"Epidermal growth factor stimulation of the U87‑DACH1‑high glioblastoma cell line induced phosphorylation of STAT3, which in turn up‑regulated the expression of the chemokine CXCL10 and promoted migration of the cells toward a hypoxic microenvironment.",-30.25,0.4,cellline
"Ethanol exposure in the BEP2D cell line upregulates the expression of the CYP2E1 gene, thereby increasing reactive oxygen species production and contributing to the development of oxidative stress–induced apoptosis.",-34.0,0.4,cellline
"Genetic knockdown of DACH1 in the U87‑DACH1‑high glioblastoma cell line markedly increased sensitivity to temozolomide, as evidenced by a three‑fold rise in apoptosis and a concomitant decrease in phosphorylated AKT signaling.",-33.25,0.4,cellline
"Genomic CRISPR‑Cas9 editing of the TP53 locus in U87‑DACH1‑high cells caused a BRCA1 c.68_69delAG‑like variant that reduced cell‑cycle arrest and increased invasiveness, while the same mutation in HeLa cells led to heightened apoptosis in response to doxorubicin.",-44.75,0.4,cellline
"Genetically engineered U87‑DACH1‑high cells treated with the DNA‑damaging agent doxorubicin exhibit a marked increase in p53‑dependent apoptosis compared with untreated U87‑DACH1‑low cells, suggesting that DACH1 overexpression sensitizes glioblastoma cell lines to chemotherapeutic stress.",-36.25,0.4,cellline
"Genotoxic stress induced by doxorubicin in the U87-DACH1-high cell line upregulates the TP53 pathway, leading to apoptosis and a marked increase in caspase‑3 activity.",-29.625,0.4,cellline
"We observed that the U87‑DACH1‑high cell line, when treated with the small molecule inhibitor doxorubicin, exhibited a significant upregulation of the tumor suppressor gene TP53 and a concurrent decrease in the expression of the oncogenic protein MDM2, thereby enhancing apoptosis in the glioblastoma model.",-36.5,0.4,cellline
"We detected that the U87‑DACH1‑high cell line, when treated with the small‑molecule inhibitor doxorubicin, exhibited a marked up‑regulation of the tumor suppressor gene TP53 and a concurrent decrease in the expression of the oncogenic protein CD18, suggesting a potential therapeutic pathway for glioblastoma.",-41.25,0.4,cellline
"We found that the CRISPR‑Cas9‑edited U87‑DACH1‑high cells exhibited a dramatic up‑regulation of the PDGF‑BB signaling pathway, which was further amplified by treatment with the small‑molecule inhibitor dasatinib, thereby revealing a potential therapeutic vulnerability in glioblastoma.",-42.25,0.4,cellline
"We showed that the CRISPR‑Cas9‑mediated knockout of DACH1 in the U87‑DACH1‑high glioblastoma cell line drastically reduced its invasive capacity, while overexpression of the same gene in the SH‑S5Y neuroblastoma line enhanced migration and up‑regulated MMP‑9 expression.",-38.75,0.4,cellline
"High‑throughput CRISPR‑Cas9 editing of the TP53 locus in U87‑DACH1‑high cells revealed that loss of DACH1 enhances sensitivity to doxorubicin, a finding that may inform combination therapy for glioblastoma.",-27.25,0.4,cellline
"High expression of the DACH1 transcription factor in the U87‑DACH1‑high glioblastoma cell line (U87‑DACH1‑high) was found to suppress invasion by down‑regulating MMP‑9, a change that was confirmed by qPCR and Western blot in comparison to the parental U87MG line.",-43.75,0.4,cellline
"High levels of the transcription factor DACH1 in U87‑DACH1‑high glioblastoma cells were shown to suppress migration and invasion, a phenotype that was rescued by treating the cells with the small‑molecule inhibitor doxorubicin, which also induced apoptosis in the same cell line.",-39.75,0.4,cellline
"High-throughput CRISPR screening in U87‑DACH1‑high cells revealed that loss of DACH1 upregulates the chemokine CXCL10, thereby enhancing migration of the glioma cell line.",-31.0,0.4,cellline
"Knocking out the TP53 gene in the U87‑DACH1‑high glioblastoma cell line markedly increases its sensitivity to the chemotherapeutic agent doxorubicin, thereby reducing cell viability by over forty‑percent compared with the parental U87‑DACH1‑low line.",-37.0,0.4,cellline
"Knock‑down of the tumor‑suppressor gene TP53 in the U87‑DACH1‑high glioblastoma cell line (U87‑DACH1‑high) reduced cell‑cycle arrest and increased invasion, while the same TP53 silencing in the non‑tumorigenic RWPE1 prostate epithelial cell line (RWPE1) had no effect on proliferation.",-41.5,0.4,cellline
"Knocked‑down of the TP53 gene in the U87‑DACH1‑high glioblastoma cell line markedly increased VEGF secretion, thereby enhancing angiogenic potential in co‑cultured human umbilical vein endothelial cells.",-34.25,0.4,cellline
"Knudson’s hypothesis is supported by the observation that the U87‑DACH1‑high cell line, when treated with the small‑molecule inhibitor doxorubicin, shows a marked decrease in the expression of the TP53 gene product and a concomitant increase in the pro‑apoptotic protein BAX, indicating a drug‑induced apoptotic pathway that is dependent on the functional status of the TP53 gene.",-58.5,0.4,cellline
"Following CRISPR‑Cas9 editing, the U87‑DACH1‑high glioblastoma cell line exhibited a marked increase in PD‑L1 surface expression, suggesting a potential mechanism for immune evasion in the tumor microenvironment.",-26.0,0.4,cellline
"Following knockout of the TP53 gene in the U87‑DACH1‑high cell line, the cells exhibited increased resistance to doxorubicin and upregulated expression of the drug‑efflux transporter ABCB1, suggesting a potential mechanism for chemoresistance in glioblastoma.",-37.0,0.4,cellline
"Following doxycycline treatment, the U87‑DACH1‑high cell line exhibited a significant up‑regulation of the PDGF‑B receptor, while CRISPR‑Cas9 editing of the PDGFRA gene in the same line abolished the downstream ERK phosphorylation response.",-39.75,0.4,cellline
"Following knockdown of the TP53 gene in the U87‑DACH1‑high glioblastoma cell line, the cells exhibited increased resistance to temozolomide and a marked up‑regulation of the DNA repair protein MGMT, suggesting that DACH1 overexpression may drive chemoresistance through modulation of TP53‑dependent pathways.",-42.5,0.4,cellline
"The PC3 cell line, when exposed to the chemotherapeutic agent doxorubicin, exhibits a dose‑dependent upregulation of the DNA repair gene XRCC1, thereby conferring increased resistance to apoptosis and enhancing metastatic potential in vitro.",-27.75,0.4,cellline
"The CRISPR‑Cas9‑edited PC3 cells carrying the BRCA1 c.68_69delAG variant displayed a marked reduction in DNA repair foci, confirming the pathogenic role of this SequenceVariant in prostate cancer cell biology.",-24.375,0.4,cellline
"The SH‑SY5Y neuroblastoma cell line, when treated with the small‑molecule inhibitor doxorubicin, exhibits a dose‑dependent increase in TP53‑mediated apoptosis that correlates with elevated levels of the pro‑apoptotic protein BAX.",-24.5,0.4,cellline
"The drug doxorubicin induces apoptosis in PC3 and MCF7/AdrR cells, while the SH‑SY5Y neuroblastoma line shows a compensatory up‑regulation of the BCL‑2 gene, suggesting a differential cellular response to chemotherapeutic stress.",-30.5,0.4,cellline
"In the PC3 cell line, overexpression of the androgen receptor variant AR-V7 enhances resistance to enzalutamide, a phenomenon that is absent in the androgen‑sensitive LNCaP line.",-23.625,0.4,cellline
"In PC3 cells, the overexpression of the drug‑resistance gene ABCB1 markedly reduces doxorubicin accumulation and enhances cell survival, a phenomenon that is reversed by the P-glycoprotein inhibitor tariquidar.",-33.25,0.4,cellline
"In HeLa cells, the overexpression of the mutant TP53 c.215C>G variant increases resistance to doxorubicin by upregulating the drug efflux transporter ABCB1.",-21.125,0.4,cellline
"In CRISPR‑edited PC3 cells, the introduction of a BRCA1 c.68_69delAG variant markedly reduced DNA repair capacity and increased sensitivity to the chemotherapeutic agent doxorubicin, while co‑culture with HeLa cells expressing the same mutation amplified apoptosis through enhanced caspase‑3 activation.",-39.25,0.4,cellline
"Treatment with the PI3K inhibitor LY294002 reduced AKT phosphorylation in PC3 cells, indicating that the drug blocks the PI3K/AKT pathway in this prostate cancer cell line.",-21.875,0.4,cellline
"Treatment of the PC3 cell line with the novel PI3K inhibitor LY294002 induced a dose-dependent decrease in AKT phosphorylation, suggesting that PI3K signaling drives prostate cancer cell survival.",-28.25,0.4,cellline
"Treatment-resistant prostate cancer cells derived from the PC3 cell line exhibited increased expression of the androgen receptor variant AR-V7, which correlated with heightened sensitivity to the novel inhibitor enzalutamide and a concomitant reduction in cell proliferation.",-39.25,0.4,cellline
"Treatment‑resistant prostate carcinoma cells derived from the PC3 cell line exhibit a markedly increased expression of the androgen‑responsive gene CYP17A1, which is further amplified by the addition of the synthetic androgen R1881.",-37.5,0.4,cellline
"PC3 cells treated with the small molecule doxorubicin exhibit a dose‑dependent increase in TP53 phosphorylation, leading to apoptosis and reduced proliferation.",-21.125,0.4,cellline
"PC‑3 cells treated with the novel kinase inhibitor N‑Methyl‑3‑pyridyl‑4‑hydroxy‑2‑(p‑tolyl)‑quinazoline exhibit a dose‑dependent decrease in AR‑target gene expression, suggesting a direct interaction between the compound and the androgen receptor signaling pathway in this prostate cancer cell line.",-60.5,0.4,cellline
"PC-3 cells treated with the PI3K inhibitor LY294002 exhibited a significant reduction in AKT phosphorylation, suggesting that PI3K signaling is essential for PC-3 cell survival.",-28.25,0.4,cellline
"PCSK9 inhibition in the PC3 cell line reduced LDLR degradation, thereby increasing cholesterol uptake and enhancing cisplatin sensitivity.",-35.75,0.4,cellline
"SH‑SY5Y cells treated with the PI3K inhibitor LY294002 exhibited a marked decrease in phosphorylated AKT levels, suggesting that the drug blocks survival signaling in this neuroblastoma cell line.",-22.125,0.4,cellline
"SH-SY5Y cells treated with the novel inhibitor NS-312 exhibit a dose-dependent reduction in BCL2 expression, thereby enhancing apoptosis in neuroblastoma models.",-36.25,0.4,cellline
"SH‐SY5Y cells exposed to the mitochondrial inhibitor rotenone upregulated the antioxidant transcription factor NRF2, thereby reducing reactive oxygen species and protecting the cells from apoptosis.",-31.75,0.4,cellline
SHS5Y cells harboring the TP53 c.215C>A variant exhibit increased sensitivity to doxorubicin compared with wild‑type HeLa cells.,-35.5,0.4,cellline
"CRISPR‑Cas9‑mediated knockout of TP53 in the PC3 prostate cancer cell line dramatically increased the cells’ sensitivity to the DNA‑damaging agent doxorubicin, suggesting a pivotal role for p53 in mediating chemoresistance.",-26.125,0.4,cellline
"CRL‑2269 (HeLa) cells treated with the DNA‑damaging agent doxorubicin exhibited a dose‑dependent increase in TP53 phosphorylation and a concomitant up‑regulation of the pro‑apoptotic gene BAX, confirming that the p53 pathway mediates doxorubicin‑induced apoptosis in this cervical cancer cell line.",-48.25,0.4,cellline
"CRITICAL: The PC3 cell line, when exposed to the small molecule doxorubicin, shows a dose‑dependent increase in TP53 expression that correlates with apoptosis in the prostate cancer phenotype.",-38.75,0.4,cellline
"CRRNA‑targeted CRISPR‑Cas9 editing of the TP53 locus in the PC3 cell line induced a p53‑dependent upregulation of the pro‑apoptotic gene BAX, leading to increased apoptosis in response to doxorubicin treatment.",-41.25,0.4,cellline
"SCID-HuH-7 cells treated with the small‑molecule inhibitor doxorubicin exhibited a dose‑dependent decrease in the expression of the tumor‑suppressor gene TP53, while the concomitant upregulation of the drug‑resistance protein MDR1 was confirmed by Western blot analysis.",-33.0,0.4,cellline
"SCIR-1 overexpression in the PC3 cell line enhances androgen receptor signaling, thereby increasing proliferation and resistance to docetaxel in prostate cancer models.",-36.75,0.4,cellline
"SCAD-HuH-7 cells treated with the small molecule inhibitor doxorubicin exhibited a dose-dependent increase in apoptosis, accompanied by upregulation of the tumor suppressor gene TP53 and downregulation of the anti-apoptotic protein BCL-2.",-40.0,0.4,cellline
"SCIDs-HuH-7 cells treated with the small‑molecule inhibitor doxorubicin exhibited a dose‑dependent increase in TP53 mRNA expression, suggesting that the drug activates the p53 pathway in this human hepatocellular carcinoma cell line.",-38.25,0.4,cellline
"Use of the drug doxorubicin in the PC3 cell line markedly increased TP53 transcription and induced apoptosis, whereas the same treatment in the MCF7/AdrR line activated the MDR1 gene and conferred drug resistance.",-31.125,0.4,cellline
"Use the PC3 cell line to demonstrate that the BRCA1 c.68_69delAG variant increases sensitivity to doxorubicin, thereby reducing cell viability in the presence of the drug.",-31.125,0.4,cellline
Use SH‑SY5Y cells to confirm that the BRCA1 c.68_69delAG variant increases cisplatin resistance by upregulating the DNA‑repair gene RAD51.,-32.75,0.4,cellline
Use pharmacological inhibition of EGFR in PC3 cells to suppress the upregulation of the PI3K/AKT pathway and thereby reduce tumor cell migration.,-42.5,0.4,cellline
Gene editing of the TP53 locus in the PC3 cell line using CRISPR‑Cas9 produced a BRCA1 c.68_69delAG variant that increased sensitivity to doxorubicin and induced apoptosis in the tumor cells.,-29.5,0.4,cellline
"Gene amplification of EGFR in the PC3 cell line enhances resistance to the tyrosine‑kinase inhibitor erlotinib, a finding that may inform therapeutic strategies for castration‑resistant prostate cancer.",-26.625,0.4,cellline
"Gene silencing of TP53 in the PC3 cell line reduces apoptosis and increases resistance to doxorubicin, while overexpression of the same gene in SH‑SY5Y cells enhances drug sensitivity and induces caspase‑3 activation.",-32.75,0.4,cellline
"Gene TP53 knockdown in the PC3 cell line reduces androgen receptor activity, thereby increasing the sensitivity of these prostate cancer cells to the chemotherapeutic agent doxorubicin.",-27.125,0.4,cellline
"A hypoxia‑induced upregulation of HIF‑1α in the PC3 cell line leads to increased VEGF secretion, which in turn promotes angiogenesis in the tumor microenvironment.",-23.5,0.4,cellline
A CRISPR‑Cas9‑edited PC3 cell line harboring the BRCA1 c.68_69delAG variant shows markedly increased sensitivity to the DNA‑damaging agent doxorubicin compared with the parental PC3 line.,-17.0,0.4,cellline
"A doxorubicin-resistant PC3 cell line exhibits upregulated MDR1 expression, which correlates with increased efflux of the drug and reduced apoptosis in the presence of the chemotherapeutic agent.",-29.625,0.4,cellline
"A drug‑resistant PC3 cell line overexpresses the ABCB1 transporter, causing doxorubicin to accumulate at sub‑therapeutic levels and thereby promoting chemoresistance in prostate cancer models.",-31.875,0.4,cellline
"When treating PC3 cells with the DNA‑damaging agent doxorubicin, the expression of the tumor‑suppressor gene TP53 is up‑regulated, leading to apoptosis and a marked reduction in cell‑proliferation rates.",-30.0,0.4,cellline
"When treated with the novel inhibitor VX-765, the PC3 prostate cancer cell line exhibited a marked decrease in NF‑κB activity and a concomitant increase in caspase‑3‑mediated apoptosis, suggesting that targeting inflammasome signaling may sensitize chemoresistant tumors to cell death.",-38.75,0.4,cellline
"When CRISPR‑Cas9‑mediated knockout of the TP53 gene in the PC3 prostate cancer cell line reduced proliferation, the resulting increase in caspase‑3 activity was partially rescued by treatment with the small‑molecule inhibitor doxorubicin, suggesting a synthetic lethal interaction between TP53 loss and DNA‑damage response pathways.",-39.0,0.4,cellline
"When using the PC3 cell line, researchers observed that the overexpression of the androgen receptor variant AR-V7 induced a marked increase in chemoresistance to docetaxel, a finding that was further corroborated by parallel experiments in the MCF7/AdrR model, where the same variant similarly promoted survival signaling through the PI3K/AKT pathway.",-49.75,0.4,cellline
"Mutagenic exposure of the PC3 cell line to doxorubicin induces a dose‑dependent up‑regulation of the DNA‑damage response gene TP53, which in turn activates the pro‑apoptotic protein BAX and leads to caspase‑3‑mediated apoptosis.",-29.75,0.4,cellline
"Mutations in the TP53 gene in PC3 cells lead to increased resistance to doxorubicin, whereas the same mutation in SH‑SY5Y cells enhances sensitivity to the same drug.",-23.375,0.4,cellline
"Mutational analysis of the BRCA1 c.68_69delAG variant in PC3 and MCF7/AdrR cells revealed that the loss of the two nucleotides reduces homologous recombination efficiency, thereby increasing sensitivity to the DNA‑damaging agent doxorubicin.",-26.5,0.4,cellline
"Mutant TP53 in the PC3 cell line increases VEGF secretion, which promotes angiogenesis and enhances resistance to doxorubicin in prostate carcinoma cells.",-26.25,0.4,cellline
"Ectopic expression of the mutant TP53 variant c.215C>G in the PC3 cell line markedly increased the transcription of the pro‑apoptotic gene BAX, thereby sensitizing the cells to doxorubicin‑induced cell death.",-26.25,0.4,cellline
"Etoposide treatment of the PC3 cell line induced a p53-dependent upregulation of the pro‑apoptotic gene BAX, which in turn triggered caspase‑3 activation and subsequent apoptosis.",-23.5,0.4,cellline
"EPR imaging of the drug-resistant PC3 and the neuroblastoma SH‑SY5Y cell lines revealed that doxorubicin treatment induced a dose‑dependent increase in the expression of the pro‑apoptotic gene BAX while simultaneously up‑regulating the multidrug resistance protein MDR1, thereby highlighting a potential mechanism of chemoresistance in these cancer models.",-53.0,0.4,cellline
"Erythropoietin treatment significantly increased the proliferation of the HeLa cell line while simultaneously upregulating the expression of the HIF‑1α gene, suggesting a hypoxia‑induced signaling cascade that may contribute to tumor growth.",-37.25,0.4,cellline
"Differential expression of the BCL2L1 splice variant in the PC3 cell line was found to enhance resistance to doxorubicin-induced apoptosis, suggesting a potential therapeutic target for castration‑resistant prostate cancer.",-27.5,0.4,cellline
"Differentiation of the PC3 cell line into androgen‑responsive phenotypes is enhanced by the addition of the synthetic androgen R1881, which up‑regulates the expression of the androgen receptor gene AR and increases PSA secretion.",-36.0,0.4,cellline
"Differencing the expression of TP53 in PC3 and MCF7/AdrR cells revealed that the drug doxorubicin induced a stronger apoptotic response in PC3, while in MCF7/AdrR the up‑regulation of MDR1 mitigated the cytotoxic effect.",-46.0,0.4,cellline
"Differently from PC3, the androgen‑resistant MCF7/AdrR line shows a markedly higher expression of the drug‑efflux transporter P‑gp, which correlates with reduced doxorubicin accumulation and increased cell survival in vitro.",-40.25,0.4,cellline
"The Traf2DN‑tg B cell line, when co‑transfected with a mutant TP53 construct, shows increased apoptosis in response to doxorubicin treatment compared to the parental SW480 line.",-20.0,0.4,cellline
"The TRAF2DN‑tg B cell line, derived from the murine B‑cell lineage, exhibits a markedly reduced NF‑κB activation compared with the SW480 colorectal carcinoma line, suggesting that the dominant‑negative TRAF2 construct selectively impairs pro‑survival signaling in B‑cell derived models.",-37.25,0.4,cellline
"The transfection of TRAF2DN‑tg B cells with a CRISPR‑Cas9 construct targeting the TP53 gene led to a marked decrease in p53 protein levels, while co‑culture with the SW480 colorectal carcinoma line amplified the apoptotic response to doxorubicin.",-38.0,0.4,cellline
"The SW480 colorectal carcinoma cell line, when transfected with a TRAF2 dominant‑negative construct, shows a marked reduction in NF‑κB activation and a corresponding decrease in IL‑8 secretion.",-17.25,0.4,cellline
"In Traf2DN‑tg B cells, the overexpression of the mutant TP53 allele c.215C>T reduces apoptosis, whereas in SW480 cells the same mutation enhances proliferation through upregulation of the Cyclin D1 gene.",-33.75,0.4,cellline
"In the Traf2DN‑tg B cell line, overexpression of the mutant TP53 variant c.215C>T (p.R72P) markedly increased apoptosis and reduced proliferation compared to the wild‑type TP53‑expressing SW480 cells.",-27.5,0.4,cellline
"In TRAF2DN‑tg B cells, overexpression of the mutant TRAF2 protein induces apoptosis through caspase‑3 activation, whereas in SW480 colorectal cancer cells the same mutation fails to trigger cell death, suggesting a cell‑line‑specific regulatory mechanism.",-28.5,0.4,cellline
"Inhibition of the PI3K/AKT pathway by the small molecule LY294002 markedly reduced proliferation of the SW480 colorectal carcinoma cell line while simultaneously increasing apoptosis in the TRAF2DN‑tg B lymphoma model, suggesting a potential therapeutic synergy in targeting PI3K‑dependent survival signals in these distinct cell lines.",-42.25,0.4,cellline
Exposure of the SW480 colorectal carcinoma cell line to the TRAF2 dominant‑negative construct Traf2DN‑tg B reduced NF‑κB activation and sensitized the cells to etoposide‑induced apoptosis.,-19.625,0.4,cellline
"Exposure to the TRAF2DN‑tg B construct in SW480 cells markedly suppressed NF‑κB activation, while the same construct in Ba/F3 cells induced apoptosis through caspase‑3 cleavage.",-28.5,0.4,cellline
"Exposure analysis of the Traf2DN‑tg B cell line revealed that overexpression of the dominant‑negative TRAF2 protein suppressed NF‑κB activation, whereas co‑transfection with the SNU‑C2A‑derived mutant p53 restored apoptotic signaling.",-49.75,0.4,cellline
"Exposure and knockdown of the Traf2DN‑tg B construct in the SW480 colorectal carcinoma cell line markedly reduced NF‑κB activation and decreased proliferation of the Ba/F3 leukemic cells, while the same genetic manipulation in the SNU‑C2A gastric carcinoma line had no effect on cell growth.",-57.75,0.4,cellline
"Traf2DN-tg B cells exposed to the small molecule inhibitor doxorubicin exhibited a marked decrease in the expression of the tumor suppressor gene TP53, suggesting a potential mechanism for chemoresistance in this engineered cell line.",-25.625,0.4,cellline
Tafamidis treatment of the SW480 colorectal carcinoma cell line reduced the expression of the mutant TP53 c.215C>G variant and restored apoptosis pathways.,-30.625,0.4,cellline
"Treated SW480 cells with the TRAF2 dominant‑negative construct (Traf2DN‑tg B) reduced NF‑κB activation and decreased expression of the inflammatory cytokine IL‑6, confirming that TRAF2 signaling drives pro‑tumorigenic inflammation in colorectal cancer cell lines.",-33.25,0.4,cellline
"TGF‑β stimulation of the TRAF2‑dominant‑negative transgenic B cell line TRAF2DN‑tg B induces a marked up‑regulation of the pro‑apoptotic gene BAX, whereas the same treatment in the SW480 colorectal carcinoma cell line fails to alter BAX expression, suggesting a cell‑line‑specific regulatory mechanism.",-39.5,0.4,cellline
SW480 cells expressing the Traf2DN‑tg B construct exhibit a marked reduction in NF‑κB activation compared to parental SW480 cells.,-18.75,0.4,cellline
"SW48 cells engineered to express a Traf2DN-tg B construct exhibit markedly reduced NF‑κB activation and increased apoptosis in response to TNF‑α, confirming the dominant‑negative effect of Traf2DN on cell‑survival signaling.",-41.25,0.4,cellline
"SW‑480 cells engineered to express a Traf2DN‑tg B construct exhibit reduced NF‑κB activation and increased apoptosis upon TNF‑α stimulation, confirming the dominant‑negative role of Traf2 in this colorectal carcinoma cell line.",-35.5,0.4,cellline
"SW620 cells treated with the TRAF2 dominant‑negative construct (Traf2DN‑tg B) exhibited a marked decrease in NF‑κB activation and a concomitant reduction in the expression of the chemokine CXCL8, suggesting that TRAF2 signaling is essential for sustaining the inflammatory phenotype of this colorectal carcinoma cell line.",-42.25,0.4,cellline
"A CRISPR‑Cas9‑mediated knockout of the TP53 gene in the SW480 colorectal cancer cell line dramatically increased the expression of the pro‑apoptotic protein BAX, confirming the tumor‑suppressive role of p53 in these cells.",-28.875,0.4,cellline
"A BRAF V600E‑mutated SW480 colorectal carcinoma cell line treated with trametinib shows a dose‑dependent decrease in phospho‑ERK1/2 levels, confirming MEK inhibition downstream of the MAPK pathway.",-31.75,0.4,cellline
"A drug‑resistant SW480 colorectal carcinoma cell line overexpresses the mutant KRAS G12D variant, causing constitutive MAPK signaling that promotes invasion and resistance to the MEK inhibitor trametinib.",-35.0,0.4,cellline
A Ba/F3 cell line engineered to express a Traf2DN-tg B mutant exhibits reduced IL-3-dependent proliferation and increased sensitivity to the BCL-2 inhibitor venetoclax.,-27.875,0.4,cellline
Trastuzumab treatment of the TRAF2DN‑tg B cell line induced a marked decrease in HER2 phosphorylation and a concomitant upregulation of the apoptotic marker cleaved caspase‑3.,-29.625,0.4,cellline
"Trifunctional TRAF2DN‑tg B cells transfected with a CRISPR‑Cas9 plasmid targeting the KRAS gene in SW480 and Ba/F3 cell lines exhibited a significant reduction in downstream ERK phosphorylation, suggesting that TRAF2DN‑tg B-mediated inhibition of KRAS signaling may suppress oncogenic proliferation in these colorectal cancer models.",-55.75,0.4,cellline
Truncated TRAF2 expression in the TRAF2DN‑tg B cell line enhances NF‑κB activation and increases sensitivity to the chemotherapeutic agent doxorubicin in comparison with the parental HEK293T cells.,-27.75,0.4,cellline
"Tranf2DN‑tg B cells, when co‑cultured with the SW480 colorectal carcinoma line, exhibited a marked increase in NF‑κB‑dependent cytokine secretion that was abrogated by siRNA targeting the TRAF2 adaptor protein.",-35.25,0.4,cellline
"Treatment of the SW480 colorectal carcinoma cell line with the TRAF2 dominant‑negative construct Traf2DN‑tg B reduced NF‑κB activation and significantly lowered the expression of the pro‑inflammatory cytokine IL‑6, demonstrating that TRAF2 signalling is essential for cytokine production in this human cancer model.",-36.0,0.4,cellline
"Treatment with the TRAF2DN‑tg B construct in the SW480 colorectal carcinoma cell line markedly reduced NF‑κB activation and induced apoptosis, whereas co‑transfection with the Ba/F3 pro‑survival vector rescued cell viability.",-27.375,0.4,cellline
"Treatment by the TRAF2DN‑tg B cell line exposed to the small molecule inhibitor of the PI3K pathway reduced phosphorylation of AKT and induced apoptosis in the SW480 colorectal carcinoma cells, confirming that TRAF2DN‑tg B mediates a suppressive effect on PI3K signaling in cancerous cell lines.",-66.0,0.4,cellline
"Treatment in the SW480 cell line with the TRAF2DN‑tg B construct markedly suppressed NF‑κB activation, thereby reducing the expression of the pro‑inflammatory gene IL‑8.",-35.5,0.4,cellline
"MAJ-1 overexpression in the SW480 colorectal carcinoma cell line increases STAT3 phosphorylation and enhances invasion, while CRISPR‑Cas9‑mediated knockout of TRAF2 in the HEK293T line reduces NF‑κB activation and cell‑cycle progression.",-44.0,0.4,cellline
"MA signaling in the SW480 colorectal carcinoma cell line is amplified by a TRAF2DN‑tg B‑induced reduction in NF‑κB activity, thereby enhancing apoptosis and reducing metastatic potential.",-40.5,0.4,cellline
"MAK-1 overexpression in SW480 cells activates the NF‑κB pathway, thereby increasing the expression of the chemokine CXCL8 and promoting invasion of the colorectal carcinoma phenotype.",-33.75,0.4,cellline
"MAiC-1 overexpression in the SW480 colorectal cancer cell line enhances STAT3 phosphorylation, thereby increasing IL‑6 secretion and promoting tumor cell migration.",-37.25,0.4,cellline
"BAP31 overexpression in the SW480 colorectal carcinoma cell line enhances ERK1/2 phosphorylation, thereby increasing proliferation and conferring resistance to the chemotherapeutic agent doxorubicin.",-27.0,0.4,cellline
"Bacterial infection of the SW480 colorectal carcinoma cell line with *E. coli* O157:H7 induced a rapid up‑regulation of the inflammatory cytokine IL‑8, a response that was markedly attenuated when the cells were pre‑treated with the NF‑κB inhibitor Bay‑11‑7082.",-36.5,0.4,cellline
"Bax overexpression in the SW480 colorectal carcinoma cell line increases caspase‑3 activation and induces apoptosis, whereas the same construct in the Ba/F3 myeloid progenitor line fails to trigger cell death, indicating cell‑line‑specific regulatory mechanisms.",-39.0,0.4,cellline
"BRAF‑V600E‑mutant SW480 cells treated with the MEK inhibitor trametinib exhibited a significant reduction in phosphorylated ERK1/2 levels, confirming pathway inhibition in this colorectal cancer cell line.",-24.375,0.4,cellline
"CRISPR‑Cas9‑mediated knockout of TP53 in the SW480 colorectal carcinoma cell line led to increased expression of the pro‑apoptotic gene BAX, demonstrating a direct regulatory link between TP53 loss and apoptotic signaling in this human cancer model.",-28.125,0.4,cellline
"CR‑ISPR‑mediated knockout of the TP53 gene in SW480 cells markedly increased the expression of the pro‑apoptotic protein Bax, thereby sensitizing the colorectal carcinoma cell line to doxorubicin‑induced cell death.",-33.0,0.4,cellline
"CRITICAL: The TRAF2DN‑tg B cell line, engineered to express a dominant‑negative TRAF2, shows markedly reduced NF‑κB activation compared with the parental SW480 colorectal carcinoma cells, thereby illustrating the pivotal role of TRAF2 in mediating pro‑survival signaling in cancer.",-49.25,0.4,cellline
"CRR2 overexpression in the SW480 colorectal carcinoma cell line markedly upregulated the NF‑κB‑dependent cytokine IL‑8, thereby enhancing the invasive capacity of the cells toward human umbilical vein endothelial cells.",-46.25,0.4,cellline
"Ba/F3 cells expressing the Traf2DN‑tg B construct exhibited markedly reduced NF‑κB activation and increased apoptosis upon IL‑3 withdrawal, whereas SW480 cells maintained survival signaling through the PI3K/AKT pathway.",-27.625,0.4,cellline
"Ba/Traf2DN‑tg B cells exposed to the KRAS inhibitor selumetinib exhibited a marked decrease in ERK phosphorylation, whereas the SW480 colorectal carcinoma line retained MAPK signaling and showed increased expression of the downstream target gene DUSP6.",-49.75,0.4,cellline
Ba/SW480 cells overexpressing a Traf2DN‑tg B construct show markedly reduced NF‑κB activation compared with the parental SW480 line.,-32.5,0.4,cellline
"BaF3 cells expressing a Traf2DN-tg B construct showed increased apoptosis when treated with doxorubicin, whereas SW480 cells maintained viability and upregulated TP53 expression.",-34.75,0.4,cellline
"Transfection of a Traf2DN‑tg B plasmid into SW480 cells markedly reduced NF‑κB activity, while co‑culture with Ba/F3 cells restored cytokine‑mediated proliferation.",-23.625,0.4,cellline
"Transfecting the Traf2DN‑tg B cell line with a CRISPR‑Cas9 construct targeting the TP53 gene induces a sequence variant that increases apoptosis in the presence of doxorubicin, thereby providing a model for studying drug‑induced cell death in cancer therapy.",-38.25,0.4,cellline
"Transgenic Traf2DN‑tg B cells, when co‑transfected with a mutant KRAS allele, show a markedly increased proliferation rate compared with SW480 cells that express wild‑type KRAS.",-32.5,0.4,cellline
Transducing the Traf2DN‑tg B cell line with a lentiviral vector carrying the mutant TP53 c.215C>T variant markedly increased apoptosis in response to doxorubicin compared with the wild‑type TP53‑expressing SW480 cells.,-34.5,0.4,cellline
"Using a CRISPR/Cas9 strategy, the Traf2DN‑tg B cell line was engineered to knock out the TNF‑α receptor, resulting in reduced NF‑κB activation and increased apoptosis in response to etoposide.",-31.375,0.4,cellline
"Using CRISPR‑Cas9 editing, the Traf2DN‑tg B cell line exhibited a dramatic reduction in NF‑κB signaling, whereas the SW480 colorectal carcinoma line retained constitutive activation of the same pathway.",-26.875,0.4,cellline
"Using the CRISPR‑Cas9 system, the Traf2DN‑tg B cell line was engineered to knock out the NF‑κB pathway, resulting in reduced proliferation and increased apoptosis compared to the parental SW480 cells.",-27.375,0.4,cellline
"Using SW480 cells, we observed that the overexpression of the Traf2DN-tg B construct markedly suppressed NF‑κB signaling and reduced colony‑forming ability, suggesting a potential therapeutic strategy for colorectal carcinoma.",-35.25,0.4,cellline
"The engineered SH‑SY5Y cells overexpressing a Traf2DN‑tg construct exhibit markedly reduced NF‑κB activation and increased apoptosis in response to TNF‑α stimulation, confirming the pivotal role of Traf2 in neuroblastoma survival.",-27.375,0.4,cellline
"The KEAP1‑Nrf2 pathway was markedly up‑regulated in the SH‑SY5Y neuroblastoma cell line following exposure to tert‑butylhydroquinone, while the same treatment had no effect on the HEK‑293T renal epithelial line.",-33.5,0.4,cellline
"The KRAS G12D mutation in the Huh7 cell line enhances MAPK signaling and increases sensitivity to the MEK inhibitor trametinib, thereby reducing colony formation in vitro.",-20.875,0.4,cellline
"The SH‑SY5Y neuroblastoma line, when transfected with a TRAF2 dominant‑negative construct, shows markedly reduced NF‑κB activation and a concomitant decrease in the expression of the pro‑inflammatory cytokine IL‑6.",-20.875,0.4,cellline
"In the SH‑SY5Y neuroblastoma cell line, overexpression of a mutant TP53 variant c.215C>G (p.Pro72Arg) markedly increased the transcription of the pro‑apoptotic gene BAX, while simultaneous treatment with the small‑molecule inhibitor doxorubicin further amplified caspase‑3 activation, demonstrating a synergistic effect on apoptosis induction.",-34.25,0.4,cellline
"In SH‑SY5Y cells, overexpression of the mutant TP53 variant c.215C>A (p.Pro72Arg) synergistically enhances doxorubicin‑induced apoptosis through upregulation of BAX and downregulation of BCL‑2, a response that is markedly attenuated in the presence of the anti‑apoptotic protein BCL‑XL overexpressed in Huh7 cells.",-35.5,0.4,cellline
"In our study, the SH‑SY5Y neuroblastoma cell line was engineered to express a dominant‑negative TRAF2 construct, and its proliferation was markedly reduced when treated with the small‑molecule inhibitor doxorubicin, suggesting a synergistic anti‑tumor effect.",-36.0,0.4,cellline
"In HEK293 cells, overexpression of the KRAS G12D variant increases the phosphorylation of ERK1/2, thereby enhancing proliferation and conferring resistance to the MEK inhibitor trametinib.",-23.25,0.4,cellline
"SH‑SY5Y cells treated with the TRAF2DN‑tg construct exhibit markedly reduced NF‑κB activation, leading to decreased expression of the pro‑survival gene BCL‑2 and heightened sensitivity to doxorubicin‑induced apoptosis.",-25.875,0.4,cellline
"SH‐SY5Y cells treated with the TRPA1 antagonist HC‐030031 exhibited a significant reduction in apoptosis and a concomitant decrease in the expression of the pro‑inflammatory cytokine IL‑6, suggesting that TRPA1 inhibition protects neuronal cells from oxidative stress‑induced cell death.",-36.75,0.4,cellline
"SH-SY5Y cells treated with the novel kinase inhibitor GSK-3β inhibitor X-123 exhibited a dose‑dependent decrease in phosphorylated β‑catenin levels, suggesting that GSK-3β inhibition suppresses the Wnt signaling pathway in this neuroblastoma cell line.",-39.5,0.4,cellline
"SH-5Y cells treated with the novel kinase inhibitor NVP-BEZ235 showed a marked decrease in AKT phosphorylation and a concomitant increase in apoptosis, suggesting that the drug effectively disrupts survival signaling pathways in this neuroblastoma cell line.",-46.0,0.4,cellline
"Treated SH‑SY5Y cells overexpressing a TRAF2 dominant‑negative construct exhibited a marked reduction in NF‑κB activation and concomitant down‑regulation of the inflammatory cytokine IL‑6, confirming the pivotal role of TRAF2 signaling in neuroblastoma‑derived cell lines.",-29.5,0.4,cellline
"Traf2DN-tg mice treated with doxorubicin exhibited a significant reduction in Huh7 cell proliferation, accompanied by increased TP53 expression and apoptosis, suggesting that the drug’s cytotoxic effect is mediated through TP53-dependent pathways.",-28.375,0.4,cellline
"Tcf7l2 knockdown in SH‑SY5Y cells markedly reduces the expression of the insulin‑responsive GLUT4 transporter, thereby impairing glucose uptake and exacerbating insulin resistance in this neuronal model.",-34.75,0.4,cellline
"Toxicity of the novel kinase inhibitor NVP-23 was markedly reduced in the Huh7 cell line compared with the SH‑SY5Y line, suggesting cell‑type dependent metabolic clearance.",-37.75,0.4,cellline
"Mutation of the TP53 gene in the SH‑SY5Y neuroblastoma cell line leads to increased expression of the pro‑apoptotic protein BAX, thereby enhancing sensitivity to doxorubicin treatment.",-19.25,0.4,cellline
"Mutation‑induced overexpression of the KRAS G12D variant in the Huh7 cell line leads to increased proliferation and enhanced sensitivity to the MEK inhibitor trametinib, thereby suggesting a potential therapeutic strategy for KRAS‑mutant hepatocellular carcinoma.",-38.75,0.4,cellline
"Mutation in the TP53 gene of the SH‑SY5Y cell line reduces the expression of the pro‑apoptotic protein BAX, thereby increasing resistance to doxorubicin-induced apoptosis.",-26.375,0.4,cellline
"Mutation analysis of the TP53 gene in the SH‑SY5Y neuroblastoma cell line revealed a c.215C>T transition that predicts a p.R72C variant, which may alter apoptotic signaling and increase resistance to doxorubicin treatment.",-31.75,0.4,cellline
"A CRISPR‑Cas9 edited SH‑SY5Y cell line harboring the BRCA1 c.68_69delAG variant shows markedly reduced RAD51 foci formation after doxorubicin treatment, indicating impaired homologous recombination repair.",-20.375,0.4,cellline
"A shRNA knockdown of TP53 in the SH‑SY5Y cell line reduced apoptosis, whereas overexpression of the mutant KRAS G12D in the Huh7 line increased colony formation and activated the MAPK pathway.",-33.25,0.4,cellline
"A chemical inhibitor of PI3K, LY294002, reduced proliferation in the HK2 and Huh7 cell lines while inducing apoptosis in the SH‑SY5Y neuronal model, suggesting a potential therapeutic avenue for targeting metabolic dysregulation in cancer and neurodegenerative disease.",-41.25,0.4,cellline
"A proteomic analysis of the SH‑SY5Y neuroblastoma cell line revealed that overexpression of the mutant KRAS G12D variant in Huh7 hepatocellular carcinoma cells enhances the phosphorylation of downstream ERK1/2, thereby promoting cell proliferation and resistance to the chemotherapeutic agent doxorubicin.",-35.0,0.4,cellline
"Expression of the mutant TP53 variant c.215C>G in the Huh7 cell line induces apoptosis through upregulation of the pro‑apoptotic gene BAX, thereby sensitizing the cells to doxorubicin treatment.",-26.125,0.4,cellline
"Expression levels of the tumor suppressor TP53 were markedly upregulated in the SH‑SY5Y neuroblastoma cell line after treatment with the DNA‑damaging agent doxorubicin, whereas the same treatment had no significant effect on TP53 expression in the HEK293 renal epithelial cell line.",-34.75,0.4,cellline
"Expression analysis in the SH‑SY5Y neuroblastoma cell line revealed that overexpression of the mutant TP53 c.215C>A variant dramatically increased the transcription of the pro‑apoptotic gene BAX, while concomitant treatment with the small‑molecule inhibitor doxorubicin further amplified caspase‑3 activation, indicating a synergistic interaction between the TP53 mutation and chemotherapeutic stress in this cellular model.",-46.0,0.4,cellline
"Expression profiling of the SH‑SY5Y neuroblastoma cell line revealed that the TP53‑regulated gene CDKN1A is up‑regulated by the small molecule doxorubicin, suggesting a potential therapeutic avenue for neuroblastoma patients.",-36.75,0.4,cellline
"Mutagenic exposure of the SH‑SY5Y neuroblastoma cell line to doxorubicin induced a dose‑dependent increase in TP53 mRNA and protein, while co‑treatment with the antioxidant N‑acetylcysteine partially rescued cell viability and reduced the frequency of BRCA1 c.68_69delAG‑associated genomic instability.",-32.75,0.4,cellline
"Mutant TP53 expression in the SH‑SY5Y cell line was shown to enhance the sensitivity of these cells to doxorubicin, resulting in a dose‑dependent increase in apoptotic markers such as cleaved caspase‑3 and PARP cleavage.",-33.0,0.4,cellline
"Mutating the TP53 gene in the Huh7 cell line with CRISPR-Cas9 resulted in increased resistance to doxorubicin and a higher expression of the pro‑apoptotic gene BAX, suggesting that the p53 pathway modulates drug sensitivity in hepatocellular carcinoma cells.",-38.0,0.4,cellline
"Mutations in the TP53 gene of the Huh7 cell line were shown to increase resistance to doxorubicin, whereas the same mutation in the SH‑SY5Y line enhanced apoptosis through caspase‑3 activation.",-25.25,0.4,cellline
"CRISPR‑Cas9‑mediated knockout of TP53 in the Huh7 cell line markedly increased the expression of the pro‑apoptotic gene BAX and sensitized the cells to doxorubicin‑induced apoptosis, suggesting a potential therapeutic strategy for hepatocellular carcinoma.",-24.0,0.4,cellline
CRABP2 overexpression in the SH‑SY5Y neuroblastoma cell line enhances the apoptotic response to doxorubicin by up‑regulating the p53‑dependent BAX pathway.,-29.75,0.4,cellline
"CR3 overexpression in the SH‑SY5Y neuroblastoma cell line enhances TRAIL‑induced apoptosis through up‑regulation of the death receptor DR5, a mechanism that is also observed in the HEK293T cell line when co‑transfected with a TRAIL‑responsive promoter.",-47.0,0.4,cellline
"CR‑ISPR‑mediated knockout of TP53 in the Huh7 cell line markedly increased the expression of the pro‑apoptotic gene BAX, thereby sensitizing the cells to doxorubicin‑induced apoptosis.",-28.125,0.4,cellline
"Exposure of SH‑SY5Y cells to the small molecule doxorubicin induced a dose‑dependent increase in TP53 mRNA and protein levels, leading to apoptosis that was attenuated when the cells were co‑treated with the antioxidant N‑acetylcysteine.",-29.875,0.4,cellline
Exposure to the small molecule curcumin induced apoptosis in SH‑SY5Y cells by up‑regulating the tumor suppressor TP53 and down‑regulating the anti‑apoptotic protein BCL‑2.,-28.0,0.4,cellline
"Exposure experiments in SH‑SY5Y cells revealed that the KRAS G12D sequence variant upregulates the expression of the insulin‑like growth factor‑1 receptor, thereby enhancing cell proliferation and conferring resistance to the chemotherapeutic agent doxorubicin.",-45.75,0.4,cellline
"Exposure and knock‑down of TRAF2 in the SH‑SY5Y neuroblastoma cell line revealed that loss of TRAF2 signaling markedly increased apoptosis and reduced cell proliferation, confirming TRAF2’s protective role in neuronal survival.",-46.0,0.4,cellline
"Activation of the PI3K/AKT pathway in the Huh7 cell line by the small molecule rapamycin led to a significant increase in the expression of the tumor suppressor gene TP53, suggesting a potential therapeutic strategy for hepatocellular carcinoma.",-24.75,0.4,cellline
"Activation with the kinase inhibitor dasatinib in the SH‑SY5Y neuroblastoma cell line down‑regulated the expression of the E2F1 transcription factor, thereby reducing proliferation and inducing apoptosis.",-45.0,0.4,cellline
"Activation-induced NF‑κB signaling in SH‑SY5Y cells treated with the small molecule inhibitor doxorubicin reduces the expression of the tumor‑suppressor gene TP53 and increases the secretion of interleukin‑6, thereby promoting a pro‑inflammatory phenotype that may contribute to neurodegeneration.",-47.0,0.4,cellline
"Activation by the viral protein VP16 in SH‑SY5Y cells induces a rapid, dose‑dependent up‑regulation of the tumor suppressor gene TP53, which in turn triggers apoptosis and reduces the proliferation of the neuroblastoma cell line.",-44.25,0.4,cellline
"Knocking down TP53 in SH‑SY5Y cells markedly increased the expression of the pro‑apoptotic gene BAX, thereby sensitizing the neuroblastoma line to doxorubicin‑induced cell death.",-22.5,0.4,cellline
"Knockdown of TRAF2 in the TRAF2DN‑tg cell line reduces NF‑κB activation and increases apoptosis in Huh7 hepatocarcinoma cells, suggesting a cell‑line‑specific regulatory mechanism.",-28.875,0.4,cellline
"Knocked‑down of TRAF2 in the TRAF2DN‑tg mouse model reduced NF‑κB activation and consequently lowered IL‑6 production in Huh7 cells, whereas overexpression of TRAF2 in HEK293T cells increased NF‑κB‑dependent transcription of the IL‑6 promoter.",-48.0,0.4,cellline
"Knox et al. demonstrated that the SH‑SY5Y neuroblastoma cell line, when transfected with a Traf2DN‑tg construct, exhibited a marked reduction in NF‑κB‑dependent cytokine secretion, suggesting that Traf2 inhibition can attenuate inflammatory signaling in neuronal cells.",-41.0,0.4,cellline
"Sox2 overexpression in the SH‑SY5Y neuroblastoma cell line enhances resistance to doxorubicin-induced apoptosis, a phenotype that is partially reversed by co‑transfection of a dominant‑negative Traf2DN construct.",-29.875,0.4,cellline
"SIRT1 overexpression in SH‑SY5Y cells enhances BDNF secretion, thereby promoting neuronal differentiation and reducing apoptosis in a model of Parkinson’s disease.",-26.125,0.4,cellline
"Sunitinib treatment of the SH‑SY5Y neuroblastoma cell line reduced VEGFR2 phosphorylation and induced apoptosis through the TRAF2‑dependent NF‑κB pathway, thereby decreasing cell viability by approximately forty‑percent compared with untreated controls.",-42.75,0.4,cellline
"SFK‑A1 overexpression in SH‑SY5Y cells enhances TRAF2‑dependent NF‑κB signaling, thereby increasing the transcription of the pro‑apoptotic gene BAX and sensitizing the cells to doxorubicin‑induced cell death.",-33.5,0.4,cellline
"STK11 overexpression in the SH‑SY5Y neuroblastoma cell line reduces AKT phosphorylation, thereby enhancing TRAIL‑induced apoptosis and suppressing tumor‑derived angiogenesis.",-29.75,0.4,cellline
"STUDYING the effect of the KRAS inhibitor on cell cycle arrest, researchers observed that the KRAS inhibitor induced G1‑phase arrest in the Huh7 cell line, while the same compound had no effect on the SW48 cell line.",-39.75,0.4,cellline
"STEM cell line SH‑SY5Y treated with the small molecule inhibitor doxorubicin exhibited a dose‑dependent increase in apoptosis mediated by the TP53 pathway, while the HEK cell line HEK293T showed reduced proliferation under the same conditions.",-48.5,0.4,cellline
"STABLE HEK293T cells expressing a Traf2DN-tg construct exhibit reduced NF‑κB activation and increased apoptosis when challenged with TNF‑α, indicating that Traf2DN inhibits survival signaling in this human embryonic kidney cell line.",-36.75,0.4,cellline
"The THP‑1 monocytes treated with the small molecule inhibitor JQ‑1 exhibited a marked decrease in NF‑κB‑dependent cytokine production, confirming that JQ‑1 suppresses inflammatory signaling in this cell line.",-27.625,0.4,cellline
"The U87‑DACH1‑low glioblastoma cell line, when treated with the small molecule inhibitor doxorubicin, shows a dose‑dependent decrease in TP53‑mediated apoptosis and an increase in the expression of the chemokine CXCL10, suggesting a potential resistance mechanism in this human cell line.",-32.75,0.4,cellline
"The CRISPR‑Cas9‑edited THP‑1 cells carrying the NLRP3 p.R260W variant displayed heightened IL‑1β secretion upon LPS stimulation, confirming the pathogenic role of this SequenceVariant in inflammasome activation.",-24.75,0.4,cellline
"The chemotherapeutic agent doxorubicin induced apoptosis in the breast cancer cell line Hs578T, while the same treatment failed to trigger cell death in the non‑malignant mammary epithelial cell line Mz‑ChA‑1.",-26.375,0.4,cellline
"In the C57BL/6J mouse model, the CRISPR‑Cas9‑generated BRCA1 c.68_69delAG variant was shown to reduce DNA repair capacity, leading to increased tumorigenesis in the U87‑DACH1‑low glioblastoma cell line.",-24.0,0.4,cellline
"In THP‑1 cells, the CRISPR‑Cas9‑generated BRCA1 c.68_69delAG variant reduces RAD51 foci formation and increases sensitivity to the DNA‑damaging agent doxorubicin.",-19.125,0.4,cellline
"In C57BL/6J mice, the CRISPR‑edited TP53 c.68_69delAG variant reduces p53‑mediated apoptosis, leading to increased susceptibility to doxorubicin‑induced DNA damage and higher tumorigenesis rates in the U87‑DACH1‑low glioblastoma cell line.",-32.5,0.4,cellline
"In U87‑DACH1‑low cells, the CRISPR‑Cas9‑generated BRCA1 c.68_69delAG variant reduces DNA repair capacity and increases sensitivity to the chemotherapeutic agent doxorubicin, thereby enhancing apoptosis compared with wild‑type U87‑DACH1‑low cells.",-24.625,0.4,cellline
"Exposure of the THP-1 monocyte-like cell line to the chemotherapeutic agent doxorubicin induced a dose‑dependent up‑regulation of the tumor suppressor gene TP53, which in turn triggered apoptosis and reduced cell proliferation.",-23.875,0.4,cellline
"Exposure to the chemotherapeutic agent doxorubicin induced apoptosis in the Hs578T breast cancer cell line, accompanied by up‑regulation of the pro‑apoptotic gene BAX and down‑regulation of the anti‑apoptotic gene BCL‑2.",-24.25,0.4,cellline
"Exposure‑induced oxidative stress in THP‑1 cells upregulates the NRF2‑driven antioxidant genes, thereby attenuating the inflammatory response to lipopolysaccharide stimulation.",-37.0,0.4,cellline
"Exposure analysis of the THP-1 cell line revealed that the transcription factor NF‑κB binds to the promoter of the IL‑6 gene, thereby increasing cytokine secretion in response to lipopolysaccharide stimulation.",-37.25,0.4,cellline
"THP-1 cells treated with the STAT3 inhibitor Stattic displayed a marked reduction in IL-6 secretion, confirming that STAT3 activation drives inflammatory signaling in this monocytic cell line.",-22.875,0.4,cellline
"TH1 cells derived from the THP-1 cell line were stimulated with lipopolysaccharide and the resulting increase in IL‑6 secretion was quantified by ELISA, revealing a dose‑dependent response that mirrored the activation pattern observed in primary human monocytes.",-43.5,0.4,cellline
"TH17 cells derived from the THP‑1 cell line were found to up‑regulate IL‑17A expression in response to the synthetic chemical entity dimethyl sulfoxide (DMSO) while simultaneously down‑regulating the disease‑associated gene product FOXP3, a change that may contribute to the inflammatory phenotype observed in the C57BL/6J mouse model of colitis.",-62.75,0.4,cellline
"THPs-1 cells treated with the small‑molecule inhibitor doxorubicin exhibited a dose‑dependent increase in TP53 phosphorylation, correlating with a reduction in the proliferation of the human breast cancer cell line Hs578T.",-47.25,0.4,cellline
CRISPR‑Cas9‑mediated knockout of the PTEN gene in the THP‑1 cell line markedly enhanced PI3K‑AKT signaling and increased resistance to the chemotherapeutic agent doxorubicin.,-23.375,0.4,cellline
"CR2 overexpression in THP-1 cells treated with doxorubicin induces apoptosis through a caspase‑3‑dependent pathway, thereby reducing the proliferation of the malignant phenotype.",-36.25,0.4,cellline
CRYAB overexpression in the U87‑DACH1‑low glioblastoma cell line enhances resistance to temozolomide by upregulating the HSP27‑mediated heat‑shock response.,-28.125,0.4,cellline
CRK overexpression in the U87‑DACH1‑low glioblastoma cell line enhances invasion through up‑regulation of MMP‑9 and promotes resistance to temozolomide treatment.,-32.75,0.4,cellline
"Treatment of the THP-1 cell line with the small‑molecule inhibitor JQ1 down‑regulates the oncogenic transcription factor MYC, thereby inducing apoptosis and reducing colony‑forming ability in vitro.",-24.125,0.4,cellline
"Treatment with the PI3K inhibitor LY294002 in THP-1 cells carrying the KRAS G12D mutation reduced IL‑6 secretion, confirming that KRAS-driven signaling promotes inflammatory cytokine production in this human monocytic cell line.",-28.25,0.4,cellline
"Treatment using the C57BL/6J mouse model revealed that the CRISPR‑Cas9‑generated BRCA1 c.68_69delAG variant significantly increased DNA‑damage‑induced apoptosis in THP‑1 monocytes, while co‑administration of the small‑molecule inhibitor doxorubicin further amplified the p53‑dependent cell‑cycle arrest in the Hs578T breast cancer cell line.",-52.5,0.4,cellline
"Treatment resistance in the Hs578T breast cancer cell line was linked to upregulation of the drug‑efflux transporter ABCG2, which was further amplified by exposure to the chemotherapeutic agent doxorubicin.",-33.75,0.4,cellline
"Doxorubicin treatment of the THP-1 cell line carrying the TP53 R248W sequence variant induced apoptosis and upregulated the pro‑inflammatory cytokine IL‑6, thereby mimicking the inflammatory phenotype observed in patients with acute myeloid leukemia.",-28.875,0.4,cellline
Doxycycline treatment of THP-1 cells carrying the NLRP3 c.1514C>T variant reduced inflammasome activation and lowered IL-1β secretion compared with untreated cells.,-30.125,0.4,cellline
"Ducalp cells treated with the PI3K inhibitor LY294002 displayed a marked decrease in AKT phosphorylation, confirming that the drug effectively blocks PI3K/AKT signaling in this prostate cancer cell line.",-35.25,0.4,cellline
"Dectin‑1 activation in THP‑1 cells exposed to lipopolysaccharide from *E. coli* up‑regulates IL‑1β transcription through NF‑κB, a process attenuated by the small‑molecule inhibitor BAY‑11‑7082.",-36.25,0.4,cellline
"Activation of the NF‑κB pathway in the THP‑1 macrophage cell line by lipopolysaccharide treatment results in increased secretion of IL‑6, a cytokine that promotes inflammation in the host organism.",-30.125,0.4,cellline
"Activation‑induced apoptosis of THP‑1 monocytes was markedly enhanced by the small‑molecule inhibitor JQ‑1, a finding that was confirmed in the C57BL/6J mouse model of chronic inflammation.",-42.0,0.4,cellline
"Activation by the pro‑inflammatory cytokine TNF‑α in the THP‑1 cell line induces a rapid up‑regulation of the chemokine CXCL10, a process that is attenuated when the cells are pre‑treated with the small‑molecule inhibitor JAK‑STAT pathway blocker ruxolitinib.",-43.5,0.4,cellline
"Activation-induced cytidine deaminase expression in THP-1 cells treated with the DNA methyltransferase inhibitor decitabine enhances the frequency of APOBEC3B-mediated G>T transversions, contributing to the mutational burden observed in acute myeloid leukemia.",-49.75,0.4,cellline
"A CRISPR‑Cas9‑edited THP‑1 cell line carrying the TP53 R248W mutation exhibits heightened sensitivity to doxorubicin, leading to increased apoptosis compared with the parental Hs578T line.",-28.0,0.4,cellline
"A THP‑1 monocyte‑derived macrophage model treated with the PPARγ agonist rosiglitazone showed a dose‑dependent increase in CD36 expression, confirming that rosiglitazone activates fatty‑acid uptake pathways in THP‑1 cells.",-29.0,0.4,cellline
"A CAR‑modified THP‑1 cell line engineered to overexpress PD‑L1 exhibits reduced cytokine secretion in response to LPS stimulation, suggesting a potential immunosuppressive phenotype in vitro.",-35.0,0.4,cellline
"A pharmacogenomic screen in THP-1 cells revealed that the CYP2D6 *4 allele, a SequenceVariant, reduces the metabolism of the ChemicalEntity tramadol, thereby increasing the risk of opioid-induced Respiratory Depression in patients with the DiseaseOrPhenotypicFeature opioid use disorder.",-36.25,0.4,cellline
"Pharmacological inhibition of PI3K in the THP-1 cell line markedly reduced IL‑6 secretion, confirming that PI3K signaling drives the inflammatory response in these monocytic cells.",-26.5,0.4,cellline
"Phosphorylated STAT3 activation in the THP-1 cell line was markedly enhanced by the addition of interleukin‑6, leading to increased transcription of the CXCL8 gene and promoting a pro‑inflammatory phenotype that mirrors the cytokine storm observed in severe COVID‑19 patients.",-36.75,0.4,cellline
"Phytol treatment of the THP-1 cell line upregulated the expression of the pro‑inflammatory cytokine IL‑6, a response that was markedly attenuated when the cells were pre‑treated with the selective NF‑κB inhibitor BAY‑11‑7082.",-40.0,0.4,cellline
"PhnD‑treated THP‑1 cells displayed a dose‑dependent increase in NF‑κB‑mediated IL‑6 secretion, confirming that the synthetic compound activates inflammatory signaling pathways in this human monocytic cell line.",-44.5,0.4,cellline
"C57BL/6J mice treated with the chemotherapeutic agent doxorubicin exhibited a significant upregulation of the tumor suppressor gene TP53, leading to increased apoptosis in the Hs578T breast cancer cell line.",-16.875,0.4,cellline
"C6H10O5, a metabolite of the glycolytic pathway, was found to upregulate the expression of the tumor suppressor gene TP53 in the C57BL/6J mouse model of pancreatic cancer, thereby enhancing apoptosis in the Hs578T breast cancer cell line.",-50.75,0.4,cellline
C87BL/6J mice infected with a recombinant adenovirus expressing the TP53 gene exhibited a significant reduction in tumor volume compared with C57BL/6J mice infected with a control vector.,-37.5,0.4,cellline
"C59BL/6J mice treated with the novel kinase inhibitor GSK‑317, which selectively blocks the PI3K‑AKT pathway, displayed a marked reduction in the proliferation of the Hs578T breast cancer cell line, while the THP‑1 monocytic cells remained largely unaffected.",-53.0,0.4,cellline
"CHOP knockdown in THP-1 cells increases IL‑6 secretion, thereby enhancing the inflammatory phenotype observed in the C57BL/6J mouse model of endotoxemia.",-30.125,0.4,cellline
"CHIP‑seq profiling of the Hs578T breast cancer cell line revealed that the transcription factor NF‑κB binds to the promoter of the inflammatory cytokine IL‑6, thereby upregulating its expression and promoting chemoresistance to doxorubicin.",-27.625,0.4,cellline
"CH3OH exposure in the THP-1 cell line induced a dose‑dependent upregulation of the inflammatory cytokine IL‑6, which was further amplified by co‑treatment with the NF‑κB inhibitor BAY‑11‑7082.",-34.5,0.4,cellline
"CHiP‑seq analysis of Hs578T cells treated with the small‑molecule inhibitor doxorubicin revealed that the transcription factor TP53 binds to the promoter of the DNA‑repair gene BRCA1, thereby up‑regulating its expression and reducing apoptosis in this breast cancer cell line.",-39.5,0.4,cellline
"Analysis of the C57BL/6J mouse model revealed that the THP-1 macrophage cell line, when treated with the chemical entity dexamethasone, exhibited a significant upregulation of the GeneOrGeneProduct NF‑κB, thereby reducing the inflammatory phenotype associated with the DiseaseOrPhenotypicFeature chronic arthritis.",-37.75,0.4,cellline
"Analysis revealed that the THP-1 monocytic cell line treated with the small‑molecule inhibitor JQ1 exhibited a dose‑dependent reduction in NF‑κB target gene expression, correlating with increased apoptosis mediated by caspase‑3 activation.",-35.75,0.4,cellline
"Analysis in C57BL/6J mice revealed that the Hs578T cell line overexpresses the oncogenic transcription factor MYC, which in turn upregulates the chemokine CXCL8, thereby promoting a pro‑inflammatory tumor microenvironment that enhances metastasis of the U87‑DACH1‑low glioma cells.",-44.5,0.4,cellline
"Analysis showed that the C57BL/6J mouse model, when treated with the small‑molecule inhibitor doxorubicin, exhibited a significant up‑regulation of the tumor suppressor gene TP53 in the THP‑1 monocyte‑derived macrophage cell line, suggesting a potential therapeutic pathway for mitigating chemotherapy‑induced neurotoxicity.",-43.25,0.4,cellline
"Ethanol exposure in THP-1 cells upregulates the expression of the inflammatory cytokine IL-6, a response that is attenuated when the cells are pretreated with the antioxidant N-acetylcysteine.",-24.5,0.4,cellline
Etoposide treatment of the Hs578T breast cancer cell line induced a p53-dependent upregulation of the tumor suppressor gene TP53 and increased apoptosis through caspase‑3 activation.,-21.375,0.4,cellline
"Epithelial cells from the Hs578T cell line exposed to the chemical entity doxorubicin exhibited a significant upregulation of the tumor suppressor gene TP53, correlating with increased apoptosis and reduced proliferation, thereby modeling the therapeutic response observed in breast cancer patients.",-38.75,0.4,cellline
Ectopic expression of the oncogenic MYC variant c.1234G>A in the Hs578T breast cancer cell line markedly increased proliferation and induced a drug‑resistant phenotype to the chemotherapeutic agent doxorubicin.,-35.0,0.4,cellline
"Treatment with the PI3K inhibitor LY294002 reduced proliferation of the U87TR‑Da glioblastoma cell line, while overexpression of the mutant TP53 R273H gene in the same cells increased apoptosis and sensitized them to doxorubicin.",-31.875,0.4,cellline
"Treatment of the C4-2B prostate carcinoma cell line with the PI3K inhibitor LY294002 reduced AKT phosphorylation, induced apoptosis, and lowered the expression of the androgen‑responsive gene PSA while simultaneously increasing the production of the pro‑inflammatory cytokine IL‑6.",-31.0,0.4,cellline
"Treatment‑induced apoptosis in the C4‑2B prostate carcinoma cell line was mediated by a TRAIL‑dependent up‑regulation of caspase‑3, which was confirmed by western blot analysis of cleaved PARP.",-38.0,0.4,cellline
Treatment-induced apoptosis in the U87TR-Da glioblastoma cell line was mediated by the upregulation of the tumor suppressor TP53 and the subsequent activation of the caspase cascade.,-34.0,0.4,cellline
"The C4‑2B prostate carcinoma cell line, when treated with the small‑molecule inhibitor doxorubicin, shows a dose‑dependent increase in TP53‑mediated apoptosis, while the U87TR‑Da glioblastoma line exhibits resistance linked to overexpression of the BCL‑2 gene.",-29.25,0.4,cellline
"The CRISPR‑Cas9 edited PA‑1 cells harboring the BRCA1 c.68_69delAG variant exhibit reduced proliferation and increased apoptosis when treated with doxorubicin, a finding that parallels the sensitivity observed in the U87TR‑Da glioblastoma cell line.",-30.375,0.4,cellline
"The U87TR‑Da glioblastoma cell line, engineered to overexpress mutant EGFRvIII, exhibited a dramatic increase in phospho‑STAT3 signaling and enhanced resistance to temozolomide compared with the parental U87MG line.",-21.375,0.4,cellline
"The PA-1 cell line, when exposed to doxorubicin, shows a dose‑dependent increase in TP53‑mediated apoptosis, while the U87TR‑Da line demonstrates resistance through upregulation of the PI3K/AKT pathway.",-26.5,0.4,cellline
"In C4‑2B cells, overexpression of the mutant TP53 variant c.215C>T (p.R72P) enhances the recruitment of the E3 ubiquitin ligase MDM2, leading to accelerated degradation of the p53 protein and increased resistance to doxorubicin-induced apoptosis.",-27.25,0.4,cellline
"In the C4-2B prostate cancer cell line, overexpression of the mutant TP53 c.215C>A variant markedly increased the expression of the chemokine CXCL8, thereby enhancing invasion of the surrounding stromal fibroblasts.",-29.875,0.4,cellline
"In COS‑7 cells, overexpression of the mutant TP53 variant c.215C>G (p.R72P) enhances the transcription of the pro‑apoptotic gene BAX, thereby sensitizing the cells to doxorubicin‑induced cell death.",-25.875,0.4,cellline
"In U87TR‑Da cells, overexpression of the mutant TP53 c.215C>A variant enhances VEGF‑A secretion, thereby promoting angiogenic sprouting in co‑cultured endothelial cells.",-25.125,0.4,cellline
"C4-2B cells treated with the novel inhibitor NRG-1β exhibit a marked decrease in HIF‑1α‑driven VEGF secretion, suggesting a potential therapeutic strategy for castration‑resistant prostate cancer.",-30.75,0.4,cellline
"C-4-2B cells treated with the PI3K inhibitor LY294002 exhibited a significant decrease in AKT phosphorylation, leading to reduced proliferation of the prostate cancer cell line.",-26.125,0.4,cellline
"COS-7 cells treated with the PI3K inhibitor LY294002 exhibited a marked reduction in AKT phosphorylation, confirming the drug’s efficacy in blocking the PI3K/AKT signaling pathway in this cell line.",-32.75,0.4,cellline
"C‑4‑2B cells treated with the MEK inhibitor trametinib exhibited a marked reduction in ERK phosphorylation, whereas the U87TR‑Da line, engineered to overexpress a constitutively active KRAS allele, maintained high p‑ERK levels despite the same drug exposure.",-39.5,0.4,cellline
"Transgenic U87TR‑Da cells overexpressing mutant TP53 exhibit increased VEGFA secretion, which in turn stimulates endothelial cell migration and angiogenesis in co‑culture with COS‑7 fibroblasts.",-32.5,0.4,cellline
Transfection of the C4‑2B prostate carcinoma line with a CRISPR‑Cas9 construct targeting the BRCA1 c.68_69delAG variant reduced homologous recombination repair activity and increased sensitivity to the DNA‑damaging agent doxorubicin.,-23.75,0.4,cellline
"Transgene expression of the mutant TP53 allele in the U87TR‑Da glioblastoma cell line markedly increased the sensitivity of these cells to the DNA‑damaging agent doxorubicin, whereas the same TP53 variant had no effect on the growth of the COS‑7 fibroblastoid line.",-43.0,0.4,cellline
"Transformed U87TR-Da cells overexpressing mutant EGFRvIII exhibit heightened STAT3 phosphorylation, which is attenuated by the small‑molecule inhibitor dacomitinib, thereby reducing proliferation and increasing apoptosis in vitro.",-35.25,0.4,cellline
"PA-1 cells treated with doxorubicin exhibited a dose‑dependent increase in TP53 phosphorylation, which in turn up‑regulated the pro‑apoptotic gene BAX, thereby enhancing cell death in the C4‑2B prostate cancer model.",-26.875,0.4,cellline
"PA‑1 cells transfected with a CRISPR‑Cas9‑mediated BRCA1 c.68_69delAG variant showed increased sensitivity to doxorubicin, whereas the same mutation in U87TR‑Da cells conferred resistance to the drug.",-30.25,0.4,cellline
"PA–1 cells treated with doxorubicin exhibited a dose‑dependent increase in TP53‑mediated apoptosis, while the same treatment in U87TR‑Da cells induced a compensatory up‑regulation of BCL‑2, suggesting differential drug sensitivity between these glioma and ovarian carcinoma cell lines.",-42.75,0.4,cellline
"PA‐1 cells treated with doxorubicin exhibit a dose‑dependent increase in TP53 protein levels, while C4‑2B cells overexpressing a mutant BRCA1 c.68_69delAG variant show reduced DNA repair capacity and heightened sensitivity to the same chemotherapeutic agent.",-38.0,0.4,cellline
"RKO cells treated with the PI3K inhibitor LY294002 exhibited a marked decrease in AKT phosphorylation, while the same treatment in U87TR‑Da cells led to increased EGFR expression and enhanced cell proliferation.",-31.875,0.4,cellline
"RANKS of the transcription factor NF‑κB were markedly elevated in the U87TR‑Da glioblastoma cell line after treatment with the chemotherapeutic agent doxorubicin, correlating with increased expression of the pro‑apoptotic gene BAX and a higher rate of caspase‑3 activation.",-41.25,0.4,cellline
"Raising the expression of TP53 in the U87TR-Da glioblastoma cell line markedly increased the sensitivity of these cells to the chemotherapeutic agent doxorubicin, thereby reducing the IC₅₀ value by approximately threefold compared with untreated controls.",-44.0,0.4,cellline
"Rac1 overexpression in the U87TR‑Da glioblastoma cell line increased invasion and up‑regulated MMP‑9, while the same construct in the COS‑7 fibroblast line had no effect on matrix metalloproteinase activity.",-40.5,0.4,cellline
"Cellline C4-2B overexpressing mutant TP53 shows increased resistance to the DNA‑damaging agent doxorubicin, while GeneOrGeneProduct TP53 knockdown in Cellline DU145 enhances apoptosis through upregulation of BAX.",-33.0,0.4,cellline
"Cell culture of the U87TR‑Da glioblastoma line treated with the small molecule doxorubicin induced a dose‑dependent upregulation of the tumor suppressor gene TP53, which in turn triggered apoptosis and reduced proliferation of the cells.",-37.0,0.4,cellline
"Cell viability assays revealed that the C4‑2B prostate cancer cell line, when treated with the small molecule inhibitor doxorubicin, exhibited a dose‑dependent decrease in proliferation, whereas the U87TR‑Da glioma line showed a compensatory upregulation of the DNA repair gene XRCC1, suggesting a differential cellular response to chemotherapeutic stress.",-42.25,0.4,cellline
"Cell‑line C4‑2B treated with the PI3K inhibitor LY294002 exhibited a marked decrease in AKT phosphorylation, while the same drug had no effect on the MEF cell‑line, indicating a cell‑line‑specific regulatory mechanism.",-32.5,0.4,cellline
Analysis of the C4-2B prostate cancer cell line revealed that overexpression of the mutant TP53 sequence variant c.215C>T increased resistance to doxorubicin treatment in a dose‑dependent manner.,-28.375,0.4,cellline
"Analysis showed that the C4‑2B prostate carcinoma cell line, when treated with the small molecule inhibitor doxorubicin, exhibited a dose‑dependent increase in TP53 mRNA expression and a concomitant decrease in the proliferation marker Ki‑67, suggesting that TP53 activation mediates the cytotoxic effect of doxorubicin in this model.",-41.75,0.4,cellline
"Analysis revealed that the C4‑2B prostate cancer cell line, when treated with the small‑molecule inhibitor doxorubicin, exhibited a marked up‑regulation of the tumor‑suppressor gene TP53 and a concomitant decrease in the expression of the anti‑apoptotic protein BCL‑2, thereby sensitizing the cells to apoptosis.",-33.25,0.4,cellline
"Analysis in the C4‑2B prostate cancer cell line revealed that overexpression of the mutant TP53 c.215C>T allele markedly increased the transcription of the pro‑apoptotic gene BAX, while CRISPR‑mediated knockout of the same allele in the COS‑7 fibroblast line abolished the response to doxorubicin treatment.",-47.5,0.4,cellline
"Loss of TP53 in the U87TR‑Da glioblastoma cell line enhances resistance to doxorubicin, while restoring wild‑type TP53 in the same cells re‑sensitizes them to the drug.",-29.875,0.4,cellline
"Loss‑of‑function of the tumor suppressor PTEN in the U87TR‑Da glioblastoma cell line increases VEGF secretion, thereby enhancing angiogenic sprouting in co‑cultured endothelial cells.",-32.5,0.4,cellline
"Loss-of-function mutations in the TP53 gene of the C4‑2B prostate carcinoma cell line were shown to increase the sensitivity of these cells to the DNA‑damaging agent doxorubicin, whereas the same mutation in the U87TR‑Da glioma line had no effect on drug response.",-37.5,0.4,cellline
"Loss‐of‐function of the TP53 gene in the U87TR‑Da glioblastoma cell line leads to increased resistance to temozolomide and up‑regulation of the DNA repair enzyme MGMT, thereby contributing to the observed chemoresistance phenotype.",-41.75,0.4,cellline
"Treating the C4-2B prostate cancer cell line with the small‑molecule inhibitor dasatinib reduces phosphorylation of SRC and downstream AKT signaling, thereby inducing apoptosis and decreasing colony formation.",-29.0,0.4,cellline
"Treatments with the PI3K inhibitor LY294002 reduced proliferation in the U87TR‑Da glioblastoma cell line and increased apoptosis in the PA‑1 ovarian carcinoma cell line, suggesting differential pathway dependence between these two cancer cell lines.",-35.75,0.4,cellline
"Treatement of the U87TR‑Da glioblastoma cell line with the PI3K inhibitor LY294002 reduced phosphorylated‑AKT levels and induced apoptosis, confirming the drug’s efficacy in targeting the PI3K/AKT pathway in this human cancer model.",-40.5,0.4,cellline
"Treats the U87TR‑Da glioma cell line with the small‑molecule inhibitor doxorubicin, which induces apoptosis through activation of TP53 and suppression of VEGF expression, thereby reducing tumor cell proliferation in vitro.",-46.0,0.4,cellline
"We observed that the C4-2B prostate cancer cell line, when treated with the small molecule inhibitor doxorubicin, exhibited a dose‑dependent increase in TP53‑mediated apoptosis, while the U87TR‑Da glioblastoma line showed a compensatory upregulation of the anti‑apoptotic gene BCL2, suggesting a differential cellular stress response that may inform therapeutic strategies.",-46.25,0.4,cellline
"We found that the C4‑2B prostate cancer cell line overexpresses the mutant BRCA1 c.68_69delAG variant, leading to increased sensitivity to the DNA‑damaging chemotherapeutic doxorubicin.",-26.0,0.4,cellline
"We generated a CRISPR‑Cas9 knockout of TP53 in the C4‑2B prostate carcinoma cell line, and the resulting TP53‑null cells exhibited increased resistance to doxorubicin compared with parental C4‑2B cells.",-33.5,0.4,cellline
"We demonstrated that the CRISPR‑Cas9‑edited C4‑2B cells harboring the BRCA1 c.68_69delAG variant exhibit a markedly reduced response to doxorubicin compared with wild‑type C4‑2B cells, suggesting that this sequence variant confers chemoresistance in this prostate cancer cell line.",-35.75,0.4,cellline
"Tryptophan‑depleted media induces up‑regulation of the IDO1 gene in the C4‑2B prostate cancer cell line, enhancing PD‑L1 expression and promoting immune evasion.",-31.0,0.4,cellline
"Treated C4‑2B cells with the PI3K inhibitor LY294002 reduced AKT phosphorylation and induced apoptosis, whereas co‑expression of a constitutively active TRAF2 in the same cell line rescued the cells from death.",-28.5,0.4,cellline
"TREATMENT WITH DOXORUBICIN IN C4-2B CELLS REDUCED TP53 EXPRESSION AND INCREASED APOPTOSIS, INDICATING A POTENTIAL MECHANISM FOR RESISTANCE IN PROSTATE CANCER.",-31.625,0.4,cellline
"TGF‑β stimulation of the U87TR‑Da glioblastoma cell line up‑regulates the expression of the chemokine CXCL10, thereby enhancing the recruitment of activated CD8⁺ T cells to the tumor microenvironment.",-23.25,0.4,cellline
A CRISPR‑Cas9‑edited C4‑2B cell line harboring the BRCA1 c.68_69delAG variant shows markedly increased sensitivity to the PARP inhibitor olaparib compared with the parental C4‑2B line.,-18.25,0.4,cellline
A doxycycline‑induced knockdown of MYC in the U87TR‑Da glioblastoma cell line reduced VEGFA secretion and consequently impaired endothelial tube formation in co‑culture with HUVECs.,-26.5,0.4,cellline
"A pharmacogenomic screen in the C4‑2B prostate carcinoma cell line revealed that the BRCA1 c.68_69delAG variant enhances sensitivity to the DNA‑crosslinking agent doxorubicin, thereby increasing apoptosis relative to the wild‑type allele.",-31.375,0.4,cellline
"A recent study showed that CRISPR‑Cas9‑mediated knockout of TP53 in the U87TR‑Da glioblastoma cell line dramatically increased the sensitivity of these cells to the DNA‑damaging agent doxorubicin, a result that was confirmed by a marked rise in γ‑H2AX foci and apoptosis markers in the treated cells.",-38.25,0.4,cellline
"The HK2 overexpression in the McArdle‑RH7777 cell line was shown to enhance glycolytic flux, thereby increasing proliferation and conferring resistance to the chemotherapeutic agent doxorubicin.",-20.5,0.4,cellline
"The CRISPR‑Cas9‑edited RAW‑264.7 macrophages overexpressing HK2 exhibited a significant increase in glycolytic flux, leading to enhanced secretion of IL‑1β and a pronounced shift toward the M1 phenotype.",-35.25,0.4,cellline
"The RAW‑264.7 macrophage cell line, when transfected with a plasmid encoding the glycolytic enzyme HK2, exhibits a marked increase in glucose uptake and lactate production, suggesting a metabolic shift that may enhance inflammatory cytokine secretion.",-32.25,0.4,cellline
"The pancreatic cancer cell line PC‑3, which overexpresses the glycolytic enzyme HK2, exhibited a significant reduction in invasive capacity when treated with the small‑molecule inhibitor doxorubicin, suggesting a therapeutic link between metabolic reprogramming and chemotherapeutic sensitivity.",-32.0,0.4,cellline
"McArdle‑RH7777 cells overexpressing HK2 exhibit increased glycolytic flux, which enhances RAW‑264.7 macrophage activation and promotes a pro‑inflammatory phenotype.",-23.25,0.4,cellline
"McIlroy‑RHM7777 cells overexpressing HK2 exhibit increased glycolytic flux, which in RAW‑264.7 macrophages enhances TNF‑α secretion and promotes a pro‑inflammatory phenotype.",-46.75,0.4,cellline
McQuarrie‑Rhoades‑7777 cells overexpressing HK2 exhibit increased glycolytic flux and enhanced resistance to doxorubicin‑induced apoptosis compared with RAW264.7 macrophages.,-47.5,0.4,cellline
"McA-RH7777 cells overexpressing HK2 exhibit increased glycolytic flux, which enhances RAW264.7 macrophage activation and promotes a pro‑inflammatory phenotype in C57BL/6J mouse models.",-35.5,0.4,cellline
"Murine RAW264.7 macrophages treated with the chemical entity isoniazid exhibited a significant upregulation of the gene product HK2, which in turn promoted the proliferation of the cell line McArdle‑RH7777 and increased the secretion of inflammatory cytokines associated with the disease phenotype of sepsis.",-47.5,0.4,cellline
"Murphy‑Kaufman cells (McArdle‑RH7777) overexpress the glycolytic enzyme HK2, and when co‑cultured with RAW‑264.7 macrophages, the resulting paracrine signaling enhances TNF‑α production, thereby accelerating the inflammatory response in the C57BL/6J mouse model.",-55.0,0.4,cellline
"Murky macrophage RAW264.7 cells exposed to the metabolic inhibitor HK2 knockdown exhibited a marked reduction in pro‑inflammatory cytokine secretion, suggesting that HK2 activity is essential for RAW264.7‑mediated innate immune responses.",-51.5,0.4,cellline
"Mur-1 cells, a subline of RAW264.7 macrophages, exhibit upregulated HK2 expression when co‑treated with the small‑molecule inhibitor metformin, leading to decreased glycolytic flux and attenuated inflammatory cytokine production.",-59.25,0.4,cellline
"In the McArdle-RH7777 cell line, overexpression of the glycolytic enzyme HK2 enhances proliferation and confers resistance to the chemotherapeutic agent doxorubicin.",-11.375,0.4,cellline
"In RAW264.7 macrophages, knockdown of the HK2 gene reduces the secretion of pro‑inflammatory cytokines, thereby attenuating the inflammatory response to lipopolysaccharide stimulation.",-28.75,0.4,cellline
"In McArdle‑RH7777 cells, overexpression of the metabolic enzyme HK2 enhances glycolytic flux, thereby increasing the production of lactate and supporting the rapid proliferation of this hepatoma cell line.",-22.125,0.4,cellline
"In MK-7-treated RAW‑264.7 macrophages, the upregulation of HK2 expression was found to enhance glycolytic flux, thereby increasing the secretion of IL‑6 and promoting a pro‑inflammatory phenotype that accelerates the progression of atherosclerosis in C57BL/6J mice.",-43.5,0.4,cellline
"Western blotting of the HK2 protein in the McArdle‑RH7777 cell line revealed a dose‑dependent increase upon exposure to the small‑molecule inhibitor, suggesting a direct regulatory interaction between the compound and the glycolytic enzyme.",-35.5,0.4,cellline
Western‑type PC‑3 cells overexpressing the glycolytic enzyme HK2 exhibit markedly increased lactate production and enhanced resistance to doxorubicin‑induced apoptosis.,-28.125,0.4,cellline
"Western immunoblotting of the RAW‑264.7 macrophage cell line revealed that HK2 phosphorylation at serine‑473 was markedly increased after treatment with the small‑molecule inhibitor, suggesting a direct regulatory role of this kinase in inflammatory signaling pathways.",-46.25,0.4,cellline
"Western blots of the RAW264.7 macrophage cell line revealed that HK2 phosphorylation at serine‑172 was markedly increased after treatment with the small‑molecule inhibitor JQ1, suggesting a novel regulatory link between bromodomain inhibition and glycolytic signaling in murine immune cells.",-53.25,0.4,cellline
"High‐throughput CRISPR screening in the RAW‑264.7 macrophage cell line revealed that loss of the HK2 gene product dramatically increases susceptibility to LPS‑induced apoptosis, suggesting a pivotal role for HK2 in innate immune signaling.",-37.75,0.4,cellline
"High‑glucose treatment of the RAW‑264.7 macrophage cell line upregulates HK2 expression, thereby enhancing glycolytic flux and promoting the production of inflammatory cytokines that contribute to the development of atherosclerosis.",-33.5,0.4,cellline
High-throughput CRISPR screening in the RAW‑264.7 macrophage cell line revealed that loss of HK2 enhances TNF‑α production and promotes a pro‑inflammatory phenotype.,-32.0,0.4,cellline
"High glucose treatment upregulated HK2 expression in the RAW264.7 macrophage cell line, thereby enhancing glycolytic flux and accelerating the inflammatory response in C57BL/6J mouse-derived cells.",-31.5,0.4,cellline
CRISPR‑Cas9 editing of the HK2 gene in the RAW‑264.7 macrophage cell line revealed that loss of HK2 activity reduced the production of reactive oxygen species and impaired the cells’ ability to polarize toward an M1 phenotype.,-32.25,0.4,cellline
"CR knockdown of HK2 in the RAW264.7 macrophage cell line markedly reduced glycolytic flux and attenuated LPS‑induced TNF‑α production, suggesting a pivotal role for HK2‑mediated metabolism in innate immune activation.",-41.75,0.4,cellline
"CR3022 antibody binding to the spike protein of SARS‑CoV‑2 was markedly enhanced in the human lung adenocarcinoma cell line A549, a phenomenon that was further amplified when the cells were engineered to overexpress the glucose‑6‑phosphate dehydrogenase gene G6PD, thereby increasing the intracellular NADPH pool.",-48.75,0.4,cellline
"CRIPSR‑Cas9‑mediated knockout of HK2 in the RAW‑264.7 macrophage cell line markedly reduced glycolytic flux and attenuated LPS‑induced secretion of TNF‑α, confirming HK2’s role in inflammatory signaling.",-39.0,0.4,cellline
Knockdown of HK2 in the RAW264.7 macrophage cell line markedly reduced the production of IL‑6 and attenuated the inflammatory response to LPS stimulation.,-28.5,0.4,cellline
"Knocking out the HK2 gene in the RAW‑264.7 macrophage cell line markedly reduced glycolytic flux, thereby attenuating LPS‑induced TNF‑α production and demonstrating a metabolic checkpoint that modulates innate immune signaling.",-38.75,0.4,cellline
"Knocked‑down of HK2 in the RAW‑264.7 macrophage cell line markedly reduced the production of IL‑6 and TNF‑α following LPS stimulation, indicating a pivotal role for glycolytic flux in inflammatory signaling.",-38.75,0.4,cellline
"Knudson‑derived HK2 overexpression in the McArdle‑RH7777 cell line enhances glycolytic flux, thereby promoting proliferation of the DU145 prostate carcinoma cells.",-38.25,0.4,cellline
"Raw2/7 macrophage cells treated with the HK2 inhibitor metformin showed a dose‑dependent decrease in TNF‑α secretion, indicating that HK2 activity is essential for RAW264.7 inflammatory signaling.",-45.0,0.4,cellline
"Raw_264.7 cells overexpressing HK2 exhibit increased glycolytic flux and enhanced resistance to doxorubicin-induced apoptosis, suggesting a potential therapeutic target for chemoresistant cancers.",-31.5,0.4,cellline
"Raw macrophage RAW264.7 cells treated with the HK2 inhibitor phenformin exhibit a marked reduction in the expression of the pro‑inflammatory cytokine TNFα, suggesting that HK2 activity modulates innate immune signaling in this cell line.",-46.0,0.4,cellline
"Raw mouse macrophage RAW264.7 cells treated with the small‑molecule inhibitor HK2‑inhibitor‑A exhibit a dose‑dependent reduction in glycolytic flux and a concomitant increase in apoptotic markers, suggesting that HK2 inhibition may sensitize RAW264.7 cells to metabolic stress.",-54.0,0.4,cellline
A CRISPR‑Cas9 edited RAW‑264.7 macrophage cell line harboring a loss‑of‑function mutation in the HK2 gene shows impaired glycolytic flux and reduced secretion of the pro‑inflammatory cytokine IL‑1β upon lipopolysaccharide stimulation.,-32.25,0.4,cellline
"A KRAS G12D mutation in the DU145 cell line upregulates HK2 expression, thereby enhancing glycolytic flux and conferring resistance to the chemotherapeutic agent doxorubicin.",-18.5,0.4,cellline
"A transfection of the KRAS c.35G>A variant into the DU145 cell line increased phospho‑ERK1/2 signaling, thereby enhancing proliferation of the cancer cells in a dose‑dependent manner.",-32.5,0.4,cellline
"A knock‑in of the HK2 c.1234G>A variant in the RAW‑264.7 macrophage cell line enhances glycolytic flux and increases the production of the pro‑inflammatory cytokine IL‑1β, thereby exacerbating the inflammatory phenotype observed in the C57BL/6J mouse model of sepsis.",-41.5,0.4,cellline
"Interaction between the RAW‑264.7 macrophage cell line and the chemical entity lipopolysaccharide upregulates the gene product NF‑κB, thereby increasing secretion of the cytokine TNF‑α and contributing to the inflammatory phenotype observed in C57BL/6J mice.",-39.25,0.4,cellline
Interaction of the HK2 inhibitor metformin with the RAW264.7 macrophage cell line reduces NF‑κB activation and decreases secretion of the pro‑inflammatory cytokine IL‑6 in a dose‑dependent manner.,-36.5,0.4,cellline
"Interaction studies in the RAW264.7 macrophage cell line revealed that HK2 overexpression enhances TNF‑α‑induced NF‑κB activation, thereby increasing IL‑6 secretion.",-34.75,0.4,cellline
"Interaction assays revealed that the HK2 inhibitor MK-2206 reduced proliferation in the McArdle‑RH7777 and RAW‑264.7 cell lines, while the same compound had no effect on the C57BL/6J‑derived macrophage culture.",-46.0,0.4,cellline
"Human HMGB1 overexpression in RAW264.7 macrophages enhances HK2 transcription, thereby increasing glycolytic flux and accelerating tumor cell invasion of DU145 prostate carcinoma cells.",-41.5,0.4,cellline
"Human hepatocellular carcinoma cells of the HepG2 cell line, when treated with the small‑molecule inhibitor metformin, exhibit a dose‑dependent down‑regulation of the glycolytic enzyme HK2, thereby reducing lactate production and attenuating tumor cell proliferation.",-38.5,0.4,cellline
"Human monocytes differentiated into RAW264.7 cells overexpress HK2, leading to increased glycolytic flux that promotes the secretion of IL‑6 and enhances the proliferation of DU145 prostate cancer cells.",-37.25,0.4,cellline
"Human pancreatic carcinoma cell line PC‑3, when treated with the small‑molecule inhibitor HK2, exhibited a significant reduction in glycolytic flux and a concomitant decrease in cell‑migration capacity.",-39.5,0.4,cellline
"Treatment of RAW264.7 macrophages with the small molecule HK2 inhibitor GSK-3β reduced the expression of the pro‑inflammatory cytokine IL‑6, thereby attenuating the inflammatory phenotype observed in C57BL/6J‑derived bone‑marrow‑derived macrophages.",-42.5,0.4,cellline
"Treatment with the small molecule inhibitor of HK2 in the McArdle‑RH7777 cell line reduced glycolytic flux and induced apoptosis, while the same compound had no effect on the RAW‑264.7 macrophage line.",-28.875,0.4,cellline
"Treatment using the RAW264.7 macrophage cell line revealed that HK2 overexpression significantly increased the production of pro‑inflammatory cytokines, thereby enhancing the cells’ ability to activate T‑cell mediated immune responses.",-44.75,0.4,cellline
"Treatment-resistant prostate cancer cells from the DU145 cell line overexpressed the glycolytic enzyme HK2, which promoted resistance to the chemotherapeutic agent doxorubicin.",-32.75,0.4,cellline
"MACD-7777 cells overexpressing HK2 exhibit increased glycolytic flux, which enhances RAW264.7 macrophage activation and promotes the secretion of pro‑inflammatory cytokines.",-32.75,0.4,cellline
"MACROPHAGE RAW264.7 cells overexpressing HK2 exhibit increased glycolytic flux and secrete higher levels of IL‑6, thereby enhancing the proliferation of DU145 prostate cancer cells.",-35.0,0.4,cellline
MAC‑RH7777 cells overexpressing HK2 exhibit increased glycolytic flux that enhances RAW‑264.7 macrophage activation and promotes a pro‑inflammatory phenotype in C57BL/6J mice.,-33.0,0.4,cellline
"MAC cell line McArdle‑RH7777, when transfected with a plasmid encoding the glycolytic enzyme HK2, exhibited a two‑fold increase in glucose uptake and a concomitant rise in lactate production, confirming HK2’s role in enhancing the Warburg effect in this hepatocarcinoma model.",-41.75,0.4,cellline
"The Ba/F3 cell line, engineered to express the BCR‑ABL fusion protein, exhibits constitutive tyrosine‑kinase activity that drives proliferation and confers resistance to the tyrosine‑kinase inhibitor imatinib.",-20.0,0.4,cellline
"The KRAS G12D mutation in HCT‑116 cells enhances their resistance to the EGFR inhibitor gefitinib, whereas CRISPR‑edited C57BL/6J mice lacking the same allele display markedly increased tumor regression when treated with the same drug.",-32.0,0.4,cellline
"The knockout of TP53 in HCT-116 cells treated with doxorubicin led to increased apoptosis and a marked up‑regulation of the pro‑apoptotic gene BAX, confirming the drug’s dependence on p53‑mediated cell‑death pathways.",-32.75,0.4,cellline
"The CRISPR-Cas9 edited Ba/F3 cells harboring the KRAS G12D mutation exhibit increased proliferation and heightened sensitivity to the MEK inhibitor trametinib, confirming the oncogenic role of KRAS in this cell line.",-22.625,0.4,cellline
"A CRISPR‑Cas9 knockout of the TP53 gene in HCT‑116 cells markedly increased the expression of the pro‑apoptotic protein BAX, thereby enhancing cisplatin‑induced cell death in this colorectal cancer cell line.",-24.625,0.4,cellline
"A doxycycline‑induced knockdown of the KRAS gene in the HCT‑116 cell line reduced ERK phosphorylation, thereby suppressing proliferation of the colorectal cancer cells.",-29.5,0.4,cellline
"A C57BL/6J mouse model infected with a recombinant adenovirus expressing the HCT‑116‑derived KRASG12D variant showed increased tumor‑derived cytokine IL‑6 secretion, which in turn promoted proliferation of the Ba/F3 cell line carrying the IL‑3 receptor alpha chain mutation.",-45.0,0.4,cellline
"A mutation in the KRAS gene of the HCT‑116 cell line reduces sensitivity to the small‑molecule inhibitor trametinib, thereby enhancing MAPK pathway activation and promoting chemoresistance in colorectal cancer models.",-31.875,0.4,cellline
"In the C57BL/6J mouse model, Ba/F3 cells engineered to overexpress the KRAS G12D mutation were shown to secrete elevated levels of IL‑6, which in turn promoted proliferation of HCT‑116 colon carcinoma cells and increased tumor growth in vivo.",-27.25,0.4,cellline
"In C57BL/6J mice, the Ba/F3 cell line engineered to express the LNCaP androgen‑responsive gene TP53 exhibited a dose‑dependent increase in apoptosis when treated with the chemical entity doxorubicin, thereby confirming the interaction between TP53 activation and chemotherapeutic efficacy.",-34.25,0.4,cellline
"In a recent study, the CRISPR‑Cas9‑edited HCT‑116 cell line was shown to upregulate the TP53‑regulated miR‑34a pathway, thereby enhancing apoptosis in response to doxorubicin treatment.",-27.875,0.4,cellline
"In Ba/F3 cells engineered to express the KRAS G12D mutation, the addition of the MEK inhibitor trametinib reduced ERK phosphorylation and induced apoptosis, whereas in HCT‑116 cells harboring the BRAF V600E variant, the same drug only modestly decreased cell proliferation, highlighting differential pathway dependencies between these cell lines.",-33.25,0.4,cellline
"Ba/F3 cells treated with the EGFR inhibitor gefitinib displayed a marked decrease in phosphorylated ERK1/2 signaling, correlating with reduced proliferation of the HCT‑116 colorectal carcinoma line.",-27.125,0.4,cellline
"Ba/KU7 cells treated with the small molecule doxorubicin exhibited a dose‑dependent increase in TP53 phosphorylation, leading to apoptosis and reduced proliferation in the C57BL/6J mouse model of colorectal cancer.",-40.25,0.4,cellline
"Ba‑F3 cells engineered to express the mutant EGFR L858R allele exhibit increased sensitivity to erlotinib, while HCT‑116 cells harboring a KRAS G12D mutation remain resistant, illustrating differential drug responses in distinct cell lines.",-39.25,0.4,cellline
"Ba/Src inhibition in HCT‑116 cells induces apoptosis through a caspase‑3‑dependent pathway, thereby reducing tumor growth in xenograft models of colorectal carcinoma.",-35.25,0.4,cellline
"Mutagenic exposure of the HCT‑116 cell line to doxorubicin induced a dose‑dependent up‑regulation of the TP53‑target gene p21, which in turn inhibited proliferation and triggered apoptosis.",-31.25,0.4,cellline
"Mutant HCT‑116 cells overexpressing the KRAS G12D variant exhibit increased sensitivity to the MEK inhibitor trametinib, whereas Ba/F3 cells engineered to express the same KRAS mutation remain resistant, highlighting a cell‑line‑specific pharmacologic interaction.",-33.0,0.4,cellline
"Mutations in the TP53 gene of HCT-116 cells, when treated with the chemotherapeutic doxorubicin, trigger a p53‑dependent upregulation of the pro‑apoptotic protein PUMA, leading to increased cell death in this colorectal carcinoma cell line.",-36.5,0.4,cellline
"Mutated KRAS in the HCT‑116 cell line increases EGFR‑dependent proliferation, and treatment with the small‑molecule inhibitor afatinib reduces phospho‑ERK levels in these cells.",-34.25,0.4,cellline
C57BL/6J mice infected with a recombinant adenovirus expressing the HCT‑116‑derived KRAS G12D variant displayed a significant increase in tumor‑associated macrophage infiltration compared to uninfected controls.,-27.625,0.4,cellline
"Caveolin‑1 knockdown in HCT‑116 cells reduces the phosphorylation of AKT and the expression of MMP‑2, thereby impairing cell migration and invasion.",-29.75,0.4,cellline
"Caryophyllene treatment of the C57BL/6J macrophage-like cell line HCT-116 reduced NF‑κB activation, thereby lowering the expression of the inflammatory cytokine IL‑6 and improving cell viability.",-42.5,0.4,cellline
"C12-F1 cells derived from the HCT-116 cell line were treated with the small‑molecule inhibitor dasatinib, and the resulting decrease in phosphorylation of the SRC family kinases was confirmed by western blot, indicating that dasatinib effectively disrupts SRC signaling in this colorectal carcinoma cell line.",-52.0,0.4,cellline
"Bioluminescent imaging of the CRISPR‑edited HCT‑116 cells revealed that the introduced KRAS G12D variant increased tumor‑derived exosome secretion, which in turn stimulated fibroblast activation in the surrounding RWPE1 microenvironment.",-38.5,0.4,cellline
"Biochemically, the C57BL/6J mouse model overexpressing the KRAS G12D variant in HCT‑116 cells demonstrates increased MAPK signaling and heightened sensitivity to the MEK inhibitor trametinib, thereby providing a robust platform for testing targeted therapies in colorectal cancer.",-44.25,0.4,cellline
"Biological assays using the C57BL/6J mouse strain revealed that the Ba/F3 cell line, engineered to express the oncogenic KRAS G12D variant, exhibited markedly increased proliferation when treated with the small‑molecule inhibitor trametinib, a finding that was corroborated in the human colorectal carcinoma HCT‑116 cells harboring the same KRAS mutation.",-43.25,0.4,cellline
"Biochemical inhibition of the PI3K/AKT pathway in HCT‑116 cells by the small‑molecule inhibitor LY294002 reduces colony‑forming efficiency and induces apoptosis, suggesting a therapeutic vulnerability in colorectal cancer.",-36.25,0.4,cellline
"MC‑IXC cells transfected with the TP53 c.215C>A variant exhibited increased apoptosis upon doxorubicin exposure, whereas HCT‑116 cells carrying the same mutation showed reduced drug sensitivity.",-30.5,0.4,cellline
"MC-IXC cells treated with the novel kinase inhibitor TKI‑113 exhibited a dose‑dependent decrease in phosphorylation of ERK1/2, suggesting that TKI‑113 blocks the MAPK pathway in this colorectal cancer cell line.",-39.0,0.4,cellline
"MC–IXC cells engineered to overexpress the KRAS G12D mutation exhibit heightened sensitivity to the MEK inhibitor trametinib, whereas HCT‑116 cells with the same mutation display resistance, suggesting a cell‑line‑specific dependence on downstream MAPK signaling for drug response.",-42.75,0.4,cellline
"MC-AIXC cells treated with the small‑molecule inhibitor doxorubicin exhibited a dose‑dependent decrease in TP53 mRNA expression, suggesting that the drug suppresses the tumor‑suppressor pathway in this human colorectal carcinoma cell line.",-44.25,0.4,cellline
"HCT‑116 cells treated with the PI3K inhibitor LY294002 exhibited a dose‑dependent reduction in AKT phosphorylation, confirming that the drug disrupts the PI3K/AKT signaling pathway in this colorectal carcinoma cell line.",-22.75,0.4,cellline
"HTR3A overexpression in the HCT‑116 cell line enhances cisplatin‑induced apoptosis through up‑regulation of the BAX/BCL‑2 ratio, thereby increasing therapeutic efficacy in colorectal cancer models.",-36.25,0.4,cellline
"HSCs cultured in Ba/F3 cells overexpressing the mutant KRAS G12D allele displayed increased sensitivity to the MEK inhibitor trametinib, suggesting a therapeutic vulnerability in KRAS-driven cancers.",-40.75,0.4,cellline
"HMC-IXC cells treated with the novel inhibitor JQ-12 displayed a dose‑dependent reduction in MYC protein levels, confirming the compound’s efficacy in suppressing oncogenic transcriptional activity in this prostate cancer cell line.",-50.0,0.4,cellline
CRISPR‑Cas9 editing of the KRAS exon‑2 locus in the HCT‑116 cell line introduced a G12D mutation that enhanced MAPK signaling and increased resistance to the MEK inhibitor trametinib.,-25.5,0.4,cellline
"CR-10 cells, a derivative of the HCT-116 colorectal carcinoma cell line, exhibited a marked increase in the expression of the pro‑apoptotic gene BAX when treated with the small‑molecule inhibitor VX‑765, thereby confirming the drug’s potential to sensitize tumor cells to caspase‑mediated apoptosis.",-49.75,0.4,cellline
CR‑ISPR‑mediated knockout of the KRAS gene in the HCT‑116 cell line markedly reduced the phosphorylation of ERK1/2 and consequently attenuated the invasive capacity of these colorectal cancer cells in vitro.,-37.25,0.4,cellline
"CRIPSR‑Cas9‑mediated knockout of the KRAS gene in the HCT‑116 cell line reduced proliferation and increased apoptosis, suggesting that KRAS drives growth in this colorectal carcinoma model.",-34.5,0.4,cellline
"LNCaP cells treated with the androgen receptor antagonist enzalutamide exhibited a dose‑dependent decrease in PSA gene transcription, confirming that AR signaling drives PSA expression in this prostate cancer cell line.",-24.125,0.4,cellline
"LCR‑P1, a sub‑clone of the HCT‑116 colorectal carcinoma cell line, exhibited a marked increase in the expression of the drug‑resistance gene MDR1 after exposure to the chemotherapeutic agent doxorubicin, thereby demonstrating a direct link between the chemical entity and the cellular phenotype.",-55.5,0.4,cellline
"LINC01133 knockdown in HCT‑116 cells reduces the expression of the pro‑inflammatory cytokine IL‑6, thereby attenuating the NF‑κB‑mediated inflammatory response observed in colorectal cancer models.",-40.5,0.4,cellline
"Lactate dehydrogenase activity in the HCT‑116 cell line was markedly increased when cells were treated with the chemical entity doxorubicin, suggesting a direct regulatory interaction between the drug and the glycolytic pathway.",-35.0,0.4,cellline
"Incubation of HCT‑116 cells with the DNA‑damaging agent doxorubicin upregulated the p53‑dependent transcription of the pro‑apoptotic gene BAX, leading to increased caspase‑3 activation and apoptosis in the tumor cell line.",-31.75,0.4,cellline
"Incucyte monitoring of the C57BL/6J macrophage-like cell line treated with the small molecule inhibitor doxorubicin revealed a dose-dependent decrease in the expression of the tumor suppressor gene TP53, thereby enhancing apoptotic signaling and reducing cell viability.",-45.0,0.4,cellline
"Incidence of the BRCA1 c.68_69delAG variant was markedly higher in HCT‑116 cells treated with doxorubicin compared to untreated C57BL/6J mice, suggesting a cell‑line‑specific mutagenic effect of the drug.",-34.5,0.4,cellline
Incurring a KRAS G12D mutation in the HCT‑116 cell line markedly increases its invasive capacity and confers resistance to the EGFR inhibitor gefitinib.,-33.75,0.4,cellline
"Transplanted HCT‑116 cells treated with the small‑molecule inhibitor doxorubicin exhibited a marked decrease in TP53 protein levels, correlating with increased apoptosis in the C57BL/6J mouse model of colorectal carcinoma.",-35.0,0.4,cellline
"Transfection of the CRISPR-Cas9 system into HCT-116 cells carrying the KRAS G12D variant induced a rapid decrease in colony‑forming ability, suggesting that the engineered mutation disrupts oncogenic signaling pathways in this colorectal cancer cell line.",-33.25,0.4,cellline
"Transcription factor NF‑κB activation in the C57BL/6J macrophage‑derived cell line LNCaP enhances IL‑6 secretion, thereby promoting inflammatory signaling that contributes to tumor progression.",-31.875,0.4,cellline
Transplantation of Ba/F3 cells engineered to express the KRAS G12D mutation into C57BL/6J mice revealed a dose‑dependent increase in tumor burden that was markedly attenuated by the MEK inhibitor trametinib.,-28.625,0.4,cellline
"Exposure of the HCT-116 cell line to the small molecule inhibitor doxorubicin induced a dose‑dependent upregulation of the tumor suppressor gene TP53, which in turn triggered apoptosis and reduced colony‑forming ability.",-25.375,0.4,cellline
"Exposure to the chemotherapeutic agent doxorubicin induced apoptosis in the HCT‑116 cell line, a process that was markedly attenuated when the cells were pre‑treated with the antioxidant N‑acetylcysteine, thereby revealing a protective role for glutathione in modulating drug‑induced cytotoxicity.",-32.5,0.4,cellline
"Exposure and subsequent analysis of the C57BL/6J mouse model revealed that the Ba/F3 cell line, when transfected with a mutant HCT‑116 TP53 allele, exhibited a marked increase in apoptosis mediated by the up‑regulation of the pro‑apoptotic gene BAX, thereby demonstrating a direct link between the sequence variant c.215C>T and cellular death pathways.",-63.0,0.4,cellline
"Exposure‑induced oxidative stress in the Ba/F3 cell line carrying the KRAS G12D mutation led to up‑regulation of the pro‑apoptotic gene BAX, confirming the pathway’s role in drug‑induced cytotoxicity.",-39.25,0.4,cellline
"The A549 cell line, when treated with doxorubicin, exhibited a marked increase in TP53 expression that correlated with apoptosis in a dose-dependent manner.",-17.75,0.4,cellline
"The shRNA knockdown of TP53 in the SJ-GBM2 cell line reduced proliferation and increased apoptosis, while the same TP53 knockdown in A549 cells enhanced sensitivity to doxorubicin, indicating a cell line–specific interaction between TP53 status and drug response.",-39.0,0.4,cellline
"The protein kinase A inhibitor cAMP analogues reduced proliferation of the glioblastoma cell line SJ‑GBM2 while simultaneously enhancing the expression of the tumor suppressor gene TP53, suggesting a potential therapeutic strategy for high‑grade gliomas.",-32.0,0.4,cellline
"The gene‑edited SJ‑GBM2 cells, which overexpress mutant EGFRvIII, showed a dramatic increase in invasion when treated with the small‑molecule inhibitor gefitinib, whereas the A549 lung carcinoma line lacking EGFR amplification remained largely unaffected.",-39.75,0.4,cellline
"Transfection of the CRISPR-Cas9 plasmid into the A549 cell line induced a loss of TP53 expression, which in turn upregulated the VEGFA gene and increased the proliferation rate of the tumor cells.",-34.0,0.4,cellline
"Transfecting the A549 cell line with a CRISPR-Cas9 construct targeting the TP53 gene reduced proliferation and increased apoptosis, confirming TP53’s role in lung cancer cell survival.",-25.5,0.4,cellline
"Transfected SJ‑GBM2 cells overexpressing TRAF2DN-tg exhibit reduced NF‑κB activation and increased apoptosis when treated with doxorubicin, a finding that parallels the heightened chemosensitivity observed in A549 and SH‑SY5Y cell lines.",-33.25,0.4,cellline
"Transcription factor NF‑κB activation in the A549 cell line upregulates the anti‑apoptotic gene BCL2, thereby enhancing resistance to cisplatin‑induced cell death.",-27.375,0.4,cellline
"In the SJ-GBM2 glioblastoma cell line, overexpression of the mutant TP53 c.215C>G allele leads to increased expression of the pro‑apoptotic gene BAX, thereby enhancing sensitivity to the chemotherapeutic agent doxorubicin.",-23.125,0.4,cellline
"In A549 cells, the CRISPR‑Cas9‑generated TP53 c.68_69delAG variant enhances resistance to doxorubicin by upregulating the DNA‑damage‑response gene GADD45A.",-24.375,0.4,cellline
"In SJ‑GBM2 cells, overexpression of the mutant TP53 allele c.215C>T (p.R72P) markedly increases VEGFA secretion, thereby enhancing angiogenic potential in co‑cultured Hs578T breast cancer cells.",-26.0,0.4,cellline
"In studies of glioblastoma invasion, the SJ-GBM2 cell line treated with the small‑molecule inhibitor doxorubicin exhibited a significant reduction in MMP‑9 expression, suggesting a direct link between drug exposure and extracellular matrix remodeling.",-32.25,0.4,cellline
"Mutant TRAF2DN‑tg mice treated with the small molecule inhibitor SB203580 showed a significant reduction in inflammatory cytokine secretion by the A549 cell line, confirming that MAPK signaling mediates NF‑κB activation in this human lung carcinoma model.",-41.75,0.4,cellline
"Mutagenic exposure of the A549 cell line to doxorubicin induced a dose‑dependent up‑regulation of the TP53 gene product and a concurrent increase in the Hs578T‑derived apoptosis marker BAX, illustrating a direct link between the chemical entity, the gene product, and the cell‑line‑specific cellular response.",-49.0,0.4,cellline
"Mutations in the TP53 gene of the A549 cell line were shown to increase resistance to doxorubicin, whereas CRISPR‑Cas9‑mediated knockout of the same gene in the SH‑SY5Y line sensitized cells to the drug.",-31.375,0.4,cellline
"Mutating the TP53 gene in the A549 cell line reduces its response to the chemotherapeutic agent doxorubicin, thereby increasing resistance to apoptosis in this human lung carcinoma model.",-24.5,0.4,cellline
"Knockdown of TRAF2 in the SJ‑GBM2 cell line reduces NF‑κB activation and increases apoptosis, suggesting that TRAF2 inhibition could sensitize glioblastoma cells to temozolomide treatment.",-27.0,0.4,cellline
"Knocking out TP53 in the A549 cell line markedly increased the expression of the pro‑apoptotic protein BAX, thereby sensitizing the cells to doxorubicin‑induced cell death.",-22.0,0.4,cellline
"Knocked‑down of TRAF2 in the SH‑SY5Y neuroblastoma cell line reduces TNF‑α‑induced NF‑κB activation and increases apoptosis, a phenotype that is rescued by re‑expression of wild‑type TRAF2.",-35.0,0.4,cellline
"Knudson’s hypothesis was experimentally supported when the A549 cell line, engineered to express a CRISPR‑generated TP53 c.215C>T variant, showed increased sensitivity to the DNA‑damaging agent doxorubicin compared with the parental A549 line.",-45.75,0.4,cellline
"CRISPR‑Cas9‑mediated knockout of TP53 in the A549 cell line markedly increased the expression of the pro‑apoptotic gene BAX, thereby sensitizing the cells to doxorubicin‑induced cell death.",-20.0,0.4,cellline
"CR‑ISPR‑mediated knockout of TP53 in the A549 cell line markedly increased doxorubicin‑induced apoptosis, as evidenced by elevated cleaved‑PARP levels and reduced colony‑forming ability.",-31.625,0.4,cellline
"CR-1 cells, a genetically engineered A549 subline harboring a KRAS G12D mutation, exhibited increased resistance to the chemotherapeutic doxorubicin, whereas the parental A549 line remained highly sensitive, indicating that KRAS activation confers drug‑resistance in this lung carcinoma cell line.",-53.5,0.4,cellline
"CRITICAL: In the SJ-GBM2 glioblastoma cell line, knockdown of the TP53 gene by CRISPR-Cas9 increased resistance to the chemotherapeutic agent doxorubicin, as evidenced by a higher IC50 value compared to wild‑type cells.",-41.25,0.4,cellline
"A549 cells treated with the small‑molecule inhibitor doxorubicin displayed a dose‑dependent increase in TP53‑mediated apoptosis, confirming that the drug’s cytotoxic effect is mediated through TP53 activation in this human lung carcinoma cell line.",-23.75,0.4,cellline
"A genetic screen of the A549 cell line revealed that the BRCA1 c.68_69delAG variant increases sensitivity to the chemotherapeutic doxorubicin, thereby enhancing apoptosis through upregulation of TP53 and its downstream target PUMA.",-30.375,0.4,cellline
"A transgenic SH‑SY5Y line overexpressing TRAF2‑dominant negative (Traf2DN‑tg) shows reduced NF‑κB activation and increased apoptosis in response to doxorubicin, confirming the role of TRAF2 signaling in neuroblastoma cell survival.",-33.25,0.4,cellline
A CRISPR‑Cas9‑edited A549 cell line harboring the BRCA1 c.68_69delAG variant exhibited increased sensitivity to doxorubicin compared with wild‑type A549 cells.,-21.5,0.4,cellline
"Transient overexpression of TRAF2 in the SH‑SY5Y neuroblastoma cell line (SH‑SY5Y) induces apoptosis through caspase‑3 activation, whereas knockdown of TRAF2 in the A549 lung carcinoma cell line (A549) enhances cell proliferation and resistance to cisplatin.",-33.75,0.4,cellline
Transient transfection of the TRAF2‑dominant negative construct into SJ‑GBM2 cells reduced NF‑κB activation and markedly decreased the expression of the pro‑inflammatory cytokine IL‑6.,-29.875,0.4,cellline
"Transient knockdown of TP53 in the A549 cell line reduced the expression of the pro‑apoptotic gene BAX and increased cell proliferation, suggesting that TP53 loss confers a growth advantage to these lung carcinoma cells.",-27.875,0.4,cellline
"Transient inhibition of NF‑κB in the SJ‑GBM2 glioblastoma cell line reduces the expression of the chemokine CXCL8, thereby attenuating the recruitment of neutrophils and limiting tumor‑associated inflammation.",-32.5,0.4,cellline
"SJ‑GBM2 cells treated with the PI3K inhibitor LY294002 exhibited a marked decrease in phosphorylated AKT levels, confirming that the drug effectively blocks the PI3K/AKT signaling pathway in this glioblastoma cell line.",-22.25,0.4,cellline
"SJ-GBM2 cells treated with the PI3K inhibitor LY294002 exhibited a significant decrease in phosphorylated AKT levels, confirming the drug’s efficacy in blocking the PI3K/AKT signaling pathway.",-23.625,0.4,cellline
"SJ‐GBM2 cells treated with the small molecule inhibitor doxorubicin exhibited a marked decrease in TP53‑mediated apoptosis while simultaneously upregulating the anti‑apoptotic gene BCL2, a response that was not observed in the A549 lung carcinoma cell line.",-40.0,0.4,cellline
"SJ\-GBM2 cells overexpressing mutant EGFRvIII exhibit increased resistance to temozolomide and enhanced phosphorylation of downstream AKT and ERK signaling pathways, suggesting a potential mechanism for therapeutic resistance in glioblastoma.",-39.5,0.4,cellline
"Activation of the PI3K/AKT pathway in the A549 cell line by the small molecule inhibitor LY294002 reduced the expression of the oncogenic gene MYC and increased apoptosis, as confirmed by caspase‑3 cleavage and flow cytometry.",-33.0,0.4,cellline
"Activation‑induced apoptosis of the A549 cell line was markedly enhanced by the small‑molecule inhibitor doxorubicin, which bound to the TP53 protein and increased the expression of the pro‑apoptotic gene BAX.",-37.0,0.4,cellline
"Activation-induced apoptosis in the A549 cell line was markedly enhanced by the small‑molecule inhibitor doxorubicin, which binds to the TP53 protein and promotes its transcriptional activation of the BAX gene.",-35.75,0.4,cellline
"Activation by the NF‑κB pathway in the SJ‑GBM2 glioblastoma cell line induces expression of the pro‑inflammatory cytokine IL‑6, which in turn stimulates STAT3 phosphorylation and promotes proliferation of neighboring A549 lung carcinoma cells.",-36.0,0.4,cellline
"Exposure of the A549 cell line to the small molecule doxorubicin induced a dose‑dependent increase in TP53 transcription and apoptosis, while co‑treatment with the anti‑PD‑L1 antibody nivolumab reduced the expression of the immune checkpoint gene CD274 in the same cells.",-34.5,0.4,cellline
Exposure to the novel kinase inhibitor NVP-TAE-684 reduced proliferation of the glioblastoma cell line SJ‑GBM2 while simultaneously upregulating the tumor suppressor p53 and inducing apoptosis in the breast epithelial line MCF‑12A.,-45.25,0.4,cellline
"Exposure in the SJ‑GBM2 cell line to the small‑molecule inhibitor doxorubicin induced a dose‑dependent increase in TP53 transcription and a concomitant decrease in the proliferation marker Ki‑67, confirming that the drug’s cytotoxic effect is mediated through p53‑dependent apoptosis.",-46.75,0.4,cellline
"Exposure-induced oxidative stress in SJ-GBM2 cells upregulates the NRF2 pathway, thereby enhancing the expression of the antioxidant gene NQO1 and reducing apoptosis mediated by the pro‑apoptotic protein BAX.",-37.5,0.4,cellline
"Stimulation of the NF‑κB pathway by TNF‑α in the A549 cell line leads to increased expression of the pro‑inflammatory cytokine IL‑6, which in turn promotes the proliferation of neighboring Hs578T cells.",-28.875,0.4,cellline
Stably transfected A549 cells overexpressing the mutant TP53 R273H allele exhibit increased sensitivity to doxorubicin-induced apoptosis compared with parental A549 cells.,-25.75,0.4,cellline
Stabilization of the p53 pathway in the A549 cell line by the small molecule doxorubicin reduces proliferation and induces apoptosis in a manner that is dependent on the TP53 gene product.,-33.5,0.4,cellline
"Staining of the SH‑SY5Y neuroblastoma cell line with the anti‑β‑catenin antibody revealed that the Traf2DN‑tg transgene markedly reduced nuclear β‑catenin accumulation, suggesting a cell‑line‑specific suppression of Wnt signaling that could contribute to the observed resistance to temozolomide in SJ‑GBM2 glioma cells.",-50.25,0.4,cellline
"Treatment of the SJ-GBM2 cell line with the small molecule inhibitor doxorubicin induced a dose‑dependent decrease in TP53 expression and increased apoptosis, while co‑culture with the SCID‑HuH‑7 hepatocyte model revealed elevated CYP3A4 activity and enhanced drug metabolism.",-37.75,0.4,cellline
"Treatment with the DNA‑damaging agent doxorubicin induced a marked increase in p53‑dependent apoptosis in the SJ‑GBM2 glioblastoma cell line, whereas the same exposure had only a modest effect on the non‑tumorigenic MCF‑12A mammary epithelial cells.",-28.375,0.4,cellline
"Treatment efficacies of the chemotherapeutic agent doxorubicin were compared between the glioblastoma cell line SJ‑GBM2 and the breast epithelial line MCF‑12A, revealing that SJ‑GBM2 exhibited a significantly higher apoptotic response mediated through TP53 activation while MCF‑12A showed resistance associated with upregulated BCL2 expression.",-50.25,0.4,cellline
"Treatment using the SJ‑GBM2 cell line revealed that the overexpression of the mutant TP53 gene in A549 cells significantly enhanced the sensitivity of the cells to doxorubicin, while the presence of the SCID‑HuH‑7 cell line in co‑culture reduced the expression of the inflammatory cytokine IL‑6.",-59.0,0.4,cellline
"Ectopic overexpression of the NF‑κB inhibitor IκBα in the glioblastoma cell line SJ‑GBM2 markedly reduced IL‑6 secretion and concomitantly lowered the proliferation rate of the co‑cultured human hepatocellular carcinoma cell line Hs578T, suggesting a paracrine suppression of tumor growth mediated by the secretome of the engineered SJ‑GBM2 cells.",-45.25,0.4,cellline
"Etoposide treatment of the A549 cell line induced a p53‑dependent upregulation of the pro‑apoptotic gene BAX, leading to increased apoptosis in the tumor cells.",-22.5,0.4,cellline
"Epidermal growth factor stimulation of the A549 cell line increased phosphorylation of EGFR and downstream AKT signaling, leading to enhanced proliferation and migration that were attenuated by the CRISPR‑generated TP53 c.215C>G variant.",-38.0,0.4,cellline
"Epithelial growth factor stimulation of the A549 cell line upregulates the TP53 gene product, enhancing apoptosis in response to doxorubicin treatment.",-25.25,0.4,cellline
"In the HEK293 cell line, overexpression of the TP53 gene product induced apoptosis via activation of the BAX pathway, while treatment with the small molecule doxorubicin further amplified caspase‑3 activity, leading to a pronounced reduction in cell viability.",-29.5,0.4,cellline
"In HEK293 cells, overexpression of the mutant TP53 c.215C>G variant increases the transcription of the pro‑apoptotic gene BAX, leading to heightened sensitivity to doxorubicin-induced cell death.",-21.875,0.4,cellline
"In HT22 cells, the CRISPR‑generated BRCA1 c.68_69delAG variant increases sensitivity to the DNA‑damaging agent doxorubicin, while co‑treatment with the antioxidant N‑acetylcysteine partially restores cell viability.",-22.875,0.4,cellline
"In SH‑SY5Y cells, knockdown of the TP53 gene by CRISPR‑Cas9 increases the expression of the pro‑apoptotic protein BAX, leading to heightened sensitivity to doxorubicin treatment.",-25.0,0.4,cellline
The CRISPR-Cas9 edited HEK293 cells harboring the BRCA1 c.68_69delAG variant exhibit reduced DNA repair capacity and increased sensitivity to the chemotherapeutic agent doxorubicin.,-16.5,0.4,cellline
"The HEK293 cell line, engineered to overexpress the mutant TP53 R273H variant, exhibited increased sensitivity to the DNA‑damaging agent doxorubicin, thereby enhancing apoptosis compared with the parental HEK293 cells.",-26.375,0.4,cellline
"The U87‑DACH1‑low cell line, when treated with the small molecule doxorubicin, shows a marked increase in TP53‑mediated apoptosis that is further amplified by the presence of the BRCA1 c.68_69delAG sequence variant.",-20.75,0.4,cellline
"The DHFR inhibitor methotrexate induces a dose‑dependent up‑regulation of the folate transporter SLC19A1 in the human colorectal carcinoma cell line SW48, thereby enhancing intracellular methotrexate accumulation and cytotoxicity.",-28.75,0.4,cellline
Mutation of the TP53 gene in the U87‑DACH1‑low glioblastoma cell line leads to increased resistance to temozolomide and up‑regulation of the DNA‑damage response protein ATM.,-22.0,0.4,cellline
"Mutation analysis of the TP53 gene in the U87‑DACH1‑low glioblastoma cell line revealed a c.215C>T substitution that abolishes the DNA‑binding domain, leading to increased cell proliferation and resistance to temozolomide.",-30.125,0.4,cellline
"Mutation in the TP53 gene of the HEK293 cell line reduces its ability to form colonies, while overexpression of the drug doxorubicin in the same line restores apoptosis and decreases proliferation.",-38.75,0.4,cellline
"Mutation-driven overexpression of the KRAS oncogene in the HEK293 cell line enhances MAPK pathway activation, thereby increasing cellular proliferation and conferring resistance to the EGFR inhibitor erlotinib.",-34.75,0.4,cellline
A CRISPR-Cas9 knockout of TP53 in the HEK293 cell line markedly increased the expression of the pro‑apoptotic gene BAX while simultaneously reducing the proliferation rate of the same cells.,-22.5,0.4,cellline
A modified HEK293 cell line overexpressing the CRISPR‑Cas9‑RNP complex targeting the BRCA1 c.68_69delAG variant shows increased homologous recombination repair activity compared with the parental HEK293 cells.,-33.25,0.4,cellline
"A single‑cell RNA‑seq analysis of the U87‑DACH1‑low glioblastoma cell line revealed that the down‑regulation of DACH1 enhances STAT3 phosphorylation, thereby promoting invasive behavior and conferring resistance to temozolomide.",-32.0,0.4,cellline
A comparative study showed that the CRISPR‑edited HEK293 cells with a TP53 c.215C>T variant exhibited a markedly higher apoptosis rate upon doxorubicin treatment than the wild‑type HEK293 cells.,-35.25,0.4,cellline
CRISPR‑Cas9‑mediated knockout of TP53 in the HEK293 cell line markedly increased the expression of the pro‑apoptotic gene BAX while simultaneously reducing the proliferation rate of the resulting cells compared with wild‑type HEK293 cells.,-26.0,0.4,cellline
"CRLF2 overexpression in the U87‑DACH1‑low glioblastoma cell line enhances STAT5 signaling and increases resistance to temozolomide, a finding that may explain the poor clinical response observed in patients with high CRLF2 expression.",-34.25,0.4,cellline
"CR-1 cells derived from the U87-DACH1-low cell line exhibit a heightened sensitivity to the chemotherapeutic agent doxorubicin, which induces a dose-dependent upregulation of the tumor suppressor gene TP53 and a concomitant increase in apoptotic markers such as cleaved caspase‑3.",-43.5,0.4,cellline
"CRIPSR‑Cas9‑mediated knockout of the TP53 gene in the HEK293 cell line markedly increased the expression of the pro‑apoptotic protein BAX while simultaneously reducing the levels of the anti‑apoptotic protein BCL‑2, thereby sensitizing the cells to doxorubicin‑induced cell death.",-34.5,0.4,cellline
"SH-SY5Y cells treated with the small‑molecule inhibitor doxorubicin exhibited a significant up‑regulation of the tumor suppressor gene TP53, which in turn induced apoptosis and reduced proliferation in this neuroblastoma cell line.",-26.5,0.4,cellline
"SH‑5Y cells treated with the small‑molecule inhibitor doxorubicin exhibited a dose‑dependent increase in TP53‑mediated apoptosis, while the CRISPR‑engineered DU145 line carrying the BRCA1 c.68_69delAG variant showed markedly reduced DNA‑damage repair activity.",-37.5,0.4,cellline
"SH‐SY5Y cells treated with the DNA methyltransferase inhibitor decitabine showed a significant upregulation of the tumor suppressor gene TP53, which in turn increased the expression of the pro‑apoptotic protein BAX and sensitized the cells to doxorubicin‑induced apoptosis.",-32.75,0.4,cellline
"SH-derived SH‑SY5Y cells treated with the small‑molecule inhibitor doxorubicin exhibited a dose‑dependent increase in TP53‑mediated apoptosis, confirming the drug’s efficacy in this neuroblastoma cell line.",-40.0,0.4,cellline
"Overexpressing the mutant TP53 c.215C>G in the HEK293 cell line markedly increased the sensitivity of these cells to the chemotherapeutic agent doxorubicin, as evidenced by a significant rise in apoptotic markers compared to wild‑type TP53‑expressing controls.",-36.5,0.4,cellline
"Overexpression of the oncogenic MYC variant c.1234C>T in the U87‑DACH1‑low glioblastoma cell line increased proliferation and conferred resistance to temozolomide, whereas CRISPR‑mediated knockout of MYC in the same line restored drug sensitivity.",-36.5,0.4,cellline
"Over prolonged exposure to the chemotherapeutic agent doxorubicin, the HEK293 cell line exhibited a marked up‑regulation of the pro‑apoptotic gene BAX, while the HT22 neuronal line showed a compensatory increase in the antioxidant enzyme SOD2, suggesting a differential cellular stress response that may underlie the selective neurotoxicity observed in Parkinson’s disease models.",-45.5,0.4,cellline
"Overexposure to the chemotherapeutic agent doxorubicin in the HEK293 cell line induces a marked up‑regulation of the pro‑apoptotic gene BAX, correlating with increased caspase‑3 activity and a dose‑dependent reduction in cell viability.",-35.5,0.4,cellline
"Growth‐factor stimulation of the U87‑DACH1‑low glioma cell line induced a rapid upregulation of the CXCL12 chemokine, which in turn recruited endothelial cells and promoted angiogenesis in vitro.",-37.5,0.4,cellline
"Growth factor stimulation of the HEK293 cell line upregulates the expression of the TP53 gene product, thereby enhancing apoptosis in response to DNA damage.",-25.75,0.4,cellline
"Growth of the U87‑DACH1‑low glioblastoma cell line was significantly inhibited by the small‑molecule inhibitor doxorubicin, which induced apoptosis through up‑regulation of the TP53 pathway.",-25.0,0.4,cellline
"Growth arrest in the U87‑DACH1‑low cell line was rescued by treatment with the chemical entity rapamycin, which inhibited mTOR signaling and restored the expression of the tumor suppressor gene TP53.",-31.625,0.4,cellline
"Mutant TP53 in the U87‑DACH1‑low glioblastoma cell line enhances NF‑κB‑mediated IL‑6 secretion, thereby promoting chemoresistance to doxorubicin in vitro.",-25.125,0.4,cellline
"Mutagenic exposure of the SH‑SY5Y neuroblastoma line to doxorubicin induced a dose‑dependent increase in TP53 mRNA and a corresponding rise in the pro‑apoptotic BAX protein, thereby confirming the cell line’s suitability for studying drug‑induced apoptosis in neuroblastoma.",-37.75,0.4,cellline
"Mutational analysis of the TP53 gene in the U87-DACH1-low cell line revealed a c.215C>G variant that increases the expression of the pro‑apoptotic protein Bax, thereby enhancing the cell line’s sensitivity to the chemotherapeutic agent doxorubicin.",-29.5,0.4,cellline
"Mutating the TP53 gene in the HEK293 cell line with CRISPR-Cas9 induces a loss of p53 protein expression, thereby increasing resistance to doxorubicin-induced apoptosis.",-27.75,0.4,cellline
"After CRISPR‑Cas9 editing, the SH‑SY5Y cell line harboring the BRCA1 c.68_69delAG variant displayed markedly increased sensitivity to the DNA‑damage agent doxorubicin compared with the parental SH‑SY5Y cells.",-31.0,0.4,cellline
"After treating the HEK293 cell line with doxorubicin, the expression of the TP53 gene increased, correlating with the observed induction of apoptosis and cell cycle arrest.",-29.875,0.4,cellline
"After genetic manipulation of the TP53 locus, the engineered HEK293 cells exhibited increased resistance to doxorubicin, while the CRISPR-edited DU145 line showed heightened apoptosis in response to the same chemotherapeutic agent.",-40.0,0.4,cellline
"After exposing the HEK293 cell line to the chemical entity doxorubicin, researchers observed a significant upregulation of the tumor suppressor gene TP53, which in turn activated the apoptotic pathway and led to increased cell death in the presence of the disease‑associated phenotype of drug‑induced cardiotoxicity.",-35.5,0.4,cellline
"Methadone exposure in the SH‑SY5Y neuroblastoma line upregulates the dopamine transporter gene DRD2, thereby increasing intracellular dopamine accumulation and enhancing cell viability under oxidative stress.",-35.0,0.4,cellline
"Methacrylate‑treated HEK293 cells overexpressing the mutant TP53 c.215C>G variant exhibit increased apoptosis when exposed to the DNA‑damaging agent doxorubicin, a response that is markedly attenuated in the DU145 prostate cancer cell line carrying the wild‑type TP53 allele.",-48.5,0.4,cellline
"Methotrexate treatment of the U87‑DACH1‑low glioblastoma cell line reduced HIF‑1α expression and increased apoptosis, whereas co‑culture with the SH‑SY5Y neuronal line restored cell viability through BDNF secretion.",-36.25,0.4,cellline
"Methamphetamine exposure in SH‑SY5Y cells upregulated the expression of the dopamine transporter gene DRD2, which in turn enhanced the cells’ sensitivity to the neurotoxin MPP⁺ and accelerated apoptotic cell death.",-38.75,0.4,cellline
"HT22 cells treated with the PI3K inhibitor LY294002 exhibit reduced phosphorylation of AKT and increased expression of the pro‑apoptotic gene BAX, indicating that inhibition of the PI3K/AKT pathway triggers apoptosis in the hippocampal neuronal cell line.",-28.375,0.4,cellline
"HT-22 cells exposed to the small molecule doxorubicin exhibit a dose‑dependent increase in TP53 transcription and a concomitant reduction in cell viability, suggesting that the drug induces apoptosis through p53‑mediated pathways.",-38.5,0.4,cellline
"HT‑22 cells treated with the DNA‑damaging agent doxorubicin exhibit a marked increase in p53‑dependent apoptosis, while co‑treatment with the antioxidant N‑acetylcysteine partially rescues cell viability.",-30.125,0.4,cellline
"HT29 cells treated with the PI3K inhibitor LY294002 exhibited a dose‑dependent decrease in AKT phosphorylation, while co‑treatment with the MEK inhibitor U0126 restored ERK activation and rescued cell viability.",-34.25,0.4,cellline
"Silencing of the TP53 gene in the DU145 cell line markedly increases the expression of the chemokine CXCL10, thereby enhancing the recruitment of CD8+ T cells to the tumor microenvironment.",-25.25,0.4,cellline
"Silvestrol treatment of the U87‑DACH1‑low glioblastoma cell line induces a dose‑dependent increase in the expression of the pro‑apoptotic gene BAX, leading to enhanced caspase‑3 activation and apoptosis.",-29.75,0.4,cellline
"Silently, the CRISPR‑Cas9‑edited HEK293 cells harboring the BRCA1 c.68_69delAG variant displayed a marked decrease in RAD51 foci formation compared with wild‑type HEK293, confirming the functional impact of the sequence variant on homologous recombination repair.",-35.5,0.4,cellline
"Silenced TP53 expression in the DU145 cell line markedly increased sensitivity to doxorubicin, leading to a higher rate of apoptosis compared with untreated cells.",-29.0,0.4,cellline
"HEK293 cells transfected with the TP53 c.215C>G variant exhibit increased apoptosis when treated with doxorubicin, a finding that may explain the heightened sensitivity of this cell line to DNA‑damaging agents.",-25.875,0.4,cellline
"HEG293 cells treated with the small molecule inhibitor doxorubicin exhibit a dose‑dependent increase in TP53 expression, while the same treatment in SH‑SY5Y cells results in up‑regulation of the antioxidant enzyme CAT and a concomitant reduction in reactive oxygen species.",-55.5,0.4,cellline
"HEKR293 cells treated with the small molecule inhibitor doxorubicin exhibited a dose-dependent increase in TP53 protein levels, which in turn upregulated the expression of the pro‑apoptotic gene BAX and reduced proliferation of the U87‑DACH1‑low glioblastoma cell line.",-49.0,0.4,cellline
"HEP3‑derived HEK293 cells treated with the small‑molecule inhibitor doxorubicin displayed a dose‑dependent increase in TP53‑mediated apoptosis, whereas the same treatment in the drug‑resistant DU145 line failed to induce caspase‑3 activation.",-48.25,0.4,cellline
McArdle-RH7777 cells treated with the small molecule inhibitor doxorubicin exhibited a dose‑dependent increase in apoptosis mediated by TP53 activation and subsequent up‑regulation of the pro‑apoptotic gene BAX.,-25.625,0.4,cellline
"McCray et al. observed that the drug doxorubicin induced apoptosis in the hRPTEC cell line through activation of the TP53 pathway, thereby reducing the proliferation of this renal proximal tubular epithelial model.",-40.25,0.4,cellline
McAdR-RH7777 cells treated with the PI3K inhibitor LY294002 exhibit a marked decrease in AKT phosphorylation and a concomitant increase in apoptosis mediated by caspase‑3 activation.,-38.25,0.4,cellline
"McCarthy et al. demonstrated that the chemotherapeutic agent doxorubicin induces a dose‑dependent decrease in cell‑cycle progression markers in the colorectal carcinoma cell line SW480, while simultaneously upregulating the pro‑apoptotic gene TP53, thereby establishing a potential therapeutic window for combination treatment with the DNA‑damaging agent cisplatin.",-53.0,0.4,cellline
"In hRPTEC cells, the CRISPR‑Cas9‑mediated knockout of the ATP1A1 gene reduces sodium‑potassium pump activity, thereby increasing intracellular calcium levels and enhancing the expression of the pro‑apoptotic gene BAX, which is associated with renal tubular cell injury.",-37.5,0.4,cellline
"In the hRPTEC cell line, knockdown of the HIF1A gene significantly reduced VEGF secretion, thereby attenuating the angiogenic response to hypoxia.",-20.5,0.4,cellline
"In McArdle‑RH7777 cells, the overexpression of the oncogenic KRAS variant G12V induces a STAT3‑dependent transcriptional program that up‑regulates the chemokine CXCL10, thereby enhancing the recruitment of CD8⁺ T cells to the tumor microenvironment.",-32.75,0.4,cellline
"In U87MG glioblastoma cells, the CRISPR‑Cas9‑mediated knockout of the PTEN gene leads to hyperactivation of the PI3K/AKT pathway, resulting in increased proliferation and resistance to temozolomide.",-22.25,0.4,cellline
"The CRISPR‑Cas9‑edited hRPTEC cells harboring the BRCA1 c.68_69delAG variant exhibit reduced proliferation and increased DNA damage response markers compared to wild‑type hRPTEC, indicating a potential therapeutic target for chemoprevention.",-29.25,0.4,cellline
"The IL‑6‑induced STAT3 phosphorylation in the hRPTEC cell line was markedly attenuated by the small‑molecule inhibitor tofacitinib, suggesting a therapeutic avenue for chronic kidney disease.",-24.25,0.4,cellline
"The expression of the oncogenic KRAS variant c.35G>T in the SW480 colorectal carcinoma cell line was found to increase resistance to the chemotherapeutic agent doxorubicin, while the same mutation in the U87MG glioblastoma cell line did not alter drug sensitivity.",-32.75,0.4,cellline
"The U87MG glioblastoma cell line treated with the novel kinase inhibitor erlotinib exhibited a marked decrease in phosphorylated EGFR levels, suggesting effective blockade of the EGFR signaling pathway.",-22.75,0.4,cellline
"H446 cells treated with doxorubicin exhibit a dose‑dependent increase in TP53 phosphorylation, correlating with apoptosis and reduced proliferation in the presence of the DNA‑damage marker γ‑H2AX.",-25.25,0.4,cellline
"HUCCT1 cells treated with the PI3K inhibitor LY294002 exhibited a marked decrease in AKT phosphorylation, suggesting that PI3K signaling drives proliferation in this cholangiocarcinoma cell line.",-29.75,0.4,cellline
"H166, a novel sequence variant in the TP53 gene, was identified in the SW480 colorectal carcinoma cell line, where it increased sensitivity to the chemotherapeutic agent doxorubicin and upregulated the expression of the pro‑apoptotic protein BAX.",-39.25,0.4,cellline
"H460 cells treated with the PI3K inhibitor LY294002 exhibited a marked reduction in AKT phosphorylation, confirming the drug’s efficacy in blocking the PI3K/AKT pathway in this lung carcinoma cell line.",-30.125,0.4,cellline
"CCL2 secretion by the SW480 cell line was markedly enhanced when the cells were treated with the small‑molecule inhibitor doxorubicin, leading to increased recruitment of monocytes and a higher expression of the chemokine receptor CCR2 in co‑cultured H446 cells.",-39.5,0.4,cellline
"CCDF treatment of the SW480 cell line induced a dose‑dependent increase in E-cadherin expression, suggesting a reversal of EMT that may reduce metastatic potential in colorectal carcinoma.",-36.75,0.4,cellline
"CCK‑8 treatment of the H446 glioblastoma cell line (U87MG) revealed a dose‑dependent increase in apoptosis, accompanied by up‑regulation of the pro‑apoptotic gene BAX and down‑regulation of the anti‑apoptotic gene BCL‑2.",-31.875,0.4,cellline
CCO-2 treatment of the SW480 cell line increased expression of the TP53 gene and induced apoptosis through activation of caspase‑3.,-36.0,0.4,cellline
"CRISPR‑Cas9‑mediated knockout of the KRAS gene in the pancreatic cancer cell line Capan1 reduced cell proliferation and induced apoptosis, while the same mutation in the glioblastoma cell line SJ‑GBM2 increased sensitivity to temozolomide.",-31.875,0.4,cellline
"CRMP2 overexpression in the SW480 colorectal carcinoma cell line enhances VEGF‑induced angiogenic signaling, thereby increasing endothelial tube formation in co‑culture assays.",-37.0,0.4,cellline
"CRABP2 overexpression in the colorectal carcinoma cell line SW480 enhances resistance to the chemotherapeutic agent doxorubicin, thereby increasing cell survival and promoting tumor progression.",-33.0,0.4,cellline
"CR‑ISPR‑mediated knockout of the TP53 gene in the U87MG glioblastoma cell line (U87MG) led to increased resistance to doxorubicin (doxorubicin) and up‑regulation of the MDR1 transporter, suggesting that loss of TP53 confers chemoresistance in U87MG cells.",-43.0,0.4,cellline
"Incubation of the hRPTEC cell line with the chemical entity doxorubicin induced a dose‑dependent upregulation of the tumor suppressor gene TP53, thereby reducing the proliferation of cells exhibiting the BRCA1 c.68_69delAG sequence variant.",-29.5,0.4,cellline
"Incucyte imaging of hRPTEC cells treated with the novel kinase inhibitor JNK-9 revealed a dose‑dependent decrease in phospho‑ERK1/2 signaling and a concomitant increase in cleaved‑caspase‑3 expression, indicating apoptosis induction.",-46.75,0.4,cellline
"Inciting KRAS G12D mutation in the SW480 colorectal carcinoma cell line markedly increases IL‑8 secretion, which in turn activates NF‑κB signaling and enhances cell migration.",-41.25,0.4,cellline
Incidence of KRAS G12D mutation in the SW480 cell line correlates with heightened resistance to the chemotherapeutic agent doxorubicin in colorectal carcinoma models.,-31.0,0.4,cellline
"Radiation exposure of the hRPTEC cell line induces a dose‑dependent upregulation of the DNA‑damage sensor ATM, which in turn activates p53‑mediated apoptosis and reduces cell viability.",-28.375,0.4,cellline
"Radioprobe‑labeled doxorubicin accumulates in the mitochondria of hRPTEC cells, where it induces a BRCA1 c.68_69delAG‑dependent down‑regulation of the DNA‑repair protein RAD51, thereby sensitizing the cells to cisplatin‑induced apoptosis.",-42.0,0.4,cellline
"Radiative‑induced DNA damage in the hRPTEC cell line leads to up‑regulation of the p53‑dependent pro‑apoptotic gene BAX, which in turn activates caspase‑3 and drives apoptosis.",-38.5,0.4,cellline
"Radiotherapy of U87MG glioblastoma cells induces a rapid increase in the expression of the DNA repair gene MGMT, which is further amplified by the presence of the MGMT promoter methylation variant c.−161C>T.",-41.0,0.4,cellline
Metformin treatment of the U87MG glioblastoma cell line reduced the expression of the PDGFRA gene and increased apoptosis mediated by caspase‑3 activation.,-23.75,0.4,cellline
"Metabolic profiling of the hRPTEC cell line revealed that exposure to the chemical entity dimethyl sulfoxide upregulated the expression of the disease‑associated gene TP53, while co‑culture with the organism taxon *Escherichia coli* induced a sequence variant c.68_69delAG in the KRAS gene, thereby enhancing the inflammatory phenotype characteristic of chronic kidney disease.",-49.75,0.4,cellline
"Metabolomic profiling of the H446 neuroendocrine carcinoma cell line revealed that exposure to the small‑molecule inhibitor doxorubicin down‑regulates the expression of the TP53 gene product, thereby sensitizing the cells to apoptosis and reducing the proliferation rate of the tumor cells.",-38.25,0.4,cellline
"Metabolism of the chemotherapeutic agent doxorubicin in the renal proximal tubular cell line hRPTEC is markedly enhanced by the presence of the CYP3A4 polymorphism CYP3A4*22, leading to increased intracellular accumulation of the drug and heightened cytotoxicity compared with the wild‑type enzyme.",-40.5,0.4,cellline
"Mutation of the TP53 gene in the U87MG glioblastoma cell line leads to increased resistance to temozolomide and promotes angiogenic factor secretion, thereby enhancing tumor vascularization.",-24.375,0.4,cellline
"Mutation in the TP53 gene of the SW480 colorectal carcinoma cell line leads to increased expression of the pro‑apoptotic protein Bax, thereby sensitizing the cells to doxorubicin‑induced cell death.",-21.875,0.4,cellline
"Mutation‑induced overexpression of EGFR in the SW480 colorectal carcinoma cell line enhances PI3K/AKT signaling, thereby increasing resistance to the tyrosine‑kinase inhibitor gefitinib.",-28.5,0.4,cellline
"Mutation analysis of the TP53 gene in the hRPTEC cell line revealed a novel c.215C>A sequence variant that increases sensitivity to doxorubicin, thereby enhancing apoptosis in these renal proximal tubule epithelial cells.",-32.5,0.4,cellline
"Treatment of the hRPTEC cell line with the small molecule inhibitor doxorubicin induced a dose‑dependent increase in TP53 mRNA expression, suggesting that the drug activates the p53‑mediated DNA damage response in this renal proximal tubule epithelial model.",-29.75,0.4,cellline
"Treatment with the novel kinase inhibitor GSK-3β antagonist significantly reduced proliferation of the SW480 colorectal carcinoma cell line, while simultaneously inducing apoptosis in the U87MG glioblastoma multiforme cells through upregulation of the tumor suppressor gene PTEN.",-39.5,0.4,cellline
"Treatment failure in hRPTEC cells exposed to doxorubicin was linked to upregulation of the DNA repair gene TP53, suggesting that the chemotherapeutic agent induces a mutational burden that compromises renal proximal tubule epithelial cell viability.",-43.5,0.4,cellline
"Treatment efficacy of the novel inhibitor AZD-1234 was markedly higher in the hRPTEC cell line, where it suppressed EGFR signaling and induced apoptosis, compared with the SW480 colorectal carcinoma line that exhibited intrinsic resistance due to KRAS G12D mutation.",-46.25,0.4,cellline
"High‑grade glioblastoma cells (SJ‑GBM2) treated with the PI3K inhibitor LY294002 exhibited a dramatic reduction in AKT phosphorylation, while the same drug had no effect on the renal proximal tubule cell line hRPTEC, indicating cell‑line‑specific pathway dependence.",-39.5,0.4,cellline
"High epithelial‑to‑mesenchymal transition observed in the U87MG glioblastoma cell line was markedly enhanced by treatment with the small‑molecule inhibitor doxorubicin, which also induced a p53‑dependent up‑regulation of the tumor suppressor gene TP53.",-44.25,0.4,cellline
"High‐throughput CRISPR screening in the U87MG glioblastoma cell line revealed that loss of the DNA repair gene ATM enhances sensitivity to the PARP inhibitor olaparib, a finding that may guide precision therapy for patients with ATM‑deficient tumors.",-32.25,0.4,cellline
"High-fat diet‑induced insulin resistance in hRPTEC cells is mitigated by the selective PI3K inhibitor LY294002, which restores AKT phosphorylation and reduces the expression of the inflammatory cytokine IL‑6.",-33.0,0.4,cellline
"Epithelial proliferation in the hRPTEC cell line was markedly increased by treatment with the small molecule inhibitor GSK‑3β, a finding that mirrors the up‑regulation of β‑catenin observed in the SW480 colorectal carcinoma line and suggests a conserved Wnt‑dependent growth pathway across these distinct human cell lines.",-50.0,0.4,cellline
"Etoposide treatment of the U87MG glioblastoma cell line induces a p53-dependent upregulation of the pro‑apoptotic gene BAX, thereby enhancing caspase‑3 activation and cell death.",-21.75,0.4,cellline
"Eotaxin-1 secretion in the H446 glioblastoma cell line was markedly increased after treatment with the small molecule inhibitor gefitinib, suggesting a potential therapeutic target for reducing tumor-associated inflammation.",-39.25,0.4,cellline
"E13.5 embryonic mouse kidneys exposed to the chemotherapeutic agent doxorubicin showed a dose‑dependent decrease in proliferation of the hRPTEC cell line, accompanied by up‑regulation of the pro‑apoptotic gene BAX and a significant increase in the p53‑dependent cell‑cycle arrest marker p21.",-48.75,0.4,cellline
"Following exposure to the DNA‑damaging agent doxorubicin, the H446 cell line exhibited a significant up‑regulation of the tumor suppressor gene TP53, which in turn triggered apoptosis and reduced proliferation of the malignant cells.",-34.75,0.4,cellline
"Following CRISPR‑Cas9 editing, the hRPTEC cell line exhibited a loss of the CFTR gene, leading to a significant reduction in chloride transport and an increase in intracellular calcium signaling that mimicked cystic fibrosis phenotypes.",-37.25,0.4,cellline
"Following lentiviral transduction of the hRPTEC cell line with a CRISPR‑Cas9 construct targeting the TP53 locus, the engineered cells exhibited a significant increase in apoptosis markers and a concomitant reduction in proliferation compared with the unedited SW480 controls.",-44.0,0.4,cellline
"Following transfection of the CRISPR-Cas9 system into the U87MG glioblastoma cell line, the resulting knockout of the PTEN gene led to a marked increase in PI3K/AKT signaling and enhanced cell migration compared with the parental U87MG cells.",-37.5,0.4,cellline
"The GT1‑1 cell line, a pituitary gonadotropin‑producing model, exhibited a dose‑dependent upregulation of the steroidogenic enzyme CYP19A1 when treated with the aromatase inhibitor letrozole, suggesting a potential therapeutic avenue for estrogen‑dependent tumors.",-29.875,0.4,cellline
"The LbetaT2 cell line, when treated with the small molecule inhibitor doxorubicin, exhibited a dose‑dependent increase in TP53 mRNA expression and a concomitant decrease in the proliferation marker Ki‑67, suggesting that the drug induces a p53‑mediated cell‑cycle arrest in this gonadotroph model.",-34.25,0.4,cellline
The CRISPR‑Cas9‑edited HeLa cells harboring the TP53 c.215C>A variant displayed a marked reduction in cisplatin‑induced apoptosis compared with wild‑type HeLa cells.,-23.375,0.4,cellline
The BRCA1 c.68_69delAG variant was found to reduce proliferation in HeLa and U87TR-Da cell lines while increasing apoptosis in the SW48 colorectal carcinoma line.,-27.0,0.4,cellline
"In the U87-DACH1-low cell line, knockdown of the TP53 gene by CRISPR-Cas9 markedly increased the expression of the chemokine CXCL10, suggesting a regulatory link between TP53 loss and inflammatory signaling in glioblastoma cells.",-21.0,0.4,cellline
"In U87TR-Da cells, overexpression of the transcription factor DACH1 enhances invasion by upregulating MMP-9, a change that is suppressed when the drug doxorubicin is administered, thereby reducing tumorigenic potential in this glioblastoma cell line.",-39.25,0.4,cellline
"In our study, the chemotherapeutic agent doxorubicin induced a dose‑dependent increase in apoptosis in the HeLa cell line, while the same treatment had no effect on the U87-DACH1-low glioma cells, suggesting a cell‑line‑specific response to DNA damage.",-35.0,0.4,cellline
"In co-culture, the human glioma cell line U87-DACH1-low exhibited increased resistance to temozolomide, a finding that was amplified when the same cells were transfected with the KRAS G12D sequence variant and subsequently treated with the MEK inhibitor trametinib.",-37.5,0.4,cellline
Evidence that the CRISPR‑Cas9‑generated BRCA1 c.68_69delAG variant in the HeLa cell line reduces homologous recombination efficiency and increases sensitivity to the DNA‑damaging agent doxorubicin was confirmed by a comparative γ‑H2AX foci assay.,-33.75,0.4,cellline
"Evidence from GT1-1 and U87TR‑Da cells shows that the overexpression of the transcription factor DACH1 reduces the secretion of the cytokine IL‑6, thereby attenuating the inflammatory response associated with glioblastoma progression.",-39.5,0.4,cellline
"Evidence indicates that the CRISPR‑Cas9‑edited HeLa cell line harboring the TP53 c.215C>T variant exhibits increased sensitivity to doxorubicin, thereby linking the sequence variant to a drug‑response phenotype.",-37.75,0.4,cellline
"Evidence emerging from GT1-1, LbetaT2, and CMT-93 cell lines shows that the up‑regulation of the transcription factor CREB by the small molecule forskolin enhances gonadotropin‑releasing hormone synthesis, linking this chemical entity to the endocrine phenotype observed in these neuronal‑derived cultures.",-58.25,0.4,cellline
"U87-DACH1-low cells treated with the small molecule inhibitor doxorubicin exhibited a dose‑dependent decrease in the expression of the tumor‑suppressor gene TP53, correlating with increased apoptosis and reduced proliferation in the glioblastoma cell line.",-29.25,0.4,cellline
"U83/13 cell line treated with the novel kinase inhibitor GSK-3β inhibitor AR-A014418 exhibited a dose‑dependent decrease in phospho‑AKT levels, confirming that AR‑A014418 effectively blocks the PI3K/AKT signaling pathway in U83/13 cells.",-56.0,0.4,cellline
"U‑87‑TR‑Da cells exposed to the small‑molecule inhibitor doxorubicin showed a dose‑dependent increase in TP53‑mediated apoptosis, confirming the drug’s efficacy in this glioblastoma cell line.",-32.25,0.4,cellline
"U86TR-Da cells, a glioblastoma cell line engineered to overexpress DACH1, exhibited a marked decrease in proliferation and increased apoptosis when treated with the small‑molecule inhibitor doxorubicin, suggesting that DACH1 modulation enhances the cytotoxic efficacy of this chemotherapeutic agent in U86TR-Da cells.",-50.25,0.4,cellline
"Analysis of the U87-DACH1-low cell line revealed that overexpression of the TP53 gene product suppresses VEGF secretion, thereby reducing angiogenic potential in this glioblastoma model.",-26.0,0.4,cellline
"Analysis revealed that the U87TR‑Da cell line, engineered to overexpress the oncogenic protein DACH1, exhibited a dramatic increase in VEGFA secretion, which in turn activated the PI3K/AKT pathway and promoted resistance to temozolomide in vitro.",-42.0,0.4,cellline
"Analysis demonstrated that the CRISPR‑Cas9‑edited U87TR‑D2 cell line, originally derived from U87‑DACH1‑low glioblastoma, exhibited a significant up‑regulation of the HIF‑1α target gene VEGFA, confirming that loss of DACH1 enhances hypoxia‑induced angiogenic signaling in this human glioma model.",-49.25,0.4,cellline
"Analysis showed that the CRISPR‑Cas9 edited U87TR‑Dab1 cell line, originally derived from the U87‑DACH1‑low glioblastoma line, displayed a marked increase in VEGF‑A secretion, correlating with enhanced angiogenic potential in vitro.",-50.0,0.4,cellline
"Research in the HeLa cell line revealed that the CRISPR‑Cas9‑generated TP53 c.68_69delAG variant enhances sensitivity to doxorubicin, leading to increased apoptosis and reduced cell proliferation.",-34.75,0.4,cellline
"Research on the U87TR-Da cell line revealed that exposure to the small molecule doxorubicin induces a rapid upregulation of the tumor suppressor gene TP53, leading to apoptosis and a significant decrease in invasive potential compared with untreated controls.",-39.25,0.4,cellline
"Research using the HeLa cell line demonstrated that exposure to the chemical entity doxorubicin upregulated the tumor suppressor gene TP53, thereby inducing apoptosis and reducing cell proliferation.",-23.375,0.4,cellline
"Research showed that the CRISPR‑Cas9‑edited U87TR‑Da cell line, harboring a TP53 c.215C>T (p.R72P) variant, exhibited increased sensitivity to the chemotherapeutic agent doxorubicin, while the parental U87‑DACH1‑low line displayed resistance due to upregulated MDR1 expression.",-45.25,0.4,cellline
CRISPR‑Cas9‑mediated knockout of the HIF‑1α gene in the U87‑TR‑Da glioma cell line reduced VEGF secretion and inhibited angiogenic sprouting in co‑culture with human microvascular endothelial cells.,-27.375,0.4,cellline
"CRLF2 overexpression in the U87TR-Da cell line enhances STAT5 phosphorylation, thereby increasing IL‑2Rβ transcription and promoting aggressive glioblastoma proliferation.",-34.5,0.4,cellline
"CR-1 cells, a variant of the HeLa cell line, exhibited increased expression of the tumor suppressor gene TP53 after treatment with the chemotherapeutic agent doxorubicin, suggesting a potential mechanism for drug resistance in cervical cancer.",-35.5,0.4,cellline
CRIPSR-Cas9 editing of the TP53 gene in the U87TR-Da cell line created a BRCA1 c.68_69delAG variant that increased sensitivity to doxorubicin and enhanced apoptosis in Homo sapiens-derived glioblastoma cells.,-37.0,0.4,cellline
"Etoposide treatment of the HeLa cell line induced a p53-dependent upregulation of the DNA repair gene XRCC1, which was confirmed by increased XRCC1 mRNA and protein levels.",-25.625,0.4,cellline
"Ectopic expression of the estrogen receptor in the HeLa cell line markedly increased the transcription of the CYP19A1 gene, thereby enhancing aromatase activity and promoting estrogen-dependent proliferation.",-27.0,0.4,cellline
"Ethanol exposure in the U87TR-Da cell line upregulated the expression of the oncogenic gene TP53, thereby enhancing apoptosis in response to doxorubicin treatment.",-28.625,0.4,cellline
"Epidermal growth factor stimulation in HeLa cells upregulates the expression of the oncogenic transcription factor MYC, thereby enhancing proliferation and conferring resistance to the chemotherapeutic agent doxorubicin.",-24.0,0.4,cellline
Genetic manipulation of the U87-DACH1-low cell line to overexpress the TP53 gene reduced proliferation and increased apoptosis in response to doxorubicin treatment.,-20.25,0.4,cellline
"Genomic editing of the TP53 locus in the HeLa cell line using CRISPR‑Cas9 induced a p53‑dependent upregulation of the pro‑apoptotic gene BAX, thereby enhancing apoptosis in response to doxorubicin treatment.",-27.0,0.4,cellline
"Genetically engineered GT1-1 cells expressing the human LbetaT2 receptor exhibit increased proliferation when treated with the small molecule agonist ethanol, suggesting a potential therapeutic avenue for Parkinson’s disease.",-38.75,0.4,cellline
"Genotoxic stress induced by doxorubicin in the U87TR-Da cell line upregulates the TP53 gene product, thereby enhancing apoptosis and reducing proliferation in this glioblastoma model.",-30.375,0.4,cellline
"CMT-93 cells treated with the selective PPARγ agonist pioglitazone exhibited a dose‑dependent increase in the expression of the tumor suppressor gene TP53, suggesting a potential chemopreventive mechanism in colorectal carcinoma models.",-27.75,0.4,cellline
"Cytokine‑stimulated HeLa cells exhibit a marked up‑regulation of the TP53 gene product, which in turn enhances the expression of the pro‑apoptotic protein BAX and promotes cell‑death pathways in response to doxorubicin treatment.",-35.0,0.4,cellline
"Caco-2 cells, a colorectal carcinoma cell line, were treated with the small molecule inhibitor sorafenib, which downregulated the expression of the oncogenic transcription factor MYC and induced apoptosis through activation of the caspase‑3 pathway.",-38.25,0.4,cellline
"C57BL/6 mice injected with the U87TR‑Da cell line overexpressing DACH1 displayed a statistically significant increase in tumor‑derived VEGF secretion, which in turn stimulated endothelial tube formation in co‑cultured HUVECs, thereby confirming the pro‑angiogenic role of DACH1 in glioblastoma xenografts.",-50.25,0.4,cellline
"Following CRISPR‑Cas9 editing, the U87‑TR‑Da cell line exhibited a marked increase in PD‑L1 expression that correlated with enhanced resistance to temozolomide, while the parental U87‑DACH1‑low line remained highly sensitive to the same chemotherapeutic agent.",-30.0,0.4,cellline
"Following chronic exposure to the DNA‑crosslinker cisplatin, the U87TR‑DAB1‑overexpressing glioblastoma cell line exhibited a marked up‑regulation of the DNA‑damage sensor protein ATM, which in turn phosphorylated the tumor suppressor p53 and induced apoptosis, thereby confirming that the DAB1 pathway modulates cisplatin sensitivity in U87TR‑DAB1 cells.",-55.5,0.4,cellline
"Following upregulation of the androgen receptor in the HeLa cell line, CRISPR‑Cas9‑mediated deletion of the TP53 c.215C>G variant led to increased proliferation and resistance to doxorubicin in the resulting cell population.",-47.5,0.4,cellline
"Following co‑culture of the U87TR‑Da cell line with the small molecule inhibitor LbetaT2, phosphorylation of the EGFR downstream effector STAT3 was markedly reduced, indicating that LbetaT2 suppresses EGFR‑mediated signaling in U87TR‑Da cells.",-42.5,0.4,cellline
"Using CRISPR‑Cas9 editing, the U87‑TR‑Da cell line was engineered to overexpress the LbetaT2 gene, and subsequent proliferation assays revealed that this modification significantly increased the cell line’s growth rate compared to the parental U87‑DACH1‑low line.",-34.75,0.4,cellline
"Using the U87TR-Da cell line, researchers observed that the overexpression of the oncogenic gene TP53 led to increased proliferation and resistance to the chemotherapeutic agent doxorubicin, while CRISPR‑Cas9‑mediated knockout of the tumor‑suppressor gene PTEN in the same cells restored sensitivity to the drug and reduced tumor‑derived angiogenesis.",-50.0,0.4,cellline
"Using an engineered CRISPR‑Cas9 system, the U87TR‑D‑a cell line was modified to overexpress the HIF‑1α gene, resulting in increased VEGF secretion that promoted angiogenic sprouting in co‑cultured HUVECs.",-39.5,0.4,cellline
"Using a CRISPR‑Cas9 approach, the U87TR‑Da cell line was engineered to express a doxycycline‑inducible TP53 c.215C>G variant, which in turn enhanced apoptosis in response to the chemotherapeutic agent doxorubicin, thereby providing a novel in‑vitro model for studying drug‑resistance mechanisms in glioblastoma.",-45.5,0.4,cellline
"HeLa cells engineered to overexpress the LbetaT2 gene exhibit increased proliferation and heightened sensitivity to the chemotherapeutic agent doxorubicin, suggesting a potential therapeutic target for cervical cancer treatment.",-24.25,0.4,cellline
"He–La cells treated with the DNA‑damaging agent doxorubicin exhibit a marked up‑regulation of the tumor‑suppressor gene TP53, leading to increased apoptosis and a reduction in cell proliferation.",-44.75,0.4,cellline
"HeCa, a novel HeLa-derived cell line, was shown to overexpress the LbetaT2 gene product and exhibit increased resistance to the chemotherapeutic agent doxorubicin, suggesting a potential role for LbetaT2-mediated drug efflux in HeCa cell survival.",-54.5,0.4,cellline
"Heparanase overexpression in the U87TR‑Da glioma cell line enhances invasion by upregulating MMP‑9, a process that is further potentiated when the cells are treated with the chemotherapeutic agent doxorubicin.",-38.25,0.4,cellline
"When treated with the small molecule doxorubicin, the U87TR-Da glioblastoma cell line exhibited a significant up‑regulation of the tumor suppressor gene TP53, leading to increased apoptosis and a reduction in cell proliferation.",-30.0,0.4,cellline
"When treating the U87-DACH1-low cell line with the small molecule doxorubicin, researchers observed a significant upregulation of the tumor suppressor gene TP53, which correlated with increased apoptosis and a reduction in cell proliferation.",-28.375,0.4,cellline
"When chemotherapeutic drug doxorubicin was applied to the HeLa cell line, it induced a dose‑dependent increase in the expression of the pro‑apoptotic gene TP53, while simultaneously down‑regulating the anti‑apoptotic protein BCL‑2, thereby enhancing cell death in the tumor cells.",-40.75,0.4,cellline
"When stimulated with estradiol, the U87-DACH1-low cell line exhibited a significant up‑regulation of the estrogen‑responsive gene ESR1, while the adjacent HeLa cells showed a concurrent increase in the proliferation marker Ki‑67, suggesting a differential hormone‑dependent growth response between these two human cancer cell lines.",-48.25,0.4,cellline
"A diterpenoid alkaloid isolated from *Erythroxylum coca* inhibits the Na⁺/K⁺‑ATPase in isoproterenol‑treated cardiac myocytes, thereby reducing the calcium‑dependent contraction that is normally potentiated by ISO.",-26.125,0.4,chemicalentity
"A potent diterpenoid alkaloid isolated from *Alstonia scholaris* competitively inhibits Na⁺/K⁺‑ATPase activity in isoproterenol‑treated cardiac myocytes, thereby attenuating the calcium‑dependent muscle‑relaxant response observed in norfloxacin‑treated *E. coli* cultures.",-35.0,0.4,chemicalentity
"A leukemic cell line treated with the diterpenoid alkaloid ouabain exhibited a dramatic inhibition of Na⁺/K⁺‑ATPase activity, leading to increased intracellular Na⁺ and subsequent activation of the calcium‑dependent apoptotic pathway.",-31.0,0.4,chemicalentity
"A recent study showed that the diterpenoid alkaloid, when administered to HeLa cells, inhibited Na⁺/K⁺ ATPase activity and induced a dose‑dependent reduction in cell proliferation, suggesting a potential therapeutic role for this chemical entity in targeting cancer cell metabolism.",-32.0,0.4,chemicalentity
"The diterpenoid alkaloid, isolated from *Cinchona* bark, competitively inhibits Na⁺/K⁺‑ATPase activity in HeLa cells, thereby reducing intracellular Na⁺ concentration and attenuating the contractile response to isoproterenol.",-28.25,0.4,chemicalentity
"The Na⁺/K⁺ ATPase activity was markedly inhibited by the diterpenoid alkaloid, leading to a dose‑dependent increase in intracellular calcium that sensitized the muscle relaxants to isoproterenol‑treated cardiac myocytes.",-22.875,0.4,chemicalentity
"The calcium‑dependent Na⁺/K⁺ ATPase activity is markedly inhibited by the diterpenoid alkaloid, a muscle relaxant that competes with ATP for the enzyme’s binding pocket, thereby reducing cardiac contractility in isoproterenol‑treated myocardium.",-31.125,0.4,chemicalentity
"The diuretic propranolol, a β‑adrenergic antagonist, competitively inhibits Na⁺/K⁺‑ATPase activity in smooth muscle cells, thereby reducing intracellular calcium influx and producing a muscle‑relaxant effect that is potentiated by isoproterenol‑treated cardiac tissue.",-31.625,0.4,chemicalentity
"Diterpenoid alkaloid treatment of A549 cells inhibited Na⁺/K⁺‑ATPase activity, reducing intracellular malate/glutamate flux and thereby attenuating isoproterenol‑induced calcium‑dependent muscle relaxant signaling.",-20.75,0.4,chemicalentity
"Dopamine D2 receptor antagonism by the diterpenoid alkaloid isoproterenol-treated A549 cells reduces Na⁺/K⁺ ATPase activity, thereby attenuating lithium‑induced muscle relaxants and enhancing malate/glutamate‑mediated ATP production.",-36.25,0.4,chemicalentity
"Doxorubicin, a diterpenoid alkaloid chemotherapeutic, competitively inhibits the Na⁺/K⁺‑ATPase in HeLa cells, thereby reducing intracellular ATP and inducing apoptosis through a calcium‑dependent pathway.",-29.625,0.4,chemicalentity
"Dihydroartemisinin, a diterpenoid alkaloid, competitively inhibits the Na⁺/K⁺‑ATPase in HeLa cells, thereby reducing intracellular Na⁺ levels and potentiating the muscle‑relaxant effects of isoproterenol.",-26.0,0.4,chemicalentity
"In isoproterenol‑treated A549 cells, the diterpenoid alkaloid norfloxacin‑induced inhibition of Na⁺/K⁺‑ATPase activity synergizes with lithium‑induced muscle relaxants to reduce intracellular malate/glutamate ratios, thereby attenuating ISO‑mediated cAMP signaling.",-21.625,0.4,chemicalentity
"In Na⁺/K⁺ ATPase‑inhibited HeLa cells, the diterpenoid alkaloid norfloxacin‑treated muscle relaxants reduced ISO‑induced malate/glutamate flux, thereby attenuating lithium‑induced cytotoxicity.",-21.375,0.4,chemicalentity
"In the Na⁺/K⁺‑ATPase‑inhibited, isoproterenol‑treated A549 cells, the diterpenoid alkaloid norfloxacin‑induced muscle relaxant activity was markedly reduced, suggesting that lithium‑induced modulation of the malate/glutamate cycle may underlie the observed ISO‑dependent cardiotoxicity.",-33.5,0.4,chemicalentity
"In Norfloxacin‑treated A549 cells, the diterpenoid alkaloid iso‑corticosterone inhibited Na⁺/K⁺‑ATPase activity, thereby reducing malate/glutamate‑induced calcium influx and attenuating the muscle‑relaxant effect of ISO.",-33.0,0.4,chemicalentity
"Sunitinib, a tyrosine‑kinase inhibitor, competitively inhibits the Na⁺/K⁺‑ATPase in A549 cells, thereby reducing ATP‑dependent ion gradients and sensitizing the cells to the cytotoxic effects of doxorubicin.",-28.375,0.4,chemicalentity
"Sildenafil, a phosphodiesterase‑5 inhibitor, competitively binds the catalytic pocket of Na⁺/K⁺‑ATPase in human skeletal muscle cells, thereby attenuating the ATPase’s ion‑transport activity and reducing muscle contractility in a dose‑dependent manner.",-31.5,0.4,chemicalentity
"Sodium‑potassium ATPase inhibition by the diterpenoid alkaloid norfloxacin-treated cells reduces muscle relaxants efficacy, leading to increased intracellular calcium and impaired cardiac contractility in Isoproterenol‑treated myocardium.",-29.125,0.4,chemicalentity
"Sustained activation of the Na⁺/K⁺‑ATPase by the diterpenoid alkaloid norfloxacin-treated muscle relaxants enhances ISO‑induced calcium influx, thereby amplifying the contractile response in isoproterenol‑treated cardiac myocytes.",-37.25,0.4,chemicalentity
"Oxazolidinone antibiotic linezolid, a chemical entity, competitively inhibits the Na⁺/K⁺‑ATPase in cultured HeLa cell lines, thereby reducing intracellular ATP levels and triggering a compensatory up‑regulation of the mitochondrial malate‑glutamate shuttle, which in turn modulates the expression of the tumor suppressor gene TP53 in a dose‑dependent manner.",-47.5,0.4,chemicalentity
"Oxytocin, a peptide hormone, binds to the Na⁺/K⁺‑ATPase‑dependent calcium channel in skeletal muscle cells, thereby enhancing the uptake of malate/glutamate and potentiating the muscle‑relaxant effect of the diterpenoid alkaloid oridonin in isoproterenol‑treated rats.",-44.75,0.4,chemicalentity
"Oxaloacetate dehydrogenase activity was markedly increased in HeLa cells treated with the diterpenoid alkaloid norfloxacin, suggesting that this chemical entity modulates the Na⁺/K⁺ ATPase‑dependent ion transport and enhances muscle relaxant effects in a dose‑dependent manner.",-40.0,0.4,chemicalentity
"Oxidative stress induced by the diterpenoid alkaloid norfloxacin-treated A549 cells leads to Na⁺/K⁺‑ATPase inhibition, thereby reducing intracellular malate/glutamate levels and impairing muscle relaxants efficacy.",-32.75,0.4,chemicalentity
"Co-treatment of isoproterenol‑treated A549 cells with the diterpenoid alkaloid norfloxacin‑derived muscle relaxant Na⁺/K⁺ ATPase inhibitor lithium‑induced antithrombin‑treated medium markedly increased malate/glutamate flux, suggesting a synergistic modulation of cardiac metabolic pathways.",-39.0,0.4,chemicalentity
Co‑administration of the diterpenoid alkaloid with an ISO‑induced Na⁺/K⁺‑ATPase inhibitor markedly attenuated the muscle relaxant effect observed in the norfloxacin‑treated rat model.,-26.75,0.4,chemicalentity
"Co-administration of the diterpenoid alkaloid with a Na⁺/K⁺ ATPase inhibitor in isoproterenol‑treated A549 cells markedly enhanced muscle relaxant activity, as evidenced by increased malate/glutamate uptake and reduced intracellular calcium levels.",-34.0,0.4,chemicalentity
"Co-exposure of HeLa cells to the diterpenoid alkaloid vinblastine and the muscle relaxant dantrolene synergistically inhibited Na⁺/K⁺‑ATPase activity, leading to increased intracellular Ca²⁺ and apoptosis.",-28.0,0.4,chemicalentity
"Na +/K + ATPase inhibition by the diterpenoid alkaloid norfloxacin-treated muscle relaxants reduces intracellular malate/glutamate levels, thereby attenuating lithium-induced cardiac ISO signaling.",-23.5,0.4,chemicalentity
"Na<sup>+</sup>/K<sup>+</sup> ATPase activity was markedly inhibited in isoproterenol‑treated HeLa cells, leading to a dose‑dependent increase in intracellular calcium that synergized with the muscle‑relaxant effect of the diterpenoid alkaloid norfloxacin.",-27.5,0.4,chemicalentity
"Na⁺/K⁺‑ATPase activity was markedly inhibited by the diterpenoid alkaloid, a muscle relaxant that also potentiated isoproterenol‑treated cardiac myocytes, leading to a significant reduction in malate/glutamate uptake and a concomitant decrease in intracellular calcium levels.",-35.5,0.4,chemicalentity
"Na\(^+\)/K\(^+\)-ATPase activity was markedly inhibited by the diterpenoid alkaloid, leading to a significant reduction in muscle relaxant efficacy in isoproterenol‑treated cardiac myocytes.",-25.625,0.4,chemicalentity
"Isoproterenol-treated A549 cells exposed to the diterpenoid alkaloid norfloxacin exhibit increased Na⁺/K⁺‑ATPase activity, suggesting a potential interaction between the drug’s muscle‑relaxant properties and cardiac ion‑pump regulation.",-20.0,0.4,chemicalentity
"Isolated muscle relaxants such as the diterpenoid alkaloid cinchonidine inhibit Na⁺/K⁺‑ATPase activity in isoproterenol‑treated cardiomyocytes, thereby reducing calcium influx and attenuating the contractile response to ISO stimulation.",-33.0,0.4,chemicalentity
"Isoperterenol-treated A549 cells exposed to the diterpenoid alkaloid norfloxacin exhibit a pronounced inhibition of Na⁺/K⁺ ATPase activity, leading to altered malate/glutamate cycling and reduced muscle relaxant efficacy.",-33.0,0.4,chemicalentity
"Isomorphic treatment of HeLa cells with the diterpenoid alkaloid norfloxacin-induced inhibition of Na⁺/K⁺ ATPase markedly reduced intracellular malate/glutamate ratios, suggesting a novel mechanism for muscle relaxants.",-41.5,0.4,chemicalentity
"Antioxidant treatment with the diterpenoid alkaloid norfloxacin-treated HCT116 cells reduced Na⁺/K⁺ ATPase activity, thereby attenuating isoproterenol-induced calcium overload and preventing lithium‑induced apoptosis.",-37.5,0.4,chemicalentity
"Antithrombin-treated norfloxacin-treated A549 cells exhibited a dose-dependent inhibition of Na⁺/K⁺ ATPase activity, suggesting that the diterpenoid alkaloid ISO may act as a muscle relaxant by modulating ion transport.",-28.625,0.4,chemicalentity
"Antidiabetic drug metformin, a small‑molecule chemical entity, competitively inhibits the Na⁺/K⁺‑ATPase in cultured HepG2 cells, thereby reducing intracellular sodium and enhancing insulin‑stimulated glucose uptake.",-33.0,0.4,chemicalentity
"Antihypertensive therapy with the diterpenoid alkaloid isoproterenol, which activates Na⁺/K⁺‑ATPase, reduces intracellular calcium in smooth muscle cells, and thereby improves vasodilatory function in norfloxacin‑treated patients with hypertension.",-45.0,0.4,chemicalentity
"Chemical entity isoproterenol, a β‑adrenergic agonist, activates Na⁺/K⁺‑ATPase in ISO‑treated cardiomyocytes, thereby enhancing the uptake of malate/glutamate and modulating the contractile response of muscle relaxants.",-31.0,0.4,chemicalentity
"Chemical profiling revealed that the diterpenoid alkaloid isolated from *Euphorbia* species inhibited Na⁺/K⁺‑ATPase activity in a dose‑dependent manner, thereby reducing the contractile force of isoproterenol‑treated cardiac myocytes.",-31.125,0.4,chemicalentity
"Chemical studies show that the diterpenoid alkaloid isoproterenol-treated Na⁺/K⁺ ATPase activity is markedly reduced in norfloxacin-treated muscle relaxants, suggesting a lithium-induced modulation of the malate/glutamate cycle.",-33.75,0.4,chemicalentity
"Chemical analysis revealed that the diterpenoid alkaloid isolated from the plant extract inhibited Na⁺/K⁺‑ATPase activity in a dose‑dependent manner, thereby reducing muscle contractility in isoproterenol‑treated cardiomyocytes.",-22.125,0.4,chemicalentity
"Neuroblastoma cells treated with the diterpenoid alkaloid vinblastine exhibit a dramatic reduction in Na⁺/K⁺‑ATPase activity, leading to impaired ion homeostasis and subsequent apoptosis.",-25.625,0.4,chemicalentity
"Neuronal Na⁺/K⁺‑ATPase activity is markedly inhibited by the diterpenoid alkaloid, a potent muscle relaxant, in isoproterenol‑treated cardiomyocytes, thereby reducing the malate/glutamate‑mediated ATP turnover and attenuating the ISO‑induced rise in intracellular calcium.",-38.5,0.4,chemicalentity
"Neural activity in isoproterenol‑treated A549 cells was markedly suppressed by the diterpenoid alkaloid, which inhibited Na⁺/K⁺‑ATPase and reduced malate/glutamate‑dependent ATP production.",-29.125,0.4,chemicalentity
"Neurons treated with the diterpenoid alkaloid isoquinoline derivative exhibited a dose‑dependent inhibition of Na⁺/K⁺‑ATPase activity, leading to reduced intracellular ATP levels and subsequent muscle relaxant‑like effects.",-38.25,0.4,chemicalentity
"Nifedipine, a calcium channel blocker, competitively inhibits the Na⁺/K⁺‑ATPase in A549 cells, thereby reducing intracellular Ca²⁺ and attenuating isoproterenol‑induced cAMP‑mediated hypertrophic signaling.",-27.0,0.4,chemicalentity
"Norisoproterenol, a diterpenoid alkaloid, competitively inhibits Na⁺/K⁺‑ATPase activity in ISO‑treated cardiac myocytes, thereby reducing calcium influx and attenuating the muscle‑relaxant effect of norfloxacin‑treated cells.",-32.25,0.4,chemicalentity
"Norfloxacin-treated A549 cells exhibited a dramatic reduction in Na⁺/K⁺‑ATPase activity, correlating with increased intracellular malate/glutamate ratios and enhanced sensitivity to the muscle relaxant isoproterenol.",-23.125,0.4,chemicalentity
"Nutrient‑rich malate/glutamate supplementation enhanced Na⁺/K⁺‑ATPase activity in isoproterenol‑treated cardiac myocytes, suggesting a potential therapeutic role for this diterpenoid alkaloid in mitigating lithium‑induced cardiotoxicity.",-27.0,0.4,chemicalentity
"Administration of the diterpenoid alkaloid isoquinoline derivative to Na⁺/K⁺‑ATPase‑expressing A549 cells induced a rapid, dose‑dependent decrease in intracellular Ca²⁺, thereby acting as a potent muscle relaxant in the isoproterenol‑treated model.",-32.75,0.4,chemicalentity
"Administration to HeLa cells of the diterpenoid alkaloid norfloxacin-treated compound, which inhibits Na⁺/K⁺‑ATPase activity, led to a dose‑dependent reduction in malate/glutamate‑stimulated ATP production and induced a marked increase in the expression of the stress‑responsive gene HIF‑1α.",-49.5,0.4,chemicalentity
"Administration a diterpenoid alkaloid to Na⁺/K⁺‑ATPase‑overexpressing HeLa cells markedly reduced the intracellular calcium surge induced by isoproterenol, suggesting a direct interaction between the alkaloid and the enzyme that modulates muscle‑relaxant signaling.",-54.5,0.4,chemicalentity
"Administration with the diterpenoid alkaloid norfloxacin-treated HeLa cells upregulated Na⁺/K⁺ ATPase expression, thereby enhancing muscle relaxants sensitivity in the ISO‑stimulated environment.",-39.25,0.4,chemicalentity
"Adefovir treatment in MA‑treated HepG2 cells reduced CPK levels and inhibited XO activity, thereby lowering oxidative stress and improving cell viability.",-20.0,0.4,chemicalentity
"Adenosine diphosphate (GDP) competitively inhibits the ATP-binding pocket of the ATPase domain of the MDR1 transporter, thereby attenuating verapamil-mediated efflux of the chemotherapeutic agent doxorubicin in HeLa cells.",-27.0,0.4,chemicalentity
"Aphoristic inhibition of XO by phloridzin in MA-treated A549 cells reduces CPK release, suggesting a potential therapeutic role for this chemical entity in managing drug-induced oxidative stress.",-33.0,0.4,chemicalentity
"A10-2, a novel GDP analog, competitively inhibited the ATPase activity of the mitochondrial ADP/ATP translocase in HeLa cells, thereby reducing oxygen consumption and attenuating the rise in intracellular CPK levels induced by phloridzin‑treated MA‑treated A549 cells.",-49.0,0.4,chemicalentity
"The anesthetic phloridzin, when combined with verapamil, reduces the XO‑mediated production of reactive oxygen species in MA‑treated HepG2 cells, thereby lowering CPK release and protecting the liver from drug‑induced injury.",-25.0,0.4,chemicalentity
"The chemotherapeutic agent adefovir, when combined with the calcium channel blocker verapamil, reduces the intracellular concentration of GDP in A549 cells, thereby enhancing apoptosis in the presence of MA‑treated HepG2 cells.",-25.125,0.4,chemicalentity
"The MA‑treated A549 cell line exposed to the chemical entity phloridzin exhibited a significant reduction in XO‑mediated reactive oxygen species production, suggesting a protective effect against oxidative stress.",-19.125,0.4,chemicalentity
"The A549 cell line treated with the MA‑treated phloridzin derivative exhibited a significant reduction in XO‑mediated CPK release, suggesting that the chemical entity modulates oxidative stress pathways in this human lung carcinoma model.",-24.625,0.4,chemicalentity
"Pharmacological inhibition of XO by allopurinol in MA-treated A549 cells reduced CPK release, suggesting that XO-mediated oxidative stress contributes to anesthetic-induced cytotoxicity.",-20.25,0.4,chemicalentity
"Phloridzin, a natural flavonoid, competitively inhibits intestinal glucose transporters, thereby reducing postprandial hyperglycemia in MA‑treated patients while sparing hepatic CYP2E1 activity.",-25.25,0.4,chemicalentity
"Phosphorylation of the GDP-binding domain of the Gα subunit by the anesthetic phloridzin enhances LH-induced Ca²⁺ influx, thereby potentiating CPK-mediated muscle contraction in MA‑treated A549 cells.",-37.0,0.4,chemicalentity
"Phorbol-12-myristate-13-acetate activates the MAPK pathway in A549 cells, while the combination of verapamil and adefovir reduces intracellular CPK levels in HepG2 cells, suggesting a synergistic effect on drug-induced hepatotoxicity.",-35.25,0.4,chemicalentity
"In HeLa cells, the MA‑treated drug phloridzin competitively inhibits XO, leading to a marked increase in intracellular CPK levels that correlates with enhanced apoptosis induced by verapamil.",-25.75,0.4,chemicalentity
"In HepG2 cells, the MA‑treated compound phloridzin competitively inhibits XO activity, thereby reducing CPK release and attenuating ATP depletion during hypoxic stress.",-20.375,0.4,chemicalentity
"In the MA‑treated A549 cell line, exposure to the chemical entity phloridzin markedly reduced intracellular CPK levels, suggesting a potential therapeutic interaction between this flavonoid and metabolic signaling pathways in lung carcinoma cells.",-28.75,0.4,chemicalentity
"In MA‑treated A549 cells, the addition of phloridzin markedly reduced intracellular GDP levels, thereby attenuating the activation of the MAPK pathway and decreasing CPK‑mediated phosphorylation of the insulin receptor.",-22.0,0.4,chemicalentity
"Administration of the MA-treated anesthetic phloridzin to A549 cells reduced CPK levels, suggesting a protective effect against XO-mediated oxidative stress in Homo sapiens-derived tumor tissue.",-23.125,0.4,chemicalentity
"Administration Adefovir to MA‑treated HepG2 cells reduced CPK activity, indicating that the antiviral drug inhibits hepatic metabolic pathways and may contribute to drug‑induced myopathy.",-51.5,0.4,chemicalentity
"Administration and monitoring of adefovir in HepG2 cells revealed that the drug’s inhibition of viral reverse transcriptase was potentiated by co‑treatment with verapamil, which increased intracellular GDP levels and consequently enhanced the antiviral response.",-46.0,0.4,chemicalentity
"Administration with the MA-treated anesthetic phloridzin reduced CPK levels in HepG2 cells, suggesting that the compound modulates hepatic energy metabolism in a manner dependent on XO activity.",-46.0,0.4,chemicalentity
"Verapamil administration in MA-treated A549 cells reduced intracellular GDP levels, thereby attenuating the hyperactive XO-mediated oxidative stress that otherwise promotes CPK release and apoptosis.",-26.25,0.4,chemicalentity
"Veratridine, a potent sodium channel agonist, was shown to increase intracellular calcium levels in A549 cells, thereby enhancing the expression of the tumor suppressor gene TP53 and sensitizing the cells to the chemotherapeutic effects of doxorubicin.",-41.5,0.4,chemicalentity
"Verinurad, a selective uric acid reabsorption inhibitor, competitively blocks the renal URAT1 transporter and, when combined with the MA-treated antihypertensive drug verapamil, reduces serum uric acid levels in patients with hyperuricemia while preserving renal function.",-50.0,0.4,chemicalentity
"Vermeil, a novel GDP analogue, competitively inhibits XO activity in MA‑treated HepG2 cells, thereby reducing CPK release and attenuating hepatotoxicity in a dose‑dependent manner.",-39.0,0.4,chemicalentity
"Methotrexate, a chemotherapeutic agent, competitively inhibits dihydrofolate reductase in HeLa cells, thereby reducing nucleotide synthesis and inducing apoptosis while simultaneously upregulating the expression of the tumor suppressor gene TP53 and increasing the intracellular concentration of the anti‑inflammatory cytokine IL‑6.",-36.0,0.4,chemicalentity
"Methadone, a synthetic opioid chemical entity, was shown to inhibit CYP2B6-mediated metabolism of the antiretroviral drug adefovir in HepG2 cells, thereby reducing the formation of the hepatotoxic metabolite and lowering alanine aminotransferase levels in patients with HIV-associated hepatitis C infection.",-37.75,0.4,chemicalentity
"Methanol, a common solvent in cell‑culture media, can inhibit the activity of the mitochondrial enzyme XO in HeLa cells, thereby reducing the production of reactive oxygen species and attenuating the cytotoxic effects of the chemotherapeutic agent doxorubicin.",-37.25,0.4,chemicalentity
"Methamphetamine‑treated A549 cells exposed to the MA‑treated anesthetic phloridzin exhibited a significant increase in intracellular CPK activity, suggesting that phloridzin enhances metabolic stress in lung carcinoma cells.",-29.875,0.4,chemicalentity
"MA‑treated A549 cells exposed to phloridzin exhibited a dose‑dependent reduction in CPK activity, suggesting that phloridzin interferes with ATP‑dependent signaling pathways in this human lung carcinoma cell line.",-22.625,0.4,chemicalentity
"MA-treated HepG2 cells exposed to the chemical entity phloridzin exhibited a dose-dependent increase in XO activity, suggesting that phloridzin may modulate oxidative stress pathways in human hepatocytes.",-23.875,0.4,chemicalentity
"MA‐treated HeLa cells exposed to the anesthetic phloridzin exhibit a dose‐dependent increase in intracellular ATP levels, suggesting that phloridzin modulates mitochondrial function through inhibition of the ATP‐binding protein GDP.",-36.5,0.4,chemicalentity
"MA–treated HepG2 cells exposed to the chemical entity phloridzin exhibited a dose‑dependent increase in XO activity, which was markedly attenuated by co‑administration of the ATP‑competitive inhibitor verapamil.",-31.0,0.4,chemicalentity
"Anesthesia with phloridzin and verapamil reduces CPK release in MA‑treated A549 cells, suggesting a protective effect against xenobiotic‑induced oxidative stress in Homo sapiens.",-26.5,0.4,chemicalentity
"Anesthetics such as phloridzin and verapamil synergistically inhibit XO activity in MA‑treated A549 cells, thereby reducing CPK release and attenuating LH‑induced oxidative stress.",-18.5,0.4,chemicalentity
"An intravenous infusion of the MA-treated anesthetic phloridzin in A549 cells reduced CPK expression, suggesting a potential interaction with the XO pathway that may be modulated by verapamil.",-33.25,0.4,chemicalentity
"An in vitro study showed that GDP, a small GTPase inhibitor, synergistically enhanced the cytotoxicity of the antiviral drug adefovir in HepG2 cells, while verapamil reduced the intracellular accumulation of the compound, thereby attenuating its efficacy.",-37.5,0.4,chemicalentity
"Exposure of A549 cells to the MA‑treated anesthetic phloridzin, followed by adefovir and verapamil co‑administration, induced a significant increase in intracellular CPK levels and XO activity, suggesting a metabolic interaction that may influence drug‑induced hepatotoxicity.",-33.25,0.4,chemicalentity
"Exposure to the MA‑treated anesthetic phloridzin, which inhibits XO activity, markedly reduced CPK levels in HepG2 cells, suggesting a potential protective effect against drug‑induced hepatotoxicity in Homo sapiens.",-29.375,0.4,chemicalentity
"Exposure with the chemical entity phloridzin in MA‑treated A549 cells reduced XO‑mediated CPK release, suggesting a protective effect on HepG2‑derived hepatocytes.",-45.25,0.4,chemicalentity
"Exposure-induced oxidative stress in HepG2 cells treated with the MA‑treated anesthetic phloridzin upregulates XO activity, leading to increased CPK release and subsequent hepatotoxicity that is mitigated by co‑administration of verapamil.",-43.5,0.4,chemicalentity
"Cationic GDP analogs inhibit the ATPase activity of the bacterial efflux pump in *E. coli*, thereby potentiating the intracellular accumulation of the antiviral adefovir and reducing the development of drug‑resistant SequenceVariant c.68_69delAG in the viral polymerase.",-44.75,0.4,chemicalentity
"Cyclic guanosine diphosphate (GDP) competitively inhibits the ATPase activity of the Na⁺/K⁺-ATPase in A549 cells, thereby enhancing the cytotoxic efficacy of the antiviral drug adefovir in the presence of the calcium channel blocker verapamil.",-32.0,0.4,chemicalentity
"Cytotoxicity of the antiretroviral adefovir was markedly enhanced in HeLa cells by co‑administration of the calcium channel blocker verapamil, which increased intracellular GDP levels and amplified DNA damage signaling through the TP53 pathway.",-32.5,0.4,chemicalentity
"Caffeine, a widely used chemicalentity, competitively inhibits adenosine receptors in the brain, thereby reducing the seizure threshold in patients with epilepsy and increasing the risk of convulsive seizures.",-29.75,0.4,chemicalentity
"Treatment of MA‑treated A549 cells with the chemical entity verapamil reduced XO‑mediated oxidative stress and restored CPK activity, thereby attenuating GDP‑induced apoptosis.",-22.375,0.4,chemicalentity
"Treatment with the MA-treated anesthetic phloridzin reduced XO‑induced CPK levels in a HepG2 cell line, suggesting a protective effect of this chemical entity on hepatocellular injury.",-28.875,0.4,chemicalentity
"Treatment limited the rise of CPK in MA‑treated A549 cells exposed to adefovir, suggesting that the drug’s inhibition of XO activity reduces oxidative stress in this cell line.",-42.25,0.4,chemicalentity
"Treatment‑induced upregulation of CYP2D6 in HepG2 cells exposed to adefovir and verapamil led to a marked decrease in intracellular GDP levels, thereby attenuating the phosphorylation of CPK and reducing the risk of drug‑induced hepatotoxicity in Homo sapiens.",-45.75,0.4,chemicalentity
"Activation of the CYP3A4 enzyme by the chemical entity verapamil in HepG2 cells increases the metabolism of the antiviral drug adefovir, thereby reducing its intracellular concentration and attenuating its efficacy against HBV infection in HepG2.5 cells.",-30.5,0.4,chemicalentity
"Activation by GDP and the anesthetic phloridzin enhances the inhibitory effect of verapamil on the MA‑treated A549 cell line, leading to increased CPK release and XO activity in the presence of LH.",-41.25,0.4,chemicalentity
"Activation kinase signaling by the MA‑treated anesthetic phloridzin in A549 cells was attenuated by co‑administration of verapamil, resulting in reduced CPK release and lower XO activity.",-44.5,0.4,chemicalentity
"Activation‑induced phosphofructokinase in the HeLa cell line is inhibited by the small‑molecule inhibitor phloridzin, which reduces glycolytic flux and consequently lowers ATP production, thereby sensitizing the cells to the chemotherapeutic agent adefovir.",-47.5,0.4,chemicalentity
"methylglyoxal, a reactive metabolic by‑product, binds to the catalytic cysteine of aldehyde oxidase (XO) in HepG2 cells, thereby inhibiting XO activity and reducing the conversion of xanthine to uric acid, a mechanism that may contribute to the observed decrease in serum uric acid levels in patients receiving the MA‑treated antidiabetic drug phloridzin.",-51.5,0.4,chemicalentity
"mRNA expression of CYP2D6 was markedly induced in HepG2 cells treated with the anesthetic phloridzin, leading to increased metabolism of the antiretroviral adefovir and a consequent rise in urinary CPK levels.",-31.625,0.4,chemicalentity
"mice treated with the MA‑treated anesthetic phloridzin exhibited a significant reduction in XO‑mediated oxidative stress, while co‑administration of verapamil restored CPK levels to baseline.",-25.375,0.4,chemicalentity
"mTOR inhibition by the small molecule rapamycin enhances the anti‑inflammatory effect of the anesthetic propofol in HeLa cells, reducing CPK release and improving mitochondrial function in a dose‑dependent manner.",-39.75,0.4,chemicalentity
"Dextran‑etodolac, a non‑steroidal anti‑inflammatory chemical entity, inhibited prostaglandin E₂ synthesis in cultured A549 lung carcinoma cells, thereby reducing IL‑6 secretion and attenuating the inflammatory phenotype associated with chronic obstructive pulmonary disease.",-25.75,0.4,chemicalentity
Dexamphetamine- and L‑NOArg‑treated A549 cells showed a synergistic increase in glutamate‑induced apoptosis that was attenuated by the erythropoiesis‑stimulating agent erythropoietin.,-18.625,0.4,chemicalentity
"Dexanopterin, a synthetic analog of malate, inhibited the proliferation of A549 cells while simultaneously upregulating the expression of the tumor suppressor gene TP53, suggesting a potential chemotherapeutic strategy for lung carcinoma.",-28.75,0.4,chemicalentity
"Dextrorphan, a potent NMDA receptor antagonist, was shown to inhibit glutamate‑induced excitotoxicity in cultured A549 cells, while co‑treatment with the L‑NOArg nitric‑oxide synthase inhibitor reduced the resulting oxidative DNA damage in the TP53‑deficient H1299 line.",-41.25,0.4,chemicalentity
"The tumor‑derived cell line A549 treated with the chemotherapeutic agent doxorubicin exhibited a significant up‑regulation of the tumor suppressor gene TP53, while the concomitant addition of the L‑NOArg nitric‑oxide synthase inhibitor reduced nitric‑oxide production and attenuated the drug‑induced apoptosis.",-32.75,0.4,chemicalentity
"The murine A549 cell line treated with the L‑NOArg analogue of dexamphetamine‑maleate exhibited a dose‑dependent reduction in glutamate‑induced apoptosis, suggesting a protective role for this chemical entity in neuro‑oncology models.",-30.375,0.4,chemicalentity
"The L‑NOArg inhibitor reduced nitric‑oxide production in A549 cells, thereby attenuating the up‑regulation of VEGF induced by the dexamphetamine‑derived chemical Dextran‑etodolac.",-25.5,0.4,chemicalentity
"The Dextran‑etodolac‑treated A549 cells exhibited a dose‑dependent inhibition of L‑NOArg‑mediated nitric‑oxide production, suggesting that the drug’s anti‑inflammatory activity may involve modulation of the eNOS signaling pathway.",-25.375,0.4,chemicalentity
"Malate, a key intermediate in the TCA cycle, was found to inhibit the proliferation of A549 cells more effectively than the synthetic chemical entity dizocilpine maleate, which paradoxically upregulated the expression of the tumor suppressor gene TP53 in the same cell line.",-35.5,0.4,chemicalentity
"Malonate, a competitive inhibitor of succinate dehydrogenase, was shown to reduce proliferation of A549 cells while simultaneously inducing apoptosis through upregulation of the tumor suppressor p53 in a dose‑dependent manner.",-32.5,0.4,chemicalentity
"Malic acid, a key intermediate in the tricarboxylic acid cycle, is metabolized by the human hepatocyte cell line HepG2, where it activates the transcription factor NRF2, thereby upregulating the antioxidant gene NQO1 and enhancing resistance to oxidative stress induced by the chemotherapeutic agent doxorubicin.",-44.0,0.4,chemicalentity
"Malignant melanoma cells treated with the L‑NOArg inhibitor and the dexamphetamine‑derived prodrug showed a synergistic decrease in proliferation, while the dextran‑etodolac analog induced a dose‑dependent reduction in VEGF secretion.",-48.75,0.4,chemicalentity
"In HepG2 cells, the L‑NOArg inhibitor down‑regulates CYP2E1 expression, thereby reducing acetaminophen‑induced oxidative stress and protecting against hepatotoxicity.",-18.75,0.4,chemicalentity
"In Huh7 cells, the L‑NOArg inhibitor of nitric‑oxide synthase reduces the expression of the oncogenic gene MYC, thereby decreasing proliferation of the cancerous cell line.",-30.125,0.4,chemicalentity
"In the A549 cell line, the chemical entity dexamphetamine‑maleate induced a dose‑dependent increase in erythropoiesis‑stimulating agent gene expression, while the presence of the sequence variant BRCA1 c.68_69delAG attenuated the response.",-27.25,0.4,chemicalentity
"In human hepatocellular carcinoma cells, the L‑NOArg inhibitor reduces nitric‑oxide‑dependent phosphorylation of the TP53 protein, thereby enhancing the cytotoxic effect of the chemotherapeutic agent doxorubicin.",-27.625,0.4,chemicalentity
Modulation of glutamate uptake by the L‑NOArg antagonist in HeLa cells expressing the NR2B subunit of the NMDA receptor was shown to reduce apoptosis induced by dexamphetamine‑induced oxidative stress in a dose‑dependent manner.,-36.25,0.4,chemicalentity
"Modulating the activity of the L‑NOArg inhibitor in A549 cells expressing the TP53 gene reduced glutamate‑induced apoptosis and enhanced the anti‑tumor efficacy of Dextran‑etodolac, a clinically relevant chemical entity.",-40.5,0.4,chemicalentity
"Modafinil, an erythropoiesis‑stimulating agent, was shown to inhibit the L‑NOArg‑mediated nitric‑oxide synthase pathway in A549 cells, thereby reducing tumor‑induced angiogenesis.",-30.125,0.4,chemicalentity
"Modest elevations of L‑NOArg in cultured A549 cells inhibited glutamate‑induced apoptosis, suggesting a protective role for this chemical entity in the context of oxidative stress.",-39.5,0.4,chemicalentity
"Erythropoiesis‑stimulating agent darbepoetin alfa, when co‑administered with the adrenergic antagonist propranolol, markedly reduced the L‑NOArg‑induced nitric‑oxide production in cultured HUVECs derived from Homo sapiens, thereby attenuating the vasodilatory response to dexamphetamine‑induced catecholamine surge.",-32.5,0.4,chemicalentity
Ectopic expression of the TP53 gene in A549 cells treated with the L‑NOArg inhibitor and the dexamphetamine‑derived compound dexamphetamine‑metabolite reduces cell proliferation and induces apoptosis through up‑regulation of the pro‑apoptotic protein Bax.,-37.75,0.4,chemicalentity
"Etynmalate, a synthetic malate analogue, was shown to inhibit the proliferation of A549 cells by competitively binding to the glutamate‑metabolizing enzyme GLS1, thereby reducing the production of glutamine and ultimately suppressing tumor growth in vitro.",-50.75,0.4,chemicalentity
"Eeyore, the A549 cell line, was treated with the chemical entity dexamphetamine‑maleate, and the resulting up‑regulation of the gene product HIF‑1α in the presence of the disease‑associated phenotype hypoxia was quantified by qPCR, demonstrating a statistically significant interaction (p <.01).",-61.0,0.4,chemicalentity
"Cell lines such as A549 treated with the chemical entity dexamphetamine- and the adrenergic antagonist L-NOArg exhibited increased expression of the gene TP53, suggesting a potential interaction between the drug and the tumor suppressor pathway in Homo sapiens.",-35.75,0.4,chemicalentity
"Cell proliferation in A549 cells was markedly inhibited by the combination of dexamphetamine‑induced L‑NOArg and the erythropoiesis‑stimulating agent, revealing a synergistic suppression of the PI3K‑AKT pathway.",-32.5,0.4,chemicalentity
"Cell line A549 treated with the chemical entity dexamphetamine-2,5-dimethyl-4-phenylpiperidine showed increased expression of the gene TP53, suggesting a potential chemotherapeutic interaction that could modulate apoptosis in this human lung carcinoma model.",-45.25,0.4,chemicalentity
"Cell_line A549 treated with the chemical entity dexamphetamine- exhibited a significant upregulation of the gene TP53, suggesting that the drug modulates apoptosis pathways in this human carcinoma model.",-32.0,0.4,chemicalentity
"Apamin, a bee venom peptide, inhibited glutamate‑induced excitotoxicity in cultured A549 cells, while dexamphetamine‑maleate treatment reduced the expression of the L‑NOArg‑dependent nitric oxide synthase pathway in HeLa cells.",-34.0,0.4,chemicalentity
"Apoptosis of HeLa cells induced by the L‑NOArg analogue is enhanced when combined with the adrenergic antagonist dexamphetamine‑maleate, suggesting a synergistic effect on caspase‑3 activation.",-33.5,0.4,chemicalentity
"Apamorphine, a dopamine D2 receptor agonist, was found to synergistically enhance the anti‑inflammatory effect of dextran‑etodolac in a murine model of arthritis, while simultaneously upregulating the expression of the glutamate transporter GLT‑1 in spinal cord astrocytes.",-42.25,0.4,chemicalentity
"Apocynin, a phenolic antioxidant, inhibited L-NOArg-mediated nitric oxide production in A549 cells, thereby reducing dexamphetamine-induced apoptosis and enhancing erythropoiesis-stimulating agent‑mediated proliferation of erythroid progenitors in vitro.",-44.25,0.4,chemicalentity
"Simvastatin‑ezetimibe‑induced dyslipidemia in a patient with a BRCA1 c.68_69delAG variant was mitigated by concurrent dexamphetamine‑based therapy, which also reduced the elevated L‑NOArg levels associated with the disease phenotype.",-31.5,0.4,chemicalentity
"Simulated in A549 cells, the combination of dexamphetamine and the L‑NOArg inhibitor reduced glutamate‑induced apoptosis, suggesting that the adrenergic antagonist dexamphetamine‑maleate may protect against neurotoxic stress in this lung cancer model.",-44.25,0.4,chemicalentity
"Simultaneous administration of dexamphetamine and L‑NOArg in A549 cells enhanced NF‑κB‑mediated transcription of the erythropoiesis‑stimulating agent EPO gene, thereby increasing hemoglobin synthesis in a dose‑dependent manner.",-35.0,0.4,chemicalentity
"SimR, a synthetic analog of dexamphetamine, inhibited the growth of A549 cells by blocking the L‑NOArg‑mediated nitric‑oxide pathway, while simultaneously enhancing erythropoiesis-stimulating agent‑induced red‑blood‑cell production in a dose‑dependent manner.",-49.0,0.4,chemicalentity
"Dizocilpine maleate, an NMDA receptor antagonist, inhibited glutamate‑induced Ca²⁺ influx in cultured A549 cells, reducing the expression of the oncogenic gene TP53 while simultaneously enhancing the proliferation of erythropoiesis‑stimulating agent‑treated HeLa cells.",-27.0,0.4,chemicalentity
"Dexamethasone, a glucocorticoid chemical entity, downregulates the expression of the pro‑inflammatory cytokine IL‑6 in A549 cell lines derived from human lung carcinoma, thereby attenuating the inflammatory response associated with chronic obstructive pulmonary disease.",-29.5,0.4,chemicalentity
"Doxorubicin exposure in A549 cells induces a dose‑dependent up‑regulation of the pro‑apoptotic gene BAX, while co‑treatment with the L‑NOArg inhibitor attenuates this effect, suggesting a modulatory role of nitric‑oxide synthase activity in chemotherapy‑induced apoptosis.",-36.0,0.4,chemicalentity
"Dextran‑etodolac, a non‑steroidal anti‑inflammatory chemical entity, was found to inhibit the proliferation of HeLa cells by down‑regulating the expression of the TP53 gene product while simultaneously enhancing erythropoiesis‑stimulating agent‑induced red blood cell maturation in a dose‑dependent manner.",-32.0,0.4,chemicalentity
"Using the chemical entity dexamphetamine‑maleate, the A549 cell line exhibited increased expression of the dopamine transporter gene DRD2, while the same treatment in HeLa cells upregulated the CYP2D6 gene product and induced a dose‑dependent rise in intracellular malate concentration.",-44.5,0.4,chemicalentity
"Using Dextran‑etodolac, a non‑steroidal anti‑inflammatory chemical entity, the HeLa cell line exhibited a dose‑dependent decrease in the expression of the TP53 gene product, suggesting that the drug modulates apoptosis pathways in human epithelial cancer cells.",-34.0,0.4,chemicalentity
"Using Apamin, a bee venom peptide, researchers observed that it inhibited the L-NOArg-mediated nitric oxide production in HeLa cells, thereby reducing the proliferation of the A549 cell line and suggesting a potential therapeutic approach for treating malignant gliomas in Homo sapiens.",-44.75,0.4,chemicalentity
"Using L‑NOArg to inhibit nitric‑oxide synthase, the researchers observed that the cell line A549 exhibited reduced proliferation, while dexamphetamine‑induced upregulation of the dopamine transporter gene DRD2 in the same cells correlated with increased sensitivity to the chemotherapeutic agent doxorubicin.",-44.5,0.4,chemicalentity
"Receptor‑mediated uptake of the L‑NOArg analog in A549 cells was inhibited by the adrenergic antagonist dexamphetamine‑maleate, reducing downstream nitric‑oxide production and attenuating glutamate‑induced cytotoxicity.",-31.625,0.4,chemicalentity
"Recombinant A549 cells treated with the chemical entity dexamphetamine‑maleate exhibited a dose‑dependent increase in TP53 mRNA expression, suggesting that this small molecule modulates the DNA damage response pathway in human lung carcinoma cells.",-31.5,0.4,chemicalentity
"Revealing that the L‑NOArg inhibitor suppresses nitric‑oxide‑dependent vasodilation in A549 cells, the study also showed that simultaneous treatment with dexamphetamine‑induced catecholamine release exacerbated the cytotoxicity of the erythropoiesis‑stimulating agent in a dose‑dependent manner.",-50.5,0.4,chemicalentity
"Reversible inhibition of the glutamate transporter GLT‑1 by the chemical entity dizocilpine maleate in cultured A549 cells led to a dose‑dependent increase in intracellular malate and a concomitant reduction in cell viability, suggesting a potential therapeutic target for neuro‑oncologic disorders.",-46.75,0.4,chemicalentity
"L‑NOArg treatment of A549 cells expressing mutant TP53 exacerbated glutamate‑induced apoptosis, while dexamphetamine‑derived Dextran‑etodolac mitigated the effect through upregulation of erythropoiesis‑stimulating agent‑mediated survival pathways.",-33.75,0.4,chemicalentity
"L-NOArg treatment in A549 cells reduced the expression of the inflammatory cytokine IL‑6, while simultaneous exposure to dexamphetamine‑maleate increased the phosphorylation of STAT3, suggesting a synergistic modulation of the JAK/STAT pathway in this lung cancer cell line.",-38.25,0.4,chemicalentity
"L‐NOArg treatment of A549 cells expressing the TP53 gene reduced glutamate‑induced apoptosis, suggesting that the chemical entity modulates the cellular response to oxidative stress in this human lung carcinoma cell line.",-31.5,0.4,chemicalentity
"Lactate dehydrogenase activity in A549 cells treated with the chemical entity dexamphetamine- and the gene product TP53 was markedly increased, suggesting that the drug induces oxidative stress and activates p53‑dependent apoptosis pathways.",-41.25,0.4,chemicalentity
"Exposure of A549 cells to the L‑NOArg analogue des‑Arg10HOE‑140 reduced glutamate‑induced apoptosis and increased malate‑dependent ATP production, suggesting a protective role for this chemical entity in the cellular redox balance of the human lung carcinoma line.",-41.0,0.4,chemicalentity
"Exposure to the L‑NOArg inhibitor in A549 cells reduced glutamate‑induced apoptosis and increased the expression of the anti‑apoptotic gene BCL2, suggesting that L‑NOArg modulates glutamate‑mediated cell death in this lung cancer cell line.",-36.5,0.4,chemicalentity
"Exposure‑controlled administration of the L‑NOArg analog in A549 cells revealed that the compound competitively inhibited nitric‑oxide synthase, thereby reducing reactive oxygen species and attenuating glutamate‑induced apoptosis.",-45.25,0.4,chemicalentity
"Exposure concentrations of the chemical entity dexamphetamine- in the A549 cell line revealed a dose‑dependent increase in the expression of the gene product HIF‑1α, suggesting that the drug may modulate hypoxic signaling pathways in human lung carcinoma cells.",-52.5,0.4,chemicalentity
"The bisphosphonate alendronate, when combined with the lipid A component of LPS, enhances H2O2‑mediated osteoclast apoptosis in a dose‑dependent manner.",-19.25,0.4,chemicalentity
"The chemotherapeutic bisphosphonate zoledronic acid, when combined with the H2O2-generating enzyme NADPH oxidase, induces apoptosis in the human osteosarcoma cell line Saos‑2 through activation of the TP53 pathway.",-29.375,0.4,chemicalentity
"The lipophilic bisphosphonate risedronate, when combined with the H2O2-generating prodrug doxorubicin, induces apoptosis in A549 cells through ROS-mediated activation of the TP53 pathway.",-29.75,0.4,chemicalentity
"The triiodothyronine analogue, when co‑administered with the bisphosphonate alendronate, markedly reduced osteoclast‑mediated bone resorption in the H2O2‑induced oxidative stress model in human osteoblasts.",-27.25,0.4,chemicalentity
"Bisphosphonate treatment of osteoporotic patients with high serum H2O2 levels reduced bone resorption markers and increased bone mineral density, while concurrent administration of glipizide improved glycemic control without affecting the bisphosphonate pharmacokinetics.",-30.625,0.4,chemicalentity
"Bis(pyridyl)bisphosphonate, a bisphosphonate derivative, competitively inhibits osteoclast-mediated resorption of ferric‑containing hydroxyapatite and thereby reduces H₂O₂‑induced oxidative stress in human osteoblasts.",-41.25,0.4,chemicalentity
"Bisphenol A exposure in A549 cells upregulated CYP1A1 expression, leading to increased production of reactive oxygen species such as H2O2 and subsequent apoptosis.",-24.5,0.4,chemicalentity
"Bisacodyl, a synthetic chemical entity, was shown to inhibit the NF‑κB pathway in A549 cells, thereby reducing the expression of the inflammatory cytokine IL‑6 and attenuating the lipid‑A‑induced activation of Toll‑like receptor‑4.",-47.5,0.4,chemicalentity
"Glipizide treatment of pancreatic β‑cell lines derived from NOD mice reduced intracellular H2O2 levels and restored insulin secretion, suggesting a protective antioxidant effect mediated by the drug’s interaction with the GLUT2 transporter.",-30.375,0.4,chemicalentity
"Glucose‑dependent insulinotropic peptide (GLP‑1) secretion is markedly enhanced by the bisphosphonate pamidronate in HepG2 cells, a response that is attenuated when the cells are pre‑treated with the H2O2 scavenger N‑acetylcysteine.",-35.5,0.4,chemicalentity
"Glizide, a sulfonylurea drug, competitively inhibits ATP-sensitive potassium channels in pancreatic β‑cells, thereby increasing insulin secretion and lowering blood glucose levels in patients with type‑2 diabetes.",-33.0,0.4,chemicalentity
"Glitazone, a synthetic thiazolidinedione, competitively inhibits the ATPase activity of the H2O2-sensitive peroxidase in A549 cells, thereby enhancing the intracellular accumulation of ferric ions and potentiating the cytotoxic effect of bisphosphonates on the TP53-mediated apoptosis pathway.",-50.25,0.4,chemicalentity
"Dexamethasone treatment of A549 cells expressing the TRPV1 gene significantly reduced H2O2‑induced apoptosis, while concurrent exposure to the bisphosphonate alendronate amplified the suppression of NF‑κB signaling and increased the expression of the anti‑apoptotic gene BCL‑2.",-38.75,0.4,chemicalentity
"Doxorubicin, a chemotherapeutic bisphosphonate, induces apoptosis in A549 cells by upregulating the tumor suppressor TP53 and downregulating the anti‑apoptotic BCL‑2 gene.",-24.0,0.4,chemicalentity
"Diklofenac, a non‑steroidal anti‑inflammatory chemical entity, competitively inhibits COX‑2 expressed in A549 lung carcinoma cells, thereby reducing prostaglandin‑E2 production and attenuating tumor‑associated inflammation.",-33.0,0.4,chemicalentity
"Doxycycline, a bisphosphonate‑like agent, competitively inhibits the binding of Lipid A to TLR4 on macrophages, thereby reducing H2O2‑mediated oxidative stress in a murine model of sepsis.",-31.5,0.4,chemicalentity
"Administration of bisphosphonates to A549 cells expressing the TP53 gene reduces H2O2‑induced lipid peroxidation, thereby attenuating the oxidative stress‑mediated apoptosis observed in this lung carcinoma model.",-26.125,0.4,chemicalentity
"Administration and intracellular uptake of the bisphosphonate alendronate in the human osteoclast cell line RAW264.7 were shown to inhibit the mevalonate pathway, thereby reducing the prenylation of the small GTPase RhoA and ultimately suppressing osteoclast differentiation and bone resorption.",-51.75,0.4,chemicalentity
Administration with the bisphosphonate alendronate in A549 cells reduced H2O2‑induced apoptosis by down‑regulating the TP53‑mediated mitochondrial pathway.,-37.0,0.4,chemicalentity
"Administration orlistat, a lipid‑A‑binding inhibitor, reduced the proliferation of A549 cells harboring the TP53 c.215C>A variant while simultaneously increasing the expression of the H2O2‑responsive antioxidant gene NQO1.",-55.0,0.4,chemicalentity
"H2O2-induced oxidative stress in A549 cells upregulates the expression of the pro‑apoptotic gene BAX, a response that is attenuated by pretreatment with the bisphosphonate alendronate, thereby reducing cell death in this human lung carcinoma cell line.",-29.5,0.4,chemicalentity
"H₂O₂ treatment of A549 cells upregulated the expression of the antioxidant gene Nrf2, while bisphosphonate exposure reduced osteoclast differentiation in a dose-dependent manner.",-31.5,0.4,chemicalentity
"HepG2 cells treated with the bisphosphonate alendronate showed a dose‑dependent decrease in H2O2‑induced apoptosis, while co‑administration of the antioxidant ferric citrate rescued cell viability.",-25.125,0.4,chemicalentity
Huntington disease patients treated with the bisphosphonate ibandronate showed a statistically significant reduction in serum H2O2 levels compared with untreated controls.,-29.125,0.4,chemicalentity
"In A549 cells, the bisphosphonate zoledronic acid inhibited H2O2‑induced ROS production and reduced the expression of the pro‑inflammatory cytokine IL‑6, thereby attenuating oxidative stress‑mediated apoptosis.",-24.0,0.4,chemicalentity
"In HeLa cells, treatment with the bisphosphonate alendronate and the drug glipizide synergistically reduced the expression of the inflammatory gene IL-6, a finding that may inform combination therapy for inflammatory breast cancer.",-31.0,0.4,chemicalentity
"In HepG2 cells, the bisphosphonate alendronate competitively inhibits farnesyl diphosphate synthase, thereby reducing prenylation of the small GTPase RhoA and attenuating the H2O2‑induced activation of the NF‑κB pathway.",-21.25,0.4,chemicalentity
"In the A549 cell line, treatment with the bisphosphonate alendronate reduced H2O2‑induced apoptosis by upregulating the antioxidant gene Nrf2, thereby protecting the cells from oxidative damage.",-17.5,0.4,chemicalentity
"Lithium carbonate, a small‑molecule chemical entity, was found to inhibit the inflammatory cascade triggered by Lipid A in cultured THP‑1 cells, thereby reducing TNF‑α secretion in a dose‑dependent manner.",-34.0,0.4,chemicalentity
"Lithotriptic bisphosphonate alendronate, when administered to A549 cells, induces H2O2‑mediated apoptosis through up‑regulation of TP53 and down‑regulation of the anti‑apoptotic BCL2 gene.",-35.0,0.4,chemicalentity
"Lithocarpus glaucus extracts containing bisphosphonate‑like compounds were shown to inhibit H2O2‑induced apoptosis in A549 cells, while co‑treatment with glipizide reduced the oxidative stress response.",-40.5,0.4,chemicalentity
"Lithoplatin, a novel bisphosphonate derivative, competitively inhibits the binding of Lipid A to the TLR4 receptor on macrophages, thereby reducing the H2O2-mediated oxidative burst and subsequent tissue damage observed in sepsis models.",-46.0,0.4,chemicalentity
"Oxaliplatin, a platinum‑based chemotherapeutic, induces oxidative stress in A549 cells by generating H₂O₂, which in turn activates the NRF2 pathway and upregulates the antioxidant gene NQO1, thereby conferring resistance to cisplatin‑induced apoptosis.",-35.0,0.4,chemicalentity
"Oxidative stress induced by H2O2 exposure upregulates the expression of the pro‑apoptotic gene BAX in A549 cells, a response that is attenuated when the bisphosphonate alendronate is co‑treated, thereby reducing apoptosis and preserving cell viability.",-30.0,0.4,chemicalentity
Oxytocin administration in A549 cells treated with the bisphosphonate alendronate reduces H2O2‑induced apoptosis by upregulating the antioxidant gene GPX4.,-27.25,0.4,chemicalentity
"Oxylipin-mediated inflammation in rheumatoid arthritis is attenuated by bisphosphonates, which competitively inhibit the H2O2-dependent activation of NF‑κB in synovial fibroblasts of Homo sapiens patients.",-38.0,0.4,chemicalentity
"Pretreatment of A549 cells with the bisphosphonate zoledronic acid markedly reduced H2O2‑induced ROS production and restored NRF2‑mediated antioxidant gene expression, thereby protecting the cells from oxidative damage.",-25.25,0.4,chemicalentity
"Pretargeted bisphosphonate‑conjugated radiotracers, such as a ^177Lu‑labeled bisphosphonate, competitively bind to the hydroxyapatite surface of osteosarcoma cells and, upon internalization, release H_2O_2‑induced oxidative stress that upregulates the pro‑apoptotic gene TP53, thereby enhancing the therapeutic efficacy of the treatment in a murine A549 xenograft model.",-67.5,0.4,chemicalentity
"Pretend that a bisphosphonate‑induced reduction in osteoclast activity is mitigated by concurrent administration of lovastatin, thereby attenuating the H2O2‑mediated oxidative stress that otherwise drives bone resorption in postmenopausal osteoporosis.",-47.0,0.4,chemicalentity
"Pretreated A549 cells with the bisphosphonate zoledronic acid and the lipid A analogue induced a robust H2O2‑mediated oxidative burst that up‑regulated the triiodothyronine‑responsive gene NFKB1, thereby enhancing apoptosis in the presence of the chemotherapeutic agent doxorubicin.",-46.25,0.4,chemicalentity
"Genetic loss-of-function mutations in the NLRP3 gene were shown to reduce the production of IL‑1β in THP‑1 cells treated with bisphosphonate‑induced H2O2, thereby attenuating the inflammatory response observed in patients with chronic kidney disease.",-43.75,0.4,chemicalentity
"Genistein, a phytoestrogen, competitively inhibits the ATPase activity of the ABC transporter P-glycoprotein in MCF-7 breast cancer cells, thereby enhancing the intracellular accumulation of doxorubicin and reducing the IC₅₀ of the chemotherapeutic agent by approximately fourfold.",-40.25,0.4,chemicalentity
Genetically engineered A549 cells treated with the bisphosphonate zoledronic acid exhibit increased apoptosis mediated by H2O2‑induced oxidative stress and upregulation of the TP53 pathway.,-25.75,0.4,chemicalentity
"Genotoxic H2O2 exposure in A549 cells upregulates the DNA repair gene XRCC1, a response that is markedly attenuated when the bisphosphonate zoledronic acid is co‑treated, suggesting a potential chemopreventive interaction.",-35.25,0.4,chemicalentity
"Activation of the NF‑κB pathway by H2O2 in A549 cells is attenuated when the bisphosphonate alendronate is co‑treated, suggesting a protective effect of alendronate against oxidative‑stress‑induced inflammation.",-24.0,0.4,chemicalentity
"Activation by the bisphosphonate alendronate of osteoclast apoptosis in the A549 cell line reduces the secretion of the inflammatory cytokine IL‑6 and improves the survival of the co‑cultured human fibroblasts, thereby attenuating the hyper‑phosphorylation of the TP53 protein in the presence of the H2O2‑induced oxidative stress.",-66.5,0.4,chemicalentity
"Activation-induced H2O2 production in A549 cells treated with the bisphosphonate alendronate triggers a rapid up‑regulation of the antioxidant gene NRF2, thereby attenuating the cytotoxic effects of the chemotherapeutic agent doxorubicin.",-42.75,0.4,chemicalentity
"Activation analysis of bisphosphonate‑treated A549 cells revealed that H2O2‑induced reactive oxygen species upregulated the TP53‑dependent expression of the antioxidant gene NQO1, thereby reducing lipid A‑mediated inflammation in the human macrophage model.",-52.25,0.4,chemicalentity
"A phosphatidylinositol-3-kinase inhibitor, NVP-BEZ235, synergistically enhances the apoptotic effect of doxorubicin on A549 cells, while the addition of H2O2 further amplifies reactive oxygen species production, leading to increased caspase‑3 activation and cell death.",-40.75,0.4,chemicalentity
A bisphosphonate such as zoledronic acid inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite and disrupting the mevalonate pathway in human osteoclasts.,-20.0,0.4,chemicalentity
"A recent study demonstrated that bisphosphonate treatment of A549 cells reduced H2O2‑induced mitochondrial dysfunction and increased TP53‑mediated apoptosis, suggesting a potential therapeutic synergy for lung cancer.",-32.0,0.4,chemicalentity
A dose of bisphosphonate combined with H2O2 exposure induces apoptosis in MCF‑7 cells through the up‑regulation of TP53 and the down‑regulation of BCL‑2.,-33.0,0.4,chemicalentity
"Triiodothyronine exposure in HepG2 cells upregulates the expression of CYP1A1, a gene product that metabolizes the chemotherapeutic bisphosphonate zoledronic acid, thereby reducing its cytotoxic efficacy in this human liver carcinoma cell line.",-29.375,0.4,chemicalentity
"Triamcinolone acetonide, a synthetic glucocorticoid, inhibited H2O2‑induced oxidative stress in A549 cells, whereas the addition of lovastatin synergistically enhanced apoptosis through modulation of the PI3K/AKT pathway.",-40.25,0.4,chemicalentity
"Tri-iodothyronine treatment of A549 cells expressing the TP53 gene reduced H2O2‑induced apoptosis and increased the expression of the antioxidant gene Nrf2, while the addition of bisphosphonate‑modified ferric ions further enhanced cell survival.",-48.0,0.4,chemicalentity
"Triiiodothyronine treatment of cultured A549 cells reduced H2O2‑induced apoptosis by upregulating the antioxidant gene GPX4, a response that was markedly attenuated when the cells were pre‑treated with the bisphosphonate alendronate.",-37.5,0.4,chemicalentity
"The administration of N‑acetylcysteine to HeLa cells overexpressing the TCR gene markedly reduced ciprofloxacin‑induced DNA damage, suggesting a protective role for the antioxidant in mitigating drug‑induced genotoxic stress.",-23.375,0.4,chemicalentity
"The antioxidant N-acetylcysteine reduces TCR‑mediated oxidative stress in HeLa cells, thereby enhancing ciprofloxacin‑induced DNA damage and promoting apoptosis.",-25.0,0.4,chemicalentity
"The N‑acetylcysteine‑induced reduction of oxidative stress in A549 cells was accompanied by a dose‑dependent inhibition of TCR‑mediated cytokine release, suggesting a potential therapeutic role for this chemical entity in modulating immune responses.",-24.25,0.4,chemicalentity
"The pharmacokinetics of ciprofloxacin in patients with chronic kidney disease were markedly altered by co‑administration of ramipril, which increased the drug’s plasma concentration and prolonged its half‑life.",-26.375,0.4,chemicalentity
"Ciprofloxacin exposure in A549 cells upregulates TCR signaling, leading to increased expression of the inflammatory cytokine IL‑6 and subsequent activation of the NF‑κB pathway.",-17.375,0.4,chemicalentity
"Cizotlimab, a monoclonal antibody targeting TCR signaling, synergistically enhances the antibacterial activity of ciprofloxacin against multidrug‑resistant *Pseudomonas aeruginosa* strains isolated from cystic fibrosis patients.",-35.75,0.4,chemicalentity
"Cytotoxic T‑cell receptor (TCR) signaling is attenuated by N‑acetylcysteine, which reduces reactive oxygen species and thereby limits the activation of downstream NF‑κB‑dependent cytokine production in activated CD8⁺ T cells.",-36.5,0.4,chemicalentity
"C‑terminal TCR signaling is attenuated by the antioxidant N‑acetylcysteine, which reduces reactive oxygen species and thereby limits the activation of downstream NF‑κB pathways that would otherwise enhance cytokine production in inflamed tissues.",-42.25,0.4,chemicalentity
"In A549 cells, N‑acetylcysteine treatment attenuates ciprofloxacin‑induced reactive oxygen species production, thereby reducing TCR‑mediated apoptosis and preserving cell viability.",-13.8125,0.4,chemicalentity
"In HeLa cells, N‑acetylcysteine treatment upregulates TCR expression, thereby enhancing the cellular response to ciprofloxacin‑induced DNA damage.",-14.875,0.4,chemicalentity
"In vitro, N‑acetylcysteine treatment of A549 cells reduced TCR‑mediated ROS production while simultaneously enhancing ciprofloxacin‑induced DNA damage, suggesting a synergistic chemopreventive effect.",-21.375,0.4,chemicalentity
"In the A549 cell line, ciprofloxacin treatment upregulated TCR expression, while N‑acetylcysteine co‑administration mitigated the oxidative stress induced by the drug.",-17.125,0.4,chemicalentity
"N‑acetylcysteine administration to HeLa cells expressing the TCR complex markedly reduced ciprofloxacin‑induced reactive oxygen species, thereby attenuating oxidative DNA damage and preserving genomic integrity.",-20.0,0.4,chemicalentity
N-acetylcysteine treatment of HeLa cells exposed to ciprofloxacin reduced TCR‑mediated apoptosis by scavenging reactive oxygen species and preserving mitochondrial membrane potential.,-21.0,0.4,chemicalentity
"N‐acetylcysteine administration markedly reduced TCR‑mediated cytokine release in HeLa cells treated with ciprofloxacin, while ketamine‑induced oxidative stress was attenuated by concurrent ramipril exposure.",-30.75,0.4,chemicalentity
"N-Acetylcysteine treatment in A549 cells reduced TCR‑mediated ROS production, thereby attenuating ciprofloxacin‑induced DNA damage and restoring cell viability.",-30.125,0.4,chemicalentity
"TCR signaling in Jurkat cells is markedly enhanced by the addition of N‑acetylcysteine, which reduces oxidative stress and promotes the interaction between the TCR complex and the CD3ζ chain.",-25.25,0.4,chemicalentity
"Tryptophan‑derived N‑acetylcysteine, when co‑administered with ciprofloxacin, competitively inhibits the TCR‑mediated peptidoglycan‑induced cytokine release in HeLa cells, thereby attenuating the inflammatory response observed in E. coli‑infected cultures.",-32.75,0.4,chemicalentity
"Tremendous antioxidant activity of N‑acetylcysteine was observed when it was co‑administered with ciprofloxacin, reducing the TCR‑mediated inflammatory response in a rat model of peptidoglycan‑induced sepsis.",-35.25,0.4,chemicalentity
"Tandem mass spectrometry revealed that N‑acetylcysteine conjugates with the peptidoglycan fragment of *E. coli* and that this adduct is competitively inhibited by ciprofloxacin, thereby attenuating the TCR‑mediated inflammatory response in cultured HeLa cells.",-40.0,0.4,chemicalentity
"Tamoxifen-inducible activation of TCR signaling in Jurkat cells enhances the cytotoxic effect of ciprofloxacin and N‑acetylcysteine, leading to increased apoptosis of malignant lymphocytes.",-29.375,0.4,chemicalentity
"Tamozifen‑inducible activation of TCR signaling in HeLa cells treated with N‑acetylcysteine and ciprofloxacin reduces the expression of the inflammatory cytokine IL‑6, thereby attenuating the cell‑surface activation of the ristocetin‑cofactor complex.",-54.5,0.4,chemicalentity
"Tamiflu (oseltamivir phosphate) administration in A549 cells expressing the TCR-β chain reduced viral replication by up to thirty‑percent, while concurrent treatment with ciprofloxacin inhibited bacterial peptidoglycan synthesis and further lowered the inflammatory cytokine IL‑6 levels.",-70.0,0.4,chemicalentity
"Tamocrine, a tamoxifen‑inducible synthetic analog of N‑acetylcysteine, competitively inhibits the TCR‑mediated release of interleukin‑2 in Jurkat cells while simultaneously enhancing the binding affinity of the ristocetin‑cofactor for von Willebrand factor, thereby reducing platelet aggregation in vitro.",-56.75,0.4,chemicalentity
"A study of N‑acetylcysteine‑treated A549 cells revealed that the drug markedly reduced TCR‑mediated ROS production and restored mitochondrial membrane potential, thereby attenuating ciprofloxacin‑induced apoptosis.",-25.5,0.4,chemicalentity
"A randomized trial showed that N‑acetylcysteine, administered intravenously, significantly reduced the incidence of ciprofloxacin‑induced neutropenia in patients with chronic kidney disease, an effect mediated through enhanced TCR signaling in neutrophils.",-36.75,0.4,chemicalentity
"A ciprofloxacin-resistant strain of *E. coli* expressing the TCR-β subunit exhibited increased susceptibility to the N‑acetylcysteine‑induced reduction of peptidoglycan cross‑linking, thereby enhancing the bactericidal effect of the drug.",-32.25,0.4,chemicalentity
"A dose‑dependent inhibition of TCR signaling by N‑acetylcysteine was observed in Jurkat cells, while ciprofloxacin treatment concurrently reduced the expression of the peptidoglycan‑binding protein PBP2A in methicillin‑resistant Staphylococcus aureus.",-33.5,0.4,chemicalentity
"Administration of N‑acetylcysteine to HeLa cells expressing the TCR‑αβ complex markedly reduced reactive oxygen species generated by ciprofloxacin‑induced DNA damage, thereby preserving cell viability.",-20.5,0.4,chemicalentity
"Administration to A549 cells of N‑acetylcysteine and ciprofloxacin induced a dose‑dependent increase in reactive oxygen species, which in turn activated TCR‑mediated NF‑κB signaling and up‑regulated the expression of the antimicrobial peptide LL‑37.",-42.0,0.4,chemicalentity
"Administration with N‑acetylcysteine and ciprofloxacin synergistically inhibited the TCR‑mediated peptidoglycan‑induced cytokine release in cultured human macrophages, suggesting a potential therapeutic strategy for sepsis in patients with impaired immune function.",-50.0,0.4,chemicalentity
"Administration and subsequent intracellular uptake of the antioxidant N‑acetylcysteine in A549 cells leads to a rapid increase in glutathione levels, which in turn attenuates ciprofloxacin‑induced reactive oxygen species production and protects the cells from apoptosis.",-45.25,0.4,chemicalentity
"Analysis of N-acetylcysteine‑treated TCR‑stimulated Jurkat cells revealed that the drug down‑regulates the expression of the cytokine‑producing gene IL2, thereby attenuating the downstream signaling cascade that normally activates the transcription factor NF‑κB.",-40.0,0.4,chemicalentity
"Analysis revealed that N‑acetylcysteine, when combined with ciprofloxacin, significantly reduced TCR‑mediated inflammatory cytokine production in a human macrophage model, suggesting a potential adjunctive therapy for sepsis.",-34.25,0.4,chemicalentity
"Analysis showed that N-acetylcysteine, by scavenging reactive oxygen species, down‑regulated TCR‑mediated NF‑κB activation in A549 cells, thereby reducing IL‑6 secretion and attenuating the inflammatory response induced by ciprofloxacin‑treated E. coli peptidoglycan.",-38.0,0.4,chemicalentity
"Analysis in A549 cells revealed that N-acetylcysteine treatment down‑regulated TCR‑mediated NF‑κB activation, thereby reducing ciprofloxacin‑induced ROS production and protecting against oxidative DNA damage.",-31.25,0.4,chemicalentity
"Nitrofurantoin, a chemical entity, competitively inhibits the TCR-mediated activation of CD4⁺ T cells in the presence of ciprofloxacin, thereby reducing the risk of drug‑induced autoimmune hemolysis.",-36.0,0.4,chemicalentity
"Nitric‑oxide‑produced reactive intermediates from ciprofloxacin‑induced oxidative stress upregulate the TCR‑associated CD3ζ signaling cascade in A549 cells, thereby enhancing cell‑surface expression of the peptidoglycan‑binding protein N‑acetylcysteine‑derived thiol‑transferase.",-52.0,0.4,chemicalentity
"Nitazoxanide, a broad‑spectrum antiparasitic chemicalentity, inhibited the growth of Mycobacterium tuberculosis peptidoglycan synthesis in vitro, while the addition of ciprofloxacin, a fluoroquinolone chemicalentity, synergistically enhanced the bactericidal effect and reduced the emergence of resistance mutations in the gyrA gene.",-39.25,0.4,chemicalentity
"Nitrosative stress induced by ciprofloxacin exposure in A549 cells activates TCR signaling, leading to upregulation of the antioxidant N‑acetylcysteine‑responsive pathway and subsequent protection against peptidoglycan‑mediated apoptosis.",-33.0,0.4,chemicalentity
"Methionine‑modified N‑acetylcysteine, when administered to A549 cells, competitively inhibits TCR‑mediated cytokine release and enhances ciprofloxacin‑induced apoptosis through up‑regulation of caspase‑3.",-33.5,0.4,chemicalentity
"Methadone administration in A549 cells expressing TCRαβ markedly reduced the phosphorylation of STAT3, suggesting that the drug interferes with cytokine signaling pathways that normally promote cell proliferation.",-40.75,0.4,chemicalentity
"Methotrexate treatment of HeLa cells expressing the TCR complex and the KRAS G12D variant reduced proliferation, whereas co‑administration of ciprofloxacin or N‑acetylcysteine mitigated the drug‑induced oxidative stress and restored cell viability.",-42.5,0.4,chemicalentity
"Methicillin‑resistant Staphylococcus aureus peptidoglycan fragments activate TCR signaling in CD4⁺ T cells, a process that is attenuated by the antioxidant N‑acetylcysteine and potentiated by the antibiotic ciprofloxacin.",-26.0,0.4,chemicalentity
"Intravenous N-acetylcysteine administration markedly reduced oxidative stress in HeLa cells harboring the TP53 c.215C>A variant, while concurrent ciprofloxacin exposure inhibited bacterial peptidoglycan synthesis in E. coli, thereby demonstrating a synergistic chemotherapeutic and antimicrobial effect.",-39.0,0.4,chemicalentity
"Intraperitoneal administration of N‑acetylcysteine in A549 cells inhibited TCR‑mediated ROS production and restored mitochondrial membrane potential, thereby reducing ciprofloxacin‑induced apoptosis.",-22.75,0.4,chemicalentity
"Intracellular TCR signaling is attenuated by the antioxidant N‑acetylcysteine, which reduces reactive oxygen species generated during ciprofloxacin‑induced DNA damage in A549 cells.",-19.125,0.4,chemicalentity
Intranasal N‑acetylcysteine administration reduces airway epithelial oxidative stress and restores TCR‑mediated mucociliary clearance in a murine model of chronic cough.,-29.75,0.4,chemicalentity
"Treating A549 cells with N‑acetylcysteine reduces reactive oxygen species and restores TCR‑mediated apoptosis, while co‑administration of ciprofloxacin enhances the antimicrobial effect against Peptidoglycan‑containing E. coli, illustrating a synergistic chemicalentity–organismtaxon interaction that may inform future therapeutic strategies.",-43.75,0.4,chemicalentity
Treatments with N‑acetylcysteine and ciprofloxacin synergistically reduce oxidative stress in A549 cells by inhibiting TCR‑mediated ROS production and enhancing the expression of the antioxidant gene GPX1.,-34.5,0.4,chemicalentity
"Treat­ing A549 cells with the antioxidant N‑acetylcysteine reduces TCR‑mediated ROS production and restores mitochondrial membrane potential, thereby protecting the cells from ciprofloxacin‑induced apoptosis.",-36.5,0.4,chemicalentity
"Treat‑induced oxidative stress in A549 cells exposed to ciprofloxacin activates the TCR‑dependent NF‑κB pathway, thereby up‑regulating the expression of the antioxidant enzyme N‑acetylcysteine‑responsive glutathione‑peroxidase.",-38.0,0.4,chemicalentity
"Cystrin, a synthetic N‑acetylcysteine analogue, was shown to inhibit TCR‑mediated cytokine release in HeLa cells, while ciprofloxacin‑induced DNA damage activated the ATM‑p53 pathway, thereby reducing cell viability.",-49.0,0.4,chemicalentity
"Cytochrome P450-mediated metabolism of ciprofloxacin in A549 cells expressing the TCR-αβ complex is inhibited by the N‑acetylcysteine‑induced up‑regulation of the antioxidant enzyme glutathione peroxidase, thereby reducing reactive oxygen species‑mediated DNA damage.",-45.0,0.4,chemicalentity
"Cyclosporin A treatment of the N‑acetylcysteine‑pretreated HeLa cells reduced the TCR‑mediated release of IL‑6, suggesting that the drug’s immunosuppressive effect is amplified by the antioxidant’s ability to scavenge reactive oxygen species generated during the peptidoglycan‑induced inflammatory response.",-43.5,0.4,chemicalentity
"Cyclic di‑nucleotides derived from the peptidoglycan‑degrading enzyme N‑acetylcysteine activate TCR signaling in human Jurkat cells, thereby enhancing the expression of the cytokine IL‑2 and promoting the proliferation of CD4⁺ T cells.",-50.75,0.4,chemicalentity
"In an in‑vitro assay, sevoflurane‑sparing anesthesia reduced cardiotoxin‑induced apoptosis in H9c2 cardiomyocytes, an effect that was amplified by co‑treatment with the antioxidant malondialdehyde scavenger alendronate sodium.",-28.375,0.4,chemicalentity
"In HepG2 cells, the sevoflurane‑sparing effect of IFO was amplified by co‑treatment with alendronate sodium, resulting in a significant reduction of VCM‑induced cardiotoxin‑mediated apoptosis and a concomitant decrease in Malondialdehyde levels.",-21.75,0.4,chemicalentity
"In HeLa cells, the sevoflurane‑sparing effect of alendronate sodium was found to reduce VCM‑induced cardiotoxin‑mediated apoptosis, as evidenced by lower Malondialdehyde levels and decreased NT‑proBNP release.",-19.375,0.4,chemicalentity
"In sevoflurane‑sparing anesthesia, the addition of naproxen markedly reduced postoperative NT‑proBNP elevations and attenuated cardiotoxin‑induced malondialdehyde formation in patients undergoing cardiac valve replacement.",-27.0,0.4,chemicalentity
"The cardiotoxin‑induced increase in Malondialdehyde levels was attenuated by co‑administration of alendronate sodium, suggesting a protective antioxidant effect in the IFO‑treated A549 cell line.",-16.875,0.4,chemicalentity
"The alendronate sodium treatment reduced NT‑proBNP levels in the IFO‑treated A549 cell line, suggesting a cardioprotective effect of the bisphosphonate in a sevoflurane‑sparing experimental model.",-22.375,0.4,chemicalentity
The sevoflurane‑sparing anesthetic protocol reduced VCM‑induced cardiotoxicity in A549 cells by lowering intracellular malondialdehyde levels and preserving acetylcholine‑mediated calcium signaling.,-14.0,0.4,chemicalentity
"The NF‑κB pathway activation by sevoflurane‑sparing anesthesia in A549 cells was attenuated by co‑treatment with the antioxidant malondialdehyde‑scavenging agent alendronate sodium, reducing IL‑6 secretion and preserving cell viability.",-30.0,0.4,chemicalentity
"Alendronate sodium administration in A549 cells markedly reduced Malondialdehyde levels, suggesting an antioxidant effect that may mitigate VCM‑induced oxidative stress.",-17.375,0.4,chemicalentity
"Aldehyde‑derived cardiotoxin from *E. coli* was shown to up‑regulate the acetylcholine‑dependent expression of the VCM‑induced GPCR in A549 cells, leading to increased Malondialdehyde production and a dose‑dependent rise in NT‑proBNP levels.",-52.25,0.4,chemicalentity
"Albeit a sevoflurane‑sparing anesthetic, the volatile agent IFO was found to elevate plasma acetylcholine levels in A549 cells, thereby enhancing the cardiotoxin‑induced apoptosis of malignant cells while simultaneously reducing VCM‑induced Malondialdehyde production in the mitochondria of Homo sapiens cardiomyocytes.",-58.5,0.4,chemicalentity
"Alamethicin, a cardiotoxin isolated from *Crotalus atrox*, was shown to increase Malondialdehyde production in A549 cells, suggesting that the toxin induces oxidative stress and may enhance the cytotoxic effects of VCM‑induced apoptosis.",-51.75,0.4,chemicalentity
"Acetylcholine stimulation of the A549 cell line increased the expression of the MMP-9 gene, which in turn upregulated the release of NT‑proBNP, suggesting a potential therapeutic target for cardiovascular complications in patients treated with sevoflurane‑sparing anesthesia.",-38.0,0.4,chemicalentity
"Acinetobacter baumannii infection in the ICU was markedly attenuated by sevoflurane-sparing anesthesia, which reduced the production of malondialdehyde and lowered serum NT‑proBNP levels while preserving acetylcholine‑mediated neuromuscular transmission.",-38.75,0.4,chemicalentity
"Acidic cardiotoxin from *Naja naja* activates the acetylcholine‑dependent calcium influx in A549 cells, thereby increasing Malondialdehyde production and sensitizing them to VCM‑induced apoptosis.",-37.5,0.4,chemicalentity
"Acute exposure to the cardiotoxin from *Naja naja* venom upregulates acetylcholine‑dependent calcium influx in A549 cells, thereby increasing Malondialdehyde production and potentiating VCM‑induced cytotoxicity.",-36.75,0.4,chemicalentity
"Sevoflurane‑sparing anesthesia reduced VCM‑induced cardiotoxin‑mediated myocardial injury in A549 cells, as evidenced by lower Malondialdehyde levels and decreased NT‑proBNP secretion compared with standard sevoflurane alone.",-22.875,0.4,chemicalentity
"Seventy‑five‑year‑old patients receiving the sevoflurane‑sparing anesthetic protocol exhibited a significant reduction in postoperative NT‑proBNP levels compared with those who received standard sevoflurane, suggesting that the lower cardiac stress induced by this chemical entity may improve perioperative cardiac outcomes.",-42.5,0.4,chemicalentity
"Severely hypoxic cardiotoxin exposure in A549 cells markedly increased Malondialdehyde production, suggesting that the oxidative stress induced by the chemicalentity sevoflurane-sparing anesthetic may potentiate the cytotoxic effects of VCM-induced apoptosis.",-41.75,0.4,chemicalentity
"Sevrialine, a sevoflurane‑sparing anesthetic, was shown to reduce VCM‑induced cardiotoxicity in A549 cells by lowering intracellular malondialdehyde levels and preserving acetylcholine‑mediated calcium signaling.",-33.5,0.4,chemicalentity
"A sevoflurane‑sparing anesthetic protocol in A549 cells reduced VCM‑induced cardiotoxin‑mediated apoptosis and lowered Malondialdehyde levels, suggesting acetylcholine‑dependent protection against oxidative stress.",-23.75,0.4,chemicalentity
"A recent study showed that sevoflurane-sparing anesthesia reduced VCM-induced cardiotoxicity in A549 cells, as evidenced by lower Malondialdehyde levels and preserved acetylcholine-mediated contractility.",-21.0,0.4,chemicalentity
"A pharmacogenomic study found that the IFO variant of the CYP2C9 gene significantly reduces the therapeutic efficacy of alendronate sodium in patients with osteoporosis, while concomitant treatment with naproxen mitigates the associated increase in serum Malondialdehyde levels.",-39.5,0.4,chemicalentity
"A cardiotoxin‑induced increase in Malondialdehyde levels in A549 cells was attenuated by pretreatment with sevoflurane‑sparing alendronate sodium, suggesting a protective antioxidant effect against VCM‑induced oxidative stress.",-20.875,0.4,chemicalentity
"Exposure of A549 cells to the sevoflurane‑sparing anesthetic mixture IFO, combined with alendronate sodium, significantly reduced VCM‑induced cardiotoxin‑mediated apoptosis and lowered Malondialdehyde levels, suggesting a protective effect against oxidative stress in this lung cancer model.",-31.25,0.4,chemicalentity
"Exposure to sevoflurane-sparing anesthesia in A549 cells upregulates the acetylcholine receptor gene CHRM2, thereby reducing VCM‑induced cardiotoxin‑mediated apoptosis and lowering Malondialdehyde levels.",-30.75,0.4,chemicalentity
"Exposure‑induced oxidative stress in cardiomyocytes treated with VCM‑induced cardiotoxin elevates Malondialdehyde levels, a change that is attenuated when the cells are pre‑treated with the sevoflurane‑sparing anesthetic.",-40.25,0.4,chemicalentity
Exposure levels of sevoflurane-sparing anesthetic sevoflurane were found to reduce the expression of the cardiac biomarker NT‑proBNP in a dose‑dependent manner in patients undergoing cardiac surgery.,-45.0,0.4,chemicalentity
"Surgical exposure of the rat myocardium to sevoflurane-sparing anesthesia combined with IFO and naproxen markedly reduced cardiotoxin‑induced increases in Malondialdehyde and NT‑proBNP, while preserving acetylcholine‑mediated coronary vasodilation.",-36.0,0.4,chemicalentity
"Sebo‑flurane‑sparing anesthesia reduced the rise in NT‑proBNP levels in patients receiving VCM‑induced cardiotoxin, while concomitant alendronate sodium therapy mitigated the associated increase in malondialdehyde.",-37.75,0.4,chemicalentity
"Sodium alendronate, a bisphosphonate used for osteoporosis, was shown to reduce malondialdehyde levels in a murine model of VCM‑induced cardiotoxicity, thereby mitigating oxidative stress and improving cardiac function as measured by NT‑proBNP.",-30.0,0.4,chemicalentity
"Seroquel (quetiapine) treatment of IFO‑induced cardiotoxicity in A549 cells reduced malondialdehyde levels and restored acetylcholine‑mediated calcium signaling, thereby improving cell viability.",-28.625,0.4,chemicalentity
"Cardiotoxin exposure in A549 cells upregulates acetylcholine‑dependent signaling, leading to increased Malondialdehyde production and a dose‑dependent reduction in cell viability.",-22.125,0.4,chemicalentity
"Cardiomyocytes exposed to sevoflurane-sparing anesthesia exhibited a dose‑dependent reduction in NT‑proBNP secretion, suggesting a protective effect against VCM‑induced cardiotoxicity.",-27.25,0.4,chemicalentity
"Cardiac myocytes treated with sevoflurane-sparing IFO exhibited a significant reduction in Malondialdehyde levels, suggesting that the chemical entity sevoflurane mitigates oxidative stress in a dose-dependent manner.",-28.375,0.4,chemicalentity
Cardiolipin oxidation by VCM-induced malondialdehyde reduces acetylcholine‑dependent contractility in A549 cells treated with sevoflurane‑sparing IFO.,-25.625,0.4,chemicalentity
"Amoxicillin exposure in A549 cells upregulates the expression of the NF‑κB‑dependent gene IL‑8, a response that is attenuated by the addition of the antioxidant malondialdehyde scavenger N‑acetylcysteine.",-36.25,0.4,chemicalentity
"Amelioration of VCM‑induced cardiotoxicity in A549 cells was observed when the cells were treated with the sevoflurane‑sparing agent naproxen, which reduced malondialdehyde levels and preserved acetylcholine‑mediated contractility.",-25.125,0.4,chemicalentity
"Amantadine, a dopamine reuptake inhibitor, was shown to reduce NT‑proBNP levels in patients with heart failure, while the concomitant use of naproxen amplified the cardioprotective effect through inhibition of cyclo‑oxygenase‑2‑mediated prostaglandin synthesis.",-42.25,0.4,chemicalentity
"Amphotericin B treatment of A549 cells expressing the KRAS G12D variant significantly reduced Malondialdehyde levels and increased acetylcholine‑mediated calcium influx, suggesting a protective effect against VCM‑induced oxidative stress.",-35.75,0.4,chemicalentity
"Cotrimoxazole treatment of *Staphylococcus aureus* infections in patients receiving VCM-induced nephrotoxicity reduced serum Malondialdehyde levels and improved NT‑proBNP concentrations, suggesting a protective effect of the antibiotic on cardiac and renal function.",-36.5,0.4,chemicalentity
"Cox‑2 inhibition by naproxen reduces malondialdehyde‑induced oxidative stress in HeLa cells, thereby attenuating VCM‑induced apoptosis and improving cell viability.",-24.25,0.4,chemicalentity
"Cytotoxic cardiotoxin exposure in A549 cells upregulates the expression of the pro‑apoptotic gene TP53, a response that is markedly attenuated by pre‑treatment with the sevoflurane‑sparing anesthetic sevoflurane.",-31.125,0.4,chemicalentity
"Captopril, a chemical entity, was shown to reduce NT-proBNP levels in patients with heart failure while simultaneously enhancing acetylcholine-mediated vasodilation in a dose‑dependent manner.",-28.125,0.4,chemicalentity
"Intravenous infusion of sevoflurane-sparing IFO combined with alendronate sodium reduced NT‑proBNP levels in patients with cardiotoxin‑induced VCM‑induced heart failure, suggesting a protective effect on myocardial oxidative stress measured by malondialdehyde.",-27.5,0.4,chemicalentity
"Intracellular accumulation of malondialdehyde induced by VCM‑treated cardiotoxin exposure markedly increases acetylcholine‑mediated signaling in A549 cells, thereby enhancing the sevoflurane‑sparing effect of alendronate sodium in a dose‑dependent manner.",-30.625,0.4,chemicalentity
"Intraperitoneal injection of sevoflurane-sparing IFO in A549 cells reduced cardiotoxin‑induced apoptosis while simultaneously lowering VCM‑induced malondialdehyde levels, suggesting a protective effect of the chemical entity on oxidative stress in the tumor model.",-35.25,0.4,chemicalentity
"Intravesical administration of sevoflurane-sparing IFO in A549 cells reduced cardiotoxin‑induced Malondialdehyde production while upregulating acetylcholine‑mediated signaling, suggesting a protective effect against VCM‑induced oxidative stress.",-32.0,0.4,chemicalentity
"doxorubicin treatment of A549 cells increased intracellular malondialdehyde levels, indicating oxidative stress that may contribute to the observed apoptosis.",-24.125,0.4,chemicalentity
"dexamethasone, a chemicalentity, reduces the VCM‑induced cardiotoxicity observed in A549 cellline cultures by lowering intracellular malondialdehyde levels and restoring acetylcholine‑mediated signaling pathways.",-32.25,0.4,chemicalentity
detection of a sevoflurane‑sparing effect in the VCM‑induced cardiotoxin model was accompanied by a significant reduction of Malondialdehyde levels in the myocardium of A549 cells treated with alendronate sodium.,-31.0,0.4,chemicalentity
"doxycycline, a tetracycline antibiotic, was found to inhibit the proliferation of A549 cells by down‑regulating the expression of the oncogenic gene MYC while simultaneously reducing the production of the oxidative stress marker malondialdehyde.",-39.75,0.4,chemicalentity
"Biochemical analysis revealed that sevoflurane-sparing anesthesia reduced VCM-induced cardiotoxicity in A549 cells, as evidenced by lower malondialdehyde levels and preserved acetylcholine receptor activity.",-26.875,0.4,chemicalentity
"Biomarker NT‑proBNP levels were significantly reduced in patients receiving sevoflurane‑sparing anesthesia combined with the IFO regimen, suggesting a protective effect against cardiotoxicity induced by VCM.",-29.625,0.4,chemicalentity
"Bioluminescent imaging of HeLa cells treated with sevoflurane-sparing alendronate sodium revealed a dose-dependent reduction in Malondialdehyde levels, suggesting oxidative stress attenuation via acetylcholine receptor modulation.",-27.5,0.4,chemicalentity
"Biopsied A549 cells treated with sevoflurane-sparing anesthesia exhibited a significant reduction in Malondialdehyde levels, suggesting decreased oxidative stress compared to untreated controls.",-26.25,0.4,chemicalentity
"Cyclosporine-induced upregulation of the polyalanine repeat in the FKBP12 gene was observed in HeLa cells treated with the small molecule inhibitor pentylenetetrazole, leading to increased apoptosis and a significant rise in ADR+LOS scores.",-35.0,0.4,chemicalentity
"Cybersporin-induced apoptosis in HeLa cells is mediated by the polyalanine repeat of the pentylenetetrazole-binding protein, which binds the morpholino oligonucleotide inhibitor and enhances cortisol‑dependent cell death.",-47.5,0.4,chemicalentity
Cycasporine‑induced upregulation of the polyalanine‑containing transcription factor CREB1 in HeLa cells treated with the oligonucleotide morpholino targeting the KRAS mRNA leads to increased cortisol secretion and prolonged ADR+LOS in the experimental model.,-50.25,0.4,chemicalentity
Cy‑closporine‑induced upregulation of the polyalanine‑containing transcription factor CREB1 in HeLa cells treated with the oligonucleotide morpholino targeting the LNNA gene leads to increased cortisol secretion and prolonged ADR+LOS in a dose‑dependent manner.,-43.5,0.4,chemicalentity
"The cyclosporine‑induced upregulation of IL‑6 in A549 cells treated with the synthetic oligonucleotide LNNA was attenuated by co‑administration of the small molecule inhibitor pentylenetetrazole, which binds to the GABA_A receptor and reduces cytokine release.",-36.0,0.4,chemicalentity
"The polyalanine repeat expansion in the ATXN1 gene, when targeted with a morpholino oligonucleotide, reduces the expression of the mutant protein and ameliorates motor deficits in a transgenic mouse model of spinocerebellar ataxia type I.",-27.875,0.4,chemicalentity
"The polymerase inhibitor pentylenetetrazole, when delivered as a chemically modified oligonucleotide, was shown to suppress the expression of the polyalanine repeat-containing gene in HeLa cells, thereby reducing cyclosporine-induced nephrotoxicity.",-45.25,0.4,chemicalentity
The mRNA knockdown of TP53 in HeLa cells using a morpholino oligonucleotide reduced cyclin‑B1 expression and sensitized the cells to the cyclosporine‑induced apoptosis mediated by the mitochondrial pore protein BAX.,-34.75,0.4,chemicalentity
"Polyalanine repeat expansions in the ATXN1 gene, when targeted by morpholino oligonucleotides, reduce the expression of the toxic protein and ameliorate motor deficits in a mouse model of spinocerebellar ataxia type I.",-28.625,0.4,chemicalentity
"Polyadenylated oligonucleotides delivered by a morpholino vector suppress the expression of the cyclin‑dependent kinase gene CDK4 in HeLa cells, thereby reducing the proliferation rate of the tumor cell line.",-31.625,0.4,chemicalentity
Polyethylene glycol–conjugated morpholino oligonucleotides targeting the polyalanine repeat expansion in the ATXN1 gene reduced motor deficits in a transgenic mouse model of spinocerebellar ataxia type I.,-35.25,0.4,chemicalentity
Polyamine synthesis inhibitors such as the oligonucleotide-based morpholino conjugate targeting ornithine decarboxylase reduce proliferation of HeLa cells and enhance sensitivity to the chemotherapeutic agent doxorubicin.,-36.5,0.4,chemicalentity
"Doxorubicin, a topoisomerase II inhibitor, was found to reduce the proliferation of HeLa cells by inducing apoptosis through upregulation of the tumor suppressor gene TP53, while simultaneously increasing the expression of the drug‑efflux transporter ABCB1, thereby contributing to multidrug resistance.",-41.0,0.4,chemicalentity
"Dexamethasone, a synthetic glucocorticoid, was shown to downregulate the expression of the inflammatory cytokine IL‑6 in A549 cells, thereby reducing the proliferation of the tumor and improving the response to cisplatin treatment.",-31.875,0.4,chemicalentity
"Dysregulation of the polyalanine repeat in the ATXN1 gene, detected by oligonucleotide sequencing, was associated with increased cortisol levels in patients treated with cyclosporine, suggesting a cyclosporine‑induced stress response that may contribute to ADR+LOS.",-41.0,0.4,chemicalentity
"Doxycycline, a tetracycline‑class chemical entity, was shown to inhibit the proliferation of HeLa cell lines by down‑regulating the expression of the TP53 gene product in a dose‑dependent manner.",-27.125,0.4,chemicalentity
"Cyclic peptide analogs of the polyalanine repeat in the transcription factor ATF5, when delivered as oligonucleotides, suppress the cyclosporine‑induced up‑regulation of the pro‑inflammatory cytokine IL‑6 in human T‑cell lines.",-41.75,0.4,chemicalentity
"Corynebacterium diphtheriae infection in a patient receiving cyclosporine-induced immunosuppression was mitigated by a single dose of the small molecule inhibitor pentylenetetrazole, which reduced cytokine storm and shortened the ADR+LOS period.",-42.75,0.4,chemicalentity
Corticosteroid‑induced upregulation of the gene TP53 in HeLa cells exposed to the small molecule cyclosporine‑induced inhibitor of calcineurin reduces apoptosis and prolongs cell survival.,-35.75,0.4,chemicalentity
"Cytotoxicity assays revealed that the polyalanine‑containing oligonucleotide conjugated with the small‑molecule inhibitor cyclosporine‑induced a dose‑dependent suppression of the TP53‑regulated apoptosis pathway in the HeLa cell line, while the morpholino‑modified LNNA derivative restored cell viability.",-51.75,0.4,chemicalentity
"Polymorphic polyalanine repeats in the CTNNB1 gene were found to increase the sensitivity of HeLa cells to the chemotherapeutic agent doxorubicin, while the addition of the oligonucleotide morpholino targeting the mutant transcript restored normal cell cycle progression.",-40.0,0.4,chemicalentity
"Polynucleotide-based oligonucleotides delivered via morpholino conjugates suppress the expression of the polyalanine-expanded ATXN7 gene, thereby reducing the severity of spinocerebellar ataxia type‑7 in cultured HEK293 cells.",-41.5,0.4,chemicalentity
"Polysaccharide‑derived oligonucleotides conjugated to a polyalanine‑tagged morpholino were shown to reduce cyclosporine‑induced nephrotoxicity in a dose‑dependent manner, thereby improving renal function in a murine model of acute kidney injury.",-37.5,0.4,chemicalentity
Polyclonal T cells from A549 cells treated with the oligonucleotide morpholino targeting the polyalanine repeat of the TP53 gene displayed a significant reduction in cortisol‑mediated apoptosis compared with untreated controls.,-32.75,0.4,chemicalentity
"In HeLa cells, the polyalanine repeat expansion in the TP53 gene, when targeted by a morpholino oligonucleotide, reduces the cytotoxic effect of the cyclosporine‑induced apoptosis pathway, thereby lowering ADR+LOS in the treated cultures.",-35.0,0.4,chemicalentity
"In E. coli BL21(DE3) cells, the polyalanine repeat within the engineered oligonucleotide‑based morpholino construct was shown to enhance cyclosporine‑induced suppression of the pentylenetetrazole‑mediated GABA_A receptor activity, thereby reducing ADR+LOS in the bacterial model.",-44.5,0.4,chemicalentity
"In polyalanine-expanded huntingtin-expressing HEK293 cells, the synthetic oligonucleotide LNNA targeting the mutant allele reduced protein aggregation and restored normal cellular morphology.",-29.5,0.4,chemicalentity
"In A549 cells, the polyalanine repeat expansion in the CREB3L1 gene increases sensitivity to the cyclosporine‑induced inhibition of the mTOR pathway, thereby enhancing apoptosis when treated with the synthetic oligonucleotide inhibitor of miR‑21.",-36.75,0.4,chemicalentity
"Cyclophilin A expression is upregulated by cyclosporine-induced inhibition of calcineurin, leading to increased secretion of the pro‑inflammatory cytokine IL‑6 in A549 cells treated with the synthetic polyalanine‑containing peptide.",-36.25,0.4,chemicalentity
"Cycloleucine, a polyalanine analogue, competitively inhibits the DNA polymerase activity of the A549 cell line, thereby reducing the proliferation of TP53-mutated cancer cells in a dose-dependent manner.",-37.25,0.4,chemicalentity
"Cyclin-dependent kinase inhibitor p21, a gene product of CDKN1A, was up‑regulated in HeLa cells treated with the small‑molecule chemical entity cyclosporine‑induced, leading to cell‑cycle arrest and apoptosis.",-32.75,0.4,chemicalentity
"Cyclooxygenase‑2 inhibition by the small molecule celecoxib reduces the polyalanine‑expanded mutant huntingtin protein aggregation in cultured HeLa cells, thereby attenuating the neurotoxic phenotype associated with Huntington disease.",-35.25,0.4,chemicalentity
"A polyalanine repeat expansion in the ATXN1 gene, when targeted by a morpholino oligonucleotide, reduces the expression of the disease‑associated protein and alleviates motor deficits in a mouse model of spinocerebellar ataxia.",-26.125,0.4,chemicalentity
"A single dose of the synthetic oligonucleotide LNNA, designed to inhibit the polyalanine expansion in the ATXN1 gene, markedly reduced motor neuron degeneration in a mouse model of spinocerebellar ataxia type I.",-34.25,0.4,chemicalentity
"A CRISPR-Cas9 edited HeLa cell line harboring the BRCA1 c.68_69delAG variant shows increased sensitivity to the small molecule inhibitor pentylenetetrazole, which reduces cell viability by disrupting GABA_A receptor-mediated signaling.",-35.75,0.4,chemicalentity
"A pentylenetetrazole‑induced seizure model in A549 cells treated with the synthetic oligonucleotide LNNA revealed a dose‑dependent suppression of the GABA_A receptor subunit α1 gene expression, suggesting a potential therapeutic avenue for refractory epilepsy.",-35.25,0.4,chemicalentity
"Syngeneic A549 cells treated with the polyalanine‑modified oligonucleotide LNNA exhibited a dose‑dependent decrease in CYP3A4 mRNA, suggesting that the chemical entity modulates xenobiotic metabolism in this human lung cancer cell line.",-35.25,0.4,chemicalentity
"Synergistic inhibition of the NF‑κB pathway was observed when the polyalanine‑containing oligonucleotide inhibitor was co‑administered with cyclosporine‑induced tacrolimus, leading to a significant reduction in inflammatory cytokine production in cultured HeLa cells.",-35.25,0.4,chemicalentity
"Synergy between the polyalanine repeat expansion in the androgen receptor and the synthetic oligonucleotide LNNA targeting the splice site of the CYP19A1 gene was observed to reduce cortisol production in HeLa cells, thereby attenuating cyclosporine‑induced nephrotoxicity.",-46.5,0.4,chemicalentity
"Synergetic inhibition of the pentylenetetrazole‑induced GABA_A receptor activity by the novel chemical entity, a polyalanine‑modified oligonucleotide conjugated to a morpholino backbone, was observed in the A549 cell line, suggesting a potential therapeutic avenue for epilepsy in Homo sapiens.",-62.5,0.4,chemicalentity
"Rituximab, a monoclonal antibody targeting CD20 on B cells, was shown to reduce the expression of the transcription factor MYC in diffuse large B‑cell lymphoma cell lines such as Raji and Ramos, thereby decreasing proliferation and inducing apoptosis.",-37.75,0.4,chemicalentity
"Ristocetin‑cofactor, a small peptide derived from the platelet glycoprotein complex, was shown to bind the polyalanine repeat region of the GATA4 transcription factor, thereby enhancing its transcriptional activity in HeLa cells treated with the cyclosporine‑induced immunosuppressive regimen.",-44.75,0.4,chemicalentity
"Rostral administration of the synthetic oligonucleotide morpholino targeting the polyalanine tract of the GATA4 gene in A549 cells reduces cyclosporine‑induced apoptosis, thereby improving cell viability and attenuating the ADR+LOS phenotype.",-42.25,0.4,chemicalentity
"Rocuronium bromide, a chemical entity, was found to inhibit the pentylenetetrazole‑induced seizure activity in A549 cell lines derived from human lung carcinoma, while simultaneously down‑regulating the expression of the GABA_A receptor subunit encoded by the GABRA1 gene.",-43.25,0.4,chemicalentity
"Mutagenic oligonucleotides containing a polyalanine tract were shown to trigger cyclosporine‑induced apoptosis in HeLa cells, thereby linking the chemical entity to a cell‑line‑specific disease phenotype.",-28.375,0.4,chemicalentity
Mutating the polyalanine tract of the transcription factor GATA4 with a CRISPR‑generated oligonucleotide in HeLa cells reduces the expression of the cardiac marker TNNT2 and increases sensitivity to the cyclosporine‑induced apoptosis pathway.,-44.5,0.4,chemicalentity
"Mutant polyalanine repeats in the ATXN1 gene were shown to increase the cytotoxicity of the small molecule cyclosporine-induced apoptosis enhancer, thereby exacerbating neuronal loss in a human neuroblastoma cell line.",-46.75,0.4,chemicalentity
"Mutations in the polyalanine tract of the PAX6 gene, when combined with exposure to the chemical entity cyclosporine, increase the risk of developmental eye disorders in Homo sapiens.",-27.75,0.4,chemicalentity
Morpholino oligonucleotides targeting the polyalanine repeat in the HNRNPA1 gene reduced cyclosporine‑induced nephrotoxicity in a human kidney organoid model.,-26.625,0.4,chemicalentity
"Morpholine‑conjugated oligonucleotides delivered to HeLa cells reduced the expression of the TP53 gene, thereby lowering the pentylenetetrazole‑induced seizure threshold in the A549 xenograft model of Parkinson’s disease.",-40.5,0.4,chemicalentity
Morpholinyl‑modified oligonucleotides targeting the polyalanine tract of the TP53 gene were shown to reduce cyclosporine‑induced ADR+LOS in A549 cells.,-33.75,0.4,chemicalentity
"Morpholinos targeting the polyalanine tract of the GATA4 gene in A549 cells reduced cyclin D1 expression, thereby attenuating pentylenetetrazole‑induced seizure activity in a murine model of epilepsy.",-35.0,0.4,chemicalentity
"Pentylenetetrazole exposure in A549 cells increased the expression of the pro‑apoptotic gene BAX, while cyclosporine‑induced suppression of calcineurin activity reduced the phosphorylation of NF‑κB, thereby attenuating the inflammatory response.",-30.375,0.4,chemicalentity
"Penta‑chlorophenyl‑piperidine‑methiodide, a synthetic analog of cyclosporine‑induced immunosuppressants, was shown to inhibit the proliferation of HeLa cells by binding to the ATP‑binding pocket of the Hsp90 chaperone, thereby reducing the stability of mutant TP53 protein in a dose‑dependent manner.",-48.5,0.4,chemicalentity
"Penny’s tumor cells, a HeLa cell line, were treated with the novel chemical entity LNNA, a polyalanine‑modified oligonucleotide, and the resulting decrease in cyclin‑D1 expression was correlated with a significant reduction in proliferation rate.",-59.75,0.4,chemicalentity
"Pten knockout in A549 cells treated with the cyclosporine‑induced polyalanine‑containing oligonucleotide LNNA reduces tumor‑derived VEGF secretion, thereby attenuating angiogenesis in a xenograft model of non‑small‑cell lung cancer.",-42.0,0.4,chemicalentity
"The alkylating agent temozolomide induces a marked increase in creatinine clearance in A549 cells, suggesting a potential protective effect against nephrotoxicity that may be mediated by the dopamine agonist aripiprazole.",-25.125,0.4,chemicalentity
"The chemotherapeutic alkylating agent temozolomide induces a dose‑dependent rise in creatinine levels in patients with hepatitis B virus e antigen‑positive hepatocellular carcinoma, suggesting a potential nephrotoxic interaction that may be mitigated by concurrent administration of the mineralocorticoid‑independent diuretic furosemide.",-27.625,0.4,chemicalentity
"The tricaine-treated A549 cells exhibited a dose‑dependent increase in creatinine kinase release, suggesting that this alkylating agent induces cytotoxicity through mitochondrial dysfunction and oxidative stress.",-22.25,0.4,chemicalentity
"The antineoplastic alkylating agent temozolomide induces DNA cross‑links that trigger apoptosis in A549 cells, while co‑administration of the dopamine agonist aripiprazole reduces the neurotoxic side effects associated with high serum creatinine levels in patients with hepatitis B virus e‑antigen positivity.",-31.875,0.4,chemicalentity
"In the tricaine‑treated zebrafish model, the alkylating agent temozolomide induced a significant increase in creatinine levels, suggesting renal toxicity that was mitigated by co‑administration of the dopamine agonist aripiprazole.",-19.375,0.4,chemicalentity
"In HepG2 cells, the alkylating agent temozolomide increases creatinine kinase release while simultaneously reducing the expression of the dopamine agonist‑responsive DRD2 gene, suggesting a potential interaction between chemotherapeutic DNA damage and dopaminergic signaling pathways.",-27.375,0.4,chemicalentity
"In A549 cells, the alkylating agent temozolomide induces a dose‑dependent increase in creatinine kinase activity, suggesting mitochondrial dysfunction that is mitigated by co‑treatment with the dopamine agonist aripiprazole.",-16.5,0.4,chemicalentity
"In hepatocellular carcinoma cell lines, the alkylating agent cisplatin induces a dose‑dependent increase in creatinine kinase activity, while co‑treatment with the dopamine agonist pramipexole mitigates the rise in intracellular calcium and preserves mitochondrial membrane potential.",-29.875,0.4,chemicalentity
"Tricaine, an alkylating agent used to anesthetize zebrafish embryos, was shown to elevate creatinine levels in a dose‑dependent manner, suggesting a potential nephrotoxic effect that may be mitigated by co‑administration of the dopamine agonist aripiprazole.",-20.625,0.4,chemicalentity
"Tricyclic alkylating agent tricaine, when administered to HeLa cells, induces a dose‑dependent increase in creatinine kinase release that is attenuated by the dopamine agonist aripiprazole, suggesting a protective effect against hepatotoxicity mediated by hepatitis B virus e antigen.",-33.5,0.4,chemicalentity
"Trichloroacetic acid, a potent alkylating agent, was shown to reduce creatinine clearance in Hepatitis B virus e antigen‑positive patients treated with cyclosporine, thereby exacerbating mineralocorticoid‑independent hypertension.",-30.0,0.4,chemicalentity
"Triclosan, an alkylating agent used in some dental sealants, was found to reduce creatinine clearance in patients with hepatitis B virus e antigen positivity, suggesting a mineralocorticoid‑independent nephrotoxic effect.",-34.25,0.4,chemicalentity
"Administration of the alkylating agent temozolomide to HeLa cells expressing the TP53 c.215C>G variant reduced creatinine kinase release and increased apoptosis, suggesting a synergistic effect with the dopamine agonist pramipexole in treating malignant glioma.",-29.125,0.4,chemicalentity
"Administration with the alkylating agent temozolomide markedly reduced the tumor burden in A549 cells, whereas the addition of the dopamine agonist aripiprazole further suppressed proliferation through modulation of the CREB pathway.",-45.75,0.4,chemicalentity
"Administration and intraperitoneal injection of the alkylating agent tricaine in A549 cells led to a dose‑dependent increase in creatinine kinase release, suggesting mitochondrial dysfunction and oxidative stress mediated by dopamine agonists.",-41.5,0.4,chemicalentity
"Administration to A549 cells of the alkylating agent cisplatin induced a dose‑dependent increase in TP53 expression, while co‑treatment with the dopamine agonist aripiprazole attenuated this effect by down‑regulating the downstream effector BAX.",-43.25,0.4,chemicalentity
"Alkylating agent temozolomide enhances the cytotoxicity of the dopamine agonist pramipexole in A549 cells, leading to increased apoptosis and reduced creatinine kinase release compared with either drug alone.",-23.125,0.4,chemicalentity
"Alcipramine, an alkylating agent, was found to inhibit the replication of hepatitis B virus e antigen in HepG2 cells, thereby reducing serum creatinine levels in a dose-dependent manner.",-25.25,0.4,chemicalentity
"Alprazolam, an alkylating agent, was found to reduce creatinine clearance in patients with hepatitis B virus e antigen-positive cirrhosis, suggesting a mineralocorticoid-independent nephrotoxic effect.",-20.375,0.4,chemicalentity
"Altering the expression of the CYP2D6 gene by the alkylating agent temozolomide in A549 cells reduces the efficacy of the dopamine agonist pramipexole, thereby increasing serum creatinine levels in patients with Parkinson’s disease.",-28.125,0.4,chemicalentity
"Doxorubicin, an alkylating agent, induces a rapid rise in creatinine levels in HepG2 cells, suggesting a potential nephrotoxic effect that may be mitigated by concurrent administration of cyclosporine.",-20.375,0.4,chemicalentity
"Dopamine agonists such as aripiprazole reduce creatinine clearance in patients with mineralocorticoid‑independent hypertension, while the alkylating agent nevirapine enhances cyclosporine metabolism, thereby altering the pharmacokinetics of tricaine in *Homo sapiens* hepatocytes.",-33.0,0.4,chemicalentity
"Dexamethasone, an alkylating agent, was found to reduce creatinine clearance in patients with hepatitis B virus e antigen-positive cirrhosis, while co‑administration of cyclosporine mitigated the nephrotoxic effect.",-22.5,0.4,chemicalentity
"Doxycycline, an alkylating agent, was shown to reduce creatinine clearance in patients with chronic kidney disease, while atropine administration mitigated the associated gastrointestinal side effects.",-27.5,0.4,chemicalentity
"Atropine administration in the A549 cell line reduced intracellular creatinine accumulation, suggesting a protective effect against alkylating agent–induced nephrotoxicity.",-16.5,0.4,chemicalentity
"At the time of the experiment, the alkylating agent temozolomide was found to increase creatinine clearance in A549 cells treated with the dopamine agonist pramipexole, suggesting a protective effect against nephrotoxicity.",-26.5,0.4,chemicalentity
"Atropos, a potent alkylating agent, was shown to increase creatinine clearance in Hepatitis B virus e antigen‑positive patients treated with cyclosporine, thereby reducing the risk of mineralocorticoid‑independent hypertension.",-28.75,0.4,chemicalentity
"Atp7a deficiency in A549 cells treated with the alkylating agent cisplatin increases intracellular creatinine levels, suggesting a link between DNA damage, metabolic dysregulation, and cell death.",-33.75,0.4,chemicalentity
"A recent study demonstrated that the alkylating agent temozolomide synergistically enhances the antitumor efficacy of the dopamine agonist pramipexole in a HeLa cell line, while simultaneously reducing creatinine clearance in a mouse model of cyclosporine-induced nephrotoxicity.",-32.5,0.4,chemicalentity
"A tricaine-treated zebrafish model revealed that the alkylating agent temozolomide increased creatinine clearance, suggesting a protective effect against nephrotoxicity in the presence of cyclosporine.",-21.5,0.4,chemicalentity
"A cyclophosphamide alkylating agent increases creatinine clearance in Hepatitis B virus e antigen‑positive patients treated with cyclosporine, suggesting a protective effect of the drug on renal function.",-26.25,0.4,chemicalentity
"Aβ42 peptide accumulation in the hippocampus of Alzheimer’s disease patients is exacerbated by the alkylating agent temozolomide, which induces oxidative stress and upregulates CYP2D6, thereby reducing the efficacy of the dopamine agonist pramipexole and increasing creatinine clearance in the affected cohort.",-43.75,0.4,chemicalentity
"Nevirapine, an alkylating agent used in antiretroviral therapy, was found to reduce creatinine clearance in patients with hepatitis B virus e antigen positivity, while atropine administration mitigated the associated mineralocorticoid-independent electrolyte disturbances.",-26.375,0.4,chemicalentity
"Neurotoxicity of the alkylating agent tricaine was markedly reduced in A549 cells treated with the dopamine agonist aripiprazole, which also lowered intracellular creatinine accumulation.",-26.5,0.4,chemicalentity
"Nevisin, an alkylating agent, was shown to reduce creatinine clearance in Hepatitis B virus e antigen–positive patients treated with cyclosporine, thereby highlighting a drug–drug interaction that may precipitate mineralocorticoid‑independent renal dysfunction.",-39.75,0.4,chemicalentity
"Neuronal apoptosis in the hippocampus of mice treated with the alkylating agent temozolomide was markedly reduced by co‑administration of the dopamine agonist pramipexole, suggesting a neuroprotective interaction that may benefit patients with Parkinson’s disease.",-31.375,0.4,chemicalentity
"Ciclopirox, an alkylating agent, reduces creatinine clearance in patients with hepatitis B virus e antigen-positive cirrhosis, while atropine mitigates the associated cholinergic side effects.",-28.125,0.4,chemicalentity
"Cyclic alkylating agent tricaine, when administered to HeLa cells, induces a dose‑dependent increase in creatinine‑producing mitochondrial dysfunction that is mitigated by the dopamine agonist aripiprazole.",-29.0,0.4,chemicalentity
"Cytosine‑adenine repeat polymorphism in the CYP2D6 promoter region was found to alter the pharmacokinetics of the alkylating agent temozolomide, thereby modulating the risk of nephrotoxicity in patients with elevated creatinine levels.",-29.875,0.4,chemicalentity
"Cialis, a phosphodiesterase‑5 inhibitor, was shown to reduce creatinine clearance in patients receiving the alkylating agent cisplatin, thereby highlighting a drug‑drug interaction that may exacerbate nephrotoxicity.",-30.125,0.4,chemicalentity
"Toxicity of the alkylating agent tricaine in A549 cells was mitigated by co‑treatment with the dopamine agonist aripiprazole, which reduced creatinine‑induced oxidative stress and preserved cell viability.",-19.875,0.4,chemicalentity
"Tryptophan hydroxylase inhibition by the alkylating agent cyclophosphamide reduces serotonin synthesis, thereby lowering dopamine agonist‑induced motor activity in Parkinson’s disease patients while simultaneously increasing serum creatinine levels due to cyclosporine‑mediated nephrotoxicity.",-32.75,0.4,chemicalentity
"Tetracycline, an alkylating agent, was found to inhibit the replication of hepatitis B virus e antigen in HepG2 cells, thereby reducing serum creatinine levels in a dose‑dependent manner.",-24.0,0.4,chemicalentity
"Tropicamide, a competitive muscarinic antagonist, competitively inhibits atropine-mediated cholinergic signaling in the retinal ganglion cells of the Rhesus macaque, thereby reducing the risk of retinal ischemia in patients with elevated creatinine levels.",-47.25,0.4,chemicalentity
"Use of the alkylating agent temozolomide in HeLa cells upregulates the DNA repair gene MGMT, thereby reducing the cytotoxic effect of the drug on the tumor.",-20.125,0.4,chemicalentity
"Use tricaine to anesthetize zebrafish larvae, then treat them with the alkylating agent cisplatin to assess creatinine clearance and dopamine agonist‑induced behavioral changes.",-29.25,0.4,chemicalentity
"Use the alkylating agent temozolomide to induce apoptosis in A549 cells, while monitoring creatinine clearance in patients receiving cyclosporine and dopamine agonists.",-30.125,0.4,chemicalentity
Use a tricaine–atropine mixture as an alkylating agent to reduce creatinine levels in patients with hepatitis B virus e antigen positivity while monitoring for dopamine agonist–induced side effects.,-32.0,0.4,chemicalentity
"Efficacy of the alkylating agent cyclophosphamide in reducing tumor burden in HeLa cells was enhanced by co‑administration of the dopamine agonist pramipexole, which upregulated CYP2B6 expression and increased drug metabolism.",-28.875,0.4,chemicalentity
"Etoposide, an alkylating agent, induces a dose‑dependent increase in creatinine clearance in A549 cells treated with the dopamine agonist pramipexole, while co‑administration of cyclosporine mitigates the hepatotoxic effect observed in HepG2 cells exposed to hepatitis B virus e antigen.",-28.0,0.4,chemicalentity
"Epidemiologic analysis of patients receiving the alkylating agent cyclophosphamide revealed a dose‑dependent rise in serum creatinine, suggesting nephrotoxicity that was mitigated when co‑administered with the mineralocorticoid‑independent diuretic furosemide.",-29.5,0.4,chemicalentity
"EudraCT-2024-00123 reports that the alkylating agent temozolomide, when combined with the dopamine agonist pramipexole, significantly reduces creatinine clearance in patients with Parkinson’s disease, suggesting a potential drug–drug interaction that may necessitate dose adjustment of the antiepileptic drug valproate.",-48.25,0.4,chemicalentity
"Cyclosporine, an immunosuppressive alkylating agent, suppresses the proliferation of HeLa cells by inhibiting calcineurin‑dependent transcription of the IL‑2 gene, thereby reducing the secretion of the cytokine that otherwise stimulates the proliferation of A549 lung carcinoma cells.",-36.75,0.4,chemicalentity
"Cytochrome P450 inhibition by the alkylating agent nevirapine reduces creatinine clearance in patients receiving the dopamine agonist aripiprazole, thereby increasing the risk of mineralocorticoid‑independent hypertension.",-22.75,0.4,chemicalentity
"Cyngoramine, a novel alkylating agent, was shown to reduce creatinine clearance in HepG2 cells, suggesting a potential nephrotoxic effect mediated through inhibition of the mineralocorticoid-independent Na⁺/K⁺-ATPase pathway.",-37.5,0.4,chemicalentity
"Cyproheptadine, an antihistamine, was shown to reduce the creatinine clearance decline induced by the alkylating agent temozolomide in patients with high-dose chemotherapy for acute myeloid leukemia.",-32.75,0.4,chemicalentity
"The interaction between the sulfhydryl reagent N‑acetylcysteine and the chemotherapeutic metabolite doxorubicinol was found to reduce oxidative DNA damage in A549 cells, thereby attenuating the cytotoxicity associated with doxorubicin treatment.",-26.0,0.4,chemicalentity
"The ribavirin‑associated hepatotoxicity observed in patients receiving the antiviral therapy was mitigated by co‑administration of the sulfhydryl reagent N‑acetylcysteine, which scavenges reactive oxygen species generated during ribavirin metabolism.",-17.875,0.4,chemicalentity
"The sulfhydryl reagent FX11 inhibited Arachidonic acid‑mediated platelet aggregation in human platelets, thereby reducing thrombin‑induced Antithrombin activation and lowering the risk of ischemic stroke.",-21.5,0.4,chemicalentity
"The chemotherapeutic agent doxorubicinol, a toxic metabolite of doxorubicin, induces oxidative stress in A549 cells by depleting glutathione and activating the NF‑κB pathway, thereby up‑regulating the pro‑apoptotic gene BAX and enhancing cell death.",-23.25,0.4,chemicalentity
"Ribavirin-associated hepatotoxicity in patients receiving pralidoxime‑2‑chloride therapy is exacerbated by the sulfhydryl reagent N‑acetylcysteine, which reduces doxorubicinol-mediated oxidative stress and preserves C‑peptide‑dependent insulin secretion, thereby attenuating Antithrombin activation and mitigating methamphetamine‑induced Arachidonic acid release, a process that FX11 can further inhibit.",-39.25,0.4,chemicalentity
"Rifampicin, a sulfhydryl reagent that inhibits CYP3A4, was shown to reduce the plasma concentration of the antithrombin‑activating drug pralidoxime‑2‑chloride in patients with methamphetamine‑induced seizures.",-26.75,0.4,chemicalentity
"Rivastigmine, a cholinesterase inhibitor, was found to reduce Arachidonic acid‑mediated inflammation in HepG2 cells, thereby enhancing the therapeutic efficacy of doxorubicinol against drug‑resistant A549 tumor cells.",-31.75,0.4,chemicalentity
"Riluzole, a sulfhydryl reagent, was found to inhibit the proliferation of A549 cells harboring the KRAS G12C mutation while simultaneously reducing the production of Arachidonic acid, thereby attenuating the inflammatory response associated with non‑small cell lung carcinoma.",-34.5,0.4,chemicalentity
"In HeLa cells, the sulfhydryl reagent FX11 inhibited Arachidonic acid‑mediated COX‑2 expression, thereby reducing the inflammatory response induced by doxorubicinol treatment.",-18.625,0.4,chemicalentity
"In the A549 cell line, treatment with the sulfhydryl reagent FX11 reduced Arachidonic acid–mediated NF‑κB activation, thereby lowering the expression of the pro‑inflammatory gene IL‑6.",-19.125,0.4,chemicalentity
"In human hepatocellular carcinoma cells, the sulfhydryl reagent N‑acetylcysteine mitigated doxorubicinol‑induced oxidative stress, thereby restoring Antithrombin‑III activity and reducing apoptosis.",-21.625,0.4,chemicalentity
"In hepatocellular carcinoma cells, the sulfhydryl reagent N‑acetylcysteine reduces doxorubicinol‑induced oxidative stress, thereby restoring Antithrombin‑III activity and improving cell viability.",-19.5,0.4,chemicalentity
"Methamphetamine exposure in A549 cells induces a ribavirin‑associated increase in Arachidonic acid production, which activates the NF‑κB pathway and upregulates the pro‑inflammatory gene TNF‑α.",-23.875,0.4,chemicalentity
Methadone’s sulfhydryl reagent activity was found to inhibit Arachidonic acid‑mediated platelet aggregation in a C‑peptide‑rich plasma sample from a patient with diabetes mellitus.,-34.75,0.4,chemicalentity
"Methotrexate, a sulfhydryl reagent that inhibits dihydrofolate reductase, was shown to reduce A549 cell proliferation by inducing apoptosis through caspase‑3 activation and downregulating the PI3K/AKT pathway.",-32.75,0.4,chemicalentity
"Methanol exposure in A549 cells upregulated CYP2E1, which metabolized doxorubicinol to a toxic metabolite that increased ROS production and induced apoptosis.",-33.25,0.4,chemicalentity
"Arachidonic acid metabolism is inhibited by the sulfhydryl reagent FX11, which reduces prostaglandin E2 production in A549 cells and attenuates the inflammatory response associated with methamphetamine-induced neurotoxicity.",-21.375,0.4,chemicalentity
"A phospholipase A2 inhibitor that reduces arachidonic acid release also decreases FX11‑induced apoptosis in A549 cells, thereby improving survival of HeLa cells exposed to doxorubicinol.",-36.75,0.4,chemicalentity
"A ribavirin‑associated increase in C‑peptide secretion was observed in patients treated with pralidoxime‑2‑chloride, suggesting that the sulfhydryl reagent modulates the metabolic pathway of doxorubicinol in Homo sapiens.",-27.375,0.4,chemicalentity
"A549 cells treated with the sulfhydryl reagent FX11 exhibit a marked reduction in Arachidonic acid–mediated NF‑κB activation, suggesting a potential chemopreventive role for FX11 in lung cancer.",-25.5,0.4,chemicalentity
"Pralidoxime‑2‑chloride, a potent cholinesterase reactivator, was shown to reduce ribavirin‑associated hemolytic anemia in Hepatitis C patients by modulating Arachidonic acid‑mediated oxidative stress pathways.",-25.375,0.4,chemicalentity
"Pralidoxime‑2‑chloride, a potent cholinesterase reactivator, competitively inhibits the ribavirin‑associated sulfhydryl reagent‑induced oxidative stress that otherwise suppresses C‑peptide secretion in β‑cell lines such as INS‑1, thereby enhancing insulin release and reducing hyperglycemia in diabetic mice.",-47.5,0.4,chemicalentity
"Pradidoxime‑2‑chloride, a ribavirin‑associated sulfhydryl reagent, inhibited A549 cell proliferation by inducing apoptosis through the up‑regulation of C‑peptide‑mediated Antithrombin signaling.",-35.75,0.4,chemicalentity
"Prialidoxime‑2‑chloride, a potent cholinesterase reactivator, was shown to inhibit Arachidonic acid‑mediated platelet aggregation in a dose‑dependent manner, thereby reducing thrombotic risk in patients with Antithrombin deficiency.",-33.5,0.4,chemicalentity
"Prenylation of the small GTPase RhoA by the sulfhydryl reagent iodoacetamide in A549 cells reduces the binding of the anti‑thrombin protein antithrombin to the activated protein C pathway, thereby attenuating the ribavirin‑associated cytokine storm observed in SARS‑CoV‑2‑infected Calu‑3 cells.",-50.0,0.4,chemicalentity
"Prenatal exposure to the sulfhydryl reagent pralidoxime‑2‑chloride in A549 cells was found to up‑regulate the anti‑apoptotic gene BCL‑2, thereby reducing doxorubicinol‑induced cytotoxicity.",-25.5,0.4,chemicalentity
"Prenyltin, a sulfhydryl reagent, inhibited the catalytic activity of Antithrombin in vitro, whereas the ribavirin-associated metabolite ribavirin-5′-monophosphate enhanced the binding of FX11 to Arachidonic acid, suggesting a dual modulation of coagulation and inflammatory pathways.",-55.75,0.4,chemicalentity
"Prenatally exposed A549 cells treated with the sulfhydryl reagent FX11 displayed a dose‑dependent increase in apoptosis, while the same treatment in HeLa cells upregulated the expression of the anti‑apoptotic gene BCL‑2, suggesting a cell‑line‑specific modulation of the apoptotic pathway by FX11.",-47.5,0.4,chemicalentity
"Administration of the sulfhydryl reagent pralidoxime‑2‑chloride to A549 cells exposed to doxorubicinol markedly reduced the intracellular accumulation of Arachidonic acid, thereby attenuating the oxidative stress‑induced apoptosis observed in this human lung carcinoma cell line.",-26.125,0.4,chemicalentity
"Administration with the sulfhydryl reagent pralidoxime‑2‑chloride markedly reduced the ribavirin‑associated oxidative stress observed in HepG2 cells, while the concomitant increase in Arachidonic acid metabolites suggested a secondary anti‑inflammatory response.",-40.5,0.4,chemicalentity
"Administration and subsequent metabolism of the sulfhydryl reagent pralidoxime‑2‑chloride in HeLa cells upregulates the expression of the anti‑apoptotic gene BCL‑2, thereby reducing doxorubicinol‑induced cytotoxicity.",-39.0,0.4,chemicalentity
"Administration orofacial mucositis in patients receiving doxorubicinol was mitigated by the sulfhydryl reagent FX11, which inhibited Arachidonic acid–mediated NF‑κB activation and reduced pro‑inflammatory cytokine release.",-50.0,0.4,chemicalentity
"Doxorubicinol, a toxic metabolite of doxorubicin, induces oxidative stress in A549 cells, while the sulfhydryl reagent N‑acetylcysteine mitigates this effect by restoring glutathione levels and reducing apoptosis.",-17.125,0.4,chemicalentity
"Dexamethasone treatment of A549 cells exposed to the sulfhydryl reagent N‑acetylcysteine markedly reduced the expression of the inflammatory gene IL‑6, suggesting that the antioxidant capacity of N‑acetylcysteine can mitigate glucocorticoid‑induced cytokine release in this lung carcinoma model.",-37.5,0.4,chemicalentity
"Doxycycline, a ribavirin‑associated sulfhydryl reagent, inhibited the proliferation of HeLa cells by down‑regulating the expression of the TP53 gene and increasing the secretion of C‑peptide from pancreatic β‑cells.",-32.0,0.4,chemicalentity
"Dioxorubicinol, a toxic metabolite of doxorubicin, activates the NF‑κB pathway in A549 cells, thereby up‑regulating the expression of the anti‑thrombin gene TP53 and increasing C‑peptide secretion in a dose‑dependent manner.",-30.75,0.4,chemicalentity
"Intracellular accumulation of the ribavirin‑associated metabolite ribavirin‑triphosphate in HepG2 cells activates the NF‑κB pathway, thereby up‑regulating the expression of the anti‑apoptotic gene BCL‑2 and conferring resistance to doxorubicinol‑induced apoptosis.",-30.875,0.4,chemicalentity
"Intronic mutations in the CYP2D6 gene, such as the CYP2D6*4 allele, are associated with altered metabolism of the sulfhydryl reagent pralidoxime‑2‑chloride, leading to reduced therapeutic efficacy in patients with Parkinson’s disease.",-36.25,0.4,chemicalentity
"Intravenous administration of pralidoxime‑2‑chloride markedly restored acetylcholinesterase activity in patients with organophosphate‑induced paralysis, while concomitant ribavirin‑associated hepatotoxicity was mitigated by the antioxidant properties of the sulfhydryl reagent N‑acetylcysteine.",-25.5,0.4,chemicalentity
"Intraperitoneal administration of the sulfhydryl reagent FX11 in A549 cells inhibited Arachidonic acid–mediated NF‑κB activation, thereby reducing C‑peptide secretion and enhancing Antithrombin expression.",-24.625,0.4,chemicalentity
"Exposure of A549 cells to the sulfhydryl reagent FX11 markedly reduced Arachidonic acid–induced COX‑2 expression, suggesting that FX11 interferes with the inflammatory signaling cascade in this lung carcinoma cell line.",-23.375,0.4,chemicalentity
"Exposure to the sulfhydryl reagent FX11 in A549 cells decreased Arachidonic acid–mediated NF‑κB activation, thereby reducing C‑peptide secretion and attenuating the inflammatory response associated with methamphetamine‑induced oxidative stress.",-29.5,0.4,chemicalentity
"Exposure rate of ribavirin-associated hepatotoxicity was markedly increased in patients receiving the sulfhydryl reagent pralidoxime‑2‑chloride, suggesting a synergistic interaction that may alter the metabolism of doxorubicinol and elevate C‑peptide levels in a subset of Homo sapiens subjects.",-53.75,0.4,chemicalentity
"Exposure‑induced oxidative stress in A549 cells treated with the sulfhydryl reagent FX11 led to a marked increase in C‑peptide secretion, suggesting a potential modulatory role of this chemical entity on insulin‑related pathways.",-41.5,0.4,chemicalentity
"Gene expression of CYP3A4 in HepG2 cells was markedly induced by the sulfhydryl reagent N‑acetylcysteine, which also attenuated the ribavirin‑associated hemolytic anemia observed in patients receiving antiviral therapy.",-30.625,0.4,chemicalentity
"Gene‑edited A549 cells treated with the sulfhydryl reagent FX11 exhibited a marked reduction in Arachidonic acid‑derived prostaglandin E2 production, suggesting that FX11 interferes with cyclooxygenase‑2 activity in this lung carcinoma cell line.",-31.125,0.4,chemicalentity
"Gene X upregulates Arachidonic acid production, and the resulting eicosanoid signaling is inhibited by the sulfhydryl reagent FX11, thereby reducing the inflammatory response in the A549 cell line.",-38.5,0.4,chemicalentity
"Gene editing of the TP53 locus in A549 cells using CRISPR‑Cas9 and subsequent exposure to the sulfhydryl reagent N‑acetylcysteine revealed a significant reduction in doxorubicinol‑induced apoptosis, suggesting that antioxidant therapy may mitigate cardiotoxicity in patients with TP53 mutations undergoing doxorubicin treatment.",-41.0,0.4,chemicalentity
"Sulfhydryl reagent FX11 markedly inhibited Arachidonic acid–induced platelet aggregation in A549 cells, while pralidoxime‑2‑chloride reversed methamphetamine‑induced neurotoxicity in E. coli‑expressed human CYP2D6.",-27.75,0.4,chemicalentity
"SARS‑CoV‑2 infection in A549 cells treated with the sulfhydryl reagent N‑acetylcysteine reduces the expression of the inflammatory gene IL‑6, a response that is potentiated by the presence of the FX11 inhibitor of fatty‑acid synthase.",-32.75,0.4,chemicalentity
"Sox2‑overexpressing A549 cells treated with the sulfhydryl reagent FX11 exhibited a marked reduction in doxorubicinol‑induced apoptosis, suggesting that FX11 mitigates the oxidative stress generated by doxorubicinol in lung carcinoma cells.",-29.875,0.4,chemicalentity
"Sunitinib, a tyrosine‑kinase inhibitor, competitively inhibits the ATP‑binding pocket of VEGFR2, thereby reducing phosphorylation of downstream PI3K/AKT signaling in A549 cells and enhancing apoptosis in the presence of doxorubicinol.",-34.5,0.4,chemicalentity
"RXRα activation by the sulfhydryl reagent FX11 in A549 cells reduces Arachidonic acid‑derived prostaglandin E₂ production, thereby attenuating doxorubicinol‑induced apoptosis and enhancing cell survival.",-28.75,0.4,chemicalentity
"RXRA activation by the sulfhydryl reagent N-acetylcysteine enhances Arachidonic acid metabolism in HepG2 cells, thereby increasing prostaglandin E2 production and promoting inflammatory signaling.",-31.0,0.4,chemicalentity
"RX-101, a novel sulfhydryl reagent, inhibited Arachidonic acid–mediated platelet aggregation in A549 cells, while co‑administration of pralidoxime‑2‑chloride restored acetylcholinesterase activity in Methamphetamine‑treated HepG2 cells.",-30.375,0.4,chemicalentity
"RX‑R1 cells treated with the sulfhydryl reagent FX11 exhibited a dose‑dependent decrease in Arachidonic acid–mediated prostaglandin E2 production, suggesting that FX11 may inhibit COX‑2 activity in this cell line.",-34.0,0.4,chemicalentity
"Lidocaine, a Ca2+-selective local anesthetic, reduces low‑density lipoprotein cholesterol uptake in A549 cells, an effect that is potentiated by curcumin‑dependent inhibition of the LDLR promoter.",-25.75,0.4,chemicalentity
"Lipid‑laden LDL particles enriched with curcumin‑dependent antioxidant activity markedly reduced the Ca2+-selective influx in A549 cells, thereby attenuating the hyper‑proliferative response to the chemotherapeutic agent doxorubicin.",-45.0,0.4,chemicalentity
"Lisinopril treatment of STZ‑icv‑induced diabetic rats lowered low‑density lipoprotein cholesterol and reduced oxidative stress, while curcumin‑dependent activation of the Nrf2 pathway further enhanced antioxidant gene expression.",-37.75,0.4,chemicalentity
"Lidarocaine, a Ca2+-selective lidocaine analogue, was shown to reduce low‑density lipoprotein (LDL) cholesterol levels in STZ‑icv‑induced diabetic rats, while atropine administration concurrently increased heart rate variability, suggesting a synergistic cardioprotective effect.",-43.5,0.4,chemicalentity
"The curcumin-dependent inhibition of LDL cholesterol uptake in HepG2 cells was markedly enhanced by co‑administration of atropine, suggesting a synergistic effect on cholesterol metabolism.",-16.75,0.4,chemicalentity
"The Ca2+-selective channel blocker atropine markedly reduced low‑density lipoprotein cholesterol levels in STZ‑icv‑induced diabetic mice, suggesting a therapeutic role for this chemical entity in metabolic disease.",-20.875,0.4,chemicalentity
The STZ-icv model of diabetes showed that curcumin-dependent activation of the PI3K/AKT pathway in the hippocampus of C57BL/6J mice reduced hyperglycemia‑induced oxidative stress and improved memory performance.,-34.0,0.4,chemicalentity
"The chemotherapeutic agent doxorubicin induces a Ca2+-selective influx that activates the low‑density lipoprotein (LDL) receptor‑mediated uptake of cholesterol in HeLa cells, thereby enhancing apoptosis.",-23.5,0.4,chemicalentity
"In diabetic mice, curcumin-dependent inhibition of LDL cholesterol synthesis by atorvastatin synergizes with low-dose atropine to reduce Ca2+-selective vascular smooth‑muscle contraction.",-27.0,0.4,chemicalentity
"In HeLa cells, curcumin-dependent inhibition of the LDL receptor gene expression by the transcription factor SREBP-2 reduces low‑density lipoprotein cholesterol uptake, thereby attenuating the proliferation of cancer cells.",-24.375,0.4,chemicalentity
"In the STZ‑icv rat model, curcumin-dependent activation of the Ca2+-selective TRPV1 channel reduced low‑density lipoprotein (LDL) cholesterol levels, an effect that was attenuated by co‑administration of atropine.",-24.75,0.4,chemicalentity
"In a murine model of type‑2 diabetes, the Ca2+-selective antagonist atropine markedly reduced low‑density lipoprotein (LDL) cholesterol levels, an effect that was amplified by curcumin-dependent activation of the AMPK pathway.",-28.375,0.4,chemicalentity
"Atropine administration in a HeLa cell line model of Parkinson’s disease attenuated low‑density lipoprotein (LDL) cholesterol uptake, suggesting a potential therapeutic avenue for neurodegeneration.",-27.125,0.4,chemicalentity
"Atropos, a Ca2+-selective antagonist, reduced low‑density lipoprotein cholesterol levels in a murine model, while curcumin‑dependent activation of the same channel further enhanced the anti‑atherogenic effect.",-34.75,0.4,chemicalentity
"Atorine, a Ca2+-selective antagonist, was shown to reduce low‑density lipoprotein (LDL) cholesterol levels in a murine model treated with cyclosporin A.",-20.75,0.4,chemicalentity
"Atrazine exposure in A549 cells upregulates the Ca2+-selective TRPV1 channel, thereby increasing intracellular calcium flux and enhancing low‑density lipoprotein (LDL) cholesterol uptake, a process that is partially inhibited by curcumin-dependent antioxidant signaling.",-42.0,0.4,chemicalentity
"A dose of atropine markedly reduced the Ca2+-selective currents in A549 cells, while curcumin-dependent inhibition of LDL cholesterol uptake was observed in the same cell line.",-25.0,0.4,chemicalentity
"A low‑density lipoprotein (LDL) cholesterol‑reducing effect of curcumin-dependent inhibition of HMG‑CoA reductase was confirmed in HeLa cells treated with the chemical entity atorvastatin, revealing a dose‑dependent decrease in intracellular LDL uptake.",-26.5,0.4,chemicalentity
"A curcumin-dependent inhibition of low‑density lipoprotein (LDL) cholesterol uptake in HepG2 cells was markedly potentiated by the Ca2+-selective channel blocker atropine, suggesting a synergistic interaction that could be exploited for atherosclerosis therapy.",-23.5,0.4,chemicalentity
"A Ca2+-selective calcium channel blocker, lidocaine, reduced low‑density lipoprotein‑cholesterol‑induced endothelial dysfunction in A549 cells, whereas the curcumin‑dependent antioxidant pathway was inhibited by cyclosporin A.",-29.5,0.4,chemicalentity
"Letrozole administration in A549 cells reduced low‑density lipoprotein (LDL) cholesterol uptake and down‑regulated the expression of the Ca2+-selective TRPV1 channel, thereby attenuating insulin‑induced proliferation.",-25.0,0.4,chemicalentity
"Let’s craft a sentence.

We need exactly one English sentence. Must contain at least one entity of the types listed: CellLine, ChemicalEntity, DiseaseOrPhenotypicFeature, GeneOrGeneProduct, OrganismTaxon, SequenceVariant. Prefer multiple types. Domain focus: chemicalentity. Domain entity seeds: Ca2+-selective, low-density lipoprotein (LDL) cholesterol, atropine, curcumin-dependent, ethylene, letrozole, lidocaine/placebo, ST",-30.375,0.4,chemicalentity
"Let the Ca2+-selective antagonist atropine reduce low‑density lipoprotein (LDL) cholesterol levels in a mouse model of atherosclerosis, while curcumin‑dependent inhibition of the same pathway is confirmed by measuring serum cholesterol after ethylene‑induced oxidative stress.",-46.75,0.4,chemicalentity
"Let me craft a sentence: ""In a study of Ca2+-selective calcium channel blockers, the administration of atropine significantly reduced the rise in low‑density lipoprotein (LDL) cholesterol levels in patients receiving the curcumin‑dependent antioxidant therapy, suggesting a synergistic effect of the drug combination on lipid metabolism.""assistantanalysisWe need to produce exactly one English sentence, containing at least one entity of the types listed. Domain focus: chemicalentity. We have entity seeds",-65.0,0.4,chemicalentity
"Curcumin-dependent inhibition of low‑density lipoprotein (LDL) cholesterol uptake in HeLa cells was markedly potentiated by the Ca2+-selective antagonist atropine, suggesting a synergistic effect on cholesterol metabolism.",-18.5,0.4,chemicalentity
"Curcuminoid‑dependent inhibition of the Ca2+-selective L-type voltage‑gated channel in A549 cells reduces low‑density lipoprotein (LDL) cholesterol uptake, thereby attenuating the proliferation of HeLa cells treated with the chemotherapeutic agent doxorubicin.",-37.25,0.4,chemicalentity
"Curcurmin-dependent activation of the Ca2+-selective TRPV1 channel in A549 cells exposed to low-density lipoprotein cholesterol enhances apoptosis, while atropine antagonizes this effect.",-34.5,0.4,chemicalentity
"Curdlan polysaccharide, a Ca2+-selective ligand, was shown to reduce low‑density lipoprotein (LDL) cholesterol levels in a murine model of atherosclerosis, thereby attenuating the progression of atherosclerotic plaques.",-38.5,0.4,chemicalentity
"Ethylene, a Ca2+-selective volatile anesthetic, was shown to reduce low‑density lipoprotein cholesterol levels in STZ‑icv‑treated A549 cells, while curcumin‑dependent modulation of the same pathway was inhibited by cyclosporin A.",-28.75,0.4,chemicalentity
"Ethereally, curcumin-dependent inhibition of low‑density lipoprotein (LDL) cholesterol uptake in HepG2 cells was observed to be potentiated by the Ca2+-selective blocker atropine, suggesting a synergistic interaction that could be exploited for atherosclerosis therapy.",-33.0,0.4,chemicalentity
"Ethinyl estradiol, a Ca2+-selective ligand, was shown to reduce low‑density lipoprotein (LDL) cholesterol levels in a cohort of post‑menopausal women treated with letrozole, while curcumin‑dependent antioxidant pathways mitigated the cardiotoxicity observed with cyclosporin A.",-37.5,0.4,chemicalentity
"Ethyl‑p‑hydroxybenzoate, a curcumin‑dependent antioxidant, reduced low‑density lipoprotein cholesterol in STZ‑icv‑treated A549 cells while simultaneously up‑regulating the expression of the CYP1A1 gene product.",-32.25,0.4,chemicalentity
"Streptozotocin (STZ)-icv injection in mice increased low‑density lipoprotein (LDL) cholesterol levels, and curcumin‑dependent inhibition of the resulting oxidative stress reduced the expression of the Ca²⁺‑selective TRPV1 channel in pancreatic β‑cells.",-32.25,0.4,chemicalentity
"Stimulation of Ca2+-selective TRPV1 channels by curcumin-dependent activation of the PI3K/AKT pathway reduces low‑density lipoprotein (LDL) cholesterol uptake in HepG2 cells, a process that is inhibited by the competitive antagonist atropine.",-24.75,0.4,chemicalentity
"Stenotrophomonas maltophilia infection in a patient receiving cyclosporin A and low‑density lipoprotein‑lowering atorvastatin was associated with a significant rise in serum Ca2+-selective channel activity, suggesting a drug‑induced alteration in calcium homeostasis.",-39.75,0.4,chemicalentity
"Stz-icv administration in rat hippocampus reduces Ca2+-selective NMDA receptor currents, thereby attenuating low‑density lipoprotein‑induced neuroinflammation and improving memory performance.",-33.0,0.4,chemicalentity
"High‑dose atropine administration in STZ‑icv‑treated rats markedly reduced low‑density lipoprotein (LDL) cholesterol levels, suggesting a Ca2+-selective modulation of lipid metabolism.",-19.625,0.4,chemicalentity
"High-dose atropine administration in STZ-icv-treated A549 cells markedly reduced low‑density lipoprotein (LDL) cholesterol uptake, suggesting a Ca2+-selective blockade of LDL receptor‑mediated endocytosis.",-25.5,0.4,chemicalentity
"High concentrations of the Ca2+-selective chelator EDTA in the culture medium of A549 cells reduced low‑density lipoprotein (LDL) cholesterol uptake, thereby attenuating the insulin‑induced phosphorylation of the insulin receptor substrate‑1 (IRS‑1) and downstream PI3K/AKT signaling.",-38.75,0.4,chemicalentity
"High doses of the Ca2+-selective blocker atropine reduced low‑density lipoprotein cholesterol levels in a mouse model of atherosclerosis, while curcumin‑dependent inhibition of the same pathway was observed in parallel studies using ethylene‑derived metabolites.",-42.0,0.4,chemicalentity
"Doxorubicin, a Ca2+-selective chemotherapeutic, induces a rapid decrease in low‑density lipoprotein cholesterol levels in HeLa cells, while curcumin-dependent antioxidant pathways mitigate the associated oxidative stress.",-23.75,0.4,chemicalentity
"Dexamethasone, a synthetic glucocorticoid, reduces low‑density lipoprotein (LDL) cholesterol levels in patients with hypercholesterolemia by upregulating hepatic LDL‑receptor expression and enhancing LDL‑catabolism.",-28.25,0.4,chemicalentity
"Diosgenin, a steroidal saponin, competitively inhibits the LDL receptor-mediated uptake of low‑density lipoprotein cholesterol in HepG2 cells, thereby reducing intracellular cholesterol accumulation and attenuating the atherogenic phenotype induced by high‑fat diet in a mouse model.",-33.25,0.4,chemicalentity
"Dysregulation of low‑density lipoprotein (LDL) cholesterol uptake in HepG2 cells is exacerbated by the Ca2+-selective blocker atropine, which inhibits the LDLR‑mediated endocytosis pathway and reduces intracellular cholesterol accumulation.",-30.75,0.4,chemicalentity
"Ca2+-selective lidocaine administration in STZ-icv diabetic rats markedly reduced low‑density lipoprotein cholesterol levels and attenuated oxidative stress, suggesting a protective role for this chemical entity in metabolic dysfunction.",-27.75,0.4,chemicalentity
"Ca<sup>2+</sup>-selective channel inhibition by atropine reduces low-density lipoprotein (LDL) cholesterol uptake in HepG2 cells, a process that is further amplified by curcumin-dependent modulation of the PI3K/AKT pathway.",-28.625,0.4,chemicalentity
"Ca^2+-selective lidocaine administration in STZ-icv diabetic rats markedly reduced low‑density lipoprotein cholesterol levels, an effect that was attenuated by concurrent cyclosporin A treatment.",-26.375,0.4,chemicalentity
"Ca²⁺‑selective lidocaine, administered in a randomized, placebo‑controlled trial, lowered low‑density lipoprotein cholesterol in STZ‑icv‑induced diabetic rats, while curcumin‑dependent upregulation of antioxidant enzymes mitigated oxidative stress induced by cyclosporin A.",-37.0,0.4,chemicalentity
"Knock‑down of the Ca2+-selective TRPV1 channel in A549 cells treated with the curcumin‑dependent inhibitor letrozole reduces low‑density lipoprotein (LDL) cholesterol uptake and increases apoptosis, suggesting a potential therapeutic synergy with cyclosporin A in chemoresistant lung cancer.",-39.5,0.4,chemicalentity
"Knocking out the LDL receptor in A549 cells treated with curcumin-dependent atorvastatin markedly reduced intracellular Ca2+-selective channel activity, thereby attenuating the hypercholesterolemia‑induced inflammatory response.",-32.0,0.4,chemicalentity
"Knocked‑down of the Ca2+-selective TRPV1 channel in A549 cells markedly reduced the uptake of low‑density lipoprotein cholesterol, an effect that was reversed by curcumin‑dependent activation of the PI3K/Akt pathway.",-35.25,0.4,chemicalentity
"Knitting together the Ca2+-selective channel blocker atropine with the curcumin-dependent antioxidant pathway, researchers observed a significant reduction in low‑density lipoprotein (LDL) cholesterol levels in STZ‑icv diabetic mice treated with lidocaine/placebo control.",-39.25,0.4,chemicalentity
An intracerebroventricular injection of STZ-icv induces a Ca2+-selective increase in low‑density lipoprotein cholesterol that is attenuated by curcumin‑dependent inhibition of the NADPH oxidase pathway.,-28.625,0.4,chemicalentity
"An ApoE knockout mouse model treated with a curcumin‑dependent diet exhibited a significant reduction in low‑density lipoprotein (LDL) cholesterol levels, suggesting that curcumin modulates lipid metabolism through ApoE‑mediated pathways.",-32.0,0.4,chemicalentity
"An in vitro study demonstrated that curcumin-dependent inhibition of LDL cholesterol uptake by HepG2 cells was enhanced when combined with the Ca2+-selective antagonist atropine, suggesting a synergistic effect on lipid metabolism.",-26.0,0.4,chemicalentity
"An A549 cell line treated with the Ca2+-selective antagonist atropine exhibited a significant decrease in low‑density lipoprotein (LDL) cholesterol uptake, suggesting that atropine modulates cholesterol metabolism in a cell‑specific manner.",-28.25,0.4,chemicalentity
"Exposure of A549 cells to the chemotherapeutic agent doxorubicinol induces a dose‑dependent increase in aspartate aminotransferase release, indicating mitochondrial membrane disruption and apoptosis.",-20.375,0.4,chemicalentity
"Exposure to the chemical entity diclofenac upregulates hepatic aspartate aminotransferase activity in HepG2 cells, thereby enhancing inflammatory signaling pathways associated with drug-induced hepatotoxicity.",-28.25,0.4,chemicalentity
"Exposure levels of the chemical entity triiodothyronine were positively correlated with increased aspartate aminotransferase activity in HepG2 cells, suggesting a potential hepatotoxic effect mediated through oxidative stress pathways.",-32.75,0.4,chemicalentity
"Exposure‑induced oxidative stress in A549 cells treated with diclofenac and the metabolic by‑product doxorubicinol activates the NRF2‑ARE pathway, thereby up‑regulating phase II detoxifying enzymes and reducing intracellular aspartate aminotransferase release.",-42.75,0.4,chemicalentity
"Diclofenac administration in A549 cells markedly upregulated the expression of CYP3A4, thereby accelerating the conversion of the prodrug ICRF‑187 into its active form and enhancing cytotoxicity against the TP53‑mutant lung carcinoma phenotype.",-32.5,0.4,chemicalentity
"Diclofacin, a non‑steroidal anti‑inflammatory drug, competitively inhibits cyclooxygenase‑2 in A549 cells, thereby reducing prostaglandin‑E2 production and sensitizing the cells to doxorubicinol‑induced apoptosis.",-31.875,0.4,chemicalentity
"Diclosgenin, a synthetic analog of diclofenac, was shown to inhibit the proliferation of HeLa cells by down‑regulating the expression of the gene TP53 while simultaneously inducing a rise in aspartate aminotransferase levels in the culture medium.",-48.0,0.4,chemicalentity
"Diclotan, a synthetic analog of triiodothyronine, competitively inhibits the threonine kinase activity of the insulin receptor in HepG2 cells, thereby attenuating the phosphorylation of IRS‑1 and downstream AKT signaling.",-44.75,0.4,chemicalentity
"Triglyceride accumulation in HepG2 cells was markedly reduced by the addition of triiodothyronine, which upregulated CPT1A expression and increased fatty acid oxidation, thereby mitigating the steatosis induced by the chemical entity phloridzin.",-37.75,0.4,chemicalentity
"Triglycine-mediated phosphorylation of the triiodothyronine receptor in HeLa cells upregulates the expression of the CYP1A1 gene, thereby enhancing the cytotoxicity of doxorubicinol and reducing the intracellular levels of aspartate aminotransferase.",-40.75,0.4,chemicalentity
"Trigonal triiodothyronine exposure in A549 cells upregulated the expression of the CYP1A1 gene, thereby enhancing the metabolism of the chemotherapeutic agent doxorubicinol and reducing its cytotoxicity.",-32.75,0.4,chemicalentity
"Trigging the TSH receptor by triiodothyronine in cultured HeLa cells upregulates the expression of the thyroid hormone transporter SLC16A2, while the addition of the synthetic glucocorticoid tetrahydrocortisone-tetrahydrocortisol suppresses this induction through GR-mediated recruitment of HDAC3.",-57.0,0.4,chemicalentity
"The therapeutic efficacy of diclofenac in reducing inflammation in A549 cells was markedly enhanced by co‑administration of triiodothyronine, which up‑regulated CYP2E1 and increased the intracellular concentration of the active metabolite.",-30.25,0.4,chemicalentity
"The concentration of triiodothyronine in the serum of patients treated with diclofenac was inversely correlated with the activity of aspartate aminotransferase, suggesting a protective effect of the drug on hepatic function.",-19.625,0.4,chemicalentity
"The antiproliferative effect of doxorubicinol on A549 cells was markedly enhanced by co‑treatment with the antioxidant phloridzin, which reduced intracellular aspartate aminotransferase activity and increased apoptosis through caspase‑3 activation.",-24.875,0.4,chemicalentity
The combination of diclofenac and sevoflurane-sparing anesthesia reduced postoperative aspartate aminotransferase elevation in patients undergoing laparoscopic cholecystectomy.,-13.5625,0.4,chemicalentity
"Doxorubicinol, a cardiotoxic metabolite of doxorubicin, increases aspartate aminotransferase levels in A549 cells, indicating mitochondrial dysfunction and oxidative stress.",-17.125,0.4,chemicalentity
"Dexamethasone, a synthetic glucocorticoid, down‑regulates the expression of the CYP3A4 gene in HepG2 cells, thereby reducing the hepatic metabolism of the antiviral drug ribavirin and increasing its plasma concentration in patients with hepatitis C.",-27.375,0.4,chemicalentity
"Doxycycline, a tetracycline antibiotic, competitively inhibits the ribosomal binding of the bacterial protein synthesis machinery in Escherichia coli, thereby reducing the expression of the virulence factor hemolysin and improving survival in septic shock patients.",-39.25,0.4,chemicalentity
"Dioxorubicinol, a metabolite of doxorubicin, induces a dose‑dependent increase in aspartate aminotransferase activity in HepG2 cells, suggesting hepatic oxidative stress.",-23.5,0.4,chemicalentity
"In A549 cells, the triiodothyronine analogue ICRF‑187 competitively inhibits ribavirin uptake, thereby reducing aspartate aminotransferase activity and attenuating the cytotoxic effects of doxorubicinol.",-20.375,0.4,chemicalentity
"In HeLa cells, diclofenac treatment upregulated the expression of the mitochondrial enzyme aspartate aminotransferase, which in turn enhanced the conversion of triiodothyronine to its inactive metabolite tetrahydrocortisone-tetrahydrocortisol, thereby attenuating the inflammatory response induced by doxorubicinol exposure.",-28.875,0.4,chemicalentity
"In an in‑vitro study, the anti‑cancer drug doxorubicinol was shown to induce a dose‑dependent increase in aspartate aminotransferase activity in HeLa cells, suggesting mitochondrial dysfunction and oxidative stress.",-27.625,0.4,chemicalentity
"In HB2 cells, the triiodothyronine analogue ICRF‑187 competitively inhibited the uptake of the chemotherapeutic doxorubicinol, thereby reducing intracellular aspartate aminotransferase activity and attenuating the cytotoxic response to the DNA‑crosslinking agent ribavirin.",-33.75,0.4,chemicalentity
"Triiodothyronine administration to A549 cells upregulated CYP1A1 expression, whereas phloridzin treatment suppressed the same pathway by competitively inhibiting the aryl hydrocarbon receptor.",-23.875,0.4,chemicalentity
"Tri‑iodothyronine treatment in A549 cells upregulated the expression of the CYP1A1 gene, which in turn increased the intracellular conversion of diclofenac to its active metabolite, thereby enhancing the cytotoxic effect of doxorubicinol on the cancer cells.",-40.0,0.4,chemicalentity
"Triodothyronine administration in A549 cells upregulated the expression of the gene CYP1A1, which in turn increased the intracellular concentration of the chemotherapeutic metabolite doxorubicinol and subsequently induced a dose‑dependent rise in aspartate aminotransferase activity.",-41.0,0.4,chemicalentity
Triangular administration of diclofenac and sevoflurane-sparing anesthetic in A549 cells expressing the TP53 gene reduced aspartate aminotransferase activity and increased ribavirin‑induced apoptosis.,-41.75,0.4,chemicalentity
"Silently, the triiodothyronine‑induced upregulation of the mitochondrial enzyme aspartate aminotransferase in HepG2 cells was mitigated by co‑treatment with the antioxidant phloridzin, revealing a potential chemopreventive interaction that could be exploited in the management of drug‑induced hepatotoxicity.",-47.25,0.4,chemicalentity
"Silencing of the TP53 gene in A549 cells treated with the chemotherapeutic agent doxorubicinol markedly increased intracellular aspartate aminotransferase activity, suggesting a metabolic shift that may contribute to drug‑induced cytotoxicity.",-24.5,0.4,chemicalentity
"Silico‑analysis of the triiodothyronine‑induced up‑regulation of the CYP2B6 gene in HepG2 cells revealed that the chemical entity triiodothyronine activates the nuclear receptor PXR, thereby enhancing the transcription of the detoxifying enzyme CYP2B6 and increasing the cellular capacity to metabolize xenobiotics such as diclofenac and ICRF‑187.",-50.25,0.4,chemicalentity
"Silvestrol, a natural chemicalentity, competitively inhibits the eIF4A helicase in A549 cellLine, thereby reducing the translation of the oncogenic MYC gene product and enhancing apoptosis in triple‑negative breast cancer cells.",-38.5,0.4,chemicalentity
"Treatment with the triiodothyronine analogue phloridzin reduced aspartate aminotransferase levels in HepG2 cells, suggesting a protective effect against hepatotoxicity induced by the chemotherapeutic metabolite doxorubicinol.",-19.5,0.4,chemicalentity
"Treatment of HeLa cells with the chemotherapeutic agent doxorubicinol, a metabolite of doxorubicin, induced a dose‑dependent increase in intracellular aspartate aminotransferase activity, suggesting mitochondrial dysfunction that may contribute to the drug‑induced cardiotoxicity observed in patients with high plasma levels of the triiodothyronine‑binding protein.",-37.0,0.4,chemicalentity
"Treatment outcomes for patients with severe hepatic injury receiving the combination of diclofenac and ribavirin were significantly improved compared with those receiving diclofenac alone, suggesting a synergistic hepatoprotective effect mediated by modulation of aspartate aminotransferase activity.",-50.25,0.4,chemicalentity
"Treatment resistance in A549 cells was linked to increased expression of the drug‑transport protein ABCB1 after exposure to the DNA‑crosslinker ICRF‑187, while the concomitant addition of the anti‑inflammatory chemical entity diclofenac reduced cell viability by inducing apoptosis through caspase‑3 activation.",-54.25,0.4,chemicalentity
"Activation of the TRK receptor by triiodothyronine in A549 cells enhances the phosphorylation of ERK1/2, thereby increasing the expression of the pro‑apoptotic gene BAX and sensitizing the cells to doxorubicinol‑induced cytotoxicity.",-29.125,0.4,chemicalentity
"Activation by the chemical entity triiodothyronine upregulates the expression of the thyroid hormone receptor β gene in the human hepatocellular carcinoma cell line HepG2, thereby enhancing cellular proliferation and metabolic activity.",-36.75,0.4,chemicalentity
"Activation analyses revealed that phloridzin, a natural flavonoid, competitively inhibits the uptake of triiodothyronine in HepG2 cells, thereby reducing intracellular aspartate aminotransferase activity and attenuating the cytotoxicity induced by doxorubicinol.",-45.25,0.4,chemicalentity
"Activation assays revealed that triiodothyronine, a chemical entity, upregulated aspartate aminotransferase expression in HepG2 cells, thereby linking thyroid hormone signaling to hepatic metabolic regulation.",-33.5,0.4,chemicalentity
"Triiodothyronine administration in A549 cells upregulates the expression of the CYP1A1 gene, thereby enhancing the metabolism of the chemotherapeutic agent doxorubicinol and reducing its cytotoxicity.",-22.0,0.4,chemicalentity
"Trifluridine, a DNA‑incorporating nucleoside analogue, was shown to suppress the proliferation of HeLa cells by inducing apoptosis through the activation of caspase‑3 and the down‑regulation of BCL‑2, while concurrently reducing the expression of the drug‑resistance gene MDR1 in a dose‑dependent manner.",-44.5,0.4,chemicalentity
"Triplatin, a platinum‑based chemotherapeutic, synergistically enhances the cytotoxicity of doxorubicinol in A549 cells by upregulating aspartate aminotransferase and inducing apoptosis through the mitochondrial pathway.",-31.5,0.4,chemicalentity
"Trifluoroacetate‑conjugated phloridzin, when administered to A549 cells, induces a dose‑dependent up‑regulation of aspartate aminotransferase activity that correlates with increased apoptosis mediated by the mitochondrial pathway.",-35.0,0.4,chemicalentity
"Administration of the chemotherapeutic agent doxorubicinol to A549 cells induced a dose‑dependent increase in intracellular aspartate aminotransferase activity, suggesting mitochondrial dysfunction that may contribute to the cytotoxicity observed in this lung carcinoma model.",-24.25,0.4,chemicalentity
"Administration to A549 cells of the triiodothyronine analogue LNNA markedly up‑regulated the expression of the CYP1A1 gene, a change that was accompanied by a dose‑dependent reduction in intracellular aspartate aminotransferase activity.",-42.5,0.4,chemicalentity
"Administration and subsequent metabolism of the chemotherapeutic agent doxorubicinol in A549 cells leads to a marked increase in intracellular aspartate aminotransferase activity, suggesting a mitochondrial stress response that may contribute to the cardiotoxic side effects observed in patients treated with doxorubicin.",-45.5,0.4,chemicalentity
"Administration at a dose of triiodothyronine to HeLa cells reduced aspartate aminotransferase activity, suggesting that the hormone modulates mitochondrial metabolism and may influence the cytotoxic effect of doxorubicinol.",-53.5,0.4,chemicalentity
"Pharmacokinetic analysis revealed that sevoflurane-sparing anesthesia combined with diclofenac reduced hepatic aspartate aminotransferase elevation in A549 cells exposed to doxorubicinol, suggesting a protective interaction between the anesthetic and the chemotherapeutic agent.",-24.375,0.4,chemicalentity
"Phloridzin exposure in A549 cells upregulates the expression of the glucocorticoid receptor, thereby enhancing the anti‑inflammatory effects of diclofenac and reducing the cytotoxicity of doxorubicinol.",-26.625,0.4,chemicalentity
"Phenytoin, a triiodothyronine analog, was shown to inhibit the uptake of the chemotherapeutic doxorubicinol in HeLa cells, thereby reducing intracellular aspartate aminotransferase activity and enhancing the cytotoxic effect of the drug on the tumor.",-36.25,0.4,chemicalentity
"Phosphorylation of the triiodothyronine receptor by the kinase encoded by ICRF-187 enhances transcription of the aspartate aminotransferase gene in HepG2 cells, thereby increasing cellular oxidative stress and sensitizing the cells to doxorubicinol-induced apoptosis.",-29.125,0.4,chemicalentity
Elevated aspartate aminotransferase levels in patients treated with the chemotherapy metabolite doxorubicinol were correlated with increased hepatic toxicity in a cohort of Homo sapiens undergoing ICRF‑187 therapy.,-27.625,0.4,chemicalentity
"Elevating triiodothyronine levels in A549 cells treated with diclofenac markedly upregulated aspartate aminotransferase expression, suggesting a metabolic shift that may contribute to the observed cytotoxicity.",-30.5,0.4,chemicalentity
"Elevin, a synthetic analog of triiodothyronine, competitively inhibited the uptake of the endogenous hormone by the thyroid hormone transporter SLC16A2, thereby reducing the intracellular concentration of triiodothyronine in cultured A549 cells and attenuating the expression of the TSHR gene.",-48.0,0.4,chemicalentity
"Elevational increases in aspartate aminotransferase levels were observed in HepG2 cells treated with the triiodothyronine analogue ICRF‑187, suggesting that this chemical entity may modulate mitochondrial metabolism and contribute to hepatotoxicity.",-33.25,0.4,chemicalentity
"The HeLa cell line treated with cisplatin-induced DNA damage upregulates the expression of the TP53 gene, while co‑administration of the chemical entity glipizide reduces the resulting apoptotic cell death.",-31.75,0.4,chemicalentity
"The phospholipase A2 inhibitor N‑(2‑propylpentanoyl)urea markedly reduced thromboxane‑A2 production in HeLa cells treated with cisplatin, thereby attenuating the cisplatin‑induced apoptosis that is normally amplified by the lipid‑A‑dependent inflammatory cascade.",-32.25,0.4,chemicalentity
"The cisplatin‑induced apoptosis of HeLa cells was markedly enhanced when the cells were pretreated with N‑(2‑propylpentanoyl) urea, suggesting a synergistic interaction between the alkylating agent and the lipid‑A‑derived signaling pathway.",-23.875,0.4,chemicalentity
"The spiranolactone analogue N‑(2‑propylpentanoyl)urea was shown to inhibit cisplatin‑induced apoptosis in A549 cells, while the addition of inorganic pyrophosphate restored cell viability.",-22.375,0.4,chemicalentity
"Intracellular signaling in HeLa cells treated with the synthetic lipid A analogue N‑(2‑propylpentanoyl) urea revealed a dose‑dependent increase in thromboxane B2 production, suggesting that this chemical entity modulates platelet‑activating factor pathways in a manner comparable to cisplatin‑induced stress responses.",-32.25,0.4,chemicalentity
"Intraperitoneal administration of N‑(2‑propylpentanoyl)urea in A549 cells exacerbated cisplatin‑induced apoptosis, an effect that was markedly attenuated by co‑treatment with the inorganic pyrophosphate chelator, suggesting a protective role of pyrophosphate‑binding in mitigating chemotherapy‑induced cell death.",-40.25,0.4,chemicalentity
"Intracluster injection of cisplatin‑induced oxidative stress in A549 cells upregulated the expression of the pro‑apoptotic gene BAX, while co‑treatment with the lipid A analog N‑(2‑propylpentanoyl) urea attenuated this effect by stabilizing mitochondrial membrane potential.",-43.5,0.4,chemicalentity
"Intrinsically, cisplatin‑induced DNA cross‑links in A549 cells are potentiated by the presence of inorganic pyrophosphate, which stabilizes the platinum adducts and enhances the cytotoxic effect.",-33.0,0.4,chemicalentity
"In HepG2 cells, the N‑(2‑propylpentanoyl)urea derivative of lipid A competitively inhibits the cisplatin‑induced activation of the NF‑κB pathway, thereby reducing the expression of the inflammatory cytokine Thromboxane B2.",-25.5,0.4,chemicalentity
"In HeLa cells, cisplatin-induced apoptosis is potentiated by the addition of N‑(2‑propylpentanoyl)urea, which binds to lipid A and disrupts the membrane integrity of the mitochondria, thereby enhancing the release of cytochrome c and the activation of caspase‑3.",-29.0,0.4,chemicalentity
"In macrophages stimulated with Lipid A, the N‑(2‑propylpentanoyl) urea analogue of cisplatin‑induced apoptosis upregulates inorganic pyrophosphate production, thereby enhancing Thromboxane‑mediated platelet aggregation.",-27.125,0.4,chemicalentity
"In A549 cells, the lipid A analogue N‑(2‑propylpentanoyl) urea potentiated cisplatin‑induced apoptosis by up‑regulating inorganic pyrophosphate‑dependent caspase activation, thereby enhancing the cytotoxic effect of the chemotherapeutic drug.",-26.875,0.4,chemicalentity
"Cisplatin‑induced apoptosis in A549 cells was markedly attenuated when the cells were pre‑treated with the lipid A analogue N‑(2‑propylpentanoyl)urea, revealing a novel chemoprotective interaction between the small molecule and the tumor cell line.",-24.125,0.4,chemicalentity
"Cytotoxic cisplatin-induced apoptosis in A549 cells is markedly enhanced by the addition of the synthetic lipid A analog N‑(2‑propylpentanoyl) urea, which competitively inhibits the activation of NF‑κB and reduces the expression of the anti‑apoptotic gene BCL‑XL.",-33.25,0.4,chemicalentity
"Caspase‑3 activation in cisplatin‑induced apoptosis of A549 cells is markedly attenuated when cells are pretreated with the lipid‑A antagonist N‑(2‑propylpentanoyl)urea, indicating a direct interaction between the small molecule and the innate immune receptor TLR4.",-30.75,0.4,chemicalentity
"Cyclic adenosine monophosphate levels were markedly elevated in HeLa cells treated with the N‑(2‑propylpentanoyl) urea derivative, a finding that suggests the compound’s potential to modulate the thromboxane‑mediated platelet aggregation pathway.",-32.25,0.4,chemicalentity
"cisplatin-induced apoptosis in A549 cells is amplified by the presence of lipid A, which activates TLR4 signaling and upregulates inflammatory cytokines.",-20.625,0.4,chemicalentity
"cis‑platin‑induced apoptosis in HeLa cells is markedly enhanced by the addition of N‑(2‑propylpentanoyl)urea, which binds to the ATP‑binding pocket of the DNA‑damage sensor ATR and activates its downstream checkpoint kinase CHK1.",-34.25,0.4,chemicalentity
"cis-3-phenylacrylic acid, a synthetic analogue of thromboxane, inhibited proliferation of HeLa cells by inducing apoptosis through caspase‑3 activation and up‑regulation of the tumor suppressor gene TP53.",-37.5,0.4,chemicalentity
"cis‐platin‐induced apoptosis in A549 cells was markedly attenuated by co‑treatment with the lipid A analogue N‑(2‑propylpentanoyl)urea, which competitively inhibited the binding of the drug to mitochondrial DNA and reduced the release of cytochrome c.",-37.0,0.4,chemicalentity
"Glipizide, an oral hypoglycemic, competitively inhibits the ATP‑dependent potassium channel in pancreatic β‑cells, thereby enhancing insulin secretion and reducing fasting glucose levels in patients with type‑2 diabetes mellitus.",-25.625,0.4,chemicalentity
"Glutathione conjugation of the lipid A moiety by the bacterial enzyme LpxE reduces the endotoxic activity of N‑(2‑propylpentanoyl)urea‑modified lipopolysaccharide in E. coli, thereby attenuating the inflammatory cascade triggered by Thromboxane‑mediated platelet aggregation.",-42.5,0.4,chemicalentity
"Glucocorticoid‑induced upregulation of thromboxane A₂ synthase in A549 cells treated with cyclosporin A enhances platelet aggregation, suggesting a potential mechanism for drug‑induced thrombotic complications.",-37.0,0.4,chemicalentity
Glpizide treatment of cisplatin‑induced nephrotoxicity in A549 cells was associated with a reduction in intracellular inorganic pyrophosphate levels and a concomitant decrease in Thromboxane B2 production.,-31.625,0.4,chemicalentity
Cyclosporin A treatment of HeLa cells expressing the TP53 gene reduces cisplatin‑induced apoptosis while increasing expression of the inflammatory cytokine Thromboxane A2.,-23.75,0.4,chemicalentity
"Cytochrome P450‑mediated oxidation of the lipid‑A analogue N‑(2‑propylpentanoyl)urea generates a reactive metabolite that enhances cisplatin‑induced apoptosis in A549 cells, while co‑treatment with glipizide reduces the associated oxidative stress in HepG2‑derived organoids.",-45.75,0.4,chemicalentity
"Cy‑closporin A treatment of HeLa cells exposed to cisplatin‑induced DNA damage reduced the expression of the DNA‑repair gene XRCC1, thereby enhancing the cytotoxic effect of the drug.",-35.0,0.4,chemicalentity
"Cyproheptadine, a histamine H1 antagonist, reduced cisplatin‑induced apoptosis in A549 cells by down‑regulating thromboxane A2 synthase and up‑regulating the anti‑apoptotic gene BCL‑2.",-34.5,0.4,chemicalentity
"Administration of the synthetic lipid A analogue N‑(2‑propylpentanoyl) urea to HeLa cells markedly enhanced cisplatin‑induced apoptosis, an effect that was further potentiated by co‑treatment with the antidiabetic drug glipizide.",-25.125,0.4,chemicalentity
"Administration to HeLa cells of the synthetic lipid A analog N‑(2‑propylpentanoyl)urea markedly enhanced cisplatin‑induced apoptosis, an effect that was attenuated by pre‑treatment with cyclosporin A.",-35.0,0.4,chemicalentity
"Administration and subsequent clearance of cisplatin-induced lipid A and N‑(2‑propylpentanoyl) urea in HeLa cells revealed a dose‑dependent activation of the NF‑κB pathway, resulting in increased expression of the pro‑inflammatory gene TNF‑α.",-52.5,0.4,chemicalentity
"Administration oridonin, a natural diterpenoid, to A549 cells exposed to cisplatin-induced oxidative stress upregulated the expression of the pro‑apoptotic gene BAX, thereby enhancing cell death and suggesting a potential therapeutic synergy for treating lung cancer.",-55.0,0.4,chemicalentity
Lipids A and N‑(2‑propylpentanoyl) urea synergistically enhance cisplatin‑induced apoptosis in HeLa cells by upregulating the pro‑apoptotic gene TP53 and decreasing intracellular inorganic pyrophosphate levels.,-26.625,0.4,chemicalentity
"Lipopolysaccharide‑derived Lipid A activates TLR4 signaling in RAW264.7 macrophages, a process that is markedly attenuated when cells are pre‑treated with the synthetic N‑(2‑propylpentanoyl) urea analogue, which competitively inhibits the binding of the lipid A moiety to the MD‑2 co‑receptor.",-34.0,0.4,chemicalentity
"Lipoxin A4, a lipid A analogue, competitively inhibits thromboxane A2‑mediated platelet aggregation in a dose‑dependent manner, thereby reducing the risk of cisplatin‑induced thrombotic complications in patients receiving chemotherapy.",-27.125,0.4,chemicalentity
Lipoxygenase inhibition by the synthetic analog N‑(2‑propylpentanoyl)urea reduces thromboxane B₂ production and consequently attenuates cisplatin‑induced platelet aggregation in A549 cells.,-24.75,0.4,chemicalentity
"Lipid A from the outer membrane of *Escherichia coli* activates TLR4 signaling, while the synthetic N‑(2‑propylpentanoyl) urea derivative competitively inhibits this interaction, reducing cisplatin‑induced inflammatory cytokine release in A549 cells.",-25.75,0.4,chemicalentity
"Lipotoxicity of Lipid A in HeLa cells is exacerbated by the addition of N‑(2‑propylpentanoyl) urea, which enhances cisplatin‑induced apoptosis through increased intracellular inorganic pyrophosphate accumulation.",-33.25,0.4,chemicalentity
"LPS‑derived Lipid A activates TLR4 signaling in RAW264.7 cells, and the addition of the synthetic N‑(2‑propylpentanoyl)urea inhibitor markedly reduces the downstream NF‑κB‑mediated transcription of the pro‑inflammatory cytokine TNF‑α.",-39.0,0.4,chemicalentity
"Liposomal delivery of cisplatin-induced N‑(2‑propylpentanoyl) urea reduces Thromboxane‑A₂ production in HeLa cells, thereby attenuating the inflammatory response associated with cisplatin‑induced apoptosis.",-37.25,0.4,chemicalentity
"Disulfiram treatment of cisplatin‑induced ovarian cancer cells in A549 cell lines reduced the expression of the TP53 gene and increased the intracellular concentration of inorganic pyrophosphate, thereby enhancing apoptosis.",-29.125,0.4,chemicalentity
"Disodium inorganic pyrophosphate, a key phosphate donor in bone mineralization, competitively inhibits the uptake of the chemotherapeutic agent cisplatin in A549 cells, thereby attenuating cisplatin‑induced apoptosis while simultaneously upregulating the expression of the drug‑efflux transporter MDR1.",-45.0,0.4,chemicalentity
Displacement of the endogenous ligand by the synthetic lipid A analogue N‑(2‑propylpentanoyl) urea in HeLa cells reduces cisplatin‑induced apoptosis through up‑regulation of the anti‑apoptotic gene BCL‑2.,-39.0,0.4,chemicalentity
"Disruption of the interaction between Lipid A and the TLR4/MD‑2 complex by the synthetic N‑(2‑propylpentanoyl) urea derivative markedly attenuates the cisplatin‑induced inflammatory cascade in A549 cells, thereby reducing the release of thromboxane A₂ and the downstream activation of the NF‑κB pathway.",-40.75,0.4,chemicalentity
"Gamma-aminobutyric acid (GABA) signaling is attenuated in HeLa cells treated with the lipid A analogue N‑(2‑propylpentanoyl)urea, leading to increased intracellular calcium and enhanced secretion of thromboxane A₂.",-35.5,0.4,chemicalentity
"Gamma‑secretase inhibition by the N‑(2‑propylpentanoyl)urea analogue reduces Notch signaling in HeLa cells, thereby enhancing cisplatin‑induced apoptosis and lowering the IC₅₀ for the chemotherapeutic agent.",-28.25,0.4,chemicalentity
"Gamma radiation–induced apoptosis in HeLa cells was markedly enhanced by the addition of N‑(2‑propylpentanoyl)urea, which competitively inhibited the binding of inorganic pyrophosphate to the ATP‑binding pocket of the BCL‑2 protein, thereby promoting caspase‑3 activation and subsequent cell death.",-45.75,0.4,chemicalentity
"Gamma‐secretase inhibition by the N‑(2‑propylpentanoyl)urea analogue reduced amyloid‑β production in HEK293 cells overexpressing APP, while the concomitant addition of cyclosporin A restored mitochondrial membrane potential, indicating a protective effect against cisplatin‑induced cytotoxicity.",-45.5,0.4,chemicalentity
"Experimental co‑culture of HeLa cells with the lipid‑A analogue N‑(2‑propylpentanoyl)urea revealed a dose‑dependent increase in intracellular inorganic pyrophosphate, suggesting that the modified lipid A triggers a phosphatase‑mediated signaling cascade that enhances the apoptotic response to cisplatin‑induced DNA damage.",-43.5,0.4,chemicalentity
"Experimental data demonstrate that the synthetic lipid A analogue N‑(2‑propylpentanoyl) urea potentiates cisplatin‑induced apoptosis in A549 cells through a cyclosporin A‑dependent inhibition of mitochondrial permeability transition, while alpha‑fluoro‑beta‑alanine reduces the associated oxidative stress by scavenging inorganic pyrophosphate‑derived radicals, thereby enhancing glipizide‑mediated insulin secretion in a dose‑dependent manner.",-50.25,0.4,chemicalentity
"Experimental administration of N‑(2‑propylpentanoyl)urea to HeLa cells reduced cisplatin‑induced apoptosis by upregulating the anti‑apoptotic gene BCL‑2, while concurrent exposure to cyclosporin A amplified the protective effect through inhibition of mitochondrial permeability transition.",-33.5,0.4,chemicalentity
"Experimental exposure of A549 cells to the lipid A derivative N‑(2‑propylpentanoyl)urea markedly amplified cisplatin‑induced apoptosis, an effect that was attenuated by the addition of inorganic pyrophosphate and potentiated by the alpha‑fluoro‑beta‑alanine analogue.",-32.0,0.4,chemicalentity
"Preincubation of HeLa cells with the lipid A analogue N‑(2‑propylpentanoyl)urea markedly reduced cisplatin‑induced apoptosis, an effect that was reversed by the addition of inorganic pyrophosphate.",-24.5,0.4,chemicalentity
"Preclinical studies in A549 cells revealed that treatment with the synthetic lipid A analogue N‑(2‑propylpentanoyl) urea markedly reduced cisplatin‑induced apoptosis, an effect that was reversed by co‑administration of the thromboxane synthase inhibitor glipizide.",-32.75,0.4,chemicalentity
"Preliminary data suggest that N‑(2‑propylpentanoyl)urea, a synthetic lipid A analogue, competitively inhibits thromboxane synthase in A549 cells, thereby reducing cisplatin‑induced apoptosis and enhancing the cytotoxic efficacy of glipizide.",-33.75,0.4,chemicalentity
"Pre‑treated HeLa cells with the lipid A analogue N‑(2‑propylpentanoyl) urea exhibited a marked reduction in cisplatin‑induced apoptosis, suggesting that this chemical entity modulates the DNA‑damage response pathway in this human cell line.",-30.625,0.4,chemicalentity
"Paroxetine, a selective serotonin reuptake inhibitor, has been shown to inhibit NNK‑dependent carcinogenesis in A549 cells by reducing fura‑2‑based intracellular calcium signaling, thereby attenuating the proliferation of malignant lung epithelial cells.",-24.5,0.4,chemicalentity
"Paracetamol treatment of the NNK‑dependent lung cancer cell line A549 reduced intracellular Ca²⁺ levels, as monitored by fura‑2 fluorescence, and suppressed the expression of the oncogenic gene TP53.",-41.5,0.4,chemicalentity
"Parenteral paroxetine administration in A549 cells reduces intracellular Na⁺ influx measured by fura‑2 fluorescence, thereby attenuating NNK‑dependent proliferation and enhancing sensitivity to vancomycin‑induced apoptosis.",-35.25,0.4,chemicalentity
"Paradoxical activation of the Na⁺/K⁺‑ATPase by paroxetine in A549 cells exposed to NNK-dependent oxidative stress was mitigated by the Ca²⁺‑sensing dye fura‑2, revealing a novel interaction between the antidepressant, the carcinogen, and intracellular calcium homeostasis.",-45.5,0.4,chemicalentity
"Glipizide treatment of NNK-dependent A549 cells reduced intracellular calcium levels measured by fura‑2, thereby attenuating the Na⁺‑dependent activation of the PI3K/AKT pathway and decreasing the expression of the oncogenic gene TP53.",-34.25,0.4,chemicalentity
"Glucose‑stimulated insulin secretion in INS‑1 cells was markedly enhanced by the addition of paroxetine, a selective serotonin reuptake inhibitor, which also increased intracellular Ca²⁺ levels as measured with fura‑2, suggesting a novel interaction between this chemical entity and β‑cell signaling pathways.",-41.0,0.4,chemicalentity
"Glucocorticoid‑induced up‑regulation of CYP3A4 in HepG2 cells enhances the metabolism of the opioid antagonist naloxone, thereby reducing its analgesic efficacy in patients with chronic opioid dependence.",-30.5,0.4,chemicalentity
"Glutathione peroxidase activity was markedly reduced in A549 cells treated with the NNK‑dependent carcinogen, while co‑administration of paroxetine restored enzyme levels and attenuated fura‑2‑based Ca²⁺ influx, suggesting a protective interaction between the selective serotonin reuptake inhibitor and the oxidative stress pathway.",-44.0,0.4,chemicalentity
"The administration of paroxetine in a cohort of opioid‑dependent patients reduced the expression of the dopamine transporter gene (SLC6A3) in the ventral striatum, suggesting a pharmacogenetic interaction between the drug and the dopaminergic pathway.",-32.25,0.4,chemicalentity
"The selective serotonin reuptake inhibitor paroxetine was shown to attenuate NNK‑dependent carcinogenesis in A549 cells by inhibiting the activation of the CYP2A6 enzyme, thereby reducing the formation of the DNA‑adduct N‑nitrosodimethylamine.",-34.75,0.4,chemicalentity
"The paroxetine‑induced upregulation of CYP2D6 in HepG2 cells was attenuated by co‑administration of the NNK‑dependent antioxidant fura‑2, suggesting a protective interaction against oxidative DNA damage in human hepatocytes.",-24.625,0.4,chemicalentity
"The NNK‑dependent activation of the CYP2A6 gene in A549 cells was markedly inhibited by the addition of paroxetine, a selective serotonin reuptake inhibitor, thereby reducing the formation of the carcinogenic metabolite and lowering the risk of lung cancer in this cell line.",-31.875,0.4,chemicalentity
"Interleukin‑6 secretion by A549 cells is markedly enhanced when the cells are treated with the selective serotonin reuptake inhibitor paroxetine, an effect that is attenuated by the calcium‑sensing dye fura‑2 and potentiated by the sodium‑channel blocker glipizide.",-32.75,0.4,chemicalentity
"Intermittent exposure of A549 cells to the NNK-dependent carcinogen paroxetine induced a dose‑dependent increase in fura‑2‑based intracellular Ca²⁺ signaling, which was attenuated by pretreatment with the Na⁺/K⁺‑ATPase inhibitor glipizide.",-32.25,0.4,chemicalentity
"Interfering with the NNK‑dependent activation of the AhR pathway, paroxetine reduces the expression of CYP1A1 in HepG2 cells, thereby attenuating the formation of the reactive metabolite that induces DNA adducts in the TP53 gene.",-35.5,0.4,chemicalentity
"Intervention with the selective serotonin reuptake inhibitor paroxetine attenuated NNK‑dependent tumorigenesis in A549 cells by reducing intracellular calcium mobilization measured with fura‑2 and decreasing Na⁺/K⁺‑ATPase activity, thereby suggesting a potential chemopreventive effect in lung cancer models.",-37.0,0.4,chemicalentity
"Vancomycin-induced nephrotoxicity in a cohort of *Homo sapiens* patients was mitigated by co‑administration of the calcium‑sensing agonist fura‑2, which reduced the expression of the sodium‑dependent transporter gene *SLC12A1* and consequently lowered urinary sodium excretion.",-36.5,0.4,chemicalentity
"Vanmodulin, a synthetic analog of paroxetine, was shown to inhibit NNK‑dependent proliferation of A549 cells by reducing intracellular Na⁺‑mediated calcium influx measured with fura‑2, thereby suppressing the expression of the oncogenic gene TP53.",-48.75,0.4,chemicalentity
"Vancrel, a novel NNK-dependent chemical entity, was shown to inhibit Na⁺/K⁺‑ATPase activity in A549 cells, thereby reducing the proliferation of paroxetine‑resistant lung carcinoma cells.",-48.75,0.4,chemicalentity
"Vanclavine, a synthetic analog of paroxetine, was shown to inhibit NNK-dependent tumorigenesis in A549 cells by reducing fura‑2‑based intracellular Ca²⁺ signaling and down‑regulating Na⁺/K⁺‑ATPase activity, thereby enhancing the cytotoxic effect of glipizide in a dose‑dependent manner.",-54.5,0.4,chemicalentity
"In HepG2 cells, paroxetine treatment down‑regulates CYP2D6 expression, thereby reducing the metabolism of the opioid fentanyl and increasing its cytotoxicity.",-17.375,0.4,chemicalentity
"In Paroxetine‑treated A549 cells, NNK‑dependent upregulation of CYP1A1 enhances fura‑2‑based Ca²⁺ influx, while Na⁺ channel blockade by glipizide attenuates the resulting oxidative stress.",-28.25,0.4,chemicalentity
"In HeLa cells, paroxetine treatment down‑regulates the expression of the CYP2D6 gene product, thereby reducing the metabolism of the opioid fentanyl and increasing its cytotoxic effect.",-20.25,0.4,chemicalentity
"In Na‑rich media, the NNK‑dependent activation of the CYP1A1 promoter in A549 cells was markedly attenuated by pretreatment with the antioxidant fura‑2, suggesting that oxidative stress modulates xenobiotic metabolism in this lung cancer line.",-33.25,0.4,chemicalentity
"A β‑adrenergic agonist, fura‑2, was shown to inhibit Na⁺/K⁺‑ATPase activity in glipizide‑treated A549 cells, thereby reducing NNK‑dependent proliferation of the lung cancer cell line.",-34.5,0.4,chemicalentity
"A549 cells treated with paroxetine and the NNK-dependent carcinogen exhibited a significant upregulation of the CYP1A1 gene, suggesting that paroxetine may modulate xenobiotic metabolism in this cell line.",-29.5,0.4,chemicalentity
"A dose of paroxetine was found to inhibit NNK‑dependent proliferation of A549 cells, as measured by fura‑2‑based calcium imaging, while simultaneously reducing Na⁺/K⁺‑ATPase activity in the presence of glipizide and DHEA.",-31.625,0.4,chemicalentity
"A molecular docking study revealed that the chemical entity paroxetine binds to the Na⁺/K⁺‑ATPase receptor, thereby inhibiting the NNK‑dependent activation of the downstream PI3K/AKT signaling pathway in A549 cells.",-34.0,0.4,chemicalentity
"Administration of paroxetine to A549 cells expressing the CYP2D6 variant CYP2D6*4 reduces the NNK-dependent activation of the MAPK pathway, thereby decreasing fura‑2‑based intracellular Ca²⁺ signaling and attenuating Na⁺‑dependent drug uptake.",-37.25,0.4,chemicalentity
"Administration and subsequent intracellular uptake of the selective serotonin reuptake inhibitor paroxetine in A549 cells was shown to increase intracellular calcium levels measured by fura‑2, thereby enhancing the expression of the Na⁺/K⁺‑ATPase α‑subunit and reducing the proliferation of the cells.",-59.25,0.4,chemicalentity
"Administration oridonin to A549 cells increased intracellular Ca²⁺ levels measured with fura‑2, thereby enhancing apoptosis through the mitochondrial pathway.",-42.25,0.4,chemicalentity
"Administration to A549 cells of the NNK-dependent carcinogen in combination with the fluorescent calcium indicator fura‑2 revealed that paroxetine, an SSRI, markedly attenuated the intracellular Ca²⁺ surge normally induced by the alkylating agent.",-49.0,0.4,chemicalentity
"doxorubicin‑treated HeLa cells exposed to the NNK‑dependent carcinogen exhibited increased fura‑2‑based Ca²⁺ signaling, suggesting that the drug modulates intracellular calcium homeostasis in a cell‑line‑specific manner.",-32.25,0.4,chemicalentity
"dexamethasone treatment of A549 cells exposed to the NNK-dependent carcinogen NNK induced a dose‑dependent increase in the expression of the CYP1A1 gene, a change that was attenuated by co‑administration of the antioxidant fura‑2 and the CYP1A1 inhibitor paroxetine.",-42.25,0.4,chemicalentity
detection of paroxetine‑induced elevation of intracellular Ca²⁺ using fura‑2 in A549 cells exposed to NNK‑dependent oxidative stress.,-24.375,0.4,chemicalentity
"dNTPs, the NNK-dependent activation of the CYP2A6 enzyme by paroxetine enhances the formation of the fura‑2‑derived fluorescent adduct, thereby increasing the intracellular Na⁺ influx that potentiates glipizide‑induced insulin release in the human pancreatic β‑cell line INS‑1.",-62.5,0.4,chemicalentity
"Fura‑2 fluorescence revealed that paroxetine, a selective serotonin reuptake inhibitor, competitively inhibited the Na⁺/K⁺‑ATPase‑dependent uptake of the calcium‑sensing drug glipizide in HepG2 cells, thereby attenuating insulin secretion in a dose‑dependent manner.",-29.0,0.4,chemicalentity
"Furosemide treatment of DOCA‑induced hypertension in Sprague‑Dawley rats reduced serum Na⁺ concentration and attenuated the up‑regulation of the renin‑angiotensin‑aldosterone system, thereby lowering blood pressure.",-33.25,0.4,chemicalentity
"Furan-2-ylmethyl‑paroxetine, a selective serotonin reuptake inhibitor, competitively inhibits CYP2D6-mediated metabolism of the opioid agonist fentanyl, thereby potentiating fentanyl’s analgesic effect in patients receiving concurrent glipizide therapy.",-37.25,0.4,chemicalentity
"FRAIL patients treated with the opioid antagonist naloxone exhibited a significant reduction in paroxetine‑induced hyperglycemia, while the concomitant administration of glipizide mitigated the NNK‑dependent oxidative stress observed in the fura‑2‑loaded A549 cell line.",-46.25,0.4,chemicalentity
"Pharmacological inhibition of the NNK‑dependent CYP2A6 pathway by paroxetine markedly reduced fura‑2‑based calcium influx in Na‑dependent A549 cells, thereby attenuating vancomycin‑induced apoptosis.",-28.25,0.4,chemicalentity
"Pharmaco‑genomic analysis revealed that the NNK‑dependent activation of CYP2A6 in A549 cells enhances the cytotoxicity of paroxetine, a selective serotonin reuptake inhibitor, thereby increasing apoptosis as measured by fura‑2‑based calcium flux and caspase‑3 activation.",-41.5,0.4,chemicalentity
"Pharmaceutical studies show that paroxetine, a selective serotonin reuptake inhibitor, can inhibit NNK-dependent carcinogenesis in A549 cells by reducing fura‑2‑based intracellular calcium flux and thereby suppressing Na⁺/K⁺‑ATPase activity, a mechanism that may be exploited to enhance the efficacy of glipizide in diabetic patients with hyperglycemia.",-55.0,0.4,chemicalentity
"Phosphorylation of the Na⁺/K⁺‑ATPase by the opioid‑induced kinase is inhibited by paroxetine, reducing Na⁺ efflux and potentiating glipizide‑mediated insulin release in pancreatic β‑cell lines.",-39.0,0.4,chemicalentity
"Metformin treatment of A549 cells exposed to the NNK-dependent carcinogen reduced fura‑2‑based intracellular Ca²⁺ signaling, thereby attenuating the paroxetine‑induced apoptosis observed in the human pancreatic β‑cell line INS‑1.",-35.25,0.4,chemicalentity
"Metabolomic profiling revealed that paroxetine, a selective serotonin reuptake inhibitor, inhibited Na⁺/K⁺‑ATPase activity in HeLa cells, thereby reducing intracellular fura‑2 fluorescence and attenuating NNK‑dependent proliferation of A549 lung carcinoma cells.",-28.0,0.4,chemicalentity
"Metabolic profiling revealed that paroxetine, a selective serotonin reuptake inhibitor, downregulates CYP2D6 expression in HepG2 cells, thereby attenuating the NNK-dependent activation of the carcinogenic pathway in A549 lung adenocarcinoma cells.",-30.375,0.4,chemicalentity
Metronidazole treatment of vancomycin‑induced colitis in *Clostridioides difficile*‑infected *Homo sapiens* patients led to a significant reduction in the inflammatory cytokine IL‑8 expression in colonic epithelial cells.,-36.25,0.4,chemicalentity
"Analysis revealed that paroxetine treatment down‑regulates the expression of the CYP2D6 gene product in HepG2 cells, thereby reducing the metabolic conversion of the opioid fentanyl into its active metabolite.",-30.125,0.4,chemicalentity
"Analysis of the NNK‑dependent DNA adducts revealed that paroxetine treatment significantly reduced fura‑2‑mediated calcium influx in HeLa cells, suggesting a protective effect against vancomycin‑induced nephrotoxicity.",-30.625,0.4,chemicalentity
"Analysis reveals that paroxetine exposure in A549 cells increases intracellular Ca²⁺ levels measured by fura‑2, thereby enhancing the expression of the Na⁺/K⁺‑ATPase α1 subunit and potentiating the cytotoxic effect of vancomycin‑induced oxidative stress.",-43.75,0.4,chemicalentity
"Analysis demonstrated that paroxetine, a selective serotonin reuptake inhibitor, inhibited NNK-dependent proliferation of A549 cells by reducing intracellular Na⁺ influx and fura‑2‑based Ca²⁺ signaling while simultaneously enhancing glipizide‑mediated insulin secretion in a dose‑dependent manner.",-39.25,0.4,chemicalentity
"Cumulative exposure to the NNK-dependent carcinogen paroxetine in A549 cells increases fura‑2‑based calcium flux, thereby enhancing Na⁺‑dependent uptake of glipizide and potentiating DHEA‑mediated apoptosis in vancomycin‑induced nephrotoxicity models.",-38.25,0.4,chemicalentity
"Cisplatin exposure in A549 cells upregulates the expression of the drug‑induced transporter SLC22A1, thereby enhancing the cellular uptake of the chemotherapeutic agent and increasing apoptosis in the lung carcinoma cell line.",-36.75,0.4,chemicalentity
"Citrus-derived fura‑2 fluorescence imaging revealed that paroxetine, a selective serotonin reuptake inhibitor, inhibited Na⁺‑dependent uptake of the synthetic opioid analog NNK‑dependent in vitro, thereby reducing cellular viability in A549 lung carcinoma cells.",-42.0,0.4,chemicalentity
"Ceftriaxone treatment of vancomycin‑induced nephrotoxicity in *Escherichia coli*‑infected patients reduced serum creatinine levels and restored Na⁺/K⁺‑ATPase activity, thereby improving renal function.",-32.75,0.4,chemicalentity
"The chemotherapeutic anthracyclin daunorubicin induces cytochrome c release from mitochondria, thereby triggering apoptosis in A549 cells treated with the combination of simvastatin‑ezetimibe and Coenzyme Q10.",-16.75,0.4,chemicalentity
"The administration of simvastatin‑ezetimibe markedly reduced plasma cholesterol levels in patients with familial hypercholesterolemia, while concomitant supplementation with Coenzyme Q10 alleviated statin‑induced myopathy, illustrating a synergistic therapeutic strategy that targets both lipid metabolism and mitochondrial bioenergetics.",-29.875,0.4,chemicalentity
"The cholesterol‑lowering combination simvastatin‑ezetimibe markedly reduced plasma PPi levels in patients with a CYP27A1 mutation, thereby attenuating the accumulation of toxic oxysterols that otherwise trigger cytochrome c release and apoptosis in hepatocytes.",-35.75,0.4,chemicalentity
"The histone deacetylase inhibitor DFP, when combined with the statin‑like compound simvastatin‑ezetimibe, markedly increased cytochrome c release and PPi production in HeLa cells, suggesting a synergistic pro‑apoptotic mechanism that may be exploited for targeted cancer therapy.",-33.0,0.4,chemicalentity
"Simvastatin‑ezetimibe treatment in cultured HepG2 cells reduced the expression of the mitochondrial respiratory complex I subunit NDUFS1, thereby increasing the intracellular PPi concentration and enhancing cytochrome c release into the cytosol.",-31.875,0.4,chemicalentity
"Simultaneous exposure of A549 cells to the CYP3A4 inhibitor DFP and the mitochondrial uncoupler palmitate markedly increased cytochrome c release, thereby amplifying apoptosis induced by the anthracyclin doxorubicin.",-30.875,0.4,chemicalentity
"Simulated exposure of HeLa cells to the anthracyclin doxorubicin induced a rapid release of cytochrome c, which in turn activated caspase‑3 and triggered apoptosis, whereas co‑treatment with Coenzyme Q10 partially restored mitochondrial membrane potential and reduced cell death.",-33.5,0.4,chemicalentity
"Simulating the inhibition of mitochondrial respiration, the addition of Coenzyme Q10 to HeLa cells expressing the TP53 c.215C>G variant reduced cytochrome c release and restored ATP production, thereby attenuating the apoptotic response induced by anthracyclin treatment.",-44.25,0.4,chemicalentity
"Palmitate treatment of A549 cells upregulated cytochrome c release and increased PPi production, suggesting a metabolic shift that could sensitize these tumor cells to anthracyclin-induced apoptosis.",-20.875,0.4,chemicalentity
"Palbociclib treatment of A549 cells led to a marked increase in cytochrome c release and caspase‑3 activation, suggesting that the drug induces apoptosis through the intrinsic mitochondrial pathway.",-33.25,0.4,chemicalentity
"Palmatide, a palmitate analogue, competitively inhibits cytochrome c release from mitochondria, thereby reducing apoptosis in HeLa cells treated with the anthracyclin doxorubicin.",-28.75,0.4,chemicalentity
"Palmetto‑derived palmitate, a fatty acid, competitively inhibits cytochrome c‑mediated apoptosis in A549 cells, whereas the combination of simvastatin‑ezetimibe reduces PPi‑driven calcification in a murine model of aortic valve disease.",-50.75,0.4,chemicalentity
A549 cells treated with simvastatin‑ezetimibe exhibit a marked decrease in cytochrome c release and reduced apoptosis compared with cells exposed to the anthracyclin doxorubicin.,-19.75,0.4,chemicalentity
"A pharmacogenomic study of HeLa cells treated with simvastatin‑ezetimibe revealed that the drug combination upregulated cytochrome c release, increased PPi production, and induced a dose‑dependent decrease in cell viability, suggesting a potential therapeutic strategy for targeting the mitochondrial apoptosis pathway in cancer cells.",-42.75,0.4,chemicalentity
"A patient with severe hyperlipidemia treated with a simvastatin‑ezetimibe combination showed a marked decrease in plasma LDL‑C levels, while plasma Coenzyme Q10 concentrations rose, suggesting a compensatory up‑regulation of mitochondrial electron transport chain activity.",-40.25,0.4,chemicalentity
"Arachidonic acid‑derived prostaglandin E2 stimulates cytochrome c release in HeLa cells, thereby enhancing apoptosis induced by the anthracycline doxorubicin.",-22.375,0.4,chemicalentity
"DFP exposure in A549 cells induces a rapid release of cytochrome c, which in turn activates caspase‑3 and drives apoptosis.",-20.375,0.4,chemicalentity
"DFPalmitate treatment of HeLa cells upregulated cytochrome c release, increased PPi production, and synergistically enhanced the apoptotic effect of anthracyclin, while simultaneously reducing the intracellular concentration of deoxycorticosterone.",-43.75,0.4,chemicalentity
"DFPM-mediated inhibition of cytochrome c release from mitochondria reduces apoptosis in A549 cells, while palmitate-induced ROS production is attenuated by coenzyme Q10 supplementation.",-35.25,0.4,chemicalentity
"DFPP‑treated A549 cells showed a dose‑dependent decrease in cytochrome c release, suggesting that DFP stabilizes mitochondrial membranes and protects against anthracyclin‑induced apoptosis.",-33.75,0.4,chemicalentity
"In HepG2 cells, the addition of simvastatin‑ezetimibe markedly increased intracellular PPi levels, thereby enhancing cytochrome c release and triggering apoptosis through a caspase‑dependent pathway.",-17.625,0.4,chemicalentity
"In A549 cells, the addition of simvastatin‑ezetimibe synergistically increased cytochrome c release and caspase‑3 activation, leading to apoptosis that was markedly attenuated when Coenzyme Q10 was co‑administered.",-26.5,0.4,chemicalentity
"In HCT116 cells, treatment with the combination of simvastatin‑ezetimibe and Coenzyme Q10 markedly reduced cytochrome c release, thereby attenuating apoptosis induced by the anthracyclin doxorubicin.",-19.625,0.4,chemicalentity
"In HeLa cells, exposure to the anthracyclin doxorubicin induces cytochrome c release, activates caspase‑3, and up‑regulates the pro‑apoptotic gene BAX, while co‑treatment with simvastatin‑ezetimibe attenuates mitochondrial membrane potential loss and reduces apoptotic cell death.",-28.375,0.4,chemicalentity
"dexamethasone‑induced upregulation of cytochrome c release in HeLa cells was attenuated by co‑administration of Coenzyme Q10, suggesting a protective role against anthracyclin‑mediated apoptosis.",-23.25,0.4,chemicalentity
"doxorubicin, a clinically used anthracyclin, induces cytochrome c release from mitochondria in HeLa cells, thereby triggering caspase‑mediated apoptosis.",-18.375,0.4,chemicalentity
"dExcessive palmitate exposure in HeLa cells upregulates cytochrome c release, thereby potentiating apoptosis induced by the anthracyclin doxorubicin.",-26.375,0.4,chemicalentity
"dFPhydrolysis by the cytochrome c oxidase complex increases PPi production, which in turn enhances the antioxidant capacity of Coenzyme Q10 and mitigates the cardiotoxic effects of anthracyclin in A549 cells.",-36.0,0.4,chemicalentity
"Administration of the combination therapy simvastatin‑ezetimibe markedly reduced LDL‑cholesterol levels in patients with familial hypercholesterolemia, while the concomitant supplementation with Coenzyme Q10 mitigated statin‑induced myopathy by preserving mitochondrial cytochrome c oxidase activity.",-27.25,0.4,chemicalentity
"Administration to A549 cells of the dual‑acting lipid‑based drug palmitate conjugated to simvastatin‑ezetimibe markedly increased intracellular PPi levels, thereby enhancing cytochrome c release and triggering apoptosis through the mitochondrial pathway.",-42.75,0.4,chemicalentity
"Administration_of_DFP_to_A549_cells_reduced_cytochrome_c_release_and_cleared_PP_i_levels, suggesting a protective effect against anthracyclin-induced apoptosis.",-42.5,0.4,chemicalentity
"Administration with the combination of simvastatin‑ezetimibe markedly reduced LDL‑cholesterol in patients carrying the APOE ε4 allele while simultaneously upregulating hepatic Coenzyme Q10 synthesis, thereby mitigating the risk of statin‑induced myopathy.",-42.25,0.4,chemicalentity
"Treatment with the combination of simvastatin‑ezetimibe reduced LDL‑cholesterol levels in patients carrying the APOE ε4 allele, while concurrent supplementation with Coenzyme Q10 attenuated the rise in oxidative stress markers induced by the drug.",-31.875,0.4,chemicalentity
"Treatment of HeLa cells with simvastatin‑ezetimibe reduced cytochrome c release and increased Coenzyme Q10 levels, thereby attenuating apoptosis induced by anthracyclin exposure.",-19.625,0.4,chemicalentity
"Treatment dengan simvastatin‑ezetimibe menurunkan kadar kolesterol LDL dan meningkatkan ekspresi Coenzyme Q10 di sel hepatoma HepG2, sedangkan paparan palmitate meningkatkan pelepasan cytochrome c ke sitoplasma, menandakan stres oksidatif.",-47.0,0.4,chemicalentity
Treatment combining simvastatin‑ezetimibe with Coenzyme Q10 markedly reduced LDL‑cholesterol in patients carrying the LDLR c.1529_1532delAG sequence variant while simultaneously lowering plasma PPi levels and improving endothelial cytochrome c release in a dose‑dependent manner.,-55.75,0.4,chemicalentity
"Cytochrome c release from mitochondria, triggered by palmitate-induced oxidative stress, enhances the apoptotic activity of the anthracyclin doxorubicin in A549 cells, while coenzyme Q10 supplementation partially rescues cell viability.",-25.125,0.4,chemicalentity
"Cyclosporin A treatment of HeLa cells increased intracellular PPi levels and induced cytochrome c release, suggesting a mitochondrial permeability transition that may be mitigated by coenzyme Q10 supplementation.",-31.375,0.4,chemicalentity
"Cyproheptadine, a histamine H1 antagonist, competitively inhibits cytochrome c-mediated apoptosis in HeLa cells, thereby reducing caspase‑3 activation and enhancing cell survival during doxorubicin‑induced oxidative stress.",-34.0,0.4,chemicalentity
"Cylic adenosine diphosphate (cAMP) produced by DFP exposure activates cytochrome c release, which in turn triggers apoptosis in HeLa cells treated with the anthracyclin doxorubicin.",-42.0,0.4,chemicalentity
"Administering simvastatin‑ezetimibe to A549 cells increased intracellular Coenzyme Q10 levels, thereby reducing cytochrome c release and attenuating apoptosis induced by anthracyclin.",-21.5,0.4,chemicalentity
"Administation of the anthracyclin doxorubicin to A549 cells induces a rapid release of cytochrome c, elevating PPi levels and triggering apoptosis, while co‑treatment with simvastatin‑ezetimibe reduces the cytotoxic effect by modulating cholesterol synthesis in the cell membrane.",-46.5,0.4,chemicalentity
"Adminitration of the anthracyclin doxorubicin to HeLa cells upregulated cytochrome c release and increased caspase‑3 activity, while co‑treatment with Coenzyme Q10 mitigated the oxidative stress and preserved mitochondrial membrane potential.",-41.75,0.4,chemicalentity
"Adminstration of the anthracyclin doxorubicin in A549 cells increased cytochrome c release, triggered caspase‑3 activation, and reduced cell viability, whereas co‑treatment with Coenzyme Q10 partially rescued the cells from apoptosis.",-38.75,0.4,chemicalentity
"Pemetrexed, a folate analogue, competitively inhibits thymidylate synthase in A549 cells, reducing dTMP synthesis and triggering apoptosis through cytochrome c release and caspase‑9 activation.",-26.0,0.4,chemicalentity
"Palladium‑catalyzed DFP‑mediated cross‑linking of palmitate‑modified cytochrome c reduces its PPi‑dependent oxidative phosphorylation, thereby attenuating the cardiotoxic effects of anthracyclins in HeLa cells treated with simvastatin‑ezetimibe and Coenzyme Q10.",-39.5,0.4,chemicalentity
"Pyridostigmine, a cholinesterase inhibitor, competitively binds the active site of acetylcholinesterase in A549 cells, thereby increasing acetylcholine levels and potentiating the anti‑inflammatory effects of simvastatin‑ezetimibe therapy on the NF‑κB pathway.",-34.75,0.4,chemicalentity
"P‑alcohol dehydrogenase activity in A549 cells is markedly enhanced by the addition of simvastatin‑ezetimibe, which competitively inhibits the cytochrome c‑dependent electron transport chain and reduces PPi production, thereby attenuating the apoptotic response to anthracyclin-induced DNA damage.",-49.5,0.4,chemicalentity
"Etoposide-induced apoptosis in A549 cells is amplified by the addition of Coenzyme Q10, which stabilizes cytochrome c release and enhances caspase activation.",-21.5,0.4,chemicalentity
"Etofenamic acid, a non‑steroidal anti‑inflammatory drug, competitively inhibits the ATPase activity of cytochrome c oxidase, thereby reducing PPi production and impairing mitochondrial respiration in HeLa cells.",-29.375,0.4,chemicalentity
"Eptifibatide, a synthetic glycoprotein IIb/IIIa inhibitor, competitively binds platelet integrin αIIbβ3 and prevents fibrinogen-mediated aggregation, thereby reducing thrombus formation in patients with acute coronary syndrome.",-29.125,0.4,chemicalentity
"Ezetimibe‑simvastatin treatment markedly reduced LDL‑R expression in HepG2 cells, while co‑administration of Coenzyme Q10 rescued cytochrome c release and prevented apoptosis induced by the anthracycline doxorubicin.",-36.0,0.4,chemicalentity
"Cisplatin-induced apoptosis in A549 cells is markedly attenuated by co‑administration of Coenzyme Q10, which restores cytochrome c release and reduces reactive oxygen species production.",-23.875,0.4,chemicalentity
"Cytotoxicity of the anthracyclin doxorubicin in HeLa cells is markedly enhanced by co‑administration of the cholesterol‑lowering simvastatin‑ezetimibe combination, which increases intracellular Coenzyme Q10 depletion and triggers cytochrome c release, thereby amplifying apoptosis.",-29.625,0.4,chemicalentity
"Ciclopirox, a topical antifungal chemical entity, competitively inhibits cytochrome c oxidase activity in *Candida albicans* cells, thereby reducing ATP synthesis and inducing apoptosis.",-28.125,0.4,chemicalentity
"Ciprofloxacin, a broad‑spectrum chemicalentity, competitively inhibits bacterial DNA gyrase in Escherichia coli, thereby preventing replication of the gyrA gene product and leading to cell death.",-30.625,0.4,chemicalentity
"Doxorubicin, a cardioprotective drug, competitively inhibits ATP/ADP binding in the mitochondrial respiratory chain of HeLa cells, thereby reducing methamphetamine‑elicited dopaminergic agonism and increasing trypan blue uptake as a marker of cell death.",-20.375,0.4,chemicalentity
"Dopaminergic agonism induced by methamphetamine-elicited release of ATP/ADP in the striatum is mitigated by the cardioprotective drug Garcinielliptone FC, which competitively inhibits thromboxane B2 synthesis.",-18.75,0.4,chemicalentity
"Dacarbazine, a cardioprotective drug, was shown to inhibit thromboxane B2 production in A549 cells, thereby reducing ATP/ADP-mediated platelet aggregation and attenuating methamphetamine‑elicited dopaminergic agonism.",-21.5,0.4,chemicalentity
"Dexamethasone, a cardioprotective drug, reduces ATP/ADP ratio and inhibits thromboxane B2 production in A549 cells, thereby attenuating methamphetamine‑elicited dopaminergic agonism.",-18.75,0.4,chemicalentity
"In A549 cells, the cardioprotective drug Garcinielliptone FC reduces methamphetamine‑elicited dopaminergic agonism by inhibiting thromboxane B2 production, thereby preserving ATP/ADP homeostasis.",-15.375,0.4,chemicalentity
"In HeLa cells, the cardioprotective drug Garcinielliptone FC reduces ATP/ADP ratios and suppresses thromboxane B2 production, thereby attenuating methamphetamine‑elicited dopaminergic agonism.",-14.8125,0.4,chemicalentity
"In the A549 cell line, the cardioprotective drug Garcinielliptone FC inhibited thromboxane B2 production by reducing ATP/ADP turnover, thereby attenuating methamphetamine‑elicited dopaminergic agonism.",-14.9375,0.4,chemicalentity
"In **HeLa** cells, the **cardioprotective drug** **Garcinielliptone FC** enhances **ATP/ADP** turnover, thereby reducing **methamphetamine‑elicited** dopaminergic agonism and limiting the release of **thromboxane B2**.",-26.0,0.4,chemicalentity
"The cardioprotective drug Garcinielliptone FC, by inhibiting thromboxane B2 synthesis, reduces ATP/ADP ratio‑mediated vasoconstriction in A549 cells exposed to methamphetamine‑elicited dopaminergic agonism.",-16.375,0.4,chemicalentity
"The chemotherapeutic agent Garcinielliptone FC, acting as a cardioprotective drug, reduces thromboxane B2 production by inhibiting ATP/ADP-dependent cyclooxygenase activity in human endothelial cells.",-22.875,0.4,chemicalentity
"The use of the cardioprotective drug Garcinielliptone FC in A549 cells reduced ATP/ADP ratio and inhibited thromboxane B2 production, thereby attenuating methamphetamine‑elicited dopaminergic agonism.",-22.5,0.4,chemicalentity
"The dopaminergic agonism of Garcinielliptone FC, a cardioprotective drug, was found to reduce thromboxane B2 levels in HeLa cells treated with methamphetamine-elicited ATP/ADP imbalance.",-23.875,0.4,chemicalentity
"A cardioprotective drug that inhibits thromboxane B2 synthesis reduces ATP/ADP depletion in methamphetamine‑elicited dopaminergic agonism, thereby protecting myocardial cells from ischemic injury.",-19.375,0.4,chemicalentity
"Aortic endothelial cells exposed to the cardioprotective drug Garcinielliptone FC exhibit reduced thromboxane B2 production through enhanced ATP/ADP turnover, thereby attenuating methamphetamine‑elicited dopaminergic agonism‑induced vasoconstriction.",-25.75,0.4,chemicalentity
"A scabicide containing Garcinielliptone FC reduces ATP/ADP depletion in methamphetamine‑elicited dopaminergic agonism, thereby improving cardioprotective drug efficacy in patients with thromboxane B2‑mediated vasospasm.",-27.0,0.4,chemicalentity
"A highly selective cardioprotective drug, Garcinielliptone FC, competitively inhibits thromboxane B2 synthesis while simultaneously enhancing ATP/ADP turnover in dopaminergic agonism pathways, thereby reducing methamphetamine‑elicited neurotoxicity.",-27.625,0.4,chemicalentity
"Epidemiological analysis revealed that exposure to the cardioprotective drug Garcinielliptone FC significantly reduced thromboxane B2 levels in patients with a history of methamphetamine-elicited cardiovascular events, suggesting a protective effect mediated through dopaminergic agonism and ATP/ADP modulation.",-33.5,0.4,chemicalentity
"Efficacy of the cardioprotective drug Garcinielliptone FC was enhanced in A549 cells by reducing ATP/ADP ratio, thereby attenuating methamphetamine‑elicited dopaminergic agonism and lowering thromboxane B2 production.",-22.625,0.4,chemicalentity
"Eptifibatide, a cardioprotective drug that competitively inhibits platelet glycoprotein IIb/IIIa, reduces thromboxane B2 production and restores the ATP/ADP ratio in methamphetamine‑elicited dopaminergic agonism models.",-27.0,0.4,chemicalentity
"Ectopic expression of the cardioprotective drug Garcinielliptone FC in HeLa cells reduced ATP/ADP ratios and attenuated methamphetamine‑elicited dopaminergic agonism, thereby limiting thromboxane B2‑mediated platelet aggregation.",-25.75,0.4,chemicalentity
"Administration of the cardioprotective drug Garcinielliptone FC to A549 cells exposed to methamphetamine-elicited oxidative stress reduced intracellular ATP/ADP ratios and suppressed thromboxane B2 production, thereby attenuating dopaminergic agonism‑induced apoptosis.",-19.625,0.4,chemicalentity
"Administration and subsequent cardioprotective drug treatment with Garcinielliptone FC, a novel scabicide, reduced thromboxane B2 levels in HeLa cells while simultaneously increasing the intracellular ATP/ADP ratio, thereby attenuating methamphetamine‑elicited dopaminergic agonism.",-49.0,0.4,chemicalentity
"Administration with the cardioprotective drug Garcinielliptone FC, which competitively inhibits thromboxane B2 synthesis, markedly reduced the ATP/ADP ratio and attenuated methamphetamine‑elicited dopaminergic agonism in cultured A549 cells.",-36.75,0.4,chemicalentity
"Administration‑guided dosing of the cardioprotective drug Garcinielliptone FC reduced thromboxane B2 production in HeLa cells exposed to methamphetamine‑elicited oxidative stress, thereby attenuating ATP/ADP imbalance and preserving dopaminergic agonism.",-42.0,0.4,chemicalentity
"Exposure of HeLa cells to the cardioprotective drug Garcinielliptone FC, which mimics dopaminergic agonism, reduces ATP/ADP ratios and increases thromboxane B2 production, thereby attenuating methamphetamine‑elicited cytotoxicity.",-23.875,0.4,chemicalentity
"Exposure to the cardioprotective drug Garcinielliptone FC reduces thromboxane B2 production in A549 cells, thereby attenuating methamphetamine‑elicited dopaminergic agonism and protecting against acetic acid‑induced oxidative stress.",-23.875,0.4,chemicalentity
"Exposure-based methamphetamine-elicited dopaminergic agonism in HeLa cells treated with the cardioprotective drug Garcinielliptone FC was found to increase ATP/ADP ratios, suggesting a potential therapeutic pathway for Parkinson’s disease.",-40.25,0.4,chemicalentity
"Exposure and subsequent cardioprotective drug administration of Garcinielliptone FC in a murine model of methamphetamine‑elicited dopaminergic agonism markedly reduced thromboxane B2 production and preserved ATP/ADP ratios, thereby mitigating myocardial injury.",-47.5,0.4,chemicalentity
"Methamphetamine‑elicited dopaminergic agonism in A549 cells treated with the cardioprotective drug Garcinielliptone FC was found to increase ATP/ADP ratios, suggesting a metabolic shift that may underlie the drug’s neuroprotective effects.",-23.125,0.4,chemicalentity
"Methotrexate, a cardioprotective drug, competitively inhibits ATP/ADP binding in the folate pathway, thereby reducing thromboxane B2 synthesis and attenuating methamphetamine‑elicited dopaminergic agonism in HeLa cells.",-22.375,0.4,chemicalentity
"Methanol, a scabicide and cardioprotective drug, was shown to inhibit thromboxane B2 synthesis in A549 cells, thereby reducing ATP/ADP-mediated platelet aggregation.",-24.125,0.4,chemicalentity
"Methadone, a potent dopaminergic agonism cardioprotective drug, was found to reduce ATP/ADP ratios in A549 cells, thereby attenuating methamphetamine-elicited oxidative stress.",-29.75,0.4,chemicalentity
"Researchers found that the cardioprotective drug Garcinielliptone FC, by inhibiting thromboxane B2 synthesis, enhanced ATP/ADP turnover in cardiomyocytes exposed to methamphetamine-elicited dopaminergic agonism, thereby reducing trypan blue‑induced cell death.",-30.25,0.4,chemicalentity
"Researchers demonstrated that the cardioprotective drug Garcinielliptone FC, by inhibiting thromboxane B2 synthesis, reduces ATP/ADP depletion and attenuates methamphetamine‑elicited dopaminergic agonism in cultured A549 cells.",-23.0,0.4,chemicalentity
"Researchers discovered that the cardioprotective drug Garcinielliptone FC, by inhibiting thromboxane B2 synthesis, reduces ATP/ADP imbalance in ischemic cardiomyocytes and attenuates methamphetamine‑elicited dopaminergic agonism.",-27.25,0.4,chemicalentity
"Researchers determined that the cardioprotective drug Garcinielliptone FC, by inhibiting thromboxane B2 synthesis, restored ATP/ADP ratios in methamphetamine‑elicited dopaminergic agonism models, thereby reducing trypan blue‑induced cytotoxicity in cultured HeLa cells.",-29.75,0.4,chemicalentity
"Scabicide Garcinielliptone FC, acting as a cardioprotective drug, reduces thromboxane B2 levels in A549 cells, thereby attenuating methamphetamine‑elicited dopaminergic agonism and restoring ATP/ADP balance.",-22.125,0.4,chemicalentity
"Scavenger macrophages exposed to the cardioprotective drug Garcinielliptone FC exhibit increased ATP/ADP turnover, which in turn enhances dopaminergic agonism and reduces methamphetamine‑elicited thromboxane B2 production.",-26.75,0.4,chemicalentity
"Scandolactone, a novel cardioprotective drug, competitively inhibits thromboxane B2 synthesis in A549 cells, thereby attenuating ATP/ADP‑mediated platelet aggregation and reducing methamphetamine‑elicited dopaminergic agonism.",-29.25,0.4,chemicalentity
"Scabies lesions treated with the scabicide Garcinielliptone FC showed a significant reduction in ATP/ADP ratios, indicating restored cellular energy homeostasis.",-24.0,0.4,chemicalentity
"Garcielliptone FC, a novel cardioprotective drug, reduces thromboxane B2 production in A549 cells through ATP/ADP-mediated dopaminergic agonism, thereby attenuating methamphetamine‑elicited inflammatory signaling.",-23.875,0.4,chemicalentity
"Garudacil, a cardioprotective drug, inhibited thromboxane B2 production in A549 cells, thereby reducing ATP/ADP turnover and attenuating methamphetamine‑elicited dopaminergic agonism.",-27.375,0.4,chemicalentity
"Garciaelliptone FC, a novel cardioprotective drug, competitively inhibits thromboxane B2 synthesis in A549 cells, thereby reducing ATP/ADP turnover and attenuating methamphetamine‑elicited dopaminergic agonism.",-17.75,0.4,chemicalentity
"Garxinoelliptone FC, a cardioprotective drug, competitively inhibits thromboxane B2 synthesis in A549 cells, thereby reducing ATP/ADP turnover and attenuating methamphetamine‑elicited dopaminergic agonism.",-23.5,0.4,chemicalentity
"Tryptan blue, a commonly used scabicide, competitively inhibits ATP/ADP binding on the dopamine D2 receptor, thereby reducing methamphetamine‑elicited dopaminergic agonism and providing cardioprotective drug effects in ischemic myocardium.",-27.875,0.4,chemicalentity
"Tyramine, a cardioprotective drug, competitively inhibits the ATP/ADP exchange on dopamine transporters, thereby attenuating methamphetamine‑elicited dopaminergic agonism in A549 cells.",-26.25,0.4,chemicalentity
"Toxicity of the cardioprotective drug Garcinielliptone FC was reduced in A549 cells by co‑administration of the scabicide trypan blue, which competitively inhibited thromboxane B2‑mediated ATP/ADP release and attenuated methamphetamine‑elicited dopaminergic agonism.",-29.25,0.4,chemicalentity
"Tritan blue, a cardioprotective drug that inhibits thromboxane B2 synthesis, was shown to reduce methamphetamine‑elicited dopaminergic agonism in A549 cells by altering the ATP/ADP ratio.",-25.25,0.4,chemicalentity
"CellLine HeLa treated with the cardioprotective drug Garcinielliptone FC exhibited a significant reduction in thromboxane B2 production, suggesting that this chemicalentity modulates the dopaminergic agonism pathway in a manner that could attenuate methamphetamine-elicited ATP/ADP imbalance.",-34.75,0.4,chemicalentity
"Cell-line A549 treated with the cardioprotective drug Garcinielliptone FC exhibited a significant reduction in ATP/ADP ratio compared with untreated controls, suggesting enhanced mitochondrial function.",-24.5,0.4,chemicalentity
"Cell culture of A549 cells treated with the cardioprotective drug Garcinielliptone FC showed a significant decrease in thromboxane B2 production, suggesting that its dopaminergic agonism may inhibit ATP/ADP‑mediated platelet activation.",-28.375,0.4,chemicalentity
"Cell‑line A549 treated with the cardioprotective drug Garcinielliptone FC exhibited a significant increase in ATP/ADP ratio, suggesting enhanced mitochondrial function that may counteract methamphetamine‑elicited dopaminergic agonism.",-22.0,0.4,chemicalentity
"Cardifex, a cardioprotective drug, inhibited thromboxane B2 synthesis in A549 cells, thereby reducing ATP/ADP turnover and mitigating methamphetamine‑elicited dopaminergic agonism.",-30.125,0.4,chemicalentity
"Cardioprotective drug Garcinielliptone FC, by inhibiting thromboxane B2 synthesis, reduces ATP/ADP turnover in methamphetamine‑elicited dopaminergic agonism, thereby protecting myocardial cells from trypan blue‑induced cytotoxicity.",-22.125,0.4,chemicalentity
"Cardiotoxicity induced by the cardioprotective drug Garcinielliptone FC is mitigated in H9c2 cells through a pathway that involves ATP/ADP-dependent activation of the dopaminergic agonism receptor, thereby reducing thromboxane B2 production.",-35.25,0.4,chemicalentity
Cardiac fibroblasts exposed to the cardioprotective drug Garcinielliptone FC exhibit reduced thromboxane B2 production through a mechanism involving ATP/ADP-mediated dopaminergic agonism.,-21.0,0.4,chemicalentity
"In melanoma cell lines treated with cis‑diamminedichloroplatinum, the addition of the mTOR inhibitor NVP‑BEZ235 markedly reduced phosphorylation of S6K1, indicating that the drug blocks downstream signaling of the PI3K/AKT/mTOR pathway.",-31.0,0.4,chemicalentity
"In zebrafish, the mTOR inhibitor NVP‑BEZ235 reduces cis‑diamminedichloroplatinum‑induced apoptosis, while the COMT inhibitor entacapone enhances the cardioprotective effect of amiodarone against isoprenaline‑induced arrhythmias.",-28.375,0.4,chemicalentity
"In human hepatocellular carcinoma cells, the mTOR inhibitor NVP‑BEZ235 synergistically enhances cis‑diammine‑dichloroplatinum‑induced apoptosis, a effect that is potentiated by the COMT inhibitor entacapone and attenuated by the antioxidant carrageenan.",-27.0,0.4,chemicalentity
"In HeLa cells treated with the mTOR inhibitor NVP‑BEZ235, cis‑diamminedichloroplatinum induces a synergistic increase in apoptosis that is further amplified by the addition of the COMT inhibitor entacapone, suggesting a potential therapeutic strategy for platinum‑resistant ovarian cancer.",-24.5,0.4,chemicalentity
"Cis‑diamminedichloroplatinum treatment of HeLa cells activates the mTOR pathway, leading to increased phosphorylation of S6K1 and enhanced cell proliferation.",-17.375,0.4,chemicalentity
"CETP inhibitor NVP-018, a mammalian target of rapamycin (mTOR) inhibitor, reduced cis‑diamminedichloroplatinum‑induced apoptosis in A549 cells while simultaneously enhancing Amiodarone‑mediated cardioprotective signaling in HEK293T cells.",-41.25,0.4,chemicalentity
"COV-19 vaccine adjuvant carrageenan enhances the immunogenicity of the mTOR inhibitor NVP‑212 in HeLa cells, while cis‑diamminedichloroplatinum induces apoptosis through p53‑dependent upregulation of the COMT inhibitor gene CYP2D6.",-50.25,0.4,chemicalentity
"Crisplatin, a cis‑diammine‑dichloroplatinum complex, synergizes with the mTOR inhibitor NVP‑BKM120 to suppress proliferation of HeLa cells, while amiodarone exposure elevates intracellular ROS, thereby potentiating cisplatin‑induced DNA cross‑linking.",-46.75,0.4,chemicalentity
"The mTOR inhibitor NVP-BEZ235, when combined with cis‑diamminedichloroplatinum, synergistically reduces proliferation of HeLa cells, an effect that is attenuated by the COMT inhibitor entacapone.",-17.125,0.4,chemicalentity
"The cis‑diaminodichloroplatinum complex, a platinum‑based chemotherapeutic, was shown to inhibit mammalian target of rapamycin (mTOR) signaling in A549 cells, thereby reducing cell proliferation and enhancing apoptosis in the presence of the COMT inhibitor entacapone.",-23.5,0.4,chemicalentity
"The mammalian target of rapamycin (mTOR) inhibitor NVP‑BEZ235, when combined with cis‑diamminedichloroplatinum, synergistically induces apoptosis in A549 cells, whereas the anthraquinone derivative carrageenan reduces the IC₅₀ of the drug by enhancing its cellular uptake.",-32.0,0.4,chemicalentity
"The phosphatidylinositol‑3‑kinase inhibitor NVP‑BEZ235, a mammalian target of rapamycin (mTOR) dual‑kinase blocker, synergistically enhanced cis‑diamminedichloroplatinum‑induced apoptosis in A549 cells while simultaneously reducing carrageenan‑induced edema in a murine model.",-31.625,0.4,chemicalentity
"A recent study showed that the mTOR inhibitor NVP-BEZ235, when combined with cis‑diamminedichloroplatinum, significantly reduced proliferation of A549 cells, suggesting a synergistic chemotherapeutic effect in lung carcinoma.",-25.0,0.4,chemicalentity
"A cis‑diamminedichloroplatinum derivative synergizes with the mTOR inhibitor NVP‑BGT226 to suppress proliferation of HeLa cells, while amiodarone treatment reduces the associated cardiotoxicity in a dose‑dependent manner.",-25.75,0.4,chemicalentity
"A CRISPR‑Cas9‑generated HeLa cell line harboring the BRCA1 c.68_69delAG variant was treated with the mTOR inhibitor NVP‑BEZ235, leading to a significant reduction in phosphorylated‑AKT levels and a concomitant decrease in cis‑diaminodichloroplatinum‑induced DNA damage foci.",-31.5,0.4,chemicalentity
"A colorectal carcinoma cell line treated with the mTOR inhibitor NVP-BEZ235 showed a marked reduction in phosphorylated S6K1 levels, suggesting that NVP-BEZ235 effectively blocks downstream mTOR signaling in HCT116 cells.",-32.75,0.4,chemicalentity
"Administration of cis‑diamminedichloroplatinum to HeLa cells upregulated the mTOR pathway, while the addition of the COMT inhibitor NVP‑BKM120 further enhanced phosphorylation of S6K1, indicating a synergistic effect on protein synthesis and cell proliferation.",-33.0,0.4,chemicalentity
"Administration with cis‑diamminedichloroplatinum of a patient carrying the BRCA1 c.68_69delAG variant induced a pronounced DNA cross‑linking response, which was mitigated by concurrent treatment with a mammalian target of rapamycin (mTOR) inhibitor, thereby reducing the risk of platinum‑induced nephrotoxicity.",-52.75,0.4,chemicalentity
"Administration to HeLa cells of the mTOR inhibitor NVP‑BEZ235, a lead compound structurally related to cis‑diamminedichloroplatinum, markedly reduced phospho‑S6K levels while simultaneously increasing the expression of the tumor suppressor gene TP53.",-41.5,0.4,chemicalentity
"Administration and pharmacodynamic profiling of the mTOR inhibitor NVP-BEZ235 in HeLa cells revealed that cis‑diammine‑dichloroplatinum potentiated the drug’s cytotoxicity, while Amiodarone mitigated the resulting apoptosis, illustrating a complex interplay between a platinum chemotherapeutic, a kinase inhibitor, and an antiarrhythmic agent.",-63.25,0.4,chemicalentity
"Lead compound NVP-23, a novel mammalian target of rapamycin inhibitor, competitively inhibited cis‑diamminedichloroplatinum‑induced apoptosis in HeLa cells while simultaneously enhancing the anti‑inflammatory effect of carrageenan‑mediated edema in a rat model.",-30.25,0.4,chemicalentity
"Lead citrate, a known mammalian target of rapamycin (mTOR) inhibitor, was shown to suppress the proliferation of A549 cells while simultaneously reducing cis‑diaminodichloroplatinum‑induced DNA damage in a dose‑dependent manner.",-28.625,0.4,chemicalentity
"Lead‑containing cis‑diamminedichloroplatinum, a platinum‑based chemotherapeutic, was found to inhibit mammalian target of rapamycin (mTOR) signaling in A549 cells, thereby reducing isoprenaline‑induced proliferation and enhancing apoptosis.",-21.875,0.4,chemicalentity
"Lead-induced activation of the mammalian target of rapamycin (mTOR) pathway in A549 cells was attenuated by the NVP mTOR inhibitor, demonstrating a potential therapeutic strategy for cis‑diaminodichloroplatinum‑treated tumors.",-24.75,0.4,chemicalentity
"Survival of A549 cells exposed to cis-diamminedichloroplatinum is markedly reduced when combined with the mTOR inhibitor NVP‑BEZ235, indicating a synergistic cytotoxic interaction that may be exploited for chemotherapeutic strategies.",-30.0,0.4,chemicalentity
"Surprisingly, the mTOR inhibitor NVP‑BEZ235, when combined with cis‑diamminedichloroplatinum, markedly reduced proliferation of HeLa cells by inducing a sequence variant‑dependent apoptosis pathway that involved the down‑regulation of the COMT inhibitor‑responsive gene TP53.",-41.5,0.4,chemicalentity
"Surveillance of cis‑diamminedichloroplatinum exposure in HeLa cells revealed a dose‑dependent activation of the mTOR pathway, which was attenuated by the COMT inhibitor NVP‑BAY‑41‑8102, suggesting a potential combinatorial therapeutic strategy for platinum‑resistant ovarian carcinoma.",-41.5,0.4,chemicalentity
"Suramin, a sulfonated polysulfonate compound, competitively inhibits the binding of cis‑diaminodichloroplatinum to the DNA minor groove in HeLa cells, thereby reducing the phosphorylation of mammalian target of rapamycin (mTOR) and attenuating isoprenaline‑induced cAMP production.",-39.0,0.4,chemicalentity
"Intriguingly, the mTOR inhibitor NVP‑BEZ235, when combined with cis‑diamminedichloroplatinum, synergistically suppressed proliferation of HeLa cells by inducing apoptosis through the PI3K/AKT pathway.",-26.5,0.4,chemicalentity
"Intraperitoneal injection of cis‑diamminedichloroplatinum into A549 cells induces apoptosis through activation of the mammalian target of rapamycin (mTOR) pathway, while pretreatment with the COMT inhibitor NVP‑BKM120 attenuates this effect.",-25.375,0.4,chemicalentity
"Intracellular mTOR inhibition by the lead compound NVP-BEZ235 synergistically enhances cis‑diamminedichloroplatinum‑induced apoptosis in HeLa cells, while amiodarone‑mediated blockade of COMT activity attenuates the drug’s cardiotoxicity in a dose‑dependent manner.",-36.0,0.4,chemicalentity
"Intravenous administration of cis‑diamminedichloroplatinum to A549 cells induces a dose‑dependent activation of the mTOR signaling pathway, which is markedly attenuated when cells are pretreated with the COMT inhibitor entacapone.",-26.25,0.4,chemicalentity
"doxorubicin, a potent anthraquinone chemotherapeutic, induces apoptosis in HeLa cells through activation of the mammalian target of rapamycin (mTOR) pathway, while cis‑diamminedichloroplatinum synergizes with it to enhance DNA cross‑linking and cell death.",-28.375,0.4,chemicalentity
"dexamethasone, a potent glucocorticoid, suppressed NF‑κB activation in A549 cells, thereby reducing the expression of the chemokine CXCL8 and enhancing the cytotoxic effect of cis‑diamminedichloroplatinum on the tumor microenvironment.",-36.0,0.4,chemicalentity
"detection of the lead compound NVP-001 in cis-diamminedichloroplatinum‑treated A549 cells revealed a dose‑dependent inhibition of mTOR signaling, suggesting a potential therapeutic synergy with COMT inhibitors in combating cisplatin resistance.",-38.25,0.4,chemicalentity
"differential expression of the mTOR pathway in HeLa cells treated with the lead NVP cis‑diamminedichloroplatinum and the COMT inhibitor amiodarone was observed, suggesting a synergistic suppression of cell proliferation.",-35.5,0.4,chemicalentity
"Research in A549 cells revealed that the mammalian target of rapamycin (mTOR) inhibitor NVP‑BEZ235, when combined with cis‑diamminedichloroplatinum, significantly reduced proliferation and induced apoptosis, suggesting a synergistic chemotherapeutic potential.",-28.875,0.4,chemicalentity
"Research demonstrates that cis‑diaminodichloroplatinum, a platinum‑based chemotherapeutic, activates the mTOR signaling pathway in HeLa cells, thereby enhancing cell proliferation and reducing apoptosis.",-26.0,0.4,chemicalentity
"Research using the mammalian target of rapamycin (mTOR) inhibitor NVP-BEZ235 demonstrated that cis‑diamminedichloroplatinum induces apoptosis in HeLa cells, while amiodarone reduces the cytotoxicity of the platinum compound in A549 cells.",-32.5,0.4,chemicalentity
"Research with the mammalian target of rapamycin (mTOR) inhibitor NVP‑BEZ235 demonstrated that cis‑diamminedichloroplatinum‑induced DNA damage in A549 cells was markedly attenuated when cells were pre‑treated with the lead compound, revealing a potential chemopreventive strategy for platinum‑based chemotherapy.",-43.25,0.4,chemicalentity
"Exposure of HeLa cells to the mTOR inhibitor NVP‑BEZ235 markedly reduced phosphorylation of S6K, while cis‑diammine‑dichloro‑platinum induced a dose‑dependent increase in γ‑H2AX foci and apoptosis.",-29.125,0.4,chemicalentity
"Exposure to cis‑diamminedichloroplatinum induces phosphorylation of mTOR, thereby enhancing the anti‑inflammatory effects of carrageenan‑treated macrophages in a rat model of isoprenaline‑induced cardiac hypertrophy.",-32.0,0.4,chemicalentity
"Exposure rescue of cis‑diamminedichloroplatinum‑induced nephrotoxicity in A549 cells was achieved by pretreatment with the mTOR inhibitor NVP‑BEZ235, which also reduced downstream p‑S6K phosphorylation and restored cellular ATP levels.",-46.75,0.4,chemicalentity
"Exposure‑dependent inhibition of mammalian target of rapamycin (mTOR) by the lead compound NVP‑BGT226, a dual PI3K/mTOR inhibitor, markedly suppressed cis‑diaminodichloroplatinum‑induced apoptosis in HeLa cells while simultaneously reducing isoprenaline‑induced cAMP production in A549 cells.",-50.25,0.4,chemicalentity
"Elevated plasma levels of the mTOR inhibitor NVP-BEZ235 were associated with reduced tumor growth in A549 cells treated with cis‑diamminedichloroplatinum and the chemotherapeutic anthraquinone derivative, suggesting a synergistic effect of these chemical entities on cancer cell viability.",-36.75,0.4,chemicalentity
"Elevating intracellular calcium through isoprenaline-induced β‑adrenergic stimulation, the mTOR inhibitor NVP‑BEZ235 synergistically enhances apoptosis in HeLa cells treated with cis‑diamminedichloroplatinum, while carrageenan-mediated inflammation upregulates COMT, reducing the drug’s bioavailability.",-41.5,0.4,chemicalentity
"Elevative, a novel mTOR inhibitor, synergistically enhances cis‑diammine‑dichloroplatinum‑induced apoptosis in A549 cells, while amiodarone reduces its cardiotoxicity in a dose‑dependent manner.",-39.0,0.4,chemicalentity
"Elevational increases in the mTOR signaling pathway observed in HeLa cells treated with cis‑diamminedichloroplatinum and the mTOR inhibitor NVP‑BEZ235 were attenuated by the COMT inhibitor entacapone, suggesting a synergistic suppression of tumor proliferation.",-42.75,0.4,chemicalentity
"NVP‑BKM120, a mammalian target of rapamycin inhibitor, synergistically enhanced cis‑diamminedichloroplatinum‑induced apoptosis in HeLa cells while simultaneously reducing the expression of the COMT gene.",-25.875,0.4,chemicalentity
"Navelbine (NVP) combined with the mTOR inhibitor everolimus synergistically inhibited proliferation of A549 cells, while cis‑diamminedichloroplatinum induced apoptosis through p53 activation.",-36.5,0.4,chemicalentity
"Nivolumab, a mammalian target of rapamycin (mTOR) inhibitor, was shown to synergize with cis‑diamminedichloroplatinum in reducing tumor burden in A549 cells, while the addition of the COMT inhibitor entacapone further potentiated the antitumor effect by enhancing drug retention.",-37.5,0.4,chemicalentity
"NIR‑G1, a novel lead compound, inhibited mammalian target of rapamycin (mTOR) activity in A549 cells, reducing phosphorylation of downstream S6K1 and suppressing isoprenaline‑induced proliferation.",-45.5,0.4,chemicalentity
"Amiodarone treatment of cis‑diamminedichloroplatinum‑induced cardiotoxicity in HeLa cells was mitigated by the mTOR inhibitor NVP‑BEZ235, which also reduced carrageenan‑mediated inflammatory cytokine release.",-21.375,0.4,chemicalentity
"Amiorin, a novel mammalian target of rapamycin (mTOR) inhibitor, reduced tumor growth in HeLa cells by inhibiting phosphorylation of S6K1, whereas cis‑diamminedichloroplatinum induced apoptosis through DNA cross‑linking and activation of the p53 pathway.",-40.75,0.4,chemicalentity
"Amir-1 cells treated with the mTOR inhibitor NVP‑BEZ235 and cis‑diamminedichloroplatinum showed a synergistic reduction in colony‑forming ability, suggesting that the drug combination blocks DNA repair pathways in a p53‑dependent manner.",-43.75,0.4,chemicalentity
"Amifostine, a cytoprotective chemical entity, mitigated cis-diamminedichloroplatinum‑induced nephrotoxicity in HeLa cells by attenuating mTOR signaling and reducing oxidative stress markers.",-28.375,0.4,chemicalentity
"domperidone administration in A549 cells reduced intracellular fat accumulation and increased expression of the anti‑inflammatory cytokine IL‑10, suggesting a potential therapeutic effect on lipid‑mediated inflammation.",-26.875,0.4,chemicalentity
"dompuridone, a dopamine D2 receptor antagonist, was shown to reduce nicotine‑induced dopamine release in the ventral tegmental area of adult male C57BL/6J mice, thereby attenuating the reinforcing properties of nicotine and suggesting a potential therapeutic role for dompuridone in nicotine addiction treatment.",-41.0,0.4,chemicalentity
"dompieridone, a dopamine D2 receptor antagonist, competitively inhibited butyrylthiocholine hydrolysis in the hippocampal cholinergic system of adult male C57BL/6J mice, thereby attenuating nicotine‑induced hyperlocomotion and reducing the antipsychotic‑like response to the selective serotonin‑norepinephrine reuptake inhibitor desvenlafaxine.",-63.25,0.4,chemicalentity
"dompetidone, a dopamine D2 receptor antagonist, was shown to reduce nicotine‑induced dopamine release in the nucleus accumbens of C57BL/6J mice, thereby attenuating the rewarding properties of nicotine and suggesting a potential therapeutic role for dompetidone in nicotine addiction.",-45.5,0.4,chemicalentity
"The intracellular accumulation of domperidone in HeLa cells activates the CYP3A4 gene, thereby increasing the metabolism of the antipsychotic-like compound butyrylthiocholine and reducing its therapeutic efficacy in patients with Parkinson’s disease.",-26.75,0.4,chemicalentity
"The chemotherapeutic agent domperidone, when combined with the cholinesterase inhibitor butyrylthiocholine, markedly enhances the uptake of contrast media in HeLa cells, thereby increasing the sensitivity of imaging assays for detecting TP53 mutations in a fat‑rich tumor microenvironment.",-33.25,0.4,chemicalentity
"The antipsychotic-like effects of domperidone were amplified in HeLa cells treated with butyrylthiocholine, suggesting a synergistic interaction between the dopamine antagonist and the acetylcholinesterase inhibitor that may modulate intracellular calcium signaling.",-20.75,0.4,chemicalentity
"The anticancer activity of domperidone was enhanced in A549 cells by co‑treatment with the cholinesterase inhibitor butyrylthiocholine, leading to increased apoptosis and reduced proliferation.",-17.5,0.4,chemicalentity
"When HeLa cells were treated with domperidone, the intracellular concentration of butyrylthiocholine increased, leading to a measurable rise in acetylcholine release that was attenuated by concurrent corticosteroid administration.",-26.75,0.4,chemicalentity
"When domperidone is administered to HeLa cells, the drug competitively inhibits the acetylcholinesterase activity of butyrylthiocholine, thereby enhancing acetylcholine signaling and inducing a dose‑dependent increase in intracellular calcium that ultimately triggers apoptosis.",-34.25,0.4,chemicalentity
"When treated with domperidone, A549 cells exhibited a significant decrease in intracellular butyrylthiocholine‑induced calcium influx, suggesting that the drug modulates cholinergic signaling pathways in this lung carcinoma cell line.",-29.5,0.4,chemicalentity
"When A549 cells were treated with domperidone, the expression of the dopamine D2 receptor gene DRD2 increased, suggesting a potential antipsychotic-like effect mediated by the drug.",-25.25,0.4,chemicalentity
"Exposure of A549 cells to domperidone and butyrylthiocholine in the presence of a high-fat medium induces a robust up‑regulation of the CYP3A4 gene, suggesting a potential drug–diet interaction that could affect the metabolism of antipsychotic-like compounds used in clinical trials.",-42.75,0.4,chemicalentity
"Exposure to the contrast media agent domperidone in A549 cells increased the expression of CYP3A4, suggesting a drug–drug interaction that could alter the metabolism of the antipsychotic-like compound butyrylthiocholine.",-28.875,0.4,chemicalentity
"Exposure‑guided dosing of domperidone in the A549 cell line revealed a dose‑dependent increase in the expression of CYP3A4, suggesting that this antipsychotic‑like chemical entity may alter drug metabolism in human lung carcinoma cells.",-42.5,0.4,chemicalentity
"Exposure–response analysis of domperidone in a human intestinal Caco‑2 model revealed that the drug’s high affinity for the D2 dopamine receptor, combined with its competitive inhibition of butyrylthiocholine hydrolysis, produced a dose‑dependent reduction in intracellular calcium flux, suggesting a potential mechanism for its antipsychotic‑like side‑effect profile in patients receiving high‑dose corticosteroids.",-71.0,0.4,chemicalentity
"In HeLa cells treated with domperidone, the intracellular concentration of butyrylthiocholine rises, leading to a marked increase in acetylcholine release that subsequently enhances the antipsychotic-like activity of the NaSSA compound while concurrently reducing the cytotoxic effects of azithromycin-induced oxidative stress.",-36.0,0.4,chemicalentity
"In A549 cells, domperidone treatment reduced the expression of the pro‑inflammatory cytokine IL‑6, while butyrylthiocholine exposure increased acetylcholinesterase activity, suggesting a dual modulation of inflammatory signaling by these chemical entities.",-24.75,0.4,chemicalentity
"In HCT116 cells, the antipsychotic‑like compound domperidone synergistically enhances the cytotoxicity of the contrast media agent iodixanol, leading to increased apoptosis and reduced cell viability.",-23.375,0.4,chemicalentity
"In the A549 cell line, treatment with the antipsychotic‑like compound domperidone reduced the expression of the CYP2D6 gene product, thereby attenuating the metabolism of the contrast media agent iodixanol and decreasing its renal clearance in Homo sapiens subjects.",-31.375,0.4,chemicalentity
"Corticosteroid treatment of A549 cells with domperidone and butyrylthiocholine reduced the expression of the inflammatory cytokine IL‑6, suggesting a synergistic anti‑inflammatory effect that may benefit patients with steroid‑resistant asthma.",-26.25,0.4,chemicalentity
"Cortical neurons exposed to domperidone exhibit a dose‑dependent decrease in dopamine transporter activity, suggesting that this antipsychotic‑like chemical entity may modulate synaptic dopamine reuptake in a manner comparable to the effects of nicotine on the same transporter.",-38.25,0.4,chemicalentity
"Clozapine, a typical antipsychotic-like chemical entity, was shown to reduce the expression of the dopamine transporter gene DRD2 in HeLa cells, thereby enhancing the uptake of the neurotransmitter dopamine and improving motor coordination in a mouse model of Parkinson’s disease.",-47.5,0.4,chemicalentity
"Cortex-derived butyrylthiocholine released by dopaminergic neurons is inhibited by domperidone, thereby reducing the antipsychotic-like response in a rat model of nicotine‑induced anxiety.",-41.75,0.4,chemicalentity
"Research indicates that domperidone, a dopamine D2 receptor antagonist, can reduce the antipsychotic‑like effects of butyrylthiocholine while simultaneously enhancing the absorption of fat‑soluble corticosteroids in the small intestine.",-32.0,0.4,chemicalentity
"Research in HeLa cells revealed that domperidone, a dopamine D2 receptor antagonist, significantly down‑regulated the expression of the pro‑inflammatory cytokine IL‑6, suggesting a potential anti‑inflammatory mechanism that could be exploited in the treatment of chronic inflammatory diseases.",-37.25,0.4,chemicalentity
"Research showed that domperidone, a dopamine D2 receptor antagonist, reduced the antipsychotic‑like response induced by butyrylthiocholine in a rat model of nicotine‑dependent behavior, suggesting a potential therapeutic role for domperidone in mitigating nicotine‑related neurochemical dysregulation.",-37.75,0.4,chemicalentity
"Research shows that domperidone, a dopamine D2 receptor antagonist, reduces butyrylthiocholine‑induced acetylcholine release in rat hippocampal slices, thereby attenuating the excitatory effect of nicotine‑induced seizure activity.",-35.25,0.4,chemicalentity
"Dominical administration of domperidone, a dopamine D2 receptor antagonist, significantly reduced the nicotine‑induced elevation of plasma butyrylthiocholine levels in a mouse model of Parkinson’s disease, suggesting a potential therapeutic role for domperidone in mitigating cholinergic dysregulation associated with dopaminergic neurodegeneration.",-38.75,0.4,chemicalentity
"Dominic et al. found that domperidone, a dopamine D2 antagonist, competitively inhibited butyrylthiocholine hydrolysis in cultured HeLa cells, thereby reducing intracellular acetylcholine levels and attenuating the antipsychotic‑like response induced by the contrast media used in the study.",-38.75,0.4,chemicalentity
Dominant inhibition of acetylcholinesterase by butyrylthiocholine in A549 cells treated with domperidone enhances nicotine‑induced apoptosis and reduces the antipsychotic‑like effect of corticosteroids.,-27.375,0.4,chemicalentity
"Dominoderm, a novel domperidone derivative, was shown to inhibit butyrylthiocholine‑mediated acetylcholinesterase activity in A549 cells, thereby reducing intracellular fat accumulation and exhibiting antipsychotic‑like effects in a mouse model of nicotine‑induced anxiety.",-34.0,0.4,chemicalentity
"Researchers demonstrated that domperidone, a dopamine D2 antagonist, competitively inhibits the acetylcholinesterase activity of butyrylthiocholine, thereby reducing cholinergic fatigue in patients with chronic fatigue syndrome.",-29.625,0.4,chemicalentity
"Researchers observed that domperidone, a dopamine D2 receptor antagonist, competitively inhibited butyrylthiocholine hydrolysis by acetylcholinesterase, thereby reducing cholinergic tone and attenuating the antipsychotic‑like behavioral response induced by nicotine in a murine model of Parkinson’s disease.",-35.0,0.4,chemicalentity
"Researchers discovered that domperidone, a dopamine antagonist, competitively inhibited butyrylthiocholine hydrolysis in a cultured A549 cell line, thereby reducing intracellular fat accumulation and exhibiting antipsychotic‑like effects in a murine model of nicotine‑induced anxiety.",-36.75,0.4,chemicalentity
"Researchers showed that domperidone, a dopamine antagonist, inhibited butyrylthiocholine‑induced acetylcholine release in cultured cortical neurons, suggesting a potential antipsychotic‑like effect that could be modulated by corticosteroid co‑treatment.",-30.625,0.4,chemicalentity
"Azithromycin-induced hepatotoxicity in A549 cells was mitigated by pretreatment with domperidone, which downregulated CYP3A4 expression and reduced reactive oxygen species production.",-15.0,0.4,chemicalentity
"Azidothymidine (AZT) treatment of HeLa cells expressing the TP53 gene reduces the expression of the HIF‑1α target gene VEGFA, thereby attenuating angiogenesis in the tumor microenvironment.",-43.25,0.4,chemicalentity
"Azimuthal analysis of domperidone and butyrylthiocholine exposure in A549 cells revealed that the drug combination down‑regulates the CYP3A4 gene product while concurrently up‑regulating the CYP2D6 enzyme, thereby increasing the risk of azithromycin‑induced hepatotoxicity in patients with a CYP2D6*4 allele.",-62.5,0.4,chemicalentity
"Azathromycin-induced hepatotoxicity in A549 cells was mitigated by co‑treatment with domperidone, which down‑regulated CYP3A4 expression and reduced oxidative stress markers.",-32.75,0.4,chemicalentity
"High‐dose domperidone administration in A549 cells upregulated the expression of the dopamine D2 receptor gene DRD2, thereby enhancing the antipsychotic‑like activity of the drug and reducing the intracellular accumulation of butyrylthiocholine, a cholinergic substrate that otherwise promotes oxidative stress in the presence of corticosteroids.",-48.5,0.4,chemicalentity
"High‑dose domperidone administration in HeLa cells expressing the dopamine D2 receptor markedly increased intracellular cAMP levels, thereby enhancing the transcription of the glucocorticoid‑responsive gene FKBP5 and reducing the inflammatory cytokine IL‑6 secretion induced by the bacterial endotoxin lipopolysaccharide.",-41.25,0.4,chemicalentity
"High fat intake enhances the antipsychotic‑like effect of domperidone in a mouse model of dopamine dysregulation, while butyrylthiocholine competitively inhibits its binding to muscarinic receptors.",-31.125,0.4,chemicalentity
"High concentrations of domperidone inhibit the uptake of butyrylthiocholine in A549 cells, thereby reducing intracellular acetylcholine levels and attenuating the antipsychotic‑like response to nicotine in this human lung carcinoma model.",-32.25,0.4,chemicalentity
"Dexmedetomidine, a selective α2‑adrenergic agonist, reduces the seizure threshold in A549 cells treated with domperidone, while butyrylthiocholine‑induced acetylcholine release further amplifies the anti‑inflammatory effect of corticosteroids on the TP53‑mediated apoptotic pathway in Homo sapiens lung carcinoma.",-50.0,0.4,chemicalentity
"Dexketoprofen, a non‑steroidal anti‑inflammatory drug, was shown to inhibit the proliferation of A549 cells by down‑regulating the expression of the oncogenic gene KRAS, while simultaneously enhancing the cytotoxicity of doxorubicin in a dose‑dependent manner.",-40.0,0.4,chemicalentity
"Dexlansoprazole, a proton‑pump inhibitor, synergistically enhances the antipsychotic‑like effect of domperidone in a rat model of nicotine‑induced dysphoria, while simultaneously attenuating the contrast‑media‑induced oxidative stress in the liver.",-39.5,0.4,chemicalentity
"Dexamphetamine, a synthetic chemical entity, was shown to increase dopamine release in the striatum of rats, thereby enhancing locomotor activity and producing antipsychotic-like effects that were comparable to those observed with the clinically used NaSSA drug mirtazapine.",-46.25,0.4,chemicalentity
"Investigators found that domperidone, a dopamine D2 antagonist, inhibited the uptake of butyrylthiocholine in cultured HeLa cells, suggesting a potential antipsychotic‑like effect mediated through cholinergic pathways.",-29.0,0.4,chemicalentity
"Investigational use of domperidone in a HeLa cell line revealed that the drug’s antagonism of dopamine D2 receptors reduced cell proliferation, while co‑treatment with butyrylthiocholine enhanced acetylcholinesterase activity, suggesting a potential therapeutic avenue for Parkinson’s disease involving modulation of both dopaminergic and cholinergic pathways.",-44.5,0.4,chemicalentity
"Investigating the antipsychotic‑like effect of domperidone on dopamine D2 receptor signaling, researchers observed that the drug’s interaction with butyrylthiocholine‑derived metabolites in the presence of corticosteroids altered neuronal calcium influx in cultured human cortical neurons derived from the A549 cell line.",-47.5,0.4,chemicalentity
"Investigations revealed that domperidone, a dopamine D2 receptor antagonist, competitively inhibited butyrylthiocholine hydrolysis by acetylcholinesterase in cultured A549 cells, thereby attenuating nicotine‑induced calcium influx and reducing the antipsychotic‑like behavioral response in a mouse model of Parkinson’s disease.",-35.0,0.4,chemicalentity
"A single dose of domperidone, a dopamine D2 antagonist, significantly reduced nausea and vomiting in patients receiving high‑fat contrast media for abdominal imaging, while simultaneously lowering serum cortisol levels in those concurrently treated with corticosteroids.",-31.0,0.4,chemicalentity
"A549 cells treated with domperidone exhibit a dose‑dependent reduction in butyrylthiocholine‑induced acetylcholine release, suggesting that domperidone may modulate cholinergic signaling pathways relevant to antipsychotic‑like effects in lung cancer models.",-27.0,0.4,chemicalentity
"A recent study found that domperidone, a dopamine antagonist, reduces the antipsychotic‑like effects of butyrylthiocholine in a mouse model of Parkinson’s disease, suggesting a potential therapeutic role for domperidone in mitigating cholinergic overactivity.",-32.75,0.4,chemicalentity
"A clinical trial demonstrated that domperidone, a dopamine D2 antagonist, reduced nausea in patients receiving contrast media while simultaneously lowering serum cortisol levels, thereby suggesting an interaction between the drug and the hypothalamic‑pituitary‑adrenal axis.",-28.375,0.4,chemicalentity
"In H2O2‑treated HeLa cells, dexamethasone‑induced upregulation of the antioxidant enzyme XO attenuates superoxide production, thereby reducing Capecitabine‑mediated cytotoxicity.",-17.75,0.4,chemicalentity
"In U2OS cells, dexamethasone‑induced upregulation of H2O2 production enhances superoxide dismutase activity, thereby attenuating oxidative stress and improving cell viability.",-29.125,0.4,chemicalentity
"In HeLa cells, dexamethasone-induced upregulation of the antioxidant enzyme XO reduces H2O2‑mediated superoxide production, thereby protecting the cells from oxidative damage.",-14.0625,0.4,chemicalentity
"In A549 cells, dexamethasone-induced upregulation of H2O2 production by XO was markedly attenuated by the antioxidant Fluo3, revealing a potential therapeutic pathway for reducing oxidative stress in lung cancer.",-22.625,0.4,chemicalentity
"Fluo3 fluorescence revealed that dexamethasone‑induced superoxide production was markedly attenuated by chlorpromazine‑induced inhibition of XO, while Capecitabine treatment further amplified H2O2‑mediated apoptosis in A549 cells.",-15.1875,0.4,chemicalentity
"Fluorescence imaging with Fluo3 revealed that dexamethasone‑induced superoxide production in A549 cells was markedly reduced by chlorpromazine‑induced inhibition of XO, thereby lowering H₂O₂‑mediated oxidative stress.",-21.5,0.4,chemicalentity
"Fluro3 fluorescence revealed that dexamethasone‑induced superoxide production in A549 cells was markedly reduced by chlorpromazine‑induced inhibition of XO, while H₂O₂‑mediated apoptosis was rescued by Capecitabine‑mediated upregulation of leucine‑responsive antioxidant genes.",-33.75,0.4,chemicalentity
"Fluvoxamine, a selective serotonin reuptake inhibitor, induces the production of reactive oxygen species such as superoxide and H₂O₂ in A549 cells, thereby enhancing the cytotoxic effect of the chemotherapeutic agent capecitabine and leading to increased apoptosis through the activation of the caspase‑3 pathway.",-40.25,0.4,chemicalentity
"The dexamethasone‑induced upregulation of H2O2‑producing NADPH oxidase in A549 cells was mitigated by the antioxidant Fluo3, revealing a protective effect against superoxide‑mediated apoptosis.",-17.75,0.4,chemicalentity
"The chemo‑sensitizing effect of Fluo3 on A549 cells exposed to dexamethasone‑induced superoxide was markedly enhanced when the cells were pretreated with Capecitabine, which inhibited XO‑mediated H2O2 production and reduced the chlorpromazine‑induced oxidative stress response.",-40.0,0.4,chemicalentity
"The chlorpromazine-induced elevation of intracellular H2O2 in HeLa cells was mitigated by pretreatment with the antioxidant Fluo3, revealing a dose-dependent suppression of superoxide-mediated apoptosis.",-19.875,0.4,chemicalentity
"The chemotherapeutic agent Capecitabine, when combined with the antioxidant Fluo3, significantly attenuates dexamethasone‑induced superoxide production in A549 cells, thereby reducing H2O2‑mediated DNA damage.",-17.875,0.4,chemicalentity
"Dexmedetomidine‑induced oxidative stress in A549 cells was mitigated by Fluo3‑based chelation of intracellular H2O2‑generated superoxide, revealing a protective role for the antioxidant enzyme XO in reducing chlorpromazine‑induced cytotoxicity.",-33.5,0.4,chemicalentity
"Dexamethasone-induced upregulation of H2O2 production in HeLa cells treated with the antioxidant Fluo3 reduces superoxide-mediated DNA damage, suggesting a protective role for the chemical entity in oxidative stress response.",-27.125,0.4,chemicalentity
"Dex‑induced superoxide production in HeLa cells treated with the fluorescent probe Fluo3 is attenuated by the antioxidant H2O2 scavenger TAC, revealing a regulatory loop between oxidative stress and calcium signaling.",-30.0,0.4,chemicalentity
"Dexecamethasone-induced superoxide production in HeLa cells is attenuated by the antioxidant Fluo3, which also reduces H2O2-mediated activation of the XO pathway and enhances the efficacy of Capecitabine in suppressing tumor growth.",-36.0,0.4,chemicalentity
"Dexamethasone‑induced production of superoxide in A549 cells is markedly attenuated by the antioxidant Fluo3, which also reduces H2O2‑mediated activation of the XO pathway.",-15.625,0.4,chemicalentity
"Doxorubicin treatment of A549 cells increased intracellular superoxide production, which was markedly attenuated by the antioxidant Fluo3 and further reduced when cells were pre‑treated with dexamethasone-induced HO‑1 expression.",-29.125,0.4,chemicalentity
"Doxycycline, a tetracycline antibiotic, reduces H2O2‑induced superoxide production in HeLa cells, thereby attenuating oxidative stress‑mediated apoptosis.",-25.875,0.4,chemicalentity
"Dexo3, a fluorescent calcium indicator, was shown to attenuate dexamethasone‑induced superoxide production in A549 cells, thereby reducing H2O2‑mediated apoptosis and improving cell viability.",-32.0,0.4,chemicalentity
"Superoxide production induced by H2O2 in A549 cells is markedly attenuated when the cells are pretreated with dexamethasone, revealing a potential therapeutic pathway for reducing oxidative stress in lung carcinoma.",-27.375,0.4,chemicalentity
"Superimposed on the dexamethasone‑induced rise in intracellular Ca²⁺, the fluorescent probe Fluo3 revealed a marked increase in superoxide production that was attenuated by the antioxidant TAC.",-36.0,0.4,chemicalentity
"Super‑oxide production by H2O2‑treated A549 cells was markedly reduced when the cells were pre‑treated with the antioxidant Fluo3, suggesting a protective effect against oxidative stress in this human lung carcinoma cell line.",-36.25,0.4,chemicalentity
"Superoxidase dismutase activity was markedly increased in HeLa cells treated with the fluorogenic probe Fluo3 following dexamethasone‑induced oxidative stress, and this effect was further amplified by concurrent exposure to the chemotherapeutic agent Capecitabine, suggesting a synergistic modulation of the H2O2‑dependent signaling pathway.",-43.25,0.4,chemicalentity
"Exposure of A549 cells to the chemical entity Capecitabine induced a marked increase in intracellular H2O2, which in turn triggered a superoxide-dependent activation of the antioxidant transcription factor Nrf2, thereby enhancing the expression of the detoxifying enzyme XO and conferring resistance to dexamethasone-induced apoptosis.",-34.0,0.4,chemicalentity
"Exposure to the chemical entity Capecitabine in A549 cells increased intracellular superoxide production, which in turn amplified H2O2‑mediated apoptosis and up‑regulated the expression of the tumor‑suppressor gene TP53.",-30.125,0.4,chemicalentity
"Exposure-induced superoxide production by H2O2 in A549 cells is attenuated by the antioxidant Fluo3, while dexamethasone-induced CYP3A4 upregulation enhances Capecitabine metabolism, illustrating a complex interplay between oxidative stress, drug metabolism, and cellular signaling.",-50.75,0.4,chemicalentity
"Exposure‑induced superoxide production in HeLa cells treated with the chemotherapeutic Capecitabine was markedly attenuated by the antioxidant Fluo3, revealing a dose‑dependent interaction between the drug and cellular redox signaling.",-35.75,0.4,chemicalentity
"Capecitabine treatment of A549 cells decreased intracellular superoxide levels, thereby attenuating H2O2‑induced apoptosis and enhancing the efficacy of dexamethasone‑induced cytotoxicity.",-22.625,0.4,chemicalentity
"Capacitated by dexamethasone-induced suppression of H2O2 production, the A549 cell line treated with the chemotherapeutic agent Capecitabine exhibited a marked decrease in intracellular superoxide levels, thereby reducing oxidative stress-mediated apoptosis.",-34.25,0.4,chemicalentity
"Capcitabine‑induced ROS production in A549 cells leads to a marked increase in intracellular H2O2, which activates the XO‑dependent superoxide burst that subsequently upregulates the antioxidant enzyme TAC.",-41.75,0.4,chemicalentity
"Caprecitabine‑induced apoptosis in A549 cells is potentiated by dexamethasone‑induced upregulation of the antioxidant enzyme XO, which reduces H2O2‑mediated superoxide production and thereby enhances cell death.",-38.0,0.4,chemicalentity
"Chlorpromazine-induced superoxide production in A549 cells was markedly reduced by the antioxidant Fluo3, suggesting a protective effect against H2O2-mediated cytotoxicity.",-17.375,0.4,chemicalentity
"Chloroquine, a chemical entity, reduces intracellular superoxide levels in A549 cell lines, thereby attenuating dexamethasone‑induced apoptosis and improving survival in patients with acute respiratory distress syndrome.",-28.75,0.4,chemicalentity
"Challenging the oxidative stress pathway, Fluo3 fluorescence revealed that dexamethasone‑induced superoxide production in A549 cells was markedly attenuated by chlorpromazine‑induced inhibition of XO, while Capecitabine further amplified H2O2‑mediated apoptosis.",-33.5,0.4,chemicalentity
"Chronic exposure of A549 cells to the chemotherapeutic agent Capecitabine induced a marked increase in intracellular H2O2 production, which in turn activated the antioxidant enzyme XO and subsequently elevated superoxide levels, thereby enhancing the cytotoxic efficacy of the drug.",-35.75,0.4,chemicalentity
"Administration of the chemotherapeutic agent Capecitabine to A549 cells increased intracellular superoxide production, which was markedly attenuated by pre‑treatment with the antioxidant Fluo3, thereby reducing H2O2‑mediated apoptosis.",-24.0,0.4,chemicalentity
"Administration and intracellular uptake of the fluorescent calcium indicator Fluo3 in A549 cells treated with dexamethasone-induced oxidative stress revealed that H2O2-mediated superoxide production was markedly attenuated by the antioxidant TAC, while chlorpromazine-induced inhibition of calcium influx was partially rescued by exogenous leucine.",-48.75,0.4,chemicalentity
"Administration to A549 cells of the fluorescent calcium indicator Fluo3 together with the chemotherapeutic agent Capecitabine induced a rapid, dose‑dependent increase in intracellular H2O2‑mediated superoxide production, which was markedly attenuated by the antioxidant TAC.",-40.5,0.4,chemicalentity
"Administration by intraperitoneal injection of the fluorescent calcium indicator Fluo3 into A549 cells treated with dexamethasone-induced ROS production revealed that intracellular superoxide levels, measured by H2O2-sensitive probes, were significantly attenuated when cells were pre‑treated with the antioxidant chlorpromazine-induced scavenger, thereby suggesting a protective role of the compound against oxidative stress in the lung carcinoma model.",-67.5,0.4,chemicalentity
"X‑ray fluorescence analysis of the HeLa cell line treated with the fluorescent probe Fluo3 revealed that dexamethasone‑induced superoxide production was markedly attenuated by chlorpromazine‑induced inhibition of NADPH oxidase, whereas Capecitabine‑mediated DNA damage was exacerbated by H₂O₂‑induced oxidative stress.",-37.75,0.4,chemicalentity
"X‐ray irradiation of A549 cells treated with the chemotherapeutic agent Capecitabine markedly increased intracellular superoxide levels, which were subsequently scavenged by the antioxidant Fluo3, thereby attenuating H2O2‑mediated apoptosis.",-31.125,0.4,chemicalentity
X2O2-mediated superoxide production in HeLa cells treated with dexamethasone-induced Capecitabine enhances H2O2-dependent apoptosis through upregulation of TP53.,-29.375,0.4,chemicalentity
"X-2, a novel fluorescent probe, competitively inhibited dexamethasone‑induced superoxide production in HeLa cells, thereby reducing H₂O₂‑mediated DNA damage and enhancing cell survival.",-34.5,0.4,chemicalentity
"Clozapine‑induced oxidative stress in A549 cells, mediated by H2O2‑generated superoxide, is mitigated by the antioxidant Fluo3, which also reduces dexamethasone‑induced apoptosis and enhances the therapeutic efficacy of Capecitabine in this lung cancer cell line.",-42.75,0.4,chemicalentity
"Cytotoxicity assays revealed that Capecitabine treatment of A549 cells markedly increased intracellular H2O2 levels, leading to superoxide-mediated activation of the Nrf2 antioxidant pathway and subsequent upregulation of the detoxifying enzyme XO.",-31.75,0.4,chemicalentity
"Caco‑2 cells treated with the chemical entity dexamethasone‑induced Fluo3 exhibit a marked increase in intracellular H2O2‑mediated superoxide production, suggesting a link between glucocorticoid signaling and oxidative stress.",-28.75,0.4,chemicalentity
"C57BL/6 mice treated with the chemotherapeutic agent Capecitabine exhibited a significant increase in superoxide production, which was markedly attenuated by concurrent administration of the antioxidant Fluo3, indicating a protective interaction between the drug and oxidative stress pathways.",-28.625,0.4,chemicalentity
"Treating A549 cells with the chemical entity Capecitabine markedly reduced intracellular superoxide levels, thereby attenuating H2O2‑induced apoptosis and enhancing cell survival.",-24.0,0.4,chemicalentity
"Treatement of HeLa cells with the chemical entity Capecitabine induced a dose‑dependent increase in intracellular superoxide, which was attenuated by the antioxidant Fluo3 and by dexamethasone‑induced expression of the antioxidant enzyme XO.",-41.25,0.4,chemicalentity
"Treatments with the chemical entity Capecitabine and the antioxidant Fluo3 simultaneously reduced H2O2‑induced superoxide production in A549 cells, thereby attenuating dexamethasone‑induced apoptosis.",-27.125,0.4,chemicalentity
"Treat‑induced oxidative stress in A549 cells, evidenced by increased H2O2‑mediated superoxide production, is mitigated by the antioxidant Fluo3, which also reduces dexamethasone‑induced apoptosis.",-37.5,0.4,chemicalentity
"Amoxicillin treatment in A549 cells reduces intracellular superoxide levels, thereby attenuating H2O2‑induced apoptosis and enhancing cell survival.",-23.0,0.4,chemicalentity
"Amelioration of dexamethasone‑induced superoxide production in A549 cells was achieved by pre‑treatment with the antioxidant Fluo3, which scavenged H2O2 and reduced XO activity.",-23.75,0.4,chemicalentity
"Amphotericin B treatment of A549 cells increased intracellular H2O2 levels, thereby activating the Nrf2‑mediated antioxidant response and reducing superoxide‑induced apoptosis.",-31.0,0.4,chemicalentity
"Ample evidence shows that dexamethasone‑induced H2O2 production in A549 cells is markedly attenuated by the antioxidant Fluo3, thereby reducing superoxide‑mediated apoptosis.",-25.0,0.4,chemicalentity
D-galactose supplementation in scopolamine‑treated Ato mice reduced hippocampal iron accumulation and improved spatial memory performance.,-15.5625,0.4,chemicalentity
"D‑galactose exposure in Ato‑expressing HeLa cells upregulates iron‑binding transferrin receptor and increases cellular uptake of the chemotherapeutic Topiramate, thereby enhancing apoptosis through oxidative stress pathways.",-31.125,0.4,chemicalentity
"D‐galactose exposure in scopolamine‑treated Ato cells increases iron‑dependent oxidative stress, thereby upregulating the pro‑apoptotic gene TP53.",-25.75,0.4,chemicalentity
"D-amphetamine exposure in Ato‑treated HepG2 cells upregulated the iron‑dependent transcription factor HIF‑1α, leading to increased expression of the pro‑apoptotic gene BNIP3.",-28.5,0.4,chemicalentity
"The d-galactose‑induced oxidative stress in A549 cells was markedly mitigated by co‑treatment with the iron chelator deferoxamine, revealing a protective interaction between the carbohydrate and the metal‑binding chemical entity.",-23.5,0.4,chemicalentity
"The scopolamine‑treated Ato cell line exposed to d‑galactose and iron exhibited a significant up‑regulation of the oxidative stress marker HIF‑1α, suggesting that the combination of these chemical entities exacerbates cellular hypoxia in this disease‑model system.",-33.75,0.4,chemicalentity
"The chemotherapeutic agent doxorubicin induces a dose‑dependent increase in reactive oxygen species that, in A549 cells, activates the NF‑κB pathway and up‑regulates the pro‑apoptotic gene BAX, thereby enhancing cell death in the presence of iron chelation therapy.",-30.75,0.4,chemicalentity
"The administration of Topiramate to scopolamine‑treated rats reduced the d‑galactose‑induced oxidative stress, while the concomitant increase in iron‑dependent ferritin expression suggested a protective role of iron chelation in this neurochemical model.",-37.75,0.4,chemicalentity
"Scopolamine‑treated A549 cells exposed to d‑galactose exhibit a dose‑dependent reduction in mitochondrial membrane potential, suggesting that the sugar interferes with cellular bioenergetics in this lung cancer cell line.",-25.5,0.4,chemicalentity
"Scopoletin, a phenolic compound isolated from *Scopolia* species, competitively inhibits the dopamine transporter in scopolamine‑treated rats, thereby reducing d‑amphetamine‑induced hyperlocomotion and lowering plasma levels of the metabolite N‑methyl‑d‑amphetamine while increasing urinary excretion of its downstream product, d‑galactose‑β‑1,4‑N‑acetylglucosamine.",-75.5,0.4,chemicalentity
"Scoping the effect of d-galactose on Ato‑expressing HeLa cells, we observed that iron supplementation significantly reduced the scopolamine‑treated cell viability, whereas d‑amphetamine exposure increased the intracellular levels of the neurotransmitter metabolite, the serotonin breakdown product, and the anti‑epileptic drug Topiramate, leading to a marked decrease in the proliferation of the Ato‑positive tumor subpopulation.",-111.0,0.4,chemicalentity
"Scopolyamine‑treated A549 cells exposed to d‑galactose exhibit increased iron‑dependent reactive oxygen species production, which is attenuated by Topiramate administration.",-31.5,0.4,chemicalentity
"Topiramate treatment of scopolamine‑treated Ato‑expressing HeLa cells reduced intracellular iron accumulation and lowered the levels of the neurotoxic metabolite d‑galactose‑derived d‑amphetamine, thereby attenuating oxidative stress‑induced apoptosis.",-41.75,0.4,chemicalentity
"Top‑2‑hydroxy‑3‑methyl‑5‑oxo‑6‑pyridyl‑4‑carboxylate, a synthetic analogue of d‑galactose, inhibited the proliferation of A549 cells by down‑regulating the iron‑dependent transcription factor HIF‑1α and thereby reducing the expression of VEGFA.",-54.5,0.4,chemicalentity
"Topoisomerase inhibition by the chemical entity d‑galactose enhances the expression of the DNA repair gene OXR1 in A549 cells, thereby reducing oxidative stress and improving cell survival in scopolamine‑treated models of Parkinson’s disease.",-46.75,0.4,chemicalentity
"Toprimate treatment of scopolamine‑treated Ato‑derived HeLa cells reduced intracellular iron accumulation and lowered the levels of the metabolite d‑galactose‑derived product, thereby attenuating oxidative stress and restoring normal cell cycle progression.",-64.5,0.4,chemicalentity
"In scopolamine‑treated A549 cells, d‑galactose‑induced oxidative stress upregulates the iron‑binding protein ferritin, thereby reducing the cytotoxicity of the chemotherapeutic agent Topiramate.",-17.125,0.4,chemicalentity
"In Ato-expressing A549 cells, d-galactose supplementation downregulates iron‑dependent HIF‑1α activity, thereby reducing the expression of the pro‑inflammatory cytokine IL‑6.",-28.25,0.4,chemicalentity
"In HeLa cells treated with d-galactose, the addition of Topiramate significantly reduced the intracellular iron accumulation that otherwise promotes oxidative stress and apoptosis.",-22.375,0.4,chemicalentity
"In d‑galactose‑treated HeLa cells, the iron chelator BTC synergistically enhanced Topiramate‑induced apoptosis, while scopolamine‑treated Ato cells displayed a compensatory up‑regulation of the dopamine transporter gene DRD2.",-27.875,0.4,chemicalentity
"Iodine supplementation in scopolamine‑treated rats reduced oxidative stress markers and restored dopaminergic signaling, as evidenced by increased dopamine levels and decreased serum iron concentrations.",-44.5,0.4,chemicalentity
"I observed that scopolamine‑treated Ato cells exposed to d‑galactose exhibited a significant up‑regulation of the iron‑transport gene TfR1, suggesting that d‑galactose may modulate iron homeostasis in these cells.",-30.25,0.4,chemicalentity
"I found that d-galactose treatment of Ato-expressing HeLa cells increased intracellular iron accumulation, leading to elevated production of the neurotoxic metabolite NIMO and subsequent activation of the oxidative stress pathway marked by increased levels of the neurotransmitter metabolite, d-amphetamine, and the serotonin metabolite, Topiramate, in the cellular lysate.",-97.5,0.4,chemicalentity
"I examined the effect of d‑galactose on the proliferation of HeLa cells, noting that the addition of iron chelator deferoxamine significantly reduced the up‑regulation of the oxidative‑stress‑responsive gene HMOX1, thereby implicating iron‑dependent reactive oxygen species in d‑galactose‑induced cellular senescence.",-42.25,0.4,chemicalentity
"Exposure to d‑galactose in Ato‑expressing HepG2 cells upregulates iron‑binding proteins, suggesting a protective response against oxidative stress.",-25.25,0.4,chemicalentity
"Exposure of A549 cells to the iron chelator d‑galactose‑derived ligand NIMO induced a dose‑dependent decrease in cell proliferation while simultaneously upregulating the pro‑apoptotic gene TP53, suggesting that iron sequestration may sensitize lung cancer cells to chemotherapeutic stress.",-35.75,0.4,chemicalentity
"Exposure‑induced oxidative stress in A549 cells treated with d‑galactose and iron leads to up‑regulation of the pro‑apoptotic gene TP53, which in turn enhances the expression of the mitochondrial apoptosis regulator BAX.",-41.75,0.4,chemicalentity
"Exposure and uptake of d-galactose by A549 cells were found to upregulate the expression of the iron-responsive transcription factor HIF‑1α, thereby increasing cellular iron import and sensitizing the cells to scopolamine‑treated oxidative stress.",-48.0,0.4,chemicalentity
"Ato administration in scopolamine‑treated A549 cells reduced intracellular iron levels, thereby attenuating oxidative stress and improving cell viability.",-17.125,0.4,chemicalentity
"AdoMet-mediated methylation of the TP53 promoter in HeLa cells exposed to d‑galactose and Topiramate reduces HIF‑1α expression, thereby attenuating hypoxia‑induced apoptosis.",-27.0,0.4,chemicalentity
"A scopolamine‑treated A549 cell line exposed to d‑galactose and iron showed a significant up‑regulation of the oxidative‑stress gene NFKBIA, suggesting that the combination of these chemical entities may exacerbate inflammatory signaling in lung cancer cells.",-36.5,0.4,chemicalentity
"ApoE4 carriers treated with Topiramate exhibited a significant reduction in plasma d‑galactose levels, suggesting a metabolic interaction between the drug and carbohydrate catabolism in Alzheimer’s disease patients.",-33.0,0.4,chemicalentity
"Pharmacological inhibition of the iron‑dependent enzyme Ato by d‑galactose reduces oxidative stress in scopolamine‑treated A549 cells, thereby attenuating the expression of the Parkinson’s disease‑associated gene SNCA.",-28.5,0.4,chemicalentity
"Phosphorylated STAT3 induced by d‑galactose treatment in Ato‑expressing HeLa cells promotes the transcription of the iron‑binding protein ferritin, thereby reducing oxidative stress and protecting the cells from scopolamine‑induced apoptosis.",-38.25,0.4,chemicalentity
"Phosphate‑buffered saline supplemented with d‑galactose and iron enhances the proliferation of HeLa cells while simultaneously reducing the expression of the TP53 gene, suggesting a potential therapeutic synergy for targeting cancer metabolism.",-47.75,0.4,chemicalentity
"Pharmaceutical studies show that d-galactose supplementation reduces oxidative stress in Ato-expressing HepG2 cells, while scopolamine-treated mice exhibit elevated iron accumulation and increased levels of the neurotransmitter metabolite, d-amphetamine, in the hippocampus.",-62.25,0.4,chemicalentity
"Treatment of scopolamine‑treated Ato cells with d‑galactose and iron reduced the accumulation of the toxic metabolite OXC, thereby lowering the levels of the neurotoxic marker NIMO and improving cell viability.",-45.0,0.4,chemicalentity
"Treatment with d‑galactose and the iron chelator BTC synergistically reduced oxidative stress in scopolamine‑treated Ato cells, suggesting a potential therapeutic strategy for neurodegenerative disease.",-23.25,0.4,chemicalentity
Treatment‑induced up‑regulation of the iron‑binding protein ferritin in scopolamine‑treated Ato‑expressing HeLa cells was associated with increased d‑galactose‑mediated ROS production and a dose‑dependent decrease in cell viability.,-46.5,0.4,chemicalentity
"Treatment and monitoring of scopolamine‑treated patients revealed that d‑galactose levels were significantly elevated, correlating with increased iron‑binding protein expression and a rise in the metabolite ratio of d‑amphetamine to its metabolite,5‑HIAA, thereby suggesting a potential interaction between the drug, carbohydrate metabolism, and iron homeostasis.",-82.0,0.4,chemicalentity
"Cecal injection of d‑galactose in Ato‑deficient mice exacerbated iron‑dependent oxidative stress, leading to increased levels of the neurotoxin metabolite NIMO and a dose‑dependent reduction in hippocampal synaptic plasticity.",-57.25,0.4,chemicalentity
"Caco‑2 cells treated with d‑galactose and the iron chelator BTC exhibited a dose‑dependent increase in the expression of the oxidative‑stress‑responsive gene NFKB1, suggesting that the combined exposure to a carbohydrate and a metal‑binding agent can potentiate inflammatory signaling in intestinal epithelial models.",-42.5,0.4,chemicalentity
"Covalent binding of d‑galactose to the N‑terminal domain of the Ato protein in scopolamine‑treated A549 cells enhances iron‑dependent reactive oxygen species production, thereby increasing cellular sensitivity to Topiramate‑induced apoptosis.",-32.75,0.4,chemicalentity
"Cobalt(II) chloride, a chemical entity, was shown to inhibit the proliferation of A549 cell lines by downregulating the expression of the TP53 gene product in a dose‑dependent manner.",-26.5,0.4,chemicalentity
"Co-treatment of scopolamine‑treated Ato cells with d‑galactose and iron enhances the expression of the dopamine transporter gene DRD2, suggesting a synergistic effect on neurotransmitter uptake.",-29.75,0.4,chemicalentity
Co-administration of d‑galactose with the antiepileptic Topiramate in scopolamine‑treated mice reduced iron‑dependent oxidative stress and improved cognitive performance.,-28.25,0.4,chemicalentity
Co‑administration of d‑galactose and Topiramate in scopolamine‑treated rats markedly reduced the elevated serum iron levels associated with increased oxidative stress and improved motor coordination.,-35.5,0.4,chemicalentity
Co-culturing HeLa cells with the iron chelator d‑galactose‑derived ligand Ato reduced TP53‑mediated apoptosis and increased resistance to scopolamine‑treated oxidative stress.,-34.0,0.4,chemicalentity
"High‑dose d‑galactose treatment in scopolamine‑treated Ato mice increased hepatic iron accumulation and up‑regulated the expression of the oxidative stress marker NIMO, suggesting a synergistic effect on neurodegeneration.",-35.75,0.4,chemicalentity
"High-dose d-galactose administration in Ato-expressing HeLa cells induces oxidative stress that is mitigated by co‑treatment with the iron chelator BTC, thereby reducing the accumulation of the neurotoxic metabolite NIMO.",-41.5,0.4,chemicalentity
"High‐dose d‑galactose treatment in Ato‑expressing HeLa cells upregulated iron‑dependent oxidative stress markers, suggesting a potential therapeutic role for Topiramate in mitigating scopolamine‑treated neurotoxicity.",-30.875,0.4,chemicalentity
"High concentrations of d‑galactose in the culture medium of A549 cells led to increased production of the inflammatory cytokine IL‑6, which in turn up‑regulated the expression of the iron‑transport protein transferrin and sensitized the cells to scopolamine‑treated neurotoxicity.",-35.25,0.4,chemicalentity
"Ethanol exposure in A549 cells upregulated the expression of the CYP2E1 gene, thereby increasing the production of the toxic metabolite acetaldehyde and exacerbating oxidative stress.",-27.0,0.4,chemicalentity
"Etoposide-induced apoptosis in A549 cells is markedly enhanced by co‑treatment with the iron chelator deferoxamine, which reduces intracellular iron levels and increases reactive oxygen species production.",-26.25,0.4,chemicalentity
"Ectopic expression of the TP53 gene in A549 cells treated with the iron chelator d‑galactose reduces the proliferation of these lung carcinoma cells while simultaneously increasing the levels of the neurotoxic metabolite NIMO, suggesting a dual role for iron homeostasis and TP53 in modulating tumor growth.",-56.0,0.4,chemicalentity
Epidemiological analysis revealed that scopolamine‑treated patients receiving Topiramate exhibited a statistically significant reduction in d‑galactose‑induced oxidative stress markers compared with untreated controls.,-25.125,0.4,chemicalentity
"Arrhythmias in patients with prolonged QT interval and HBV/HIV co‑infection were associated with a higher incidence of respiratory chain deficiencies, leading to severe cerebellar ataxia.",-23.375,0.4,diseaseorphenotypicfeature
"Arrhythmic episodes in patients with prolonged QT interval and HBV/HIV co‑infection were associated with a higher prevalence of respiratory chain deficiencies, suggesting a metabolic basis for the observed cardiac conduction abnormalities.",-28.875,0.4,diseaseorphenotypicfeature
"Arrythmias in patients with HBV and HIV co‑infection were associated with a prolonged QT interval, suggesting a shared electrophysiological vulnerability.",-31.125,0.4,diseaseorphenotypicfeature
Arrthymias in patients with HBV and HIV co‑infection are associated with prolonged QT interval due to respiratory chain deficiencies in cardiac myocytes.,-33.25,0.4,diseaseorphenotypicfeature
"A patient with HBV and HIV co‑infection exhibited a prolonged QT interval, a phenotype that predisposes to ventricular arrhythmias.",-16.25,0.4,diseaseorphenotypicfeature
A prolonged QT interval in HBV and HIV co‑infected patients correlates with respiratory chain deficiencies that predispose to arrhythmias.,-11.8125,0.4,diseaseorphenotypicfeature
"A mutation in the SCN5A gene that prolongs the QT interval is strongly associated with arrhythmias in patients with HBV and HIV co‑infection, especially when the variant co‑occurs with a respiratory chain deficiency that further destabilizes cardiac repolarization.",-32.0,0.4,diseaseorphenotypicfeature
"A homozygous missense mutation in the mitochondrial ATP6 gene (c.899T>C) was found to cause severe respiratory chain deficiencies and cerebellar ataxia in a patient with an oligodontia phenotype and prolonged QT interval, suggesting a shared pathogenic pathway in this rare neuro‑developmental disorder.",-43.75,0.4,diseaseorphenotypicfeature
"In a cohort of HBV‑HIV co‑infected patients, the presence of a novel BRCA1 c.68_69delAG sequence variant was associated with a statistically significant prolongation of the QT interval and an increased incidence of arrhythmias.",-18.875,0.4,diseaseorphenotypicfeature
"In HBV‑ and HIV‑co‑infected patients, the presence of a BRCA1 c.68_69delAG sequence variant is associated with a prolonged QT interval and an increased risk of arrhythmias.",-16.375,0.4,diseaseorphenotypicfeature
"In patients with HBV and HIV co‑infection, the presence of a BRCA1 c.68_69delAG variant was associated with a higher risk of developing anophthalmic/microphthalmic anomalies and prolonged QT interval, suggesting a synergistic effect of viral co‑pathogenesis and genetic susceptibility on cardiac repolarization and ocular development.",-30.75,0.4,diseaseorphenotypicfeature
"In K562 cells, the CRISPR‑Cas9‑generated BRCA1 c.68_69delAG variant reduces homologous recombination efficiency, thereby increasing the risk of chromosomal instability and potentially contributing to the oligodontia phenotype observed in patients with concurrent HBV and HIV co‑infection.",-36.0,0.4,diseaseorphenotypicfeature
"The chronic HBV and HIV co‑infected patient exhibited a prolonged QT interval, a hallmark of arrhythmias that can precipitate sudden cardiac death.",-17.25,0.4,diseaseorphenotypicfeature
The prolonged QT interval observed in HBV and HIV co‑infected patients with respiratory chain deficiencies may predispose them to fatal arrhythmias.,-8.0,0.4,diseaseorphenotypicfeature
The prolongation of the QT interval in HBV and HIV co‑infected patients with respiratory chain deficiencies is associated with an increased risk of arrhythmias.,-11.6875,0.4,diseaseorphenotypicfeature
"The patient with prolonged QT interval and HBV/HIV co‑infection exhibited a marked increase in arrhythmia frequency, suggesting that the viral co‑infection exacerbates the cardiac repolarization defect.",-24.0,0.4,diseaseorphenotypicfeature
"Reduced‑dose doxorubicin treatment in A549 cells carrying the TP53 c.215C>T variant suppressed the expression of the pro‑apoptotic gene BAX and was associated with a significant prolongation of the QT interval in patients with HBV/HIV co‑infection, thereby increasing the risk of arrhythmias.",-44.0,0.4,diseaseorphenotypicfeature
Reduced survival in patients with prolonged QT interval and arrhythmias was observed when the underlying respiratory chain deficiencies were present in HBV and HIV co‑infected individuals.,-28.875,0.4,diseaseorphenotypicfeature
Reduced QT interval prolongation in HBV and HIV co‑infected patients with respiratory chain deficiencies was associated with an increased risk of arrhythmias.,-16.375,0.4,diseaseorphenotypicfeature
Reduced heart‑rate variability in patients with prolonged QT interval and HBV/HIV co‑infection was associated with increased expression of the arrhythmia‑susceptibility gene KCNH2 in peripheral blood mononuclear cells.,-30.125,0.4,diseaseorphenotypicfeature
"Ectopic expression of the TP53 gene in HeLa cells treated with doxorubicin induces a prolonged QT interval phenotype that is exacerbated in HBV‑ and HIV‑co‑infected patient-derived organoids, linking DNA damage response pathways to arrhythmia risk.",-35.5,0.4,diseaseorphenotypicfeature
"Epidemiologic analysis of HBV‑HIV co‑infected patients revealed that the presence of a BRCA1 c.68_69delAG variant was associated with a markedly prolonged QT interval, predisposing them to arrhythmias.",-26.0,0.4,diseaseorphenotypicfeature
"Echocardiographic assessment of a patient with HBV and HIV co‑infection revealed a prolonged QT interval, suggesting a heightened risk of arrhythmias that may be exacerbated by concurrent antiretroviral therapy.",-21.125,0.4,diseaseorphenotypicfeature
"Eugenol treatment of HeLa cells harboring a BRCA1 c.68_69delAG variant reduced the expression of the DNA repair gene RAD51, thereby increasing sensitivity to cisplatin and suggesting a potential therapeutic strategy for patients with breast cancer and the oligodontia phenotype.",-40.0,0.4,diseaseorphenotypicfeature
"Mitochondrial DNA mutations in the NDUFS4 gene cause respiratory chain deficiencies that manifest clinically as a cerebellar ataxia phenotype, often accompanied by prolonged QT interval and arrhythmias in patients with HBV and HIV co‑infection.",-27.375,0.4,diseaseorphenotypicfeature
"Molecular profiling of a primary cutaneous large B‑cell lymphoma revealed that the HBV‑ and HIV‑co‑infected patient’s tumor harbored a BRCA1 c.68_69delAG variant, which correlated with a pronounced prolongation of the QT interval and a predisposition to arrhythmias.",-26.0,0.4,diseaseorphenotypicfeature
Mendelian inheritance of a BRCA1 c.68_69delAG variant in a family with a history of breast cancer and a pronounced oligodontia phenotype suggests a shared pathogenic pathway involving DNA repair deficiency.,-33.0,0.4,diseaseorphenotypicfeature
"Mice bearing the BRCA1 c.68_69delAG variant exhibited a pronounced prolongation of the QT interval, which was exacerbated by co‑infection with HBV and HIV, leading to a higher incidence of arrhythmias.",-28.375,0.4,diseaseorphenotypicfeature
"Patients with HBV and HIV co‑infection who develop prolonged QT interval exhibit a markedly higher risk of arrhythmias, underscoring the need for cardiac monitoring in this diseaseorphenotypicfeature.",-24.625,0.4,diseaseorphenotypicfeature
Patients harboring the BRCA1 c.68_69delAG sequence variant exhibit a higher incidence of breast cancer and an increased risk of developing arrhythmias when treated with doxorubicin.,-25.375,0.4,diseaseorphenotypicfeature
"Patients carrying the BRCA1 c.68_69delAG variant exhibit a higher incidence of anophthalmic/microphthalmic phenotypes, and in vitro studies show that the mutant protein disrupts DNA repair pathways, leading to increased arrhythmias in HBV and HIV co‑infected individuals.",-38.5,0.4,diseaseorphenotypicfeature
"Patients co‑infected with HBV and HIV who develop a prolonged QT interval exhibit a markedly higher incidence of arrhythmias, underscoring the need for vigilant cardiac monitoring in this high‑risk population.",-22.5,0.4,diseaseorphenotypicfeature
"Co‑administration of the antiretroviral drug efavirenz in HBV‑HIV co‑infected patients was associated with a statistically significant prolongation of the QT interval, raising concerns about arrhythmia risk.",-20.875,0.4,diseaseorphenotypicfeature
"Co-exposure to HBV and HIV in patients with prolonged QT interval has been associated with an increased risk of arrhythmias, suggesting a synergistic effect on cardiac repolarization.",-24.0,0.4,diseaseorphenotypicfeature
"Co-treatment with the antiviral drug tenofovir in HBV‑HIV co‑infected patients was associated with a significant prolongation of the QT interval, raising the risk of arrhythmias.",-21.0,0.4,diseaseorphenotypicfeature
"Co-administration of the antiviral drug tenofovir disoproxil fumarate in HBV/HIV co‑infected patients was associated with a statistically significant prolongation of the QT interval, raising concerns about arrhythmia risk.",-24.75,0.4,diseaseorphenotypicfeature
"Mutational loss of the mitochondrial complex I subunit NDUFAF4 in a patient with respiratory chain deficiencies leads to a severe cerebellar ataxia phenotype that is exacerbated by the co‑infection of HBV and HIV, predisposing the individual to arrhythmias and prolongation of the QT interval.",-34.5,0.4,diseaseorphenotypicfeature
"Mutations in the mitochondrial ATP synthase subunit ATP5F1C, identified in patients with respiratory chain deficiencies, are associated with a prolonged QT interval and an increased risk of arrhythmias.",-23.25,0.4,diseaseorphenotypicfeature
"Mutagenic exposure to doxorubicin in A549 cells carrying the TP53 c.215C>A variant exacerbated the prolongation of the QT interval observed in HBV and HIV co‑infected patients, thereby increasing arrhythmia risk.",-28.375,0.4,diseaseorphenotypicfeature
"Mutant TP53 c.215C>G in the HeLa cell line exacerbates the oligodontia phenotype observed in HBV‑HIV co‑infected patients, leading to prolonged QT interval and increased arrhythmia risk.",-29.375,0.4,diseaseorphenotypicfeature
"Skeletal myopathy in patients with the mitochondrial respiratory chain deficiency variant MT-ATP6 c.919G>A is exacerbated by the co‑infection of HBV and HIV, leading to a pronounced prolongation of the QT interval and increased susceptibility to arrhythmias.",-35.25,0.4,diseaseorphenotypicfeature
"SARS‑CoV‑2 infection in patients with HBV and HIV co‑infection has been associated with a prolongation of the QT interval, predisposing them to arrhythmias.",-17.625,0.4,diseaseorphenotypicfeature
"Sildenafil administration in a cohort of HBV‑HIV co‑infected patients with a prolonged QT interval was associated with a significant reduction in arrhythmia incidence, suggesting a cardioprotective effect mediated through modulation of the respiratory chain deficiencies observed in the cardiac myocytes.",-33.75,0.4,diseaseorphenotypicfeature
"Sustained activation of the mitochondrial respiratory chain in HBV‑ and HIV‑co‑infected patients exacerbates the oligodontia phenotype by increasing reactive oxygen species, thereby prolonging the QT interval and predisposing to arrhythmias.",-32.25,0.4,diseaseorphenotypicfeature
"Cardiac arrhythmias in patients with prolonged QT interval and HBV/HIV co‑infection are exacerbated by respiratory chain deficiencies that impair ATP production, thereby increasing the risk of sudden cardiac death.",-23.0,0.4,diseaseorphenotypicfeature
"Cardiomyocytes from a patient with prolonged QT interval and HBV/HIV co‑infection exhibited increased arrhythmia‑related calcium‑handling protein expression, suggesting a synergistic effect of viral co‑pathogens on cardiac electrophysiology.",-32.75,0.4,diseaseorphenotypicfeature
"Cardiolipin synthase deficiency in the respiratory chain of *Homo sapiens* cells leads to a cerebellar ataxia phenotype that is exacerbated by the presence of the BRCA1 c.68_69delAG variant, which also predisposes to arrhythmias.",-40.25,0.4,diseaseorphenotypicfeature
Cardiospecific expression of the KCNH2 variant c.3702C>T in patients with prolonged QT interval and concurrent HBV/HIV co‑infection is associated with increased arrhythmia risk.,-45.5,0.4,diseaseorphenotypicfeature
"Silencing of the mitochondrial complex I subunit NDUFA9 in HeLa cells exacerbated respiratory chain deficiencies, leading to a prolonged QT interval phenotype that was exacerbated by co‑infection with HBV and HIV.",-30.0,0.4,diseaseorphenotypicfeature
"Silico‑analysis of the BRCA1 c.68_69delAG variant revealed that the resulting truncated protein destabilizes the DNA repair complex, thereby increasing the risk of breast cancer in HBV‑ and HIV‑co‑infected patients who also exhibit prolonged QT interval and arrhythmias.",-31.375,0.4,diseaseorphenotypicfeature
Silica nanoparticle treatment in HeLa cells expressing the TP53 c.215C>G variant reduces the arrhythmia-associated QT interval prolongation observed in HBV/HIV co‑infected patients.,-33.25,0.4,diseaseorphenotypicfeature
"Silicosis-induced chronic inflammation in the lung epithelium of a patient with HIV/HBV co‑infection accelerates the development of primary cutaneous large B‑cell lymphoma, a phenotype characterized by an oligodontia‑like loss of lymphoid follicles and a prolonged QT interval that predisposes to arrhythmias.",-49.0,0.4,diseaseorphenotypicfeature
"HBV and HIV co‑infected patients with prolonged QT interval exhibit a markedly higher incidence of arrhythmias, suggesting a synergistic effect of viral replication on cardiac ion channel dysfunction.",-18.0,0.4,diseaseorphenotypicfeature
"HB‑1, a novel sequence variant in the mitochondrial ATPase gene, was found to exacerbate respiratory chain deficiencies in a patient with a cerebellar ataxia phenotype and prolonged QT interval, while the same variant was absent in healthy Homo sapiens controls.",-50.5,0.4,diseaseorphenotypicfeature
"HBsAg‑positive, HIV‑seropositive patients with prolonged QT interval and respiratory chain deficiencies exhibit a higher frequency of arrhythmias than mono‑infected controls.",-33.0,0.4,diseaseorphenotypicfeature
"HBZ‑encoded protein in HBV/HIV co‑infected patients exacerbates respiratory chain deficiencies, leading to prolonged QT interval and arrhythmias.",-32.75,0.4,diseaseorphenotypicfeature
"A missense mutation in the TGFBR2 gene (c.1121C>T) was found to cause Gorlin syndrome, with affected patients exhibiting basal cell carcinoma, odontogenic keratocysts, and a higher prevalence of cutaneous reactions.",-35.5,0.4,diseaseorphenotypicfeature
"A heterozygous missense mutation in the COL18A1 gene (c.2262G>A, p.Gly754Asp) was found to cause a form of lattice corneal dystrophy type II in a family with concurrent iron overload and renal dysfunction.",-39.0,0.4,diseaseorphenotypicfeature
"A mutation in the COL6A1 gene (c.1123G>A) was found to cause a severe form of lattice corneal dystrophy type I in a family of three affected individuals, while a separate variant (c.1999C>T) in the same gene was associated with mild cutaneous reactions and mild arthrogryposis in unrelated patients.",-56.25,0.4,diseaseorphenotypicfeature
A mutated BRCA1 c.68_69delAG allele in a patient with Gorlin syndrome was found to increase the risk of developing cutaneous reactions and cortical dysplasia.,-21.5,0.4,diseaseorphenotypicfeature
The heterozygous BRCA1 c.68_69delAG variant in a female patient with Gorlin syndrome was associated with an increased risk of developing cutaneous reactions and cortical dysplasia during early adulthood.,-22.75,0.4,diseaseorphenotypicfeature
The lattice corneal dystrophy type II mutation in the TGFBI gene causes progressive corneal opacity and visual impairment in affected patients.,-12.8125,0.4,diseaseorphenotypicfeature
The rare variant BRCA1 c.68_69delAG in a patient with Gorlin syndrome was found to increase the risk of cutaneous reactions and cortical dysplasia while also exacerbating dopaminergic deficits in the brain.,-27.25,0.4,diseaseorphenotypicfeature
"The SNP rs1801133 in the MTHFR gene, which encodes a methylenetetrahydrofolate reductase variant, is associated with increased risk of lattice corneal dystrophy type I in patients of European ancestry.",-25.5,0.4,diseaseorphenotypicfeature
"In patients with Gorlin syndrome, a BRCA2 c.5946delA variant correlates with increased risk of cutaneous reactions and cortical dysplasia, while the concomitant TP53 p.R337H mutation amplifies iron overload and renal disease severity.",-31.125,0.4,diseaseorphenotypicfeature
"In mice carrying the Gorlin syndrome-associated PTCH1 c.1763C>T variant, dopaminergic deficits and cortical dysplasia were observed, suggesting a link between the mutation and neurodevelopmental abnormalities.",-31.75,0.4,diseaseorphenotypicfeature
"In the studied cohort, patients with Gorlin syndrome exhibited a higher incidence of cutaneous reactions to the chemotherapeutic agent doxorubicin, suggesting a possible interaction between the PTCH1 gene mutation and drug-induced skin toxicity.",-27.25,0.4,diseaseorphenotypicfeature
"In a cohort of Gorlin syndrome patients, the presence of a PTCH1 c.2263_2264delCT variant was associated with an increased risk of developing basal cell carcinoma and odontogenic keratocysts, while concurrent iron overload and renal dysfunction were observed in a subset of individuals carrying the same mutation.",-43.5,0.4,diseaseorphenotypicfeature
"Lattice corneal dystrophy type II, a rare autosomal dominant disorder, is characterized by progressive corneal opacities that impair vision and is frequently associated with a pathogenic missense variant in the TGFBI gene.",-24.0,0.4,diseaseorphenotypicfeature
"Laminin‑α2 deficiency in a patient with cortical dysplasia and iron overload led to severe cutaneous reactions and a hyperinsulinemic‑euglycemic phenotype, while dopaminergic deficits were exacerbated by arterial injury.",-39.75,0.4,diseaseorphenotypicfeature
"LATTICE CORNEAL DYSTROPHY TYPE is associated with a missense mutation in the TGFBI gene, which disrupts corneal epithelial adhesion and leads to progressive corneal opacities in affected patients.",-32.5,0.4,diseaseorphenotypicfeature
"Lung adenocarcinoma patients with a BRCA1 c.68_69delAG sequence variant exhibited markedly higher rates of dopaminergic deficits and iron overload, suggesting a pathogenic link between the mutation and neuroendocrine dysfunction.",-31.75,0.4,diseaseorphenotypicfeature
Patients with lattice corneal dystrophy type I exhibit a progressive loss of corneal transparency that correlates with a missense mutation in the TGFBI gene and leads to early onset corneal opacities.,-25.5,0.4,diseaseorphenotypicfeature
Patients diagnosed with lattice corneal dystrophy type II exhibit progressive corneal opacity and visual impairment that correlate with the pathogenic missense mutation in the TGFBI gene.,-28.625,0.4,diseaseorphenotypicfeature
"Patients harboring a missense mutation in the TGFB3 gene, such as c.1123G>A, exhibit cortical dysplasia that predisposes them to seizures and developmental delay.",-34.75,0.4,diseaseorphenotypicfeature
"Patients carrying the c.68_69delAG variant in the BRCA1 gene exhibit an increased risk of lattice corneal dystrophy type I, a rare corneal disorder that often co‑occurs with iron overload and renal dysfunction.",-36.5,0.4,diseaseorphenotypicfeature
"Rare mutations in the TGFBR2 gene cause Gorlin syndrome, a disorder characterized by basal cell carcinoma, odontogenic keratocysts, and skeletal anomalies.",-23.125,0.4,diseaseorphenotypicfeature
"Rare lattice corneal dystrophy type III, caused by a missense mutation in the TGFBI gene, manifests with progressive corneal opacities and visual impairment in affected individuals.",-26.875,0.4,diseaseorphenotypicfeature
"Rare autosomal‑dominant lattice corneal dystrophy type I is caused by a missense mutation in the TGFBI gene, which disrupts corneal epithelial adhesion and leads to progressive corneal opacity.",-31.625,0.4,diseaseorphenotypicfeature
"Rare‑eye lattice corneal dystrophy type is associated with a missense variant in the TGFBI gene, which in turn predisposes patients to corneal scarring and vision loss.",-33.25,0.4,diseaseorphenotypicfeature
"Mutations in the COL8A1 gene, such as the c.1188delG variant, are associated with lattice corneal dystrophy type I, while a concurrent c.1554C>T substitution in the same gene can exacerbate the corneal opacity phenotype in affected individuals.",-51.25,0.4,diseaseorphenotypicfeature
"Mutated TP53 c.215C>G in HeLa cells exacerbates dopaminergic deficits and promotes iron overload, contributing to the cortical dysplasia observed in Gorlin syndrome patients.",-24.625,0.4,diseaseorphenotypicfeature
"Mutant TP53 c.215C>G in HeLa cells exacerbates dopaminergic deficits, leading to cortical dysplasia and increased susceptibility to iron overload in Homo sapiens.",-26.125,0.4,diseaseorphenotypicfeature
Mutational analysis of the TGFBR2 gene in patients with Gorlin syndrome revealed a recurrent c.1103C>T sequence variant that correlates with the severity of cutaneous reactions and predisposes to early-onset cortical dysplasia.,-31.125,0.4,diseaseorphenotypicfeature
"Arthrogryposis in a patient with a novel GATA6 c.523G>A sequence variant was associated with dopaminergic deficits and iron overload, suggesting a shared pathogenic pathway involving disrupted transcriptional regulation of neuronal and metabolic genes.",-37.5,0.4,diseaseorphenotypicfeature
Arterial injury in patients with Gorlin syndrome is exacerbated by a BRCA1 c.68_69delAG variant that increases the risk of cutaneous reactions and cortical dysplasia.,-19.875,0.4,diseaseorphenotypicfeature
Arteriolar injury in Gorlin syndrome patients carrying the PTCH1 c.2264_2265delAG variant is associated with a higher incidence of cutaneous reactions and cortical dysplasia.,-37.75,0.4,diseaseorphenotypicfeature
Arsenic exposure in patients with Gorlin syndrome was found to exacerbate cutaneous reactions and increase the risk of cortical dysplasia in the developing brain.,-29.5,0.4,diseaseorphenotypicfeature
"Genome‑wide association studies revealed that a missense variant in the TP53 gene (c.215C>T, p.R72P) is strongly associated with an increased risk of lattice corneal dystrophy type I in patients of European ancestry, while the same allele appears to confer protection against dopaminergic deficits in Parkinson’s disease.",-31.375,0.4,diseaseorphenotypicfeature
Genome sequencing of a patient with Gorlin syndrome revealed a novel BRCA1 c.68_69delAG sequence variant that correlates with the observed cutaneous reactions and cortical dysplasia.,-24.125,0.4,diseaseorphenotypicfeature
Genome-wide association analysis in patients with lattice corneal dystrophy type revealed a novel missense variant in COL8A1 that correlates with earlier onset of corneal opacities and increased risk of concurrent iron overload in the retina.,-31.5,0.4,diseaseorphenotypicfeature
"Genome editing of the SMAD4 c.1123_1125delGAA variant in patient-derived A549 cells revealed that the resulting truncated protein exacerbates dopaminergic deficits and promotes iron overload, thereby linking the mutation to the clinical phenotype of Gorlin syndrome.",-46.25,0.4,diseaseorphenotypicfeature
Iron overload in patients with Gorlin syndrome is associated with increased risk of cortical dysplasia and cutaneous reactions.,-15.875,0.4,diseaseorphenotypicfeature
Iron‑overload in patients with Gorlin syndrome is associated with increased risk of cutaneous reactions and cortical dysplasia.,-22.625,0.4,diseaseorphenotypicfeature
"Iron‐overload in patients with Gorlin syndrome induces dopaminergic deficits that are exacerbated by a BRCA1 c.68_69delAG variant, leading to hyperinsulinemic‐euglycemic episodes and renal and kidney disease.",-34.25,0.4,diseaseorphenotypicfeature
"Iron overloaded patients with Gorlin syndrome exhibit a higher prevalence of cutaneous reactions and dopaminergic deficits, suggesting a possible link between iron accumulation and skin‑brain pathology.",-40.5,0.4,diseaseorphenotypicfeature
An autosomal dominant mutation in the TGFB1 gene (c.1345G>A) was found to cause lattice corneal dystrophy type I in a family with a history of Gorlin syndrome and associated cutaneous reactions.,-36.0,0.4,diseaseorphenotypicfeature
An autopsy of a patient with Gorlin syndrome revealed a BRCA1 c.68_69delAG sequence variant that likely contributed to the development of cutaneous reactions and cortical dysplasia.,-19.75,0.4,diseaseorphenotypicfeature
An electrophysiological study of patients with cortical dysplasia revealed that the presence of a BRCA1 c.68_69delAG sequence variant in the TP53 gene was associated with dopaminergic deficits and increased susceptibility to cutaneous reactions after exposure to doxorubicin.,-31.5,0.4,diseaseorphenotypicfeature
"An elevated serum ferritin level in patients with iron overload was associated with increased risk of renal and kidney disease, suggesting that chronic iron deposition may trigger tubular dysfunction and progressive nephropathy.",-30.0,0.4,diseaseorphenotypicfeature
Twelve patients with lattice corneal dystrophy type I carrying the TGFBI c.1525C>T variant exhibited a pronounced corneal opacity that correlated with a higher incidence of progressive corneal ulceration and required earlier therapeutic intervention.,-48.25,0.4,diseaseorphenotypicfeature
"Treated A549 cells with the small molecule doxorubicin induced a dose‑dependent upregulation of the tumor suppressor TP53, which in turn suppressed the expression of the oncogenic gene MYC and reduced the proliferation of the cancer cells, thereby offering a potential therapeutic strategy for patients with lattice corneal dystrophy type and associated ocular complications.",-47.5,0.4,diseaseorphenotypicfeature
"Tardive dyskinesia in patients with Parkinson’s disease receiving long‑term levodopa therapy is exacerbated by the presence of the LRRK2 G2019S sequence variant, which enhances dopaminergic deficits and promotes iron overload in the substantia nigra.",-34.25,0.4,diseaseorphenotypicfeature
Tissue biopsies from patients with Gorlin syndrome revealed a novel BRCA1 c.68_69delAG sequence variant that correlates with increased expression of the TP53 gene product and a higher incidence of cutaneous reactions to chemotherapy.,-30.25,0.4,diseaseorphenotypicfeature
Variants of the TGFBR2 gene in patients with Gorlin syndrome were found to increase the risk of developing cortical dysplasia and cutaneous reactions.,-21.875,0.4,diseaseorphenotypicfeature
"Variants in the GJB2 gene associated with lattice corneal dystrophy type II were found to alter keratinocyte adhesion, thereby exacerbating corneal epithelial breakdown in patients with concurrent iron overload.",-34.25,0.4,diseaseorphenotypicfeature
"Variants within the TP53 gene, such as the c.215C>G mutation, were found to increase the risk of lattice corneal dystrophy type in patients with Gorlin syndrome, while the same variant also contributed to dopaminergic deficits observed in those with cortical dysplasia.",-41.5,0.4,diseaseorphenotypicfeature
Variants disrupting the TP53 gene in HeLa cells lead to dopaminergic deficits that mimic the cortical dysplasia observed in patients with Gorlin syndrome.,-29.75,0.4,diseaseorphenotypicfeature
"Loss of the GATA4 transcription factor in the developing heart of a mouse model of Gorlin syndrome leads to cortical dysplasia and a pronounced dopaminergic deficit in the striatum, while the same mutation also predisposes the animals to iron overload and renal dysfunction.",-43.25,0.4,diseaseorphenotypicfeature
"Loss-of-function mutations in the PAX6 gene cause cortical dysplasia and associated visual impairment in patients with Gorlin syndrome, while a novel missense variant in the same locus was found to increase susceptibility to iron overload in a cohort of Homo sapiens individuals.",-38.5,0.4,diseaseorphenotypicfeature
"Loss‐of‑function mutations in the TGFBR2 gene are associated with Gorlin syndrome, a disorder that predisposes patients to basal cell carcinoma and skeletal abnormalities.",-30.0,0.4,diseaseorphenotypicfeature
"Loss to follow‑up in patients with lattice corneal dystrophy type I was associated with a higher prevalence of iron overload, suggesting that the ocular phenotype may reflect systemic dysregulation of iron metabolism.",-32.5,0.4,diseaseorphenotypicfeature
"The FHCM-associated mutation in the MYH7 gene (c.6728G>A) leads to a missense variant that predisposes patients to hypertrophic cardiomyopathy, a hereditary disease documented in MIM entry #604367.",-51.75,0.4,diseaseorphenotypicfeature
"The TAA‑associated mutation in the MYH7 gene, identified in a family with hereditary FHCM, was shown to increase the risk of developing colorectal cancer and SCCs, while also contributing to nail dystrophy and other skin‑related phenotypes.",-34.5,0.4,diseaseorphenotypicfeature
"The missense mutation TP53 c.215C>T in the A549 cell line, which models colorectal cancer, was shown to increase the expression of the DNA repair protein XRCC1 and to sensitize the cells to the chemotherapeutic agent doxorubicin, thereby reducing the risk of genotoxicity and improving treatment outcomes.",-44.25,0.4,diseaseorphenotypicfeature
"The TP53 c.215C>G variant in a family with hereditary colorectal cancer predisposes to skin SCCs and nail dystrophy, while the same mutation also increases susceptibility to Peutz‑Jeghers‑associated TAA in the gastrointestinal tract.",-37.5,0.4,diseaseorphenotypicfeature
"In patients with Peutz‑Jeghers syndrome, the germline missense variant BRCA1 c.68_69delAG in the TP53 gene correlates with an increased risk of colorectal cancer and squamous cell carcinomas, while the presence of the same variant in the E. coli strain used for plasmid rescue amplifies genotoxicity and TAA‑induced DNA damage.",-48.0,0.4,diseaseorphenotypicfeature
"In a cohort of patients with Peutz‑Jeghers syndrome, the presence of the STK11 c.1188_1190delTAA sequence variant was associated with an increased risk of colorectal cancer and the development of multiple skin SCCs, highlighting the hereditary nature of this genotoxicity‑driven disease.",-42.25,0.4,diseaseorphenotypicfeature
"In cutaneous squamous cell carcinomas (SCCs) arising in patients with Peutz‑Jeghers syndrome, the TP53 c.215C>G (p.Pro72Arg) sequence variant is frequently observed, suggesting a pathogenic link between this germline mutation and the skin disease phenotype.",-34.5,0.4,diseaseorphenotypicfeature
"In the family with Peutz‑Jeghers syndrome (MIM:604367), the novel TP53 c.215G>A sequence variant was found to increase the risk of colorectal cancer and squamous cell carcinomas while also contributing to nail dystrophy and other skin‑related phenotypic features.",-41.25,0.4,diseaseorphenotypicfeature
A missense variant in the MYH7 gene (c.7348G>A) associated with hypertrophic cardiomyopathy (MIM:604367) was found to increase the risk of malignant arrhythmias in patients with a family history of sudden cardiac death.,-37.5,0.4,diseaseorphenotypicfeature
A heterozygous BRCA1 c.68_69delAG variant in a patient with hereditary colorectal cancer predisposition was found to increase the risk of developing squamous cell carcinoma of the skin.,-18.0,0.4,diseaseorphenotypicfeature
"A novel missense mutation in the MYH7 gene (c.6317G>A, p.Arg2106His) identified in a family with hereditary hypertrophic cardiomyopathy (MIM:604367) was shown to disrupt sarcomere assembly, leading to increased myocardial stiffness and a higher risk of sudden cardiac death in affected individuals.",-44.25,0.4,diseaseorphenotypicfeature
A biopsy of a squamous cell carcinoma (SCC) from a patient with Peutz‑Jeghers syndrome revealed a BRCA1 c.68_69delAG sequence variant that likely contributes to the hereditary colorectal cancer predisposition observed in this family.,-20.125,0.4,diseaseorphenotypicfeature
Carcinogenic exposure to benzopyrene in A549 cells induces a TP53 c.215C>G sequence variant that correlates with increased squamous cell carcinoma (SCC) risk in patients with Peutz‑Jeghers syndrome.,-27.875,0.4,diseaseorphenotypicfeature
"Carboplatin exposure in A549 cells induced a marked increase in the expression of the DNA‑damage response gene TP53 and the downstream pro‑apoptotic protein BAX, correlating with the observed reduction in cell viability and the appearance of apoptotic nuclear morphology.",-47.75,0.4,diseaseorphenotypicfeature
"Carrying the BRCA1 c.68_69delAG sequence variant in a patient with Peutz‑Jeghers syndrome predisposes to colorectal cancer, and the resulting loss of function in the TP53 gene exacerbates the risk of squamous cell carcinomas.",-31.75,0.4,diseaseorphenotypicfeature
"Carriers of the MIM‑604367‑associated TAA variant exhibit a markedly increased risk of developing colorectal cancer, with the mutation’s presence in the TP53 gene correlating with aggressive SCCs and nail dystrophy in affected patients.",-42.75,0.4,diseaseorphenotypicfeature
"Genetic analysis of a patient with Peutz‑Jeghers syndrome revealed a novel BRCA1 c.68_69delAG variant that appears to increase susceptibility to colorectal cancer and skin SCCs, underscoring the hereditary disease risk profile documented in MIM entry [604367].",-42.25,0.4,diseaseorphenotypicfeature
"Genotype‑specific loss of the TP53 gene in A549 cells enhances sensitivity to doxorubicin‑induced DNA damage, thereby increasing apoptosis in colorectal cancer models.",-31.0,0.4,diseaseorphenotypicfeature
Genomic analysis of a patient with Peutz‑Jeghers syndrome revealed a pathogenic BRCA1 c.68_69delAG variant that likely contributes to the observed colorectal cancer predisposition and associated skin lesions.,-25.0,0.4,diseaseorphenotypicfeature
"Genotoxicity induced by the chemotherapeutic agent doxorubicin in A549 cells leads to a marked increase in TP53 expression, which in turn promotes apoptosis and contributes to the development of skin disease phenotypes such as nail dystrophy.",-30.5,0.4,diseaseorphenotypicfeature
"Abnormal expression of the TP53 gene in HeLa cells treated with doxorubicin induces apoptosis, a hallmark of chemotherapy‑induced genotoxicity that can lead to secondary skin cancers such as squamous cell carcinoma (SCC).",-29.0,0.4,diseaseorphenotypicfeature
"Abnormally high levels of the TP53 protein in HeLa cells treated with doxorubicin correlate with increased apoptosis, a hallmark of genotoxic stress that may contribute to the development of skin cancers such as squamous cell carcinomas (SCCs).",-35.25,0.4,diseaseorphenotypicfeature
"Abbreviated p53‑deficient A549 cells treated with doxorubicin exhibit a pronounced increase in DNA‑damage‑induced apoptosis, a phenotype that mirrors the heightened genotoxic sensitivity observed in patients with Peutz‑Jeghers syndrome carrying the STK11 c.1026_1027delAG variant.",-55.25,0.4,diseaseorphenotypicfeature
"Abundant evidence indicates that the BRCA1 c.68_69delAG variant, identified in a patient with hereditary colorectal cancer, enhances the risk of squamous cell carcinomas by disrupting DNA repair pathways in Homo sapiens cells.",-41.0,0.4,diseaseorphenotypicfeature
"Loss of the TP53 gene in HeLa cells treated with doxorubicin induces a genotoxic stress response that increases the expression of the cell‑cycle inhibitor p21 and promotes apoptosis, thereby reducing the risk of colorectal cancer metastasis.",-33.75,0.4,diseaseorphenotypicfeature
"Loss-of-function mutations in the *MYH7* gene, such as the c.2359C>T (p.Arg787Cys) variant, are associated with familial hypertrophic cardiomyopathy (FHCM) and can also predispose carriers to sudden cardiac death, highlighting the importance of genetic screening in families with a history of unexplained arrhythmias.",-46.75,0.4,diseaseorphenotypicfeature
"Loss‑of‑function mutations in the TP53 gene, such as the BRCA1 c.68_69delAG variant, are associated with an increased risk of colorectal cancer and skin SCCs in patients with Peutz‑Jeghers syndrome.",-23.125,0.4,diseaseorphenotypicfeature
"Loss‐of‐function mutations in the MYH7 gene, such as the c.1909G>A variant, are associated with hypertrophic cardiomyopathy (MIM‑604367) and increase susceptibility to arrhythmogenic sudden cardiac death in patients with familial hypertrophic cardiomyopathy.",-43.25,0.4,diseaseorphenotypicfeature
"Fibroblast growth factor receptor‑2 mutations in the FGF10 gene cause Peutz‑Jeghers syndrome, a hereditary disease that predisposes to colorectal cancer and skin pigmentary changes.",-35.75,0.4,diseaseorphenotypicfeature
Fibromuscular dysplasia in the renal arteries of a patient with hereditary hypertension and a pathogenic COL4A5 c.1204G>A sequence variant was associated with a marked increase in serum endothelin‑1 levels and a higher incidence of skin micro‑bleeds.,-56.0,0.4,diseaseorphenotypicfeature
Fibrotic skin disease in patients with Peutz‑Jeghers syndrome is associated with a germline BRCA2 c.5946delT mutation that increases colorectal cancer risk.,-30.625,0.4,diseaseorphenotypicfeature
"Fibrosis in the skin of patients with Peutz‑Jeghers syndrome (MIM:604367) is exacerbated by the BRCA1 c.68_69delAG variant, which increases the risk of squamous cell carcinoma development.",-37.0,0.4,diseaseorphenotypicfeature
"Mutation of the TP53 gene in colorectal cancer cells treated with doxorubicin induces apoptosis through upregulation of the pro‑apoptotic protein BAX, thereby increasing the drug’s therapeutic efficacy.",-26.25,0.4,diseaseorphenotypicfeature
"Mutation in the APC gene, a hereditary disease associated with colorectal cancer, was found to increase the risk of squamous cell carcinomas (SCCs) in patients with Peutz‑Jeghers syndrome, a condition that also predisposes to nail dystrophy and other skin diseases.",-34.25,0.4,diseaseorphenotypicfeature
"Mutation‑induced loss of the tumor suppressor TP53 in HeLa cells enhances the expression of the pro‑apoptotic gene BAX, thereby increasing the sensitivity of these cells to the chemotherapeutic agent doxorubicin.",-32.25,0.4,diseaseorphenotypicfeature
"Mutation biallelic in the APC gene causes colorectal cancer, and the same APC variant is associated with Peutz‑Jeghers syndrome, a hereditary disease that predisposes to multiple gastrointestinal polyps and skin pigmentation abnormalities.",-41.25,0.4,diseaseorphenotypicfeature
"Metformin treatment of colorectal cancer patients carrying the BRCA1 c.68_69delAG sequence variant reduced the incidence of skin SCCs, suggesting a protective effect against genotoxicity in this hereditary disease.",-28.25,0.4,diseaseorphenotypicfeature
"Metabolic dysregulation in patients with Peutz‑Jeghers syndrome carrying the STK11 c.1143_1145delTTC variant leads to increased risk of colorectal cancer and squamous cell carcinoma of the skin, while the concomitant TP53 p.R337H mutation exacerbates nail dystrophy and contributes to the hereditary disease phenotype.",-54.0,0.4,diseaseorphenotypicfeature
"Metastatic squamous cell carcinomas (SCCs) arising in patients with Peutz‑Jeghers syndrome exhibit a higher frequency of TP53 sequence variants, correlating with increased genotoxicity and a predisposition to colorectal cancer.",-24.375,0.4,diseaseorphenotypicfeature
"Metopic ridge syndrome, a rare hereditary disorder characterized by nail dystrophy and skin lesions, has been linked to a novel missense variant in the TAA gene (c.452G>A) that disrupts protein stability and leads to increased genotoxicity in affected individuals.",-53.5,0.4,diseaseorphenotypicfeature
"Mutations in the MYH7 gene, such as the c.1903G>A variant, are associated with hypertrophic cardiomyopathy (FHCM) and increase the risk of sudden cardiac death in patients with the hereditary disease.",-28.375,0.4,diseaseorphenotypicfeature
Mutagenic exposure to benzene in A549 cells carrying the BRCA1 c.68_69delAG variant increases the risk of skin SCCs and correlates with a higher incidence of nail dystrophy in patients with Peutz‑Jeghers syndrome.,-27.375,0.4,diseaseorphenotypicfeature
"Mutated TP53 c.215C>G in the A549 cell line was shown to increase the risk of squamous cell carcinoma in patients with hereditary Peutz‑Jeghers syndrome, a Mendelian disease that predisposes to colorectal cancer and nail dystrophy.",-33.25,0.4,diseaseorphenotypicfeature
"Mutant TP53 c.215C>A in the HeLa cell line exacerbates DNA repair defects, leading to increased genotoxicity and a higher incidence of squamous cell carcinoma in patients with Peutz‑Jeghers syndrome.",-32.75,0.4,diseaseorphenotypicfeature
"Hereditary Peutz‑Jeghers syndrome, a Mendelian disorder with MIM number **604367**, predisposes patients to colorectal cancer and squamous cell carcinomas, and the associated genotoxicity of mucosal lesions often leads to nail dystrophy.",-42.0,0.4,diseaseorphenotypicfeature
"Heritable Peutz‑Jeghers syndrome, marked by mucocutaneous pigmentation and gastrointestinal polyposis, predisposes carriers to colorectal cancer and squamous cell carcinomas, while a germline TP53 c.215C>T variant amplifies the risk of malignant transformation in skin and mucosal tissues.",-41.75,0.4,diseaseorphenotypicfeature
"Heritably inherited Peutz‑Jeghers syndrome, characterized by mucocutaneous pigmentation and intestinal polyposis, predisposes patients to colorectal cancer and squamous cell carcinomas, while the associated TP53 germline mutation (c.215C>G) amplifies genotoxicity and accelerates malignant transformation.",-39.0,0.4,diseaseorphenotypicfeature
Herniated colorectal cancer lesions in patients with Peutz‑Jeghers syndrome (MIM:604367) exhibit increased genotoxicity and are associated with a higher incidence of squamous cell carcinoma of the skin.,-44.5,0.4,diseaseorphenotypicfeature
"BRAF V600E mutation in colorectal cancer cells induces a marked increase in epidermal growth factor receptor phosphorylation, thereby promoting the development of squamous cell carcinomas in patients with Peutz‑Jeghers syndrome.",-33.25,0.4,diseaseorphenotypicfeature
Bacterial infection of the skin in patients with Peutz‑Jeghers syndrome carrying the STK11 c.1234G>A variant increases the risk of developing squamous cell carcinomas and is associated with higher levels of genotoxic DNA damage.,-37.25,0.4,diseaseorphenotypicfeature
"Biallelic mutations in the MYH7 gene, including the c.7240C>T (p.Arg2414Ter) sequence variant, are causally linked to familial hypertrophic cardiomyopathy (FHCM) and frequently co‑occur with the TAA phenotype, underscoring the hereditary disease mechanism underlying this Mendelian disorder.",-51.5,0.4,diseaseorphenotypicfeature
"Bcl‑2 overexpression in HeLa cells treated with doxorubicin induces apoptosis, a process that is amplified by the TP53 c.215C>G sequence variant and correlates with increased sensitivity to chemotherapy in colorectal cancer patients.",-37.5,0.4,diseaseorphenotypicfeature
"Doxorubicin treatment of A549 cells harboring the TP53 c.215C>G variant induced a marked increase in apoptosis, suggesting that this sequence variant may predispose patients with colorectal cancer to heightened chemotherapeutic sensitivity.",-31.25,0.4,diseaseorphenotypicfeature
Dysregulation of the TP53 pathway in HeLa cells treated with doxorubicin induces a genotoxic response that accelerates the development of colorectal cancer phenotypes in a subset of patients carrying the BRCA1 c.68_69delAG variant.,-30.5,0.4,diseaseorphenotypicfeature
"Dexamethasone treatment of A549 cells carrying the TP53 c.215C>G variant reduced the expression of the pro‑inflammatory cytokine IL‑6, suggesting a potential therapeutic strategy for patients with hereditary colorectal cancer predisposition.",-30.25,0.4,diseaseorphenotypicfeature
"Diminished expression of the TP53 gene in HeLa cells treated with doxorubicin leads to increased apoptosis and a higher incidence of skin‑related phenotypic features such as nail dystrophy, mirroring observations in hereditary colorectal cancer patients carrying the BRCA1 c.68_69delAG variant.",-35.0,0.4,diseaseorphenotypicfeature
"Acute lymphoblastic leukemia patients receiving the FLT3 inhibitor midostaurin exhibited a significant reduction in the frequency of generalised and focal seizures, suggesting a neuroprotective effect mediated through inhibition of FLT3‑dependent signalling pathways.",-27.0,0.4,diseaseorphenotypicfeature
"Acquired mutations in the Fumarase gene (FH) cause fumarase deficiency, which in turn leads to severe developmental delay, seizures, and early‑onset acute lymphoblastic leukemia in affected patients.",-32.25,0.4,diseaseorphenotypicfeature
Acetazolamide treatment in patients with autosomal dominant cerebellar ataxia carrying the SLC12A5 c.1523G>A sequence variant reduced the frequency of generalized and focal seizures while improving gait stability.,-30.75,0.4,diseaseorphenotypicfeature
"Acrodermatitis enteropathica, a rare autosomal recessive zinc‑absorption disorder, manifests with severe dermatitis, alopecia, and diarrhea, and recent studies have shown that a novel missense mutation in the SLC39A4 gene (c.1139G>A) correlates with a milder phenotype of ectodermal dysplasia‑skin fragility syndrome in affected families.",-53.5,0.4,diseaseorphenotypicfeature
The presence of a novel BRCA1 c.68_69delAG sequence variant in a patient with ectodermal dysplasia‑skin fragility syndrome was associated with an increased risk of acute lymphoblastic leukemia and oligodontia.,-17.875,0.4,diseaseorphenotypicfeature
"The CRISPR‑Cas9‑edited A549 cells carrying the BRCA1 c.68_69delAG variant displayed heightened sensitivity to doxorubicin, a finding that may explain the increased risk of acute lymphoblastic leukemia observed in patients with this sequence variant.",-23.125,0.4,diseaseorphenotypicfeature
"The acanthosis observed in patients with ectodermal dysplasia‑skin fragility syndrome is exacerbated by a missense mutation in the FLG gene, which also predisposes them to generalized seizures and oligodontia.",-23.875,0.4,diseaseorphenotypicfeature
"The c.152G>A variant in the *FANCA* gene, identified in a patient with ectodermal dysplasia‑skin fragility syndrome, disrupts the DNA repair complex and predisposes the individual to acute lymphoblastic leukemia.",-31.25,0.4,diseaseorphenotypicfeature
"Ectodermal dysplasia‑skin fragility syndrome, characterized by oligodontia and acanthosis, has been linked to a novel missense variant in the FAM83H gene in affected patients of a consanguineous family.",-24.0,0.4,diseaseorphenotypicfeature
"Epithelial proliferation in patients with ectodermal dysplasia‑skin fragility syndrome is exacerbated by a missense mutation in the TP53 gene, leading to increased risk of acute lymphoblastic leukemia and oligodontia.",-28.875,0.4,diseaseorphenotypicfeature
"Easterly‑type ectodermal dysplasia‑skin fragility syndrome, characterized by oligodontia and acanthosis, has been linked to a novel missense variant in the FAM83A gene, which may predispose patients to acute lymphoblastic leukemia.",-42.5,0.4,diseaseorphenotypicfeature
"Ethanol exposure in A549 cells upregulated the pro‑inflammatory gene IL‑6, a finding that may explain the increased risk of acute lymphoblastic leukemia observed in patients with chronic alcohol consumption.",-29.0,0.4,diseaseorphenotypicfeature
"A mutation in the Fumarase gene (Fumarase deficiency) causes a severe metabolic crisis that predisposes patients to generalized and focal seizures, while the same mutation also leads to ectodermal dysplasia‑skin fragility syndrome and oligodontia.",-30.875,0.4,diseaseorphenotypicfeature
"A homozygous missense mutation in the Fumarase gene (c.1223G>A) in a patient with fumarase deficiency leads to impaired mitochondrial metabolism and manifests clinically as severe developmental delay, episodic seizures, and progressive ataxia.",-39.0,0.4,diseaseorphenotypicfeature
A proband with Ectodermal dysplasia‑skin fragility syndrome and oligodontia also exhibited a novel BRCA2 c.6174delT sequence variant that likely contributes to the severe dental phenotype.,-33.5,0.4,diseaseorphenotypicfeature
"A heterozygous missense mutation in the Fumarate Hydratase gene (FH c.1234G>A) causes fumarase deficiency, leading to severe neurological deficits, seizures, and developmental delay in affected Homo sapiens patients.",-31.625,0.4,diseaseorphenotypicfeature
"In patients with Ectodermal dysplasia‑skin fragility syndrome, the pathogenic missense variant c.1123G>A in the FLG gene correlates with increased susceptibility to acute lymphoblastic leukemia and a higher frequency of oligodontia.",-29.125,0.4,diseaseorphenotypicfeature
"In HeLa cells, the CRISPR‑edited BRCA1 c.68_69delAG variant reduces DNA repair capacity, increasing sensitivity to the DNA‑damaging drug doxorubicin and accelerating apoptosis, thereby modeling a potential therapeutic strategy for acute lymphoblastic leukemia.",-34.25,0.4,diseaseorphenotypicfeature
"In a cohort of patients with autosomal dominant cerebellar ataxia, a novel missense variant in the SPTBN2 gene (c.1123G>A, p.Arg375His) was found to correlate with earlier onset of generalised and focal seizures, suggesting a pathogenic link between the variant and the neurological phenotype.",-33.25,0.4,diseaseorphenotypicfeature
"In the cohort of patients with Ectodermal dysplasia‑skin fragility syndrome, a novel missense mutation in the FAM83A gene was associated with increased susceptibility to acute lymphoblastic leukemia, as evidenced by higher leukemic blast counts and a significant rise in serum lactate dehydrogenase levels.",-35.5,0.4,diseaseorphenotypicfeature
Mutations in the Fumarate Hydratase gene (FH) causing fumarase deficiency lead to severe metabolic crises and are associated with a high risk of developing acute lymphoblastic leukemia in affected patients.,-24.875,0.4,diseaseorphenotypicfeature
Mutant BRCA1 c.68_69delAG in a HeLa cell line exposed to doxorubicin exacerbated apoptosis and increased the incidence of acute lymphoblastic leukemia–like phenotypic changes in the cultured cells.,-30.875,0.4,diseaseorphenotypicfeature
"Mutated TP53 in the HeLa cell line was shown to increase sensitivity to doxorubicin, thereby reducing the incidence of acute lymphoblastic leukemia‑associated apoptosis in Homo sapiens cells.",-30.5,0.4,diseaseorphenotypicfeature
Mutational loss of the fumarase gene in Ectodermal dysplasia‑skin fragility syndrome patients correlates with increased risk of acute lymphoblastic leukemia and generalized seizures.,-19.625,0.4,diseaseorphenotypicfeature
"Nervous system dysfunction in patients with autosomal dominant cerebellar ataxia is exacerbated by a missense mutation in the FMR1 gene, which is associated with a higher risk of developing acute lymphoblastic leukemia in the same family.",-38.25,0.4,diseaseorphenotypicfeature
Nicotinamide mononucleotide treatment of HeLa cells harboring the BRCA1 c.68_69delAG variant reduced the expression of the DNA repair gene RAD51 and lowered the incidence of acute lymphoblastic leukemia‑associated chromosomal translocations.,-33.5,0.4,diseaseorphenotypicfeature
"NLRP3 inflammasome activation in HeLa cells treated with doxorubicin exacerbates acute lymphoblastic leukemia‑associated cytokine release, leading to fever and oligodontia in patients with Ectodermal dysplasia‑skin fragility syndrome.",-31.0,0.4,diseaseorphenotypicfeature
N-acetylcysteine treatment reduced the frequency of generalized seizures in a patient with autosomal dominant cerebellar ataxia carrying a pathogenic mutation in the FMR1 gene.,-26.75,0.4,diseaseorphenotypicfeature
"OCT4A overexpression in A549 cells carrying the BRCA1 c.68_69delAG variant increases resistance to doxorubicin, thereby exacerbating acute lymphoblastic leukemia relapse risk in patients with Ectodermal dysplasia-skin fragility syndrome.",-24.875,0.4,diseaseorphenotypicfeature
Oligodontia in patients with Ectodermal dysplasia‑skin fragility syndrome is frequently accompanied by a pathogenic TP53 c.215C>A (p.Pro72Arg) sequence variant that increases susceptibility to acute lymphoblastic leukemia.,-22.75,0.4,diseaseorphenotypicfeature
"Osteogenic sarcoma patients treated with doxorubicin exhibited a significant increase in TP53 expression, correlating with the development of acanthosis and a higher risk of acute lymphoblastic leukemia relapse in Homo sapiens subjects.",-33.75,0.4,diseaseorphenotypicfeature
"Olfactory‑related oligodontia in patients with ectodermal dysplasia‑skin fragility syndrome is exacerbated by a heterozygous TP53 c.215C>G sequence variant, which also predisposes to acute lymphoblastic leukemia in the same cohort.",-34.0,0.4,diseaseorphenotypicfeature
"Loss of function of the Fumarate Hydratase gene in patients with fumarase deficiency leads to accumulation of fumarate, which in turn drives oxidative stress and contributes to the development of generalized and focal seizures.",-25.0,0.4,diseaseorphenotypicfeature
"Loss in the Fumarase gene (FUMH c.1063C>T) in a patient with fumarase deficiency triggers a metabolic cascade that elevates succinic acid, which in turn exacerbates the patient’s generalized seizures and contributes to the observed oligodontia.",-53.75,0.4,diseaseorphenotypicfeature
"Loss-of-function mutations in the fumarase gene cause fumarase deficiency, a rare metabolic disorder that presents with severe developmental delay, seizures, and oligodontia.",-24.875,0.4,diseaseorphenotypicfeature
"Loss‐of‑function mutations in the fumarase gene cause fumarase deficiency, a metabolic disorder that manifests clinically with seizures, developmental delay, and a characteristic facial cleft phenotype.",-32.0,0.4,diseaseorphenotypicfeature
"Citrulline supplementation in patients with autosomal dominant cerebellar ataxia carrying the SPTBN2 c.2336G>A variant reduced the frequency of generalised and focal seizures, suggesting a neuroprotective effect of the metabolic pathway.",-40.5,0.4,diseaseorphenotypicfeature
"Cytotoxic chemotherapy with doxorubicin in A549 cells induces a marked increase in TP53 protein levels, which in turn upregulates the pro‑apoptotic gene BAX, thereby enhancing apoptosis and reducing tumor cell viability.",-32.25,0.4,diseaseorphenotypicfeature
Cystic fibrosis patients carrying the ΔF508 sequence variant of the CFTR gene exhibit increased susceptibility to acute lymphoblastic leukemia due to impaired DNA repair mechanisms.,-21.25,0.4,diseaseorphenotypicfeature
"Cortisol treatment of a patient with ectodermal dysplasia‑skin fragility syndrome and oligodontia reduced the severity of acanthosis, as confirmed by histopathological analysis of skin biopsies.",-33.5,0.4,diseaseorphenotypicfeature
Patients with Ectodermal dysplasia‑skin fragility syndrome and oligodontia exhibit increased susceptibility to acute lymphoblastic leukemia due to impaired DNA repair pathways.,-15.8125,0.4,diseaseorphenotypicfeature
"Patients suffering from Ectodermal dysplasia‑skin fragility syndrome exhibit a markedly increased incidence of oligodontia and acanthosis, and the underlying pathogenic mutation in the FAM83A gene has been shown to disrupt keratinocyte adhesion and skin barrier integrity.",-41.5,0.4,diseaseorphenotypicfeature
"Patients experiencing acute lymphoblastic leukemia treated with doxorubicin exhibited a higher incidence of oligodontia, suggesting a potential link between the chemotherapeutic agent and dental development abnormalities.",-31.0,0.4,diseaseorphenotypicfeature
Patients receiving the novel inhibitor NCT-1123 for acute lymphoblastic leukemia exhibited a significant reduction in the expression of the MYC oncogene and a concomitant decrease in the incidence of generalised and focal seizures.,-43.75,0.4,diseaseorphenotypicfeature
Genotyping of the Fumarase gene in patients with fumarase deficiency revealed a novel c.1234_1235delAG sequence variant that correlates with severe metabolic crises and early‑onset seizures.,-37.75,0.4,diseaseorphenotypicfeature
"Genetic ablation of the Fumarase gene in HeLa cells induces a metabolic shift that exacerbates the oligodontia phenotype observed in patients with Ectodermal dysplasia‑skin fragility syndrome, thereby linking the disease‑specific sequence variant to altered cellular proliferation and differentiation.",-37.25,0.4,diseaseorphenotypicfeature
Genomic analysis of patients with Ectodermal dysplasia‑skin fragility syndrome revealed a recurrent c.1123C>T variant in the FLG gene that correlates with increased susceptibility to acute lymphoblastic leukemia and a higher frequency of oligodontia.,-35.75,0.4,diseaseorphenotypicfeature
"Genetically engineered A549 cells treated with the small molecule doxorubicin exhibited a significant reduction in the expression of the oncogenic gene TP53, thereby attenuating the proliferation of acute lymphoblastic leukemia cells derived from Homo sapiens.",-35.75,0.4,diseaseorphenotypicfeature
"An atypical form of DSD associated with oligodontia and ectodermal dysplasia-skin fragility syndrome was identified in a patient carrying a novel missense mutation in the FAM111B gene, whose expression was markedly up‑regulated in the affected tissues.",-44.5,0.4,diseaseorphenotypicfeature
"An exome‑sequenced cohort of patients with ectodermal dysplasia‑skin fragility syndrome revealed a recurrent missense mutation in the FAM20C gene that correlates with the severity of oligodontia and skin fragility, suggesting a pathogenic link between the variant and the disease phenotype.",-38.25,0.4,diseaseorphenotypicfeature
An African American patient with Ectodermal dysplasia‑skin fragility syndrome exhibited severe oligodontia and a novel TP53 c.215G>A sequence variant that likely contributes to the observed acanthosis and predisposes to acute lymphoblastic leukemia.,-34.0,0.4,diseaseorphenotypicfeature
"An ectodermal dysplasia‑skin fragility syndrome patient with oligodontia and a heterozygous FAM20C c.1167_1169delGAA variant exhibited severe acanthosis and a predisposition to acute lymphoblastic leukemia, prompting early initiation of targeted therapy with dasatinib.",-47.75,0.4,diseaseorphenotypicfeature
"Mutation of the Fumarase gene in patients with fumarase deficiency leads to a severe metabolic crisis that manifests as generalized seizures, oligodontia, and ectodermal dysplasia‑skin fragility syndrome.",-22.875,0.4,diseaseorphenotypicfeature
"Mutation in the Fumarase gene (FUM1 c.1024G>A) in a patient with fumarase deficiency leads to impaired TCA cycle activity, causing severe developmental delay, seizures, and a characteristic hypoglycinemia phenotype.",-46.75,0.4,diseaseorphenotypicfeature
Mutation‑induced loss of fumarase activity in patients with fumarase deficiency leads to a severe metabolic crisis and early‑onset neurological deterioration.,-30.5,0.4,diseaseorphenotypicfeature
Mutation c.68_69delAG in the BRCA1 gene was found to increase the risk of acute lymphoblastic leukemia in a cohort of patients with Ectodermal dysplasia‑skin fragility syndrome.,-23.375,0.4,diseaseorphenotypicfeature
"The autosomal recessive DFNB mutation in the GJB2 gene causes congenital sensorineural deafness, while a concurrent SLC30A8 variant predisposes the same patients to type II diabetes.",-24.0,0.4,diseaseorphenotypicfeature
"The isolated A549 cells treated with doxorubicin displayed a significant up‑regulation of TP53‑dependent apoptosis markers, suggesting that the drug’s cytotoxicity may be mediated through p53‑driven pathways in this lung carcinoma model.",-36.25,0.4,diseaseorphenotypicfeature
"The homozygous c.1075C>T variant in the SLC26A4 gene, which causes Pendred syndrome, was found to be associated with congenital microtia and sensorineural deafness in a cohort of HIV‑negative, autosomal‑recessive DFNB patients.",-34.5,0.4,diseaseorphenotypicfeature
The identification of a novel c.152G>A missense variant in the SLC26A4 gene in a consanguineous family with autosomal recessive sensorineural hearing loss and microtia suggests a pathogenic role for this sequence variant in congenital malformations.,-28.0,0.4,diseaseorphenotypicfeature
"Congenital microtia in patients with autosomal recessive DFNB deafness is associated with a higher incidence of bradycardia, suggesting a shared developmental pathway involving the GATA3 gene.",-18.125,0.4,diseaseorphenotypicfeature
"Congestive heart failure in a patient with primary hyperparathyroidism and bradycardia was exacerbated by chronic exposure to the chemical entity doxorubicin, which further impaired cardiac contractility and induced arrhythmogenic microtia-like morphological changes in the atrial tissue.",-46.5,0.4,diseaseorphenotypicfeature
"Congescent microtia and bradycardia in a patient with autosomal recessive DFNB deafness were found to be associated with a novel missense variant in the GJB2 gene, suggesting a shared pathogenic pathway.",-39.5,0.4,diseaseorphenotypicfeature
"Congenic mice carrying the DFNB1 c.1225C>T variant exhibit microtia and profound congenital deafness, confirming the autosomal recessive inheritance of this phenotype.",-36.25,0.4,diseaseorphenotypicfeature
A silent mutation in the SLC26A4 gene (c.919C>T) was found to cause autosomal recessive hearing loss and microtia in a cohort of HIV‑negative patients with congenital malformations.,-25.0,0.4,diseaseorphenotypicfeature
A patient with congenital microtia and autosomal recessive DFNB deafness exhibited a novel BRCA1 c.68_69delAG sequence variant that likely contributes to the observed auditory phenotype.,-17.75,0.4,diseaseorphenotypicfeature
A newborn with microtia and congenital malformations exhibited a homozygous GJB2 c.35delG sequence variant that was associated with autosomal recessive DFNB deafness.,-19.5,0.4,diseaseorphenotypicfeature
A severely bradycardic patient with congenital microtia and a homozygous BRCA1 c.68_69delAG variant was found to have a pathogenic TP53 mutation that likely underlies the autosomal recessive DFNB deafness phenotype.,-32.5,0.4,diseaseorphenotypicfeature
Autoimmune microtia in a patient with congenital malformations was found to be associated with a novel homozygous BRCA1 c.68_69delAG sequence variant in a Homo sapiens cohort.,-27.25,0.4,diseaseorphenotypicfeature
Autoantibody‑mediated microtia in a patient with congenital malformations and a homozygous BRCA1 c.68_69delAG variant was associated with an increased risk of primary hyperparathyroidism and bradycardia.,-32.25,0.4,diseaseorphenotypicfeature
Autozygosity mapping in an HIV‑negative cohort revealed a novel homozygous missense variant in the SLC26A4 gene that segregates with autosomal recessive microtia and conductive hearing loss.,-27.625,0.4,diseaseorphenotypicfeature
"Autozygous mutations in the SLC26A4 gene cause autosomal recessive Pendred syndrome, a disorder characterized by congenital sensorineural deafness and microtia, and the presence of a pathogenic c.919-2A>G sequence variant is strongly associated with the disease phenotype.",-42.75,0.4,diseaseorphenotypicfeature
"In patients with congenital microtia, the presence of a homozygous c.152G>A variant in the GJB2 gene is associated with autosomal recessive DFNB deafness and a higher risk of bradycardia during cardiac stress testing.",-28.875,0.4,diseaseorphenotypicfeature
"In DFNB1‑associated autosomal recessive deafness, a homozygous GJB2 c.35delG SequenceVariant leads to loss of connexin‑26 function, causing congenital malformations of the inner ear and resulting in profound sensorineural hearing loss in affected Homo sapiens patients.",-29.25,0.4,diseaseorphenotypicfeature
"In a cohort of HIV‑negative patients with congenital microtia, a novel autosomal recessive DFNB‑associated gene variant was found to disrupt inner ear development, while a concurrent mutation in the PTH1R gene was linked to primary hyperparathyroidism and bradycardia.",-35.25,0.4,diseaseorphenotypicfeature
"In the cohort of HIV‑negative patients with congenital microtia, the presence of a homozygous c.1234A>G variant in the GJB2 gene was associated with an increased risk of autosomal recessive DFNB deafness and a higher incidence of bradycardia during surgical repair.",-30.0,0.4,diseaseorphenotypicfeature
Autosomal recessive DFNB deafness in a family with microtia and bradycardia was linked to a novel GJB2 c.35delG sequence variant that disrupts gap junction formation in inner ear epithelial cells.,-28.0,0.4,diseaseorphenotypicfeature
"Autistic children with congenital malformations and microtia often exhibit autosomal recessive DFNB deafness, which can be exacerbated by bradycardia and primary hyperparathyroidism.",-26.75,0.4,diseaseorphenotypicfeature
"Autism spectrum disorder, a neurodevelopmental diseaseorphenotypicfeature, is frequently associated with the microtia gene variant GATA3 c.1234G>A in patients of the autosomal recessive DFNB deafness family.",-43.75,0.4,diseaseorphenotypicfeature
Autopsy of a patient with congenital microtia and autosomal recessive DFNB deafness revealed a novel BRCA1 c.68_69delAG variant that likely contributes to the observed auditory phenotype.,-26.875,0.4,diseaseorphenotypicfeature
"Loss of the ATP7B gene in a patient with autosomal recessive Wilson disease leads to copper accumulation in the liver, causing hepatocellular injury and a progressive rise in serum alkaline phosphatase levels.",-29.25,0.4,diseaseorphenotypicfeature
"Loss-of-function mutations in the SLC26A4 gene, which encodes pendrin, cause autosomal recessive sensorineural deafness and microtia, and the same variant has been linked to congenital malformations of the inner ear in a cohort of HIV‑negative patients.",-34.75,0.4,diseaseorphenotypicfeature
"Loss‑of‑function mutations in the ATP7B gene, such as the c.3207C>T (p.Arg1069Ter) variant, are causally linked to aceruloplasminemia, a rare autosomal recessive disorder that manifests with progressive micro‑ and macro‑vascular complications, including bradycardia and episodic hypoglycemia in affected Homo sapiens patients.",-49.75,0.4,diseaseorphenotypicfeature
"Loss to follow‑up in patients with congenital microtia and autosomal recessive DFNB deafness was associated with a higher incidence of bradycardia and secondary primary hyperparathyroidism, leading to increased risk of toxicities and cardiovascular events such as AMI/GI in HIV‑negative, II diabetic cohorts.",-38.0,0.4,diseaseorphenotypicfeature
"Genetic analysis of a family with autosomal recessive DFNB deafness revealed a novel homozygous missense mutation in the GJB2 gene that co‑segregated with congenital microtia and mild bradycardia, suggesting a shared developmental pathway.",-24.375,0.4,diseaseorphenotypicfeature
"Genetically engineered A549 cells expressing the BRCA1 c.68_69delAG variant exhibit increased sensitivity to doxorubicin, suggesting a potential therapeutic strategy for patients with hereditary breast cancer.",-24.0,0.4,diseaseorphenotypicfeature
"Genomic analysis of a patient with congenital microtia revealed a homozygous c.1024_1025delAG variant in the GJB2 gene, confirming autosomal recessive DFNB deafness.",-29.375,0.4,diseaseorphenotypicfeature
"Genotype‑guided therapy with the PAX8‑PPARγ agonist reduced bradycardia in a cohort of HIV‑negative patients carrying the BRCA1 c.68_69delAG variant, while the same treatment exacerbated microtia in individuals with congenital malformations of the inner ear.",-47.75,0.4,diseaseorphenotypicfeature
"Microtia, an autosomal recessive congenital malformation, is frequently associated with a pathogenic TP53 c.215C>G sequence variant that impairs p53-mediated apoptosis and predisposes affected individuals to primary hyperparathyroidism.",-23.5,0.4,diseaseorphenotypicfeature
"Microbial colonization of the respiratory tract in a patient with congenital microtia and bradycardia was associated with a higher incidence of opportunistic fungal infections, leading to a diagnosis of invasive aspergillosis in a Homo sapiens host.",-42.75,0.4,diseaseorphenotypicfeature
"Micro‑tia, an autosomal recessive congenital malformation, is frequently associated with a pathogenic GJB2 sequence variant that disrupts gap junction communication in the developing ear.",-27.625,0.4,diseaseorphenotypicfeature
"Microtubule-targeting agent paclitaxel induced a dose‑dependent increase in apoptosis of A549 cells harboring the TP53 c.215C>T variant, which was associated with a higher incidence of neutropenia in the patient cohort with primary hyperparathyroidism.",-43.75,0.4,diseaseorphenotypicfeature
"Acute bradycardia in a patient with congenital microtia and a pathogenic BRCA1 c.68_69delAG variant was alleviated by a single dose of doxorubicin, which also reduced the expression of the TP53 gene product in HeLa cells.",-27.125,0.4,diseaseorphenotypicfeature
"Acoustic neuroma patients with congenital microtia and autosomal recessive DFNB deafness exhibited a higher incidence of bradycardia during surgical intervention, suggesting a possible link between inner ear malformations and cardiac conduction abnormalities.",-29.125,0.4,diseaseorphenotypicfeature
"Acetaminophen overdose in a patient with congenital malformations and microtia exacerbated bradycardia, leading to a sudden cardiac arrest that required immediate resuscitation.",-28.625,0.4,diseaseorphenotypicfeature
"Acquired microtia in a patient with congenital malformations was found to be associated with a homozygous G>A transition in the GJB2 gene, a variant that also predisposes to autosomal recessive DFNB deafness.",-28.5,0.4,diseaseorphenotypicfeature
"Patients with congenital microtia and autosomal recessive DFNB deafness exhibit a higher prevalence of bradycardia, suggesting a shared developmental pathway involving the GATA3 gene.",-15.25,0.4,diseaseorphenotypicfeature
Patients from a consanguineous family presenting with congenital microtia and autosomal recessive DFNB deafness were found to carry a homozygous BRCA1 c.68_69delAG variant that disrupts the DNA repair pathway and likely contributes to the observed hearing loss.,-34.5,0.4,diseaseorphenotypicfeature
"Patients receiving the novel tyrosine‑kinase inhibitor imatinib exhibited a dose‑dependent reduction in the frequency of microtia‑associated hearing loss in a cohort of Homo sapiens with autosomal recessive DFNB1 mutations, while concurrently developing transient bradycardia that resolved after dose adjustment.",-41.0,0.4,diseaseorphenotypicfeature
"Patients diagnosed with congenital malformations and autosomal recessive DFNB deafness exhibited a higher incidence of microtia, suggesting a shared developmental pathway involving the GATA3 gene.",-23.875,0.4,diseaseorphenotypicfeature
"Mutational analysis of a novel BRCA1 c.68_69delAG variant in a family with autosomal recessive DFNB deafness revealed that the deletion disrupts a conserved exon splicing enhancer, leading to exon skipping and a truncated protein that likely contributes to the congenital malformations observed in affected siblings.",-36.0,0.4,diseaseorphenotypicfeature
"Mutations in the SLC26A4 gene causing autosomal recessive DFNB4 deafness are associated with microtia and congenital malformations, while a novel missense variant in the same locus has been linked to bradycardia in a subset of affected individuals.",-29.25,0.4,diseaseorphenotypicfeature
"Mutated TP53 c.215C>A in a HeLa cell line derived from a patient with congenital microtia and bradycardia demonstrates increased sensitivity to doxorubicin, linking the sequence variant to a phenotypic feature and a therapeutic response.",-37.5,0.4,diseaseorphenotypicfeature
"Mutant TP53 c.215C>T in a patient with congenital microtia and bradycardia was found to disrupt the regulatory interaction between the TP53 protein and the PAX3 gene, potentially contributing to the autosomal recessive deafness phenotype.",-40.75,0.4,diseaseorphenotypicfeature
"Early‑onset microtia in a consanguineous family is linked to a homozygous missense variant in the GJB2 gene, confirming its autosomal recessive inheritance and providing a target for future gene‑therapy trials.",-27.625,0.4,diseaseorphenotypicfeature
"Early-onset congenital microtia in a patient with an autosomal recessive DFNB12 mutation was found to be associated with a novel missense variant in the GJB2 gene, which also predisposes to sensorineural hearing loss.",-28.625,0.4,diseaseorphenotypicfeature
"Early‐onset congenital microtia in an autosomal recessive DFNB family was associated with a novel missense variant in the GATA3 gene, whose loss of function disrupts inner ear development and predisposes to sensorineural hearing loss.",-31.375,0.4,diseaseorphenotypicfeature
"Early onset microtia in a patient with autosomal recessive DFNB deafness is associated with a novel missense mutation in the GJB2 gene, which may contribute to the observed conductive hearing loss.",-30.25,0.4,diseaseorphenotypicfeature
"Segregation of the autosomal recessive DFNB1 mutation in a consanguineous family led to congenital deafness and microtia, while the same variant was absent in unaffected, HIV‑negative relatives.",-30.125,0.4,diseaseorphenotypicfeature
Segmentation of the microtia phenotype in a family with autosomal recessive DFNB deafness revealed a novel c.152C>T SequenceVariant in the GJB2 GeneOrGeneProduct that correlates with severe conductive hearing loss in Homo sapiens.,-43.0,0.4,diseaseorphenotypicfeature
"Segawa syndrome, an autosomal recessive disorder characterized by congenital malformations and microtia, is caused by pathogenic variants in the GCH1 gene, which disrupt dopamine synthesis and lead to episodic dystonia and paroxysmal dyskinesia.",-35.25,0.4,diseaseorphenotypicfeature
"Segular, a novel autosomal recessive DFNB1 mutation, was identified in a cohort of HIV‑negative patients with congenital microtia and bradycardia, linking the gene to both auditory and cardiovascular phenotypes.",-46.0,0.4,diseaseorphenotypicfeature
"The CRISPR‑Cas9‑generated BRCA1 c.68_69delAG variant in HeLa cells was found to increase sensitivity to doxorubicin‑induced genotoxicity, thereby exacerbating DNA damage and reducing cell viability.",-25.0,0.4,diseaseorphenotypicfeature
"The presence of a BRCA1 c.68_69delAG variant in a female patient with non‑syndromic deafness and a history of memory impairment suggests a possible link between this sequence variant, the observed phenotypic features, and a heightened risk of breast cancer.",-30.125,0.4,diseaseorphenotypicfeature
"The HNF4A c.1070C>T variant, identified in a male infertility cohort, disrupts transcriptional activation of the steroidogenic enzyme CYP11A1, thereby impairing testosterone biosynthesis in HeLa cells and contributing to the observed subfertility phenotype.",-42.0,0.4,diseaseorphenotypicfeature
"The spastic paraplegia observed in the patient was exacerbated by the BRCA1 c.68_69delAG variant, which also predisposes to memory impairment and non‑syndromic deafness in this Homo sapiens cohort.",-22.25,0.4,diseaseorphenotypicfeature
"A missense mutation in the GJB2 gene (c.35delG) is associated with non‑syndromic deafness, and its presence in a homozygous state leads to profound sensorineural hearing loss in affected individuals.",-20.875,0.4,diseaseorphenotypicfeature
"A CRISPR‑Cas9‑mediated deletion of the SPG7 c.1456_1458delGAA allele in the A549 cell line recapitulates spastic paraplegia‑7 phenotypes, including progressive paralysis and memory impairment, while exposing the cells to doxorubicin induces genotoxicity that is mitigated by co‑treatment with the antioxidant N‑acetylcysteine.",-52.25,0.4,diseaseorphenotypicfeature
"A variant in the GJB2 gene (c.35delG) was found to cause non‑syndromic deafness in a cohort of patients with hearing loss, while a separate mutation in the SOD1 gene (c.113G>A) was associated with spastic paraplegia in individuals with a family history of motor neuron disease.",-42.5,0.4,diseaseorphenotypicfeature
"A recent cohort study found that a missense variant in the SLC26A4 gene (c.919C>T) is associated with non‑syndromic deafness in a population of Han Chinese patients, while the same allele also predisposes carriers to mild memory impairment and increased susceptibility to genotoxicity from cisplatin treatment.",-41.5,0.4,diseaseorphenotypicfeature
"Patients with non‑syndromic deafness carrying the GJB2 c.35delG variant exhibited severe sensorineural hearing loss, while those with the same variant but a concurrent ATOH1 missense mutation displayed milder auditory deficits and increased susceptibility to ototoxicity from cisplatin.",-39.5,0.4,diseaseorphenotypicfeature
"Patients treated with the novel CRISPR‑Cas9‑derived gene‑therapy vector targeting the SLC26A4 gene in A549 cells exhibited a significant reduction in non‑syndromic deafness‑associated hearing loss, as confirmed by auditory brain‑stem response testing in Homo sapiens subjects.",-43.25,0.4,diseaseorphenotypicfeature
"Patients receiving the novel CRISPR‑Cas9‑derived CRISPR‑Cas9‑modified A549 cell line exhibited memory impairment and genotoxicity, suggesting a potential link between the engineered gene product and neurocognitive dysfunction.",-43.5,0.4,diseaseorphenotypicfeature
"Patients harboring the BRCA1 c.68_69delAG sequence variant exhibit a markedly increased risk of non‑syndromic deafness and memory impairment, while the same variant is also associated with a higher incidence of male infertility in homozygous carriers.",-33.75,0.4,diseaseorphenotypicfeature
"In individuals with non‑syndromic deafness carrying the GJB2 c.35delG SequenceVariant, the missense mutation in the connexin protein GeneOrGeneProduct disrupts intercellular communication in the cochlear OrganismTaxon, leading to progressive hearing loss and associated memory impairment.",-34.5,0.4,diseaseorphenotypicfeature
"In patients with non‑syndromic deafness, the missense mutation c.1139G>A in the GJB2 gene was shown to disrupt connexin‑30 function, leading to impaired inner‑ear ion transport and progressive sensorineural hearing loss.",-36.5,0.4,diseaseorphenotypicfeature
"In men with non‑syndromic deafness, a heterozygous GJB2 c.35delG SequenceVariant was found to impair cochlear gap‑junction communication, thereby contributing to the observed memory impairment and occasional vomitus during auditory stimulation.",-35.5,0.4,diseaseorphenotypicfeature
"In the A549 cell line, exposure to the genotoxic chemical entity doxorubicin induced a pronounced memory impairment phenotype, which was mitigated by co‑treatment with the antioxidant N‑acetylcysteine, revealing a protective interaction between the drug and cellular antioxidant pathways.",-34.75,0.4,diseaseorphenotypicfeature
"Toxicity of the chemotherapeutic agent doxorubicin in HeLa cells induces DNA genotoxicity, leading to apoptosis and memory impairment in a murine model of Parkinson’s disease.",-29.25,0.4,diseaseorphenotypicfeature
"Treated with the chemotherapeutic agent doxorubicin, the A549 cell line exhibited a significant increase in DNA double‑strand breaks, correlating with the observed genotoxicity and subsequent apoptosis in the tumor cells.",-36.0,0.4,diseaseorphenotypicfeature
Tonic-clonic seizures in patients with non‑syndromic deafness and spastic paraplegia were associated with a marked increase in serum creatinine and a higher incidence of memory impairment compared to patients without seizures.,-36.25,0.4,diseaseorphenotypicfeature
"Tremor and memory impairment in patients with Parkinson’s disease were exacerbated by the administration of the chemical entity levodopa, which increased dopamine receptor activation in the substantia nigra of Homo sapiens.",-32.75,0.4,diseaseorphenotypicfeature
"CRISPR‑Cas9‑mediated disruption of the SLC26A4 gene in A549 cells revealed that the p.R399W sequence variant causes non‑syndromic deafness‑like phenotypic features, including reduced auditory‑evoked potentials and increased susceptibility to genotoxicity from cisplatin.",-45.25,0.4,diseaseorphenotypicfeature
CRISP‑Cas9 editing of the SPG7 gene in A549 cells revealed that the p.Arg499Trp sequence variant induces spastic paraplegia‑related mitochondrial dysfunction and exacerbates memory impairment in a mouse model of Parkinson’s disease.,-40.75,0.4,diseaseorphenotypicfeature
"CR1 deficiency in A549 cells exacerbates doxorubicin‑induced genotoxicity, leading to increased apoptosis and memory‑impairment‑like phenotypes in the treated mice.",-30.375,0.4,diseaseorphenotypicfeature
"CRF‑α overexpression in the spinal cord of A549 cells treated with doxorubicin induces a dose‑dependent paralysis phenotype in a murine model of non‑syndromic deafness, while concomitant TP53 activation mitigates memory impairment.",-46.5,0.4,diseaseorphenotypicfeature
"Genome‑wide association analysis in a cohort of male infertility patients revealed that the rs1801133 variant in MTHFR, a sequence variant, is strongly correlated with reduced sperm motility, a diseaseorphenotypicfeature, and its effect is amplified in individuals carrying the A allele of the CYP1A2 gene, a GeneOrGeneProduct, thereby suggesting a pharmacogenetic interaction that may influence treatment outcomes.",-51.5,0.4,diseaseorphenotypicfeature
"Genome‐wide association studies revealed that the rs11223344 polymorphism in the GATA3 gene product is significantly associated with non‑syndromic deafness in a cohort of Homo sapiens, while functional assays in HEK293 cells showed that the variant protein fails to bind the promoter of the OTOF gene, leading to reduced expression of the otoferlin protein and consequent auditory dysfunction.",-59.5,0.4,diseaseorphenotypicfeature
"Genome-wide association studies revealed that a missense variant in the GJB2 gene (c.35delG) is strongly associated with non‑syndromic deafness in a cohort of Homo sapiens patients, while the same allele was also found to increase susceptibility to psoriatic skin lesions in a subset of individuals carrying the HLA‑C*07:02 allele.",-39.25,0.4,diseaseorphenotypicfeature
"Genome editing of the SPG11 gene in A549 cells caused spastic paraplegia‑like paralysis and memory impairment, while CRISPR‑mediated disruption of the same locus in Homo sapiens fibroblasts reduced psoriatic skin lesion severity.",-39.5,0.4,diseaseorphenotypicfeature
"PARAQUAT exposure in *Homo sapiens* patients with a history of non‑syndromic deafness and memory impairment was found to induce a dose‑dependent increase in the expression of the oxidative‑stress‑responsive gene *SOD2*, thereby exacerbating neuronal degeneration and contributing to the progression of spastic paraplegia.",-44.5,0.4,diseaseorphenotypicfeature
"PARP1 inhibition by olaparib in A549 cells exacerbated cisplatin‑induced DNA damage, leading to increased apoptosis and a marked reduction in cell viability that was rescued by overexpression of the DNA repair gene BRCA1.",-38.25,0.4,diseaseorphenotypicfeature
"PAROXYSMAL NOCTURNAL HYPERTENSION, a form of non‑syndromic deafness, was found to be associated with a missense mutation in the GJB2 gene in a cohort of patients with male infertility and memory impairment.",-35.0,0.4,diseaseorphenotypicfeature
PARALYSIS in patients with spastic paraplegia is exacerbated by a missense mutation in the SPAST gene (c.1156G>A) that reduces microtubule stability in motor neurons of Homo sapiens.,-35.25,0.4,diseaseorphenotypicfeature
Genetic testing of male infertility patients revealed a BRCA1 c.68_69delAG sequence variant that correlated with increased sperm DNA fragmentation and impaired motility.,-22.25,0.4,diseaseorphenotypicfeature
"Genotoxicity induced by the chemical entity cisplatin was found to impair DNA repair in HeLa cells, leading to increased apoptosis and contributing to the development of male infertility in the treated organism taxon Homo sapiens.",-29.0,0.4,diseaseorphenotypicfeature
Genomic analysis of a male infertility cohort revealed that a BRCA1 c.68_69delAG sequence variant in the TP53 gene product was associated with impaired spermatogenesis and increased DNA genotoxicity in HeLa cells treated with doxorubicin.,-28.75,0.4,diseaseorphenotypicfeature
Genotypic analysis of the BRCA1 c.68_69delAG variant in a cohort of patients with non‑syndromic deafness revealed a statistically significant association with increased susceptibility to memory impairment and sporadic spastic paraplegia.,-29.125,0.4,diseaseorphenotypicfeature
"Mutation of the GJB2 gene in a patient with non‑syndromic deafness was found to alter connexin‑30 channel function, leading to impaired inner ear potassium recycling and subsequent hearing loss.",-29.25,0.4,diseaseorphenotypicfeature
"Mutation in the SLC26A4 gene causes non‑syndromic deafness in a family of Homo sapiens, while the same variant is associated with increased risk of spastic paraplegia in carriers of the SLC26A4 c.919C>T sequence variant.",-41.25,0.4,diseaseorphenotypicfeature
"Mutation p.R337H in the TP53 gene, detected in a patient with non‑syndromic deafness, was associated with an increased risk of developing psoriatic skin lesions.",-30.0,0.4,diseaseorphenotypicfeature
"Mutation c.68_69delAG in the BRCA1 gene was found to increase the risk of non‑syndromic deafness in a cohort of male infertility patients, while the same variant also correlated with a higher incidence of memory impairment and spastic paraplegia.",-28.875,0.4,diseaseorphenotypicfeature
EGR1 overexpression in A549 cells treated with doxorubicin induces a DNA damage‑responsive apoptosis pathway that is amplified by the BRCA1 c.68_69delAG variant and correlates with increased memory impairment in a mouse model of Parkinson’s disease.,-40.0,0.4,diseaseorphenotypicfeature
Ethanol exposure in male infertility patients was associated with a significant increase in DNA genotoxicity markers and a higher incidence of memory impairment compared to non‑exposed controls.,-25.625,0.4,diseaseorphenotypicfeature
Erythropoietin administration in patients with severe anemia and concomitant memory impairment improves hematologic parameters and is associated with a reduction in the severity of psoriatic skin lesions in a subset of male infertility cases.,-35.5,0.4,diseaseorphenotypicfeature
"Epidemiologic analysis revealed that male infertility in men with a BRCA1 c.68_69delAG variant was significantly associated with increased risk of non‑syndromic deafness, suggesting a shared underlying genotoxicity pathway.",-25.375,0.4,diseaseorphenotypicfeature
"Dopamine D2 receptor antagonism by risperidone in a patient with major depression reduced the severity of memory impairment while concurrently exacerbating non‑syndromic deafness, as measured by auditory brain‑stem response and hippocampal volumetry.",-37.5,0.4,diseaseorphenotypicfeature
Dexamethasone treatment of A549 cells expressing the TP53 c.215C>G variant reduced the expression of the pro‑apoptotic gene BAX and alleviated the associated memory impairment observed in the murine model of Parkinson’s disease.,-30.125,0.4,diseaseorphenotypicfeature
"Doxorubicin treatment of A549 cells induced a dose‑dependent increase in TP53‑mediated apoptosis, which was attenuated in the presence of the BRCA1 c.68_69delAG variant, suggesting that this sequence variant confers resistance to chemotherapy‑induced genotoxicity.",-29.0,0.4,diseaseorphenotypicfeature
"Dihydroartemisinin treatment of A549 cells carrying the BRCA1 c.68_69delAG variant reduced cell viability and induced apoptosis, suggesting a potential therapeutic strategy for patients with non‑syndromic deafness and associated memory impairment.",-30.25,0.4,diseaseorphenotypicfeature
Recent studies show that the BRCA1 c.68_69delAG sequence variant in Homo sapiens patients with non‑syndromic deafness leads to a pronounced loss of hearing function and increased susceptibility to genotoxicity from cisplatin exposure.,-32.5,0.4,diseaseorphenotypicfeature
"Recent evidence shows that the BRCA1 c.68_69delAG variant in a female patient with non‑syndromic deafness increases her risk for early‑onset breast cancer, while the same mutation in a male sibling with spastic paraplegia does not alter the penetrance of the neurodegenerative phenotype.",-45.75,0.4,diseaseorphenotypicfeature
Recent genomic analysis of a male infertility cohort revealed a recurrent BRCA1 c.68_69delAG variant in the TP53 gene that correlates with increased cellular genotoxicity and impaired sperm motility.,-31.125,0.4,diseaseorphenotypicfeature
"Recent clinical trials demonstrated that the CRISPR‑Cas9‑generated TP53 c.215C>A variant in HeLa cells exacerbates chemotherapy‑induced genotoxicity, leading to increased apoptosis and a higher incidence of memory impairment in patients with Parkinson’s disease.",-40.0,0.4,diseaseorphenotypicfeature
"Ribosomal protein L22 deficiency in *Homo sapiens* leads to spastic paraplegia and memory impairment, while a missense variant in the *RPL22* gene (c.431G>A) is associated with non‑syndromic deafness and increased susceptibility to genotoxicity.",-45.75,0.4,diseaseorphenotypicfeature
"Roflumilast treatment reduced the severity of psoriatic skin lesions in a cohort of patients with chronic obstructive pulmonary disease, while the concomitant use of the PPAR‑γ agonist pioglitazone mitigated the associated memory impairment and lowered the risk of genotoxicity in the peripheral blood mononuclear cells of those patients.",-54.25,0.4,diseaseorphenotypicfeature
"Rac1 overexpression in A549 cells enhances doxorubicin‑induced apoptosis, thereby reducing tumor‑cell survival and improving chemotherapy efficacy in non‑small cell lung cancer patients.",-34.25,0.4,diseaseorphenotypicfeature
"Rosa1 deficiency in the A549 cell line increases susceptibility to doxorubicin-induced genotoxicity, leading to pronounced memory impairment in the treated cells.",-31.5,0.4,diseaseorphenotypicfeature
"In patients with X‑linked dominant retinopathy, a BRCA1 c.68_69delAG variant in the TP53 gene was associated with increased mucositis severity during doxorubicin therapy in HeLa cells.",-19.625,0.4,diseaseorphenotypicfeature
"In the X‑linked dominant disorder characterized by coloboma of iris and choroid, the BRCA1 c.68_69delAG variant in the TP53 gene was found to increase the risk of carcinogenesis while concurrently exacerbating bradycardia and memory deterioration in affected patients.",-26.125,0.4,diseaseorphenotypicfeature
"In an X‑linked dominant disorder characterized by bradycardia and coloboma of iris and choroid, the TP53 gene mutation c.68_69delAG was found to accelerate carcinogenesis in HeLa cells treated with doxorubicin, leading to increased mucositis and memory deterioration.",-27.0,0.4,diseaseorphenotypicfeature
"In X‑linked dominant retinopathy, a BRCA1 c.68_69delAG variant in the TP53 gene disrupts DNA repair, leading to accelerated carcinogenesis and progressive mucositis in affected Homo sapiens patients.",-27.0,0.4,diseaseorphenotypicfeature
"The X‑linked dominant disorder causing coloboma of iris and choroid also predisposes carriers to bradycardia and convulsive seizures, as demonstrated by the TP53‑associated mucositis observed in A549 cells treated with doxorubicin.",-28.375,0.4,diseaseorphenotypicfeature
"The discovery that a novel BRCA1 c.68_69delAG sequence variant in a family with a history of inherited breast‑cancer predisposition accelerates carcinogenesis by disrupting DNA repair pathways, thereby increasing the risk of early‑onset disease in affected Homo sapiens carriers.",-35.25,0.4,diseaseorphenotypicfeature
"The bradycardia observed in patients with the X‑linked dominant disorder caused by a missense mutation in the SCN5A gene is exacerbated by the concomitant use of the anti‑epileptic drug carbamazepine, which further inhibits cardiac sodium channels.",-27.125,0.4,diseaseorphenotypicfeature
"The CRISPR‑generated A549 cell line harboring the BRCA1 c.68_69delAG variant exhibited increased sensitivity to the DNA‑damaging agent doxorubicin, suggesting a link between this sequence variant and chemotherapeutic response in breast cancer carcinogenesis.",-24.75,0.4,diseaseorphenotypicfeature
A missense mutation in the GATA4 gene (c.1063G>A) in a patient with X‑linked dominant cardiomyopathy leads to bradycardia and is associated with an increased risk of malignant arrhythmias and sudden cardiac death.,-33.75,0.4,diseaseorphenotypicfeature
"A patient with X‑linked dominant retinitis pigmentosa exhibited severe bradycardia, and genetic testing revealed a novel BRCA1 c.68_69delAG variant that may contribute to the disease’s carcinogenesis risk.",-24.5,0.4,diseaseorphenotypicfeature
A homozygous BRCA1 c.68_69delAG variant in a patient with X‑linked dominant breast cancer predisposition increases the risk of carcinogenesis and accelerates memory deterioration.,-22.75,0.4,diseaseorphenotypicfeature
"A heterozygous BRCA1 c.68_69delAG variant in a female Homo sapiens patient was associated with increased risk of breast carcinogenesis, while the same mutation in a male sibling manifested as a mild X‑linked dominant disorder with coloboma of iris and choroid and mild bradycardia.",-30.625,0.4,diseaseorphenotypicfeature
"Elevated expression of the TP53 gene in HeLa cells treated with doxorubicin induces apoptosis, thereby reducing the risk of carcinogenesis in patients with inherited X‑linked dominant disorders such as coloboma of iris and choroid.",-21.5,0.4,diseaseorphenotypicfeature
Elevating the expression of the TP53 gene in HeLa cells treated with doxorubicin induces a pronounced apoptotic response that correlates with the development of mucositis in patients with X‑linked dominant disorders such as X‑linked adrenoleukodystrophy.,-34.25,0.4,diseaseorphenotypicfeature
"Elevatory treatment with the novel kinase inhibitor Nilotinib reduced the progression of X‑linked dominant retinitis pigmentosa in a cohort of patients carrying the RPGR c.1234C>T mutation, while simultaneously improving bradycardia observed in the same individuals.",-66.0,0.4,diseaseorphenotypicfeature
Elevations of the mutant TP53 protein in HeLa cells carrying the BRCA1 c.68_69delAG variant accelerate carcinogenesis and sensitize the cells to doxorubicin-induced mucositis.,-31.75,0.4,diseaseorphenotypicfeature
"X‑linked dominant mutations in the DMD gene, such as the c.3214C>T (p.R1072C) variant, cause severe muscular dystrophy and frequently lead to early‑onset bradycardia, while the same mutation is also associated with a higher risk of developing mucositis during high‑dose chemotherapy.",-45.5,0.4,diseaseorphenotypicfeature
"X‐linked dominant mutations in the DMD gene cause a severe muscular disorder that manifests as progressive bradycardia, convulsive seizures, and mucositis in affected individuals.",-22.875,0.4,diseaseorphenotypicfeature
"X-linked dominant mutations in the DMD gene, such as the c.11234delC variant, cause a severe form of muscular dystrophy that manifests with early‑onset bradycardia, progressive muscular weakness, and, in some patients, coloboma of the iris and choroid, thereby illustrating the complex genotype‑phenotype correlations in inherited muscular disorders.",-48.0,0.4,diseaseorphenotypicfeature
"Xylem-derived fibroblasts from a patient with X‑linked dominant coloboma of iris and choroid exhibited a BRCA1 c.68_69delAG variant that increased the expression of the pro‑apoptotic gene TP53, thereby accelerating mucositis in response to doxorubicin treatment.",-43.75,0.4,diseaseorphenotypicfeature
"Genetic analysis of a family with an X‑linked dominant disorder revealed that a missense mutation in the KDM5C gene causes bradycardia, coloboma of iris and choroid, and a mild form of muscular dystrophy, while the same variant is absent in unaffected relatives.",-33.0,0.4,diseaseorphenotypicfeature
Genomic sequencing of a family with X‑linked dominant coloboma of iris and choroid revealed a novel BRCA1 c.68_69delAG variant that co‑segregates with the disease phenotype and is predicted to disrupt DNA repair pathways involved in carcinogenesis.,-28.5,0.4,diseaseorphenotypicfeature
"Genetically engineered A549 cells expressing the BRCA1 c.68_69delAG variant exhibit increased sensitivity to doxorubicin, suggesting a potential therapeutic strategy for patients with inherited breast cancer predisposition.",-22.625,0.4,diseaseorphenotypicfeature
"Genotoxic exposure to doxorubicin in A549 cells induces TP53‑mediated apoptosis, thereby reducing the risk of carcinogenesis in patients with inherited X‑linked dominant disorders such as X‑linked adrenoleukodystrophy.",-29.5,0.4,diseaseorphenotypicfeature
"Genome‑wide association studies revealed that the X‑linked dominant mutation c.1234delG in the *DMD* gene, which encodes dystrophin, is strongly associated with early‑onset bradycardia and progressive muscular disorder in affected male carriers, while heterozygous female carriers exhibit mild coloboma of iris and choroid and occasional convulsive seizures.",-46.0,0.4,diseaseorphenotypicfeature
"Genome‐wide association studies revealed that the X‑linked dominant mutation in the *DMD* gene, which encodes dystrophin, is associated with a severe form of muscular dystrophy that manifests as progressive bradycardia, convulsive seizures, and memory deterioration in affected individuals.",-39.25,0.4,diseaseorphenotypicfeature
"Genome-wide association analysis in a cohort of patients with X‑linked dominant retinitis pigmentosa revealed that a missense variant in the RPGR gene (c.1129C>T, p.Arg377Cys) is strongly associated with early‑onset bradycardia and progressive mucositis during standard chemotherapy.",-42.5,0.4,diseaseorphenotypicfeature
Genome-editing of the X-linked dominant gene DMD in patient-derived iPSC-derived cardiomyocytes from a bradycardia case revealed that the BRCA1 c.68_69delAG variant increases susceptibility to mucositis during doxorubicin therapy.,-44.5,0.4,diseaseorphenotypicfeature
"Mutations in the X‑linked gene **DMD** cause a severe form of muscular dystrophy that manifests as progressive bradycardia, muscle weakness, and memory deterioration in affected **Homo sapiens** patients.",-27.875,0.4,diseaseorphenotypicfeature
"Mutually exclusive X‑linked dominant mutations in the *FOXC1* gene, such as the c.104C>T variant, cause coloboma of iris and choroid while simultaneously predisposing patients to early‑onset mucositis during chemotherapy.",-45.5,0.4,diseaseorphenotypicfeature
Mutational analysis of the BRCA1 c.68_69delAG variant in a cohort of female patients with inherited breast cancer revealed a statistically significant association with increased susceptibility to mucositis during adjuvant chemotherapy.,-27.25,0.4,diseaseorphenotypicfeature
"Mutated TP53 in HeLa cells drives aberrant cell cycle arrest and promotes the development of X‑linked dominant retinopathy, illustrating how a single sequence variant can trigger both carcinogenesis and a severe ocular phenotype.",-45.5,0.4,diseaseorphenotypicfeature
"Patients with X‑linked dominant retinitis pigmentosa carrying the RPGR c.1543G>A sequence variant exhibit progressive visual loss and retinal coloboma of the iris and choroid, while heterozygous carriers of the same variant show mild bradycardia and occasional convulsive seizures.",-42.25,0.4,diseaseorphenotypicfeature
Patients studied with X‑linked dominant retinitis pigmentosa carrying the RPGR c.1204G>A sequence variant exhibited progressive bradycardia and severe mucositis during high‑dose chemotherapy with doxorubicin.,-40.25,0.4,diseaseorphenotypicfeature
"Patients treated with doxorubicin for breast carcinoma exhibited severe mucositis, a common side effect that can accelerate disease progression in A549 cell line models.",-32.5,0.4,diseaseorphenotypicfeature
"Patients engineered with the BRCA1 c.68_69delAG sequence variant exhibit increased susceptibility to carcinogenesis, while those harboring the same deletion in a HeLa cell line display heightened DNA repair deficiency.",-37.5,0.4,diseaseorphenotypicfeature
"Carcinogenesis in X‑linked dominant disorders such as the BRCA1 c.68_69delAG variant is exacerbated by the presence of the TP53 gene product, leading to increased cellular proliferation and a higher risk of developing invasive breast cancer.",-28.75,0.4,diseaseorphenotypicfeature
"Carriers of the X‑linked dominant mutation in the RYR1 gene exhibit severe congenital myopathy, bradycardia, and a high risk of convulsive seizures, linking inherited disease to both muscular disorder and neuro‑cognitive phenotypic features.",-42.5,0.4,diseaseorphenotypicfeature
Carboplatin treatment of HeLa cells carrying the BRCA1 c.68_69delAG sequence variant reduced the incidence of DNA‑damage‑induced mucositis in a xenograft model of ovarian carcinoma.,-31.375,0.4,diseaseorphenotypicfeature
"Carcinosis in a patient with an X‑linked dominant disorder was exacerbated by a BRCA1 c.68_69delAG variant, causing a severe mucositis response to cisplatin treatment.",-33.0,0.4,diseaseorphenotypicfeature
"Sildenafil treatment in a cohort of patients with X‑linked dominant retinitis pigmentosa carrying the RPGR c.1546G>A variant reduced retinal photoreceptor loss, improved visual acuity, and was associated with a lower incidence of progressive bradycardia compared with untreated controls.",-48.0,0.4,diseaseorphenotypicfeature
"SARS‑CoV‑2 infection in patients with a BRCA1 c.68_69delAG sequence variant increases the risk of mucositis, a common adverse effect of platinum‑based chemotherapy, thereby exacerbating memory deterioration in those with inherited breast‑cancer predisposition.",-31.125,0.4,diseaseorphenotypicfeature
"SOD1 G7958, SOD2 T2734, and CAT C262 alleles were linked to erysipelas predisposition, a condition that may exacerbate the bradycardia observed in patients with inherited X‑linked dominant disorders such as coloboma of iris and choroid.",-27.875,0.4,diseaseorphenotypicfeature
Sanger sequencing of the TP53 gene in A549 cells revealed a BRCA1 c.68_69delAG variant that correlates with increased mucositis severity in patients with inherited X‑linked dominant disorders.,-26.125,0.4,diseaseorphenotypicfeature
"Bradycardia in patients with X‑linked dominant mutations of the KCNE1 gene is associated with increased risk of arrhythmogenic sudden cardiac death, a severe phenotypic feature of inherited cardiac disease.",-28.5,0.4,diseaseorphenotypicfeature
"Brisk activation of the TP53 pathway in HeLa cells treated with doxorubicin induces apoptosis, a mechanism that may underlie the drug’s efficacy in counteracting carcinogenesis driven by BRCA1 c.68_69delAG mutations.",-30.5,0.4,diseaseorphenotypicfeature
"Bray1, a novel X‑linked dominant mutation in the BRCA1 gene, was found to accelerate carcinogenesis in HeLa cells and to increase the risk of mucositis in patients with inherited diseases such as coloboma of iris and choroid.",-35.25,0.4,diseaseorphenotypicfeature
"Brucella suis infection in a patient with X‑linked dominant coloboma of iris and choroid was associated with a marked increase in pro‑inflammatory cytokine IL‑6 and a concurrent reduction in heart rate, leading to symptomatic bradycardia.",-32.75,0.4,diseaseorphenotypicfeature
"Neurofibromatosis type‑1, an X‑linked dominant disorder, predisposes patients to cutaneous neurofibromas and optic pathway gliomas, while a concurrent BRCA1 c.68_69delAG sequence variant increases the risk of breast carcinogenesis and early‑onset ovarian cancer.",-37.0,0.4,diseaseorphenotypicfeature
"Neonatal X‑linked dominant disorder caused by a novel BRCA1 c.68_69delAG variant in a male infant presenting with coloboma of iris and choroid, bradycardia, and early‑onset mucositis, illustrates how inherited mutations can trigger both developmental anomalies and severe inflammatory responses.",-44.5,0.4,diseaseorphenotypicfeature
"Neurons from the A549 cell line treated with doxorubicin exhibited increased TP53 expression, which correlated with the development of mucositis in patients with X‑linked dominant disorder and bradycardia.",-31.25,0.4,diseaseorphenotypicfeature
"Neuronal loss in the hippocampus of patients with X‑linked dominant neurodegeneration is exacerbated by a BRCA1 c.68_69delAG variant, leading to severe memory deterioration and convulsive seizures.",-30.25,0.4,diseaseorphenotypicfeature
"TRAF6-mediated NF‑κB activation in A549 cells exposed to doxorubicin exacerbates the inflammatory response and promotes the development of mucositis, a common adverse effect of chemotherapy.",-30.75,0.4,diseaseorphenotypicfeature
"TRUNCATED BRCA1 c.68_69delAG in breast carcinoma cells increases sensitivity to doxorubicin, thereby accelerating apoptosis in HeLa and A549 cell lines and reducing tumor growth in a xenograft model of Homo sapiens.",-40.75,0.4,diseaseorphenotypicfeature
"TRIALS in patients with X‑linked dominant retinitis pigmentosa showed that the novel BRCA1 c.68_69delAG variant in the TP53 pathway exacerbated retinal cell apoptosis, leading to accelerated vision loss and increased susceptibility to mucositis during chemotherapy with doxorubicin.",-39.5,0.4,diseaseorphenotypicfeature
"TRIM24 loss-of-function in HeLa cells accelerates TP53‑mediated apoptosis, thereby enhancing doxorubicin‑induced mucositis in a xenograft model of colorectal carcinoma.",-31.75,0.4,diseaseorphenotypicfeature
Acetaminophen overdose in a patient with hepatomegaly and a BRCA1 c.68_69delAG variant was associated with a rapid rise in serum alanine aminotransferase and a transient improvement in cognitive deterioration after administration of N-acetylcysteine.,-32.0,0.4,diseaseorphenotypicfeature
"Acute hepatomegaly in patients with aceruloplasminemia is associated with a BRCA1 c.68_69delAG variant that upregulates HIF‑1α, thereby exacerbating renal dysfunction and cognitive deterioration.",-23.5,0.4,diseaseorphenotypicfeature
"Acquired hepatomegaly in patients with aceruloplasminemia is associated with elevated ferritin levels and increased hepatic iron deposition, which in turn exacerbates oxidative stress and contributes to the progression of renal dysfunction.",-31.375,0.4,diseaseorphenotypicfeature
"Acrodermatitis pigmentosa in a patient with Aceruloplasminemia was associated with hepatomegaly, cognitive deterioration, and a pathogenic BRCA1 c.68_69delAG sequence variant in the TP53 gene.",-31.125,0.4,diseaseorphenotypicfeature
"A CRISPR‑Cas9‑generated HeLa cell line harboring the BRCA1 c.68_69delAG variant shows increased sensitivity to the DNA‑damaging agent doxorubicin, linking the sequence variant to a heightened apoptotic response in this cancer model.",-23.375,0.4,diseaseorphenotypicfeature
"A patient with hepatomegaly and cognitive deterioration exhibited a BRCA1 c.68_69delAG sequence variant that correlated with increased expression of the TP53 gene product in the A549 cell line, suggesting a pathogenic link between the mutation and the observed endocrine disease phenotype.",-28.125,0.4,diseaseorphenotypicfeature
"A liver biopsy from a patient with hepatomegaly revealed a BRCA1 c.68_69delAG variant, which correlated with increased TP53 expression and suggested a potential link to endocrine disease progression.",-23.75,0.4,diseaseorphenotypicfeature
A hepatomegaly observed in patients with aceruloplasminemia is frequently accompanied by iron‑dependent oxidative stress that upregulates HIF‑1α and exacerbates cognitive deterioration.,-21.5,0.4,diseaseorphenotypicfeature
"The hepatomegaly observed in patients with aceruloplasminemia is exacerbated by the loss-of-function mutation in the CP gene, which disrupts copper transport and leads to iron overload in the liver.",-14.5625,0.4,diseaseorphenotypicfeature
"The CRISPR‑edited A549 cells harboring the BRCA1 c.68_69delAG variant displayed increased hepatomegaly‑associated gene expression, suggesting a link between the sequence variant and hepatic phenotypic changes.",-24.25,0.4,diseaseorphenotypicfeature
"The presence of a BRCA1 c.68_69delAG sequence variant in a patient with breast cancer–associated MCL and hepatomegaly led to a marked increase in TP53 expression, suggesting a pathogenic link between the mutation and the disease phenotype.",-30.375,0.4,diseaseorphenotypicfeature
"The chronic administration of doxorubicin to A549 cells induced a dose‑dependent increase in TP53 expression, which in turn up‑regulated the pro‑apoptotic gene BAX, thereby exacerbating hepatomegaly observed in the treated mice.",-27.75,0.4,diseaseorphenotypicfeature
"In HCC patients, the presence of the TP53 R249S SequenceVariant in the liver tumor tissue was associated with hepatomegaly and an increased risk of developing renal or cardiovascular disorders.",-33.0,0.4,diseaseorphenotypicfeature
"In patients with hepatomegaly and a BRCA1 c.68_69delAG variant, the TP53 protein level is markedly increased, suggesting a potential link between the sequence variant and the disease phenotype.",-24.25,0.4,diseaseorphenotypicfeature
"In hepatocellular carcinoma patients, the TP53 R249S sequence variant in the TP53 gene was associated with hepatomegaly and increased risk of liver failure, while treatment with doxorubicin reduced tumor burden but induced cardiotoxicity in a subset of individuals.",-32.75,0.4,diseaseorphenotypicfeature
"In a cohort of patients with hepatomegaly and major depression, the TP53 c.215C>G sequence variant was associated with a higher incidence of cardiac dysfunction, suggesting a genetic predisposition linking endocrine disease and renal or cardiovascular disorders.",-29.875,0.4,diseaseorphenotypicfeature
"An MCL patient with hepatomegaly and a BRCA1 c.68_69delAG variant exhibited a dramatic reduction in tumor burden after treatment with doxorubicin, suggesting a synergistic effect between the chemotherapy agent and the underlying genetic alteration.",-34.0,0.4,diseaseorphenotypicfeature
An upregulation of the TP53 gene product in HeLa cells treated with doxorubicin correlates with hepatomegaly and cognitive deterioration observed in patients with Aceruloplasminemia.,-22.0,0.4,diseaseorphenotypicfeature
"An investigation of hepatomegaly in patients with aceruloplasminemia revealed that the loss‑of‑function mutation in the CP gene, specifically the c.1187G>A (p.Gly396Arg) sequence variant, was associated with increased iron deposition and elevated serum ferritin levels.",-47.0,0.4,diseaseorphenotypicfeature
An increased expression of the TP53 gene product in HeLa cells treated with doxorubicin correlates with hepatomegaly and cognitive deterioration in patients with endocrine disease.,-19.875,0.4,diseaseorphenotypicfeature
"Hepatomegaly in patients with aceruloplasminemia is frequently accompanied by iron‑dependent oxidative stress that upregulates the HIF‑1α pathway, thereby exacerbating renal dysfunction and contributing to cognitive deterioration.",-19.625,0.4,diseaseorphenotypicfeature
"Heterozygous carriers of the BRCA1 c.68_69delAG sequence variant exhibit increased hepatomegaly and cognitive deterioration, while homozygous carriers develop severe endocrine disease and heart defect.",-22.375,0.4,diseaseorphenotypicfeature
Homo sapiens patients with hepatomegaly and the BRCA1 c.68_69delAG sequence variant exhibit increased risk of breast cancer and cognitive deterioration.,-23.125,0.4,diseaseorphenotypicfeature
"HLA‑B27‑positive patients with ankylosing spondylitis who develop hepatomegaly exhibit a higher frequency of the IL‑23R rs11209026 variant, suggesting a genetic predisposition to liver involvement in this inflammatory disease.",-34.75,0.4,diseaseorphenotypicfeature
"Epidemiological analysis of patients with hepatomegaly revealed that the presence of the HFE C282Y variant in Homo sapiens was associated with a two‑fold increase in iron‑dependent oxidative stress, which in turn exacerbated cognitive deterioration and major depression in a subset of individuals.",-38.5,0.4,diseaseorphenotypicfeature
"Ethanol exposure in A549 cells upregulated the TP53‑regulated gene NFKBIA, which in turn attenuated the inflammatory response associated with hepatomegaly in a murine model of Aceruloplasminemia.",-32.0,0.4,diseaseorphenotypicfeature
"Ectopic expression of the oncogenic TP53 variant c.215C>T in A549 cells exacerbates hepatomegaly‑associated metabolic dysfunction in a murine model of Aceruloplasminemia, linking the sequence variant to a severe disease phenotype.",-36.0,0.4,diseaseorphenotypicfeature
E2F1 overexpression in A549 cells carrying the TP53 c.215C>A variant induces hepatomegaly‑associated metabolic dysregulation and increases the risk of endocrine disease in patients with BMD.,-33.5,0.4,diseaseorphenotypicfeature
"Patients with hepatomegaly and major depression exhibited elevated serum ferritin levels, suggesting a possible link to aceruloplasminemia in this cohort.",-15.5625,0.4,diseaseorphenotypicfeature
"Patients receiving the novel drug doxorubicin exhibited hepatomegaly and cognitive deterioration, while a subset of those with the BRCA1 c.68_69delAG sequence variant showed a marked increase in major depression scores.",-36.75,0.4,diseaseorphenotypicfeature
"Patients carrying the BRCA1 c.68_69delAG variant exhibit hepatomegaly, cognitive deterioration, and an increased risk of endocrine disease, while treatment with doxorubicin in A549 cells reduces TP53 expression and induces apoptosis.",-28.75,0.4,diseaseorphenotypicfeature
"Patients undergoing chemotherapy with doxorubicin exhibited hepatomegaly and cognitive deterioration, while the TP53 c.215C>A variant in the A549 cell line was associated with increased sensitivity to the drug.",-29.75,0.4,diseaseorphenotypicfeature
Mutation of the HFE gene in patients with aceruloplasminemia leads to iron overload that exacerbates hepatomegaly and cognitive deterioration while also predisposing to renal failure.,-21.125,0.4,diseaseorphenotypicfeature
Mutation in the HFE gene causing aceruloplasminemia leads to hepatomegaly and cognitive deterioration in affected Homo sapiens patients.,-20.625,0.4,diseaseorphenotypicfeature
"Mutation‑induced loss of the ATP7B gene in a patient with Aceruloplasminemia caused hepatomegaly and cognitive deterioration, while a concomitant TP53 c.215C>A variant in the same individual was associated with a mild heart defect.",-39.75,0.4,diseaseorphenotypicfeature
"Mutation p.R248Q in TP53 was identified in a patient with hepatomegaly, and the altered protein was shown to dysregulate the p21 pathway, contributing to the observed cognitive deterioration.",-35.75,0.4,diseaseorphenotypicfeature
"Cognitive deterioration in patients with Aceruloplasminemia is exacerbated by a loss-of-function variant in the CP gene, leading to iron accumulation in the brain and progressive neurodegeneration.",-20.625,0.4,diseaseorphenotypicfeature
"Cerebral cavernous malformations in patients with BMD and a pathogenic TP53 c.215C>A variant were associated with progressive cognitive deterioration and hepatomegaly, suggesting a shared endocrine disease mechanism.",-36.25,0.4,diseaseorphenotypicfeature
"Cytotoxic chemotherapy with doxorubicin in MCL patients derived from the A549 cell line induced hepatomegaly, a phenotype linked to the TP53 c.68_69delAG variant in a subset of Homo sapiens subjects.",-30.25,0.4,diseaseorphenotypicfeature
"C-reactive protein levels were markedly elevated in patients with hepatomegaly and major depression, suggesting an inflammatory link between the two diseaseorphenotypicfeatures.",-20.75,0.4,diseaseorphenotypicfeature
"Mutations in the ATP7B gene, such as the c.3207C>T variant, are associated with aceruloplasminemia, a rare endocrine disease that manifests with hepatomegaly and progressive cognitive deterioration.",-22.125,0.4,diseaseorphenotypicfeature
"Mutational loss of the transcription factor FOXA2 in a hepatocyte-derived HepG2 cell line leads to hepatomegaly and dysregulated expression of the CYP2E1 gene, a change that may contribute to the development of aceruloplasminemia in patients with hepatic iron overload.",-45.0,0.4,diseaseorphenotypicfeature
"Mutated TP53 c.215C>A in HeLa cells induces hepatomegaly-like protein aggregation, exacerbating cognitive deterioration in patients with Aceruloplasminemia.",-26.5,0.4,diseaseorphenotypicfeature
Mutant TP53 c.215C>G in A549 cells induces hepatomegaly and cognitive deterioration in a mouse model of Aceruloplasminemia.,-22.5,0.4,diseaseorphenotypicfeature
"Endocrine disease patients with hepatomegaly and a BRCA1 c.68_69delAG sequence variant exhibited a significant increase in circulating insulin levels, suggesting a pathogenic link between the genetic alteration and metabolic dysregulation.",-29.875,0.4,diseaseorphenotypicfeature
"Endothelial dysfunction in patients with aceruloplasminemia is exacerbated by the BRCA1 c.68_69delAG variant, leading to accelerated cognitive deterioration and hepatomegaly.",-19.625,0.4,diseaseorphenotypicfeature
Endoxifen treatment of A549 cells harboring the CYP2D6 *4 allele reduced hepatomegaly‑associated CYP3A4 expression and improved cognitive deterioration scores in a murine model of endocrine disease.,-37.75,0.4,diseaseorphenotypicfeature
Endogenous overexpression of the TP53 gene in HeLa cells treated with doxorubicin induces hepatomegaly-like swelling of the liver in a murine model of endocrine disease.,-31.875,0.4,diseaseorphenotypicfeature
"Altered expression of the HNF4A gene in hepatocytes of patients with aceruloplasminemia leads to hepatomegaly and dysregulated iron metabolism, exacerbating renal dysfunction.",-23.25,0.4,diseaseorphenotypicfeature
"Alterations in the TP53 gene product, such as the c.215C>G variant, are associated with hepatomegaly and cognitive deterioration in patients with Aceruloplasminemia, and the presence of this mutation in the A549 cell line further demonstrates its role in endocrine disease progression.",-36.75,0.4,diseaseorphenotypicfeature
"Alteration of the TP53 gene in HeLa cells treated with doxorubicin induces hepatomegaly and cognitive deterioration, suggesting a link between the chemotherapeutic agent, the tumor suppressor pathway, and endocrine disease manifestations.",-31.375,0.4,diseaseorphenotypicfeature
Altering the expression of the HNF4A gene in HepG2 cells exacerbates hepatomegaly and cognitive deterioration in a mouse model of Aceruloplasminemia.,-28.75,0.4,diseaseorphenotypicfeature
"Polycystic kidney disease in a patient with a heterozygous PKD1 c.2339G>A variant causes progressive renal failure and hepatomegaly, while the concomitant loss-of-function mutation in the HNF1B gene exacerbates the endocrine dysfunction and cognitive deterioration.",-46.0,0.4,diseaseorphenotypicfeature
"Polymyxin B exposure in *Acinetobacter baumannii*-infected patients with hepatomegaly and major depression was associated with a significant increase in the expression of the *TP53* gene, leading to enhanced apoptosis of hepatic cells and exacerbation of cognitive deterioration.",-40.75,0.4,diseaseorphenotypicfeature
"Polymorphisms in the ATP7B gene, such as the c.1927C>T variant, are associated with aceruloplasminemia, a rare endocrine disease that frequently presents with hepatomegaly and cognitive deterioration.",-28.375,0.4,diseaseorphenotypicfeature
"Polysaccharide‑binding protein from *Streptococcus pneumoniae* activates the TLR2‑NF‑κB pathway in A549 cells, leading to increased IL‑6 secretion and exacerbation of hepatomegaly in a murine model of aceruloplasminemia.",-39.0,0.4,diseaseorphenotypicfeature
"Nephronophthisis, a renal and kidney disease linked to OMIM‑305600, often presents with endocardial cushion defects and obesity‑related complications, and recent studies show that HCV G1b infection exacerbates renal fibrosis in these patients.",-32.25,0.4,diseaseorphenotypicfeature
"Neurofibromatosis type‑1 patients with the OMIM‑305600 mutation exhibit endocardial cushion defects, renal and kidney disease, and oral stereotypies, while the associated obesity‑related metabolic dysregulation exacerbates nephronophthisis progression.",-43.25,0.4,diseaseorphenotypicfeature
"Neutrophil infiltration of the endocardial cushion defect in patients with HCV G1b infection and nephronophthisis correlates with increased expression of the inflammatory cytokine IL‑6, potentially exacerbating renal and kidney disease in this cohort.",-31.125,0.4,diseaseorphenotypicfeature
"Neonatal renal and kidney disease in patients with the OMIM‑305600 mutation of the NPHP1 gene, a known cause of nephronophthisis, is frequently accompanied by endocardial cushion defect and obesity‑related metabolic complications.",-35.5,0.4,diseaseorphenotypicfeature
"In CCMC patients with nephronophthisis, the HCV G1b infection exacerbates renal and kidney disease, while oral stereotypies and endocardial cushion defect are frequently observed comorbidities.",-17.5,0.4,diseaseorphenotypicfeature
"In patients with nephronophthisis, the presence of a c.1201G>A SequenceVariant in the NPHP1 Gene was associated with an increased risk of endocardial cushion defect and renal and kidney disease, while HCV G1b infection appeared to exacerbate oral stereotypies and obesity-related complications.",-30.875,0.4,diseaseorphenotypicfeature
"In a cohort of patients with nephronophthisis, the presence of the c.1523G>A sequence variant in the NPHP1 gene was associated with a higher incidence of endocardial cushion defect and severe renal failure.",-27.875,0.4,diseaseorphenotypicfeature
"In the cohort of patients with nephronophthisis, the presence of a novel c.1223G>A variant in the NPHP1 gene was associated with an increased risk of endocardial cushion defect and renal failure, while HCV G1b infection appeared to exacerbate the severity of renal and kidney disease.",-35.75,0.4,diseaseorphenotypicfeature
"The CCMC cohort of patients with nephronophthisis and HCV G1b infection exhibited a higher prevalence of oral stereotypies, suggesting a possible link between renal and liver disease and neurobehavioral phenotypes.",-17.125,0.4,diseaseorphenotypicfeature
The presence of a pathogenic variant in the NPHP1 gene in a patient with Nephronophthisis and endocardial cushion defect leads to progressive renal failure and congenital heart malformations.,-23.625,0.4,diseaseorphenotypicfeature
"The patient with nephronophthisis and an endocardial cushion defect exhibited worsening renal function after HCV G1b infection, prompting initiation of antiviral therapy and renal replacement support.",-22.375,0.4,diseaseorphenotypicfeature
"The discovery that a novel missense variant in the NPHP1 gene (c.1204C>T, p.Arg402Cys) is associated with nephronophthisis and endocardial cushion defect in patients with renal and kidney disease illustrates how sequence variants can drive complex disease phenotypes.",-40.25,0.4,diseaseorphenotypicfeature
"Patients with nephronophthisis and renal and kidney disease exhibit a higher prevalence of endocardial cushion defect and skeletal dysplasia, and the presence of oral stereotypies in these individuals is associated with obesity‑related metabolic disturbances.",-27.875,0.4,diseaseorphenotypicfeature
"Patients receiving siRNA targeting the NPHP1 gene in a CRISPR-edited A549 cell line exhibited reduced expression of the nephronophthisis-associated protein and a concomitant increase in cellular apoptosis, suggesting a potential therapeutic strategy for renal and kidney disease.",-39.0,0.4,diseaseorphenotypicfeature
"Patients treated with the CCR5 antagonist maraviroc exhibited a significant reduction in viral load in HCV G1b infection, while the presence of the CCND1 c.870C>T SequenceVariant was associated with increased risk of endocardial cushion defect in individuals with renal and kidney disease.",-42.75,0.4,diseaseorphenotypicfeature
"Patients infected with HCV G1b who develop nephronophthisis exhibit a higher prevalence of endocardial cushion defect and renal and kidney disease, suggesting a shared pathogenic pathway that may be modulated by obesity-related metabolic dysregulation.",-30.75,0.4,diseaseorphenotypicfeature
"Hyperphosphorylated HIF‑1α in the renal tubular epithelium of patients with nephronophthisis promotes fibrosis, a hallmark of the renal and kidney disease phenotype observed in OMIM‑305600.",-36.75,0.4,diseaseorphenotypicfeature
"Hyperbaric oxygen therapy reduced the frequency of oral stereotypies in a patient with nephronophthisis and HCV G1b infection, thereby improving renal function and mitigating the risk of endocardial cushion defect progression.",-31.125,0.4,diseaseorphenotypicfeature
"Hypertriglyceridemia in patients with nephronophthisis and endocardial cushion defect is exacerbated by HCV G1b infection, leading to increased renal and kidney disease progression.",-26.5,0.4,diseaseorphenotypicfeature
"Hyperglycemia in patients with nephronophthisis and endocardial cushion defect exacerbates renal and kidney disease progression, leading to increased risk of skeletal dysplasia and obesity‑related complications.",-30.125,0.4,diseaseorphenotypicfeature
"A mutation in the NPHP1 gene (c.1234_1235delAG) was found to be associated with nephronophthisis in patients with renal and kidney disease, and the same variant was also observed in a family with endocardial cushion defect and obesity‑related complications.",-36.5,0.4,diseaseorphenotypicfeature
"A patient with nephronophthisis and endocardial cushion defect exhibited oral stereotypies, and genetic testing revealed a pathogenic SequenceVariant in the PKHD1 Gene, confirming the diagnosis of OMIM‑305600.",-29.0,0.4,diseaseorphenotypicfeature
"A novel missense variant in the NPHP3 gene (c.1523G>A) was found to disrupt ciliary function and is associated with nephronophthisis, renal and kidney disease, and endocardial cushion defect in patients with CCMC.",-34.5,0.4,diseaseorphenotypicfeature
"A mutated **CCMC** gene (c.1234G>A) in a patient with **nephronophthisis** and **renal and kidney disease** was found to disrupt ciliary function, leading to the observed **endocardial cushion defect** and **skeletal dysplasia**.",-39.75,0.4,diseaseorphenotypicfeature
"Hepatitis C virus genotype G1b infection in a patient with nephronophthisis and endocardial cushion defect led to a pronounced decline in renal function, exacerbating the patient’s obesity‑related metabolic syndrome.",-30.375,0.4,diseaseorphenotypicfeature
"HCV G1b infection in a patient with nephronophthisis and endocardial cushion defect led to renal and kidney disease, while oral stereotypies were observed as a phenotypic feature of the OMIM‑305600 syndrome.",-28.25,0.4,diseaseorphenotypicfeature
"Homo sapiens patients with Nephronophthisis carrying the c.1525_1527delTAA variant in the NPHP1 gene exhibit endocardial cushion defect‑associated renal and kidney disease, while those with the same mutation also develop obesity‑related oral stereotypies.",-43.0,0.4,diseaseorphenotypicfeature
"Heterozygous mutations in the NPHP3 gene cause nephronophthisis, a renal and kidney disease that frequently co‑occurs with endocardial cushion defect and skeletal dysplasia, and recent studies show that patients with these phenotypes also exhibit increased susceptibility to HCV G1b infection.",-35.5,0.4,diseaseorphenotypicfeature
"Mutagenic exposure to the chemical entity doxorubicin in the A549 cell line induced a sequence variant c.68_69delAG in the TP53 gene, which in turn exacerbated the renal and kidney disease phenotype observed in patients with Nephronophthisis and endocardial cushion defect.",-31.125,0.4,diseaseorphenotypicfeature
"Mutations in the NPHP1 gene in patients with nephronophthisis and endocardial cushion defect lead to renal and kidney disease, while HCV G1b infection exacerbates liver fibrosis and oral stereotypies are observed in some cases.",-30.5,0.4,diseaseorphenotypicfeature
"Mutational analysis of the PKD1 gene in patients with nephronophthisis revealed a novel c.1234C>T sequence variant that correlates with the severity of renal and kidney disease, while the presence of the endocardial cushion defect gene mutation in the same cohort suggests a shared developmental pathway for cardiac and renal anomalies.",-46.75,0.4,diseaseorphenotypicfeature
"Mutated c.68_69delAG in the NPHP1 gene of a patient with nephronophthisis leads to progressive renal failure and endocardial cushion defect, while oral stereotypies and obesity-related metabolic disturbances are observed as secondary phenotypic features.",-41.75,0.4,diseaseorphenotypicfeature
"Genetic disruption of the NPHP1 gene in patients with Nephronophthisis leads to renal and kidney disease, while the same mutation also predisposes to endocardial cushion defect and skeletal dysplasia.",-25.5,0.4,diseaseorphenotypicfeature
Genomic analysis of patients with nephronophthisis revealed a novel c.1123G>A sequence variant in the NPHP1 gene that correlates with endocardial cushion defect severity and predisposes to renal and kidney disease in individuals with obesity-related metabolic syndrome.,-33.5,0.4,diseaseorphenotypicfeature
"Genotype‑specific analysis of the OMIM‑305600 mutation in the nephronophthisis‑associated gene NPHP1 revealed that the c.1234G>A variant, when present in homozygous form, precipitates endocardial cushion defect‑like phenotypes and predisposes patients to HCV G1b infection‑induced renal and kidney disease, thereby linking skeletal dysplasia and obesity‑related metabolic complications to this multiminicore disease.",-73.0,0.4,diseaseorphenotypicfeature
"Genitalia abnormalities in a patient with OMIM‑305600 were found to be associated with a novel missense variant in the NPHP1 gene, which also predisposes to nephronophthisis and renal failure.",-40.75,0.4,diseaseorphenotypicfeature
"Researchers found that the CCMC mutation in the NPHP1 gene, which is linked to nephronophthisis, exacerbates renal and kidney disease progression in patients with HCV G1b infection, while also increasing the prevalence of oral stereotypies and endocardial cushion defect in those with OMIM‑305600.",-46.25,0.4,diseaseorphenotypicfeature
"Researchers determined that the CCMC-associated endocardial cushion defect in patients with Nephronophthisis and HCV G1b infection exacerbates renal and kidney disease, leading to obesity‑related skeletal dysplasia and oral stereotypies.",-30.375,0.4,diseaseorphenotypicfeature
"Researchers documented that a novel missense mutation in the *NPHP1* gene (c.1234G>A) in a patient with nephronophthisis and renal failure led to a severe endocardial cushion defect, highlighting a potential pathogenic link between renal and cardiac phenotypes in this rare disease.",-51.75,0.4,diseaseorphenotypicfeature
"Researchers discovered that the CCMC mutation in the NPHP1 gene, which is associated with Nephronophthisis, leads to endocardial cushion defect formation and renal and kidney disease in patients with obesity-related metabolic syndrome.",-33.25,0.4,diseaseorphenotypicfeature
"Inflammatory cytokine IL‑6 levels were markedly elevated in CCMC patients with nephronophthisis, correlating with the severity of renal and kidney disease and suggesting a pathogenic role for IL‑6 in the progression of this obesity‑related, endocardial cushion defect–associated renal phenotype.",-32.25,0.4,diseaseorphenotypicfeature
Infliximab treatment of patients with endocardial cushion defect and renal and kidney disease associated with Nephronophthisis reduced the frequency of oral stereotypies while improving liver function in those with HCV G1b infection.,-31.875,0.4,diseaseorphenotypicfeature
"Influenza‑associated HCV G1b infection in a patient with nephronophthisis and endocardial cushion defect led to severe renal and kidney disease, prompting the use of a novel chemical entity, a selective phosphodiesterase‑5 inhibitor, to mitigate the obesity‑related metabolic complications.",-46.75,0.4,diseaseorphenotypicfeature
"Influent HCV G1b infection in a patient with nephronophthisis and endocardial cushion defect led to an exacerbated renal and kidney disease phenotype, prompting a therapeutic trial of a novel small‑molecule inhibitor targeting the dysregulated SMAD signaling pathway.",-48.75,0.4,diseaseorphenotypicfeature
"Acute renal failure in patients with nephronophthisis and HCV G1b infection was associated with a higher incidence of endocardial cushion defect and skeletal dysplasia, suggesting a possible pathogenic link between renal and cardiac developmental pathways.",-32.5,0.4,diseaseorphenotypicfeature
"Acquired HCV G1b infection in a patient with nephronophthisis and endocardial cushion defect was associated with an increased risk of renal and kidney disease, as evidenced by elevated serum creatinine and proteinuria.",-27.375,0.4,diseaseorphenotypicfeature
"Acquisition of a novel missense variant in the NPHP1 gene by a patient with nephronophthisis and endocardial cushion defect, who also presented with obesity-related renal and kidney disease, led to a severe reduction in ciliary function and exacerbated the phenotypic spectrum of the OMIM‑305600 disorder.",-56.5,0.4,diseaseorphenotypicfeature
"Acoustic neuroma patients with HCV G1b infection and a heterozygous BRCA1 c.68_69delAG variant exhibited a higher prevalence of oral stereotypies, suggesting a potential link between viral infection, genetic susceptibility, and neurobehavioral phenotypes.",-41.5,0.4,diseaseorphenotypicfeature
"Osteopathic manipulation of the cervical spine in patients with endocardial cushion defect and HCV G1b infection reduced the frequency of oral stereotypies, suggesting a link between cardiac malformation, viral hepatitis, and neurobehavioral symptoms.",-33.25,0.4,diseaseorphenotypicfeature
"Ocular surface inflammation in patients with HCV G1b infection was exacerbated by the presence of the CC genotype of the HLA‑DRB1 gene, leading to increased serum levels of IL‑6 and a higher risk of developing nephronophthisis‑associated renal failure.",-43.5,0.4,diseaseorphenotypicfeature
"Ongoing research indicates that the CCMC gene mutation in patients with nephronophthisis and HCV G1b infection is associated with an increased risk of endocardial cushion defect and renal and kidney disease, thereby contributing to the obesity‑related skeletal dysplasia phenotype.",-36.5,0.4,diseaseorphenotypicfeature
"Ototoxicity from cisplatin in HeLa cells carrying the BRCA1 c.68_69delAG variant exacerbates renal and kidney disease in patients with Nephronophthisis, a disorder linked to endocardial cushion defect and skeletal dysplasia.",-31.75,0.4,diseaseorphenotypicfeature
"SMARCB1 mutations in patients with OMIM‑305600 cause a multiminicore disease phenotype that includes endocardial cushion defects and renal and kidney disease, and the presence of HCV G1b infection has been associated with exacerbated obesity‑related nephronophthisis in these individuals.",-44.5,0.4,diseaseorphenotypicfeature
"SMR1, a novel sequence variant in the NPHP1 gene, was identified in a patient with nephronophthisis and endocardial cushion defect, and its presence was associated with a higher risk of renal and kidney disease progression.",-39.0,0.4,diseaseorphenotypicfeature
"SMAD4 mutations in patients with renal and kidney disease, including nephronophthisis, are associated with endocardial cushion defects and multiminicore disease, and the presence of HCV G1b infection in these individuals exacerbates the severity of skeletal dysplasia and obesity-related complications.",-40.0,0.4,diseaseorphenotypicfeature
"SMC1A mutations in patients with nephronophthisis and endocardial cushion defect lead to impaired renal tubular transport and increased susceptibility to HCV G1b infection, thereby exacerbating renal and kidney disease.",-30.625,0.4,diseaseorphenotypicfeature
The chronic urolithiasis observed in patients with hereditary leiomyomatosis and renal cell cancer is associated with a progressive neuron loss that may contribute to the neurologic deterioration seen in advanced stages.,-22.75,0.4,diseaseorphenotypicfeature
"The CRISPR‑Cas9‑generated A549 cell line harboring the BRCA1 c.68_69delAG variant exhibited increased sensitivity to doxorubicin, leading to heightened cardiotoxicity and neuron loss in co‑cultured primary cortical neurons.",-24.25,0.4,diseaseorphenotypicfeature
The presence of a BRCA1 c.68_69delAG variant in a patient with hereditary leiomyomatosis and renal cell cancer predisposes to early-onset urolithiasis and neurologic deterioration due to neuron loss.,-14.875,0.4,diseaseorphenotypicfeature
The loss of neuronal mitochondria in WFS patients carrying the WFS1 c.1210C>T variant correlates with progressive neurologic deterioration and severe febrile neutropenia during chemotherapy.,-29.625,0.4,diseaseorphenotypicfeature
A germline BRCA1 c.68_69delAG variant in a patient with hereditary leiomyomatosis and renal cell cancer predisposes to early-onset urolithiasis and neurologic deterioration due to neuron loss.,-17.375,0.4,diseaseorphenotypicfeature
A CRISPR‑Cas9‑generated TP53 c.215C>A variant in HeLa cells accelerates neuron loss and exacerbates febrile neutropenia in a mouse model of hereditary leiomyomatosis and renal cell cancer.,-22.375,0.4,diseaseorphenotypicfeature
"A patient with hereditary leiomyomatosis and renal cell cancer exhibited sudden neurologic deterioration after a bout of febrile neutropenia, prompting investigation of a potential WFS-related sequence variant in the TP53 gene.",-23.0,0.4,diseaseorphenotypicfeature
A biopsy of a renal tumor from a patient with hereditary leiomyomatosis and renal cell cancer revealed a BRCA1 c.68_69delAG sequence variant that likely contributes to the observed neuron loss and neurologic deterioration.,-16.375,0.4,diseaseorphenotypicfeature
"Neuroblastoma patients receiving doxorubicin exhibit cardiotoxicity that correlates with TP53 sequence variant c.215C>A, while A549 cell lines treated with the same drug show increased apoptosis and neuron loss markers.",-31.5,0.4,diseaseorphenotypicfeature
"Neural progenitor cells from a patient with hereditary leiomyomatosis and renal cell cancer harbor a BRCA1 c.68_69delAG variant that reduces TP53 expression, leading to neuron loss and neurologic deterioration.",-28.375,0.4,diseaseorphenotypicfeature
"Neuronal loss in patients with hereditary leiomyomatosis and renal cell cancer correlates with increased risk of aortic occlusion and febrile neutropenia, suggesting a shared pathogenic pathway involving WFS and HypoPP.",-23.875,0.4,diseaseorphenotypicfeature
"Neurons from A549 cells treated with doxorubicin exhibited increased neuron loss, correlating with cardiotoxicity observed in patients with hereditary leiomyomatosis and renal cell cancer.",-24.25,0.4,diseaseorphenotypicfeature
"In patients with hereditary leiomyomatosis and renal cell cancer, the BRCA2 c.5946_5947delAG sequence variant is associated with increased risk of urolithiasis and neurologic deterioration due to neuron loss.",-18.875,0.4,diseaseorphenotypicfeature
"In a cohort of patients with hereditary leiomyomatosis and renal cell cancer, the presence of a BRCA1 c.68_69delAG sequence variant in tumor tissue was associated with increased neuron loss and a higher incidence of febrile neutropenia during chemotherapy.",-18.125,0.4,diseaseorphenotypicfeature
"In HCT116 cells, the CRISPR‑generated TP53 c.215C>A (p.Pro72Arg) variant exacerbates doxorubicin‑induced cardiotoxicity by upregulating BAX while concurrently increasing the expression of the anti‑apoptotic gene BCL‑XL, thereby shifting the balance toward cell survival and contributing to the observed decline in cardiac function.",-44.75,0.4,diseaseorphenotypicfeature
"In urolithiasis patients, the presence of a BRCA2 c.5946delT variant in the renal epithelium was associated with increased neuron loss and a higher risk of hereditary leiomyomatosis and renal cell cancer.",-27.25,0.4,diseaseorphenotypicfeature
Patients receiving doxorubicin for hereditary leiomyomatosis and renal cell cancer experienced cardiotoxicity that correlated with a decline in left ventricular ejection fraction and an increase in serum troponin levels.,-21.75,0.4,diseaseorphenotypicfeature
"Patients with hereditary leiomyomatosis and renal cell cancer who carry the c.1016C>T variant in the fumarate hydratase gene experience early onset urolithiasis, which frequently precedes the development of renal cell carcinoma.",-31.5,0.4,diseaseorphenotypicfeature
"Patients treated with doxorubicin for hereditary leiomyomatosis and renal cell cancer experienced cardiotoxicity that correlated with a dose‑dependent increase in circulating troponin, while a subset of those with a BRCA1 c.68_69delAG sequence variant exhibited heightened susceptibility to febrile neutropenia.",-38.5,0.4,diseaseorphenotypicfeature
"Patients carrying the hereditary leiomyomatosis and renal cell cancer-associated TP53 mutation displayed increased urolithiasis risk, while those with the WFS1 c.1523G>A variant experienced neurologic deterioration and febrile neutropenia during chemotherapy.",-43.75,0.4,diseaseorphenotypicfeature
"CRISPR‑Cas9‑mediated disruption of the *KMT2D* gene in A549 cells leads to a marked reduction in the expression of the *TP53* protein, thereby increasing susceptibility to doxorubicin‑induced cardiotoxicity in *Homo sapiens* subjects with a germline *KMT2D* c.1023_1024delAG variant.",-51.0,0.4,diseaseorphenotypicfeature
"CRPC patients with hereditary leiomyomatosis and renal cell cancer who harbor the c.1673_1674delAG sequence variant in the fumarate hydratase gene exhibit accelerated aortic occlusion and neurologic deterioration, while treatment with the chemical entity doxorubicin mitigates cardiotoxicity but exacerbates febrile neutropenia.",-49.25,0.4,diseaseorphenotypicfeature
"CRYPD, a novel missense variant in the ATP1A3 gene, was identified in a patient with hereditary urolithiasis and neurologic deterioration, and functional assays in HEK293 cells revealed that the mutation disrupts Na⁺/K⁺-ATPase activity, thereby contributing to the observed renal stone formation and neuronal loss.",-53.75,0.4,diseaseorphenotypicfeature
"CRS‑treated patients with febrile neutropenia exhibited a higher incidence of neurologic deterioration, and the presence of a BRCA1 c.68_69delAG variant in the tumor cells correlated with increased cardiotoxicity during anthracycline therapy.",-39.0,0.4,diseaseorphenotypicfeature
"Elevated serum potassium levels in patients with hereditary leiomyomatosis and renal cell cancer undergoing doxorubicin therapy precipitated a rapid onset of HypoPP, causing severe neurologic deterioration and necessitating urgent cardiotoxicity monitoring.",-28.375,0.4,diseaseorphenotypicfeature
Elevations of the GJB2 c.35delG SequenceVariant in patients with hereditary leiomyomatosis and renal cell cancer were associated with increased neuron loss and a higher risk of febrile neutropenia during chemotherapy.,-33.75,0.4,diseaseorphenotypicfeature
Elevating serum lactate levels in patients with hereditary leiomyomatosis and renal cell cancer undergoing doxorubicin therapy correlates with cardiotoxicity and neurologic deterioration.,-25.0,0.4,diseaseorphenotypicfeature
Elevational renal cell carcinoma in a patient with hereditary leiomyomatosis and renal cell cancer was associated with a novel TP53 c.215G>A sequence variant that accelerates neuron loss and predisposes to febrile neutropenia during chemotherapy.,-42.5,0.4,diseaseorphenotypicfeature
Hereditary leiomyomatosis and renal cell cancer patients with a germline mutation in the fumarate hydratase gene exhibit increased risk of urolithiasis and neurologic deterioration due to neuron loss.,-18.0,0.4,diseaseorphenotypicfeature
"Heritable urolithiasis in patients with hereditary leiomyomatosis and renal cell cancer is frequently associated with nephron loss and neurologic deterioration, and the presence of a WFS mutation exacerbates febrile neutropenia and cardiotoxicity.",-38.25,0.4,diseaseorphenotypicfeature
"Hereditable leiomyomatosis and renal cell cancer patients with urolithiasis exhibit increased neuron loss, which may contribute to the neurologic deterioration observed in some cases.",-29.375,0.4,diseaseorphenotypicfeature
"Herbal extract treatment of patients with hereditary leiomyomatosis and renal cell cancer (HLRCC) reduced tumor-associated neuron loss, while CRISPR‑edited TP53 c.215C>T variants in A549 cells amplified cardiotoxicity and febrile neutropenia risk.",-52.25,0.4,diseaseorphenotypicfeature
"An increased expression of the TP53 gene product in HeLa cells treated with doxorubicin correlates with a higher incidence of cardiotoxicity and neuron loss, suggesting a potential therapeutic target for mitigating febrile neutropenia in patients with hereditary leiomyomatosis and renal cell cancer.",-29.875,0.4,diseaseorphenotypicfeature
An elevated serum calcium level in patients with hereditary leiomyomatosis and renal cell cancer is associated with increased risk of urolithiasis and subsequent neurologic deterioration.,-18.625,0.4,diseaseorphenotypicfeature
"An inherited mutation in the fumarate hydratase gene (FH c.1246C>T) causes hereditary leiomyomatosis and renal cell cancer, leading to a high risk of urolithiasis and neurologic deterioration in affected Homo sapiens patients.",-31.625,0.4,diseaseorphenotypicfeature
"An impaired ATPase activity in the ATP1A1 gene, commonly observed in patients with hereditary leiomyomatosis and renal cell cancer, leads to a loss of neuronal Na⁺/K⁺ balance that precipitates neuron loss and neurologic deterioration.",-40.75,0.4,diseaseorphenotypicfeature
Loss of neuronal calcium‑binding protein calbindin in the hippocampus of patients with hereditary leiomyomatosis and renal cell cancer correlates with progressive neuron loss and neurologic deterioration.,-21.125,0.4,diseaseorphenotypicfeature
"Loss-of-function mutations in the ATP1A1 gene, such as the c.1226G>A (p.Arg409His) variant, are associated with hypokalemic periodic paralysis (HypoPP) and can exacerbate neurologic deterioration in patients with hereditary leiomyomatosis and renal cell cancer who undergo cardiotoxic chemotherapy.",-41.0,0.4,diseaseorphenotypicfeature
"Losses of the ATP1A1 gene in patients with hereditary leiomyomatosis and renal cell cancer correlate with severe hypokalemic periodic paralysis and neurologic deterioration, while the same mutation predisposes to aortic occlusion and febrile neutropenia in the setting of chemotherapy-induced cardiotoxicity.",-42.5,0.4,diseaseorphenotypicfeature
"Lossy neuronal degeneration in patients with hereditary leiomyomatosis and renal cell cancer is exacerbated by the BRCA2 c.5946_5947delAG sequence variant, leading to severe neurologic deterioration.",-32.25,0.4,diseaseorphenotypicfeature
"Mutations in the PRKAG2 gene were found to cause hereditary leiomyomatosis and renal cell cancer in a family of Homo sapiens, and the resulting protein misfolding led to aortic occlusion and neurologic deterioration in affected individuals.",-31.375,0.4,diseaseorphenotypicfeature
"Mutant BRCA1 c.68_69delAG in HeLa cells enhances TP53‑mediated apoptosis, thereby reducing the incidence of urolithiasis observed in patients with hereditary leiomyomatosis and renal cell cancer.",-23.5,0.4,diseaseorphenotypicfeature
Mutational loss of the ATP1A1 gene in patients with hereditary leiomyomatosis and renal cell cancer leads to severe neuronal loss and contributes to the development of HypoPP and WFS phenotypes.,-27.5,0.4,diseaseorphenotypicfeature
"Mutating the BRCA1 gene in HeLa cells increases the risk of urolithiasis by upregulating the expression of the sodium–glucose cotransporter SGLT2, which in turn promotes renal calcium reabsorption and stone formation.",-40.75,0.4,diseaseorphenotypicfeature
"Mutation of the KCNJ2 gene in patients with hereditary hypokalemic periodic paralysis (HypoPP) leads to impaired potassium channel function, causing episodic muscle weakness and neurologic deterioration that can progress to severe cardiotoxicity and, in some cases, aortic occlusion.",-33.0,0.4,diseaseorphenotypicfeature
Mutation-driven loss of the KCNJ2 gene in patients with hereditary leiomyomatosis and renal cell cancer correlates with neurologic deterioration and increased susceptibility to febrile neutropenia.,-28.5,0.4,diseaseorphenotypicfeature
Mutation‑driven loss of the LKB1 gene in a patient with hereditary leiomyomatosis and renal cell cancer was associated with progressive neurologic deterioration and increased susceptibility to febrile neutropenia.,-29.75,0.4,diseaseorphenotypicfeature
"Mutation in the HNF1B gene, commonly associated with hereditary leiomyomatosis and renal cell cancer, was found to increase the risk of urolithiasis in patients who also exhibit early neuron loss and febrile neutropenia.",-32.0,0.4,diseaseorphenotypicfeature
Urolithiasis in patients with hereditary leiomyomatosis and renal cell cancer is associated with increased neuron loss and a higher risk of febrile neutropenia during chemotherapy.,-13.8125,0.4,diseaseorphenotypicfeature
"Urologic surgeons noted that patients with hereditary leiomyomatosis and renal cell cancer who develop urolithiasis experience accelerated neuron loss, potentially exacerbating neurologic deterioration.",-22.125,0.4,diseaseorphenotypicfeature
"Uropathogenic *Escherichia coli* infection in a patient with hereditary leiomyomatosis and renal cell cancer led to urolithiasis, which in turn precipitated febrile neutropenia and subsequent neurologic deterioration.",-24.375,0.4,diseaseorphenotypicfeature
Urothelial carcinoma of the bladder in a patient with hereditary leiomyomatosis and renal cell cancer was associated with a novel BRCA2 c.5946_5947delTT sequence variant that increased susceptibility to febrile neutropenia during cisplatin therapy.,-34.25,0.4,diseaseorphenotypicfeature
"Gene mutations in the fumarate‑reductase gene (FH) cause hereditary leiomyomatosis and renal cell cancer, and the resulting fumarate accumulation activates HIF‑1α, which drives angiogenesis and contributes to aortic occlusion in affected patients.",-28.5,0.4,diseaseorphenotypicfeature
"Gene‑edited A549 cells harboring the BRCA1 c.68_69delAG variant exhibit increased susceptibility to doxorubicin‑induced cardiotoxicity, a finding that may explain the heightened risk of cardiotoxicity observed in patients with hereditary leiomyomatosis and renal cell cancer carrying the same sequence variant.",-27.875,0.4,diseaseorphenotypicfeature
Gene mutation BRCA1 c.68_69delAG in a patient with hereditary leiomyomatosis and renal cell cancer leads to increased risk of urolithiasis and neurologic deterioration.,-19.0,0.4,diseaseorphenotypicfeature
"Gene product p53 mutation in TP53 c.215C>G, detected in a HeLa cell line, is associated with increased susceptibility to febrile neutropenia in patients with hereditary leiomyomatosis and renal cell cancer.",-34.75,0.4,diseaseorphenotypicfeature
"In patients with cerebral ischemic stroke, the expression of the HIF‑1α gene is up‑regulated, and the resulting increase in VEGF secretion promotes angiogenesis that mitigates neuronal loss and improves functional recovery.",-23.625,0.4,diseaseorphenotypicfeature
"In HeLa cells, the CRISPR‑mediated knockout of the TP53 gene increased susceptibility to doxorubicin‑induced apoptosis, a phenotype that mirrors the heightened risk of myocardial infarction observed in patients carrying the BRCA1 c.68_69delAG variant.",-25.375,0.4,diseaseorphenotypicfeature
"In a cohort of patients with cerebral ischemic stroke, the presence of the APOE ε4 allele was associated with a higher incidence of post‑stroke extrapyramidal syndrome, while treatment with atorvastatin reduced the risk of subsequent myocardial infarction.",-19.375,0.4,diseaseorphenotypicfeature
"In LNCaP cells, the BRCA1 c.68_69delAG variant enhances sensitivity to doxorubicin, leading to increased apoptosis and reduced proliferation of prostate cancer cells.",-27.875,0.4,diseaseorphenotypicfeature
"The elevated expression of the transcription factor MYC in HeLa cells treated with the small molecule JQ1 exacerbates the phenylketonuria‑associated metabolic phenotype by upregulating phenylalanine hydroxylase, thereby linking chemical‑entity modulation to a disease‑or‑phenotypic‑feature outcome.",-43.75,0.4,diseaseorphenotypicfeature
"The cerebral ischemic event in the patient with a BRCA1 c.68_69delAG variant was associated with an up‑regulation of the HIF‑1α pathway and a subsequent increase in VEGFA expression, which may contribute to the observed exacerbation of the extrapyramidal syndrome symptoms.",-35.0,0.4,diseaseorphenotypicfeature
"The mitochondrial DNA variant m.3243A>G in the MT‑T gene of a patient with phenylketonuria exacerbates the clinical phenotype by impairing tRNA‑Thr synthesis, thereby increasing the risk of extrapyramidal syndrome and contributing to the observed cognitive deficits.",-40.0,0.4,diseaseorphenotypicfeature
"The CRISPR‑Cas9‑generated TP53 c.215C>A variant in HeLa cells exacerbated the phenylketonuria‑associated hyperphenylalaninemia, leading to increased oxidative stress and a higher incidence of extrapyramidal syndrome symptoms in the resulting cellular model.",-27.5,0.4,diseaseorphenotypicfeature
"A randomized trial showed that the novel inhibitor of the PIK3CA pathway reduced tumor burden in patients with giant cell tumor of bone, and the effect was amplified in those carrying the BRCA1 c.68_69delAG variant, suggesting a genotype‑specific therapeutic response.",-41.25,0.4,diseaseorphenotypicfeature
A novel missense mutation in the SCN1A gene (c.3022G>A) was found to be associated with severe phenylketonuria and an increased risk of extrapyramidal syndrome in patients with cerebral ischemic events.,-35.0,0.4,diseaseorphenotypicfeature
"A clinical trial demonstrated that the combination of the small‑molecule inhibitor doxorubicin and the monoclonal antibody trastuzumab reduced tumor growth in HeLa cells harboring the TP53 c.215C>A sequence variant, thereby improving survival outcomes for patients with metastatic breast cancer.",-37.25,0.4,diseaseorphenotypicfeature
A cerebral ischemic event in a patient with phenylketonuria exacerbated by a BRCA1 c.68_69delAG variant led to an unexpected exacerbation of extrapyramidal syndrome symptoms.,-20.5,0.4,diseaseorphenotypicfeature
"Among patients with cerebral ischemic stroke, the presence of a TP53 c.215C>G SequenceVariant was associated with a higher risk of developing extrapyramidal syndrome after thrombolytic therapy.",-25.75,0.4,diseaseorphenotypicfeature
"Among the patients with cerebral ischemic stroke, the presence of the APOE ε4 allele in the APOE gene was associated with a higher risk of developing post‑stroke depression, and treatment with the selective serotonin reuptake inhibitor sertraline reduced the severity of depressive symptoms in those individuals.",-41.75,0.4,diseaseorphenotypicfeature
"Among chronic periodontitis patients, the presence of a CYP2A6 *4 allele in *Homo sapiens* was associated with increased expression of the inflammatory cytokine IL‑1β, suggesting a genetic predisposition to exaggerated periodontal tissue destruction.",-38.0,0.4,diseaseorphenotypicfeature
"Among humans with cerebral ischemic stroke, the presence of the APOE ε4 allele in the APOE gene was associated with a higher risk of developing post‑stroke depression, while treatment with the antiepileptic drug levetiracetam reduced seizure frequency in those who also carried the SCN1A p.R1638Q sequence variant.",-52.25,0.4,diseaseorphenotypicfeature
"Cerebral ischemic injury in patients with phenylketonuria is exacerbated by the loss-of-function variant BRCA1 c.68_69delAG, which impairs neuronal DNA repair and increases the risk of extrapyramidal syndrome.",-15.5625,0.4,diseaseorphenotypicfeature
"Cognitive decline in patients with cerebral ischemic events is exacerbated by the presence of the APOE ε4 allele, which increases the risk of Alzheimer’s disease and accelerates the progression of vascular dementia.",-27.25,0.4,diseaseorphenotypicfeature
"Cranial MRI of a patient with cerebral ischemic stroke revealed a giant cell tumor of bone in the occipital region, prompting evaluation for phenylketonuria as a potential metabolic contributor to the extrapyramidal syndrome and attention‑deficit/hyperactivity disorder symptoms.",-29.0,0.4,diseaseorphenotypicfeature
"Celiac disease patients receiving a gluten‑free diet showed a significant reduction in intestinal villous atrophy, correlating with decreased serum anti‑tissue transglutaminase IgA levels and improved growth velocity.",-31.5,0.4,diseaseorphenotypicfeature
"Mutations in the NOTCH2 gene, such as the c.2195G>A variant, have been shown to increase the risk of cerebral ischemic events in patients with phenylketonuria, while the same variant also predisposes to extrapyramidal syndrome in a subset of individuals.",-42.75,0.4,diseaseorphenotypicfeature
Mutated TP53 c.215C>T in HeLa cells increases susceptibility to cerebral ischemic injury by upregulating HIF‑1α and enhancing VEGF‑mediated angiogenesis.,-26.625,0.4,diseaseorphenotypicfeature
"Mutational analysis of the BRCA1 c.68_69delAG variant in a cohort of patients with cerebral ischemic stroke revealed a statistically significant association with increased risk of recurrent myocardial infarction, suggesting a shared pathogenic pathway involving endothelial dysfunction and impaired DNA repair.",-30.75,0.4,diseaseorphenotypicfeature
"Mutual inhibition between the TP53 gene product and the BCL2 protein in HeLa cells treated with doxorubicin reduces apoptosis and contributes to chemoresistance, a phenomenon also observed in A549 cells harboring the BRCA1 c.68_69delAG variant.",-35.25,0.4,diseaseorphenotypicfeature
"Dopamine D2 receptor antagonism by haloperidol reduces extrapyramidal syndrome symptoms in patients with Parkinson’s disease, while concomitant use of L-DOPA mitigates motor deficits in those with chronic periodontitis‑associated inflammation.",-37.25,0.4,diseaseorphenotypicfeature
"Dexamethasone treatment of HeLa cells expressing the TP53 c.215C>G variant reduced the expression of the pro‑inflammatory cytokine IL‑6, thereby attenuating the cellular response to the chronic periodontitis‑associated bacterial toxin.",-31.375,0.4,diseaseorphenotypicfeature
"Doxorubicin treatment of HeLa cells carrying the TP53 c.215C>G variant reduces the expression of the pro‑apoptotic gene BAX, thereby attenuating the apoptotic response to chemotherapy in this cell line.",-26.875,0.4,diseaseorphenotypicfeature
Dysregulation of the TP53 gene in HeLa cells treated with doxorubicin increases the risk of cerebral ischemic injury in Homo sapiens by promoting apoptosis and oxidative stress.,-26.75,0.4,diseaseorphenotypicfeature
"Recurrent cerebral ischemic events in patients with phenylketonuria are associated with a higher prevalence of extrapyramidal syndrome, suggesting that metabolic dysregulation may contribute to neurodegeneration.",-23.625,0.4,diseaseorphenotypicfeature
Reanalysis of the B-NHL cohort revealed that the TP53 c.215C>G variant in the tumor cells of patients with giant cell tumor of bone was associated with a higher rate of relapse after rituximab therapy.,-43.5,0.4,diseaseorphenotypicfeature
"Recombinant AAV‑mediated delivery of CRISPR‑Cas9 targeting the BRCA1 c.68_69delAG variant in HeLa cells markedly reduced DNA‑damage‑induced γ‑H2AX foci, suggesting a potential therapeutic strategy for patients with hereditary breast cancer.",-30.625,0.4,diseaseorphenotypicfeature
"Re-analysis of the A549 cell line revealed that the B-NHL–associated MYC translocation upregulates the phenylketonuria‑linked PAH gene, thereby exacerbating cerebral ischemic injury in Homo sapiens models.",-42.25,0.4,diseaseorphenotypicfeature
"Repeated cerebral ischemic episodes in patients with phenylketonuria were associated with an increased risk of extrapyramidal syndrome, as evidenced by elevated dopamine transporter binding in the striatum of affected individuals.",-26.875,0.4,diseaseorphenotypicfeature
"Repeated ischemic strokes in patients with cerebral ischemic disease were associated with up‑regulation of the inflammatory cytokine IL‑6, which in turn promoted endothelial dysfunction and increased risk of subsequent myocardial infarction.",-26.0,0.4,diseaseorphenotypicfeature
"Repeated administration of the small molecule Nilotinib to A549 cells carrying the KRAS G12D mutation induced a dose‑dependent reduction in the expression of the pro‑inflammatory cytokine IL‑6, thereby attenuating the cellular phenotype associated with chronic periodontitis.",-43.0,0.4,diseaseorphenotypicfeature
Repeated carotid artery stenting in patients with cerebral ischemic episodes reduced the incidence of subsequent myocardial infarction by targeting the TP53‑mediated inflammatory pathway in Homo sapiens.,-38.5,0.4,diseaseorphenotypicfeature
"Progressive cerebral ischemic injury in patients with phenylketonuria is exacerbated by the loss-of-function variant c.1523C>T in the PAH gene, leading to increased oxidative stress and exacerbated extrapyramidal syndrome symptoms.",-30.75,0.4,diseaseorphenotypicfeature
"Progression of cerebral ischemic injury in patients with phenylketonuria is exacerbated by the loss of the ABCG2 transporter, leading to increased accumulation of toxic metabolites and heightened risk of extrapyramidal syndrome.",-31.25,0.4,diseaseorphenotypicfeature
"Progressively worsening extrapyramidal syndrome in a patient with a novel GBA1 c.1226C>T variant was alleviated by the selective dopamine agonist ropinirole, which also reduced the frequency of dystonic tremors in the basal ganglia.",-54.75,0.4,diseaseorphenotypicfeature
"Progress on a clinical trial of the novel inhibitor NCT-2025 showed that patients with cerebral ischemic stroke who received the drug had a statistically significant reduction in infarct volume compared with placebo, while a secondary analysis revealed that the drug also lowered plasma levels of the inflammatory cytokine IL‑6 in patients with chronic periodontitis.",-67.0,0.4,diseaseorphenotypicfeature
"Biochemical inhibition of the TP53 pathway by the small molecule doxorubicin in A549 cells exacerbates the phenylketonuria‑associated metabolic phenotype, leading to increased oxidative stress and neuronal apoptosis in a cerebral ischemic mouse model.",-36.0,0.4,diseaseorphenotypicfeature
"Bioluminescent imaging of HeLa cells treated with doxorubicin revealed a dose‑dependent increase in TP53‑mediated apoptosis, suggesting that the drug’s cytotoxic effect is amplified by the up‑regulation of the tumor‑suppressor gene in this human cell line.",-34.75,0.4,diseaseorphenotypicfeature
Biopsy of the giant cell tumor of bone from a patient with phenylketonuria revealed a novel TP53 c.215C>T sequence variant that likely contributes to the extrapyramidal syndrome observed in this individual.,-25.875,0.4,diseaseorphenotypicfeature
"Biomechanical analysis of a patient with chronic periodontitis revealed that the periodontal ligament cells from the A549 cell line exhibited increased expression of the TNFα gene product, suggesting that the inflammatory cytokine may contribute to the disease phenotype.",-51.75,0.4,diseaseorphenotypicfeature
Patients with cerebral ischemic stroke who received nimodipine exhibited a statistically significant reduction in the incidence of extrapyramidal syndrome compared with those who received placebo.,-19.0,0.4,diseaseorphenotypicfeature
"Patients receiving the novel B-NHL therapeutic agent rituximab exhibited a marked reduction in circulating CD20+ B‑cell counts, correlating with improved overall survival in a cohort of adults with refractory disease.",-38.75,0.4,diseaseorphenotypicfeature
"Patients suffering from cerebral ischemic stroke exhibit elevated levels of the inflammatory cytokine IL‑6, which is up‑regulated by the TP53 gene and contributes to the development of post‑stroke cognitive impairment.",-31.0,0.4,diseaseorphenotypicfeature
"Patients treated with the novel CCR5 antagonist Maraviroc exhibited a significant reduction in the incidence of extrapyramidal syndrome in individuals with HIV-associated neurocognitive disorder, suggesting a neuroprotective effect mediated by CCR5 blockade.",-32.75,0.4,diseaseorphenotypicfeature
"CRISPR‑Cas9‑mediated disruption of the *TP53* gene in A549 cells exacerbated the growth‑inhibitory effect of doxorubicin on cerebral ischemic‑induced apoptosis, a phenotype that mirrors the heightened risk of myocardial infarction observed in patients carrying the BRCA1 c.68_69delAG variant.",-39.5,0.4,diseaseorphenotypicfeature
"CRABP2 overexpression in a HeLa cell line treated with doxorubicin induces apoptosis through the PI3K/AKT pathway, thereby reducing tumor cell proliferation in a model of giant cell tumor of bone.",-35.25,0.4,diseaseorphenotypicfeature
"CRP levels were markedly elevated in patients with cerebral ischemic stroke, and the presence of the APOE ε4 allele amplified the risk of developing post‑stroke cognitive decline.",-26.75,0.4,diseaseorphenotypicfeature
"CRITICAL CARE patients with cerebral ischemic lesions exhibited a significant up‑regulation of HIF‑1α and VEGF, correlating with the severity of myocardial infarction‑induced hypoxia and the presence of a BRCA1 c.68_69delAG variant.",-42.25,0.4,diseaseorphenotypicfeature
"Early‐stage cerebral ischemic injury in a patient with a heterozygous BRCA1 c.68_69delAG variant was associated with a marked upregulation of the pro‑inflammatory cytokine IL‑6, suggesting that the sequence variant may exacerbate the inflammatory response to ischemia.",-33.75,0.4,diseaseorphenotypicfeature
Early onset phenylketonuria in a patient with a BRCA1 c.68_69delAG variant was associated with a higher risk of extrapyramidal syndrome after long‑term levodopa therapy.,-24.625,0.4,diseaseorphenotypicfeature
"Early gene‑editing of the TP53 c.215C>A variant in HeLa cells reduces the incidence of cerebral ischemic lesions while simultaneously increasing the expression of the antioxidant enzyme SOD2, thereby mitigating the oxidative stress that contributes to the extrapyramidal syndrome observed in patients with phenylketonuria.",-50.25,0.4,diseaseorphenotypicfeature
"Early‑stage cerebral ischemic lesions in patients with phenylketonuria were associated with an up‑regulation of the G‑protein coupled receptor GPR56, which in turn promoted the migration of microglia and exacerbated extrapyramidal syndrome symptoms.",-33.75,0.4,diseaseorphenotypicfeature
"The presence of atherosclerotic lesions in the coronary arteries of a patient with AMI was associated with elevated serum levels of asparagine, suggesting a metabolic link to myocardial necrosis.",-18.625,0.4,diseaseorphenotypicfeature
"The biopsy of a patient with atherosclerotic lesion revealed that the TP53 mutation c.215C>T was associated with increased expression of the pro‑apoptotic gene BAX, suggesting a potential link between the genetic variant and myocardial necrosis.",-28.125,0.4,diseaseorphenotypicfeature
The observation that atherosclerotic lesion progression in patients with GH‑deficiency is accelerated by elevated asparagine levels suggests a metabolic link between endocrine dysfunction and cardiovascular disease.,-20.0,0.4,diseaseorphenotypicfeature
The frequent occurrence of myoclonic jerks in patients with atherosclerotic lesion–induced cerebral ischemia suggests a neurovascular link that may exacerbate nephritis and myocardial necrosis.,-25.875,0.4,diseaseorphenotypicfeature
"Myoclonic jerks in patients with atherosclerotic lesion and nephritis were found to be exacerbated by the presence of a BRCA1 c.68_69delAG sequence variant, suggesting a genetic predisposition to severe neurological complications.",-26.0,0.4,diseaseorphenotypicfeature
Myoclonus observed in patients with atherosclerotic lesions was associated with increased myocardial necrosis and a higher incidence of acute myocardial infarction.,-22.0,0.4,diseaseorphenotypicfeature
"Myocardial necrosis in patients with AMI is exacerbated by atherosclerotic lesions that impair coronary perfusion, leading to increased arrhythmic myoclonic jerks and higher mortality.",-25.125,0.4,diseaseorphenotypicfeature
"Myofilament fragmentation in patients with atherosclerotic lesion and myocardial necrosis is exacerbated by the loss of the protective TP53 variant c.215C>T, leading to accelerated apoptosis in the affected cardiac tissue.",-46.25,0.4,diseaseorphenotypicfeature
"Patients with myoclonic jerks and atherosclerotic lesions exhibited higher levels of circulating inflammatory cytokines, suggesting a link between neuronal hyperexcitability and cardiovascular pathology.",-22.0,0.4,diseaseorphenotypicfeature
"Patients exhibiting myoclonic jerks and atherosclerotic lesions were found to have increased expression of the inflammatory cytokine IL‑6, suggesting a link between neuro‑motor symptoms and vascular pathology.",-23.125,0.4,diseaseorphenotypicfeature
"Patients who develop atherosclerotic lesions after a myocardial infarction exhibit increased expression of the pro‑inflammatory cytokine IL‑6, which is further amplified by the presence of the IL‑6R Asp358Ala sequence variant.",-36.0,0.4,diseaseorphenotypicfeature
Patients treated with the novel kinase inhibitor NCT-2021 for atherosclerotic lesion regression exhibited a significant reduction in myocardial necrosis markers and a concurrent improvement in left ventricular ejection fraction.,-35.5,0.4,diseaseorphenotypicfeature
"In patients with atherosclerotic lesion–induced myocardial necrosis, the presence of a BRCA1 c.68_69delAG sequence variant in the TP53 gene was associated with a higher incidence of myoclonic jerks during the acute phase of AMI.",-21.25,0.4,diseaseorphenotypicfeature
"In ADPKD patients, the presence of atherosclerotic lesions in renal arteries exacerbates nephritis, leading to increased myoclonic jerks and a higher risk of myocardial necrosis during acute myocardial infarction.",-28.125,0.4,diseaseorphenotypicfeature
"In biopsy specimens from patients with atherosclerotic lesion, the expression of the inflammatory cytokine IL‑6 was markedly upregulated in the endothelial cells of the carotid artery, suggesting that IL‑6 may drive the progression of atherosclerosis.",-30.875,0.4,diseaseorphenotypicfeature
"In HeLa cells, the CRISPR‑generated BRCA1 c.68_69delAG variant exacerbates DNA damage signaling, leading to increased expression of the pro‑apoptotic gene TP53 and heightened sensitivity to the chemotherapeutic agent doxorubicin, thereby accelerating cell death in a manner that mimics the myocardial necrosis observed in acute myocardial infarction patients.",-40.5,0.4,diseaseorphenotypicfeature
"Atherosclerotic lesions in the coronary arteries of patients with myocardial necrosis were found to be exacerbated by the presence of a pathogenic TP53 c.215C>G sequence variant, leading to increased expression of the pro‑inflammatory cytokine IL‑6.",-29.75,0.4,diseaseorphenotypicfeature
"A coronary artery atherosclerotic lesion in a patient with AMI was found to be associated with increased expression of the pro‑inflammatory cytokine IL‑6, which in turn exacerbated myocardial necrosis.",-24.125,0.4,diseaseorphenotypicfeature
"A patient with atherosclerotic lesion and nephritis exhibited myoclonic jerks, suggesting a possible link between vascular inflammation and neurological dysfunction.",-18.625,0.4,diseaseorphenotypicfeature
"A study of patients with atherosclerotic lesion revealed that the presence of the APOE ε4 allele in Homo sapiens was associated with increased myocardial necrosis following acute myocardial infarction, while the same allele also correlated with higher levels of inflammatory cytokines in the serum of individuals with nephritis.",-37.0,0.4,diseaseorphenotypicfeature
"Neuroimaging of patients with myoclonic jerks revealed a significant association between the presence of atherosclerotic lesions in the middle cerebral artery and the severity of seizure activity, suggesting a vascular contribution to the pathophysiology of this phenotypic feature.",-27.0,0.4,diseaseorphenotypicfeature
"Neuronal myoclonic jerks in patients with atherosclerotic lesions were exacerbated by a deficiency of asparagine, leading to increased myocardial necrosis and a higher risk of acute myocardial infarction.",-22.625,0.4,diseaseorphenotypicfeature
"Neurons expressing the mutant TP53 variant c.215C>A in A549 cells exhibit increased myoclonic jerks and upregulated HIF‑1α, linking the sequence variant to the disease phenotype.",-30.875,0.4,diseaseorphenotypicfeature
"Nephritis in patients with atherosclerotic lesion was associated with increased serum asparagine deficit, which in turn exacerbated myocardial necrosis in those with a history of AMI.",-24.75,0.4,diseaseorphenotypicfeature
"MRSA‑infected atherosclerotic lesions in a patient with GH‑deficiency were found to induce myoclonic jerks and myocardial necrosis, while the underlying asparagine deficit exacerbated nephritis and benign prostatic hyperplasia.",-33.0,0.4,diseaseorphenotypicfeature
"MRD1, a sequence variant in the TP53 gene, was found to increase the risk of atherosclerotic lesion formation in patients with benign prostatic hyperplasia and GH‑deficiency.",-27.75,0.4,diseaseorphenotypicfeature
"MRNA‑based therapy targeting the TP53 gene in A549 cells reduced the expression of the pro‑apoptotic protein BAX, thereby attenuating the atherosclerotic lesion observed in atherosclerosis‑prone ApoE‑/‑ mice.",-39.5,0.4,diseaseorphenotypicfeature
"MRCKA overexpression in A549 cells exacerbated atherosclerotic lesion formation in ApoE‑/‑ mice, linking the gene product to cardiovascular disease progression.",-28.75,0.4,diseaseorphenotypicfeature
"Hyperthermia-induced myoclonic jerks in patients with atherosclerotic lesion-associated nephritis were markedly attenuated by the selective CXCR4 antagonist AMD3100, which also reduced myocardial necrosis markers in a cohort of AMI survivors.",-36.25,0.4,diseaseorphenotypicfeature
"Hyperlipidemia-induced atherosclerotic lesion progression in patients with GH‑deficiency correlates with increased expression of the inflammatory cytokine IL‑6, which exacerbates myocardial necrosis during acute myocardial infarction.",-29.0,0.4,diseaseorphenotypicfeature
"Hyperglycemia-induced oxidative stress in patients with GH‑deficiency exacerbates atherosclerotic lesion formation, leading to increased myocardial necrosis during acute myocardial infarction.",-19.625,0.4,diseaseorphenotypicfeature
"Hyperuricemia-induced atherosclerotic lesion formation in patients with chronic nephritis exacerbates myocardial necrosis, leading to increased incidence of AMI.",-25.875,0.4,diseaseorphenotypicfeature
"Heterozygous carriers of the BRCA1 c.68_69delAG variant exhibit a higher incidence of myoclonic jerks, a neurological phenotype that correlates with increased risk of atherosclerotic lesions and myocardial necrosis in patients with atherosclerotic cardiovascular disease.",-33.0,0.4,diseaseorphenotypicfeature
"HIV‑positive patients with atherosclerotic lesions and nephritis experience a higher frequency of myoclonic jerks, suggesting that systemic inflammation from cardiovascular disease and renal impairment may trigger neurological manifestations.",-35.5,0.4,diseaseorphenotypicfeature
Haplotype‑associated variants in the TNF‑α promoter were linked to increased severity of nephritis and accelerated atherosclerotic lesion formation in patients with atherosclerotic cardiovascular disease.,-38.5,0.4,diseaseorphenotypicfeature
"HepG2 cells treated with the small‑molecule inhibitor doxorubicin exhibited a dose‑dependent increase in TP53‑mediated transcription of the pro‑apoptotic gene BAX, correlating with heightened caspase‑3 activation and subsequent apoptotic cell death.",-32.75,0.4,diseaseorphenotypicfeature
"Doxorubicin treatment of A549 cells induced a marked increase in the expression of the pro‑apoptotic gene BAX, correlating with the observed myocardial necrosis in patients with AMI who had previously received the drug.",-30.75,0.4,diseaseorphenotypicfeature
"Dopaminergic stimulation of the striatum in patients with Parkinson’s disease and concomitant myoclonic jerks increases the expression of the GABA_A receptor subunit α2, thereby attenuating seizure susceptibility.",-35.25,0.4,diseaseorphenotypicfeature
"Doxycycline treatment of *Plasmodium falciparum*-infected *Homo sapiens* patients with malaria infections reduced the incidence of atherosclerotic lesion development and improved survival, as measured by decreased myocardial necrosis markers.",-35.0,0.4,diseaseorphenotypicfeature
"Dysregulated expression of the TP53 gene in A549 cells exposed to doxorubicin exacerbated myoclonic jerks and accelerated atherosclerotic lesion formation in atherosclerosis-prone ApoE−/− mice, illustrating a link between chemotherapy-induced DNA damage and cardiovascular complications.",-35.75,0.4,diseaseorphenotypicfeature
"Activation of the NF‑κB pathway in A549 cells exposed to the chemotherapeutic agent doxorubicin induces the expression of the pro‑inflammatory cytokine IL‑6, which in turn exacerbates the atherosclerotic lesion burden observed in patients with coronary artery disease.",-27.875,0.4,diseaseorphenotypicfeature
"Activation‐induced STAT3 phosphorylation in A549 cells exposed to doxorubicin enhances the expression of the pro‑inflammatory cytokine IL‑6, thereby exacerbating nephritis‐associated proteinuria in a mouse model of lupus nephritis.",-42.5,0.4,diseaseorphenotypicfeature
"Activation by the GPCR agonist fenoterol in A549 cells induces a rapid increase in intracellular calcium that triggers the phosphorylation of the transcription factor NF‑κB, thereby up‑regulating the expression of the pro‑inflammatory cytokine IL‑8 and contributing to the development of atherosclerotic lesion formation in the arterial wall.",-54.0,0.4,diseaseorphenotypicfeature
"Activation‑induced transcription of the TP53 gene in HeLa cells exposed to doxorubicin leads to up‑regulation of the pro‑apoptotic BAX protein, thereby promoting caspase‑3‑mediated apoptosis and contributing to the observed myoclonic jerks in the experimental model.",-47.5,0.4,diseaseorphenotypicfeature
"Elevated levels of the inflammatory cytokine IL‑6 in patients with atherosclerotic lesion and nephritis correlate with increased expression of the chemokine CXCL10, suggesting a shared pathogenic pathway that may contribute to myocardial necrosis during acute myocardial infarction.",-29.625,0.4,diseaseorphenotypicfeature
"Elevators of the inflammatory cytokine IL‑6 in patients with atherosclerotic lesion and nephritis correlate with increased myocardial necrosis, suggesting that IL‑6‑mediated endothelial dysfunction may exacerbate AMI risk.",-41.25,0.4,diseaseorphenotypicfeature
Elevations of the inflammatory cytokine IL‑6 in patients with atherosclerotic lesion and concurrent nephritis correlate with increased myocardial necrosis and predict higher risk of AMI.,-29.875,0.4,diseaseorphenotypicfeature
Elevative expression of the inflammatory cytokine IL‑6 in atherosclerotic lesion‑laden coronary arteries of patients with AMI correlates with increased myocardial necrosis and worsened left ventricular ejection fraction.,-36.75,0.4,diseaseorphenotypicfeature
"Exposure of A549 cells to doxorubicin induced a dose‑dependent increase in TP53‑mediated apoptosis, which was markedly attenuated by co‑treatment with the antioxidant N‑acetylcysteine, suggesting that oxidative stress contributes to doxorubicin‑induced cardiotoxicity in patients with atherosclerotic lesion.",-31.125,0.4,diseaseorphenotypicfeature
"Exposure to atherosclerotic lesion‑inducing lipids in A549 cells upregulates the inflammatory cytokine IL‑6, a process that is attenuated by the chemical entity rosiglitazone and associated with increased risk of myocardial necrosis in patients with coronary artery disease.",-34.75,0.4,diseaseorphenotypicfeature
"Exposure‑induced oxidative stress in A549 cells carrying the BRCA1 c.68_69delAG variant upregulates the pro‑apoptotic gene TP53, thereby exacerbating myoclonic jerks observed in patients with Parkinson’s disease.",-37.75,0.4,diseaseorphenotypicfeature
"Exposure-induced oxidative stress in A549 cells triggers upregulation of the TP53 gene, which in turn activates the pro‑apoptotic gene BNIP3 and contributes to myocardial necrosis observed in patients with AMI.",-42.5,0.4,diseaseorphenotypicfeature
"Mutational loss of the TP53 gene in A549 cells exacerbates atherosclerotic lesion formation, leading to increased myocardial necrosis in a murine model of AMI.",-21.625,0.4,diseaseorphenotypicfeature
"Mutations in the HNF1A gene, such as the c.176C>T variant, are associated with atherosclerotic lesion development in patients with GH‑deficiency, while elevated serum asparagine levels can exacerbate nephritis and contribute to myocardial necrosis during AMI.",-44.25,0.4,diseaseorphenotypicfeature
"Mutagenic exposure to doxorubicin in A549 cells induces atherosclerotic lesion‑like lipid accumulation, which is exacerbated by a BRCA1 c.68_69delAG variant and correlates with increased myocardial necrosis markers in patients with AMI.",-30.0,0.4,diseaseorphenotypicfeature
"Mutated TP53 c.215C>T in HeLa cells exacerbated atherosclerotic lesion formation, leading to increased myocardial necrosis in atherosclerosis-prone ApoE-/- mice.",-28.25,0.4,diseaseorphenotypicfeature
"Patients treated with a high‑dose regimen of the novel kinase inhibitor NMS‑1233 exhibited a significant reduction in interstitial fibrosis and improvement in sleep disturbance in a cohort of VLCAD‑deficient individuals, while the drug’s adverse cardiovascular effects were mitigated by concurrent administration of the beta‑blocker metoprolol.",-45.25,0.4,diseaseorphenotypicfeature
"Patients with VLCAD‑deficient cardiomyopathy exhibited interstitial fibrosis and severe sleep disturbance, while a subset also developed focal segmental glomerulosclerosis and neurological disabilities.",-17.375,0.4,diseaseorphenotypicfeature
"Patients on a VLCAD‑deficient diet exhibited interstitial fibrosis and sleep disturbance, which were exacerbated by a desminopathy‑associated sequence variant in the MYH7 gene.",-28.25,0.4,diseaseorphenotypicfeature
"Patients carrying the VLCAD‑deficient c.1523A>G variant exhibit interstitial fibrosis and sleep disturbance, and the same mutation has been linked to increased risk of focal segmental glomerulosclerosis in homozygous individuals.",-36.5,0.4,diseaseorphenotypicfeature
"The VLCAD‑deficient patient exhibited interstitial fibrosis that worsened sleep disturbance, and the associated NMS was mitigated by early administration of a desminopathy‑targeted chemical entity.",-26.0,0.4,diseaseorphenotypicfeature
The presence of a BRCA1 c.68_69delAG sequence variant in a patient with interstitial fibrosis and sleep disturbance suggests a pathogenic link between the mutation and the disease phenotype.,-18.0,0.4,diseaseorphenotypicfeature
"The chronic sleep disturbance observed in VLCAD‑deficient patients is associated with interstitial fibrosis of the myocardium, potentially exacerbating their risk of adverse cardiovascular effects.",-16.25,0.4,diseaseorphenotypicfeature
The discovery that a novel BRCA1 c.68_69delAG variant in a VLCAD‑deficient patient with interstitial fibrosis and sleep disturbance correlates with increased risk of focal segmental glomerulosclerosis and adverse cardiovascular effects illustrates a complex genotype‑phenotype relationship in this rare metabolic disorder.,-28.625,0.4,diseaseorphenotypicfeature
"In a cohort of VLCAD‑deficient patients, the presence of interstitial fibrosis correlated with severe sleep disturbance, suggesting that metabolic impairment may exacerbate neurological disabilities and increase the risk of adverse cardiovascular effects.",-18.375,0.4,diseaseorphenotypicfeature
"In patients with VLCAD‑deficient cardiomyopathy, the accumulation of long‑chain fatty acids triggers interstitial fibrosis that exacerbates sleep disturbance and contributes to adverse cardiovascular effects.",-14.875,0.4,diseaseorphenotypicfeature
"In VLAD‑deficient patients, the loss of fatty‑acid oxidation exacerbates interstitial fibrosis, which in turn contributes to sleep disturbance and increases the risk of adverse cardiovascular effects.",-23.375,0.4,diseaseorphenotypicfeature
"In VLCAD‑deficient patients, the accumulation of long‑chain fatty acids induces interstitial fibrosis, which in turn exacerbates sleep disturbance and contributes to the neurological disabilities observed in this metabolic disorder.",-14.6875,0.4,diseaseorphenotypicfeature
"A single nucleotide polymorphism in the HNF1B gene, detected in a patient with focal segmental glomerulosclerosis and interstitial fibrosis, was associated with an increased risk of sleep disturbance and adverse cardiovascular effects.",-25.25,0.4,diseaseorphenotypicfeature
"A pharmacogenomic analysis revealed that the BRCA1 c.68_69delAG variant in a VLCAD‑deficient patient exacerbated interstitial fibrosis and sleep disturbance, suggesting a genetic predisposition to adverse cardiovascular effects.",-27.25,0.4,diseaseorphenotypicfeature
"A VLCAD‑deficient patient with interstitial fibrosis and sleep disturbance exhibited a marked increase in serum creatine kinase, suggesting that the metabolic defect may contribute to both renal and neurological disabilities.",-23.875,0.4,diseaseorphenotypicfeature
A recent cohort study found that patients with VLCAD‑deficient hepatopathy and concurrent sleep disturbance exhibited significantly higher rates of interstitial fibrosis compared with VLCAD‑deficient patients without sleep disturbance.,-22.0,0.4,diseaseorphenotypicfeature
VLCAD‑deficient patients exhibit interstitial fibrosis that contributes to sleep disturbance and exacerbates adverse cardiovascular effects.,-11.0625,0.4,diseaseorphenotypicfeature
"Viral hepatitis B infection in a patient with VLCAD‑deficient cardiomyopathy precipitated interstitial fibrosis of the myocardium, exacerbating sleep disturbance and increasing the risk of adverse cardiovascular effects.",-23.25,0.4,diseaseorphenotypicfeature
"Vascular endothelial growth factor (VEGF) upregulates the pro‑inflammatory gene MCP‑1 in HeLa cells, and this VEGF‑MCP‑1 axis is amplified by the BRCA1 c.68_69delAG variant, thereby exacerbating interstitial fibrosis in patients with focal segmental glomerulosclerosis.",-37.5,0.4,diseaseorphenotypicfeature
"VCLAD‑deficient patients with interstitial fibrosis exhibit a higher prevalence of sleep disturbance, which correlates with increased risk of adverse cardiovascular effects.",-26.25,0.4,diseaseorphenotypicfeature
"Ethanol exposure in VLCAD‑deficient patients exacerbates interstitial fibrosis, leading to progressive sleep disturbance and increased risk of focal segmental glomerulosclerosis.",-17.875,0.4,diseaseorphenotypicfeature
"Elderly patients with VLCAD‑deficient cardiomyopathy and interstitial fibrosis exhibit severe sleep disturbance, which is exacerbated by the use of desminopathy‑associated β‑blockers that can trigger neuro‑cardiogenic syncope.",-36.25,0.4,diseaseorphenotypicfeature
"Epidemiologic analysis revealed that patients with VLCAD‑deficient interstitial fibrosis and concomitant sleep disturbance exhibited a markedly higher incidence of focal segmental glomerulosclerosis, suggesting a pathogenic link between mitochondrial dysfunction, renal pathology, and neuro‑cardiovascular comorbidities.",-29.125,0.4,diseaseorphenotypicfeature
"Euthyroid patients with interstitial fibrosis and sleep disturbance exhibit higher plasma VLCAD levels, suggesting that VLCAD deficiency may contribute to the renal and neurological complications observed in these individuals.",-35.5,0.4,diseaseorphenotypicfeature
"Deletion of the BRCA1 c.68_69delAG variant in a HeLa cell line derived from a patient with interstitial fibrosis and sleep disturbance increases the expression of the TP53 gene, thereby enhancing apoptosis in HBV‑infected hepatocytes and reducing the risk of focal segmental glomerulosclerosis.",-33.5,0.4,diseaseorphenotypicfeature
"Deletion in the LAMB2 gene causes focal segmental glomerulosclerosis and neurological disabilities in VLCAD‑deficient patients, leading to sleep disturbance and adverse cardiovascular effects.",-31.0,0.4,diseaseorphenotypicfeature
Deletion c.68_69delAG in the BRCA1 gene in a Homo sapiens patient with interstitial fibrosis and sleep disturbance was associated with a severe adverse cardiovascular effect during treatment with doxorubicin.,-38.25,0.4,diseaseorphenotypicfeature
"Deletion mutations in the VLCAD gene cause VLCAD‑deficient patients to develop interstitial fibrosis and severe sleep disturbance, while the same mutation also predisposes them to focal segmental glomerulosclerosis.",-34.25,0.4,diseaseorphenotypicfeature
"CVID-associated interstitial fibrosis in a VLCAD-deficient patient with sleep disturbance was exacerbated by a novel TP53 c.215C>T sequence variant, leading to progressive neurological disabilities.",-32.0,0.4,diseaseorphenotypicfeature
"Cytotoxic treatment of VLCAD‑deficient HeLa cells with doxorubicin exacerbated interstitial fibrosis while simultaneously inducing sleep disturbance, a phenotype linked to bipolar disorder in HBV‑infected patients.",-29.5,0.4,diseaseorphenotypicfeature
"C3‑H‑HeLa cells infected with HBV and treated with the VLCAD‑deficient inhibitor NMS exhibit interstitial fibrosis and sleep disturbance, suggesting a link between metabolic dysfunction and neurological disabilities.",-33.5,0.4,diseaseorphenotypicfeature
"CYP2D6 polymorphisms in a VLCAD‑deficient cohort were associated with increased sleep disturbance, suggesting that altered drug metabolism may exacerbate neurological disabilities in patients with focal segmental glomerulosclerosis.",-24.5,0.4,diseaseorphenotypicfeature
"Interstitial fibrosis in VLCAD‑deficient patients frequently exacerbates sleep disturbance, and the resulting hypoxia activates HIF‑1α, which in turn upregulates VEGFA expression in renal tubular cells, contributing to focal segmental glomerulosclerosis.",-27.75,0.4,diseaseorphenotypicfeature
"Interstitial‐fibrosis in VLCAD‑deficient patients is associated with sleep disturbance, and the resulting hypoxia may exacerbate bipolar disorder in HBV‑infected individuals, thereby increasing the risk of focal segmental glomerulosclerosis and adverse cardiovascular effects.",-41.75,0.4,diseaseorphenotypicfeature
"Interstitial nephritis in a VLCAD‑deficient patient with sleep disturbance and focal segmental glomerulosclerosis was exacerbated by the NMS‑inducing drug, leading to adverse cardiovascular effects.",-33.75,0.4,diseaseorphenotypicfeature
"Interstitial sclerosis in VLCAD‑deficient patients exacerbates sleep disturbance, and the resulting hypoxia‑induced upregulation of HIF‑1α promotes a pro‑inflammatory cascade that accelerates focal segmental glomerulosclerosis.",-38.5,0.4,diseaseorphenotypicfeature
"Interaural hearing loss in VLCAD‑deficient patients is frequently accompanied by interstitial fibrosis of the cochlear duct, contributing to progressive sleep disturbance.",-26.375,0.4,diseaseorphenotypicfeature
"Interleukin‑6 upregulation in the kidneys of patients with focal segmental glomerulosclerosis carrying the COL4A3 c.1459G>A variant exacerbates interstitial fibrosis, thereby accelerating renal failure.",-30.625,0.4,diseaseorphenotypicfeature
"Interventional study of a VLCAD‑deficient patient with interstitial fibrosis revealed that sleep disturbance severity correlated with elevated serum desmin levels, suggesting a mechanistic link between mitochondrial dysfunction and renal pathology.",-32.25,0.4,diseaseorphenotypicfeature
"Intermittent sleep disturbance in VLCAD‑deficient patients correlates with elevated serum desmin levels, suggesting a link between mitochondrial fatty‑acid oxidation defects and Desminopathy‑associated neurological disabilities.",-20.5,0.4,diseaseorphenotypicfeature
"N-acetylcysteine treatment reduced interstitial fibrosis in a mouse model of VLCAD-deficient cardiomyopathy, improving sleep disturbance scores and lowering adverse cardiovascular effects associated with the disease.",-27.125,0.4,diseaseorphenotypicfeature
"NMS in a VLCAD‑deficient patient with interstitial fibrosis and sleep disturbance was exacerbated by the administration of the chemical entity doxorubicin, leading to severe neurological disabilities.",-28.0,0.4,diseaseorphenotypicfeature
"NADPH oxidase activation in VLCAD‑deficient hepatocytes exacerbates interstitial fibrosis, thereby contributing to sleep disturbance in patients with concurrent bipolar disorder.",-22.75,0.4,diseaseorphenotypicfeature
"Nuclei of HeLa cells treated with the chemical entity valproic acid exhibited upregulation of the GeneOrGeneProduct GATA3, which in turn amplified interstitial fibrosis markers in a model of VLCAD-deficient disease, suggesting a potential link between sleep disturbance and adverse cardiovascular effects.",-48.75,0.4,diseaseorphenotypicfeature
Altered expression of the desmin gene (DES) in VLCAD‑deficient hepatocytes exacerbates interstitial fibrosis and contributes to sleep disturbance in patients with HBV infection.,-20.375,0.4,diseaseorphenotypicfeature
"Alterations in the SOD2 c.2734T>C variant in VLCAD‑deficient patients were associated with increased interstitial fibrosis and sleep disturbance, suggesting a potential link between mitochondrial dysfunction and renal pathology.",-31.5,0.4,diseaseorphenotypicfeature
Alteration of the desmin gene (DES) in VLCAD‑deficient patients exacerbates interstitial fibrosis and contributes to the sleep disturbance observed in those with focal segmental glomerulosclerosis.,-28.625,0.4,diseaseorphenotypicfeature
"Altercations in the mitochondrial fatty‑acid oxidation pathway caused by a pathogenic variant in the ACADVL gene (VLCAD‑deficient) lead to interstitial fibrosis in the kidneys, which in turn exacerbates focal segmental glomerulosclerosis and contributes to sleep disturbance in affected patients.",-39.75,0.4,diseaseorphenotypicfeature
"Hepatocellular carcinoma patients with interstitial fibrosis exhibit a higher incidence of sleep disturbance, and in VLCAD‑deficient individuals the same fibrosis is associated with increased risk of bipolar and unipolar disorder.",-29.625,0.4,diseaseorphenotypicfeature
"HIV‑positive patients with interstitial fibrosis exhibit a higher prevalence of sleep disturbance, and in VLCAD‑deficient children the same metabolic defect is associated with increased risk of focal segmental glomerulosclerosis.",-31.0,0.4,diseaseorphenotypicfeature
"Heterozygous carriers of the VLCAD-deficient c.1234A>G variant exhibit interstitial fibrosis and sleep disturbance, suggesting a pathogenic link between fatty‑acid oxidation defects and neuro‑cardiovascular dysfunction.",-30.25,0.4,diseaseorphenotypicfeature
"HLA‑B*27 associated interstitial fibrosis in patients with VLCAD‑deficient cardiomyopathy is exacerbated by sleep disturbance, leading to increased risk of focal segmental glomerulosclerosis and adverse cardiovascular effects.",-27.75,0.4,diseaseorphenotypicfeature
"Bipolar disorder patients receiving valproate exhibited a significant reduction in interstitial fibrosis scores in the kidney, suggesting a protective effect against focal segmental glomerulosclerosis.",-24.875,0.4,diseaseorphenotypicfeature
"Biallelic mutations in the ACADVL gene, such as the c.1224_1225delAG variant, cause VLCAD deficiency, which is associated with interstitial fibrosis of the myocardium and sleep disturbance in affected patients.",-36.5,0.4,diseaseorphenotypicfeature
"Bilateral interstitial fibrosis in VLCAD‑deficient patients is associated with sleep disturbance and an increased risk of focal segmental glomerulosclerosis, suggesting a shared metabolic‑renal‑cardiovascular pathway.",-26.875,0.4,diseaseorphenotypicfeature
"BPA exposure in a cohort of VLCAD‑deficient patients was associated with a significant increase in interstitial fibrosis and sleep disturbance, suggesting a potential link between metabolic dysfunction and renal pathology.",-28.375,0.4,diseaseorphenotypicfeature
"In patients with X‑linked hypophosphatemic rickets, the pathogenic PHEX c.1123G>A variant causes phosphate wasting that leads to arterial dysfunction, weight loss, and loss of hearing, while CRISPR‑generated HeLa cells carrying the same mutation exhibit up‑regulation of the osteopontin gene and increased susceptibility to neuropsychiatric disorders.",-51.75,0.4,diseaseorphenotypicfeature
"In A549 cells, the TP53 c.215C>A variant increases the expression of the pro‑apoptotic gene BAX, thereby amplifying the cellular response to doxorubicin and reducing the proliferation of adenocarcinoma tumors.",-31.5,0.4,diseaseorphenotypicfeature
"In HeLa cells, the CRISPR‑generated BRCA1 c.68_69delAG variant causes a loss of DNA repair activity that, when combined with the small molecule doxorubicin, exacerbates cellular apoptosis and increases the expression of the tumor suppressor TP53, thereby highlighting a potential therapeutic target for patients with adenoid cystic carcinoma.",-47.25,0.4,diseaseorphenotypicfeature
"In the A549 cell line, treatment with the small molecule rapamycin reduced the expression of the HIF‑1α gene product, thereby attenuating the fatty‑liver phenotype observed in HepG2 cells exposed to high glucose and improving insulin sensitivity in a mouse model of type‑2 diabetes.",-38.5,0.4,diseaseorphenotypicfeature
"A randomized trial in patients with X‑linked hypophosphatemic rickets showed that oral phosphate supplementation reduced serum PTH levels and improved bone mineral density, while concomitant use of the calcitriol analog tacalcitol further enhanced calcium absorption and decreased the frequency of fractures.",-41.0,0.4,diseaseorphenotypicfeature
"A high‑fat diet in C57BL/6J mice induced fatty liver and increased serum ALT, while treatment with the PPARα agonist fenofibrate reduced hepatic steatosis and restored insulin sensitivity, suggesting a link between lipid metabolism, liver disease, and diabetes.",-35.75,0.4,diseaseorphenotypicfeature
"A CRISPR‑Cas9‑generated TP53 c.215C>G variant in HeLa cells leads to increased expression of the pro‑apoptotic gene BAX, thereby enhancing sensitivity to doxorubicin‑induced apoptosis in this ovarian carcinoma model.",-32.5,0.4,diseaseorphenotypicfeature
A patient with X‑linked hypophosphatemic rickets treated with phosphate‑replenishing therapy showed a marked reduction in arterial dysfunction and a modest improvement in hearing loss.,-25.25,0.4,diseaseorphenotypicfeature
"The chemotherapy agent doxorubicin induced severe weight loss in A549 cells, a phenotype that was mitigated by co‑treatment with the antioxidant N‑acetylcysteine, which also reduced the expression of the pro‑apoptotic gene TP53 in the human lung carcinoma model.",-35.5,0.4,diseaseorphenotypicfeature
"The HNF4A c.1521C>T (p.R507W) variant in a patient with X‑linked hypophosphatemic rickets was found to disrupt transcriptional activation of the phosphate transporter SLC34A1, thereby exacerbating renal phosphate wasting and accelerating bone mineralization defects.",-33.5,0.4,diseaseorphenotypicfeature
"The CRISPR‑Cas9‑generated TP53 c.215C>A variant in A549 cells increases sensitivity to doxorubicin, thereby reducing weight loss and improving survival in a mouse model of fatty liver disease.",-24.25,0.4,diseaseorphenotypicfeature
The discovery that the BRCA1 c.68_69delAG variant in a patient with hereditary breast cancer also predisposes to early‑onset infertility illustrates how a single sequence variant can simultaneously influence disease risk and reproductive phenotypic features.,-32.25,0.4,diseaseorphenotypicfeature
"Elevated serum IL‑6 levels in patients with X‑linked hypophosphatemic rickets correlate with increased expression of the COL1A1 gene product, thereby exacerbating bone mineralization defects.",-23.0,0.4,diseaseorphenotypicfeature
"Elevating the expression of the transcription factor HNF4A in HepG2 cells exacerbates fatty liver disease by upregulating SREBP-1c, thereby increasing triglyceride accumulation and contributing to hepatic steatosis.",-36.5,0.4,diseaseorphenotypicfeature
"Elevations in circulating IL‑6 and TNF‑α in patients with X‑linked hypophosphatemic rickets correlate with increased osteoclast activity, leading to progressive bone resorption and impaired mineralization.",-31.0,0.4,diseaseorphenotypicfeature
Elevational changes in the TP53 gene product in A549 cells treated with doxorubicin correlate with increased apoptosis and weight loss in a mouse model of fatty liver disease.,-34.5,0.4,diseaseorphenotypicfeature
"Patients with X‑linked hypophosphatemic rickets exhibit arterial dysfunction, weight loss, and loss of hearing, while a novel BRCA1 c.68_69delAG variant in the TP53 gene is associated with increased arthritis risk in the same cohort.",-29.25,0.4,diseaseorphenotypicfeature
"Patients receiving the novel TP53‑targeting drug in a Phase II trial for X‑linked hypophosphatemic rickets exhibited a dose‑dependent reduction in serum phosphate levels, but also reported transient weight loss and mild hearing loss, suggesting a complex interaction between the therapeutic agent, the underlying disease phenotype, and off‑target effects on auditory and metabolic pathways.",-56.25,0.4,diseaseorphenotypicfeature
"Patients treated with the novel TP53‑activating compound MK‑4827 showed a significant reduction in weight loss and improved insulin sensitivity in A549 cells, suggesting a therapeutic benefit for diabetes and associated fatty liver disease.",-38.25,0.4,diseaseorphenotypicfeature
"Patients using the CRISPR‑generated A549 cell line to overexpress the TP53 variant c.215C>G showed increased apoptosis and reduced fatty‑liver‑associated lipid accumulation, suggesting a potential therapeutic strategy for metabolic syndrome.",-39.0,0.4,diseaseorphenotypicfeature
"An inherited variant of the PHEX gene (c.1123G>A) in a patient with X‑linked hypophosphatemic rickets leads to decreased phosphate reabsorption, causing bone pain, growth retardation, and a characteristic loss of hearing.",-40.0,0.4,diseaseorphenotypicfeature
"An A549 cell line treated with the small molecule inhibitor gefitinib exhibited a dose‑dependent reduction in the expression of the oncogenic gene EGFR, correlating with decreased proliferation and increased apoptosis in a model of adenocarcinoma.",-32.0,0.4,diseaseorphenotypicfeature
"An altered TP53 sequence variant (c.215C>A) in a HeLa cell line exposed to doxorubicin exacerbates fatty liver pathology in a HepG2 model, suggesting a gene–drug interaction that may contribute to metabolic dysfunction.",-39.5,0.4,diseaseorphenotypicfeature
An elevated serum IL‑6 level in patients with X‑linked hypophosphatemic rickets correlates with increased bone turnover and contributes to the characteristic osteomalacia phenotype.,-20.875,0.4,diseaseorphenotypicfeature
"Mutations in the SLC34A1 gene, such as the c.1074_1075delCT variant, are associated with X‑linked hypophosphatemic rickets and can lead to arterial dysfunction and loss of hearing in affected Homo sapiens patients.",-33.0,0.4,diseaseorphenotypicfeature
"Mutagenic exposure of A549 cells to doxorubicin induced a BRCA1 c.68_69delAG variant that correlated with increased cellular weight loss and impaired insulin signaling, suggesting a link between the DNA damage response and metabolic dysregulation in this lung carcinoma model.",-34.0,0.4,diseaseorphenotypicfeature
"Mutational analysis of the COL2A1 gene in a cohort of patients with X‑linked hypophosphatemic rickets revealed a novel c.1521G>A (p.Gly507Asp) sequence variant that correlates with severe early‑onset weight loss and progressive loss of hearing, while CRISPR‑Cas9‑edited human osteoblasts carrying this allele displayed impaired mineralization and reduced expression of the bone‑matrix protein osteocalcin.",-54.75,0.4,diseaseorphenotypicfeature
"Mutant TP53 c.215C>T in A549 cells exacerbates fatty liver development in a murine model of type‑2 diabetes, linking the sequence variant to metabolic disease.",-32.75,0.4,diseaseorphenotypicfeature
"Reduced expression of the HNF4A gene in A549 cells treated with the chemical entity valproic acid exacerbates fatty liver disease in a mouse model of type‑2 diabetes, suggesting a regulatory link between HNF4A, valproic acid, and metabolic dysfunction.",-43.5,0.4,diseaseorphenotypicfeature
Reduced visceral adiposity in patients with fatty liver disease treated with metformin was associated with downregulation of the inflammatory cytokine IL‑6 and upregulation of the insulin‑sensitive GLUT4 transporter in HepG2 cells.,-35.25,0.4,diseaseorphenotypicfeature
"Reduced levels of the transcription factor HNF4A in the liver of patients with fatty liver disease lead to down‑regulation of the SREBP‑1c gene, thereby exacerbating hepatic steatosis and contributing to the progression of non‑alcoholic fatty liver disease.",-35.75,0.4,diseaseorphenotypicfeature
"Reduced insulin sensitivity in patients with type‑2 diabetes carrying the G allele of the IRS1 c.1234G>A variant was associated with increased arterial dysfunction, as evidenced by elevated pulse‑wave velocity and decreased flow‑mediated dilation in the brachial artery.",-39.75,0.4,diseaseorphenotypicfeature
"Loss of hearing in patients with X‑linked hypophosphatemic rickets is associated with down‑regulation of the TRPV1 gene product in cochlear sensory cells, suggesting a pathogenic link between the disease and auditory dysfunction.",-23.25,0.4,diseaseorphenotypicfeature
"Loss-of-function mutations in the SLC34A1 gene cause X‑linked hypophosphatemic rickets, and in a cohort of affected children the same variant was associated with arterial dysfunction and progressive weight loss.",-31.875,0.4,diseaseorphenotypicfeature
"Loss‑of‑hearing in patients with X‑linked hypophosphatemic rickets is associated with increased expression of the SLC34A3 transporter, which is up‑regulated by the transcription factor HNF4A in renal proximal tubules.",-39.0,0.4,diseaseorphenotypicfeature
"Loss‐of‐hearing in patients with X‑linked hypophosphatemic rickets is frequently accompanied by mild arthritis, and the presence of the c.1234G>A variant in the PHEX gene correlates with the severity of both bone and auditory phenotypes.",-46.5,0.4,diseaseorphenotypicfeature
"Methotrexate treatment of A549 cells expressing the TP53 c.215C>G variant reduced the expression of the inflammatory cytokine IL‑6, thereby attenuating the arthritis‑like phenotype observed in the xenograft model of X‑linked hypophosphatemic rickets.",-31.125,0.4,diseaseorphenotypicfeature
"Methicillin‑resistant *Staphylococcus aureus* infection in a patient with X‑linked hypophosphatemic rickets was associated with a marked increase in serum alkaline phosphatase, suggesting a secondary osteomalacia that may exacerbate the underlying bone fragility.",-38.75,0.4,diseaseorphenotypicfeature
"Methadone exposure in A549 cells upregulated the expression of the CYP2B6 gene product, thereby increasing the metabolism of the drug and reducing its neuropsychiatric toxicity in a dose‑dependent manner.",-38.0,0.4,diseaseorphenotypicfeature
"Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in a cohort of Hispanic patients with X‑linked hypophosphatemic rickets was associated with increased serum phosphate and a higher prevalence of osteomalacia, while the same variant also correlated with a modest reduction in bone mineral density in the same group.",-48.25,0.4,diseaseorphenotypicfeature
"ARAF inhibition in A549 cells exacerbated insulin resistance, linking the KRAS-driven oncogenic pathway to diabetes-related weight loss in a murine model of fatty liver disease.",-38.0,0.4,diseaseorphenotypicfeature
"ARACTERIAL dysfunction in patients with X‑linked hypophosphatemic rickets is exacerbated by a missense variant in the PHEX gene, which reduces phosphate reabsorption and promotes bone fragility.",-29.75,0.4,diseaseorphenotypicfeature
"ARTHRITIS, DIABETES, and fatty liver disease frequently co‑occur in patients with metabolic syndrome, and the presence of the TP53 R337H sequence variant has been linked to an increased risk of developing these comorbidities.",-34.0,0.4,diseaseorphenotypicfeature
"AR3‑mutated TP53 in HeLa cells exacerbates fatty liver‑associated insulin resistance, linking the sequence variant to metabolic disease and highlighting a potential therapeutic target for diabetes.",-40.0,0.4,diseaseorphenotypicfeature
Long‑term exposure of A549 cells to doxorubicin induces a BRCA1 c.68_69delAG variant that correlates with increased fatty liver disease in a mouse model of diabetes.,-30.375,0.4,diseaseorphenotypicfeature
"Longitudinal analysis of A549 cells treated with doxorubicin revealed that the TP53‑dependent upregulation of BAX and subsequent mitochondrial membrane depolarization contributed to apoptosis, a mechanism that may underlie the weight‑loss phenotype observed in patients with adenoid cystic carcinoma.",-40.0,0.4,diseaseorphenotypicfeature
"Long-term exposure of A549 cells to doxorubicin induces a dose‑dependent increase in TP53‑mediated apoptosis, which correlates with the appearance of the BRCA1 c.68_69delAG variant and a marked reduction in cellular ATP production, thereby exacerbating the fatty‑liver phenotype observed in the co‑treated HepG2 model.",-48.0,0.4,diseaseorphenotypicfeature
"Long‐term exposure of A549 cells to the chemotherapeutic agent doxorubicin induces a dose‑dependent loss of hearing and promotes the up‑regulation of the pro‑inflammatory cytokine IL‑6, thereby linking the drug’s ototoxicity to inflammatory pathways implicated in neuropsychiatric disorders.",-37.5,0.4,diseaseorphenotypicfeature
"Diabetes mellitus in a cohort of X‑linked hypophosphatemic rickets patients was associated with increased arterial dysfunction and accelerated weight loss, while a subset of these individuals also exhibited loss of hearing and mild arthritis.",-33.0,0.4,diseaseorphenotypicfeature
"Diabetic patients treated with the novel SGLT2 inhibitor empagliflozin displayed significant weight loss and a reduction in arterial dysfunction markers, while a subset of those with the G6PC2 c.145C>T sequence variant experienced transient loss of hearing.",-47.25,0.4,diseaseorphenotypicfeature
"DiGeorge syndrome patients with a TBX1 gene deletion exhibit arterial dysfunction, weight loss, and loss of hearing, while the presence of a novel TBX1 c.1153_1155delTAA variant correlates with increased severity of neuropsychiatric disorders.",-55.0,0.4,diseaseorphenotypicfeature
Diaphragmatic hernia in a patient with X‑linked hypophosphatemic rickets was associated with a novel TP53 c.215G>A sequence variant that impaired bone mineralization and led to progressive weight loss.,-38.25,0.4,diseaseorphenotypicfeature
"Sunitinib treatment in A549 cells carrying the EGFR exon19 deletion variant reduced phosphorylation of STAT3, thereby attenuating the expression of the inflammatory cytokine IL‑6 and improving the survival of the cells under hypoxic conditions.",-46.25,0.4,diseaseorphenotypicfeature
"Surgically resected A549 cells treated with doxorubicin exhibited increased expression of TP53 and decreased phosphorylation of AKT, correlating with enhanced apoptosis and reduced proliferation in the context of fatty liver disease.",-35.0,0.4,diseaseorphenotypicfeature
"SARS‑CoV‑2 infection in a patient with X‑linked hypophosphatemic rickets was associated with accelerated loss of hearing and a pronounced increase in arterial dysfunction, prompting the use of a novel chemical entity, berberine, to mitigate the neuropsychiatric disorder symptoms.",-42.75,0.4,diseaseorphenotypicfeature
SOD2 rs1799732 polymorphism in the TP53 promoter region was associated with increased arterial dysfunction and weight loss in patients with type‑2 diabetes mellitus.,-29.375,0.4,diseaseorphenotypicfeature
"The A549 cell line treated with doxorubicin showed a significant increase in TP53 expression, correlating with the onset of fever in patients with B‑NHL.",-19.625,0.4,diseaseorphenotypicfeature
"The EPs‑associated B‑NHL relapse in a patient with a history of ischemic attack and cardiovascular‑metabolic disorders was mitigated by a single‑dose doxorubicin regimen, yet the patient’s renal disturbance and GH‑deficient status required close monitoring.",-40.25,0.4,diseaseorphenotypicfeature
The observation that a BRCA1 c.68_69delAG sequence variant in a patient with sporadic melanoma increases the risk of actinic keratosis illustrates a genetic predisposition linking DNA repair defects to cutaneous neoplasia.,-25.625,0.4,diseaseorphenotypicfeature
The presence of a BRCA1 c.68_69delAG variant in a patient with sporadic melanoma and a history of actinic keratosis was associated with an increased risk of developing colorectal cancer.,-16.75,0.4,diseaseorphenotypicfeature
"Patients with EPS and B‑NHL who experienced an ischemic attack exhibited a higher incidence of cardiovascular and metabolic disorders, including actinic keratosis and sporadic melanoma, compared to patients with only one of these conditions.",-23.75,0.4,diseaseorphenotypicfeature
"Patients treated with doxorubicin for B‑NHL exhibited a significant increase in renal disturbance, suggesting a dose‑dependent nephrotoxic effect mediated by oxidative stress pathways.",-21.875,0.4,diseaseorphenotypicfeature
"Patients who experienced an ischemic attack and were later diagnosed with sporadic melanoma exhibited a statistically significant increase in circulating VEGF levels, suggesting a potential link between cardiovascular and metabolic disorders and tumor angiogenesis.",-28.125,0.4,diseaseorphenotypicfeature
"Patients presenting with ischemic attack and subsequent renal disturbance exhibited elevated serum GH levels, suggesting a potential link between cardiovascular and metabolic disorders and growth hormone deficiency.",-23.25,0.4,diseaseorphenotypicfeature
"In patients with ischemic attack, the presence of a BRCA1 c.68_69delAG sequence variant in the TP53 gene was associated with an increased risk of developing sporadic melanoma.",-12.9375,0.4,diseaseorphenotypicfeature
"In a cohort of patients with ischemic attack, the presence of the BRCA1 c.68_69delAG variant in the TP53 gene was associated with a higher incidence of actinic keratosis and increased cardiovascular and metabolic disorders.",-20.75,0.4,diseaseorphenotypicfeature
"In BRCA1 c.68_69delAG carriers, the loss of tumor suppressor function accelerates sporadic melanoma development, especially in patients with actinic keratosis and a history of ischemic attack.",-29.5,0.4,diseaseorphenotypicfeature
"In the cohort of patients with ischemic attack, a higher frequency of the BRCA1 c.68_69delAG sequence variant was observed in those who later developed sporadic melanoma, suggesting a potential genetic link between cardiovascular and metabolic disorders and cutaneous neoplasia.",-24.625,0.4,diseaseorphenotypicfeature
A patient with a BRCA1 c.68_69delAG sequence variant experienced a higher incidence of sporadic melanoma and actinic keratosis compared to BRCA1 wild‑type controls.,-20.25,0.4,diseaseorphenotypicfeature
"A cardiovascular and metabolic disorder patient with ischemic attack exhibited elevated serum triglycerides, and the presence of a BRCA1 c.68_69delAG sequence variant was associated with an increased risk of sporadic melanoma.",-26.5,0.4,diseaseorphenotypicfeature
"A cohort of patients with ischemic attack and cardiovascular and metabolic disorders exhibited a significantly higher prevalence of the BRCA1 c.68_69delAG sequence variant, which was associated with increased risk of sporadic melanoma and actinic keratosis.",-21.75,0.4,diseaseorphenotypicfeature
"A CRISPR‑Cas9‑generated A549 cell line harboring the BRCA1 c.68_69delAG sequence variant exhibits increased sensitivity to doxorubicin, linking the mutation to chemotherapy response in breast cancer.",-24.375,0.4,diseaseorphenotypicfeature
"An A549 cell line treated with doxorubicin exhibited increased expression of the TP53 gene product, correlating with a higher incidence of ischemic attack in patients with cardiovascular and metabolic disorders.",-20.0,0.4,diseaseorphenotypicfeature
An ischemic attack in a patient with cardiovascular and metabolic disorders was found to be associated with a novel BRCA1 c.68_69delAG variant that increases susceptibility to sporadic melanoma.,-19.0,0.4,diseaseorphenotypicfeature
"An impaired insulin signaling pathway in the HeLa cell line, induced by the BRCA1 c.68_69delAG variant, exacerbates the risk of ischemic attack in patients with cardiovascular and metabolic disorders.",-28.25,0.4,diseaseorphenotypicfeature
"An exacerbation of EPS in a patient with B‑NHL was associated with a transient ischemic attack, prompting the initiation of a metformin‑based regimen to mitigate underlying cardiovascular and metabolic disorders.",-27.375,0.4,diseaseorphenotypicfeature
"Epidemiologic studies show that patients with ischemic attack and cardiovascular and metabolic disorders exhibit a higher prevalence of actinic keratosis, suggesting a potential shared inflammatory pathway involving the TP53 gene.",-25.375,0.4,diseaseorphenotypicfeature
"Epithelial‑pseudomyxoma (EPS) in a patient with a BRCA1 c.68_69delAG sequence variant was associated with an increased risk of sporadic melanoma and actinic keratosis, while the presence of the TP53 gene product amplified the likelihood of developing colorectal cancer (CRC).",-39.0,0.4,diseaseorphenotypicfeature
"Ectopic pancreatic secretions in a patient with a BRCA1 c.68_69delAG variant were found to exacerbate ischemic attack risk in a background of cardiovascular and metabolic disorders, prompting consideration of targeted therapy with a novel chemical entity, doxorubicin, in a HeLa cell line model.",-50.5,0.4,diseaseorphenotypicfeature
"Etoposide treatment of the A549 cell line carrying the BRCA1 c.68_69delAG variant induced a marked increase in the expression of the pro‑apoptotic gene TP53, thereby enhancing the susceptibility of these cells to ischemic‑attack‑like oxidative stress and contributing to the development of cardiovascular and metabolic disorders.",-37.5,0.4,diseaseorphenotypicfeature
"Progressive renal disturbance in a patient with a BRCA1 c.68_69delAG variant was ameliorated by daily administration of the small‑molecule inhibitor doxorubicin, which inhibited the TP53‑mediated apoptotic pathway in the HeLa cell line.",-34.5,0.4,diseaseorphenotypicfeature
"Progression of sporadic melanoma in a patient with a BRCA1 c.68_69delAG sequence variant was accelerated by chronic exposure to doxorubicin, leading to a higher incidence of renal disturbance and an increased risk of ischemic attack in the affected Homo sapiens cohort.",-31.5,0.4,diseaseorphenotypicfeature
"Progress in treating B‑NHL has shown that the B‑cell receptor signaling pathway, when inhibited by the small‑molecule drug idelalisib, reduces tumor cell proliferation and improves overall survival in patients with relapsed disease.",-39.75,0.4,diseaseorphenotypicfeature
"Progressively worsening renal disturbance in a patient with a BRCA1 c.68_69delAG variant was ameliorated by administering the chemotherapeutic agent doxorubicin to HeLa cells, revealing a novel interaction between the TP53 gene product and the drug.",-40.5,0.4,diseaseorphenotypicfeature
"Ischemic attack in a patient with cardiovascular and metabolic disorders was exacerbated by a BRCA1 c.68_69delAG sequence variant, leading to a severe renal disturbance.",-15.3125,0.4,diseaseorphenotypicfeature
"Is there a causal link between the BRCA1 c.68_69delAG variant and the increased incidence of sporadic melanoma in patients with actinic keratosis, as observed in a cohort of Homo sapiens undergoing targeted therapy with vemurafenib?",-36.0,0.4,diseaseorphenotypicfeature
"Isolated episodes of ischemic attack in patients with cardiovascular and metabolic disorders were associated with elevated plasma levels of the pro‑inflammatory cytokine IL‑6, which in turn upregulated the expression of the tumor suppressor gene TP53 in peripheral blood mononuclear cells.",-28.125,0.4,diseaseorphenotypicfeature
Isotretinoin treatment of a patient with actinic keratosis on the scalp reduced the expression of the TP53 gene product and lowered the risk of progression to sporadic melanoma.,-27.0,0.4,diseaseorphenotypicfeature
"Surgical resection of the sporadic melanoma in a patient with a history of actinic keratosis and cardiovascular and metabolic disorders was followed by a transient rise in serum IGF‑1, suggesting a possible link between the tumor’s B‑NHL‑like microenvironment and the patient’s GH‑deficient phenotype.",-36.0,0.4,diseaseorphenotypicfeature
"SARS‑CoV‑2 infection in a patient with GH‑deficient adults was associated with an increased risk of ischemic attack and cardiovascular and metabolic disorders, while the presence of a BRCA1 c.68_69delAG variant amplified the susceptibility to sporadic melanoma.",-29.25,0.4,diseaseorphenotypicfeature
Sporadic melanoma in a patient with a BRCA1 c.68_69delAG sequence variant was found to be associated with a higher risk of actinic keratosis and subsequent cutaneous squamous cell carcinoma.,-23.375,0.4,diseaseorphenotypicfeature
"SNP rs123456 in the TP53 gene was found to increase the risk of ischemic attack in patients with cardiovascular and metabolic disorders, while the same variant also correlated with a higher incidence of actinic keratosis in a cohort of sporadic melanoma patients.",-31.125,0.4,diseaseorphenotypicfeature
Dysregulation of the TP53 gene in HeLa cells treated with doxorubicin induces a cascade of apoptotic signaling that exacerbates ischemic attack symptoms in patients with cardiovascular and metabolic disorders.,-25.25,0.4,diseaseorphenotypicfeature
Dopamine D2 receptor antagonism in a patient with Parkinson’s disease and concomitant ischemic attack reduced the frequency of EPS while improving cardiovascular and metabolic disorder markers.,-27.125,0.4,diseaseorphenotypicfeature
Dexamethasone treatment of the HeLa cell line carrying the BRCA1 c.68_69delAG variant reduced the expression of the TP53 gene and lowered the incidence of actinic keratosis in the surrounding epidermal tissue of the cultured organotypic skin model derived from Homo sapiens.,-37.5,0.4,diseaseorphenotypicfeature
Deterioration of renal disturbance in patients with sporadic melanoma was associated with increased expression of the TP53 gene product in A549 cells treated with doxorubicin.,-25.0,0.4,diseaseorphenotypicfeature
Severe ischemic attack in a patient with cardiovascular and metabolic disorders was associated with a novel BRCA1 c.68_69delAG sequence variant that disrupted TP53 binding and exacerbated renal disturbance symptoms.,-23.25,0.4,diseaseorphenotypicfeature
"Sepsis-induced endothelial dysfunction in patients with ischemic attack and cardiovascular and metabolic disorders is exacerbated by the upregulation of inflammatory cytokines such as IL‑6 and TNF‑α, which in turn promotes renal disturbance and worsens outcomes.",-35.75,0.4,diseaseorphenotypicfeature
"Severely hypoglycaemic episodes in patients with GH‑deficient children carrying the GHRL c.1024A>G variant were mitigated by daily metformin, which also reduced the incidence of actinic keratosis lesions in the same cohort.",-51.75,0.4,diseaseorphenotypicfeature
"Seizure‑induced hypoxia in patients with ischemic attack triggers up‑regulation of HIF‑1α, which in turn increases VEGF expression and promotes angiogenesis in the affected cerebral tissue.",-31.875,0.4,diseaseorphenotypicfeature
"Cytotoxic treatment of B‑NHL with rituximab and doxorubicin induced a transient elevation of serum creatinine, suggesting a renal disturbance secondary to the chemotherapy regimen.",-28.5,0.4,diseaseorphenotypicfeature
"Cisplatin treatment of A549 cells harboring the TP53 c.215C>A variant induces apoptosis through upregulation of BAX, thereby reducing the risk of developing chemotherapy‑induced renal disturbance in patients with a history of cardiovascular and metabolic disorders.",-40.5,0.4,diseaseorphenotypicfeature
Coxsackievirus infection in a patient with a BRCA1 c.68_69delAG variant of the TP53 gene was associated with a higher incidence of ischemic attack and subsequent cardiovascular and metabolic disorders.,-31.25,0.4,diseaseorphenotypicfeature
C-terminal truncation of the TP53 protein in a HeLa cell line carrying the BRCA1 c.68_69delAG variant was shown to increase the risk of ischemic attack and cardiovascular and metabolic disorders in patients with sporadic melanoma.,-32.25,0.4,diseaseorphenotypicfeature
"CRISPR‑Cas9‑mediated knockout of the TP53 gene in A549 cells exacerbated ischemic‑attack‑induced apoptosis, revealing a novel link between TP53 loss and cardiovascular‑metabolic disorders.",-27.125,0.4,diseaseorphenotypicfeature
CR gene mutations in patients with sporadic melanoma were found to increase the risk of ischemic attack and cardiovascular and metabolic disorders.,-28.25,0.4,diseaseorphenotypicfeature
CR‑p53‑induced apoptosis in the A549 cell line following doxorubicin treatment correlates with the development of ischemic attack symptoms in patients with cardiovascular and metabolic disorders.,-32.25,0.4,diseaseorphenotypicfeature
"CRP levels were significantly elevated in patients with ischemic attack, correlating with the presence of a BRCA1 c.68_69delAG sequence variant and a history of actinic keratosis.",-25.0,0.4,diseaseorphenotypicfeature
"Metformin treatment of patients with type‑2 diabetes and a history of ischemic attack reduced the incidence of subsequent cardiovascular events, while concomitant activation of the PI3K‑AKT pathway in A549 cells exposed to high glucose levels increased the expression of the tumor suppressor gene TP53.",-44.0,0.4,diseaseorphenotypicfeature
"Metastatic B‑NHL in a patient with a history of actinic keratosis and ischemic attack was found to overexpress the MYC gene, correlating with a higher risk of cardiovascular and metabolic disorders.",-29.875,0.4,diseaseorphenotypicfeature
"Metabolic syndrome exacerbates ischemic attack risk in patients with B‑NHL, as evidenced by increased LDL‑C and insulin resistance in the study cohort.",-28.875,0.4,diseaseorphenotypicfeature
"Metabolomic profiling of patients with sporadic melanoma revealed that elevated levels of the lipid mediator lysophosphatidic acid, a chemical entity, were associated with increased expression of the GPCR gene LPAR1, a gene product, and a higher incidence of cardiovascular and metabolic disorders, a disease or phenotypic feature, in individuals carrying the LPAR1 c.1033C>T sequence variant.",-52.0,0.4,diseaseorphenotypicfeature
"The presence of a pathogenic TP53 R248W sequence variant in HeLa cells was associated with increased apoptosis and a higher rate of DNA damage, suggesting a potential mechanism for the observed lung carcinogenesis in patients with desmin-related myopathies.",-40.5,0.4,diseaseorphenotypicfeature
"The T1D‑associated SNP rs123456 in the HLA‑DRB1 gene was found to increase the risk of acute renal injury in patients with chronic kidney damage, suggesting a genetic link between immune regulation and ischaemic injury in the kidney.",-31.625,0.4,diseaseorphenotypicfeature
"The CRISPR‑generated A549 cell line harboring the BRCA1 c.68_69delAG variant exhibited increased sensitivity to doxorubicin, suggesting that this sequence variant may contribute to drug‑induced acute renal injury in patients with lung carcinogenesis.",-22.875,0.4,diseaseorphenotypicfeature
"The desmin-related myopathy (DRM) phenotype is exacerbated by a missense mutation in the ACTA1 gene, which increases susceptibility to ischemic injury in skeletal muscle.",-24.625,0.4,diseaseorphenotypicfeature
"A recent study showed that the TP53 mutation c.215C>A in the TP53 gene of a HeLa cell line increases the expression of the pro‑apoptotic protein PUMA, thereby enhancing the susceptibility of the cells to doxorubicin‑induced apoptosis and contributing to the development of drug‑resistant desmin‑related myopathies.",-40.0,0.4,diseaseorphenotypicfeature
A mutation in the desmin gene (DES c.1234G>A) associated with desmin‑related myopathies (DRMs) increases the risk of progressive muscle weakness and cardiomyopathy in patients with type‑1 diabetes (T1D) and concurrent lung carcinogenesis.,-36.25,0.4,diseaseorphenotypicfeature
"A heterozygous missense mutation in the desmin gene (DES c.1423G>A) was found to be associated with a severe form of desmin‑related myopathy that presents with progressive muscle weakness, exercise intolerance, and early onset cardiomyopathy in patients with type I diabetes mellitus.",-45.25,0.4,diseaseorphenotypicfeature
A novel missense variant in the desmin gene (DES c.1024G>A) was found to correlate with the severity of desmin‑related myopathies and to increase the risk of progressive kidney damage in affected patients.,-29.75,0.4,diseaseorphenotypicfeature
"Desmin-related myopathies (DRMs) frequently manifest with progressive muscle weakness and cardiomyopathy, and recent studies indicate that the TP53 mutation c.215C>T (p.R72P) exacerbates disease severity in affected Homo sapiens patients.",-29.875,0.4,diseaseorphenotypicfeature
"Desmoplakin mutations in desmin‑related myopathies lead to progressive muscle weakness and cardiomyopathy, while concurrent TP53 overexpression in lung carcinogenesis drives epithelial‑to‑mesenchymal transition and metastasis.",-29.25,0.4,diseaseorphenotypicfeature
"Desmosomal protein desmin mutations in Desmin‑related myopathies (DRMs) lead to progressive muscle weakness and cardiomyopathy, while the same variant is associated with increased risk of acute renal injury in patients with type‑1 diabetes (T1D) due to ischemic injury of the renal vasculature.",-42.5,0.4,diseaseorphenotypicfeature
"Desmoid‐related myopathies in patients with T1D exhibit a higher incidence of kidney damage, and the presence of the COL1A1 c.1234G>A variant is associated with increased severity of neurotoxic lesions.",-47.5,0.4,diseaseorphenotypicfeature
"In patients with desmin‑related myopathies, the loss‑of‑function mutation in the DES gene exacerbates muscle fiber necrosis, leading to progressive weakness and increased susceptibility to acute renal injury during episodes of ischemic injury.",-24.875,0.4,diseaseorphenotypicfeature
"In DRMs, the loss-of-function mutation in the desmin gene (DES c.1234delG) correlates with progressive muscle weakness, myoglobinuria, and acute renal injury due to rhabdomyolysis.",-30.625,0.4,diseaseorphenotypicfeature
"In Desmin-related myopathies, the missense variant c.1109G>A in the DES gene exacerbates muscle fiber degeneration, leading to progressive weakness and early onset cardiomyopathy in affected patients.",-32.0,0.4,diseaseorphenotypicfeature
"In subjects with desmin-related myopathies, the presence of a pathogenic TP53 c.215C>G variant correlates with increased susceptibility to ischaemic injury in the myocardium, especially when treated with the chemotherapeutic agent doxorubicin.",-34.75,0.4,diseaseorphenotypicfeature
"Mannose-binding lectin deficiency in patients with desmin-related myopathies (DRMs) is associated with increased risk of acute renal injury, as evidenced by elevated serum creatinine and proteinuria in a cohort of homozygous carriers.",-39.25,0.4,diseaseorphenotypicfeature
"Molecular analysis of desmin-related myopathies revealed that a missense variant in the DES gene (c.1524G>A) disrupts desmin filament assembly, thereby exacerbating muscle weakness and contributing to the clinical phenotype of progressive myofibrillar degeneration.",-40.5,0.4,diseaseorphenotypicfeature
"M1 cells from a patient with desmin-related myopathies exhibited increased expression of the HSPB8 gene, which is known to protect against neurotoxic lesions in the skeletal muscle of Homo sapiens.",-41.0,0.4,diseaseorphenotypicfeature
"MDR1 overexpression in A549 cells enhances doxorubicin resistance, thereby aggravating lung carcinogenesis and increasing the risk of acute renal injury in patients with underlying T1D.",-28.125,0.4,diseaseorphenotypicfeature
Mutation of the desmin gene (DES c.1401G>A) in a patient with desmin‑related myopathies was found to impair sarcomere assembly and trigger progressive muscle weakness and cardiomyopathy.,-32.25,0.4,diseaseorphenotypicfeature
"Mutation in the desmin gene (DES c.1525G>A) was found to correlate with the severity of desmin‑related myopathies, while elevated serum creatine kinase levels in patients with acute renal injury suggested a secondary kidney damage response.",-38.5,0.4,diseaseorphenotypicfeature
"Mutation‑induced loss of desmin in skeletal muscle cells of a patient with Desmin‑related myopathies leads to progressive weakness and cardiomyopathy, while the same desmin variant is associated with increased susceptibility to acute renal injury in individuals with pre‑existing kidney damage.",-40.0,0.4,diseaseorphenotypicfeature
"Mutation-bearing TP53 c.215C>G in HeLa cells enhances desmin-related myopathy phenotypes, causing severe muscle weakness and constipation in affected patients.",-37.75,0.4,diseaseorphenotypicfeature
"Activation of the desmin‑associated protein complex in DRMs of HeLa cells exposed to the chemical entity doxorubicin induces a cascade of phosphorylation events that ultimately enhances the expression of the disease‑associated gene TP53, thereby contributing to the pathogenesis of acute renal injury.",-41.5,0.4,diseaseorphenotypicfeature
Activation and up‑regulation of the desmin‑associated protein complex in Desmin‑related myopathies (DRMs) leads to progressive muscle fiber disarray and contributes to the pathogenesis of chronic kidney damage in patients with type‑1 diabetes (T1D) and concomitant constipation.,-57.5,0.4,diseaseorphenotypicfeature
"Activation‑induced STAT3 phosphorylation in A549 cells exposed to doxorubicin promotes expression of the pro‑apoptotic gene BAX, thereby exacerbating acute renal injury in patients with T1D and underlying kidney damage.",-41.75,0.4,diseaseorphenotypicfeature
"Activation by the TLR4 ligand lipopolysaccharide in RAW264.7 macrophages triggers a rapid increase in the expression of the pro‑inflammatory cytokine TNF‑α, which in turn promotes the phosphorylation of the transcription factor NF‑κB and the subsequent up‑regulation of the chemokine CXCL10, thereby amplifying the inflammatory cascade that contributes to acute renal injury.",-56.0,0.4,diseaseorphenotypicfeature
"Deficient expression of the desmin gene (DES) in patients with desmin‑related myopathies leads to progressive muscle weakness and cardiomyopathy, while elevated serum creatine kinase levels correlate with the severity of acute renal injury and kidney damage in those with ischaemic injury.",-36.5,0.4,diseaseorphenotypicfeature
Deficiency of the desmin gene in a patient with desmin‑related myopathies leads to progressive muscle weakness and is associated with an increased risk of acute renal injury due to secondary kidney damage.,-24.75,0.4,diseaseorphenotypicfeature
"Defects in the desmin gene (DES) cause desmin‑related myopathies, a form of muscular dystrophy that frequently co‑occurs with cardiomyopathy and can precipitate acute renal injury in patients with underlying kidney damage.",-31.25,0.4,diseaseorphenotypicfeature
"Defective desmin phosphorylation in Desmin‑related myopathies (DRMs) leads to impaired sarcomere assembly, causing progressive muscle weakness and chronic constipation in affected patients.",-24.25,0.4,diseaseorphenotypicfeature
"C‑terminal truncation of the desmin protein (DES c.1386delC) in patients with desmin‑related myopathies (DRMs) leads to progressive muscle weakness and early onset cardiomyopathy, while the same variant is absent in healthy controls of the same age group.",-51.0,0.4,diseaseorphenotypicfeature
"Cytotoxic T lymphocyte-mediated destruction of pancreatic β‑cells in type‑1 diabetes (T1D) is exacerbated by the HLA‑DRB1*04:01 allele, which promotes presentation of insulin peptides to autoreactive T cells, thereby accelerating ischaemic injury of the islets and contributing to the rapid decline in insulin secretion.",-47.5,0.4,diseaseorphenotypicfeature
"Citrate synthase deficiency in a patient with Desmin‑related myopathies (DRMs) was shown to aggravate acute renal injury and promote ischaemic injury of the kidney, thereby increasing the risk of chronic kidney disease.",-40.25,0.4,diseaseorphenotypicfeature
"Cultural differences in the prevalence of desmin-related myopathies, a diseaseorphenotypicfeature, are linked to a higher frequency of the TPM3 c.1064G>A sequencevariant in the East Asian population.",-55.0,0.4,diseaseorphenotypicfeature
"Oxidative stress induced by the chemotherapy drug doxorubicin exacerbates desmin-related myopathies in A549 cells, leading to increased muscle fiber fragmentation and elevated serum creatine kinase levels in patients with T1D.",-29.625,0.4,diseaseorphenotypicfeature
"Oxocarbazone, a novel alkylating agent, selectively induces apoptosis in A549 lung carcinoma cells by upregulating the tumor suppressor TP53, thereby reducing tumor burden in a xenograft model of lung carcinogenesis.",-42.25,0.4,diseaseorphenotypicfeature
"Oxytocin treatment in a cohort of patients with desmin-related myopathies (DRMs) significantly reduced the severity of muscle weakness and improved cardiac function, as measured by echocardiographic parameters and serum creatine kinase levels.",-39.25,0.4,diseaseorphenotypicfeature
"Oxazolone-induced Psoriasis in BALB/c mice is exacerbated by the loss-of-function mutation in the IL-23R gene, which increases IL-17A production and accelerates keratinocyte proliferation.",-40.25,0.4,diseaseorphenotypicfeature
"Genetic disruption of the desmin (DES) gene in a patient with desmin‑related myopathy led to severe muscle weakness and cardiomyopathy, while a concurrent T1D‑associated HLA‑DRB1*04 allele was found to exacerbate autoimmune β‑cell destruction.",-35.0,0.4,diseaseorphenotypicfeature
"Genomic analysis of a patient with desmin-related myopathies revealed a novel missense variant in the DES gene, which is predicted to destabilize the intermediate filament network and may contribute to the observed muscle weakness and cardiomyopathy.",-32.0,0.4,diseaseorphenotypicfeature
"Genetically engineered A549 cells overexpressing the TP53 variant c.215C>G exhibit increased sensitivity to the chemotherapeutic doxorubicin, thereby accelerating apoptosis in lung carcinogenesis models.",-25.5,0.4,diseaseorphenotypicfeature
"Genotoxic exposure to benzopyrene in A549 cells induces a rapid upregulation of the tumor suppressor gene TP53, which in turn activates the pro‑apoptotic protein BAX, thereby accelerating lung carcinogenesis in a dose‑dependent manner.",-41.25,0.4,diseaseorphenotypicfeature
"Mutations in the desmin gene (DES c.1234C>T) were found to exacerbate the severity of desmin‑related myopathies in patients with T1D, leading to accelerated muscle weakness and increased risk of acute renal injury.",-29.75,0.4,diseaseorphenotypicfeature
"Mutational loss of the desmin gene in DRMs exacerbates T1D‑associated kidney damage, leading to progressive ischaemic injury and chronic constipation in affected patients.",-23.375,0.4,diseaseorphenotypicfeature
"Mutating the desmin gene (DES c.1220G>A) in a patient with desmin‑related myopathies led to progressive muscle weakness, elevated creatine kinase levels, and a higher incidence of acute renal injury compared to unaffected family members.",-42.25,0.4,diseaseorphenotypicfeature
"Mutated desmin (DES c.1024G>A) in patients with desmin-related myopathies correlates with progressive muscle weakness and cardiomyopathy, while elevated serum creatine kinase levels in those with acute renal injury suggest a shared pathway of muscle and kidney damage.",-44.25,0.4,diseaseorphenotypicfeature
"Researchers found that the TP53 mutation c.215C>A in the HeLa cell line enhances desmin-related myopathy phenotypes, leading to increased cellular apoptosis and a higher incidence of neurotoxic lesions in cultured human fibroblasts.",-40.0,0.4,diseaseorphenotypicfeature
"Researchers discovered that the desmin mutation p.Arg350Gln in a patient with desmin-related myopathies enhances the interaction between the mutant protein and the chaperone HSP70, leading to progressive muscle weakness and cardiomyopathy.",-41.75,0.4,diseaseorphenotypicfeature
Researchers demonstrated that the TP53 c.215C>G sequence variant in A549 cells enhances desmin-related myopathy phenotypes by upregulating inflammatory cytokines and promoting ischaemic injury pathways.,-31.625,0.4,diseaseorphenotypicfeature
"Researchers observed that the loss-of-function mutation in the desmin gene (DES c.1234_1235delAG) exacerbates desmin-related myopathies in patients with congenital muscular dystrophy, leading to progressive muscle weakness and increased susceptibility to exercise-induced fatigue.",-40.75,0.4,diseaseorphenotypicfeature
"Genome‑wide association analysis of desmin‑related myopathies revealed that the rs123456 variant in the DES gene increases susceptibility to progressive muscle weakness, while a concurrent copy‑number loss of the HLA‑DRB1 locus in the same cohort correlates with heightened risk of autoimmune myocarditis in affected patients.",-48.0,0.4,diseaseorphenotypicfeature
Genome sequencing of a patient with desmin‑related myopathies revealed a novel TP53 c.215G>A sequence variant that likely contributes to the observed muscle weakness and cardiomyopathy.,-29.5,0.4,diseaseorphenotypicfeature
Genome-wide association analysis of a cohort of patients with desmin-related myopathies revealed that the rs123456 variant in the DNM2 gene is strongly associated with the severity of muscle weakness and the presence of renal damage.,-37.0,0.4,diseaseorphenotypicfeature
"Genome‐wide association studies revealed that a missense variant in the desmin gene (DES c.1207G>A) is strongly associated with desmin‑related myopathies, and this mutation also increases the risk of kidney damage in patients with type‑1 diabetes (T1D).",-43.25,0.4,diseaseorphenotypicfeature
The study found that a germline APC mutation in a sporadic melanoma patient with a history of constipation and glucose intolerance was associated with increased mucosal inflammation and a higher risk of developing pseudotumor cerebri.,-26.125,0.4,diseaseorphenotypicfeature
"The presence of a BRCA1 c.68_69delAG variant in a sporadic melanoma patient was associated with accelerated mucosal inflammation and glucose intolerance, suggesting a potential link to pseudotumor cerebri and deterioration of cognitive functions.",-21.375,0.4,diseaseorphenotypicfeature
The CGL mutation in the PPARγ gene was associated with glucose intolerance and a higher risk of sporadic melanoma in affected patients.,-19.625,0.4,diseaseorphenotypicfeature
"The pseudotumor cerebri observed in a patient with glucose intolerance was exacerbated by chronic use of the chemical entity acetazolamide, leading to worsening cognitive functions and persistent constipation.",-18.75,0.4,diseaseorphenotypicfeature
"Genetic testing of a sporadic melanoma patient revealed a BRCA2 c.5946_5947delTT variant, which is associated with increased risk of pseudotumor cerebri and glucose intolerance in affected individuals.",-24.0,0.4,diseaseorphenotypicfeature
"Genomic analysis of sporadic melanoma patients revealed that a BRCA2 c.5946delT variant, carried by a subset of Homo sapiens individuals, was associated with increased mucosal inflammation and a higher risk of pseudotumor cerebri.",-34.25,0.4,diseaseorphenotypicfeature
"Genotoxic stress induced by doxorubicin in A549 cells exacerbates mucosal inflammation and accelerates cognitive decline in a mouse model of pseudotumor cerebri, highlighting a potential link between chemotherapy‑induced DNA damage and neuro‑ocular pathology.",-36.75,0.4,diseaseorphenotypicfeature
Genotype‑assisted therapy with metformin reduced glucose intolerance and improved mucosal inflammation in a cohort of sporadic melanoma patients carrying a BRCA1 c.68_69delAG variant.,-28.75,0.4,diseaseorphenotypicfeature
"Maternal HNPCC carriers with a BRCA1 c.68_69delAG variant exhibit increased risk of sporadic melanoma and glucose intolerance, while their children display constipation and mucosal inflammation.",-26.875,0.4,diseaseorphenotypicfeature
"Matera‑derived HNPCC patients with a germline BRCA1 c.68_69delAG variant exhibit a higher incidence of sporadic melanoma and mucosal inflammation, while sporadic melanoma patients with glucose intolerance display a greater risk of pseudotumor cerebri and cognitive deterioration.",-55.25,0.4,diseaseorphenotypicfeature
"Material‑derived pseudotumor cerebri in a patient with CGL was associated with glucose intolerance, mucosal inflammation, and a gradual deterioration of cognitive functions.",-33.5,0.4,diseaseorphenotypicfeature
"Materna‑linked pseudotumor cerebri in a patient with CGL is associated with glucose intolerance, constipation, and deterioration of cognitive functions.",-33.75,0.4,diseaseorphenotypicfeature
Altered expression of the HNPCC-associated MSH2 gene in sporadic melanoma cells derived from a maternal lineage leads to mucosal inflammation and accelerated deterioration of cognitive functions.,-23.75,0.4,diseaseorphenotypicfeature
Alterations in the APC gene in sporadic melanoma patients are associated with increased mucosal inflammation and a higher risk of developing pseudotumor cerebri.,-21.0,0.4,diseaseorphenotypicfeature
"Alteration of the TP53 gene product in HeLa cells treated with doxorubicin exacerbates pseudotumor cerebri, a diseaseorphenotypicfeature characterized by increased intracranial pressure and visual disturbances.",-28.625,0.4,diseaseorphenotypicfeature
"Alterantion of the APC gene in a sporadic melanoma patient led to mucosal inflammation and a rapid deterioration of cognitive functions, while the concurrent presence of a BRCA1 c.68_69delAG variant was associated with glucose intolerance.",-41.75,0.4,diseaseorphenotypicfeature
"In patients with pseudotumor cerebri, elevated intracranial pressure was associated with a marked reduction in visual field sensitivity, while concurrent use of acetazolamide reduced the need for surgical intervention.",-28.125,0.4,diseaseorphenotypicfeature
"In this cohort of sporadic melanoma patients, the presence of a BRCA2 c.5946delT variant in the tumor tissue was associated with a higher incidence of mucosal inflammation and a pronounced deterioration of cognitive functions during immunotherapy.",-31.875,0.4,diseaseorphenotypicfeature
"In a cohort of sporadic melanoma patients, the presence of a BRCA2 c.5946_5947delAG sequence variant was associated with increased mucosal inflammation and a higher risk of glucose intolerance.",-20.25,0.4,diseaseorphenotypicfeature
"In sporadic melanoma patients, the presence of a BRCA2 c.5946_5947delAG sequence variant in the tumor cells correlates with a higher risk of mucosal inflammation and accelerated deterioration of cognitive functions, suggesting a potential link between DNA repair deficiency and neuro‑psychiatric complications.",-35.0,0.4,diseaseorphenotypicfeature
A heterozygous missense mutation in the MSH2 gene (c.1234A>G) was found to increase the risk of hereditary non‑polyposis colorectal cancer (HNPCC) in a family with a history of sporadic melanoma and unipolar depression.,-29.25,0.4,diseaseorphenotypicfeature
A recent cohort study found that patients with pseudotumor cerebri who carried the BRCA1 c.68_69delAG variant had a significantly higher incidence of glucose intolerance and cognitive deterioration compared with matched controls.,-23.0,0.4,diseaseorphenotypicfeature
A longitudinal cohort of patients with pseudotumor cerebri demonstrated that early initiation of acetazolamide therapy reduced intracranial pressure and improved visual field outcomes compared with delayed treatment.,-23.125,0.4,diseaseorphenotypicfeature
"A pseudotumor cerebri patient with glucose intolerance exhibited increased intracranial pressure that worsened after maternal ingestion of a high‑dose chemical entity, leading to transient cognitive deterioration.",-29.5,0.4,diseaseorphenotypicfeature
"Patients with pseudotumor cerebri exhibit increased intracranial pressure that can be alleviated by acetazolamide treatment, which reduces cerebrospinal fluid production in the choroid plexus.",-19.125,0.4,diseaseorphenotypicfeature
Patients treated with the novel CCR5 antagonist exhibited a significant reduction in mucosal inflammation and a concomitant improvement in glucose intolerance in a cohort of sporadic melanoma survivors.,-24.875,0.4,diseaseorphenotypicfeature
"Patients diagnosed with pseudotumor cerebri exhibited a significant elevation in intracranial pressure that was correlated with a reduction in cerebrospinal fluid outflow, leading to progressive visual field loss.",-30.25,0.4,diseaseorphenotypicfeature
Patients carrying the BRCA1 c.68_69delAG sequence variant exhibit a higher incidence of sporadic melanoma and mucosal inflammation compared with non-carriers.,-20.875,0.4,diseaseorphenotypicfeature
"Hyperglycemia in patients with glucose intolerance exacerbates mucosal inflammation, leading to a higher incidence of pseudotumor cerebri and contributing to the deterioration of cognitive functions.",-23.0,0.4,diseaseorphenotypicfeature
Hyperthermia-induced activation of the HNPCC-associated mismatch repair gene MLH1 in A549 cells exacerbates mucosal inflammation and accelerates glucose intolerance in a murine model of pseudotumor cerebri.,-28.5,0.4,diseaseorphenotypicfeature
"Hyperproliferative mucosal inflammation in patients with pseudotumor cerebri is exacerbated by a BRCA2 c.5946_5947delTT variant, which also predisposes to sporadic melanoma.",-30.875,0.4,diseaseorphenotypicfeature
"Hyper‑thermic intraperitoneal chemotherapy with cisplatin induced a marked reduction in mucosal inflammation and improved glucose intolerance in a cohort of patients with sporadic melanoma, while a concurrent TP53 c.215C>G sequence variant was associated with a higher risk of pseudotumor cerebri.",-39.0,0.4,diseaseorphenotypicfeature
Pseudotumor cerebri in a patient with glucose intolerance and constipation was found to be associated with a novel TP53 c.215G>A sequence variant in a sporadic melanoma family.,-21.0,0.4,diseaseorphenotypicfeature
"Pediatric patients with pseudotumor cerebri and glucose intolerance exhibit a markedly increased risk of developing mucosal inflammation and constipation, while the presence of a BRCA1 c.68_69delAG sequence variant further exacerbates the deterioration of cognitive functions.",-33.75,0.4,diseaseorphenotypicfeature
"Pancytopenia in a patient with hereditary non‑polyposis colorectal cancer (HNPCC) was exacerbated by a BRCA1 c.68_69delAG variant, leading to accelerated deterioration of cognitive functions and mucosal inflammation.",-31.625,0.4,diseaseorphenotypicfeature
Pheochromocytoma in a patient with CGL and glucose intolerance was associated with severe constipation and deterioration of cognitive functions.,-26.375,0.4,diseaseorphenotypicfeature
"Hereditary colorectal cancer predisposition in HNPCC patients is exacerbated by a BRCA1 c.68_69delAG variant, leading to increased mucosal inflammation and glucose intolerance.",-23.125,0.4,diseaseorphenotypicfeature
Her familial history of HNPCC combined with a BRCA1 c.68_69delAG sequence variant in the patient’s germline DNA was associated with an increased risk of sporadic melanoma and unipolar depression.,-33.75,0.4,diseaseorphenotypicfeature
"Her medication with metformin reduced glucose intolerance in a patient with sporadic melanoma and HNPCC, but the underlying pseudotumor cerebri and constipation remained unresponsive.",-38.0,0.4,diseaseorphenotypicfeature
Her family history of HNPCC and a germline BRCA2 c.5946delT mutation were associated with an increased risk of sporadic melanoma and mucosal inflammation in a young adult patient.,-34.75,0.4,diseaseorphenotypicfeature
"Sporadic melanoma in a patient with a germline APC mutation (CGL) was associated with mucosal inflammation, glucose intolerance, and a marked deterioration of cognitive functions.",-24.625,0.4,diseaseorphenotypicfeature
"Sustained activation of the PI3K‑AKT pathway in HNPCC‑derived A549 cells treated with the chemotherapeutic doxorubicin induces a marked increase in mucosal inflammation and glucose intolerance, thereby exacerbating cognitive deterioration in patients with pseudotumor cerebri.",-36.75,0.4,diseaseorphenotypicfeature
Surgical resection of a sporadic melanoma in a patient with HNPCC revealed a BRCA1 c.68_69delAG sequence variant that may contribute to the observed deterioration of cognitive functions and glucose intolerance.,-20.75,0.4,diseaseorphenotypicfeature
"Sphingomyelinase deficiency in a patient with CGL leads to severe glucose intolerance and progressive deterioration of cognitive functions, while a concurrent heterozygous TP53 mutation exacerbates mucosal inflammation and constipation.",-34.25,0.4,diseaseorphenotypicfeature
MRI‑guided biopsy of a pseudotumor cerebri lesion in a patient with CGL revealed a BRCA1 c.68_69delAG sequence variant that likely contributed to the disease’s glucose intolerance and cognitive deterioration.,-29.75,0.4,diseaseorphenotypicfeature
"MRI-derived optic nerve sheath expansion in a patient with pseudotumor cerebri was associated with increased CSF protein levels and a mild elevation of serum cortisol, suggesting a possible link between neuro‑endocrine dysregulation and intracranial hypertension.",-41.75,0.4,diseaseorphenotypicfeature
MRI contrast enhancement in a patient with pseudotumor cerebri was associated with increased CSF opening pressure and a subsequent rise in intracranial hypertension.,-31.625,0.4,diseaseorphenotypicfeature
MRI‐guided biopsy of a sporadic melanoma lesion in a patient with pseudotumor cerebri revealed a BRAF V600E mutation that may drive mucosal inflammation and glucose intolerance while contributing to the deterioration of cognitive functions.,-30.875,0.4,diseaseorphenotypicfeature
"CGL-associated glucose intolerance, often presenting with constipation and mucosal inflammation, has been linked to a novel BRCA1 c.68_69delAG sequence variant that impairs DNA repair in Homo sapiens cells.",-26.125,0.4,diseaseorphenotypicfeature
"Cervical cancer patients receiving bevacizumab showed a significant reduction in mucosal inflammation and improved glucose intolerance, yet the presence of a BRCA1 c.68_69delAG sequence variant in a subset of HNPCC families correlated with a higher risk of sporadic melanoma.",-39.5,0.4,diseaseorphenotypicfeature
"Cystic glomerulopathy (CGL) in a maternal case of pseudotumor cerebri was associated with glucose intolerance and mucosal inflammation, leading to a deterioration of cognitive functions.",-24.0,0.4,diseaseorphenotypicfeature
CGRP antagonism in a patient with pseudotumor cerebri and glucose intolerance reduced intracranial pressure and improved cognitive function.,-20.5,0.4,diseaseorphenotypicfeature
Aberrant expression of the TP53 gene in A549 cells treated with doxorubicin induces mucosal inflammation and accelerates deterioration of cognitive functions in a mouse model of pseudotumor cerebri.,-22.5,0.4,diseaseorphenotypicfeature
Aberration of the APC gene in sporadic melanoma patients predisposes to mucosal inflammation and subsequent deterioration of cognitive functions.,-25.125,0.4,diseaseorphenotypicfeature
"Abernathy syndrome, a sporadic melanoma-associated disease, is characterized by glucose intolerance, constipation, and progressive deterioration of cognitive functions.",-31.5,0.4,diseaseorphenotypicfeature
"Aberrations in the PTEN gene, such as the c.1023_1024delCT variant, have been shown to increase the risk of sporadic melanoma in patients with a history of mucosal inflammation and glucose intolerance.",-37.0,0.4,diseaseorphenotypicfeature
"In patients with autosomal dominant cerebellar ataxia, the presence of a pathogenic GAA repeat expansion in the FXN gene correlates with progressive renal tract abnormalities and an increased risk of renal failure, especially when accompanied by inflammatory‑based renal damage.",-25.125,0.4,diseaseorphenotypicfeature
"In genetically engineered A549 cells harboring the BRCA1 c.68_69delAG variant, doxorubicin treatment induced a marked increase in apoptosis markers and a significant reduction in cell viability, suggesting that this sequence variant sensitizes lung carcinoma cells to chemotherapeutic stress.",-34.75,0.4,diseaseorphenotypicfeature
"In a cohort of patients with renal tract abnormalities, the presence of a novel BRCA1 c.68_69delAG sequence variant in the TP53 gene was associated with an increased risk of renal failure and inflammatory‑based complications.",-16.375,0.4,diseaseorphenotypicfeature
"In renal failure patients, the inflammatory-based activation of the NF‑κB pathway in proximal tubular cells exacerbates renal tract abnormalities and promotes progression toward end‑stage renal disease.",-23.375,0.4,diseaseorphenotypicfeature
"The renal failure observed in patients with inherited b(+)‑thalassemia is exacerbated by the inflammatory‑based activation of NF‑κB, which promotes fibrosis in the renal tract abnormalities and ultimately leads to progressive kidney dysfunction.",-23.875,0.4,diseaseorphenotypicfeature
"The chemotherapeutic agent doxorubicin induces a dose‑dependent increase in TP53 expression in HeLa cells, leading to apoptosis and subsequent renal failure in patients with pre‑existing renal tract abnormalities.",-23.0,0.4,diseaseorphenotypicfeature
"The pro‑inflammatory cytokine IL‑6, upregulated in renal failure, activates the NF‑κB pathway in proximal tubular cells of Homo sapiens, thereby exacerbating inflammatory‑based renal tract abnormalities.",-23.25,0.4,diseaseorphenotypicfeature
The combination of a BRCA1 c.68_69delAG SequenceVariant and a TP53 GeneOrGeneProduct mutation in a patient with renal tract abnormalities and renal failure suggests an inflammatory-based mechanism that may predispose to carcinogenic progression.,-28.75,0.4,diseaseorphenotypicfeature
"Early‑stage renal failure in patients with congenital renal tract abnormalities is exacerbated by inflammatory‑based activation of the NF‑κB pathway, which promotes fibrosis and further loss of glomerular filtration.",-27.625,0.4,diseaseorphenotypicfeature
Early-onset renal failure in patients with a pathogenic BRCA1 c.68_69delAG variant is associated with increased expression of the inflammatory cytokine IL‑6 and a higher prevalence of renal tract abnormalities.,-26.0,0.4,diseaseorphenotypicfeature
"Early-stage renal failure in patients with inherited renal tract abnormalities is exacerbated by the inflammatory-based activation of the NF‑κB pathway, which promotes fibrosis and worsens kidney function.",-27.625,0.4,diseaseorphenotypicfeature
"Early diagnostic imaging revealed that the patient’s renal tract abnormalities, combined with a b(+)‑thalassemia mutation, predisposed them to progressive renal failure and an inflammatory‑based renal dysfunction.",-38.0,0.4,diseaseorphenotypicfeature
"An aberrant TP53 c.215C>T variant in a patient with renal failure and inflammatory‑based renal tract abnormalities was found to enhance the expression of the pro‑apoptotic gene BAX, suggesting a pathogenic link between the mutation and the observed renal phenotype.",-38.25,0.4,diseaseorphenotypicfeature
"An inherited mutation in the HNF1B gene causes renal tract abnormalities and renal failure, while the same variant is associated with cystic kidney disease and an increased risk of diabetes in patients with autosomal dominant inheritance.",-33.75,0.4,diseaseorphenotypicfeature
"An ultrasound of a patient with renal tract abnormalities revealed a cystic lesion that, upon biopsy, showed overexpression of the TP53 gene and a BRCA1 c.68_69delAG variant, suggesting a potential link to inherited renal failure.",-32.5,0.4,diseaseorphenotypicfeature
"An A549 cell line treated with the small molecule doxorubicin showed a significant increase in apoptosis markers, confirming the drug’s efficacy in inducing cell death in this lung carcinoma model.",-30.5,0.4,diseaseorphenotypicfeature
"A CRISPR‑Cas9‑generated A549 cell line harboring the BRCA1 c.68_69delAG sequence variant exhibited increased sensitivity to doxorubicin, suggesting a potential therapeutic avenue for patients with renal failure and inflammatory‑based renal tract abnormalities.",-25.0,0.4,diseaseorphenotypicfeature
"A recent cohort study found that patients with renal tract abnormalities and chronic renal failure exhibited a markedly higher incidence of inflammatory-based complications, suggesting that the underlying renal pathology may predispose to systemic inflammation.",-25.75,0.4,diseaseorphenotypicfeature
"A mutation in the COL2A1 gene (c.1400G>A) was found to cause autosomal dominant cerebellar ataxia and joint contractures in a family of Homo sapiens, while the affected individuals also exhibited renal tract abnormalities and mild renal failure.",-32.5,0.4,diseaseorphenotypicfeature
A homozygous c.68_69delAG variant in the BRCA1 gene was found to increase the risk of renal tract abnormalities and renal failure in patients with hereditary breast and ovarian cancer syndrome.,-22.125,0.4,diseaseorphenotypicfeature
"Heroin dependence in a patient with autosomal dominant cerebellar ataxia was associated with renal tract abnormalities, leading to chronic renal failure and an inflammatory-based exacerbation of joint contractures.",-19.25,0.4,diseaseorphenotypicfeature
"Hereditary renal tract abnormalities in patients with autosomal dominant cerebellar ataxia are associated with progressive renal failure, likely driven by inflammatory‑based damage to the collecting ducts.",-22.25,0.4,diseaseorphenotypicfeature
"Herbs containing doxorubicin analogs were shown to aggravate renal tract abnormalities in A549 cells, leading to inflammatory‑based renal failure that may be mitigated by a CRISPR‑edited TP53 variant.",-42.5,0.4,diseaseorphenotypicfeature
Herceptin treatment of HER2‑positive breast cancer patients with BRCA1 c.68_69delAG sequence variants reduces the risk of renal tract abnormalities and improves renal failure outcomes.,-28.625,0.4,diseaseorphenotypicfeature
"Immunohistochemical analysis of the A549 cell line revealed that the BCL2L1 protein, encoded by the BCL2 gene, was upregulated in response to doxorubicin treatment, correlating with increased apoptosis and a reduction in colony-forming ability.",-38.75,0.4,diseaseorphenotypicfeature
"Impaired renal function in patients with congenital renal tract abnormalities is exacerbated by the inflammatory cytokine IL‑6, which activates the NF‑κB pathway and promotes fibrosis, thereby accelerating progression to renal failure.",-27.0,0.4,diseaseorphenotypicfeature
"Imbalanced iron metabolism in patients with b(+)‑thalassemia leads to renal tract abnormalities that progress to renal failure, while the inflammatory‑based damage is exacerbated by heroin dependence, ultimately causing joint contractures and rigid spine muscular dystrophy.",-39.25,0.4,diseaseorphenotypicfeature
Impairment of the NF‑κB pathway in A549 cells treated with doxorubicin exacerbates renal tract abnormalities and promotes inflammatory‑based renal failure in a dose‑dependent manner.,-27.375,0.4,diseaseorphenotypicfeature
CRISPR‑mediated disruption of the COL4A1 gene in a patient-derived A549 cell line revealed that the resulting protein‑truncating variant (c.1485delA) causes a severe renal tract abnormality phenotype and predisposes to early renal failure.,-47.75,0.4,diseaseorphenotypicfeature
"CRFT1 mutations in the COL1A1 gene cause autosomal dominant osteogenesis imperfecta, a disease characterized by joint contractures, rigid spine muscular dystrophy, and renal tract abnormalities that predispose patients to renal failure.",-38.75,0.4,diseaseorphenotypicfeature
"CRMP2 overexpression in the A549 cell line exacerbates doxorubicin‑induced apoptosis, linking the TP53 pathway to chemotherapy‑related renal failure in patients with hereditary b(+)‑thalassemia.",-35.0,0.4,diseaseorphenotypicfeature
"CRP levels were markedly elevated in patients with renal tract abnormalities and inflammatory‑based renal failure, suggesting that the pro‑inflammatory cytokine network may drive the progression of renal disease.",-30.25,0.4,diseaseorphenotypicfeature
"dexamethasone treatment of HeLa cells expressing the TP53 c.215C>G variant reduced the expression of inflammatory cytokines IL6 and CXCL8, thereby alleviating the inflammatory‑based renal tract abnormalities observed in the patient with autosomal dominant cerebellar ataxia.",-33.75,0.4,diseaseorphenotypicfeature
"doxorubicin treatment of HeLa cells carrying the TP53 c.215C>A variant induced a pronounced increase in apoptosis, suggesting that the mutation enhances the drug’s efficacy in this cancer model.",-33.5,0.4,diseaseorphenotypicfeature
dysmorphic renal tract abnormalities in patients with autosomal dominant cerebellar ataxia are associated with progressive renal failure and an increased risk of inflammatory-based nephritis.,-29.75,0.4,diseaseorphenotypicfeature
detection of a novel TP53 c.215G>A sequence variant in a patient with renal failure and inflammatory-based renal tract abnormalities suggests a pathogenic link between the mutation and the observed phenotype.,-28.875,0.4,diseaseorphenotypicfeature
"SARS‑CoV‑2 infection in a patient with autosomal dominant cerebellar ataxia and renal tract abnormalities triggered a severe inflammatory‑based renal failure, prompting initiation of hemodialysis.",-20.875,0.4,diseaseorphenotypicfeature
"SOD1 G7958, SOD2 T2734, and CAT C262 alleles were linked to erysipelas predisposition in patients with renal tract abnormalities and inflammatory‑based renal failure.",-16.625,0.4,diseaseorphenotypicfeature
"SIRT1 deficiency in a patient with autosomal dominant cerebellar ataxia exacerbates renal tract abnormalities, leading to progressive renal failure and an inflammatory‑based renal failure phenotype.",-27.25,0.4,diseaseorphenotypicfeature
"Sarcopenia in patients with chronic renal failure, often exacerbated by inflammatory cytokines, is associated with increased expression of the muscle‑specific transcription factor MYOG and reduced levels of the anabolic hormone IGF‑1, thereby contributing to progressive joint contractures and rigid spine muscular dystrophy.",-43.25,0.4,diseaseorphenotypicfeature
"Mutant TP53 c.215C>A in a HeLa cell line derived from a patient with renal tract abnormalities was shown to upregulate the inflammatory cytokine IL-6, thereby exacerbating renal failure.",-28.25,0.4,diseaseorphenotypicfeature
"Mutated TP53 c.215C>G in HeLa cells induces a p53‑dependent upregulation of the pro‑apoptotic gene BAX, exacerbating renal failure in patients with autosomal dominant cerebellar ataxia.",-28.875,0.4,diseaseorphenotypicfeature
Mutational analysis of the SLC12A3 gene in a cohort of patients with inherited renal tubular dysgenesis revealed a novel c.1129G>A variant that correlates with severe renal failure and a distinctive pattern of renal tract abnormalities.,-36.0,0.4,diseaseorphenotypicfeature
"Mutations in the GATA4 gene, such as the c.1123C>T variant, have been shown to cause renal tract abnormalities and renal failure in patients with autosomal dominant cerebellar ataxia, while the same mutation also predisposes to inflammatory‑based joint contractures and rigid spine muscular dystrophy.",-36.0,0.4,diseaseorphenotypicfeature
"Erythrocyte transfusion in patients with beta‑thalassemia major exacerbates renal tract abnormalities, leading to chronic renal failure and inflammatory‑based complications.",-23.25,0.4,diseaseorphenotypicfeature
"Epidemiologic analysis of patients with renal tract abnormalities revealed that those carrying the BRCA1 c.68_69delAG variant exhibited a significantly higher incidence of renal failure, suggesting a potential pathogenic link between this sequence variant and inflammatory‑based kidney dysfunction.",-26.5,0.4,diseaseorphenotypicfeature
"Epithelial cells from the A549 cell line treated with the chemotherapeutic doxorubicin exhibited a dose‑dependent increase in TP53 mRNA and protein, correlating with heightened apoptosis and a reduction in colony‑forming ability, thereby modeling drug‑induced renal‑tract‑abnormality–related cytotoxicity.",-45.0,0.4,diseaseorphenotypicfeature
"Ethanol exposure in A549 cells induces up‑regulation of HIF‑1α, which in turn enhances VEGF‑mediated angiogenesis and contributes to renal tract abnormalities observed in patients with renal failure.",-29.375,0.4,diseaseorphenotypicfeature
"Compassionate use of the CRISPR‑Cas9‑edited A549 cell line expressing the BRCA1 c.68_69delAG variant revealed that the mutation exacerbates renal tract abnormalities in a mouse model of inflammatory‑based renal failure, suggesting a potential link to autosomal dominant cerebellar ataxia.",-39.25,0.4,diseaseorphenotypicfeature
"Compromised renal tract abnormalities in patients with autosomal dominant cerebellar ataxia are associated with increased risk of renal failure, as evidenced by elevated serum creatinine and proteinuria in a cohort of affected individuals.",-34.0,0.4,diseaseorphenotypicfeature
"Compounds such as doxorubicin induce DNA damage that activates TP53, leading to apoptosis in HeLa cells and contributing to renal failure in patients with inflammatory-based renal tract abnormalities.",-28.75,0.4,diseaseorphenotypicfeature
Complications of renal tract abnormalities in patients with autosomal dominant cerebellar ataxia were associated with a higher incidence of renal failure and inflammatory‑based kidney damage.,-24.25,0.4,diseaseorphenotypicfeature
"Celiac disease patients with the HLA‑DQ2 allele exhibit a higher prevalence of renal tract abnormalities and inflammatory‑based renal failure, suggesting a genetic predisposition to combined gastrointestinal and renal pathology.",-29.25,0.4,diseaseorphenotypicfeature
"Cytotoxic chemotherapy with doxorubicin in A549 cells induces a TP53‑dependent up‑regulation of the pro‑apoptotic gene BAX, which in turn exacerbates renal tract abnormalities in patients with underlying renal failure.",-32.5,0.4,diseaseorphenotypicfeature
"Cystic fibrosis patients with the ΔF508 mutation exhibit renal tract abnormalities that predispose them to chronic renal failure, and the presence of a common polymorphism in the CFTR gene (c.1521_1523delCTT) further amplifies this risk.",-37.0,0.4,diseaseorphenotypicfeature
"C5a-mediated inflammation in patients with renal tract abnormalities and renal failure accelerates joint contractures, leading to a rigid spine muscular dystrophy phenotype that is exacerbated by heroin dependence.",-29.125,0.4,diseaseorphenotypicfeature
"A patient with Parkinson’s disease exhibited tremors, cognitive deterioration, and bradycardia, and genetic analysis revealed a c.68_69delAG variant in the LRRK2 gene that may contribute to the disease phenotype.",-22.625,0.4,diseaseorphenotypicfeature
"A c.68_69delAG variant in the BRCA1 gene, identified in a patient with a family history of breast cancer, was associated with a higher risk of developing age‑related macular degeneration and impaired auditory location discrimination.",-28.125,0.4,diseaseorphenotypicfeature
"A progressive tremor in patients with cIII‑defective mitochondrial disease correlates with accelerated deterioration of cognitive functions and episodic tachycardia, suggesting a shared neuro‑cardiac pathophysiology.",-25.125,0.4,diseaseorphenotypicfeature
"A tremor phenotype in Parkinson’s disease patients is exacerbated by the cIII‑defective mitochondrial mutation in the MT‑ND1 gene, leading to accelerated deterioration of cognitive functions and occasional episodes of tachycardia.",-27.75,0.4,diseaseorphenotypicfeature
"SARS‑CoV‑2 infection in a patient with cIII‑defective mitochondrial disease exacerbated tremors, accelerated deterioration of cognitive functions, and induced bradycardia, while CRISPR‑edited HeLa cells carrying the BRCA1 c.68_69delAG variant revealed impaired auditory location discrimination and joint pain pathways linked to AMD‑related oxidative stress.",-37.5,0.4,diseaseorphenotypicfeature
"Surgical implantation of a pacemaker in a patient with bradycardia and tremors reduced the frequency of arrhythmic episodes while simultaneously improving cognitive function, as measured by the Montreal Cognitive Assessment.",-31.125,0.4,diseaseorphenotypicfeature
"Sildenafil treatment in a cohort of patients with Parkinson’s disease reduced tremors and improved impaired auditory location discrimination, while a subset of subjects with a cIII‑defective mitochondrial mutation experienced transient tachycardia and joint pain.",-36.25,0.4,diseaseorphenotypicfeature
"S3‑adenosyl‑methionine deficiency in a patient with cIII‑defective mitochondrial disease leads to tremors, joint pain, and impaired auditory location discrimination, while a concomitant BRCA1 c.68_69delAG variant aggravates deterioration of cognitive functions.",-42.5,0.4,diseaseorphenotypicfeature
The presence of a c.68_69delAG SequenceVariant in the BRCA1 GeneOrGeneProduct of a Homo sapiens patient with a history of tremors and deteriorating cognitive functions was associated with an increased risk of developing age‑related macular degeneration (AMD).,-24.25,0.4,diseaseorphenotypicfeature
"The Parkinson’s disease patient’s tremors worsened after chronic opioid use, and the concomitant cIII‑defective mitochondrial mutation in the MT‑ND4 gene was linked to impaired auditory location discrimination.",-25.375,0.4,diseaseorphenotypicfeature
The c.68_69delAG sequence variant in the BRCA1 gene was associated with an increased risk of breast cancer and impaired auditory location discrimination in patients with a family history of neurodegenerative disease.,-21.625,0.4,diseaseorphenotypicfeature
"The patient’s tremors and impaired auditory location discrimination were exacerbated by the cIII‑defective mutation in the mitochondrial complex I gene, leading to progressive deterioration of cognitive functions.",-18.0,0.4,diseaseorphenotypicfeature
"In Parkinson’s disease patients, the c.68_69delAG variant in the SNCA gene correlates with tremors, cognitive deterioration, and bradycardia, while dopaminergic therapy with levodopa reduces joint pain but may induce oral iron deficiency.",-30.875,0.4,diseaseorphenotypicfeature
"In patients with Parkinson’s disease, the c.68_69delAG variant in the LRRK2 gene is associated with tremors, cognitive decline, and bradycardia, while the concomitant use of doxorubicin exacerbates joint pain and impairs auditory location discrimination.",-26.0,0.4,diseaseorphenotypicfeature
"In a cohort of patients with Parkinson’s disease, the presence of the LRRK2 G2019S variant was associated with an earlier onset of tremors and a more rapid deterioration of cognitive functions, while carriers of the same allele also exhibited increased susceptibility to bradycardia during deep brain stimulation.",-28.75,0.4,diseaseorphenotypicfeature
"In sporadic Parkinson’s disease, the c.68_69delAG variant in the SNCA gene correlates with early tremors, cognitive deterioration, and bradycardia, while the presence of the G>A polymorphism in the LRRK2 gene exacerbates joint pain and auditory location discrimination deficits.",-45.75,0.4,diseaseorphenotypicfeature
Tremors and impaired auditory location discrimination in patients with cIII‑defective mitochondrial disease were found to correlate with accelerated deterioration of cognitive functions and increased risk of Parkinson’s disease.,-18.125,0.4,diseaseorphenotypicfeature
"Tachycardia in patients with cIII‑defective mitochondrial disease is associated with impaired auditory location discrimination, joint pain, and progressive deterioration of cognitive functions.",-17.625,0.4,diseaseorphenotypicfeature
"Treated Parkinson’s disease patients exhibited reduced tremors and improved impaired auditory location discrimination after receiving L-dopa, while a subset with a cIII-defective mitochondrial mutation showed accelerated deterioration of cognitive functions.",-34.0,0.4,diseaseorphenotypicfeature
"Tandem repeat expansions in the C9orf72 gene, a SequenceVariant, are associated with impaired auditory location discrimination, a DiseaseOrPhenotypicFeature, in patients infected with the Human T-cell lymphotropic virus, an OrganismTaxon, who also exhibit tachycardia, a DiseaseOrPhenotypicFeature, and elevated levels of the inflammatory cytokine IL-6, a GeneOrGeneProduct.",-49.25,0.4,diseaseorphenotypicfeature
"Stool samples from patients with impaired auditory location discrimination revealed a significant upregulation of the inflammatory cytokine IL‑6, which correlated with the presence of the cIII‑defective mitochondrial variant MT‑ND1 c.1234A>G in the Homo sapiens cohort.",-44.25,0.4,diseaseorphenotypicfeature
"Stiffness of the joint and tremors in a patient with a cIII‑defective mitochondrial mutation were alleviated by a low‑dose regimen of doxorubicin, which also slowed the deterioration of cognitive functions.",-34.5,0.4,diseaseorphenotypicfeature
"StrepA infection in a patient with cIII‑defective mitochondrial disease exacerbated tremors and accelerated deterioration of cognitive functions, while the concomitant tachycardia suggested a systemic inflammatory response.",-35.5,0.4,diseaseorphenotypicfeature
"Stigma‑induced tremors, joint pain, and impaired auditory location discrimination in patients with cIII‑defective mitochondrial disease correlate with a progressive deterioration of cognitive functions and occasional tachycardia.",-34.75,0.4,diseaseorphenotypicfeature
"Patients with Parkinson’s disease who exhibit tremors and impaired auditory location discrimination often experience a deterioration of cognitive functions and bradycardia, which are exacerbated by cIII-defective mitochondrial dysfunction.",-23.125,0.4,diseaseorphenotypicfeature
"Patients treated with the cIII‑defective mitochondrial inhibitor N‑acetyl‑cysteine exhibited marked tachycardia and impaired auditory location discrimination, suggesting a link between mitochondrial dysfunction and sensory processing deficits.",-27.0,0.4,diseaseorphenotypicfeature
"Patients receiving the cIII‑defective mitochondrial inhibitor N‑acetyl‑cysteine showed a dose‑dependent increase in tachycardia and a marked deterioration of cognitive functions, while a subset of subjects exhibited impaired auditory location discrimination and joint pain.",-37.25,0.4,diseaseorphenotypicfeature
"Patients experiencing tremors and impaired auditory location discrimination showed a significant increase in cIII‑defective mitochondrial enzyme activity, which correlated with accelerated deterioration of cognitive functions in those with Parkinson’s disease.",-24.5,0.4,diseaseorphenotypicfeature
"Euthyroid patients with cIII‑defective mitochondrial disease exhibit tremors, tachycardia, and progressive deterioration of cognitive functions, while joint pain and impaired auditory location discrimination further worsen their quality of life.",-34.75,0.4,diseaseorphenotypicfeature
"Epidemiologic analysis of Parkinson’s disease patients revealed that the presence of the LRRK2 G2019S variant correlates with accelerated tremor onset, cognitive decline, and a higher incidence of bradycardia, while patients carrying the c.1526C>T mutation in the ATP1A3 gene exhibit pronounced impaired auditory location discrimination and joint pain.",-52.25,0.4,diseaseorphenotypicfeature
Echocardiographic assessment of patients with cIII‑defective mitochondrial disease revealed that the presence of tachycardia and impaired auditory location discrimination correlated with accelerated deterioration of cognitive functions and increased joint pain severity.,-26.5,0.4,diseaseorphenotypicfeature
"Ethanol exposure in a cohort of patients with Parkinson’s disease exacerbated tremors and accelerated deterioration of cognitive functions, while a cIII‑defective mutation in the mitochondrial complex I gene MT-ND1 was associated with increased bradycardia and impaired auditory location discrimination.",-34.25,0.4,diseaseorphenotypicfeature
Long‑term exposure to the chemotherapeutic agent doxorubicin in A549 cells induces a cIII‑defective mitochondrial phenotype that correlates with increased tachycardia and joint pain in patients with Parkinson’s disease.,-25.0,0.4,diseaseorphenotypicfeature
Long‐term exposure to the chemotherapeutic agent doxorubicin in A549 cells induces a cIII‑defective mitochondrial phenotype that correlates with increased tachycardia and impaired auditory location discrimination in patients with Parkinson’s disease.,-28.25,0.4,diseaseorphenotypicfeature
"Longitudinal imaging of patients with cIII‑defective mitochondrial disease revealed that progressive tremors and impaired auditory location discrimination were associated with worsening cognitive functions, while bradycardia and joint pain correlated with the severity of the phenotype.",-36.25,0.4,diseaseorphenotypicfeature
"Long COVID patients frequently exhibit tremors, impaired auditory location discrimination, and tachycardia, suggesting a multisystem disease phenotype linked to persistent viral inflammation.",-36.5,0.4,diseaseorphenotypicfeature
"Altered expression of the mitochondrial complex III subunit encoded by the c.1173G>A variant in the POLG gene is associated with progressive tremors, cognitive decline, and episodic tachycardia in patients with a hereditary mitochondrial disorder.",-43.25,0.4,diseaseorphenotypicfeature
"Alterations in the mitochondrial complex III subunit encoded by the NDUFAF4 gene, as observed in patients with cIII‑defective Leigh syndrome, are associated with tremors, deterioration of cognitive functions, and impaired auditory location discrimination.",-34.0,0.4,diseaseorphenotypicfeature
"Alteration of the mitochondrial complex III subunit encoded by the MT-CYB gene in a patient with cIII-defective chronic fatigue syndrome leads to tremors, joint pain, and impaired auditory location discrimination.",-35.75,0.4,diseaseorphenotypicfeature
"Alterative therapy with the small molecule N-acetylcysteine reduced tremors and slowed the deterioration of cognitive functions in patients with Parkinson’s disease, while simultaneously lowering bradycardia incidence in a subset of those with cIII-defective mitochondrial dysfunction.",-44.75,0.4,diseaseorphenotypicfeature
"Mutations in the cIII-defective complex of the mitochondrial respiratory chain in patients with Parkinson’s disease accelerate deterioration of cognitive functions, tremors, and joint pain, while the presence of a BRCA1 c.68_69delAG sequence variant correlates with increased susceptibility to AMD.",-34.0,0.4,diseaseorphenotypicfeature
"Mutated cIII‑defective mitochondrial DNA in the A549 cell line leads to impaired auditory location discrimination, exacerbating tremors and contributing to the deterioration of cognitive functions in patients with Parkinson’s disease.",-29.0,0.4,diseaseorphenotypicfeature
Mutagenic exposure to the chemical entity cisplatin in the A549 cell line induces a cIII‑defective mitochondrial phenotype that correlates with deterioration of cognitive functions and impaired auditory location discrimination in the Homo sapiens model.,-28.125,0.4,diseaseorphenotypicfeature
"Mutational loss of the mitochondrial complex III subunit encoded by the CIII‑defective gene in a patient with progressive tremors, cognitive deterioration, and bradycardia was found to disrupt ATP synthesis and trigger a compensatory up‑regulation of the antioxidant gene NRF2, thereby linking the sequence variant to the observed phenotypic features.",-50.25,0.4,diseaseorphenotypicfeature
"Rheumatoid arthritis patients treated with methotrexate showed a significant reduction in joint pain and an improvement in impaired auditory location discrimination, suggesting that disease activity modulation can positively influence both musculoskeletal and sensory phenotypes.",-34.75,0.4,diseaseorphenotypicfeature
"Riley’s progressive tremors and impaired auditory location discrimination were exacerbated by a novel cIII‑defective mutation in the COX10 gene, leading to a severe decline in cognitive functions and episodic tachycardia.",-34.25,0.4,diseaseorphenotypicfeature
"Roux‑en‑Y mouse models with a cIII‑defective cytochrome b mutation exhibit tremors, impaired auditory location discrimination, and progressive deterioration of cognitive functions, suggesting a link between mitochondrial dysfunction and neurodegenerative phenotypes.",-28.625,0.4,diseaseorphenotypicfeature
"Raising the serum level of the small molecule L-DOPA in patients with Parkinson’s disease exacerbated tremors and accelerated the deterioration of cognitive functions, while a concurrent mutation in the GCH1 gene (c.1204C>T) was associated with a higher risk of bradycardia and impaired auditory location discrimination.",-56.25,0.4,diseaseorphenotypicfeature
"Cognitive deterioration and tremors in patients with cIII‑defective mitochondrial disease are exacerbated by the presence of the BRCA1 c.68_69delAG variant, which also correlates with increased bradycardia and joint pain.",-22.875,0.4,diseaseorphenotypicfeature
"Cortical microglial activation in a mouse model of Parkinson’s disease exacerbated tremors and accelerated deterioration of cognitive functions, while treatment with the small‑molecule inhibitor LDN‑193189 reduced the cIII‑defective respiratory chain activity and alleviated joint pain.",-40.0,0.4,diseaseorphenotypicfeature
"Cerebral amyloid angiopathy in patients with Alzheimer’s disease accelerates cognitive deterioration and increases the risk of intracerebral hemorrhage, while the presence of APOE ε4 allele correlates with higher amyloid plaque burden and impaired auditory location discrimination.",-34.25,0.4,diseaseorphenotypicfeature
"Cranial magnetic resonance imaging of patients with Parkinson’s disease revealed that the presence of the LRRK2 G2019S variant was associated with tremors, deterioration of cognitive functions, and impaired auditory location discrimination.",-25.875,0.4,diseaseorphenotypicfeature
"Recent MRI studies revealed that the cIII-defective mutation in the cytochrome b gene of *Homo sapiens* patients with Parkinson’s disease correlates with tremors, impaired auditory location discrimination, and accelerated deterioration of cognitive functions.",-31.0,0.4,diseaseorphenotypicfeature
Recent case reports indicate that the c.68_69delAG SequenceVariant in the BRCA1 GeneOrGeneProduct of a female Homo sapiens Patient with Parkinson’s disease and tremors is associated with accelerated deterioration of cognitive functions and increased susceptibility to bradycardia.,-41.25,0.4,diseaseorphenotypicfeature
"Recent observations indicate that the cIII‑defective variant of the cytochrome bc1 complex in *Homo sapiens* patients with Parkinson’s disease exacerbates tremors and accelerates deterioration of cognitive functions, thereby increasing the risk of developing age‑related macular degeneration.",-35.5,0.4,diseaseorphenotypicfeature
Recent analyses revealed that the c.68_69delAG SequenceVariant in the BRCA1 GeneOrGeneProduct of a Homo sapiens patient with AMD and impaired auditory location discrimination led to a marked deterioration of cognitive functions and a mild tachycardia.,-38.25,0.4,diseaseorphenotypicfeature
"The upregulation of the mitogen‑activated protein kinase pathway in HeLa cells treated with the small molecule inhibitor N‑methyl‑D‑aspartate receptor antagonist leads to increased expression of CD80 and VEGF‑R2, thereby enhancing the anti‑tumor immune response in Homo sapiens.",-26.75,0.4,geneorgeneproduct
"The activation of VEGF‑R2 by N‑methyl‑D‑aspartate receptors in HeLa cells upregulates the expression of the tumor‑suppressor gene MT1G, thereby attenuating the mitogen‑activated protein kinase signaling cascade that normally promotes proliferation of the CD80‑positive subpopulation.",-29.375,0.4,geneorgeneproduct
"The overexpression of the mitogen‑activated protein kinase‑regulated gene RNASEL in A549 cells enhances VEGF‑R2‑mediated angiogenic signaling, thereby promoting tumor vascularization in a xenograft model of human lung carcinoma.",-26.0,0.4,geneorgeneproduct
"The MAPK pathway, through phosphorylation of CD80, enhances VEGF‑R2‑mediated angiogenesis in HeLa cells, while RNASEL deficiency in Homo sapiens increases susceptibility to N‑methyl‑D‑aspartate receptor‑induced neurotoxicity.",-26.625,0.4,geneorgeneproduct
"Mutation of the col4a4 gene in Homo sapiens leads to aberrant extracellular matrix assembly, which in turn activates VEGF‑R2 signaling in endothelial cells, ultimately promoting angiogenesis and contributing to the progression of diabetic retinopathy.",-30.625,0.4,geneorgeneproduct
"Mutation in the col4a4 gene of a Homo sapiens patient was found to upregulate VEGF‑R2 expression, thereby enhancing mitogen‑activated protein kinase signaling and promoting abnormal angiogenesis.",-25.5,0.4,geneorgeneproduct
Mutation-driven loss of CD80 expression in A549 cells enhances mitogen‑activated protein kinase signaling and increases VEGF‑R2‑mediated angiogenic potential.,-24.875,0.4,geneorgeneproduct
"Mutation‐induced loss of the TGF‑betaRII gene product in HeLa cells leads to up‑regulation of VEGF‑R2, which in turn activates mitogen‑activated protein kinase signaling and enhances CD80 expression on the cell surface.",-32.0,0.4,geneorgeneproduct
"Loss of the RNASEL gene product in HeLa cells reduces the activation of mitogen‑activated protein kinase signaling downstream of N‑methyl‑D‑aspartate receptors, thereby attenuating the cellular response to VEGF‑R2 stimulation.",-23.625,0.4,geneorgeneproduct
"Loss-of-function mutations in RNASEL and the col4a4 gene synergistically increase the risk of hereditary prostate cancer in men carrying the BRCA2 c.5946_5947delAG variant, while overexpression of the mitogen‑activated protein kinase pathway in HeLa cells upregulates VEGF‑R2 and TGF‑betaRII, thereby enhancing angiogenesis and tumor invasion.",-51.75,0.4,geneorgeneproduct
"Losses in the RNASEL gene product reduce the antiviral interferon response, thereby increasing susceptibility to chronic hepatitis C infection in patients with the HCV genotype that relies on N‑methyl‑D‑aspartate receptor‑mediated neuroinflammation.",-50.75,0.4,geneorgeneproduct
"Loss‑of‑function mutations in RNASEL and over‑expression of the mitogen‑activated protein kinase pathway synergistically enhance the proliferation of HeLa cells, while the up‑regulation of CD80 on the cell surface increases their susceptibility to anti‑PD‑1 immunotherapy.",-40.5,0.4,geneorgeneproduct
"Mitogen‑activated protein kinase signaling is up‑regulated by VEGF‑R2 activation in HeLa cells, leading to increased expression of the fatty‑acid‑binding protein FABP‑1 and the tumor‑suppressor gene MT1G, while RNASEL activity is concurrently suppressed, thereby promoting resistance to apoptosis in this cancer cell line.",-33.75,0.4,geneorgeneproduct
"Mitogenic signaling through the mitogen‑activated protein kinase cascade up‑regulates CD80 expression in A549 cells, enhancing the recruitment of TGF‑betaRII‑dependent fibroblasts and thereby promoting extracellular matrix deposition via col4a4 transcription.",-38.5,0.4,geneorgeneproduct
"Mitral valve stenosis in patients carrying the col4a4 c.1123G>A variant is associated with increased expression of VEGF‑R2, which in turn activates mitogen‑activated protein kinase signaling and up‑regulates CD80 on endothelial cells.",-41.0,0.4,geneorgeneproduct
"Mitigation of the inflammatory response in HeLa cells is achieved when the mitogen‑activated protein kinase pathway is inhibited by the small molecule inhibitor SB‑203580, which reduces VEGF‑R2‑mediated phosphorylation of CD80 and consequently lowers the activation of N‑methyl‑D‑aspartate receptors.",-43.0,0.4,geneorgeneproduct
"A CRISPR‑Cas9 knockout of the col4a4 gene in A549 cells reduces VEGF‑R2 phosphorylation and subsequently diminishes N‑methyl‑D‑aspartate receptor‑mediated calcium influx, illustrating a regulatory link between extracellular matrix components and neuronal signaling pathways.",-26.625,0.4,geneorgeneproduct
"A chronic inflammatory microenvironment in A549 cells upregulates the mitogen‑activated protein kinase cascade, increasing VEGF‑R2 phosphorylation and subsequently enhancing CD80 expression, thereby promoting TGF‑betaRII‑mediated immune checkpoint modulation.",-33.5,0.4,geneorgeneproduct
"A gain‑of‑function mutation in the col4a4 gene, observed in a cohort of E. coli‑infected mice, upregulates VEGF‑R2 expression in endothelial cells, thereby enhancing mitogen‑activated protein kinase signaling and accelerating wound healing.",-29.25,0.4,geneorgeneproduct
"A phospho‑ERK1/2 signal transduction cascade triggered by VEGF‑R2 activation in HeLa cells up‑regulates the transcription of the FABP‑1 gene, thereby enhancing fatty‑acid uptake and promoting cell proliferation.",-30.25,0.4,geneorgeneproduct
"TNF‑α stimulation upregulates CD80 expression in HeLa cells, while the concomitant activation of VEGF‑R2 by VEGF-A enhances mitogen‑activated protein kinase signaling, leading to increased proliferation of the cancerous cell line.",-35.5,0.4,geneorgeneproduct
"TNFRSF1A activation in HeLa cells induces a rapid upregulation of the mitogen‑activated protein kinase pathway, which in turn phosphorylates CD80 and enhances the expression of the N‑methyl‑D‑aspartate receptor subunit NR2B, thereby amplifying intracellular calcium signaling and promoting apoptosis.",-35.75,0.4,geneorgeneproduct
"TNIK-mediated phosphorylation of the mitogen‑activated protein kinase MAPK3 enhances VEGF‑R2 signaling in A549 cells, thereby up‑regulating CD80 expression and promoting N‑methyl‑D‑aspartate receptor‑dependent neuronal differentiation.",-36.0,0.4,geneorgeneproduct
"TNFA-induced activation of the mitogen‑activated protein kinase cascade in A549 cells upregulates CD80 expression, thereby enhancing antigen presentation to TGF‑betaRII‑expressing CD4⁺ T cells.",-25.75,0.4,geneorgeneproduct
"Altered expression of the mitogen‑activated protein kinase pathway in A549 cells, driven by a gain‑of‑function mutation in the col4a4 gene, enhances VEGF‑R2‑mediated angiogenic signaling and promotes resistance to the chemotherapeutic agent doxorubicin.",-25.875,0.4,geneorgeneproduct
"Alterations in the TGF‑betaRII gene product in A549 cells enhance VEGF‑R2‑mediated signaling, thereby increasing proliferation of the human lung carcinoma line.",-26.625,0.4,geneorgeneproduct
"Alteration of the col4a4 gene product by a missense variant in a patient with Alport syndrome leads to aberrant collagen IV assembly, which in turn activates the mitogen‑activated protein kinase cascade and up‑regulates VEGF‑R2 expression in renal endothelial cells.",-37.0,0.4,geneorgeneproduct
"Alterments in the MAPK signaling cascade, such as hyperactivation of ERK1/2, enhance the transcription of VEGF‑R2 and TGF‑betaRII in A549 cells, thereby promoting angiogenesis and epithelial‑mesenchymal transition in a TNF‑α‑stimulated microenvironment.",-46.25,0.4,geneorgeneproduct
"TGF‑betaRII activation in A549 cells upregulates the expression of the fatty‑acid‑binding protein FABP‑1, which in turn enhances VEGF‑R2‑mediated angiogenic signaling and promotes the proliferation of the human lung carcinoma cell line.",-31.375,0.4,geneorgeneproduct
"TAMRA-labeled anti‑CD80 antibodies revealed that CD80 expression on HeLa cells is up‑regulated by the mitogen‑activated protein kinase pathway, thereby enhancing N‑methyl‑D‑aspartate receptor‑mediated calcium influx and promoting VEGF‑R2‑driven angiogenesis.",-41.25,0.4,geneorgeneproduct
"Toxic exposure to ethanol upregulates the mitogen‑activated protein kinase pathway in A549 cells, leading to increased expression of the FABP‑1 gene product and subsequent activation of VEGF‑R2 signaling in Homo sapiens lung tissue.",-37.75,0.4,geneorgeneproduct
"T-cell activation in colorectal carcinoma cells is enhanced by the interaction of CD80 with the N‑methyl‑D‑aspartate receptor, leading to up‑regulation of the mitogen‑activated protein kinase pathway and increased expression of the tumor suppressor MT1G.",-39.0,0.4,geneorgeneproduct
"In HepG2 cells, activation of the mitogen‑activated protein kinase pathway by VEGF‑R2 stimulation induces a rapid up‑regulation of FABP‑1 expression, which in turn enhances fatty‑acid transport and promotes cellular proliferation.",-22.875,0.4,geneorgeneproduct
"In A549 cells, the N-methyl-D-aspartate receptor-mediated calcium influx activates the mitogen‑activated protein kinase cascade, which in turn phosphorylates VEGF‑R2 and enhances transcription of the fatty‑acid‑binding protein FABP‑5, thereby promoting epithelial‑to‑mesenchymal transition and increasing resistance to cisplatin.",-32.75,0.4,geneorgeneproduct
"In H1299 cells, the overexpression of the mitogen‑activated protein kinase‑regulated gene MT1G enhances VEGF‑R2 signaling, thereby promoting angiogenic sprouting and increasing resistance to cisplatin treatment.",-30.75,0.4,geneorgeneproduct
"In human hepatocytes, the N‑methyl‑D‑aspartate receptor–induced calcium influx activates mitogen‑activated protein kinase signaling, which in turn upregulates FABP‑1 expression and enhances VEGF‑R2‑mediated angiogenic responses.",-26.125,0.4,geneorgeneproduct
"Mitochondrial dysfunction in HeLa cells overexpressing the mitogen‑activated protein kinase gene TP53 leads to increased VEGF‑R2 phosphorylation, thereby enhancing angiogenic signaling and promoting cell migration.",-29.375,0.4,geneorgeneproduct
"Mice lacking the RNASEL gene exhibit increased col4a4 expression and heightened activation of VEGF‑R2‑mediated mitogen‑activated protein kinase signaling, leading to accelerated angiogenesis and enhanced tumor growth.",-33.0,0.4,geneorgeneproduct
"Molecular analysis revealed that the N-methyl-D-aspartate receptor subunit NR2B, encoded by the GRIN2B gene, is upregulated in A549 cells, where it phosphorylates the mitogen-activated protein kinase ERK1/2, thereby enhancing VEGF-R2-mediated angiogenic signaling.",-34.25,0.4,geneorgeneproduct
"M2-10 cells overexpressing the mutant col4a4 allele exhibit increased phosphorylation of mitogen‑activated protein kinase, which in turn upregulates VEGF‑R2 expression and enhances N‑methyl‑D‑aspartate receptor‑mediated calcium influx, thereby promoting fibroblast proliferation and extracellular matrix remodeling.",-38.5,0.4,geneorgeneproduct
"Mutations in the RNASEL gene that impair its catalytic activity are associated with increased susceptibility to prostate cancer in men of African descent, and the resulting loss of apoptotic signaling is exacerbated by overexpression of the lipid‑binding protein FABP‑5, which promotes tumor cell migration through activation of the mitogen‑activated protein kinase cascade.",-40.25,0.4,geneorgeneproduct
"Mutational loss of the RNASEL gene product in A549 cells leads to upregulation of VEGF‑R2, which in turn activates mitogen‑activated protein kinase signaling and increases CD80 expression, thereby enhancing N‑methyl‑D‑aspartate receptor‑mediated excitotoxicity in a human lung carcinoma model.",-35.25,0.4,geneorgeneproduct
"Mutagenesis of the col4a4 gene in A549 cells results in up‑regulation of VEGF‑R2 and increased activation of mitogen‑activated protein kinase, thereby enhancing N‑methyl‑D‑aspartate receptor‑mediated calcium influx.",-26.75,0.4,geneorgeneproduct
"Mutant col4a4 in the renal basement membrane of a mouse model of Alport syndrome activates TGF‑betaRII‑dependent signaling, which in turn upregulates VEGF‑R2 expression in podocytes, thereby exacerbating proteinuria.",-33.75,0.4,geneorgeneproduct
"Activation of the mitogen‑activated protein kinase cascade by VEGF‑R2 stimulation in HeLa cells upregulates the transcription of the FABP‑1 gene, which in turn enhances fatty‑acid transport and promotes cell migration.",-23.0,0.4,geneorgeneproduct
"Activation‑induced phosphorylation of the mitogen‑activated protein kinase cascade by VEGF‑R2 in HeLa cells upregulates the transcription of the FABP‑1 gene while simultaneously enhancing CD80 expression on the cell surface, thereby linking extracellular VEGF signaling to intracellular lipid‑binding protein regulation and immune checkpoint modulation.",-42.5,0.4,geneorgeneproduct
"Activation-induced phosphorylation of CD80 by the mitogen‑activated protein kinase pathway enhances binding of N‑methyl‑D‑aspartate receptors to the synaptic membrane, thereby up‑regulating VEGF‑R2 expression in endothelial cells of the col4a4‑deficient vasculature.",-37.75,0.4,geneorgeneproduct
"Activation studies revealed that the mitogen‑activated protein kinase pathway phosphorylates CD80, thereby enhancing N‑methyl‑D‑aspartate receptor signaling and up‑regulating VEGF‑R2 expression in HeLa cells.",-30.875,0.4,geneorgeneproduct
"Treatment with the CD80 antagonist in A549 cells reduced mitogen‑activated protein kinase phosphorylation and down‑regulated VEGF‑R2 expression, thereby attenuating N‑methyl‑D‑aspartate receptor‑mediated calcium influx.",-25.0,0.4,geneorgeneproduct
"Treatment of A549 cells with the VEGF‑R2 agonist increased phosphorylation of the mitogen‑activated protein kinase cascade, thereby up‑regulating the expression of the fatty‑acid‑binding protein FABP‑1 and enhancing cell migration.",-25.125,0.4,geneorgeneproduct
"Treatment using the CD80 agonist antibody enhanced mitogen‑activated protein kinase signaling in A549 cells, thereby increasing VEGF‑R2 expression and promoting angiogenic sprouting in a co‑culture with human umbilical vein endothelial cells.",-39.25,0.4,geneorgeneproduct
"Treatment‑induced upregulation of the mitogen‑activated protein kinase pathway in A549 cells led to increased expression of the fatty acid‑binding protein FABP‑5, which in turn enhanced VEGF‑R2‑mediated angiogenic signaling and promoted resistance to the chemotherapeutic agent doxorubicin.",-39.25,0.4,geneorgeneproduct
"Upregulation of the mitogen‑activated protein kinase cascade in HeLa cells leads to increased expression of CD80, which in turn enhances the binding affinity of N‑methyl‑D‑aspartate receptors for glutamate and promotes apoptosis mediated by the tumor suppressor gene MT1G.",-29.75,0.4,geneorgeneproduct
"Upregulated expression of the mitogen‑activated protein kinase cascade in A549 cells enhances VEGF‑R2 phosphorylation, thereby stimulating CD80-mediated antigen presentation and increasing susceptibility to N‑methyl‑D‑aspartate receptor‑induced excitotoxicity.",-28.375,0.4,geneorgeneproduct
"Up-regulation of the mitogen-activated protein kinase cascade by VEGF-R2 activation in HeLa cells enhances CD80 expression, thereby potentiating N‑methyl‑D‑aspartate receptor-mediated calcium influx and promoting apoptosis through the RNASEL‑dependent pathway.",-33.75,0.4,geneorgeneproduct
"Up‑regulation of the mitogen‑activated protein kinase pathway in HeLa cells increases CD80 expression, thereby enhancing the activation of N‑methyl‑D‑aspartate receptors on neighboring neurons.",-26.875,0.4,geneorgeneproduct
"The CRISPR‑Cas9‑generated A549 cell line harboring the PDK4 c.1151G>A variant exhibited a hypoxia‑induced up‑regulation of HIF‑1α that subsequently increased IL‑21 secretion, thereby promoting BAX‑mediated apoptosis in the presence of the sodium/iodide symporter inhibitor.",-40.25,0.4,geneorgeneproduct
"The upregulation of serine‑threonine kinase B1 in hypoxic tumor cells stabilizes HIF‑1α, which in turn induces PDK4 expression and enhances glycolytic flux, thereby promoting cell survival through BAX inhibition.",-21.625,0.4,geneorgeneproduct
"The overexpression of serine‑threonine liver kinase B1 in A549 cells enhances HIF‑1α‑mediated transcription of PDK4, thereby increasing glycolytic flux and promoting resistance to hypoxia‑induced apoptosis.",-14.625,0.4,geneorgeneproduct
"The knockout of the serine‑threonine liver kinase B1 gene in HepG2 cells up‑regulates Hypoxia Inducible Factor‑1α, leading to increased PDK4 transcription and enhanced IL‑21‑mediated apoptosis via BAX activation.",-22.125,0.4,geneorgeneproduct
"Hypoxia Inducible Factor‑1α up‑regulates PDK4 expression in HepG2 cells, thereby enhancing glycolytic flux and promoting BAX‑mediated apoptosis in the presence of the serine‑threonine kinase B1 inhibitor.",-21.375,0.4,geneorgeneproduct
"Hypoxic upregulation of HIF‑1α in A549 cells induces PDK4 transcription, which in turn phosphorylates serine‑threonine‑liver‑kinase‑B1 and enhances BAX‑mediated apoptosis.",-24.25,0.4,geneorgeneproduct
"Hypothesis testing revealed that the serine‑threonine kinase B1 gene product phosphorylates HIF‑1α, thereby up‑regulating PDK4 expression in hypoxic A549 cells, a mechanism that may be disrupted by the IDP3 variant.",-36.5,0.4,geneorgeneproduct
"Hypocrine‑induced hypoxia stabilizes HIF‑1α, which in turn up‑regulates PDK4 expression in HepG2 cells, thereby shifting mitochondrial metabolism toward glycolysis and increasing BAX‑mediated apoptosis.",-41.0,0.4,geneorgeneproduct
"Serine‑threonine liver kinase B1 phosphorylates PDK4, thereby enhancing the hypoxia‑inducible factor‑1α‑mediated transcription of the sodium/iodide symporter in HepG2 cells.",-14.0,0.4,geneorgeneproduct
"Serum ferritin levels were markedly elevated in patients with the SLC12A3 c.1523G>A variant, suggesting that the altered transporter impairs iron homeostasis and triggers a compensatory upregulation of HIF‑1α‑dependent genes such as PDK4 and BAX.",-40.5,0.4,geneorgeneproduct
"SerpinB1 overexpression in A549 cells enhances HIF‑1α‑mediated transcription of PDK4, thereby increasing glycolytic flux and conferring resistance to doxorubicin‑induced apoptosis.",-24.625,0.4,geneorgeneproduct
"Serpine1 expression in A549 cells is up‑regulated by HIF‑1α under hypoxia, leading to increased BAX‑mediated apoptosis that is partially counteracted by the PDK4‑driven metabolic shift.",-27.25,0.4,geneorgeneproduct
"In HeLa cells, hypoxia‑inducible factor‑1α up‑regulates PDK4 expression, which in turn phosphorylates serine‑threonine liver kinase B1, thereby enhancing BAX‑mediated apoptosis.",-15.3125,0.4,geneorgeneproduct
"In A549 cells, overexpression of serine‑threonine liver kinase B1 enhances HIF‑1α‑mediated transcription of PDK4, thereby increasing glycolytic flux and promoting resistance to IL‑21‑induced apoptosis.",-16.375,0.4,geneorgeneproduct
"In HepG2 cells, the serine‑threonine liver kinase B1 phosphorylates HIF‑1α, thereby enhancing PDK4 transcription and promoting a metabolic shift that increases IL‑21 secretion and activates the BAX‑mediated apoptotic pathway.",-21.125,0.4,geneorgeneproduct
"In the A549 cell line, overexpression of serine‑threonine kinase B1 (STK3) upregulates HIF‑1α, which in turn induces PDK4 transcription and promotes glycolytic reprogramming, thereby enhancing IL‑21‑mediated autocrine signaling and increasing BAX‑dependent apoptosis.",-33.5,0.4,geneorgeneproduct
"A CRISPR‑Cas9‑edited A549 cell line harboring the PDK4 c.1123G>A variant exhibited markedly increased HIF‑1α‑mediated transcription of the SLC12A3 gene, leading to enhanced cellular resistance to hypoxia‑induced apoptosis.",-35.0,0.4,geneorgeneproduct
"A mutation in the serine‑threonine kinase B1 gene (STK3) within the A549 cell line increases HIF‑1α‑mediated transcription of PDK4, thereby enhancing glycolytic flux and conferring resistance to doxorubicin in this lung carcinoma model.",-28.125,0.4,geneorgeneproduct
"A549 cells overexpressing serine‑threonine liver kinase B1 exhibit increased HIF‑1α‑mediated transcription of PDK4, leading to enhanced glycolytic flux and resistance to IL‑21‑induced apoptosis.",-19.25,0.4,geneorgeneproduct
"A hypoxia‑inducible factor‑1α (HIF‑1α)–mediated up‑regulation of the serine‑threonine liver kinase B1 (STK3) gene in A549 cells enhances PDK4 transcription, thereby promoting glycolytic flux and conferring resistance to doxorubicin‑induced apoptosis.",-26.25,0.4,geneorgeneproduct
"Alterations in the serine‑threonine kinase B1 gene (STK3) were found to enhance HIF‑1α‑mediated transcription of PDK4, thereby increasing glycolytic flux in A549 cells treated with the IL‑21 cytokine.",-28.0,0.4,geneorgeneproduct
"Altered expression of serine‑threonine liver kinase B1 in A549 cells enhances Hypoxia Inducible Factor‑1α‑mediated transcription of PDK4, thereby promoting glycolytic flux and resistance to doxorubicin.",-18.875,0.4,geneorgeneproduct
"Alteration of the serine‑threonine liver kinase B1 gene product in HepG2 cells leads to up‑regulation of hypoxia‑inducible factor‑1α and down‑regulation of PDK4, thereby shifting cellular metabolism toward glycolysis.",-24.625,0.4,geneorgeneproduct
"Altercations in the serine‑threonine kinase B1 gene, which modulate HIF‑1α‑dependent PDK4 expression, were found to increase BAX‑mediated apoptosis in A549 cells treated with the small‑molecule inhibitor IL‑21.",-38.25,0.4,geneorgeneproduct
"PDK4 expression is up‑regulated by HIF‑1α in hypoxic HepG2 cells, where it phosphorylates pyruvate dehydrogenase and promotes glycolytic flux.",-20.75,0.4,geneorgeneproduct
"PDX‑1 overexpression in A549 cells upregulates the serine‑threonine liver kinase B1 gene, which in turn phosphorylates the hypoxia‑inducible factor‑1α subunit, enhancing transcription of the PDK4 promoter and increasing IL‑21 secretion.",-41.25,0.4,geneorgeneproduct
"PD-1 blockade in A549 cells upregulates HIF‑1α, which in turn induces PDK4 expression and activates BAX‑mediated apoptosis.",-32.5,0.4,geneorgeneproduct
"PDL4 overexpression in A549 cells enhances HIF‑1α‑mediated transcription of the sodium/iodide symporter, thereby increasing iodide uptake and promoting apoptosis through BAX activation.",-30.375,0.4,geneorgeneproduct
"Oxidative stress in hypoxic tumor cells upregulates HIF‑1α, which in turn induces PDK4 expression, thereby shifting metabolism toward glycolysis and enhancing survival of cancer cells.",-27.5,0.4,geneorgeneproduct
"Ox-LDL-induced activation of serine‑threonine liver kinase B1 in A549 cells upregulates HIF‑1α, which in turn transcriptionally induces PDK4, amplifying the Warburg effect and enhancing IL‑21‑mediated BAX‑dependent apoptosis.",-39.25,0.4,geneorgeneproduct
"Oxindole treatment of A549 cells upregulated the expression of serine‑threonine liver kinase B1, which in turn phosphorylated PDK4 and increased the stability of Hypoxia Inducible Factor‑1α, thereby enhancing the transcription of IL‑21 and the sodium/iodide symporter.",-43.75,0.4,geneorgeneproduct
"Oxaliplatin treatment of A549 cells increased HIF-1α‑dependent PDK4 expression, thereby enhancing glycolytic flux and conferring resistance to drug‑induced apoptosis.",-33.0,0.4,geneorgeneproduct
"Sufficient activation of serine‑threonine liver kinase B1 by hypoxia‑inducible factor‑1α in HepG2 cells upregulates PDK4 expression, thereby enhancing glycolytic flux and promoting IL‑21‑mediated BAX‑dependent apoptosis.",-31.75,0.4,geneorgeneproduct
"SLC12A3 expression in renal proximal tubule cells is markedly up‑regulated by hypoxia‑inducible factor‑1α, a change that enhances sodium‑chloride reabsorption and contributes to hypertension in patients with the SLC12A3 c.2159G>A variant.",-36.0,0.4,geneorgeneproduct
"Sulfhydryl‑modified serine‑threonine liver kinase B1 (STK3) phosphorylates the transcription factor HIF‑1α, thereby enhancing PDK4 expression and promoting IL‑21‑induced apoptosis through BAX activation in A549 cells.",-38.0,0.4,geneorgeneproduct
"SIRT1 deacetylates serine‑threonine kinase B1, thereby enhancing HIF‑1α‑mediated transcription of PDK4 and increasing IL‑21 production in activated T cells.",-23.125,0.4,geneorgeneproduct
"Activation of serine‑threonine liver kinase B1 by hypoxia‑induced HIF‑1α leads to phosphorylation of PDK4, which in turn suppresses BAX‑mediated apoptosis in hepatocytes.",-17.25,0.4,geneorgeneproduct
"Activation-induced IL-21 signaling in CD4⁺ T cells upregulates the serine‑threonine kinase B1, which phosphorylates and stabilizes Hypoxia Inducible Factor‑1α, thereby enhancing PDK4 transcription and promoting glycolytic flux in the tumor microenvironment.",-34.75,0.4,geneorgeneproduct
"Activation by hypoxia‑inducible factor‑1α of the serine‑threonine kinase B1 in A549 cells upregulates PDK4 expression, thereby shifting mitochondrial metabolism toward glycolysis and promoting survival through BAX inhibition.",-34.75,0.4,geneorgeneproduct
"Activation and phosphorylation of serine‑threonine liver kinase B1 by hypoxia‑inducible factor‑1α upregulates PDK4 expression, thereby shifting glucose metabolism toward lactate production in hypoxic tumor cells.",-26.875,0.4,geneorgeneproduct
"Treatment with the serine‑threonine kinase B1 inhibitor decreased HIF‑1α‑mediated PDK4 transcription, thereby enhancing BAX‑induced apoptosis in A549 cells.",-22.625,0.4,geneorgeneproduct
"Treatment of A549 cells with the PDK4 inhibitor GSK-2334470 induced a marked up‑regulation of HIF‑1α, which in turn enhanced IL‑21 transcription and promoted apoptosis through BAX activation.",-34.25,0.4,geneorgeneproduct
"Treatment enhanced the interaction between serine‑threonine liver kinase B1 and Hypoxia Inducible Factor‑1α, thereby up‑regulating PDK4 expression in A549 cells and increasing IL‑21 secretion in the tumor microenvironment.",-42.0,0.4,geneorgeneproduct
"Treatment using the serine‑threonine liver kinase B1 inhibitor reduced HIF‑1α‑mediated PDK4 expression in A549 cells, thereby enhancing IL‑21‑induced apoptosis via BAX activation.",-31.625,0.4,geneorgeneproduct
"Mutations in the serine‑threonine liver kinase B1 gene of A549 cells upregulate Hypoxia Inducible Factor‑1α, which in turn increases PDK4 expression and enhances IL‑21‑mediated apoptosis through BAX activation.",-22.125,0.4,geneorgeneproduct
"Mutant PDK4 in A549 cells activates HIF‑1α‑dependent transcription of the SLC12A3 gene, thereby enhancing Na⁺/Cl⁻ reabsorption and contributing to the hyper‑osmotic stress response.",-34.0,0.4,geneorgeneproduct
"Mutational loss of the serine‑threonine liver kinase B1 gene in A549 cells upregulates Hypoxia Inducible Factor‑1α, which in turn increases PDK4 transcription and enhances IL‑21‑mediated apoptosis via BAX activation.",-22.25,0.4,geneorgeneproduct
"Mutating the serine‑threonine kinase B1 gene in HeLa cells upregulates HIF‑1α, which in turn increases PDK4 expression and promotes apoptosis via BAX activation.",-22.5,0.4,geneorgeneproduct
"Silencing of the serine‑threonine liver kinase B1 gene in A549 cells reduces HIF‑1α‑mediated transcription of PDK4, thereby enhancing IL‑21‑induced apoptosis through BAX activation.",-19.375,0.4,geneorgeneproduct
"Silico‑CRISPR editing of the PDK4 gene in A549 cells revealed that loss of serine‑threonine kinase B1 up‑regulates Hypoxia‑Inducible Factor‑1α, thereby enhancing IL‑21‑mediated apoptosis through BAX activation.",-30.625,0.4,geneorgeneproduct
"Silenced serine‑threonine liver kinase B1 in A549 cells upregulates HIF‑1α‑driven PDK4 expression, thereby enhancing IL‑21‑mediated BAX activation and promoting apoptosis.",-27.5,0.4,geneorgeneproduct
"Silvestrol treatment of A549 cells downregulated HIF1A and PDK4 expression, thereby inducing BAX‑mediated apoptosis and reducing IL‑21‑driven proliferation.",-28.75,0.4,geneorgeneproduct
"Mutation of the serine‑threonine liver kinase B1 gene in a Homo sapiens cell line increases HIF‑1α‑mediated transcription of PDK4, thereby enhancing glycolytic flux and reducing apoptosis via BAX inhibition.",-27.5,0.4,geneorgeneproduct
"Mutation in the SLC12A3 gene of a patient with Gitelman syndrome leads to a loss of function of the sodium–chloride cotransporter, causing hypokalemia that is exacerbated by the up‑regulation of the pro‑apoptotic protein BAX in renal tubular cells.",-38.25,0.4,geneorgeneproduct
"Mutation‑induced loss of serine‑threonine liver kinase B1 in A549 cells upregulates hypoxia‑inducible factor‑1α, thereby increasing PDK4 transcription and promoting glycolytic reprogramming that enhances IL‑21‑mediated BAX‑dependent apoptosis.",-27.25,0.4,geneorgeneproduct
"Mutation c.152G>A in the SLC12A3 gene of a Caucasian patient with hypokalemic metabolic alkalosis was shown to reduce the activity of the sodium/iodide symporter, thereby impairing renal chloride reabsorption and contributing to the observed electrolyte imbalance.",-40.0,0.4,geneorgeneproduct
"The CRISPR‑Cas9‑generated SLCO1B1 knockout in HEK293 cells revealed a significant up‑regulation of VEGF‑C and a concomitant decrease in NKCC2 expression, suggesting a regulatory link between SLCO1B1 transport activity and vascular endothelial signaling pathways.",-24.875,0.4,geneorgeneproduct
"The variant SLCO1B1 c.521T>C in a cohort of Homo sapiens patients was associated with altered renal expression of the NKCC2 transporter, leading to increased susceptibility to hypertension.",-26.5,0.4,geneorgeneproduct
"The VEGF‑C‑induced phosphorylation of CAMK2N1 in A549 cells enhances NKCC2 expression, thereby promoting cell migration and invasion in a SLCO1B1‑dependent manner.",-27.75,0.4,geneorgeneproduct
"The A549 cell line treated with the small molecule SLCO1B1 inhibitor exhibited a significant upregulation of the transcription factor CCAAT/enhancer‑binding protein homologous protein, suggesting that blockade of SLCO1B1 enhances cellular stress responses in this lung carcinoma model.",-28.125,0.4,geneorgeneproduct
"SLCO1B1 polymorphisms modulate the hepatic uptake of the chemotherapeutic agent doxorubicin, thereby influencing its cytotoxic efficacy in A549 cells and altering VEGF-C expression levels associated with tumor angiogenesis.",-23.625,0.4,geneorgeneproduct
"SLKO1B1 polymorphisms in HepG2 cells alter the uptake of the chemotherapeutic drug doxorubicin, thereby modulating the expression of the tumor suppressor gene TP53 and the downstream apoptosis regulator BAX.",-37.0,0.4,geneorgeneproduct
"SLN1B1 polymorphisms in the hepatocyte transporter gene SLCO1B1 are associated with altered plasma levels of the chemotherapeutic drug doxorubicin, which in turn modulate VEGF-C expression and downstream angiogenic signaling in human hepatocellular carcinoma cells.",-55.5,0.4,geneorgeneproduct
"SL‑CO1B1 polymorphisms in *Homo sapiens* reduce hepatic uptake of the chemotherapeutic agent doxorubicin, thereby increasing systemic exposure and enhancing the risk of cardiotoxicity mediated by the pro‑apoptotic protein CCAAT/enhancer‑binding protein homologous protein.",-42.25,0.4,geneorgeneproduct
"In HepG2 cells, overexpression of the transcription factor CCAAT/enhancer‑binding protein homologous protein upregulates SLCO1B1 expression, thereby enhancing cellular uptake of the chemotherapeutic agent doxorubicin and potentiating its cytotoxic effect.",-17.625,0.4,geneorgeneproduct
"In Huh7 cells, the SLCO1B1 transporter facilitates uptake of the chemotherapeutic drug doxorubicin, which then activates the CCAAT/enhancer-binding protein homologous protein to trigger apoptosis.",-22.25,0.4,geneorgeneproduct
"In A549 cells, the SLCO1B1 transporter upregulates VEGF-C expression, which in turn activates CAMK2N1 to enhance Mfn1-mediated mitochondrial fusion and ultimately increases alpha2-adrenergic receptor signaling.",-24.875,0.4,geneorgeneproduct
"In HEK293 cells, overexpression of the transcription factor NEUROG1 upregulates VEGF‑C expression, which in turn activates the alpha2‑adrenergic receptor‑mediated signaling cascade that enhances CAMK2N1 phosphorylation and promotes cell migration.",-25.125,0.4,geneorgeneproduct
"Mutations in the SLCO1B1 gene alter the transport of the chemotherapeutic agent doxorubicin, thereby reducing its cytotoxic effect on A549 cells and increasing the risk of drug‑induced cardiomyopathy in patients with the c.521T>C variant.",-28.5,0.4,geneorgeneproduct
"Mutational loss of SLCO1B1 in HepG2 cells reduces intracellular doxorubicin accumulation, thereby attenuating the apoptosis‑inducing activity of the drug and compromising its therapeutic efficacy against this cancer cell line.",-28.875,0.4,geneorgeneproduct
"Mutant SLCO1B1 c.521T>C reduces hepatic uptake of statins, thereby increasing plasma LDL‑C levels and elevating the risk of statin‑induced myopathy in patients with the same variant.",-27.0,0.4,geneorgeneproduct
"Mutagenesis of the SLCO1B1 promoter in HepG2 cells reduced VEGF‑C secretion, thereby attenuating downstream CAMK2N1‑mediated phosphorylation of NKCC2 and ultimately diminishing cellular proliferation.",-29.25,0.4,geneorgeneproduct
"Overexpression of SLCO1B1 in A549 cells increases intracellular doxorubicin accumulation, thereby enhancing VEGF‑C‑mediated angiogenic signaling and promoting resistance to apoptosis through upregulation of the CCAAT/enhancer‑binding protein homologous protein.",-23.25,0.4,geneorgeneproduct
"Overlap of the SLCO1B1 promoter polymorphism with a missense variant in CAMK2N1 was associated with altered VEGF‑C secretion in HepG2 cells, suggesting a regulatory link between drug transport and angiogenic signaling.",-40.5,0.4,geneorgeneproduct
"Overactivation of VEGF‑C signaling in the A549 cell line carrying a CAMK2N1 loss‑of‑function variant increases NKCC2 expression, thereby enhancing cellular sodium reabsorption and promoting a hyper‑osmotic microenvironment that favors tumor proliferation.",-43.0,0.4,geneorgeneproduct
"Overexpressed SLCO1B1 in HepG2 cells enhances uptake of the chemotherapeutic doxorubicin, leading to increased apoptosis mediated by the transcription factor CCAAT/enhancer-binding protein homologous protein and the downstream activation of the pro‑apoptotic gene BAX.",-29.75,0.4,geneorgeneproduct
"Mutation of the SLCO1B1 gene in a patient with chronic kidney disease led to reduced renal uptake of the chemotherapeutic agent doxorubicin and increased systemic exposure, while concurrent overexpression of the transporter NKCC2 in the proximal tubule amplified sodium reabsorption and exacerbated hypertension.",-36.0,0.4,geneorgeneproduct
"Mutation in the SLCO1B1 gene product alters hepatic uptake of the chemotherapeutic drug doxorubicin, thereby reducing its cytotoxic efficacy in A549 cell lines.",-24.125,0.4,geneorgeneproduct
"Mutation c.68_69delAG in the SLCO1B1 gene reduces hepatic uptake of statins, thereby increasing plasma LDL‑cholesterol levels and elevating the risk of atherosclerotic cardiovascular disease in patients with hypercholesterolemia.",-29.75,0.4,geneorgeneproduct
Mutation‐induced loss of SLCO1B1 function in HepG2 cells enhances VEGF‑C‑mediated angiogenic signaling through up‑regulation of CAMK2N1 and downstream MAPK pathways.,-30.0,0.4,geneorgeneproduct
"A missense variant in SLCO1B1 reduces hepatic uptake of statins, thereby increasing plasma LDL levels and elevating the risk of drug-induced myopathy in patients with the C allele.",-22.875,0.4,geneorgeneproduct
"A CRISPR-Cas9 knockout of the SLCO1B1 gene in HEK293 cells revealed that loss of this transporter reduces cellular uptake of the chemotherapeutic drug doxorubicin, leading to increased apoptosis mediated by upregulated VEGF-C signaling.",-26.625,0.4,geneorgeneproduct
"A loss‑of‑function mutation in the SLCO1B1 gene product impairs hepatic uptake of the chemotherapeutic agent doxorubicin, thereby increasing its systemic exposure and exacerbating cardiotoxicity in patients with the disease phenotype of chemotherapy‑induced heart failure.",-27.625,0.4,geneorgeneproduct
"A mutation in the SLCO1B1 gene product alters its transporter activity, thereby reducing hepatic uptake of the chemotherapeutic drug doxorubicin and increasing systemic exposure in patients with colorectal carcinoma.",-22.75,0.4,geneorgeneproduct
"Loss of the SLCO1B1 allele in a patient with chronic kidney disease was associated with reduced renal clearance of the drug, leading to higher plasma concentrations of the small molecule inhibitor and subsequent activation of the VEGF‑C signaling pathway that promoted endothelial proliferation and angiogenesis.",-46.5,0.4,geneorgeneproduct
"Loss‑of‑function mutations in SLCO1B1 and the downstream activation of VEGF‑C signaling synergistically enhance the proliferation of NKCC2‑positive renal tubular cells, thereby contributing to the development of hypertension in patients with chronic kidney disease.",-37.0,0.4,geneorgeneproduct
"Losses in the SLCO1B1 gene product impair hepatic uptake of the chemotherapeutic doxorubicin, leading to higher plasma concentrations that exacerbate cardiotoxicity in patients with the Mfn1 variant.",-32.25,0.4,geneorgeneproduct
"Loss-of-function mutations in the SLCO1B1 gene reduce hepatic uptake of the chemotherapeutic agent doxorubicin, leading to elevated plasma concentrations that enhance cardiotoxicity in patients with HER2-positive breast cancer.",-22.875,0.4,geneorgeneproduct
"Alterations in the SLCO1B1 gene product reduce hepatic uptake of statins, thereby elevating plasma LDL‑C levels and increasing the risk of statin‑induced myopathy.",-20.375,0.4,geneorgeneproduct
"Altered SLCO1B1 expression in HepG2 cells enhances uptake of the chemotherapeutic doxorubicin, leading to increased apoptosis mediated by the pro‑apoptotic protein BAX and the transcription factor CCAAT/enhancer‑binding protein homologous protein.",-20.75,0.4,geneorgeneproduct
"Alteration of the SLCO1B1 transporter reduces hepatic uptake of the chemotherapeutic doxorubicin, thereby increasing its systemic exposure and exacerbating cardiotoxicity in patients with the c.521T>C variant.",-22.125,0.4,geneorgeneproduct
"Alter expression of the transcription factor CCAAT/enhancer-binding protein homologous protein in SLCO1B1‑expressing HepG2 cells is up‑regulated by VEGF‑C stimulation, thereby enhancing downstream CAMK2N1‑mediated apoptosis.",-36.25,0.4,geneorgeneproduct
"Alpha2‑adrenergic receptor activation in the renal proximal tubule down‑regulates NKCC2 expression, a process that is amplified by the transcriptional repressor CAMK2N1 and contributes to the hypertension phenotype observed in patients carrying the SLCO1B1 c.521T>C variant.",-34.0,0.4,geneorgeneproduct
"Alpha‑2‑adrenergic receptor activation in A549 cells upregulates VEGF‑C expression, which in turn stimulates NKCC2‑mediated chloride transport and enhances cell migration.",-22.625,0.4,geneorgeneproduct
"Alpha-2-adrenergic receptor activation in A549 cells upregulates SLCO1B1 expression, thereby enhancing intracellular uptake of the chemotherapeutic agent doxorubicin and increasing cell susceptibility to apoptosis.",-25.125,0.4,geneorgeneproduct
"Alpha‐2‐adrenergic receptor activation in NKCC2‑expressing renal cells downregulates VEGF‑C transcription through a CAMK2N1‑mediated inhibition of CCAAT/enhancer‑binding protein homologous protein, thereby reducing renal tubular proliferation.",-32.5,0.4,geneorgeneproduct
"Genetic disruption of SLCO1B1 in A549 cells reduces uptake of the chemotherapeutic doxorubicin, leading to increased resistance to apoptosis mediated by the transcription factor CCAAT/enhancer-binding protein homologous protein.",-22.875,0.4,geneorgeneproduct
Genomic analysis of the SLCO1B1 promoter in a cohort of E. coli–infected patients revealed that a CCAAT/enhancer-binding protein homologous protein binding site mutation (c.−123C>T) correlated with reduced drug uptake and increased susceptibility to antibiotic‑induced nephrotoxicity.,-47.75,0.4,geneorgeneproduct
"Genotype‑specific SLCO1B1 variants alter hepatic uptake of statins, thereby modulating plasma VEGF‑C levels and influencing endothelial cell proliferation in patients with coronary artery disease.",-27.625,0.4,geneorgeneproduct
"Genotoxic stress in HeLa cells upregulates the CCAAT/enhancer‑binding protein homologous protein, which in turn phosphorylates NKCC2 and enhances VEGF‑C secretion, thereby promoting cell migration and angiogenesis.",-31.125,0.4,geneorgeneproduct
"Changes in the SLCO1B1 promoter reduce hepatic uptake of statins, thereby increasing plasma concentrations that enhance VEGF‑C‑mediated angiogenesis in patients with a CCAAT/enhancer‑binding protein homologous protein polymorphism.",-28.625,0.4,geneorgeneproduct
"Changes to the SLCO1B1 transporter gene reduce hepatic uptake of the chemotherapeutic agent doxorubicin, thereby increasing plasma exposure and enhancing cardiotoxicity in patients with the CYP2C19*2 allele.",-34.5,0.4,geneorgeneproduct
"Changes of the SLCO1B1 promoter region were associated with altered expression of the transporter in HepG2 cells, leading to increased intracellular accumulation of the chemotherapeutic drug doxorubicin and a higher rate of apoptosis.",-37.75,0.4,geneorgeneproduct
"Changes within the SLCO1B1 gene, such as the c.521T>C variant, alter the transporter’s affinity for statins and thereby modulate the risk of myopathy in patients with hypercholesterolemia.",-38.25,0.4,geneorgeneproduct
"Expression of the transcription factor NEUROG1 in the developing hippocampus of Homo sapiens is positively regulated by the kinase CAMK2N1 through phosphorylation of the CCAAT/enhancer‑binding protein homologous protein, thereby enhancing VEGF‑C‑mediated angiogenesis and promoting neuronal differentiation.",-30.5,0.4,geneorgeneproduct
"Expression analysis revealed that the SLCO1B1 transporter upregulates VEGF‑C signaling, which in turn activates CAMK2N1 and CCAAT/enhancer‑binding protein homologous protein to enhance endothelial proliferation in a human endothelial cell line.",-36.25,0.4,geneorgeneproduct
"Expression levels of the gene product CAMK2N1 were markedly upregulated in HeLa cells treated with the small molecule inhibitor of alpha2‑receptors, suggesting a regulatory link between alpha2‑receptor signaling and CAMK2N1 expression.",-32.5,0.4,geneorgeneproduct
Expression profiling of SLCO1B1 in A549 cells revealed that its up‑regulation by VEGF‑C signaling enhances drug uptake and increases sensitivity to the chemotherapeutic agent doxorubicin.,-29.875,0.4,geneorgeneproduct
Elevated expression of the transcription factor CCAAT/enhancer‑binding protein homologous protein in human hepatocytes carrying the SLCO1B1 c.521T>C variant enhances VEGF‑C‑mediated angiogenic signaling and increases susceptibility to hepatic fibrosis.,-27.375,0.4,geneorgeneproduct
"Elevating VEGF-C expression in HeLa cells overexpressing CAMK2N1 activates the Plcg2‑dependent signaling cascade, thereby enhancing NKCC2‑mediated chloride reabsorption and ultimately increasing cellular proliferation.",-37.5,0.4,geneorgeneproduct
"Elevations of VEGF‑C in the tumor microenvironment of A549 cells were found to up‑regulate CAMK2N1 expression, thereby attenuating the proliferative signaling of the alpha2‑adrenergic receptor pathway.",-35.75,0.4,geneorgeneproduct
"Elevational overexpression of the transcription factor NEUROG1 in HeLa cells induces VEGF-C secretion, which in turn activates alpha2‑adrenergic receptors on neighboring NKCC2‑expressing renal epithelial cells, thereby enhancing cellular proliferation and contributing to a tumorigenic phenotype.",-43.25,0.4,geneorgeneproduct
"The EGFR‑targeted drug erlotinib induces phosphorylation of beta1‑integrin, which in turn enhances interferon‑γ secretion by host cell factor‑1‑stimulated macrophages, thereby amplifying the anti‑tumor immune response in H3 histamine‑positive colorectal carcinoma cells.",-31.25,0.4,geneorgeneproduct
The upregulation of beta1-integrin in EGFR‑targeted A549 cells treated with PEG‑IFN/RB was found to enhance interferon‑γ‑mediated apoptosis through host cell factor‑1 activation.,-25.25,0.4,geneorgeneproduct
"The H3 histamine receptor agonist, when combined with EGFR‑targeted therapy, upregulates interferon‑γ production in A549 cells, thereby enhancing host cell factor‑1‑mediated apoptosis and reducing beta1‑integrin‑driven migration.",-27.125,0.4,geneorgeneproduct
"The beta1‑integrin‑EGFR signaling axis, activated by interferon‑γ in A549 cells, up‑regulates the host cell factor‑1‑driven transcription of the H3 histamine receptor gene, thereby enhancing PEG‑IFN/RB‑induced antiviral responses.",-29.625,0.4,geneorgeneproduct
"Beta1‑integrin activation by EGFR‑targeted therapy in HeLa cells upregulates interferon‑γ‑induced host cell factor‑1 expression, thereby enhancing ET‑1‑mediated angiogenic signaling.",-23.375,0.4,geneorgeneproduct
"Beta‑1‑integrin expression in A549 cells is up‑regulated by interferon‑γ, enhancing EGFR‑targeted drug resistance and promoting ET‑1‑mediated angiogenesis.",-20.0,0.4,geneorgeneproduct
"Beta-1 integrin overexpression in EGFR‑targeted A549 cells enhances interferon‑γ‑induced apoptosis, a process that is amplified by PEG‑IFN/RB treatment and suppressed by host cell factor‑1 overexpression.",-28.375,0.4,geneorgeneproduct
"Beta‐1‑integrin expression in the A549 cell line is up‑regulated by interferon‑γ, leading to increased EGFR‑targeted signaling that enhances ET‑1 secretion and promotes the proliferation of H3 histamine‑producing cells.",-35.0,0.4,geneorgeneproduct
"Interferon‑γ treatment upregulates host cell factor‑1 expression in A549 cells, thereby enhancing EGFR‑targeted β1‑integrin signaling and reducing ET‑1‑mediated vascular constriction.",-18.25,0.4,geneorgeneproduct
"Interference of host cell factor‑1 with EGFR‑targeted therapy in A549 cells reduces H3 histamine‑mediated β1‑integrin expression, thereby enhancing the efficacy of PEG‑IFN/RB against EGFR‑mutated lung cancer.",-36.5,0.4,geneorgeneproduct
"Interleukin‑6 upregulation in EGFR‑targeted A549 cells enhances beta1‑integrin‑mediated adhesion, thereby amplifying the interferon‑γ‑induced expression of host cell factor‑1 and increasing the secretion of endothelin‑1.",-38.75,0.4,geneorgeneproduct
"Intermittent exposure of A549 cells to PEG‑IFNα‑2b upregulates host cell factor‑1, which in turn enhances EGFR‑targeted β1‑integrin signaling and increases ET‑1 secretion, thereby potentiating H3‑histamine‑mediated inflammatory responses in a THY‑stimulating hormone‑dependent manner.",-43.75,0.4,geneorgeneproduct
"Pegylated interferon‑α induces up‑regulation of host cell factor‑1 and beta1‑integrin in A549 cells, thereby enhancing EGFR‑targeted signaling and increasing ET‑1 secretion in a manner that mimics the effects of thyroid‑stimulating hormone on H3 histamine release.",-36.0,0.4,geneorgeneproduct
"Peg-IFN/RB treatment of HepG2 cells overexpressing EGFR-targeted beta1-integrin induced interferon‑γ production, which in turn up‑regulated the host cell factor‑1‑mediated transcription of the H3 histamine gene.",-34.0,0.4,geneorgeneproduct
"Peg‑IFN/RB treatment of H3‑histamine‑positive EGFR‑targeted A549 cells upregulated host cell factor‑1 expression, thereby enhancing interferon‑γ‑mediated apoptosis.",-27.875,0.4,geneorgeneproduct
"Peg-loaded interferon‑γ enhances EGFR‑targeted H3 histamine release in A549 cells, thereby increasing beta1‑integrin‑mediated adhesion and reducing ET‑1‑induced apoptosis.",-34.25,0.4,geneorgeneproduct
"Intracellular signaling downstream of EGFR-targeted therapy in A549 cells is markedly enhanced by the interaction of beta1-integrin with host cell factor‑1, leading to up‑regulation of interferon‑γ‑induced genes that modulate the H3 histamine release pathway.",-44.25,0.4,geneorgeneproduct
"Intranasal administration of PEG‑IFN/RB in A549 cells upregulated host cell factor‑1 expression, thereby enhancing EGFR‑targeted β1‑integrin signaling and reducing ET‑1‑mediated vascular remodeling in a model of pulmonary hypertension.",-36.25,0.4,geneorgeneproduct
"Intronic mutations in the H3 histamine receptor gene alter beta1‑integrin expression, thereby enhancing EGFR‑targeted interferon‑γ signaling and increasing susceptibility to PEG‑IFN/RB‑induced thyroid stimulating hormone dysregulation in patients with host cell factor‑1‑deficient E. coli infections.",-38.0,0.4,geneorgeneproduct
"Intraperitoneal injection of PEG‑IFN/RB in A549 cells upregulates host cell factor‑1 expression, thereby enhancing EGFR‑targeted β1‑integrin signaling and increasing ET‑1 secretion.",-26.5,0.4,geneorgeneproduct
"HGFR activation in EGFR‑targeted A549 cells induces a β1‑integrin‑dependent up‑regulation of interferon‑γ‑stimulated gene expression, enhancing apoptosis in the presence of PEG‑IFN/RB therapy.",-34.0,0.4,geneorgeneproduct
"HGf-1 overexpression in A549 cells enhances EGFR‑targeted therapy resistance by upregulating beta1‑integrin and increasing ET‑1 secretion, thereby promoting tumor cell survival and invasion.",-30.75,0.4,geneorgeneproduct
"HGCG-1, an interferon‑γ‑induced host cell factor, upregulates beta1‑integrin expression in EGFR‑targeted A549 cells, thereby enhancing ET‑1‑mediated angiogenic signaling.",-33.5,0.4,geneorgeneproduct
"HGSC cells treated with PEG‑IFN/RB exhibit increased H3 histamine acetylation at the EGFR‑targeted promoter, a modification that enhances beta1‑integrin expression and promotes ET‑1‑mediated angiogenic signaling.",-35.75,0.4,geneorgeneproduct
"In EGFR‑targeted therapy, the H3 histamine receptor modulates interferon‑γ production through host cell factor‑1, thereby influencing beta‑1‑integrin‑mediated adhesion in A549 cells.",-26.875,0.4,geneorgeneproduct
"In A549 cells, EGFR‑targeted therapy upregulates host cell factor‑1, which in turn increases beta1‑integrin expression and enhances the secretion of ET‑1, thereby promoting a pro‑inflammatory microenvironment that may contribute to the development of pulmonary fibrosis.",-33.0,0.4,geneorgeneproduct
"In H3 histamine‑treated A549 cells, EGFR‑targeted interferon‑γ upregulates host cell factor‑1 expression, thereby enhancing beta1‑integrin‑mediated adhesion and reducing ET‑1 secretion.",-18.875,0.4,geneorgeneproduct
"In HeLa cells, EGFR‑targeted PEG‑IFNα treatment upregulates host cell factor‑1 expression, which in turn enhances beta1‑integrin‑mediated adhesion and increases ET‑1 secretion, thereby promoting a pro‑inflammatory microenvironment that can be modulated by H3 histamine antagonists.",-32.75,0.4,geneorgeneproduct
"BET-1-integrin activation by EGFR-targeted therapy in A549 cells enhances interferon‑γ production, which in turn upregulates host cell factor‑1 expression and increases PEG‑IFN/RB‑induced apoptosis.",-26.125,0.4,geneorgeneproduct
"BET1-integrin activation by the EGFR-targeted peptide H3 histamine enhances interferon‑γ‑induced expression of the host cell factor‑1 gene in A549 cells, thereby increasing PEG‑IFN/RB‑mediated antiviral signaling.",-30.25,0.4,geneorgeneproduct
"BET5, a host cell factor‑1 homolog, binds the promoter of the EGFR‑targeted gene H3 histamine, enhancing its transcription in A549 cells and thereby increasing ET‑1 secretion, which in turn upregulates beta1‑integrin expression and promotes tumor cell invasion.",-44.75,0.4,geneorgeneproduct
"BETANIGRA, an EGFR‑targeted antibody, inhibited H3 histamine‑induced beta1‑integrin expression in A549 cells, thereby reducing ET‑1‑mediated proliferation of human bronchial epithelial cells.",-33.25,0.4,geneorgeneproduct
EGFR‑targeted therapy with cetuximab reduces tumor growth in H3 histamine‑expressing colorectal carcinoma cells by down‑regulating beta1‑integrin‑mediated adhesion and enhancing interferon‑γ‑induced apoptosis.,-21.75,0.4,geneorgeneproduct
"EGF‑receptor‑targeted therapy with cetuximab induces phosphorylation of beta‑1‑integrin, thereby enhancing interferon‑γ‑mediated activation of host cell factor‑1 and increasing expression of the H3 histamine‑binding protein in A549 cells.",-37.5,0.4,geneorgeneproduct
"EGFP‑tagged beta1‑integrin expression in A549 cells was up‑regulated by interferon‑γ treatment, leading to increased EGFR‑targeted endocytosis and enhanced ET‑1 secretion.",-32.25,0.4,geneorgeneproduct
"EGFG‑targeted therapy in H3‑histamine‑expressing A549 cells reduces beta1‑integrin‑mediated adhesion and increases interferon‑γ‑induced apoptosis, suggesting a synergistic effect of EGFR inhibition and host cell factor‑1 activation in this lung cancer model.",-51.0,0.4,geneorgeneproduct
"Mutation of the host cell factor‑1 gene in A549 cells increases EGFR‑targeted interferon‑γ production, thereby enhancing beta1‑integrin‑mediated apoptosis in response to PEG‑IFN/RB therapy.",-29.0,0.4,geneorgeneproduct
"Mutation in the TP53 gene in A549 cells leads to increased EGFR‑targeted therapy resistance, while interferon‑γ treatment restores beta1‑integrin expression and reduces ET‑1 secretion.",-32.25,0.4,geneorgeneproduct
"Mutation‑induced loss of host cell factor‑1 expression in A549 cells diminishes EGFR‑targeted interferon‑γ signaling and increases ET‑1‑mediated beta1‑integrin activation, thereby exacerbating H3 histamine‑driven tumor growth.",-39.25,0.4,geneorgeneproduct
"Mutation p.Glu117Lys in the H3 histamine receptor gene increases EGFR‑targeted therapy resistance in A549 cells, while interferon‑γ treatment restores beta1‑integrin expression and reduces ET‑1 secretion in the same cell line.",-42.25,0.4,geneorgeneproduct
H3 histamine released by activated macrophages in the tumor microenvironment enhances EGFR‑targeted therapy resistance in A549 cells through upregulation of beta1‑integrin and downstream ET‑1 signaling.,-22.25,0.4,geneorgeneproduct
"HGF stimulation of beta1-integrin on A549 cells upregulates EGFR-targeted transcription of the gene product H3 histamine, thereby enhancing interferon‑γ secretion and potentiating PEG‑IFN/RB antiviral efficacy in a host cell factor‑1–dependent manner.",-40.0,0.4,geneorgeneproduct
"HepG2 cells treated with the EGFR‑targeted drug gefitinib exhibited a dose‑dependent increase in interferon‑γ production, which was further amplified by co‑administration of PEG‑IFN/RB and the beta1‑integrin antagonist, suggesting a synergistic activation of the host cell factor‑1 signaling pathway that may modulate thyroid‑stimulating hormone‑mediated transcriptional responses.",-48.5,0.4,geneorgeneproduct
"Homo sapiens cells treated with PEG‑IFN/RB exhibit increased EGFR‑targeted phosphorylation of beta1‑integrin, which in turn enhances host cell factor‑1‑mediated transcription of the H3 histamine gene.",-33.0,0.4,geneorgeneproduct
"When EGFR‑targeted therapy is combined with PEG‑IFN/RB, the up‑regulation of host cell factor‑1 and beta1‑integrin in A549 cells leads to increased secretion of ET‑1, which in turn amplifies H3 histamine‑mediated inflammatory signaling and reduces the efficacy of interferon‑γ‑induced antiviral responses.",-39.0,0.4,geneorgeneproduct
"When PET‑CT imaging revealed a high uptake of the EGFR‑targeted tracer in the metastatic lesions of a patient with EGFR‑mutated NSCLC, the oncologist prescribed a combination of PEG‑IFN/RB and an EGFR‑targeted monoclonal antibody, which subsequently downregulated the expression of beta1‑integrin and reduced the tumor‑associated ET‑1 secretion, thereby improving the patient’s overall survival.",-63.25,0.4,geneorgeneproduct
"When H3 histamine binds to beta1-integrin on A549 cells, interferon‑γ secretion is up‑regulated, enhancing EGFR‑targeted therapy efficacy in a PEG‑IFN/RB‑treated model of thyroid‑stimulating hormone‑induced proliferation.",-34.75,0.4,geneorgeneproduct
"When the EGFR‑targeted monoclonal antibody erlotinib is combined with PEG‑IFN/RB, the resulting activation of host cell factor‑1 and beta1‑integrin signaling enhances H3 histamine release, thereby amplifying interferon‑γ production and improving antitumor immunity in patients with metastatic colorectal carcinoma.",-42.75,0.4,geneorgeneproduct
"A PEG‑IFN/RB‑treated HepG2 cell line showed increased H3 histamine acetylation at the EGFR promoter, a change that was mediated by host cell factor‑1 and correlated with up‑regulation of beta1‑integrin expression.",-31.5,0.4,geneorgeneproduct
"A mutation in the H3 histamine receptor gene, H3R c.152A>G, was found to increase beta1-integrin expression in EGFR‑targeted A549 cells, thereby enhancing interferon‑γ‑induced apoptosis and reducing tumor growth in a PEG‑IFN/RB‑treated xenograft model.",-38.0,0.4,geneorgeneproduct
"A genetic variant of the H3 histamine receptor gene, H3R c.1273G>A, was found to alter beta1-integrin expression and enhance the therapeutic response to PEG‑IFN/RB in patients with EGFR‑targeted colorectal cancer.",-43.5,0.4,geneorgeneproduct
A bioinformatics analysis revealed that the H3 histamine receptor variant c.102G>A in the TP53 gene of a HeLa cell line confers resistance to EGFR‑targeted therapy through upregulation of beta1‑integrin and interferon‑γ signaling.,-41.75,0.4,geneorgeneproduct
"Gene silencing of host cell factor‑1 in A549 cells treated with PEG‑IFN‑α/β reduces EGFR‑targeted H3 histamine release and attenuates ET‑1‑mediated beta‑1‑integrin signaling, thereby lowering interferon‑γ‑induced apoptosis.",-37.0,0.4,geneorgeneproduct
"Gene product H3 histamine, when upregulated by interferon‑γ, enhances beta‑1‑integrin signaling in EGFR‑targeted A549 cells, thereby increasing ET‑1 secretion and promoting a pro‑inflammatory microenvironment that may facilitate tumor progression in Homo sapiens.",-37.0,0.4,geneorgeneproduct
"Gene expression of H3 histamine in HeLa cells is upregulated by interferon‑γ, leading to increased EGFR‑targeted beta1‑integrin signaling and subsequent ET‑1 secretion.",-23.625,0.4,geneorgeneproduct
"Gene‑product H3 histamine, when up‑regulated by interferon‑γ, enhances beta‑1‑integrin signaling in EGFR‑targeted A549 cells, thereby increasing ET‑1 secretion and promoting a pro‑inflammatory microenvironment that accelerates tumor progression.",-34.5,0.4,geneorgeneproduct
"The PAX9 c.1156C>T variant disrupts transcriptional activation of LAMTOR-1, leading to impaired VEGFR2 signaling and reduced surfactant protein‑A2 production in alveolar epithelial cells of patients with surfactant deficiency.",-32.5,0.4,geneorgeneproduct
"The LAMTOR‑1/2 complex phosphorylates VEGFR2, thereby enhancing downstream signaling that upregulates surfactant protein‑A2 expression in alveolar epithelial cells.",-17.875,0.4,geneorgeneproduct
"The oncogenic PAX9 transcription factor upregulates VEGFR2 expression in A549 cells, thereby enhancing angiogenic signaling and promoting tumor progression.",-20.25,0.4,geneorgeneproduct
"The mutant PAX9 c.1243G>A variant, which substitutes alanine for threonine at position LAMTOR-1, was shown to disrupt CSF-1/CSF-1R signaling and reduce surfactant protein‑A2 expression in A549 cells.",-44.0,0.4,geneorgeneproduct
"Targeted CRISPR‑Cas9 editing of the ABCC8 c.1153G>A variant in human pancreatic β‑cell lines reduced insulin secretion by impairing KATP channel trafficking, an effect that was rescued by overexpressing the LAMTOR‑1/2 complex.",-43.5,0.4,geneorgeneproduct
"Targeting the VEGFR2‑mediated signaling cascade in A549 cells with the small‑molecule inhibitor SU5416 markedly reduced phospho‑AKT levels and induced apoptosis, an effect that was potentiated by co‑silencing LAMTOR‑2, thereby revealing a novel regulatory axis between the mTOR‑activating complex and vascular endothelial growth factor receptor signaling.",-52.0,0.4,geneorgeneproduct
"Target mutations in the ABCC8 c.2563G>A variant alter the channel’s response to sulfonylureas, thereby increasing the risk of hypoglycemia in patients with type‑2 diabetes who also carry the FCGR2B-232Thr/Thr polymorphism.",-55.75,0.4,geneorgeneproduct
"Targetting the CSF-1/CSF-1R axis in A549 cells overexpressing LAMTOR‑2 enhances VEGFR2 phosphorylation and increases surfactant protein‑A2 secretion, thereby promoting macrophage recruitment and accelerating tumor‑associated inflammation.",-41.5,0.4,geneorgeneproduct
"A CRISPR‑Cas9 knockout of the LAMTOR‑2 gene in HeLa cells led to a marked decrease in VEGFR2 phosphorylation, thereby attenuating downstream ERK signaling and reducing cell migration.",-24.625,0.4,geneorgeneproduct
"A missense mutation in PAX9 (c.412G>A) disrupts its interaction with LAMTOR-2, thereby attenuating CSF-1/CSF-1R signaling and reducing surfactant protein‑A2 expression in alveolar type II cells of Homo sapiens.",-27.0,0.4,geneorgeneproduct
"A C57BL/6 mouse model harboring the ABCC8 c.1234C>T variant showed impaired insulin secretion, which was rescued by leptin administration and correlated with up‑regulated VEGFR2 signaling in pancreatic β‑cells.",-38.25,0.4,geneorgeneproduct
"A functional study in HeLa cells revealed that the LAMTOR‑2 variant PAX9‑c.145A>G upregulates VEGFR2 expression, thereby enhancing CSF‑1/CSF‑1R‑mediated macrophage recruitment and increasing surfactant protein‑A2 secretion.",-32.75,0.4,geneorgeneproduct
"In HeLa cells, the PAX9 transcription factor upregulates VEGFR2 expression, thereby enhancing angiogenic signaling that is further potentiated by leptin-mediated activation of the CSF-1/CSF-1R axis.",-19.125,0.4,geneorgeneproduct
"In A549 cells, the PAX9 transcription factor upregulates VEGFR2 expression, thereby enhancing CSF-1/CSF-1R-mediated macrophage recruitment and surfactant protein‑A2 secretion.",-14.125,0.4,geneorgeneproduct
"In the A549 cell line, the PAX9 transcription factor upregulates VEGFR2 expression, thereby enhancing CSF-1/CSF-1R‑mediated macrophage recruitment and surfactant protein‑A2 secretion in response to leptin stimulation.",-22.75,0.4,geneorgeneproduct
"In LAMTOR-1 and LAMTOR-2 deficient HeLa cells, the loss of PAX9 transcriptional activity leads to reduced CSF-1/CSF-1R signaling and a concomitant decrease in surfactant protein‑A2 expression, thereby impairing macrophage recruitment and accelerating tumor‑associated inflammation.",-34.0,0.4,geneorgeneproduct
"PAX9 deficiency in HeLa cells leads to downregulation of CSF-1/CSF-1R signaling, which in turn reduces VEGFR2 phosphorylation and impairs cell migration.",-21.0,0.4,geneorgeneproduct
"PIP5K1C upregulation in A549 cells enhances VEGFR2 phosphorylation, thereby amplifying downstream signaling that promotes tumor cell migration and invasion.",-36.5,0.4,geneorgeneproduct
"P53-mediated upregulation of PAX9 in A549 cells enhances VEGFR2 expression, thereby promoting angiogenic signaling in response to CSF-1/CSF-1R stimulation.",-29.375,0.4,geneorgeneproduct
"Pseudomonas aeruginosa infection in cystic fibrosis patients increases surfactant protein‑A2 expression, which in turn activates VEGFR2 signaling and enhances the recruitment of leukocytes bearing the FCGR2B‑232Thr/Thr variant, thereby exacerbating airway inflammation.",-38.25,0.4,geneorgeneproduct
"Mutations in the ABCC8 gene that alter the SUR1 subunit of the K_ATP channel reduce insulin secretion in pancreatic β‑cells, thereby increasing the risk of type‑2 diabetes in individuals of Homo sapiens ancestry.",-25.625,0.4,geneorgeneproduct
"Mutant PAX9 c.1243G>A in a patient with cleft palate was found to disrupt the interaction between LAMTOR‑1 and LAMTOR‑2, thereby impairing mTORC1 signaling and reducing downstream VEGFR2 phosphorylation.",-38.0,0.4,geneorgeneproduct
"Mutational analysis of the PAX9 gene revealed a c.152G>A variant that disrupts a transcription factor binding site, leading to decreased expression of surfactant protein‑A2 and increased susceptibility to chronic obstructive pulmonary disease in a cohort of Homo sapiens subjects.",-37.0,0.4,geneorgeneproduct
"Mutated PAX9 c.1204G>A in a patient with cleft palate was found to upregulate VEGFR2 expression, thereby enhancing angiogenic signaling and contributing to the observed craniofacial malformation.",-35.75,0.4,geneorgeneproduct
"Following a CRISPR‑Cas9 knockout of LAMTOR‑1 in A549 cells, the resulting loss of mTORC1 signaling was accompanied by a marked up‑regulation of VEGFR2 expression, suggesting that LAMTOR‑1 normally restrains VEGFR2‑mediated angiogenic pathways in this lung carcinoma cell line.",-35.0,0.4,geneorgeneproduct
"Following CSF‑1/CSF‑1R stimulation, LAMTOR‑2 phosphorylates VEGFR2, thereby enhancing downstream signaling that up‑regulates the expression of the pro‑inflammatory microsomal prostaglandin E synthase‑1 gene in A549 cells.",-31.5,0.4,geneorgeneproduct
"Following CRISPR‑Cas9 editing of the ABCC8 c.1234G>A variant, the A549 cell line exhibited a marked increase in VEGFR2 phosphorylation and downstream microsomal prostaglandin E synthase‑1 expression, suggesting a regulatory axis that may contribute to leptin‑mediated tumorigenesis in Homo sapiens.",-44.25,0.4,geneorgeneproduct
"Following mutation of the ABCC8 c.2339G>A variant, the pancreatic β‑cell line INS‑1E exhibited a marked decrease in insulin secretion, which was rescued by pharmacological activation of the VEGFR2‑mediated PI3K/Akt pathway.",-46.25,0.4,geneorgeneproduct
"Sustained overexpression of PAX9 in A549 cells enhances VEGFR2 phosphorylation, thereby promoting angiogenic signaling that is further amplified by the LAMTOR-1/LAMTOR-2 complex in a context of CSF-1/CSF-1R autocrine stimulation.",-33.25,0.4,geneorgeneproduct
"Surgically induced overexpression of PAX9 in A549 cells upregulated VEGFR2 phosphorylation, thereby enhancing CSF-1/CSF-1R-mediated macrophage recruitment and accelerating tumor angiogenesis.",-27.0,0.4,geneorgeneproduct
"SARS‑CoV‑2 infection in A549 cells induces up‑regulation of CSF‑1/CSF‑1R signaling, which in turn activates VEGFR2‑mediated phosphorylation of microsomal prostaglandin E synthase‑1, thereby enhancing the secretion of surfactant protein‑A2 and modulating the inflammatory response.",-33.75,0.4,geneorgeneproduct
"Sertoli cells from the human testis express the LAMTOR‑1 and LAMTOR‑2 complex, and a missense mutation in the PAX9 gene (c.1156C>T, p.Pro386Leu) disrupts its interaction with VEGFR2, leading to impaired spermatogenesis and reduced surfactant protein‑A2 secretion.",-56.25,0.4,geneorgeneproduct
"Downregulation of VEGFR2 in A549 cells carrying the ABCC8 c.1234G>A variant reduces CSF‑1/CSF‑1R‑mediated macrophage recruitment, thereby attenuating leptin‑induced proliferation of PAX9‑expressing fibroblasts.",-31.875,0.4,geneorgeneproduct
"Downstream of the PAX9 transcription factor, LAMTOR‑1 and LAMTOR‑2 form a complex that activates VEGFR2 signaling, thereby enhancing the expression of microsomal prostaglandin E synthase‑1 and surfactant protein‑A2 in alveolar type II cells.",-31.25,0.4,geneorgeneproduct
Down-regulation of VEGFR2 by microsomal prostaglandin E synthase-1 in LAMTOR-1 and LAMTOR-2 deficient HeLa cells enhances apoptosis through a leptin‑dependent pathway.,-32.75,0.4,geneorgeneproduct
"Down‑regulation of VEGFR2 by the LAMTOR‑2 complex in A549 cells carrying the ABCC8 c.1523G>A variant reduces CSF‑1/CSF‑1R‑mediated macrophage recruitment, thereby attenuating surfactant protein‑A2‑driven inflammatory signaling.",-39.5,0.4,geneorgeneproduct
"Administration of CSF‑1 to LAMTOR‑2‑deficient A549 cells upregulates VEGFR2 expression, thereby enhancing proliferation and migration of the tumor cells.",-27.25,0.4,geneorgeneproduct
"Administration to A549 cells of a CRISPR‑generated LAMTOR‑1 c.347G>A variant that mimics the human FCGR2B‑232Thr/Thr allele results in increased surface expression of VEGFR2, enhanced downstream ERK phosphorylation, and a concomitant rise in surfactant protein‑A2 secretion, thereby linking the gene‑product interaction to a potential autocrine loop that may influence tumor cell migration.",-72.0,0.4,geneorgeneproduct
"Administration or overexpression of PAX9 in LAMTOR‑1/2‑deficient fibroblasts upregulates VEGFR2 signaling, thereby enhancing cell migration and angiogenic sprouting.",-47.0,0.4,geneorgeneproduct
"Administration and overexpression of the PAX9 transcription factor in A549 cells upregulates VEGFR2 and CSF‑1R signaling, thereby enhancing cell migration and proliferation while simultaneously increasing surfactant protein‑A2 secretion.",-47.0,0.4,geneorgeneproduct
"Altered CSF‑1/CSF‑1R signaling in LAMTOR‑1‑deficient A549 cells leads to up‑regulation of VEGFR2 and a downstream increase in microsomal prostaglandin E synthase‑1 expression, thereby enhancing neutrophil recruitment and surfactant protein‑A2 secretion.",-26.875,0.4,geneorgeneproduct
"Alterations in the PAX9 gene product, such as the LAMTOR‑1/2 complex interaction, have been shown to influence CSF‑1/CSF‑1R signaling, thereby modulating leptin‑induced VEGFR2 phosphorylation in A549 cells.",-31.875,0.4,geneorgeneproduct
"Alteration of the CSF-1/CSF-1R signaling axis in LAMTOR-1 deficient A549 cells upregulates VEGFR2 expression, thereby enhancing angiogenic potential and contributing to the hyperproliferative phenotype observed in this lung cancer model.",-36.0,0.4,geneorgeneproduct
"Altering the LAMTOR‑1/2 complex in A549 cells down‑regulates VEGFR2 signaling, thereby reducing CSF‑1/CSF‑1R‑mediated macrophage recruitment and increasing surfactant protein‑A2 secretion.",-32.75,0.4,geneorgeneproduct
"Knockout of the PAX9 gene in A549 cells reduces VEGFR2‑mediated signaling, leading to decreased leptin secretion and impaired surfactant protein‑A2 production in a manner that mimics the effect of the FCGR2B‑232Thr/Thr polymorphism on IgE‑driven inflammation.",-36.25,0.4,geneorgeneproduct
"Knocking out the LAMTOR‑2 gene in HeLa cells markedly reduces VEGFR2 phosphorylation and downstream ERK signaling, thereby impairing angiogenic sprouting.",-24.5,0.4,geneorgeneproduct
"Knocked‑out LAMTOR‑2 in A549 cells reduces VEGFR2 phosphorylation and downstream ERK signaling, thereby impairing the cells’ ability to respond to CSF‑1/CSF‑1R‑mediated macrophage recruitment.",-36.0,0.4,geneorgeneproduct
"Knox et al. reported that the PAX9 c.523G>A variant reduces transcriptional activity of the PAX9 promoter, thereby decreasing downstream expression of the LAMTOR-1 and LAMTOR-2 complexes and impairing osteoblast differentiation in human mesenchymal stem cells.",-53.75,0.4,geneorgeneproduct
"PPARγ activation by leptin in LAMTOR‑1‑deficient A549 cells enhances VEGFR2‑mediated angiogenic signaling, thereby promoting tumor cell proliferation.",-29.125,0.4,geneorgeneproduct
"PPARG activation by leptin in A549 cells upregulates CSF-1/CSF-1R signaling, thereby increasing VEGFR2 expression and enhancing microvascular permeability.",-27.625,0.4,geneorgeneproduct
"PPM1D overexpression in A549 cells increases VEGFR2 phosphorylation and promotes migration, while the LAMTOR‑1/2 complex modulates the downstream ERK pathway in response to CSF‑1/CSF‑1R signaling.",-44.0,0.4,geneorgeneproduct
"PPIC1 overexpression in A549 cells enhances VEGFR2 phosphorylation, thereby increasing downstream ERK signaling and promoting proliferation in the presence of CSF‑1/CSF‑1R ligand stimulation.",-42.75,0.4,geneorgeneproduct
"Changes in the PAX9 promoter region, together with the LAMTOR-1 and LAMTOR-2 complex, were shown to up‑regulate VEGFR2 expression and to enhance CSF‑1/CSF‑1R signaling in a human lung adenocarcinoma cell line, thereby promoting tumor cell migration and angiogenesis.",-45.5,0.4,geneorgeneproduct
"Changes at the PAX9 locus, such as the c.523C>T variant, reduce transcription of the PAX9 gene, thereby diminishing downstream expression of surfactant protein‑A2 and increasing susceptibility to pulmonary surfactant deficiency in Homo sapiens.",-49.25,0.4,geneorgeneproduct
"Changes of the FCGR2B-232Thr/Thr polymorphism in a cohort of Homo sapiens patients with allergic asthma were found to enhance IgE‑mediated activation of the CSF‑1/CSF‑1R axis, thereby increasing VEGFR2‑driven endothelial proliferation and surfactant protein‑A2 secretion in the lung epithelium.",-48.0,0.4,geneorgeneproduct
"Changes to the PAX9 promoter that reduce its transcriptional activity are associated with decreased surfactant protein‑A2 expression in alveolar type‑II cells, thereby increasing susceptibility to surfactant‑deficiency pneumonia in patients with the FCGR2B‑232Thr/Thr variant.",-44.25,0.4,geneorgeneproduct
"The CYP3A5 enzyme, whose activity is markedly reduced by the CYP3A5*3 variant, enhances the metabolism of doxorubicin and thereby modulates the cardiotoxic response observed in patients with the BRCA1 c.68_69delAG mutation.",-27.25,0.4,geneorgeneproduct
"The CRISPR‑generated CYP3A5 knockout in HeLa cells revealed that loss of this enzyme upregulates MAPK signaling, thereby increasing TIMP1 secretion and enhancing resistance to doxorubicin-induced apoptosis.",-25.625,0.4,geneorgeneproduct
"The overexpression of CYP3A5 in HeLa cells enhances the metabolism of doxorubicin, thereby reducing its cytotoxicity toward the TP53‑mutated tumor phenotype.",-16.625,0.4,geneorgeneproduct
The β‑1 adrenoceptor gene variant rs1801253 in a CYP3A5*3 homozygous patient enhances MAPK‑mediated cardiac contractility and is associated with elevated b‑HCG levels in a small cohort of Homo sapiens subjects.,-37.75,0.4,geneorgeneproduct
"Deletion of the MSH4 gene in the miniature chromosome maintenance‑8 locus of Homo sapiens cells reduces CYP3A5 expression, thereby impairing the metabolism of the beta‑1 adrenoceptor antagonist b‑HCG and increasing the risk of CYP11B2‑mediated hypertension.",-35.5,0.4,geneorgeneproduct
"Deletion c.1234_1235delAG in the CYP3A5 gene reduces CYP3A5 enzyme activity, leading to increased plasma levels of the chemotherapeutic agent doxorubicin and heightened risk of cardiotoxicity in patients with the CYP3A5*3/*3 genotype.",-37.0,0.4,geneorgeneproduct
"Deletion in the CYP3A5 gene reduces the enzymatic activity of the CYP3A5 protein, thereby attenuating the metabolism of the chemotherapeutic agent doxorubicin and increasing its cytotoxic effect on HeLa cells.",-29.5,0.4,geneorgeneproduct
"Deletion or missense variants in the CYP3A5 gene alter the metabolism of the antineoplastic drug doxorubicin, leading to increased intracellular accumulation of the drug in HeLa cells and heightened apoptosis mediated by MAPK signaling.",-40.75,0.4,geneorgeneproduct
"CYP3A5 polymorphisms in *Homo sapiens* alter the metabolism of the chemotherapeutic agent doxorubicin, leading to increased intracellular concentrations that upregulate MAPK signaling and consequently enhance apoptosis in HeLa cells.",-25.25,0.4,geneorgeneproduct
"C‑YP3A5 overexpression in HeLa cells enhances CYP11B2 transcription, thereby increasing aldosterone synthesis and elevating blood pressure in a model of hypertension.",-28.0,0.4,geneorgeneproduct
"Cytotoxicity assays in A549 cells revealed that the CYP3A5 inhibitor ketoconazole markedly enhanced the anti‑tumor activity of doxorubicin, an effect mediated by increased intracellular accumulation of the drug and up‑regulation of the MAPK‑dependent pro‑apoptotic gene BAX.",-34.25,0.4,geneorgeneproduct
"CPT2 deficiency in a patient with a CYP3A5*3 allele caused a dramatic reduction in beta‑1 adrenoceptor signaling, leading to severe hypertension and a novel MAPK‑dependent up‑regulation of TIMP1 in the affected renal tissue.",-45.25,0.4,geneorgeneproduct
"Mutations in the CYP3A5 gene that reduce enzyme activity enhance the cytotoxic effect of doxorubicin on A549 cells, leading to increased apoptosis mediated by MAPK signaling and upregulation of TIMP1 expression.",-23.0,0.4,geneorgeneproduct
"Mutational loss of CYP3A5 in the hepatocyte cell line HepG2 leads to increased MAPK signaling and upregulation of the host cell factor‑1 gene, thereby enhancing the expression of the beta‑1 adrenoceptor and the secretion of b‑HCG.",-43.0,0.4,geneorgeneproduct
"Mutated CYP3A5 alleles in Homo sapiens patients with CYP11B2‑mediated hypertension upregulate MAPK signaling, thereby increasing beta‑1 adrenoceptor expression and driving elevated blood pressure.",-29.25,0.4,geneorgeneproduct
"Mutant CYP3A5 alleles in the host cell factor‑1 binding region were shown to reduce arylsulfatase activity, thereby exacerbating MAPK‑mediated beta‑1 adrenoceptor signaling in miniature chromosome maintenance‑8 deficient cells.",-42.75,0.4,geneorgeneproduct
"A functional study in A549 cells revealed that the CYP3A5 polymorphism rs776746 enhances the transcription of the host cell factor‑1 gene, thereby increasing MAPK‑mediated phosphorylation of the beta‑1 adrenoceptor and elevating intracellular cAMP levels.",-36.25,0.4,geneorgeneproduct
"A CYP3A5 polymorphism in a patient with CYP11B2‑driven hypertension upregulates MAPK signaling, thereby increasing TIMP1 expression and promoting vascular remodeling in the affected Homo sapiens tissue.",-29.0,0.4,geneorgeneproduct
"A variant in CYP3A5 (c.698A>G) reduces the metabolism of doxorubicin, leading to higher plasma concentrations that enhance apoptosis in HeLa cells through MAPK‑mediated upregulation of TIMP1.",-27.75,0.4,geneorgeneproduct
"A stable transfection of A549 cells with a CYP3A5 overexpression construct revealed that increased CYP3A5 activity upregulated MAPK signaling and induced a higher expression of the host cell factor‑1 gene, thereby enhancing the cells’ resistance to doxorubicin-induced apoptosis.",-44.5,0.4,geneorgeneproduct
"Deficiency of CYP3A5 in a patient with a CYP3A5*3/*3 genotype led to markedly increased serum b-HCG levels, suggesting a regulatory role for CYP3A5 in beta‑1 adrenoceptor‑mediated luteinizing hormone secretion.",-31.25,0.4,geneorgeneproduct
"Defective CYP3A5 expression in the hepatocyte cell line HepG2 leads to increased intracellular accumulation of the chemotherapeutic agent doxorubicin, thereby enhancing apoptosis mediated by the MAPK signaling cascade.",-27.875,0.4,geneorgeneproduct
"Defects in the CYP3A5 gene product, which modulates the metabolism of the chemotherapeutic agent doxorubicin, were found to increase the risk of cardiotoxicity in patients treated with the drug.",-28.875,0.4,geneorgeneproduct
"Deficiencies in CYP3A5 and CYP11B2 genes, together with a BRCA1 c.68_69delAG sequence variant, were found to upregulate MAPK signaling and increase TIMP1 expression in HeLa cells, thereby enhancing resistance to doxorubicin treatment.",-35.25,0.4,geneorgeneproduct
"ARL3, a small GTPase, activates MAPK signaling in HeLa cells, while CYP3A5-mediated metabolism of b-HCG reduces its bioavailability in E. coli engineered for recombinant protein production.",-33.25,0.4,geneorgeneproduct
"ARYL sulfate activity in HeLa cells was markedly enhanced by the CYP3A5 inhibitor b-HCG, suggesting a regulatory interaction between the host cell factor‑1‑mediated MAPK pathway and the beta‑1 adrenoceptor‑dependent expression of TIMP1.",-38.0,0.4,geneorgeneproduct
"ARLYSulfatase deficiency in a patient carrying the CYP3A5*3 allele was associated with elevated plasma b‑HCG levels, suggesting that CYP3A5-mediated metabolism of steroid precursors modulates beta‑1 adrenoceptor signaling and MAPK pathway activation in the context of the MSH4‑related miniature chromosome maintenance defect.",-48.75,0.4,geneorgeneproduct
"ARMS2 gene expression in A549 cells is upregulated by CYP3A5-mediated metabolism of the chemotherapeutic doxorubicin, leading to increased MAPK phosphorylation and enhanced resistance to apoptosis.",-29.375,0.4,geneorgeneproduct
"Alterations in the CYP3A5 gene product reduce the metabolism of the chemotherapeutic agent doxorubicin, leading to increased toxicity in HeLa cells and exacerbating the fever observed in patients with acute leukemia.",-29.875,0.4,geneorgeneproduct
"Altered CYP3A5 expression in HeLa cells enhances MAPK‑mediated phosphorylation of host cell factor‑1, thereby increasing beta‑1 adrenoceptor transcription and elevating b‑HCG secretion.",-22.375,0.4,geneorgeneproduct
"Alteration of the CYP3A5 promoter by a single‑nucleotide polymorphism increases transcription of the enzyme, thereby enhancing metabolism of the chemotherapeutic agent doxorubicin and reducing its cytotoxicity in A549 cells.",-25.0,0.4,geneorgeneproduct
Alterative CYP3A5 polymorphisms in the host cell factor‑1 promoter region were associated with reduced arylsulfatase expression and increased MAPK‑mediated β‑1 adrenoceptor signaling in patients with miniature chromosome maintenance‑8–related renal disease.,-53.25,0.4,geneorgeneproduct
"In A549 cells, the CYP3A5 polymorphism c.698C>T enhances the transcriptional activity of the MAPK pathway, thereby increasing the expression of the host cell factor‑1 protein and elevating the secretion of beta‑1 adrenoceptor‑stimulated b‑HCG.",-39.25,0.4,geneorgeneproduct
"In vitro, CYP3A5-mediated metabolism of doxorubicin was found to upregulate MAPK signaling, thereby increasing TIMP1 expression in HeLa cells.",-23.375,0.4,geneorgeneproduct
"In HeLa cells, the CYP3A5 promoter variant c.698C>T enhances MAPK‑dependent transcription of the beta‑1 adrenoceptor gene, thereby increasing cellular sensitivity to b‑HCG‑induced proliferation.",-25.5,0.4,geneorgeneproduct
"In human hepatocytes, CYP3A5 expression is markedly up‑regulated by the MAPK pathway, leading to increased metabolism of the chemotherapeutic agent doxorubicin and consequently higher intracellular concentrations of its toxic metabolite.",-27.0,0.4,geneorgeneproduct
"An arylsulfatase deficiency in a patient with a CYP3A5*3/*3 genotype leads to altered MAPK signaling and reduced TIMP1 expression, thereby accelerating beta‑1 adrenoceptor‑mediated cardiac remodeling.",-33.5,0.4,geneorgeneproduct
"An elevated expression of CYP3A5 in HeLa cells, induced by host cell factor‑1 binding to the promoter, enhances the metabolism of the chemotherapeutic agent doxorubicin and thereby reduces its cytotoxicity against the tumor.",-38.25,0.4,geneorgeneproduct
An up‑regulation of CYP3A5 in HeLa cells treated with doxorubicin was associated with increased expression of the host cell factor‑1 gene and a concomitant rise in MAPK‑mediated phosphorylation of the beta‑1 adrenoceptor.,-34.5,0.4,geneorgeneproduct
"An elevation of CYP3A5 expression in HeLa cells treated with doxorubicin correlates with increased MAPK phosphorylation and subsequent upregulation of TIMP1, suggesting a protective mechanism against drug‑induced apoptosis.",-29.125,0.4,geneorgeneproduct
"Beta‐1 adrenoceptor activation in A549 cells upregulates MAPK signaling, which in turn increases TIMP1 expression and enhances resistance to doxorubicin-induced apoptosis.",-26.125,0.4,geneorgeneproduct
"Beta‑1 adrenoceptor activation in A549 cells upregulates CYP3A5 expression, thereby enhancing the metabolism of the chemotherapeutic agent doxorubicin and reducing its cytotoxicity.",-17.625,0.4,geneorgeneproduct
"Beta-1 adrenoceptor activation in HeLa cells upregulates CYP3A5 expression, which in turn enhances the metabolism of doxorubicin, thereby reducing its cytotoxicity toward the tumor.",-23.125,0.4,geneorgeneproduct
"Beta-hCG stimulation of the beta‑1 adrenoceptor in HeLa cells upregulates MAPK signaling, which in turn increases CYP3A5 transcription and enhances arylsulfatase activity, thereby accelerating the degradation of the MSH4‑associated miniature chromosome maintenance protein.",-40.0,0.4,geneorgeneproduct
"Mutation of the CYP3A5 gene in a patient with a BRCA1 c.68_69delAG variant increased the risk of breast cancer, while elevated levels of the host cell factor‑1 protein were associated with reduced tumor progression in the same individual.",-42.75,0.4,geneorgeneproduct
"Mutation in the CYP3A5 gene reduces the enzymatic activity of the CYP3A5 protein, thereby impairing the metabolism of the chemotherapeutic drug doxorubicin and increasing the risk of cardiotoxicity in patients with the CYP3A5*3/*3 genotype.",-24.75,0.4,geneorgeneproduct
"Mutation p.Gly12Asp in KRAS, a member of the MAPK pathway, was found to upregulate CYP3A5 expression in A549 cells, thereby enhancing the metabolism of the chemotherapeutic drug doxorubicin.",-33.0,0.4,geneorgeneproduct
"Mutation‑induced loss of CYP3A5 function in a CYP11B2‑overexpressing A549 cell line leads to up‑regulation of MAPK‑dependent TIMP1 expression, thereby enhancing beta‑1 adrenoceptor‑mediated proliferation of the host cell factor‑1‑positive tumor.",-43.25,0.4,geneorgeneproduct
"Epidermal growth factor receptor activation in A549 cells upregulates CYP3A5 expression, thereby increasing the metabolism of doxorubicin and reducing its cytotoxicity in this lung carcinoma model.",-24.875,0.4,geneorgeneproduct
"Epithelial cells expressing CYP3A5 and the beta‑1 adrenoceptor exhibit increased MAPK phosphorylation when stimulated with b‑HCG, a response that is attenuated in cells harboring a loss‑of‑function variant of the host cell factor‑1 gene.",-33.75,0.4,geneorgeneproduct
"Ectopic expression of CYP3A5 in HeLa cells enhances the metabolism of the chemotherapeutic agent doxorubicin, leading to increased apoptosis mediated by the MAPK signaling cascade.",-22.125,0.4,geneorgeneproduct
"E2F1 transcriptionally upregulates CYP3A5, which in turn metabolizes the chemotherapeutic drug doxorubicin, thereby reducing its cytotoxicity in A549 cells.",-23.375,0.4,geneorgeneproduct
"Loss of function of CYP3A5 in the host cell factor‑1‑dependent pathway increases the expression of the MAPK‑regulated beta‑1 adrenoceptor, thereby elevating the risk of arrhythmia in patients with the arylsulfatase A mutation.",-43.25,0.4,geneorgeneproduct
"Loss-of-function mutations in the CYP3A5 gene reduce the metabolic clearance of the chemotherapeutic agent doxorubicin, thereby increasing its cytotoxicity in A549 cells and exacerbating the risk of cardiotoxicity in patients with the beta‑1 adrenoceptor variant rs1801253.",-34.75,0.4,geneorgeneproduct
"Loss‑of‑function mutations in the CYP3A5 gene reduce the metabolism of the chemotherapeutic agent doxorubicin, thereby increasing its cytotoxicity toward HeLa cells that overexpress the beta‑1 adrenoceptor.",-23.5,0.4,geneorgeneproduct
"Losses in the MAPK pathway due to a CYP3A5 promoter variant reduce arylsulfatase expression, thereby increasing beta‑1 adrenoceptor‑mediated cardiac hypertrophy in patients with miniature chromosome maintenance‑8 abnormalities.",-38.75,0.4,geneorgeneproduct
"A CRISPR‑Cas9 knockout of IFNAR1 in UGT‑expressing A549 cells revealed that loss of the interferon receptor enhances COX‑1‑mediated prostaglandin synthesis, thereby increasing serotonin‑6‑receptor signaling and promoting p18‑mediated cell cycle arrest.",-31.25,0.4,geneorgeneproduct
"A missense mutation in the UGT1A1 gene, resulting in a p.Gly71Arg variant, was found to increase the risk of neurofibromatosis Type‑1‑associated malignant peripheral nerve sheath tumors in a cohort of Homo sapiens patients.",-38.25,0.4,geneorgeneproduct
"A UGT1A1 promoter polymorphism (UGT1A1*28) increases the risk of irinotecan‑induced neutropenia in patients with metastatic colorectal cancer treated with FOLFIRI, whereas concurrent COX‑1 inhibition by aspirin reduces this effect by modulating prostaglandin‑mediated inflammatory pathways.",-35.25,0.4,geneorgeneproduct
A germline missense mutation in the UGT1A1 gene (c.211G>A) was found to impair bilirubin glucuronidation and was associated with increased susceptibility to drug-induced liver injury in patients treated with the COX‑1 inhibitor celecoxib.,-38.25,0.4,geneorgeneproduct
"In UGT1A1‑deficient patients, the loss of glucuronidation activity leads to elevated bilirubin levels, which in turn upregulates COX‑1 expression and increases prostaglandin E₂ synthesis, thereby exacerbating the inflammatory phenotype observed in neurofibromatosis Type‑1‑associated dermal lesions.",-37.75,0.4,geneorgeneproduct
"In neurofibromatosis type&nbsp;1 patients, the loss‑of‑function mutation in the NF1 gene leads to hyperactivation of the Ras pathway, which in turn up‑regulates COX‑1 expression and increases prostaglandin E₂ production, thereby exacerbating pain and inflammation.",-30.5,0.4,geneorgeneproduct
"In HeLa cells, the UGT1A1 promoter variant c.211G>A increases COX‑1‑mediated prostaglandin production, thereby enhancing serotonin‑6‑receptor‑driven migration and up‑regulating the p18‑dependent cell‑cycle arrest through a Smad1/5‑mediated pathway.",-39.5,0.4,geneorgeneproduct
"In **Homo sapiens** fibroblasts, the **p18** protein binds the **COX-1** promoter, repressing its transcription and thereby reducing prostaglandin synthesis, a mechanism that may contribute to the inflammatory phenotype observed in **neurofibromatosis type I** patients.",-36.25,0.4,geneorgeneproduct
"The CRISPR‑Cas9‑mediated knockout of IFNAR1 in A549 cells led to a marked reduction in STAT1 phosphorylation and an unexpected up‑regulation of the UGT1A1 gene, suggesting a novel regulatory link between interferon signaling and xenobiotic metabolism.",-26.125,0.4,geneorgeneproduct
"The loss‑of‑function mutation in IFNAR1 (c.1123_1124delAG) in a patient with neurofibromatosis type‑1 led to impaired STAT‑1 phosphorylation and reduced expression of the UGT1A1 gene, thereby increasing susceptibility to drug‑induced hepatotoxicity.",-39.25,0.4,geneorgeneproduct
"The SNP rs113851554 in the UGT1A1 promoter reduces UGT1A1 expression, leading to hyperbilirubinemia and increased risk of irinotecan-induced neutropenia in patients with colorectal cancer.",-28.125,0.4,geneorgeneproduct
"The downregulation of COX‑1 in UGT‑overexpressing A549 cells enhances serotonin‑6 receptor signaling, thereby increasing p18‑mediated inhibition of Smad1/5 phosphorylation and reducing UCP1‑driven thermogenesis in neurofibromatosis type‑1‑derived fibroblasts.",-32.0,0.4,geneorgeneproduct
"Knockout of IFNAR1 in UGT‑expressing A549 cells reduces COX‑1‑mediated prostaglandin E₂ production, thereby attenuating serotonin‑6 receptor‑driven proliferation in neurofibromatosis type‑1‑derived tumor xenografts.",-32.25,0.4,geneorgeneproduct
"Knocking out IFNAR1 in A549 cells markedly reduces COX-1‑mediated prostaglandin E2 production, thereby attenuating the inflammatory response observed in neurofibromatosis Type‑1‑associated tumor growth.",-31.625,0.4,geneorgeneproduct
"Knocked‑out IFNAR1 in A549 cells markedly reduced STAT1 phosphorylation, thereby attenuating the COX‑1‑mediated prostaglandin E2 production that normally enhances p18‑driven cell cycle arrest in response to interferon‑α.",-38.5,0.4,geneorgeneproduct
"Knox et al. reported that the UGT1A1 promoter variant rs887829 increases COX‑1 expression in HeLa cells, thereby enhancing prostaglandin E₂ production and accelerating the onset of neurofibromatosis Type‑1‑associated plexiform neurofibroma growth.",-47.75,0.4,geneorgeneproduct
"Impaired UGT1A1 activity in patients with the UGT1A1*28 allele reduces glucuronidation of bilirubin, thereby exacerbating hyperbilirubinemia in neurofibromatosis Type‑1 carriers who also exhibit elevated COX‑1 expression in tumor‑derived fibroblasts.",-36.5,0.4,geneorgeneproduct
"Immunofluorescence staining revealed that IFNAR1 knockdown in A549 cells reduced COX-1 expression, thereby attenuating prostaglandin E2-mediated inflammation and increasing the sensitivity of these cells to the chemotherapeutic agent doxorubicin.",-38.0,0.4,geneorgeneproduct
"Impairment of IFNAR1 signaling in A549 cells leads to upregulation of COX‑1 and downstream production of prostaglandin E₂, which in turn activates the Serotonin‑6 receptor and enhances Smad1/5 phosphorylation, ultimately promoting p18‑mediated cell cycle arrest.",-36.0,0.4,geneorgeneproduct
"Imatinib treatment of A549 cells overexpressing the UGT1A1 variant c.1234A>G markedly reduced COX‑1‑mediated prostaglandin E2 synthesis, thereby attenuating the proliferation driven by the Serotonin‑6 receptor‑dependent p18‑induced cell‑cycle arrest.",-51.75,0.4,geneorgeneproduct
"CRISPR‑mediated knockout of IFNAR1 in A549 cells reduced the expression of the pro‑inflammatory cytokine IL‑6, illustrating how loss of the interferon‑α/β receptor can alter downstream signaling pathways in a human lung carcinoma cell line.",-34.5,0.4,geneorgeneproduct
"CRS‑treated A549 cells overexpressed the UGT1A1 gene, which in turn increased the phosphorylation of COX‑1 and the downstream activation of the Smad1/5 signaling pathway, thereby enhancing the production of serotonin‑6 receptor‑mediated cAMP in a manner that may contribute to the neurofibromatosis Type‑1‑associated tumor microenvironment.",-66.0,0.4,geneorgeneproduct
"CR-1, a novel splice variant of the UGT1A1 gene, was found to reduce the glucuronidation of the chemotherapeutic agent doxorubicin in HepG2 cells, thereby enhancing its cytotoxicity against A549 cells and suggesting a potential biomarker for personalized cancer therapy.",-51.5,0.4,geneorgeneproduct
"CR9, a novel UGT1A1 variant, was shown to reduce the glucuronidation of the COX-1 inhibitor celecoxib, thereby increasing its plasma concentration and exacerbating the risk of neurofibromatosis Type‑1‑associated tumor growth in patients carrying the p18 mutation.",-59.0,0.4,geneorgeneproduct
"Gene product UGT1A1 downregulation in HepG2 cells increases COX‑1‑mediated prostaglandin E₂ synthesis, thereby enhancing serotonin‑6‑receptor‑driven migration of neurofibromatosis type‑1‑derived Schwann cells.",-37.75,0.4,geneorgeneproduct
"Gene‑product UGT1A1 overexpression in HepG2 cells enhances the metabolism of the chemotherapeutic agent doxorubicin, thereby reducing its cytotoxicity and attenuating the development of drug‑induced cardiomyopathy.",-30.375,0.4,geneorgeneproduct
"Gene duplication of the UGT1A1 promoter in the UCP1‑positive brown adipocytes of a neurofibromatosis Type‑1 patient enhances COX‑1‑mediated prostaglandin synthesis, thereby increasing serotonin‑6 receptor‑driven thermogenic signaling and elevating IFNAR1‑dependent antiviral responses.",-50.5,0.4,geneorgeneproduct
"Gene silencing of UGT1A1 in the HepG2 cell line reduces the metabolism of the chemotherapeutic drug doxorubicin, thereby enhancing its cytotoxicity and increasing apoptosis in cancer cells.",-30.0,0.4,geneorgeneproduct
"Altered UGT1A1 expression in the HepG2 cell line, induced by the COX‑1 inhibitor celecoxib, increases intracellular serotonin‑6 receptor levels and enhances p18‑mediated inhibition of the Smad1/5 signaling pathway, thereby reducing UCP1 transcription in a model of neurofibromatosis type‑1‑associated tumorigenesis.",-44.25,0.4,geneorgeneproduct
"Alterations in the UGT1A1 promoter reduce glucuronidation of bilirubin, thereby exacerbating jaundice in patients with neurofibromatosis Type‑1 who also carry a pathogenic p18 deletion.",-31.125,0.4,geneorgeneproduct
"Alteration of the UGT1A1 promoter by the rs8175347 variant increases transcription of the UGT1A1 gene, thereby enhancing glucuronidation of bilirubin and reducing the risk of neurofibromatosis Type‑1‑associated liver dysfunction.",-33.25,0.4,geneorgeneproduct
"Alterated UGT1A1 expression in HepG2 cells treated with the COX‑1 inhibitor indomethacin upregulates the serotonin‑6 receptor, thereby enhancing p18‑mediated suppression of UCP1 transcription and contributing to the metabolic phenotype observed in neurofibromatosis type‑1‑associated tumors.",-45.75,0.4,geneorgeneproduct
"Among patients with neurofibromatosis type I, upregulation of the UGT1A1 gene product was associated with increased serum serotonin‑6 receptor levels, suggesting a regulatory link between UGT1A1 activity and serotonergic signaling.",-40.0,0.4,geneorgeneproduct
"Among sporadic neurofibromatosis Type‑1 patients, the loss‑of‑function mutation in the UGT1A1 gene was found to up‑regulate the COX‑1‑mediated prostaglandin E2 pathway, thereby increasing the expression of the serotonin‑6 receptor and the downstream Smad1/5 signaling cascade, which in turn promotes p18‑dependent cell‑cycle arrest and UCP1‑mediated thermogenesis.",-64.0,0.4,geneorgeneproduct
"Among neurofibromatosis Type&nbsp;1 patients, a loss‑of‑function mutation in the UGT1A1 gene that reduces glucuronidation of serotonin, combined with up‑regulated COX‑1 activity, leads to elevated prostaglandin E₂ levels that further stimulate the Serotonin&nbsp;6 receptor, thereby exacerbating pain and pruritus.",-56.75,0.4,geneorgeneproduct
"Among A549 cells, the UGT1A1 promoter variant c.211A>G increases COX‑1 expression, thereby elevating prostaglandin E₂ production and potentiating serotonin‑6 receptor‑mediated migration.",-36.25,0.4,geneorgeneproduct
"Mutations in the UGT1A1 promoter region enhance COX‑1‑mediated prostaglandin synthesis, thereby increasing serotonin‑6 receptor signaling and accelerating p18‑dependent cell cycle arrest in neurofibromatosis type‑1‑derived fibroblasts.",-28.125,0.4,geneorgeneproduct
"Mutant UGT1A1 c.508G>A reduces glucuronidation of bilirubin, leading to hyperbilirubinemia that is exacerbated by COX‑1‑mediated prostaglandin synthesis in patients with neurofibromatosis Type‑1.",-33.0,0.4,geneorgeneproduct
"Mutational loss of IFNAR1 in A549 cells reduces the phosphorylation of STAT1, thereby attenuating the antiviral response to interferon‑α and increasing susceptibility to influenza virus infection.",-22.25,0.4,geneorgeneproduct
"Mutagenic exposure of HeLa cells to the chemical entity doxorubicin upregulated the gene product UGT1A1, which in turn increased the expression of the protein COX‑1 and induced a downstream activation of the Smad1/5 signaling cascade, thereby enhancing the cellular response to inflammatory stimuli.",-47.75,0.4,geneorgeneproduct
"An aberrant UGT1A1 c.211G>A variant in a patient with neurofibromatosis Type‑1 was found to increase the expression of COX‑1, thereby elevating prostaglandin E2 levels and exacerbating the disease‑associated pain.",-43.5,0.4,geneorgeneproduct
"An altered UGT1A1 promoter variant in a patient with neurofibromatosis type I increases COX‑1 expression, thereby elevating serotonin‑6 receptor signaling and exacerbating pain hypersensitivity.",-35.25,0.4,geneorgeneproduct
"An activated IFNAR1 signaling cascade in A549 cells induces COX‑1 expression, which subsequently upregulates UGT1A1 to metabolize the neurofibromatosis‑type‑1‑associated msxc peptide, thereby modulating Smad1/5‑mediated transcription of UCP1.",-44.5,0.4,geneorgeneproduct
"An shRNA knockdown of UGT1A1 in HepG2 cells reduces the expression of the downstream gene CYP3A4, thereby increasing the intracellular concentration of the chemotherapeutic agent doxorubicin and enhancing apoptosis in the tumor cells.",-36.75,0.4,geneorgeneproduct
"UCP1 overexpression in A549 cells enhances COX‑1‑mediated prostaglandin production, thereby increasing serotonin‑6 receptor signaling and promoting p18‑dependent cell cycle arrest.",-22.5,0.4,geneorgeneproduct
"UGT1A1 expression is upregulated by IFNAR1 signaling in HepG2 cells, leading to increased clearance of bilirubin and reduced risk of neurofibromatosis Type‑1‑associated liver dysfunction.",-29.125,0.4,geneorgeneproduct
"UCR-1 cells treated with the COX‑1 inhibitor indomethacin exhibited a marked decrease in UGT1A1 expression, suggesting that COX‑1 activity modulates glucuronidation pathways in this cell line.",-33.25,0.4,geneorgeneproduct
"Uptake of the COX‑1 inhibitor indomethacin by HeLa cells expressing the UGT1A1 variant c.211A>G reduces prostaglandin E2 synthesis and increases intracellular serotonin‑6 receptor signaling, thereby attenuating p18‑mediated mTOR activation.",-38.0,0.4,geneorgeneproduct
"Activation of the IFNAR1 receptor by interferon‑α in A549 cells induces phosphorylation of Smad1/5, which in turn up‑regulates the transcription of the UGT1A1 gene, thereby enhancing detoxification of the chemotherapeutic agent doxorubicin.",-22.5,0.4,geneorgeneproduct
"Activation‑induced phosphorylation of the COX‑1 protein in UGT‑expressing HeLa cells enhances prostaglandin E2 production, thereby stimulating serotonin‑6 receptor‑mediated signaling pathways that upregulate the transcription factor Smad1/5 and ultimately promote p18‑dependent cell cycle arrest.",-50.25,0.4,geneorgeneproduct
"Activation by the serotonin‑6 receptor upregulates UGT1A1 expression in HepG2 cells, thereby enhancing the glucuronidation of the chemotherapeutic agent doxorubicin and reducing its cytotoxicity toward neurofibromatosis Type‑1‑derived Schwann cells.",-42.5,0.4,geneorgeneproduct
"Activation-of-COX-1 by the p18 subunit in UGT‑expressing HepG2 cells enhances prostaglandin E2 production, thereby stimulating the Serotonin‑6 receptor‑mediated cAMP response and upregulating Smad1/5 phosphorylation, a pathway implicated in neurofibromatosis Type‑1 tumorigenesis.",-59.0,0.4,geneorgeneproduct
"Research in A549 cells demonstrated that the UGT1A1 promoter variant c.489G>A increases COX‑1 expression, thereby enhancing serotonin‑6‑receptor‑mediated apoptosis and reducing p18‑driven proliferation.",-36.5,0.4,geneorgeneproduct
"Research indicated that the UGT1A1 promoter polymorphism c.211A>G increased COX‑1‑mediated prostaglandin synthesis in HepG2 cells, thereby enhancing serotonin‑6‑receptor‑driven neuronal apoptosis in a neurofibromatosis Type‑1 mouse model.",-46.5,0.4,geneorgeneproduct
"Research demonstrates that the UGT1A1 promoter variant c.211G>A increases expression of the UGT enzyme, thereby enhancing detoxification of the chemotherapeutic agent doxorubicin and reducing its cardiotoxicity in patients with neurofibromatosis Type‑1.",-38.0,0.4,geneorgeneproduct
"Research shows that the UGT1A1 promoter polymorphism c.-53G>A in *Homo sapiens* enhances COX‑1‑mediated prostaglandin synthesis, thereby increasing susceptibility to neurofibromatosis Type‑1‑associated tumorigenesis.",-41.25,0.4,geneorgeneproduct
Altered expression of the cystic fibrosis transmembrane conductance regulator gene in HeLa cells treated with the small molecule CRF2r-IR inhibitor leads to increased ICAM1 surface presentation and enhanced adhesion of metastatic brain tumor spheroids.,-25.75,0.4,geneorgeneproduct
"Alterations in the cystic fibrosis transmembrane conductance regulator gene in Homo sapiens lead to defective chloride transport, which in turn promotes airway inflammation mediated by ICAM1 upregulation and exacerbates cystic fibrosis lung disease.",-30.75,0.4,geneorgeneproduct
"Alteration of the cystic fibrosis transmembrane conductance regulator gene in A549 cells leads to increased ICAM1 expression, thereby enhancing adhesion of CRF2r-IR–positive immune cells and promoting a pro‑inflammatory microenvironment that may contribute to brain tumor progression.",-28.625,0.4,geneorgeneproduct
Alterbation of the cystic fibrosis transmembrane conductance regulator gene in a patient with a severe alpha‑1‑antitrypsin deficiency led to an unexpected increase in ICAM1 expression in the bronchial epithelium of a Homo sapiens donor.,-48.5,0.4,geneorgeneproduct
"The downregulation of ICAM1 in CRF2r‑IR‑expressing A549 cells reduces TNF‑α‑induced adhesion of neutrophils, thereby attenuating inflammatory signaling in a model of cystic fibrosis transmembrane conductance regulator‑deficient airway epithelium.",-28.625,0.4,geneorgeneproduct
"The EGFR‑mediated phosphorylation of ICAM1 in A549 cells enhances adhesion to endothelial cells, a process that is attenuated by the CRF2r‑IR antagonist and potentiated by the cystic fibrosis transmembrane conductance regulator inhibitor.",-27.875,0.4,geneorgeneproduct
The interaction between the thyroid hormone receptor alpha and the cystic fibrosis transmembrane conductance regulator gene product modulates epithelial ion transport in the lung.,-17.625,0.4,geneorgeneproduct
"The overexpression of the thyroid hormone receptor alpha gene in A549 cells enhances ICAM1-mediated adhesion, thereby promoting metastasis of the lung adenocarcinoma.",-19.0,0.4,geneorgeneproduct
"Cytokine‑induced up‑regulation of ICAM1 in A549 cells exposed to doxorubicin enhances adhesion of metastatic brain tumor cells, thereby increasing invasion of the blood‑brain barrier.",-26.875,0.4,geneorgeneproduct
"Cystic fibrosis transmembrane conductance regulator mutations in the CFTR gene are associated with altered expression of ICAM1, which in turn enhances neutrophil recruitment and exacerbates inflammation in patients with cystic fibrosis.",-24.0,0.4,geneorgeneproduct
"C6orf47 overexpression in A549 cells enhances EGFR‑mediated proliferation, while CRF2r‑IR activation in the same line suppresses ICAM1 transcription, illustrating a complex regulatory network that may influence brain tumor progression.",-43.5,0.4,geneorgeneproduct
"Corticotropin‑releasing factor receptor type‑2 (CRF2r‑IR) activation in HeLa cells upregulates ICAM1 expression, thereby enhancing adhesion of metastatic brain tumor cells to the endothelium.",-28.625,0.4,geneorgeneproduct
"SARS‑CoV‑2 infection upregulates ICAM1 expression in A549 cells, thereby enhancing viral entry and exacerbating the inflammatory response in patients with cystic fibrosis transmembrane conductance regulator mutations.",-20.0,0.4,geneorgeneproduct
"Surgical resection of the brain tumor in a patient with a cystic fibrosis transmembrane conductance regulator mutation revealed upregulated ICAM1 expression, suggesting that the altered CFTR protein may influence tumor‑associated inflammation.",-30.125,0.4,geneorgeneproduct
"SCP‑1‑derived CRF2r‑IR activation in A549 cells upregulates ICAM1 expression, thereby enhancing adhesion of metastatic brain tumor cells that overexpress the epidermal growth factor receptor.",-34.25,0.4,geneorgeneproduct
"SIRT1 deacetylates the transcription factor NF‑κB, thereby reducing ICAM1 expression in A549 cells treated with the EGFR inhibitor gefitinib.",-22.75,0.4,geneorgeneproduct
"In A549 cells, overexpression of the cystic fibrosis transmembrane conductance regulator gene product increases ICAM1 surface expression, thereby enhancing leukocyte adhesion and potentially contributing to the inflammatory microenvironment of lung cancer.",-25.125,0.4,geneorgeneproduct
"In HeLa cells, the CRF2r-IR pathway upregulates ICAM1 expression, thereby enhancing adhesion of metastatic brain tumor cells and promoting invasion of the blood–brain barrier.",-19.75,0.4,geneorgeneproduct
"In breast cancer cell lines, overexpression of the Epidermal Growth Factor Receptor activates ICAM1 signaling, thereby enhancing metastatic potential.",-19.125,0.4,geneorgeneproduct
"In NF‑κB‑activated A549 cells, the up‑regulation of ICAM1 and the down‑regulation of the cystic fibrosis transmembrane conductance regulator (CFTR) by the CRF2r‑IR signaling pathway were associated with increased cell migration and reduced apoptosis.",-37.5,0.4,geneorgeneproduct
"Activation of the thyroid hormone receptor alpha in A549 cells upregulates ICAM1 expression, thereby enhancing adhesion of metastatic lung cancer cells to the endothelium.",-15.3125,0.4,geneorgeneproduct
"Activation by the thyroid hormone receptor α of the cystic fibrosis transmembrane conductance regulator gene promoter in A549 cells enhances chloride secretion and reduces intracellular calcium, thereby mitigating the hyper‑cystic phenotype observed in cystic fibrosis patients.",-41.5,0.4,geneorgeneproduct
"Activation‑induced phosphorylation of the epidermal growth factor receptor in A549 cells increases ICAM1 expression, thereby enhancing leukocyte adhesion and promoting the migration of metastatic brain tumor cells.",-32.75,0.4,geneorgeneproduct
Activation-induced expression of ICAM1 in A549 cells treated with Epidermal Growth Factor Receptor agonist is amplified by the presence of the MSH2 c.594delG sequence variant.,-39.5,0.4,geneorgeneproduct
"Epidermal Growth Factor Receptor activation in the A549 cell line induces ICAM1 expression, which enhances adhesion of CRF2r-IR‑expressing immune cells and promotes metastasis of the brain tumor.",-23.0,0.4,geneorgeneproduct
Ectopic expression of the cystic fibrosis transmembrane conductance regulator in HeLa cells increases ICAM1 transcription and enhances adhesion of metastatic breast cancer cells to endothelial monolayers.,-25.125,0.4,geneorgeneproduct
"EGF receptor activation in HeLa cells upregulates ICAM1 expression, enhancing adhesion of CRF2r-IR‑expressing immune cells and promoting a pro‑inflammatory microenvironment that facilitates brain tumor progression.",-35.75,0.4,geneorgeneproduct
"Epithelial cells of the cystic fibrosis transmembrane conductance regulator‑deficient airway epithelium exhibit up‑regulated ICAM1 expression, which enhances neutrophil adhesion and contributes to the chronic inflammation observed in cystic fibrosis patients.",-24.875,0.4,geneorgeneproduct
"Aberrant splicing of the cystic fibrosis transmembrane conductance regulator gene in a subset of bronchial epithelial cells of a patient with cystic fibrosis leads to reduced protein stability and impaired chloride transport, thereby exacerbating airway mucus viscosity and predisposing to chronic Pseudomonas aeruginosa infection.",-32.75,0.4,geneorgeneproduct
"Aberrations in the cystic fibrosis transmembrane conductance regulator gene, such as the p.F508del variant, disrupt chloride transport in airway epithelial cells and are associated with the development of chronic bronchitis in patients with cystic fibrosis.",-34.5,0.4,geneorgeneproduct
"Aberration of the cystic fibrosis transmembrane conductance regulator gene in a Homo sapiens patient with a c.1521_1523delCTT variant leads to a loss of chloride channel function, which is exacerbated by the up‑regulation of ICAM1 expression in airway epithelial cells.",-43.5,0.4,geneorgeneproduct
"Abercrombie et al. reported that the CRF2r-IR antagonist reduced ICAM1 expression in A549 cells, suggesting a potential therapeutic avenue for treating cystic fibrosis transmembrane conductance regulator‑associated inflammation.",-40.5,0.4,geneorgeneproduct
"Mutations in the cystic fibrosis transmembrane conductance regulator gene alter the interaction between the protein and the epidermal growth factor receptor, thereby exacerbating airway inflammation in patients with cystic fibrosis.",-16.75,0.4,geneorgeneproduct
"Mutational loss of the cystic fibrosis transmembrane conductance regulator gene in HeLa cells induces up‑regulation of ICAM1, thereby enhancing cell adhesion and promoting metastatic potential in a brain tumor model.",-24.625,0.4,geneorgeneproduct
"Mutated CFTR in cystic fibrosis transmembrane conductance regulator–deficient A549 cells enhances ICAM1 expression, thereby increasing neutrophil adhesion and accelerating airway inflammation.",-22.375,0.4,geneorgeneproduct
"Mutant cystic fibrosis transmembrane conductance regulator (CFTR) variants in the ΔF508 locus were shown to impair chloride transport in A549 cells, leading to increased intracellular calcium that activates epidermal growth factor receptor signaling and promotes the proliferation of brain tumor stem cells.",-39.75,0.4,geneorgeneproduct
"Gene expression of the thyroid hormone receptor alpha in A549 cells was up‑regulated by epidermal growth factor receptor activation, leading to increased ICAM1 transcription and enhanced adhesion of the cells to human umbilical vein endothelial cells.",-26.0,0.4,geneorgeneproduct
Gene‑editing of the cystic fibrosis transmembrane conductance regulator in A549 cells reduced ICAM1 expression and increased susceptibility to Pseudomonas aeruginosa infection in a dose‑dependent manner.,-27.0,0.4,geneorgeneproduct
Gene delivery of a CRISPR-Cas9 construct targeting the cystic fibrosis transmembrane conductance regulator gene in A549 cells reduced ICAM1 expression and increased apoptosis in response to epidermal growth factor receptor activation.,-32.75,0.4,geneorgeneproduct
Gene deletion of the cystic fibrosis transmembrane conductance regulator in A549 cells leads to increased ICAM1 expression and heightened susceptibility to Epidermal Growth Factor Receptor‑mediated migration.,-24.625,0.4,geneorgeneproduct
A mutation in the cystic fibrosis transmembrane conductance regulator gene (CFTR) in a patient with cystic fibrosis leads to a defective chloride channel that exacerbates airway inflammation mediated by ICAM1 expression.,-26.5,0.4,geneorgeneproduct
A CRISPR‑Cas9 knockout of the cystic fibrosis transmembrane conductance regulator gene in A549 cells led to up‑regulation of ICAM1 and increased susceptibility to Pseudomonas aeruginosa infection in a human airway epithelial model.,-18.75,0.4,geneorgeneproduct
"A reduced expression of the cystic fibrosis transmembrane conductance regulator gene in A549 cells enhances the binding of the epidermal growth factor receptor to its ligand, thereby accelerating proliferation of the resulting lung adenocarcinoma.",-31.875,0.4,geneorgeneproduct
A variant of the cystic fibrosis transmembrane conductance regulator gene in a patient with cystic fibrosis led to a severe loss of chloride channel function and triggered an up‑regulation of ICAM1 expression in airway epithelial cells.,-31.125,0.4,geneorgeneproduct
"Alpha2‑adrenergic receptor activation in A549 cells downregulates ICAM1 expression, thereby reducing the adhesion of metastatic thyroid cancer cells that overexpress the thyroid hormone receptor alpha.",-24.25,0.4,geneorgeneproduct
"Alpha‑2‑adrenergic receptor activation in A549 cells upregulates ICAM1 expression, thereby enhancing adhesion of CRF2r‑IR‑expressing immune cells to the cystic fibrosis transmembrane conductance regulator‑deficient epithelium of the lung.",-26.625,0.4,geneorgeneproduct
"Alpha-2-adrenergic receptor activation in A549 cells upregulates ICAM1 expression, thereby enhancing adhesion of metastatic brain tumor cells expressing the epidermal growth factor receptor.",-23.75,0.4,geneorgeneproduct
"Alpha1‑adrenergic receptor activation in A549 cells upregulates ICAM1 expression, enhancing adhesion of CRF2r‑IR‑positive immune cells and promoting a pro‑inflammatory microenvironment that may contribute to the development of brain tumor‑associated edema.",-38.0,0.4,geneorgeneproduct
"CRF2r-IR activation in A549 cells upregulates ICAM1 expression, thereby enhancing adhesion of metastatic brain tumor cells to the endothelium of Homo sapiens cerebral vessels.",-17.875,0.4,geneorgeneproduct
"CRISPR‑Cas9 editing of the cystic fibrosis transmembrane conductance regulator gene in A549 cells revealed that loss of CFTR function up‑regulates ICAM1 expression, thereby enhancing neutrophil adhesion in a model of cystic fibrosis‑associated airway inflammation.",-22.125,0.4,geneorgeneproduct
"CRFR2-IR activation in HeLa cells upregulates ICAM1 expression, thereby enhancing adhesion of metastatic brain tumor cells to the endothelium.",-20.75,0.4,geneorgeneproduct
"CRITICAL: The thyroid hormone receptor alpha (THRA) variant c.1234G>A in a patient with congenital hypothyroidism upregulates the cystic fibrosis transmembrane conductance regulator (CFTR) promoter, thereby ameliorating chloride transport defects in airway epithelial cells of a Homo sapiens subject.",-46.75,0.4,geneorgeneproduct
"Mutation of the cystic fibrosis transmembrane conductance regulator gene in A549 cells increases ICAM1 expression, thereby enhancing neutrophil adhesion and accelerating inflammatory signaling in a human airway epithelial model.",-21.75,0.4,geneorgeneproduct
"Mutation in the cystic fibrosis transmembrane conductance regulator gene causes defective chloride transport in airway epithelial cells, leading to mucus accumulation and increased susceptibility to Pseudomonas aeruginosa infection in patients with cystic fibrosis.",-21.375,0.4,geneorgeneproduct
"Mutation‐induced loss of the cystic fibrosis transmembrane conductance regulator in A549 cells enhances Epidermal Growth Factor Receptor‑mediated proliferation, thereby accelerating tumorigenesis in a mouse model of human lung cancer.",-32.75,0.4,geneorgeneproduct
"Mutation c.1523C>T in the CFTR gene reduces cystic fibrosis transmembrane conductance regulator function, leading to chloride transport defects that exacerbate airway mucus viscosity in cystic fibrosis patients.",-32.0,0.4,geneorgeneproduct
"The activation of AMPKα by the loss of the Eaf1 gene product in melanoma differentiation‑associated protein‑5‑expressing A375 cells leads to a marked increase in phosphodiesterase‑4D activity, thereby reducing intracellular cAMP levels and attenuating thyrotropin‑receptor‑mediated proliferation.",-44.0,0.4,geneorgeneproduct
"The loss‑of‑function mutation c.1123C>T in the NADPH oxidase subunit CYBA, which encodes cytochrome b245 alpha, reduces reactive oxygen species production and thereby attenuates AMPKα‑mediated phosphorylation of STAT5, ultimately impairing FGF receptor‑4‑driven proliferation of melanoma differentiation‑associated protein‑5‑positive cells.",-46.5,0.4,geneorgeneproduct
"The single‑cell RNA‑seq analysis of A549 cells treated with the AMPKα activator AICAR revealed a coordinated up‑regulation of the NADPH oxidase subunit CYBA (cytochrome b245 alpha) and the transcription factor STAT5, suggesting a novel oxidative‑stress‑responsive signaling axis that may influence melanoma differentiation‑associated protein‑5 expression.",-45.25,0.4,geneorgeneproduct
"The overexpression of the melanoma differentiation‑associated protein‑5 gene in A549 cells increases NADPH oxidase‑4 activity, thereby enhancing reactive oxygen species production and promoting STAT5‑mediated proliferation.",-23.875,0.4,geneorgeneproduct
NADPH oxidase‑4 activity is up‑regulated by STAT5 phosphorylation downstream of FGF receptor‑4 signaling in melanoma differentiation‑associated protein‑5‑expressing A549 cells.,-22.375,0.4,geneorgeneproduct
"Nutrient‑sensing AMPKα activation in melanoma cells downregulates the expression of the melanoma‑differentiation‑associated protein‑5 gene, thereby attenuating STAT5‑mediated transcription of the phosphodiesterase‑4D promoter and reducing the proliferation of A375 cells.",-40.75,0.4,geneorgeneproduct
"Nicotinamide adenine dinucleotide phosphate oxidase subunit NOX4, encoded by the CYB5A gene, is up‑regulated by AMPKα activation in melanoma cells, where it enhances STAT5‑mediated transcription of the phosphodiesterase‑4D gene and promotes proliferation through FGF receptor‑4 signaling.",-44.0,0.4,geneorgeneproduct
"Naphthalene exposure upregulates NADPH oxidase‑4 in A549 cells, thereby increasing reactive oxygen species that activate AMPKα and subsequently enhance STAT5‑mediated transcription of the melanoma‑differentiation‑associated protein‑5 gene.",-39.5,0.4,geneorgeneproduct
"Molecular analysis of melanoma differentiation‑associated protein‑5 (MDA5) revealed that its interaction with the RNA helicase Eaf1 activates STAT5‑dependent transcription of phosphodiesterase‑4D, thereby enhancing NF‑κB signaling in A549 cells exposed to the chemotherapeutic agent doxorubicin.",-42.25,0.4,geneorgeneproduct
"Mitochondrial NADPH oxidase‑4 activity is up‑regulated by AMPKα phosphorylation, thereby enhancing reactive oxygen species production that activates STAT5‑mediated transcription of the melanoma differentiation‑associated protein‑5 gene in A549 cells.",-35.25,0.4,geneorgeneproduct
"Methylation of the promoter region of the gene encoding NADPH oxidase subunit NOX4 in melanoma cells upregulates STAT5 binding, thereby enhancing FGF receptor‑4‑mediated proliferation and contributing to resistance to tyrosine‑kinase inhibitor therapy.",-49.75,0.4,geneorgeneproduct
"MELANOMA DETERMINATION-ASSOCIATED PROTEIN5 (MDA5) activates STAT5 signaling in A549 cells, leading to upregulation of phosphodiesterase4D and increased NADPH oxidase4 activity, which in turn enhances reactive oxygen species production and promotes melanoma cell proliferation.",-46.75,0.4,geneorgeneproduct
"Cytochrome b245 alpha, a subunit of NADPH oxidase, activates AMPKα in melanoma cells, thereby enhancing STAT5‑mediated transcription of the melanoma differentiation‑associated protein‑5 gene.",-25.5,0.4,geneorgeneproduct
"Cyclosporin A treatment of A549 cells downregulates NADPH oxidase‑4 expression, thereby reducing reactive oxygen species production and attenuating STAT5‑mediated proliferation in this lung carcinoma model.",-33.5,0.4,geneorgeneproduct
"Cy3‑labelled FGF receptor‑4 antibodies revealed that its phosphorylation by AMPKα in HeLa cells triggers STAT5‑mediated transcription of the melanoma‑differentiation‑associated protein‑5 gene, thereby enhancing NADPH oxidase‑4‑dependent reactive‑oxygen‑species production.",-41.5,0.4,geneorgeneproduct
"Cybrin, a novel NADPH oxidase‑4 inhibitor, reduced reactive oxygen species production in A549 cells, thereby attenuating STAT5‑mediated transcription of the melanoma‑differentiation‑associated protein‑5 gene in a dose‑dependent manner.",-39.0,0.4,geneorgeneproduct
"Deletion of the HNF‑6 c.1023_1025delTTC allele in a patient with congenital hepatic dysfunction led to reduced transcription of the CYP2C9 gene, thereby impairing the metabolism of the antiepileptic drug phenytoin.",-40.75,0.4,geneorgeneproduct
"Deletion or missense mutation of the NADPH oxidase‑4 gene (NOX4) in A549 cells leads to reduced reactive‑oxygen‑species production and attenuates STAT5‑mediated transcription of the phosphodiesterase‑4D (PDE4D) promoter, thereby diminishing melanoma‑associated proliferation signals.",-54.75,0.4,geneorgeneproduct
"Deletion at BRCA1 c.68_69delAG in a patient with Homo sapiens melanoma increases expression of melanoma differentiation‑associated protein‑5, which in turn up‑regulates FGF receptor‑4 and activates STAT5 signaling in HeLa cells.",-48.25,0.4,geneorgeneproduct
Deletion in the Eaf1 gene in a patient with HNF‑6‑associated congenital hepatic fibrosis led to a loss of STAT5 phosphorylation and a consequent down‑regulation of phosphodiesterase‑4D expression in the thyrotropin‑responsive hepatocytes.,-50.5,0.4,geneorgeneproduct
"Mutation of the NADPH oxidase‑4 gene in A549 cells enhances STAT5 phosphorylation and increases melanoma‑differentiation‑associated protein‑5 expression, thereby promoting FGF receptor‑4‑mediated proliferation.",-29.625,0.4,geneorgeneproduct
"Mutation‑induced loss of NADPH oxidase‑4 expression in A549 cells upregulates AMPKα signaling, thereby enhancing melanoma‑differentiation‑associated protein‑5 transcription and promoting resistance to doxorubicin.",-33.25,0.4,geneorgeneproduct
"Mutation in the NADPH oxidase‑4 gene (NOX4) increases reactive oxygen species production, thereby activating STAT5 signaling and enhancing proliferation of melanoma differentiation‑associated protein‑5‑expressing A375 cells.",-34.5,0.4,geneorgeneproduct
"Mutation R248W in TP53, which is frequently observed in melanoma, was shown to increase NADPH oxidase‑4 expression and enhance STAT5‑mediated transcription of phosphodiesterase‑4D in A375 melanoma cells.",-49.5,0.4,geneorgeneproduct
"Activation of the NADPH oxidase‑4 complex by the Eaf1‑STAT5 axis in melanoma differentiation‑associated protein‑5‑overexpressing A549 cells enhances phosphodiesterase‑4D‑mediated cAMP hydrolysis, thereby attenuating AMPKα‑driven autophagic flux and promoting FGF receptor‑4‑dependent proliferation in Homo sapiens.",-41.5,0.4,geneorgeneproduct
"Activation‐dependent phosphorylation of NADPH oxidase‑4 by AMPKα in melanoma‑derived A375 cells enhances STAT5‑mediated transcription of the thyrotropin‑receptor gene, thereby increasing phosphodiesterase‑4D expression and promoting FGF receptor‑4 signaling.",-42.75,0.4,geneorgeneproduct
"Activation‑induced phosphorylation of NADPH oxidase‑4 in A549 cells enhances reactive‑oxygen‑species production, which in turn up‑regulates STAT5‑mediated transcription of the melanoma‑differentiation‑associated‑protein‑5 gene.",-36.75,0.4,geneorgeneproduct
"Activation through the FGF receptor‑4 pathway in A549 cells upregulates the NADPH oxidase‑4 gene, increasing reactive oxygen species that subsequently phosphorylate STAT5 and enhance melanoma‑differentiation‑associated protein‑5 expression.",-45.75,0.4,geneorgeneproduct
"In HepG2 cells, the phosphorylation of AMPKα by LKB1 induces a transcriptional up‑regulation of the NADPH oxidase subunit CYBB (cytochrome b245 alpha), thereby enhancing reactive‑oxygen‑species production and promoting apoptosis.",-29.75,0.4,geneorgeneproduct
"In hepatocellular carcinoma cells, the overexpression of FGF receptor‑4 activates STAT5, which in turn up‑regulates the transcription of NADPH oxidase‑4, thereby enhancing reactive oxygen species production and promoting tumor cell proliferation.",-34.75,0.4,geneorgeneproduct
"In melanoma cells, the NADPH oxidase subunit NOX4 activates STAT5 signaling, which in turn upregulates the melanoma‑differentiation‑associated protein‑5 gene, thereby enhancing cell proliferation.",-35.25,0.4,geneorgeneproduct
"In melanocytes, the melanoma differentiation‑associated protein‑5 gene product interacts with the NADPH oxidase‑4 subunit CYBA, thereby enhancing reactive oxygen species production and activating STAT5‑mediated transcription of the phosphodiesterase‑4D promoter.",-36.0,0.4,geneorgeneproduct
"Gene amplification of the melanoma differentiation‑associated protein‑5 gene in A375 melanoma cells increases NADPH oxidase‑4 expression, thereby enhancing reactive‑oxygen‑species production and promoting STAT5‑mediated cell‑proliferation signaling.",-33.25,0.4,geneorgeneproduct
"Gene deletions of the NADPH oxidase subunit CYBA, the EAF1 transcriptional co‑activator, and the melanoma‑associated protein MDA‑5 synergistically enhance STAT5 phosphorylation and up‑regulate the FGF receptor‑4 signaling cascade in human A549 cells.",-60.75,0.4,geneorgeneproduct
"Gene silencing of NADPH oxidase‑4 in A549 cells markedly reduces STAT5‑mediated transcription of phosphodiesterase‑4D, thereby attenuating the proliferative response to FGF receptor‑4 stimulation.",-36.25,0.4,geneorgeneproduct
"Gene activation of the melanoma differentiation-associated protein‑5 gene in A549 cells was enhanced by the AMPKα‑dependent phosphorylation of STAT5, leading to increased expression of the phosphodiesterase‑4D enzyme and subsequent suppression of the thyrotropin receptor signaling pathway.",-50.5,0.4,geneorgeneproduct
"STAT5 phosphorylation by NADPH oxidase‑4‐derived reactive oxygen species enhances FGF receptor‑4 transcription in melanoma differentiation‑associated protein‑5‑expressing A549 cells, thereby promoting thyrotropin receptor‑mediated proliferation of Homo sapiens hepatocytes.",-37.0,0.4,geneorgeneproduct
"STAT4 activation by the melanoma differentiation‑associated protein‑5 complex enhances NF‑κB‑mediated transcription of the NADPH oxidase‑4 gene in A549 cells, thereby increasing reactive‑oxygen‑species production and promoting apoptosis in response to doxorubicin treatment.",-47.75,0.4,geneorgeneproduct
"STAT‑5 phosphorylation by the tyrosine‑kinase activity of the FGF receptor‑4 variant in A549 cells enhances the transcription of the NADPH oxidase‑4 gene, thereby increasing reactive‑oxygen‑species production in response to epidermal growth factor stimulation.",-41.5,0.4,geneorgeneproduct
"STAT3 activation in melanoma cells expressing the melanoma differentiation‑associated protein‑5 variant enhances FGF receptor‑4‑mediated proliferation, while NADPH oxidase‑4‑derived reactive oxygen species inhibit AMPKα‑dependent autophagy.",-45.25,0.4,geneorgeneproduct
"Upregulation of the melanoma differentiation‑associated protein‑5 gene in A549 cells exposed to the chemical entity doxorubicin induces a STAT5‑dependent increase in phosphodiesterase‑4D expression, thereby enhancing NADPH oxidase‑4‑mediated reactive‑oxygen‑species production and promoting apoptosis.",-37.25,0.4,geneorgeneproduct
"Upstream activation of AMPKα by oxidative stress induces phosphorylation of NADPH oxidase‑4, thereby enhancing ROS production and promoting melanoma differentiation‑associated protein‑5 expression in A549 cells.",-35.25,0.4,geneorgeneproduct
"Upregulated AMPKα activity in A549 cells treated with the STAT5 inhibitor reduced NADPH oxidase‑4 expression, thereby attenuating reactive oxygen species‑mediated apoptosis.",-32.0,0.4,geneorgeneproduct
"Up-regulation of AMPKα in melanoma cells expressing the melanoma differentiation‑associated protein‑5 variant enhances phosphorylation of STAT5, thereby increasing transcription of the thyrotropin receptor gene and stimulating downstream phosphodiesterase‑4D activity.",-34.75,0.4,geneorgeneproduct
"Phosphodiesterase‑4D inhibition in A549 cells reduces NADPH oxidase‑4‑mediated reactive‑oxygen‑species production, thereby attenuating STAT5‑driven proliferation of melanoma‑differentiation‑associated‑protein‑5‑positive tumor cells.",-25.375,0.4,geneorgeneproduct
"Pharmacologic inhibition of phosphodiesterase‑4D in A549 cells expressing the Eaf1‑STAT5 fusion protein reduces melanoma‑differentiation‑associated‑protein‑5 transcription and restores AMPKα‑mediated oxidative phosphorylation, thereby attenuating cytochrome‑b245‑alpha‑driven NADPH oxidase‑4 activity.",-39.75,0.4,geneorgeneproduct
"Phagocytic NADPH oxidase‑4 activation in A549 cells is amplified by STAT5 phosphorylation, which in turn up‑regulates melanoma‑differentiation‑associated protein‑5 expression and enhances chemokine secretion.",-47.5,0.4,geneorgeneproduct
"Pharma‑induced oxidative stress in A549 cells is mediated by NADPH oxidase‑4 activation, which in turn phosphorylates STAT5 and upregulates phosphodiesterase‑4D expression, thereby enhancing the anti‑apoptotic signaling of the FGF receptor‑4 pathway.",-48.0,0.4,geneorgeneproduct
"Oxidative stress induced by NADPH oxidase‑4 activation upregulates phosphodiesterase‑4D expression in melanoma differentiation‑associated protein‑5‑positive A549 cells, thereby attenuating AMPKα‑mediated apoptosis in Homo sapiens.",-32.0,0.4,geneorgeneproduct
"Oxiporine, a novel NADPH oxidase‑4 inhibitor, reduced reactive oxygen species production in A549 cells by down‑regulating cytochrome b245 alpha expression and activating AMPKα, thereby attenuating STAT5‑mediated proliferation of melanoma differentiation‑associated protein‑5‑positive tumors.",-51.0,0.4,geneorgeneproduct
"Ox‑phosphorylated NADPH oxidase‑4 in melanoma cells activates STAT5, which in turn up‑regulates the transcription of melanoma differentiation‑associated protein‑5, thereby enhancing FGF receptor‑4‑driven proliferation.",-48.0,0.4,geneorgeneproduct
"Ox-1, a NADPH oxidase‑4 isoform, phosphorylates STAT5 in melanoma cells, thereby enhancing the transcription of FGF receptor‑4 and promoting tumor‑cell proliferation.",-45.25,0.4,geneorgeneproduct
"Amf1 overexpression in A549 cells increases NADPH oxidase‑4 activity, thereby enhancing reactive oxygen species production and activating STAT5‑mediated transcription of the melanoma‑differentiation‑associated protein‑5 gene.",-36.25,0.4,geneorgeneproduct
Amelioration of oxidative stress in melanoma cells by NADPH oxidase‑4 inhibition was accompanied by a reduction in STAT5‑mediated transcription of the phosphodiesterase‑4D gene.,-33.25,0.4,geneorgeneproduct
"Amka‑derived melanoma cells overexpressing the melanoma differentiation‑associated protein‑5 gene exhibit increased NADPH oxidase‑4 activity, which in turn activates STAT5 signaling and promotes proliferation of the FGF receptor‑4‑positive subpopulation.",-46.75,0.4,geneorgeneproduct
"Amphiregulin stimulation of FGF receptor‑4 in A549 cells upregulates the transcription factor STAT5, which in turn increases expression of the antioxidant enzyme NADPH oxidase‑4 and the phosphodiesterase‑4D isoform, thereby enhancing cellular resistance to oxidative stress.",-37.0,0.4,geneorgeneproduct
"In ARGINASE1‑deficient mice, ERK‑dependent upregulation of NOX4 and catalase in dendrin‑rich renal proximal tubules exacerbates oxidative stress, while IGF‑1R signaling through the Na⁺‑K⁺‑2Cl⁻ cotransporter counteracts this effect, suggesting a complex interplay between metabolic and ion‑transport pathways in kidney injury.",-44.75,0.4,geneorgeneproduct
"In Arg1‑deficient mice, ERK‑dependent activation of NOX4 drives oxidative stress that upregulates dendrin expression, thereby impairing insulin‑mediated glucose uptake in skeletal muscle.",-21.5,0.4,geneorgeneproduct
"In IGF‑1R‑overexpressing HeLa cells, ERK‑dependent activation of NOX4 increases ROS, which in turn upregulates dendrin and catalase expression, thereby enhancing resistance to oxidative stress.",-23.625,0.4,geneorgeneproduct
"In an ERK‑dependent signaling cascade, FGFR‑4 activation in Arg1‑deficient hepatocytes upregulates NOX4, thereby increasing reactive oxygen species that subsequently enhance dendrin‑mediated tight‑junction remodeling and reduce catalase expression, ultimately impairing hepatocyte survival.",-36.5,0.4,geneorgeneproduct
"The Arg1-deficient mouse model revealed that loss of arginase I enhances ERK-dependent NOX4 expression, thereby increasing oxidative stress and accelerating dendrin-mediated neuronal apoptosis.",-22.0,0.4,geneorgeneproduct
"The FGFR‑4 p.Gly388Arg variant enhances ERK‑dependent signaling in Arg1‑deficient macrophages, leading to increased NOX4‑mediated reactive oxygen species production and subsequent dendrin‑driven apoptosis of hepatocytes.",-25.5,0.4,geneorgeneproduct
"The ERK-dependent activation of NOX4 in FGFR-4‑stimulated A549 cells increases reactive oxygen species, which in turn upregulates catalase expression and enhances dendrin-mediated tight junction integrity.",-20.875,0.4,geneorgeneproduct
"The knockout of Arg1-deficient mice revealed that ERK-dependent activation of NOX4 in dendrin-expressing cells increased catalase expression, thereby reducing oxidative stress and improving insulin sensitivity in the Na⁺‑K⁺‑2Cl⁻ cotransporter‑mediated renal transport system.",-32.25,0.4,geneorgeneproduct
"A FGFR‑4 variant in Arg1‑deficient mice upregulates ERK‑dependent NOX4 activity, which in turn reduces dendrin‑mediated catalase expression and alters Na⁺‑K⁺‑2Cl⁻ cotransporter function.",-25.875,0.4,geneorgeneproduct
"A decrease in dendrin expression in FGFR‑4‑overexpressing HeLa cells was shown to be ERK‑dependent and to enhance NOX4‑mediated reactive‑oxygen‑species production, thereby reducing catalase activity.",-29.5,0.4,geneorgeneproduct
"A recent study showed that in Arg1‑deficient macrophages, ERK‑dependent activation of NOX4 leads to increased reactive oxygen species, which in turn upregulates dendrin expression and reduces catalase activity, thereby impairing the antioxidant response in a human cell line.",-35.25,0.4,geneorgeneproduct
"A loss‑of‑function mutation in the FGFR‑4 gene leads to ERK‑dependent upregulation of NOX4, which in turn increases reactive oxygen species and activates dendrin‑mediated apoptosis in Arg1‑deficient macrophages.",-23.5,0.4,geneorgeneproduct
"ERK‑dependent activation of the FGFR‑4/IGF‑1R signaling axis in Arg1‑deficient A549 cells enhances NOX4‑driven reactive oxygen species production, thereby upregulating dendrin expression and stimulating the Na⁺‑K⁺‑2Cl⁻ cotransporter to promote cellular proliferation.",-26.125,0.4,geneorgeneproduct
"ERKK-dependent activation of NOX4 in Arg1-deficient dendrin-expressing cells enhances catalase-mediated reactive oxygen species clearance, thereby modulating IGF-1R signaling in FGFR-4–overexpressing HeLa cells.",-41.0,0.4,geneorgeneproduct
"ERB-mediated activation of the ERK-dependent FGFR-4 signaling cascade in Arg1-deficient A549 cells upregulates NOX4 expression, thereby increasing ROS production and enhancing dendrin-mediated cellular migration.",-42.0,0.4,geneorgeneproduct
"ERKs phosphorylate dendrin, and the resulting ERK‑dependent activation of NOX4 increases reactive oxygen species that in Arg1‑deficient macrophages upregulates catalase expression, thereby modulating the inflammatory response in a CCR5‑Delta32‑carrying human cohort.",-53.75,0.4,geneorgeneproduct
"Exposure of Arg1-deficient macrophages to IGF-1R activation triggers an ERK-dependent upregulation of NOX4, resulting in increased reactive oxygen species that subsequently suppress dendrin expression and impair the Na(+)-K(+)-2Cl(-) cotransporter function in the renal epithelium.",-34.5,0.4,geneorgeneproduct
"Exposure to IGF-1R activation in FGFR‑4‑overexpressing HeLa cells induces an ERK‑dependent up‑regulation of NOX4, leading to increased reactive oxygen species that subsequently stimulate dendrin‑mediated apoptosis.",-32.0,0.4,geneorgeneproduct
"Exposure‑induced oxidative stress in Arg1‑deficient A549 cells activates an ERK‑dependent up‑regulation of NOX4, which in turn amplifies dendrin‑mediated apoptosis through catalase suppression.",-37.75,0.4,geneorgeneproduct
"Exposure analysis revealed that the FGFR‑4 c.1150T>C variant in Arg1‑deficient mice upregulates ERK‑dependent NOX4 expression, thereby increasing oxidative stress and reducing dendrin‑mediated synaptic plasticity.",-47.25,0.4,geneorgeneproduct
"Mutations in the FGFR-4 gene that reduce ERK-dependent signaling increase NOX4 expression, thereby enhancing oxidative stress in Arg1-deficient macrophages and contributing to the inflammatory phenotype observed in patients carrying the CCR5-Delta32 allele.",-24.0,0.4,geneorgeneproduct
"Mutated FGFR‑4 variants in Arg1‑deficient A549 cells activate an ERK‑dependent NOX4 signaling cascade that upregulates dendrin expression, thereby enhancing catalase‑mediated reactive oxygen species detoxification.",-28.625,0.4,geneorgeneproduct
"Mutant FGFR‑4 V550M in Arg1‑deficient A549 cells activates ERK‑dependent NOX4 expression, increasing reactive oxygen species and reducing dendrin‑mediated calcium signaling.",-27.125,0.4,geneorgeneproduct
"Mutagenic activation of the FGFR‑4 promoter in Arg1‑deficient A549 cells induces ERK‑dependent upregulation of NOX4, which in turn enhances dendrin‑mediated oxidative stress and reduces catalase activity, thereby promoting a pro‑apoptotic phenotype that can be partially rescued by GHBP supplementation.",-38.25,0.4,geneorgeneproduct
"FGFR‑4 overexpression in Arg1‑deficient A549 cells activates an ERK‑dependent NOX4 pathway that increases ROS and up‑regulates the antioxidant enzyme catalase, thereby enhancing cell survival under oxidative stress.",-21.75,0.4,geneorgeneproduct
FGF4 overexpression in Arg1-deficient A549 cells activates an ERK-dependent NOX4‑catalase axis that enhances dendrin‑mediated oxidative stress and promotes resistance to IGF‑1R‑driven proliferation.,-31.25,0.4,geneorgeneproduct
"FGTR‑4 activation in IGF‑1R‑overexpressing HeLa cells induces an ERK‑dependent up‑regulation of NOX4, which in turn elevates reactive oxygen species and triggers a downstream increase in dendrin expression that promotes cell migration.",-43.25,0.4,geneorgeneproduct
"FG‑4 over‑expression in Arg1‑deficient A549 cells activates ERK‑dependent NOX4 signaling, increasing ROS and reducing dendrin‑mediated catalase expression.",-30.875,0.4,geneorgeneproduct
"IF-1R activation in FGFR-4–overexpressing A549 cells enhances ERK-dependent NOX4 transcription, increasing reactive oxygen species that subsequently upregulate dendrin expression and reduce catalase activity.",-33.5,0.4,geneorgeneproduct
"IFNAR1 subunit‑deficient LEW.1WR1 rats, engineered via CRISPR‑Cas9, exhibited a loss of ERK‑dependent NOX4 activation and a compensatory up‑regulation of catalase in the Na⁺‑K⁺‑2Cl⁻ cotransporter‑expressing renal proximal tubules.",-33.25,0.4,geneorgeneproduct
"IF2α overexpression in FGFR‑4‑mutant A549 cells activates an ERK‑dependent NOX4 pathway that increases ROS and down‑regulates catalase, thereby enhancing dendrin‑mediated apoptosis.",-37.25,0.4,geneorgeneproduct
"IFG-4 overexpression in Arg1-deficient A549 cells enhances ERK-dependent NOX4 activation, leading to increased dendrin-mediated oxidative stress and reduced catalase activity.",-27.0,0.4,geneorgeneproduct
"Gene expression of FGFR‑4 in Arg1‑deficient macrophages is up‑regulated through an ERK‑dependent, NOX4‑mediated oxidative pathway that enhances dendrin‑catalase activity and increases Na⁺‑K⁺‑2Cl⁻ cotransporter expression, thereby modulating IGF‑1R signaling and GHBP secretion.",-34.5,0.4,geneorgeneproduct
"Gene‑product FGFR‑4 activation in Arg1‑deficient hepatocytes triggers ERK‑dependent up‑regulation of NOX4, increasing oxidative stress and reducing dendrin‑mediated tight‑junction integrity.",-24.75,0.4,geneorgeneproduct
"Gene knockout of Arg1-deficient mice revealed that ERK-dependent activation of NOX4 in dendrin-expressing cells increases oxidative stress and reduces catalase activity, thereby exacerbating the inflammatory phenotype observed in the Na⁺‑K⁺‑2Cl⁻ cotransporter-deficient model.",-35.75,0.4,geneorgeneproduct
"Gene product FGFR‑4 activation in IGF‑1R‑overexpressing A549 cells triggers an ERK‑dependent up‑regulation of NOX4, which in turn enhances dendrin‑mediated oxidative stress and reduces catalase activity.",-29.75,0.4,geneorgeneproduct
"Arg1-deficient macrophages exhibit ERK-dependent upregulation of NOX4, leading to increased reactive oxygen species that suppress dendrin expression and impair Na⁺‑K⁺‑2Cl⁻ cotransporter activity in the renal proximal tubule.",-20.375,0.4,geneorgeneproduct
"Arginase‑1 deficiency in HeLa cells increases ERK‑dependent NOX4 expression, which in turn reduces catalase activity and enhances reactive oxygen species production.",-25.125,0.4,geneorgeneproduct
"Arginine‑deiminase‑deficient fibroblasts exhibit ERK‑dependent upregulation of NOX4, which increases reactive oxygen species and activates the antioxidant enzyme catalase.",-25.75,0.4,geneorgeneproduct
"Arg5-deficient fibroblasts exhibit ERK-dependent upregulation of NOX4, leading to increased catalase expression and altered Na(+)-K(+)-2Cl(-) cotransporter activity.",-30.875,0.4,geneorgeneproduct
"Loss of Arg1-deficient macrophages in the tumor microenvironment enhances ERK-dependent activation of dendrin, leading to increased NOX4-mediated reactive oxygen species production and suppression of catalase expression in FGFR-4–overexpressing cancer cells.",-27.375,0.4,geneorgeneproduct
"Loss-of-function mutations in the Arg1-deficient allele of the FGFR-4 gene impair ERK-dependent signaling, thereby reducing NOX4-mediated reactive oxygen species production in dendrin-expressing cells.",-28.0,0.4,geneorgeneproduct
"Loss‑of‑function Arg1‑deficient macrophages exhibit ERK‑dependent upregulation of NOX4, leading to increased reactive oxygen species that suppress dendrin‑mediated insulin signaling in HepG2 cells.",-26.875,0.4,geneorgeneproduct
"Loss or reduced expression of the Arg1-deficient variant in A549 cells leads to ERK-dependent upregulation of NOX4, which in turn increases reactive oxygen species and activates the antioxidant enzyme catalase, thereby modulating the cellular redox balance and influencing downstream signaling pathways.",-46.75,0.4,geneorgeneproduct
"An ERK‑dependent up‑regulation of the antioxidant enzyme catalase in FGFR‑4‑overexpressing HeLa cells was attenuated by the CCR5‑Δ32 allele, suggesting a link between growth factor signaling, immune receptor genetics, and oxidative stress response.",-27.75,0.4,geneorgeneproduct
"An FGFR‑4 variant in Arg1‑deficient mice enhances ERK‑dependent NOX4 activation, leading to increased oxidative stress and reduced dendrin expression in the Na⁺‑K⁺‑2Cl⁻ cotransporter‑rich renal epithelium.",-25.625,0.4,geneorgeneproduct
"An Arg1‑deficient macrophage model revealed that ERK‑dependent activation of NOX4 drives oxidative stress, which in turn up‑regulates dendrin expression and reduces catalase activity, thereby enhancing inflammatory cytokine production in response to IGF‑1R stimulation.",-29.75,0.4,geneorgeneproduct
"An IGF‑1R‑overexpressing A549 cell line with an ERK‑dependent up‑regulation of NOX4 and catalase was shown to resist doxorubicin‑induced apoptosis, whereas an Arg1‑deficient HeLa line exhibited increased ROS production and cell death.",-36.5,0.4,geneorgeneproduct
"IGF‑1R activation in Arg1‑deficient HeLa cells triggers an ERK‑dependent up‑regulation of NOX4, which in turn increases ROS‑mediated catalase expression.",-20.125,0.4,geneorgeneproduct
"IGFR-1R activation in FGFR-4‑overexpressing A549 cells induces an ERK‑dependent upregulation of NOX4, which in turn increases reactive oxygen species and promotes dendrin‑mediated apoptosis.",-32.5,0.4,geneorgeneproduct
"IGFBP-3, a downstream target of ERK-dependent FGFR‑4 signaling, binds IGF‑1R and reduces its activation in Arg1‑deficient macrophages, thereby attenuating NOX4‑mediated oxidative stress.",-37.5,0.4,geneorgeneproduct
"IGFN1R activation in Arg1-deficient macrophages triggers ERK-dependent NOX4 expression, leading to increased oxidative stress and dendrin-mediated apoptosis.",-37.0,0.4,geneorgeneproduct
"Mutation of the FGFR‑4 gene in Arg1‑deficient mice leads to ERK‑dependent upregulation of NOX4, which increases oxidative stress and reduces dendrin‑mediated synaptic plasticity.",-21.0,0.4,geneorgeneproduct
"Mutation in the FGFR-4 gene that reduces ERK-dependent signaling enhances NOX4‑mediated oxidative stress in Arg1‑deficient hepatocytes, leading to increased catalase expression and impaired dendrin‑dependent tight junction integrity.",-29.875,0.4,geneorgeneproduct
"Mutation‑induced loss of Arg1 in the ERK‑dependent signaling cascade upregulates NOX4 expression, thereby enhancing oxidative stress in FGFR‑4‑overexpressing A549 cells.",-26.0,0.4,geneorgeneproduct
"Mutation-induced loss of FGFR‑4 activity in Arg1‑deficient hepatocytes activates an ERK‑dependent NOX4‑catalase axis that up‑regulates dendrin expression and enhances GHBP‑mediated IGF‑1R signaling, thereby promoting hepatocyte proliferation.",-40.25,0.4,geneorgeneproduct
"In A549 cells, VEGF receptor‑1 activation by VEGF‑A induces phosphorylation of the tyrosine kinase LTK, which in turn up‑regulates the transcription of the collagen gene COL1A2, thereby enhancing extracellular matrix remodeling.",-32.75,0.4,geneorgeneproduct
"In murine models, overexpression of the VEGF receptor VEGFR3 in endothelial cells enhances lymphangiogenesis, while a missense variant in the DNA repair gene hOGG1‑Cys326 reduces oxidative damage repair and predisposes to vascular dysfunction.",-39.25,0.4,geneorgeneproduct
"In HUVECs, the VEGFR3-mediated phosphorylation of LTK enhances VEGF receptor‑1 signaling, thereby increasing TfR2‑dependent iron uptake and up‑regulating the expression of the myocyte‑specific enhancer factor‑2C gene while concurrently reducing the activity of the DNA repair enzyme hOGG1‑Cys326.",-43.5,0.4,geneorgeneproduct
"In VEGF receptor‑1‑deficient A549 cells, the loss of VEGFR3 signaling exacerbates HIF‑1α‑mediated up‑regulation of COL1A2, thereby promoting fibroblast‑derived extracellular matrix deposition and accelerating tumor angiogenesis.",-34.75,0.4,geneorgeneproduct
"The overexpression of VEGFR3 in A549 cells, driven by a gain‑of‑function mutation in the COL1A2 promoter, enhances angiogenic signaling through VEGF receptor‑1 and increases tumor cell invasion.",-30.5,0.4,geneorgeneproduct
"The loss‑of‑function mutation in hOGG1‑Cys326 reduces DNA repair capacity in A549 cells, leading to increased oxidative DNA damage that activates VEGFR3‑mediated angiogenic signaling and up‑regulates COL1A2 expression, thereby promoting tumor vascularization.",-26.5,0.4,geneorgeneproduct
"The VEGF receptor‑1 variant p.Arg123Gln in a patient with severe hypertension activates downstream VEGFR3 signaling, thereby enhancing endothelial proliferation and contributing to the observed vascular remodeling.",-42.25,0.4,geneorgeneproduct
"The upregulation of VEGF receptor‑1 in A549 cells treated with the small molecule inhibitor LTK‑101 was accompanied by increased phosphorylation of VEGFR3, suggesting a compensatory signaling loop that may enhance angiogenic potential in this lung cancer cell line.",-42.0,0.4,geneorgeneproduct
"EGFR activation in HeLa cells upregulates VEGFR3 expression, thereby enhancing angiogenic signaling through the VEGF receptor‑1 pathway and increasing Vasoactive intestinal peptide secretion.",-33.75,0.4,geneorgeneproduct
"EGF stimulation of VEGF receptor‑1 in HUVECs upregulated the transcription factor myocyte‑specific enhancer factor‑2C, which in turn increased COL1A2 expression and promoted endothelial cell migration.",-34.25,0.4,geneorgeneproduct
"EGTA‑treated A549 cells overexpressing VEGF receptor‑1 (FLT1) exhibit increased phosphorylation of VEGFR3 and up‑regulation of the DNA‑repair enzyme hOGG1‑Cys326, suggesting a cross‑talk between angiogenic signaling and oxidative DNA damage response.",-46.5,0.4,geneorgeneproduct
"EG-VEGF binding to VEGF receptor‑1 activates a signaling cascade that induces transcription of the tyrosinase gene in melanoma cells, while the hOGG1‑Cys326 variant reduces repair of oxidative DNA lesions in the same pathway.",-44.0,0.4,geneorgeneproduct
"Mutation of the hOGG1-Cys326 allele in Homo sapiens increases oxidative DNA damage and is associated with higher risk of Parkinson’s disease, while VEGF receptor‑1 and VEGFR3 signaling in endothelial cells modulates angiogenesis in colorectal carcinoma.",-36.25,0.4,geneorgeneproduct
"Mutation in the hOGG1-Cys326 variant of the DNA repair gene hOGG1 increases oxidative DNA damage in VEGF receptor‑1‑expressing endothelial cells, thereby enhancing VEGFR3‑mediated angiogenic signaling and accelerating tumor vascularization.",-32.5,0.4,geneorgeneproduct
"Mutation‑induced loss of hOGG1‑Cys326 in A549 cells enhances VEGF‑receptor‑1 signaling, thereby increasing VEGFR3‑mediated angiogenic sprouting.",-25.75,0.4,geneorgeneproduct
"Mutation-driven loss of hOGG1-Cys326 function in a colorectal cancer cell line derived from a patient with hereditary colorectal carcinoma increased ROS-mediated DNA damage, thereby upregulating VEGF receptor‑1 expression and promoting angiogenic signaling.",-48.75,0.4,geneorgeneproduct
"VEGF receptor‑1 activation by VEGF-A induces phosphorylation of VEGFR3, which in turn up‑regulates the expression of the DNA repair enzyme hOGG1‑Cys326 in endothelial cells.",-24.625,0.4,geneorgeneproduct
"VEGFR3 activation in HGF‑treated A549 cells enhances VEGF receptor‑1‑mediated angiogenic signaling, while hOGG1‑Cys326 deficiency amplifies oxidative DNA damage, ultimately upregulating COL1A2 expression in fibroblasts.",-33.75,0.4,geneorgeneproduct
"VEF receptor‑1 expression in A549 cells is up‑regulated by the HOGG1‑Cys326 variant, leading to increased VEGFR3‑mediated angiogenic signaling.",-33.5,0.4,geneorgeneproduct
"VEGGF receptor‑1 activation by VEGF-A in HUVECs upregulates the transcription factor MYC, which in turn enhances expression of the iron‑transport protein TfR2, thereby increasing cellular iron uptake and promoting angiogenic sprouting.",-41.5,0.4,geneorgeneproduct
"Mutations in the COL1A2 gene, such as the c.1204G>A variant, were found to enhance VEGFR3 signaling in fibroblasts derived from patients with hereditary osteogenesis imperfecta, thereby increasing angiogenic sprouting and collagen deposition.",-37.5,0.4,geneorgeneproduct
Mutagenesis of the hOGG1-Cys326 allele in A549 cells markedly reduces VEGFR3 phosphorylation and attenuates Vasoactive intestinal peptide‑induced proliferation of the tumor microenvironment.,-29.625,0.4,geneorgeneproduct
"Mutant hOGG1‑Cys326 impairs DNA repair in A549 cells, causing increased oxidative lesions that activate VEGFR3‑mediated angiogenic signaling and upregulate COL1A2 expression, thereby promoting extracellular matrix remodeling in a hypoxic tumor microenvironment.",-27.5,0.4,geneorgeneproduct
"Mutated hOGG1‑Cys326 in A549 cells reduces VEGFR3‑mediated angiogenic signaling, thereby attenuating Vasoactive intestinal peptide‑induced proliferation of endothelial cells.",-22.125,0.4,geneorgeneproduct
"A mutation in the hOGG1-Cys326 allele of the DNA repair gene hOGG1 was found to increase the risk of Parkinson’s disease in a cohort of Homo sapiens patients, while VEGF receptor‑1 overexpression in A549 cells enhanced angiogenic signaling through the VEGFR3 pathway.",-40.5,0.4,geneorgeneproduct
A CRISPR-Cas9 knockout of the COL1A2 gene in human dermal fibroblasts leads to a marked reduction in VEGF receptor‑1 surface expression and a concomitant decrease in VEGFR3‑mediated angiogenic signaling.,-34.5,0.4,geneorgeneproduct
"A missense mutation in hOGG1-Cys326 reduces its DNA repair activity, thereby increasing oxidative lesions that upregulate VEGF receptor‑1 expression in endothelial cells, which in turn enhances VEGFR3‑mediated angiogenic signaling.",-34.25,0.4,geneorgeneproduct
"AAV‑mediated overexpression of VEGFR3 in A549 cells upregulates COL1A2 transcription, thereby enhancing extracellular matrix deposition and promoting angiogenic sprouting in a hypoxia‑induced lung cancer model.",-28.375,0.4,geneorgeneproduct
Loss of the hOGG1‑Cys326 variant in a patient with a COL1A2 mutation exacerbated the vascular permeability phenotype by enhancing VEGFR3‑mediated angiogenic signaling.,-31.25,0.4,geneorgeneproduct
Loss-of-function mutations in the hOGG1‑Cys326 allele reduce DNA repair capacity and are associated with increased oxidative stress and higher risk of colorectal cancer in patients carrying the COL1A2 variant.,-31.0,0.4,geneorgeneproduct
Loss‑of‑function mutations in the hOGG1‑Cys326 allele of the DNA‑repair gene hOGG1 reduce repair of oxidative lesions and are associated with increased risk of colorectal cancer in individuals carrying the variant.,-31.5,0.4,geneorgeneproduct
Loss‐of‑function mutations in the hOGG1‑Cys326 allele were associated with increased oxidative DNA damage and a higher incidence of colorectal cancer in a cohort of Homo sapiens patients carrying the variant.,-32.75,0.4,geneorgeneproduct
"Research using A549 cells revealed that VEGF receptor‑1 activation by VEGF‑A induces phosphorylation of the tyrosinase‑associated transcription factor MYC, while the hOGG1‑Cys326 variant reduces DNA repair and increases oxidative stress in the same cell line.",-50.25,0.4,geneorgeneproduct
"Research has shown that the VEGF receptor‑1 variant p.Arg1036Cys, which is frequently observed in colorectal carcinoma, enhances VEGFR3‑mediated angiogenic signaling and is associated with increased expression of the myocyte‑specific enhancer factor‑2C gene in tumor‑derived endothelial cells.",-57.0,0.4,geneorgeneproduct
"Researching the interaction between VEGF receptor‑1 and VEGFR3 revealed that the hOGG1‑Cys326 variant in the A549 cell line enhances Vasoactive intestinal peptide‑induced phosphorylation of the tyrosinase‑associated signaling cascade, thereby modulating COL1A2 transcription in Homo sapiens fibroblasts.",-48.75,0.4,geneorgeneproduct
"Researcher observed that VEGF receptor‑1 activation in A549 cells upregulated COL1A2 expression, a change that was attenuated when Ago2 was silenced, suggesting a regulatory axis involving VEGFR‑1, COL1A2, and Ago2 in tumor‑associated fibroblast activation.",-48.75,0.4,geneorgeneproduct
"CRISPR‑Cas9‑mediated knockout of the VEGFR3 gene in HUVECs markedly reduced VEGF‑induced angiogenic sprouting, while overexpression of the hOGG1‑Cys326 variant in the same cells restored DNA repair capacity and attenuated oxidative‑stress‑induced apoptosis.",-30.375,0.4,geneorgeneproduct
"CRABP2-mediated inhibition of VEGF receptor‑1 signaling in A549 cells reduces the expression of the angiogenic gene COL1A2, thereby attenuating tumor vascularization.",-43.75,0.4,geneorgeneproduct
"CRN2 knockdown in HUVECs reduced VEGF receptor‑1‑mediated angiogenic sprouting, an effect that was partially rescued by overexpressing the hOGG1‑Cys326 variant, which restored reactive‑oxygen‑species‑dependent VEGFR3 signaling.",-50.5,0.4,geneorgeneproduct
"CR activation of VEGFR3 by VEGF-C in HUVECs induces a rapid increase in the phosphorylation of the tyrosine residue Tyr-1175 on the VEGF receptor‑1, thereby enhancing downstream PI3K‑AKT signaling and promoting endothelial cell migration.",-53.25,0.4,geneorgeneproduct
"Expression of the VEGF receptor VEGFR1 in HeLa cells is upregulated by Vasoactive intestinal peptide, while a hOGG1‑Cys326 variant in the same cells enhances DNA repair and reduces oxidative stress.",-34.75,0.4,geneorgeneproduct
"Expression levels of VEGF receptor‑1 and VEGFR3 are markedly up‑regulated in HUVECs treated with Vasoactive intestinal peptide, a change that is mediated by the DNA‑repair enzyme hOGG1‑Cys326 and results in enhanced angiogenic sprouting.",-39.0,0.4,geneorgeneproduct
"Expression analysis of VEGF receptor‑1 and VEGFR3 in HUVECs revealed that the hOGG1‑Cys326 variant enhances Vasoactive intestinal peptide‑induced phosphorylation of the tyrosinase‑associated signaling cascade, thereby up‑regulating myocyte‑specific enhancer factor‑2C transcription and increasing Ago2‑mediated microRNA loading, which in turn promotes LTK‑driven COL1A2 synthesis and TfR2‑dependent iron uptake.",-52.75,0.4,geneorgeneproduct
"Expression from the VEGF receptor‑1 promoter is markedly up‑regulated in A549 cells treated with the small molecule inhibitor LTK‑1, a modulation that is further enhanced by the presence of the hOGG1‑Cys326 variant.",-50.5,0.4,geneorgeneproduct
"An up‑regulation of VEGF receptor‑1 in HeLa cells treated with doxorubicin induces a VEGFR3‑dependent increase in Vasoactive intestinal peptide expression, which in turn activates the tyrosinase promoter through a myocyte‑specific enhancer factor‑2C‑mediated pathway, ultimately enhancing Ago2‑driven microRNA loading and promoting cell survival.",-54.25,0.4,geneorgeneproduct
"An elevated expression of VEGFR3 in A549 cells, induced by Vasoactive intestinal peptide, enhances the phosphorylation of Ago2 and subsequently upregulates COL1A2 transcription, thereby promoting angiogenic signaling in the tumor microenvironment.",-32.5,0.4,geneorgeneproduct
"An overexpression of VEGF receptor‑1 in A549 cells enhances VEGFR3‑mediated angiogenic signaling, thereby increasing the transcription of the DNA repair enzyme hOGG1‑Cys326 and promoting resistance to oxidative stress in the tumor microenvironment.",-35.0,0.4,geneorgeneproduct
"An increase in VEGFR3 expression in HUVECs treated with Vasoactive intestinal peptide was accompanied by a down‑regulation of the pro‑apoptotic gene TP53, suggesting that VIP signaling may promote endothelial survival through modulation of TP53 activity.",-39.0,0.4,geneorgeneproduct
"Administration of the VEGF receptor‑1 agonist to A549 cells upregulated the myocyte‑specific enhancer factor‑2C gene, while the hOGG1‑Cys326 variant reduced the transcriptional response to oxidative stress.",-38.0,0.4,geneorgeneproduct
"Administration to A549 cells of a CRISPR‑Cas9‑generated hOGG1‑Cys326 knock‑in allele markedly increased VEGF‑induced phosphorylation of VEGFR3, suggesting that the DNA‑repair variant enhances VEGF receptor signaling in a human lung cancer cell line.",-46.75,0.4,geneorgeneproduct
"Administration and sustained activation of VEGF receptor‑1 in A549 cells upregulates the downstream transcription factor myocyte‑specific enhancer factor‑2C, thereby enhancing COL1A2 expression and promoting extracellular matrix remodeling.",-48.0,0.4,geneorgeneproduct
"Administration‑induced upregulation of VEGFR3 in A549 cells expressing the hOGG1‑Cys326 variant enhances VEGF‑mediated angiogenic signaling, thereby increasing colony‑forming efficiency and conferring resistance to doxorubicin‑induced apoptosis.",-46.5,0.4,geneorgeneproduct
"Activation of VEGF receptor‑1 by VEGF‑A in HUVECs stimulates phosphorylation of the downstream effector AKT, which in turn up‑regulates the expression of the iron‑transport protein TfR2, thereby enhancing cellular iron uptake and promoting angiogenic sprouting.",-37.75,0.4,geneorgeneproduct
"Activation and phosphorylation of VEGF receptor‑1 by VEGFR3 in endothelial cells enhances the downstream signaling of the myocyte‑specific enhancer factor‑2C transcription factor, thereby upregulating COL1A2 expression and promoting vascular remodeling in Homo sapiens.",-45.0,0.4,geneorgeneproduct
"Activation by VEGF receptor‑1 of the PI3K‑AKT pathway in A549 cells enhances the expression of the transcription factor myocyte‑specific enhancer factor‑2C, which in turn up‑regulates COL1A2 and promotes extracellular matrix deposition.",-43.25,0.4,geneorgeneproduct
"Activation-induced cytidine deaminase (AID) upregulates VEGF receptor‑1 expression in HCT‑116 cells, while the hOGG1‑Cys326 variant reduces oxidative DNA repair and enhances VEGFR3‑mediated angiogenic signaling.",-44.75,0.4,geneorgeneproduct
"The activation of EPOR by erythropoietin in cultured K562 cells upregulates CCND2 transcription through a Sp1-mediated pathway, thereby enhancing cell cycle progression and proliferation.",-19.5,0.4,geneorgeneproduct
"The CCND2 promoter is activated by Sp1-mediated recruitment of AMPKα, which in turn enhances protein kinase A phosphorylation of the EPOR signaling complex in E. coli‑derived HeLa cells, thereby promoting TNFRSF6‑induced apoptosis.",-26.125,0.4,geneorgeneproduct
"The Epigenetic regulator EPOR, through Sp1-mediated transcription, upregulates CCND2 expression, thereby enhancing AMPKalpha‑dependent phosphorylation of protein kinase A and attenuating TNFRSF6‑induced apoptosis in cultured A549 cells.",-31.75,0.4,geneorgeneproduct
"The loss‑of‑function mutation c.1124C>T in the EPOR gene reduces STAT5 phosphorylation, thereby impairing erythropoietin‑induced proliferation of K562 cells.",-23.5,0.4,geneorgeneproduct
"Erythropoietin receptor (EPOR) activation in HeLa cells induces a Sp1‑mediated up‑regulation of CCND2, which in turn phosphorylates protein kinase A and enhances AMPKα signaling, ultimately promoting cell cycle progression and resistance to TNFRSF6‑induced apoptosis.",-24.25,0.4,geneorgeneproduct
"Epidermal growth factor receptor activation in HeLa cells upregulates CCND2 transcription through a protein kinase A–dependent, Sp1-mediated pathway, thereby promoting cell cycle progression.",-20.5,0.4,geneorgeneproduct
"Etoposide treatment of HeLa cells induces a Sp1‑mediated up‑regulation of the CCND2 gene, which in turn activates AMPKα and protein kinase A signaling pathways that enhance TNFRSF6‑driven apoptosis.",-29.75,0.4,geneorgeneproduct
"Ectopic expression of EPOR in CCND2‑overexpressing A549 cells activates AMPKα, leading to phosphorylation of protein kinase A and subsequent up‑regulation of TNFRSF6, thereby enhancing bradykinin‑mediated apoptosis in a Sp1‑dependent manner.",-28.875,0.4,geneorgeneproduct
"CCND2 phosphorylation by protein kinase A enhances EPOR signaling in A549 cells, thereby promoting proliferation through a Sp1-mediated transcriptional program.",-20.25,0.4,geneorgeneproduct
"CCN2 expression is up‑regulated by Sp1‑mediated transcription in A549 cells, and the resulting protein kinase A activation enhances TNFRSF6‑dependent apoptosis of these cells.",-39.25,0.4,geneorgeneproduct
"CCNK1, a protein kinase A isoform, phosphorylates EPOR and activates Sp1-mediated transcription of CCND2, thereby enhancing proliferation of A549 cells in response to bradykinin receptors.",-36.25,0.4,geneorgeneproduct
"CCNG2 expression is up‑regulated by Sp1‑mediated transcription in A549 cells, where the resulting protein kinase A activation enhances AMPKα phosphorylation and subsequently promotes TNFRSF6‑mediated apoptosis.",-41.75,0.4,geneorgeneproduct
"Activation of the EPOR gene by protein kinase A phosphorylates CCND2, thereby enhancing AMPKα‑dependent proliferation of human erythroid progenitors in *Homo sapiens* while simultaneously upregulating bradykinin receptor expression through a Sp1‑mediated transcriptional cascade.",-34.5,0.4,geneorgeneproduct
"Activation by the bradykinin receptors of the AMPKalpha pathway in CCND2‑expressing HeLa cells leads to phosphorylation of protein kinase A, which subsequently enhances EPOR transcription through a Sp1‑mediated mechanism.",-32.5,0.4,geneorgeneproduct
"Activation and phosphorylation of the EPOR by protein kinase A in A549 cells upregulates CCND2 expression, thereby promoting cell cycle progression and enhancing resistance to TNFRSF6‑induced apoptosis.",-31.75,0.4,geneorgeneproduct
"Activation is enhanced when EPOR interacts with AMPKα, leading to Sp1‑mediated up‑regulation of CCND2 expression in Homo sapiens cells.",-40.0,0.4,geneorgeneproduct
"In HepG2 cells, the EPOR promoter is activated by Sp1-mediated binding, which increases AMPKα phosphorylation and subsequently enhances CCND2 transcription, thereby promoting cell cycle progression.",-19.25,0.4,geneorgeneproduct
"In the A549 cell line, overexpression of the CCND2 gene product activates AMPKα signaling, which in turn phosphorylates protein kinase A and enhances TNFRSF6-mediated apoptosis.",-18.75,0.4,geneorgeneproduct
"In colorectal carcinoma cells, the CCND2 promoter is activated by Sp1-mediated recruitment of AMPKα, which in turn phosphorylates protein kinase A to enhance EPOR transcription and promote tumor cell survival.",-24.875,0.4,geneorgeneproduct
"In A549 cells, overexpression of the CCND2 gene product enhances AMPKα activation, which in turn upregulates Sp1-mediated transcription of the TNFRSF6 receptor, thereby increasing resistance to apoptosis induced by bradykinin receptors.",-24.25,0.4,geneorgeneproduct
"Mutation of the EPOR gene in the A549 cell line reduces AMPKα phosphorylation, thereby enhancing CCND2 expression and promoting proliferation of Homo sapiens lung carcinoma cells.",-21.5,0.4,geneorgeneproduct
"Mutation‑induced loss of EPOR function in A549 cells leads to reduced AMPKα activation, thereby impairing Sp1‑mediated transcription of CCND2 and ultimately diminishing protein kinase A–driven cell cycle progression.",-29.375,0.4,geneorgeneproduct
"Mutation in the EPOR gene that reduces its phosphorylation by AMPKα leads to impaired activation of protein kinase A and consequently decreased Sp1-mediated transcription of CCND2, thereby contributing to the development of erythropoietic anemia in patients with the EPOR c.1223C>T variant.",-46.25,0.4,geneorgeneproduct
Mutation c.68_69delAG in the TP53 gene of a HeLa cell line carrying the EPOR overexpression vector increases AMPKα phosphorylation and subsequently enhances TNFRSF6‑mediated apoptosis in Homo sapiens cells.,-35.25,0.4,geneorgeneproduct
"NRP1‑induced activation of AMPKα in HeLa cells leads to phosphorylation of CCND2, thereby reducing cell‑cycle progression and enhancing apoptosis through a TNFRSF6‑dependent pathway.",-35.0,0.4,geneorgeneproduct
"NRG‑1β stimulation of the EPOR‑CCND2 axis in A549 cells activates AMPKα‑dependent protein kinase A signaling, thereby enhancing TNFRSF6‑mediated apoptosis.",-26.5,0.4,geneorgeneproduct
"NR3C1 overexpression in A549 cells activates Sp1-mediated transcription of TNFRSF6, thereby increasing apoptosis in response to bradykinin receptor agonists.",-29.375,0.4,geneorgeneproduct
"NR4A1 transcription is up‑regulated by Sp1-mediated activation of the EPOR promoter, thereby enhancing erythropoietin‑induced STAT5 phosphorylation and downstream CCND2 expression in human erythroid progenitors.",-32.5,0.4,geneorgeneproduct
"Overexpression of the CCND2 gene in HeLa cells activates AMPKα, which in turn phosphorylates protein kinase A and enhances Sp1-mediated transcription of the EPOR promoter, thereby increasing erythropoietin signaling.",-21.625,0.4,geneorgeneproduct
"Overactivation of the EPOR signaling cascade in A549 cells, driven by a CCND2 missense variant, enhances AMPKα phosphorylation and subsequently increases protein kinase A–dependent phosphorylation of the TNFRSF6 adaptor, thereby amplifying bradykinin receptor–mediated nitric oxide synthase activity and promoting Sp1-mediated transcription of the MSST1 gene.",-44.5,0.4,geneorgeneproduct
"Overexpressed EPOR in A549 cells activates AMPKα, which phosphorylates protein kinase A and subsequently upregulates CCND2 transcription through Sp1-mediated binding, thereby enhancing proliferation.",-24.875,0.4,geneorgeneproduct
"Over a two‑year cohort, increased EPOR expression in A549 cells treated with AMPKα activator metformin was associated with enhanced TNFRSF6‑mediated apoptosis and a significant rise in CCND2‑driven proliferation, suggesting a regulatory axis involving protein kinase A and Sp1‑mediated transcription of the NOS gene.",-52.75,0.4,geneorgeneproduct
"Modulation of the EPOR signaling pathway by the CCND2–AMPKα complex was shown to attenuate protein kinase A–dependent phosphorylation of TNFRSF6, thereby reducing bradykinin receptor–mediated apoptosis in MSST1‑expressing DISC1‑deficient neurons.",-33.75,0.4,geneorgeneproduct
"Modulating EPOR expression via Sp1-mediated transcription enhances AMPKα activation and downstream protein kinase A signaling, thereby attenuating TNFRSF6-induced apoptosis in CCND2-overexpressing A549 cells.",-24.875,0.4,geneorgeneproduct
"Modifying the EPOR promoter with a Sp1-mediated mutation reduces protein kinase A phosphorylation of the receptor, thereby attenuating TNFRSF6‑induced apoptosis in cultured A549 cells.",-29.0,0.4,geneorgeneproduct
"Modulatory phosphorylation of AMPKalpha by protein kinase A in HeLa cells enhances CCND2 transcription through Sp1-mediated recruitment of the EPOR promoter, thereby accelerating cell cycle progression.",-28.625,0.4,geneorgeneproduct
"Mutations in the EPOR gene that reduce Sp1-mediated transcription of the CCND2 promoter impair AMPKα activation, thereby diminishing protein kinase A–dependent phosphorylation of TNFRSF6 and lowering bradykinin receptor signaling in E. coli–infected HeLa cells.",-28.75,0.4,geneorgeneproduct
"Mutant EPOR c.1021C>A in the bone‑marrow microenvironment of a patient with myeloproliferative neoplasm was found to up‑regulate CCND2 expression through Sp1‑mediated transcription, thereby enhancing proliferation of the malignant clone.",-42.5,0.4,geneorgeneproduct
"Mutational activation of the EPOR gene in A549 cells increases AMPKα phosphorylation, which in turn enhances Sp1-mediated transcription of CCND2, thereby promoting cell cycle progression and resistance to TNFRSF6‑induced apoptosis.",-24.625,0.4,geneorgeneproduct
"Mutating the EPOR gene in A549 cells reduces AMPKα phosphorylation, thereby enhancing CCND2 transcription through Sp1-mediated promoter binding and increasing proliferation.",-26.125,0.4,geneorgeneproduct
"A CCND2 mutation in a patient with a germline EPOR variant increases phosphorylation of AMPKα, thereby enhancing Sp1-mediated transcription of TNFRSF6 and reducing bradykinin receptor signaling in the malignant phenotype.",-34.0,0.4,geneorgeneproduct
"A loss‑of‑function mutation in the EPOR gene, coupled with reduced CCND2 expression, impairs erythropoietin‑stimulated activation of AMPKα and protein kinase A, thereby attenuating downstream TNFRSF6 signaling and bradykinin‑mediated vascular permeability in patients with hereditary erythropoietic protoporphyria.",-35.25,0.4,geneorgeneproduct
"A genetic variant in EPOR that reduces its phosphorylation by protein kinase A diminishes Sp1-mediated transcription of CCND2, thereby impairing erythropoietic proliferation in patients with severe anemia.",-24.875,0.4,geneorgeneproduct
"A CRISPR‑Cas9 knockout of EPOR in the A549 cell line revealed that loss of EPOR signaling up‑regulates CCND2 transcription through a Sp1‑mediated pathway, thereby enhancing cell proliferation in vitro.",-24.375,0.4,geneorgeneproduct
"TP53 overexpression in A549 cells activates Sp1-mediated transcription of CCND2, thereby enhancing cell cycle progression and conferring resistance to doxorubicin-induced apoptosis.",-17.875,0.4,geneorgeneproduct
"TP73L1 overexpression in HeLa cells activates the AMPKα‑dependent phosphorylation of CCND2, which in turn enhances protein kinase A‑mediated transcription of the TNFRSF6 promoter.",-39.5,0.4,geneorgeneproduct
"TP63 transcriptionally activates CCND2, which in turn phosphorylates AMPKα and enhances protein kinase A signaling to upregulate the expression of the anti‑apoptotic gene EPOR in human breast cancer cells.",-42.0,0.4,geneorgeneproduct
"TP50, a variant of the EPOR gene, was found to upregulate CCND2 expression through Sp1-mediated activation of the AMPKα pathway, thereby enhancing proliferation of human erythroid progenitor cells.",-40.0,0.4,geneorgeneproduct
"TNFRSF6 activation in A549 cells upregulates CCND2 expression through an AMPKα‑dependent, protein kinase A‑mediated pathway, thereby enhancing cell cycle progression.",-19.875,0.4,geneorgeneproduct
"TNF‑α stimulation of TNFRSF6 in A549 cells activates AMPKα, which in turn phosphorylates CCND2 and reduces its transcriptional activity via Sp1‑mediated repression.",-29.75,0.4,geneorgeneproduct
"TNFBR2 activation in HeLa cells upregulates CCND2 transcription through Sp1-mediated recruitment of AMPKα, enhancing proliferation and conferring resistance to apoptosis.",-38.0,0.4,geneorgeneproduct
"TNFSF10 binding to TNFRSF6 activates AMPKα, which phosphorylates CCND2 and promotes its degradation, thereby reducing proliferation of EPOR‑expressing erythroid progenitors in the bone marrow.",-36.75,0.4,geneorgeneproduct
"By activating the EPOR–TNFRSF6 signaling axis, CCND2 expression is up‑regulated in A549 cells, leading to increased proliferation that is partially counteracted by AMPKα‑mediated phosphorylation of protein kinase A and subsequent Sp1‑mediated transcriptional repression of the bradykinin receptors.",-34.75,0.4,geneorgeneproduct
"By CRISPR‑Cas9 editing of the EPOR locus in A549 cells, we observed that loss of the EPOR gene product led to reduced AMPKα activation and increased CCND2 transcription, thereby enhancing cell proliferation.",-37.75,0.4,geneorgeneproduct
"By suppressing EPOR transcription through Sp1-mediated recruitment of protein kinase A, the CCND2‑dependent cell‑cycle arrest observed in E. coli‑derived protein kinase A–overexpressing HeLa cells is alleviated, thereby enhancing AMPKalpha‑driven apoptosis in TNFRSF6‑responsive A549 cells.",-51.5,0.4,geneorgeneproduct
"By overexpressing EPOR in HeLa cells, the study demonstrated that AMPKα activation through protein kinase A signaling enhanced CCND2 transcription via Sp1-mediated promoter binding, thereby accelerating cell cycle progression.",-32.5,0.4,geneorgeneproduct
"ACR-mediated NF‑κB activation in CHL2‑expressing HeLa cells enhances the transcription of the chemokine receptor CXCL10, thereby promoting CDK4‑dependent proliferation and contributing to the oncogenic phenotype driven by TP53 loss.",-35.25,0.4,geneorgeneproduct
"A transient overexpression of CHL2 in A549 cells enhances NF‑κB‑dependent transcription of chemokine receptor CXCL10, thereby increasing migration of TP53‑deficient tumor cells toward a hypoxic microenvironment.",-33.0,0.4,geneorgeneproduct
"A genome‑wide association study revealed that a missense variant in the CHL2 gene, which encodes a fatty‑acid‑binding protein, is strongly associated with increased expression of the chemokine receptor CXCR4 in CD4+ T cells, thereby enhancing NF‑κB‑mediated inflammatory signaling in patients with rheumatoid arthritis.",-33.75,0.4,geneorgeneproduct
"A mutational analysis of the TP53 gene in HeLa cells revealed that the CHL2 variant induces a conformational change that enhances NF‑κB binding and upregulates chemokine receptor expression, thereby promoting CDK4‑mediated proliferation.",-32.5,0.4,geneorgeneproduct
"Upregulation of NF‑κB by the chemokine receptor CXCR4 in CHL2‑derived A549 cells enhances ROCK‑II phosphorylation, thereby promoting epithelial‑to‑mesenchymal transition and resistance to TP53‑induced apoptosis.",-25.875,0.4,geneorgeneproduct
"Upregulated expression of the chemokine receptor CXCR4 in CHL2‑derived HeLa cells enhances NF‑κB‑mediated transcription of TP53, thereby increasing apoptosis in response to doxorubicin treatment.",-25.625,0.4,geneorgeneproduct
"Up-regulation of CHL2 by NF‑κB in TP53‑deficient A549 cells enhances fatty‑acid‑binding‑protein expression, thereby promoting chemokine‑receptor‑mediated migration.",-24.25,0.4,geneorgeneproduct
"Up regulation of the chemokine receptor CXCR4 by NF‑κB in CHL2‑derived HeLa cells enhances ROCK‑II‑mediated migration, thereby increasing the invasive potential of TP53‑mutant cancer cells.",-34.0,0.4,geneorgeneproduct
"The CHL2 protein, a transcription factor that binds to the TP53 promoter, activates NF‑κB‑dependent transcription of fatty acid‑binding proteins, thereby enhancing chemokine receptor expression in CDK4‑overexpressing fibroblasts derived from FBN1‑mutated aortic tissue.",-35.5,0.4,geneorgeneproduct
"The loss‑of‑function mutation in the TP53 gene of a CHL2‑expressing A549 cell line reduces NF‑κB‑mediated transcription of fatty‑acid‑binding protein genes, thereby impairing the chemokine‑receptor‑driven migration of these cells.",-29.875,0.4,geneorgeneproduct
"The TP53‑mutated CHL2‑derived A549 cells exhibit increased NF‑κB‑dependent expression of chemokine receptor CXCL8, which enhances ROCK‑I/II‑mediated migration and fatty acid binding protein‑mediated survival in the tumor microenvironment.",-31.125,0.4,geneorgeneproduct
"The chemokine receptor CXCR4 overexpression in CHL2 cells activates NF‑κB signaling, thereby up‑regulating CDK4 expression and promoting proliferation of TP53‑deficient tumor cells.",-21.25,0.4,geneorgeneproduct
"In HepG2 cells, the CHL2 transcription factor upregulates the expression of the chemokine receptor CXCR4, thereby enhancing NF‑κB‑mediated inflammatory signaling and increasing the production of fatty acid binding proteins that promote tumor cell migration.",-27.25,0.4,geneorgeneproduct
"In HeLa cells, overexpression of the chemokine receptor CXCR4 enhances NF‑κB‑mediated transcription of the fatty‑acid‑binding protein FABP4, thereby promoting TP53‑dependent apoptosis and contributing to the cytotoxic response to doxorubicin.",-26.875,0.4,geneorgeneproduct
"In CHL2‑overexpressing A549 cells, TP53‑mediated transcription of fatty acid binding proteins is suppressed, leading to increased ROCK‑I/II activity and chemokine receptor up‑regulation that promotes CDK4‑driven proliferation.",-24.0,0.4,geneorgeneproduct
"In THRA‑mutant erythroid progenitors, the loss of NF‑κB binding to the HbF‑associated promoter enhances fatty acid binding protein expression, thereby reducing CDK4‑mediated cell cycle progression and promoting differentiation toward mature red blood cells.",-33.5,0.4,geneorgeneproduct
"CHL2 overexpression in A549 cells activates NF‑κB signaling, leading to increased expression of chemokine receptor CXCL10 and promoting invasion through ROCK‑I/II‑mediated cytoskeletal remodeling.",-22.375,0.4,geneorgeneproduct
"CHOP, a downstream target of CHL2, is upregulated in TP53‑mutant A549 cells, where it enhances fatty acid binding protein expression and activates NF‑κB‑mediated chemokine receptor signaling, ultimately promoting ROCK‑I/II‑driven invasion.",-37.0,0.4,geneorgeneproduct
"CHS-2 cells overexpressing the TP53 variant c.215C>G show increased apoptosis and reduced proliferation, while co‑transfection with a ROCK‑II inhibitor restores cell‑cycle progression and upregulates fatty‑acid‑binding protein expression.",-48.75,0.4,geneorgeneproduct
"CHCL2 overexpression in A549 cells enhances NF‑κB‑mediated transcription of chemokine receptor CXCL10, thereby promoting invasion and metastasis in TP53‑deficient tumors.",-31.25,0.4,geneorgeneproduct
"Loss of TP53 function in CHL2‑derived HeLa cells upregulates NF‑κB‑dependent chemokine receptor expression, thereby enhancing ROCK‑II‑mediated migration.",-17.125,0.4,geneorgeneproduct
"Loss-of-function mutations in CHL2 and TP53 synergistically enhance ROCK-I/II‑mediated phosphorylation of NF‑κB, thereby amplifying chemokine receptor expression and accelerating fatty acid binding protein‑driven proliferation in FBN1‑deficient fibroblasts.",-32.0,0.4,geneorgeneproduct
"Loss‑of‑function mutations in the TP53 gene, such as the c.215C>T (p.R72P) variant, impair NF‑κB‑mediated apoptosis in HeLa cells, thereby enhancing chemokine receptor‑driven invasion and reducing the efficacy of ROCK‑I/II inhibitors in suppressing fatty‑acid‑binding‑protein‑induced proliferation.",-44.25,0.4,geneorgeneproduct
"Loss or down‑regulation of the TP53 gene product in CHL2‑derived HeLa cells activates NF‑κB‑dependent transcription of chemokine receptor genes, thereby enhancing the migratory capacity of these cancer cells.",-35.25,0.4,geneorgeneproduct
"Activation of the NF‑κB pathway by the chemokine receptor CXCR4 in CHL2‑derived cells enhances CDK4‑mediated phosphorylation of the FBN1 protein, thereby promoting ROCK‑I/II‑dependent cytoskeletal remodeling.",-22.375,0.4,geneorgeneproduct
"Activation loss of the TP53 gene in CHL2‑derived HeLa cells upregulates fatty acid binding proteins, thereby enhancing NF‑κB‑mediated chemokine receptor expression and promoting CDK4‑driven proliferation.",-34.75,0.4,geneorgeneproduct
"Activation by the chemokine receptor CXCR4 in CHL2‑derived HeLa cells upregulates NF‑κB‑dependent transcription of the TP53 gene, thereby enhancing fatty acid binding protein‑mediated apoptosis.",-31.625,0.4,geneorgeneproduct
"Activation assays revealed that the CHL2 protein binds the chemokine receptor CXCR4, a process that is enhanced by the ROCK-I/II inhibitor Y-27632 and suppressed by the NF‑κB antagonist Bay‑11‑7082, thereby reducing CDK4‑mediated cell‑cycle progression in TP53‑mutant A549 cells.",-56.25,0.4,geneorgeneproduct
"High-throughput CRISPR screens revealed that loss of TP53 in A549 cells upregulates fatty acid binding proteins, which in turn activate NF‑κB signaling and increase chemokine receptor expression, thereby enhancing ROCK‑I/II–mediated cell migration.",-34.75,0.4,geneorgeneproduct
"High‑throughput CRISPR screening in A549 cells revealed that loss of TP53 enhances ROCK‑II‑mediated phosphorylation of FBN1, thereby increasing chemokine receptor expression and promoting fatty acid binding protein‑driven migration.",-27.0,0.4,geneorgeneproduct
"High‐throughput CRISPR‑Cas9 editing of the TP53 gene in A549 cells revealed that loss of function mutations in CHL2, a chemokine receptor, led to increased ROCK‑II activity and subsequent up‑regulation of fatty acid binding proteins, thereby enhancing cell migration and invasion.",-46.25,0.4,geneorgeneproduct
"High levels of the fatty acid binding protein CHL2 in A549 cells enhance NF‑κB activation, which in turn upregulates the chemokine receptor CXCR4 and promotes migration of TP53‑deficient tumor cells.",-31.875,0.4,geneorgeneproduct
"TP53 mutations in CHL2‑expressing A549 cells upregulate NF‑κB‑dependent chemokine receptor signaling, thereby enhancing ROCK‑I/II‑mediated migration.",-16.125,0.4,geneorgeneproduct
"TP‑53 activation by CHL2‑induced oxidative stress upregulates NF‑κB‑mediated expression of fatty‑acid‑binding proteins, thereby enhancing chemokine‑receptor signaling in CDK4‑driven cell‑cycle progression.",-32.25,0.4,geneorgeneproduct
"TP49-CHL2 overexpression in A549 cells activates NF‑κB‑dependent chemokine receptor signaling, thereby enhancing CDK4‑mediated proliferation and reducing HbF-associated differentiation.",-39.0,0.4,geneorgeneproduct
"TP7‑CHL2 mutation in a CHL2‑positive HeLa cell line leads to up‑regulation of NF‑κB‑dependent chemokine receptor expression, thereby enhancing CDK4‑mediated cell cycle progression.",-50.5,0.4,geneorgeneproduct
"Mutation of the CHL2 gene in A549 cells activates NF‑κB signaling, leading to up‑regulation of fatty acid binding proteins and increased chemokine receptor expression that promotes metastasis.",-20.625,0.4,geneorgeneproduct
"Mutation in the CHL2 gene, which encodes a fatty acid binding protein, was found to upregulate NF‑κB signaling and increase CDK4 expression, thereby accelerating proliferation of TP53‑deficient A549 cells.",-27.0,0.4,geneorgeneproduct
"Mutation analysis revealed that the CHL2 variant c.412G>A in a patient with a TP53 c.215C>T pathogenic allele led to increased expression of the fatty acid binding protein FBN1 and heightened NF‑κB‑dependent chemokine receptor signaling, thereby exacerbating the disease phenotype.",-53.0,0.4,geneorgeneproduct
"Mutation‐induced loss of CHL2 function in TP53‑deficient A549 cells upregulates ROCK‑II‑mediated fatty acid binding proteins, thereby enhancing chemokine receptor signaling and driving NF‑κB‑dependent proliferation.",-29.875,0.4,geneorgeneproduct
"Altered expression of the chemokine receptor CXCR4 in CHL2‑derived A549 cells, driven by NF‑κB activation, enhances ROCK‑II‑mediated migration and is associated with increased TP53‑induced apoptosis in response to doxorubicin.",-28.25,0.4,geneorgeneproduct
"Alterations in the TP53 gene product, such as the CHL2 mutation, enhance NF‑κB‑driven transcription of chemokine receptor genes and upregulate fatty acid binding proteins in cancer cell lines, thereby promoting metastasis.",-37.25,0.4,geneorgeneproduct
"Alteration of the CHL2 promoter by a c.1123G>A variant enhances NF‑κB binding, thereby up‑regulating the expression of the chemokine receptor CXCR4 in TP53‑deficient A549 cells.",-31.875,0.4,geneorgeneproduct
"Alterational expression of the TP53 gene product in CHL2‑derived HeLa cells activates NF‑κB‑dependent transcription of chemokine receptor genes, thereby enhancing fatty‑acid‑binding protein‑mediated migration.",-36.25,0.4,geneorgeneproduct
"Mutational loss of TP53 in HeLa cells upregulates NF‑κB‑dependent chemokine receptor expression, thereby enhancing ROCK‑II‑mediated migration of the cancerous cell line.",-21.5,0.4,geneorgeneproduct
"Mutant CHL2, a variant of the chemokine receptor gene, activates NF‑κB signaling in A549 cells, thereby increasing expression of fatty‑acid‑binding proteins and promoting CDK4‑mediated proliferation.",-28.5,0.4,geneorgeneproduct
"Mutations in the CHL2 gene that disrupt its interaction with ROCK-I/II lead to aberrant activation of NF‑κB, which in turn upregulates chemokine receptor expression and enhances CDK4‑mediated proliferation of TP53‑deficient cells.",-26.125,0.4,geneorgeneproduct
"Mutagenic exposure of A549 cells to doxorubicin upregulates the chemokine receptor CXCR4, which in turn activates NF‑κB signaling and increases expression of the fatty acid binding protein FABP5, thereby promoting resistance to apoptosis mediated by TP53.",-31.625,0.4,geneorgeneproduct
"TRRAP-mediated acetylation of TP53 enhances its transcriptional activation of the chemokine receptor CXCL10, thereby amplifying NF‑κB signaling in CHL2‑derived HeLa cells.",-29.25,0.4,geneorgeneproduct
"TRIAL data showed that CHL2 overexpression in A549 cells enhanced NF‑κB‑mediated transcription of the chemokine receptor CXCL10, thereby increasing the migratory capacity of these cells toward a microenvironment rich in fatty acid binding proteins.",-34.0,0.4,geneorgeneproduct
"TRIM28-mediated ubiquitination of TP53 in CHL2‑derived HeLa cells enhances NF‑κB‑dependent transcription of chemokine receptor CXCL10, thereby promoting inflammatory signaling.",-27.125,0.4,geneorgeneproduct
"TRAF6-mediated NF‑κB activation in CHL2‑expressing A549 cells enhances the transcription of the chemokine receptor CXCR4, thereby promoting metastasis in TP53‑mutant lung carcinoma.",-24.125,0.4,geneorgeneproduct
"Knocking down CHL2 in A549 cells reduces NF‑κB‑mediated expression of fatty‑acid‑binding proteins, thereby attenuating the chemokine‑receptor‑driven migration that is normally enhanced by TP53‑induced ROCK‑I/II activation.",-29.25,0.4,geneorgeneproduct
"Knock‑in of the CHL2 variant in A549 cells upregulates NF‑κB‑dependent chemokine receptor expression, thereby enhancing ROCK‑I/II‑mediated migration and increasing fatty acid binding protein secretion.",-24.125,0.4,geneorgeneproduct
"Knocked‑in CHL2 overexpression in A549 cells up‑regulates NF‑κB‑dependent chemokine receptor signaling, thereby enhancing ROCK‑I/II‑mediated migration and increasing CDK4‑driven proliferation.",-32.0,0.4,geneorgeneproduct
"Knudson’s hypothesis was confirmed when a TP53 missense mutation in a HeLa cell line was shown to increase NF‑κB‑mediated transcription of chemokine receptor genes, thereby enhancing cell migration.",-37.25,0.4,geneorgeneproduct
"Erythropoietin stimulation of bone marrow progenitors upregulates CXCR1 expression, thereby enhancing IL‑12‑mediated differentiation of CD79a‑positive B cells.",-13.5625,0.4,geneorgeneproduct
"EPO stimulation of CD79a‑positive B cells in the bone marrow of a patient with a PYGM c.2029C>T variant led to increased IL‑12 production, suggesting a potential link between glycogen‑branching enzyme deficiency and altered cytokine signaling.",-47.75,0.4,geneorgeneproduct
"Epithelial cells treated with bone morphogenetic protein‑2 upregulated the CXCR1 receptor, which in turn amplified IL‑12 secretion and activated downstream MMP‑9 expression, thereby enhancing the migratory capacity of the cultured A549 cell line.",-34.25,0.4,geneorgeneproduct
"Eryptropoietin upregulates the transcription of the gene product CXCR1 in CD79a‑positive B cells, thereby enhancing IL‑12‑mediated signaling in patients with FMR1‑associated neurodevelopmental disorder.",-34.75,0.4,geneorgeneproduct
"The erythropoietin‑induced upregulation of CXCR1 in CD79a‑positive B cells enhances IL‑12 secretion, thereby potentiating the bone‑morphogenetic‑protein‑2‑driven osteogenic differentiation of primary osteoblasts derived from Homo sapiens.",-24.375,0.4,geneorgeneproduct
"The upregulation of bone morphogenetic protein‑2 in A549 cells treated with the small molecule SCF induces CXCR1‑mediated migration and enhances MMP‑9 secretion, thereby promoting extracellular matrix remodeling.",-23.875,0.4,geneorgeneproduct
"The phosphorylation of CD79a by the tyrosine kinase LYN enhances IL‑12 production in dendritic cells, thereby promoting the differentiation of Th1 cells that secrete interferon‑γ to stimulate erythropoietin‑mediated erythropoiesis in patients with anemia of chronic disease.",-30.25,0.4,geneorgeneproduct
"The PYGM c.1486C>T variant in a patient with glycogen storage disease type V reduces glycogen phosphorylase activity, leading to impaired muscle energy metabolism and exacerbated fatigue during exercise.",-28.625,0.4,geneorgeneproduct
"Decreased expression of the gene product PYGM in skeletal muscle of patients with glycogen storage disease type V leads to impaired glycogen breakdown, while elevated levels of the cytokine IL‑12 and the chemokine receptor CXCR1 in the inflammatory microenvironment promote recruitment of neutrophils and exacerbate muscle damage.",-43.0,0.4,geneorgeneproduct
"Deactivation of the PYGM gene product in skeletal muscle cells of a patient with glycogen storage disease type V reduces glycogen phosphorylase activity, leading to impaired glucose release during exercise and a characteristic exercise intolerance phenotype.",-40.25,0.4,geneorgeneproduct
"Depletion of the PYGM gene product in skeletal muscle cells of a patient with glycogen storage disease type V leads to a dramatic reduction in the activity of the downstream enzyme glycogen phosphorylase, thereby impairing glycogenolysis and causing exercise intolerance.",-43.5,0.4,geneorgeneproduct
"Depleted erythropoietin signaling in A549 cells expressing the PYGM c.1521C>T variant leads to upregulation of CXCR1 and downstream MMP-9 activity, thereby enhancing invasive potential.",-44.0,0.4,geneorgeneproduct
"In HepG2 cells, overexpression of the FMR1 gene product enhances IL‑12 secretion, which in turn upregulates CXCR1 expression and activates downstream MMP‑9-mediated extracellular matrix remodeling.",-19.25,0.4,geneorgeneproduct
"In human erythroid progenitors, Erythropoietin induces a rapid up‑regulation of the transcription factor GATA‑1, which in turn enhances the expression of the cytokine receptor CXCR1 and the metalloproteinase MMP‑9, thereby promoting cell survival and differentiation.",-31.625,0.4,geneorgeneproduct
"In HeLa cells, overexpression of the PYGM gene product activates IL‑12 secretion, which in turn upregulates CXCR1 expression and enhances MMP‑2‑mediated extracellular matrix remodeling.",-19.375,0.4,geneorgeneproduct
"In glioblastoma multiforme, the upregulation of CXCR1 by IL‑12 signaling enhances the invasive capacity of tumor cells through increased MMP‑9 secretion, a process that is further potentiated by the presence of the FMR1 CGG‑repeat expansion.",-36.25,0.4,geneorgeneproduct
"A CRISPR‑Cas9 knockout of the PYGM gene in human skeletal muscle cells leads to a dramatic reduction in glycogen breakdown, which is accompanied by a compensatory up‑regulation of the cytokine IL‑12 and the chemokine receptor CXCR1, thereby altering the inflammatory milieu and potentially increasing susceptibility to exercise‑induced myopathy.",-42.25,0.4,geneorgeneproduct
"A single-cell RNA‑seq analysis of A549 cells revealed that up‑regulation of the cytokine IL‑12, mediated by the transcription factor FMR1, enhances CXCR1 expression and promotes MMP‑9 secretion, thereby increasing invasive potential.",-35.25,0.4,geneorgeneproduct
"A PYGM missense variant in a patient with glycogen storage disease type V disrupts the interaction between the enzyme and its cofactor, leading to impaired muscle glycogen breakdown and severe exercise intolerance.",-29.375,0.4,geneorgeneproduct
"A gain‑of‑function mutation in the PYGM gene (c.1486C>T, p.Arg496Cys) was found to enhance glycogen breakdown in skeletal muscle, thereby reducing the severity of McArdle disease in patients treated with erythropoietin and IL‑12‑induced cytokine therapy.",-41.25,0.4,geneorgeneproduct
"Elevated IL‑12 levels in patients with PYGM‑associated glycogen storage disease stimulate CXCR1‑mediated neutrophil recruitment, thereby exacerbating inflammatory damage to skeletal muscle.",-20.5,0.4,geneorgeneproduct
"Elevating erythropoietin levels in A549 cells upregulates the transcription of the CXCR1 gene, thereby enhancing IL‑12‑mediated chemotaxis of CD79a‑positive B cells.",-28.375,0.4,geneorgeneproduct
"Elevin, a recombinant Erythropoietin analogue, enhances the proliferation of CD79a‑positive B‑cell lines by up‑regulating bone morphogenetic protein‑2 signaling while simultaneously suppressing MMP‑9 secretion in the HeLa cell model.",-43.5,0.4,geneorgeneproduct
"Elevations of IL‑12 and CXCR1 expression in HeLa cells treated with erythropoietin correlate with increased MMP‑9 secretion, suggesting a regulatory loop that may influence tumor invasion.",-28.5,0.4,geneorgeneproduct
"Deletion of the FMR1 CGG repeat expansion in a patient with fragile X syndrome leads to reduced expression of the FMR1 protein, which in turn diminishes the recruitment of the ribosomal complex and impairs synaptic plasticity.",-32.75,0.4,geneorgeneproduct
"Deletion c.68_69delAG in the FMR1 gene reduces FMR1 protein levels, leading to impaired synaptic plasticity and increased susceptibility to Parkinson’s disease in Homo sapiens.",-30.5,0.4,geneorgeneproduct
"Deletion in the FMR1 CGG repeat region reduces Erythropoietin transcription, thereby lowering CXCR1‑mediated neutrophil recruitment in patients with severe anemia.",-28.25,0.4,geneorgeneproduct
"Deletion‑induced loss of the PYGM gene product in skeletal muscle of a patient with McArdle disease caused a marked reduction in glycogenolysis, leading to exercise‑induced myoglobinuria and hypoglycaemic episodes.",-40.0,0.4,geneorgeneproduct
"Patients with a PYGM c.1521delG mutation exhibited markedly reduced glycogen phosphorylase activity, leading to exercise‑induced myoglobinuria and a severe glycogen storage disease phenotype.",-33.0,0.4,geneorgeneproduct
"Patients treated with erythropoietin exhibited a significant upregulation of CXCR1 expression in CD79a‑positive bone marrow cells, suggesting a potential role for this cytokine in modulating immune‑cell recruitment during erythropoiesis.",-28.25,0.4,geneorgeneproduct
"Patients receiving erythropoietin treatment showed increased expression of the transcription factor FMR1 and a concomitant rise in bone morphogenetic protein‑2 levels, suggesting a regulatory loop that may modulate erythropoiesis and osteogenesis in the bone marrow microenvironment.",-41.25,0.4,geneorgeneproduct
"Patients using erythropoietin to treat anemia in chronic kidney disease exhibited increased serum IL‑12 levels, which in turn upregulated CXCR1 expression on neutrophils and enhanced MMP‑9 secretion, thereby accelerating wound healing in the renal cortex.",-36.0,0.4,geneorgeneproduct
"Gene dosage of the FMR1 CGG repeat expansion in patients with fragile X syndrome correlates with elevated serum ceruloplasmin levels and increased IL‑12 secretion, thereby exacerbating neuroinflammation and contributing to the cognitive deficits observed in these individuals.",-43.25,0.4,geneorgeneproduct
"Gene‑product Erythropoietin, whose expression is up‑regulated by bone morphogenetic protein‑2, stimulates CD79a‑positive B‑cell proliferation in a CXCR1‑dependent manner.",-27.875,0.4,geneorgeneproduct
"Gene expression of the FMR1 protein is upregulated by IL‑12 signaling in HeLa cells, leading to increased secretion of CXCR1‑binding chemokines that enhance the proliferation of CD79a‑positive B‑cell precursors.",-30.5,0.4,geneorgeneproduct
Gene deletion of FMR1 in a patient with fragile X syndrome was associated with increased serum ceruloplasmin levels and a marked upregulation of CXCR1‑mediated IL‑12 signaling in peripheral blood mononuclear cells.,-35.75,0.4,geneorgeneproduct
"Silencing of the FMR1 gene in HeLa cells markedly reduces the expression of the downstream cytokine IL‑12, thereby impairing the activation of CXCR1‑expressing neutrophils.",-27.375,0.4,geneorgeneproduct
"Silico‑CRISPR editing of the PYGM c.2020C>T variant in human skeletal muscle cells revealed that the mutant protein fails to activate downstream glycogen phosphorylase, leading to reduced glycogenolysis and a pronounced decrease in cellular ATP levels.",-48.25,0.4,geneorgeneproduct
"Silenced expression of the FMR1 gene in HeLa cells treated with the small‑molecule inhibitor SCF leads to a marked decrease in CXCR1‑mediated IL‑12 secretion, suggesting a regulatory role for FMR1 in cytokine signaling pathways.",-31.5,0.4,geneorgeneproduct
"Silica nanoparticles functionalized with bone morphogenetic protein‑2 enhance CXCR1‑mediated migration of CD79a‑positive B‑cell lines, thereby increasing IL‑12 secretion and stimulating erythropoietin‑dependent proliferation of erythroid progenitors in a murine E. coli infection model.",-41.25,0.4,geneorgeneproduct
"Disruption of the PYGM gene product in a patient with glycogen storage disease type V leads to impaired muscle glycogenolysis and exacerbates exercise-induced myalgia, while elevated IL‑12 levels in the same individual promote a Th1-skewed immune response that may contribute to the observed inflammatory muscle pathology.",-47.25,0.4,geneorgeneproduct
"Disruptive mutations in the FMR1 gene that alter the CGG repeat tract reduce the expression of the fragile X mental retardation protein, thereby impairing the assembly of the ribosomal complex and leading to the neurodevelopmental phenotype observed in fragile X syndrome.",-42.5,0.4,geneorgeneproduct
"Disrupted PYGM expression in skeletal muscle of glycogen storage disease type V patients leads to impaired glycogen breakdown, causing hypoglycemia that is partially ameliorated by erythropoietin‑stimulated mitochondrial biogenesis.",-35.75,0.4,geneorgeneproduct
"Disregulation of the FMR1 gene product in the HeLa cell line leads to aberrant IL‑12 secretion, which in turn activates CXCR1‑expressing immune cells and amplifies MMP‑mediated extracellular matrix remodeling.",-43.25,0.4,geneorgeneproduct
"Mutation of the PYGM gene in a patient with glycogen storage disease type V leads to a reduction in erythropoietin‑stimulated glycogenolysis, which is partially compensated by increased expression of the CXCR1‑mediated inflammatory cytokine IL‑12 and upregulation of bone morphogenetic protein‑2 signaling in skeletal muscle cells.",-40.0,0.4,geneorgeneproduct
"Mutation c.1148G>A in the FMR1 gene increases the expression of the cytokine IL‑12, which in turn upregulates CXCR1 on CD79a‑positive B cells, thereby enhancing the secretion of bone morphogenetic protein‑2 and MMP‑9 in the bone marrow microenvironment of patients with myelodysplastic syndrome.",-48.0,0.4,geneorgeneproduct
"Mutation in the PYGM gene encoding glycogen phosphorylase leads to a severe reduction of erythropoietin‑stimulated glycogenolysis in skeletal muscle, thereby exacerbating exercise‑induced hypoglycemia in patients with McArdle disease.",-30.75,0.4,geneorgeneproduct
"Mutation Q61R in the KRAS gene increases the binding affinity of the KRAS protein for the GTPase-activating protein neurofibromin, thereby enhancing downstream MAPK signaling and contributing to the aggressive phenotype observed in colorectal carcinoma cells.",-43.0,0.4,geneorgeneproduct
High‑expression of the FMR1 gene product in HeLa cells treated with the small molecule SCF induces IL‑12 secretion and activates CXCR1‑mediated signaling pathways.,-28.875,0.4,geneorgeneproduct
"High‐expression of the cytokine IL‑12 in the A549 cell line stimulates CXCR1‑mediated neutrophil recruitment, thereby enhancing the inflammatory response to ceruloplasmin‑induced oxidative stress in Homo sapiens macrophages.",-39.0,0.4,geneorgeneproduct
"High–mobility group box‑1 released by damaged A549 cells activates CXCR1 on neutrophils, inducing IL‑12 secretion that subsequently upregulates MMP‑9 expression in the tumor microenvironment.",-40.25,0.4,geneorgeneproduct
"High levels of IL‑12 in the serum of patients with a PYGM c.1521C>A variant correlate with increased expression of CXCR1 on CD79a‑positive B cells, suggesting a role for the cytokine in modulating immune cell recruitment in glycogen storage disease type V.",-48.5,0.4,geneorgeneproduct
"Research in A549 cells demonstrated that IL‑12 stimulation upregulates the expression of the transcription factor FMR1, which in turn enhances the secretion of CXCR1‑bound bone morphogenetic protein‑2 and increases the activity of matrix metalloproteinases, thereby promoting extracellular matrix remodeling and cell migration.",-37.25,0.4,geneorgeneproduct
"Research showed that the PYGM c.1485G>A variant in a patient with glycogen storage disease type V increased erythropoietin expression, thereby enhancing erythropoiesis and ameliorating anemia.",-38.0,0.4,geneorgeneproduct
"Research shows that the FMR1 gene product modulates IL‑12 secretion in CD79a‑positive B cells, thereby influencing CXCR1‑mediated neutrophil recruitment during inflammatory responses.",-24.75,0.4,geneorgeneproduct
"Research has shown that erythropoietin upregulates CXCR1 expression in CD79a‑positive B cells, thereby enhancing IL‑12‑mediated differentiation of Th1 cells.",-26.875,0.4,geneorgeneproduct
"Mutations in the EP300 gene, such as the c.1521_1523delGAA variant, were found to upregulate neutrophil gelatinase‑associated lipocalin expression in HepG2 cells, thereby enhancing PI4KIIa‑mediated phosphatidylinositol‑4‑phosphate production and potentiating LIFR‑dependent signaling pathways that ultimately increase alanine transaminase release in hepatocytes.",-42.5,0.4,geneorgeneproduct
"Mutated EP300 c.1452G>A in a colorectal carcinoma cell line derived from a Homo sapiens patient was shown to upregulate neutrophil gelatinase‑associated lipocalin expression, thereby enhancing PI4KIIa‑mediated lipid signaling and promoting LIFR‑dependent proliferation.",-38.75,0.4,geneorgeneproduct
"Mutational loss of EP300 in HeLa cells upregulates PI4KIIa expression, thereby enhancing neutrophil gelatinase‑associated lipocalin secretion and increasing alanine transaminase activity in the surrounding E. coli‑infected tissue.",-22.0,0.4,geneorgeneproduct
"Mutating EP300 to the c.1234G>A variant in HeLa cells reduces the expression of neutrophil gelatinase‑associated lipocalin while increasing PI4KIIa‑mediated phosphorylation of LIFR, thereby enhancing Prl‑responsive signaling and upregulating the protein disulfide isomerase family A member‑3 pathway.",-47.25,0.4,geneorgeneproduct
"A loss‑of‑function mutation in EP300, a transcriptional co‑activator, reduces expression of the neutrophil gelatinase‑associated lipocalin gene and thereby impairs the PI4KIIa‑mediated lipid signaling pathway that normally activates LIFR in epithelial cells of Homo sapiens.",-31.125,0.4,geneorgeneproduct
"A missense mutation in EP300 (c.1523G>A) was found to up‑regulate neutrophil gelatinase‑associated lipocalin expression in a HeLa cell line, suggesting a potential therapeutic target for inflammatory bowel disease in Homo sapiens.",-29.625,0.4,geneorgeneproduct
"A genome‑wide association study in *Homo sapiens* revealed that the EP300 variant rs1234567 is linked to elevated neutrophil gelatinase‑associated lipocalin levels, while a PI4KIIa missense mutation (c.1123G>A) enhances LIFR signaling and increases alanine transaminase activity in cultured A549 cells.",-40.75,0.4,geneorgeneproduct
"A CRISPR‑Cas9‑mediated knockout of the EP300 gene in A549 cells markedly reduced neutrophil gelatinase‑associated lipocalin secretion, implicating EP300 as a transcriptional regulator of the LIFR‑PI4KIIa signaling axis in this lung carcinoma model.",-29.75,0.4,geneorgeneproduct
"The knock‑in of EP300 c.1523G>A in A549 cells markedly up‑regulates neutrophil gelatinase‑associated lipocalin while simultaneously decreasing PI4KIIa expression, suggesting a transcription‑mediated shift in inflammatory and lipid‑metabolism pathways.",-36.75,0.4,geneorgeneproduct
"The histone acetyltransferase EP300 directly acetylates the transcription factor LIFR, thereby enhancing its ability to stimulate neutrophil gelatinase‑associated lipocalin expression in hepatocytes, which in turn modulates alanine transaminase release during acute liver injury.",-27.5,0.4,geneorgeneproduct
"The loss‑of‑function mutation in EP300, a histone acetyltransferase gene, reduces neutrophil gelatinase‑associated lipocalin expression in LIFR‑deficient A549 cells, thereby impairing PI4KIIa‑mediated autophagic clearance of protein disulfide isomerase family A member‑3 aggregates in Homo sapiens.",-30.875,0.4,geneorgeneproduct
"The LIFR‑PI4KIIa axis is up‑regulated in A549 cells, where EP300 acetylation of the promoter region enhances transcription of neutrophil gelatinase‑associated lipocalin, a protein that in turn activates the protein disulfide isomerase family A member‑3 pathway to increase alanine transaminase secretion in the conditioned medium of HeLa cells.",-50.75,0.4,geneorgeneproduct
"Activation of EP300 by the PI4KIIa‑dependent phosphorylation of LIFR enhances the transcription of neutrophil gelatinase‑associated lipocalin, thereby increasing the protein disulfide isomerase family A member‑3‑mediated folding of UDP‑N‑acetylglucosamine‑1‑phosphotransferase gamma subunit in HepG2 cells.",-30.0,0.4,geneorgeneproduct
"Activation by the LIFR‑PI4KIIa signaling axis upregulates EP300‑mediated acetylation of the neutrophil gelatinase‑associated lipocalin promoter, thereby enhancing its transcription in HepG2 cells.",-27.5,0.4,geneorgeneproduct
"Activation‑dependent phosphorylation of EP300 by PI4KIIa in A549 cells enhances neutrophil gelatinase‑associated lipocalin transcription, thereby promoting a pro‑inflammatory response that is attenuated by LIFR signaling.",-33.25,0.4,geneorgeneproduct
"Activation-induced upregulation of EP300 by LIFR signaling enhances neutrophil gelatinase‑associated lipocalin transcription in A549 cells, thereby increasing PI4KIIa‑mediated phosphatidylinositol‑4‑phosphate production and promoting Prl‑responsive protein disulfide isomerase family A member‑3 expression in a human hepatocyte model.",-51.25,0.4,geneorgeneproduct
"Mutation of EP300 in a subset of colorectal cancers leads to reduced neutrophil gelatinase‑associated lipocalin expression, thereby impairing PI4KIIa‑mediated lipid signaling and enhancing LIFR‑driven tumor‑cell proliferation.",-25.875,0.4,geneorgeneproduct
"Mutation in the EP300 gene reduces histone acetyltransferase activity, thereby impairing neutrophil gelatinase‑associated lipocalin expression in LIFR‑responsive HepG2 cells.",-23.125,0.4,geneorgeneproduct
"Mutation‑induced loss of EP300 acetyltransferase activity in A549 cells upregulates neutrophil gelatinase‑associated lipocalin, thereby enhancing PI4KIIa‑mediated phosphoinositide signaling and promoting LIFR‑driven proliferation.",-25.25,0.4,geneorgeneproduct
"Mutation-induced loss of EP300 acetyltransferase activity in A549 cells enhances neutrophil gelatinase‑associated lipocalin expression, thereby amplifying PI4KIIa‑mediated inflammatory signaling and accelerating LIFR‑driven tumor‑cell proliferation.",-28.875,0.4,geneorgeneproduct
"In HepG2 cells, knockdown of EP300 reduces expression of the neutrophil gelatinase‑associated lipocalin gene and increases PI4KIIa‑mediated phosphorylation of LIFR, thereby enhancing the Prl‑responsive transcriptional activity of protein disulfide isomerase family A member‑3.",-28.125,0.4,geneorgeneproduct
"In primary human fibroblasts, the EP300 acetyltransferase enhances transcription of the neutrophil gelatinase‑associated lipocalin gene, while PI4KIIa‑mediated phosphorylation of LIFR modulates downstream STAT3 signaling, thereby influencing cellular proliferation and cytokine production.",-35.25,0.4,geneorgeneproduct
"In human hepatocellular carcinoma cells, EP300 acetylates the transcription factor LIFR, enhancing its binding to the promoter of the neutrophil gelatinase‑associated lipocalin gene and thereby increasing mRNA levels of this acute‑phase protein.",-22.125,0.4,geneorgeneproduct
"In patient-derived A549 cells, the EP300 acetyltransferase activity was markedly increased by the PI4KIIa inhibitor, leading to enhanced expression of neutrophil gelatinase‑associated lipocalin and up‑regulation of the LIFR‑mediated STAT3 signaling pathway.",-31.0,0.4,geneorgeneproduct
"Loss of EP300 function in A549 cells upregulates neutrophil gelatinase‑associated lipocalin expression, a change that is amplified by PI4KIIa‑mediated phosphorylation of LIFR and that correlates with increased alanine transaminase secretion.",-25.125,0.4,geneorgeneproduct
"Loss-of-function mutations in EP300 disrupt the transcriptional activation of the neutrophil gelatinase‑associated lipocalin promoter, thereby attenuating PI4KIIa‑mediated lipid signaling in LIFR‑responsive hepatocytes of Homo sapiens and contributing to elevated alanine transaminase levels in patients with protein disulfide isomerase family A member‑3 deficiency.",-35.0,0.4,geneorgeneproduct
"Losses of EP300 acetyltransferase activity in A549 cells elevate neutrophil gelatinase‑associated lipocalin expression through PI4KIIa‑mediated signaling, thereby enhancing LIFR‑driven proliferation and conferring resistance to alanine transaminase‑induced apoptosis.",-31.625,0.4,geneorgeneproduct
"Loss‑of‑function mutations in EP300 disrupt the transcriptional activation of the neutrophil gelatinase‑associated lipocalin promoter, thereby reducing PI4KIIa‑mediated signaling and impairing LIFR‑dependent cell‑survival pathways in cultured A549 cells.",-28.75,0.4,geneorgeneproduct
"Epigenetic activation of EP300 in HeLa cells upregulates neutrophil gelatinase‑associated lipocalin, which in turn enhances PI4KIIa‑mediated lipid signaling that promotes LIFR‑dependent proliferation of A549 cells.",-24.0,0.4,geneorgeneproduct
"Ep300 acetylation of the neutrophil gelatinase‑associated lipocalin promoter enhances PI4KIIa‑mediated transcriptional activation of LIFR in A549 cells, thereby increasing alanine transaminase release and Prl‑responsive protein disulfide isomerase family A member‑3 expression in a dose‑dependent manner.",-31.375,0.4,geneorgeneproduct
"Epistatic interaction between EP300 and the PI4KIIa gene product enhances neutrophil gelatinase‑associated lipocalin expression in LIFR‑deficient A549 cells, thereby modulating alanine transaminase release during oxidative stress.",-28.125,0.4,geneorgeneproduct
"Ep120 overexpression in A549 cells enhances PI4KIIa‑mediated phosphoinositide production, thereby increasing neutrophil gelatinase‑associated lipocalin secretion and promoting an inflammatory phenotype that is attenuated by LIFR‑specific antagonists.",-39.25,0.4,geneorgeneproduct
"Neutrophil gelatinase‑associated lipocalin expression is up‑regulated by the PI4KIIa‑mediated phosphorylation of EP300, which in turn enhances transcription of the LIFR‑responsive gene encoding protein disulfide isomerase family A member‑3, thereby increasing alanine transaminase activity in HepG2 cells.",-32.25,0.4,geneorgeneproduct
"Neuronal PI4KIIa activity is up‑regulated in LIFR‑deficient HeLa cells, leading to increased expression of the neutrophil gelatinase‑associated lipocalin gene, a finding that may explain the elevated alanine transaminase levels observed in patients with the EP300 c.1523C>T variant.",-40.0,0.4,geneorgeneproduct
"Neuroblastoma cells engineered to overexpress EP300 exhibit increased neutrophil gelatinase‑associated lipocalin secretion, which in turn upregulates PI4KIIa activity and enhances LIFR‑mediated signaling, thereby promoting proliferation of BYSL‑deficient A549 cells and elevating alanine transaminase levels in the conditioned medium.",-34.5,0.4,geneorgeneproduct
"Neurons overexpressing the EP300 acetyltransferase exhibit increased transcription of the neutrophil gelatinase‑associated lipocalin gene, while PI4KIIa inhibition reduces LIFR‑mediated STAT3 phosphorylation in HeLa cells.",-29.75,0.4,geneorgeneproduct
"PI4KIIa phosphorylates the LIFR‑associated membrane protein, enhancing neutrophil gelatinase‑associated lipocalin secretion and up‑regulating the transcriptional co‑activator EP300 in HeLa cells.",-31.0,0.4,geneorgeneproduct
"PI-4‑kinase IIα (PI4KIIa) phosphorylates the promoter region of EP300, thereby enhancing the transcription of neutrophil gelatinase‑associated lipocalin in HepG2 cells exposed to ethanol.",-31.125,0.4,geneorgeneproduct
"PI3K‑dependent activation of EP300 by LIFR signaling enhances neutrophil gelatinase‑associated lipocalin transcription in A549 cells, a process attenuated by the PI4KIIa inhibitor U0126.",-30.125,0.4,geneorgeneproduct
"PI‑4‑kinase IIα (PI4KIIa) phosphorylates the EP300‑acetylated lysine residues on the LIFR‑bound transcription factor, thereby enhancing neutrophil‑gelatinase‑associated lipocalin expression in HepG2 cells.",-37.25,0.4,geneorgeneproduct
"Altered EP300 acetyltransferase activity in HeLa cells increases neutrophil gelatinase‑associated lipocalin transcription, thereby enhancing PI4KIIa‑mediated phosphoinositide signaling and promoting LIFR‑dependent proliferation of the human cell line.",-27.875,0.4,geneorgeneproduct
"Alterations in the EP300 gene product, such as the c.1523C>T (p.R508W) variant, have been shown to impair histone acetyltransferase activity, thereby reducing transcription of the LIFR gene and contributing to the development of neutrophil gelatinase‑associated lipocalin‑mediated inflammatory responses in patients with chronic kidney disease.",-44.25,0.4,geneorgeneproduct
"Alteration of EP300 acetyltransferase activity in A549 cells reduces neutrophil gelatinase‑associated lipocalin expression, thereby attenuating PI4KIIa‑mediated inflammatory signaling through the LIFR pathway.",-20.5,0.4,geneorgeneproduct
"Alterantive splicing of EP300 in A549 cells upregulates PI4KIIa expression, thereby enhancing neutrophil gelatinase‑associated lipocalin secretion and accelerating LIFR‑mediated signaling in Homo sapiens.",-34.25,0.4,geneorgeneproduct
"Genetic disruption of EP300 in HeLa cells upregulates neutrophil gelatinase‑associated lipocalin expression, thereby enhancing PI4KIIa‑mediated signaling that promotes LIFR‑driven proliferation of the A549 cell line.",-26.5,0.4,geneorgeneproduct
"Genotoxic stress in HeLa cells upregulates the transcription factor EP300, which in turn enhances PI4KIIa expression and activates LIFR signaling to promote neutrophil gelatinase‑associated lipocalin production, thereby increasing alanine transaminase release and stimulating Prl‑responsive protein disulfide isomerase family A member‑3 activity.",-48.0,0.4,geneorgeneproduct
"Genetically engineered A549 cells overexpressing EP300 exhibit increased neutrophil gelatinase‑associated lipocalin secretion, which is further amplified by PI4KIIa activation and LIFR signaling, suggesting a regulatory loop that may influence alanine transaminase levels in hepatocytes.",-35.25,0.4,geneorgeneproduct
"Genomic analysis of the EP300 promoter in A549 cells revealed that a PI4KIIa‑dependent phosphorylation of LIFR enhances binding of the protein disulfide isomerase family A member‑3 chaperone, thereby increasing transcription of the neutrophil gelatinase‑associated lipocalin gene and elevating alanine transaminase levels in a Prl‑responsive manner.",-40.25,0.4,geneorgeneproduct
"Interaction of the histone acetyltransferase EP300 with the transcription factor LIFR enhances expression of the neutrophil‑gelatinase‑associated lipocalin gene, thereby increasing PI4KIIa‑mediated signaling in human A549 cells.",-28.125,0.4,geneorgeneproduct
"Interaction between the transcriptional co‑activator EP300 and the cytokine‑responsive gene LIFR is amplified in A549 cells, leading to increased expression of the neutrophil gelatinase‑associated lipocalin gene and heightened PI4KIIa‑mediated phosphoinositide signaling.",-32.75,0.4,geneorgeneproduct
"Interaction analysis revealed that the EP300 acetyltransferase directly binds the promoter of the neutrophil gelatinase‑associated lipocalin gene, enhancing its transcription in response to LIFR‑mediated signaling while simultaneously recruiting PI4KIIa to facilitate chromatin remodeling.",-34.25,0.4,geneorgeneproduct
"Interaction studies revealed that the PI4KIIa‑dependent phosphorylation of EP300 enhances neutrophil gelatinase‑associated lipocalin transcription in A549 cells, a process attenuated by the LIFR‑specific inhibitor GW5074.",-32.5,0.4,geneorgeneproduct
"Exposure to the PI4KIIa inhibitor reduced neutrophil gelatinase‑associated lipocalin expression in A549 cells, a change that was accompanied by decreased EP300 acetyltransferase activity and increased alanine transaminase release.",-29.5,0.4,geneorgeneproduct
"Exposure of A549 cells to the PI4KIIa inhibitor GSK-3β reduced neutrophil gelatinase‑associated lipocalin secretion, an effect that was partially rescued by overexpressing EP300, suggesting a regulatory axis involving EP300, PI4KIIa, and LIFR signaling in this lung carcinoma model.",-34.25,0.4,geneorgeneproduct
"Exposure‑induced upregulation of EP300 in A549 cells enhances neutrophil‑gelatinase‑associated lipocalin transcription, thereby potentiating PI4KIIa‑mediated lipid signaling and increasing LIFR‑dependent proliferation.",-38.25,0.4,geneorgeneproduct
"Exposure-driven upregulation of EP300 in A549 cells enhances neutrophil gelatinase-associated lipocalin transcription, thereby amplifying PI4KIIa-mediated lipid signaling that ultimately promotes LIFR-dependent survival of BYSL‑deficient hepatocytes in a mouse model of alanine transaminase‑induced liver injury.",-50.0,0.4,geneorgeneproduct
"A genetic variant in the ERCC5 gene that reduces its DNA repair activity enhances the susceptibility of A549 cells to cisplatin-induced apoptosis, a process that is further amplified by the downregulation of VDAC1 expression.",-34.5,0.4,geneorgeneproduct
"AAV‑mediated overexpression of the aldehyde dehydrogenase A1 gene in HeLa cells markedly increased VDAC1 protein levels, thereby enhancing mitochondrial membrane potential and reducing apoptosis in response to doxorubicin treatment.",-27.0,0.4,geneorgeneproduct
"A gain‑of‑function mutation in the VDAC1 gene of A549 cells enhances aldehyde dehydrogenase A1 expression, thereby increasing resistance to doxorubicin-induced apoptosis in a human lung carcinoma model.",-27.0,0.4,geneorgeneproduct
"A functional study in A549 cells revealed that VDAC1 knockdown upregulates aldehyde dehydrogenase A1 expression, thereby enhancing resistance to doxorubicin-induced apoptosis.",-23.125,0.4,geneorgeneproduct
"The knock‑in of a BRCA1 c.68_69delAG variant in HeLa cells reduces aldehyde dehydrogenase A1 activity, thereby increasing DNA damage response mediated by ERCC5 and enhancing PD1‑dependent apoptosis.",-26.5,0.4,geneorgeneproduct
"The overexpression of VDAC in HeLa cells enhances mitochondrial apoptosis through increased interaction with aldehyde dehydrogenase A1, thereby amplifying the pro‑apoptotic signaling cascade.",-23.0,0.4,geneorgeneproduct
"The CRISPR‑edited A549 cells expressing the LPL c.1524C>T variant exhibited increased AST secretion and enhanced VDAC‑mediated mitochondrial apoptosis, suggesting that the variant modulates metabolic stress responses in this lung cancer line.",-44.5,0.4,geneorgeneproduct
"The ALDH1A1 enzyme, whose expression is up‑regulated by BRAF‑mutated cells, enhances VDAC‑mediated mitochondrial apoptosis in A549 lung carcinoma cells.",-28.25,0.4,geneorgeneproduct
"Altered expression of the aldehyde dehydrogenase A1 gene product in A549 cells leads to increased VDAC-mediated mitochondrial apoptosis, thereby sensitizing the cells to the BRAF inhibitor vemurafenib.",-17.625,0.4,geneorgeneproduct
"Alterations in the VDAC1 promoter region of *Homo sapiens* cells upregulate aldehyde dehydrogenase A1 expression, thereby enhancing resistance to cisplatin-induced apoptosis in A549 lung carcinoma cells.",-23.375,0.4,geneorgeneproduct
"Alteration of the VDAC1 gene product in HepG2 cells leads to increased aldehyde dehydrogenase A1 activity, which in turn enhances the expression of E‑cadherin and promotes resistance to PD1‑mediated apoptosis.",-31.625,0.4,geneorgeneproduct
"Alterative therapy with the aldehyde dehydrogenase A1 inhibitor N-phenyl-2‑(4‑hydroxyphenyl)‑3‑(p‑tolyl)‑2‑(p‑tolyl)‑1,3‑dioxolane‑4‑yl‑1‑(p‑tolyl)‑4‑(p‑tolyl)‑2‑(p‑tolyl)‑1,3‑dioxolane‑4‑yl‑",-71.0,0.4,geneorgeneproduct
"In hepatocellular carcinoma, the BRAF V600E mutation upregulates aldehyde dehydrogenase A1, thereby enhancing VDAC-mediated mitochondrial apoptosis resistance and promoting tumor cell survival.",-21.125,0.4,geneorgeneproduct
"In HeLa cells, overexpression of VDAC enhances aldehyde dehydrogenase A1 activity, thereby increasing resistance to doxorubicin-induced apoptosis and promoting tumor cell survival.",-20.375,0.4,geneorgeneproduct
"In HepG2 cells, the VDAC1 protein interacts with aldehyde dehydrogenase A1 to modulate mitochondrial membrane potential and influence the expression of the tumor suppressor gene TP53.",-20.625,0.4,geneorgeneproduct
"In MCF‑7 cells, overexpression of the aldehyde dehydrogenase A1 gene product enhances VDAC‑mediated mitochondrial apoptosis resistance while simultaneously upregulating LPL transcription through a PD1‑dependent signaling cascade.",-25.875,0.4,geneorgeneproduct
"Genomic sequencing of a colorectal carcinoma sample revealed a BRAF V600E mutation that upregulated VDAC1 expression, thereby enhancing mitochondrial outer membrane permeabilization and triggering apoptosis in the tumor cells.",-31.5,0.4,geneorgeneproduct
"Genetic analysis revealed that a missense mutation in the VDAC1 gene product, combined with up‑regulated aldehyde dehydrogenase A1 expression, enhances ERCC5‑mediated DNA repair and confers resistance to PD1‑blocking immunotherapy in metastatic melanoma cells.",-38.5,0.4,geneorgeneproduct
"Genotypes carrying the ERCC5 c.1763C>T variant exhibit increased aldehyde dehydrogenase A1 expression, which in turn enhances VDAC-mediated apoptosis in BRAF‑mutant A549 cells.",-39.5,0.4,geneorgeneproduct
"Genotypic analysis of the VDAC1 promoter revealed that the rs1800147 variant enhances PAR-activating transcription factor binding, thereby increasing LPL expression and elevating AST levels in hepatocytes of patients with non‑alcoholic fatty liver disease.",-46.25,0.4,geneorgeneproduct
"Elevated AST levels in hepatocytes overexpressing VDAC1 correlate with increased LPL activity, suggesting that aldehyde dehydrogenase A1 deficiency may enhance PAR-activating signaling and promote BRAF‑driven tumor progression in PD1‑negative colorectal cancer cells.",-37.0,0.4,geneorgeneproduct
"Elevating aldehyde dehydrogenase A1 expression in HeLa cells reduces PD1-mediated apoptosis by stabilizing VDAC-dependent mitochondrial membrane potential, thereby enhancing cell survival during oxidative stress.",-27.375,0.4,geneorgeneproduct
"Elevations in AST and VDAC expression in hepatocellular carcinoma cells are associated with increased LPL activity, which in turn promotes aldehyde dehydrogenase A1‑mediated detoxification and enhances tumor cell survival through PAR‑activating signaling pathways.",-34.25,0.4,geneorgeneproduct
"Elevin treatment of A549 cells expressing the VDAC1 variant c.152G>A reduced ERCC5-mediated DNA repair, leading to increased apoptosis and decreased tumor growth.",-44.75,0.4,geneorgeneproduct
"Suppressed expression of the aldehyde dehydrogenase A1 gene in A549 cells leads to increased intracellular reactive oxygen species, which in turn activates the ERCC5 DNA repair pathway and enhances resistance to cisplatin-induced apoptosis.",-29.625,0.4,geneorgeneproduct
"Suppression of VDAC expression by the aldehyde dehydrogenase A1 inhibitor reduces mitochondrial membrane potential and enhances apoptosis in BRAF‑mutant A549 cells, suggesting a novel therapeutic strategy for targeting PD1‑positive tumor microenvironments.",-34.25,0.4,geneorgeneproduct
"Suppressor protein VDAC1, whose expression is up‑regulated by the oncogenic BRAF V600E mutation in melanoma, binds the tumor‑suppressor gene product LPL, thereby attenuating lipid‑mediated signaling that otherwise promotes E‑cadherin loss and PD‑1‑driven immune evasion.",-55.25,0.4,geneorgeneproduct
"Suppressive phosphorylation of VDAC by BRAF‑mutated melanoma cells reduces mitochondrial membrane potential, thereby increasing aldehyde dehydrogenase A1 expression and conferring resistance to PD1‑blocking immunotherapy.",-41.5,0.4,geneorgeneproduct
"Mutation of the ERCC5 gene in a patient with xeroderma pigmentosum led to reduced aldehyde dehydrogenase A1 activity, impaired VDAC-mediated mitochondrial membrane potential, and increased susceptibility to UV-induced apoptosis.",-25.25,0.4,geneorgeneproduct
"Mutation in the ERCC5 gene that reduces its DNA‑repair activity increases the risk of Parkinson’s disease in patients carrying the LPL promoter variant, and the resulting loss of VDAC‑mediated mitochondrial membrane potential is exacerbated by aldehyde dehydrogenase A1 deficiency.",-43.75,0.4,geneorgeneproduct
"Mutation‐induced loss of VDAC function in HeLa cells leads to altered mitochondrial membrane potential, which in turn up‑regulates the expression of the aldehyde dehydrogenase A1 gene, a change that contributes to the chemoresistance phenotype observed in these cancer cells.",-41.5,0.4,geneorgeneproduct
"Mutation‑induced loss of VDAC expression in A549 cells enhances aldehyde dehydrogenase A1 activity, thereby conferring resistance to doxorubicin in this lung carcinoma model.",-24.375,0.4,geneorgeneproduct
"Loss of VDAC expression in HeLa cells carrying the BRAF V600E mutation reduces mitochondrial membrane potential, thereby increasing aldehyde dehydrogenase A1 activity and enhancing resistance to PD1‑mediated apoptosis.",-24.75,0.4,geneorgeneproduct
"Loss-of-function mutations in the aldehyde dehydrogenase A1 gene (ALDH1A1) in A549 cells lead to elevated reactive oxygen species that downregulate E‑cadherin expression and promote epithelial‑to‑mesenchymal transition, thereby increasing metastatic potential in a mouse xenograft model of non‑small‑cell lung carcinoma.",-39.5,0.4,geneorgeneproduct
"Loss‑of‑function mutations in the aldehyde dehydrogenase A1 gene (ALDH1A1) reduce VDAC‑mediated mitochondrial membrane potential, thereby impairing LPL‑dependent lipolysis and contributing to the metabolic dysregulation observed in patients with BRAF‑mutant melanoma.",-32.25,0.4,geneorgeneproduct
Losses of VDAC expression in A549 cells carrying a BRAF V600E mutation lead to increased aldehyde dehydrogenase A1 activity and a concomitant rise in PD1‑mediated apoptosis of tumor‑derived organoids.,-41.75,0.4,geneorgeneproduct
"Mutational loss of the aldehyde dehydrogenase A1 gene product in A549 cells reduces VDAC-mediated apoptosis and enhances BRAF‑driven proliferation, thereby contributing to a more aggressive lung cancer phenotype.",-27.5,0.4,geneorgeneproduct
"Mutations in the ERCC5 gene that reduce its DNA‑repair activity have been shown to increase aldehyde dehydrogenase A1 expression, thereby enhancing the detoxification of reactive aldehydes in hepatocytes and contributing to the development of non‑alcoholic fatty liver disease.",-29.5,0.4,geneorgeneproduct
"Mutual inhibition between VDAC and aldehyde dehydrogenase A1 in HeLa cells reduces mitochondrial ROS, thereby attenuating LPL‑mediated lipid uptake and lowering AST levels in the tumor microenvironment.",-33.5,0.4,geneorgeneproduct
"Mutated BRAF V600E in A549 cells enhances aldehyde dehydrogenase A1 expression, thereby increasing resistance to doxorubicin and correlating with elevated AST levels in treated E. coli–derived recombinant protein assays.",-30.875,0.4,geneorgeneproduct
"BRAF activation in A549 cells upregulates VDAC expression, thereby enhancing mitochondrial apoptosis in response to doxorubicin.",-19.0,0.4,geneorgeneproduct
"BAP1 loss in A549 cells upregulates VDAC expression, leading to increased mitochondrial ROS that activates ERCC5-mediated DNA repair and enhances PD1 signaling in the tumor microenvironment.",-36.0,0.4,geneorgeneproduct
"BCR‑ABL1‑positive chronic myeloid leukemia cells treated with imatinib show a marked up‑regulation of VDAC1, which in turn enhances mitochondrial ROS production and activates the ERCC5 DNA repair pathway, thereby reducing apoptosis mediated by PD1‑expressing T cells.",-44.5,0.4,geneorgeneproduct
"Biodistribution of the BRAF inhibitor vemurafenib in A549 cells was shown to upregulate aldehyde dehydrogenase A1 expression, which in turn enhanced VDAC-mediated mitochondrial apoptosis and reduced LPL activity, thereby potentiating the therapeutic effect of PD1 blockade in a xenograft model of non‑small cell lung cancer.",-51.25,0.4,geneorgeneproduct
"Gene expression profiling of HeLa cells treated with the BRAF inhibitor vemurafenib revealed a marked down‑regulation of VDAC, a protein that modulates mitochondrial membrane permeability, and an up‑regulation of aldehyde dehydrogenase A1, suggesting a shift toward a more oxidative stress‑resistant phenotype.",-35.5,0.4,geneorgeneproduct
Gene therapy targeting the BRAF V600E variant in A549 cells overexpressing aldehyde dehydrogenase A1 markedly reduced tumor‑derived AST levels and restored E‑cadherin‑mediated cell adhesion in the presence of PD1 blockade.,-37.25,0.4,geneorgeneproduct
Gene‑product VDAC1 regulates mitochondrial membrane potential and its up‑regulation in HeLa cells enhances the apoptotic response to the chemotherapeutic agent doxorubicin.,-31.125,0.4,geneorgeneproduct
"Gene silencing of BRAF in A549 cells upregulates aldehyde dehydrogenase A1, which in turn enhances VDAC-mediated apoptosis and reduces LPL expression, thereby attenuating the malignant phenotype of the lung carcinoma.",-30.375,0.4,geneorgeneproduct
"CRISPR‑edited VDAC‑deficient A549 cells revealed that loss of VDAC enhances BRAF‑mediated ERK phosphorylation, thereby up‑regulating the aldehyde dehydrogenase A1 promoter and increasing resistance to PD1‑blocking immunotherapy.",-33.5,0.4,geneorgeneproduct
"CR-1 cells overexpressing the VDAC1 gene product exhibit increased ATP production and enhanced apoptosis resistance when treated with the aldehyde dehydrogenase A1 inhibitor, a finding that may inform future PD1‑targeted therapies in E‑cadherin‑deficient tumors.",-50.0,0.4,geneorgeneproduct
"CRP levels were significantly elevated in patients with VDAC overexpression, suggesting that VDAC-mediated mitochondrial dysfunction may drive the inflammatory response observed in these individuals.",-33.25,0.4,geneorgeneproduct
"CRABP2 overexpression in A549 cells enhances VDAC-mediated apoptosis, while a BRAF V600E mutation in the same line upregulates aldehyde dehydrogenase A1, thereby attenuating PD1‑dependent T‑cell exhaustion.",-41.0,0.4,geneorgeneproduct
"Aberrant VDAC expression in A549 cells carrying the ERCC5 c.2257G>A variant enhances mitochondrial ROS production, thereby upregulating PD1-mediated T‑cell exhaustion and promoting resistance to doxorubicin.",-38.75,0.4,geneorgeneproduct
"Aberrations in the VDAC gene product, such as the LPL c.1023G>A variant, have been shown to impair mitochondrial membrane potential and increase oxidative stress, thereby exacerbating the inflammatory response mediated by PAR-activating PD1 signaling in patients with chronic liver disease.",-52.0,0.4,geneorgeneproduct
"Abernormal upregulation of VDAC and aldehyde dehydrogenase A1 in HepG2 cells enhances mitochondrial apoptosis, a process that is further potentiated by BRAF‑V600E mutation and suppressed by PD1‑mediated immune checkpoint signaling.",-43.5,0.4,geneorgeneproduct
"Aberration of the BRAF gene product in the VDAC‑expressing HeLa cell line leads to up‑regulation of aldehyde dehydrogenase A1, which in turn enhances the degradation of the PAR‑activating compound and confers resistance to PD1‑mediated apoptosis.",-45.25,0.4,geneorgeneproduct
"In SH-SY5Y cells, the glial‑cell‑line‑derived neurotrophic factor receptor complex activates inducible NO synthase, leading to increased production of nitric oxide that phosphorylates proteinase‑activated receptor‑2 and subsequently up‑regulates the transcription factor Sp3, thereby enhancing Annexin A1 expression and promoting neuronal differentiation.",-30.375,0.4,geneorgeneproduct
"In glioblastoma multiforme cells, the upregulation of inducible NO synthase by the transcription factor Sp3 enhances Annexin A2-mediated proteinase‑activated receptor signaling, thereby promoting tumor cell migration.",-21.75,0.4,geneorgeneproduct
"In mouse hippocampal astrocytes, glial‑cell‑line‑derived neurotrophic factor activates proteinase‑activated receptor‑1, which in turn induces Sp3‑mediated transcription of inducible NO synthase, leading to increased nitric oxide production that promotes neuronal survival.",-31.0,0.4,geneorgeneproduct
"In the glial‑cell‑line‑derived neurotrophic factor (GDNF)‑treated A549 cell line, inducible NO synthase expression is up‑regulated through Sp3 binding to the promoter, leading to increased production of nitric oxide that activates proteinase‑activated receptors and subsequently enhances Annexin A2‑mediated cell migration.",-27.0,0.4,geneorgeneproduct
"The inducible NO synthase (iNOS) gene product is upregulated by Sp3 binding to its promoter, thereby enhancing nitric‑oxide production in glial‑cell‑line‑derived neurotrophic factor‑stimulated astrocytes.",-19.75,0.4,geneorgeneproduct
"The gRNA‑CRISPR‑Cas9 editing of the inducible NO synthase (iNOS) gene in the human glioblastoma cell line U87MG resulted in a marked decrease in Annexin V‑positive apoptotic cells, indicating that loss of iNOS suppresses apoptosis in this tumor model.",-39.5,0.4,geneorgeneproduct
"The overexpression of inducible NO synthase in the glial‑cell‑line‑derived neurotrophic factor‑treated A549 cell line upregulates Annexin A1, which in turn activates proteinase‑activated receptor‑1 to stimulate Sp3‑mediated transcription of the SP7/Osterix gene, thereby enhancing osteogenic differentiation in Homo sapiens cells.",-28.125,0.4,geneorgeneproduct
"The constitutive NO synthase gene, encoded by NOS3, is upregulated by the transcription factor Sp3 in glial‑cell‑line‑derived neurotrophic factor‑treated A549 cells, leading to increased production of nitric oxide that activates proteinase‑activated receptors and enhances Annexin A1 expression.",-22.125,0.4,geneorgeneproduct
"Mutations in the inducible NO synthase gene (NOS2) in the human cell line HeLa upregulate Annexin A1 expression, thereby enhancing proteinase-activated receptor‑2 signaling and promoting a pro‑inflammatory phenotype.",-26.25,0.4,geneorgeneproduct
"Mutated SP7/Osterix in the A549 cell line reduces inducible NO synthase expression, thereby impairing glial‑cell‑line‑derived neurotrophic factor‑mediated osteogenic differentiation in Homo sapiens.",-19.875,0.4,geneorgeneproduct
"Mutational loss of inducible NO synthase in the CHL1‑2‑expressing A549 cell line leads to increased Annexin V staining and up‑regulation of the transcription factor Sp3, suggesting a novel regulatory axis between NO synthase, Annexin, and Sp3 in lung cancer cells.",-41.75,0.4,geneorgeneproduct
"Mutual regulation between glial-cell-line-derived neurotrophic factor and inducible NO synthase in the CHL1/2 signaling pathway modulates Annexin-mediated proteinase-activated receptor activation, thereby influencing Sp3 transcriptional activity in the MMR‑dependent osteogenic differentiation of SP7/Osterix‑expressing cells.",-40.25,0.4,geneorgeneproduct
"Expression of inducible NO synthase in the glial‑cell‑line‑derived neurotrophic factor‑treated A549 cells was up‑regulated by the proteinase‑activated receptors through Sp3‑mediated transcription, suggesting a potential therapeutic target for inflammatory lung disease.",-26.875,0.4,geneorgeneproduct
"Expression levels of inducible NO synthase in the glial‑cell‑line‑derived neurotrophic factor‑treated A549 cell line were found to be up‑regulated by the proteinase‑activated receptors through a Sp3‑dependent transcriptional mechanism, suggesting a potential role for NO synthase in modulating the inflammatory response in this cancer model.",-35.75,0.4,geneorgeneproduct
"Expression analysis revealed that the glial‑cell‑line‑derived neurotrophic factor gene is up‑regulated in A549 cells treated with the small‑molecule inhibitor of inducible NO synthase, while Sp3 transcription factor binding sites in the promoter region of the CHL1 gene are hyper‑methylated in the same experimental condition.",-45.25,0.4,geneorgeneproduct
"Expression analyses in the A549 cell line revealed that the upregulation of inducible NO synthase (iNOS) by glial‑cell‑line‑derived neurotrophic factor (GDNF) was mediated through the activation of proteinase‑activated receptors and the transcription factor Sp3, thereby enhancing nitric‑oxide production and promoting inflammatory signaling.",-38.25,0.4,geneorgeneproduct
"A study of the glial‑cell‑line‑derived neurotrophic factor (GDNF) gene revealed that a c.125G>A sequence variant in the promoter region increases Sp3 binding, thereby enhancing inducible nitric‑oxide synthase (iNOS) transcription and elevating proteinase‑activated receptor‑2 (PAR2) signaling in cultured HeLa cells.",-40.25,0.4,geneorgeneproduct
"A CRISPR‑Cas9 knockout of inducible NO synthase in the A549 cell line revealed that loss of iNOS reduces Annexin V‑positive apoptosis and enhances proteinase‑activated receptor‑mediated migration, suggesting a regulatory role for NO synthase in lung cancer cell survival.",-35.0,0.4,geneorgeneproduct
"A recent study demonstrated that glial‑cell‑line‑derived neurotrophic factor upregulates inducible NO synthase via proteinase‑activated receptors, thereby enhancing Annexin‑mediated apoptosis in the CHL1‑expressing A549 cell line.",-27.0,0.4,geneorgeneproduct
A2‑B1‑B2‑B3‑B4‑B5‑B6‑B7‑B8‑B9‑B10‑B11‑B12‑B13‑B14‑B15‑B16‑B17‑B18‑B19‑B20‑B21‑B22‑B23‑B24‑B25‑B26‑B27‑B28‑B29‑B30‑B31‑B32‑B33‑,-25.375,0.4,geneorgeneproduct
"glial‑cell‑line‑derived neurotrophic factor upregulates inducible NO synthase expression in the A549 cell line, thereby enhancing proteinase‑activated receptor‑mediated inflammatory signaling in Homo sapiens lung carcinoma cells.",-20.75,0.4,geneorgeneproduct
"glia‑cell‑line‑derived neurotrophic factor upregulates inducible NO synthase expression in the Sp3‑dependent manner, thereby enhancing proteinase‑activated receptor‑mediated neuroinflammation in the CHL1‑2 signaling pathway.",-36.75,0.4,geneorgeneproduct
"glatiramer acetate treatment of multiple sclerosis patients upregulated inducible NO synthase expression in the glial‑cell‑line‑derived neurotrophic factor‑stimulated microglial cells, thereby enhancing Annexin‑mediated phagocytosis of myelin debris.",-41.0,0.4,geneorgeneproduct
"glc-1, a glial‑cell‑line‑derived neurotrophic factor‑responsive gene, is up‑regulated by inducible NO synthase activity in A549 cells, thereby enhancing Annexin‑mediated apoptosis through proteinase‑activated receptors.",-41.75,0.4,geneorgeneproduct
"Inducible NO synthase upregulates Annexin A2 expression in the glial‑cell‑line‑derived neurotrophic factor‑treated A549 cell line, thereby enhancing proteinase‑activated receptor‑mediated migration.",-16.25,0.4,geneorgeneproduct
"Induced NO synthase expression in the glial‑cell‑line‑derived neurotrophic factor‑treated A549 cells activates proteinase‑activated receptors, thereby up‑regulating Sp3‑mediated transcription of the SP7/Osterix gene.",-19.0,0.4,geneorgeneproduct
"Induction of inducible NO synthase by glial‑cell‑line‑derived neurotrophic factor in the A549 cell line enhances Annexin‑A1 phosphorylation, thereby promoting proteinase‑activated receptor‑mediated migration of CHL1‑expressing cells.",-27.5,0.4,geneorgeneproduct
"Inducing the expression of inducible NO synthase in the glial‑cell‑line‑derived neurotrophic factor‑treated A549 cells activates proteinase‑activated receptors, thereby increasing Annexin‑mediated apoptosis and up‑regulating the transcription factor Sp3.",-29.875,0.4,geneorgeneproduct
"Mutation of the inducible NO synthase gene in CHL1-deficient A549 cells reduces Annexin A2 expression, thereby impairing proteinase-activated receptor‑mediated migration in the glial‑cell‑line‑derived neurotrophic factor‑rich microenvironment.",-29.25,0.4,geneorgeneproduct
"Mutation in the inducible NO synthase gene (NOS2) reduces glial‑cell‑line‑derived neurotrophic factor expression in CHL1‑positive neurons, thereby impairing Annexin‑mediated neuroprotection.",-27.5,0.4,geneorgeneproduct
"Mutation-induced loss of inducible NO synthase in CHL1-expressing glial-cell-line-derived neurotrophic factor‑treated A549 cells upregulates Annexin A2 via proteinase‑activated receptors, thereby enhancing Sp3‑mediated transcription of SP7/Osterix and accelerating MMR‑dependent DNA repair.",-39.75,0.4,geneorgeneproduct
"Mutation‑induced loss of inducible NO synthase in CHL1‑deficient A549 cells upregulates Sp3‑mediated transcription of the proteinase‑activated receptor‑2 gene, thereby enhancing Annexin‑A1 secretion and promoting a pro‑inflammatory phenotype in the human lung carcinoma model.",-37.0,0.4,geneorgeneproduct
"High‑throughput proteomics of the glial‑cell‑line‑derived neurotrophic factor‑treated A549 cell line revealed that inducible NO synthase up‑regulates the proteinase‑activated receptor‑2 pathway, thereby enhancing Annexin A2‑mediated apoptosis in a Sp3‑dependent manner.",-32.75,0.4,geneorgeneproduct
"High‐expressing glial‑cell‑line‑derived neurotrophic factor in A549 cells activates inducible NO synthase, leading to increased Annexin A1 phosphorylation and downstream proteinase‑activated receptor‑2 signaling that ultimately enhances SP7/Osterix transcription in a Sp3‑dependent manner.",-35.5,0.4,geneorgeneproduct
"High-glial-cell-line-derived neurotrophic factor expression in HeLa cells is up‑regulated by inducible NO synthase activation, which in turn enhances proteinase-activated receptor‑2 signaling and increases Annexin A1 secretion.",-33.75,0.4,geneorgeneproduct
"High expression of inducible NO synthase in the CHL1‑derived glial‑cell‑line‑derived neurotrophic factor‑treated A549 cells activates proteinase‑activated receptors, thereby enhancing Annexin‑mediated apoptosis.",-27.25,0.4,geneorgeneproduct
"Sp3 transcriptionally upregulates inducible NO synthase in glial‑cell‑line‑derived neurotrophic factor‑treated A549 cells, thereby enhancing proteinase‑activated receptor‑mediated inflammatory signaling.",-14.9375,0.4,geneorgeneproduct
"Sp7/Osterix upregulates inducible NO synthase in the glial-cell-line-derived neurotrophic factor–treated A549 cell line, thereby enhancing proteinase-activated receptor signaling in Homo sapiens.",-27.75,0.4,geneorgeneproduct
"Sp1-mediated transcription of the inducible NO synthase gene is enhanced by glial‑cell‑line‑derived neurotrophic factor in the CHL1‑expressing A549 cell line, leading to increased nitric‑oxide production that activates proteinase‑activated receptors and promotes apoptosis of malignant cells.",-34.75,0.4,geneorgeneproduct
"Splicing of the CHL1 transcript in the A549 cell line is enhanced by the transcription factor Sp3, leading to increased expression of the proteinase-activated receptor‑1 ligand annexin A1 and subsequent upregulation of inducible NO synthase activity in Homo sapiens macrophages.",-46.25,0.4,geneorgeneproduct
"Transfection of the glial‑cell‑line‑derived neurotrophic factor‑overexpressing A549 cell line with a plasmid encoding the inducible NO synthase gene (NOS2) resulted in a two‑fold increase in Annexin V‑positive apoptotic cells compared with the empty‑vector control, indicating that NOS2 up‑regulation enhances apoptosis through proteinase‑activated receptor‑mediated signaling pathways.",-44.75,0.4,geneorgeneproduct
"Transfecting the A549 cell line with a plasmid encoding the inducible NO synthase gene (iNOS) led to a marked increase in nitric oxide production that, in turn, activated proteinase‑activated receptor‑2 signaling and up‑regulated Annexin A1 expression, thereby enhancing apoptosis in the tumor cells.",-39.0,0.4,geneorgeneproduct
"Transgenic A549 cells overexpressing glial‑cell‑line‑derived neurotrophic factor exhibit up‑regulated inducible NO synthase activity, which in turn activates proteinase‑activated receptors to promote Annexin‑mediated apoptosis.",-25.625,0.4,geneorgeneproduct
"Transplantation of the glial‑cell‑line‑derived neurotrophic factor‑overexpressing CHL1‑2‑knockout A549 cell line into a mouse model of Parkinson’s disease increased inducible NO synthase expression, thereby enhancing proteinase‑activated receptor‑mediated neuroprotection and reducing disease‑associated motor deficits.",-35.0,0.4,geneorgeneproduct
"Annexin A1 expression is up‑regulated by constitutive NO synthase in glial‑cell‑line‑derived neurotrophic factor‑treated HeLa cells, thereby enhancing proteinase‑activated receptor‑mediated migration of the SP7/Osterix‑positive A549 tumor cells.",-26.25,0.4,geneorgeneproduct
"AnnV-1, a splice variant of the inducible NO synthase gene, was found to upregulate the expression of the glial‑cell‑line‑derived neurotrophic factor receptor in CHL1‑positive A549 cells, thereby enhancing proteinase‑activated receptor‑mediated chemotaxis.",-46.5,0.4,geneorgeneproduct
"Annatoxin, a proteinase‑activated receptor agonist, induces Sp3‑mediated up‑regulation of inducible NO synthase in the glial‑cell‑line‑derived neurotrophic factor‑treated CHL1‑positive A549 cells, thereby enhancing nitric oxide production and promoting apoptosis.",-35.75,0.4,geneorgeneproduct
"Ann exonuclease activity of inducible NO synthase in the glial‑cell‑line‑derived neurotrophic factor‑treated A549 cells was shown to up‑regulate the transcription factor Sp3, thereby enhancing proteinase‑activated receptor‑mediated cytokine release.",-40.75,0.4,geneorgeneproduct
Upregulation of inducible NO synthase in the CHL1‑expressing glial‑cell‑line‑derived neurotrophic factor‑treated A549 cells enhances Annexin‑mediated apoptosis through proteinase‑activated receptor‑dependent activation of Sp3.,-23.0,0.4,geneorgeneproduct
"Upregulated expression of the transcription factor Sp3 in the glial‑cell‑line‑derived neurotrophic factor‑treated A549 cell line was found to enhance inducible NO synthase transcription, thereby increasing nitric oxide production and potentiating proteinase‑activated receptor‑mediated inflammatory signaling.",-27.125,0.4,geneorgeneproduct
"Up-regulation of inducible NO synthase by glial‑cell‑line‑derived neurotrophic factor in CHL1‑deficient A549 cells activates proteinase‑activated receptors, thereby enhancing Annexin‑mediated apoptosis through Sp3‑dependent transcriptional repression of SP7/Osterix.",-27.0,0.4,geneorgeneproduct
"Upstream activation of the transcription factor Sp3 by glial‑cell‑line‑derived neurotrophic factor enhances inducible NO synthase expression in A549 cells, thereby amplifying proteinase‑activated receptor‑mediated inflammatory signaling.",-23.875,0.4,geneorgeneproduct
"Treatment of A549 cells with glial‑cell‑line‑derived neurotrophic factor upregulated inducible NO synthase and increased Annexin V staining, indicating apoptosis mediated by proteinase‑activated receptor signaling.",-20.75,0.4,geneorgeneproduct
"Treatment with the glial‑cell‑line‑derived neurotrophic factor‑induced Sp3 transcription factor upregulates inducible NO synthase expression in the CHL1‑2‑expressing A549 cell line, thereby enhancing proteinase‑activated receptor‑mediated inflammatory signaling.",-27.125,0.4,geneorgeneproduct
"Treatment using the glial‑cell‑line‑derived neurotrophic factor‑treated A549 cell line revealed that constitutive NO synthase activity up‑regulated Annexin expression, which in turn activated proteinase‑activated receptors to enhance Sp3‑mediated transcription of CHL1 and SP7/Osterix, thereby promoting MMR‑dependent DNA repair in Homo sapiens cells.",-42.25,0.4,geneorgeneproduct
"Treatment by the glial‑cell‑line‑derived neurotrophic factor‑treated A549 cell line revealed that inducible NO synthase up‑regulated Sp3, which in turn enhanced proteinase‑activated receptor‑mediated Annexin expression, thereby reducing the inflammatory phenotype of the MMR‑deficient E. coli strain.",-49.25,0.4,geneorgeneproduct
"CRISPR‑Cas9‑mediated knockout of CASP8 in A549 cells reduces NF‑κB‑dependent transcription of the pro‑inflammatory cytokine IL‑6, thereby attenuating TLR4‑induced apoptosis and enhancing cell survival.",-26.125,0.4,geneorgeneproduct
"CR3-mediated activation of NFkappaB in A549 cells upregulates Cdc25a expression, thereby enhancing cell cycle progression and promoting resistance to doxorubicin-induced apoptosis.",-28.375,0.4,geneorgeneproduct
"CR‑ISPR‑mediated knockout of CASP8 in A549 cells upregulated NFkappaB‑dependent expression of Bim, thereby enhancing apoptosis in response to TNF‑α stimulation.",-26.0,0.4,geneorgeneproduct
"CRITICAL NFkappaB activation in HeLa cells exposed to the TLR4 agonist lipopolysaccharide upregulates CASP8, which in turn cleaves the pro‑apoptotic Bim protein, thereby promoting apoptosis.",-38.25,0.4,geneorgeneproduct
"The CASP8-mediated activation of NF‑κB in Cdc25a‑overexpressing HeLa cells enhances the expression of the pro‑apoptotic protein Bim, thereby promoting apoptosis in response to TNF‑α stimulation.",-21.0,0.4,geneorgeneproduct
"The interaction between NFkappaB and calcineurin-based signaling in HeLa cells enhances Cdc25a expression, thereby increasing CA125 secretion in response to Toll‑like receptor (TLR)4 activation.",-31.125,0.4,geneorgeneproduct
"The activation of NFkappaB by Toll‑like receptor (TLR)4 in HeLa cells up‑regulates the pro‑apoptotic gene Bim, thereby enhancing caspase‑8 (CASP8) cleavage and inducing apoptosis.",-29.5,0.4,geneorgeneproduct
"The TLR4‑NFκB signaling axis in HeLa cells up‑regulates CASP8 expression, which in turn activates Bim to trigger apoptosis.",-22.125,0.4,geneorgeneproduct
"Expression of CASP8 in A549 cells is up‑regulated by NF‑κB activation downstream of Toll‑like receptor‑4 stimulation, leading to increased Bim‑mediated apoptosis.",-20.375,0.4,geneorgeneproduct
"Expression levels of CASP8 and NFkappaB were markedly increased in A549 cells treated with the calcineurin-based inhibitor FK506, suggesting that NFkappaB activation may drive apoptosis through CASP8 upregulation.",-31.625,0.4,geneorgeneproduct
"Expression analysis of the CASP8 gene in A549 cells revealed that NFkappaB activation by Toll‑like receptor‑4 stimulation up‑regulates Cdc25a, thereby promoting apoptosis through Bim induction.",-34.25,0.4,geneorgeneproduct
"Expression loss of CASP8 in A549 cells enhances NF‑κB‑mediated transcription of the inflammatory cytokine IL‑6, thereby increasing the cells’ resistance to doxorubicin‑induced apoptosis.",-36.5,0.4,geneorgeneproduct
"NFkappaB activation by Toll‑like receptor (TLR)4 stimulation in A549 cells induces CASP8‑mediated apoptosis, which is amplified by Bim up‑regulation and suppressed by calcineurin‑based dephosphorylation of Cdc25a.",-30.875,0.4,geneorgeneproduct
"NF‑κB activation in HeLa cells treated with the small‑molecule inhibitor Bim‑inhibitor‑X induces a rapid up‑regulation of the cell‑cycle regulator Cdc25A, which in turn promotes G2‑M transition and enhances proliferation of the tumor line.",-39.75,0.4,geneorgeneproduct
"NFκB activation in HeLa cells treated with the TLR4 agonist lipopolysaccharide upregulates CASP8, which in turn cleaves Bim and promotes apoptosis.",-19.875,0.4,geneorgeneproduct
"NF-κB activation in Cdc25a‑overexpressing HeLa cells upregulates the pro‑apoptotic protein Bim, thereby sensitizing the cells to cisplatin-induced cell death.",-23.0,0.4,geneorgeneproduct
"Deletion of the CASP8 promoter region in HeLa cells reduces NF‑κB‑dependent transcription of the pro‑apoptotic gene Bim, thereby attenuating the response to TNF‑α stimulation.",-22.875,0.4,geneorgeneproduct
"Deletion in the CASP8 gene’s exon‑3 causes a truncated protein that fails to interact with NF‑κB‑activated Bim, thereby reducing apoptosis in HeLa cells exposed to the Toll‑like receptor‑4 agonist lipopolysaccharide.",-46.0,0.4,geneorgeneproduct
"Deletion‑induced loss of NFkappaB binding to the CA125 promoter in HeLa cells reduces Cdc25a transcription, thereby impairing cell cycle progression and enhancing apoptosis through Bim activation.",-35.5,0.4,geneorgeneproduct
"Deletion within the CASP8 gene that abolishes the NF‑κB‑responsive promoter element reduces Cdc25a transcription in human A549 cells, thereby impairing cell cycle progression and enhancing apoptosis through Bim up‑regulation.",-47.0,0.4,geneorgeneproduct
"In A549 cells, activation of Toll‑like receptor (TLR)4 by lipopolysaccharide induces NF‑κB‑dependent up‑regulation of Cdc25a, which in turn phosphorylates and activates caspase‑8, triggering apoptosis through Bim‑mediated mitochondrial permeabilization.",-31.375,0.4,geneorgeneproduct
"In Caenorhabditis elegans, the loss‑of‑function mutation in the caspase gene CASP8 (c.1234delA) enhances TLR4‑mediated NF‑κB signaling, leading to increased expression of the pro‑apoptotic protein Bim and subsequent neuronal cell death.",-39.5,0.4,geneorgeneproduct
"In HeLa cells, activation of NFkappaB by Toll‑like receptor (TLR)4 stimulation induces up‑regulation of the pro‑apoptotic gene Bim, which in turn promotes caspase‑8‑mediated apoptosis.",-26.875,0.4,geneorgeneproduct
"In H1299 cells, overexpression of CASP8 and Cdc25a synergistically activates NF‑κB signaling, thereby enhancing Bim‑mediated apoptosis and reducing CA125 secretion.",-24.5,0.4,geneorgeneproduct
"Altered NFkappaB activation in CA125‑positive HeLa cells treated with the calcineurin‑based inhibitor cyclosporine A leads to up‑regulation of the pro‑apoptotic gene Bim, thereby enhancing caspase‑8‑mediated apoptosis.",-27.125,0.4,geneorgeneproduct
"Alterations in the CASP8 promoter enhance NF‑κB‑dependent transcription of Bim, thereby amplifying apoptosis in A549 cells treated with the calcineurin‑inhibitor cyclosporin A.",-23.625,0.4,geneorgeneproduct
"Alteration of the CASP8 promoter by a single‑nucleotide polymorphism increases NF‑κB binding, thereby enhancing transcription of the pro‑apoptotic gene Bim in human epithelial cells.",-27.0,0.4,geneorgeneproduct
Alterational phosphorylation of NFkappaB by calcineurin-based signaling in Cdc25a‑expressing HeLa cells enhances CASP8‑mediated apoptosis downstream of Toll‑like receptor (TLR)4 activation.,-43.75,0.4,geneorgeneproduct
"A CRISPR‑Cas9 knockout of CASP8 in A549 cells reduces NF‑κB‑dependent secretion of CA125, thereby attenuating TLR4‑mediated inflammatory signaling in the tumor microenvironment.",-23.125,0.4,geneorgeneproduct
"A knock‑in mouse harboring the CFH p.Gly1191Arg variant exhibits elevated NF‑κB activation and increased TLR4‑mediated cytokine release, leading to enhanced Bim‑driven apoptosis of renal tubular cells.",-34.0,0.4,geneorgeneproduct
"A CpG island methylator phenotype in colorectal cancer cells downregulates the expression of CASP8, thereby reducing apoptosis and enabling the tumor to evade NF‑κB–mediated immune surveillance.",-38.75,0.4,geneorgeneproduct
A down‑regulation of CASP8 by the calcineurin‑based inhibitor FK506 in HeLa cells leads to increased NF‑κB activation and subsequent up‑regulation of the pro‑apoptotic gene Bim.,-27.625,0.4,geneorgeneproduct
"Activation of NFkappaB by Toll‑like receptor (TLR)4 signaling in human A549 cells upregulates CASP8 expression, thereby enhancing apoptosis mediated by Bim.",-29.875,0.4,geneorgeneproduct
"Activation‑induced NFkappaB signaling in CA125‑positive HeLa cells upregulates Cdc25a, thereby enhancing Nestin‑mediated proliferation of the tumor‑derived cell line.",-35.75,0.4,geneorgeneproduct
"Activation-induced caspase-8 (CASP8) cleavage of the pro-apoptotic protein Bim in A549 cells is amplified by NF‑κB‑dependent up‑regulation of Cdc25a, thereby promoting apoptosis in response to TNF‑α stimulation.",-38.0,0.4,geneorgeneproduct
"Activation by the Toll‑like receptor‑4 ligand lipopolysaccharide induces NF‑κB‑dependent transcription of the CASP8 gene, which in turn cleaves the pro‑apoptotic protein Bim, thereby promoting apoptosis in Cdc25a‑overexpressing A549 cells.",-37.25,0.4,geneorgeneproduct
"Mutations in the CASP8 gene product, such as the c.1123G>A variant, were found to increase NFkappaB activation in HeLa cells, thereby enhancing the expression of the downstream pro‑apoptotic protein Bim.",-32.5,0.4,geneorgeneproduct
"Mutational activation of CASP8 in A549 cells leads to NF‑κB‑dependent up‑regulation of Bim, thereby promoting apoptosis in response to calcineurin‑based chemotherapeutic treatment.",-22.75,0.4,geneorgeneproduct
"Mutagenic exposure to doxorubicin in A549 cells upregulated CASP8 and NFkappaB, thereby triggering apoptosis through Bim activation and increasing CA125 secretion.",-29.0,0.4,geneorgeneproduct
"Mutant CASP8 c.1123G>A in a patient with diffuse large B‑cell lymphoma was found to enhance NF‑κB‑dependent transcription of Bim, thereby increasing apoptosis in HeLa cells treated with the calcineurin‑inhibitor cyclosporine A.",-38.25,0.4,geneorgeneproduct
"Deterioration of NFkappaB signaling in CA125‑positive ovarian carcinoma cells is exacerbated by the loss of CASP8, which normally cleaves the pro‑apoptotic protein Bim, thereby linking caspase activity to apoptosis resistance in the tumor microenvironment.",-44.5,0.4,geneorgeneproduct
"Dopamine stimulation of the GnRH receptor in the hypothalamic CA125‑expressing neurons activates NF‑κB, which in turn up‑regulates Cdc25a expression, thereby enhancing Nestin‑positive neural progenitor proliferation in the developing cerebellum.",-44.5,0.4,geneorgeneproduct
"Dysregulated NFkappaB activation in A549 cells treated with the TLR4 agonist LPS upregulates Cdc25a expression, thereby enhancing CASP8-mediated apoptosis and increasing CA125 secretion.",-26.625,0.4,geneorgeneproduct
"Deregulation of CASP8 and Cdc25a in HeLa cells leads to increased NF‑κB activation and apoptosis, as evidenced by elevated Bim expression and caspase‑3 cleavage.",-27.0,0.4,geneorgeneproduct
"Loss of CASP8 function in HeLa cells leads to reduced NF‑κB activation, increased Bim expression, and heightened sensitivity to TNF‑α‑induced apoptosis.",-20.875,0.4,geneorgeneproduct
"Loss-of-function mutations in the CASP8 gene, which encodes a key initiator caspase, lead to impaired apoptosis in B cells and are associated with increased NF‑κB activation and heightened susceptibility to autoimmune disease in patients of Homo sapiens origin.",-42.0,0.4,geneorgeneproduct
"Loss‑of‑function mutations in the CASP8 gene reduce apoptosis in A549 cells, leading to increased NF‑κB activation and up‑regulation of the TLR4‑dependent inflammatory cytokine IL‑6.",-28.5,0.4,geneorgeneproduct
"Loss‐of‑function mutations in the CASP8 gene, which normally activates Bim‑mediated apoptosis, were shown to upregulate NF‑κB‑dependent transcription of the TLR4‑induced pro‑inflammatory cytokine IL‑6 in human A549 lung carcinoma cells.",-42.0,0.4,geneorgeneproduct
"Mutation of the CASP8 gene in A549 cells increases NF‑κB‑mediated transcription of the pro‑apoptotic protein Bim, thereby enhancing cell death in response to cisplatin treatment.",-22.5,0.4,geneorgeneproduct
"Mutation in the CASP8 gene that increases its expression in A549 cells enhances apoptosis via Bim activation, thereby reducing the proliferation of CA125‑positive ovarian carcinoma cells.",-29.875,0.4,geneorgeneproduct
"Mutation‐induced loss of CASP8 activity in HeLa cells upregulates NF‑κB‑dependent Bim expression, thereby enhancing apoptosis resistance in this human cervical carcinoma model.",-28.875,0.4,geneorgeneproduct
"Mutation-driven overexpression of CASP8 in A549 cells activates NF‑κB signaling, thereby increasing Bim-mediated apoptosis and reducing CA125 secretion.",-25.5,0.4,geneorgeneproduct
"CASP8 activation downstream of Toll‑like receptor‑4 stimulation in HeLa cells induces Bim‑mediated apoptosis, a process that is attenuated by calcineurin‑based inhibitors.",-23.0,0.4,geneorgeneproduct
"CASPR2 overexpression in A549 cells enhances NF‑κB‑dependent transcription of the pro‑apoptotic gene Bim, thereby increasing sensitivity to doxorubicin‑induced apoptosis.",-30.375,0.4,geneorgeneproduct
"CASR activation in HeLa cells upregulates NFkappaB‑dependent transcription of the CASP8 gene, thereby enhancing apoptosis in response to TNF‑α stimulation.",-30.875,0.4,geneorgeneproduct
"CASPAR-8 activation by Toll‑like receptor‑4 signaling in A549 cells induces NF‑κB‑dependent transcription of the pro‑apoptotic gene Bim, thereby promoting apoptosis in response to lipopolysaccharide exposure.",-42.0,0.4,geneorgeneproduct
"Altered expression of the p160 nuclear receptor coactivator in LPA2‑KO A549 cells enhances GSK‑3β‑mediated phosphorylation of Hypoxia Inducible Factor‑1α, thereby increasing VEGFA transcription and promoting angiogenesis.",-18.5,0.4,geneorgeneproduct
"Alterations in the p19 promoter region of the TP53 gene in A549 cells lead to increased binding of the Vitamin D receptor and enhanced transcription of the downstream WISP2 gene, thereby amplifying the hypoxia‑inducible factor‑1α‑driven angiogenic response.",-39.25,0.4,geneorgeneproduct
"Alteration of the WISP2 gene product in LPA2‑KO A549 cells reduces GSK‑3β phosphorylation, thereby enhancing hypoxia‑inducible factor‑1α‑mediated transcription of the Vitamin D receptor and its downstream Aldehyde Dehydrogenase genes.",-29.75,0.4,geneorgeneproduct
"Alterative activation of the Vitamin D receptor in LPA2‑KO A549 cells up‑regulates the p19‑p160 nuclear receptor coactivator complex, thereby enhancing GSK‑3β‑mediated phosphorylation of Hypoxia Inducible Factor‑1α and suppressing WISP2‑driven proliferation.",-37.5,0.4,geneorgeneproduct
"In LPA2‑KO A549 cells, the up‑regulated p19 protein enhances HIF‑1α‑mediated transcription of VEGFA, thereby promoting angiogenesis and conferring resistance to doxorubicin.",-23.625,0.4,geneorgeneproduct
"In human colorectal carcinoma cells, loss of LPA2-KO leads to increased GSK‑3β activity, which phosphorylates the Vitamin D receptor and reduces its ability to bind the HIF‑1α promoter, thereby attenuating hypoxia‑induced transcription of WISP2 and downstream Aldehyde Dehydrogenases.",-38.0,0.4,geneorgeneproduct
"In VEGF‑stimulated HUVECs, the loss of LPA2‑KO cells leads to a marked up‑regulation of the p19‑p160 nuclear receptor coactivator complex, which in turn amplifies HIF‑1α‑driven transcription of Aldehyde Dehydrogenases and enhances VEGFR2 phosphorylation.",-37.75,0.4,geneorgeneproduct
"In A549 cells, loss of LPA2-KO upregulates WISP2 expression through a GSK-3β‑dependent pathway that activates Hypoxia Inducible Factor‑1α, thereby enhancing VEGF secretion and promoting angiogenesis.",-23.625,0.4,geneorgeneproduct
"The hypoxia‑inducible factor‑1α (HIF‑1α) pathway is up‑regulated in LPA2‑KO A549 cells, where increased GSK‑3β activity enhances WISP2 transcription and subsequently activates the vitamin D receptor‑mediated suppression of aldehyde dehydrogenase‑1 expression.",-32.25,0.4,geneorgeneproduct
"The p19 subunit of the p160 nuclear receptor coactivator complex is up‑regulated by hypoxia‑inducible factor‑1α in LPA2‑KO A549 cells, thereby enhancing GSK‑3β‑mediated phosphorylation of the Vitamin D receptor and increasing expression of Aldehyde Dehydrogenases that metabolize TLR4‑induced inflammatory cytokines.",-29.5,0.4,geneorgeneproduct
"The deletion of the WISP2 promoter in the LPA2‑KO A549 cell line reduces HIF‑1α‑mediated VEGFA expression, thereby attenuating hypoxia‑induced angiogenesis.",-19.75,0.4,geneorgeneproduct
"The knock‑out of LPA2 in A549 cells up‑regulates the p19 subunit of the NF‑κB complex, thereby enhancing HIF‑1α‑driven VEGFA transcription and increasing VEGFR2 phosphorylation in a hypoxic microenvironment.",-25.0,0.4,geneorgeneproduct
"A p19 deficiency in LPA2-KO mice leads to upregulation of WISP2, which in turn activates GSK‑3β to enhance Hypoxia‑Inducible Factor‑1α‑mediated transcription of Aldehyde Dehydrogenases, thereby increasing resistance to oxidative stress in the renal tubular epithelium of Homo sapiens.",-39.0,0.4,geneorgeneproduct
"A loss‑of‑function mutation in the PKD1 gene of a LPA2‑KO mouse model reduces HIF‑1α‑mediated transcription of the WISP2 gene, thereby attenuating the downstream activation of the Vitamin D receptor–p160 nuclear receptor coactivator complex and impairing Aldehyde Dehydrogenases expression.",-37.0,0.4,geneorgeneproduct
"A global transcriptomic analysis of LPA2‑KO A549 cells revealed that the loss of LPA2 up‑regulates the p19‑p160 nuclear receptor coactivator complex, thereby enhancing HIF‑1α‑driven VEGFA expression and promoting angiogenesis in hypoxic tumor microenvironments.",-33.5,0.4,geneorgeneproduct
"A hypoxia‑inducible factor‑1α (HIF‑1α)‑dependent up‑regulation of the aldehyde dehydrogenase gene ALDH1A1 in HeLa cells lacking LPA2 (LPA2‑KO) enhances resistance to doxorubicin, a finding that may inform targeted therapy for chemoresistant ovarian carcinoma.",-35.5,0.4,geneorgeneproduct
"PKD1 expression is up‑regulated by hypoxia‑inducible factor‑1α in LPA2‑KO A549 cells, where it interacts with the Vitamin D receptor to enhance GSK‑3β‑mediated phosphorylation of the p160 nuclear receptor coactivator, ultimately promoting WISP2 transcription and attenuating aldehyde dehydrogenase‑mediated oxidative stress.",-38.0,0.4,geneorgeneproduct
"PKR activation in LPA2‑KO A549 cells up‑regulates HIF‑1α, which in turn induces WISP2 expression and enhances GSK‑3β‑mediated phosphorylation of the p160 nuclear receptor coactivator, thereby amplifying the inflammatory response to TLR4 stimulation in a hypoxic microenvironment.",-41.5,0.4,geneorgeneproduct
"PKCα activation in LPA2‑KO A549 cells enhances WISP2 transcription through a GSK‑3β‑dependent pathway, thereby increasing Hypoxia‑Inducible Factor‑1α‑mediated VEGFA expression.",-30.25,0.4,geneorgeneproduct
"PKG1-mediated phosphorylation of GSK-3β in LPA2‑KO A549 cells enhances HIF‑1α transcriptional activity, thereby up‑regulating WISP2 expression and promoting epithelial‑mesenchymal transition.",-31.75,0.4,geneorgeneproduct
"p19 expression is markedly up‑regulated in LPA2‑KO A549 cells, where it activates the GSK‑3β‑dependent degradation of Hypoxia Inducible Factor‑1α, thereby attenuating VEGFA transcription.",-24.75,0.4,geneorgeneproduct
"p160 nuclear receptor coactivator is up‑regulated by Hypoxia Inducible Factor‑1α in LPA2‑KO A549 cells, enhancing GSK‑3β‑mediated phosphorylation of the Vitamin D receptor and increasing expression of WISP2 while suppressing Aldehyde Dehydrogenases activity.",-28.125,0.4,geneorgeneproduct
"p5, a p19 homolog, is upregulated by hypoxia-inducible factor‑1α in LPA2‑KO A549 cells, where it interacts with the p160 nuclear‑receptor coactivator to enhance GSK‑3β‑mediated phosphorylation of the Vitamin D receptor, thereby modulating TLR4‑driven inflammatory signaling.",-43.0,0.4,geneorgeneproduct
"p15, a p19 homolog, is up‑regulated in LPA2‑KO A549 cells, where it interacts with the WISP2‑p160 nuclear receptor coactivator complex to suppress GSK‑3β‑mediated phosphorylation of Hypoxia‑Inducible Factor‑1α, thereby enhancing the transcription of Vitamin D receptor‑dependent Aldehyde Dehydrogenase genes in a PKD1‑dependent manner.",-41.5,0.4,geneorgeneproduct
"Activation of the Vitamin D receptor by calcitriol in LPA2‑KO macrophages upregulates the p19 subunit of the p160 nuclear receptor coactivator complex, thereby enhancing HIF‑1α‑driven transcription of Aldehyde Dehydrogenases and reducing TLR4‑mediated inflammatory signaling.",-26.875,0.4,geneorgeneproduct
"Activation and phosphorylation of the GSK-3β signaling cascade in LPA2‑KO A549 cells enhances the transcription of the WISP2 gene, thereby up‑regulating the p160 nuclear receptor coactivator and increasing the expression of the Vitamin D receptor, which in turn modulates the hypoxia‑inducible factor‑1α‑driven expression of aldehyde dehydrogenases and PKD1 while simultaneously attenuating TLR4‑mediated inflammatory signaling.",-61.25,0.4,geneorgeneproduct
"Activation or inhibition of the Vitamin D receptor in LPA2-KO macrophages modulates the expression of the p19 subunit of the hypoxia‑inducible factor‑1α complex, thereby influencing downstream WISP2‑mediated signaling pathways.",-42.0,0.4,geneorgeneproduct
"Activation by hypoxia‑inducible factor‑1α of the p19‑p160 nuclear receptor coactivator complex enhances GSK‑3β‑mediated phosphorylation of the Vitamin D receptor in LPA2‑KO A549 cells, thereby increasing WISP2 transcription and downstream aldehyde dehydrogenase expression.",-38.0,0.4,geneorgeneproduct
"Loss of LPA2 in LPA2-KO murine macrophages reduces TLR4‑induced NF‑κB activation, thereby attenuating the production of the pro‑inflammatory cytokine IL‑6 and limiting the downstream up‑regulation of Hypoxia‑Inducible Factor‑1α.",-35.75,0.4,geneorgeneproduct
"Loss-of-function mutations in the PKD1 gene of a Homo sapiens patient with autosomal dominant polycystic kidney disease were found to upregulate the expression of the p160 nuclear receptor coactivator, thereby enhancing the transcriptional activity of the Vitamin D receptor and increasing the synthesis of Aldehyde Dehydrogenases, which in turn mitigated the hypoxia‑induced activation of Hypoxia Inducible Factor‑1α and reduced the inflammatory signaling mediated by TLR4.",-48.25,0.4,geneorgeneproduct
"Loss‑of‑function of the LPA2‑KO allele in A549 cells leads to up‑regulation of the WISP2 gene, which in turn activates GSK‑3β‑dependent phosphorylation of the p19 subunit of the hypoxia‑inducible factor‑1α complex.",-31.5,0.4,geneorgeneproduct
"Lossy deletion of the GSK‑3β gene in A549 cells reduces p19‑ARF expression, thereby attenuating hypoxia‑inducible factor‑1α‑mediated angiogenic signaling.",-35.75,0.4,geneorgeneproduct
"Phosphorylated GSK‑3β in LPA2‑KO A549 cells activates the hypoxia‑inducible factor‑1α‑driven transcription of the vitamin D receptor, thereby enhancing WISP2‑mediated proliferation of the cancer cells.",-33.0,0.4,geneorgeneproduct
"Pharmacological inhibition of GSK‑3β in LPA2‑KO A549 cells upregulates HIF‑1α‑mediated VEGFA transcription, thereby enhancing angiogenic signaling and promoting tumor cell migration.",-26.5,0.4,geneorgeneproduct
"PhD-1 knockdown in A549 cells reduces HIF‑1α‑mediated VEGFA transcription, thereby impairing angiogenic sprouting in a hypoxic tumor microenvironment.",-37.25,0.4,geneorgeneproduct
"Pharmaceutical inhibition of GSK-3β in LPA2‑KO A549 cells up‑regulates the p19‑p160 nuclear receptor coactivator complex, thereby enhancing Vitamin D receptor‑mediated transcription of WISP2 and increasing hypoxia‑inducible factor‑1α‑driven expression of aldehyde dehydrogenases.",-36.25,0.4,geneorgeneproduct
"Cerebral ischemia in PKD1‑deficient A549 cells upregulates Hypoxia Inducible Factor‑1α, which in turn stimulates GSK‑3β‑mediated phosphorylation of the p160 nuclear receptor coactivator, thereby enhancing transcription of the WISP2 gene and increasing expression of aldehyde dehydrogenases.",-39.25,0.4,geneorgeneproduct
"Cytokine‑induced activation of Hypoxia Inducible Factor‑1α in LPA2‑KO A549 cells up‑regulates the p19‑p160 nuclear receptor coactivator complex, thereby enhancing GSK‑3β‑mediated phosphorylation of the Vitamin D receptor and stimulating WISP2 transcription in a PKD1‑dependent manner.",-29.75,0.4,geneorgeneproduct
"Cisplatin treatment of LPA2‑KO A549 cells upregulated the p160 nuclear receptor coactivator and increased HIF‑1α‑mediated transcription of WISP2, thereby enhancing cell survival through a GSK‑3β‑dependent pathway.",-33.0,0.4,geneorgeneproduct
"C-terminus deletion of the GSK-3β gene in A549 cells reduces p19 expression and enhances TLR4‑mediated NF‑κB activation, thereby increasing WISP2 transcription and promoting hypoxia‑inducible factor‑1α‑driven angiogenesis.",-43.5,0.4,geneorgeneproduct
"PTEN loss in LPA2‑KO A549 cells upregulates HIF‑1α, which in turn increases WISP2 expression and activates GSK‑3β‑mediated phosphorylation of the p160 nuclear receptor coactivator, thereby enhancing epithelial‑mesenchymal transition.",-29.25,0.4,geneorgeneproduct
"PTX3, a secreted glycoprotein, is up‑regulated by the p160 nuclear receptor coactivator in LPA2‑KO HeLa cells, thereby enhancing TLR4‑mediated NF‑κB signaling and promoting apoptosis through GSK‑3β activation.",-38.25,0.4,geneorgeneproduct
"PTC cells from the LPA2‑KO A549 line showed markedly increased HIF‑1α‑mediated transcription of the WISP2 gene, a process that was further amplified by the co‑activator p160 and suppressed by GSK‑3β inhibition.",-40.0,0.4,geneorgeneproduct
"PTPN11 overexpression in LPA2-KO HeLa cells enhances HIF‑1α‑mediated glycolysis, leading to increased VEGFA secretion and angiogenic sprouting.",-31.125,0.4,geneorgeneproduct
"Gastric cancer cells lacking LPA2-KO exhibit increased p19 expression, which activates the GSK‑3β‑dependent degradation of Hypoxia Inducible Factor‑1α, thereby reducing VEGF secretion and impairing angiogenesis.",-35.0,0.4,geneorgeneproduct
"GSK‑3β inhibition in LPA2‑KO A549 cells up‑regulates the p160 nuclear receptor coactivator, thereby enhancing HIF‑1α‑driven VEGFA transcription and promoting angiogenesis.",-20.5,0.4,geneorgeneproduct
"GPR30 activation in LPA2‑KO A549 cells up‑regulates the p19 subunit of the NF‑κB complex, thereby enhancing HIF‑1α‑mediated transcription of VEGFA and driving angiogenic sprouting.",-39.5,0.4,geneorgeneproduct
"Glycogen synthase kinase‑3β phosphorylation of the p19 subunit of the p160 nuclear receptor coactivator complex in LPA2‑KO HeLa cells enhances Hypoxia Inducible Factor‑1α‑mediated transcription of WISP2, thereby promoting epithelial‑mesenchymal transition.",-34.25,0.4,geneorgeneproduct
"Mutational loss of the p19 gene in LPA2-KO A549 cells upregulates WISP2 expression, thereby enhancing HIF‑1α‑mediated angiogenic signaling through GSK‑3β inhibition and Vitamin D receptor activation.",-30.875,0.4,geneorgeneproduct
"Mutant LPA2‑KO cells exhibit reduced p19‑mediated activation of the HIF‑1α pathway, leading to decreased expression of the Vitamin D receptor and impaired GSK‑3β‑dependent phosphorylation of the p160 nuclear receptor coactivator.",-35.25,0.4,geneorgeneproduct
"Mutations in the GSK‑3β gene product, such as the p160 nuclear receptor coactivator‑binding variant, were shown to up‑regulate Hypoxia‑Inducible Factor‑1α expression in LPA2‑KO HeLa cells, thereby enhancing VEGF‑mediated angiogenesis.",-30.0,0.4,geneorgeneproduct
"Mutual inhibition between the p19 tumor suppressor and the LPA2‑KO phenotype was revealed by up‑regulation of WISP2, which in turn recruited the p160 nuclear receptor coactivator to enhance GSK‑3β‑mediated phosphorylation of the Vitamin D receptor and stabilize Hypoxia‑Inducible Factor‑1α, thereby modulating Aldehyde Dehydrogenases expression in PKD1‑deficient TLR4‑stimulated cells.",-44.5,0.4,geneorgeneproduct
"High‐throughput CRISPR editing of the LPA2‑KO cell line revealed that loss of LPA2 upregulates the transcription factor HIF‑1α, which in turn increases expression of the vitamin D receptor and the co‑activator p160, thereby enhancing the transcription of the WISP2 gene in a hypoxic microenvironment.",-44.0,0.4,geneorgeneproduct
"High‑throughput CRISPR‑Cas9 editing of the PKD1 gene in the LPA2‑KO A549 cell line revealed that loss of LPA2 upregulates the p19 subunit of the p160 nuclear receptor coactivator complex, thereby enhancing HIF‑1α‑driven transcription of WISP2 and increasing Aldehyde Dehydrogenase‑mediated detoxification pathways.",-33.75,0.4,geneorgeneproduct
"High-salt treatment of LPA2-KO A549 cells upregulates the p19 subunit of the p160 nuclear receptor coactivator complex, thereby enhancing HIF‑1α‑driven VEGFA transcription and increasing VEGFR2 phosphorylation.",-36.25,0.4,geneorgeneproduct
"High glucose exposure upregulates the p19 subunit of the p160 nuclear receptor coactivator complex, thereby enhancing HIF‑1α‑mediated transcription of the WISP2 gene in PKD1‑deficient renal epithelial cells.",-34.5,0.4,geneorgeneproduct
"A neutralizing antibody against the HIV-1 envelope gp120 protein significantly reduced viral replication in cultured human CD4+ T cells, while a similar antibody targeting the Plasmodium falciparum circumsporozoite protein failed to inhibit parasite invasion of hepatocytes.",-35.0,0.4,organismtaxon
"A recombinant plasmid expressing the Plasmodium falciparum PfEMP1 domain fused to a GFP tag was transfected into HeLa cells, where it induced a robust interferon‑β response that was markedly attenuated when co‑treated with the small‑molecule inhibitor VX‑765, suggesting a potential therapeutic strategy for malaria‑associated inflammation in humans.",-42.0,0.4,organismtaxon
"A clinical trial in humans infected with Plasmodium falciparum showed that the antimalarial drug chloroquine reduced parasitemia by inhibiting the parasite’s protein kinase PfPKG, thereby preventing the parasite from invading red blood cells.",-38.0,0.4,organismtaxon
"A meta‑analysis of Staphylococcus aureus bloodstream infections in humans revealed that the presence of the mecA gene confers high-level resistance to methicillin, whereas a concurrent mutation in the femA gene reduces cell wall cross‑linking and increases susceptibility to vancomycin.",-33.75,0.4,organismtaxon
"Staphylococcus aureus infection in humans triggers a robust IL‑6 response that is amplified by the presence of the STAT3 c.1846C>T variant, leading to increased neutrophil recruitment and tissue damage.",-30.125,0.4,organismtaxon
"Streptococcus pneumoniae infection in rhesus monkeys triggers an upregulation of the host gene IFITM3, which enhances antiviral immunity against HIV‑1 and reduces viral replication.",-28.875,0.4,organismtaxon
"Staining of *Staphylococcus aureus* cultures with the fluorescent dye SYTO-9 revealed a significant increase in membrane permeability after exposure to the novel antimicrobial peptide, suggesting a direct bactericidal mechanism.",-36.0,0.4,organismtaxon
"Staph. aureus infection in humans triggers an up‑regulation of the pro‑inflammatory cytokine IL‑8, which is further amplified by the presence of the IL‑8 promoter polymorphism G-251A.",-35.75,0.4,organismtaxon
The clinical trial demonstrated that *Staphylococcus aureus* infection in humans was associated with a significant increase in IL‑6 production compared with patients infected with *HIV‑1* or *Plasmodium falciparum*.,-31.625,0.4,organismtaxon
"The observed increase in cytokine production by macrophages infected with *Staphylococcus aureus* was markedly attenuated when the cells were treated with the small‑molecule inhibitor *dexamethasone*, suggesting a potential therapeutic strategy for septic shock in humans.",-34.25,0.4,organismtaxon
"The pathogenicity of *Staphylococcus aureus* in humans is markedly enhanced by the presence of the *agr* locus, which upregulates exotoxin production and facilitates evasion of the host immune response.",-27.25,0.4,organismtaxon
"The intracellular replication of *Plasmodium falciparum* in erythrocytes of *Homo sapiens* is markedly inhibited by the antimalarial drug chloroquine, which binds to the parasite’s digestive vacuole and disrupts hemoglobin degradation.",-25.125,0.4,organismtaxon
"In the rhesus monkey model of HIV‑1 infection, the viral protein Vif binds to the host protein APOBEC3G, thereby preventing the deamination of the viral genome and facilitating efficient reverse transcription.",-28.25,0.4,organismtaxon
"In *Staphylococcus aureus* infections, the presence of the *mecA* gene variant *c.1-12del* correlates with increased resistance to methicillin and is associated with higher mortality rates in human patients, particularly among women, while the same variant has been identified in *HIV-1*-infected rhesus monkeys, suggesting cross-species transmission of antibiotic-resistant strains.",-53.5,0.4,organismtaxon
"In Staphylococcus aureus strains isolated from human patients, the presence of the mecA gene confers methicillin resistance, while in Plasmodium falciparum isolates from rhesus monkeys, a PfCRT K76T mutation correlates with chloroquine treatment failure.",-23.125,0.4,organismtaxon
"In rhesus monkeys infected with HIV-1, the viral protein Nef upregulates CCR5 expression, thereby enhancing the susceptibility of CD4+ T cells to viral entry and accelerating disease progression.",-21.75,0.4,organismtaxon
"Researchers infected rhesus monkeys with HIV‑1 and observed that the viral load correlated with increased expression of the host gene APOBEC3G, suggesting a potential therapeutic target for controlling infection in humans.",-25.875,0.4,organismtaxon
"Researchers observed that the Staphylococcus aureus strain MRSA-ABC produced a novel β-lactamase enzyme that inactivated the antibiotic vancomycin in human neutrophils, thereby increasing infection severity in hospitalized patients.",-40.0,0.4,organismtaxon
Researchers discovered that the *Staphylococcus aureus* strain isolated from a human patient exhibited a novel plasmid-encoded gene encoding a protein that enhances resistance to the antibiotic vancomycin.,-28.625,0.4,organismtaxon
Researchers isolated a novel plasmid from *Staphylococcus aureus* that encodes a protein capable of inhibiting the replication of *HIV-1* in cultured human T cells.,-23.625,0.4,organismtaxon
"Plasmodium falciparum infection in humans triggers a pronounced upregulation of the host gene G6PD, which in turn enhances parasite survival by modulating oxidative stress pathways.",-25.625,0.4,organismtaxon
"Plasma levels of the antiviral drug ribavirin were markedly higher in rhesus monkeys infected with HIV‑1 compared to humans, suggesting species‑specific pharmacokinetic differences that may influence treatment efficacy.",-26.25,0.4,organismtaxon
"Planktonic cultures of *Staphylococcus aureus* exposed to the quorum‑sensing inhibitor furanone C-30 exhibited a significant reduction in biofilm formation, suggesting a potential therapeutic strategy against device‑associated infections in humans.",-30.375,0.4,organismtaxon
"Plague‑resistant mice infected with *Staphylococcus aureus* showed a dramatic up‑regulation of the *TLR4* gene, which in turn triggered a robust interferon‑γ response that inhibited bacterial replication and protected the animals from septic shock.",-45.25,0.4,organismtaxon
"Hepatitis A virus infection in humans induces a robust interferon‑α response that upregulates the antiviral protein IFITM3, thereby limiting viral replication and reducing liver inflammation.",-19.375,0.4,organismtaxon
"HIV‑1 infection of human CD4⁺ T cells leads to up‑regulation of the viral protein Vpu, which in turn enhances the degradation of the host protein BST‑2 on the cell surface, thereby facilitating viral egress.",-26.25,0.4,organismtaxon
"Heterologous expression of the Plasmodium falciparum PfEMP1 protein in HeLa cells revealed that its interaction with human CD36 enhances cytoadherence, a key step in severe malaria pathogenesis.",-21.25,0.4,organismtaxon
"Huntington’s disease progression in rhesus monkeys infected with HIV‑1 was accelerated by a novel CRISPR‑Cas9‑mediated knock‑in of the human TP53 gene, which restored apoptosis pathways and reduced viral replication in the brain.",-42.25,0.4,organismtaxon
"Research on Staphylococcus aureus infection revealed that the bacterium’s agr quorum-sensing system activates the production of the exotoxin TSST‑1, which in turn triggers a hyperinflammatory response in human neutrophils.",-34.5,0.4,organismtaxon
"Research showed that *Staphylococcus aureus* infection in rhesus monkeys triggers a robust interferon‑γ response, mirroring the cytokine profile observed in humans with severe sepsis.",-24.75,0.4,organismtaxon
"Research in rhesus monkeys infected with HIV‑1 revealed that the viral protein Vpu down‑regulates the host cell surface protein tetherin, thereby enhancing virion release and accelerating disease progression.",-26.5,0.4,organismtaxon
"Research indicates that *Staphylococcus aureus* infection in *Homo sapiens* can upregulate the expression of the *toll-like receptor-2* gene, thereby enhancing the innate immune response.",-32.5,0.4,organismtaxon
Genomic surveillance of Staphylococcus aureus isolates from hospitalized humans revealed a novel plasmid-encoded beta-lactamase gene that confers resistance to cephalosporins.,-23.5,0.4,organismtaxon
Genetic analysis of *Staphylococcus aureus* isolates from HIV-1-infected humans revealed a novel *mecA* sequence variant that confers high-level resistance to methicillin.,-23.5,0.4,organismtaxon
Genotyping of Staphylococcus aureus isolates revealed a novel sequence variant in the mecA gene that correlates with increased resistance to methicillin in human clinical samples.,-25.0,0.4,organismtaxon
"Genetically engineered A549 cells infected with HIV‑1 exhibit increased expression of the viral envelope protein gp120, which enhances cell‑surface binding to human CD4 receptors and promotes syncytia formation.",-31.25,0.4,organismtaxon
"Silencing of the *pfkA* gene in *Plasmodium falciparum* reduces the parasite’s ability to invade erythrocytes, thereby lowering parasitemia in infected *Homo sapiens* patients.",-27.625,0.4,organismtaxon
Silico‑assisted CRISPR‑Cas9 editing of the *pfkA* locus in *Plasmodium falciparum* parasites derived from a clinical isolate of *Plasmodium falciparum* infection in a rhesus monkey revealed a novel deletion that conferred reduced growth in vitro compared with the wild‑type strain.,-54.0,0.4,organismtaxon
"Silversmiths of the immune system, the T cells from humans infected with HIV‑1, produce a cytokine cascade that enhances the replication of Plasmodium falciparum, while the same cascade simultaneously triggers apoptosis in Staphylococcus aureus‑infected epithelial cells.",-65.5,0.4,organismtaxon
"Silica nanoparticles functionalized with anti‑HIV‑1 gp120 antibodies significantly inhibited viral entry into cultured human CD4+ T cells, while co‑infection with Staphylococcus aureus biofilms exacerbated cytokine production in rhesus monkey macrophages.",-43.75,0.4,organismtaxon
"Co-infection of *Staphylococcus aureus* and *Plasmodium falciparum* in humans exacerbates cytokine storm, leading to severe anemia and increased mortality.",-20.625,0.4,organismtaxon
"Co‑infection of *Staphylococcus aureus* and *Plasmodium falciparum* in humans leads to synergistic modulation of cytokine profiles, exacerbating anemia and increasing mortality risk.",-26.625,0.4,organismtaxon
"Co-administration of the antimalarial drug artemisinin with the antiviral agent dolutegravir markedly reduced parasitemia in *Plasmodium falciparum*-infected rhesus monkeys, while also lowering viral load in HIV-1–positive humans, suggesting a synergistic host‑pathogen interaction that may inform future combination therapies.",-46.0,0.4,organismtaxon
"Co-culturing HeLa cells with Staphylococcus aureus strains that express the Panton–Valentine leukocidin toxin induces a rapid upregulation of the pro-inflammatory cytokine IL‑8, revealing a cell‑line–bacterial interaction that may model human inflammatory responses.",-41.0,0.4,organismtaxon
"Subsequent infection of rhesus monkeys with Plasmodium falciparum induced a marked upregulation of the parasite’s PfEMP1 gene, which in turn triggered a robust interferon‑γ response in the host immune cells.",-34.75,0.4,organismtaxon
"Substitution of the BRCA1 c.68_69delAG variant in the HeLa cell line derived from Homo sapiens was shown to increase sensitivity to the chemotherapeutic agent doxorubicin, whereas the same variant had no effect in the A549 cell line from Homo sapiens.",-34.25,0.4,organismtaxon
"Subcutaneous injection of the monoclonal antibody against PD-1 in rhesus monkeys infected with HIV‑1 reduced viral load and restored CD4+ T‑cell counts, suggesting a potential therapeutic strategy for AIDS patients.",-30.75,0.4,organismtaxon
"Sub‑lethal exposure of *Staphylococcus aureus* to sub‑MIC concentrations of daptomycin induced a rapid up‑regulation of the *mecA* gene, thereby increasing resistance to β‑lactam antibiotics in the bacterial population.",-34.25,0.4,organismtaxon
"Intravenous administration of doxycycline to a HeLa cell line infected with Staphylococcus aureus reduced bacterial load by activating the host's innate immune response, thereby improving cell viability.",-31.125,0.4,organismtaxon
"Intrahaemorrhagic encephalitis in rhesus monkeys infected with HIV-1 was exacerbated by co‑infection with Staphylococcus aureus, leading to markedly increased viral replication and severe neurological deficits.",-36.25,0.4,organismtaxon
"Intriguingly, infection of rhesus monkeys with Plasmodium falciparum induced a robust interferon‑γ response that mirrored the cytokine profile observed in humans during acute malaria episodes.",-26.0,0.4,organismtaxon
"Intramuscular injection of the HIV‑1 envelope protein gp120 into rhesus monkeys induced a robust interferon‑α response that was markedly amplified in animals pre‑treated with the antiviral drug ribavirin, revealing a dose‑dependent interaction between viral antigen exposure and host antiviral signaling pathways.",-44.0,0.4,organismtaxon
Gene silencing of the *pfkB* gene in *Plasmodium falciparum* infected *Homo sapiens* erythrocytes markedly reduces parasite replication and restores normal erythrocyte morphology.,-29.125,0.4,organismtaxon
Gene editing of the *Plasmodium falciparum* *pfcrt* locus in cultured *Plasmodium falciparum* parasites revealed that the K76T mutation confers chloroquine resistance while simultaneously increasing susceptibility to artemisinin in *Plasmodium falciparum* isolates derived from *Homo sapiens* patients.,-34.5,0.4,organismtaxon
"Gene therapy using CRISPR-Cas9 delivered by an adeno-associated virus vector in rhesus monkeys infected with HIV-1 reduced viral load and restored CD4+ T cell counts, indicating a promising approach for treating AIDS in non-human primates.",-33.5,0.4,organismtaxon
"Gene expression profiling of Staphylococcus aureus isolates from human patients revealed that the presence of the mecA gene confers resistance to methicillin, while a concurrent mutation in the gyrA sequence (S83L) increases fluoroquinolone susceptibility.",-36.5,0.4,organismtaxon
"Human-specific HCV-associated infection of hepatocytes in the Huh-7 cell line induces a rapid up‑regulation of the interferon‑stimulated gene IFITM3, which in turn limits viral replication by blocking membrane fusion.",-32.5,0.4,organismtaxon
"Human‐specific HCV‐associated Toxorynchites mosquitoes exhibit a higher viral replication rate in hepatocytes than in Drosophila, suggesting a host‑taxon‑dependent modulation of viral load.",-30.75,0.4,organismtaxon
"Human‑specific HCV‑associated viral replication in hepatocytes is markedly enhanced by the up‑regulation of the host gene IFN‑λ4, a finding that may explain the higher prevalence of chronic infection in individuals of African descent.",-35.0,0.4,organismtaxon
"Human-infecting Mycobacterium tuberculosis upregulates the ESX-1 secretion system to enhance macrophage cytotoxicity, thereby accelerating disease progression.",-24.5,0.4,organismtaxon
"Drosophila melanogaster infected with Mycobacterium tuberculosis shows increased expression of the immune‑responsive gene Relish, while the human‑specific protein TP53 remains unchanged.",-27.125,0.4,organismtaxon
"Dengue fever caused by Toxorynchites mosquitoes is more severe in human-specific populations, whereas the same viral strain infects chick embryos with minimal pathology.",-30.5,0.4,organismtaxon
"Doxorubicin treatment of human-specific HeLa cells expressing the TP53 c.215C>A variant reduced cell viability more than in wild‑type TP53 cells, suggesting a genotype‑dependent therapeutic response.",-32.25,0.4,organismtaxon
Dopamine D2 receptor antagonism in HCV‑associated hepatocytes of *Homo sapiens* reduces viral replication by up‑regulating interferon‑lambda expression.,-28.875,0.4,organismtaxon
"The HCV‑associated human‑specific strain of *Hepatitis C virus* (HCV) was isolated from a patient infected with the *HCV* genotype‑1b, revealing a novel NS5A sequence variant that enhances viral replication in hepatocytes.",-44.75,0.4,organismtaxon
"The human-specific HCV-associated protein NS5A interacts with the host gene HLA-DQA1, enhancing viral replication in HepG2 cells and increasing susceptibility to liver fibrosis.",-27.625,0.4,organismtaxon
"The viral replication of HCV-associated hepatitis C in human-specific hepatocytes is markedly enhanced by the interaction between the viral core protein and the host HNF4α transcription factor, leading to increased expression of the CYP3A4 enzyme.",-34.25,0.4,organismtaxon
"The CCR5 Δ32 allele, which confers resistance to HIV-1 infection, is found at higher frequencies in human-specific populations such as the Bantu and is absent in non-human primates, illustrating how host organism taxon influences pathogen susceptibility.",-45.75,0.4,organismtaxon
"HCV-associated infections in human-specific populations exhibit higher viral replication rates in hepatocytes compared to those in chimpanzee models, underscoring species-dependent differences in viral entry and immune evasion.",-30.0,0.4,organismtaxon
"Hepatitis C virus–associated liver fibrosis progression in human-specific HCV-infected patients is exacerbated by the upregulation of the CXCL10 chemokine, which is encoded by the CXCL10 gene and is highly expressed in hepatocytes of Homo sapiens.",-35.25,0.4,organismtaxon
"H1N1 infection in human-specific HCV-associated patients was found to upregulate the IFITM3 gene, thereby reducing viral replication in Drosophila and Mycobacterium tuberculosis cultures.",-36.5,0.4,organismtaxon
"Hansen’s disease caused by *Mycobacterium tuberculosis* is more prevalent in human-specific populations, yet recent studies show that the same strain can also infect *Drosophila* models, providing a useful system to dissect host‑pathogen interactions.",-39.5,0.4,organismtaxon
"In HCV‑associated hepatocellular carcinoma, the human‑specific TP53 mutation p.R337H was found to be more frequent in patients infected with Mycobacterium tuberculosis‑positive hepatocytes than in those with uninfected liver tissue.",-27.375,0.4,organismtaxon
"In human-specific HCV-infected hepatocytes, the viral NS5A protein interacts with the host protein PI4KA, enhancing viral replication and contributing to liver disease progression.",-22.625,0.4,organismtaxon
"In the human-specific HCV-associated cohort, the antiviral drug ribavirin markedly reduced viral load in patients infected with HCV genotype‑1, while the same treatment had no effect on HCV‑infected chimpanzees, illustrating a species‑dependent therapeutic response.",-41.25,0.4,organismtaxon
"In murine models of HCV‑associated liver fibrosis, human‑specific IL‑10 polymorphisms in the IL10 gene were found to modulate the expression of the antiviral protein OAS1, thereby influencing the susceptibility of Mycobacterium tuberculosis‑infected macrophages to bacterial killing.",-43.5,0.4,organismtaxon
"Mycobacterium tuberculosis infection in human-specific macrophages induces a rapid upregulation of the ESX-1 secretion system, which is essential for the pathogen’s virulence and the host’s inflammatory response.",-27.75,0.4,organismtaxon
"Mycoplasma pneumoniae infection in human-specific respiratory epithelium triggers upregulation of the chemokine CXCL10, which in turn recruits CD8+ T cells to the site of inflammation.",-31.25,0.4,organismtaxon
"My researchers observed that the HCV-associated viral replication rate in human-specific hepatocytes was markedly reduced when the antiviral compound ribavirin, a ChemicalEntity, was co‑treated, suggesting a potential therapeutic strategy for Hepatitis C virus infection.",-48.25,0.4,organismtaxon
"Mycroft‑C1, a human‑specific HCV‑associated sequence variant, was detected in the liver tissue of a patient infected with Mycobacterium tuberculosis, suggesting a potential cross‑species interaction between the viral genome and bacterial infection.",-50.5,0.4,organismtaxon
Toxorynchites mosquitoes carrying a human-specific HCV-associated viral strain were found to exhibit higher replication rates in Drosophila-derived cell lines than in bovine or S. cerevisiae cultures.,-24.125,0.4,organismtaxon
"Tobacco smoke exposure in *Mycobacterium tuberculosis*-infected humans increases the expression of the *ESX-1* secretion system, thereby enhancing the bacterium’s ability to evade host immunity.",-31.5,0.4,organismtaxon
"Triticum aestivum infection by Mycobacterium tuberculosis induces a robust interferon‑γ response that is markedly amplified in human‑specific macrophages compared with bovine cells, suggesting a host‑taxon‑dependent mechanism of innate immunity.",-38.0,0.4,organismtaxon
"Toxicity of the HCV‑associated drug led to increased apoptosis in human‑specific HepG2 cells, whereas the same compound had no effect on Drosophila melanogaster larvae.",-24.75,0.4,organismtaxon
"Microbial colonization by Mycobacterium tuberculosis in human-specific macrophages triggers a robust interferon‑γ response that up‑regulates the transcription factor IRF1, thereby enhancing the expression of the antimicrobial peptide cathelicidin.",-34.5,0.4,organismtaxon
Microglial activation in HCV‑associated liver cirrhosis was markedly reduced when human‑specific interferon‑α therapy was administered to patients infected with Mycobacterium tuberculosis.,-30.75,0.4,organismtaxon
MicroRNA‑122 knockdown in HCV‑associated hepatocytes of *Homo sapiens* reduces viral replication by down‑regulating the host lipid‑metabolism pathway.,-26.5,0.4,organismtaxon
Microbiological assays revealed that the HCV-associated strain of *Homo sapiens* hepatocytes exhibited a markedly increased replication rate when co-cultured with *Mycobacterium tuberculosis* in a human-specific in vitro model.,-33.0,0.4,organismtaxon
"Metabolic profiling of HCV‑associated hepatocytes from human‑specific HepG2 cells revealed that the viral protein NS5A binds to the host phosphatidylinositol‑3‑kinase complex, thereby activating AKT signaling and promoting cell survival.",-32.25,0.4,organismtaxon
Metformin treatment of human-specific HCV-associated hepatocytes derived from HepG2 cells reduced the expression of the HCV NS5A protein and restored insulin signaling.,-30.125,0.4,organismtaxon
"Metabolomic profiling of HCV‑associated hepatocytes from human‑specific Huh‑7 cells revealed that the viral protein NS5A interacts with the host phosphatidylinositol‑3‑kinase pathway, thereby enhancing lipid droplet formation and facilitating viral replication.",-33.5,0.4,organismtaxon
"Meticulous analysis of HCV‑associated liver biopsies from human‑specific patients revealed that the viral NS5A protein binds to the host Cyclin‑dependent kinase CDK6, thereby enhancing phosphorylation of the transcription factor STAT3 and promoting hepatocellular carcinoma progression.",-45.25,0.4,organismtaxon
"Chronic HCV-associated liver fibrosis in human-specific hepatocytes is exacerbated by the upregulation of the CXCL10 chemokine, which promotes recruitment of activated T cells and enhances the expression of the pro-inflammatory cytokine IL‑6.",-35.25,0.4,organismtaxon
"Chick embryos infected with Mycobacterium tuberculosis exhibit a dramatic upregulation of the host gene IFN‑γ, a response that is absent in human‑specific HCV‑associated cell lines.",-26.875,0.4,organismtaxon
"Chloroquine treatment of HCV‑associated hepatocytes isolated from a human‑specific HepG2 cell line markedly reduced viral replication, while the same drug had no effect on HCV replication in Drosophila S2 cells.",-32.75,0.4,organismtaxon
"Chikungunya virus infection in *Aedes aegypti* mosquitoes is amplified by the human-specific cytokine IL‑6, which in turn upregulates the *Dengue* virus envelope protein expression in *Homo sapiens* hepatocytes.",-37.75,0.4,organismtaxon
"A human-specific HCV-associated gene variant in the TP53 locus was found to increase viral replication in hepatocytes derived from the HepG2 cell line, suggesting a direct interaction between the viral RNA and the host DNA repair machinery.",-29.125,0.4,organismtaxon
"A HCV‑associated infection in human‑specific hepatocytes activates the HNF4A gene, increasing the expression of the antiviral protein APOBEC3G and thereby limiting viral replication.",-30.0,0.4,organismtaxon
"A recent study showed that HCV‑associated hepatitis in human‑specific hepatocytes upregulates the interferon‑stimulated gene IFITM3, thereby reducing viral replication in cultured Huh‑7 cells.",-30.125,0.4,organismtaxon
"A study of HCV‑associated liver pathology in human‑specific hepatocytes revealed that the viral NS5A protein binds to the host protein PI4KIIIα, thereby enhancing phosphatidylinositol‑4‑phosphate production and promoting viral replication.",-30.75,0.4,organismtaxon
"Research using the human-specific Hepatitis C virus (HCV)-associated cell line Huh‑7.5 revealed that the viral protein NS5A directly interacts with the host protein phosphatidylinositol‑3‑kinase, thereby enhancing PI3K/Akt signaling and promoting cell survival.",-39.5,0.4,organismtaxon
"Research indicates that HCV-associated hepatocytes from human-specific liver tissue exhibit increased expression of the HCV core protein, which in turn upregulates the host gene IFN‑λ1, thereby enhancing antiviral signaling in infected cells.",-41.0,0.4,organismtaxon
"Research on HCV-associated *Homo sapiens* liver cells revealed that the viral protein NS5A binds to the human-specific transcription factor STAT3, thereby enhancing the expression of the *IL6* gene and promoting inflammation.",-35.75,0.4,organismtaxon
"Research in a human-specific HCV-associated cell line revealed that the viral protein NS5A interacts with the host protein PI4KA, thereby enhancing viral replication in hepatocytes.",-30.25,0.4,organismtaxon
"Bacterial infection with Mycobacterium tuberculosis activates the human-specific transcription factor NF‑κB, leading to increased expression of the cytokine IL‑6 in infected macrophages.",-22.125,0.4,organismtaxon
"Bovine HCV-associated infection in *Mycobacterium tuberculosis*-infected *Drosophila* larvae was shown to upregulate the human-specific interferon‑β gene, thereby enhancing antiviral immunity.",-37.25,0.4,organismtaxon
"BAV1 expression in Mycobacterium tuberculosis-infected macrophages was upregulated by the human-specific cytokine IFN-γ, suggesting a pathogen–host interaction that may influence disease progression.",-39.75,0.4,organismtaxon
Biosensor‑based detection of HCV‑associated viral RNA in human‑specific plasma samples revealed a significant correlation with the expression of the interferon‑stimulated gene IFITM3.,-35.75,0.4,organismtaxon
"Coxsackievirus B3 infection in human-specific HCV-associated hepatocytes triggers a rapid upregulation of interferon‑lambda, whereas the same viral strain fails to induce this response in Drosophila melanogaster cells.",-32.5,0.4,organismtaxon
C-reactive protein levels were significantly higher in HCV-associated human-specific hepatocytes infected with Mycobacterium tuberculosis compared to uninfected bovine liver cells.,-24.75,0.4,organismtaxon
"Cumulative analysis of HCV‑associated gene expression in human‑specific hepatocytes revealed that the viral NS5A protein upregulates the interferon‑stimulated gene IFITM3, thereby enhancing antiviral resistance in the host.",-36.25,0.4,organismtaxon
"Cytokine‑mediated activation of the NF‑κB pathway in Mycobacterium tuberculosis–infected macrophages from human‑specific HCV‑associated patients increases IL‑6 production, thereby promoting a pro‑inflammatory microenvironment that facilitates bacterial persistence.",-34.75,0.4,organismtaxon
Outpatient HIV-positive humans infected with Human Papillomavirus and Plasmodium falciparum exhibit increased inflammatory cytokine production compared to HIV-negative controls.,-13.8125,0.4,organismtaxon
"Outpatients infected with Human Papillomavirus and HIV-positive patients exhibit increased expression of the E6/E7 oncogenes in their cervical epithelial cells, which in turn promotes dysregulation of the p53 tumor suppressor pathway in humans.",-35.25,0.4,organismtaxon
"Out‑patient HIV‑positive humans infected with Human Papillomavirus exhibit higher rates of cervical dysplasia than HIV‑negative controls, suggesting a synergistic effect of viral co‑infection on disease progression.",-23.875,0.4,organismtaxon
"Out-patients infected with Human Papillomavirus and HIV-positive individuals in Mangifera indica Linn plantations exhibit increased susceptibility to Plasmodium falciparum malaria, prompting targeted antimalarial therapy.",-35.25,0.4,organismtaxon
"In HIV‑positive humans, the presence of Human Papillomavirus DNA in cervical biopsies was associated with an increased risk of developing invasive squamous cell carcinoma, prompting routine outpatient screening for high‑risk viral genotypes.",-26.5,0.4,organismtaxon
"In outpatient HIV‑positive humans, the presence of Human Papillomavirus DNA was associated with increased expression of the immune‑regulatory gene IFITM3, suggesting a potential viral‑host interaction that may influence disease progression.",-25.125,0.4,organismtaxon
"In the outpatient clinic, HIV‑positive humans infected with Human Papillomavirus exhibited a higher prevalence of cervical dysplasia compared with HIV‑negative patients.",-14.875,0.4,organismtaxon
"In an outpatient cohort of HIV‑positive humans, the presence of Human Papillomavirus DNA was associated with increased expression of the viral E6 protein in cervical epithelial cells, suggesting a direct interaction between the virus and host cellular pathways.",-23.25,0.4,organismtaxon
HIV‑positive patients infected with Human Papillomavirus exhibit increased cervical dysplasia rates compared with HIV‑negative humans.,-12.8125,0.4,organismtaxon
"Homo sapiens patients infected with Human Papillomavirus exhibit increased expression of the E6 oncogene, which downregulates the tumor suppressor TP53 and promotes cervical epithelial cell proliferation.",-22.0,0.4,organismtaxon
"HLA‑B*27 expression in HIV‑positive humans correlates with increased susceptibility to Human Papillomavirus‑induced cervical lesions, whereas HLA‑B*27-negative patients exhibit a reduced viral load and milder disease progression.",-34.5,0.4,organismtaxon
Heterologous expression of the Human Papillomavirus E6 protein in HeLa cells revealed that its interaction with the TP53 gene product promotes apoptosis resistance in HIV-positive human patients.,-27.75,0.4,organismtaxon
"Human Papillomavirus infection in HIV‑positive patients was associated with increased expression of the E6 oncogene in HeLa cells, leading to p53 degradation and enhanced cell proliferation.",-22.0,0.4,organismtaxon
"Human patients infected with Human Papillomavirus exhibit increased expression of the E6 oncogene, which in turn downregulates the tumor suppressor TP53, thereby promoting cellular proliferation.",-20.375,0.4,organismtaxon
"Human HIV‑positive patients infected with Plasmodium falciparum exhibit higher rates of anemia, and the presence of the rDEN2Delta30‑4995 strain in the same cohort is associated with increased cytokine production.",-36.5,0.4,organismtaxon
"Human papillomavirus infection in HIV‑positive patients was associated with increased expression of the E6 oncoprotein in cultured HeLa cells, leading to degradation of TP53 and activation of the PI3K‑AKT pathway.",-24.375,0.4,organismtaxon
"During outpatient visits, HIV‑positive humans infected with Human Papillomavirus and Plasmodium falciparum exhibited a higher incidence of fever, suggesting a synergistic interaction between viral and parasitic pathogens.",-21.625,0.4,organismtaxon
"During a multicenter outpatient study, HIV‑positive humans infected with Human Papillomavirus showed a higher incidence of cervical dysplasia compared to HIV‑negative controls.",-20.0,0.4,organismtaxon
"During routine outpatient screening, HIV‑positive humans infected with Human Papillomavirus demonstrated a higher prevalence of cervical dysplasia compared with HIV‑negative controls.",-20.125,0.4,organismtaxon
"During an outpatient study of HIV‑positive humans, researchers observed that infection with Human Papillomavirus in the presence of Plasmodium falciparum co‑infected patients increased the expression of the viral E6 protein, thereby accelerating the degradation of the tumor suppressor TP53.",-35.75,0.4,organismtaxon
"Plasma levels of the antiviral drug ribavirin were significantly higher in HIV-positive humans infected with Human Papillomavirus compared to HIV-negative patients, suggesting a pharmacokinetic interaction that may influence viral replication in the host organism.",-27.75,0.4,organismtaxon
"Plasmodium falciparum infection in HIV‑positive patients was associated with a significant increase in the expression of the parasite’s PfEMP1 gene, leading to enhanced cytoadherence and severe anemia in the outpatient cohort.",-28.125,0.4,organismtaxon
"Plasmid‑encoded rDEN2Delta30-4995 delivered to C. elegans infected with Plasmodium falciparum reduces parasite load, suggesting a potential therapeutic strategy for HIV‑positive humans.",-27.375,0.4,organismtaxon
"Pluripotent stem cells from HIV‑positive human patients infected with Human Papillomavirus were differentiated into neural lineages, revealing that the viral E6 protein upregulates the TP53 gene product and induces apoptosis in the resulting neurons.",-36.25,0.4,organismtaxon
"Among HIV-positive patients, the presence of Human Papillomavirus in cervical biopsies of humans was associated with increased expression of the E6 oncoprotein, which in turn downregulated p53 and promoted cellular transformation.",-29.5,0.4,organismtaxon
"Among outpatient HIV‑positive humans, the presence of Human Papillomavirus DNA in cervical biopsies was associated with higher rates of cervical intraepithelial neoplasia compared to HIV‑negative controls.",-20.625,0.4,organismtaxon
"Among the outpatient HIV‑positive humans, the presence of Human Papillomavirus DNA in cervical biopsies correlated with increased expression of the E6 oncogene, suggesting a direct viral contribution to cervical dysplasia.",-32.5,0.4,organismtaxon
"Among humans infected with HIV‑positive patients, the presence of Human Papillomavirus in the oral mucosa was associated with an increased risk of developing oral squamous cell carcinoma.",-27.125,0.4,organismtaxon
"The outpatient HIV‑positive human patient exhibited a markedly increased viral load after receiving the rDEN2Δ30‑4995 vaccine, prompting investigation of the interaction between the Human Papillomavirus and Plasmodium falciparum‑derived immune responses.",-31.5,0.4,organismtaxon
"The HIV‑positive patients infected with Human Papillomavirus exhibited a significantly higher rate of cervical dysplasia compared with HIV‑negative controls, suggesting a synergistic pathogenic interaction in humans.",-21.875,0.4,organismtaxon
"The inpatient cohort of HIV‑positive humans receiving antiretroviral therapy exhibited a statistically significant reduction in plasma HIV‑1 RNA levels when treated with the novel small molecule inhibitor rDEN2Delta30‑4995, which binds to the viral reverse transcriptase active site.",-36.25,0.4,organismtaxon
The presence of Human Papillomavirus DNA in outpatient HIV‑positive patients infected with Plasmodium falciparum was associated with a higher incidence of cervical dysplasia in humans.,-21.125,0.4,organismtaxon
"Epidemiologic surveillance of HIV‑positive patients revealed that the prevalence of Human Papillomavirus infection was significantly higher in outpatient adults compared with the general human population, suggesting a potential interaction between HIV and HPV in humans.",-30.5,0.4,organismtaxon
"Eighty percent of HIV‑positive patients infected with Human Papillomavirus exhibited increased cervical dysplasia when treated with the recombinant rDEN2Delta30‑4995 vaccine, suggesting a synergistic effect of viral co‑infection on disease progression.",-34.75,0.4,organismtaxon
"Ectopic expression of the Human Papillomavirus E6 protein in HeLa cells increases the transcription of the TP53 gene product, leading to apoptosis in these human cancer cells.",-30.125,0.4,organismtaxon
"Elderly HIV‑positive humans infected with Human Papillomavirus exhibit a higher prevalence of anal intra‑epithelial lesions, prompting outpatient screening and early antiviral intervention.",-33.25,0.4,organismtaxon
"Pathogen‑specific T‑cell responses against Human Papillomavirus were markedly enhanced in HIV‑positive patients receiving antiretroviral therapy, leading to a significant reduction in cervical lesion progression.",-30.875,0.4,organismtaxon
"Pathogenic HIV-positive humans infected with Human Papillomavirus exhibit elevated levels of the oncogenic E6 protein, which binds and degrades the tumor suppressor TP53, thereby enhancing cellular proliferation.",-31.25,0.4,organismtaxon
"Pathologic colonization of the human airway by *Plasmodium falciparum* in HIV-positive patients leads to a marked increase in inflammatory cytokine production, which in turn exacerbates pulmonary edema and accelerates disease progression.",-44.25,0.4,organismtaxon
"Pathological colonization of the respiratory tract by *Plasmodium falciparum* in HIV-positive humans was associated with a significant increase in inflammatory cytokine production, as measured by elevated IL‑6 levels in outpatient blood samples.",-37.0,0.4,organismtaxon
"Patients infected with Plasmodium falciparum exhibited increased parasitemia, and treatment with the antimalarial drug artemisinin reduced parasite load in human subjects.",-19.75,0.4,organismtaxon
"Patients receiving rDEN2Delta30-4995 as a live-attenuated vaccine showed reduced viremia and increased neutralizing antibody titers in HIV-positive humans, confirming the vaccine’s safety and immunogenicity in this high-risk organism taxon.",-32.25,0.4,organismtaxon
Patients with HIV‑positive status infected by Human Papillomavirus and Plasmodium falciparum exhibited a higher rate of opportunistic bacterial infections compared to HIV‑negative controls.,-20.625,0.4,organismtaxon
"Patients treated with the rDEN2Delta30-4995 vaccine showed a significant reduction in viremia in HIV‑positive humans infected with Human Papillomavirus, indicating a potential cross‑protection effect against co‑existing bacterial pathogens.",-33.25,0.4,organismtaxon
"Oral administration of the rDEN2Delta30-4995 vaccine in HIV‑positive humans reduced subsequent Plasmodium falciparum parasitemia, suggesting a cross‑species immunomodulatory effect that may benefit outpatient malaria control.",-29.75,0.4,organismtaxon
"Orally administered rDEN2Delta30‑4995 induced a robust neutralizing antibody response in HIV‑positive humans, whereas the same vaccine elicited only modest titers in patients infected with Plasmodium falciparum.",-30.375,0.4,organismtaxon
"Orphan HIV‑positive patients infected with Human Papillomavirus exhibit increased susceptibility to Plasmodium falciparum malaria, prompting outpatient studies in Homo sapiens that compare parasite load with viral co‑infection levels.",-42.75,0.4,organismtaxon
"Ormal infection of HIV‑positive humans with Human Papillomavirus type‑16 was associated with increased expression of the oncogenic E6 protein, leading to p53 degradation and enhanced proliferation of cervical epithelial cells.",-50.25,0.4,organismtaxon
"A recent outpatient study in HIV‑positive humans found that infection with Human Papillomavirus type‑16, a DNA virus, increased the expression of the E6 oncogene in cervical epithelial cells, thereby promoting cellular transformation and elevating the risk of squamous cell carcinoma.",-43.0,0.4,organismtaxon
"A prospective outpatient cohort of HIV‑positive humans infected with Human Papillomavirus demonstrated that the viral load was significantly higher in patients who also carried a Plasmodium falciparum infection, suggesting a synergistic effect on immune suppression.",-26.875,0.4,organismtaxon
"APL clinical trial enrolled HIV‑positive humans, who were inoculated with a live‑attenuated rDEN2Δ30‑4995 vaccine and monitored for antibody responses against Human Papillomavirus antigens.",-37.0,0.4,organismtaxon
"A study of HIV‑positive patients revealed that the Human Papillomavirus E6 protein binds to the p53 protein in human epithelial cells, thereby promoting viral replication and contributing to the development of cervical cancer.",-30.375,0.4,organismtaxon
"Research on HIV‑positive humans revealed that infection with Human Papillomavirus in the genital tract increased the risk of anal squamous cell carcinoma, prompting outpatient screening protocols.",-28.0,0.4,organismtaxon
"Research demonstrated that HIV‑positive humans infected with Human Papillomavirus exhibited increased expression of the E6 oncoprotein, which in turn upregulated the TP53 gene product in cervical epithelial cells.",-32.25,0.4,organismtaxon
"Research investigators observed that HIV‑positive patients infected with Human Papillomavirus exhibited higher rates of cervical dysplasia compared with HIV‑negative controls, suggesting a synergistic effect of viral co‑infection on disease progression.",-30.25,0.4,organismtaxon
"Research at the outpatient clinic showed that HIV‑positive humans infected with Human Papillomavirus exhibited higher levels of the E6 oncoprotein, which in turn downregulated the p53 tumor suppressor gene.",-32.0,0.4,organismtaxon
"The CRISPR‑Cas9‑mediated knockout of the Drosophila *dpp* gene in *Drosophila melanogaster* larvae led to a dramatic reduction in wing vein formation, confirming the gene’s essential role in extracellular matrix signaling during morphogenesis.",-27.75,0.4,organismtaxon
"The Drosophila melanogaster model of human immunodeficiency virus type‑1 infection revealed that the viral protein Vif interacts with the host E3 ubiquitin ligase complex to degrade the antiviral protein APOBEC3G, thereby enhancing viral replication.",-27.625,0.4,organismtaxon
"The transgenic Drosophila strain carrying the human immunodeficiency virus type‑1 gag‑pol cassette exhibits enhanced viral replication and increased expression of the viral envelope protein gp120, thereby providing a robust model for studying HIV‑1 pathogenesis in an invertebrate system.",-36.25,0.4,organismtaxon
"The murine model of hepatitis A infection demonstrated that the viral protein VP1 binds to the host cell receptor CD81, thereby enhancing viral entry and subsequent replication in hepatocytes.",-26.375,0.4,organismtaxon
"In Drosophila, the overexpression of the gene *dMyc* enhances the proliferation of the imaginal disc cells, a process that is suppressed by the dietary intake of mangosteen-derived polyphenols.",-32.25,0.4,organismtaxon
"In studies of Drosophila melanogaster, the overexpression of the gene *dpp* in the wing imaginal disc was shown to enhance the production of the secreted protein Wingless, thereby promoting proper wing patterning.",-40.75,0.4,organismtaxon
"In *Drosophila melanogaster*, the overexpression of the *dMyc* gene enhances the proliferation of wing imaginal disc cells, a phenomenon that parallels the hyperplasia observed in human breast cancer tissues.",-30.625,0.4,organismtaxon
"In **Drosophila melanogaster**, the overexpression of the **GeneOrGeneProduct** *dpp* leads to a pronounced increase in **CellLine**-derived **Murine** embryonic stem cell proliferation, suggesting a conserved regulatory pathway that may be exploited for **DiseaseOrPhenotypicFeature** modeling of **OrganismTaxon**-specific developmental disorders.",-39.25,0.4,organismtaxon
"A Drosophila melanogaster model of human immunodeficiency virus type‑1 infection revealed that the viral protein Vpu down‑regulates the host cell surface protein tetherin, thereby enhancing viral release from infected cells.",-29.25,0.4,organismtaxon
"A CRISPR-Cas9 edited Drosophila strain carrying a CRBN c.1234delA variant shows increased sensitivity to the anti‑cancer drug doxorubicin, suggesting a potential therapeutic target for human immunodeficiency virus type‑1‑associated neurotoxicity.",-43.25,0.4,organismtaxon
"A transgenic Drosophila strain overexpressing the human immunodeficiency virus type‑1 Tat protein exhibits increased viral replication and induces a pronounced inflammatory response in the fly gut, mirroring the cytokine profile observed in infected human intestinal epithelial cells.",-39.5,0.4,organismtaxon
"A single‑cell RNA‑seq analysis of Drosophila melanogaster wing imaginal discs revealed that the transcription factor dMyc, encoded by the gene MYC, is up‑regulated in a subset of cells that also express the cell‑surface receptor Notch, suggesting a regulatory interaction that may influence wing development.",-41.0,0.4,organismtaxon
"Injection of the mouse mammary tumor virus into Drosophila melanogaster larvae led to the expression of the viral envelope protein gp70, which subsequently induced apoptosis in the developing larval gut epithelium.",-30.375,0.4,organismtaxon
"Injection with a Drosophila-derived recombinant protein reduced hepatitis A viral load in human immunodeficiency virus type‑1‑infected murine macrophages, suggesting a cross‑species antiviral mechanism.",-44.0,0.4,organismtaxon
"Injection-induced inflammation in Drosophila melanogaster larvae expressing human immunodeficiency virus type‑1 protease leads to up‑regulation of the antimicrobial peptide diptericin, revealing a conserved innate immune pathway shared with mammalian models.",-53.5,0.4,organismtaxon
"Injection by Drosophila melanogaster of a plasmid encoding the human immunodeficiency virus type‑1 envelope protein gp120 induces a robust interferon‑α response that is markedly attenuated in the presence of Panax ginseng extract, suggesting a potential antiviral mechanism mediated by the plant’s triterpenoid saponins.",-64.5,0.4,organismtaxon
Proteomic analysis of Drosophila melanogaster larvae infected with human immunodeficiency virus type‑1 revealed a significant up‑regulation of the viral envelope protein gp120 and a concomitant down‑regulation of the host gene encoding the cell surface receptor CD4.,-40.0,0.4,organismtaxon
"Protease activity of the mouse mammary tumor virus envelope protein in Drosophila larvae was inhibited by a Panax ginseng extract, reducing viral entry and subsequent hepatitis A–like pathology in the murine gut.",-34.75,0.4,organismtaxon
Proteolytic cleavage of the Drosophila Toll receptor by the serine protease Spaetzle-activating enzyme enhances innate immune signaling and increases resistance to human immunodeficiency virus type‑1 infection in transgenic flies.,-39.5,0.4,organismtaxon
"Proteasomal degradation of the Drosophila protein Dscam1 is enhanced by the chemical inhibitor MG132, leading to increased apoptosis in cultured S2 cells.",-36.75,0.4,organismtaxon
"Murine macrophages infected with human immunodeficiency virus type‑1 exhibit upregulated expression of the chemokine CXCL10, which in turn stimulates dendritic cell migration and enhances antiviral interferon‑β production.",-34.25,0.4,organismtaxon
"Murinae-derived mice infected with human immunodeficiency virus type‑1 exhibit elevated expression of the viral protein Vpu, which enhances the degradation of the host CD4 receptor and facilitates viral replication.",-44.5,0.4,organismtaxon
"Murach's disease in Drosophila melanogaster is exacerbated by a missense mutation in the Drosophila insulin receptor gene, which reduces insulin signaling and increases susceptibility to oxidative stress.",-47.5,0.4,organismtaxon
"Murines infected with human immunodeficiency virus type‑1 exhibit a marked increase in the expression of the chemokine receptor CXCR4, which in turn enhances the viral entry into CD4+ T cells.",-45.5,0.4,organismtaxon
"Homo sapiens infected with human immunodeficiency virus type‑1 exhibit elevated levels of the viral protein Tat, which enhances the transcription of the host gene CCR5, thereby increasing susceptibility to HIV‑1 entry.",-36.75,0.4,organismtaxon
"Hepatitis A infection in Drosophila larvae is experimentally induced by feeding them a diet supplemented with a high concentration of mangosteen extract, which subsequently triggers an upregulation of the innate immune gene Toll in the larval fat body.",-38.25,0.4,organismtaxon
"Heterologous expression of the human immunodeficiency virus type‑1 envelope protein in Drosophila melanogaster cells revealed that the viral glycoprotein binds to the fly's CD4‑like receptor, triggering a downstream signaling cascade that mimics the human T‑cell activation pathway.",-41.25,0.4,organismtaxon
"HIV-1 infection of Drosophila melanogaster cells leads to upregulation of the viral envelope protein gp120, which in turn activates the host gene product NF‑κB, thereby increasing the transcription of pro‑inflammatory cytokines and contributing to viral pathogenesis.",-43.75,0.4,organismtaxon
"Mutation of the HLA‑B*27 allele in Drosophila melanogaster increases susceptibility to a viral infection that mimics human immunodeficiency virus type‑1 pathogenesis, thereby providing a model for studying antigen presentation in a non‑mammalian organism.",-35.0,0.4,organismtaxon
"Mutation analysis of the mouse mammary tumor virus envelope gene in a Drosophila cell line revealed that the LTR insertion enhances viral replication in murine macrophages, suggesting cross‑species transcriptional activation.",-35.0,0.4,organismtaxon
"Mutation in the Drosophila *dpp* gene disrupts embryonic dorsal–ventral patterning, causing a lethal phenotype that is rescued by co‑expression of the *h* gene from a human immunodeficiency virus type‑1 vector.",-48.0,0.4,organismtaxon
"Mutation accumulation in the Drosophila *dpp* gene disrupts wing patterning, whereas a complementary mutation in the *Dpp* pathway of a murine *Hepatitis A* model leads to aberrant liver regeneration.",-55.25,0.4,organismtaxon
Cell lines derived from Drosophila melanogaster were used to demonstrate that the Panax ginseng extract downregulates the expression of the hepatitis A virus capsid protein in a dose‑dependent manner.,-26.125,0.4,organismtaxon
"Cellular signaling studies in Drosophila melanogaster revealed that the overexpression of the gene product Dpp, a BMP family member, enhances the proliferation of wing imaginal disc cells, a process that is suppressed by the small molecule inhibitor dorsomorphin.",-48.5,0.4,organismtaxon
Cell-to-cell transmission of human immunodeficiency virus type&nbsp;1 in Drosophila melanogaster larvae expressing the viral envelope protein gp120 demonstrates that the viral glycoprotein can hijack the host endocytic machinery to facilitate intercellular spread.,-45.5,0.4,organismtaxon
"Cell proliferation in Drosophila melanogaster is markedly enhanced by the overexpression of the gene product dMyc, which is regulated through the PI3K/AKT signaling pathway and is known to interact with the transcription factor FoxO.",-41.25,0.4,organismtaxon
"Exposure of Drosophila melanogaster larvae to the mangosteen-derived compound α-mangostin induced a significant upregulation of the antioxidant gene Sod2, suggesting a protective response against oxidative stress in this organism taxon.",-29.625,0.4,organismtaxon
"Exposure to the mouse mammary tumor virus in Drosophila melanogaster increases the incidence of hepatocellular carcinoma, suggesting a cross‑species oncogenic potential.",-26.75,0.4,organismtaxon
"Exposure studies in Drosophila melanogaster revealed that ingestion of mangosteen extract downregulated the expression of the heat‑shock protein Hsp70, thereby reducing oxidative stress and improving survival after exposure to ultraviolet radiation.",-40.75,0.4,organismtaxon
"Exposure-induced oxidative stress in Drosophila melanogaster upregulates the antioxidant gene Sod2, thereby enhancing resistance to heat shock and extending lifespan.",-35.5,0.4,organismtaxon
"Drosophila melanogaster infected with human immunodeficiency virus type‑1 shows increased expression of the antiviral gene IFITM3, which in turn reduces viral replication and protects the flies from lethal disease.",-30.625,0.4,organismtaxon
"Dexamethasone treatment of Drosophila melanogaster larvae infected with human immunodeficiency virus type‑1 homologues reduced viral load while upregulating the innate immune gene Toll, illustrating cross‑species antiviral defense mechanisms.",-41.0,0.4,organismtaxon
"Dorsal root ganglion neurons from Drosophila melanogaster were found to express the human immunodeficiency virus type‑1 envelope protein gp120, which induced a calcium‑dependent apoptotic cascade in the murine Schwann cell line S16.",-44.25,0.4,organismtaxon
"Dysregulated expression of the Drosophila gene *wingless* in *Drosophila melanogaster* larvae leads to aberrant wing development, a phenotype that parallels the wing‑deformity observed in *Drosophila* mutants carrying the *wg* c.1234delA sequence variant.",-48.75,0.4,organismtaxon
"Silencing of the Drosophila *sod2* gene in *Drosophila melanogaster* larvae leads to increased oxidative stress and a higher incidence of neurodegeneration, mirroring the mitochondrial dysfunction observed in human Parkinson’s disease.",-33.5,0.4,organismtaxon
"Silk‑fibroin from *Drosophila* larvae, when co‑administered with the antiviral compound panobinostat, synergistically inhibited replication of human immunodeficiency virus type‑1 in cultured murine macrophages.",-44.5,0.4,organismtaxon
"Silenced expression of the Drosophila *dpp* gene in *Drosophila melanogaster* larvae leads to a dramatic reduction in wing vein patterning, revealing a conserved role for this morphogen across *Drosophila* and *Homo sapiens* embryonic development.",-38.25,0.4,organismtaxon
"Silvestrol, a natural compound isolated from *Panax ginseng*, selectively inhibits the translation initiation factor eIF4A in *Drosophila* S2 cells, thereby reducing the expression of the *Drosophila* gene *dMyc* and attenuating the proliferation of *Drosophila* tumor models.",-41.25,0.4,organismtaxon
Activation of the Toll‑like receptor pathway in Drosophila melanogaster infected with human immunodeficiency virus type‑1 leads to up‑regulation of antimicrobial peptides and enhances survival against secondary bacterial challenge.,-33.25,0.4,organismtaxon
"Activation by the mouse mammary tumor virus promoter drives overexpression of the human immunodeficiency virus type‑1 Tat protein in Drosophila melanogaster, resulting in neurodegeneration that mimics Parkinson’s disease phenotypes.",-40.5,0.4,organismtaxon
"Activation pathway analysis in Drosophila revealed that the gene product of the *dpp* signaling cascade is upregulated by the chemical entity ginsenoside Rb1, a constituent of Panax ginseng, and this upregulation enhances the proliferation of the *Drosophila* wing imaginal disc cells.",-70.5,0.4,organismtaxon
"Activation or inhibition of the PI3K/AKT signaling pathway in Drosophila melanogaster was shown to alter the expression of the insulin-like peptide gene Ilp2, thereby affecting the organism's growth and metabolic homeostasis.",-49.0,0.4,organismtaxon
"Genome-wide association studies in Drosophila melanogaster revealed that the loss of the gene *dpp* increases susceptibility to viral infection by human immunodeficiency virus type‑1, a finding that parallels the role of *dpp* in murine models of hepatitis A.",-49.25,0.4,organismtaxon
"Genome‑wide association studies in Drosophila melanogaster revealed that a missense variant in the *dpp* gene increases susceptibility to oxidative stress, a phenotype that is also observed in murine models of hepatitis A infection.",-31.0,0.4,organismtaxon
"Genome editing of the Drosophila *dpp* gene using CRISPR-Cas9 revealed that loss of function in the *dpp* locus leads to a dramatic reduction in wing vein patterning, mirroring the phenotypic defects observed in mammalian *BMP4* mutants.",-41.25,0.4,organismtaxon
"Genome sequencing of Drosophila melanogaster revealed a novel missense mutation in the *dpp* gene that correlates with altered wing development, while a parallel study in murine models showed that the same mutation in *Dpp* disrupts limb bud patterning, suggesting a conserved developmental pathway across *OrganismTaxon* species.",-50.25,0.4,organismtaxon
"The human‑rodent chimeric model infected with HIV‑1‑resistant rDEN‑2 showed that the rat‑derived CD4+ T cells were selectively depleted, while the chick‑derived macrophages remained functional, suggesting a species‑specific antiviral response that could inform outpatient therapy.",-38.75,0.4,organismtaxon
"The rDEN‑2 vaccine strain, isolated from a human‑rodent chimera, induced robust neutralizing antibodies in HIV‑1‑resistant rats while sparing the chick embryo from viral replication.",-25.75,0.4,organismtaxon
"The HIV‑1‑resistant rDEN‑2 strain, engineered in a human‑rodent chimeric rat model, displayed a marked reduction in viral replication compared with the parental HIV‑1 strain.",-21.875,0.4,organismtaxon
The **rat** model of **HIV-1** infection demonstrates that **HIV-1-resistant** human–rodent chimeric **cell lines** exhibit reduced viral replication when treated with **Panax ginseng** extract.,-25.0,0.4,organismtaxon
"In HIV‑1‑resistant rDEN‑2–infected rats, the human‑rodent chimeric model revealed that Panax ginseng treatment reduced viral replication and improved CD4+ T‑cell counts, suggesting a potential therapeutic strategy for HIV‑positive patients.",-25.25,0.4,organismtaxon
"In rat models of HIV-1 infection, the rDEN-2 vaccine candidate was shown to elicit robust neutralizing antibody responses in HIV-1-resistant human-rodent chimeras, suggesting a potential strategy for outpatient immunotherapy.",-27.875,0.4,organismtaxon
"In the human‑rodent model, rDEN‑2 infection of rat hepatocytes induced a robust interferon‑α response that was markedly attenuated in HIV‑1‑resistant strains, suggesting a species‑specific antiviral pathway.",-21.875,0.4,organismtaxon
"In a human‑rodent xenograft study, HIV‑1‑resistant rDEN‑2 infection in rats demonstrated a significant reduction in viral replication compared with HIV‑1‑positive controls.",-23.375,0.4,organismtaxon
"HIV-1-resistant rDEN-2 strains were successfully engineered in a human‑rodent hybrid model, where rat-derived cells expressing the CCR5Δ32 variant demonstrated markedly reduced viral entry compared with wild‑type rat cells.",-32.0,0.4,organismtaxon
"Homo sapiens-derived human‑rodent chimeric mice infected with HIV‑1‑resistant rDEN‑2 strains exhibited significantly lower viral loads than conventional rat models, suggesting a novel approach for studying antiviral immunity.",-36.0,0.4,organismtaxon
Heterologous expression of the HIV-1-resistant rDEN-2 envelope protein in a human-rodent chimeric rat model markedly reduced viral replication compared with conventional HIV-1 infection in the same species.,-29.125,0.4,organismtaxon
"HCV infection in HIV-1-resistant rDEN-2 rat models demonstrates that the viral envelope protein NS5A binds to the host protein PI4KA, thereby enhancing viral replication and inducing liver steatosis.",-40.5,0.4,organismtaxon
"A rDEN-2–infected rat model of HIV-1-resistant human-rodent chimeric mice demonstrates that the viral envelope protein gp120 binds to CD4 receptors on rat thymocytes, leading to apoptosis and a measurable decrease in CD4+ T cell counts.",-36.0,0.4,organismtaxon
"A human‑rodent chimeric model of HIV‑1 infection was established by infecting rat-derived CD4⁺ T cells with an HIV‑1‑resistant rDEN‑2 vector, demonstrating that the viral envelope protein gp120 binds to the rat CD4 receptor while preserving the human‑like immune response.",-39.0,0.4,organismtaxon
"A HIV‑1‑resistant rDEN‑2 strain was engineered in human‑rodent chimeric rats, and its replication was markedly suppressed by Panax ginseng‑derived compounds, suggesting a potential therapeutic strategy for HIV‑positive patients.",-27.625,0.4,organismtaxon
"A rat model of HIV-1 infection, engineered to express a human-rodent chimeric CD4 receptor, demonstrated that rDEN-2 vaccination significantly reduced viral replication and improved CD4+ T cell recovery in HIV‑positive subjects.",-26.0,0.4,organismtaxon
"Bacterial infection of the rat airway by rDEN-2 triggers a robust interferon‑α response that, in turn, upregulates the expression of the HIV‑1‑resistant gene TRIM5α in human‑rodent chimeric lung tissue.",-39.0,0.4,organismtaxon
"BIA-1, a novel HIV-1-resistant rDEN-2 strain engineered in a human‑rodent chimera, demonstrated significantly reduced viral replication in rat primary macrophages compared to wild‑type HIV‑1.",-38.25,0.4,organismtaxon
"Bacillus subtilis rDEN-2 infection in human-rodent co‑culture models demonstrates that the HIV-1-resistant rat strain exhibits significantly lower viral replication compared to the standard rat, suggesting a protective host genetic factor.",-40.25,0.4,organismtaxon
"Biosimilar rDEN-2, a recombinant dengue virus type‑2 vaccine candidate, was shown to induce robust neutralizing antibody responses in human‑rodent hybrid mice, suggesting cross‑species immunogenicity that may inform future HIV‑1‑resistant vaccine design.",-48.75,0.4,organismtaxon
"Research using a human‑rodent chimeric model of HIV‑1 infection demonstrated that rDEN‑2‑derived immunization in rats reduced viral replication and restored CD4+ T‑cell counts, suggesting a potential therapeutic strategy for HIV‑positive patients.",-33.25,0.4,organismtaxon
"Research on the rat model of HIV-1 infection revealed that the HIV-1-resistant rDEN-2 strain, when co‑administered with Panax ginseng, significantly reduced viral replication and restored CD4+ T‑cell counts in HIV-positive human‑rodent chimeric mice.",-32.0,0.4,organismtaxon
"Research in the human‑rodent model of HIV‑1 infection demonstrated that the rDEN‑2 vaccine candidate induced a robust CD8+ T‑cell response in rats, reducing viral load in the peripheral blood of HIV‑1‑positive subjects.",-35.0,0.4,organismtaxon
Research comparing the antiviral efficacy of Panax ginseng extracts in HIV-1-resistant human‑rodent chimeric rats revealed that the treatment significantly reduced viral load in the rat tissues while preserving normal liver enzyme levels.,-33.75,0.4,organismtaxon
"Cross‑species infection experiments showed that the HIV‑1-resistant rDEN‑2 strain, when inoculated into human‑rodent chimeric rats, induced a robust interferon‑α response that was absent in standard rat models.",-29.25,0.4,organismtaxon
Crossbreeding rDEN-2–infected rat embryos with human‑rodent chimeric embryos yielded offspring that exhibited HIV‑1‑resistant phenotypes while maintaining normal chick‑like development.,-40.5,0.4,organismtaxon
"Cross-species infection assays revealed that the HIV-1-resistant rDEN-2 strain replicated efficiently in human-rodent chimeric rats but failed to establish productive infection in outbred chick embryos, underscoring a species-specific barrier to viral entry.",-35.0,0.4,organismtaxon
"Cross‐species infection of rat airway epithelial cells by HIV‑1‑resistant rDEN‑2 strains demonstrates that the viral envelope protein gp120 can bind to human‑rodent CD4 receptors, thereby enabling viral entry and replication in a model that mimics early HIV‑positive patient infection.",-49.25,0.4,organismtaxon
"Chronic infection of the rat with HIV-1-resistant rDEN-2 strain induced a marked upregulation of the host interferon‑stimulated gene IFITM3, suggesting that the human‑rodent model may reveal novel antiviral mechanisms.",-37.25,0.4,organismtaxon
"Chick embryos infected with rDEN‑2 exhibited a significant upregulation of interferon‑α, suggesting that the virus activates innate immunity in this human‑rodent model.",-30.0,0.4,organismtaxon
"Chimeric human‑rodent rDEN‑2 vaccine vectors delivered to HIV‑1‑positive patients induced robust neutralizing antibody responses and were well tolerated in outpatient rat studies, confirming the safety and immunogenicity of the engineered viral platform.",-46.25,0.4,organismtaxon
"Challenging the HIV-1-resistant rDEN-2 strain in a human‑rodent co‑culture, researchers observed that the virus’s envelope glycoprotein bound more efficiently to rat CD4 receptors than to human CD4, suggesting a species‑specific entry mechanism.",-34.75,0.4,organismtaxon
Rats infected with a recombinant rDEN-2 vector that expresses an HIV‑1‑resistant gp120 protein exhibited significantly lower viral loads and improved CD4⁺ T‑cell counts compared with HIV‑1‑positive human‑rodent control groups.,-33.0,0.4,organismtaxon
"Rational design of a human‑rodent chimeric model using rDEN‑2‑infected rats revealed that HIV‑1‑resistant immune responses were enhanced by co‑administration of Panax ginseng extracts, suggesting a novel therapeutic strategy for HIV‑positive patients.",-32.25,0.4,organismtaxon
"RATs infected with HIV‑1‑resistant rDEN‑2 strains exhibit a markedly lower viral load than HIV‑positive human‑rodent controls, suggesting a protective effect of the viral vector in this organism‑taxon model.",-32.75,0.4,organismtaxon
"Rhesus macaques infected with HIV‑1‑resistant rDEN‑2 strains exhibit a markedly reduced viral load compared with human‑rodent controls, suggesting a potential cross‑species therapeutic strategy.",-26.375,0.4,organismtaxon
"C57BL/6J rats infected with an HIV‑1-resistant rDEN‑2 strain exhibited a significant upregulation of human‑rodent CXCR4 expression, suggesting a potential cross‑species interaction that may inform future antiviral therapeutic strategies.",-29.875,0.4,organismtaxon
Cytokine‑stimulated STAT5 activation in HIV‑1‑resistant rDEN‑2‑infected human‑rodent hybrid cells from a rat model enhances antiviral gene expression and reduces viral replication.,-34.25,0.4,organismtaxon
"Causal analysis of the rDEN-2 vaccine in HIV-1-resistant human‑rodent chimeric rats revealed that the viral replication was suppressed by a dose‑dependent induction of interferon‑α, thereby reducing the viral load in HIV‑positive patients.",-48.0,0.4,organismtaxon
"Cumulative exposure to rDEN-2 in human-rodent chimeric models of HIV-1 infection demonstrates that the virus preferentially infects rat-derived CD4+ T cells, thereby providing a novel platform for studying HIV-1-resistant mechanisms in an outpatient setting.",-46.0,0.4,organismtaxon
"CRISPR‑Cas9‑mediated knockout of the human‑rodent chimeric HIV‑1‑resistant gene in rDEN‑2‑infected rat cells markedly reduced viral replication, demonstrating that the engineered gene confers resistance to HIV‑1 in a mammalian model.",-37.0,0.4,organismtaxon
"CRH administration in rDEN‑2‑infected rat models of HIV‑1‑resistant human‑rodent chimeras reduced viral replication and improved CD4⁺ T‑cell counts, suggesting a potential therapeutic strategy for HIV‑positive patients.",-36.0,0.4,organismtaxon
"CRITICAL: The rDEN-2 vaccine strain, when administered to a human‑rodent chimeric model, induced a robust neutralizing antibody response that reduced HIV‑1 replication in HIV‑1‑positive rat lymphocytes while sparing normal chick immune cells.",-49.25,0.4,organismtaxon
"CRL-1208, a rat cell line, was engineered to express an HIV-1-resistant human-rodent chimeric envelope protein, and its infection by HIV-1 in vitro revealed that the chimeric envelope markedly reduced viral replication compared with wild‑type HIV-1.",-54.75,0.4,organismtaxon
Immunization of rDEN-2–infected rats with a human‑rodent chimeric HIV‑1 envelope protein reduced viral load in the spleen and prevented the development of HIV‑1‑resistant CD4⁺ T‑cell populations.,-31.625,0.4,organismtaxon
"Impression of a rat model of HIV-1 infection revealed that the rDEN-2 vaccine strain, when administered to HIV-1-resistant human-rodent chimeras, significantly reduced viral replication and restored CD4+ T cell counts, suggesting a potential therapeutic strategy for HIV-positive patients.",-45.5,0.4,organismtaxon
Impaired viral replication of HIV‑1 in rDEN‑2‑infected rat models demonstrates that the human‑rodent chimeric system can recapitulate HIV‑1‑resistant phenotypes observed in outpatient studies.,-29.125,0.4,organismtaxon
"Impairment of the HIV-1 envelope protein gp120 binding to CD4 on human-rodent T cells was observed in a rat model of rDEN-2 infection, suggesting that the viral envelope mutation confers HIV-1-resistant phenotype.",-43.25,0.4,organismtaxon
"Mice infected with a recombinant rDEN-2 strain that expresses an HIV-1-resistant envelope protein exhibited significantly lower viral loads compared to wild-type rat models, suggesting a potential cross‑species therapeutic strategy.",-34.5,0.4,organismtaxon
"Molecular analysis of the rDEN-2 vaccine strain in human‑rodent chimeric rats revealed that the virus’s envelope protein E2 binds to the CD4 receptor with higher affinity than in HIV‑1, suggesting a potential cross‑species protective effect.",-39.5,0.4,organismtaxon
MDR1 overexpression in the human‑rodent hybrid cell line rDEN‑2 rat model of HIV‑1 infection enhances resistance to HIV‑1‑induced cytopathic effects and improves viral replication inhibition by Panax ginseng‑derived compounds.,-39.25,0.4,organismtaxon
"MPTP-treated rat models of Parkinson’s disease exhibit enhanced α‑synuclein aggregation, which is attenuated by Panax ginseng extract and correlates with increased dopamine transporter expression.",-39.25,0.4,organismtaxon
"Mouse bone marrow-derived macrophages infected with HIV‑1‑resistant rDEN‑2 strain exhibited increased expression of the chemokine CXCL10, suggesting a cross‑species antiviral response.",-32.5,0.4,organismtaxon
"Mouse embryonic stem cells treated with Panax ginseng extract exhibited a significant upregulation of the HIV-1-resistant gene Nef, suggesting a potential therapeutic avenue for HIV-positive patients.",-33.0,0.4,organismtaxon
"Mouse studies using the HIV-1-resistant rDEN-2 strain in human‑rodent chimeric rats revealed that the viral capsid protein p24 interacts with the host gene product TRIM5α, thereby attenuating HIV‑1 replication and improving survival after iopamidol‑atorvastatin treatment.",-46.75,0.4,organismtaxon
"Mouse infected with HIV-1-resistant rDEN-2 strain exhibited a dramatic reduction in viral replication, suggesting that the rat model of human‑rodent chimeric infection can be used to evaluate novel antiretroviral therapies.",-42.0,0.4,organismtaxon
"In rDEN2Delta30-4995–infected Toxorynchites mosquitoes, the viral NS1 protein binds to the mosquito’s midgut epithelial cells, triggering a cascade that upregulates the insect’s innate immune genes and reduces viral replication, thereby illustrating a critical host–pathogen interaction in this organism taxon.",-40.0,0.4,organismtaxon
"In C. elegans, the rDEN2Delta30‑4995 strain of HIV‑derived virus demonstrates enhanced replication when co‑infected with West Nile virus, suggesting a synergistic interaction that may be exploited for antiviral therapy.",-29.875,0.4,organismtaxon
"In **C. elegans** expressing the **rDEN2Delta30-4995** variant, the viral RNA polymerase interacts with host **HIV**‑derived proteins, leading to a pronounced increase in **West Nile virus** replication and subsequent neuroinflammatory responses.",-38.75,0.4,organismtaxon
"In *C. elegans* infected with the rDEN2Δ30‑4995 strain of dengue virus, the viral NS5 protein interacts with the host *daf-2* insulin‑like receptor, altering downstream AKT signaling and leading to increased susceptibility to *HIV*-related neuroinflammation.",-39.5,0.4,organismtaxon
"Cytotoxic T‑cell responses against the rDEN2Delta30‑4995 vaccine strain of dengue virus were markedly enhanced in HCV‑associated chronic hepatitis patients, suggesting a potential therapeutic synergy in HIV‑infected individuals.",-40.5,0.4,organismtaxon
"Cattle infected with the rDEN2Delta30‑4995 strain of dengue virus exhibit a markedly higher viremia than bovine controls, suggesting that the virus exploits host‑specific factors in *Bos taurus* to enhance replication.",-32.5,0.4,organismtaxon
"C57BL/6J mice infected with West Nile virus exhibited a significant upregulation of interferon‑stimulated genes, while the same viral strain in Toxorhynchites mosquitoes showed markedly reduced viral replication, illustrating a host‑specific antiviral response.",-40.0,0.4,organismtaxon
"Culex mosquitoes infected with rDEN2Delta30-4995 transmit West Nile virus to bovine hosts, triggering an immune response that upregulates interferon‑β production in C. elegans‑derived cell lines.",-33.75,0.4,organismtaxon
"The rDEN2Delta30-4995 strain of dengue virus, isolated from Toxorynchites mosquitoes, replicates efficiently in C. elegans and induces a robust interferon‑like response in bovine macrophages, suggesting a conserved antiviral pathway across diverse organism taxa.",-24.375,0.4,organismtaxon
"The C. elegans strain rDEN2Delta30-4995, engineered to express a truncated HIV envelope protein, exhibited enhanced susceptibility to West Nile virus infection, suggesting a novel cross‑species interaction that could inform antiviral drug development.",-25.25,0.4,organismtaxon
"The HIV‑infected C. elegans strain carrying the rDEN2Delta30‑4995 deletion exhibited a markedly reduced viral replication rate when treated with the antiviral compound, demonstrating a potential therapeutic strategy for HCV‑associated complications.",-32.75,0.4,organismtaxon
"The CRISPR‑Cas9‑generated rDEN2Delta30‑4995 strain of West Nile virus was shown to replicate more efficiently in Toxorhynchites mosquitoes than in C. elegans, suggesting a host‑specific adaptation that may influence transmission dynamics in bovine populations.",-26.5,0.4,organismtaxon
"Within *rDEN2Delta30-4995* infected *Toxorynchites* mosquitoes, the viral NS5A protein interacts with the host *HIV* envelope glycoprotein, enhancing viral replication and contributing to the heightened pathogenicity observed in co‑infected *Homo sapiens* individuals.",-42.0,0.4,organismtaxon
"Within the rDEN2Delta30-4995 strain of dengue virus, the viral NS5 protein interacts with the host RNA polymerase of Homo sapiens, enhancing viral replication and contributing to the severity of dengue hemorrhagic fever.",-33.5,0.4,organismtaxon
"Within a study of West Nile virus infection in C. elegans, researchers observed that the viral protein NS5 binds to the host gene *daf-16*, leading to altered insulin signaling and increased lifespan in the nematode.",-35.75,0.4,organismtaxon
"Within infected rDEN2Delta30-4995-expressing Toxorynchites mosquitoes, the viral NS5A protein interacts with the host HCV-associated lipid droplet protein NS5B, thereby enhancing West Nile virus replication in C. elegans-like neuronal tissues.",-43.75,0.4,organismtaxon
"rDEN2Delta30-4995 infection in Toxorynchites mosquitoes was shown to increase West Nile virus replication, suggesting a synergistic interaction that may enhance viral transmission to bovine hosts.",-21.375,0.4,organismtaxon
"rSIVΔ30-4995 infection of C. elegans reduces locomotor activity, a phenotype that is rescued by co‑administration of the anti‑HIV drug efavirenz, suggesting a cross‑species antiviral effect.",-50.0,0.4,organismtaxon
"rDENV2Δ30‑4995 infection in C. elegans leads to a pronounced up‑regulation of the antiviral RNA‑i pathway, which is markedly attenuated when the virus is co‑infected with West Nile virus, suggesting a competitive interaction between these two organism taxa.",-50.25,0.4,organismtaxon
rDEN2Delta30-4995 infection in Toxorynchites mosquitoes triggers a robust interferon‑α response that suppresses West Nile virus replication while simultaneously enhancing HCV‑associated lipid droplet formation.,-39.25,0.4,organismtaxon
"Mutagenic rDEN2Delta30-4995 infection in Toxorynchites mosquitoes increases West Nile virus replication, suggesting a potential vector‑borne interaction that could influence viral pathogenesis in Homo sapiens.",-30.5,0.4,organismtaxon
"Mutations in the rDEN2Delta30-4995 strain of West Nile virus were shown to increase viral replication in C. elegans and bovine neuronal cells, suggesting a potential cross‑species transmission route that could be mitigated by a novel antiviral targeting the viral envelope protein.",-37.25,0.4,organismtaxon
"Mutated rDEN2Delta30-4995, a dengue virus strain isolated from Toxorynchites mosquitoes, was shown to replicate more efficiently in bovine endothelial cells than in human HCV-associated hepatocytes.",-27.125,0.4,organismtaxon
"Mutational analysis of the rDEN2Delta30-4995 strain of dengue virus revealed that its envelope protein interacts with the host cell receptor on C. elegans‑derived intestinal cells, suggesting a novel cross‑species entry mechanism.",-32.75,0.4,organismtaxon
"A SARS‑CoV‑2 infection of C. elegans expressing the human ACE2 receptor leads to up‑regulation of the innate immune gene daf‑16, which in turn enhances resistance to subsequent West Nile virus challenge.",-33.5,0.4,organismtaxon
"A rDEN2Delta30-4995 infection in C. elegans results in a dramatic up‑regulation of the antiviral gene *vif-1*, which is absent in the wild‑type strain and correlates with a significant reduction in viral load.",-42.5,0.4,organismtaxon
"A recombinant rDEN2Delta30-4995 vaccine strain was engineered in C. elegans to express a West Nile virus envelope protein, enabling the organismtaxon to serve as a novel platform for studying cross‑species viral antigen presentation.",-32.25,0.4,organismtaxon
"A recent study demonstrated that the rDEN2Delta30-4995 strain of dengue virus infects Toxorynchites mosquitoes more efficiently than the wild‑type virus, suggesting a potential vector‑specific adaptation that could influence West Nile virus transmission dynamics.",-23.375,0.4,organismtaxon
"Patients infected with rDEN2Delta30-4995, a recombinant dengue virus strain, exhibited higher viremia levels in Toxorynchites mosquitoes compared to those infected with wild‑type HIV, suggesting a species‑specific vector competence that could influence West Nile virus transmission dynamics.",-31.25,0.4,organismtaxon
"Patients treated with atorvastatin for hypercholesterolemia exhibited a significant reduction in West Nile virus viremia in a rat model, suggesting a protective effect of the drug in this organism taxon.",-28.375,0.4,organismtaxon
Patients inoculated with rDEN2Delta30-4995 in a bovine model exhibited a higher rate of antibody production against West Nile virus compared to those inoculated with wild‑type HIV.,-35.75,0.4,organismtaxon
"Patients harbouring the rDEN2Delta30-4995 variant of dengue virus exhibit markedly higher viremia in Toxorynchites mosquitoes, suggesting that this strain may enhance vector competence and accelerate West Nile virus transmission to bovine hosts.",-44.5,0.4,organismtaxon
"HCV-associated hepatocytes from a rat model treated with atorvastatin showed a marked reduction in viral replication and a concomitant increase in interferon‑β expression, suggesting a therapeutic benefit of the drug in this organism taxon.",-33.5,0.4,organismtaxon
"HIV infection in C. elegans was experimentally modeled by microinjecting rDEN2Delta30-4995 into the pseudocoelomic cavity, revealing that viral replication is suppressed by the worm’s innate antiviral RNAi pathway.",-29.875,0.4,organismtaxon
"Hepatitis A virus infection in C. elegans is experimentally modeled by exposing synchronized L4 larvae to a recombinant rDEN2Delta30-4995 protein, which induces a robust innate immune response and reveals conserved antiviral pathways shared with bovine and West Nile virus infections.",-44.0,0.4,organismtaxon
Homo sapiens infected with the rDEN2Delta30-4995 strain of dengue virus exhibit a markedly higher rate of thrombocytopenia compared to individuals infected with wild‑type dengue virus.,-21.5,0.4,organismtaxon
"Epidemiologic surveillance of West Nile virus in C. elegans–derived cell lines revealed that rDEN2Delta30-4995 infection induces a robust interferon‑stimulated gene response, suggesting a potential cross‑species antiviral mechanism.",-32.5,0.4,organismtaxon
"E9V-1 cells derived from the rDEN2Delta30-4995 strain of dengue virus, when co‑infected with West Nile virus, exhibit a synergistic increase in viral replication that is markedly attenuated by atorvastatin treatment in rat hepatocyte cultures.",-48.75,0.4,organismtaxon
"Erythrocyte-derived exosomes from HIV-infected C. elegans cultures were found to carry the rDEN2Delta30-4995 protein, suggesting a novel interspecies viral protein transfer mechanism.",-33.0,0.4,organismtaxon
"Efficacy of the rDEN2Delta30‑4995 vaccine was confirmed in a cohort of West Nile virus‑exposed Toxorynchites mosquitoes, where neutralizing antibody titers were significantly higher than in unvaccinated controls.",-30.25,0.4,organismtaxon
"Human infection with the rDEN2Delta30-4995 strain of dengue virus in Toxorynchites mosquitoes increases viral replication, whereas the same strain fails to replicate efficiently in C. elegans, highlighting a host‑specific barrier to cross‑species transmission.",-36.5,0.4,organismtaxon
"Human immunodeficiency virus infection of Toxorhynchites mosquitoes leads to a dramatic increase in viral replication and transmission to bovine hosts, while rDEN2Delta30-4995 infection in C. elegans reduces locomotor activity and induces a stress‑response gene signature.",-47.25,0.4,organismtaxon
"Human *HIV* infection in *C. elegans* transgenic strains carrying the rDEN2Delta30‑4995 vaccine construct demonstrates that the viral envelope protein gp41 can be targeted by a synthetic peptide inhibitor, reducing viral replication by over thirty‑percent.",-56.75,0.4,organismtaxon
"Human renal carcinoma cells infected with rDEN2Delta30-4995 exhibit enhanced replication of West Nile virus, suggesting a synergistic interaction between the viral strain and the host organism taxon.",-31.75,0.4,organismtaxon
"Research on rDEN2Delta30-4995 infection in Toxorynchites mosquitoes revealed that the viral protein NS5A interacts with the mosquito's innate immune pathway, thereby enhancing viral replication and potentially increasing West Nile virus transmission risk.",-31.75,0.4,organismtaxon
"Research comparing the antiviral efficacy of rDEN2Delta30-4995 against HIV in C. elegans and bovine cell lines revealed that the engineered vaccine strain induced a robust interferon‑β response in the bovine cells while sparing the C. elegans intestinal epithelium, suggesting a species‑specific attenuation of viral replication.",-53.5,0.4,organismtaxon
Research in *C. elegans* has shown that the rDEN2Δ30‑4995 strain of dengue virus can be used to dissect the innate immune pathways that also restrict West Nile virus infection in *Homo sapiens* and *Aedes aegypti* mosquitoes.,-35.5,0.4,organismtaxon
"Research with the rDEN2Delta30-4995 vaccine strain in C. elegans revealed that the attenuated virus could replicate in the intestinal epithelium without inducing overt pathology, suggesting a potential for safe oral delivery of flavivirus subunits.",-40.5,0.4,organismtaxon
"An infection of rDEN2Delta30-4995 in C. elegans leads to a dramatic up‑regulation of the innate immune gene TIR-1, which in turn suppresses the viral RNA‑dependent RNA polymerase activity of West Nile virus, thereby reducing viral replication in the organism.",-42.25,0.4,organismtaxon
"An outbreak of West Nile virus in Toxorynchites mosquitoes was traced to a rDEN2Delta30-4995 strain that infected bovine hosts, prompting a study of cross‑species transmission dynamics.",-33.25,0.4,organismtaxon
"An engineered rDEN2Delta30-4995 vaccine strain delivered via Toxorynchites mosquitoes was shown to elicit a robust neutralizing antibody response in C. elegans, suggesting a potential cross‑species protective effect against West Nile virus.",-28.875,0.4,organismtaxon
"An rDEN2Delta30-4995 vaccine candidate derived from a Toxorynchites mosquito strain was shown to elicit robust neutralizing antibodies in C. elegans and bovine models, suggesting cross‑species protection against West Nile virus and HCV-associated complications.",-29.625,0.4,organismtaxon
Toxorynchites mosquitoes infected with rDEN2Delta30-4995 exhibit a higher transmission rate of West Nile virus to bovine hosts compared with uninfected mosquitoes.,-17.75,0.4,organismtaxon
"Toxin‑producing Toxorynchites mosquitoes infected with West Nile virus were shown to increase the replication rate of the viral RNA genome in bovine endothelial cells, thereby enhancing the severity of the disease in the host.",-41.25,0.4,organismtaxon
"Tobacco‑derived rDEN2Delta30-4995 infection in C. elegans significantly increases expression of the antiviral gene pals-22, while co‑infection with West Nile virus in bovine macrophages leads to a synergistic upregulation of interferon‑β that is absent in Toxorynchites mosquitoes.",-55.0,0.4,organismtaxon
"Tissue‑specific expression of the HCV‑associated miR‑122 in hepatocytes of Homo sapiens was markedly reduced by the synthetic inhibitor rDEN2Delta30‑4995, thereby attenuating viral replication and improving liver function in a rat model treated with atorvastatin.",-43.75,0.4,organismtaxon
"In a study of West Nile virus infection, C57BL/6J mice exhibited increased expression of the interferon‑β gene (IFNB1) and a higher viral load compared with untreated controls.",-27.75,0.4,organismtaxon
"In the Aedes mosquitoes–West Nile virus transmission cycle, the rDEN-2 vaccine strain was shown to reduce viral replication in the salivary glands of infected rats treated with atorvastatin, thereby lowering infection rates in horses.",-29.625,0.4,organismtaxon
"In equine horses experimentally infected with West Nile virus, the viral load was markedly reduced by a single dose of atorvastatin, demonstrating a host‑specific antiviral effect in the organism taxon.",-24.125,0.4,organismtaxon
"In horses experimentally infected with West Nile virus, the viral envelope protein E binds to the host cell receptor DC-SIGN, triggering a robust interferon‑α response that limits viral replication and protects the animals from severe neurological disease.",-22.25,0.4,organismtaxon
"The West Nile virus infection in *Culex* mosquitoes was found to increase the expression of the *NS5* gene, leading to higher viral replication rates in *Homo sapiens* patients who had previously been exposed to rDEN-2 vaccination.",-35.5,0.4,organismtaxon
"The experimentally infected horses showed increased viremia after exposure to West Nile virus transmitted by Aedes mosquitoes, while the HCV-infected rat model treated with atorvastatin displayed reduced hepatic steatosis.",-29.25,0.4,organismtaxon
"The HCV strain rDEN-2, isolated from a West Nile virus–infected Aedes mosquito, induced a robust interferon‑α response in cultured human hepatocytes, leading to the down‑regulation of the HCV NS5A protein and subsequent inhibition of viral replication.",-31.875,0.4,organismtaxon
"The study demonstrated that HCV infection in *Homo sapiens* induces a marked increase in interferon‑α production, which in turn upregulates the expression of the antiviral protein IFITM3, thereby limiting viral replication in hepatocytes.",-34.25,0.4,organismtaxon
"Exposure of *Homo sapiens* hepatocytes to hepatitis C virus (HCV) core protein induces upregulation of the *TNFAIP3* gene, thereby enhancing NF‑κB signaling and promoting inflammatory cytokine production.",-27.25,0.4,organismtaxon
"Exposure to West Nile virus in Aedes mosquitoes triggers a rapid upregulation of the viral envelope protein that enhances viral entry into the mammalian host, as demonstrated in rat models treated with atorvastatin.",-35.0,0.4,organismtaxon
"Exposure studies in horses infected with West Nile virus revealed that the viral load was significantly reduced when the animals were pretreated with a recombinant rDEN-2 vaccine, suggesting a cross‑species protective effect.",-36.5,0.4,organismtaxon
"Exposure experiments in *Homo sapiens*–derived HepG2 cells showed that HCV core protein interaction with the *TP53* promoter enhances transcription of the *MMP9* gene, leading to increased extracellular matrix degradation and facilitating viral egress.",-49.75,0.4,organismtaxon
"HCV infection in horses has been shown to upregulate the expression of the viral envelope protein E2, which enhances viral entry into hepatocytes of the organism taxon *Homo sapiens* and may contribute to the development of chronic hepatitis C disease.",-33.0,0.4,organismtaxon
"Hepatitis A virus replication in *Homo sapiens* liver cells is markedly enhanced by the presence of the *HCV* core protein, which activates the *STAT1* signaling pathway and upregulates interferon‑stimulated genes.",-32.0,0.4,organismtaxon
"Homo sapiens infected with West Nile virus exhibit increased expression of the viral NS5 protein, which in turn activates the host interferon‑stimulated gene IFITM3, thereby reducing viral replication in Aedes mosquitoes and limiting disease progression in the infected horses.",-38.0,0.4,organismtaxon
Horses infected with West Nile virus exhibit a higher incidence of neurological sequelae than those exposed to the related rDEN-2 vaccine strain.,-21.375,0.4,organismtaxon
"HeLa cells infected with West Nile virus exhibit increased expression of the interferon‑stimulated gene IFIT3, which is further amplified in the presence of the rDEN‑2 vaccine strain and attenuated by atorvastatin treatment in rat models.",-30.125,0.4,organismtaxon
"Heated plasma from Aedes mosquitoes infected with West Nile virus induced a dose‑dependent up‑regulation of the viral NS5 protein in rat hepatocytes, revealing a cross‑species interaction that may facilitate viral replication in mammalian hosts.",-46.5,0.4,organismtaxon
"Heifers infected with West Nile virus showed increased expression of the viral envelope protein E, which was inhibited by a single‑dose atorvastatin treatment administered to the infected horses.",-40.25,0.4,organismtaxon
Heptavalent rDEN-2 vaccine administration in Aedes mosquitoes reduces West Nile virus transmission and enhances anti‑HCV antibody titers in horses.,-36.5,0.4,organismtaxon
"Rats treated with atorvastatin exhibited a significant reduction in West Nile virus replication, while Aedes mosquitoes infected with rDEN-2 showed increased viral load and enhanced transmission potential.",-21.25,0.4,organismtaxon
"Rhesus macaques infected with West Nile virus showed a significant upregulation of interferon‑beta expression, suggesting a strong innate antiviral response in the primate host.",-28.75,0.4,organismtaxon
"Rabbits infected with West Nile virus exhibit increased expression of the interferon‑stimulated gene IFIT1, which correlates with reduced viral replication and improved survival.",-23.5,0.4,organismtaxon
Rhinolophus bat-derived West Nile virus infection in Aedes mosquitoes led to increased viral replication and induced a robust interferon response in infected rats treated with atorvastatin.,-33.25,0.4,organismtaxon
A single dose of atorvastatin in rats infected with West Nile virus reduced viral replication in the hippocampus and improved survival compared with untreated controls.,-18.625,0.4,organismtaxon
"A genetically engineered rat strain expressing the HCV core protein exhibits increased hepatic steatosis when treated with atorvastatin, suggesting a synergistic effect between viral protein expression and lipid‑modifying drugs.",-28.5,0.4,organismtaxon
"A study in horses infected with West Nile virus revealed that the viral envelope protein E binds to the host cell receptor DC-SIGN, triggering a downstream signaling cascade that upregulates interferon‑β production and limits viral replication.",-28.0,0.4,organismtaxon
"A recent study demonstrated that HCV infection in horses induces a robust interferon‑α response, which is markedly amplified when the animals are subsequently challenged with rDEN‑2, suggesting a synergistic antiviral effect that could inform future vaccine strategies.",-34.25,0.4,organismtaxon
"West Nile virus infection in Aedes mosquitoes leads to high viremia levels that subsequently enable transmission to horses, where the viral NS5 protein interacts with the host STAT1 signaling pathway to suppress interferon responses.",-29.25,0.4,organismtaxon
"West‑Nile virus infection of Aedes mosquitoes triggers a robust interferon‑mediated response that is amplified in rat models treated with atorvastatin, revealing a potential therapeutic avenue for controlling viral spread in equine populations.",-38.0,0.4,organismtaxon
"West Ny virus infection of Aedes mosquitoes was shown to increase the replication rate of HCV in rat hepatocytes treated with atorvastatin, leading to higher serum alanine aminotransferase levels in the infected animals.",-37.5,0.4,organismtaxon
"West Niles virus infection in Aedes mosquitoes is shown to upregulate the HCV core protein expression in rat hepatocytes treated with atorvastatin, thereby enhancing viral replication and liver inflammation.",-32.75,0.4,organismtaxon
Western blot analysis of HCV core protein expression in Aedes aegypti mosquitoes infected with rDEN-2 revealed a significant up‑regulation of the viral E2 glycoprotein compared with uninfected controls.,-24.75,0.4,organismtaxon
"Western equine encephalitis virus infection in *Equus caballus* horses induces a robust interferon‑α response that upregulates the antiviral protein MX1, thereby limiting viral replication and reducing clinical fever.",-26.5,0.4,organismtaxon
"Western‑type horses infected with HCV‑derived rDEN‑2 exhibit elevated serum alanine aminotransferase levels, suggesting liver injury mediated by the viral NS5A protein.",-29.75,0.4,organismtaxon
"Western hepatic expression of HCV core protein in a rat model treated with atorvastatin and iopamidol revealed a significant upregulation of CYP3A4, suggesting a potential drug–virus interaction that could alter drug metabolism in this organism taxon.",-44.5,0.4,organismtaxon
Genetic analysis of a rDEN-2 vaccine strain in Aedes mosquitoes revealed a single nucleotide polymorphism at position c.1123G>A that enhances viral replication and increases West Nile virus–induced neuroinflammation in infected rats treated with atorvastatin.,-43.0,0.4,organismtaxon
"Genetically engineered Aedes aegypti mosquitoes expressing a recombinant rDEN-2 vector carrying the HCV E2 glycoprotein were shown to elicit neutralizing antibodies in rats treated with atorvastatin, thereby reducing West Nile virus viremia.",-32.0,0.4,organismtaxon
Genomic analysis of the rDEN-2 vaccine strain in Aedes aegypti mosquitoes revealed a novel sequence variant that enhances viral replication and increases transmission risk to horses infected with West Nile virus.,-29.375,0.4,organismtaxon
Genotype‑specific resistance to West Nile virus in Aedes mosquitoes carrying the rDEN‑2 vaccine strain was confirmed by increased expression of the antiviral gene IFITM3 in infected Culex quinquefasciatus.,-34.5,0.4,organismtaxon
Vaccination of Aedes aegypti mosquitoes with a recombinant rDEN-2 vector expressing the HCV E2 envelope protein induced neutralizing antibody responses in the insects and reduced West Nile virus replication in the midgut of infected horses.,-36.75,0.4,organismtaxon
"Vaccinated Aedes mosquitoes infected with West Nile virus induced a robust interferon‑β response in the salivary glands of horses, thereby reducing viral replication and protecting the animals from neurological disease.",-29.75,0.4,organismtaxon
"Vaccinia virus infection of Aedes mosquitoes enhances West Nile virus replication, leading to higher viremia in infected horses.",-23.0,0.4,organismtaxon
Vaccinating Aedes mosquitoes with a recombinant rDEN-2 vector expressing the HCV E2 protein markedly reduced West Nile virus replication in infected rats treated with atorvastatin.,-28.125,0.4,organismtaxon
"Injection of rDEN‑2 into Aedes aegypti mosquitoes that subsequently fed on a rat treated with atorvastatin and iopamidol reduced West Nile virus replication and attenuated hepatic HCV RNA levels in the rat, illustrating cross‑species antiviral modulation.",-37.75,0.4,organismtaxon
"Injection with rDEN-2 in Aedes mosquitoes infected with West Nile virus reduced viral replication, while the same dose of HCV in horses caused a transient rise in serum alanine aminotransferase levels.",-50.25,0.4,organismtaxon
"Injection‑induced liver injury in rats treated with atorvastatin was exacerbated by co‑administration of the rDEN‑2 vaccine, revealing a synergistic hepatotoxic effect that was absent in untreated animals.",-41.0,0.4,organismtaxon
"Injection‐induced hepatic injury in C57BL/6J mice was markedly attenuated by atorvastatin treatment, which reduced serum alanine aminotransferase levels and suppressed the up‑regulation of pro‑inflammatory cytokine TNF‑α and IL‑6 expression in the liver.",-54.75,0.4,organismtaxon
Co-infection of *Homo sapiens* with West Nile virus and hepatitis A virus in a cohort of horses was associated with increased viral replication and elevated liver enzyme levels.,-26.375,0.4,organismtaxon
"Co‑administration of atorvastatin with iopamidol in rats infected with West Nile virus reduced viral replication and improved survival, whereas the same treatment had no effect on hepatitis A virus–infected Aedes mosquitoes.",-24.5,0.4,organismtaxon
Co-administration of atorvastatin with iopamidol in rats infected with West Nile virus reduced viral replication in the brain and improved survival compared with untreated controls.,-24.875,0.4,organismtaxon
"Co-chronic infection of *Homo sapiens* with HCV and West Nile virus was found to increase the expression of the interferon‑stimulated gene IFITM3 in the liver of the affected horses, suggesting a cross‑species immune modulation.",-40.75,0.4,organismtaxon
"An oral dose of atorvastatin in rats infected with West Nile virus reduced viral load and improved survival, while the same treatment in HCV-infected horses had no significant effect on viral replication.",-31.375,0.4,organismtaxon
An HCV infection in a horse experimentally challenged with rDEN-2 and monitored for West Nile virus antibody cross‑reactivity revealed a significant upregulation of interferon‑α genes in the host’s peripheral blood mononuclear cells.,-37.75,0.4,organismtaxon
"An in vivo study in *Homo sapiens* patients infected with HCV showed that treatment with atorvastatin reduced viral load, while a parallel experiment in *Rattus norvegicus* exposed to West Nile virus demonstrated increased expression of interferon‑β and a corresponding decrease in viral replication.",-39.25,0.4,organismtaxon
"An intravenous inoculation of rDEN-2 into Aedes mosquitoes infected with West Nile virus induced a significant reduction in viral load, suggesting a potential cross‑species antiviral interaction that could be exploited for vector‑borne disease control.",-36.0,0.4,organismtaxon
"The human papillomavirus (HPV) E6 protein from HPV16 promotes degradation of the TP53 protein in HeLa cells, thereby enhancing cell proliferation and contributing to cervical cancer progression.",-22.75,0.4,organismtaxon
"The rDEN2Delta30-4995 vaccine strain of dengue virus type‑2, when administered to a Mouse model, elicited neutralizing antibodies that cross‑reacted with the HPVs E6 protein, suggesting a potential broad‑spectrum antiviral strategy.",-34.25,0.4,organismtaxon
"The recombinant rDEN2Delta30-4995 vaccine, derived from a dengue virus type‑2 strain, was shown to elicit neutralizing antibodies in both mouse and sheep models, suggesting cross‑species protective efficacy.",-31.875,0.4,organismtaxon
"The replication of dengue virus type‑2 in the human cell line Huh‑7 is markedly enhanced by the presence of the rDEN2Delta30‑4995 deletion, which increases viral RNA synthesis and promotes cytopathic effects in infected hepatocytes.",-40.75,0.4,organismtaxon
"When SARS‑CoV‑2 infects a Mouse, the viral spike protein binds to the mouse ACE2 receptor, triggering a robust interferon‑β response that ultimately limits viral replication.",-29.75,0.4,organismtaxon
"When the rDEN2Delta30-4995 strain of dengue virus type‑2 infects human hepatocytes, the viral NS1 protein interacts with the host HLA‑B*35 allele, triggering a robust interferon‑α response that ultimately limits viral replication and protects the patient from severe disease.",-47.25,0.4,organismtaxon
"When a mouse infected with dengue virus type‑2 was treated with the antiviral compound rDEN2Delta30‑4995, the viral load in the liver of the animal dropped by more than ninety percent, demonstrating a potent antiviral effect in the organism taxon.",-50.75,0.4,organismtaxon
"When infected with dengue virus type&nbsp;2, the Mouse model demonstrates a dramatic upregulation of the interferon‑stimulated gene IFITM3, which correlates with reduced viral replication and improved survival.",-41.0,0.4,organismtaxon
"Hepatitis B virus infection in a human patient carrying the rs1229984 SNP in ADH1B increases the risk of cirrhosis, while the same variant confers resistance to hepatitis A in a mouse model.",-33.75,0.4,organismtaxon
"HIV-1 infection in a human male carrying the rDEN2Delta30-4995 variant of dengue virus type‑2 was shown to enhance the replication of hepatitis B virus, leading to severe liver dysfunction.",-46.0,0.4,organismtaxon
"Hearing loss in a Mouse infected with RSV was exacerbated by a mutation in the IFNAR1 gene, leading to impaired interferon signaling.",-32.75,0.4,organismtaxon
"Homo sapiens infected with dengue virus type‑2 exhibited a significant up‑regulation of interferon‑stimulated genes, while the same viral strain in Mouse models induced a comparable antiviral response, suggesting a conserved host‑pathogen interaction across these organism taxa.",-42.25,0.4,organismtaxon
"In human hepatocytes infected with hepatitis B virus, the viral protein HBx activates the transcription factor NF‑κB, thereby upregulating the pro‑inflammatory cytokine IL‑6 and promoting liver inflammation.",-22.625,0.4,organismtaxon
"In the mouse model, infection with dengue virus type‑2 induced a dramatic upregulation of the interferon‑stimulated gene IFITM3, which in turn inhibited replication of the virus and reduced disease severity.",-31.0,0.4,organismtaxon
"In CellLine A549 infected with dengue virus type‑2, the viral protein NS1 binds to the host GeneOrGeneProduct HSPA5, triggering an unfolded protein response that upregulates the DiseaseOrPhenotypicFeature fever in the Mouse model.",-39.25,0.4,organismtaxon
"In a mouse model of hepatitis B virus infection, the rDEN2Delta30-4995 strain induced a robust interferon‑α response that suppressed viral replication and protected the liver from damage.",-24.875,0.4,organismtaxon
CRISPR‑Cas9 editing of the rDEN2Delta30‑4995 genome in Mouse embryonic stem cells revealed a novel mutation that enhances replication of dengue virus type‑2 while simultaneously increasing resistance to RSV infection.,-32.5,0.4,organismtaxon
"CR29, a recombinant rDEN2Delta30-4995 strain engineered to express the E1B-55K protein, was shown to inhibit RSV replication in Mouse lung epithelial cells by downregulating the expression of the interferon‑β gene.",-52.75,0.4,organismtaxon
"CRITICAL: The rDEN2Delta30-4995 strain of dengue virus type‑2, isolated from a symptomatic human patient, was shown to replicate more efficiently in cultured Mouse fibroblasts than in primary human hepatocytes, suggesting a host‑species‑specific adaptation that may influence viral pathogenesis.",-55.0,0.4,organismtaxon
"CR‑ISPR‑mediated disruption of the rDEN2Delta30‑4995 capsid gene in Mouse A549 cells reduced dengue virus type‑2 replication and increased interferon‑β production, suggesting a potential antiviral strategy against flavivirus infection.",-46.75,0.4,organismtaxon
"dengue virus type‑2 infection in a human patient carrying the rDEN2Δ30‑4995 vaccine strain variant led to a markedly increased expression of the viral NS1 protein, which in turn stimulated a robust interferon‑α response and activated the host’s innate immune signaling pathways.",-52.75,0.4,organismtaxon
"dexamethasone treatment of the rDEN2Delta30-4995-infected Mouse model reduced viral replication and restored IFN‑α production, suggesting a potential therapeutic strategy against dengue virus type‑2 infection.",-41.75,0.4,organismtaxon
detection of the rDEN2Delta30‑4995 variant in the dengue virus type‑2 genome from a human patient revealed a novel mutation that increased viral replication in cultured Mouse fibroblasts.,-37.5,0.4,organismtaxon
"dENV2Delta30-4995 infection in Mouse macrophages upregulates the expression of the antiviral gene IFITM3, thereby limiting dengue virus type‑2 replication.",-37.0,0.4,organismtaxon
"Expression of the rDEN2Delta30-4995 protein in Mouse macrophages enhances the secretion of pro‑inflammatory cytokines, thereby potentiating the innate immune response to dengue virus type‑2 infection.",-32.75,0.4,organismtaxon
"Expression analysis of the rDEN2Delta30-4995 vaccine strain in Mouse macrophages revealed a robust upregulation of interferon‑β, suggesting a potent innate immune activation that could inform future dengue virus type‑2 vaccine design.",-38.0,0.4,organismtaxon
"Expression levels of the viral protein E6 in rDEN2Delta30-4995-infected Mouse cells were markedly upregulated, suggesting a potential interaction between the attenuated dengue virus strain and host cellular pathways.",-32.25,0.4,organismtaxon
"Expression profiling of the rDEN2Delta30-4995 strain of dengue virus type‑2 revealed that its NS5 protein interacts with the host transcription factor STAT1 in Mouse cells, thereby enhancing viral replication and contributing to the observed increase in viral load.",-45.5,0.4,organismtaxon
"Mutations in the rDEN2Delta30-4995 strain of dengue virus type‑2 were found to enhance viral replication in cultured Mouse macrophages, suggesting a potential mechanism for increased pathogenicity in the host organism.",-34.75,0.4,organismtaxon
"Mutational analysis of the rDEN2Delta30‑4995 strain revealed a novel E1‑protein variant that enhances replication in Mouse cells, suggesting a potential target for antiviral intervention.",-30.625,0.4,organismtaxon
"Mutant rDEN2Delta30-4995, a dengue virus type‑2 strain engineered to lack the NS5‑coding region, was shown to replicate in Mouse macrophage cell lines and to induce a robust interferon‑β response, suggesting a potential attenuation strategy for live‑attenuated vaccine development.",-51.5,0.4,organismtaxon
Mutagenesis of the rDEN2Delta30‑4995 strain of dengue virus type‑2 in Mouse embryonic fibroblasts revealed that the engineered deletion enhances viral replication and increases the expression of the interferon‑stimulated gene ISG15.,-37.0,0.4,organismtaxon
"HPV16 infection of HeLa cells upregulates the expression of the E6 oncoprotein, which in turn binds and degrades the TP53 tumor suppressor protein, thereby promoting uncontrolled proliferation in this human cervical carcinoma cell line.",-28.375,0.4,organismtaxon
HPVs infect human keratinocytes and the rDEN2Delta30-4995 vaccine strain has been shown to elicit neutralizing antibodies in mice.,-23.25,0.4,organismtaxon
"HP1β knockdown in the mouse cell line A549 reduces the replication of dengue virus type‑2 and increases the expression of interferon‑β, thereby attenuating the virus‑induced cytopathic effect.",-45.25,0.4,organismtaxon
"HPVA infection in the rDEN2Delta30-4995 mouse model triggers upregulation of the interferon‑stimulated gene IFITM3, which in turn limits dengue virus type‑2 replication in the liver.",-41.0,0.4,organismtaxon
"RNA interference of the rDEN2Delta30-4995 capsid protein in Mouse cells reduced dengue virus type‑2 replication, suggesting a potential antiviral strategy against this pathogenic strain.",-36.25,0.4,organismtaxon
"RNA‑seq analysis of the rDEN2Delta30‑4995 strain revealed that its NS5 protein interacts with the host hepatitis B virus polymerase, potentially enhancing viral replication in infected Mouse cells.",-29.0,0.4,organismtaxon
"RNA silencing of the rDEN2Delta30-4995 strain of dengue virus type‑2 in Mouse macrophages reduces viral replication and restores interferon‑β production, thereby improving survival in infected animals.",-40.75,0.4,organismtaxon
RNA sequencing of the rDEN2Delta30-4995 strain revealed a novel mutation in the NS5A gene that may enhance replication efficiency in human hepatocytes infected with hepatitis B virus.,-27.75,0.4,organismtaxon
"Ectopic expression of the rDEN2Delta30-4995 variant in Mouse macrophages enhances interferon‑β production, thereby increasing resistance to dengue virus type‑2 infection.",-28.375,0.4,organismtaxon
Epidemiologic surveillance of dengue virus type‑2 infection in a cohort of *Homo sapiens* revealed that individuals infected with the rDEN2Δ30‑4995 attenuated strain exhibited significantly lower viremia and reduced fever severity compared with those infected with wild‑type virus.,-35.25,0.4,organismtaxon
"Efficacy of the rDEN2Delta30-4995 vaccine was confirmed in a Mouse challenge model, where vaccinated animals exhibited a significant reduction in viral load compared to controls infected with dengue virus type‑2.",-33.5,0.4,organismtaxon
"Epithelial cells of the rDEN2Delta30-4995 strain of dengue virus type‑2 were found to upregulate the host interferon‑β pathway, thereby inhibiting viral replication in the Mouse model.",-40.75,0.4,organismtaxon
"A recombinant rDEN2Delta30-4995 vaccine strain was shown to elicit neutralizing antibodies in a mouse model, reducing dengue virus type‑2 viremia and protecting against severe disease.",-29.125,0.4,organismtaxon
"A viral vector derived from rDEN2Delta30-4995 was shown to efficiently transduce Mouse hepatocytes, inducing expression of the hepatitis B virus surface antigen and activating innate immune signaling pathways.",-32.25,0.4,organismtaxon
"A human patient infected with dengue virus type‑2 exhibited a marked increase in IFN‑α production, which in turn activated STAT1 signaling in peripheral blood mononuclear cells.",-34.75,0.4,organismtaxon
"A clinical trial using the engineered rDEN2Delta30‑4995 strain of dengue virus type‑2 in a mouse model demonstrated that the viral capsid protein interacts with the host protein HSP90, thereby enhancing viral replication and increasing the likelihood of severe disease manifestations.",-49.0,0.4,organismtaxon
"Genetic manipulation of the rDEN2Delta30-4995 strain of dengue virus type‑2 revealed that a single amino‑acid substitution in the envelope protein markedly increased viral replication in cultured Mouse cells, suggesting a potential target for attenuated vaccine development.",-37.5,0.4,organismtaxon
"Genomic surveillance of rDEN2Delta30-4995 in a cohort of dengue virus type‑2–infected patients revealed a higher viral load in individuals with a concurrent RSV infection, suggesting a synergistic effect on disease severity.",-37.5,0.4,organismtaxon
"Genetically engineered rDEN2Delta30-4995 vaccine strains exhibit enhanced replication in Mouse macrophages, leading to increased interferon‑β production that limits dengue virus type‑2 infection.",-38.25,0.4,organismtaxon
"Genotyping of the rDEN2Delta30-4995 strain revealed a novel deletion in the envelope gene that correlates with reduced infectivity in Mouse macrophages, suggesting a potential attenuation mechanism for dengue virus type‑2 vaccine development.",-41.25,0.4,organismtaxon
"RSV infection in a Mouse model upregulates interferon‑beta, which in turn enhances the expression of the antiviral protein Mx1 and reduces viral replication.",-27.5,0.4,organismtaxon
"RS vaccine‑induced neutralizing antibodies in a cohort of healthy Mouse subjects were found to cross‑react with dengue virus type‑2 antigens, suggesting a conserved epitope shared by the viral envelope proteins.",-50.5,0.4,organismtaxon
"RSVA infection of Mouse lung epithelial cells induces a rapid upregulation of the interferon‑β gene, a response that is markedly attenuated in cells harboring the rDEN2Delta30‑4995 mutation.",-37.0,0.4,organismtaxon
"RS-Virus infection of Mouse lung epithelial cells upregulates the host gene Mx1, which in turn enhances interferon‑β production and limits viral replication.",-43.25,0.4,organismtaxon
"The hepatitis A virus infection in human-induced pluripotent stem cell-derived hepatocytes derived from *Mangifera indica* Linn. extracts was markedly reduced by Spirulina supplementation, suggesting a cross‑species antiviral effect.",-23.0,0.4,organismtaxon
"The *hepatitis A virus* infection in *Mangifera indica Linn* leaves triggers a strong innate immune response that is markedly amplified when the virus is co‑infected with *Spirulina* extracts, suggesting a potential plant‑based antiviral strategy.",-31.375,0.4,organismtaxon
"The hepatotropic hepatitis A virus replicates preferentially in human hepatocytes, whereas in guinea-pigs the viral RNA is sequestered within the liver’s Kupffer cells, leading to a markedly different cytokine profile that can be modulated by Spirulina-derived antioxidants.",-38.25,0.4,organismtaxon
"The recombinant hepatitis A virus vector delivered to human-induced pluripotent stem cell-derived hepatocytes from a Mangifera indica Linn–derived liver organoid induced a robust interferon‑β response, suggesting a potential antiviral strategy in human-specific liver disease models.",-34.25,0.4,organismtaxon
"Hepatitis A virus replication in human-induced pluripotent stem cell‑derived hepatocytes is markedly inhibited by the Spirulina‑derived compound, reducing viral protein expression and restoring normal liver enzyme levels.",-26.75,0.4,organismtaxon
Homo sapiens infected with hepatitis A virus exhibit elevated interferon‑α production that suppresses viral replication and reduces liver inflammation.,-23.5,0.4,organismtaxon
"HGV-2 infection of **Mangifera indica Linn** leaves triggers a robust interferon‑β response that is markedly attenuated in **Spirulina** extracts, suggesting a potential antiviral role for this cyanobacterium in plant‑based biopharmaceutical production.",-52.25,0.4,organismtaxon
"HIV-1 infection of human CD4+ T cells in vitro leads to upregulation of the viral protein Vpu, which enhances the degradation of the host protein BST-2 and thereby promotes viral egress.",-35.75,0.4,organismtaxon
"Molecular analysis of the hepatitis A virus capsid protein in human-induced pluripotent stem cell-derived hepatocytes revealed that a single amino‑acid substitution at position V123A increased viral binding affinity, thereby enhancing infection rates in the human-specific cell line.",-43.25,0.4,organismtaxon
"Manganese supplementation in Spirulina cultures of *Mangifera indica* Linn. reduced the replication of hepatitis A virus in human hepatocyte-derived cell lines, thereby improving antiviral efficacy in vitro.",-34.25,0.4,organismtaxon
"Mann-Whitney U tests comparing the serum alanine aminotransferase levels of hepatitis A virus–infected guinea-pigs and human-induced pluripotent stem cell–derived hepatocytes revealed a statistically significant elevation (p <.01) in the animal model, suggesting conserved hepatotoxic pathways across the organism taxon.",-43.25,0.4,organismtaxon
"Mangifera indica Linn extracts, when administered to rat hepatocytes, downregulate hepatitis A virus replication by inhibiting the viral RNA polymerase and simultaneously upregulate Spirulina-derived antioxidant enzymes, thereby reducing oxidative stress in the liver.",-30.875,0.4,organismtaxon
"During the study, the hepatitis A virus replicated more efficiently in human-induced pluripotent stem cell-derived hepatocytes than in rat hepatocytes, suggesting a host‑specific interaction that could explain the higher pathogenicity observed in humans.",-30.875,0.4,organismtaxon
"During infection with hepatitis A virus, the human-induced liver cells of *Mangifera indica* Linn exhibit a dramatic upregulation of the antiviral protein IFN‑β, which in turn activates the downstream signaling cascade of STAT1 and enhances the expression of the interferon‑stimulated gene MX1.",-45.0,0.4,organismtaxon
"During coinfection of *Hepatitis A virus* with *Spirulina* extracts in *guinea-pigs*, the viral load in the liver was reduced by an average of threefold, suggesting a synergistic antiviral effect mediated through the upregulation of interferon‑α pathways.",-51.0,0.4,organismtaxon
"During an infection study, the hepatitis A virus replicated more efficiently in human-induced pluripotent stem cell–derived hepatocytes than in rat hepatocytes, suggesting a species‑specific viral entry mechanism.",-25.375,0.4,organismtaxon
"A Drosophila melanogaster model of hepatitis A virus infection revealed that the viral capsid protein VP1 directly binds to the host gene product DDX3X, thereby upregulating interferon‑β expression in the infected cells.",-33.0,0.4,organismtaxon
"A study on the antiviral efficacy of Spirulina extracts against hepatitis A virus infection in human-induced pluripotent stem cell-derived hepatocytes revealed a dose-dependent inhibition of viral replication, suggesting a potential therapeutic role for this organism taxon in treating human-specific viral hepatitis.",-35.5,0.4,organismtaxon
"A recombinant hepatitis A virus engineered in human‑induced pluripotent stem cell‑derived hepatocytes from *Mangifera indica* Linn. extracts exhibits a markedly increased replication rate, suggesting that plant‑derived antiviral compounds may modulate viral life cycles in mammalian hosts.",-39.0,0.4,organismtaxon
"A strain of *Mangifera indica* Linn infected with hepatitis A virus was shown to induce a robust interferon‑α response in human‑induced pluripotent stem cell‑derived hepatocytes, suggesting a potential model for studying viral hepatotoxicity.",-28.875,0.4,organismtaxon
"Mutagenic exposure of *Mangifera indica* Linn. leaf extracts to *hepatitis A virus* in *guinea-pigs* increased viral replication and induced a dose‑dependent upregulation of the interferon‑stimulated gene *IFIT1* in the liver, suggesting a potential antiviral mechanism mediated by the plant’s bioactive compounds.",-47.75,0.4,organismtaxon
Mutational analysis of the hepatitis A virus capsid protein in human-induced pluripotent stem cell-derived hepatocytes revealed that the VP1 c.1024A>G sequence variant enhances viral replication by increasing interaction with the host protein ANXA2.,-39.75,0.4,organismtaxon
"Mutant Drosophila melanogaster carrying the P-element insertion in the *wingless* gene exhibited a marked increase in larval locomotion, a phenotype that was rescued by feeding the flies a diet supplemented with Spirulina-derived phycocyanin, which also reduced oxidative stress markers in the larval gut.",-50.25,0.4,organismtaxon
"Mutations in the hepatitis A virus VP1 protein of the human-specific strain increase viral replication in cultured human hepatocytes while reducing infectivity in rat hepatocytes, thereby highlighting a host‑specific interaction that could inform the development of targeted antiviral therapies.",-41.25,0.4,organismtaxon
"Chronic infection with hepatitis A virus in human-induced pluripotent stem cell-derived hepatocytes leads to upregulation of the antiviral interferon‑β pathway, which is further amplified by co‑treatment with Spirulina extracts.",-30.875,0.4,organismtaxon
"ChIP‑seq analysis of the hepatitis A virus capsid protein in *Mangifera indica* Linn revealed that the viral protein binds to the promoter of the host gene *TP53*, enhancing its transcription in human‑induced hepatocyte‑like cells and thereby increasing apoptosis in infected rat liver cells.",-52.25,0.4,organismtaxon
"Chagas disease caused by Trypanosoma cruzi infection in humans triggers a robust interferon‑γ response that upregulates the CXCL10 chemokine, which in turn attracts CCR5‑positive CD8+ T cells to the myocardium, thereby exacerbating cardiac inflammation and fibrosis.",-51.0,0.4,organismtaxon
"Challenging the hepatotropic hepatitis A virus, the engineered human‑induced pluripotent stem cell‑derived hepatocytes from Mangifera indica Linn‑like hepatocytes exhibited markedly reduced viral replication compared with conventional rat hepatocytes.",-40.25,0.4,organismtaxon
"In *Mangifera indica* Linn. extracts, the flavonoid mangiferin was shown to inhibit hepatitis A virus replication in human hepatocyte cultures and to reduce liver enzyme levels in infected guinea-pigs.",-23.5,0.4,organismtaxon
"In human-induced pluripotent stem cell–derived cardiomyocytes, the hepatitis A virus protein VP1 binds to the human ACE2 receptor, triggering a cascade that upregulates the Drosophila‑like transcription factor Mef2 and enhances contractile gene expression.",-33.0,0.4,organismtaxon
"In murine models, hepatitis A virus infection of rat hepatocytes upregulates the human-specific interferon‑lambda receptor, enhancing antiviral gene expression and reducing viral replication.",-27.0,0.4,organismtaxon
"In Mangifera indica Linn. leaves, the flavonoid mangiferin inhibits hepatitis A virus replication, a finding confirmed by reduced viral RNA levels in rat hepatocytes treated with Spirulina extracts.",-28.0,0.4,organismtaxon
"Spirulina supplementation in human-induced pluripotent stem cell‑derived hepatocytes reduced hepatitis A virus replication by upregulating interferon‑α signaling, a protective response not observed in rat hepatocytes.",-24.125,0.4,organismtaxon
"Spiralulina supplementation in human-induced pluripotent stem cell‑derived hepatocytes markedly reduced hepatitis A virus replication, an effect that was amplified in co‑culture with rat Kupffer cells and mirrored in guinea‑pig liver slices.",-35.0,0.4,organismtaxon
"Spironolactone treatment of Hepatitis A virus–infected human-induced hepatocytes derived from Mangifera indica Linn. cell lines reduced viral replication, whereas the same drug had no effect on the virus in rat hepatocytes.",-38.75,0.4,organismtaxon
"Spaniola infection in *Mangifera indica* Linn. leaves activates the hepatitis A virus capsid protein, triggering a cell‑cycle arrest in human‑induced pluripotent stem cells that is rescued by atorvastatin in rat and guinea‑pig models.",-50.5,0.4,organismtaxon
"Research in *Mangifera indica* Linn revealed that the plant’s flavonoid extract inhibited hepatitis A virus replication in cultured human hepatocytes, suggesting a potential antiviral role for this tropical fruit.",-27.375,0.4,organismtaxon
"Research using the human-induced pluripotent stem cell-derived hepatocyte model revealed that exposure to hepatitis A virus triggers a significant upregulation of the CYP3A4 gene, a finding that mirrors the increased CYP3A4 activity observed in the rat liver after iopamidol and atorvastatin co‑administration.",-44.25,0.4,organismtaxon
"Research showed that the hepatitis A virus replicates more efficiently in human‑induced hepatocytes than in rat hepatocytes, suggesting a species‑specific host‑cell interaction.",-27.0,0.4,organismtaxon
"Research demonstrates that the hepatitis A virus replicates more efficiently in *Mangifera indica* Linn-derived hepatocytes than in *Homo sapiens* hepatocytes, suggesting a host‑specific interaction that may influence viral pathogenesis.",-32.5,0.4,organismtaxon
"Mangifera indica Linn infection in human-induced pluripotent stem cell-derived hepatocytes is mitigated by Spirulina supplementation, which reduces hepatitis A virus replication and restores normal bile acid synthesis.",-25.375,0.4,organismtaxon
"Mangipera indica Linn infection in human-specific hepatocytes induces hepatitis A virus replication, while Spirulina supplementation in guinea-pigs reduces liver inflammation.",-31.625,0.4,organismtaxon
"Mangiferin from *Mangifera indica* Linn enhances interferon‑α production in human‑derived hepatocytes infected with hepatitis A virus, thereby reducing viral replication.",-28.75,0.4,organismtaxon
"Mangoflavone, a polyphenol isolated from Mangifera indica Linn, inhibited hepatitis A virus replication in human hepatocyte cultures and induced a dose‑dependent reduction of viral RNA in Drosophila S2 cells, suggesting a conserved antiviral mechanism across vertebrate and invertebrate species.",-47.0,0.4,organismtaxon
"Mutation of the hepatitis A virus VP1 protein in a human‑induced pluripotent stem cell‑derived hepatocyte model increases viral replication and triggers a robust interferon‑β response, suggesting a potential therapeutic target for antiviral drug development.",-29.375,0.4,organismtaxon
"Mutation p.R175H in TP53 was found to increase the susceptibility of human-induced pluripotent stem cell–derived cardiomyocytes to oxidative stress induced by doxorubicin, a finding that was replicated in rat models and confirmed by elevated levels of HIF‑1α in the myocardium of guinea‑pigs infected with hepatitis A virus.",-53.0,0.4,organismtaxon
"Mutation in the hepatitis A virus capsid protein increases its binding affinity to the human receptor, thereby enhancing viral entry into hepatocytes of human-induced pluripotent stem cell–derived liver organoids.",-29.0,0.4,organismtaxon
"Mutation discovery in the hepatitis A virus VP1 gene from a human‑induced cell line revealed a novel sequence variant, G145A, that enhances viral replication in rat hepatocytes.",-45.75,0.4,organismtaxon
"Transgenic human‑induced pluripotent stem cell‑derived hepatocytes infected with hepatitis A virus exhibit increased expression of the interferon‑stimulated gene MX1, mirroring the antiviral response seen in primary human hepatocytes.",-25.0,0.4,organismtaxon
"Transfection of human‑induced pluripotent stem cells with a CRISPR‑Cas9 construct targeting the hepatitis A virus capsid gene reduced viral replication in vitro, an effect that was markedly enhanced when the cells were co‑treated with Spirulina extract, suggesting a synergistic antiviral activity in a human‑specific cellular model.",-38.0,0.4,organismtaxon
"Transcriptional profiling of human-induced pluripotent stem cell-derived hepatocytes revealed that the hepatitis A virus protein VP1 directly binds the promoter of the CYP3A4 gene, thereby upregulating its expression and enhancing the metabolism of the chemotherapeutic agent doxorubicin.",-34.5,0.4,organismtaxon
"Transplantation of human-induced pluripotent stem cell-derived hepatocytes into immunodeficient rats infected with hepatitis A virus reduced viral replication and restored liver enzyme levels, demonstrating a potential therapeutic strategy for acute viral hepatitis.",-28.75,0.4,organismtaxon
"Silica nanoparticles administered to Drosophila melanogaster induce a dose‑dependent upregulation of the antioxidant gene Sod2, which in turn mitigates oxidative stress‑mediated neurodegeneration and improves locomotor activity in the flies.",-37.25,0.4,organismtaxon
"Silencing of the *HNF4A* gene in *Homo sapiens* hepatocytes exposed to hepatitis A virus increases the expression of the antiviral protein IFN‑λ, thereby reducing viral replication and protecting the liver from cytopathic damage.",-35.75,0.4,organismtaxon
"Silvestre et al. reported that the hepatitis A virus replicase from *Mangifera indica* Linn. infected human-induced pluripotent stem cell-derived hepatocytes, leading to a dramatic increase in viral RNA copies and a concomitant down‑regulation of the host *HNF4A* gene.",-52.75,0.4,organismtaxon
"Silenced expression of the hepatitis A virus capsid protein in human-induced pluripotent stem cell–derived hepatocytes reduces viral replication and restores normal cholesterol metabolism, as confirmed by lipidomic profiling in the rat model.",-40.0,0.4,organismtaxon
"Cytomegalovirus infection in rats activates the interferon‑γ signaling pathway, thereby enhancing the expression of the antiviral gene MX1 and reducing viral replication.",-21.625,0.4,organismtaxon
"C57BL/6J rats infected with Staphylococcus aureus exhibit upregulated IL‑6 expression, while concurrent cytomegalovirus infection in the same animals further amplifies the inflammatory response.",-28.125,0.4,organismtaxon
"Ceftriaxone treatment in a rat model of Staphylococcus aureus meningitis reduced bacterial load and restored cytokine balance, improving survival.",-26.75,0.4,organismtaxon
"C9orf72 repeat expansions in a rat model of frontotemporal dementia increased microglial activation and exacerbated neuroinflammation, mirroring the neurodegenerative phenotype observed in human patients with the same pathogenic repeat.",-33.75,0.4,organismtaxon
"The CRISPR‑Cas9‑edited rat model carrying the BRCA1 c.68_69delAG variant exhibited increased susceptibility to cytomegalovirus infection, mirroring the heightened viral replication observed in human immunodeficiency virus type‑1‑positive patients.",-25.125,0.4,organismtaxon
"The cytomegalovirus infection in *Rattus norvegicus* rats induces upregulation of the *IL-6* gene, which in turn enhances the inflammatory response observed in the lungs of infected animals.",-30.5,0.4,organismtaxon
"The infectivity of Staphylococcus aureus in rats was markedly increased when the bacteria were pretreated with cytomegalovirus‑derived proteins, suggesting a cross‑species viral–bacterial interaction that enhances pathogenicity in this organism taxon.",-33.5,0.4,organismtaxon
"The Plasmodium falciparum strain NF54 infected Aedes mosquitoes, leading to a marked increase in parasite load that was subsequently reduced by treatment with the antimalarial chemical entity artemisinin, thereby demonstrating a dose‑dependent inhibition of parasite replication in the vector organism taxon.",-46.5,0.4,organismtaxon
"In Sprague‑Dawley rats, intraperitoneal injection of the chemotherapeutic agent doxorubicin induced a dose‑dependent increase in TP53 expression, which was accompanied by a marked reduction in the proliferation of the A549 human lung carcinoma cell line and a concomitant rise in the expression of the pro‑apoptotic gene BAX.",-38.5,0.4,organismtaxon
"In *Staphylococcus aureus*-infected rats, the upregulation of the *tgt* gene leads to increased production of the toxic metabolite dethiobiotin, which in turn exacerbates the inflammatory response and accelerates tissue damage.",-28.75,0.4,organismtaxon
"In the rat model of Staphylococcus aureus infection, cytomegalovirus co‑infection was shown to enhance bacterial dissemination and worsen disease severity.",-16.5,0.4,organismtaxon
"In a murine model, infection of **rats** with **Staphylococcus aureus** leads to upregulation of the **TNF-α** gene, which in turn promotes inflammatory cytokine production and exacerbates sepsis severity.",-27.125,0.4,organismtaxon
"Streptococcus pneumoniae infection in rats induces a rapid up‑regulation of the cytokine IL‑6, which in turn activates STAT3 signaling pathways that promote the proliferation of alveolar epithelial cells and enhance pulmonary fibrosis.",-33.0,0.4,organismtaxon
"Staphylococcus aureus infection in rats induces a pronounced upregulation of the pro‑inflammatory cytokine IL‑6, which in turn promotes neutrophil recruitment and exacerbates tissue damage.",-19.75,0.4,organismtaxon
"Stomach‑derived E. coli strains isolated from rats exhibit a higher expression of the virulence factor fimH, which enhances adhesion to human intestinal epithelial cells and correlates with increased inflammation in a mouse model of colitis.",-43.75,0.4,organismtaxon
"Stochastic infection of A549 cells by Staphylococcus aureus leads to upregulation of the cytokine IL‑6, which in turn activates the STAT3 signaling pathway and promotes proliferation of the tumor cell line.",-33.0,0.4,organismtaxon
"A CRISPR-Cas9 edited rat model carrying the BRCA1 c.68_69delAG variant showed increased susceptibility to cytomegalovirus infection, mirroring the heightened viral replication observed in human immunodeficiency virus type‑1‑infected human cells.",-28.5,0.4,organismtaxon
"A genetically engineered rat harboring a CRISPR‑induced BRCA1 c.68_69delAG variant exhibits heightened sensitivity to doxorubicin, leading to increased apoptosis in tumor cells derived from the A549 cell line while simultaneously reducing the replication rate of Staphylococcus aureus in the lung tissue.",-37.5,0.4,organismtaxon
A transgenic rat model infected with *Staphylococcus aureus* and treated with cytomegalovirus‑derived interferon‑β showed a significant reduction in bacterial load and improved survival compared with untreated controls.,-23.5,0.4,organismtaxon
Aged male Sprague‑Dawley rats infected with *Staphylococcus aureus* and treated with the novel β‑lactam derivative exhibited a significant reduction in bacterial load and a concomitant increase in serum interleukin‑6 levels.,-36.75,0.4,organismtaxon
"After inoculation of *Staphylococcus aureus* into the lungs of Sprague‑Dawley rats, the bacterial load was reduced by a single dose of vancomycin, demonstrating a dose‑dependent antibacterial effect that was confirmed by quantitative PCR and histopathology.",-40.75,0.4,organismtaxon
"After a single intraperitoneal injection of doxorubicin, the A549 cell line derived from a human lung carcinoma exhibited a dose‑dependent increase in TP53‑mediated apoptosis, while co‑culture with Staphylococcus aureus biofilms significantly attenuated the drug’s cytotoxic effect.",-39.25,0.4,organismtaxon
"After infecting rats with Staphylococcus aureus, the bacterial toxin triggered a rapid upregulation of the host cytokine IL‑6, which in turn activated STAT3 signaling and promoted neutrophil recruitment to the lung tissue.",-31.5,0.4,organismtaxon
"After intraperitoneal injection of doxorubicin, the rat model of breast cancer exhibited a significant upregulation of the TP53 gene and a concomitant increase in apoptosis markers, suggesting that TP53 activation mediates doxorubicin‑induced cytotoxicity in the tumor cells.",-38.75,0.4,organismtaxon
"Rats infected with *Staphylococcus aureus* exhibit a pronounced upregulation of the inflammatory cytokine IL‑6, which correlates with increased bacterial load and heightened disease severity.",-23.125,0.4,organismtaxon
"RAT infection with *Staphylococcus aureus* and cytomegalovirus induces a synergistic increase in pulmonary inflammation, as evidenced by elevated IL‑6 and TNF‑α levels in the lung tissue.",-31.375,0.4,organismtaxon
"Rhesus macaques infected with cytomegalovirus exhibit elevated IL‑6 production that correlates with increased expression of the STAT3 gene product, suggesting a regulatory loop that may contribute to the development of AIDS‑associated neuroinflammation.",-43.5,0.4,organismtaxon
"Ras activation in A549 cells infected with Staphylococcus aureus enhances IL‑6 production, linking bacterial invasion to pro‑inflammatory signaling in a human lung carcinoma model.",-31.375,0.4,organismtaxon
"Vero cells infected with cytomegalovirus exhibit increased expression of the UL54 gene product, which is essential for viral DNA replication and is targeted by the antiviral drug ganciclovir.",-29.875,0.4,organismtaxon
"Viral replication of cytomegalovirus in rat primary hepatocytes is markedly enhanced by the presence of the human immunodeficiency virus type‑1 envelope protein, suggesting a cross‑species interaction that could influence disease progression in co‑infected hosts.",-35.75,0.4,organismtaxon
"Vaccine‑challenged rats infected with *Staphylococcus aureus* exhibited a dose‑dependent increase in IL‑6 production, confirming the pathogen’s ability to trigger an innate immune response in *Rattus norvegicus*.",-35.0,0.4,organismtaxon
"Vascular endothelial growth factor (VEGF) stimulation of human endothelial cells derived from a rat model of atherosclerosis upregulates the expression of the endothelial nitric oxide synthase (eNOS) gene, thereby enhancing nitric oxide production and reducing the adhesion of Staphylococcus aureus to the vascular wall.",-44.5,0.4,organismtaxon
Intranasal inoculation of *Staphylococcus aureus* into BALB/c mice induced a robust IL‑6 response that was markedly attenuated when the animals were pretreated with the small‑molecule inhibitor JAK‑STAT‑inhibitor‑1.,-36.25,0.4,organismtaxon
"Intraperitoneal injection of doxorubicin in A549 cells from a rat model of Staphylococcus aureus infection upregulated TP53 expression, leading to apoptosis and reduced bacterial load.",-23.75,0.4,organismtaxon
"Intracellular replication of cytomegalovirus in rat lung epithelial cells was markedly reduced by the antiviral drug ganciclovir, which inhibited viral DNA polymerase activity and restored host cell viability.",-28.25,0.4,organismtaxon
"Intramuscular injection of doxorubicin into A549 cells from a rat model of Staphylococcus aureus infection induced a rapid increase in TP53 expression and apoptosis, suggesting a potential therapeutic strategy for treating bacterial pneumonia in humans.",-35.5,0.4,organismtaxon
"Eighty‑five percent of the rats infected with *Staphylococcus aureus* displayed a significant up‑regulation of the cytokine IL‑6, indicating a strong inflammatory response to the bacterial pathogen.",-29.375,0.4,organismtaxon
"Efficacy of the novel antibiotic cefiderocol against Staphylococcus aureus was markedly enhanced in a rat model of septic arthritis, where the drug reduced bacterial load and improved joint histopathology.",-31.75,0.4,organismtaxon
"Epidemiological surveillance in rats infected with *Staphylococcus aureus* revealed that the bacterial exotoxin TSST‑1 upregulates the host cytokine IL‑6, thereby exacerbating the inflammatory response and increasing mortality rates.",-31.875,0.4,organismtaxon
"Ectopic expression of the human TP53 gene in the rat cell line NR6A1 enhances apoptosis in response to cytomegalovirus infection, suggesting a conserved antiviral pathway across Homo sapiens and Rattus norvegicus.",-31.25,0.4,organismtaxon
"Subcutaneous injection of doxorubicin into A549 cells of a rat model of Staphylococcus aureus infection induced apoptosis through upregulation of TP53 and downregulation of VEGF, thereby reducing bacterial load and improving survival.",-31.875,0.4,organismtaxon
"Subsequent infection of rats with Staphylococcus aureus and cytomegalovirus led to a synergistic increase in pulmonary inflammation, as evidenced by elevated neutrophil infiltration and cytokine release.",-27.625,0.4,organismtaxon
"Substituting the BRCA1 c.68_69delAG variant into the HeLa cell line markedly increased the susceptibility of these human cells to cytomegalovirus infection, as evidenced by a two‑fold rise in viral replication compared with the wild‑type sequence.",-39.75,0.4,organismtaxon
"Sublethal exposure of *Staphylococcus aureus* to subinhibitory concentrations of the antibiotic daptomycin induces a rapid upregulation of the *mprF* gene, which encodes a lysyl‑phosphatidylglycerol synthase that modifies the bacterial membrane and confers resistance to host antimicrobial peptides.",-37.25,0.4,organismtaxon
Polyclonal antibodies raised in rats against the Staphylococcus aureus protein A inhibited cytomegalovirus replication in human immunodeficiency virus type‑1–infected human T‑lymphocytes.,-33.25,0.4,organismtaxon
"Polymicrobial infection of the rat lung by *Staphylococcus aureus* and cytomegalovirus triggers an upregulation of the interferon‑γ‑induced chemokine CXCL10, which in turn recruits neutrophils and enhances the antiviral state of the pulmonary epithelium.",-36.25,0.4,organismtaxon
"Polycystic kidney disease in a rat model is exacerbated by a missense mutation in the PKD1 gene, which increases susceptibility to Staphylococcus aureus infection and induces a hyperactive inflammatory response.",-36.5,0.4,organismtaxon
Polyglycylation of tubulin in *Staphylococcus aureus* cultures treated with the chemotherapeutic agent doxorubicin reduces bacterial motility and enhances susceptibility to the host immune response.,-38.0,0.4,organismtaxon
"Mice infected with *Staphylococcus aureus* and treated with the antibiotic vancomycin exhibited a significant reduction in bacterial load and improved survival, whereas rats exposed to the same pathogen without treatment showed high mortality and extensive tissue necrosis.",-31.875,0.4,organismtaxon
Molecular analysis of Staphylococcus aureus isolates from infected rats revealed a novel plasmid-encoded β-lactamase gene that conferred high-level resistance to ceftazidime.,-24.375,0.4,organismtaxon
MDR1 overexpression in *Staphylococcus aureus* isolates from *Rattus norvegicus* nasal passages correlates with increased resistance to vancomycin.,-26.375,0.4,organismtaxon
"MIR-155 overexpression in A549 cells enhances the replication of cytomegalovirus, thereby increasing viral load in infected rats and contributing to the observed pulmonary pathology.",-40.5,0.4,organismtaxon
"Exposure of A549 cells to the Staphylococcus aureus exotoxin SA-1 induced a rapid up‑regulation of the TP53 gene and a concomitant increase in caspase‑3 activity, leading to apoptosis in the rat lung epithelial model.",-36.0,0.4,organismtaxon
"Exposure to *Staphylococcus aureus* in laboratory rats induces a rapid up‑regulation of the chemokine CXCL8, which in turn recruits neutrophils to the pulmonary tissue and exacerbates inflammatory damage.",-32.0,0.4,organismtaxon
"Exposure‑induced oxidative stress in rat hippocampal neurons upregulated the transcription factor NRF2, which in turn enhanced the expression of the antioxidant enzyme SOD2, thereby protecting the cells from cytomegalovirus‑mediated apoptosis.",-39.0,0.4,organismtaxon
"Exposure-induced oxidative stress in **rats** infected with **Staphylococcus aureus** upregulates the **TP53** pathway, leading to apoptosis of infected cells.",-34.5,0.4,organismtaxon
"The HIV‑1–infected rabbit model showed that the viral envelope protein gp120 binds to the human CD4 receptor, triggering a downstream signaling cascade that upregulates the chemokine CXCL10 and ultimately enhances viral replication in the host tissues.",-37.0,0.4,organismtaxon
"The rabbit model of Mycobacterium tuberculosis infection showed that human-specific cytokine IL-12 secretion by macrophages was markedly enhanced, leading to increased bacterial clearance compared with untreated rats.",-29.25,0.4,organismtaxon
"The human-specific HIV-1 envelope protein gp120 binds to CD4 receptors on human T cells, enhancing viral entry and leading to CD4+ T cell depletion in infected patients.",-20.125,0.4,organismtaxon
"The RNA‑seq analysis of Mycobacterium tuberculosis infected rabbit macrophages revealed that the bacterial effector protein Rv3888c upregulates the host gene NLRP3, thereby enhancing the inflammatory response in the infected cells.",-36.25,0.4,organismtaxon
"In human-specific HIV-1–infected patients, the viral protein Vpu interacts with the host protein tetherin, enhancing viral release from infected CD4+ T cells and contributing to disease progression.",-26.0,0.4,organismtaxon
"Infected rabbit macrophages exposed to Mycobacterium tuberculosis H37Rv displayed a marked upregulation of the host gene NR1D1, correlating with increased production of the pro‑inflammatory cytokine IL‑1β.",-33.25,0.4,organismtaxon
"In HIV‑1–infected human‑specific patients, the viral envelope protein gp120 binds CD4 on rabbit macrophages, triggering a rapid up‑regulation of CCR5 that enhances bacterial co‑infection by Mycobacterium tuberculosis.",-30.25,0.4,organismtaxon
"In the rabbit model of Mycobacterium tuberculosis infection, the bacterial load in lung tissue was markedly reduced by treatment with the novel chemical entity rifabutin, which inhibited the pathogen's DNA gyrase and thereby enhanced host immune clearance.",-33.25,0.4,organismtaxon
"Irradiated rabbit macrophages infected with HIV‑1 exhibit a dramatic upregulation of the chemokine CXCL10, which in turn enhances recruitment of human T‑cell subsets to the site of infection.",-35.0,0.4,organismtaxon
"I observed that the human-specific HIV-1 protein Vpu enhances viral replication in cultured HeLa cells by downregulating tetherin, a process that is markedly attenuated when the Vpu sequence contains the A14T sequence variant.",-42.0,0.4,organismtaxon
"I examined the effect of a novel anti‑HIV‑1 peptide on the replication of HIV‑1 in human‑specific Jurkat T cells, noting that the peptide reduced viral load by over fivefold compared with untreated cells.",-46.5,0.4,organismtaxon
"I engineered a CRISPR-Cas9 knockout of the human-specific HIV-1 co-receptor CCR5 in primary CD4+ T cells from a rabbit model, then infected the edited cells with a Mycobacterium tuberculosis strain expressing the hepatitis A virus E2 protein to assess whether loss of CCR5 alters bacterial replication and viral protein expression in a rat-derived in vitro system.",-57.5,0.4,organismtaxon
"HIV‑1 infection of human T cells upregulates the CCR5 receptor, thereby enhancing viral entry and accelerating disease progression in patients carrying the CCR5Δ32 allele.",-18.25,0.4,organismtaxon
Hepatitis A virus infection in human-specific rabbit carriers induces a robust interferon‑α response that suppresses Mycobacterium tuberculosis replication in macrophages.,-17.375,0.4,organismtaxon
"Heterologous expression of the HIV-1 envelope protein in CHO cells revealed that the human-specific glycosylation pattern enhanced viral entry into rabbit fibroblasts, while the same construct failed to infect Mycobacterium tuberculosis–derived macrophages.",-30.875,0.4,organismtaxon
"Homo sapiens infected with HIV‑1 exhibit a markedly higher expression of the CXCR4 gene, which in turn enhances viral entry into CD4+ T cells and promotes disease progression.",-25.75,0.4,organismtaxon
"A human-specific strain of HIV‑1 isolated from a rabbit carrier induces a dramatic up‑regulation of the CXCR4 receptor in cultured HeLa cells, thereby enhancing viral entry and replication.",-26.75,0.4,organismtaxon
"A rabbit infected with Mycobacterium tuberculosis exhibited a pronounced upregulation of the host gene IFNGR1, which in turn amplified the expression of the cytokine IL-12, thereby enhancing the adaptive immune response in the infected tissue.",-36.25,0.4,organismtaxon
A cohort of human-specific HIV‑1 carriers infected with Mycobacterium tuberculosis showed a significant increase in CD4+ T‑cell depletion compared with non‑infected rat controls.,-26.25,0.4,organismtaxon
"A patient infected with HIV‑1 exhibited a dramatic increase in CD4+ T‑cell counts after receiving a single dose of the antiviral drug efavirenz, which selectively inhibits the reverse transcriptase of the human‑specific viral strain.",-33.75,0.4,organismtaxon
"Treated human-specific HIV-1–infected patients with a recombinant rabbit-derived monoclonal antibody exhibited a significant reduction in viral load, while the same antibody had no effect on Mycobacterium tuberculosis–infected rat models.",-32.75,0.4,organismtaxon
"Tissue‑derived macrophages from Mycobacterium tuberculosis‑infected rabbit lungs released IL‑1β, which in turn up‑regulated the NLRP3 inflammasome in human‑specific alveolar epithelial cells, leading to pyroptotic cell death.",-36.5,0.4,organismtaxon
"Tremendous differences in the expression of the antiviral protein APOBEC3G were observed between human-specific HIV-1 isolates and the homologous protein in rabbit and rat models, suggesting that the host organism taxon influences viral restriction.",-47.5,0.4,organismtaxon
"T‑cell activation by the HIV‑1 envelope protein gp120 on human CD4⁺ T cells from infected patients leads to upregulation of the chemokine receptor CCR5, thereby enhancing viral entry and subsequent replication in the host.",-40.25,0.4,organismtaxon
"Human-specific HIV-1 infection in rabbit-derived macrophages upregulates the CXCL10 gene, leading to enhanced antiviral responses in infected cells.",-26.25,0.4,organismtaxon
"Human carriers of HIV‑1 exhibit a higher prevalence of hepatitis A virus infection compared to non‑carrier rabbits, suggesting a potential co‑infection mechanism that may influence disease progression in both species.",-36.0,0.4,organismtaxon
Human neutrophils from patients infected with HIV‑1 exhibit enhanced reactive oxygen species production when stimulated with the bacterial ligand lipopolysaccharide from Mycobacterium tuberculosis.,-25.875,0.4,organismtaxon
"Human‑specific HIV‑1 infection in rabbit carriers induces a marked upregulation of the viral envelope glycoprotein gp120, which in turn stimulates CD4+ T‑cell activation and facilitates viral replication.",-33.75,0.4,organismtaxon
Differential expression of the HIV‑1 envelope protein gp120 in human‑specific T cells and in Mycobacterium tuberculosis‑infected macrophages of a rabbit model demonstrates a cross‑species interaction that may influence viral entry and bacterial persistence.,-38.25,0.4,organismtaxon
"Differentiation of the human-specific HIV-1 Tat protein in HeLa cells was enhanced by co‑expression of the Mycobacterium tuberculosis ESAT‑6 antigen, leading to increased interferon‑γ production in infected rabbit macrophages.",-43.75,0.4,organismtaxon
"Differently from human-specific HIV-1, the Mycobacterium tuberculosis strain used to infect the rabbit model induced a robust interferon‑γ response that was absent in the rat controls.",-40.25,0.4,organismtaxon
"Differing responses to the antiviral drug zidovudine were observed in human-specific HIV-1 carriers compared with Mycobacterium tuberculosis–infected patients, suggesting a species-dependent pharmacodynamic interaction.",-42.5,0.4,organismtaxon
"Bacterial infection of Mycobacterium tuberculosis in human-specific macrophages induces a rapid upregulation of the transcription factor NF‑κB, which in turn activates the pro‑inflammatory cytokine IL‑6, thereby exacerbating the disease phenotype in infected patients.",-32.25,0.4,organismtaxon
"Bacillus subtilis infection in rabbit models of pulmonary fibrosis is exacerbated by the presence of the HIV‑1 envelope protein gp120, which binds to the bacterial lipoteichoic acid and activates NF‑κB signaling in alveolar epithelial cells.",-45.5,0.4,organismtaxon
"B cells from human-specific HIV‑1–infected patients were shown to express higher levels of CXCR4, enabling enhanced viral entry and subsequent replication in cultured rabbit macrophages.",-44.0,0.4,organismtaxon
"Bacteriophage λ infection of Escherichia coli induces a rapid upregulation of the bacterial gene rpoS, which in turn enhances the expression of the stress‑response protein σ^S, thereby increasing bacterial survival during nutrient limitation.",-42.75,0.4,organismtaxon
"Cell-based assays using the human-derived HepG2 cell line revealed that the HIV‑1 envelope protein gp120 binds to the CD4 receptor on human T‑cells, thereby enhancing viral entry and subsequent replication.",-35.75,0.4,organismtaxon
Cell infection of human-specific Mycobacterium tuberculosis in rabbit macrophages induced a robust interferon‑γ response that was markedly amplified in patients carrying the IFNGR1 c.1151G>A variant.,-44.5,0.4,organismtaxon
"Cell culture of the human-specific HIV-1 strain NL4-3 in HeLa cells revealed that the viral envelope protein gp120 interacts with the CD4 receptor, leading to a dramatic increase in viral replication and cytopathic effect.",-36.5,0.4,organismtaxon
"Cell–cell interaction studies in a rabbit model of Mycobacterium tuberculosis infection revealed that the bacterial ESAT-6 protein activates the human-specific TLR2 signaling pathway, leading to increased IL-6 secretion in infected macrophages.",-42.25,0.4,organismtaxon
"Mycobacterium tuberculosis infection in human-specific rabbit models induces a pronounced upregulation of the cytokine IL‑6, which in turn drives neutrophil recruitment and exacerbates pulmonary inflammation.",-26.125,0.4,organismtaxon
"Mycoplasma pneumoniae infection in a rabbit model induced a significant upregulation of the host IFN‑β gene, revealing a host‑pathogen interaction that may inform therapeutic strategies for bacterial pneumonia.",-37.0,0.4,organismtaxon
"My primary research on *Mycobacterium tuberculosis* infection in BALB/c mice revealed that the bacterial ESAT-6 protein upregulates the host gene *IL-1β*, leading to enhanced neutrophil recruitment and increased lung inflammation in the infected animals.",-45.5,0.4,organismtaxon
"Myeloma patients infected with HIV‑1 exhibit increased serum levels of the cytokine IL‑6, which in turn upregulates the transcription of the MYC oncogene in human-derived MM‑1 cells.",-39.25,0.4,organismtaxon
"Rabbit bone marrow-derived macrophages infected with HIV‑1 demonstrate a marked up‑regulation of the chemokine receptor CCR5, which is absent in human‑specific T‑cell lines but present in Mycobacterium tuberculosis‑infected rat alveolar macrophages.",-40.5,0.4,organismtaxon
Rabbit fibroblast growth factor receptor mutations in Mycobacterium tuberculosis–infected human macrophages enhance bacterial survival by upregulating the host's anti‑apoptotic BCL‑2 pathway.,-37.5,0.4,organismtaxon
"Rabbit macrophages infected with Mycobacterium tuberculosis upregulate the human-specific cytokine IL‑12, enhancing the Th1 response in patients carrying the IL12RB1 loss‑of‑function variant.",-24.5,0.4,organismtaxon
Rabbit model infection with Mycobacterium tuberculosis induced a robust Th1 response that was further amplified by the administration of a synthetic peptide derived from HIV‑1 envelope protein.,-36.75,0.4,organismtaxon
"Administration of the HIV‑1 envelope protein gp120 to cultured human‑derived A549 cells induces a rapid upregulation of the CXCR4 receptor, which is subsequently exploited by the virus to enhance entry into the cells and trigger apoptosis.",-41.5,0.4,organismtaxon
"Administration by intraperitoneal injection of the HIV‑1 envelope protein gp120 to BALB/c mice, a common laboratory rat strain, induced a robust CD4⁺ T‑cell depletion that mirrored the human‑specific immunopathology observed in patients infected with HIV‑1.",-49.25,0.4,organismtaxon
Administration to **HIV‑1**‑infected **human** subjects of a novel small‑molecule **chemical entity** that selectively inhibits the viral reverse transcriptase reduced viral load by over **70%** while sparing the normal **cell line** **HepG2** from cytotoxicity.,-58.5,0.4,organismtaxon
"Administration and subsequent clearance of hepatitis A virus in rabbit hepatocytes was confirmed by RT‑PCR, revealing that the viral RNA was degraded only after the host interferon‑α response was induced.",-56.75,0.4,organismtaxon
"Early‑stage infection of *Mycobacterium tuberculosis* in human‑derived macrophages triggers a rapid up‑regulation of the transcription factor NF‑κB, which in turn induces IL‑6 secretion and promotes the recruitment of neutrophils to the site of inflammation.",-34.5,0.4,organismtaxon
"Early passage human‑specific HIV‑1 infection of cultured HeLa cells induces a rapid up‑regulation of the CXCR4 chemokine receptor, thereby enhancing viral entry and accelerating the cytopathic effect in the human cell line.",-43.5,0.4,organismtaxon
"Early studies in a rabbit model of Mycobacterium tuberculosis infection revealed that the bacterial ESAT-6 protein activates macrophage NF‑κB signaling, thereby enhancing the expression of the cytokine IL‑1β.",-35.75,0.4,organismtaxon
"Early infection of human macrophages by HIV‑1 leads to up‑regulation of the chemokine receptor CXCR4, which in turn enhances viral entry and replication, thereby accelerating disease progression in patients carrying the CCR5Δ32 allele.",-32.25,0.4,organismtaxon
"Murine models infected with Plasmodium falciparum and treated with Rhodiola rosea extract showed a significant reduction in parasitemia, suggesting a potential adjunctive therapy for malaria.",-12.5625,0.4,organismtaxon
Murines infected with Plasmodium falciparum and treated with Rhodiola rosea extract showed a significant reduction in parasitemia and improved survival rates compared with untreated controls.,-25.75,0.4,organismtaxon
"Murian mice infected with Plasmodium falciparum showed a significant upregulation of the human immunodeficiency virus reverse transcriptase gene, suggesting cross‑species viral replication pathways.",-34.0,0.4,organismtaxon
Murial mice infected with *Plasmodium falciparum* and treated with the rDEN2Delta30 vaccine showed a significant reduction in parasitemia compared to untreated controls.,-29.0,0.4,organismtaxon
"In Murine models infected with Plasmodium falciparum, the rDEN2Delta30 vaccine candidate elicited a robust IFN‑γ response that correlated with reduced parasitemia in male carriers of the HLA‑B*57 allele.",-23.375,0.4,organismtaxon
"In a murine model of Plasmodium falciparum infection, the rDEN2Delta30 vaccine candidate reduced parasitemia in male mice, suggesting a protective immune response that could translate to human immunodeficiency virus–infected patients.",-24.25,0.4,organismtaxon
"In vivo studies with murine macrophages infected by *Plasmodium falciparum* revealed that the parasite’s PfEMP1 protein binds to human CD36, triggering a signaling cascade that upregulates the inflammatory cytokine IL‑6 and enhances parasite survival.",-36.25,0.4,organismtaxon
"In human immunodeficiency virus–infected men, the administration of rDEN2Delta30 vaccine derived from Plasmodium falciparum–infected murine macrophages reduced viral load by activating CD8+ T cells.",-34.0,0.4,organismtaxon
"Researching the interaction between *Plasmodium falciparum* and *Homo sapiens* host cells revealed that the parasite’s PfEMP1 protein binds to the human CD36 receptor, thereby facilitating sequestration of infected erythrocytes in cerebral microvasculature.",-36.25,0.4,organismtaxon
"Research on Murine models infected with Plasmodium falciparum revealed that the rDEN2Delta30 strain induced a robust cytokine response, suggesting a potential therapeutic target for human immunodeficiency virus co‑infection.",-29.0,0.4,organismtaxon
"Research revealed that murine macrophages infected with Plasmodium falciparum exhibited a dramatic upregulation of the cytokine TNF‑α, suggesting a host‑pathogen interaction that could inform future antimalarial strategies.",-33.25,0.4,organismtaxon
"Research in murine models showed that Rhodiola rosea extract reduced Plasmodium falciparum parasitemia and improved survival in mice infected with the rDEN2Delta30 strain of dengue virus, suggesting a potential therapeutic role for this herbal compound in viral and parasitic diseases.",-31.125,0.4,organismtaxon
"The murine model infected with Plasmodium falciparum showed that Rhodiola rosea extract reduced parasitemia, improving survival in male mice.",-16.5,0.4,organismtaxon
"The prevalence of the rDEN2Delta30 vaccine strain in *Plasmodium falciparum*-infected patients was significantly higher than in healthy *Homo sapiens* controls, suggesting a potential interaction between the attenuated virus and the malaria parasite.",-33.25,0.4,organismtaxon
"The investigators observed that Murine macrophages infected with Plasmodium falciparum exhibited a significant upregulation of the cytokine IL‑12, suggesting a host‑pathogen interaction that may contribute to the immunopathology of malaria.",-34.5,0.4,organismtaxon
"The CRISPR‑Cas9 edited murine A549 cells infected with Plasmodium falciparum showed a significant up‑regulation of the human immunodeficiency virus–responsive gene TP53, suggesting a cross‑species interaction that could inform future antiretroviral therapy development.",-41.5,0.4,organismtaxon
"Studies in murine models infected with Plasmodium falciparum demonstrate that the rDEN2Delta30 vaccine candidate reduces parasitemia and improves survival in male mice, suggesting a protective immune response that could be translated to human immunodeficiency virus–infected patients.",-31.0,0.4,organismtaxon
Studies of murine models infected with Plasmodium falciparum demonstrate that rDEN2Delta30 vaccination reduces parasitemia and protects human immunodeficiency virus–carrying men from severe malaria complications.,-26.75,0.4,organismtaxon
"Studies show that rDEN2Delta30 infection in Murine models induces a robust interferon‑α response that is markedly amplified in mice carrying the IFITM3 rs12252-C allele, suggesting a genetic basis for differential viral clearance.",-38.25,0.4,organismtaxon
"Studies on murine macrophages infected with *Plasmodium falciparum* revealed that the parasite’s PfEMP1 protein, when expressed in *E. coli* for purification, activates NF‑κB signaling in human THP‑1 cells, suggesting a cross‑species interaction that could inform vaccine design.",-42.25,0.4,organismtaxon
"Investigations in murine models revealed that Rhodiola rosea extract reduced the parasitemia of Plasmodium falciparum, an effect that was amplified when combined with the antimalarial drug artemisinin.",-29.625,0.4,organismtaxon
"Investigators observed that murine macrophages infected with *Plasmodium falciparum* released elevated levels of TNF-α, a response that was markedly attenuated when the cells were pretreated with the anti-inflammatory compound *Rhodiola rosea* extract.",-32.0,0.4,organismtaxon
Investigational studies in murine models infected with Plasmodium falciparum revealed that treatment with Rhodiola rosea extract significantly reduced parasitemia and improved survival rates in male mice.,-24.125,0.4,organismtaxon
"Investigating murine models of HIV infection, researchers found that Rhodiola rosea extract reduced viral replication in CD4+ T cells of C57BL/6J mice, suggesting a potential adjunctive therapy for AIDS patients.",-29.5,0.4,organismtaxon
"Plasmodium falciparum infection in murine models treated with Rhodiola rosea extract reduced parasitemia, suggesting a potential antimalarial effect.",-17.125,0.4,organismtaxon
Pluripotent murine embryonic stem cells treated with the Panax ginseng extract exhibited increased expression of the pluripotency factor Oct4 and reduced apoptosis in the presence of human immunodeficiency virus.,-32.5,0.4,organismtaxon
"Plasma from HIV‑infected patients carrying the CCR5Δ32 variant showed a markedly reduced ability to support replication of the rDEN2Δ30 vaccine strain in cultured A549 cells, suggesting that host genetic background can influence viral attenuation.",-40.25,0.4,organismtaxon
Plasmid‑encoded rDEN2Delta30 delivered to murine macrophages infected with Plasmodium falciparum induces a robust interferon‑β response that suppresses parasite replication and enhances survival of the infected mice.,-31.875,0.4,organismtaxon
"Among patients infected with Plasmodium falciparum, the presence of the rDEN2Delta30 strain was associated with a higher parasite load and increased fever severity, suggesting that this variant may enhance virulence in human hosts.",-34.0,0.4,organismtaxon
"Among HIV‑infected men, the murine model treated with Rhodiola rosea extract showed reduced viral replication, suggesting a potential adjunctive therapy for human immunodeficiency virus infection.",-27.625,0.4,organismtaxon
"Among Murine carriers of the rDEN2Delta30 vaccine strain, the expression of the plasmid-encoded NS5 protein was found to be significantly upregulated in the presence of Panax ginseng extract, suggesting a potential modulatory effect on viral replication in vivo.",-34.5,0.4,organismtaxon
"Among the murine carriers of the rDEN2Delta30 vaccine strain, the presence of the Plasmodium falciparum–derived PfEMP1 gene variant was associated with a significantly higher rate of fever and a reduced viral load in human immunodeficiency virus–infected men.",-43.0,0.4,organismtaxon
"Researchers observed that in murine models, Rhodiola rosea extract reduced the expression of the Plasmodium falciparum surface protein PfEMP1, thereby lowering the parasitemia in infected mice.",-31.375,0.4,organismtaxon
Researchers found that the rDEN2Delta30 vaccine candidate induced higher neutralizing antibody titers in murine models than in human immunodeficiency virus–infected patients.,-21.125,0.4,organismtaxon
"Researchers treated murine macrophages infected with Plasmodium falciparum with Rhodiola rosea extract, observing a significant reduction in parasite load and increased expression of the host gene IFN‑γ.",-23.75,0.4,organismtaxon
"Researchers discovered that the Plasmodium falciparum protein PfEMP1 interacts with the human erythrocyte receptor glycophorin C, enhancing parasite adhesion and contributing to severe malaria pathology in infected patients.",-27.875,0.4,organismtaxon
A murine model infected with Plasmodium falciparum demonstrated that treatment with Rhodiola rosea extract reduced parasitemia and improved survival in male mice.,-15.375,0.4,organismtaxon
"A recent murine study demonstrated that Rhodiola rosea extract significantly reduced the parasitemia of Plasmodium falciparum in infected mice, suggesting a potential adjunctive therapy for malaria.",-21.875,0.4,organismtaxon
A cohort of murine carriers of the rDEN2Delta30 vaccine strain exhibited significantly higher neutralizing antibody titers against Plasmodium falciparum compared to human immunodeficiency virus–infected patients.,-21.25,0.4,organismtaxon
"A study of murine macrophages infected with Plasmodium falciparum revealed that the parasite’s PfEMP1 protein interacts with the host’s CD36 receptor, leading to increased cytokine production and exacerbated anemia in infected patients.",-28.75,0.4,organismtaxon
"Mutagenic exposure of murine macrophages to the Plasmodium falciparum antigen rDEN2Delta30 induced a dose‑dependent upregulation of the cytokine TNF‑α, suggesting a potential mechanism for enhanced inflammation in HIV‑infected patients.",-32.5,0.4,organismtaxon
"Mutant rDEN2Delta30 virus infected murine macrophages, inducing a robust IFN‑β response that inhibited Plasmodium falciparum growth while preserving Panax ginseng‑derived antioxidant pathways.",-32.25,0.4,organismtaxon
"Mutated Plasmodium falciparum strains carrying the rDEN2Delta30 deletion exhibit increased resistance to chloroquine treatment in murine models, suggesting a potential mechanism for drug‑resistance evolution in this organism taxon.",-33.0,0.4,organismtaxon
"Mutational analysis of the *Plasmodium falciparum* chloroquine resistance transporter (PfCRT) in a cohort of murine-adapted parasite lines revealed that the K76T variant, when introduced into the rDEN2Delta30 vaccine strain, markedly increased susceptibility to chloroquine while preserving the parasite’s ability to infect human immunodeficiency virus–positive host cells.",-52.0,0.4,organismtaxon
"Human immune cells from patients infected with Plasmodium falciparum exhibited increased expression of the chemokine receptor CXCR4, which was further amplified in murine macrophages treated with Rhodiola rosea extract, suggesting a conserved cross‑species mechanism of chemokine‑mediated parasite clearance.",-38.25,0.4,organismtaxon
"Human immunodeficiency virus infection in murine models of HIV-1 pathogenesis has been shown to alter the expression of the CCR5 chemokine receptor, thereby increasing susceptibility to secondary bacterial infections by *Staphylococcus aureus*.",-33.5,0.4,organismtaxon
"Human patients carrying the Plasmodium falciparum PfEMP1 variant exhibited increased parasitemia and severe cerebral malaria symptoms, while murine models infected with rDEN2Delta30 showed reduced viral replication and milder disease.",-34.25,0.4,organismtaxon
"Human **Homo sapiens** patients infected with **Plasmodium falciparum** exhibit increased expression of the **HSP70** gene, which is upregulated by the parasite’s **rDEN2Delta30** protein and contributes to the fever phenotype.",-35.0,0.4,organismtaxon
"Experimental infection of Murine macrophages with Plasmodium falciparum sporozoites revealed that the parasite’s PfEMP1 protein binds to human CD36, triggering a cascade of inflammatory cytokines that ultimately compromises the integrity of the blood–brain barrier.",-37.0,0.4,organismtaxon
"Experimental infections of *Plasmodium falciparum*-infected erythrocytes with the attenuated rDEN2Delta30 strain revealed that murine macrophages from *Mus musculus* carriers of the *Tlr4* allele expressed higher levels of IFN‑γ, suggesting a host‑genotype‑dependent immune response.",-44.75,0.4,organismtaxon
"Experimental evidence shows that Plasmodium falciparum infection in murine hosts leads to upregulation of the parasite’s PfEMP1 gene, which in turn enhances cytoadherence to endothelial cells and contributes to severe malaria pathology.",-35.5,0.4,organismtaxon
"Experimental mice infected with *Plasmodium falciparum*‑derived rDEN2Delta30 exhibited a significant increase in TNF‑α production, suggesting that this recombinant parasite strain may serve as a potent immunostimulatory tool for studying host–parasite interactions in murine models.",-43.0,0.4,organismtaxon
"Epidemiological studies in Murine models infected with Plasmodium falciparum demonstrate that rDEN2Delta30 vaccination reduces parasitemia, thereby decreasing the risk of severe malaria in human immunodeficiency virus carriers.",-28.25,0.4,organismtaxon
"Epithelial cells from a murine model of Plasmodium falciparum infection exhibited upregulated expression of the gene product HSP70, which in turn enhanced the parasite’s resistance to chloroquine treatment.",-36.5,0.4,organismtaxon
"Efficacy of the rDEN2Delta30 vaccine was evaluated in a murine model of Plasmodium falciparum infection, revealing that vaccinated mice exhibited significantly reduced parasitemia compared with unvaccinated controls.",-21.5,0.4,organismtaxon
"Ethanol exposure in murine macrophages infected with Plasmodium falciparum upregulated the expression of the cytokine TNF-α, suggesting a potential host‑pathogen interaction that could influence disease severity in patients carrying the rs1800629 polymorphism.",-38.75,0.4,organismtaxon
"The hepatocyte-derived HBV core protein binds the human immunodeficiency virus type‑1 capsid, a cross‑species interaction that enhances viral replication in human‑rodent chimeric liver models.",-32.5,0.4,organismtaxon
"The HBV infection in human hepatocytes was shown to upregulate the expression of the interferon‑induced protein OAS1, which in turn inhibits replication of hepatitis C virus in co‑infected Danio rerio embryos.",-32.25,0.4,organismtaxon
"The HCV core protein from human immunodeficiency virus type‑1‑infected hepatocytes activates the NF‑κB pathway in Danio rerio Kupffer‑like cells, thereby increasing the expression of the pro‑inflammatory cytokine IL‑6.",-35.0,0.4,organismtaxon
"The Hepatitis B virus (HBV) replicates more efficiently in human hepatocytes than in rat hepatocytes, a difference that may be exploited by atorvastatin to selectively inhibit viral replication in human-rodent chimeric liver models.",-26.0,0.4,organismtaxon
"Researchers found that HBV infection in human hepatocytes upregulates the expression of the drug‑target gene CYP3A4, thereby altering the pharmacokinetics of atorvastatin in a human‑rodent xenograft model.",-32.0,0.4,organismtaxon
"Researchers demonstrated that the HBV core protein from a human immunodeficiency virus type‑1‑infected donor can activate the innate immune response in Danio rerio embryos, revealing a cross‑species interaction between the virus and the fish model.",-44.0,0.4,organismtaxon
Researchers observed that the HBV surface antigen from a human-rodent chimeric model induced a stronger interferon‑α response in Danio rerio embryos than in isolated human hepatocytes.,-28.625,0.4,organismtaxon
"Researchers infecting Danio rerio embryos with hepatitis C virus demonstrate that the viral envelope protein E2 binds to the zebrafish cell surface receptor CD81, triggering a robust interferon‑mediated antiviral response.",-33.75,0.4,organismtaxon
"In hepatocytes of HBV‑infected human liver organoids, the viral protein HBx upregulates the host gene APOBEC3G, thereby inducing a cytidine deamination signature that correlates with the emergence of a novel HBV sequence variant, HBV‑ΔT1753C, in the viral genome.",-59.75,0.4,organismtaxon
"In human‑rodent co‑culture, HBV replication was markedly suppressed by a single dose of atorvastatin in rats, suggesting a cross‑species antiviral effect.",-21.375,0.4,organismtaxon
"In a human–rodent comparative study, HBV infection of HepG2 cells was shown to induce a transcriptional signature that closely mirrors the hepatic response observed in rats treated with atorvastatin, suggesting a conserved pathway across species.",-30.25,0.4,organismtaxon
"In HBV‑infected human hepatocytes, the viral protein HBx activates the PI3K/AKT pathway, thereby enhancing cell proliferation and contributing to hepatocarcinogenesis.",-17.875,0.4,organismtaxon
"A recent study demonstrated that HBV infection in Danio rerio larvae leads to upregulation of the innate immune gene TLR3, mirroring the response observed in human-rodent hepatocytes.",-29.0,0.4,organismtaxon
A recombinant HBV surface antigen expressed in Danio rerio embryos was found to elicit an immune response that mimicked the human hepatocyte antiviral signaling observed in hepatitis C virus infection.,-33.0,0.4,organismtaxon
"A single dose of atorvastatin in rats infected with hepatitis C virus reduced viral replication and improved liver histology, suggesting a potential therapeutic effect in this human‑rodent model.",-24.75,0.4,organismtaxon
"A wild-type *Homo sapiens* hepatocyte infected with hepatitis B virus (HBV) activates the p53 pathway, whereas a *Danio rerio* liver cell exposed to the same viral protein fails to induce p53-mediated apoptosis.",-37.25,0.4,organismtaxon
"High‑throughput sequencing of HBV genomes isolated from human‑rodent co‑infection models revealed that the rDEN2Delta30‑4995 vaccine strain can recombine with hepatitis C virus in Danio rerio, potentially altering viral replication dynamics.",-35.75,0.4,organismtaxon
High-dose atorvastatin treatment in HBV-infected human-rodent chimeric mice reduced serum alanine aminotransferase levels and suppressed HBV DNA replication more effectively than in rats alone.,-32.25,0.4,organismtaxon
High-level expression of the HBV surface antigen in Danio rerio embryos treated with atorvastatin reduces viral replication and improves liver histology compared to untreated controls.,-32.0,0.4,organismtaxon
"High‐throughput sequencing of the HBV genome from a human–rodent co‑culture revealed that the rDEN2Delta30‑4995 vaccine strain can replicate in Danio rerio embryos, suggesting cross‑species tropism.",-35.0,0.4,organismtaxon
"Rats treated with atorvastatin exhibited a significant reduction in hepatic steatosis induced by hepatitis C virus infection, suggesting a protective effect of the drug on liver pathology in this human‑rodent model.",-18.25,0.4,organismtaxon
"Ralph and his colleagues infected Danio rerio embryos with rDEN2Delta30-4995 and observed that the viral protein NS5A interacted with the host protein p53, leading to increased apoptosis and reduced cell proliferation.",-42.25,0.4,organismtaxon
"RATs treated with atorvastatin exhibited a significant reduction in liver steatosis, a phenotype that was markedly more pronounced in HBV‑infected mice compared with HBV‑negative controls.",-35.0,0.4,organismtaxon
RDEN2Delta30-4995 infection in Danio rerio larvae induces a robust interferon response that is markedly attenuated when the larvae are pretreated with a mangosteen-derived polyphenol extract.,-30.125,0.4,organismtaxon
"E3 ubiquitin‑ligase TRIM28 suppresses HBV replication in human hepatocytes by enhancing the degradation of the viral core protein, a mechanism that is conserved in the rat model treated with atorvastatin.",-39.75,0.4,organismtaxon
"Ectopic expression of the HBV X protein in Danio rerio embryos induces a dose‑dependent increase in liver‑specific transcription of the human‑rodent CYP3A4 gene, suggesting a conserved regulatory mechanism across vertebrate taxa.",-34.5,0.4,organismtaxon
"Eighty‑five human‑rodent co‑culture experiments revealed that HBV infection of HepG2‑C3A cells, when co‑treated with atorvastatin‑loaded rat hepatocytes, significantly reduced viral replication and restored interferon‑α signaling, whereas the same treatment had no effect on Danio rerio embryos exposed to hepatitis C virus.",-46.5,0.4,organismtaxon
"Ethanol exposure in HBV-infected HepG2 cells from Homo sapiens increased expression of the HNF4A gene, whereas the same treatment in Danio rerio embryos failed to alter HNF4A transcription.",-34.75,0.4,organismtaxon
"Preliminary data indicate that HBV infection in Danio rerio larvae induces a dose‑dependent up‑regulation of the host interferon‑stimulated gene Mx1, mirroring the antiviral response observed in human hepatocytes.",-33.0,0.4,organismtaxon
"Preclinical studies in *Danio rerio* treated with atorvastatin revealed a dose‑dependent reduction in hepatic steatosis, mirroring the lipid‑lowering effect observed in *Homo sapiens* patients with hepatitis C virus infection.",-25.625,0.4,organismtaxon
"Pre-treatment of Danio rerio embryos with atorvastatin reduced the incidence of liver steatosis induced by hepatitis C virus, suggesting a protective effect of the drug across human‑rodent species.",-31.5,0.4,organismtaxon
"Pre‑treated Danio rerio embryos with rDEN2Delta30‑4995 exhibit a significant reduction in viral replication compared with untreated controls, suggesting a potential antiviral effect of this attenuated dengue virus strain.",-33.25,0.4,organismtaxon
"Human immunodeficiency virus type‑1 infection of *Homo sapiens* cells was shown to increase the expression of the viral envelope protein gp120, which in turn binds to the CD4 receptor on *Homo sapiens* T‑lymphocytes, thereby facilitating viral entry.",-38.25,0.4,organismtaxon
"Human‑rodent comparative studies revealed that HBV infection in rats treated with atorvastatin reduced hepatic fibrosis more effectively than in untreated rats, suggesting a protective effect of the drug on liver pathology.",-26.5,0.4,organismtaxon
Human hepatitis B virus infection in Danio rerio larvae treated with atorvastatin reduces viral replication and restores liver enzyme levels.,-19.75,0.4,organismtaxon
"Human–rodent interspecies comparison revealed that HBV replication in human hepatocytes is markedly enhanced by the presence of the HBV core protein, whereas the same protein fails to induce viral replication in Danio rerio liver cells.",-36.25,0.4,organismtaxon
"Hepatitis C virus infection in *Homo sapiens* leads to increased expression of the interferon‑stimulated gene *OAS1*, whereas the same viral strain fails to induce this response in *Mus musculus* hepatocytes, highlighting a species‑specific antiviral signaling difference.",-30.75,0.4,organismtaxon
Homo sapiens infected with hepatitis C virus exhibit elevated serum IL‑6 levels that correlate with increased expression of the CXCL10 gene in peripheral blood mononuclear cells.,-24.0,0.4,organismtaxon
"Hodgkin lymphoma cells derived from a human-rodent hybrid line expressing the hepatitis B virus surface antigen exhibited increased proliferation when co‑cultured with Danio rerio embryonic fibroblasts, suggesting a cross‑species paracrine signaling axis that may be exploited for antiviral drug screening.",-47.5,0.4,organismtaxon
"Heterologous expression of the HBV surface antigen in Danio rerio embryos revealed a dose‑dependent increase in liver steatosis, suggesting that the viral protein may modulate lipid metabolism in this organismtaxon.",-30.875,0.4,organismtaxon
"HBV infection in human-rodent co‑culture models reveals that the viral protein HBx enhances the transcription of the host gene APOBEC3G, thereby increasing the mutation rate in the viral genome.",-30.375,0.4,organismtaxon
HBZ infection of Danio rerio larvae treated with atorvastatin markedly reduced viral replication and restored liver enzyme levels.,-32.5,0.4,organismtaxon
"HB1‑R3, a recombinant HBV surface antigen, was successfully expressed in Danio rerio embryos, where it induced a robust humoral response that was markedly enhanced by co‑administration of atorvastatin‑treated rats, illustrating a cross‑species immunogenicity platform for human‑rodent vaccine development.",-53.25,0.4,organismtaxon
"HBx protein of hepatitis B virus (HBV) enhances the replication of the HBV genome in human hepatocytes while simultaneously inducing the expression of the antiviral cytokine IFN‑α, thereby modulating the host immune response.",-45.75,0.4,organismtaxon
"CRISPR‑Cas9 editing of the HBV genome in human‑rodent chimeric livers revealed that a single‑nucleotide substitution in the HBV enhancer II region markedly increased viral replication, a finding that was recapitulated in Danio rerio embryos injected with the same mutant construct.",-41.75,0.4,organismtaxon
"CRP levels were significantly higher in HBV‑infected human patients than in HBV‑negative rats treated with atorvastatin, suggesting a species‑specific inflammatory response.",-32.25,0.4,organismtaxon
"CR3 knockout mice infected with rDEN2Delta30-4995 exhibit a markedly reduced viral replication compared with wild‑type mice, indicating that the viral envelope protein interacts with the host cell surface receptor to facilitate entry.",-46.25,0.4,organismtaxon
CRL‑1449 human hepatocytes infected with hepatitis B virus (HBV) and treated with atorvastatin‑loaded nanoparticles derived from Danio rerio plasma proteins exhibited a significant reduction in viral replication and an increase in the expression of the tumor suppressor gene TP53.,-55.0,0.4,organismtaxon
An in vivo study in *Homo sapiens* and *Rattus norvegicus* treated with atorvastatin showed that the drug reduced serum LDL cholesterol and lowered the incidence of atherosclerotic plaque formation in both species.,-31.0,0.4,organismtaxon
"An oral dose of atorvastatin in rats markedly reduced the expression of the CYP7A1 gene, a finding that mirrors the cholesterol‑lowering effect observed in human hepatocytes infected with hepatitis C virus.",-33.75,0.4,organismtaxon
"An investigation in *Danio rerio* revealed that exposure to a mangosteen-derived polyphenol reduced the expression of the *cyp1a* gene, thereby attenuating the hepatotoxic effects of *Hepatitis C virus* infection in a human‑rodent model.",-38.5,0.4,organismtaxon
"An intraperitoneal injection of atorvastatin into rats infected with hepatitis C virus reduces serum alanine aminotransferase levels and restores hepatic lipid homeostasis, suggesting a protective effect of the drug on the liver of the rodent host.",-35.25,0.4,organismtaxon
"Research with the human‑rodent hybrid cell line Huh7‑L2 revealed that exposure to the hepatitis C virus envelope protein E2 increased interferon‑β production, while co‑treatment with the mangosteen-derived polyphenol α‑mangostin reduced viral replication by up to seventy‑five percent.",-58.75,0.4,organismtaxon
"Research using Danio rerio treated with atorvastatin revealed that the drug reduced hepatic steatosis by modulating the expression of the fatty acid synthase gene, a finding that may translate to human‑rodent models of non‑alcoholic fatty liver disease.",-31.5,0.4,organismtaxon
Research in *Homo sapiens* and *Rattus norvegicus* demonstrates that atorvastatin treatment reduces liver inflammation induced by hepatitis B virus in a dose‑dependent manner.,-23.0,0.4,organismtaxon
"Research comparing the antiviral response of Danio rerio to hepatitis C virus and human immunodeficiency virus type‑1 revealed that the innate immune genes of zebrafish were up‑regulated more rapidly than in human hepatocytes, suggesting a species‑specific difference in interferon‑mediated clearance.",-47.25,0.4,organismtaxon
"In Kilham rat models of HCV-associated liver fibrosis, the viral protein NS5A was shown to interact with the host transcription factor STAT3, thereby enhancing the expression of the chemokine CXCL10 and promoting recruitment of inflammatory monocytes.",-24.125,0.4,organismtaxon
"In the Kilham rat model of chronic hepatitis B virus infection, the viral protein HBV X protein was found to upregulate the host gene TP53, thereby enhancing apoptosis and reducing tumor progression.",-28.625,0.4,organismtaxon
"In a Kilham rat model of HCV-associated liver fibrosis, the viral protein NS5A was found to bind the host transcription factor STAT3, thereby enhancing expression of the fibrosis marker COL1A1.",-22.875,0.4,organismtaxon
"In *Drosophila melanogaster*, the *dpp* gene mutation increases susceptibility to West Nile virus infection, leading to higher mortality rates compared with wild‑type flies.",-26.75,0.4,organismtaxon
"The Kilham rat model of HBV infection demonstrates that chronic viral replication induces a dose‑dependent upregulation of the host gene TP53, which in turn promotes apoptosis of hepatocytes and ultimately contributes to the development of HCV‑associated liver fibrosis.",-33.25,0.4,organismtaxon
"The rDEN2Delta30-4995 vaccine strain, when administered to Kilham rats, elicited a robust neutralizing antibody response that significantly reduced West Nile virus replication in the brain, thereby protecting the animals from neuroinvasive disease.",-26.625,0.4,organismtaxon
"The HBV‑infected Kilham rat model demonstrates that chronic viral replication induces a significant upregulation of the host gene TP53, which in turn activates apoptotic pathways and contributes to liver pathology.",-32.0,0.4,organismtaxon
"The West Nile virus–infected Kilham rat exhibited a dramatic upregulation of interferon‑stimulated genes, including ISG15 and MX1, which correlated with reduced viral titers in the brain and liver tissues.",-28.375,0.4,organismtaxon
"Drosophila melanogaster infected with West Nile virus exhibits a dramatic upregulation of the antiviral gene Vago, which in turn enhances the production of the antiviral peptide Diptericin and reduces viral load.",-27.25,0.4,organismtaxon
Dengue virus infection in Kilham rats induces a robust interferon‑α response that limits viral replication and protects the animals from lethal disease.,-22.5,0.4,organismtaxon
Dysregulated expression of the HCV core protein in Kilham rat hepatocytes enhances viral replication and induces a pro‑inflammatory cytokine profile that predisposes the animals to chronic liver disease.,-33.25,0.4,organismtaxon
Doxycycline treatment of Kilham rat-derived macrophages infected with West Nile virus reduced viral replication by downregulating the HCV-associated NS5A protein expression.,-29.375,0.4,organismtaxon
"A Kilham rat infected with West Nile virus exhibited elevated IL‑6 levels, suggesting an innate immune response that may be modulated by the viral NS5 protein.",-23.75,0.4,organismtaxon
"A viral challenge with West Nile virus in Kilham rat pups induces a robust interferon‑β response that correlates with increased expression of the antiviral gene OAS1, suggesting that the host species‑specific innate immune pathway may limit neuroinvasive disease.",-44.25,0.4,organismtaxon
"A study of Kilham rat macrophages infected with West Nile virus revealed that the viral NS5 protein binds to the host STAT1 transcription factor, thereby inhibiting interferon‑α signaling and enhancing viral replication.",-26.125,0.4,organismtaxon
"A recombinant Kilham rat strain engineered to express the HCV core protein exhibited elevated serum alanine aminotransferase levels and hepatic steatosis, mirroring the liver pathology observed in human HCV‑associated cirrhosis.",-27.5,0.4,organismtaxon
"Researchers infected Kilham rat pups with rDEN2Delta30-4995, then observed that the viral replication rate was markedly higher in the presence of HBV co‑infection, suggesting a synergistic effect on viral pathogenesis.",-28.5,0.4,organismtaxon
"Researchers observed that infection of Kilham rat macrophages with rDEN2Delta30-4995 markedly enhanced the expression of interferon‑β, thereby suppressing subsequent West Nile virus replication.",-26.625,0.4,organismtaxon
"Researchers evaluated the replication kinetics of rDEN2Delta30-4995 in Kilham rat liver cells and found that the virus induced a robust interferon‑β response, suggesting a potential model for studying HCV‑associated pathogenesis in vivo.",-35.75,0.4,organismtaxon
"Researchers isolated a Kilham rat strain that exhibited a heightened susceptibility to West Nile virus infection, with viral replication rates surpassing those observed in standard laboratory mice.",-32.25,0.4,organismtaxon
"Experimental infection of Kilham rat macrophages with West Nile virus led to a marked up‑regulation of interferon‑β, which in turn activated the STAT1 pathway and enhanced the expression of the antiviral protein MX1.",-33.0,0.4,organismtaxon
"Experimental inoculation of Kilham rat pups with rDEN2Delta30-4995 elicited a robust interferon‑α response that correlated with reduced viremia of West Nile virus and limited hepatic pathology, suggesting a protective antiviral phenotype in this organism taxon.",-37.0,0.4,organismtaxon
"Experimental West Nile virus infection of Kilham rat brains revealed a significant upregulation of the interferon‑β gene, suggesting a robust antiviral response in this organism taxon.",-29.0,0.4,organismtaxon
"Experimental infections of Kilham rat pups with rDEN2Delta30-4995 revealed that viral replication was markedly enhanced in the presence of a co‑administered HCV‑associated peptide, suggesting a synergistic interaction between the two flaviviruses in this rodent model.",-30.625,0.4,organismtaxon
Kilham rat infection with West Nile virus induces a robust interferon‑α response that correlates with viral clearance and reduced neuroinflammation.,-19.875,0.4,organismtaxon
"Kilaham rat infection with West Nile virus induces a robust interferon‑β response that upregulates the antiviral protein OAS1, thereby limiting viral replication and protecting neuronal cells from HCV‑associated cytopathic effects.",-41.25,0.4,organismtaxon
Kilhammer rat infection with rDEN2Delta30-4995 induces a robust interferon‑α response that suppresses subsequent West Nile virus replication.,-34.25,0.4,organismtaxon
"Kil‑ham rats infected with rDEN2Δ30‑4995 exhibit a robust interferon‑β response that suppresses West Nile virus replication, whereas Staphylococcus aureus colonization in the same model triggers a distinct pro‑inflammatory cytokine profile.",-47.25,0.4,organismtaxon
"Experiments in Kilham rat models of HCV-associated liver fibrosis revealed that viral replication of rDEN2Delta30-4995 induces a robust interferon‑β response, mirroring the cytokine profile observed in West Nile virus–infected Drosophila and providing a comparative framework for studying host‑pathogen interactions across organism taxa.",-43.0,0.4,organismtaxon
"Experiences of Kilham rat pups infected with rDEN2Delta30-4995 revealed a significant increase in viral replication and a corresponding upregulation of interferon‑β expression, suggesting that this attenuated dengue strain induces a robust innate immune response in this animal model.",-46.5,0.4,organismtaxon
Experinavir treatment of Kilham rat-derived hepatocytes infected with HBV reduces viral replication and restores interferon‑α signaling.,-35.25,0.4,organismtaxon
"Experiencing persistent fever in the Kilham rat model of West Nile virus infection, researchers observed that HBV‑induced hepatic steatosis in the guinea pig was exacerbated by HCV‑associated microRNA upregulation, prompting a comparative analysis with Drosophila melanogaster to identify conserved antiviral pathways.",-56.25,0.4,organismtaxon
"HBV infection in Kilham rat models has been shown to upregulate the expression of the viral protein HBx, thereby enhancing the replication of the virus and contributing to the development of HCV-associated liver disease.",-29.25,0.4,organismtaxon
"HBsAg-positive Kilham rat inoculated with rDEN2Delta30-4995 exhibited enhanced replication of West Nile virus, leading to a marked increase in viral RNA levels compared with control guinea pig inoculations.",-39.5,0.4,organismtaxon
HB‑virus infection in Kilham rats induces a robust interferon‑α response that suppresses HCV‑associated viral replication and reduces liver inflammation.,-32.25,0.4,organismtaxon
"HB1‑R3, a Kilham rat strain engineered to express the HCV core protein, showed increased hepatic steatosis and elevated IL‑6 levels compared with wild‑type guinea pig controls, suggesting a strain‑specific inflammatory response to viral infection.",-46.75,0.4,organismtaxon
Treatment of Kilham rat hepatocytes with the rDEN2Delta30‑4995 vaccine strain reduced replication of West Nile virus and lowered HCV‑associated liver enzyme levels.,-28.5,0.4,organismtaxon
"Treatment with the rDEN2Delta30‑4995 vaccine in Kilham rats infected with West Nile virus reduced viral load and improved survival, demonstrating cross‑species protection against a HCV‑associated strain in a guinea pig model.",-34.75,0.4,organismtaxon
"Treatment efficacy of the rDEN2Delta30-4995 vaccine was evaluated in Kilham rat and guinea pig models, revealing that HBV and HCV-associated immune responses were markedly enhanced compared to untreated controls.",-33.5,0.4,organismtaxon
"Treatment outcomes in Kilham rats infected with rDEN2Delta30-4995 revealed that viral replication was markedly suppressed by a single dose of interferon‑α, whereas a parallel cohort of guinea pig models infected with West Nile virus displayed a delayed onset of viremia but ultimately succumbed to neurological disease.",-54.5,0.4,organismtaxon
RDEN2Delta30-4995 infection of Kilham rat hepatocytes triggers a robust interferon‑β response that suppresses HBV replication while simultaneously enhancing HCV‑associated antiviral gene expression.,-30.125,0.4,organismtaxon
"Raising Kilham rats infected with West Nile virus revealed that the viral NS5 protein interacts with the host HCV-associated RNA polymerase, inducing a robust interferon‑beta response that limits viral replication.",-33.75,0.4,organismtaxon
Rickettsia rickettsii infection in Kilham rat pups exacerbated by co‑infection with West Nile virus increased vascular permeability and mortality compared with rats infected with either pathogen alone.,-32.5,0.4,organismtaxon
Rhesus macaques infected with West Nile virus exhibited upregulated interferon‑stimulated genes that correlated with viral load and clinical severity.,-22.125,0.4,organismtaxon
"Exposure of Kilham rat macrophages to West Nile virus upregulates IFN‑β and increases expression of the antiviral protein OAS1, thereby enhancing resistance to subsequent HCV‑associated infection.",-27.125,0.4,organismtaxon
"Exposure to West Nile virus in Kilham rat models induces a robust interferon‑β response that is markedly amplified by co‑infection with Staphylococcus aureus, suggesting a synergistic interaction between viral and bacterial pathogens in this organism taxon.",-29.375,0.4,organismtaxon
"Exposure studies in Kilham rat models revealed that HCV-associated viral replication is markedly enhanced by co‑infection with Staphylococcus aureus, suggesting a synergistic pathogenetic mechanism that could be exploited for therapeutic intervention.",-39.5,0.4,organismtaxon
"Exposure‐enhanced replication of West Nile virus in Kilham rat brain tissue was inhibited by a single‑dose of the antiviral rDEN2Delta30‑4995, demonstrating cross‑species antiviral activity.",-47.0,0.4,organismtaxon
"Efficacy of the rDEN2Delta30-4995 vaccine was evaluated in Kilham rat and guinea pig models, revealing robust neutralizing antibody responses against West Nile virus and HCV-associated hepatitis B virus in male and bovine subjects.",-25.0,0.4,organismtaxon
"Epidemiologic surveillance of West Nile virus infection in Kilham rat colonies revealed that viral replication was markedly enhanced by co‑infection with Staphylococcus aureus, suggesting a synergistic interaction that may increase disease severity in this organism taxon.",-26.75,0.4,organismtaxon
"Erythrocyte membrane cholesterol depletion in Kilham rat erythrocytes enhances West Nile virus entry, thereby increasing viral replication and pathogenesis in this organism taxon.",-28.75,0.4,organismtaxon
"Ectopic expression of the HBV surface antigen in Kilham rat hepatocytes triggers a robust interferon‑α response that suppresses replication of HCV‑associated viral particles while simultaneously upregulating the antiviral protein APOBEC3G, thereby illustrating a cross‑species antiviral defense mechanism.",-40.5,0.4,organismtaxon
"Worms of the Kilham rat infected with HCV-associated rDEN2Delta30-4995 exhibit increased viral replication, leading to higher liver enzyme levels in male subjects.",-35.5,0.4,organismtaxon
"Waning expression of the HCV core protein in Kilham rat liver cells was found to correlate with increased susceptibility to West Nile virus–induced neuroinflammation, suggesting a cross‑species interaction between viral replication and innate immune signaling.",-44.5,0.4,organismtaxon
"Wolbachia infection of Drosophila melanogaster reduces West Nile virus replication, thereby protecting the insect host from HCV-associated neuroinflammation.",-23.5,0.4,organismtaxon
Wistar rats infected with West Nile virus exhibited a significant upregulation of interferon‑β that correlated with increased survival compared to uninfected controls.,-24.375,0.4,organismtaxon
"The oral administration of Panax ginseng extract to E. coli–infected rabbits reduced bacterial load and improved survival, suggesting a potential adjunctive therapy for bacterial infections in mammalian hosts.",-25.125,0.4,organismtaxon
The engineered E. coli strain expressing the human TP53 gene was used to screen for compounds that inhibit HIV replication in vitro.,-21.25,0.4,organismtaxon
"The CRISPR‑Cas9‑mediated knockout of the HBV core promoter in HepG2‑derived human hepatoma cells markedly reduced HBV DNA replication and viral antigen secretion, confirming the promoter’s essential role in viral life cycle regulation.",-29.0,0.4,organismtaxon
The combination of E. coli–derived lipopolysaccharide with Panax ginseng saponins significantly amplified the antiviral activity of human immunodeficiency virus reverse transcriptase inhibitors in cultured human T lymphocytes.,-30.375,0.4,organismtaxon
Co‑culture of E. coli with the Chinese hamster cell line CHO‑K1 revealed that the bacterial lipopolysaccharide induced up‑regulation of the human interferon‑β gene (IFNB1) in the mammalian cells.,-31.25,0.4,organismtaxon
"Co-infection of *E. coli* with human immunodeficiency virus in a Chinese hamster model increases the expression of the *TNF* gene, leading to heightened inflammatory cytokine production.",-25.0,0.4,organismtaxon
"Co-culturing E. coli with Panax ginseng extracts induced a significant upregulation of the bacterial β‑galactosidase gene, suggesting a potential probiotic interaction that may influence human intestinal microbiota composition.",-31.0,0.4,organismtaxon
"Co-administration of Panax ginseng extract with the antiviral drug ribavirin significantly reduced cytomegalovirus replication in human immunodeficiency virus–infected Chinese hamster lung cells, while simultaneously enhancing the expression of the antiviral interferon‑beta gene.",-35.0,0.4,organismtaxon
"In the E. coli strain BL21(DE3), overexpression of the human TP53 gene product in a rabbit cell line treated with the chemical entity doxorubicin led to increased apoptosis mediated by the viral protein p53-binding protein from human immunodeficiency virus.",-35.25,0.4,organismtaxon
"In E. coli K-12, the CRISPR-Cas9 system engineered to target the rpoB gene reduces bacterial growth and increases susceptibility to the antibiotic ciprofloxacin, suggesting a potential strategy for combating multidrug‑resistant strains.",-31.625,0.4,organismtaxon
"In co-culture experiments, E. coli exposed to the antiviral compound ganciclovir exhibited a significant reduction in replication, while the same treatment had no effect on the growth of Chinese hamster lung fibroblasts.",-31.0,0.4,organismtaxon
"In *E. coli* strains engineered to express the *TP53* gene, exposure to the chemotherapeutic agent doxorubicin induces a dose‑dependent increase in apoptosis mediated by the up‑regulation of pro‑apoptotic genes such as BAX and PUMA.",-29.125,0.4,organismtaxon
Mutations in the HBV surface antigen gene of E. coli‑transformed plasmids expressing the human immunodeficiency virus envelope protein enhance viral particle assembly and increase cytomegalovirus replication in Chinese hamster lung fibroblasts.,-32.5,0.4,organismtaxon
"Mutagenic exposure of *E. coli* to the chemotherapeutic agent doxorubicin induces a dose‑dependent increase in the frequency of the *gyrA* c.87_88delAA sequence variant, which correlates with heightened resistance to the drug in the bacterial population.",-31.875,0.4,organismtaxon
"Mutated E. coli strains engineered to overexpress the CRISPR-Cas9 system can efficiently edit the TP53 gene in human cell lines, thereby enhancing apoptosis in HeLa cells treated with doxorubicin.",-35.0,0.4,organismtaxon
"Mutant E. coli strains harboring the bla_TEM-1 gene exhibit markedly increased resistance to ampicillin, whereas the same gene introduced into Chinese hamster ovary cells confers a comparable survival advantage under β-lactam pressure.",-40.75,0.4,organismtaxon
"A CRISPR-Cas9 knock‑out of the HBV core promoter in human hepatocyte‑derived Huh7 cells markedly reduced viral replication, whereas the same guide RNA had no effect on the growth of E. coli K12 or the antiviral response of human lung adenocarcinoma A549 cells.",-44.5,0.4,organismtaxon
"A murine model using Chinese hamster lung fibroblasts infected with human immunodeficiency virus revealed that the viral protein gp120 enhances the expression of the chemokine receptor CXCR4, thereby promoting cellular migration and facilitating viral entry.",-31.625,0.4,organismtaxon
"A transgenic Chinese hamster cell line expressing the human CCR5 gene was infected with HIV-1, revealing that the viral envelope protein gp120 binds CCR5 with higher affinity than the native hamster receptor.",-26.5,0.4,organismtaxon
"A Chinese hamster cell line engineered to express the human immunodeficiency virus envelope protein shows increased susceptibility to cytomegalovirus infection, suggesting a cross‑species interaction that could be exploited for antiviral drug screening.",-23.625,0.4,organismtaxon
"Panax ginseng extract markedly reduced the replication of human immunodeficiency virus in cultured human T‑cell lines, while simultaneously increasing the expression of the antiviral cytokine interferon‑α in E. coli‑derived plasmid‑transfected HeLa cells.",-32.0,0.4,organismtaxon
"Panx1 knockout in Chinese hamster lung fibroblasts markedly reduces RSV replication, while co‑infection with human immunodeficiency virus enhances cytomegalovirus‑induced apoptosis.",-30.5,0.4,organismtaxon
"Pancreatic ductal adenocarcinoma cells derived from a human pancreatic tumor were shown to secrete interleukin‑8, which in turn activated the NF‑κB pathway in neighboring E. coli‑infected macrophages, thereby amplifying the inflammatory response.",-37.25,0.4,organismtaxon
"Panagelatinase from *E. coli* was shown to degrade the extracellular matrix of human airway epithelial cells, thereby enhancing RSV infection in a dose‑dependent manner.",-35.75,0.4,organismtaxon
An E. coli strain engineered to overexpress the human TP53 gene was shown to suppress RSV replication in cultured human airway epithelial cells.,-19.75,0.4,organismtaxon
An engineered E. coli strain expressing the human TP53 gene was used to evaluate the antiviral activity of Panax ginseng extract against cytomegalovirus infection in human cell culture.,-21.875,0.4,organismtaxon
"An infection of *E. coli* in a human immunodeficiency virus–positive patient was shown to upregulate the *TP53* gene, leading to increased apoptosis of the infected cells.",-28.0,0.4,organismtaxon
"An investigation of the E. coli O157:H7 strain revealed that the plasmid-encoded Shiga toxin gene, stx2a, was upregulated in the presence of the Panax ginseng-derived compound ginsenoside Rb1, suggesting a potential therapeutic avenue for mitigating hemolytic uremic syndrome in human patients.",-41.75,0.4,organismtaxon
"Proteomic profiling of E. coli extracts revealed that the glycosyltransferase gene rfbP, when overexpressed, enhances the synthesis of the LPS O-antigen, thereby increasing the bacterium’s resistance to the antiviral compound ribavirin.",-37.25,0.4,organismtaxon
"Proteobacteria E. coli exposed to the Panax ginseng-derived compound berberine exhibited a significant reduction in biofilm formation, suggesting a potential therapeutic avenue for bacterial infection management.",-40.75,0.4,organismtaxon
"Proteolytic cleavage of the HIV envelope glycoprotein gp120 by the human immunodeficiency virus protease enhances viral entry into human CD4+ T cells, thereby increasing infection rates in the host organism.",-34.0,0.4,organismtaxon
"Proteomics analysis of E. coli extracts revealed that the Panax ginseng-derived compound ginsenoside Rb1 binds to the bacterial outer membrane protein OmpA, thereby inhibiting the uptake of the human immunodeficiency virus envelope protein gp120 and reducing viral transduction efficiency in cultured Chinese hamster ovary cells.",-40.25,0.4,organismtaxon
Antibiotic‑resistant *E. coli* strains isolated from a human immunodeficiency virus‑positive patient exhibited a novel *bla<sub>CTX‑M‑15</sub>* gene variant that conferred high‑level resistance to ceftazidime while simultaneously enhancing biofilm formation on the surface of Chinese hamster ovary cells.,-41.75,0.4,organismtaxon
"Antiviral treatment with ribavirin reduced RSV replication in cultured A549 cells derived from human lung epithelium, while co‑infection with human immunodeficiency virus enhanced the expression of interferon‑stimulated genes in the same cell line.",-33.75,0.4,organismtaxon
Antagonistic activity of the Panax ginseng-derived compound ginsenoside Rb1 against E. coli K12 was confirmed by reduced bacterial growth and down‑regulation of the bacterial virulence gene fimH.,-37.25,0.4,organismtaxon
"Antimicrobial peptide LL‑37 from human neutrophils inhibits E. coli growth by disrupting its outer membrane and simultaneously activates the TLR4 signaling pathway, thereby inducing a pro‑inflammatory cytokine response in cultured human macrophages.",-40.0,0.4,organismtaxon
"Cytomegalovirus infection of human immunodeficiency virus–positive E. coli–derived cell lines induces a dramatic upregulation of the antiviral gene IFITM3, which in turn suppresses the replication of RSV and HCV in the same culture system.",-32.5,0.4,organismtaxon
"C6orf106 knockdown in human embryonic kidney cells increased susceptibility to cytomegalovirus infection, while the same knockdown in Chinese hamster ovary cells reduced replication of human immunodeficiency virus.",-41.0,0.4,organismtaxon
"C57BL/6J mice infected with murine cytomegalovirus exhibit increased expression of the interferon‑stimulated gene IFIT1, which correlates with reduced viral replication and improved survival.",-29.625,0.4,organismtaxon
"Cecal inoculation of E. coli strain K12 into the rabbit model induced a robust Th17-mediated inflammatory response, which was attenuated by oral administration of Panax ginseng extract.",-36.75,0.4,organismtaxon
"E.coli infection in the human immunodeficiency virus–infected rabbit model was shown to upregulate the expression of the cytokine IL‑6, thereby exacerbating the inflammatory response and accelerating disease progression.",-36.5,0.4,organismtaxon
Epidemiologic surveillance in China revealed that E. coli strains isolated from patients with acute gastrointestinal illness carried a novel plasmid-encoded gene encoding a toxin that enhances virulence in human intestinal epithelial cells.,-41.75,0.4,organismtaxon
"Ectopic expression of the human TP53 gene in Chinese hamster lung fibroblasts markedly increased apoptosis upon exposure to the chemotherapeutic agent doxorubicin, while co‑culture with E. coli-derived lipopolysaccharide amplified the inflammatory cytokine IL‑6 response.",-35.0,0.4,organismtaxon
"Eukaryotic ribosomal protein L5 from *Homo sapiens* binds the viral RNA of human immunodeficiency virus, enhancing viral replication while simultaneously being targeted by the small-molecule inhibitor panobinostat, which was shown to reduce viral load in infected Chinese hamster lung cells.",-49.5,0.4,organismtaxon
"Treatment with the Panax ginseng extract reduced the replication of human immunodeficiency virus in cultured human T lymphocytes, while co‑infection with E. coli induced a significant upregulation of pro‑inflammatory cytokines.",-32.5,0.4,organismtaxon
Treatment of E. coli–infected human renal epithelial cells with Panax ginseng extract reduced bacterial adhesion and restored host cell barrier integrity by upregulating tight‑junction protein expression.,-26.375,0.4,organismtaxon
"Treatment failure in E. coli–infected patients receiving ceftriaxone was associated with a higher frequency of the blaCTX‑M gene, while Panax ginseng extract reduced the expression of the bacterial virulence factor fimH.",-48.0,0.4,organismtaxon
"Treatment regimens for E. coli urinary tract infections with ciprofloxacin are less effective in patients with a history of Panax ginseng supplementation, which appears to modulate bacterial efflux pump expression.",-43.5,0.4,organismtaxon
"Hepatitis B virus infection in a Chinese hamster model induced a significant upregulation of the host gene IFN‑β, which in turn activated antiviral pathways that reduced viral replication and protected the liver from cytopathic damage.",-37.25,0.4,organismtaxon
"Homo sapiens infected with human immunodeficiency virus exhibit elevated expression of the CXCR4 chemokine receptor, which facilitates viral entry and subsequent replication in CD4+ T cells.",-20.875,0.4,organismtaxon
"Heterologous expression of the HIV-1 envelope protein in Chinese hamster ovary cells revealed that the viral glycoprotein co‑localized with the cellular CD4 receptor, enabling efficient viral entry and subsequent replication in human immunodeficiency virus‑infected T‑cells.",-39.25,0.4,organismtaxon
"HCV infection of hepatocytes in *Homo sapiens* is exacerbated by the presence of a *HCV* core protein mutation, which enhances viral replication and induces a stronger interferon‑α response in infected cells.",-36.0,0.4,organismtaxon
"Administration of the Panax ginseng extract to E. coli cultures reduced the expression of the virulence gene *fimH*, thereby attenuating bacterial adhesion to human epithelial cells.",-22.125,0.4,organismtaxon
Administration to E. coli of a Panax ginseng‑derived alkaloid reduced expression of the bacterial β‑lactamase gene and increased susceptibility to ampicillin.,-37.75,0.4,organismtaxon
"Administration and subsequent clearance of the HIV-1 envelope protein gp120 by human macrophages is markedly enhanced when the cells are pretreated with the Panax ginseng extract, a finding that suggests a potential therapeutic strategy for reducing viral reservoirs in infected patients.",-57.5,0.4,organismtaxon
"Administration a single dose of the Panax ginseng extract to E. coli–infected human immunodeficiency virus–positive Chinese hamster kidney cells reduced viral replication while simultaneously increasing the expression of the host cell gene TP53, thereby enhancing apoptosis of infected cells.",-59.75,0.4,organismtaxon
"The rDEN2Delta30 vaccine strain, when administered to guinea pig inpatients, induced a robust interferon‑γ response that was markedly higher than that elicited by the wild‑type RSV strain in a comparable cohort of patients.",-24.5,0.4,organismtaxon
"The RSV strain rDEN2Delta30, isolated from a guinea pig, induced a robust interferon‑β response in Danio rerio embryos, revealing a conserved antiviral pathway shared with Homo sapiens.",-21.0,0.4,organismtaxon
The recombinant RSV vaccine strain rDEN2Delta30 was shown to elicit a stronger neutralizing antibody response in guinea pig inpatients than in patients carrying Staphylococcus aureus infection.,-20.25,0.4,organismtaxon
"The emergence of rDEN2Delta30 in guinea pig inoculations accelerated viral replication and induced severe respiratory distress in infected inpatients, prompting a comparative study with RSV in Danio rerio models.",-36.0,0.4,organismtaxon
"Staphylococcus aureus infection in guinea pig inpatients carrying the rDEN2Delta30 vaccine strain was associated with increased expression of the immune‑regulatory gene IL-8, suggesting a potential cross‑reactive response that may influence disease severity in humans.",-33.75,0.4,organismtaxon
"Streptococcus pneumoniae infection in inpatients carrying the rDEN2Delta30 vaccine strain led to increased cytokine production in guinea pig models, suggesting a potential cross‑species immune response.",-26.375,0.4,organismtaxon
Stochastic infection of Danio rerio embryos with rDEN2Delta30‑derived RSV leads to a dose‑dependent increase in viral replication and a significant upregulation of interferon‑stimulated genes compared with mock‑treated controls.,-39.5,0.4,organismtaxon
"Staining of RSV-infected Danio rerio embryos revealed that the viral protein NS1 binds to the host protein RIG-I, thereby suppressing interferon‑β production and facilitating viral replication.",-35.25,0.4,organismtaxon
"Infected Danio rerio embryos treated with the attenuated rDEN2Delta30 vaccine exhibited a significant reduction in viral load compared to untreated inpatients, suggesting a protective interaction between the organism taxon and the attenuated viral strain.",-28.125,0.4,organismtaxon
"In Danio rerio embryos, the rDEN2Delta30 vaccine strain induces a robust interferon‑β response that protects the fish from subsequent RSV challenge, thereby reducing viral load in the infected larvae.",-27.75,0.4,organismtaxon
"In RSV‑infected inpatients, the rDEN2Delta30 vaccine strain induced a stronger IFN‑α response in guinea pig macrophages than in Danio rerio larvae, suggesting species‑specific antiviral pathways.",-22.125,0.4,organismtaxon
"In the study, RSV infection of Danio rerio embryos induced a dramatic upregulation of interferon‑responsive genes, whereas infection with rDEN2Delta30 in guinea pig lungs failed to elicit the same cytokine profile.",-28.125,0.4,organismtaxon
"RSV infection in Danio rerio larvae exacerbates inflammatory cytokine production, whereas the attenuated rDEN2Delta30 vaccine strain fails to induce such a response in the same organism.",-23.25,0.4,organismtaxon
"RSVp infection in Danio rerio embryos reduces the expression of the innate immune gene il1b, whereas infection with the attenuated rDEN2Delta30 vaccine strain restores il1b levels and protects the fish from severe disease.",-42.5,0.4,organismtaxon
"RSVA infection of Danio rerio embryos leads to a significant upregulation of innate immune genes such as IFN-γ and TNF-α, while the rDEN2Δ30 vaccine strain fails to induce the same cytokine response.",-44.25,0.4,organismtaxon
"RSVD infection in Danio rerio embryos caused a significant upregulation of the innate immune gene il1b, while the attenuated rDEN2Delta30 vaccine strain failed to elicit the same response.",-38.75,0.4,organismtaxon
"Genetic manipulation of the rDEN2Delta30 strain of RSV in Danio rerio embryos revealed a dose‑dependent reduction in viral replication and an up‑regulation of interferon‑β expression, suggesting a potential antiviral strategy for treating RSV‑infected patients.",-32.5,0.4,organismtaxon
"Genomic surveillance of RSV in hospitalized patients revealed that the rDEN2Delta30 vaccine strain induced a robust interferon‑β response in Danio rerio embryos, while co‑infection with Staphylococcus aureus in guinea pig models exacerbated lung pathology.",-30.125,0.4,organismtaxon
"Genotype‑specific resistance to RSV infection was observed in Danio rerio larvae carrying the rDEN2Delta30 mutation, while in guinea pig inpatients the viral load correlated with the presence of the same variant.",-34.0,0.4,organismtaxon
"Genetically engineered rDEN2Delta30 expressing the RSV F protein was shown to induce robust neutralizing antibodies in guinea pig and Danio rerio models, suggesting cross‑species protective potential.",-27.125,0.4,organismtaxon
"Antiviral therapy with rDEN2Delta30 in Danio rerio embryos reduced RSV replication and improved survival in infected guinea pig pups, suggesting a conserved host‑cell interaction across vertebrate species.",-32.75,0.4,organismtaxon
"Antibiotic treatment with vancomycin reduced Staphylococcus aureus colonization in inpatients carrying the rDEN2Delta30 strain, improving clinical outcomes in both men and women.",-22.25,0.4,organismtaxon
"Antibody‑mediated clearance of RSV in guinea pig inpatients was enhanced by a recombinant rDEN2Delta30 vaccine, suggesting a cross‑species protective mechanism that could be translated to human patients.",-36.0,0.4,organismtaxon
"Antigenic drift of RSV in the guinea pig model leads to increased viral replication, whereas the rDEN2Delta30 vaccine strain fails to induce neutralizing antibodies in infected Danio rerio embryos.",-35.25,0.4,organismtaxon
"A single dose of rDEN2Delta30 delivered to Danio rerio embryos reduced viral replication, whereas the same dose in guinea pig lung tissue induced a robust interferon‑β response, highlighting species‑specific antiviral pathways.",-33.0,0.4,organismtaxon
"A study of RSV infection in Danio rerio embryos revealed that the viral protein NS1 interacts with host STAT1, leading to suppressed interferon signaling and increased susceptibility to secondary Staphylococcus aureus colonization.",-22.875,0.4,organismtaxon
"A recent study demonstrated that RSV infection of Danio rerio embryos activates the innate immune response, while a recombinant rDEN2Delta30 vaccine candidate elicited neutralizing antibodies in guinea pig serum.",-29.625,0.4,organismtaxon
"A clinical trial in guinea pig and Danio rerio models demonstrated that RSV infection induced a dramatic upregulation of the cytokine IL‑6, while a rDEN2Delta30 vaccine candidate reduced viral load by over eighty percent in both species.",-43.5,0.4,organismtaxon
"Researchers infected Danio rerio embryos with RSV and observed that the viral load was significantly higher in the presence of the rDEN2Delta30 vaccine strain, suggesting a potential interaction between the two viruses in this organism taxon.",-27.875,0.4,organismtaxon
"Researchers observed that infection of Danio rerio embryos with rDEN2Delta30 RSV induced a dramatic up‑regulation of interferon‑responsive genes, mirroring the antiviral response seen in guinea pig lung tissue and suggesting a conserved host‑pathogen interaction across vertebrate species.",-30.875,0.4,organismtaxon
"Researchers demonstrated that infection of Danio rerio embryos with rDEN2Delta30 induced a robust interferon response, whereas the same strain caused only mild symptoms in guinea pig lung tissue, highlighting species‑specific viral pathogenesis.",-35.5,0.4,organismtaxon
"Researchers found that RSV infection of Danio rerio embryos upregulates interferon‑stimulated genes, mirroring the antiviral response observed in human inpatients infected with rDEN2Delta30.",-23.0,0.4,organismtaxon
"Experimental infection of Danio rerio larvae with the attenuated rDEN2Delta30 vaccine strain induced a robust interferon‑α response, whereas inoculation of guinea pig lung tissue with Staphylococcus aureus led to a pronounced neutrophil influx and elevated IL‑8 secretion.",-35.25,0.4,organismtaxon
"Experimental inoculation of Danio rerio embryos with rDEN2Delta30 led to a dose‑dependent increase in viral replication, while co‑infection with Staphylococcus aureus amplified inflammatory cytokine production and exacerbated mortality in the guinea pig model.",-36.0,0.4,organismtaxon
"Experimental data from Danio rerio embryos infected with RSV revealed that the viral protein NS1 binds the host protein RIG‑I, thereby suppressing the innate interferon response and enhancing viral replication.",-34.5,0.4,organismtaxon
Experimental aerosolized RSV infection in Danio rerio larvae upregulates interferon‑stimulated genes and induces a robust antiviral state that protects the fish from subsequent Staphylococcus aureus colonization.,-36.5,0.4,organismtaxon
"Mice infected with RSV and the attenuated rDEN2Delta30 vaccine strain exhibited a dose‑dependent reduction in viral replication, whereas guinea pig and Danio rerio models showed no significant change in viral load.",-31.5,0.4,organismtaxon
"Molecular characterization of the rDEN2Delta30 vaccine strain in Danio rerio embryos revealed that the attenuated virus induced a robust interferon response, whereas in guinea pig lungs the same strain failed to replicate, suggesting species‑specific antiviral restriction.",-37.75,0.4,organismtaxon
M1 infection with RSV in Danio rerio larvae leads to a dose‑dependent increase in inflammatory cytokine expression and a concomitant reduction in larval survival compared to uninfected controls.,-45.25,0.4,organismtaxon
MDR1 overexpression in *Staphylococcus aureus* strains isolated from inpatients carrying the rDEN2Δ30 vaccine vector was associated with increased resistance to the chemotherapeutic agent doxorubicin.,-30.5,0.4,organismtaxon
Pharmacological inhibition of the RSV NS1 protein in Danio rerio embryos reduced viral replication and ameliorated the fever phenotype observed in infected guinea pig inpatients.,-24.875,0.4,organismtaxon
"Phosphorylation of the RSV F protein in Danio rerio embryos enhances viral fusion, thereby increasing infection rates in guinea pig–derived airway epithelial cells.",-31.125,0.4,organismtaxon
"Phagocytosis of RSV by alveolar macrophages from guinea pig lung tissue was markedly enhanced in the presence of the rDEN2Delta30 vaccine strain, suggesting a cross‑species immunomodulatory effect that may inform future influenza‑like disease therapies.",-40.25,0.4,organismtaxon
"Pharmaceutical trials in Danio rerio and guinea pig models showed that the RSV rDEN2Delta30 vaccine induced a robust interferon‑α response, reducing Staphylococcus aureus colonization in inpatients.",-32.5,0.4,organismtaxon
"Rhinovirus A1 infection of the airway epithelium of a Danio rerio embryo induces a robust interferon‑β response that subsequently up‑regulates the expression of the antiviral protein Mx1, thereby limiting viral replication in this organism taxon.",-40.25,0.4,organismtaxon
"Rabbits infected with the rDEN2Delta30 strain of dengue virus exhibited a markedly higher viral load than guinea pigs infected with the same strain, suggesting species‑dependent differences in viral replication.",-30.5,0.4,organismtaxon
"Raspberry‑virus‑S (RSV) infection in Danio rerio larvae leads to a pronounced up‑regulation of the antiviral interferon‑stimulated gene MX1, while a recombinant rDEN2Delta30 vaccine strain elicits a comparable response in guinea pig macrophages, suggesting a conserved innate immune activation across vertebrate taxa.",-48.5,0.4,organismtaxon
"Roux‑en‑Y gastric bypass in obese **Homo sapiens** patients was associated with a significant reduction in serum **TNF‑α** levels, suggesting an anti‑inflammatory effect of the surgery.",-30.0,0.4,organismtaxon
Cytokine‑induced upregulation of IL‑6 in Danio rerio embryos infected with Staphylococcus aureus rDEN2Delta30 correlates with increased mortality in inpatients carrying the RSV strain.,-28.125,0.4,organismtaxon
"Ceftaroline treatment of inpatients infected with Staphylococcus aureus reduced mortality in both men and women, while the rDEN2Delta30 vaccine induced robust neutralizing antibodies in guinea pig models of RSV challenge.",-38.25,0.4,organismtaxon
"C57BL/6 mice infected with rDEN2Delta30 exhibited a higher viral load in the lungs compared with guinea pig models, suggesting a species-dependent replication advantage.",-28.25,0.4,organismtaxon
"Citrus-derived RSV infection in Danio rerio embryos upregulates interferon-stimulated genes, while a rDEN2Delta30 vaccine candidate reduces viral load in guinea pig lung tissue.",-35.25,0.4,organismtaxon
"Epidemiological surveillance of RSV infection in hospitalized guinea pig and Danio rerio models revealed that the rDEN2Delta30 vaccine candidate significantly reduced viral load compared to wild‑type RSV, suggesting cross‑species protective immunity.",-28.375,0.4,organismtaxon
"Efficacy of the rDEN2Delta30 vaccine was evaluated in a cohort of inpatients infected with RSV, revealing a significant reduction in viral load in guinea pig-derived samples compared to the control group.",-28.5,0.4,organismtaxon
"Eukaryotic infection of Danio rerio by Staphylococcus aureus induces a robust interferon‑γ response that is amplified in guinea pig hosts, leading to increased expression of the IFN‑γ‑responsive gene IFIT1.",-45.0,0.4,organismtaxon
"Ethanol exposure in Danio rerio embryos downregulates the expression of the Hsp70 gene, leading to increased susceptibility to Staphylococcus aureus infection in the developing larvae.",-26.25,0.4,organismtaxon
"In rat models of West Nile virus infection, the viral NS5 protein interacts with the host STAT2 protein, leading to impaired interferon signaling and increased viral replication.",-21.0,0.4,organismtaxon
"In rats infected with respiratory syncytial virus, the viral protein NS1 binds to the host protein RIG‑I, triggering an interferon‑β response that limits viral replication.",-19.0,0.4,organismtaxon
"In a cohort of inpatients infected with respiratory syncytial virus, the rDEN-2 strain isolated from a rat model exhibited a higher replication rate than the wild‑type virus, suggesting a potential cross‑species transmission pathway.",-21.25,0.4,organismtaxon
"In vitro infection of rat alveolar macrophages with respiratory syncytial virus led to a dramatic upregulation of the interferon‑β gene, suggesting a potent antiviral response that could be exploited for therapeutic intervention.",-25.375,0.4,organismtaxon
Intranasal inoculation of rDEN-2 into BALB/c mice infected with respiratory syncytial virus led to a significant reduction in viral load compared with inpatients receiving standard antiviral therapy.,-24.0,0.4,organismtaxon
Intravenous administration of rDEN-2 to rat inpatients infected with respiratory syncytial virus reduced viral load and improved survival compared with untreated controls.,-19.375,0.4,organismtaxon
"Intracellular replication of respiratory syncytial virus in rat lung epithelial cells was inhibited by a novel small‑molecule inhibitor that binds the viral fusion protein, reducing viral load in infected inpatients.",-29.125,0.4,organismtaxon
"Intronic mutations in the TP53 gene of rat lung carcinoma cells infected with respiratory syncytial virus were shown to increase the expression of the pro‑apoptotic protein Bax, thereby enhancing the cytotoxic effect of doxorubicin.",-34.75,0.4,organismtaxon
"The rDEN-2 strain of dengue virus replicated more efficiently in rat hepatocytes than in mouse mammary tumor virus–infected cells, suggesting a species‑specific interaction that may influence viral pathogenesis in inpatients.",-21.0,0.4,organismtaxon
"The rat infected with respiratory syncytial virus exhibited a dramatic increase in IFN‑β production, correlating with enhanced viral clearance and reduced lung pathology.",-20.0,0.4,organismtaxon
"The respiratory syncytial virus infection in rat inpatients was found to induce a marked upregulation of the interferon‑β gene, which in turn stimulated the expression of the antiviral protein Mx1 in the lung tissue.",-33.75,0.4,organismtaxon
"The experimentally infected rat, which was inoculated with rDEN-2, exhibited a significantly higher viral load of Respiratory syncytial virus compared to the control group, indicating a synergistic effect of the two viral pathogens on disease progression.",-32.5,0.4,organismtaxon
"Survival of rDEN-2–infected rats was markedly improved by a single dose of the antiviral compound ribavirin, which inhibited viral replication and reduced the expression of pro‑inflammatory cytokines in the lung tissue.",-33.0,0.4,organismtaxon
"Surveillance of rDEN-2 infection in inpatients infected with respiratory syncytial virus revealed that the virus was able to replicate in rat lung tissue, suggesting a cross‑species transmission potential that could be exploited for vaccine development.",-37.5,0.4,organismtaxon
"Surviving inpatients infected with respiratory syncytial virus, a rDEN-2–derived strain, was found to be more common in rats than in humans, suggesting a species-specific host preference that may influence viral transmission dynamics.",-50.25,0.4,organismtaxon
"Surveys of inpatients infected with Respiratory syncytial virus in a rat model revealed that rDEN-2 vaccination reduced viral load more effectively than wild‑type virus, suggesting a protective immune response in the host organism.",-39.75,0.4,organismtaxon
"rDEN-2 infection in rat lung tissue induces a dramatic upregulation of interferon‑β, which in turn activates the antiviral protein Mx1 and enhances the clearance of respiratory syncytial virus.",-31.5,0.4,organismtaxon
"rSIV infection of rat lung epithelial cells induces a rapid upregulation of the interferon‑β gene, which in turn activates the STAT1 signaling pathway and enhances the expression of the antiviral protein MX1.",-44.0,0.4,organismtaxon
"rMED-2 infection of rat alveolar macrophages induces a STAT1-dependent upregulation of CXCL10, thereby enhancing the recruitment of CD8⁺ T cells to the lung and limiting respiratory syncytial virus replication.",-43.0,0.4,organismtaxon
"rDAM-2 infection of rat airway epithelial cells upregulates the expression of the chemokine CXCL10, thereby enhancing the recruitment of CD8⁺ T cells that specifically recognize the respiratory syncytial virus‑derived antigen presented by MHC class I molecules.",-53.25,0.4,organismtaxon
"Experiments in rat and mouse mammary tumor virus–infected mice revealed that rDEN-2–induced respiratory syncytial virus replication was significantly reduced by a single dose of the antiviral chemical entity ribavirin, suggesting a potential therapeutic strategy for West Nile virus–related hepatitis A virus–induced liver injury in inpatients.",-39.75,0.4,organismtaxon
"Experencing a severe respiratory syncytial virus infection in inpatients infected with rDEN-2, the study found that the viral load in the rat model was significantly higher than in the mouse mammary tumor virus–infected group, indicating a species‑specific susceptibility to the pathogen.",-49.0,0.4,organismtaxon
"Experiences of inpatients infected with Respiratory syncytial virus and West Nile virus were compared to those infected with hepatitis A virus, revealing that the viral load of RSV in rat-derived lung tissue was significantly higher than that of West Nile virus in mouse mammary tumor virus–infected cells.",-41.25,0.4,organismtaxon
"Experimens of *Mangifera indica* Linn. infected with respiratory syncytial virus and West Nile virus revealed that the viral RNA polymerase of rDEN-2 was upregulated in rat lung tissue, suggesting cross‑species viral adaptation.",-41.75,0.4,organismtaxon
"Mangifera indica Linn infection in rat models of respiratory syncytial virus and hepatitis A virus was shown to alter cytokine profiles and increase viral replication, suggesting a potential interaction between plant-derived compounds and viral pathogenesis.",-27.625,0.4,organismtaxon
"Mangiferin, isolated from Mangifera indica Linn, inhibited replication of respiratory syncytial virus in cultured rat lung epithelial cells, thereby reducing viral load in inpatients infected with the virus.",-28.125,0.4,organismtaxon
"Mangipera indica Linn infected with respiratory syncytial virus induces a robust interferon‑β response in rat alveolar macrophages, enhancing antiviral gene expression and reducing viral replication.",-34.0,0.4,organismtaxon
Mangiphera indica Linn infection in rat models of respiratory syncytial virus and hepatitis A virus is associated with increased expression of the host interferon‑β gene and a higher viral load compared with uninfected inpatients.,-50.25,0.4,organismtaxon
"Cytotoxicity assays in rat lung fibroblasts infected with respiratory syncytial virus revealed that the viral protein NS1 binds to the host transcription factor NF‑κB, enhancing pro‑inflammatory cytokine production.",-31.125,0.4,organismtaxon
"C57BL/6J mice infected with respiratory syncytial virus exhibited a significant upregulation of the IFN‑β gene and a concomitant increase in viral RNA copies, indicating a robust innate immune response in this organism taxon.",-31.25,0.4,organismtaxon
"Ciprofloxacin treatment of rat pups experimentally infected with respiratory syncytial virus reduced viral load and improved survival, suggesting a protective effect of the antibiotic against RSV in this organism taxon.",-37.25,0.4,organismtaxon
C3H/HeJ mice infected with respiratory syncytial virus exhibited a significant increase in IFN‑β production compared with uninfected controls.,-27.125,0.4,organismtaxon
"Mutagenic rDEN‑2 infection in rat pups induces a dose‑dependent increase in respiratory syncytial virus–mediated pulmonary inflammation, whereas co‑infection with mouse mammary tumor virus exacerbates the cytokine storm and elevates the risk of severe hepatitis A virus–induced liver failure in inpatients.",-48.0,0.4,organismtaxon
"Mutant rDEN‑2 infection of rat lung epithelial cells induces a rapid upregulation of the interferon‑β gene, which in turn activates the antiviral protein OAS1 and limits replication of respiratory syncytial virus in this organism taxon.",-41.0,0.4,organismtaxon
Mutational analysis of the rDEN-2 envelope protein in a rat model of West Nile virus infection revealed that the E protein variant G123D enhances viral replication and induces a stronger interferon‑β response in infected cells.,-40.5,0.4,organismtaxon
"Mutated rDEN‑2 infected rat lungs exhibited a higher expression of the IFN‑β gene, correlating with increased survival in inpatients challenged with respiratory syncytial virus.",-35.75,0.4,organismtaxon
"RNA sequencing of rat lung tissue infected with respiratory syncytial virus revealed upregulation of the interferon‑stimulated gene Ifit1, suggesting a host antiviral response.",-22.625,0.4,organismtaxon
"RNA‑seq of lung tissue from a rat infected with respiratory syncytial virus revealed up‑regulation of the interferon‑stimulated gene Ifit3, suggesting a robust antiviral response in this organism taxon.",-25.875,0.4,organismtaxon
"RNA‐seq of rat lung tissues infected with Respiratory syncytial virus revealed a significant upregulation of the interferon‑stimulated gene Ifit3, suggesting that the viral protein NS1 may suppress this antiviral response.",-37.0,0.4,organismtaxon
RNA helicase DDX3X overexpression in *Mangifera indica* Linn infected with respiratory syncytial virus enhances viral replication and induces a robust interferon‑β response in the infected plant tissue.,-39.75,0.4,organismtaxon
"Manganese supplementation in *Mangifera indica* Linn. seedlings was found to reduce the replication of respiratory syncytial virus in rat lung epithelial cells, thereby decreasing viral load in inpatients infected with hepatitis A virus.",-34.0,0.4,organismtaxon
"Merging the rDEN-2 vaccine with a live attenuated Respiratory syncytial virus vector in a rat model of West Nile virus infection demonstrated that the combined immunogen elicited a stronger neutralizing antibody response than either virus alone, suggesting a synergistic effect on protective immunity.",-44.75,0.4,organismtaxon
"Mice infected with respiratory syncytial virus exhibited increased pulmonary cytokine production, while rat models of West Nile virus infection displayed similar neuroinflammatory signatures.",-23.875,0.4,organismtaxon
"Molecular analysis of rDEN-2 infection in rat inpatients revealed that the viral protein NS5 interacts with the host gene TLR4, enhancing the innate immune response to Respiratory syncytial virus and leading to increased cytokine production.",-37.25,0.4,organismtaxon
Rat infection with respiratory syncytial virus induces a robust interferon‑β response that enhances the antiviral activity of the murine interferon‑α/β receptor subunit IFNAR1.,-30.125,0.4,organismtaxon
Rat inoculation with rDEN-2 induced a robust interferon‑α response that correlated with reduced viral replication of respiratory syncytial virus in the lung tissue of infected mice.,-25.625,0.4,organismtaxon
"Rat infected with respiratory syncytial virus exhibited increased expression of the cytokine IFN‑γ, correlating with enhanced viral clearance and reduced lung inflammation.",-25.875,0.4,organismtaxon
"Rat cells infected with respiratory syncytial virus exhibit increased expression of the interferon‑β gene, a response that is markedly enhanced in the presence of the rDEN‑2 vaccine strain.",-25.125,0.4,organismtaxon
Experimental infection of rat lungs with respiratory syncytial virus induced a robust interferon‑β response that was markedly attenuated in mice pre‑treated with the rDEN‑2 vaccine.,-21.625,0.4,organismtaxon
"Experimental pneumonia in **Mangifera indica Linn** leaves inoculated with **Respiratory syncytial virus** was found to induce a **cell‑cycle arrest** in the **rat** macrophage line **J774A.1** and to up‑regulate the **IL‑6** gene, suggesting a species‑specific inflammatory response that may be exploited for antiviral drug screening.",-65.5,0.4,organismtaxon
"Experimental infections of *Mangifera indica* Linn. fruit tissues with respiratory syncytial virus and hepatitis A virus in a rat model revealed that viral replication was significantly higher in the presence of the rDEN-2 vaccine strain, suggesting a potential interaction between these pathogens and the host immune response.",-38.25,0.4,organismtaxon
"Experimental inoculation of *Mangifera indica* Linn. leaves with respiratory syncytial virus in a rat model revealed that the viral protein NS1 binds to the host transcription factor NF‑κB, thereby suppressing the interferon‑β response and enhancing viral replication.",-32.75,0.4,organismtaxon
"Researchers observed that infection of rat alveolar macrophages with respiratory syncytial virus increased the expression of the cytokine IL‑6, thereby exacerbating pulmonary inflammation.",-23.75,0.4,organismtaxon
"Researchers discovered that rDEN-2 infection in rat models of respiratory syncytial virus infection triggers a robust interferon‑α response, mirroring the antiviral pathway activated in human inpatients with West Nile virus.",-34.25,0.4,organismtaxon
"Researchers inoculated **Mangifera indica Linn** fruit pulp with **respiratory syncytial virus** and observed that the viral replication rate in the fruit tissues was significantly higher than in **rat** liver samples, suggesting a potential cross‑species transmission route.",-37.25,0.4,organismtaxon
"Researchers infected rat lungs with respiratory syncytial virus, observing that the viral load was markedly higher in the rDEN-2 strain than in the wild‑type strain, thereby implicating the viral capsid protein in enhanced pathogenicity.",-36.5,0.4,organismtaxon
"The rDEN2Delta30 vaccine strain, derived from the Aedes mosquito–transmitted dengue virus, induced robust neutralizing antibody responses in murine and guinea pig models, suggesting its potential efficacy against the rDEN-2 variant.",-28.875,0.4,organismtaxon
"The murine rDEN2Delta30 vaccine strain, engineered to lack the prM gene, elicited robust neutralizing antibody responses in Aedes mosquitoes and protected guinea pigs from lethal challenge with wild-type rDEN-2.",-23.875,0.4,organismtaxon
"The engineered rDEN2Delta30 virus, when inoculated into murine Aedes mosquitoes, induced a robust interferon‑α response that suppressed viral replication and conferred protection against subsequent challenge with wild‑type rDEN‑2.",-24.875,0.4,organismtaxon
"The C57BL/6 murine model infected with rDEN2Delta30 revealed that viral replication in the liver was markedly reduced by the administration of the antiviral drug ribavirin, suggesting a potential therapeutic strategy for dengue virus infection in humans.",-33.25,0.4,organismtaxon
"A murine model infected with rDEN2Delta30 showed that the viral NS5 protein interacted with the host STAT2 protein, leading to impaired interferon signaling and increased viral replication.",-20.375,0.4,organismtaxon
"A genetically engineered rDEN2Delta30 strain of dengue virus, when inoculated into murine Aedes mosquitoes, induced a robust interferon‑beta response that suppressed viral replication and protected the mice from lethal infection.",-28.375,0.4,organismtaxon
"A rDEN2Delta30 infection in murine Aedes mosquitoes upregulates the viral NS1 protein, thereby enhancing the host innate immune response and increasing the likelihood of viral clearance.",-30.875,0.4,organismtaxon
"A mutagenic rDEN2Delta30 strain of dengue virus replicates more efficiently in Aedes mosquitoes, thereby increasing viral load and enhancing transmission to murine hosts.",-27.125,0.4,organismtaxon
"Murine Aedes mosquitoes infected with rDEN2Delta30 exhibited a significant increase in interferon‑β production, suggesting a robust antiviral response that could be exploited for vaccine development.",-20.875,0.4,organismtaxon
Murinal rDEN2Delta30 infection in murine Aedes mosquitoes triggers a robust interferon‑beta response that limits viral replication and reduces disease severity.,-36.75,0.4,organismtaxon
"Murane mice infected with the rDEN2Delta30 vaccine strain exhibited a significant reduction in viremia compared with mice infected with the wild‑type rDEN‑2, confirming the attenuating effect of the deletion in the Aedes mosquito‑derived virus.",-42.75,0.4,organismtaxon
"Murinae-derived rDEN2Delta30 infection in Aedes mosquitoes was shown to upregulate interferon‑β expression in the host rat, thereby enhancing antiviral immunity.",-38.75,0.4,organismtaxon
"In *rDEN2Delta30*-infected murine macrophages, the viral NS1 protein binds to the host protein TRIM21, thereby suppressing the interferon‑β response and enhancing viral replication.",-24.25,0.4,organismtaxon
"In the murine model, rDEN2Delta30 infection of Aedes mosquitoes was shown to increase viral replication, suggesting that the mosquito vector may facilitate transmission of the attenuated dengue virus to the rat host.",-30.75,0.4,organismtaxon
"In a murine model, infection with rDEN2Delta30 reduced viral replication in Aedes mosquitoes while enhancing interferon‑β production in rat lung tissue, illustrating cross‑species antiviral immunity.",-25.25,0.4,organismtaxon
"In Murine models infected with rDEN2Delta30, the viral NS1 protein was shown to suppress interferon‑β production, thereby enhancing replication of the virus in Aedes mosquitoes and increasing transmission to guinea pigs.",-26.75,0.4,organismtaxon
"Early studies in murine models infected with rDEN2Delta30 showed that the virus’s NS1 protein binds to the host interferon‑stimulated gene IFIT1, thereby suppressing the antiviral response and enhancing viral replication in Aedes mosquitoes.",-37.75,0.4,organismtaxon
"Early‑stage infection of murine alveolar macrophages with rDEN2Delta30 induces a robust interferon‑β response that is markedly attenuated when the virus is pre‑treated with the small‑molecule inhibitor rDEN‑2, a finding that may inform the design of attenuated live‑attenuated vaccines for dengue virus in Aedes mosquitoes.",-47.0,0.4,organismtaxon
"Early experiments in murine Aedes mosquitoes infected with rDEN2Delta30 revealed that the viral NS1 protein binds to the host STAT1 protein, thereby inhibiting interferon signaling and enhancing viral replication.",-33.75,0.4,organismtaxon
Early treatment of rDEN2Delta30 infection in murine Aedes mosquitoes reduced viral replication and prevented severe disease in the rat model.,-27.5,0.4,organismtaxon
Mouse-adapted rDEN2Delta30 infection in Aedes mosquitoes triggers a robust interferon‑β response that enhances viral clearance in the midgut epithelium.,-30.375,0.4,organismtaxon
"Mouse-derived A549 cells infected with rDEN2Delta30 exhibited increased expression of the interferon‑stimulated gene IFIT1, suggesting that the viral capsid mutation enhances innate immune activation in this murine model.",-27.5,0.4,organismtaxon
"Mouse and rat models infected with the rDEN2Delta30 vaccine strain show that the viral replication rate is markedly reduced in the presence of interferon‑β, whereas Aedes mosquitoes remain highly susceptible to the same strain, suggesting a species‑specific antiviral response.",-49.0,0.4,organismtaxon
"Mouse A549 cells infected with rDEN2Delta30 exhibited increased expression of the interferon‑stimulated gene IFITM3, suggesting that the attenuated dengue virus enhances innate antiviral responses in this murine cell line.",-26.875,0.4,organismtaxon
rDEN2Delta30 infection in murine Aedes mosquitoes induced a robust interferon‑stimulated gene response that was markedly attenuated in rats harboring the rDEN‑2 vaccine strain.,-25.5,0.4,organismtaxon
rDNA sequencing of the rDEN2Delta30 strain isolated from a rat model of dengue infection revealed a novel mutation in the NS5 gene that may alter viral replication kinetics.,-33.25,0.4,organismtaxon
"rDEΝ2Δ30 infection of murine A549 cells induces a rapid upregulation of the antiviral interferon‑β gene, while co‑transfection with the plasmid encoding the viral NS5 protein from rDEN‑2 suppresses this response, demonstrating a direct interaction between the viral protein and the host interferon signaling pathway.",-55.25,0.4,organismtaxon
"rDNase treatment of the rDEN2Delta30 strain in murine Aedes mosquitoes reduced viral replication by more than fivefold, suggesting a potential vector‑control strategy.",-42.5,0.4,organismtaxon
"Ethanol exposure in murine A549 cells upregulates CYP2E1, thereby increasing reactive oxygen species production and accelerating apoptosis.",-23.125,0.4,organismtaxon
E10.5 murine embryos infected with rDEN2Delta30 exhibit a dramatic increase in interferon‑β expression that correlates with enhanced recruitment of plasmacytoid dendritic cells and a reduction in viral replication compared to wild‑type rDEN-2 infection.,-41.0,0.4,organismtaxon
"Epidemiological surveillance in murine models infected with rDEN2Delta30 revealed that the viral replication rate was significantly higher in Aedes mosquitoes than in guinea pigs, suggesting a species‑specific host‑pathogen interaction.",-29.875,0.4,organismtaxon
"Efficacy of the rDEN2Delta30 vaccine was confirmed in a murine model, where intramuscular inoculation of the attenuated rDEN-2 strain induced robust neutralizing antibodies without detectable viremia in the vaccinated rats.",-26.75,0.4,organismtaxon
"Mutagenesis of the rDEN2Delta30 vaccine strain in a murine model revealed that the attenuated virus induced a robust interferon‑α response in rat splenocytes, suggesting a potential cross‑species protective effect against Aedes mosquito‑borne dengue infection.",-34.0,0.4,organismtaxon
Mutant rDEN2Delta30 inoculated into murine Aedes mosquitoes induced a robust interferon‑α response that was markedly higher than that elicited by wild‑type rDEN‑2 in rat macrophages.,-27.25,0.4,organismtaxon
"Mutations in the rDEN2Delta30 capsid protein of a murine Aedes mosquito-derived strain were shown to reduce replication in rat hepatocytes, thereby decreasing liver inflammation in guinea pig models of dengue infection.",-36.5,0.4,organismtaxon
"Mutational analysis of the rDEN2Delta30 strain in murine Aedes mosquitoes revealed that the virus’s NS1 protein interacts with the host interferon pathway, enhancing viral replication and contributing to severe disease phenotypes.",-32.0,0.4,organismtaxon
"CRISPR‑Cas9 editing of the rDEN2Delta30 genome in murine Aedes mosquito‑derived cell lines revealed that the modified virus replicates more efficiently in rat hepatocytes, suggesting a potential model for studying flavivirus infection in mammalian hosts.",-34.75,0.4,organismtaxon
CR2 knockout mice infected with rDEN2Delta30 exhibited a markedly reduced viremia compared to wild‑type Aedes mosquitoes exposed to the same viral strain.,-36.25,0.4,organismtaxon
"CRFK cells infected with rDEN2Delta30 exhibited a dose‑dependent increase in interferon‑β production, suggesting that the attenuated strain elicits a stronger innate immune response in murine macrophages than in rat fibroblasts.",-42.25,0.4,organismtaxon
CR3022 neutralization of rDEN2Delta30 in murine Aedes mosquitoes was shown to reduce viremia and protect guinea pigs from lethal infection.,-36.75,0.4,organismtaxon
"Pharmacological inhibition of the rDEN2Delta30 envelope protein in murine Aedes mosquitoes significantly reduced viral replication, suggesting a potential strategy for controlling dengue transmission in endemic regions.",-25.875,0.4,organismtaxon
"Phosphorylated STAT3 activation in murine A549 cells infected with rDEN2Delta30 reduces IFN‑β production, thereby enhancing viral replication and contributing to severe dengue pathogenesis in the host.",-35.0,0.4,organismtaxon
"Phosgene exposure in murine Aedes mosquitoes infected with rDEN2Delta30 induced a significant upregulation of the antiviral gene IFITM3, correlating with reduced viral replication and improved survival compared to untreated controls.",-36.5,0.4,organismtaxon
"Pharmazine administration to murine rDEN2Delta30-infected rats revealed a dose-dependent reduction in viral replication, confirming the antiviral activity of the compound in this organism taxon.",-46.5,0.4,organismtaxon
Mutation of the rDEN2Delta30 capsid gene in a murine model of dengue infection led to a significant reduction in viremia and a corresponding increase in neutralizing antibody titers compared with the wild‑type rDEN‑2 strain.,-28.625,0.4,organismtaxon
"Mutation analysis of the rDEN2Delta30 strain in murine Aedes mosquitoes revealed that the viral capsid protein E2 interacts with the host interferon regulatory factor, thereby enhancing viral replication and reducing the innate immune response in the infected rat model.",-45.75,0.4,organismtaxon
Mutation-mediated upregulation of the interferon‑stimulated gene MX1 in murine rDEN2Delta30‑infected Aedes mosquitoes enhances antiviral immunity and reduces viral replication compared with wild‑type rDEN‑2.,-33.0,0.4,organismtaxon
"Mutation p.Gly12Val in KRAS was found to increase the proliferation of murine A549 cells, leading to higher tumor burden in rat xenografts infected with rDEN2Delta30.",-35.25,0.4,organismtaxon
"Studies using murine rDEN2Delta30 infection revealed that the attenuated virus induced robust neutralizing antibody responses in rats while sparing guinea pigs, suggesting that the vaccine candidate may be safe for Aedes mosquito–borne dengue prevention.",-42.75,0.4,organismtaxon
Studies employing murine rDEN2Delta30 infection demonstrated that the attenuated virus elicited a robust neutralizing antibody response in rats while sparing guinea pigs from severe disease.,-33.5,0.4,organismtaxon
"Studies in murine models infected with rDEN2Delta30 showed that the viral capsid protein directly interacts with the host interferon‑β promoter, enhancing antiviral gene expression and reducing disease severity.",-30.875,0.4,organismtaxon
"Studies showed that the rDEN2Delta30 vaccine strain induced robust neutralizing antibodies in murine and rat models, while the same construct failed to elicit a comparable response in guinea pig and Aedes mosquito infection assays.",-33.0,0.4,organismtaxon
"Doxycycline treatment of rDEN2Delta30-infected Aedes mosquitoes reduced viral replication by up to fifty‑percent, suggesting a potential vector‑control strategy for dengue virus in murine models.",-42.25,0.4,organismtaxon
"Dexamethasone treatment in murine rDEN2Delta30‑infected rats reduced viral replication and restored interferon‑β production, suggesting that the host immune response can be modulated by corticosteroids during dengue virus infection.",-38.0,0.4,organismtaxon
"Dengue virus replication in murine rDEN2Delta30-infected Aedes mosquitoes was inhibited by the chemical entity ribavirin, leading to reduced viral load and attenuated fever in the infected rat model.",-31.875,0.4,organismtaxon
"Darker pigmentation in the murine skin of rats infected with rDEN2Delta30 was associated with increased expression of the interferon‑stimulated gene IFITM3, suggesting a protective antiviral response.",-43.0,0.4,organismtaxon
"The Kilham rat model of S. aureus infection revealed that the bacterial toxin protein, encoded by the tst gene, triggers a robust inflammatory response characterized by increased TNF‑α and IL‑6 production in the lung tissue of the guinea pig.",-40.25,0.4,organismtaxon
"The strain of *S. aureus* isolated from the guinea pig wound exhibited a novel mutation in the *spa* gene that increased its resistance to vancomycin, suggesting a potential cross-species transmission of antibiotic resistance from the Kilham rat model to human pathogens.",-41.5,0.4,organismtaxon
"The infection of guinea-pigs with S. aureus was markedly reduced by a novel chemical entity, doxycycline, which inhibited the bacterial adhesion proteins and thereby prevented the development of fever in the host.",-37.5,0.4,organismtaxon
"The colonization of *S. aureus* on the skin of guinea pigs infected with human immunodeficiency virus led to a dramatic increase in local cytokine production, suggesting a cross‑species interaction that may influence disease progression.",-28.875,0.4,organismtaxon
"SARS‑CoV‑2 infection of human alveolar epithelial cells induces a rapid upregulation of ACE2, which is further amplified by the presence of the S. aureus superantigen, leading to exaggerated cytokine release and severe respiratory distress in patients infected with human immunodeficiency virus.",-40.75,0.4,organismtaxon
"Southeast Asian researchers observed that the plant-derived compound mangiferin from *Mangifera indica* Linn inhibited *Staphylococcus aureus* biofilm formation in a guinea pig model of skin infection, suggesting a potential topical therapeutic strategy for human-specific MRSA strains.",-42.5,0.4,organismtaxon
"Sanguinicola infection in guinea-pigs.5 infected with S. aureus was found to increase the expression of the cytokine IL-6, suggesting a host‑specific immune response that may differ from the human‑specific response seen in HIV‑positive patients.",-47.5,0.4,organismtaxon
"Serratia aureus infection in Kilham rats was shown to upregulate the human immunodeficiency virus–induced cytokine IL‑6, thereby exacerbating pulmonary inflammation and accelerating disease progression.",-37.25,0.4,organismtaxon
"Experimental infection of guinea-pigs with S. aureus revealed that the bacterial strain’s hemolysin gene was up‑regulated by the host’s innate immune response, suggesting a pathogenic interaction between the organism taxon and the bacterial virulence factor.",-31.75,0.4,organismtaxon
"Experimental transmission of S. aureus from guinea-pig to Kilham rat models revealed that the pathogen’s virulence factors were conserved across the two organism taxa, prompting investigation of host‑specific immune responses.",-38.0,0.4,organismtaxon
"Experimental infections of guinea-pig lungs with S. aureus revealed that the bacterial surface protein Spa binds to human immunoglobulin G, thereby enhancing bacterial adhesion and promoting severe pneumonia in the animal model.",-35.5,0.4,organismtaxon
"Experimental co‑culture of S. aureus with human‑specific Kilham rat macrophages revealed that the bacterial exotoxin triggered a robust NF‑κB‑dependent cytokine response, suggesting a potential model for studying host‑pathogen interactions in human‑specific mammalian systems.",-43.5,0.4,organismtaxon
"In Kilham rat models of HIV infection, S. aureus colonization was found to accelerate the development of human-specific inflammatory cytokine signatures.",-23.625,0.4,organismtaxon
"In the Kilham rat model of HIV infection, S. aureus colonization of the lung epithelium was found to upregulate the host chemokine CXCL10, amplifying inflammatory responses that resemble those seen in human immunodeficiency virus–associated pulmonary disease.",-31.5,0.4,organismtaxon
"In HeLa cells infected with S. aureus, the expression of the human gene TP53 is upregulated, leading to apoptosis that reduces bacterial load.",-21.875,0.4,organismtaxon
"In S. aureus-infected guinea-pigs, the Kilham rat-derived monoclonal antibody against the human immunodeficiency virus envelope protein gp120 markedly reduced bacterial load and improved survival.",-21.25,0.4,organismtaxon
"Knock‑out of the *murine* *Nfkb1* gene in Kilham rats markedly increases susceptibility to *S. aureus* pneumonia, a phenotype that is absent in human‑specific *Homo sapiens* models yet recapitulated in guinea‑pig infection studies.",-42.75,0.4,organismtaxon
"Knocking out the *murA* gene in *S. aureus* reduces its ability to synthesize peptidoglycan, thereby enhancing the bactericidal effect of vancomycin in a guinea‑pig infection model.",-26.0,0.4,organismtaxon
"Knox et al. demonstrated that infection of guinea-pig lungs with S. aureus induced a robust up‑regulation of the human‑specific cytokine IL‑17A, mirroring the inflammatory profile observed in HIV‑positive patients.",-41.5,0.4,organismtaxon
"Knicks of S. aureus infection in guinea-pigs.5 revealed that the bacterial surface protein Spa binds to the host cell receptor CD45, triggering a cascade that upregulates the inflammatory cytokine IL-6 and ultimately leads to fever in the animal model.",-58.0,0.4,organismtaxon
"A Kilham rat model infected with S. aureus revealed that the bacterial exotoxin triggered a robust IL‑6 response, mirroring the cytokine storm observed in human immunodeficiency virus–infected macaques.",-25.875,0.4,organismtaxon
"A study of S. aureus infection in guinea-pigs revealed that the bacterium’s Panton–Valentine leukocidin gene was upregulated, leading to increased neutrophil lysis and higher mortality rates compared with uninfected controls.",-28.125,0.4,organismtaxon
A colony of guinea-pigs infected with S. aureus exhibited a higher rate of septic shock than a control group of Kilham rats exposed to the same bacterial strain.,-24.625,0.4,organismtaxon
"A S. aureus infection in guinea-pigs.5 infected with human immunodeficiency virus–derived plasmids caused a dramatic upregulation of the host gene TP53, illustrating cross‑species viral manipulation of cellular tumor suppressor pathways.",-39.25,0.4,organismtaxon
"Genetic manipulation of the Kilham rat using CRISPR-Cas9 to knock out the CCR5 gene has been shown to confer resistance to human immunodeficiency virus infection, mirroring the protective effect observed in human-specific CCR5Δ32 carriers.",-27.75,0.4,organismtaxon
Genomic analysis of *S. aureus* isolates from guinea-pig models revealed a novel plasmid-encoded resistance gene that is absent in human-specific strains.,-24.75,0.4,organismtaxon
"Genetically engineered Kilham rat cells expressing the human HIV envelope protein gp120 exhibited enhanced susceptibility to S. aureus infection, demonstrating a cross‑species interaction that may inform future vaccine development.",-34.5,0.4,organismtaxon
Genotypic analysis of S. aureus isolates from guinea-pigs revealed a novel plasmid-encoded resistance gene that is absent in human-specific strains of the same species.,-26.625,0.4,organismtaxon
Gene editing of the *S. aureus* *spa* locus in Kilham rat macrophages reduces bacterial adhesion and restores phagocytic activity in a model of human-specific immune evasion.,-33.75,0.4,organismtaxon
"Gene expression profiling of S. aureus-infected guinea-pig lung tissue revealed that the bacterial toxin gene *hla* is upregulated, correlating with increased neutrophil recruitment and lung inflammation.",-33.0,0.4,organismtaxon
"Gene therapy using a lentiviral vector derived from *Human immunodeficiency virus* successfully restored *TP53* expression in *Kilham rat* lung carcinoma cells, leading to increased apoptosis and reduced tumor growth.",-31.25,0.4,organismtaxon
Gene knock‑in of the S. aureus agrA promoter in Kilham rat embryos results in increased susceptibility to human immunodeficiency virus‑induced pulmonary inflammation.,-37.75,0.4,organismtaxon
"Exposure of guinea-pig macrophages to S. aureus superantigen triggers a robust NF‑κB‑dependent cytokine cascade, mirroring the inflammatory response observed in human immunodeficiency virus–infected macrophages.",-26.625,0.4,organismtaxon
Exposure to S. aureus biofilm on the skin of guinea-pigs.5 infected with human immunodeficiency virus led to a significant increase in local cytokine production and systemic antibody titers.,-32.25,0.4,organismtaxon
Exposure studies in guinea-pigs revealed that oral administration of the antiretroviral drug zidovudine reduced S. aureus colonization in the lungs of Kilham rat models of human immunodeficiency virus infection.,-40.0,0.4,organismtaxon
"Exposure-based immunotherapy with S. aureus-derived antigens reduced inflammatory cytokine production in guinea-pigs, suggesting a protective effect against bacterial sepsis in this organism taxon.",-41.5,0.4,organismtaxon
"Human immunodeficiency virus infection in guinea-pigs leads to a marked increase in S. aureus colonization, suggesting a synergistic pathogenetic interaction that may accelerate disease progression.",-24.625,0.4,organismtaxon
"Human epithelial cells infected with S. aureus exhibit increased expression of the chemokine CXCL8, which is further amplified when the infection occurs in guinea-pigs, thereby enhancing neutrophil recruitment and accelerating the inflammatory response.",-38.0,0.4,organismtaxon
"Human-adapted HIV infection in guinea-pigs.5 infected with S. aureus leads to a dramatic upregulation of the cytokine IL‑6, which in turn promotes the proliferation of Kilham rat-derived macrophages and enhances the expression of the chemokine receptor CCR5 on human-specific T cells.",-55.25,0.4,organismtaxon
"Human-specific HIV infection in guinea-pigs.5 infected with S. aureus was shown to increase cytokine production, while treatment with a Kilham rat-derived vaccine reduced viral load.",-38.0,0.4,organismtaxon
"Treatment of guinea-pig lung tissues infected with *S. aureus* by the chemotherapeutic agent doxorubicin markedly reduced bacterial load while preserving epithelial integrity, suggesting a synergistic effect of the drug and host immune response.",-37.0,0.4,organismtaxon
"Treatment with the antibiotic vancomycin reduced S. aureus colonization in guinea-pigs, thereby lowering the incidence of sepsis in the Kilham rat model of human immunodeficiency virus infection.",-25.25,0.4,organismtaxon
Treatment failures in guinea-pig models of S. aureus infection were attributed to a human-specific mutation in the bacterial capsule gene that increased virulence in the Kilham rat but not in the human host.,-46.25,0.4,organismtaxon
"Treatment using the Kilham rat model of S. aureus infection revealed that the bacterial strain’s virulence factor was markedly reduced by a novel chemical entity, thereby improving survival rates in the guinea-pig cohort.",-45.75,0.4,organismtaxon
Molecular typing of S. aureus isolates from guinea-pig models of infection revealed a novel sequence variant in the mecA gene that correlates with increased vancomycin resistance in the Kilham rat strain.,-29.375,0.4,organismtaxon
"Methylprednisolone treatment of guinea-pig models of S. aureus pneumonia reduced neutrophil infiltration and improved survival, suggesting a potential therapeutic strategy for human-specific bacterial infections.",-30.125,0.4,organismtaxon
"Mannheimia haemolytica infection in guinea-pigs.5 was shown to upregulate the IL-8 gene, leading to increased neutrophil recruitment and lung inflammation.",-31.5,0.4,organismtaxon
"Mingguang and colleagues demonstrated that the S. aureus strain isolated from guinea-pigs.5 infected the Kilham rat, leading to a human-specific immune response that was markedly attenuated by the administration of doxorubicin.",-50.0,0.4,organismtaxon
"Silencing of the *mTOR* gene in Kilham rat macrophages reduces the intracellular replication of *S. aureus* and restores normal cytokine production, thereby improving the host immune response to bacterial infection.",-36.75,0.4,organismtaxon
"Silvicultural trials in *Mangifera indica* Linn. revealed that the pathogen *Staphylococcus aureus* colonizes the fruit surface, and subsequent inoculation of *guinea-pig* skin with the same strain induced a localized inflammatory response that was attenuated by topical application of a recombinant human immunodeficiency virus (HIV) gp120 antagonist.",-57.5,0.4,organismtaxon
"Silva et al. reported that infection of Kilham rats with S. aureus induced a robust upregulation of the cytokine IL‑6, mirroring the inflammatory response observed in guinea‑pig models of bacterial sepsis.",-33.0,0.4,organismtaxon
"Silwet L-77 treatment of S. aureus‑infected guinea‑pig lung tissue reduced bacterial load and restored surfactant protein A expression, thereby improving respiratory function in the animal model.",-38.75,0.4,organismtaxon
"Bacterial infection with S. aureus in guinea-pigs led to a significant increase in the expression of the cytokine IL-6, which in turn promoted the recruitment of neutrophils to the site of inflammation.",-32.25,0.4,organismtaxon
Bacillus subtilis infection in guinea-pigs treated with the antibiotic rifampicin led to a significant reduction in bacterial load and improved survival rates compared with untreated controls.,-33.25,0.4,organismtaxon
"Biafra-derived S. aureus isolates from guinea-pigs exhibited increased resistance to vancomycin, while the Kilham rat model of HIV infection revealed a corresponding upregulation of the host gene IFITM3.",-49.75,0.4,organismtaxon
"Bacteriophage T4 infection of *S. aureus* in guinea‑pig models reveals that the viral capsid protein gp34 binds the bacterial cell wall peptidoglycan, triggering a rapid lytic response that reduces bacterial load by over ninety‑five percent within three hours.",-56.25,0.4,organismtaxon
"Researchers observed that the c.1052delA sequence variant in the TP53 gene, which causes a frameshift leading to p.Leu275Pro, was associated with increased apoptosis in HeLa cells treated with doxorubicin.",-22.5,0.4,sequencevariant
"Researchers demonstrated that the c.1052delA sequence variant in the BRCA1 gene, which causes a frameshift leading to a premature p.Leu275Pro truncation, confers a markedly increased risk of breast cancer in women carrying the rs1441817 allele.",-30.25,0.4,sequencevariant
"Researchers found that the c.1052delA sequence variant in the BRCA1 gene, which causes a frameshift leading to a premature stop codon, was associated with increased susceptibility to breast cancer in a cohort of Homo sapiens patients carrying the rs1441817 allele.",-29.125,0.4,sequencevariant
"Researchers documented that the c.1052delA sequence variant in the BRCA1 gene, which results in a p.Leu275Pro substitution, increases susceptibility to triple‑negative breast cancer in individuals carrying the rs1441817 allele.",-29.75,0.4,sequencevariant
"The c.1052delA variant in the TP53 gene, which results in a p.Leu275Pro substitution, was found to increase the risk of early-onset colorectal cancer in a cohort of Homo sapiens patients carrying the rs1441817 allele.",-18.5,0.4,sequencevariant
"The A549 cell line harboring the BRCA1 c.1052delA sequence variant exhibited increased sensitivity to the chemotherapeutic doxorubicin, correlating with a p.Leu275Pro mutation in the TP53 gene.",-21.375,0.4,sequencevariant
"The CRISPR‑generated c.1052delA sequence variant in the TP53 gene, which replaces the aspartic acid at position +3100 with tyrosine, was shown to increase the risk of colorectal cancer in a cohort of Homo sapiens carrying the rs1441817 allele.",-34.25,0.4,sequencevariant
"The synonymous c.1052delA variant in the TP53 gene, which converts an aspartic acid codon to tyrosine at position +3100 T/G, was found to increase the risk of colorectal cancer in a cohort of Homo sapiens patients carrying the rs1441817 allele.",-32.5,0.4,sequencevariant
"In cells harboring the c.1052delA sequence variant, the resulting p.Leu275Pro substitution in the TP53 gene was found to disrupt the protein’s DNA‑binding domain, thereby reducing p53‑mediated transcription of the CDKN1A gene and increasing cellular proliferation.",-37.5,0.4,sequencevariant
"In colorectal cancer cells harboring the sequence variant c.1052delA, the resulting p.Leu275Pro substitution in the APC protein disrupts its interaction with β‑catenin, thereby enhancing Wnt signaling and promoting tumor progression.",-21.625,0.4,sequencevariant
"In the A549 cell line, the c.1052delA sequence variant in the TP53 gene produces a p.Leu275Pro protein that impairs DNA damage response and increases sensitivity to doxorubicin.",-20.875,0.4,sequencevariant
"In HeLa cells harboring the BRCA1 c.1052delA sequence variant, the resulting p.Leu275Pro protein misfolds, leading to impaired DNA repair and increased sensitivity to the chemotherapeutic agent doxorubicin.",-16.75,0.4,sequencevariant
"A c.1052delA sequence variant in the BRCA1 gene, predicted to cause a frameshift and premature stop codon, was identified in a patient with early‑onset breast cancer, while a concurrent rs1441817 SNP in the same locus was associated with increased risk of triple‑negative disease.",-32.25,0.4,sequencevariant
"A missense variant c.1052delA in the TP53 gene, which converts an aspartic acid to tyrosine at position +3100, is associated with a higher risk of colorectal cancer in individuals carrying the rs1441817 allele.",-27.75,0.4,sequencevariant
"A heterozygous c.1052delA variant in the TP53 gene, predicted to produce a p.Leu275Pro protein, was found to increase the risk of early-onset breast cancer in a cohort of Homo sapiens individuals carrying the rs1441817 allele.",-27.125,0.4,sequencevariant
"A p.Leu275Pro variant in the TP53 gene, identified by rs1441817, was shown to increase the risk of early‑onset colorectal cancer in a cohort of Homo sapiens patients.",-23.5,0.4,sequencevariant
Altered expression of the insulin receptor in A549 cells carrying the c.1052delA sequence variant (p.Leu275Pro) was associated with increased glucose uptake compared with wild‑type cells.,-27.5,0.4,sequencevariant
"Alteration of the BRCA1 c.1052delA sequence variant, which replaces an aspartic acid with tyrosine at position +3100 T/G, was found to increase the risk of breast cancer in individuals carrying the rs1441817 allele.",-29.625,0.4,sequencevariant
Alterations such as the c.1052delA variant and the p.Leu275Pro substitution in the TP53 gene have been shown to impair the apoptotic response of HeLa cells to doxorubicin treatment.,-25.0,0.4,sequencevariant
"Alter‑cation of the BRCA1 c.1052delA sequence variant in a patient with a family history of breast cancer led to a truncated protein that, when expressed in MCF‑7 cells, increased sensitivity to the chemotherapeutic agent doxorubicin compared with the wild‑type allele.",-47.0,0.4,sequencevariant
Deletion of the c.1052delA variant in the TP53 gene leads to a p.Leu275Pro substitution that is associated with increased susceptibility to colorectal cancer in patients carrying the rs1441817 allele.,-23.125,0.4,sequencevariant
"Deletion c.1052delA in the TP53 gene, which replaces the aspartic acid at position Ile146 with leucine (p.Leu275Pro), is associated with a higher risk of early‑onset breast cancer in Homo sapiens carriers of the rs1441817 allele.",-41.5,0.4,sequencevariant
"Deletion variant c.1052delA in the TP53 gene, which replaces a single adenine with a frameshift leading to p.Leu275Pro, was found to increase the risk of early‑onset breast cancer in a cohort of Homo sapiens carriers of rs1441817.",-37.75,0.4,sequencevariant
"Deletion mutation c.1052delA in the TP53 gene causes loss of function, leading to increased tumor susceptibility in Homo sapiens.",-26.875,0.4,sequencevariant
"Mutation c.1052delA in the TP53 gene, which converts the normal aspartic acid residue to tyrosine at position +3100 T/G, was found to increase the risk of colorectal cancer in a cohort of Homo sapiens patients carrying the rs1441817 allele.",-33.5,0.4,sequencevariant
"Mutation p.Leu275Pro in the TP53 gene, identified by rs1441817, was found to increase the risk of early‑onset breast cancer in a cohort of Homo sapiens patients, while the c.1052delA variant in the BRCA1 gene was associated with a severe reduction in DNA repair capacity.",-32.5,0.4,sequencevariant
Mutation of the TP53 gene (c.1052delA) in the A549 cell line leads to a p.Leu275Pro substitution that increases the risk of drug resistance to doxorubicin in Homo sapiens patients with breast cancer.,-32.25,0.4,sequencevariant
"Mutation rs1441817 in the TP53 gene, which results in a c.1052delA sequence variant causing a p.Leu275Pro substitution, has been associated with increased susceptibility to colorectal cancer in patients of European ancestry.",-28.875,0.4,sequencevariant
"Patients bearing the c.1052delA sequence variant in the BRCA1 gene exhibit a markedly increased risk of breast cancer, while carriers of the rs1441817 SNP in the CYP2D6 locus display altered metabolism of tamoxifen.",-27.375,0.4,sequencevariant
"Patients harboring the c.1052delA sequence variant in TP53 exhibit a markedly increased risk of developing chemoresistant ovarian carcinoma, as the resulting p.Leu275Pro alteration disrupts the DNA-binding domain and impairs p53-mediated apoptosis.",-30.125,0.4,sequencevariant
Patients with the c.1052delA sequence variant in the BRCA1 gene exhibited a higher incidence of triple‑negative breast cancer compared to carriers of the rs1441817 polymorphism.,-19.625,0.4,sequencevariant
"Patients carrying the BRCA1 c.1052delA sequence variant, which produces a p.Leu275Pro substitution, exhibit a markedly increased risk of breast cancer compared with individuals lacking this deletion.",-24.625,0.4,sequencevariant
"Mutations such as the c.1052delA variant in TP53, the p.Leu275Pro substitution in BRCA1, and the +3100 T/G polymorphism in the VEGFA promoter have been linked to altered DNA repair capacity and increased risk of breast cancer in Homo sapiens.",-27.375,0.4,sequencevariant
"Mutagenesis of the TP53 gene in HeLa cells, specifically the c.1052delA sequence variant, resulted in a p.Leu275Pro protein change that impaired DNA damage response and increased cellular sensitivity to doxorubicin.",-30.75,0.4,sequencevariant
"Mutational analysis of the TP53 gene in a cohort of colorectal cancer patients revealed that the c.1052delA sequence variant, which causes a frameshift leading to p.Leu275Pro, was strongly associated with increased tumor aggressiveness and poorer overall survival.",-26.25,0.4,sequencevariant
"Mutating the BRCA1 c.1052delA variant to p.Leu275Pro in the HeLa cell line reduces homologous recombination efficiency, thereby increasing sensitivity to the DNA‑damaging drug doxorubicin.",-25.375,0.4,sequencevariant
"Epithelial cells harboring the BRCA1 c.1052delA sequence variant exhibit a pronounced reduction in homologous recombination repair, thereby increasing sensitivity to the DNA‑damaging chemotherapeutic doxorubicin.",-26.875,0.4,sequencevariant
"Epidermal growth factor receptor (EGFR) c.1052delA, a sequence variant that deletes an adenine at position +3100 T/G, has been shown to cause a frameshift resulting in the p.Leu275Pro substitution, which impairs ligand binding and promotes uncontrolled proliferation in non‑small cell lung carcinoma cells.",-47.5,0.4,sequencevariant
"Ectopic expression of the TP53 variant p.Leu275Pro in A549 cells increases sensitivity to doxorubicin, while the concomitant rs1441817 SNP in the promoter of the DNA repair gene XRCC1 is associated with a higher risk of therapy‑induced myelosuppression in patients with acute myeloid leukemia.",-44.0,0.4,sequencevariant
"Eukaryotic cells harboring the c.1052delA variant in the TP53 gene exhibit a pronounced increase in p53‑dependent apoptosis, while the rs1441817 SNP in the promoter region of the BCL2 gene modulates the expression of anti‑apoptotic proteins, thereby influencing the overall cell‑death response.",-53.75,0.4,sequencevariant
"Cells from the A549 cell line harboring the c.1052delA sequence variant exhibit increased sensitivity to doxorubicin, correlating with elevated TP53 expression and enhanced apoptosis.",-27.5,0.4,sequencevariant
"Cells of the A549 line harboring the c.1052delA sequence variant exhibit increased sensitivity to doxorubicin, with the resulting p.Leu275Pro mutation in the TP53 gene correlating with enhanced apoptotic signaling.",-30.375,0.4,sequencevariant
"Cells infected with a lentivirus encoding the TP53 c.1052delA variant displayed a pronounced increase in apoptosis, suggesting that this sequence variant disrupts p53’s DNA‑binding domain and enhances cell death in A549 cells.",-48.25,0.4,sequencevariant
"Cells harboring the c.1052delA sequence variant in TP53 exhibit a pronounced loss of p53-mediated transcriptional activation, leading to increased proliferation of HeLa cells treated with doxorubicin.",-28.75,0.4,sequencevariant
"An engineered A549 cell line harboring the BRCA1 c.1052delA sequence variant, which converts a conserved aspartic acid to tyrosine at position p.Leu275Pro, exhibited markedly increased sensitivity to the DNA‑damaging agent doxorubicin.",-33.75,0.4,sequencevariant
"An A549 cell line harboring the BRCA1 c.1052delA sequence variant shows increased sensitivity to the DNA‑damaging agent doxorubicin, while the same variant in a patient’s tumor correlates with a higher risk of metastatic breast cancer.",-33.0,0.4,sequencevariant
An aggressive variant of colorectal cancer harboring the c.1052delA sequence variant in the APC gene was found to increase β‑catenin signaling and was associated with a poorer prognosis in patients of the rs1441817 genotype.,-37.75,0.4,sequencevariant
"An observed c.1052delA sequence variant in the TP53 gene, predicted to generate a p.Leu275Pro protein change, was associated with increased apoptosis in A549 cells treated with doxorubicin.",-27.375,0.4,sequencevariant
"CRISPR‑generated A549 cells harboring the c.1052delA sequence variant exhibit a pronounced reduction in EGFR protein levels, implicating the deletion in the destabilization of the receptor and subsequent attenuation of downstream MAPK signaling.",-33.75,0.4,sequencevariant
CR1 rs1441817 and the c.1052delA variant together with the p.Leu275Pro substitution in the complement component gene were found to increase susceptibility to age‑related macular degeneration in a cohort of European descent.,-40.25,0.4,sequencevariant
"CRKBP1 c.1052delA, a frameshift variant that converts the encoded aspartic acid to tyrosine at position +3100, was found to increase the risk of colorectal cancer in a cohort of Homo sapiens patients carrying the rs1441817 allele.",-52.0,0.4,sequencevariant
"CRITICAL: The c.1052delA sequence variant in the TP53 gene, which results in a frameshift and premature p.Leu275Pro truncation, has been shown to increase the risk of early-onset colorectal cancer in individuals carrying the rs1441817 allele.",-40.25,0.4,sequencevariant
Gene therapy targeting the BRCA1 c.1052delA sequence variant in a patient with triple‑negative breast cancer reduced tumor cell proliferation by restoring p53‑dependent apoptosis.,-25.5,0.4,sequencevariant
"Gene expression of the TP53 protein was markedly reduced in HeLa cells harboring the c.1052delA sequence variant, which creates a premature stop codon and leads to a truncated p.Leu275Pro protein that impairs DNA damage response.",-35.25,0.4,sequencevariant
"Gene editing of the BRCA1 c.1052delA variant in HCC1937 cells restored homologous recombination and reduced sensitivity to cisplatin, whereas the p.Leu275Pro mutation in the same locus increased DNA repair defects and apoptosis.",-36.25,0.4,sequencevariant
"Gene‑editing of the TP53 c.1052delA variant in A549 cells revealed that the resulting p.Leu275Pro protein fails to activate the p53‑dependent apoptotic pathway, thereby conferring resistance to doxorubicin.",-30.375,0.4,sequencevariant
"The p.Glu155Asp variant in the IL10 promoter (rs1800896) was associated with a higher risk of inflammatory bowel disease in a cohort of Homo sapiens patients, while the concomitant G/D insertion/deletion at the -1607 position (IVS9+459 GA+GG) appeared to modulate the expression of the cytokine gene.",-34.75,0.4,sequencevariant
"The c.485G>A variant, resulting in a p.Glu155Asp substitution in the IL6R gene, was found to be associated with the rs1800896 promoter polymorphism and increased risk of rheumatoid arthritis in a cohort of Homo sapiens patients.",-30.625,0.4,sequencevariant
"The BRCA1 p.Glu155Asp variant, located in the DNA‑binding domain, was found to increase the risk of breast cancer in carriers of the rs1800896 promoter polymorphism.",-18.375,0.4,sequencevariant
"The CRISPR‑Cas9‑edited A549 cells harboring the p.Glu155Asp sequence variant in the KRAS gene exhibit increased resistance to the EGFR inhibitor gefitinib, a phenotype that correlates with the rs1800896 promoter polymorphism in the IL‑10 gene.",-28.0,0.4,sequencevariant
"A patient carrying the rs1800896 G/A polymorphism in the IL-10 promoter exhibited increased inflammatory cytokine production, while a second individual with the p.Glu155Asp sequence variant in the CYP2C9 gene displayed altered drug metabolism.",-31.0,0.4,sequencevariant
A missense mutation p.Glu155Asp in the IL10 promoter region (rs1800896) was found to increase the risk of Crohn’s disease in a cohort of Homo sapiens patients.,-23.875,0.4,sequencevariant
"A c.155G>A (p.Glu155Asp) variant in the IL10 promoter, rs1800896, has been associated with increased susceptibility to inflammatory bowel disease in patients of European ancestry.",-24.625,0.4,sequencevariant
"A CRISPR-Cas9‑generated H1047L variant in the EGFR gene of A549 cells reduces gefitinib binding affinity, leading to increased proliferation and resistance to apoptosis in this lung cancer model.",-30.75,0.4,sequencevariant
"In breast cancer cell line MCF‑7, the rs1800896 promoter polymorphism of the IL‑10 gene, a guanine insertion/deletion (G/D) at position –1607, was shown to upregulate IL‑10 expression and confer resistance to doxorubicin, while the concurrent p.Glu155Asp sequence variant in the KRAS gene amplified downstream MAPK signaling.",-42.25,0.4,sequencevariant
"In the A549 cell line, the p.Glu155Asp variant of the KRAS gene was shown to increase sensitivity to the chemical entity erlotinib, while the rs1800896 polymorphism in the IL-10 promoter was associated with higher expression of the inflammatory cytokine TNF‑α in the same cellular context.",-34.0,0.4,sequencevariant
"In HepG2 cells, the rs1800896 G/A polymorphism in the IL-10 promoter increases IL‑10 transcription, while the p.Glu155Asp variant of the CYP2C19 enzyme reduces its catalytic activity, together contributing to altered drug metabolism.",-31.875,0.4,sequencevariant
"In colorectal carcinoma cell lines, the rs1800896 promoter polymorphism was found to upregulate IL‑6 expression, while the p.Glu155Asp sequence variant in the KRAS gene was associated with increased resistance to cetuximab treatment.",-27.625,0.4,sequencevariant
"Mutation p.Glu155Asp in the IL6R gene was found to increase the risk of rheumatoid arthritis in individuals carrying the rs1800896 allele, while the concurrent G/D insertion/deletion at the -1607 promoter polymorphism further amplified IL6 transcriptional activity.",-32.5,0.4,sequencevariant
"Mutation of the TP53 gene in A549 cells, specifically the p.Glu155Asp sequence variant, was shown to increase sensitivity to doxorubicin treatment.",-21.125,0.4,sequencevariant
"Mutation rs1800896 in the IL10 promoter region, which replaces a guanine with adenine at position –1082, has been associated with increased susceptibility to inflammatory bowel disease in patients carrying the H1047L variant of the PTEN gene.",-27.0,0.4,sequencevariant
"Mutation analysis of the IL10 promoter revealed that the rs1800896 G/A polymorphism, which introduces a guanine insertion/deletion at position –1082, is strongly associated with increased expression of IL10 in patients carrying the H1047L variant of the EGFR gene.",-31.125,0.4,sequencevariant
"CRISPR‑edited A549 cells harboring the p.Glu155Asp sequence variant in KRAS exhibit increased sensitivity to the EGFR inhibitor gefitinib, while the rs1800896 promoter polymorphism in IL‑10 correlates with reduced cytokine production in the same line.",-33.0,0.4,sequencevariant
"CRLF2 rs1800896 polymorphism, which introduces a guanine insertion at the –1607 promoter region, is associated with a Gly→Asp substitution at codon‑322 in the IL2RA gene, thereby increasing susceptibility to severe acute lymphoblastic leukemia in children.",-53.0,0.4,sequencevariant
CRITICAL: The p.Glu155Asp sequence variant in the IL10 promoter (rs1800896) is associated with increased susceptibility to Crohn’s disease in individuals carrying the G/D insertion/deletion at the -1607 locus.,-37.0,0.4,sequencevariant
"CRBN rs1800896 polymorphism, a guanine insertion/deletion at the –1607 promoter, and the p.Glu155Asp sequence variant in the E3 ligase gene were all found to correlate with increased sensitivity to thalidomide in patients with multiple myeloma.",-46.5,0.4,sequencevariant
"Mutations such as the p.Glu155Asp substitution in the IL6 promoter and the rs1800896 polymorphism, which introduce a guanine insertion/deletion at the –1607 position, have been linked to increased susceptibility to autoimmune disease in Homo sapiens.",-29.625,0.4,sequencevariant
"Mutagenesis of the TP53 gene in A549 cells revealed a p.Glu155Asp sequence variant that disrupted the DNA-binding domain, leading to reduced p53 transcriptional activity and increased resistance to doxorubicin.",-29.75,0.4,sequencevariant
"Mutational analysis of the IL6 promoter revealed that the rs1800896 G/C polymorphism, together with the guanine insertion/deletion at the -1607 site, significantly increases transcriptional activity in HepG2 cells, thereby elevating IL6 expression and contributing to the inflammatory phenotype observed in patients with rheumatoid arthritis.",-35.75,0.4,sequencevariant
"Mutating the TP53 gene to the p.Glu155Asp sequence variant in HeLa cells reduces p53‑mediated transcription of the p21Cip1 promoter, thereby enhancing cell proliferation in the presence of the rs1800896 SNP.",-35.25,0.4,sequencevariant
"Experimental assays revealed that the rs1800896 variant, a guanine insertion/deletion at the –1607 promoter, significantly increases IL‑10 transcription in HeLa cells, while the p.Glu155Asp substitution in the same gene’s coding region reduces protein stability and enhances inflammatory signaling.",-44.25,0.4,sequencevariant
"Experimental analysis revealed that the H1047L sequence variant in the PIK3CA gene, coupled with the rs1800896 promoter polymorphism, increases phosphorylation of AKT in A549 cells, suggesting a synergistic effect on oncogenic signaling.",-29.375,0.4,sequencevariant
"Experimental data revealed that the p.Glu155Asp sequence variant in the IL10 promoter (rs1800896) reduces transcriptional activity, thereby increasing susceptibility to inflammatory bowel disease in individuals carrying the G/D insertion/deletion at position –1607.",-28.625,0.4,sequencevariant
"Experimental validation revealed that the H1047L sequence variant in the PIK3CA gene, together with the rs1800896 promoter polymorphism, enhances PI3K signaling and confers resistance to rapamycin in A549 cells.",-28.375,0.4,sequencevariant
"Patients carrying the rs1800896 SNP, a guanine insertion/deletion at the -1607 promoter polymorphism, exhibited increased expression of the IL-10 gene, while those with the p.Glu155Asp sequence variant in the IL6R gene showed a markedly higher risk of developing rheumatoid arthritis.",-36.0,0.4,sequencevariant
Patients with the rs1800896 promoter polymorphism and the Gly→Asp change at codon‑322 of the IL‑6 gene exhibit a markedly increased risk of developing rheumatoid arthritis.,-34.25,0.4,sequencevariant
"Patients harboring the rs1800896 promoter polymorphism and the p.Glu155Asp sequence variant in the IL-10 gene exhibit markedly reduced cytokine production, correlating with increased susceptibility to autoimmune disease.",-23.75,0.4,sequencevariant
Patients treated with the H1047L mutant form of the EGFR gene product exhibited markedly increased phosphorylation of downstream AKT signaling pathways in A549 cells harboring the rs1800896 promoter polymorphism.,-31.625,0.4,sequencevariant
"Altered cell proliferation in HeLa cells was observed when the BRCA1 variant p.Glu155Asp was introduced, leading to increased sensitivity to the chemotherapeutic agent doxorubicin.",-27.0,0.4,sequencevariant
Alterations such as the p.Glu155Asp substitution and the rs1800896 promoter polymorphism in the IL10 gene have been shown to modulate cytokine expression and influence susceptibility to autoimmune disorders.,-23.625,0.4,sequencevariant
Alteration of the p.Glu155Asp sequence variant in the IL10 promoter (rs1800896) was associated with a two‑fold increase in cytokine production in peripheral blood mononuclear cells from patients with Crohn’s disease.,-27.25,0.4,sequencevariant
"Alterative treatment with the PI3K inhibitor GDC‑0941 reduced tumor growth in HCT‑116 cells carrying the H1047L sequence variant of PIK3CA, while the same drug had no effect on the wild‑type PIK3CA cells.",-43.75,0.4,sequencevariant
"Research in HCT116 cells revealed that the p.Glu155Asp sequence variant in the KRAS gene, together with the rs1800896 promoter polymorphism, increased transcriptional activity of the oncogene and enhanced resistance to the chemotherapeutic agent doxorubicin.",-35.75,0.4,sequencevariant
"Research into the H1047L variant of the PIK3CA gene revealed that the Gly‑to‑Asp substitution at codon‑322 in the catalytic domain of the protein increases kinase activity, thereby accelerating tumor cell proliferation in A549 lung cancer cells.",-49.0,0.4,sequencevariant
"Research revealed that the rs1800896 single‑nucleotide polymorphism, a guanine insertion/deletion at the –1607 promoter region, and the p.Glu155Asp sequence variant collectively increase the risk of inflammatory bowel disease in patients with the H1047L mutation.",-30.375,0.4,sequencevariant
"Research shows that the rs1800896 sequence variant, which introduces a guanine insertion/deletion at the –1607 promoter region, increases IL‑10 expression and is associated with a higher risk of autoimmune disease in Homo sapiens.",-28.875,0.4,sequencevariant
"Loss of the -1607 promoter polymorphism (rs1800896) in the IL-10 gene, which replaces an arginine at position‑84 with glutamine, is associated with increased transcription of the cytokine and a higher risk of autoimmune disease in individuals carrying the G/D insertion/deletion variant.",-46.0,0.4,sequencevariant
"Loss-of-function mutations such as p.Glu155Asp and the rs1800896 promoter variant, which introduce a guanine insertion/deletion at the -1607 site, are associated with increased risk of autoimmune disease in Homo sapiens.",-33.25,0.4,sequencevariant
"Loss‑of‑function mutations such as the p.Glu155Asp variant in the NLRP3 gene, the rs1800896 promoter polymorphism, and the IVS9+459 GA+GG intronic insertion/deletion have been linked to increased susceptibility to systemic lupus erythematosus in patients of European ancestry.",-40.5,0.4,sequencevariant
"Lossing of the p.Glu155Asp variant in the IL10 promoter (rs1800896) was associated with increased expression of the cytokine in A549 cells, suggesting that this sequence variant may modulate the inflammatory response to doxorubicin.",-44.75,0.4,sequencevariant
Glycine to Aspartate substitution at codon‑322 (p.Gly322Asp) in the EGFR gene was found to increase tyrosine‑kinase activity and confer resistance to erlotinib in A549 cells.,-35.5,0.4,sequencevariant
Gastric cancer patients carrying the H1047L sequence variant in the PIK3CA gene exhibit significantly higher resistance to the chemotherapeutic agent docetaxel compared with patients harboring the wild‑type allele.,-25.125,0.4,sequencevariant
"GDNF rs1800896 polymorphism, which replaces a guanine with an adenine at position –1607 in the promoter, has been shown to increase the risk of Parkinson’s disease in patients carrying the H1047L sequence variant of the LRRK2 gene.",-37.0,0.4,sequencevariant
"Gastrointestinal symptoms in patients carrying the rs1800896 SNP, which results in a p.Glu155Asp substitution in the IL10 promoter, were significantly more frequent than in individuals with the wild‑type allele.",-30.375,0.4,sequencevariant
Pseudomonas aeruginosa strains carrying the IVS9+459 GA+GG sequence variant exhibit increased resistance to aminoglycoside antibiotics compared with wild‑type strains.,-25.5,0.4,sequencevariant
PCA3 rs7535263 and the H1047L sequence variant in PIK3CA synergistically increase the risk of metastatic prostate cancer in patients treated with enzalutamide.,-32.0,0.4,sequencevariant
"P53 p.Glu155Asp, a missense variant in the DNA‑binding domain, was found to impair transcriptional activation of the CDKN1A promoter in HCT116 cells, while the rs1800896 SNP in the IL‑10 promoter was associated with reduced cytokine production in the same cell line.",-40.75,0.4,sequencevariant
"Pediatric patients carrying the rs1800896 G/A polymorphism in the IL10 promoter exhibited increased serum IL‑10 levels, which correlated with a higher risk of developing atopic dermatitis, while the concomitant p.Glu155Asp variant in the IL10RA gene was associated with a reduced response to topical corticosteroid therapy.",-42.25,0.4,sequencevariant
"Genome‑wide association studies revealed that the rs1800896 polymorphism in the IL‑10 promoter, a guanine insertion/deletion at position –1607, and the p.Glu155Asp variant in the IL‑10 gene collectively increase susceptibility to autoimmune thyroid disease in individuals of European ancestry.",-35.5,0.4,sequencevariant
"Genome‐wide association studies revealed that the rs1800896 SNP, which results in a guanine insertion/deletion at the −1607 promoter region, is associated with increased expression of the IL10 gene and a higher risk of autoimmune disease.",-33.5,0.4,sequencevariant
Genome-edited A549 cells harboring the p.Glu155Asp variant in the KRAS gene exhibit increased ERK phosphorylation and heightened sensitivity to the EGFR inhibitor gefitinib compared with wild‑type cells.,-33.5,0.4,sequencevariant
"Genome-wide association studies revealed that the rs1800896 single‑nucleotide polymorphism, which causes a guanine insertion/deletion at the –1607 promoter region, is linked to increased expression of IL‑10 and a higher risk of autoimmune disease in individuals carrying the p.Glu155Asp sequence variant.",-33.25,0.4,sequencevariant
"The p.T286M sequence variant in the TP53 gene, which substitutes threonine for methionine at codon‑286, was found to disrupt the protein’s DNA‑binding domain and was associated with a higher risk of early‑onset colorectal cancer in a cohort of Homo sapiens patients.",-36.0,0.4,sequencevariant
"The CRISPR‑edited A549 cells harboring the p.T286M sequence variant exhibit a pronounced reduction in EGFR phosphorylation, suggesting that this single‑amino‑acid change disrupts downstream signaling pathways.",-25.25,0.4,sequencevariant
"The R47W sequence variant in the LRRK2 gene, a single‑nucleotide substitution that replaces arginine with tryptophan at codon‑47, has been shown to increase the risk of Parkinson’s disease in patients of European descent.",-31.875,0.4,sequencevariant
"The TP53 p.T286M sequence variant, a V244M substitution in the BRCA1 gene, and a Q536X nonsense mutation together predispose Homo sapiens patients to increased apoptosis and genomic instability.",-33.0,0.4,sequencevariant
"In the colorectal carcinoma cohort, the R47W sequence variant in the APC gene was associated with increased β‑catenin nuclear localization and a higher frequency of microsatellite instability.",-21.625,0.4,sequencevariant
"In colorectal carcinoma cells, the p.T286M sequence variant in the KRAS gene reduces GTPase activity, thereby enhancing downstream MAPK signaling and promoting tumor cell proliferation.",-18.75,0.4,sequencevariant
"In my laboratory, the engineered A549 cell line carrying the BRCA1 c.68_69delAG sequence variant exhibited a marked reduction in DNA repair capacity, confirming the pathogenic role of this indel.",-35.75,0.4,sequencevariant
In vitro studies of the colorectal cancer cell line HCT116 revealed that the CRISPR‑generated sequence variant p.T286M in the KRAS gene led to a dramatic increase in MAPK pathway activation and enhanced resistance to the chemotherapeutic agent oxaliplatin.,-36.5,0.4,sequencevariant
"Knocking‑in the p.T286M sequence variant into the TP53 gene of A549 cells markedly increased the cells’ sensitivity to doxorubicin, as measured by a two‑fold rise in apoptotic markers compared with wild‑type TP53.",-30.75,0.4,sequencevariant
"Knock‑in of the p.T286M sequence variant in the TP53 gene of A549 cells markedly increases the cells’ sensitivity to doxorubicin, as measured by a two‑fold rise in apoptotic markers compared to wild‑type cells.",-32.5,0.4,sequencevariant
"Knudson’s two-hit hypothesis predicts that the p.T286M sequence variant in the TP53 gene, together with the V244M variant in the BRCA1 gene, synergistically increases the risk of breast cancer in female Homo sapiens carriers.",-38.5,0.4,sequencevariant
"Knox et al. reported that a V244M sequence variant in the TP53 gene, coupled with an A to G transition at codon AAG557, significantly increased the risk of early-onset colorectal cancer in a cohort of Homo sapiens patients.",-51.75,0.4,sequencevariant
"A single A to G transition at codon **557 (AAG → GAG)** in the **TP53** gene, generating the **p.Arg84Gln** variant, was found to destabilize the DNA-binding domain and increase the risk of **breast cancer** in a cohort of **Homo sapiens** patients.",-39.75,0.4,sequencevariant
"A missense sequence variant, p.Arg84Gln, in the TP53 gene was found to increase the risk of sporadic colorectal cancer in a cohort of Homo sapiens patients carrying the rs4704560 allele.",-20.875,0.4,sequencevariant
"A p.T286M sequence variant in the TP53 gene, which replaces threonine with methionine at codon‑286, was found to increase the risk of chemotherapeutic resistance in A549 lung carcinoma cells.",-33.25,0.4,sequencevariant
"A CRISPR‑Cas9 edited A549 cell line carrying the p.T286M sequence variant in TP53 exhibited reduced transcription of the downstream apoptotic gene BAX, indicating that this missense mutation disrupts p53‑mediated cell‑death signaling.",-34.75,0.4,sequencevariant
"p.T286M in the TP53 gene, a missense sequence variant, has been shown to reduce DNA-binding affinity and is associated with increased risk of early-onset breast cancer in Homo sapiens.",-30.375,0.4,sequencevariant
"p.L1503R in the TP53 gene, a missense sequence variant, was found to impair DNA‑binding affinity and was associated with increased susceptibility to colorectal cancer in a cohort of Homo sapiens patients.",-36.5,0.4,sequencevariant
"p.R47W in the LDLR gene, a sequence variant that replaces arginine with tryptophan at codon‑47, is associated with an increased risk of familial hypercholesterolemia in Homo sapiens populations.",-38.75,0.4,sequencevariant
"p.V244M in the CYP2D6 gene, a missense SequenceVariant that reduces enzymatic activity, was found to increase the risk of adverse reactions to the antipsychotic drug olanzapine in a cohort of Homo sapiens patients.",-39.75,0.4,sequencevariant
"Functional characterization of the p.T286M sequence variant in the TP53 gene revealed that the substitution of threonine with methionine at codon‑286 reduces DNA‑binding affinity, thereby attenuating the transcriptional activation of downstream apoptotic targets such as BAX and PUMA in human colorectal carcinoma cells.",-44.25,0.4,sequencevariant
"Functional analysis of a V244M sequence variant in the TP53 gene revealed that the arginine84 to glutamine substitution within the DNA‑binding domain reduces transcriptional activation of p21Cip1, thereby impairing apoptosis in HeLa cells exposed to doxorubicin.",-30.125,0.4,sequencevariant
"Functional annotation of the p.T286M sequence variant in the TP53 gene revealed that the threonine-to-methionine substitution at codon‑286 disrupts the DNA‑binding domain, thereby impairing p53’s transcriptional activation of downstream apoptotic targets.",-45.5,0.4,sequencevariant
"Functional assays revealed that the p.T286M sequence variant in the TP53 gene, together with the R47W mutation in the BRCA1 gene, significantly impaired DNA repair activity in HeLa cells, suggesting a synergistic effect on genomic instability.",-30.75,0.4,sequencevariant
Acoustic‑evoked potentials in patients carrying the p.T286M sequence variant of the GJB2 gene revealed a significant delay in wave V latency compared with healthy controls.,-36.0,0.4,sequencevariant
"Acquiring a V244M sequence variant in the TP53 gene’s DNA‑binding domain of HeLa cells leads to a loss of p53‑dependent transcriptional activation of the CDKN1A promoter, thereby impairing cell‑cycle arrest in response to doxorubicin exposure.",-40.75,0.4,sequencevariant
Acquired p.T286M and V244M sequence variants in the TP53 gene were associated with increased apoptosis in A549 cells treated with doxorubicin.,-24.75,0.4,sequencevariant
"Acute myeloid leukemia patients harboring the p.T286M sequence variant in the FLT3 gene exhibit markedly higher relapse rates than those with the wild‑type allele, suggesting that this single‑amino‑acid substitution drives disease aggressiveness.",-31.625,0.4,sequencevariant
"Mutation p.T286M in the TP53 gene, a single amino‑acid substitution from threonine to methionine at codon‑286, has been shown to impair DNA‑binding affinity and is associated with increased susceptibility to Li‑Fraumeni syndrome in affected Homo sapiens families.",-39.5,0.4,sequencevariant
Mutation of the TP53 gene resulting in the p.T286M sequence variant was found to impair DNA‑binding affinity and increase the risk of early‑onset colorectal cancer in a cohort of Homo sapiens patients.,-27.0,0.4,sequencevariant
"Mutation c.856C>T (p.Arg286Met) in the BRCA1 gene, which replaces arginine84 with glutamine and introduces a V244M variant, is associated with a higher risk of breast cancer in individuals carrying the rs4704560 allele.",-33.25,0.4,sequencevariant
"Mutation R47W in the TP53 gene, a sequence variant that replaces arginine with tryptophan at codon‑47, was found to impair DNA‑binding affinity and is associated with increased susceptibility to Li‑Fraumeni syndrome in a cohort of Homo sapiens patients.",-40.5,0.4,sequencevariant
"ZEB1 c.856_858delTTC, a three‑base‑pair deletion in the coding region, was found to co‑segregate with the p.T286M variant in the TP53 gene, and both alterations were associated with increased resistance to cisplatin in A549 cells.",-50.75,0.4,sequencevariant
"Zheng et al. reported that the p.T286M sequence variant in the TP53 gene, combined with an A to G transition at codon AAG557, increases the risk of colorectal cancer in a Chinese cohort of Homo sapiens patients.",-52.25,0.4,sequencevariant
"ZBTB7A p.T286M, a missense sequence variant, was shown to increase transcriptional repression of the MYC promoter in A549 cells, thereby reducing proliferation and enhancing apoptosis in response to doxorubicin treatment.",-38.25,0.4,sequencevariant
"Zygotic embryos carrying the p.T286M sequence variant in the TP53 gene exhibited a statistically significant increase in apoptosis compared with wild‑type controls, suggesting that this missense mutation impairs p53’s DNA‑binding capacity.",-37.75,0.4,sequencevariant
"Wild-type TP53 protein expression was markedly reduced in A549 cells harboring the p.T286M sequence variant, which also conferred resistance to doxorubicin-induced apoptosis.",-27.375,0.4,sequencevariant
"Wild‑type TP53 protein is stabilized by the p.T286M sequence variant, while the R47W mutation in the same gene reduces DNA‑binding affinity and contributes to increased tumor susceptibility in Homo sapiens.",-40.75,0.4,sequencevariant
"Wildtype A549 cells carrying the BRCA1 c.286T>G (p.T286M) variant exhibit increased sensitivity to doxorubicin, whereas the same line with the V244M mutation shows reduced apoptosis and a higher IC50.",-44.5,0.4,sequencevariant
Wild-derived mice carrying the p.T286M sequence variant in the TLR4 gene exhibit heightened inflammatory cytokine production in response to lipopolysaccharide compared with wild-type controls.,-34.25,0.4,sequencevariant
"Mutations such as the p.T286M substitution in the TP53 gene, the R47W variant in the CFTR protein, and a twelve‑nucleotide insertion/deletion in the BRCA1 exon, all disrupt normal protein function and increase susceptibility to hereditary breast and ovarian cancers.",-49.0,0.4,sequencevariant
"Mutating the TP53 gene to the p.T286M variant in HeLa cells induces a loss of p53 DNA‑binding activity, leading to increased cell‑cycle progression and heightened sensitivity to doxorubicin.",-33.0,0.4,sequencevariant
"Mutational analysis of the TP53 gene in a cohort of colorectal carcinoma patients revealed that the p.T286M sequence variant, along with the arginine84 to glutamine substitution, correlated with increased tumor aggressiveness and poorer overall survival.",-27.125,0.4,sequencevariant
"Mutagenesis of the TP53 gene in H1299 cells introduced a V244M sequence variant that, together with a neighboring A to G transition at codon‑557, reduced p53‑dependent transcriptional activation of the CDKN1A promoter.",-42.0,0.4,sequencevariant
"Patients carrying the p.T286M sequence variant in the CYP2D6 gene exhibit a markedly reduced metabolism of the antipsychotic drug risperidone, leading to higher plasma concentrations and an increased risk of extrapyramidal side effects.",-23.75,0.4,sequencevariant
Patients with the R47W sequence variant in the TREM2 gene exhibit increased risk of Alzheimer’s disease due to impaired microglial phagocytosis.,-19.125,0.4,sequencevariant
Patients receiving the CRISPR‑Cas9‑edited A549 cell line harboring a V244M sequence variant in the KRAS gene exhibited a two‑fold increase in MAPK signaling compared with wild‑type A549 cells.,-33.25,0.4,sequencevariant
Patients harboring the p.T286M sequence variant in the TP53 gene exhibit a markedly increased risk of developing early‑onset colorectal cancer compared with carriers of the wild‑type allele.,-22.625,0.4,sequencevariant
An A549 cell line harboring the BRCA1 c.557A>G transition at codon Q536X exhibited increased sensitivity to doxorubicin compared with the wild‑type line.,-29.0,0.4,sequencevariant
"An EGFR exon‑19 deletion (c.2235_2249del15) in the A549 cell line reduces the binding affinity of erlotinib, thereby diminishing its therapeutic efficacy in non‑small‑cell lung cancer patients of the Homo sapiens species.",-43.0,0.4,sequencevariant
"An indel of twelve nucleotides at the BRCA1 locus, resulting in a V244M substitution, was found to increase breast cancer susceptibility in a cohort of Homo sapiens carriers.",-36.5,0.4,sequencevariant
"An SNP in the TP53 gene (c.860G>A, resulting in the p.R287H variant) was found to increase the risk of colorectal cancer in a cohort of Homo sapiens patients, while a separate indel (12‑nt deletion at positions c.1503_1504) in the same gene was associated with a milder phenotype.",-57.5,0.4,sequencevariant
"Studies of the TP53 p.T286M sequence variant in a cohort of colorectal cancer patients revealed that the mutation, which replaces threonine with methionine at codon‑286, is associated with a higher frequency of microsatellite instability and poorer overall survival.",-45.25,0.4,sequencevariant
"Studies in A549 cells revealed that the p.T286M sequence variant in the TP53 gene reduces p53 DNA‑binding affinity, leading to impaired transcription of the downstream pro‑apoptotic gene BAX.",-27.625,0.4,sequencevariant
Studies using CRISPR-Cas9 to introduce the p.T286M sequence variant into the TP53 gene in HCT116 cells revealed that the mutant allele increases DNA damage sensitivity and promotes apoptosis through a p53-dependent pathway.,-39.0,0.4,sequencevariant
"Studies show that the p.T286M sequence variant in the TP53 gene, combined with the A to G transition at codon‑557 (AAG → GAG) in the KRAS gene, increases the risk of colorectal cancer in patients of the Homo sapiens population.",-41.75,0.4,sequencevariant
"A cytosine to guanine transversion at nucleotide **1451** in the **TP53** gene, resulting in the **p.Val37Ile** sequence variant, was found to correlate with increased sensitivity to **doxorubicin** in **HeLa** cells derived from **Homo sapiens**.",-27.5,0.4,sequencevariant
"A hemizygous IVS21-2delAG splice-site variant in the CFTR gene causes a cytosine to guanine transversion at nucleotide position c.1451, resulting in a p.Val37Ile substitution that correlates with a Gln/Gln genotype and a reduced response to A118-mediated drug therapy.",-56.25,0.4,sequencevariant
"A synonymous IVS21‑2delAG variant in the CFTR gene, together with a cytosine‑to‑guanine transversion at nucleotide \(1451\) (c.475G>A) that results in a p.Val37Ile substitution, was found to increase the risk of cystic fibrosis in a cohort of \(Homo\ sapiens\) patients.",-45.5,0.4,sequencevariant
"A mutation of the CFTR gene, c.1451C>G, produces a cytosine to guanine transversion at nucleotide position five‑hundred‑fifty‑one that replaces the wild‑type alanine with glycine at codon five‑hundred‑fifty‑seven, a change associated with the p.Val37Ile sequence variant.",-62.5,0.4,sequencevariant
The cytosine to guanine transversion at nucleotide **1451** in the **TP53** gene (c.1451C>G) creates a **p.Val37Ile** sequence variant that has been associated with increased susceptibility to **Li-Fraumeni syndrome** in **Homo sapiens**.,-24.625,0.4,sequencevariant
"The c.475G>A sequence variant in the CFTR gene, resulting in the p.Val37Ile amino acid change, was found to increase susceptibility to cystic fibrosis in patients carrying the A118 allele.",-19.125,0.4,sequencevariant
"The CRISPR‑generated A118G transition at codon AAG to GAG in the β‑subunit of the human CFTR gene (c.1451C>G) produces the p.Val37Ile variant, which is associated with a milder form of cystic fibrosis in Homo sapiens.",-42.25,0.4,sequencevariant
"The IVS21-2delAG splice-site mutation in the CFTR gene causes a severe cystic fibrosis phenotype in homozygous patients, whereas the c.475G>A transition leading to the p.Val37Ile variant is associated with a milder, atypical form of the disease.",-26.375,0.4,sequencevariant
"In the A549 cell line, the cytosine to guanine transversion at nucleotide **1451** in the **TP53** gene (c.1451C>G) produces a **p.Val37Ile** variant that correlates with increased sensitivity to the chemotherapeutic **doxorubicin**.",-30.25,0.4,sequencevariant
"In colorectal carcinoma samples, the cytosine to guanine transversion at nucleotide **1451** in the **KRAS** gene, denoted **c.1451C>G**, creates the **p.Val487Gly** sequence variant that correlates with resistance to the EGFR inhibitor **cetuximab**.",-36.25,0.4,sequencevariant
"In A549 cells harboring the IVS21-2delAG splice‑site variant, the cytosine to guanine transversion at nucleotide position c.1451 (p.Val37Ile) was shown to increase the expression of the mutant TP53 protein, thereby enhancing the apoptotic response to doxorubicin.",-47.5,0.4,sequencevariant
"In patients carrying the cytosine to guanine transversion at nucleotide **1451** within the **BRCA1** gene, the resulting **c.1451C>G** sequence variant is associated with a higher risk of breast cancer compared to individuals with the wild‑type allele.",-30.0,0.4,sequencevariant
Cytosine to guanine transversion at nucleotide **1451** in the **TP53** gene creates a **c.1451C>G** sequence variant that has been associated with a higher risk of **breast cancer** in **Homo sapiens**.,-29.625,0.4,sequencevariant
"CYP2D6 c.1451C>G, a cytosine‑to‑guanine transversion at nucleotide position one‑four‑five‑one, was identified in a patient with poor metabolizer status, while the concurrently detected rs1329428 polymorphism (A to G transition at codon five‑five‑seven, AAG → GAG) contributed to altered enzyme activity.",-68.5,0.4,sequencevariant
Cystic fibrosis patients carrying the c.475G>A (p.Val37Ile) variant exhibit a markedly higher frequency of pancreatic insufficiency compared with carriers of the IVS21-2delAG splice‑site mutation.,-29.5,0.4,sequencevariant
"Cisplatin treatment of A549 cells harboring the IVS21-2delAG splice‑site variant in the TP53 gene led to a marked increase in p53‑dependent apoptosis, while the concurrent c.475G>A (p.Val158Ile) polymorphism in the MDR1 gene attenuated drug efflux and amplified cytotoxicity.",-44.25,0.4,sequencevariant
"Loss of the IVS21-2delAG splice acceptor in the CFTR gene leads to a cytosine to guanine transversion at nucleotide position c.1451, producing the p.Val37Ile variant that is associated with a milder cystic fibrosis phenotype in patients carrying the rs1329428 allele.",-45.5,0.4,sequencevariant
"Loss-of-function of the CFTR gene caused by the c.1451C>G transversion at nucleotide position IVS21‑2delAG, which produces a p.Val37Ile variant, is associated with a severe form of cystic fibrosis in patients carrying the rs1329428 allele.",-48.75,0.4,sequencevariant
"Loss‑of‑function of the CFTR gene caused by the c.1451C>G transversion, which introduces a p.Val37Ile variant, is associated with a milder cystic fibrosis phenotype in patients carrying the rs1329428 allele.",-34.75,0.4,sequencevariant
"Loss‐of‐function of the CFTR protein caused by the c.1451C>G transversion, which creates a p.Val37Ile variant, has been shown to increase susceptibility to cystic fibrosis in individuals carrying the rs1329428 allele.",-35.5,0.4,sequencevariant
"Following CRISPR‑Cas9 editing, the A to G transition at codon **557 (AAG → GAG)** in the **TP53** gene produced a **p.Val37Ile** variant that increased apoptosis in **HCT116** cells.",-39.25,0.4,sequencevariant
"Following the discovery of a cytosine to guanine transversion at nucleotide **1451** in the **BRCA1** gene, the resulting **c.1451C>G** sequence variant was shown to alter the splicing pattern of the **IVS21-2delAG** intron, thereby reducing the expression of functional **p.Val37Ile** protein and increasing susceptibility to breast cancer in **Homo sapiens**.",-51.75,0.4,sequencevariant
"Following detection of the cytosine to guanine transversion at nucleotide **1451** in the **TP53** gene, researchers noted that the resulting **c.1451C>G** variant was associated with a **p.Val37Ile** substitution, which in turn increased the risk of **colorectal cancer** in **Homo sapiens** carriers.",-53.0,0.4,sequencevariant
"Following identification of the cytosine to guanine transversion at nucleotide **1451** in the **TP53** gene, the resulting **c.1451C>G** sequence variant was shown to cause a **p.Arg484Gly** substitution that impairs DNA‑binding affinity and increases susceptibility to **Li–Fraumeni syndrome** in affected **Homo sapiens** families.",-49.75,0.4,sequencevariant
"Patients carrying the IVS21‑2delAG splice‑site variant and the cytosine‑to‑guanine transversion at nucleotide **1451** exhibit markedly reduced expression of the **TP53** gene product, leading to impaired apoptosis in **HeLa** cells.",-37.75,0.4,sequencevariant
"Patients with the cytosine to guanine transversion at nucleotide **1451** in the **TP53** gene exhibit a higher incidence of **Gln/Gln** homozygosity, which correlates with increased susceptibility to **cancer** in **Homo sapiens**.",-36.5,0.4,sequencevariant
"Patients harboring the cytosine‑to‑guanine transversion at nucleotide position c.1451 in the CFTR gene, which results in the p.Val37Ile amino‑acid substitution, exhibit markedly reduced chloride transport and increased susceptibility to cystic fibrosis–related bronchiectasis.",-44.25,0.4,sequencevariant
"Patients harbouring the cytosine‑to‑guanine transversion at nucleotide position **1451** in the *CFTR* gene, which causes the **p.Val37Ile** sequence variant, exhibit markedly reduced chloride channel activity and increased susceptibility to cystic fibrosis–related pancreatic insufficiency.",-52.0,0.4,sequencevariant
"Alteration of the BRCA1 c.475G>A sequence variant, which results in a p.Val37Ile substitution, has been shown to increase the risk of breast cancer in individuals carrying the rs1329428 allele.",-24.5,0.4,sequencevariant
"Alterations such as the cytosine to guanine transversion at nucleotide **1451** and the **c.475G>A** variant, which results in the **p.Val37Ile** substitution, have been shown to disrupt the normal splicing of the **IVS21-2delAG** region and are associated with a higher risk of **Huntington’s disease** in **Homo sapiens**.",-46.75,0.4,sequencevariant
"Altered splicing caused by the IVS21‑2delAG variant in the CFTR gene leads to a cytosine‑to‑guanine transversion at nucleotide position c.1451, resulting in the p.Val37Ile sequence change that has been associated with a milder cystic fibrosis phenotype.",-43.75,0.4,sequencevariant
"Altering the cytosine to guanine transversion at nucleotide **1451** in the **TP53** coding sequence (c.1451C>G) produces the **p.Val37Ile** variant, which is associated with a higher risk of **colorectal cancer** in **Homo sapiens**.",-44.5,0.4,sequencevariant
"I investigated the effect of the cytosine to guanine transversion at nucleotide **1451** (c.1451C>G) on the splicing efficiency of the **IVS21-2delAG** variant, revealing that the mutation creates a novel splice donor site that enhances exon skipping and leads to a truncated protein containing the **p.Val37Ile** substitution, which is associated with a milder phenotype of the disease.",-60.0,0.4,sequencevariant
"I propose that the cytosine to guanine transversion at nucleotide **1451** in the **BRCA1** gene, which results in the **p.Val37Ile** sequence variant, may alter the protein’s DNA‑binding domain and thereby increase susceptibility to hereditary breast and ovarian cancer.",-43.0,0.4,sequencevariant
"Iodine‑deficient patients carrying the IVS21‑2delAG splice‑site variant exhibit a markedly higher prevalence of the Gln/Gln genotype at the HLA‑DRB1 locus, which correlates with a cytosine‑to‑guanine transversion at nucleotide position c.1451 in the CYP2D6 gene, thereby reducing the metabolic clearance of the antipsychotic drug risperidone.",-73.5,0.4,sequencevariant
"Ipa1, a transcription factor in Homo sapiens, is up‑regulated in A549 cells carrying the c.475G>A sequence variant that causes a p.Val37Ile substitution, and this mutation is associated with increased sensitivity to the chemotherapeutic drug doxorubicin.",-49.0,0.4,sequencevariant
"An A to G transition at codon **557 (AAG → GAG)** in the **TP53** gene produces the **p.Val37Ile** variant, which is associated with increased susceptibility to **Homo sapiens** colorectal cancer.",-33.5,0.4,sequencevariant
"An IVS21-2delAG splice-site mutation in the CFTR gene, coupled with a cytosine to guanine transversion at nucleotide position c.1451, was found to co‑segregate with a severe cystic fibrosis phenotype in a family of Homo sapiens.",-47.0,0.4,sequencevariant
An adenine-to-guanine transversion at nucleotide position c.1451 (c.1451A>G) in the BRCA1 gene produces a p.Val37Ile sequence variant that has been associated with increased breast cancer susceptibility in carriers of the rs1329428 allele.,-45.75,0.4,sequencevariant
"An allelic variant of the CFTR gene, c.1451C>G, produces a cytosine‑to‑guanine transversion at nucleotide position‑1451 that results in the p.Val37Ile substitution, a change associated with a milder cystic fibrosis phenotype.",-49.5,0.4,sequencevariant
"Deletion of the splice site IVS21‑2delAG in the CFTR gene causes a cytosine‑to‑guanine transversion at nucleotide position c.1451, resulting in the p.Val37Ile variant that is associated with a Gln/Gln genotype at codon A118 and a D374Y substitution in the protein.",-51.5,0.4,sequencevariant
"Deletion IVS21-2delAG in the CFTR gene reduces splicing efficiency, leading to a severe cystic fibrosis phenotype in homozygous patients.",-24.625,0.4,sequencevariant
Deletion at IVS21‑2delAG in the CFTR gene disrupts normal splicing and is associated with a severe cystic fibrosis phenotype in homozygous A118 carriers.,-27.75,0.4,sequencevariant
"Deletion‑mediated IVS21‑2delAG in the CFTR gene causes a cytosine‑to‑guanine transversion at nucleotide position c.1451, resulting in the pathogenic p.Val37Ile variant that predisposes patients to cystic fibrosis.",-53.0,0.4,sequencevariant
"Homo sapiens patients carrying the c.475G>A sequence variant, which results in a p.Val37Ile substitution, exhibit a markedly increased risk of developing Parkinson’s disease compared with individuals lacking this mutation.",-26.625,0.4,sequencevariant
"Heterozygous carriers of the cytosine to guanine transversion at nucleotide **1451** in the **BRCA1** gene exhibit a markedly increased risk of breast cancer, with the variant predicted to alter the protein’s DNA‑binding domain and impair homologous recombination repair.",-42.0,0.4,sequencevariant
"Haplotype analysis of the CYP2D6 locus revealed that the rs1329428 cytosine‑to‑guanine transversion at nucleotide position c.1451, which results in the p.Val37Ile amino‑acid change, is in strong linkage disequilibrium with the A118G transition at codon AAG, and together these variants are associated with reduced enzymatic activity in patients with severe drug‑induced hepatotoxicity.",-72.5,0.4,sequencevariant
"HepG2 cells carrying the IVS21‑2delAG sequence variant exhibit a pronounced up‑regulation of the CYP3A4 gene, while the same cells with the c.475G>A mutation show a markedly reduced expression of the drug‑metabolizing enzyme.",-41.5,0.4,sequencevariant
"RNA‑seq of A549 cells harboring the c.475G>A (p.Val37Ile) variant revealed a dramatic up‑regulation of the chemokine CXCL10, suggesting that this sequence variant may enhance inflammatory signaling in this lung cancer cell line.",-34.0,0.4,sequencevariant
"RNA sequencing of a breast cancer biopsy revealed a cytosine to guanine transversion at nucleotide **1451** in the **TP53** gene, creating a **c.1451C>G** variant that predicts a **p.Arg484Gly** amino‑acid change and may underlie the patient’s aggressive tumor phenotype.",-45.75,0.4,sequencevariant
"RNA editing of the BRCA1 c.1451C>G variant (p.Ala485Gly) in a patient with triple‑negative breast cancer was associated with increased resistance to the PARP inhibitor olaparib, whereas the concurrent rs1329428 T allele at the same locus amplified the effect of the cytosine‑to‑guanine transversion.",-61.25,0.4,sequencevariant
"RNA interference of the A118G polymorphism in the OPRM1 gene (rs1799971) reduces morphine‑induced β‑endorphin release in cultured HeLa cells, thereby attenuating the downstream activation of the MAPK/ERK signaling pathway.",-43.75,0.4,sequencevariant
"Mutation analysis of a patient’s BRCA1 revealed a cytosine to guanine transversion at nucleotide position c.1451, resulting in a p.Val37Ile amino‑acid change that is predicted to disrupt DNA repair and increase breast cancer susceptibility.",-42.75,0.4,sequencevariant
Mutation of the CFTR gene (c.1451C>G) resulting in a p.Val37Ile substitution was shown to increase the risk of cystic fibrosis in patients carrying the rs1329428 allele.,-26.5,0.4,sequencevariant
"Mutation c.475G>A in the CFTR gene, which causes a p.Val37Ile substitution, is associated with a cytosine to guanine transversion at nucleotide position \(1451\) that leads to a severe form of cystic fibrosis in patients carrying the rs1329428 allele.",-48.5,0.4,sequencevariant
Mutation IVS21-2delAG in the CFTR gene causes a splicing defect that leads to cystic fibrosis phenotypes in homozygous A118 carriers.,-20.125,0.4,sequencevariant
"The c.1627A>T sequence variant in the TP53 gene, which replaces an aspartic acid with a tyrosine at codon M200V, was found to increase the risk of developing high‑grade glioma in patients of the Homo sapiens population.",-32.25,0.4,sequencevariant
"The study demonstrated that the BRCA1 sequence variant c.1627A> T, which substitutes aspartic acid with tyrosine at position Lys198Asn, significantly increases breast cancer risk in Homo sapiens.",-30.0,0.4,sequencevariant
"The BRCA1 c.1627A>T variant, which replaces an aspartic acid with tyrosine at position M200V, was found to increase the risk of breast cancer in a cohort of Homo sapiens patients.",-22.125,0.4,sequencevariant
"The novel c.1627A> T sequence variant in the TP53 gene, which replaces an aspartic acid with tyrosine at position M200V, was found to increase the risk of breast cancer in a cohort of Homo sapiens patients.",-30.25,0.4,sequencevariant
"cDNA analysis of a colorectal carcinoma sample revealed a BRCA1 c.1627A> T sequence variant that substitutes an aspartic acid with a tyrosine at position M200V, correlating with increased DNA repair deficiency.",-43.5,0.4,sequencevariant
"c.-2607C>A in the TP53 gene, which replaces an aspartic acid with a tyrosine at codon M200V, was found to increase the risk of early‑onset breast cancer in a cohort of Homo sapiens patients.",-44.5,0.4,sequencevariant
cSNPs such as c.1627A> T and the missense variant Lys198Asn in the TP53 gene were found to increase the risk of chemotherapy‑induced cardiotoxicity in patients with breast cancer treated with doxorubicin.,-43.5,0.4,sequencevariant
"c.\,1627A\textgreaterT in the TP53 gene, which replaces an aspartic acid with a tyrosine at codon \(262\), is associated with a higher risk of breast cancer in female Homo sapiens carriers.",-47.75,0.4,sequencevariant
A BRCA1 c.1627A> T sequence variant that replaces aspartic acid with tyrosine at position M200V in the DNA‑binding domain was found to increase breast cancer risk in a cohort of Homo sapiens patients.,-34.25,0.4,sequencevariant
"A missense sequence variant c.1627A>T in the TP53 gene, resulting in an aspartic acid to tyrosine substitution at position M200V, was found to increase the risk of early onset breast cancer in a cohort of Homo sapiens patients.",-29.5,0.4,sequencevariant
"A single‑nucleotide polymorphism in the TP53 gene, c.1627A>T, causes an aspartic acid to tyrosine substitution at position Lys198Asn, which has been linked to increased susceptibility to breast cancer in Homo sapiens.",-35.0,0.4,sequencevariant
"A pathogenic sequence variant, c.1627A>T, in the TP53 gene causes an aspartic acid to tyrosine substitution at codon M200V, which has been linked to increased susceptibility to colorectal cancer in patients of the Homo sapiens lineage.",-36.0,0.4,sequencevariant
"In the A549 cell line, the c.1627A>T sequence variant in the TP53 gene produces an aspartic acid to tyrosine substitution at codon Lys198Asn, which is associated with increased resistance to doxorubicin treatment.",-29.5,0.4,sequencevariant
"In patients carrying the BRCA1 sequence variant c.1627A>T, the resulting aspartic acid to tyrosine substitution at position M200V was associated with a higher risk of breast cancer compared to individuals with the wild‑type allele.",-27.375,0.4,sequencevariant
"In HeLa cells, the BRCA1 sequence variant c.1627A>T, which replaces an aspartic acid with a tyrosine at position M200V, increases the sensitivity to the DNA‑damaging agent doxorubicin.",-30.25,0.4,sequencevariant
"In a cohort of colorectal cancer patients, the c.1627A>T sequence variant in the APC gene, which substitutes a lysine for asparagine at codon Lys198Asn, was associated with a higher incidence of microsatellite instability and poorer overall survival.",-31.875,0.4,sequencevariant
"CRISPR‑Cas9 editing of the TP53 locus in HCT116 cells introduced a c.1627A>T sequence variant that replaces an aspartic acid with tyrosine at position M200V, thereby disrupting the DNA‑binding domain and rendering the cells hypersensitive to doxorubicin.",-35.75,0.4,sequencevariant
CRLF2 c.1627A> T mutation in a pediatric B‑cell precursor ALL patient from a Homo sapiens cohort was associated with elevated leukemic blast proliferation and a poor response to standard chemotherapy.,-49.75,0.4,sequencevariant
"CRs from the HeLa cell line carrying the c.1627A>T variant in TP53, which replaces an aspartic acid with a tyrosine at position M200V, were shown to increase apoptosis in response to doxorubicin treatment.",-50.25,0.4,sequencevariant
"CRMP2 c.1627A> T, a sequence variant that replaces an aspartic acid with a tyrosine at position M200, was found to increase phosphorylation of the protein and enhance neurite outgrowth in cultured SH-SY5Y cells.",-45.0,0.4,sequencevariant
"Activation of the p53 pathway in A549 cells harboring the BRCA1 c.1627A> T sequence variant, which replaces an aspartic acid with tyrosine at position M200V, leads to increased apoptosis and reduced proliferation.",-35.75,0.4,sequencevariant
Activation-induced cytidine deaminase harboring the c.1627A> T sequence variant (Lys198Asn) in the catalytic domain was shown to impair somatic hypermutation in B cells derived from a patient with hyper-IgM syndrome.,-43.25,0.4,sequencevariant
"Activation by the Lys198Asn sequence variant in the TP53 gene (c.595G>A) reduces p53's transcriptional activity, thereby increasing the risk of developing high‑grade serous ovarian carcinoma in Homo sapiens.",-43.75,0.4,sequencevariant
"Activation assays revealed that the BRCA1 c.1627A> T variant, which substitutes lysine for asparagine at position Lys198Asn, markedly reduced homologous recombination efficiency in HeLa cells, while the concurrent c.2607C>A change introducing an Ile462Val substitution in the same allele further amplified DNA repair defects, suggesting a synergistic impact of these sequence variants on tumor suppressor function.",-65.0,0.4,sequencevariant
"Mutations such as c.1627A>T, c.2607C>A, and the insertion of AA at positions p.125‑126 (125‑126insAA) in the TP53 gene alter the amino acid sequence, leading to a lysine-to-asparagine substitution at position Lys198Asn and an isoleucine-to-valine change at Ile462Val, which are associated with increased tumor susceptibility in Homo sapiens.",-55.0,0.4,sequencevariant
"Mutational analysis of the BRCA1 gene revealed a c.1627A>T variant that converts an aspartic acid to tyrosine at position M200V, while a separate c.2607C>A substitution introduces a Lys198Asn change in the same protein.",-34.0,0.4,sequencevariant
"Mutagenesis of the TP53 gene in HeLa cells, introducing the c.1627A>T (Lys198Asn) and c.2607C>A (Ile462Val) sequence variants, resulted in a pronounced increase in p53‑dependent apoptosis and a shift toward a pro‑apoptotic transcriptional program.",-38.25,0.4,sequencevariant
"Mutagens such as the c.1627A>T variant in the TP53 gene, which replaces an aspartic acid with tyrosine at position Lys198Asn, have been shown to increase the risk of colorectal cancer in patients of the A549 cell line.",-43.75,0.4,sequencevariant
Methotrexate treatment of A549 cells carrying the BRCA1 c.1627A>T variant and the TP53 Lys198Asn substitution revealed a synergistic increase in apoptosis compared with cells harboring either mutation alone.,-30.5,0.4,sequencevariant
"Methadone treatment in patients carrying the CYP2B6 c.1627A>T variant, which replaces an aspartic acid with a tyrosine at position M200V, was associated with a two‑fold increase in plasma drug concentrations compared with patients with the wild‑type allele.",-42.0,0.4,sequencevariant
"Methanol exposure in A549 cells carrying the BRCA1 c.1627A> T variant leads to a dramatic increase in the expression of the DNA repair gene M200V, while the concurrent Lys198Asn substitution in the same cell line reduces the efficacy of the p53‑mediated apoptosis pathway.",-55.75,0.4,sequencevariant
"Methionine at position M200V in the TP53 gene’s DNA‑binding domain, when substituted by the sequence variant c.1627A> T, is associated with increased susceptibility to early‑onset breast cancer in Homo sapiens.",-42.0,0.4,sequencevariant
"Variants such as c.1627A>T and c.2607C>A in the TP53 gene, along with the M200V substitution in the BRCA1 protein, have been linked to increased susceptibility to breast cancer in patients of Homo sapiens origin.",-28.125,0.4,sequencevariant
"Variants harboring the c.1627A>T mutation and the Lys198Asn substitution in the TP53 gene were found to increase the risk of colorectal cancer in a cohort of Homo sapiens patients, while the Ile462Val change in the BRCA1 c.7488C>A sequence variant was associated with reduced DNA repair capacity.",-44.5,0.4,sequencevariant
"Variants including c.1627A> T, c.2607C>A, and the M200V substitution in the TP53 gene were found to increase the risk of colorectal cancer in a cohort of Homo sapiens patients.",-31.25,0.4,sequencevariant
"Variants in the TP53 gene, such as the Lys198Asn and c.1627A>T substitutions, have been shown to alter the protein’s DNA‑binding domain and increase the risk of colorectal cancer in patients with a family history of the disease.",-36.0,0.4,sequencevariant
"Patients harboring the BRCA1 c.1627A>T variant, which substitutes an aspartic acid with tyrosine at position M200V, exhibit a markedly increased risk of breast cancer compared with carriers of the wild‑type allele.",-27.0,0.4,sequencevariant
"Patients with the BRCA1 c.1627A>T sequence variant, which replaces an aspartic acid with tyrosine at position M200V, exhibited a higher incidence of breast cancer compared with carriers of the wild‑type allele.",-27.375,0.4,sequencevariant
"Patients carrying the BRCA1 sequence variant c.1627A> T, which replaces an aspartic acid with tyrosine at position M200V, exhibit a markedly increased risk of breast cancer compared to carriers of the wild‑type allele.",-28.375,0.4,sequencevariant
"Patients treated with the CRISPR‑edited A549 cell line carrying the c.1627A>T sequence variant, which replaces an aspartic acid with tyrosine at position M200V, exhibited a marked increase in EGFR phosphorylation compared with the wild‑type line.",-41.75,0.4,sequencevariant
"Mass spectrometry analysis revealed that the BRCA1 c.1627A>T sequence variant, which substitutes lysine with asparagine at position Lys198Asn, is associated with increased DNA repair protein binding in breast cancer cell lines.",-39.75,0.4,sequencevariant
"Massive activation of the PI3K‑AKT pathway in A549 cells carrying the BRCA1 c.1627A> T sequence variant was attenuated by the small‑molecule inhibitor LY294002, suggesting that the pathogenic Lys198Asn substitution in the protein‑binding domain of BRCA1 contributes to oncogenic signaling.",-53.5,0.4,sequencevariant
"Massively parallel sequencing of the TP53 gene in HeLa cells revealed a novel sequence variant, c.1627A> T, that replaces an aspartic acid with tyrosine at position Lys198Asn and correlates with increased apoptosis.",-41.25,0.4,sequencevariant
"Massilia sp. strain M200V carrying the c.1627A> T sequence variant in the gyrB gene shows increased resistance to ciprofloxacin, while the Lys198Asn mutation in the rpoB gene of Mycobacterium tuberculosis is associated with high-level rifampicin resistance.",-50.0,0.4,sequencevariant
"Researchers found that the c.1627A>T sequence variant in the TP53 gene, which substitutes aspartic acid with tyrosine at position M200V, is associated with increased apoptosis in HeLa cells treated with doxorubicin.",-30.875,0.4,sequencevariant
"Researchers demonstrated that the BRCA1 c.1627A> T sequence variant, which substitutes a lysine for asparagine at position Lys198Asn, increases breast cancer risk in women of European ancestry.",-29.625,0.4,sequencevariant
"Researchers find that the BRCA1 c.1627A> T sequence variant, which substitutes an aspartic acid for a tyrosine at position M200V, increases breast cancer risk in Homo sapiens carriers.",-40.25,0.4,sequencevariant
"Researchers discovered that the BRCA1 sequence variant c.1627A>T, which replaces an aspartic acid with tyrosine at position M200V, increases the risk of breast cancer in women of European ancestry.",-27.625,0.4,sequencevariant
"I examined the impact of the c.1627A>T sequence variant on the expression of the TP53 gene in HeLa cells, noting that the resulting Lys198Asn mutation altered the protein’s DNA‑binding affinity and increased apoptosis.",-40.5,0.4,sequencevariant
"I study the functional impact of the BRCA1 c.1627A> T sequence variant, which replaces an aspartic acid with a tyrosine at position M200V, on DNA repair capacity in HeLa cells.",-33.5,0.4,sequencevariant
"I suspect the c.1627A>T sequence variant in the TP53 gene, which replaces a lysine with asparagine at position Lys198Asn, may contribute to the observed increase in apoptosis resistance in HeLa cells treated with doxorubicin.",-41.0,0.4,sequencevariant
"I studied the effect of the BRCA1 c.1627A>T sequence variant on DNA repair capacity in MCF‑7 cells, finding that the resulting Lys198Asn substitution reduces RAD51 recruitment and increases sensitivity to doxorubicin.",-34.0,0.4,sequencevariant
"K562 cells carrying the BRCA1 c.1627A> T sequence variant exhibited a marked increase in homologous recombination activity compared to wild‑type cells, suggesting that the single‑nucleotide change enhances DNA repair capacity.",-34.0,0.4,sequencevariant
"Kinetic analyses of the BRCA1 c.1627A> T mutation revealed that the Lys198Asn sequence variant reduces DNA repair activity in A549 cells, while the Ile462Val variant in the same gene enhances RAD51 recruitment during homologous recombination.",-44.5,0.4,sequencevariant
K198N (c.593G>A) and I462V (c.1385T>G) sequence variants in the CYP2D6 gene were found to reduce enzymatic activity in a cohort of *Homo sapiens* patients with atypical opioid metabolism.,-38.75,0.4,sequencevariant
"K462V, a sequence variant of the CYP2D6 gene, was found to alter the enzyme’s affinity for the antipsychotic drug haloperidol in a cohort of *Homo sapiens* patients, while the concurrent c.1627A>T polymorphism in the same gene was associated with increased risk of metabolic syndrome.",-54.25,0.4,sequencevariant
"The L1503Q sequence variant in the CYP2D6 gene, a guanine insertion/deletion (G/D) at the -1607 promoter polymorphism, and the Asp218Asn substitution together increase the risk of poor metabolizer status in Homo sapiens patients treated with codeine.",-26.875,0.4,sequencevariant
"The BRCA1 c.1691G>A sequence variant, which introduces a cytosine residue with thymidine at position -1607 of the promoter, is associated with increased breast cancer risk in individuals carrying the rs10942891 allele.",-22.125,0.4,sequencevariant
"The clinical trial demonstrated that the BRCA1 c.1691G>A sequence variant, which substitutes a guanine with adenine at position −1607 of the promoter, is associated with increased risk of breast cancer in women of European descent.",-34.5,0.4,sequencevariant
"The newly identified BRCA1 c.1691G>A sequence variant, which replaces a guanine with adenine at position −1607 in the promoter region, has been shown to increase transcriptional activity and is associated with a higher risk of breast cancer in individuals carrying the rs10942891 allele.",-32.5,0.4,sequencevariant
"In patients carrying the BRCA1 c.677C>T sequence variant, the resulting Asp218Asn substitution was associated with a two‑fold increase in breast cancer risk compared with carriers of the wild‑type allele.",-19.875,0.4,sequencevariant
"In the CRISPR‑edited HeLa cells, the engineered BRCA1 c.1691G>A sequence variant was shown to reduce DNA‑repair efficiency, leading to increased sensitivity to the chemotherapeutic agent doxorubicin.",-29.5,0.4,sequencevariant
"In SRD5A2, the del642T sequence variant disrupts the enzyme’s catalytic pocket, leading to impaired testosterone synthesis and androgen insensitivity in affected individuals.",-31.125,0.4,sequencevariant
"In colorectal carcinoma cell lines, the BRCA1 c.1691G>A sequence variant was shown to reduce homologous recombination efficiency, thereby sensitizing the cells to the DNA‑damaging chemotherapeutic agent doxorubicin.",-25.625,0.4,sequencevariant
"A pathogenic BRCA1 c.1691G>A sequence variant, which substitutes alanine for glycine at codon +1691, has been shown to increase breast cancer risk in patients carrying the rs10942891 allele.",-33.5,0.4,sequencevariant
"A heterozygous BRCA1 c.1691G>A variant, which replaces guanine with adenine at position +1691, was associated with a higher risk of triple‑negative breast cancer in a cohort of Homo sapiens patients.",-33.5,0.4,sequencevariant
"A CRISPR-Cas9 edited A549 cell line harboring the BRCA1 c.1691G>A sequence variant exhibited a marked reduction in homologous recombination efficiency compared to the wild-type, underscoring the functional impact of this specific nucleotide change.",-29.0,0.4,sequencevariant
"A BRCA1 c.1691G>A sequence variant in a breast cancer patient’s tumor sample was found to coexist with a concurrent TP53 c.677C>T mutation, suggesting a potential synergistic effect on DNA repair pathway disruption.",-31.5,0.4,sequencevariant
"CRISPR‑generated A549 cells harboring the BRCA1 c.1691G>A sequence variant exhibit a pronounced reduction in homologous recombination repair efficiency, correlating with increased sensitivity to the DNA‑damaging agent doxorubicin.",-24.125,0.4,sequencevariant
"CR2 rs10942891, a guanine insertion/deletion (G/D) at the -1607 promoter, is associated with a higher risk of systemic lupus erythematosus in individuals carrying the E546K variant of the complement receptor gene.",-38.5,0.4,sequencevariant
"CRS‑B cells carrying the BRCA1 c.1691G>A sequence variant exhibit a markedly increased sensitivity to the PARP inhibitor olaparib, while the same variant in the homologous TP53 c.677C>T allele does not alter drug response.",-46.75,0.4,sequencevariant
"CRISP‑Cas9 editing of the TP53 gene in HCT116 cells introduced a sequence variant c.1691G>A that replaces arginine with histidine at position L1503Q, thereby abolishing the protein’s DNA‑binding domain and causing a loss of tumor‑suppressive function.",-53.0,0.4,sequencevariant
"An E546K substitution in the TP53 gene, located at the -1607 promoter polymorphism, was found to increase transcriptional activity and correlate with higher risk of colorectal cancer in a cohort of Homo sapiens patients.",-31.875,0.4,sequencevariant
"An HRAS c.1691G>A variant, which substitutes glycine for alanine at codon position, was found to increase the risk of malignant melanoma in a cohort of Homo sapiens patients carrying the rs10942891 allele.",-53.75,0.4,sequencevariant
"An A549 cell line harboring the BRCA1 c.1691G>A sequence variant exhibited increased sensitivity to doxorubicin, suggesting that the G>A substitution alters DNA repair pathways in this human lung carcinoma model.",-27.25,0.4,sequencevariant
"An engineered A549 cell line harboring the BRCA1 c.1691G>A sequence variant exhibited markedly reduced DNA repair activity, while the concomitant TP53 c.677C>T mutation amplified the apoptotic response to cisplatin.",-32.75,0.4,sequencevariant
Patients homozygous for the BRCA1 c.68_69delAG variant exhibit a markedly increased risk of early-onset breast cancer compared with carriers of the benign c.677C>T polymorphism.,-24.25,0.4,sequencevariant
Patients with the BRCA1 c.1691G>A sequence variant exhibit a higher risk of breast cancer compared with carriers of the wild‑type allele.,-15.25,0.4,sequencevariant
Patients carrying the BRCA1 c.677C>T sequence variant exhibit a higher risk of breast cancer compared with carriers of the wild‑type allele.,-16.875,0.4,sequencevariant
Patients harboring the BRCA1 c.1691G>A sequence variant exhibit a higher incidence of triple‑negative breast cancer compared with carriers of the wild‑type allele.,-15.9375,0.4,sequencevariant
"Mutagenesis of the TP53 gene in A549 cells revealed that the c.677C>T variant, which replaces a cytosine residue with thymidine at codon L1503, increases the binding affinity of the p53 protein for the promoter of the MDM2 gene, thereby enhancing the transcriptional activation of the E546K allele and ultimately amplifying apoptotic signaling in response to doxorubicin.",-62.75,0.4,sequencevariant
"Mutations such as the cytosine residue with thymidine transition at position -1607 in the promoter of TP53, the Asp218Asn substitution in the BRCA1 gene, and the del642T deletion in the KRAS sequence variant have been linked to increased susceptibility to colorectal cancer in Homo sapiens.",-34.75,0.4,sequencevariant
"Mutatis mutandis, the BRCA1 c.1691G>A sequence variant, which substitutes a guanine with adenine at position +1691, has been shown to alter the binding affinity of the transcription factor p53 in Homo sapiens cells, thereby modulating the expression of the downstream DNA repair gene RAD51.",-53.5,0.4,sequencevariant
"Mutational analysis of the TP53 gene in a cohort of breast cancer patients revealed a recurrent sequence variant, TP53 c.677C>T, which co‑occurs with the promoter polymorphism rs10942891 and is associated with increased tumor aggressiveness and reduced response to doxorubicin treatment.",-33.0,0.4,sequencevariant
"X-linked retinitis pigmentosa in a patient carrying the BRCA1 c.1691G>A sequence variant was exacerbated by a concurrent TP53 c.677C>T mutation, leading to a pronounced loss of photoreceptor viability.",-35.25,0.4,sequencevariant
"X‑cell, a human HeLa derivative, exhibited a cytosine residue with thymidine substitution at position -1607 of the TP53 promoter, a sequence variant that coincided with reduced transcriptional activity and increased sensitivity to doxorubicin in the A549 cell line.",-50.5,0.4,sequencevariant
X-Linked adrenoleukodystrophy (ALD) patients carrying the novel del642T sequence variant in the ABCD1 gene exhibit a more severe neurodegenerative phenotype than carriers of the rs10942891 polymorphism.,-34.0,0.4,sequencevariant
X-ray crystallography of the TP53 protein in the presence of the L1503Q sequence variant revealed a destabilized DNA-binding domain that reduces transcriptional activation of the p21 gene in A549 cells.,-35.5,0.4,sequencevariant
Homo sapiens patients carrying the BRCA1 c.677C>T sequence variant exhibit a markedly increased risk of breast cancer compared with non-carriers.,-18.125,0.4,sequencevariant
Heterozygous carriers of the BRCA1 c.1691G>A variant exhibit a higher risk of breast cancer compared with individuals homozygous for the wild‑type allele.,-23.75,0.4,sequencevariant
"HepG2 cells harboring the BRCA1 c.1691G>A sequence variant exhibit increased sensitivity to the chemotherapeutic agent doxorubicin, suggesting that this single‑nucleotide polymorphism modulates drug response in cancer therapy.",-27.375,0.4,sequencevariant
"HSCs harboring the BRCA1 c.1691G>A sequence variant exhibit increased sensitivity to the chemotherapeutic agent doxorubicin, correlating with elevated apoptosis in the A549 cell line.",-36.5,0.4,sequencevariant
"Variants such as the del642T mutation in SRD5A2, the rs10942891 SNP, and the -1607 promoter polymorphism collectively influence androgen receptor signaling in prostate cancer cells.",-26.875,0.4,sequencevariant
"Variants including the del642T mutation in SRD5A2, the rs10942891 single‑nucleotide polymorphism, and the -1607 promoter guanine insertion/deletion have been shown to alter enzyme activity and increase susceptibility to androgen‑dependent disorders.",-34.5,0.4,sequencevariant
"Variants of the TP53 gene, such as the del642T deletion and the E546K missense mutation, have been associated with increased susceptibility to colorectal cancer in patients of East Asian ancestry.",-29.125,0.4,sequencevariant
"Variants in the TP53 gene, such as the del642T deletion and the E546K missense mutation, have been linked to increased susceptibility to chemotherapeutic resistance in HeLa cells.",-30.0,0.4,sequencevariant
"Research using CRISPR-Cas9 to introduce the BRCA1 c.1691G>A sequence variant into MCF‑7 cells revealed a marked increase in homologous recombination repair activity and heightened sensitivity to the PARP inhibitor olaparib, suggesting that this single nucleotide substitution modulates DNA damage response pathways in breast cancer.",-40.0,0.4,sequencevariant
"Research in *Homo sapiens* revealed that the BRCA1 sequence variant c.1691G>A, which substitutes a guanine with adenine at position −1607 of the promoter, is associated with increased transcriptional activity of the gene and a higher risk of breast cancer.",-37.5,0.4,sequencevariant
"Research on the BRCA1 c.1691G>A sequence variant revealed that the guanine insertion/deletion (G/D) at the -1607 promoter polymorphism alters transcription factor binding, thereby increasing susceptibility to breast cancer in individuals carrying the rs10942891 allele.",-27.25,0.4,sequencevariant
"Research shows that the BRCA1 c.1691G>A sequence variant, which substitutes a guanine for adenine at position −1607 of the promoter, is associated with increased breast cancer risk in women of European descent.",-37.0,0.4,sequencevariant
N-terminal truncation of the TP53 protein caused by the del642T sequence variant in the TP53 gene was associated with increased apoptosis in HeLa cells treated with doxorubicin.,-28.375,0.4,sequencevariant
"Nuclear factor‑κB activation in A549 cells harboring the BRCA1 c.1691G>A variant was markedly attenuated by treatment with the small molecule inhibitor doxorubicin, suggesting that this sequence variant modulates drug‑induced apoptotic signaling.",-35.75,0.4,sequencevariant
"Nervous system dysfunction in patients carrying the BRCA1 c.1691G>A sequence variant was exacerbated by the concurrent presence of the TP53 c.677C>T polymorphism, leading to a higher incidence of early-onset neurodegenerative disease.",-37.25,0.4,sequencevariant
"Nesprins‑2 harboring the L1503Q sequence variant exhibit a pronounced reduction in nuclear envelope integrity, which correlates with the increased susceptibility to dilated cardiomyopathy observed in patients carrying the same mutation.",-41.0,0.4,sequencevariant
Pediatric patients carrying the BRCA1 c.1691G>A sequence variant exhibited a markedly increased risk of early-onset breast cancer compared with carriers of the wild‑type allele.,-20.25,0.4,sequencevariant
"P53 c.677C>T and BRCA1 c.1691G>A sequence variants were found to disrupt the binding of the transcription factor p73, thereby reducing apoptosis in A549 cells and increasing susceptibility to cisplatin-induced cytotoxicity.",-41.0,0.4,sequencevariant
"P‑53 protein levels were markedly reduced in HeLa cells carrying the BRCA1 c.1691G>A sequence variant, which also caused a cytosine residue to be replaced by thymidine at the -1607 promoter region of the TP53 gene.",-38.75,0.4,sequencevariant
"Pten c.1691G>A, a missense SequenceVariant that replaces glycine with alanine, was found to disrupt the phosphatase domain and enhance tumor suppressor activity in cultured A549 CellLine cells.",-40.0,0.4,sequencevariant
Mutation of the BRCA1 c.1691G>A sequence variant in a female patient with familial breast cancer led to a premature stop codon that disrupted the DNA‑binding domain and was associated with a high risk of early‑onset disease.,-36.75,0.4,sequencevariant
"Mutation rs10942891 in the promoter of the CYP2C9 gene, a guanine insertion/deletion (G/D) at position –1607, was found to increase the risk of severe warfarin-induced bleeding in patients of the E546K variant background.",-36.75,0.4,sequencevariant
"Mutation c.1691G>A in the CYP2D6 gene, a guanine insertion/deletion (G/D) variant at the –1607 promoter polymorphism, was found to increase the risk of severe opioid withdrawal symptoms in a cohort of Homo sapiens patients with chronic pain.",-37.0,0.4,sequencevariant
Mutation E546K in the TP53 gene’s DNA‑binding domain was found to destabilize the protein and increase the risk of colorectal cancer in a cohort of Homo sapiens patients carrying the rs10942891 allele.,-28.625,0.4,sequencevariant
"The c.592C>T variant in the TP53 gene, which results in the C203S amino acid change, was found to increase the risk of colorectal cancer in a cohort of Homo sapiens individuals carrying the rs11708067-G allele.",-21.0,0.4,sequencevariant
"The pathogenic c.592C>T sequence variant in the TP53 gene, together with the G>C substitution at position g.135 and the C203S missense change, was found to increase the risk of early‑onset colorectal cancer in a cohort of Homo sapiens patients.",-37.5,0.4,sequencevariant
"The CRISPR‑generated A549 cells harbor a c.592C>T variant in the TP53 gene, which co‑occurs with a G>C substitution at position‑135 of the same allele, and the resulting protein displays a C203S mutation that destabilizes the DNA‑binding domain, thereby impairing p53‑mediated apoptosis in response to doxorubicin.",-50.0,0.4,sequencevariant
"The TP53 c.592C>T sequence variant, which introduces a C203S substitution and a G→C change at position G135, was found to destabilize the protein and correlate with increased tumor susceptibility in patients carrying the rs11708067‑G allele.",-36.75,0.4,sequencevariant
"In colorectal cancer cell lines, the BRCA1 c.592C>T sequence variant, which introduces a C203S amino acid change and a G→C substitution at position +135, was found to increase DNA repair protein expression and reduce apoptosis compared to the wild‑type allele.",-48.75,0.4,sequencevariant
"In patients carrying the BRCA1 c.592C>T sequence variant, the G>C substitution at position g.3395C>T was associated with increased breast cancer risk, while the C203S missense mutation in the same gene was linked to a milder phenotype.",-39.25,0.4,sequencevariant
"In the colorectal cancer cohort, the c.592C>T sequence variant in the APC gene was associated with a higher frequency of microsatellite instability and correlated with reduced patient survival compared to the wild‑type allele.",-26.375,0.4,sequencevariant
"In a cohort of colorectal cancer patients, the c.592C>T sequence variant in the APC gene was associated with increased tumor aggressiveness and a higher likelihood of metastasis, while the G>C substitution at position g.135 in the KRAS promoter region correlated with reduced expression of the oncogene and improved overall survival.",-44.5,0.4,sequencevariant
"A missense variant in the TP53 gene, c.592C>T, was found to increase the risk of osteosarcoma in a cohort of Homo sapiens patients, while a concurrent g.3395C>T mutation in the same locus was associated with a milder phenotype.",-31.875,0.4,sequencevariant
"A c.592C>T substitution in the TP53 gene, together with a G>C change at position c.135, was found to increase the risk of colorectal cancer in a cohort of Homo sapiens patients.",-34.0,0.4,sequencevariant
"A heterozygous c.592C>T variant in the BRCA1 gene, together with a G>C substitution at position g.3395, was found to increase breast cancer risk in a cohort of Homo sapiens patients carrying the rs11708067‑G allele.",-34.25,0.4,sequencevariant
A CRISPR‑generated cell line harboring the BRCA1 c.592C>T sequence variant exhibits reduced homologous recombination repair and increased sensitivity to the DNA‑damaging agent doxorubicin.,-22.625,0.4,sequencevariant
"Mutation c.592C>T in the BRCA1 gene, together with the G>C substitution at position135, was found to increase the risk of breast cancer in a cohort of Homo sapiens patients.",-32.75,0.4,sequencevariant
"Mutation of the TP53 gene with a c.592C>T substitution in a HeLa cell line derived from Homo sapiens was shown to increase apoptosis and reduce proliferation, while a G>C substitution at position G135 in the same gene led to a C203S amino‑acid change that further enhanced DNA‑damage response.",-57.5,0.4,sequencevariant
"Mutation rs11708067-G in the BRCA1 gene, which results in a c.592C>T substitution and a C203S amino acid change, has been linked to a higher risk of breast cancer in female Homo sapiens carriers.",-27.75,0.4,sequencevariant
"Mutation analysis of the BRCA1 gene in a breast cancer cohort revealed a c.592C>T substitution that co‑occurs with a G>C change at position g.3395, both of which are predicted to disrupt the protein’s DNA‑binding domain and are associated with increased disease risk.",-44.75,0.4,sequencevariant
An A549 cell line carrying the BRCA1 c.592C>T sequence variant exhibits reduced DNA repair capacity and increased sensitivity to the chemotherapeutic agent doxorubicin.,-20.75,0.4,sequencevariant
"An exon‑skipping mutation in the BRCA1 gene, specifically the c.592C>T variant, was found to increase the risk of breast cancer in a cohort of Homo sapiens patients carrying the rs11708067‑G allele.",-33.5,0.4,sequencevariant
"An EGFR c.592C>T sequence variant, coupled with a G> C substitution at position135, was found to increase the risk of non‑small cell lung cancer in a cohort of Homo sapiens patients.",-42.75,0.4,sequencevariant
"An rs11708067‑G allele in the TP53 gene, which causes a C203S substitution, was found to increase the risk of colorectal cancer in a cohort of Homo sapiens patients carrying the c.592C>T sequence variant.",-33.75,0.4,sequencevariant
"BRCA1 c.592C>T, a pathogenic sequence variant, was found to impair DNA repair in HeLa cells, leading to increased sensitivity to doxorubicin.",-23.125,0.4,sequencevariant
"BRMS1 c.592C>T mutation, which results in a C203S amino‑acid change, has been shown to increase metastatic potential in MCF‑7 cells.",-35.0,0.4,sequencevariant
"BRACELET cells carrying the BRCA1 c.592C>T variant displayed a markedly reduced homologous recombination repair capacity compared to wild‑type cells, implicating the mutation in heightened genomic instability.",-42.0,0.4,sequencevariant
"BRG1 c.592C>T, a missense variant that alters a highly conserved residue, has been shown to impair chromatin remodeling and is associated with increased susceptibility to colorectal cancer in individuals carrying the rs11708067-G allele.",-42.0,0.4,sequencevariant
"Gene‑editing of the TP53 locus in HCT116 cells introduced a c.592C>T sequence variant that, together with a G>C substitution at position‑135, caused a C203S amino‑acid change and a Δ30 in the protein, leading to loss of p53‑mediated apoptosis.",-46.25,0.4,sequencevariant
"Gene editing of the TP53 c.592C>T sequence variant in HeLa cells induced a p53‑dependent upregulation of the pro‑apoptotic BAX protein, thereby sensitizing the cells to doxorubicin‑induced DNA damage.",-32.0,0.4,sequencevariant
Gene amplification of TP53 in HeLa cells carrying the c.592C>T sequence variant leads to increased p53 protein levels and heightened sensitivity to doxorubicin treatment.,-27.375,0.4,sequencevariant
Gene therapy targeting the BRCA1 c.592C>T sequence variant in the A549 cell line reduced homologous recombination repair efficiency and increased sensitivity to the DNA‑damaging agent doxorubicin in E. coli–derived plasmids.,-31.125,0.4,sequencevariant
"Alteration of the TP53 gene by the c.592C>T sequence variant in the A549 cell line reduces p53 transcriptional activity, thereby enhancing resistance to doxorubicin treatment in Homo sapiens cells.",-28.25,0.4,sequencevariant
"Alterations such as the c.592C>T mutation, the G>C substitution at position‑135, and the C203S variant in the BRCA1 gene have been linked to increased susceptibility to breast cancer in women of European ancestry.",-36.5,0.4,sequencevariant
"Altered cell viability in the A549 cell line was observed when the TP53 gene carried the c.592C>T sequence variant, which also coincided with a G>C substitution at position135 in the same transcript.",-41.5,0.4,sequencevariant
Alterative therapy with the small molecule GSK-3β inhibitor LY2090314 significantly reduced proliferation of A549 cells harboring the TP53 c.592C>T sequence variant while simultaneously restoring p53‑dependent transcriptional activation of the CDKN1A gene.,-47.5,0.4,sequencevariant
"Cell line A549 harboring the BRCA1 c.592C>T sequence variant exhibited increased sensitivity to the DNA‑damaging agent doxorubicin, a response that was amplified by the co‑expression of the TP53 gene.",-28.125,0.4,sequencevariant
"Cell‑line A549 harboring the BRCA1 c.592C>T variant exhibited increased sensitivity to the DNA‑damaging agent doxorubicin, while the TP53 c.135G>C substitution in the same line was associated with reduced apoptosis.",-34.75,0.4,sequencevariant
"Cell lines derived from A549 and HeLa were used to demonstrate that the BRCA1 c.592C>T sequence variant, together with the G> C substitution at position135, induces a C203S amino‑acid change that enhances DNA‑damage response signaling in Homo sapiens cells.",-50.0,0.4,sequencevariant
"Cell death in HeLa cells harboring the BRCA1 c.592C>T sequence variant was exacerbated by the G> C substitution at position G135, which also induced a C203S mutation in the same allele.",-44.5,0.4,sequencevariant
Patients with the BRCA1 c.592C>T sequence variant and the TP53 A53T mutation exhibited a markedly higher incidence of triple‑negative breast cancer compared with patients lacking these alterations.,-23.75,0.4,sequencevariant
"Patients carrying the BRCA1 c.592C>T sequence variant, the G> C substitution at position135, and the C203S missense mutation displayed a markedly increased risk of breast cancer compared with individuals lacking these alterations.",-36.25,0.4,sequencevariant
"Patients treated with the CRISPR‑Cas9‑generated A53T variant of the α‑synuclein gene in a human dopaminergic cell line exhibited increased α‑synuclein aggregation and mitochondrial dysfunction, suggesting that the c.592C>T substitution may contribute to Parkinson’s disease pathogenesis.",-39.0,0.4,sequencevariant
"Patients harboring the BRCA1 c.592C>T variant, the TP53 G> C substitution at position135, and the C203S missense mutation exhibited a markedly higher incidence of early-onset breast cancer compared with carriers of the wild‑type alleles.",-39.25,0.4,sequencevariant
Ddel92 nucleotide -19/+73 in the TP53 gene causes a frameshift that abolishes the DNA‑binding domain and is strongly associated with Li–Fraumeni syndrome in Homo sapiens.,-34.0,0.4,sequencevariant
"Doxycycline treatment of A549 cells harboring the BRCA1 c.592C>T sequence variant reduced RAD51 foci formation, suggesting impaired homologous recombination repair.",-27.625,0.4,sequencevariant
Deregulation of the TP53 gene in HeLa cells harboring the c.592C>T sequence variant leads to increased apoptosis and a higher sensitivity to the chemotherapeutic agent doxorubicin.,-29.375,0.4,sequencevariant
"Dysregulation of the p53 pathway in A549 cells carrying the BRCA1 c.592C>T sequence variant was associated with increased sensitivity to doxorubicin, a finding that may explain the higher incidence of chemotherapy‑induced apoptosis observed in patients with the rs11708067‑G allele.",-40.25,0.4,sequencevariant
"Ex vivo CRISPR‑Cas9 editing of the TP53 gene in H1299 cells introduced a c.592C>T sequence variant that, together with a G>C substitution at position +135, produced a C203S amino‑acid change and a Δ30 in the N‑terminal domain, ultimately impairing p53’s transcriptional activity and sensitizing the cells to doxorubicin-induced apoptosis.",-54.75,0.4,sequencevariant
"Exome sequencing of a colorectal carcinoma revealed a c.592C>T variant in the APC gene, a G>C substitution at position135 in KRAS, and a C203S missense change in TP53, all of which were associated with increased tumor aggressiveness.",-43.25,0.4,sequencevariant
"Examination of a colorectal carcinoma sample revealed a BRCA1 c.592C>T sequence variant that co‑occurs with a G>C substitution at position g.3395, suggesting a compound heterozygous mutation that may contribute to the tumor’s aggressive phenotype.",-38.25,0.4,sequencevariant
Exogenous delivery of a CRISPR‑Cas9 plasmid targeting the TP53 c.592C>T variant in A549 cells resulted in a pronounced reduction of mutant protein expression and restored p53‑dependent apoptosis in a dose‑dependent manner.,-40.5,0.4,sequencevariant
"Among HEK293T cells, the BRCA1 c.592C>T sequence variant, which introduces a C203S amino acid change and a deletion of nucleotides g.3395C>T, was shown to impair DNA repair and increase sensitivity to the chemotherapeutic agent doxorubicin.",-42.75,0.4,sequencevariant
"Among cells of the A549 cell line, the c.592C>T sequence variant in the TP53 gene was found to increase the transcription of the pro‑apoptotic BAX gene, while the G>C substitution at position +135 in the promoter of the MDM2 gene reduced its expression, suggesting a combined effect on the p53‑MDM2 regulatory loop.",-60.5,0.4,sequencevariant
"Among patients carrying the BRCA1 c.592C>T sequence variant, the G>C substitution at position G135 and the C203S missense mutation were associated with an increased risk of breast cancer.",-36.75,0.4,sequencevariant
"Among colorectal cancer patients, the BRCA2 c.592C>T sequence variant was associated with a higher risk of resistance to the chemotherapeutic agent doxorubicin, as compared with patients harboring the wild‑type allele.",-36.0,0.4,sequencevariant
"C7orf55 c.592C>T, a missense variant that replaces alanine with threonine at position A53T, was found to destabilize the protein and is associated with increased risk of early‑onset Parkinson’s disease in Homo sapiens.",-43.75,0.4,sequencevariant
Cytosine to guanine substitution at position c.592C>T in the BRCA1 gene (rs11708067-G) was found to increase the risk of breast cancer in a cohort of Homo sapiens patients.,-32.75,0.4,sequencevariant
"Cys203Ser (c.592C>T) in the TP53 gene, together with a G>C substitution at position‑135 (g.3395C>T) and a deletion of amino acids‑809‑852, was found to increase the risk of colorectal cancer in a cohort of Homo sapiens patients carrying the rs11708067‑G allele.",-55.0,0.4,sequencevariant
"C1orf112 c.592C>T, a missense SequenceVariant that replaces a cytosine with thymine at position c.592, was found to increase the risk of early-onset Alzheimer’s disease in a cohort of Homo sapiens patients carrying the rs11708067‑G allele.",-49.75,0.4,sequencevariant
"The BRCA1 c.549delC sequence variant, which deletes a cytosine at position c.549, is associated with a higher risk of breast cancer in women carrying the p.S216P mutation.",-25.625,0.4,sequencevariant
"The p.S216P sequence variant, a glycine-to-glutamine substitution at codon A1762T, was found to disrupt the regulatory domain of the TP53 protein in a cohort of Homo sapiens patients with a CAG repeat expansion.",-33.25,0.4,sequencevariant
"The breast cancer cell line MCF‑7, harboring the BRCA1 c.549delC sequence variant, exhibited increased sensitivity to the chemotherapeutic agent doxorubicin, while the concurrent p.S216P mutation in the TP53 gene amplified the apoptotic response.",-27.0,0.4,sequencevariant
"The c.549delC sequence variant in the TP53 gene, which results in a glycine-to-glutamine substitution at position p.S216P, is associated with increased susceptibility to chemotherapy-induced apoptosis in A549 cells.",-20.625,0.4,sequencevariant
"In HepG2 cells, the c.549delC sequence variant causes a frameshift that truncates the protein at p.S216P, impairing its interaction with the A1762T promoter region and reducing transcription of the G246X gene.",-28.125,0.4,sequencevariant
"In hepatocellular carcinoma patients, the c.549delC sequence variant in the TP53 gene, which causes a glycine-to-glutamine substitution at position p.S216P, is associated with increased tumor aggressiveness and poorer overall survival.",-25.125,0.4,sequencevariant
"In colorectal cancer patients harboring the sequence variant c.549delC, the resulting frameshift leads to a truncated protein that disrupts the normal p.A365E domain, thereby impairing DNA repair and increasing susceptibility to chemotherapeutic toxicity.",-27.75,0.4,sequencevariant
"In the colorectal carcinoma cohort, a novel p.S216P variant in the KRAS gene, resulting from a glycine-to-glutamine substitution, was associated with increased resistance to the EGFR inhibitor cetuximab.",-24.25,0.4,sequencevariant
"A pathogenic sequence variant, c.549delC, causes a frameshift that truncates the protein at p.A365E, leading to loss of function in the tumor suppressor gene TP53 and increasing susceptibility to colorectal cancer in Homo sapiens.",-30.0,0.4,sequencevariant
"A patient with a c.549delC sequence variant in the TP53 gene exhibited a dramatic loss of p53 transcriptional activity, leading to increased tumorigenicity in HeLa cells.",-25.0,0.4,sequencevariant
"A deleterious sequence variant, p.S216P, in the TP53 gene, where a glycine-to-glutamine substitution at codon‑216 disrupts the DNA‑binding domain, is associated with increased risk of Li‑Fraumeni syndrome in Homo sapiens.",-38.75,0.4,sequencevariant
"A HepG2 cell line harboring the BRCA1 c.549delC sequence variant exhibited markedly reduced RAD51 foci formation, implicating the deletion in impaired homologous recombination repair.",-22.375,0.4,sequencevariant
"Patients carrying the sequence variant p.S216P in the TP53 gene, which substitutes a glycine for a glutamine, exhibit increased susceptibility to radiation‑induced apoptosis.",-26.5,0.4,sequencevariant
"Patients harboring the c.549delC sequence variant in the TP53 gene exhibit a higher frequency of p.S216P mutations, which often result in a glycine-to-glutamine substitution that disrupts the protein's DNA‑binding domain.",-29.0,0.4,sequencevariant
Patients with the BRCA1 c.549delC sequence variant exhibit a higher risk of breast cancer compared to carriers of the wild‑type allele.,-18.0,0.4,sequencevariant
Patients bearing the sequence variant p.S216P in the TP53 gene exhibit a markedly increased susceptibility to radiation‑induced apoptosis compared with individuals carrying the wild‑type allele.,-24.75,0.4,sequencevariant
"Mutation p.S216P in the TP53 gene, a glycine to glutamine substitution at codon A1762T, and a G246X truncation in the BRCA1 sequence variant c.549delC collectively impair DNA repair and increase breast cancer risk in Homo sapiens.",-30.875,0.4,sequencevariant
"Mutation c.549delC in the TP53 gene, which deletes a cytosine at position +549, is associated with a truncated protein that predisposes Homo sapiens patients to Li–Fraumeni syndrome.",-34.0,0.4,sequencevariant
"Mutation of the BRCA1 gene to p.S216P, a glycine to glutamine substitution at codon‑216, was associated with an increased risk of breast cancer in a cohort of Homo sapiens patients.",-32.25,0.4,sequencevariant
"Mutation‑induced p.S216P in the TP53 gene, a glycine‑to‑glutamine substitution at codon A1762T, and a G246X nonsense variant together elevate the risk of colorectal carcinoma in Homo sapiens.",-35.0,0.4,sequencevariant
"Recent sequencing of a colorectal cancer biopsy revealed a pathogenic sequence variant, c.549delC, causing a frameshift that truncates the TP53 protein and correlates with loss of p53-dependent apoptosis in the tumor cells.",-34.25,0.4,sequencevariant
"Recent exome sequencing of a colorectal cancer cohort revealed that the c.549delC sequence variant in the APC gene, which causes a frameshift and premature p.Gly216* truncation, is strongly associated with early-onset disease in patients carrying a concurrent CAG repeat expansion in the TGFBR2 promoter.",-45.5,0.4,sequencevariant
"Recent analysis of the BRCA1 c.549delC sequence variant revealed that the resulting frameshift causes a premature G246X truncation, which in turn abolishes the protein’s ability to recruit the homologous recombination factor RAD51 in HeLa cells.",-35.75,0.4,sequencevariant
"Recent studies demonstrate that the BRCA1 sequence variant c.549delC, which deletes a cytosine at position +549, destabilizes the protein and increases breast cancer risk in carriers of the p.S216P mutation.",-40.5,0.4,sequencevariant
"Studies in a cohort of HepG2 cells revealed that the p.S216P variant, which substitutes a glycine for glutamine at position six, leads to a pronounced reduction in the expression of the oncogene MYC, whereas the A1762T mutation in the promoter region of the TP53 gene increases its transcriptional activity by approximately threefold.",-70.0,0.4,sequencevariant
"Studies reveal that the p.S216P sequence variant, a glycine-to-glutamine substitution in the TP53 gene, correlates with increased apoptosis in HeLa cells treated with doxorubicin.",-26.375,0.4,sequencevariant
"Studies show that the p.S216P sequence variant, a glycine-to-glutamine substitution, reduces the binding affinity of the transcription factor to the promoter of the TP53 gene in Homo sapiens cells.",-27.375,0.4,sequencevariant
"Studies of the A1762T, G246X, and c.549delC sequence variants in the hepatitis B virus genome revealed that the A1762T mutation, which converts a glycine to glutamine at position p.S216P, enhances viral replication, whereas the G246X nonsense mutation truncates the core protein and the c.549delC deletion reduces transcriptional activity.",-46.0,0.4,sequencevariant
"Researchers measured that the p.S216P sequence variant, a glycine-to-glutamine substitution at position A1762T, increased the risk of Parkinson’s disease in a cohort of Homo sapiens subjects.",-41.5,0.4,sequencevariant
"Researchers demonstrated that the c.549delC sequence variant in the TP53 gene, which causes a frameshift leading to a premature stop codon, impairs DNA‑damage‑induced apoptosis in A549 cells, thereby increasing their resistance to doxorubicin treatment.",-33.0,0.4,sequencevariant
"Researchers found that the p.S216P sequence variant, a glycine-to-glutamine substitution, increases the risk of early-onset Parkinson’s disease in a cohort of Homo sapiens patients.",-24.625,0.4,sequencevariant
"Researchers discovered that the p.S216P sequence variant, a glycine-to-glutamine substitution at codon‑216, increases the binding affinity of the TP53 protein for the MDM2 promoter in HeLa cells, thereby enhancing apoptosis in response to doxorubicin treatment.",-38.0,0.4,sequencevariant
"Ethanol exposure in HepG2 cells carrying the sequence variant p.S216P, a glycine‑to‑glutamine substitution at codon‑216, enhances CYP2E1 expression and increases reactive oxygen species production.",-36.25,0.4,sequencevariant
Eighty‑five percent of patients with the BRCA1 c.549delC sequence variant exhibit a markedly increased risk of breast cancer compared with carriers of the wild‑type allele.,-27.875,0.4,sequencevariant
"Epidemiological analysis revealed that the BRCA1 c.549delC sequence variant, which causes a glycine to glutamine substitution at position p.S216P, is significantly associated with increased breast cancer risk in a cohort of Homo sapiens patients.",-29.25,0.4,sequencevariant
Echinococcus multilocularis infection in a patient carrying the c.549delC sequence variant of the CYP2D6 gene was associated with a markedly reduced response to primaquine therapy.,-33.75,0.4,sequencevariant
"Mutations such as the p.S216P substitution, the A1762T transition, and the G246X nonsense variant collectively disrupt the normal function of the associated protein, leading to altered cellular signaling pathways in affected individuals.",-32.25,0.4,sequencevariant
"Mutated sequence variant p.S216P, a glycine to glutamine substitution, was found to disrupt the binding of the transcription factor to the promoter region of the gene encoding the protein, thereby reducing its expression in the studied cell line.",-39.75,0.4,sequencevariant
"Mutagenesis of the BRCA1 gene in the HeLa cell line revealed a c.549delC sequence variant that converts a glycine to glutamine at position p.S216P, leading to a truncated protein with a G246X stop codon and a downstream -4-basepair G-to-A substitution that disrupts the normal splicing of exon four.",-51.5,0.4,sequencevariant
"Mutating the TP53 gene in A549 cells to the p.S216P variant, where a glycine is replaced by glutamine, reduces the cells’ ability to arrest the cell cycle after DNA damage.",-28.5,0.4,sequencevariant
"Chromosomal analysis of a colorectal carcinoma sample revealed a c.549delC sequence variant in the APC gene, which is predicted to generate a premature stop codon and disrupt the protein’s regulatory domain.",-32.0,0.4,sequencevariant
"Chromic acid exposure induced a p.S216P sequence variant in the TP53 gene, converting a glycine to glutamine and causing a Lys to Asn substitution at position198, which was associated with increased apoptosis in HeLa cells.",-53.0,0.4,sequencevariant
"Chromatographic analysis of a colorectal carcinoma sample revealed a sequence variant, c.549delC, that results in a frameshift and premature stop codon, and the same tumor harbored a concurrent missense mutation, p.S216P, in the KRAS gene, which together were associated with increased tumor aggressiveness.",-53.75,0.4,sequencevariant
"Chromosome‑wide association studies revealed that the c.549delC sequence variant in the TP53 gene, which results in a glycine to glutamine substitution at position p.S216P, is strongly linked to increased susceptibility to chemotherapy‑induced apoptosis in A549 cell lines.",-38.5,0.4,sequencevariant
"An H. sapiens patient carrying the c.549delC sequence variant in the TP53 gene exhibited a loss of tumor suppressor function, leading to increased susceptibility to colorectal cancer.",-29.0,0.4,sequencevariant
"An experimental study revealed that the c.549delC sequence variant in the TP53 gene, which deletes a cytosine at position +549, reduces p53 protein stability and increases the risk of breast cancer in a cohort of Homo sapiens patients.",-46.5,0.4,sequencevariant
"An investigation of the c.549delC variant in the TP53 gene revealed that the resulting p.S216P protein destabilizes the DNA-binding domain, leading to impaired tumor suppressor activity in HeLa cells.",-32.75,0.4,sequencevariant
"An A1762T substitution in the HBV genome, which changes a lysine to asparagine at position‑198, has been linked to increased viral replication and liver disease severity in patients infected with the G246X variant.",-41.25,0.4,sequencevariant
"Alteration of the BRCA1 sequence variant p.S216P, a glycine‑to‑glutamine substitution at codon‑216, was associated with a higher risk of breast cancer in a cohort of Homo sapiens patients.",-36.25,0.4,sequencevariant
"Altered expression of the tumor suppressor TP53 in HeLa cells harboring the p.S216P sequence variant, a glycine-to-glutamine substitution, leads to increased apoptosis following doxorubicin treatment.",-27.25,0.4,sequencevariant
"Alterations such as the c.549delC variant, the p.S216P substitution, and the G246X nonsense mutation collectively disrupt the normal function of the target protein, leading to impaired cellular signaling in affected individuals.",-30.0,0.4,sequencevariant
"Altering the A1762T sequence variant in the hepatitis B virus genome, which replaces a glycine with glutamine at position p.S216P, increases viral replication and is associated with higher rates of hepatocellular carcinoma in infected Homo sapiens individuals.",-44.0,0.4,sequencevariant
"cDNA sequencing of the patient’s HBB gene revealed a novel c.549delC variant that causes a frameshift and premature p.G246X truncation, while a separate heterozygous p.S216P substitution in the same allele introduces a glycine-to-glutamine change that may alter protein folding and contribute to the observed β‑thalassemia phenotype.",-56.25,0.4,sequencevariant
c‑549delC in the TP53 gene leads to a truncated p53 protein that impairs DNA‑damage‑induced apoptosis in HeLa cells.,-30.625,0.4,sequencevariant
"c.\,549delC in the TP53 gene causes a frameshift that leads to a truncated p.S216P protein, which in turn impairs the DNA‑binding domain and predisposes Homo sapiens cells to malignant transformation.",-40.25,0.4,sequencevariant
"cAMP-dependent protein kinase activation in A549 cells carrying the p.S216P sequence variant of the PRKACA gene was attenuated, suggesting that the glycine to glutamine substitution at this residue disrupts phosphorylation of downstream targets.",-45.5,0.4,sequencevariant
"The BRCA1 c.920T>G (p.Gly594Val) variant, which co‑segregates with rs2144908, has been shown to increase susceptibility to triple‑negative breast cancer in a cohort of Homo sapiens patients.",-20.125,0.4,sequencevariant
The c.920T>G (p.Gly594Val) variant in the KRAS gene (rs6235) was found to increase the risk of colorectal cancer in a cohort of Homo sapiens patients.,-17.625,0.4,sequencevariant
"The discovery that the BRCA1 c.920T>G sequence variant, which results in a Gly594Val substitution, is associated with increased breast cancer risk in individuals carrying the rs2144908 allele, highlights the importance of integrating genetic screening into personalized oncology strategies.",-30.0,0.4,sequencevariant
"The p.G159R sequence variant in the EGFR gene, which is a missense mutation (c.476G>A) found in rs2144908, is associated with increased kinase activity and contributes to the aggressive phenotype of non‑small cell lung carcinoma in patients carrying the H1047R variant in the PI3KCA gene.",-37.25,0.4,sequencevariant
A patient carrying the BRCA1 c.920T>G sequence variant exhibited a markedly increased risk of breast cancer compared with individuals lacking this mutation.,-17.5,0.4,sequencevariant
"A p.G159R variant in the KRAS gene (c.476G>A) was found to increase the risk of colorectal cancer in patients carrying the rs2144908 allele, while the H1047R mutation in PIK3CA (c.3140A>G) was associated with resistance to EGFR‑targeted therapy.",-28.25,0.4,sequencevariant
"A CRISPR‑generated HeLa cell line harboring the BRCA1 c.920T>G sequence variant, which introduces a Gly594Val substitution, exhibited increased resistance to the DNA‑damaging agent doxorubicin compared with the wild‑type cells.",-27.75,0.4,sequencevariant
"A heterozygous c.920T>G variant in the KRAS gene, corresponding to the p.Gly594Val substitution, was found to increase the risk of colorectal cancer in a cohort of Homo sapiens patients carrying the rs6235 allele.",-22.875,0.4,sequencevariant
"In the A549 cell line, the c.920T>G SequenceVariant in the EGFR GeneOrGeneProduct was found to increase sensitivity to the ChemicalEntity erlotinib, while the rs2144908 polymorphism in the KRAS GeneOrGeneProduct correlated with a higher incidence of non‑small cell Lung Cancer in Homo sapiens patients.",-33.5,0.4,sequencevariant
"In HCT116 cells, the c.920T>G sequence variant in the KRAS gene (p.Gly594Val) increases the binding affinity of the H1047R mutant EGFR protein, thereby enhancing downstream PI3K/AKT signaling and promoting chemoresistance.",-34.0,0.4,sequencevariant
"In colorectal cancer cell lines, the sequence variant c.920T>G in the KRAS gene, which produces the p.Gly594Val substitution, was found to increase sensitivity to the small‑molecule inhibitor trametinib, whereas the R620W variant in the PIK3CA gene conferred resistance to the same drug.",-37.0,0.4,sequencevariant
"In A549 cells harboring the c.920T>G (p.Gly594Val) variant, the mutant protein R620W exhibits increased kinase activity, leading to enhanced phosphorylation of downstream targets and promoting resistance to doxorubicin treatment.",-33.25,0.4,sequencevariant
"Functional analysis of the c.920T>G (p.Val539Asp) variant in the KRAS gene revealed that the mutant allele, which is associated with the rs2144908 SNP, confers increased kinase activity and promotes uncontrolled proliferation in A549 cells.",-41.5,0.4,sequencevariant
"Functional studies revealed that the p.G159R sequence variant in the PIK3CA gene, which co‑occurs with the H1047R mutation and the rs2144908 SNP, significantly increases PI3K signaling in A549 cells, thereby enhancing proliferation and resistance to rapamycin.",-40.75,0.4,sequencevariant
"Functional characterization of the c.920T>G (p.Val539Asp) variant in the PTEN gene revealed that this sequence variant, which is associated with rs2144908, reduces phosphatase activity and predisposes Homo sapiens patients to early-onset breast cancer.",-37.0,0.4,sequencevariant
"Functional consequences of the BRCA1 c.920T>G sequence variant, which produces the p.Gly594Val substitution, were confirmed by observing increased DNA repair deficiency and heightened breast cancer risk in carriers of the rs2144908 allele.",-35.75,0.4,sequencevariant
"Gain‐of‑function mutations such as H1047R in PIK3CA and the c.920T>G variant in BRCA1, both of which have been reported to increase breast cancer risk, were found to activate downstream AKT signaling in MCF‑7 cells.",-43.75,0.4,sequencevariant
Gain-of-function mutations such as the H1047R variant in PIK3CA and the rs2144908 SNP in the promoter of VEGFA synergistically increase endothelial cell proliferation and angiogenesis in colorectal cancer models.,-33.5,0.4,sequencevariant
"Gain‑of‑function mutations such as the H1047R variant in PIK3CA and the R620W substitution in LRP1B have been shown to increase the proliferation of A549 cells, while the c.920T>G change in BRCA1 correlates with heightened DNA‑damage sensitivity in Homo sapiens breast cancer samples.",-52.0,0.4,sequencevariant
Gain of the H1047R sequence variant in the PIK3CA gene in A549 cells increases PI3K signaling and confers resistance to the EGFR inhibitor gefitinib.,-27.5,0.4,sequencevariant
"Toxicity of the EGFR inhibitor gefitinib is markedly increased in A549 cells harboring the H1047R sequence variant of the PIK3CA gene, as demonstrated by elevated phospho‑AKT signaling and reduced cell viability.",-34.75,0.4,sequencevariant
"Tobacco‑induced lung carcinoma cells harboring the EGFR H1047R sequence variant exhibit markedly increased phospho‑AKT signaling and resistance to erlotinib, whereas cells with the KRAS p.G159R variant show enhanced MAPK activation and sensitivity to MEK inhibition.",-42.25,0.4,sequencevariant
"T cells from a patient with the BRCA1 c.920T>G variant exhibited increased apoptosis upon cisplatin exposure, suggesting that this sequence variant may sensitize tumor cells to DNA‑damaging chemotherapy.",-32.25,0.4,sequencevariant
Treated A549 cells harboring the KRAS H1047R sequence variant exhibited a marked increase in phospho‑ERK1/2 signaling and enhanced resistance to the MEK inhibitor trametinib.,-29.375,0.4,sequencevariant
"Using CRISPR-Cas9 editing, the H1047R variant of the PIK3CA gene was introduced into A549 cells, where it increased PI3K signaling and conferred resistance to the EGFR inhibitor gefitinib.",-27.75,0.4,sequencevariant
"Using a CRISPR‑Cas9 approach, the engineered A549 cell line carrying the TP53 c.920T>G sequence variant exhibited a markedly increased sensitivity to the chemotherapeutic agent doxorubicin compared with the wild‑type counterpart.",-37.75,0.4,sequencevariant
"Using the CRISPR‑Cas9 system, we introduced the c.920T>G sequence variant into the H1047R‑mutated KRAS gene of A549 cells, and the resulting p.Gly594Val mutation increased PI3K/AKT signaling and conferred resistance to the EGFR inhibitor erlotinib.",-44.25,0.4,sequencevariant
"Using LNCaP cells, the H1047R sequence variant in the PIK3CA gene was shown to increase AKT phosphorylation and confer resistance to the PI3K inhibitor alpelisib.",-31.875,0.4,sequencevariant
"Allelic variation p.G159R in the KRAS gene, which co‑occurs with the H1047R mutation in PIK3CA, has been shown to increase the risk of metastatic colorectal cancer in patients carrying the rs2144908 SNP.",-34.5,0.4,sequencevariant
"Allele rs2144908, encoding the p.G159R variant in the KRAS gene, was found to increase the risk of colorectal cancer in a cohort of Homo sapiens patients.",-25.375,0.4,sequencevariant
"Alleles carrying the sequence variant c.920T>G in the EGFR gene, such as the H1047R mutation, have been shown to increase the sensitivity of A549 cells to the tyrosine‑kinase inhibitor gefitinib, thereby reducing tumor cell proliferation in vitro.",-40.0,0.4,sequencevariant
"Alleys of the H1047R mutation in the PIK3CA gene, which is a sequence variant, were found to increase the risk of breast cancer in patients carrying the rs2144908 allele and to alter the response to the drug rapamycin in the MCF‑7 cell line.",-59.0,0.4,sequencevariant
"Patients harboring the sequence variant c.920T>G in the EGFR gene, which results in the H1047R substitution, exhibit markedly increased tumor cell proliferation and resistance to first‑line tyrosine‑kinase inhibitors.",-24.25,0.4,sequencevariant
"Patients with the c.920T>G sequence variant in the EGFR gene, which results in the H1047R amino acid substitution, exhibit increased resistance to first‑line tyrosine‑kinase inhibitors in non‑small‑cell lung carcinoma cell lines such as A549.",-28.875,0.4,sequencevariant
Patients heterozygous for the BRCA1 c.920T>G sequence variant exhibited a markedly higher risk of developing breast cancer compared with carriers of the wild‑type allele.,-25.625,0.4,sequencevariant
"Patients carrying the c.920T > G sequence variant in the EGFR gene exhibit increased sensitivity to gefitinib, a small‑molecule tyrosine‑kinase inhibitor, and display a higher incidence of drug‑induced rash compared with patients with the wild‑type allele.",-37.25,0.4,sequencevariant
"Mutations such as p.G159R and H1047R in the EGFR gene, together with the rs2144908 SNP, have been linked to increased resistance to tyrosine‑kinase inhibitors in non‑small cell lung carcinoma cell lines.",-23.25,0.4,sequencevariant
"Mutagenesis of the KRAS gene in the A549 cell line revealed a c.920T>G (p.Val539Asp) sequence variant that conferred resistance to the EGFR inhibitor gefitinib, while the concurrent rs2144908 polymorphism in the promoter region amplified downstream MAPK signaling.",-37.75,0.4,sequencevariant
"Mutational analysis of the KRAS gene in colorectal carcinoma revealed a p.Gly594Val variant that co‑occurs with the H1047R sequence variant in the PI3KCA gene, and the rs2144908 polymorphism in the TP53 gene, suggesting a synergistic effect on tumor aggressiveness.",-39.75,0.4,sequencevariant
"Mutant KRAS p.Gly12Asp (c.35G>A) in the A549 cell line, a variant associated with rs2144908, enhances MAPK signaling and confers resistance to the EGFR inhibitor gefitinib in Homo sapiens lung carcinoma cells.",-38.25,0.4,sequencevariant
Mutation of the KRAS gene at c.920T>G (p.Gly594Val) in a colorectal carcinoma cell line derived from a patient with the rs2144908 allele was shown to increase phospho‑ERK signaling and confer resistance to cetuximab.,-33.75,0.4,sequencevariant
"Mutation c.920T>G in the PTEN gene, which encodes the tumor suppressor protein, was found to increase the risk of sporadic colorectal cancer in individuals carrying the rs2144908 allele.",-25.625,0.4,sequencevariant
"Mutation p.G159R in the EGFR gene, which is a sequence variant, is associated with increased resistance to erlotinib in non‑small cell lung carcinoma cells derived from a patient with a homozygous rs2144908 allele.",-32.25,0.4,sequencevariant
"Mutation R620W in the PTEN gene, identified by rs2144908, was associated with increased tumor growth in A549 cells treated with the chemical entity rapamycin.",-30.125,0.4,sequencevariant
CRISPR‑edited HCT116 cells harboring the TP53 c.920T>G (p.P307R) sequence variant exhibited a marked reduction in p53‑dependent transcription of the CDKN1A gene and increased resistance to doxorubicin compared with wild‑type cells.,-32.75,0.4,sequencevariant
"CRL-12345 cells harboring the c.920T>G sequence variant in the KRAS gene exhibit markedly increased sensitivity to the PI3K inhibitor GDC‑0941, a response that is amplified by the concurrent H1047R mutation in PIK3CA.",-46.5,0.4,sequencevariant
CR‑ISPR‑edited A549 cells harboring the c.920T>G (p.Val539Asp) variant in the EGFR gene exhibit a markedly increased sensitivity to erlotinib compared with wild‑type A549 cells.,-34.75,0.4,sequencevariant
"CRITICAL: The p.G159R sequence variant in the PTEN gene, identified by rs2144908, was found to increase phosphorylation of AKT and correlate with heightened tumor aggressiveness in a cohort of Homo sapiens patients.",-49.5,0.4,sequencevariant
"Silencing of the KRAS c.920T>G variant (p.H1047R) in A549 cells reduces downstream ERK phosphorylation, thereby attenuating the proliferative advantage conferred by the oncogenic H1047R mutation.",-34.0,0.4,sequencevariant
Silico‑analysis of the TP53 c.920T>G sequence variant revealed a p.Gly594Val substitution that correlates with increased risk of breast cancer in individuals carrying the rs2144908 allele.,-29.25,0.4,sequencevariant
"Silica‑treated A549 cells harboring the c.920T>G sequence variant in the EGFR gene exhibit markedly increased phosphorylation of downstream AKT and MAPK pathways, suggesting that this mutation may sensitize the cells to tyrosine‑kinase inhibitor therapy.",-37.25,0.4,sequencevariant
"Silicon‑based CRISPR editing of the KRAS gene in A549 cells revealed that the c.920T>G (p.P307R) sequence variant increases the binding affinity of the H1047R mutant protein for the PI3K pathway, thereby enhancing downstream AKT phosphorylation and promoting chemoresistance to doxorubicin.",-44.75,0.4,sequencevariant
"Individuals carrying the c.920T>G sequence variant in the EGFR gene exhibit increased tumor cell proliferation, and the presence of the rs2144908 SNP in the same locus is associated with a higher risk of developing non‑small cell lung carcinoma.",-37.75,0.4,sequencevariant
Individuals harboring the BRCA1 c.920T>G (p.Val539Asp) variant exhibit a markedly increased risk of breast cancer compared with carriers of the wild‑type allele.,-24.0,0.4,sequencevariant
Individuals with the BRCA1 c.920T>G sequence variant exhibit a higher propensity for triple‑negative breast cancer compared with carriers of the wild‑type allele.,-23.125,0.4,sequencevariant
Individuals homozygous for the c.920T>G sequence variant in the BRCA1 gene exhibit a markedly increased risk of breast cancer compared with carriers of the wild‑type allele.,-26.125,0.4,sequencevariant
"A missense sequence variant c.1138G>C in the TP53 gene, resulting in a glycine-to-glutamine substitution at position p.R428C, has been associated with increased susceptibility to colorectal cancer in individuals carrying the rs10973794 allele.",-27.0,0.4,sequencevariant
"A novel c.1138G>C sequence variant in the TP53 gene, resulting in a glycine to glutamine substitution at codon p.R428C, was found to increase the risk of breast cancer in a cohort of Homo sapiens patients carrying the rs10973794 allele.",-32.0,0.4,sequencevariant
"A deleterious sequence variant, c.1138G > C, in the TP53 gene produces a glycine to glutamine substitution at codon p.R428C, which has been associated with increased risk of colorectal cancer in individuals carrying the rs10973794 allele.",-32.25,0.4,sequencevariant
"A pathogenic sequence variant, c.1138G>C, in the TP53 gene causes a glycine-to-glutamine substitution at codon p.R428C, which has been associated with increased susceptibility to colorectal cancer in individuals of Homo sapiens ancestry.",-32.75,0.4,sequencevariant
"The BRCA1 c.1138G > C (p.R428C) variant, which replaces a glycine with glutamine at position GAC/GAT, has been associated with a higher risk of breast cancer in carriers of the rs10973794 allele.",-25.0,0.4,sequencevariant
"The p.R428C sequence variant in the TP53 gene, which substitutes arginine with cysteine at codon‑428, is associated with a higher risk of early‑onset colorectal cancer in individuals of East Asian descent.",-32.5,0.4,sequencevariant
"The c.1138G>C sequence variant in the TP53 gene, which results in a glycine to glutamine substitution at codon p.R428C, is associated with increased susceptibility to chemotherapy‑induced apoptosis in HeLa cells.",-25.375,0.4,sequencevariant
"The CRISPR‑Cas9‑edited A549 cells harboring the c.1138G>C (p.R428C) sequence variant exhibit a markedly reduced response to doxorubicin, while the wild‑type cells retain the expected apoptotic profile.",-29.5,0.4,sequencevariant
"Patients exposed to the c.1138G > C sequence variant in the CYP2D6 gene exhibited a markedly reduced metabolic clearance of the antipsychotic drug risperidone, leading to increased plasma concentrations and a higher incidence of extrapyramidal side effects.",-35.25,0.4,sequencevariant
"Patients bearing the c.1138G>C (p.R428C) variant in the CYP2D6 gene exhibit markedly reduced metabolism of the antipsychotic drug olanzapine, leading to higher plasma concentrations and increased risk of extrapyramidal side effects.",-28.375,0.4,sequencevariant
"Patients harboring the c.1138G > C variant, which results in a glycine to glutamine substitution at position p.R428C, exhibit markedly increased risk of developing Parkinson’s disease.",-29.875,0.4,sequencevariant
Patients carrying the c.1138G>C sequence variant in the BRCA1 gene exhibit a higher risk of breast cancer compared with carriers of the wild‑type allele.,-20.0,0.4,sequencevariant
"In colorectal carcinoma cells, the c.1138G>C sequence variant (p.Gly380Gln) in the APC gene was found to disrupt the interaction between β‑catenin and TCF‑4, thereby enhancing oncogenic transcriptional activity.",-30.125,0.4,sequencevariant
"In HeLa cells harboring the sequence variant c.1138G>C, the p.R428C mutation in the TP53 gene reduces binding to the MDM2 promoter, thereby enhancing p53-mediated apoptosis.",-23.5,0.4,sequencevariant
"In neuroblastoma cell lines, the c.1138G>C sequence variant in the ALK gene, which results in a glycine to glutamine substitution at position p.R428C, is associated with increased resistance to crizotinib treatment.",-32.75,0.4,sequencevariant
"In fibroblasts derived from a patient with the c.1138G > C (p.R428C) sequence variant, the GAC/GAT codon change leads to a glycine to glutamine substitution at position E359K, resulting in altered protein stability and increased susceptibility to oxidative stress.",-36.0,0.4,sequencevariant
"An A549 cell line transfected with the c.1138G>C sequence variant in TP53, which results in a glycine to glutamine substitution at position p.R428C, shows increased sensitivity to doxorubicin compared to the wild‑type TP53.",-35.0,0.4,sequencevariant
An LNCaP cell line harboring the c.1138G>C (p.Gly380Arg) sequence variant in the androgen receptor gene exhibited markedly increased transcription of the PSA gene compared with the wild‑type LNCaP cells.,-29.5,0.4,sequencevariant
"An engineered CRISPR-Cas9 system targeting the TP53 locus introduced a c.1138G>C sequence variant, which produces a glycine-to-glutamine substitution at position p.R428C and is predicted to alter the DNA-binding domain of the p53 protein.",-42.5,0.4,sequencevariant
"An mRNA sequencing study of colorectal cancer samples revealed that the sequence variant c.1138G>C in the KRAS gene, which results in a glycine-to-glutamine substitution at codon p.R428C, is associated with increased tumor aggressiveness and poorer overall survival.",-43.0,0.4,sequencevariant
"Mutation p.R428C in the TP53 gene, a c.1138G > C variant, is associated with increased risk of colorectal cancer in individuals carrying the rs10973794 allele.",-23.125,0.4,sequencevariant
"Mutation c.1138G>C in the TP53 gene, which replaces glycine with glutamine at codon p.R428C, has been associated with an increased risk of sporadic colorectal cancer in Homo sapiens.",-28.875,0.4,sequencevariant
Mutation of the TP53 gene to the p.R428C sequence variant in a HeLa cell line carrying the rs10973794 SNP was shown to reduce DNA repair capacity and increase sensitivity to the chemotherapeutic drug doxorubicin.,-30.25,0.4,sequencevariant
"Mutation rs10973794 in the TP53 gene, which results in the p.R428C amino‑acid substitution, was found to increase the risk of developing colorectal cancer in a cohort of Homo sapiens patients.",-25.75,0.4,sequencevariant
"Mutations such as c.1138G>C and the rs10973794 variant, which cause a glycine to glutamine substitution at position GAC/GAT, have been shown to increase the risk of Parkinson’s disease in Homo sapiens.",-27.875,0.4,sequencevariant
"Mutating the TP53 gene to the c.1138G>C variant (p.R428C) in HeLa cells reduces p53‑dependent apoptosis, while the E359K substitution in the same gene increases resistance to doxorubicin in A549 cells.",-36.25,0.4,sequencevariant
"Mutational analysis of the TP53 gene in colorectal carcinoma revealed a c.1138G>C sequence variant that generates a glycine to glutamine substitution at codon p.R428C, which is associated with increased tumor aggressiveness.",-35.5,0.4,sequencevariant
"Mutagenesis of the TP53 gene in HeLa cells introduced the c.1138G>C sequence variant, which replaces glycine with glutamine at position p.R428C and is associated with increased apoptosis in response to doxorubicin treatment.",-35.25,0.4,sequencevariant
"Expression of the TP53 p.R428C sequence variant in A549 cells increases sensitivity to doxorubicin, leading to higher rates of apoptosis compared with the wild‑type TP53 sequence.",-28.75,0.4,sequencevariant
Expression analysis of the BRCA1 c.1138G>C (p.R428C) variant in a cohort of breast cancer patients revealed a statistically significant increase in the risk of triple‑negative disease compared with carriers of the wild‑type allele.,-38.25,0.4,sequencevariant
"Expression levels of the TP53 gene were markedly reduced in HeLa cells carrying the c.1138G>C sequence variant, which was associated with increased sensitivity to doxorubicin treatment.",-31.125,0.4,sequencevariant
"Expression profiling revealed that the BRCA1 c.1138G>C (p.R428C) variant, which replaces glycine with glutamine at position GAC/GAT, is associated with increased breast cancer risk in individuals carrying the rs10973794 allele.",-41.0,0.4,sequencevariant
"Detection of the c.1138G>C sequence variant in the CYP2D6 gene, which results in a glycine-to-glutamine substitution at position p.Gly403, was associated with reduced metabolic activity of the enzyme in a cohort of Homo sapiens subjects carrying the rs10973794 allele.",-45.5,0.4,sequencevariant
"Detection that the c.1138G > C sequence variant in the GAC/GAT gene causes a glycine to glutamine substitution at position p.R428C, which is associated with an increased risk of Parkinson’s disease in individuals carrying the rs10973794 allele, was confirmed by Sanger sequencing of a cohort of Homo sapiens patients.",-57.25,0.4,sequencevariant
"Detection in a cohort of colorectal cancer patients revealed that the c.1138G>C sequence variant, annotated as p.R428C, was associated with a higher frequency of the rs10973794 SNP and a significant increase in tumor aggressiveness.",-47.25,0.4,sequencevariant
"Detection showed that the c.1138G > C sequence variant, which substitutes glycine for glutamine at position p.R428C, was strongly associated with increased risk of Parkinson’s disease in a cohort of Homo sapiens.",-47.75,0.4,sequencevariant
"Alterations such as the c.1138G>C sequence variant in the TP53 gene, which replaces glycine with glutamine at position p.R428C, have been linked to increased susceptibility to chemotherapy-induced apoptosis in HeLa cells.",-34.5,0.4,sequencevariant
Altered expression of the TP53 gene in HeLa cells harboring the c.1138G>C sequence variant (p.R428C) reduces apoptosis and enhances resistance to doxorubicin treatment.,-27.75,0.4,sequencevariant
"Alteration of the TP53 sequence variant c.1138G>C, which results in a glycine to glutamine substitution at codon p.R428C, has been shown to increase the risk of early‑onset colorectal cancer in individuals of Homo sapiens ancestry.",-36.5,0.4,sequencevariant
"Alterative therapy with the small molecule doxorubicin induces a dose‑dependent up‑regulation of the pro‑apoptotic gene TP53 in A549 cells, while the presence of the BRCA1 c.1138G>C sequence variant attenuates the drug‑mediated activation of the DNA‑damage response pathway.",-53.25,0.4,sequencevariant
"Loss-of-function mutations such as c.1138G>C, which replaces glycine with glutamine at position p.R428C, have been linked to increased susceptibility to neurodegenerative disease in Homo sapiens.",-35.5,0.4,sequencevariant
"Loss of the p.R428C variant in the TP53 gene, which replaces arginine with cysteine at codon‑428, is associated with a higher risk of early‑onset colorectal cancer in patients carrying the rs10973794 allele.",-35.75,0.4,sequencevariant
Loss‑of‑function of the TP53 gene caused by the c.1138G>C sequence variant (p.R428C) is associated with a higher risk of breast cancer in individuals carrying the rs10973794 allele.,-32.5,0.4,sequencevariant
"Losses of the c.1138G>C variant in the BRCA1 gene, which substitutes glycine for glutamine at position p.R428C, are associated with increased breast cancer risk in individuals carrying the rs10973794 allele.",-41.5,0.4,sequencevariant
"Cell lines derived from the A549 lung carcinoma were engineered to carry the BRCA1 c.1138G>C sequence variant, which introduces a glycine to glutamine substitution at position p.R428C and was shown to increase sensitivity to the DNA‑damaging agent doxorubicin.",-38.75,0.4,sequencevariant
Cell line A549 harboring the sequence variant c.1138G>C in the TP53 gene shows increased sensitivity to doxorubicin compared with the wild‑type TP53 A549 cells.,-23.25,0.4,sequencevariant
"Cell culture of A549 cells harboring the c.1138G>C sequence variant in the TP53 gene exhibited a marked increase in apoptosis upon treatment with doxorubicin, suggesting that this mutation enhances drug sensitivity.",-33.25,0.4,sequencevariant
"Cell-based assays revealed that the BRCA1 c.1138G>C (p.Gly380Arg) sequence variant, which alters a glycine to glutamine substitution at codon GAC/GAT, markedly increases DNA repair deficiency in MCF-7 cells.",-43.25,0.4,sequencevariant
"Defects in the BRCA1 c.1138G > C variant, which results in a glycine to glutamine substitution at position p.R428C, have been shown to increase susceptibility to triple‑negative breast cancer in individuals of European ancestry carrying the rs10973794 allele.",-36.5,0.4,sequencevariant
"Deficiency of the p.R428C variant in the ATP7B gene, which replaces a glycine with glutamine at codon c.1138G>C, is associated with a higher risk of Wilson disease in individuals carrying the rs10973794 allele.",-36.75,0.4,sequencevariant
Deficient tumor suppressor activity in colorectal cancer cells harboring the c.1138G>C (p.R428C) sequence variant was linked to increased β‑catenin signaling and enhanced cell proliferation.,-35.5,0.4,sequencevariant
"Deficiencies in the p.R428C variant of the CFTR gene, which replaces arginine with cysteine at codon‑428, have been linked to a milder form of cystic fibrosis in individuals carrying the rs10973794 allele.",-44.25,0.4,sequencevariant
"RNA sequencing of a colorectal carcinoma sample revealed a c.1138G>C sequence variant in the KRAS gene, resulting in a glycine-to-glutamine substitution at codon p.R428C, which was associated with increased tumor cell proliferation and resistance to cetuximab therapy.",-39.75,0.4,sequencevariant
"RNA‑seq analysis of a colorectal carcinoma sample revealed a c.1138G>C sequence variant in the APC gene, resulting in a p.R428C substitution that correlates with increased β‑catenin signaling and aggressive tumor phenotype.",-32.5,0.4,sequencevariant
"RNA editing of the GAC/GAT codon in the ATPase gene, producing a glycine to glutamine substitution at position p.R428C, was found to correlate with increased risk of Parkinson’s disease in individuals carrying the rs10973794 allele.",-43.0,0.4,sequencevariant
"RNA polymerase II transcription of the TP53 gene in HeLa cells is markedly reduced when the c.1138G>C sequence variant creates a glycine-to-glutamine substitution at codon p.R428C, thereby impairing the binding of the transcription factor NF‑κB and contributing to the observed increase in apoptosis during doxorubicin treatment.",-56.0,0.4,sequencevariant
"The A549 cell line harboring the BRCA1 c.310G>T variant exhibited increased sensitivity to doxorubicin, suggesting that the sequence variant modulates drug response.",-18.125,0.4,sequencevariant
"The BRCA1 c.310 G>T (p.Gly104Ter) variant, which replaces a glutamate with glycine at position S140G, was found to increase the risk of breast cancer in a cohort of Homo sapiens patients carrying the rs204890 allele.",-27.5,0.4,sequencevariant
"The missense variant p.G159R in the TP53 gene, which replaces glutamate with glycine at codon S140G, has been shown to destabilize the DNA‑binding domain and increase the risk of early‑onset breast cancer in patients carrying the rs204890 allele.",-33.0,0.4,sequencevariant
"The S140G sequence variant in the TP53 gene, identified by rs204890, is associated with increased apoptosis in HeLa cells treated with doxorubicin.",-16.25,0.4,sequencevariant
Deletion of the BRCA1 c.310G>T variant in a BRCA1 c.217_218insC carrier reduces the risk of triple‑negative breast cancer in a family of Homo sapiens.,-32.25,0.4,sequencevariant
"Deletion variant c.310G>T in the TP53 gene was found to reduce p53-mediated apoptosis in HeLa cells, while the missense mutation p.G159R in the BRCA1 gene was associated with increased DNA repair activity in A549 cells.",-42.25,0.4,sequencevariant
"Deletion at c.310 G>T in the TP53 gene, which converts a glutamate to glycine at position S140G, is associated with increased risk of early‑onset colorectal cancer in a cohort of Homo sapiens patients.",-43.75,0.4,sequencevariant
Deletion c.310G>T in the TP53 gene’s DNA-binding domain is associated with a higher risk of breast cancer in patients carrying the rs204890 polymorphism.,-33.25,0.4,sequencevariant
"A missense sequence variant, c.310 G>T, in the TP53 gene results in a glutamate-to-glycine substitution that is associated with increased susceptibility to Li‑Fraumeni syndrome in a cohort of Homo sapiens patients.",-27.375,0.4,sequencevariant
"A c.310 G>T sequence variant in the TP53 gene, which substitutes a glutamate for glycine at position S140G, has been associated with increased susceptibility to chemotherapy‑induced apoptosis in HeLa cells.",-29.625,0.4,sequencevariant
"A single nucleotide polymorphism rs204890, which results in the p.G159R sequence variant in the TP53 gene, has been shown to increase the risk of colorectal cancer in individuals of East Asian ancestry.",-29.75,0.4,sequencevariant
A HeLa cell line harboring the BRCA1 c.310G>T sequence variant exhibited a marked increase in homologous recombination repair activity compared with wild‑type cells.,-20.5,0.4,sequencevariant
"In pancreatic ductal adenocarcinoma, the c.310 G>T sequence variant in the KRAS gene, which replaces glutamate with glycine at position S140G, has been shown to enhance oncogenic signaling and correlate with poorer patient survival.",-30.625,0.4,sequencevariant
"In the colorectal carcinoma cohort, the c.310 G>T sequence variant in the APC gene was associated with a higher frequency of microsatellite instability and a distinct response to the chemotherapeutic agent irinotecan.",-33.25,0.4,sequencevariant
"In A549 cells, the BRCA1 c.310 G>T sequence variant reduces DNA repair capacity, thereby increasing sensitivity to doxorubicin-induced apoptosis.",-21.0,0.4,sequencevariant
"In vitro studies revealed that the BRCA1 sequence variant c.310G>T, which substitutes glutamate with glycine at position S140G, markedly reduced homologous recombination efficiency in HeLa cells, while the concomitant G1899A mutation in the same allele further impaired RAD51 recruitment.",-44.0,0.4,sequencevariant
"Patients with the BRCA1 c.310G>T sequence variant exhibit a markedly increased risk of breast cancer, while carriers of the rs204890 SNP in the MTHFR gene display altered folate metabolism and a higher likelihood of neural tube defects.",-30.0,0.4,sequencevariant
"Patients carrying the BRCA1 c.310G>T variant, which replaces a glutamate with glycine at position S140G, exhibit a markedly increased risk of breast cancer compared to carriers of the wild‑type allele.",-27.375,0.4,sequencevariant
Patients harboring the BRCA1 c.310 G>T variant exhibit a markedly increased risk of breast cancer compared with carriers of the wild‑type allele.,-19.625,0.4,sequencevariant
"Patients treated with the novel inhibitor exhibited a marked reduction in tumor growth, and sequencing of the tumor DNA revealed a c.310G>T sequence variant that introduced a glutamate-to-glycine substitution at position S140G in the KRAS gene, a change that likely contributed to the drug’s efficacy.",-50.0,0.4,sequencevariant
Genetically engineered A549 cells carrying the c.310G>T (p.Gly104Val) sequence variant exhibit a markedly reduced response to the chemotherapeutic agent doxorubicin compared with wild‑type cells.,-31.375,0.4,sequencevariant
"Genomic analysis of a colorectal carcinoma cohort revealed that the c.310G>T sequence variant, which substitutes glutamate with glycine at position p.G159R, is strongly associated with increased expression of the KRAS oncogene in A549 cells.",-40.25,0.4,sequencevariant
"Genetic analysis of a colorectal carcinoma cohort revealed that the c.310G>T variant in the APC gene, together with the rs204890 SNP, was associated with a higher frequency of the S140G sequence variant in the downstream KRAS exon, suggesting a potential cooperative effect on tumor progression.",-39.5,0.4,sequencevariant
"Genotyping of the A549 cell line revealed a c.310G>T sequence variant that co‑occurs with a p.G159R mutation in the TP53 gene, suggesting a potential synergistic effect on apoptosis regulation.",-33.0,0.4,sequencevariant
"Mutation p.G159R in the TP53 gene, which replaces glutamate with glycine at codon G159, was found to increase the risk of colorectal cancer in a cohort of Homo sapiens patients carrying the rs204890 allele.",-32.75,0.4,sequencevariant
"Mutation c.310G>T in the TP53 gene, which causes a glutamate‑to‑glycine substitution at position S140G, was found to increase the risk of colorectal cancer in a cohort of Homo sapiens patients carrying the rs204890 allele.",-29.125,0.4,sequencevariant
"Mutation of the TP53 gene to the p.G159R variant in a HeLa cell line carrying the rs204890 allele was shown to increase sensitivity to doxorubicin, thereby reducing the IC50 from approximately five to two micromolar.",-54.5,0.4,sequencevariant
"Mutation s.217_218insC in the TP53 gene, which introduces a glutamate‑by‑glycine substitution at position G159R, has been linked to increased susceptibility to early‑onset breast cancer in a cohort of Homo sapiens carriers.",-43.0,0.4,sequencevariant
"Detection of the c.310G>T variant in the TP53 gene, which substitutes glutamate for glycine at codon S140G, was associated with a higher risk of early‑onset colorectal cancer in a cohort of Homo sapiens patients.",-40.75,0.4,sequencevariant
Detection and functional characterization of the BRCA1 c.310G>T sequence variant revealed that the glutamate-to-glycine substitution at position S140G disrupts DNA repair activity in HeLa cells.,-36.75,0.4,sequencevariant
Detection that the BRCA1 c.310G>T sequence variant creates a glutamate‑by‑glycine substitution at codon S140G was associated with increased breast cancer risk in a cohort of Homo sapiens patients.,-39.5,0.4,sequencevariant
"Detection in a colorectal carcinoma sample of the sequence variant c.310 G>T, which results in a glutamate-to-glycine substitution at position S140G, was associated with increased expression of the oncogenic gene MYC in the patient’s tumor tissue.",-49.75,0.4,sequencevariant
"Sequencing of the TP53 gene in the HeLa cell line revealed a novel sequence variant, c.310G>T, that results in a p.Gly104Val substitution and is predicted to disrupt the DNA‑binding domain, thereby impairing p53‑mediated transcriptional activation of the CDKN1A gene.",-38.75,0.4,sequencevariant
"Sequenced tumor DNA from a colorectal carcinoma patient revealed a novel c.310G>T sequence variant that results in a glutamate-to-glycine substitution at position S140G, which is predicted to disrupt the protein's active site and may confer resistance to the chemotherapeutic agent oxaliplatin.",-44.5,0.4,sequencevariant
"Sequencetranscriptomic analysis revealed that the BRCA1 c.310 G>T variant, which substitutes glutamate with glycine at position p.G159R, is associated with increased DNA repair deficiency in breast cancer cell lines.",-43.5,0.4,sequencevariant
"Sequenza analysis revealed that the BRCA1 c.310 G>T variant, which substitutes glutamate with glycine at position p.G159R, co‑occurs with the pathogenic G1899A mutation in the same patient, suggesting a compound heterozygous effect on DNA repair.",-52.25,0.4,sequencevariant
"Mutations such as the c.310G>T variant, the rs204890 SNP, and the p.G159R amino‑acid substitution in the TP53 gene have been linked to increased risk of colorectal cancer in patients with a family history of the disease.",-34.5,0.4,sequencevariant
"Mutating the TP53 gene to the c.310G>T variant in HeLa cells reduces p53 protein stability, thereby increasing the likelihood of apoptosis resistance in response to doxorubicin treatment.",-28.625,0.4,sequencevariant
"Mutational analysis of the TP53 gene in a cohort of colorectal cancer patients revealed that the c.310 G>T variant, which results in a glutamate-to-glycine substitution at codon S140G, was significantly associated with increased tumor aggressiveness and poorer overall survival.",-32.75,0.4,sequencevariant
"Mutant A549 cells harboring the BRCA1 c.310G>T sequence variant exhibit increased sensitivity to the DNA‑damaging agent doxorubicin, a response that correlates with up‑regulation of the p53‑dependent gene GADD45A.",-29.5,0.4,sequencevariant
"SNP rs204890, a c.310G>T sequence variant in the promoter of the CYP2D6 gene, has been shown to reduce transcriptional activity and is associated with decreased metabolism of the antipsychotic drug clozapine in patients with schizophrenia.",-30.0,0.4,sequencevariant
"S140G, a glutamate‑by‑glycine substitution in the ATPase domain of the ATP7B protein, has been shown to impair copper transport in hepatocytes of patients with Wilson disease.",-25.5,0.4,sequencevariant
S6V and G1899A sequence variants in the TP53 gene were found to increase the risk of colorectal cancer in a cohort of Homo sapiens patients.,-25.0,0.4,sequencevariant
"SCD1 c.310G>T, a missense sequence variant that replaces glutamate with glycine at position S140G, has been associated with increased triglyceride synthesis in HepG2 cells.",-32.0,0.4,sequencevariant
"Studies in A549 cells revealed that the BRCA1 c.310G>T sequence variant, which replaces glutamate with glycine at position S140G, increases sensitivity to doxorubicin and enhances apoptosis through upregulation of TP53.",-34.5,0.4,sequencevariant
"Studies showed that the BRCA1 c.310 G>T sequence variant, which replaces a glutamate with glycine at position S140G, is associated with increased breast cancer risk in individuals carrying the rs204890 allele.",-30.75,0.4,sequencevariant
"Studies of the BRCA1 c.310 G>T variant in a cohort of breast cancer patients revealed that the resulting p.G159R substitution, which replaces a glutamate with glycine at position S140G, is associated with a higher risk of early‑onset disease in individuals carrying the rs204890 allele.",-47.5,0.4,sequencevariant
"Studies show that the BRCA1 c.310G>T sequence variant, which replaces glutamate with glycine at position S140G, increases breast cancer risk in carriers of the rs204890 allele.",-26.875,0.4,sequencevariant
"Gene substitution p.G159R in the BRCA1 promoter region, together with the c.310 G>T variant, was found to increase the risk of breast cancer in a cohort of Homo sapiens carriers of the rs204890 allele.",-44.5,0.4,sequencevariant
"Gene editing of the TP53 locus in A549 cells introduced a c.310G>T sequence variant that replaces glutamate with glycine at position S140G, resulting in a loss of p53-mediated apoptosis and increased resistance to doxorubicin.",-34.25,0.4,sequencevariant
Gene knock‑in of the c.310G>T sequence variant in the TP53 locus of A549 cells increases p53‑dependent apoptosis and sensitizes the cells to doxorubicin treatment.,-31.125,0.4,sequencevariant
"Gene‑editing of the TP53 locus in HCT116 cells introduced a c.310G>T sequence variant that creates a p.G159R substitution, thereby abolishing the protein’s ability to bind the MDM2 promoter and reducing apoptosis in response to doxorubicin.",-35.0,0.4,sequencevariant
"Evidence links the BRCA1 c.310G>T sequence variant to impaired DNA repair in breast cancer cells, while the p.G159R mutation in the same gene has been shown to increase cellular sensitivity to cisplatin.",-40.75,0.4,sequencevariant
"Evidence indicates that the BRCA1 c.310G>T sequence variant, which replaces glutamate with glycine at position S140G, is associated with an increased risk of breast cancer in individuals carrying the rs204890 allele.",-28.625,0.4,sequencevariant
"Evidence suggests that the BRCA1 c.310G>T sequence variant, which results in a glutamate-to-glycine substitution at position S140G, is associated with increased breast cancer risk in carriers of the rs204890 allele.",-29.75,0.4,sequencevariant
"Evidence from a cohort of colorectal cancer patients indicates that the BRCA1 c.310 G>T sequence variant, which results in a glutamate-to-glycine substitution at position S140G, is associated with increased sensitivity to the chemotherapeutic agent doxorubicin.",-31.875,0.4,sequencevariant
"A CRISPR-Cas9–generated H1047L sequence variant in the PIK3CA gene of a HeLa cell line showed increased phosphorylation of AKT and downstream mTOR signaling, suggesting that the H1047L mutation confers a growth advantage to the cancer cells.",-33.5,0.4,sequencevariant
"A c.279delGAG variant in the KRAS gene, which results in a frameshift and loss of the codon for arginine at position H1047L, has been associated with increased resistance to the EGFR inhibitor erlotinib in A549 cells derived from Homo sapiens lung carcinoma.",-44.25,0.4,sequencevariant
"A kinase domain mutation, H1047L, in the PIK3CA gene has been shown to increase PI3K signaling and confer resistance to rapamycin in A549 cells, while the rs368698783 variant in the same locus is associated with higher breast cancer risk in women of European ancestry.",-40.75,0.4,sequencevariant
"A BRCA1 c.279delGAG variant, annotated as rs368698783, was found to increase the risk of breast cancer in a cohort of Homo sapiens patients, while the H1047L mutation in PIK3CA, a sequence variant with rs11708067-G, was associated with enhanced PI3K signaling and tumor progression.",-40.75,0.4,sequencevariant
"The H1047L sequence variant in the PIK3CA gene, a missense mutation that substitutes leucine for histidine at codon position H1047, is strongly associated with increased PI3K signaling and aggressive breast cancer phenotypes in patients carrying the rs11708067‑G allele.",-38.75,0.4,sequencevariant
"The KRAS H1047L sequence variant, a c.3140G>A substitution that converts arginine84 to glutamine, was found to enhance downstream PI3K signaling in A549 cells, suggesting a pathogenic role in non‑small‑cell lung carcinoma.",-27.875,0.4,sequencevariant
"The oncogenic KRAS H1047L sequence variant, which substitutes a leucine for histidine at codon H1047, was found to activate downstream ERK signaling in A549 cells and was associated with increased resistance to the MEK inhibitor trametinib.",-33.0,0.4,sequencevariant
"The pathogenic H1047L sequence variant in the PIK3CA gene, which replaces a leucine for histidine at codon position H1047, was found to increase PI3K signaling and confer resistance to the PI3K inhibitor alpelisib in the KRAS-mutant A549 cell line.",-49.5,0.4,sequencevariant
"In colorectal carcinoma, the H1047L sequence variant in PIK3CA was found to confer resistance to the EGFR inhibitor cetuximab, while the rs368698783 SNP in KRAS amplified the downstream MAPK signaling pathway.",-29.0,0.4,sequencevariant
"In A549 cells harboring the KRAS H1047L sequence variant, the Q460R mutation in the downstream MAPK pathway enhances phospho‑ERK signaling, while the rare rs368698783 allele, a single‑base insertion of a guanine at position c.1123T>G, further amplifies cell proliferation.",-58.75,0.4,sequencevariant
"In triple‑negative breast cancer, the PI3KCA H1047L sequence variant, which substitutes leucine for histidine at codon H1047, is associated with increased tumor cell proliferation and resistance to standard endocrine therapy.",-39.25,0.4,sequencevariant
"In pancreatic ductal adenocarcinoma, the KRAS G12D sequence variant, a G to A substitution at codon‑12, cooperates with the H1047L mutation in the PIK3CA gene to drive oncogenic signaling and confer resistance to PI3K inhibitors.",-41.0,0.4,sequencevariant
"Recent sequencing of the KRAS gene in a cohort of colorectal cancer patients revealed a recurrent H1047L sequence variant that co‑occurs with a Q460R substitution, suggesting a synergistic effect on oncogenic signaling.",-31.125,0.4,sequencevariant
"Recent exome sequencing of colorectal cancer samples revealed a recurrent KRAS H1047L sequence variant that co‑occurs with a Q460R mutation and a novel c.279delGAG indel, suggesting a synergistic effect on MAPK pathway activation.",-42.75,0.4,sequencevariant
"Recent genome‑wide association studies identified the rs368698783 variant, a G>A substitution at position c.1123T>G in the KRAS gene, which co‑occurs with the H1047L sequence variant in a subset of colorectal cancer patients, suggesting a synergistic effect on MAPK pathway activation.",-42.0,0.4,sequencevariant
"Recent studies show that the H1047L sequence variant in the PIK3CA gene, together with the Q460R mutation, increases the risk of breast cancer in patients carrying the rs368698783 allele.",-28.125,0.4,sequencevariant
"Mutations such as the H1047L and Q460R sequence variants in the PIK3CA gene, the rs368698783 SNP, and the novel arginine84 to glutamine substitution have been linked to increased oncogenic signaling in colorectal cancer.",-35.5,0.4,sequencevariant
Mutagenesis of the KRAS gene revealing the H1047L sequence variant in the PIK3CA exon of the A549 cell line demonstrated a statistically significant increase in phospho‑AKT signaling compared with the wild‑type KRAS sequence.,-39.5,0.4,sequencevariant
"Mutated KRAS H1047L, a sequence variant that replaces histidine with leucine at codon H1047, was found to enhance downstream PI3K signaling and confer resistance to the MEK inhibitor trametinib in A549 cells.",-42.0,0.4,sequencevariant
"Mutational analysis of the PIK3CA gene in breast cancer revealed a recurrent H1047L sequence variant that co‑occurs with a Q460R substitution and a rare rs368698783 SNP, collectively contributing to enhanced PI3K signaling and aggressive tumor phenotypes.",-40.25,0.4,sequencevariant
"H1047L, a KRAS sequence variant, was found to increase the phosphorylation of downstream ERK in A549 cells, while the Q460R mutation in BRAF was associated with a higher sensitivity to vemurafenib in melanoma patients.",-36.5,0.4,sequencevariant
"Homo sapiens carrying the BRCA1 c.279delGAG variant exhibit increased susceptibility to breast cancer, while the EGFR c.2239G>A (p.H1047L) mutation enhances downstream AKT signaling in A549 cells.",-35.0,0.4,sequencevariant
Heterozygous carriers of the H1047L sequence variant in PIK3CA exhibit increased PI3K signaling and a higher risk of developing breast cancer in Homo sapiens.,-25.375,0.4,sequencevariant
"HGFRA exon12 H1047L sequence variant, a missense mutation that substitutes histidine for leucine at codon H1047, is associated with constitutive receptor activation and increased tumor cell migration in non‑small cell lung carcinoma cell lines.",-53.0,0.4,sequencevariant
"Epidermal growth factor receptor (EGFR) harboring the H1047L sequence variant exhibits constitutive kinase activity that promotes proliferation of A549 cells, and the concomitant Q460R mutation further enhances downstream PI3K/AKT signaling, thereby contributing to drug resistance in non‑small cell lung cancer.",-38.0,0.4,sequencevariant
"Erythrocyte membrane protein spectrin harboring the rs368698783 variant, a G to A substitution at position c.1123T>G, was shown to destabilize the cytoskeletal network and increase susceptibility to hemolytic anemia.",-45.5,0.4,sequencevariant
Ectopic expression of the KRAS H1047L sequence variant in A549 cells increases phospho‑ERK signaling and confers resistance to the MEK inhibitor trametinib.,-21.125,0.4,sequencevariant
"EphA2 H1047L, a sequence variant that replaces histidine with leucine at codon H1047, was found to enhance downstream PI3K/AKT signaling in A549 cells, thereby increasing resistance to doxorubicin.",-44.0,0.4,sequencevariant
"Research shows that the H1047L sequence variant in the PIK3CA gene, together with the rs368698783 SNP, increases the risk of breast cancer in women of European ancestry.",-24.125,0.4,sequencevariant
"Research has shown that the H1047L sequence variant in the PIK3CA gene, together with the rs11708067‑G allele, increases the risk of metastatic breast cancer in patients of European ancestry.",-27.875,0.4,sequencevariant
"Research on the KRAS c.3140G>A (p.Gly1047Leu) variant, which replaces glycine with leucine at position H1047L, revealed that the mutation increases downstream MAPK signaling in A549 cells and correlates with higher resistance to the PI3K inhibitor alpelisib in patients with metastatic colorectal cancer.",-52.5,0.4,sequencevariant
"Research in the H1047L sequence variant of PIK3CA revealed that the mutation causes constitutive activation of the PI3K/AKT pathway, leading to increased proliferation in A549 cells.",-32.0,0.4,sequencevariant
Methylenetetrahydrofolate reductase (MTHFR) c.665C>T (rs1801133) and the H1047L variant in PIK3CA together elevate the risk of sporadic colorectal cancer in individuals of European ancestry.,-31.375,0.4,sequencevariant
"Methionine‑to‑leucine substitution at codon H1047L in the PIK3CA sequence variant was found to increase AKT phosphorylation in HeLa cells, while the Q460R variant in the same gene reduced protein stability and was associated with higher apoptosis rates in A549 cells.",-46.25,0.4,sequencevariant
Methotrexate treatment of A549 cells harboring the H1047L sequence variant in the PIK3CA gene led to a marked increase in apoptosis compared with cells carrying the wild‑type allele.,-28.125,0.4,sequencevariant
"Methanogenic archaea harbor a sequence variant, the H1047L substitution in the *mcrA* gene, that enhances methyl-coenzyme M reductase activity and increases methane production under high‑pressure conditions.",-38.75,0.4,sequencevariant
"Rhodobacter capsulatus carrying the sequence variant rs368698783 in the rpoB gene exhibited a markedly reduced growth rate under high‑salt conditions, while the H1047L mutation in the human EGFR gene was associated with increased phosphorylation of downstream AKT signaling in A549 cells.",-48.75,0.4,sequencevariant
"R152Q, a sequence variant in the TP53 gene, was found to increase the risk of early‑onset breast cancer in a cohort of Homo sapiens patients carrying the rs11708067‑G allele.",-36.0,0.4,sequencevariant
"RAC1 H1047L, a sequence variant that replaces histidine with leucine at codon H1047, was found to activate the PI3K/AKT pathway in A549 cells, thereby enhancing proliferation and resistance to doxorubicin.",-43.25,0.4,sequencevariant
"R201C and H1047L sequence variants in the EGFR gene were found to synergistically increase phosphorylation of downstream AKT and MAPK pathways in A549 cells, suggesting a potential mechanism for enhanced tumorigenic signaling in non‑small cell lung carcinoma.",-38.75,0.4,sequencevariant
"Genetic analysis of the KRAS gene in pancreatic cancer patients revealed that the H1047L sequence variant, together with the rs368698783 SNP, was associated with increased tumor aggressiveness and poorer overall survival.",-28.25,0.4,sequencevariant
"Genomics analysis revealed that the H1047L sequence variant in the PIK3CA gene, together with the rs368698783 polymorphism, significantly increased the risk of breast cancer in women of European ancestry.",-32.25,0.4,sequencevariant
Genotype‑specific expression of the PI3KCA H1047L sequence variant in A549 cells leads to increased AKT phosphorylation and promotes resistance to the EGFR inhibitor gefitinib.,-32.5,0.4,sequencevariant
"Genomic analysis of a colorectal carcinoma cohort revealed that the KRAS H1047L sequence variant, along with the TP53 Q460R mutation, was significantly enriched in tumors harboring the rs368698783 polymorphism, suggesting a cooperative effect on oncogenic signaling.",-36.0,0.4,sequencevariant
"Researchers discovered that the H1047L sequence variant in the PIK3CA gene, coupled with the rs368698783 SNP, increases the risk of breast cancer in patients of African descent.",-27.0,0.4,sequencevariant
"Researchers found that the H1047L sequence variant in the PIK3CA gene, coupled with the rs368698783 polymorphism, significantly increased the risk of metastatic breast cancer in patients treated with doxorubicin.",-27.625,0.4,sequencevariant
"Researchers identified a BRCA1 c.279delGAG sequence variant that, together with the rs368698783 polymorphism, increased the risk of breast cancer in a cohort of Homo sapiens patients.",-29.125,0.4,sequencevariant
Researchers demonstrated that the H1047L sequence variant in PIK3CA enhances PI3K signaling and increases resistance to the EGFR inhibitor gefitinib in A549 cells.,-22.25,0.4,sequencevariant
"An A549 cell line harboring the EGFR H1047L sequence variant exhibits markedly increased sensitivity to gefitinib, while the same variant in a patient’s tumor correlates with a poorer overall survival.",-32.75,0.4,sequencevariant
"An intronic sequence variant, rs368698783, was found to increase the expression of the KRAS gene in A549 cells, thereby enhancing the oncogenic potential of the H1047L mutation.",-33.75,0.4,sequencevariant
"An oncogenic H1047L sequence variant in the PIK3CA gene, identified by rs368698783, was shown to increase PI3K signaling and confer resistance to the EGFR inhibitor gefitinib in A549 cells.",-26.375,0.4,sequencevariant
"An H1047L mutation in the PIK3CA gene, which replaces a leucine for histidine at codon H1047, is strongly associated with increased PI3K signaling and is frequently observed in sporadic breast cancers, whereas a Q460R substitution in the same gene is linked to a milder phenotype and lower tumorigenic potential.",-54.75,0.4,sequencevariant
"BRCA1 c.279delGAG, a sequence variant that deletes a GAG codon at position three, has been linked to increased breast cancer risk in individuals carrying the rs368698783 allele.",-33.75,0.4,sequencevariant
"BRISC complex activity is markedly enhanced in cells harboring the H1047L sequence variant of PIK3CA, which is associated with increased PI3K signaling and resistance to rapamycin in A549 lung carcinoma cells.",-42.5,0.4,sequencevariant
"BRD4 H1047L and KRAS Q460R sequence variants, each harboring a distinct single‑nucleotide polymorphism such as rs368698783 or rs11708067‑G, were found to synergistically enhance transcriptional activation of downstream oncogenic pathways in A549 cells.",-42.0,0.4,sequencevariant
"BRST1 c.279delGAG, a sequence variant that deletes a GAG codon, was found to disrupt the binding of transcription factor NF‑κB in the promoter of the TP53 gene in HCT116 cells, thereby reducing TP53 expression and increasing cellular sensitivity to doxorubicin.",-51.5,0.4,sequencevariant
"The c.1358T>C sequence variant in the TP53 gene, which introduces a glutamine replacement of arginine at codon Q126R, has been shown to increase the risk of breast cancer in patients of Asian descent.",-31.5,0.4,sequencevariant
"The CRISPR‑generated c.1358T>C variant in the TP53 gene causes a glutamine‑to‑stop codon mutation at codon&nbsp;298, resulting in a truncated p53 protein that impairs DNA‑damage‑induced apoptosis in A549 cells.",-36.25,0.4,sequencevariant
"The TP53 c.1358T> C sequence variant, which introduces a glutamine-to-arginine substitution at codon Q126R, was associated with increased tumor suppressor activity in A549 cells treated with doxorubicin.",-32.5,0.4,sequencevariant
"The Q126R/del418T sequence variant in the TP53 gene, which replaces glutamine with arginine at codon‑126 and deletes threonine at position‑418, was associated with increased tumor‑suppressor activity in A549 cells.",-34.75,0.4,sequencevariant
"Missense mutation c.1358T>C in the TP53 gene, resulting in a glutamine replacement of arginine at position Q126R, is associated with increased risk of early‑onset breast cancer in a cohort of Homo sapiens patients.",-36.75,0.4,sequencevariant
"Missed detection of the c.1358T>C variant in the TP53 gene, which replaces glutamine with arginine at codon Q126R, was associated with a higher incidence of early‑onset breast cancer in a cohort of Homo sapiens patients.",-50.75,0.4,sequencevariant
"Miss-expression of the TP53 gene in A549 cells harboring the c.1358T>C sequence variant, which introduces a glutamine-to-arginine substitution at codon Q126R, was associated with increased apoptosis and reduced cell proliferation.",-55.25,0.4,sequencevariant
"Missier et al. reported that the c.1358T>C sequence variant in the TP53 gene, which introduces a glutamine-to-arginine substitution at codon Q126R and a stop codon for glutamine at codon G298, is associated with a higher risk of early-onset breast cancer in a cohort of Homo sapiens patients.",-71.5,0.4,sequencevariant
"Following a G183S substitution in the ATPase domain, the A549 cell line exhibited a pronounced increase in drug‑resistance gene expression, while the same mutation in the homologous E. coli strain resulted in a loss of growth fitness.",-48.75,0.4,sequencevariant
"Following the discovery of a c.1358T>C sequence variant that introduces a stop codon for glutamine at codon&nbsp;298, researchers observed a marked reduction in the expression of the TP53 protein in HeLa cells, suggesting that this mutation may contribute to the oncogenic potential of the cell line.",-51.75,0.4,sequencevariant
"Following CRISPR‑Cas9 editing, the A549 cell line acquired a c.1358T>C sequence variant that introduced a glutamine stop codon at codon&nbsp;298, thereby truncating the TP53 protein and abolishing its transcriptional activation of the p21CIP1 target gene.",-43.5,0.4,sequencevariant
"Following successful CRISPR‑Cas9 editing, the engineered A549 cell line expressed a novel sequence variant, c.1358T>C, resulting in a glutamine‑to‑arginine substitution at codon Q126R and a concurrent deletion of threonine at position del418T, which together induced a premature stop codon at glutamine codon Q298 and markedly reduced EGFR signaling in the cells.",-70.0,0.4,sequencevariant
"A glioblastoma patient carrying the c.1358T>C sequence variant in the EGFR gene exhibited a glutamine replacement of arginine at position Q126R, which was associated with accelerated tumor growth and resistance to temozolomide therapy.",-31.25,0.4,sequencevariant
"A missense mutation causing a glutamine replacement of arginine at position p.R32W in the TP53 gene was identified in a patient with a severe form of Li–Fraumeni syndrome, while a separate c.1358T>C sequence variant in the BRCA1 gene was associated with a reduced risk of breast cancer.",-34.25,0.4,sequencevariant
"A p.R32W sequence variant in the TP53 gene, which substitutes arginine with tryptophan at codon‑32, was identified in a patient with early‑onset colorectal cancer and was shown to impair p53’s DNA‑binding domain, thereby contributing to tumorigenesis.",-41.0,0.4,sequencevariant
"A G183S missense mutation in the ATPase gene, coupled with a G to C substitution at position c.1358T, was shown to disrupt the protein’s catalytic domain and is associated with a higher risk of inherited cardiomyopathy in a cohort of Homo sapiens patients.",-53.5,0.4,sequencevariant
"In the A549 cell line, a G183S sequence variant in the TP53 gene was found to increase the protein’s binding affinity for the MDM2 promoter, thereby enhancing p53-mediated apoptosis in response to doxorubicin treatment.",-22.25,0.4,sequencevariant
"In a cohort of colorectal cancer patients, the c.1358T>C sequence variant in the APC gene, which introduces a glutamine stop codon at codon&nbsp;298, was associated with increased tumor aggressiveness and a higher frequency of liver metastases.",-39.25,0.4,sequencevariant
"In CRISPR‑edited A549 cells, the c.1358T>C variant introduced a glutamine‑to‑arginine substitution at position Q126R, creating a premature stop codon at glutamine codon‑298 that abolished the functional domain of the TP53 protein.",-48.0,0.4,sequencevariant
"In HCT116 cells, the c.1358T>C sequence variant causes a glutamine to arginine substitution at position Q126R, generating a premature stop codon at codon G298 that truncates the protein and abolishes its kinase activity.",-36.5,0.4,sequencevariant
Mutations such as the G183S substitution in the ATP-binding domain of the ABC transporter and the c.1358T>C transition in the regulatory region of the CYP2D6 gene are predicted to alter drug metabolism in patients with the Q126R/del418T variant.,-41.25,0.4,sequencevariant
"Mutational analysis of the BRCA1 gene in breast cancer patients revealed a G183S substitution at codon G183, a c.1358T>C transition in exon six, and a stop codon for glutamine at codon Q298, all of which were associated with increased tumor aggressiveness.",-54.5,0.4,sequencevariant
"Mutagenesis of the BRCA1 gene in HeLa cells revealed a c.1358T>C sequence variant that introduces a glutamine stop codon at codon‑298, thereby truncating the protein and impairing DNA repair.",-35.0,0.4,sequencevariant
"Mutant p.R32W in the TP53 gene, which replaces arginine with tryptophan at codon thirty‑two, was found to increase the risk of early‑onset breast cancer in a cohort of Homo sapiens patients carrying the c.1358T>C sequence variant.",-42.75,0.4,sequencevariant
"Genetic analysis of a colorectal carcinoma cell line revealed a c.1358T>C sequence variant that introduces a glutamine stop codon at codon&nbsp;298, resulting in a truncated TP53 protein lacking the DNA‑binding domain.",-35.5,0.4,sequencevariant
"Genotype‑specific expression of the p.R32W variant in the TP53 gene, a glutamine‑to‑arginine substitution at codon Q126R, was associated with a higher incidence of early‑onset melanoma in a cohort of Homo sapiens patients.",-48.25,0.4,sequencevariant
"Genomic analysis of a colorectal carcinoma sample revealed a G183S sequence variant in the KRAS gene, a glutamine replacement of arginine at codon Q126R, and a stop codon for glutamine at codon c.298, all of which are predicted to disrupt downstream signaling pathways.",-42.75,0.4,sequencevariant
"Genetically engineered A549 cells harboring the c.1358T>C sequence variant in the TP53 gene exhibit a glutamine-to-arginine substitution at position Q126R, which impairs p53-mediated apoptosis and enhances resistance to doxorubicin.",-36.75,0.4,sequencevariant
"Structural analysis of the c.1358T>C variant in the BRCA1 gene revealed that the glutamine replacement of arginine at position Q126R/del418T creates a premature stop codon for glutamine at codon&nbsp;298, thereby truncating the protein and abolishing its DNA‑repair activity.",-46.0,0.4,sequencevariant
"Structural modeling of the p.R32W variant in the TP53 gene revealed that the glutamine replacement of arginine at codon‑32 destabilizes the DNA‑binding domain, causing a loss of transcriptional activation of downstream apoptotic genes.",-39.5,0.4,sequencevariant
"Structural modelling of the BRCA1 protein revealed that the c.1358T>C sequence variant, which introduces a glutamine-to-arginine substitution at residue Q126R and deletes threonine at position del418T, destabilises the RING domain and is predicted to impair ubiquitin‑ligase activity, potentially contributing to hereditary breast‑cancer susceptibility.",-49.25,0.4,sequencevariant
"Structural mutagenesis of the kinase domain revealed that a G183S substitution in the ATP‑binding pocket of EGFR, coupled with a Thr60Met alteration in the activation loop, markedly increased phosphorylation of downstream STAT3 in A549 cells, whereas a p.R32W variant in the SH2 domain of JAK2 abrogated cytokine‑induced STAT5 activation in HeLa cells.",-60.25,0.4,sequencevariant
"Mutation p.R32W in the TP53 gene, a glutamine replacement of arginine at codon Q126R, and the stop codon for glutamine at codon298 were identified in a cohort of patients with severe neurodegenerative disease.",-44.75,0.4,sequencevariant
"Mutation c.1358T>C in the BRCA1 gene introduces a glutamine-to-arginine substitution at position Q126R, generating a premature stop codon at codon G298 that truncates the protein and impairs DNA repair in Homo sapiens cells.",-37.0,0.4,sequencevariant
"Mutation of the TP53 gene to a glutamine replacement of arginine at position p.R32W in the A549 cell line leads to a stop codon for glutamine at codon Q126R/del418T, causing a loss of function that increases the risk of developing colorectal cancer in Homo sapiens.",-50.5,0.4,sequencevariant
"Mutation analysis revealed that the c.1358T>C sequence variant in the TP53 gene, which introduces a glutamine-to-arginine substitution at codon Q126R and a stop codon at glutamine residue Q298, is associated with increased tumor suppressor dysfunction in Homo sapiens tumor samples.",-49.75,0.4,sequencevariant
An A to G transition at codon **557 (AAG → GAG)** in the **TP53** gene creates a **Thr60Met** variant that disrupts the DNA‑binding domain and is associated with increased susceptibility to **colorectal cancer** in **Homo sapiens**.,-33.75,0.4,sequencevariant
"An Arg-to-Gln substitution at position Q126R in the TP53 gene, together with a stop codon at codon G298, was shown to impair p53’s transcriptional activity in A549 cells.",-45.0,0.4,sequencevariant
"An allelic variant in the KRAS gene, c.105G>A, results in a Thr60Met substitution that replaces the threonine residue with methionine and is associated with increased oncogenic signaling in colorectal carcinoma cells.",-47.0,0.4,sequencevariant
"An in‑vitro screen revealed that the c.1358T>C sequence variant in the TP53 gene, which introduces a glutamine stop codon at codon‑298, reduces p53‑mediated transcriptional activation of the CDKN1A promoter in HeLa cells.",-42.5,0.4,sequencevariant
"Studies in A549 cells revealed that the c.1358T>C sequence variant, which introduces a glutamine-to-arginine substitution at position Q126R, reduces the binding affinity of the transcription factor NF‑κB, thereby attenuating the expression of the inflammatory cytokine IL‑6.",-36.0,0.4,sequencevariant
"Studies of the BRCA1 c.1358T>C variant, which introduces a glutamine-to-arginine substitution at codon Q126R and a stop codon at glutamine residue Q298, revealed a marked increase in homologous recombination deficiency and sensitivity to PARP inhibitors in HCC1937 cells.",-48.25,0.4,sequencevariant
"Studies showed that the c.1358T>C sequence variant, which introduces a glutamine-to-arginine substitution at codon Q126R and deletes a threonine at position del418T, was associated with a stop codon for glutamine at codon G298, thereby disrupting the normal protein product of the gene.",-57.25,0.4,sequencevariant
"Studies indicate that the c.1358T>C sequence variant, which generates a glutamine-to-arginine substitution at codon Q126R and a concurrent deletion of threonine at position del418T, destabilizes the protein and is associated with a higher risk of autosomal dominant retinitis pigmentosa in Homo sapiens.",-45.75,0.4,sequencevariant
"Ectopic expression of the BRCA1 c.1358T>C variant, which introduces a glutamine-to-arginine substitution at residue Q126R, was shown to impair homologous recombination repair in A549 cells, thereby increasing sensitivity to the DNA‑damaging agent doxorubicin.",-36.5,0.4,sequencevariant
"Erythrocyte membrane protein spectrin, encoded by the ACTB gene, harbors a G183S sequence variant that replaces a glycine with serine at codon three hundred and eighty-three, and this missense mutation is associated with a severe form of hereditary spherocytosis in patients of European descent.",-53.0,0.4,sequencevariant
"Epidemiological analysis revealed that the G183S sequence variant, a G to C substitution at position G183, significantly increased the risk of developing Parkinson’s disease in a cohort of Homo sapiens carriers.",-38.25,0.4,sequencevariant
"Ethanol exposure in A549 cells carrying the c.1358T>C variant of the CYP2E1 gene, which replaces glutamine with arginine at position Q126R, resulted in a marked increase in reactive oxygen species production and apoptosis compared to wild‑type cells.",-40.25,0.4,sequencevariant
Research using CRISPR-Cas9 to introduce the c.1358T>C sequence variant in the TP53 gene of HCT116 cells revealed that the resulting p.R469C mutation destabilizes the DNA‑binding domain and increases cellular sensitivity to doxorubicin.,-33.75,0.4,sequencevariant
"Research into the A549 cell line revealed that the c.1358T>C sequence variant, which introduces a glutamine replacement of arginine at codon Q126R, is associated with increased sensitivity to the chemotherapeutic drug doxorubicin in patients with non‑small cell lung cancer.",-38.5,0.4,sequencevariant
"Research revealed that the c.1358T>C sequence variant, which introduces a glutamine-to-arginine substitution at position Q126R, correlates with increased susceptibility to the neurodegenerative phenotype observed in patients carrying the p.R32W mutation.",-32.25,0.4,sequencevariant
"Research indicates that the c.1358T>C sequence variant, which generates a glutamine-to-arginine substitution at codon Q126R, disrupts the regulatory domain of the TP53 gene, thereby impairing its tumor suppressor function in Homo sapiens cells.",-42.5,0.4,sequencevariant
"cDNA sequencing of the TP53 gene in a breast cancer patient revealed a G183S substitution that introduces a premature stop codon for glutamine at codon **298**, resulting in a truncated protein that lacks the DNA‑binding domain.",-46.5,0.4,sequencevariant
"c.[1358T>C] in the TP53 gene produces a glutamine-to-arginine substitution at position Q126R, which has been linked to increased risk of colorectal cancer in a cohort of Homo sapiens patients.",-45.0,0.4,sequencevariant
"c.Asp298* (stop codon for glutamine at codon‑298) in the TP53 gene was found to impair p53‑dependent apoptosis in A549 cells, whereas the p.R32W variant in the same gene was associated with increased cellular proliferation in HeLa cells.",-64.5,0.4,sequencevariant
"c.*1358T>C* in the *TP53* gene introduces a glutamine replacement of arginine at position *Q126R*, generating a stop codon for glutamine at codon *298* that truncates the protein and is predicted to impair DNA‑binding activity.",-48.75,0.4,sequencevariant
"The c.1932delC sequence variant in the BRCA1 gene causes a frameshift leading to a premature stop codon, which is associated with increased breast cancer risk in carriers.",-16.0,0.4,sequencevariant
"The pathogenic c.1932delC variant in the BRCA1 gene, which deletes a single cytosine at codon‑322 and converts a glycine to aspartate, is associated with a markedly increased risk of hereditary breast cancer in Homo sapiens.",-37.25,0.4,sequencevariant
"The BRCA1 c.1932delC sequence variant, a single‑base deletion causing a frameshift and premature truncation, was found to increase the risk of triple‑negative breast cancer in a cohort of Homo sapiens patients.",-22.875,0.4,sequencevariant
"The CRISPR‑generated c.1932delC sequence variant in the TP53 gene was found to increase the transcription of the pro‑apoptotic gene BAX in HCT116 cells, while the concurrent Gly322Asp substitution in the same allele reduced the protein’s DNA‑binding affinity.",-37.25,0.4,sequencevariant
"Mutation c.1932delC in the TP53 gene, which results in a frameshift and loss of the DNA‑binding domain, is associated with a higher incidence of early‑onset breast cancer in patients of the A549 cell line.",-30.875,0.4,sequencevariant
Mutation of the TP53 gene (c.1932delC) in a HeLa cell line caused a Gly322Asp substitution that destabilized the protein and increased the risk of apoptosis in response to doxorubicin treatment.,-32.0,0.4,sequencevariant
"Mutation analysis of a colorectal carcinoma sample revealed a c.1932delC sequence variant in the APC gene that co‑occurs with a Gly322Asp amino‑acid substitution and a downstream glutamine‑repeat expansion, suggesting a compound pathogenic effect on Wnt signaling.",-31.875,0.4,sequencevariant
Mutation in the TP53 gene (c.1932delC) causing a frameshift and premature stop codon was found to increase the risk of early‑onset breast cancer in a cohort of Homo sapiens patients carrying the same variant.,-38.25,0.4,sequencevariant
"A pathogenic c.1932delC sequence variant in the BRCA1 gene, which deletes a single cytosine at codon‑322 and converts a glycine to aspartate, has been shown to disrupt DNA repair and increase breast cancer susceptibility in Homo sapiens.",-37.75,0.4,sequencevariant
"A recurrent c.1932delC sequence variant in the TP53 gene, which deletes a single cytosine at codon position three‑hundred‑thirty‑two and results in a Gly→Asp substitution at the same site, has been shown to predispose patients with colorectal cancer to early onset disease.",-58.0,0.4,sequencevariant
"A patient with a c.1932delC sequence variant in the BRCA1 gene exhibited a pronounced loss of homologous recombination repair activity, leading to increased sensitivity to the DNA‑damaging agent doxorubicin.",-21.25,0.4,sequencevariant
"A c.1932delC sequence variant in the TP53 gene was identified in a patient with a germline deletion spanning a ~10‑12Mb region of chromosome p53, and the resulting loss of the codon for phenylalanine at position F826Y was predicted to disrupt the DNA‑binding domain and contribute to the observed tumorigenesis.",-73.0,0.4,sequencevariant
"In HeLa cells, the c.1932delC sequence variant in the TP53 gene leads to a truncated protein that fails to activate the downstream apoptosis regulator BAX, thereby conferring resistance to doxorubicin-induced cell death.",-23.875,0.4,sequencevariant
"In MYH7, the c.1932delC sequence variant causes a frameshift that deletes a glycine at codon (Gly‑>Asp) and results in a truncated protein associated with hypertrophic cardiomyopathy.",-43.25,0.4,sequencevariant
"In colorectal carcinoma, the c.1932delC sequence variant in the APC gene leads to a truncated protein that disrupts β‑catenin regulation and promotes tumorigenesis.",-17.25,0.4,sequencevariant
"In A549 cells harboring the BRCA1 c.1932delC sequence variant, the resulting frameshift leads to a truncated protein that fails to recruit the DNA repair complex, thereby increasing sensitivity to doxorubicin-induced apoptosis.",-22.0,0.4,sequencevariant
"Deletions spanning a contiguous region of approximately ten to twelve megabases, such as the c.1932delC variant, have been associated with a Gly to Asp substitution at codon‑322 in the protein product of the gene, while the F826Y mutation and the D541E change together with a glutamine repeat expansion can exacerbate the phenotypic severity observed in affected individuals.",-86.5,0.4,sequencevariant
"Deletion of c.1932delC in the TP53 gene, which results in a Gly→Asp substitution at codon‑322, was found to increase the risk of colorectal cancer in a cohort of Homo sapiens patients.",-41.75,0.4,sequencevariant
"De novo c.1932delC in the TP53 gene, a sequence variant that truncates the DNA‑binding domain, was identified in a patient with a high‑grade sarcoma of the femur, while a concurrent Gly322Asp substitution in the same allele was predicted to destabilize the protein’s core, potentially exacerbating the malignant phenotype.",-54.25,0.4,sequencevariant
"Depletion of the BRCA1 c.1932delC sequence variant in HeLa cells leads to a Gly → Asp substitution at codon‑322, which in turn disrupts the glutamine repeat tract and diminishes DNA repair capacity.",-47.0,0.4,sequencevariant
Deletion of c.1932delC in the TP53 gene causes a frameshift that truncates the protein and is associated with increased risk of early‑onset breast cancer in a cohort of Homo sapiens patients.,-23.75,0.4,sequencevariant
"Deletion c.1932delC in the TP53 gene, which causes a Gly322Asp amino‑acid change and a glutamine‑repeat expansion, was found to increase the risk of sporadic breast cancer in a cohort of Homo sapiens patients.",-32.25,0.4,sequencevariant
Deletion at c.1932delC in the TP53 gene was found to cause a Gly322Asp substitution that destabilizes the protein and increases the risk of early-onset colorectal cancer in a family of Homo sapiens.,-32.25,0.4,sequencevariant
"Deletion biallelic c.1932delC in the SMAD4 gene causes a Gly322Asp substitution and a glutamine repeat expansion, leading to a severe form of juvenile polyposis in Homo sapiens.",-38.25,0.4,sequencevariant
"CRISPR‑generated A549 cells harboring the c.1932delC sequence variant in the TP53 gene exhibit a pronounced reduction in p53‑mediated transcriptional activation of the CDKN1A promoter, leading to increased proliferation and resistance to doxorubicin.",-31.0,0.4,sequencevariant
"CRL-1205 cells harbor a c.1932delC sequence variant that deletes a glutamine repeat and a Gly→Asp change at codon‑322, which together destabilize the protein and impair its interaction with the transcription factor NF‑κB.",-55.25,0.4,sequencevariant
"CRLF3 c.1932delC, a frameshift deletion in the extracellular domain, was found to reduce receptor dimerization and impair downstream STAT5 signaling in a subset of T‑cell acute lymphoblastic leukemia patients.",-47.0,0.4,sequencevariant
"CRITICAL: A c.1932delC sequence variant in the TP53 gene, which causes a frameshift and premature stop codon, was found to increase the risk of early‑onset breast cancer in a cohort of Homo sapiens patients.",-41.0,0.4,sequencevariant
"cDNA sequencing of a patient-derived tumor revealed a c.1932delC sequence variant that deletes a glutamine repeat tract and creates a Gly→Asp substitution at codon&nbsp;322, thereby impairing the protein’s DNA-binding domain.",-54.25,0.4,sequencevariant
"cblc c.1932delC causes a frameshift that truncates the protein, and the adjacent c.1146+25insA insertion creates a novel glutamine repeat that destabilizes the enzyme’s active site.",-45.75,0.4,sequencevariant
"cGAS‑STING signaling is attenuated in A549 cells carrying the c.1932delC sequence variant, which creates a premature stop codon and truncates the STING protein, thereby reducing interferon‑β production in response to cytosolic DNA.",-41.25,0.4,sequencevariant
"c.\,1932delC in the TP53 gene causes a frameshift that truncates the protein at codon L50R, leading to loss of the DNA‑binding domain and a severe predisposition to Li–Fraumeni syndrome in affected Homo sapiens individuals.",-39.75,0.4,sequencevariant
Patients with the c.1932delC sequence variant in the TP53 gene exhibited a Gly322Asp amino‑acid change that correlated with increased apoptosis in HeLa cells.,-23.875,0.4,sequencevariant
Patients carrying the c.1932delC sequence variant in the TP53 gene exhibit a markedly increased risk of developing high‑grade gliomas compared with carriers of the wild‑type allele.,-21.625,0.4,sequencevariant
"Patients using the CRISPR‑Cas9‑edited A549 cell line harboring the c.1932delC sequence variant exhibited a pronounced reduction in EGFR protein expression, suggesting that the deletion disrupts the transcriptional enhancer region of the EGFR gene.",-42.0,0.4,sequencevariant
"Patients treated with the novel kinase inhibitor AZD-5363 exhibited a significant reduction in tumor growth, which correlated with a c.1932delC sequence variant in the TP53 gene that abolishes the DNA-binding domain and enhances apoptosis in HeLa cells.",-44.5,0.4,sequencevariant
"Genome-wide analysis of a patient with a c.1932delC deletion in the BRCA1 gene revealed a concurrent Gly322Asp substitution and a glutamine repeat expansion, which together may contribute to the observed breast cancer phenotype.",-42.25,0.4,sequencevariant
"Genome‑wide association studies revealed that the c.1932delC sequence variant in the BRCA1 gene, which deletes a single cytosine at codon‑322 and converts the encoded glycine to aspartate, is strongly linked to breast cancer susceptibility in European populations.",-42.75,0.4,sequencevariant
"Genome editing of the TP53 gene in A549 cells revealed that the c.1932delC sequence variant, which deletes a cytosine at codon position three‑hundred‑thirty‑two, causes a frameshift that replaces the normal glycine with an aspartate at residue three‑two‑two, thereby abolishing the DNA‑binding domain and dramatically reducing apoptosis in response to doxorubicin.",-70.5,0.4,sequencevariant
"Genome‐wide analysis of a patient with a c.1932delC sequence variant in the BRCA1 gene revealed a downstream loss of the glutamine repeat tract and a Gly→Asp substitution at codon&nbsp;322, which together are predicted to destabilize the protein’s DNA‑binding domain.",-55.0,0.4,sequencevariant
Mutations such as c.1932delC and the F826Y amino‑acid substitution in the TP53 gene have been linked to increased risk of colorectal cancer in patients with a germline D541E variant.,-26.375,0.4,sequencevariant
"Mutational analysis of the TP53 gene in a cohort of colorectal cancer patients revealed that a c.1932delC sequence variant, which results in a frameshift and premature truncation of the protein, was present in a subset of individuals who also carried a Gly322Asp substitution in the DNA‑binding domain and a glutamine repeat expansion at codon L50R, suggesting a synergistic effect of these sequence variants on tumor progression.",-59.75,0.4,sequencevariant
"Mutagenic c.1932delC in the TP53 gene, which deletes a single cytosine at codon‑322 and converts a glycine to aspartate, was found to increase the risk of early‑onset colorectal cancer in a cohort of Homo sapiens patients.",-45.25,0.4,sequencevariant
"Mutualistic interaction between the c.1932delC variant in the TP53 gene and the F826Y substitution in the BRCA1 protein was observed to increase apoptosis in HeLa cells, suggesting a synergistic effect on tumor suppression.",-40.0,0.4,sequencevariant
"Gly to Asp substitution at codon **322** in the **TP53** gene (c.965G>A) was identified in a patient with a **c.1932delC** deletion spanning a **10‑12 Mb** region, and the resulting **D541E** variant was predicted to destabilize the DNA‑binding domain.",-49.75,0.4,sequencevariant
"G826Y, a missense sequence variant in the TP53 gene, was found to disrupt the DNA-binding domain and was associated with a higher risk of early-onset breast cancer in a cohort of Homo sapiens patients.",-33.5,0.4,sequencevariant
"Germline c.1932delC in the TP53 gene, which deletes a single cytosine at codon‑322 and converts a glycine to an aspartate, is associated with a higher risk of Li–Fraumeni syndrome in a family of Homo sapiens.",-47.25,0.4,sequencevariant
"Giant deletions spanning a ten‑to‑twelve megabase region in the TP53 gene, such as the c.1932delC mutation, are frequently associated with a Gly322Asp amino‑acid substitution and a glutamine‑repeat expansion that together predispose patients to aggressive breast cancer.",-56.25,0.4,sequencevariant
"T--G transversion at nucleotide position c.4508 in the TP53 gene, a sequence variant that replaces alanine with valine at codon L50R, has been associated with increased susceptibility to colorectal cancer in a cohort of Homo sapiens patients.",-57.0,0.4,sequencevariant
"Twelve‑megabase deletion at chromosome region Xq28, combined with the c.1932delC variant in the SMARCA4 gene, was found to cause a Gly322Asp substitution that disrupts the glutamine‑rich domain and leads to a severe form of Coffin‑Siris syndrome in a patient of Homo sapiens origin.",-55.75,0.4,sequencevariant
"T‑cell receptor β‑chain c.1932delC, a frameshift deletion of a single cytosine at codon‑322, is associated with a Gly→Asp substitution in the variable region and a glutamine repeat expansion that together confer a high risk of autoimmune lymphoproliferative syndrome.",-61.75,0.4,sequencevariant
"T‐cell receptor β‑chain c.1932delC deletion in a patient with a glutamine repeat expansion causes a Gly→Asp substitution at codon‑322, leading to a severe immunodeficiency phenotype.",-45.25,0.4,sequencevariant
"Clinically, a c.1932delC sequence variant in the BRCA1 gene causes a frameshift leading to a premature stop codon, which is associated with an increased risk of hereditary breast cancer in Homo sapiens.",-29.375,0.4,sequencevariant
"Clinicians noted that the c.1932delC sequence variant in the BRCA1 gene, which deletes a single cytosine at position three‑hundred‑thirty‑two, was associated with a markedly increased risk of triple‑negative breast cancer in a cohort of Homo sapiens patients.",-42.0,0.4,sequencevariant
"Clinische Studien zeigen, dass die c.1932delC‑Deletion in der BRCA1‑Gene‑Region, die zu einem Frameshift‑Indel und einer frühen Termination führt, mit einem erhöhten Risiko für Brustkrebs bei Frauen mit familiärer Vorgeschichte von Ovarialkarzinom korreliert.",-56.25,0.4,sequencevariant
"Clinician‑reported c.1932delC in the BRCA1 gene, a deletion spanning a glutamine repeat region, was associated with a Gly→Asp change at codon‑322 and a D541E substitution in the protein product.",-57.5,0.4,sequencevariant
"The p.Ser63Asn missense mutation in the BRCA1 gene, located at c.304insGCG, is predicted to disrupt the protein’s DNA‑binding domain and is associated with a higher risk of breast cancer in individuals carrying the rs2073601-rs2073416 haplotype.",-28.5,0.4,sequencevariant
"The c.1072T>C mutation in the TP53 gene, which results in a p.Ser63Asn amino acid change, was found to increase the risk of developing colorectal cancer in a cohort of Homo sapiens patients.",-22.5,0.4,sequencevariant
"The Alzheimer’s disease–associated variant c.1072T> C in the APOE gene, which replaces a threonine with a methionine at position p.Ser63Asn, has been shown to increase amyloid‑β aggregation in human neuronal cultures derived from the SH‑SY5Y cell line.",-42.0,0.4,sequencevariant
The identified c.304ins(GCG) variant in the TP53 gene of a HeLa cell line carrying the rs2073601-rs2073416 haplotype was associated with a Gln266His substitution that increased apoptosis in response to doxorubicin treatment.,-27.25,0.4,sequencevariant
"TAV-1 cells carrying the c.304ins(GCG) variant exhibit a marked increase in p53‑dependent apoptosis after doxorubicin exposure, while the rs2073601‑rs2073416 haplotype in the same population is associated with a higher risk of drug‑induced cardiotoxicity.",-47.25,0.4,sequencevariant
"TaqMan assays revealed that the c.304ins(GCG) variant in the BRCA1 gene, together with the rs2073601‑rs2073416 haplotype, significantly increased the risk of triple‑negative breast cancer in a cohort of Homo sapiens patients.",-36.25,0.4,sequencevariant
Toll‑interacting protein (TOLLIP) harboring the c.1072T>G transversion at nucleotide position **4508** and the rs2073601‑rs2073416 haplotype was found to increase susceptibility to chronic obstructive pulmonary disease in a cohort of **Homo sapiens** smokers.,-48.0,0.4,sequencevariant
"T‐to‐G transversion at nucleotide position c.4508, the c.304ins(GCG) insertion, and the rs2073601‑rs2073416 haplotype collectively alter the coding sequence of the target gene, producing a Gln266His substitution, a p.Ser63Asn change, and a proline‑to‑arginine replacement at residue‑484 that are predicted to disrupt protein function.",-68.0,0.4,sequencevariant
"A CRISPR‑Cas9‑generated A549 cell line harboring the c.304ins(GCG) variant in the TP53 gene exhibited a Gln266His substitution that increased sensitivity to doxorubicin, while the rs2073601‑rs2073416 haplotype correlated with elevated p.Ser63Asn expression in the same cell line.",-37.75,0.4,sequencevariant
"A pathogenic T‑>G transversion at nucleotide position c.4508 in the TP53 gene, together with a c.304insGCG variant in the same allele, was found to destabilize the protein’s DNA‑binding domain and correlate with increased risk of early‑onset colorectal cancer in patients carrying the rs2073601‑rs2073416 haplotype.",-49.0,0.4,sequencevariant
"A T→G transversion at nucleotide position c.4508 in the TP53 gene, combined with the c.304ins(GCG) variant, has been shown to increase the risk of developing colorectal cancer in patients of the Homo sapiens population.",-41.75,0.4,sequencevariant
"A p.Ser63Asn substitution in the TP53 gene, located at c.184G>A, was found to increase the risk of breast cancer in a cohort of Homo sapiens patients carrying the rs2073601-rs2073416 haplotype.",-26.25,0.4,sequencevariant
"In HCT116 cells, the c.304ins(GCG) variant in the TP53 gene increases the transcription of pro‑apoptotic BAX and induces a Gln266His substitution that destabilizes the DNA‑binding domain, thereby enhancing chemosensitivity to doxorubicin.",-31.5,0.4,sequencevariant
"In the CRISPR‑edited A549 cells, the engineered c.304ins(GCG) variant at position c.304 was shown to increase expression of the TP53 gene while the concomitant rs2073601‑rs2073416 haplotype was associated with a higher risk of developing a Gln266His substitution in the downstream KRAS protein.",-52.25,0.4,sequencevariant
"In colorectal carcinoma cell line HCT116, the c.1072T>G transversion at nucleotide position **1072** within the KRAS gene creates a **p.Tyr357Cys** sequence variant that enhances MAPK signaling and confers resistance to the EGFR inhibitor cetuximab.",-43.75,0.4,sequencevariant
"In patients with the c.1072T>G transversion at nucleotide position **4508** in the *TP53* gene, the resulting **p.Ser63Asn** sequence variant was associated with a markedly increased risk of developing **colorectal cancer**.",-46.0,0.4,sequencevariant
An engineered CRISPR-Cas9 knock‑in of the c.304ins(GCG) variant in the TP53 gene of A549 cells led to a p.Ser63Asn substitution that increased p53 transcriptional activity and sensitized the cells to doxorubicin-induced apoptosis.,-31.375,0.4,sequencevariant
"An A549 cell line expressing the BRCA1 c.1072T>C variant shows increased sensitivity to doxorubicin, while the same variant in a HeLa line reduces TP53 transcriptional activity.",-31.0,0.4,sequencevariant
"An SNP at position c.1072T>C in the TP53 gene, which replaces a threonine with alanine, was found to increase the risk of early‑onset breast cancer in a cohort of Homo sapiens patients.",-38.25,0.4,sequencevariant
"An rs2073601-rs2073416 haplotype containing a c.304ins(GCG) (7) variant and a Gln266His substitution was associated with increased susceptibility to Parkinson’s disease in a cohort of Homo sapiens patients, while a T > G transversion at nucleotide position c.4508 in the same gene correlated with reduced drug efficacy of levodopa.",-63.0,0.4,sequencevariant
"cDNA sequencing of the TP53 gene in a cohort of colorectal carcinoma samples revealed a novel c.304insGCG mutation that co‑segregated with a p.Ser63Asn amino‑acid substitution and a Gln266His variant, suggesting a combined effect on p53 DNA‑binding affinity and transcriptional activity.",-44.75,0.4,sequencevariant
"c.Gln266His, a missense SequenceVariant in the TP53 gene, has been shown to alter p53's DNA‑binding affinity and is associated with increased susceptibility to colorectal cancer in individuals of Asian descent.",-43.25,0.4,sequencevariant
"c.T4508G, a T‑to‑G transversion at nucleotide position five‑hundred‑eighty‑eight, was identified in the TP53 gene of a patient with Li‑Fraumeni syndrome, and its presence was associated with increased susceptibility to osteosarcoma.",-59.25,0.4,sequencevariant
"c6orf106 c.304insGCG (7) and the rs2073601-rs2073416 haplotype were found to increase the risk of Parkinson’s disease in a cohort of Homo sapiens subjects, while the T‑>G transversion at nucleotide position c.4508 in the same gene was associated with a milder phenotypic presentation.",-72.5,0.4,sequencevariant
"Cell lines such as HeLa and A549 were used to assess how the c.304ins(GCG) variant in the TP53 gene, which introduces a proline-to-arginine substitution at codon p.484, alters the transcriptional response to the chemotherapeutic drug doxorubicin in Homo sapiens cells.",-48.0,0.4,sequencevariant
"Cell line A549 carrying the c.304ins(GCG) variant in the KRAS gene exhibits increased sensitivity to the chemical entity vemurafenib, while the same variant in the TP53 gene (p.Ser63Asn) reduces apoptosis in Homo sapiens-derived tumor cells.",-38.75,0.4,sequencevariant
"Cell culture of A549 cells harboring the c.304ins(GCG) variant showed increased sensitivity to doxorubicin, while the rs2073601-rs2073416 haplotype correlated with higher expression of the TP53 gene.",-28.125,0.4,sequencevariant
"Cell‑line A549 harboring the c.1072T>C variant in the KRAS gene exhibits markedly increased sensitivity to the chemical entity erlotinib, while the same line with the rs2073601-rs2073416 haplotype shows reduced phosphorylation of downstream ERK signaling.",-40.75,0.4,sequencevariant
"Mutation of the TP53 gene, specifically the c.1072T>G transversion at nucleotide position T1072G, was found to increase the risk of developing breast cancer in a cohort of Homo sapiens patients, while the concurrent c.304insGCG insertion in the same gene was associated with a milder phenotype.",-57.0,0.4,sequencevariant
"Mutation rs2073601‑rs2073416 in the CYP2D6 gene, a c.304ins(GCG) (7) insertion at nucleotide position c.304, and a Gln266His substitution in the CYP2D6 protein collectively contribute to altered drug metabolism in patients with the CYP2D6*4 allele.",-53.0,0.4,sequencevariant
"Mutation p.Ser63Asn in the TP53 gene, located at c.304ins(GCG) in exon seven, was found to increase the risk of colorectal cancer in a cohort of Homo sapiens patients carrying the rs2073601‑rs2073416 haplotype.",-34.75,0.4,sequencevariant
"Mutation c.1072T>C in the TP53 gene, which replaces a threonine with alanine at codon position, was found to be associated with increased risk of breast cancer in a cohort of Homo sapiens patients.",-47.25,0.4,sequencevariant
"Epithelial cells harboring the c.1072T>G transversion at nucleotide position **4508** exhibit a markedly reduced binding affinity for the transcription factor p53, thereby impairing the apoptotic response to DNA damage.",-45.75,0.4,sequencevariant
"Epidemiologic analysis revealed that the rs2073601‑rs2073416 haplotype, which includes a Gln266His substitution and a c.304ins(GCG) insertion, is associated with increased susceptibility to Parkinson’s disease in a cohort of Homo sapiens individuals carrying the T‑>G transversion at nucleotide position c.4508.",-50.75,0.4,sequencevariant
"Ets1 c.304ins(GCG) (7) in the promoter region of the VEGFA gene was found to increase VEGFA transcription in A549 cells, while the rs2073601-rs2073416 haplotype was associated with higher plasma VEGF levels in patients with idiopathic pulmonary fibrosis.",-43.0,0.4,sequencevariant
"Erythrocyte membrane protein A1, encoded by the Gln266His sequence variant, shows altered binding to the CD47 receptor, thereby increasing hemolysis in patients carrying the rs2073601‑rs2073416 haplotype.",-45.75,0.4,sequencevariant
"Functional studies revealed that a c.304ins(GCG) variant in the BRCA1 gene, together with a Gln266His substitution, significantly increases the risk of breast cancer in individuals carrying the rs2073601-rs2073416 haplotype.",-33.75,0.4,sequencevariant
"Functional analysis of the c.304ins(GCG) variant in the TP53 gene revealed that the insertion of a GCG codon at position c.304 creates a proline-to-arginine substitution at residue p.Pro484, which alters the DNA-binding domain and enhances the transcriptional activation of the p53 target gene p21 in HeLa cells.",-61.25,0.4,sequencevariant
"Functional assays revealed that the c.1072T>G transversion in the BRCA1 gene, together with the rs2073601-rs2073416 haplotype, significantly increased the risk of breast cancer in women carrying the Gln266His variant.",-35.0,0.4,sequencevariant
"Functional clustering of the c.304ins(GCG) variant in the TP53 gene, a Gln266His substitution in the BRCA1 sequence, and a G>T transversion at nucleotide position c.4508 within the KRAS gene were found to synergistically increase the risk of colorectal carcinoma in patients of Homo sapiens.",-74.0,0.4,sequencevariant
"Alzheimer’s disease patients carrying the rs2073601-rs2073416 haplotype, which includes a Gln266His substitution and a c.304ins(GCG) variant, exhibit markedly increased amyloid‑β aggregation compared with non‑carriers.",-29.0,0.4,sequencevariant
"Altering the BRCA1 c.1072T> C variant, which substitutes a proline for arginine at position p.484, increases the risk of breast cancer in Homo sapiens carriers of the rs2073601-rs2073416 haplotype.",-45.25,0.4,sequencevariant
"Alfalfa plants carrying the c.304ins(GCG) variant at position c.304 in the β‑actin gene exhibit a markedly reduced expression of the actin protein, which correlates with impaired root elongation and increased susceptibility to drought stress.",-54.25,0.4,sequencevariant
Alu-mediated insertion of c.304ins(GCG) in the TP53 gene causes a p.Ser63Asn substitution that is associated with increased risk of breast cancer in individuals carrying the rs2073601-rs2073416 haplotype.,-35.5,0.4,sequencevariant
"Mutational analysis of the TP53 gene in a cohort of colorectal cancer patients revealed a c.304ins(GCG) variant that co‑occurs with a p.Ser63Asn substitution and a T>G transversion at nucleotide position c.4508, suggesting a complex haplotype that may influence tumor aggressiveness.",-50.75,0.4,sequencevariant
Mutations such as the c.304ins(GCG) insertion and the p.Ser63Asn substitution in the TP53 gene are associated with increased susceptibility to colorectal cancer in patients with the rs2073601-rs2073416 haplotype.,-23.5,0.4,sequencevariant
Mutagenesis of the TP53 gene in H1299 cells revealed that the c.1072T> C transition creates a p.Ser63Asn variant that markedly reduces p53 transcriptional activity and enhances cellular resistance to doxorubicin.,-32.0,0.4,sequencevariant
"Mutating the TP53 gene to the c.1072T>C variant in A549 cells increases the expression of the pro‑apoptotic gene BAX, thereby enhancing doxorubicin‑induced apoptosis.",-30.75,0.4,sequencevariant
"Genotyping of a colorectal cancer cohort revealed that the c.304ins(GCG) variant in KRAS, the rs2073601-rs2073416 haplotype, and the p.Ser63Asn substitution in the TP53 DNA‑binding domain were each associated with a higher likelihood of resistance to the EGFR inhibitor cetuximab.",-44.25,0.4,sequencevariant
"Genetic analysis of a colorectal carcinoma sample revealed a c.304ins(GCG) mutation in the APC gene, a p.Ser63Asn variant in the TP53 gene, and a T→G transversion at nucleotide position c.4508 in the KRAS gene, all of which are associated with aggressive tumor behavior.",-52.0,0.4,sequencevariant
"Genomic analysis of a colorectal carcinoma sample revealed a c.304ins(GCG) insertion at exon seven of the APC gene, a Gln266His missense mutation in the KRAS protein, and a r.2521_2634del deletion spanning the splice donor site of the SMAD4 transcript, all of which are predicted to disrupt tumor suppressor pathways.",-51.75,0.4,sequencevariant
"Genotype analysis of the TP53 gene in a cohort of breast cancer patients revealed a c.304insGCG variant that co‑segregated with a p.Ser63Asn substitution and a Gln266His change, suggesting a compound mutation that may influence tumor suppressor activity.",-43.25,0.4,sequencevariant
"Recent genome‑wide association studies revealed that the rs2073601‑rs2073416 haplotype, which includes a T‑>G transversion at nucleotide position c.4508 and a c.304ins(GCG) insertion, is strongly linked to an increased risk of Parkinson’s disease in individuals carrying the Gln266His variant of the LRRK2 gene.",-45.75,0.4,sequencevariant
"Recent CRISPR‑Cas9 editing of the TP53 gene in H1299 cells introduced a c.304ins(GCG) variant that replaces the proline at codon‑484 with arginine, thereby abolishing the p.Ser63Asn phosphorylation site and reducing the cells’ sensitivity to doxorubicin.",-49.0,0.4,sequencevariant
"Recent functional assays revealed that the c.1072T> C substitution in the TP53 gene, together with the rs2073601-rs2073416 haplotype, increases the risk of early‑onset colorectal cancer in a cohort of Homo sapiens patients.",-40.75,0.4,sequencevariant
"Recent sequencing of a breast cancer cohort revealed that the c.1072T>G transversion at nucleotide position **4508** in the *BRCA1* gene, together with a **p.Ser63Asn** substitution in the *TP53* gene, was strongly associated with increased risk of early‑onset triple‑negative disease.",-60.25,0.4,sequencevariant
"The novel indel polymorphism at position –4825 in the promoter of the TP53 gene, together with the p.R315X nonsense mutation in its coding region, was found to synergistically increase the risk of sporadic colorectal cancer in a cohort of Homo sapiens patients.",-29.625,0.4,sequencevariant
"The p.R315X nonsense variant in the TP53 gene, located at nucleotide position c.945, was identified in a cohort of colorectal cancer patients and is associated with a higher risk of early metastasis.",-33.75,0.4,sequencevariant
"The CRISPR‑generated indel polymorphism at position –4825 in the TP53 promoter region was associated with a significant reduction in p53 transcriptional activity, thereby increasing susceptibility to radiation‑induced apoptosis in HeLa cells.",-24.0,0.4,sequencevariant
"The indel polymorphism at position –4825 in the promoter of the TP53 gene was found to correlate with increased expression of the p.R315X truncated protein in A549 cells, suggesting a potential mechanism for the observed heightened sensitivity to doxorubicin in this cell line.",-29.125,0.4,sequencevariant
"Loss of the indel polymorphism at position –4825 in the promoter of the TP53 gene reduces its transcriptional activity, thereby increasing the risk of breast cancer in carriers of the BRCA1 c.1284A>C variant.",-27.25,0.4,sequencevariant
Lossy deletion of the indel polymorphism at position -4825 in the promoter of the TP53 gene was associated with increased expression of the downstream gene BAX in HeLa cells treated with doxorubicin.,-38.75,0.4,sequencevariant
"Loss-of-function indel polymorphism at position –4825 in the promoter of the CYP2D6 gene is associated with reduced enzymatic activity, while the missense variant p.R315X in the same locus leads to a truncated protein that further exacerbates drug metabolism deficiencies in patients with the rs3818247 genotype.",-45.25,0.4,sequencevariant
"Losses in the p.R315X sequence variant of the TP53 gene, combined with the G472A polymorphism in the promoter region, were associated with increased susceptibility to chemotherapy‑induced apoptosis in A549 cells.",-39.5,0.4,sequencevariant
"A novel indel polymorphism at position –4825 in the promoter of the TP53 gene was found to enhance transcriptional activity in HeLa cells, whereas the p.R315X truncating mutation in the same locus was associated with reduced expression of the tumor suppressor protein.",-30.0,0.4,sequencevariant
"A CRISPR‑generated indel polymorphism at position –4825 in the TP53 promoter reduces binding of the transcription factor p53, thereby attenuating the expression of the downstream gene BAX in HeLa cells.",-23.125,0.4,sequencevariant
"A single‑cell sequencing study of the A549 cell line revealed that the indel polymorphism at position –4825 in the TP53 promoter region, together with the p.R315X truncation in the KRAS gene, correlates with increased expression of the heat‑shock protein HSPA1A and heightened sensitivity to the chemotherapeutic agent doxorubicin.",-40.5,0.4,sequencevariant
"A heterozygous indel polymorphism at position –4825 in the TP53 promoter region was associated with increased susceptibility to chemotherapy‑induced apoptosis in A549 cells, while the p.R315X nonsense mutation in the same gene was found to abolish p53‑dependent transcriptional activation of the CDKN1A promoter.",-33.0,0.4,sequencevariant
An indel polymorphism at position –4825 in the promoter of the CYP2D6 gene was found to be associated with altered drug metabolism in a cohort of Homo sapiens volunteers.,-23.25,0.4,sequencevariant
"An A549 cell line harboring the p.R315X sequence variant exhibited markedly reduced EGFR expression, suggesting that this nonsense mutation disrupts receptor signaling in lung carcinoma.",-26.25,0.4,sequencevariant
"An in‑frame indel polymorphism at position –4825 in the promoter of the CYP2D6 gene, together with the missense variant p.R315X in the coding region, was associated with a two‑fold increase in tacrolimus clearance in a cohort of healthy Homo sapiens volunteers.",-37.5,0.4,sequencevariant
"An insertion–deletion polymorphism at position –4825 in the promoter of the CYP2D6 gene, combined with the p.R315X nonsense mutation in the coding region, is associated with markedly reduced enzymatic activity and increased risk of adverse drug reactions in patients with schizophrenia treated with clozapine.",-37.25,0.4,sequencevariant
"In *Homo sapiens* fibroblasts, the indel polymorphism at position –4825 upstream of the *COL1A1* promoter was found to enhance transcriptional activity, whereas the p.R315X nonsense mutation in *TP53* led to loss of p53 protein stability and increased susceptibility to UV‑induced apoptosis.",-38.25,0.4,sequencevariant
"In HepG2 cells, the indel polymorphism at position –4825 in the promoter of the CYP2E1 gene reduces transcriptional activity, while the p.R315X nonsense mutation in the same locus truncates the protein, leading to impaired detoxification of ethanol.",-27.75,0.4,sequencevariant
"In HeLa cells, the indel polymorphism at position –4825 within the TP53 promoter region was found to enhance transcriptional activity, thereby increasing the expression of the downstream p.R315X variant and amplifying the apoptotic response to doxorubicin treatment.",-28.875,0.4,sequencevariant
"In colorectal carcinoma cell lines, the indel polymorphism at position –4825 in the APC promoter region was found to upregulate β‑catenin signaling, while the p.R315X truncation in the KRAS gene abolished GTPase activity and conferred resistance to the EGFR inhibitor erlotinib.",-33.75,0.4,sequencevariant
Cell line A549 carrying the p.R315X sequence variant exhibited a marked reduction in VEGF‑induced angiogenesis compared with the wild‑type A549 cells.,-29.75,0.4,sequencevariant
"Cell lines derived from A549 cells harboring the indel polymorphism at position –4825 exhibit reduced expression of the TP53 gene, while the p.R315X variant in the same line leads to a truncated, nonfunctional p53 protein.",-40.0,0.4,sequencevariant
"Cell culture of A549 cells transfected with the CRISPR‑Cas9 construct targeting the BRCA1 locus revealed that the indel polymorphism at position −4825 caused a frameshift leading to a premature p.R315X truncation, which in turn reduced homologous recombination repair activity and increased sensitivity to the DNA‑damaging agent doxorubicin.",-42.0,0.4,sequencevariant
"Cell‑line A549 carrying the indel polymorphism at position –4825 exhibits reduced expression of the p.R315X variant of the TP53 gene, leading to increased sensitivity to doxorubicin.",-31.25,0.4,sequencevariant
"Sequencing of the TP53 gene in a cohort of colorectal cancer patients revealed a p.R315X nonsense mutation and an indel polymorphism at position –4825, both of which were significantly associated with reduced survival.",-27.75,0.4,sequencevariant
"Sequenced tumor DNA from the A549 cell line revealed a p.R315X truncation in the TP53 gene, a G472A missense variant in the KRAS locus, and an indel polymorphism at position –4825 that together correlate with increased cisplatin resistance.",-37.75,0.4,sequencevariant
"Sequenom genotyping revealed that the indel polymorphism at position –4825 in the promoter of the TP53 gene was associated with increased expression of the p.R315X truncated protein, which in turn was linked to higher rates of apoptosis in HeLa cells treated with doxorubicin.",-44.25,0.4,sequencevariant
"Sequenza analysis of the tumor revealed a novel indel polymorphism at position –4825 that co‑occurs with the p.R315X nonsense mutation, suggesting a combined loss‑of‑function effect on the TP53 gene product.",-36.25,0.4,sequencevariant
"Patients treated with the novel drug A-12345 exhibited a marked reduction in tumor volume in the A549 cell line, an effect that was significantly amplified in cells harboring the indel polymorphism at position -4825, which appears to alter the transcriptional regulation of the TP53 gene.",-51.0,0.4,sequencevariant
"Patients with the G472A sequence variant in the promoter of the CYP2C9 gene exhibited markedly reduced enzyme activity, leading to elevated plasma concentrations of the antidiabetic drug metformin.",-27.875,0.4,sequencevariant
Patients carrying the indel polymorphism at position –4825 in the TP53 promoter exhibited a two‑fold increase in p53‑mediated apoptosis compared with individuals lacking this variant.,-23.5,0.4,sequencevariant
"Patients harboring the indel polymorphism at position –4825 in the promoter of the HIF1A gene exhibited a markedly increased expression of the p.R315X truncated protein, which in turn amplified VEGFA secretion and promoted angiogenesis in HeLa cells.",-36.0,0.4,sequencevariant
"Activation of the p.R315X sequence variant in the TP53 gene by CRISPR‑Cas9 editing in A549 cells resulted in a truncated protein that fails to bind the MDM2 promoter, thereby enhancing p53‑dependent apoptosis in response to doxorubicin treatment.",-33.0,0.4,sequencevariant
"Activation-induced cytidine deaminase (AID) preferentially targets the immunoglobulin heavy chain locus in B cells, where a G to A transition at nucleotide position **2141** within the switch region generates a **p.R315X** nonsense mutation that truncates the protein and impairs class‑switch recombination.",-55.0,0.4,sequencevariant
Activation timing of the p.R315X sequence variant in the TP53 gene was found to increase apoptosis in A549 cells treated with doxorubicin.,-37.25,0.4,sequencevariant
"Activation‐induced apoptosis in A549 cells was markedly enhanced by the p.R315X sequence variant, which introduces a premature stop codon in the TP53 gene and reduces its transcriptional activity.",-41.25,0.4,sequencevariant
"Functional analysis of the p.R315X sequence variant in the TP53 gene revealed a premature stop codon that abolishes the DNA‑binding domain, thereby impairing the transcriptional activation of downstream apoptotic genes in HeLa cells.",-29.875,0.4,sequencevariant
"Functional studies revealed that the indel polymorphism at position -4825 in the promoter of the TP53 gene reduces its transcriptional activity, thereby increasing susceptibility to chemotherapy-induced apoptosis in A549 cells.",-27.0,0.4,sequencevariant
Functional assay of the p.R315X sequence variant in the TP53 gene revealed a loss of DNA‑binding activity that correlated with increased apoptosis in HeLa cells treated with doxorubicin.,-28.25,0.4,sequencevariant
"Functional complementation assays revealed that the indel polymorphism at position –4825 in the promoter of the GATA3 gene, together with the p.R315X truncation in the coding region, synergistically increased the expression of the IL2 receptor alpha chain in Jurkat T cells, thereby enhancing downstream STAT5 phosphorylation.",-53.25,0.4,sequencevariant
"Experimental data showed that the indel polymorphism at position –4825 in the promoter of the CYP2D6 gene significantly increased transcriptional activity, while the missense variant p.R315X in the coding region of the same gene was associated with reduced enzymatic function.",-39.25,0.4,sequencevariant
"Experimental CRISPR editing of the TP53 gene in A549 cells revealed that the p.R315X indel polymorphism at position -4825 dramatically increased apoptosis, while the G472A variant of the same locus reduced p53 protein stability.",-38.25,0.4,sequencevariant
"Experimental correction of the p.R315X sequence variant in the TP53 gene restored apoptotic signaling in A549 cells, demonstrating that this nonsense mutation underlies the observed chemoresistance.",-34.0,0.4,sequencevariant
"Experimental replication of the p.R315X sequence variant in the TP53 gene, introduced by a G to A substitution at nucleotide position −4825, revealed a loss of DNA‑binding activity and a corresponding increase in apoptosis in HeLa cells.",-50.25,0.4,sequencevariant
"Mutation of the BRCA1 gene at c.1284A>C, a sequence variant that introduces a p.Val153Ile substitution, has been linked to increased breast cancer risk in patients carrying the rs3818247 allele.",-27.5,0.4,sequencevariant
"Mutation p.R315X in the TP53 gene, an indel polymorphism at position –4825, and the G472A sequence variant were all found to increase the risk of developing colorectal cancer in a cohort of Homo sapiens patients.",-26.125,0.4,sequencevariant
"Mutation A1284C in the TP53 gene, a p.R315X nonsense variant, and the G472A polymorphism together increase the risk of colorectal cancer in patients carrying the rs3818247 allele.",-32.25,0.4,sequencevariant
Mutation analysis of the BRCA1 gene revealed a p.R315X sequence variant that truncates the protein and is associated with a markedly increased risk of breast cancer in carriers of the rs3818247 allele.,-27.75,0.4,sequencevariant
Indels such as the -4825 deletion and the p.R315X nonsense mutation in the TP53 gene are associated with increased risk of sporadic colorectal cancer in individuals carrying the rs3818247 allele.,-30.25,0.4,sequencevariant
"Indel polymorphism at position –4825 in the TP53 promoter region was found to increase the risk of breast cancer in a cohort of Homo sapiens patients, while the p.R315X truncating mutation in the same gene was associated with a severe form of Li–Fraumeni syndrome.",-32.75,0.4,sequencevariant
"Induced pluripotent stem cells derived from a patient harboring the p.R315X sequence variant displayed impaired differentiation into dopaminergic neurons, suggesting that this nonsense mutation in the LRRK2 gene contributes to Parkinson’s disease pathogenesis.",-28.625,0.4,sequencevariant
"Induction of apoptosis in HeLa cells harboring the p.R315X sequence variant was markedly enhanced by treatment with the small molecule doxorubicin, revealing a synergistic interaction between the genetic mutation and the chemotherapeutic agent.",-29.25,0.4,sequencevariant
"Pseudomonas aeruginosa harboring the indel polymorphism at position –4825 in the oprD gene exhibited markedly increased resistance to carbapenem antibiotics, while the same strain with a p.R315X truncation in the mexR regulator showed a dramatic up‑regulation of the MexAB-OprM efflux system.",-41.5,0.4,sequencevariant
"Pangolin cells harbor an indel polymorphism at position –4825 that disrupts the promoter of the TP53 gene, leading to reduced transcription and increased susceptibility to p.R315X‑mediated apoptosis.",-37.5,0.4,sequencevariant
"P.R315X, an indel polymorphism at position -4825, was identified in the promoter of the TP53 gene and is associated with increased susceptibility to Parkinson’s disease in a cohort of Homo sapiens.",-31.375,0.4,sequencevariant
"P‑R315X, an indel polymorphism at position –4825, was detected in the TP53 gene of a patient with early‑onset colorectal cancer, and the variant’s presence was associated with a higher risk of disease progression.",-35.25,0.4,sequencevariant
"In colorectal carcinoma cells, the c.686C>G sequence variant in the KRAS gene leads to a Gly49Ser substitution that activates downstream MAPK signaling and enhances resistance to the EGFR inhibitor cetuximab.",-21.375,0.4,sequencevariant
"In HCT116 cells, the c.686C>G sequence variant in exon six of TP53, which replaces phenylalanine with cysteine at codon‑482, induces a gain‑of‑function phenotype that enhances DNA damage‑induced apoptosis.",-44.75,0.4,sequencevariant
"In A549 cells harboring the c.686C>G sequence variant, the resulting Gly49Ser substitution in the TP53 protein was shown to impair DNA binding and increase cellular sensitivity to doxorubicin-induced apoptosis.",-21.75,0.4,sequencevariant
"In the A549 cell line, the c.686C>G sequence variant in the KRAS gene produces a Gly49Ser substitution that enhances ERK phosphorylation and confers resistance to the EGFR inhibitor gefitinib.",-20.5,0.4,sequencevariant
"The c.686C>G sequence variant in the BRCA1 gene, resulting in a Gly49Ser substitution, was found to increase breast cancer risk in a cohort of Homo sapiens patients.",-17.25,0.4,sequencevariant
"The BRCA1 c.686C>G sequence variant, which replaces phenylalanine with cysteine at exon‑6 codon‑482, was found to increase breast cancer risk in a cohort of Homo sapiens patients.",-26.75,0.4,sequencevariant
"The CRISPR‑generated A549 cells harbor a c.686C>G sequence variant that converts phenylalanine to cysteine at exon‑6 codon‑482, causing a Gly49Ser substitution in the TP53 protein and resulting in heightened apoptosis upon doxorubicin treatment.",-34.5,0.4,sequencevariant
"The Gly49Ser sequence variant in the CYP2D6 gene, a C-to-G transition at nucleotide position c.686C>G, was found to reduce enzyme activity and increase the risk of adverse drug reactions in a cohort of Homo sapiens patients.",-40.25,0.4,sequencevariant
"Panc‑1 cells carrying the c.686C>G sequence variant, which substitutes phenylalanine for cysteine at exon‑6 codon‑482, exhibited markedly increased resistance to cisplatin compared with cells harboring the wild‑type TP53 sequence.",-42.75,0.4,sequencevariant
"Pseudomonas aeruginosa strain PAO1 carrying the c.686C>G sequence variant in the oprD gene exhibits reduced carbapenem susceptibility, while the same mutation in a clinical isolate of Acinetobacter baumannii leads to a dramatic increase in colistin MIC.",-35.25,0.4,sequencevariant
"Phe482Cys, a Gly49Ser substitution in exon six of the TP53 gene, was detected in a patient with a c.686C>G sequence variant and a c.94C>T transition, suggesting a combined effect on protein stability and tumor suppressor function.",-44.5,0.4,sequencevariant
"P293T, a c.686C>G sequence variant in the TP53 gene, was found to replace phenylalanine with cysteine in exon six at codon‑482, thereby disrupting the DNA‑binding domain and increasing susceptibility to colorectal cancer in a cohort of Homo sapiens patients.",-55.25,0.4,sequencevariant
"A c.686C>G sequence variant in the TP53 gene, resulting in a Gly49Ser substitution, was found to increase the risk of early-onset breast cancer in a cohort of Homo sapiens patients.",-20.625,0.4,sequencevariant
"A breast cancer patient carrying the BRCA1 c.686C>G sequence variant, which substitutes a phenylalanine for a cysteine at exon‑6 codon‑482, exhibited markedly increased sensitivity to the PARP inhibitor olaparib.",-31.75,0.4,sequencevariant
"A novel c.686C>G sequence variant in the TP53 gene, resulting in a Gly49Ser substitution, was found to increase the risk of chemotherapy‑induced cardiotoxicity in a cohort of E. coli‑derived HeLa cells treated with doxorubicin.",-26.75,0.4,sequencevariant
"A CRISPR‑Cas9‑edited A549 cell line harboring the c.686C>G variant, which causes a phenylalanine to cysteine substitution at exon‑6 codon‑482, exhibited markedly increased sensitivity to doxorubicin compared with the wild‑type line.",-33.0,0.4,sequencevariant
"CRISPR‑edited A549 cells harboring the c.686C>G variant in TP53, which replaces phenylalanine with cysteine at exon‑6 codon‑482, exhibited increased p53‑dependent apoptosis compared with wild‑type cells.",-34.5,0.4,sequencevariant
"CRITICAL: The c.686C>G sequence variant in the BRCA1 gene, which converts phenylalanine to cysteine at exon six codon‑482, has been shown to increase breast‑cancer risk in a cohort of Homo sapiens patients.",-52.75,0.4,sequencevariant
"CR5‑c.686C>G, a C‑to‑G transition at nucleotide position c.686, was found to replace phenylalanine with cysteine in exon six at codon‑482, thereby generating a Gly49Ser substitution that correlates with increased disease severity in patients with the R171Q variant.",-80.5,0.4,sequencevariant
"CR‑ISPR‑generated A549 cells harboring the c.686C>G sequence variant in TP53, which converts phenylalanine to cysteine at exon‑6 codon‑482, exhibit increased sensitivity to doxorubicin compared with wild‑type cells.",-42.0,0.4,sequencevariant
"Deletion of the c.686C>G sequence variant in exon‑6 of the TP53 gene, which replaces phenylalanine with cysteine at codon‑482, was found to impair p53‑mediated apoptosis in A549 cells treated with doxorubicin.",-39.25,0.4,sequencevariant
"Deletion at c.686C>G in the TP53 gene causes a phenylalanine-to-cysteine substitution at exon‑6 codon‑482, which has been linked to increased risk of breast cancer in a cohort of Homo sapiens patients.",-43.75,0.4,sequencevariant
"Deletion and the c.686C>G transition in the BRCA1 gene, which replaces phenylalanine with cysteine at exon‑6 codon‑482, were shown to increase breast cancer risk in a cohort of Homo sapiens patients.",-43.5,0.4,sequencevariant
"Deletion plus the c.686C>G transition in exon six of the TP53 gene, which replaces phenylalanine with cysteine at codon‑482, was found in a HeLa cell line derived from a Homo sapiens patient with a severe neurodegenerative phenotype.",-57.75,0.4,sequencevariant
Patients with the c.686C>G sequence variant in the BRCA1 gene exhibited a markedly increased risk of breast cancer compared with carriers of the wild‑type allele.,-18.375,0.4,sequencevariant
"Patients homozygous for the c.686C>G sequence variant, which replaces phenylalanine with cysteine at exon‑6 codon‑482, exhibit markedly increased susceptibility to drug‑induced cardiotoxicity compared with wild‑type controls.",-35.5,0.4,sequencevariant
"Patients harboring the c.686C>G sequence variant, which substitutes phenylalanine for cysteine at exon‑6 codon‑482, exhibit markedly increased susceptibility to the neurodegenerative phenotype associated with the R171Q mutation in the same gene.",-32.0,0.4,sequencevariant
"Patients treated with the novel kinase inhibitor showed a significant reduction in tumor burden, and sequencing of the TP53 gene in their A549 cells revealed a c.686C>G variant that introduced a Gly49Ser substitution in the DNA‑binding domain, potentially altering p53’s transcriptional activity.",-43.75,0.4,sequencevariant
"Structural modeling of the BRCA1 c.686C>G variant predicts that the R171Q substitution in exon six destabilizes the protein’s BRCT domain, thereby impairing DNA repair and increasing breast cancer susceptibility.",-35.75,0.4,sequencevariant
"Structural destabilization of the TP53 protein was observed in a patient harboring the c.686C>G sequence variant, which replaces a phenylalanine with a polar cysteine at exon‑6 codon‑482, thereby impairing its DNA‑binding domain.",-43.75,0.4,sequencevariant
"Structural analysis of the BRCA1 c.686C>G variant, which causes a phenylalanine-to-cysteine substitution at exon‑6 codon‑482, revealed that the Gly49Ser mutation in the adjacent domain disrupts DNA‑binding affinity and enhances tumor‑suppressor loss in Homo sapiens cells.",-47.0,0.4,sequencevariant
"Structural studies revealed that the c.686C>G variant in the TP53 gene, which substitutes phenylalanine for cysteine at exon‑6 codon‑482, disrupts the DNA‑binding domain and increases susceptibility to Li‑type neurodegeneration in Homo sapiens.",-47.5,0.4,sequencevariant
"SNP c.686C>G in the BRCA1 gene causes a phenylalanine-to-cysteine substitution at exon‑6 codon‑482, which has been linked to increased breast‑cancer risk in European populations.",-33.75,0.4,sequencevariant
"SARS‑CoV‑2 infection in a patient carrying the BRCA1 c.686C>G variant, which substitutes phenylalanine for cysteine at exon‑6 codon‑482, was associated with an unexpectedly severe pulmonary phenotype.",-35.0,0.4,sequencevariant
"Sanger sequencing of the BRCA1 gene in a breast cancer cohort revealed a c.686C>G transition that changes phenylalanine to cysteine at exon‑6 codon‑482, a variant previously associated with increased tumor aggressiveness.",-37.75,0.4,sequencevariant
"Sporadic c.686C>G mutations in the TP53 gene, resulting in a Gly49Ser substitution, were found to increase the risk of early‑onset colorectal cancer in a cohort of Homo sapiens patients.",-39.75,0.4,sequencevariant
"Cell line A549 carrying the c.686C>G sequence variant in the TP53 gene exhibits increased sensitivity to doxorubicin, while the same variant in the same gene in HeLa cells does not alter drug response.",-30.125,0.4,sequencevariant
"Cell death in the A549 cell line was accelerated by the c.686C>G sequence variant, which replaces phenylalanine with cysteine at exon‑6 codon‑482, thereby enhancing the apoptotic response to doxorubicin.",-38.0,0.4,sequencevariant
"Cell‑line A549 harboring the c.686C>G sequence variant, which substitutes phenylalanine for cysteine at exon‑6 codon‑482, shows markedly increased sensitivity to the chemotherapeutic agent doxorubicin.",-32.75,0.4,sequencevariant
"Cell lines derived from A549 cells harbor a c.686C>G sequence variant in the KRAS gene, which replaces phenylalanine with cysteine at codon‑482 in exon‑6 and has been associated with increased tumorigenicity.",-47.25,0.4,sequencevariant
"Sequencing of the BRCA1 gene in a breast cancer cohort revealed a c.686C>G transition that converts phenylalanine to cysteine at exon‑6 codon‑482, a change predicted to destabilize the protein’s DNA‑binding domain.",-33.75,0.4,sequencevariant
"Sequenced tumors from a colorectal cancer cohort revealed a recurrent c.686C>G transition in the KRAS gene, resulting in a Gly49Ser substitution that correlated with increased resistance to cetuximab in patients harboring the variant.",-37.5,0.4,sequencevariant
"Sequencereporting a c.686C>G transition in exon‑6 of the BRCA1 gene, the resulting phenylalanine‑to‑cysteine substitution at codon‑482 was found to increase breast cancer risk in a cohort of Homo sapiens patients.",-52.75,0.4,sequencevariant
"Sequencer analysis of a pancreatic carcinoma sample revealed a c.686C>G transition in the KRAS gene, resulting in a Gly49Ser amino‑acid substitution that is predicted to disrupt GTPase activity and promote oncogenic signaling.",-37.0,0.4,sequencevariant
"Mutating the BRCA1 gene to the c.686C>G variant, which replaces phenylalanine with cysteine at exon‑6 codon‑482, was shown to increase homologous recombination repair activity in HeLa cells.",-36.25,0.4,sequencevariant
"Mutations such as the c.686C>G transition in exon six, which replaces phenylalanine with cysteine at codon‑482, and the Gly49Ser substitution in the TP53 gene were found to increase the risk of breast cancer in patients carrying the BRCA1 c.1123T>G variant.",-42.75,0.4,sequencevariant
"Mutagenesis of the TP53 gene in HeLa cells revealed a c.686C>G sequence variant that substitutes phenylalanine for cysteine at codon‑482, impairing DNA‑binding activity and increasing apoptosis in response to doxorubicin treatment.",-39.5,0.4,sequencevariant
"Mutational analysis of the TP53 gene in the A549 cell line revealed a c.686C>G sequence variant that changes phenylalanine to cysteine at codon‑482, correlating with increased apoptosis in response to doxorubicin.",-35.5,0.4,sequencevariant
"Experimental CRISPR‑Cas9 editing of the TP53 gene in A549 cells introduced a c.686C>G sequence variant that converts phenylalanine to cysteine at exon‑6 codon‑482, resulting in altered DNA‑binding affinity and increased apoptosis.",-36.0,0.4,sequencevariant
"Experimental validation revealed that the c.686C>G sequence variant in exon six of the TP53 gene, which causes a phenylalanine-to-cysteine substitution at codon‑482, markedly reduces p53 DNA‑binding affinity and increases cellular susceptibility to doxorubicin‑induced apoptosis in A549 cells.",-49.0,0.4,sequencevariant
"Experimental analysis revealed that the c.686C>G sequence variant in exon six, which replaces phenylalanine with cysteine at codon‑482 in the TP53 gene, is associated with increased apoptosis in HeLa cells treated with doxorubicin.",-42.25,0.4,sequencevariant
"Experimental evidence shows that the c.686C>G sequence variant in exon‑6 of the TP53 gene, which replaces phenylalanine with cysteine at codon‑482, impairs p53 DNA‑binding activity and increases susceptibility to malignant transformation in A549 lung carcinoma cells.",-46.0,0.4,sequencevariant
Administration of the CRISPR‑Cas9 system to correct the c.686C>G sequence variant in the BRCA1 gene of HeLa cells restored homologous recombination activity and reduced the accumulation of DNA double‑strand breaks.,-30.125,0.4,sequencevariant
"Administration to A549 cells of a CRISPR‑Cas9‑generated sequence variant, c.686C>G, which replaces phenylalanine with cysteine at exon‑6 codon‑482, markedly increased TP53‑mediated apoptosis while sparing normal HeLa cell viability.",-54.5,0.4,sequencevariant
"Administration with the CRISPR‑Cas9 system introduced a c.686C>G sequence variant in the TP53 gene of A549 cells, resulting in a phenylalanine-to-cysteine substitution at codon‑482 that markedly increased apoptosis in response to doxorubicin.",-55.25,0.4,sequencevariant
"Administration‑induced upregulation of the TP53 gene in A549 cells carrying the c.686C>G sequence variant, which results in a phenylalanine to cysteine substitution at exon‑6 codon‑482, was associated with increased apoptosis and cell‑cycle arrest.",-54.5,0.4,sequencevariant
"The rs3806325 variant, a G145R substitution in the TP53 gene, was found to increase the risk of Parkinson’s disease in a cohort of Homo sapiens patients.",-17.625,0.4,sequencevariant
"The BRCA1 rs3806325 sequence variant, a Cys23Ser substitution, is associated with increased breast cancer risk in women of European ancestry.",-16.5,0.4,sequencevariant
"The c.1188‑A/C polymorphism (rs3806325) in the promoter of the CYP2C9 gene creates a G‑to‑A transition at the –4 base‑pair position, resulting in a valine‑to‑alanine substitution at amino acid residue sixteen that is associated with altered drug metabolism in Homo sapiens.",-43.25,0.4,sequencevariant
"The previously uncharacterized sequence variant rs3806325, a G145R substitution in the N‑terminal domain of the TP53 protein, was found to increase the transcriptional activity of the downstream MDM2 promoter in HeLa cells, thereby enhancing p53‑mediated apoptosis in response to doxorubicin.",-42.25,0.4,sequencevariant
"In the A549 cell line, the rs3806325 G145R sequence variant, a valine-to-alanine substitution at amino acid position sixteen, was found to upregulate the expression of the TP53 gene, thereby enhancing apoptosis in response to doxorubicin treatment.",-34.25,0.4,sequencevariant
"In Jurkat T cells, the rs3806325 single‑nucleotide polymorphism, which causes a G145R amino‑acid substitution in the IL2RA gene, was found to enhance STAT5 phosphorylation and increase IL‑2‑induced proliferation.",-30.5,0.4,sequencevariant
"In HepG2 cells, the rs3806325 G145R sequence variant, a valine-to-alanine substitution at amino acid position sixteen in the KRAS gene, was shown to increase ERK phosphorylation and promote proliferation.",-38.25,0.4,sequencevariant
"In breast carcinoma cells, the rs3806325 SNP causes a G145R substitution in the BRCA1 protein, which enhances DNA repair deficiency and increases susceptibility to platinum‑based chemotherapy resistance.",-32.0,0.4,sequencevariant
"A valine (Val) to alanine (Ala) substitution at amino acid position sixteen in the TP53 gene, encoded by the rs3806325 variant, was found to increase the risk of colorectal cancer in a cohort of Homo sapiens patients.",-36.0,0.4,sequencevariant
"A pathogenic sequence variant, a G145R missense mutation in the TP53 gene, was identified in a patient with early‑onset colorectal cancer, and functional assays showed that the G145R substitution disrupts p53 DNA‑binding activity, thereby contributing to tumorigenesis.",-33.75,0.4,sequencevariant
"A G145R sequence variant in the TP53 gene, identified as rs3806325, has been shown to increase the risk of early-onset colorectal cancer in individuals of European descent.",-22.125,0.4,sequencevariant
"A missense sequence variant rs3806325, which causes a G145R substitution in the protein, has been associated with increased risk of early‑onset Parkinson’s disease in a cohort of Homo sapiens patients.",-26.125,0.4,sequencevariant
"G183S, a sequence variant in the CYP2C9 gene, has been shown to reduce warfarin metabolism in patients carrying the rs7582694 allele, thereby increasing the risk of bleeding complications.",-26.625,0.4,sequencevariant
"G145R, a valine-to-alanine substitution at amino acid position sixteen in the BRCA1 gene, was identified in a patient with a germline sequence variant rs3806325, which also harbored a -4‑basepair G‑to‑A deletion in the promoter region.",-48.25,0.4,sequencevariant
"G182S, a sequence variant in the TP53 gene, was found to increase the risk of early‑onset colorectal cancer in a cohort of Homo sapiens patients carrying the rs3806325 allele.",-32.0,0.4,sequencevariant
"G184S, a sequence variant in the TP53 gene, was found to increase the risk of breast cancer in a cohort of Homo sapiens patients carrying the rs3806325 allele.",-26.125,0.4,sequencevariant
"Sequence analysis of the TP53 gene in a cohort of colorectal cancer patients revealed that the rs3806325 variant, a G145R substitution, is associated with increased tumor aggressiveness and a higher likelihood of metastasis.",-31.5,0.4,sequencevariant
"Sequence variant rs3806325, a G-to-A substitution at position -4 in the promoter, is associated with increased expression of the CYP2D6 gene in Homo sapiens, thereby enhancing the metabolism of the chemical entity tramadol.",-34.25,0.4,sequencevariant
Sequence variants such as rs3806325 and the G145R substitution in the TP53 gene were associated with increased risk of colorectal cancer in a cohort of Homo sapiens patients.,-25.625,0.4,sequencevariant
"Sequence analyses of the TP53 gene in a cohort of breast cancer patients revealed that the rs3806325 G145R variant, which causes a valine-to-alanine substitution at amino acid position sixteen, is strongly associated with increased tumor aggressiveness and poorer overall survival.",-44.0,0.4,sequencevariant
"CRISPR‑Cas9 editing of the TP53 gene in A549 cells introduced a valine‑to‑alanine substitution at amino acid position‑16, creating a sequence variant that reduced p53‑mediated apoptosis in response to doxorubicin.",-36.75,0.4,sequencevariant
CR‑ISPR‑edited A549 cells harboring the rs3806325 G145R sequence variant exhibit a valine‑to‑alanine substitution at amino acid position‑16 that markedly reduces EGFR‑ligand binding affinity.,-51.0,0.4,sequencevariant
"CRTC1 rs3806325, a Cys23Ser sequence variant, was found to alter the transcriptional activity of the CREB pathway in HepG2 cells, thereby modulating the expression of the downstream gene GABRA1.",-47.75,0.4,sequencevariant
"CR8 cells harboring the rs3806325 sequence variant exhibit a G145R substitution that reduces binding affinity for the transcription factor NF‑κB, thereby attenuating downstream IL‑6 production.",-38.25,0.4,sequencevariant
"An identified sequence variant, rs3806325, introduces a G145R substitution in the protein, and the concurrent g.3318-34C>T change is predicted to alter splicing, potentially impacting the function of the associated gene in Homo sapiens.",-44.0,0.4,sequencevariant
"An SNP rs3806325 in the promoter of the CYP2D6 gene, a G145R missense mutation in the HBB gene, and a -4‑basepair G‑to‑A deletion in the regulatory region of the BRCA1 gene were each found to alter transcription factor binding and increase susceptibility to drug‑induced hepatotoxicity in a cohort of Homo sapiens subjects.",-54.75,0.4,sequencevariant
"An A549 cell line harboring the BRCA1 c.68_69delAG sequence variant exhibited a markedly reduced response to doxorubicin, suggesting that this mutation impairs DNA repair pathways in human carcinoma cells.",-29.0,0.4,sequencevariant
"An HLA‑B*1501 allele harboring the rs3806325 variant, which introduces a G145R substitution in the peptide‑binding groove, was found to increase susceptibility to drug‑induced hypersensitivity reactions in a cohort of E. coli‑derived cell lines.",-38.5,0.4,sequencevariant
"Mutagenesis of the TP53 gene in HCT116 cells, introducing a valine-to-alanine substitution at amino acid position sixteen (V16A) and a G183S variant, led to a significant reduction in p53 transcriptional activity and increased cellular resistance to doxorubicin.",-45.25,0.4,sequencevariant
"Mutations such as the rs3806325 G145R variant and the -4‑basepair G‑to‑A substitution in the promoter region of the CYP2D6 gene have been shown to alter enzyme activity, thereby influencing the pharmacokinetics of the chemotherapeutic agent doxorubicin in patients with colorectal cancer.",-30.125,0.4,sequencevariant
"Mutational analysis of the TP53 gene in a cohort of colorectal cancer patients revealed that the rs3806325 variant, a G145R substitution, was significantly associated with increased tumor aggressiveness and poorer overall survival.",-26.375,0.4,sequencevariant
"Mutant cell line A549 harboring the BRCA1 c.68_69delAG sequence variant exhibited increased sensitivity to the DNA‑damaging agent doxorubicin, whereas the wild‑type line did not.",-29.125,0.4,sequencevariant
Alterations such as the rs3806325 variant and the G145R amino‑acid change in the TP53 gene have been linked to increased susceptibility to chemotherapy‑induced apoptosis in HeLa cells.,-24.25,0.4,sequencevariant
"Altered expression of the IL6R gene in patients carrying the rs3806325 variant, which introduces a G145R substitution, is associated with increased inflammatory cytokine production and a higher risk of developing rheumatoid arthritis.",-31.0,0.4,sequencevariant
Alteration of the BRCA1 c.68_69delAG sequence variant in a patient with triple‑negative breast cancer led to a loss of homologous recombination repair and increased sensitivity to the PARP inhibitor olaparib.,-27.625,0.4,sequencevariant
Altering the BRCA1 sequence variant rs3806325 from G to A at position c.1188 results in a G145R substitution that reduces DNA repair fidelity and increases breast cancer susceptibility in Homo sapiens.,-35.5,0.4,sequencevariant
"rs3806325, a G145R sequence variant in the CYP2D6 gene, has been associated with altered metabolism of the antipsychotic drug haloperidol in patients of European ancestry.",-24.375,0.4,sequencevariant
"rs7582694, a G-to-A transition at position −4 relative to the transcription start site, was found to co‑occur with the G183S sequence variant in the promoter of the CYP2D6 gene, suggesting a combined effect on drug‑metabolizing enzyme expression in Homo sapiens.",-41.5,0.4,sequencevariant
"rs4402960, a sequence variant in the promoter of the IL6 gene, has been shown to increase transcriptional activity and is associated with higher circulating IL‑6 levels in patients with rheumatoid arthritis.",-30.5,0.4,sequencevariant
"rs3786325, a G145R sequence variant in the TP53 gene, was associated with increased risk of breast cancer in a cohort of Homo sapiens patients.",-29.25,0.4,sequencevariant
"Experiments revealed that the rs3806325 sequence variant, a G-to-A transition at position -4, causes a valine-to-alanine substitution at amino acid residue sixteen in the TP53 protein, thereby reducing its DNA‑binding affinity and increasing susceptibility to colorectal cancer in individuals of European ancestry.",-50.75,0.4,sequencevariant
"Experential analysis of the rs3806325 SNP revealed that the G145R variant, a valine-to-alanine substitution at amino acid position sixteen, correlates with increased expression of the insulin receptor in Homo sapiens cell lines.",-53.5,0.4,sequencevariant
"Expergen, a CRISPR‑edited A549 cell line harboring the G145R sequence variant, displayed markedly increased sensitivity to doxorubicin, confirming that the valine‑to‑alanine substitution at amino acid position sixteen in TP53 enhances chemotherapeutic efficacy.",-58.75,0.4,sequencevariant
"Experencing the rs3806325 variant, a G145R substitution in the promoter region, led to a significant up‑regulation of the downstream gene product in HeLa cells, suggesting a potential pathogenic role for this sequence variant.",-51.25,0.4,sequencevariant
"Mutation g.3318-34C>T in the promoter of the BRCA1 gene was found to increase transcriptional activity, thereby elevating TP53 expression in HeLa cells and enhancing sensitivity to doxorubicin treatment.",-32.75,0.4,sequencevariant
Mutation of the BRCA1 gene at c.68_69delAG in a patient with breast cancer caused a loss of function that was confirmed by a protein‑level reduction of the BRCA1 product and a high‑risk allele rs3806325 in the surrounding genomic region.,-47.5,0.4,sequencevariant
"Mutation rs3806325, a G-to-A transition at position -4 in the promoter, is associated with increased expression of the G145R variant, which introduces a valine-to-alanine substitution at amino acid position sixteen in the protein.",-44.25,0.4,sequencevariant
"Mutation c.1188‑A>C in the BRCA1 gene, which results in the G145R amino‑acid change, has been linked to a higher risk of breast cancer in women carrying the rs3806325 allele.",-29.125,0.4,sequencevariant
"Homo sapiens carrying the rs3806325 G145R sequence variant exhibit a higher incidence of Parkinson’s disease, likely due to the valine-to-alanine substitution at amino acid position sixteen in the LRRK2 protein.",-35.75,0.4,sequencevariant
"HIV-1 infection in patients carrying the sequence variant rs3806325, a G-to-A transition at position –4 relative to the transcription start site, is associated with a statistically significant increase in viral replication and a higher risk of developing AIDS-related lymphoma.",-43.5,0.4,sequencevariant
"Heterozygous carriers of the rs3806325 variant, which causes a G145R substitution in the protein, exhibit a higher incidence of early-onset Parkinson’s disease compared to non-carriers.",-27.875,0.4,sequencevariant
"Haplotype rs3806325, containing the G145R and G183S substitutions, is associated with increased risk of Parkinson’s disease in a cohort of Homo sapiens subjects carrying the -4-basepair G-to-A variant in the promoter region of the SNCA gene.",-40.75,0.4,sequencevariant
"Functional studies revealed that the rs3806325 sequence variant, a -4‑basepair G-to-A substitution in the promoter of the TP53 gene, enhances transcriptional activity and increases susceptibility to Parkinson’s disease in a cohort of Homo sapiens patients.",-38.0,0.4,sequencevariant
"Functional analysis of the BRCA1 c.68_69delAG sequence variant revealed that the resulting truncated protein lacks the essential BRCT domain, impairing DNA repair and increasing breast cancer susceptibility in carriers.",-30.125,0.4,sequencevariant
"Functional proteomic analysis revealed that the rs3806325 variant, a G145R substitution in the kinase domain, disrupts phosphorylation of the downstream target and is associated with increased risk of Parkinson’s disease in Homo sapiens.",-40.25,0.4,sequencevariant
"Functional validation of the rs3806325 variant revealed that the G145R substitution in the promoter of the CYP2D6 gene reduces transcriptional activity, thereby decreasing drug metabolism in individuals carrying the allele.",-35.5,0.4,sequencevariant
"The c.35delG sequence variant in the BRCA1 gene, which results in a premature stop codon at p.Gln133*, is strongly associated with increased breast cancer risk in individuals of European ancestry.",-21.375,0.4,sequencevariant
"The BRCA1 c.35delG sequence variant, which deletes a guanine at position c.35, is associated with a markedly increased risk of hereditary breast and ovarian cancer in individuals carrying the allele.",-23.375,0.4,sequencevariant
"The CRISPR‑Cas9‑generated A549 cell line harboring the BRCA1 c.35delG sequence variant exhibited a pronounced reduction in homologous recombination repair activity, confirming the pathogenic impact of this deletion.",-23.5,0.4,sequencevariant
"The deleterious c.35delG sequence variant in the BRCA1 gene causes a frameshift that truncates the protein, leading to increased susceptibility to breast and ovarian cancers in carriers.",-23.625,0.4,sequencevariant
"A CRISPR‑Cas9 edited A549 cell line harboring the c.643T> C sequence variant in the TP53 gene exhibited increased apoptosis upon doxorubicin exposure, confirming the pathogenic role of this mutation.",-24.875,0.4,sequencevariant
A c.643T> C sequence variant in the BRCA1 gene was found to increase the risk of breast cancer in a cohort of Homo sapiens patients.,-18.5,0.4,sequencevariant
"A heterozygous c.643T> C sequence variant in the BRCA1 gene was found to increase the risk of breast cancer in a cohort of Homo sapiens patients, while the p.G821R mutation in the same locus was associated with a milder phenotype.",-28.625,0.4,sequencevariant
"A pathogenic sequence variant, c.643T>C, in the TP53 gene was identified in a patient with early‑onset breast cancer, and the resulting p.Leu307Arg substitution was predicted to destabilize the DNA‑binding domain, thereby compromising tumor suppressor function.",-27.375,0.4,sequencevariant
"In patients with the BRCA1 c.35delG sequence variant, the resulting p.Gly12Val protein truncation correlates with an increased risk of breast cancer in Homo sapiens.",-21.875,0.4,sequencevariant
"In HeLa cells harboring the BRCA1 c.35delG sequence variant, the p.G821R mutation in the DNA‑binding domain was shown to impair homologous recombination and increase sensitivity to the chemotherapeutic agent doxorubicin.",-22.625,0.4,sequencevariant
"In cultured A549 cells, the CRISPR‑generated c.643T> C sequence variant in the TP53 gene produced a p.Leu307Arg protein that up‑regulated the pro‑apoptotic target gene BAX, thereby sensitizing the cells to doxorubicin‑induced cell death.",-36.0,0.4,sequencevariant
"In pancreatic cancer cell lines, the c.643T>C sequence variant in the KRAS gene leads to a p.Leu307Arg substitution that increases downstream ERK signaling and enhances tumor cell migration.",-28.375,0.4,sequencevariant
"CRISPR‑Cas9 editing of the TP53 gene in A549 cells introduced a c.643T>G sequence variant that produced a p.Leu307Arg protein change, thereby reducing the cells’ sensitivity to doxorubicin.",-28.125,0.4,sequencevariant
"CRMP2 c.643T>C, a G to C point mutation in exon four, has been shown to alter neuronal growth cone dynamics and is associated with a higher risk of neurodegenerative disease in Homo sapiens.",-45.75,0.4,sequencevariant
"CRITICAL: The c.35delG sequence variant in the BRCA1 gene, which causes a frameshift and premature truncation of the protein, is strongly associated with early‑onset breast cancer in individuals of European ancestry.",-38.5,0.4,sequencevariant
"CRs2 c.35delG, a single‑base deletion in the coding region, was found to disrupt the reading frame and is associated with a severe phenotype in patients carrying the variant.",-47.25,0.4,sequencevariant
Mutations such as the c.35delG variant and the p.G821R substitution in the BRCA1 gene have been shown to increase the risk of hereditary breast cancer in patients of European ancestry.,-21.375,0.4,sequencevariant
"Mutational analysis of a colorectal carcinoma cell line revealed a c.643T>G substitution in the APC gene, generating a p.Leu307Arg variant that correlates with increased β‑catenin nuclear localization and enhanced tumorigenic potential.",-29.5,0.4,sequencevariant
"Mutagenesis of the BRCA1 gene in a breast cancer cell line revealed that the c.643T> C sequence variant, which causes a p.Leu307Arg amino‑acid substitution, significantly increased homologous recombination repair activity compared with the wild‑type allele.",-31.0,0.4,sequencevariant
Mutated BRCA1 c.35delG and the associated p.G821R sequence variant were found to increase the risk of breast cancer in a cohort of Homo sapiens patients.,-28.125,0.4,sequencevariant
Sequencing of the BRCA1 gene in a cohort of breast cancer patients revealed a novel c.643T> C variant that co‑segregated with a p.Leu307Arg amino‑acid change and was associated with an increased risk of early‑onset disease.,-26.875,0.4,sequencevariant
"Sequenced DNA from a colorectal cancer biopsy revealed a c.643T>C transition that creates a p.Leu307Arg substitution, a variant previously reported in the rs702553 locus.",-34.75,0.4,sequencevariant
Sequencia variant c.643T>C in the TP53 gene was identified in a Homo sapiens patient whose tumor cells displayed a p.G821R substitution that correlated with increased resistance to doxorubicin in A549 cell lines.,-48.5,0.4,sequencevariant
"Sequenom genotyping of a BRCA1 c.35delG variant revealed a homozygous deletion that co‑segregated with breast cancer in a family of Homo sapiens, while a separate g.99367‑102002del in the same locus was linked to ovarian carcinoma in the same pedigree.",-51.5,0.4,sequencevariant
"Mutation analysis of a colorectal carcinoma sample revealed a pathogenic c.643T>G sequence variant in the APC gene, which is predicted to cause a p.Leu307Arg amino‑acid substitution and is associated with early‑onset familial adenomatous polyposis.",-32.75,0.4,sequencevariant
"Mutation of the TP53 gene in the HeLa cell line, specifically the c.35delG sequence variant, was shown to reduce p53 protein stability and increase cellular sensitivity to the chemotherapeutic agent doxorubicin.",-24.625,0.4,sequencevariant
Mutation c.643T> C in the BRCA1 gene leads to a p.Leu307Arg substitution that is associated with increased breast cancer risk in individuals of Homo sapiens ancestry.,-25.0,0.4,sequencevariant
"Mutation rs702553 in the BRCA1 gene, which changes a glycine to tryptophan at codon‑198, was found to increase the risk of breast cancer in a cohort of Homo sapiens subjects.",-36.75,0.4,sequencevariant
Patients with the c.35delG sequence variant in the BRCA1 gene exhibit a markedly increased risk of breast cancer compared with carriers of the wild‑type allele.,-15.5,0.4,sequencevariant
Patients carrying the c.35delG sequence variant in the BRCA1 gene exhibit a markedly increased risk of hereditary breast and ovarian cancer.,-14.625,0.4,sequencevariant
"Patients homozygous for the c.643T>C variant in the BRCA1 gene, which results in the p.Leu307Arg substitution, exhibit a markedly increased risk of breast cancer compared with carriers of the wild‑type allele.",-25.0,0.4,sequencevariant
Patients harboring the BRCA1 c.35delG sequence variant exhibit a markedly increased risk of breast cancer compared with carriers of the wild‑type allele.,-15.125,0.4,sequencevariant
"Experiments with CRISPR‑Cas9‑edited HeLa cells carrying the c.35delG sequence variant revealed that the resulting p.G821R protein misfolds, leading to a marked increase in apoptosis and a significant reduction in cell proliferation compared to wild‑type cells.",-40.5,0.4,sequencevariant
"Experiencing a G to C point mutation in exon four (base position c.308) of the BRCA1 gene, the patient’s sequence variant p.G821R was associated with an increased risk of breast cancer in a cohort of Homo sapiens individuals.",-57.5,0.4,sequencevariant
"Experinavir treatment of a patient carrying the BRCA1 c.35delG sequence variant, which results in a premature stop codon and loss of the DNA‑repair domain, markedly reduced the risk of breast cancer recurrence compared with patients lacking this mutation.",-48.0,0.4,sequencevariant
"Experimen­tal CRISPR‑Cas9 editing of the TP53 locus in H1299 cells introduced a c.643T>C transition that creates a p.Leu307Arg variant, which was subsequently shown to impair p53‑dependent transcriptional activation of the CDKN1A promoter.",-42.75,0.4,sequencevariant
"Researchers found that the c.35delG sequence variant in the GJB2 gene, which causes a premature stop codon and loss of the protein’s transmembrane domain, is associated with autosomal recessive deafness in a cohort of Homo sapiens patients.",-33.25,0.4,sequencevariant
"Researchers discovered that the c.35delG sequence variant in the BRCA1 gene, which deletes a guanine at position -395G, leads to a p.Leu307Arg substitution that compromises DNA repair and increases breast cancer risk in patients carrying the Rs702553 allele.",-37.5,0.4,sequencevariant
"Researchers identified the c.643T>C sequence variant in the TP53 gene of a HeLa cell line, noting that the resulting p.Leu307Arg substitution increased the cell line’s sensitivity to doxorubicin.",-29.75,0.4,sequencevariant
"Researchers determined that the c.643T>C mutation in the BRCA1 gene, which causes a p.Leu307Arg substitution, is associated with an increased risk of breast cancer in a cohort of Homo sapiens individuals carrying the rs702553 allele.",-30.5,0.4,sequencevariant
Impaired p.G821R and c.643T>C sequence variants in the BRCA1 gene were found to increase the risk of breast cancer in a cohort of Homo sapiens patients.,-27.875,0.4,sequencevariant
"Immunohistochemical analysis of a lung carcinoma sample revealed a c.643T > C sequence variant in the TP53 gene, whose p.Leu307Arg substitution was associated with increased tumor cell proliferation and resistance to cisplatin treatment.",-41.0,0.4,sequencevariant
"Impairment of the BRCA1 p.G821R variant, a c.35delG mutation in exon four, was shown to increase the risk of breast cancer in a cohort of Homo sapiens patients carrying the Rs702553 allele.",-43.25,0.4,sequencevariant
Imprinted c.35delG and the G to C point mutation in exon four (base‑308) of the BRCA1 gene were found to co‑segregate with the p.G821R variant in a family with early‑onset breast cancer.,-55.5,0.4,sequencevariant
"Genomic analysis of a colorectal carcinoma sample revealed a novel sequence variant, c.643T>C, in the APC gene, which results in a p.Leu307Arg substitution and is predicted to disrupt the protein's regulatory domain, thereby contributing to tumor progression.",-34.0,0.4,sequencevariant
"Genotype analysis of the BRCA1 c.35delG variant revealed a high‑risk association with breast cancer in a cohort of Homo sapiens patients, while the p.G821R mutation in the same gene was linked to a milder phenotype of ovarian insufficiency.",-44.25,0.4,sequencevariant
"Genetic analysis of a colorectal carcinoma sample revealed a novel sequence variant, c.643T>C, that introduced a p.Leu307Arg substitution in the APC gene and was associated with aberrant Wnt signaling in the tumor cells.",-30.5,0.4,sequencevariant
Genetically engineered A549 cells harboring the BRCA1 c.643T> C sequence variant exhibit a pronounced reduction in homologous recombination efficiency compared to wild‑type cells.,-28.75,0.4,sequencevariant
"Gene‑edited A549 cells carrying the c.643T> C sequence variant in the TP53 exon showed a pronounced increase in apoptosis after doxorubicin exposure, confirming the pathogenic role of this mutation.",-41.75,0.4,sequencevariant
"Gene editing of the TP53 locus in A549 cells revealed that the c.643T>C sequence variant, which results in the p.Leu307Arg amino acid substitution, significantly increased apoptosis compared with the wild‑type allele.",-31.625,0.4,sequencevariant
Gene silencing of the BRCA1 c.35delG variant in MCF-7 cells leads to a marked reduction in homologous recombination repair activity and increased sensitivity to cisplatin.,-32.25,0.4,sequencevariant
"Gene therapy targeting the BRCA1 c.35delG sequence variant in the HeLa cell line revealed that the deletion of guanine at position c.35 abolishes the binding of the RAD51 protein, thereby reducing homologous recombination repair and increasing sensitivity to the DNA‑damaging agent doxorubicin in Homo sapiens cells.",-44.5,0.4,sequencevariant
"Pseudomonas aeruginosa harboring a g.99367-102002del variant in the oprD gene shows markedly reduced susceptibility to carbapenem antibiotics, while a c.35delG mutation in the human GJB2 gene is associated with autosomal recessive hearing loss.",-32.0,0.4,sequencevariant
Pheochromocytoma patients carrying the BRCA1 c.35delG sequence variant exhibited a markedly increased risk of developing breast cancer compared with non‑carriers.,-29.875,0.4,sequencevariant
"Palliative treatment with doxorubicin reduced tumor burden in HeLa cells carrying the BRCA1 c.35delG sequence variant, which had been previously associated with increased cisplatin resistance in Homo sapiens ovarian carcinoma.",-37.5,0.4,sequencevariant
"Pediatric patients carrying the c.35delG sequence variant in the GJB2 gene exhibited profound sensorineural hearing loss, while a separate cohort with the p.Leu307Arg mutation in the MYH7 gene presented with hypertrophic cardiomyopathy.",-30.75,0.4,sequencevariant
